<SEC-DOCUMENT>0000950170-25-029002.txt : 20250227
<SEC-HEADER>0000950170-25-029002.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227160132
ACCESSION NUMBER:		0000950170-25-029002
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKET PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		25678519

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		646-440-9100

	MAIL ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOTEK PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20040226
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rckt-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-27T12:53:53.0417+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:rckt="http://www.rocketpharmaceuticals.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_016296c6-b126-4873-836b-581a61dda64f" name="dei:DocumentFiscalPeriodFocus" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468">FY</ix:nonNumeric><ix:nonNumeric id="F_b4dfe319-bbd8-4694-8658-3b25b6f7567e" name="dei:AmendmentFlag" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468">false</ix:nonNumeric><ix:nonNumeric id="F_39d8dcdd-c6c2-4cc1-935e-ac8a013dcca5" name="dei:EntityCentralIndexKey" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468">0001281895</ix:nonNumeric><ix:nonFraction id="F_63f0a92f-a65a-4c84-b222-33d614db54c3" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_76b723fc-c65f-451e-978b-806aac96cad9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_dc034d90-1564-4b13-80cc-fb23b4f1b2e2" name="us-gaap:PreferredStockValue" contextRef="C_6562543d-3991-4041-aff9-088643ccce60" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_fc42e5ab-9c8c-4f21-a12e-b9264001c1d4" name="us-gaap:PreferredStockValue" contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ccfdc9a8-1b03-4d0f-b432-45e689b2bcfb" name="us-gaap:PreferredStockValue" contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4bf39ad5-2046-4fcd-9234-2456d6001b5f" name="us-gaap:PreferredStockValue" contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff">http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment</ix:nonNumeric><ix:nonNumeric id="F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_3215859f-0d66-4427-9688-3a638bd9b0c3" format="ixt-sec:duryear">3</ix:nonNumeric><ix:nonNumeric id="F_e4e33013-0944-4e5f-ae6a-24eab71a59cf" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_0a395aa8-c4ae-4063-a1b7-e3d080e5ffcf" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2">2026-12-31</ix:nonNumeric><ix:nonNumeric id="F_f8ada714-1a3a-4a7f-a2c0-3691e7ff6012" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_6bfdea93-6072-4e09-919a-4629747224e6">2026-12-31</ix:nonNumeric><ix:nonNumeric id="F_476f0015-4836-4e88-9984-744d464250a3" name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2">2038-12-31</ix:nonNumeric><ix:nonNumeric id="F_0f41fdbb-616b-4390-91ca-6c0083fedb69" name="rckt:NumberOfLeastUninterruptedYears" contextRef="C_392358ca-cf5c-43db-9d21-66153965d64c">P2Y</ix:nonNumeric><ix:nonNumeric id="F_df646047-6e29-47e2-b2b5-6f058df99877" name="rckt:NumberOfLeastUninterruptedYears" contextRef="C_d25d260a-f7e7-4db6-8072-fa02e589a560">P2Y</ix:nonNumeric><ix:nonNumeric id="F_51fd1836-2c76-4d4a-89af-503fa040d252" name="rckt:NumberOfLeastUninterruptedYears" contextRef="C_743963e7-e2f3-4156-9218-0e77929607dc">P2Y</ix:nonNumeric><ix:nonNumeric id="F_451a042b-eab6-4290-938a-8e09ce736c2b" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rckt-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_81130365-ff4b-4a54-b76d-5c0eadb8eb25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8248820b-9b6e-4904-9222-9f0abb8fa0d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8258573d-c82d-41f2-ba1a-9620f4a7976c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_842fddb4-2c73-4db6-a334-14dfdfb8754b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_845cdb5d-eeb4-4f91-b37f-77626c44f34b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84c34b9d-6390-46b6-8bd7-a209b92ac32e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88bd68f9-d4e7-4d24-ad5b-0cfd4a8572fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88e568be-e56e-4e25-9251-014e7a901a92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b46be80-cf70-47f1-91fb-b0731982128f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rckt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cae4c49-ba69-493e-87c2-811bf32aab54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cfc4f1d-1cde-40f3-8c46-dd26d0bccc8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e233e0a-2ea3-41c0-89a4-fc2fd285a9ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fde949d-0acd-44a3-9e91-5d4c632ff5be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_906a09af-a884-4b84-bbef-d07f25a1fe78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92d0c82e-65b5-4c8a-8b1c-a545c812be74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_942d6d11-281e-4b8a-9341-9398c05c7ec3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_943dc870-40c2-4855-8570-af751ebf236a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95348ff1-8262-49b2-97f9-9288584683e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_956a0bae-50e5-4afb-9e3f-ce6ad3fb91df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9571be56-aa2f-48cf-b127-0409e94057d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_991c71a4-2d8b-4a30-b81d-b081fa3aa360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_995a47c0-d6eb-4aac-a735-b345f6e0d985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b1dc6b9-f15b-42c3-88cc-60968fdcd0ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b231eaf-1cc1-439b-be3b-21ff07a55616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ca4967a-2d36-4cf3-813a-a556cf2894e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:NewJerseyLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9db51dfa-02b3-4033-8f63-ae0680935120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a067d039-439e-4ceb-af2b-1cde0cbe0191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:LADICIRMGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0c2517b-dc96-4c54-8ca8-8365a9a71c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a111d06c-dc8e-4e3a-8e0d-78a1e5369023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rckt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1502da7-9920-4457-8a72-b7448a4ac6aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20e6031-eb30-4c47-8d1b-adc6495a52e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a24c8827-54a1-427b-bed0-b964f5520e1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2ac1bfa-acd2-4922-9ccd-25d39d1ed512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a390a215-8672-44fe-88df-66981bedc86b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3a9b56e-e418-462d-87f6-73709057c6a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a589b03e-fb9c-4bfa-83f1-f8a8d07ed1fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a62b5264-3059-4dbe-b8df-0bb7b813db23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6f9948b-434e-4c07-bdf1-b761c191b422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7d9a7dd-fff1-4380-9e5f-b878d0a03f2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab8144ca-12d4-48b2-a36b-ecea9a99ea61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abe62c65-86b2-4c28-a166-de2d40714fe1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-12</xbrli:startDate><xbrli:endDate>2024-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad2fb098-5ecf-47f9-9732-d89dedec0a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad45b344-bcc3-4fab-a36c-d35bf9065472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:LADICIRMGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad72efaf-99b2-46be-9995-845d7bf8494c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae6b3516-7a34-414f-a317-8b7d0434e4e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af781e94-ac4a-4e0a-b76d-1f546fae593e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-15</xbrli:startDate><xbrli:endDate>2023-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b27c603f-0be6-4a87-b784-35a6acc0b66b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b579542c-2ebf-4d4c-99f6-66f0c8bde726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b57bb250-c7e3-4d28-a381-947cb29c01f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7504ddd-7215-4a12-a2a7-05b47998068b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b75d21e1-b615-445e-a851-9927373017c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf12f724-78e9-4689-a9d8-6cfcdb16921d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf567e9b-5f3d-4efa-a215-8c9b02dd65f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfe02d27-19e3-433a-95db-5d94f0827b20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c05bc945-3f19-4133-993a-f7a7c46cf63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0959b18-8b8a-48d0-97a6-aefc2f4ade16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0a9f08c-83d5-4fde-9bc3-f69654e05e5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0e3b9f1-cd58-4ddc-8dac-3bce6794b077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c12614f0-c656-4035-8e89-9961453df24f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c182ea63-0464-4304-ac90-99a8af5eefc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3286afb-2e4a-4c4c-99a2-97e9d815732a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3c68b77-90ed-4616-a582-7d53b5f05ebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c72bc269-579c-4d57-ac72-5d5633259ea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c72cfefa-5df0-4873-ad35-93e437d2fecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7874f61-2268-4af4-888a-25b614890494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c85f9ea7-c5e2-4223-8d66-d75ebaec1617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-15</xbrli:startDate><xbrli:endDate>2023-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8dbc4c6-e882-4412-ac54-add80894cf82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9cbcf73-650e-4bae-b575-14bb681c7fcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc91e4ce-92d4-493e-b585-ed3ef5272e3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATAndUCLBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d25d260a-f7e7-4db6-8072-fa02e589a560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2c1c330-8750-4b70-8dba-88ed15df03d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d48d3908-3513-4784-ae1b-75c7c67ca6e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4b68ab5-2b41-4121-b8f8-df6a4d864157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6baac6b-72b3-4bad-a3e9-4bd2c34ab5f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7655a81-c814-49e4-8f59-bed89f97e80c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7da2197-3558-4b5e-baa6-7e95259215a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da15f6ac-8878-4d40-8036-e1c273a0e120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dab486eb-7044-4902-b0e7-0bf059248bfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc209532-0fd3-44e9-9598-91da8bb7ea6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df02e688-dcfc-497e-8173-c2fefd94643a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df19c97a-a904-4e39-bf6b-380f08b81962"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0a89db5-ae0b-4a17-b75d-9c2a60a086ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-12</xbrli:startDate><xbrli:endDate>2024-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1b43b69-998d-4796-b42a-aea9aafdd667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1c16979-17a8-4d46-9822-2b46b4a8cb39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e289c72e-5a2f-4c23-8a80-507c89a70c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6d96dee-383b-4648-a425-7febaa2eae01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e74a48a3-05d2-4751-8cd8-1f14b04dcc09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e769f56b-a3fa-4858-826e-d12445d19397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9d92f5a-8151-4cab-ad6d-17971fdc56a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebdeda00-9ced-49ab-96a0-78c4cdd5ca46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec293a7f-d32b-4a44-a134-201656a16ec8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec6889e5-cd60-493d-a8e3-c53b58b5fa3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f241f631-e65d-4cb2-96fd-2e31846e930f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4e43627-1bfb-49a1-9d5a-28545ff3ce67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f58025d4-77f4-4bb3-a4eb-7fe3d5f5ebf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-30</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6793c34-d860-442e-be6e-737f243f3d98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f68555a5-2282-4a77-abe9-8ff2dee0202d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6f45e22-281d-462c-89e9-34ded8f15e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7122f45-e86b-4832-8a3c-08b89787f233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7e81d9b-0896-4ad4-ba24-d00ff70c5380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-31</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8197a09-186b-424a-b44f-83d44b69c54d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f889aac3-200d-4251-9867-6d16afb64a27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f89a9364-484a-44e7-a942-5ef3c5798d0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9abc263-c852-40e4-bb93-fffa5f59bb9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:AAVCurrentGoodManufacturingPracticecGMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fadd17aa-74ce-41d1-ba1c-01a9d30e8d5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe041e39-6da1-43a6-9419-34b2d437cff8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe613fec-8a94-4877-8745-1c95fb74dd4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0037c99e-c1ca-4b23-b24c-81e17fdc512c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_053815b6-adc7-4370-b942-f77a4c14f8b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05d3269a-9c6d-44e5-9b7c-99c1bf950fb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_069e4998-345d-4f31-93a6-b24211692b71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-03</xbrli:startDate><xbrli:endDate>2025-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07a7dd6a-45bf-41e3-812c-421cdda9cc6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07c3747f-e2f3-42a9-89ac-9acfd5f74970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08780583-41ea-448f-ad3c-a32d151f99de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a90aae5-1098-4d84-8da8-2fb68133b607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b068067-3bc4-428c-8a9a-66ff44763c0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cfac2e7-eea8-42c7-88ef-e2f0746599fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ea9594b-03e6-487e-a61a-c1acf9b39205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15399861-ccb4-4e70-8bbd-0ddf51277dc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_192b6914-1bac-4600-8f9d-77f09fef2c75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a9df4ee-5889-42bf-97e5-3fe2409b390d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1adde562-4738-4477-bfc6-f6adc114c4a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-12</xbrli:startDate><xbrli:endDate>2024-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bae87d0-dd44-44ba-9b20-91cc4df8a8be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d96ec30-1174-441b-a600-2e0b2c261eb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e1369d9-110a-42d0-b7c0-84ac9ece8089"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f827aab-8c58-4267-acb7-76cf53e8db5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20f6fd52-2ba1-4fa6-be1d-d13c170008e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23045695-c17e-4d48-ab1f-bb772f60c66e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_231c38bb-1d40-4602-a048-1a166b10048d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2323ae46-2e58-4ceb-9952-42b0e8c29897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-06</xbrli:startDate><xbrli:endDate>2022-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2401d799-1468-4c2d-8db7-16420132a1ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25bb15f2-0efc-482c-a2c6-da231c955822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2752ee0c-715c-4d1f-bee7-73f449628989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2765a887-d17f-45bb-83df-c1b045d9460d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rckt:HopewellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b8daae2-1c08-437a-af18-31fd63828d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingAndPrivatPlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-12</xbrli:startDate><xbrli:endDate>2024-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c3ff4eb-7ecb-4647-a320-5c43c59dd844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c40b128-241d-4c5e-acaf-fed48f581245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c62f640-e90d-405f-b768-464bdc8fe131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-15</xbrli:startDate><xbrli:endDate>2023-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c739877-da67-4ce9-9177-ac7aba511326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f0b3d23-92ac-4213-bd74-31dcf6bf23dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f0c010b-87c8-42b0-9da6-1c012fc63603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:NewJerseyLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_308b60bc-adf6-4c0d-98f7-6dd8faf1845b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30eee4ca-639d-42b3-9810-aa01632a49b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3215859f-0d66-4427-9688-3a638bd9b0c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3300233d-86ba-4c8f-9f81-9fb876b5012f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34f5602a-7c3f-4806-8c95-b68c3340e325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37654162-418a-45b1-acc3-24642763a46c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_392358ca-cf5c-43db-9d21-66153965d64c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForPKDWithCIEMATGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39d4c570-76ba-4c52-80e3-dde4aa7b4c66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a2dd3b1-3fb8-410c-ab6a-47d3ffbd35f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3abe252d-55ed-4732-a04d-1b253a82ba3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c6df573-5d38-4acd-8c24-1b20574901cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d43c909-ed76-4cd3-8437-c11a815217b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:DanonDiseaseLicenseAgreementWithUCSDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f829c1c-8313-4171-8476-384337e26d5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ffc89cd-c5e5-47b4-9f7d-0851382b9894"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForPKDWithCIEMATGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41fabef3-0abe-4db6-b3ec-ae0243277332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_427ef717-f6ba-4ddc-87e2-99ea816b4e39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4610418f-69ff-4383-8d4b-b7f932f3e7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46f31250-5670-4e2c-961d-6755291c25a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_479a9661-05cc-4e37-ac7c-06504e617691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:AdenoAssociatedVirusProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4aa60fef-eb52-492b-9a6b-0ce93d49fb48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4debd961-aac7-48c4-9e45-f2780c6806f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e8fe46b-7cf9-4f88-b35f-815f319dccc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:DanonDiseaseCIRMGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ec9d6be-c702-40fd-a041-258f0191e5ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f55fe36-f663-484f-9f05-d10d67ae3a41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ff6c49f-8407-479c-80d4-c307efd55622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50276bb0-33c1-4f8f-878e-9cd8590b54aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:REGENXBIOIncLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51821ea0-ebf2-416d-b94b-558384084f5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_522afc24-fadc-4b87-92bc-1830764fccf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_546e10b4-ff00-4699-b1d3-6c11db3121d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5579d6c9-7175-4d28-8d03-b3467227e674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55db9cf5-dacb-451e-bc48-da645969b76a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56deae45-2475-4724-92a9-1a0f1898168d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5788384e-0e15-4c14-b7f3-ea8098caef5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58582e6a-472e-48eb-b983-e4e33afabbd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58974243-708a-4a81-a595-749260b730ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59178516-f6c7-4b30-a565-d0b9d51d21d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForBAG3WithTempleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_594c6d62-c2cf-41a3-886a-1934d4223d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bed0892-88b1-4193-a2a6-7964d153c972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d022c41-2abf-4b66-9515-d9ce9e263b44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d1d40da-cfd2-4824-a96b-b4971b74b346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LentiviralVectorProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d4ff701-3d41-47cd-8660-59707d56d468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5de73c69-3b3e-412b-a788-62510c450a86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f849fe8-09d4-4c36-86ef-cef05c3dbc49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f9d43f8-45ec-4f28-93a5-f42279655025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_600a0f88-6bde-40ff-97bd-99954442846a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_614d6896-e6d5-492d-9c77-ffb84b0406db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61647b0b-b5df-4485-8420-e20842c8ff39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61ed228c-04b4-492d-9653-316c1c51bb39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62e99bbf-513f-4f99-b0ea-bcc4f892c8d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForPKDWithCIEMATGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-31</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63ad2220-d8b8-479c-b35d-56ecb8208ca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63ca01b0-e7b0-45e5-aa8a-17201501dd48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_648e9485-2de4-4dbf-b7be-6f5b0c53d513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65579abf-153c-44b1-82d0-fd8168b17b2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6562543d-3991-4041-aff9-088643ccce60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69408d2a-0545-4d3a-a4f7-3c54eb9825f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-12</xbrli:startDate><xbrli:endDate>2024-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6949dc0c-ac58-42f1-b238-512744e2f55a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69c35b9b-2ef7-4ee6-b016-6923857d4819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b479ce2-ba9e-4e7a-9b6e-64a21f473b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:LADICIRMGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bfdea93-6072-4e09-919a-4629747224e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d0adb09-8317-454a-af5e-3df33b3384e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e010d18-1522-44a9-b62f-331c4708e6ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f626844-ba06-4567-931e-02c5cb0a1650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7132f227-a70e-41d6-9438-433555a0c26d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:DanonDiseaseCIRMGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7192b875-69fe-4a97-bfab-df69481b623d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7196725c-a392-4a09-b1a2-b1a1aec580da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71fbe897-d128-4353-aa54-ac82b0209669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_743963e7-e2f3-4156-9218-0e77929607dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74b364e5-c1c4-45b4-9711-2e7d66596427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74f8d0f8-a7bf-4f11-928f-7f1a09f755c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76dc7d6c-2561-4ef0-81f4-82f6593b6052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_775eb4a6-0d31-417a-ac1c-4d459d9a1b5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77b45e56-1ad3-417d-8a7f-066853f32825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78dca576-a930-4462-aa00-b27c81826e49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79626284-c57a-465a-9017-f3638fa6a020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d36cd7b-896c-4b98-9546-ea32bed606cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e23f455-be7b-426a-9098-daac61a450fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Milestone"><xbrli:measure>rckt:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>rckt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_Program"><xbrli:measure>rckt:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Patent"><xbrli:measure>rckt:Patent</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>rckt:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Leaseagreement"><xbrli:measure>rckt:Leaseagreement</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, DC 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04370629-a4cf-4773-9e67-ce50419f1143" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ed934fa8-e561-415c-8fe4-e455ce81b16b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_340d7d87-240a-486a-b291-feb69d55bae4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd0e85d1-0a9b-4f15-b9ed-6c3ce52dd963" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9daf1b6-886e-4aec-a50a-51e127c42674" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p><p style="text-indent:-19.885%;padding-left:16.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_5d7fa59a-cb84-45be-ab8f-947df36dfd2f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9633;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from                to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">               </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5593215-765c-40a5-ab1d-b7847e274481" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-36829</span></ix:nonNumeric></span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_204f5f95-7ac5-41a1-a999-d62b4363a8dd" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5be7cfeb-95c3-48bb-a247-b9f6b8e1e2aa" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a4a6a4bc-b948-4cd7-8f7c-20823ac3d479" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">04-3475813</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction of Incorporation or Organization)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4b4bac96-59e4-4c49-adff-2dea82a2a5fa" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9 Cedarbrook Drive</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_9befe8cc-8e6b-4472-b276-851251bed538" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cranbury</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_4332390e-fcae-46c3-b2dc-549a7e155991" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NJ</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b5454e71-a8e4-4d5a-a184-033cd2cff3fe" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">08512</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0950bc44-940f-4d91-a2ea-ea89e5807178" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">609</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57a1d8a5-f951-4bec-b052-f8e9ca447bbf" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">659-8001</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s Telephone Number, including Area Code)</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:24%;box-sizing:content-box;"/>
     <td style="width:38%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0820c7b3-cc96-45f8-b165-e2afe79c2c9f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, $0.01 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a2730a36-be88-4bda-98dd-b0fcfb7f7389" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">RCKT</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_f3fb417a-954e-4531-b79a-b56a7a046883" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NASDAQ Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28c2057e-cba5-4fb4-b843-a72e10961664" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633; </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6947117d-2ece-4e12-98f5-7540ebcfed88" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e3969b2-59ac-47db-b864-645307c91a2d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3187cb93-ab9f-4d17-893d-71847f7c82f9" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of </span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">large accelerated filer,</span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accelerated filer,</span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">smaller reporting company</span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">emerging growth company</span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in Rule 12b-2 of the Exchange Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:29%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:37.8%;box-sizing:content-box;"/>
     <td style="width:28.66%;box-sizing:content-box;"/>
     <td style="width:2.54%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_18cbb91f-29cf-46ed-81f0-111f739d3e17" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e70e6369-3c3d-4c87-9aec-7c47d8b07d72" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9633;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ddbfc64a-1d6e-498a-bb7b-7265cec251e4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntitySmallBusiness" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9633;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6a5c7474-bd00-4987-a3c4-b1bcdd30c924" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ef839645-ba8a-4f22-88a8-aec6f6e0a8d1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9633; </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a0fd0de5-32f3-404e-84d9-0ac9fd51dec2" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4c034a5-aafe-45b3-ad32-61ca939162e6" contextRef="C_f4e43627-1bfb-49a1-9d5a-28545ff3ce67" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion, based upon the closing price on the NASDAQ Global Market reported for such date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 21, 2025, there were </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcf41708-654d-4f87-9535-66075bb25250" contextRef="C_77b45e56-1ad3-417d-8a7f-066853f32825" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">106,629,701</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of common stock, $0.01 par value per share, outstanding.</span></p><div style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab6f6e70-7268-4688-8c4e-bd0950aa4177" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents Incorporated by Reference</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part III of this annual report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from the registrant&#8217;s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the </span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proxy Statement</span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days of the end of the period covered by this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="margin-left:0.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:9.184%;box-sizing:content-box;"/>
     <td style="width:85.714%;box-sizing:content-box;"/>
     <td style="width:5.102%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I.</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1_a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1b_unresolved_sec_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved SEC Comments</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
    </tr>
    <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II.</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item5_market_registrant_common_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7_management_discussion_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7a_quantitative_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item8_financial_statements_supplementary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9_changes_disagreements_accountants"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#partiii_other_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers, and Corporate Governance</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item12_security_ownership_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item13_certain_relationships_related"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item14_principal_accountant_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
    </tr>
    <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item15_exhibits_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item16_form_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Abbreviated Terms</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. may be referred to as Rocket, the Company, we, our or us, in this Annual Report, unless the context otherwise indicates. Throughout this Annual Report, we have used terms which are defined below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:16.26%;box-sizing:content-box;"/>
     <td style="width:35.32%;box-sizing:content-box;"/>
     <td style="width:13.1%;box-sizing:content-box;"/>
     <td style="width:35.32%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AAV</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adeno-associated virus</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GLP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Good Laboratory Practice</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ACA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Affordable Care Act</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GMP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Good Manufacturing Practice</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ACM</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Arrhythmogenic cardiomyopathy</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HIPAA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Health Insurance Portability and Accountability Act</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounting Standard Codification</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HHS</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Department of Health and Human Services</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASH</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">American Society of Hematology</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HNJ</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hospital Infantil de Ni&#241;o Jes&#250;s</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASGCT</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">American Society of Gene &amp; Cell Therapy</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HSCT</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hematopoietic stem cell transplant</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BAG3</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BLC2-associated athanogene 3</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ICD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Implantable cardiac defibrillator</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BAG3-DCM</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BLC2-associated athanogene 3 mutations associated with dialted cardiomyopathy</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IND</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investigational New Drug application</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BLA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Biologics License Application</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IBC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Institutional biosafety committee</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BNP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brain natriuretic peptide</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">IPR&amp;D</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In process research and development</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CAT</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Committee for Advanced Therapies</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">KCCQ</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kansas City Cardiovascular Questionnaire</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CHF</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Congestive heart failure</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LAD-I</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CHMP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Committee for Medicinal Products for Human Use</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LAMP2</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lysosome-associated membrane protein 2</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">cGMP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Good Manufacturing Practice</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LV</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lentiviral vector</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">cGTP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Good Tissue Practice</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MAA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketing Authorization Application</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CIBER</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Centro de Investigaci&#243;n Biom&#233;dica En Red</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MHRA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Medicines and Healthcare Products Regulatory Agency</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CIEMAT</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Centro de Investigaciones Energ&#233;ticas, Medioambientales y Tecnol&#243;gicas</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NIH</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institutes for Health</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CIEMAT Group</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CIEMAT, CIBER and FIISFJD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NYHA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York Heart Association</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CIRM</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">California Institute for Regenerative Medicine</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Offering</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity offering on December 12, 2024</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CMC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry Manufacturing Controls</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PKD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CMS</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Centers for Medicare &amp; Medicaid Services</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PKP2-ACM</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CODM</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Operating Decision Maker</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRIME</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Priority Medicines</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CCPA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">California Consumer Privacy Act</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private Placement</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of warrants on December 12, 2024</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CRL</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete Response Letter</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CRO</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract research organization</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRIME</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Priority Medicines</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cowen</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cowen and Company, LLC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RBC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Red blood cell</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CTIS</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical Trials Information Systems</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">REMS</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk Evalation and Mitigation Strategy</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DCM</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilated cardiomyopathy</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RGNX</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">REGENXBIO Inc</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Danon Disease</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Renovacor</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Renovacor, Inc. acquired on December 1, 2022</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DNA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deoxyrubonucleic acid</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RMAT</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regenerative Medicine Advanced Therapy</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EMA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">European Medicines Agency</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSU</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock unit</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESB Lease Agreement</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office lease in the Empire State Building in NYC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RTW</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RTW Investments, L.P</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESG</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Environmental, Social and Governance</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SCD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sudden cardiac death</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EU</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">European Union</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SEC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Securities and Exchange Commission</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fanconi Anemia</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stanford</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Center for Definitive and Curative Medicine at Stanford University School of Medicine</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FANCA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fanconi Anemia Complementation Group A</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UCLA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">University of California, Los Angeles</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Food and Drug Administration</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UCLB</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UCL Business PLC</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDCA</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal Food, Drug and Cosmetic Act</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UCSD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Regents of the University of California, San Diego</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIBHNJS</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fundaci&#243;n para la Investigacion Biom&#233;dica del Hospital del Nino Jesus</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UPC</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unitary Patent Court</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIISFJD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fundacion Instituto de Investigaci&#243;n Sanitaria Fundacion Jim&#233;nez D&#237;az</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GCP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Good Clinical Practices</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. GAAP</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Generally Accepted Accounting Principles</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GDPR</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Data Protection Regulation</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USPTO</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Patent and Trademark Office</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;develop,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;expand,&#8221; &#8220;future,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;pursue,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to meet our anticipated milestones for our various drug candidates with respect to the initiation and timing of clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal, state, and non-U.S. regulatory requirements, including regulation of our current or any other future product candidates by the FDA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and our ability to submit regulatory filings, including filings with the FDA, and to obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors&#8217; activities, including decisions as to the timing of competing product launches, pricing and discounting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether safety and efficacy results of our clinical trials and other required tests for approval of our product candidates provide data to warrant progression of clinical trials, potential regulatory approval or further development of any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, and our ability to apply for and obtain regulatory approval for such product candidates, within currently anticipated timeframes, or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish key collaborations and vendor relationships for our product candidates and any other future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to develop our sales and marketing capabilities or enter into agreements with third parties to sell and market any of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain additional funding to conduct our planned research and development efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to acquire additional businesses, form strategic alliances or create joint ventures and our ability to realize the benefit of such acquisitions, alliances or joint ventures;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development of our direct manufacturing capabilities for our AAV programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to expand our pipeline to target additional indications that are compatible with our gene therapy technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully operate in non-U.S. jurisdictions in which we currently or in the future do business, including compliance with applicable regulatory requirements and laws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and enforce patents to protect our product candidates, and our ability to successfully defend ourselves against unforeseen third-party infringement claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">anticipated trends and challenges in our business and the markets in which we operate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding our capital requirements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any forward-looking statements in this Annual Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. Risk Factors and elsewhere in this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. Unless stated otherwise, references in this Annual Report to &#8220;us,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or our &#8220;Company&#8221; and similar terms refer to Rocket Pharmaceuticals, Inc.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks and uncertainties include, but are not limited to, the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any of our product candidates, we may not be successful in commercializing those product candidates if and when they are approved.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to obtain necessary additional funding to conduct our planned research and development efforts, we could be forced to delay, reduce, or eliminate our product development programs or commercial development efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never generated any revenue from product sales and may never be profitable.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in commencement, enrollment or completion of our clinical trials or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing our current and future product candidates on a timely basis, if at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit, or terminate planned clinical trials, the occurrence of any of which would harm our business, financial condition, results of operations and prospects.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary, interim or topline results in our ongoing clinical studies may not be indicative of results obtained when these studies are completed and success in early clinical studies may not be indicative of results obtained in later studies.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which<br/>could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our gene therapy product candidates are based on novel technology, which makes it difficult to predict the time and cost<br/>of product candidate development and subsequently obtaining regulatory approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we successfully complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never obtain approval for any of our product candidates in the U.S. or the EU, or other jurisdictions, which would limit our ability to realize our full market potential.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory obligations and continued regulatory scrutiny.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved, our product candidates may face competition from biosimilars approved through an abbreviated regulatory<br/>pathway.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are successful in commercializing any product, our relationships with customers and third-party payors will be<br/>subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to<br/>criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational<br/>harm and diminished profits and future earnings.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to stringent laws, rules, regulations, policies, industry standards and contractual obligations regarding data<br/>privacy and security and may be subject to additional related laws and regulations in jurisdictions into which we expand.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and<br/>substantial expenses in connection with environmental compliance or remediation activities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise harm our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in manufacturing, and there can be no assurance that we will be able to successfully manufacture products.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the potential<br/>commercialization of any products that we may develop.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to successfully develop and commercialize our product candidates will substantially depend upon the availability of reimbursement funds for the costs of the resulting drugs and related treatments.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of any of our product candidates will depend upon the degree of market acceptance of gene<br/>therapy by physicians, patients, third-party payors and others in the medical community.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ethical, legal, and social issues may reduce demand for any gene therapy products for which we obtain marketing<br/>approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline of additional product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our research and development activities, clinical testing, and commercialization, upon which we primarily focus, is uncertain.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to rely on third parties to conduct some or all aspects of our drug product manufacturing, research, and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages, Executive Orders, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our rights to intellectual property for the development and commercialization of our product candidates are subject to the<br/>terms and conditions of licenses granted to us by others.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our products and related technology or are unable to<br/>otherwise protect our intellectual property rights and trade secrets related to our product candidates, we may not be able to<br/>compete effectively in our markets.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in<br/>general, thereby impairing our ability to protect our products.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we breach our license agreements, it could have a material adverse effect on our commercialization efforts for our<br/>product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business could suffer if it loses the services of, or fails to attract, key personnel.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading which could harm our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given our commercial relationships outside of the U.S., in particular the EU, a variety of risks associated with international operations could harm our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may fail to realize the anticipated benefits of potential acquisitions or business combinations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future formations of strategic alliances or joint ventures with third parties could disrupt our business and harm our<br/>financial condition and operating results.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us<br/>and could limit our ability to implement our strategies.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RTW Investments, LP, our largest stockholder, may have the ability to significantly influence matters submitted to stockholders for approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future sales of our common stock in the public market could cause the market price of our common stock to drop<br/>significantly, even if our business is performing well.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and<br/>timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a<br/>result, the value of our common stock.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our third-party collaborators or other contractors, may fail or suffer security<br/>breaches, which could result in a material disruption of our development programs.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unfavorable national or global economic conditions or political developments could adversely affect our business,<br/>financial condition or results of operations.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summary risk factors described above should be read together with the text of the full risk factors below and in the other information set forth in this Annual Report, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. If any such risks and uncertainties actually occur, our business, prospects, financial condition, and results of operations could be materially and adversely affected. The risks summarized above or described in full elsewhere in this Annual Report are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition, and results of operations.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:0.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT I</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">usiness</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have two clinical stage and one pre-clinical stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adeno-associated viral (AAV) programs in the U.S., which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The DD program is currently in an ongoing Phase 2 trial (RP-A501); </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. Our program utilizes recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to slow or halt progression of BAG3-DCM. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced our alignment with the FDA on our pivotal study design for RP-A501 in DD. Completion of enrollment in this study was announced in September 2024, and dosing and follow-up are ongoing. We have received FDA clearance of an investigational new drug (IND) application for RP-A601, and we have initiated a Phase 1 study for this program. For the BAG3 program, nonclinical and IND enabling studies are ongoing. Submission of the IND is anticipated in the first half of 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have three clinical-stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lentiviral (LV) programs, which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for RP-L201 for the treatment of severe LAD-I. In June 2024, we announced that the FDA had issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025. With respect to RP-L201, treatments in the FA Phase 2 studies were completed in 2023 and submission of a BLA on a rolling review basis was initiated in September 2024. In April 2024, the European Medicines Agency (EMA) accepted our Marketing Authorization Application (MAA) for RP-L102. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. With respect to RP-L301, we have reached agreement with the FDA on the study design of the Phase 2 pivotal trial for RP-L301, our ex vivo LV-based program targeting PKD. While the Phase 2 RP-L301 study is ready for patient enrollment, we are currently focusing our resources on other programs and have not initiated enrollment in the Phase 2 RP-L301 study.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have global commercialization and development rights to all of these product candidates under royalty-bearing license agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gene Therapy Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genes are composed of sequences of deoxyribonucleic acid, which provide the code for proteins that perform a broad range of physiologic functions in all living organisms. Although genes are passed on from generation to generation, genetic changes, also known as mutations, can occur in this process. These changes can result in the lack of production of proteins or the production of altered proteins with reduced or abnormal function, which can in turn result in disease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gene therapy is a therapeutic approach in which an isolated gene sequence or segment of DNA is administered to a patient, most commonly for the purpose of treating a genetic disease that is caused by genetic mutations. Currently available therapies for many genetic diseases focus on administration of large proteins or enzymes and typically address only the symptoms of the disease. Gene therapy aims to address the disease-causing effects of absent or dysfunctional genes by delivering functional copies of the gene sequence directly into the patient&#8217;s cells, offering the potential for curing the genetic disease, rather than simply addressing symptoms.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are using modified non-pathogenic viruses for the development of our gene therapy treatments. Viruses are particularly well suited as delivery vehicles because they are adept at penetrating cells and delivering genetic material inside a cell. In creating our viral delivery vehicles, the viral (pathogenic) genes are removed and are replaced with a functional form of the missing or mutant gene that is the cause of the patient&#8217;s genetic disease. The functional form of a missing or mutant gene is called a therapeutic gene, or the &#8220;transgene.&#8221; The process of inserting the transgene is called &#8220;transduction.&#8221; Once a virus is modified by replacement of the viral genes with a transgene, the modified virus is called a &#8220;viral vector.&#8221; The viral vector delivers the transgene into the targeted tissue or organ (such as the cells inside a patient&#8217;s bone marrow). We have two types of viral vectors in development, LV and AAV. We believe that our LV and AAV-based programs have the potential to offer a significant and long-lasting therapeutic benefit to patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gene therapies can be delivered either (1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (outside the body), in which case the patient&#8217;s cells are extracted and the vector is delivered to these cells in a controlled, safe laboratory setting, with the modified cells then being reinserted into the patient, or (2) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (inside the body), in which case the vector is injected directly into the patient, either intravenously or directly into a specific tissue at a targeted site, with the aim of the vector delivering the transgene to the targeted cells.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that scientific advances, clinical progress, and the greater regulatory acceptance of gene therapy have created a promising environment to advance gene therapy products as these products are being designed to restore cell function and improve clinical outcomes, which in many cases include prevention of death at an early age. The FDA approval of several gene therapies in recent years indicates that there is a regulatory pathway forward for gene therapy products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to bring hope and relief to patients with devastating, undertreated and rare pediatric diseases through the development and commercialization of potentially curative first in class gene therapies. As a fully-integrated biotechnology company, we are well positioned to achieve these objectives. In the near and medium-term, we intend to develop our first-in-class product candidates, which target devastating diseases with substantial unmet need, develop proprietary in-house analytics and manufacturing capabilities and continue to conduct registration trials for our currently planned programs. In the medium and long-term, pending favorable data, we expect to submit BLAs for the rest of our suite of clinical programs, and establish our gene therapy platform and expand our pipeline to target additional indications that we believe to be potentially compatible with our gene therapy technologies. In addition, during that time, we believe that our currently planned programs will become eligible for priority review vouchers from the FDA that provide expedited review. We have assembled a leadership and research team with expertise in cell and gene therapy, rare disease drug development, product approval and commercial launches.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our competitive advantage lies in our disease-based selection approach, a rigorous process to identify target diseases and ability to develop products to treat identified target diseases. We believe that this approach to asset development differentiates us as a gene therapy company and potentially provides us with a first-mover advantage and first-to-market of meaningful treatments for devastating, undertreated, and rare pediatric diseases.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pipeline Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The chart below shows the current phases of development of our programs and product candidates:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img173888082_0.jpg" alt="img173888082_0.jpg" style="width:720px;height:326px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cardiovascular Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Danon Disease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DD is a multi-organ lysosomal-associated disorder leading to early death due to heart failure. DD is caused by mutations in the gene encoding lysosome-associated membrane protein 2, a mediator of autophagy. This mutation results in the accumulation of autophagic vacuoles, predominantly in cardiac and skeletal muscle. Male patients often require heart transplantation and typically die in their teens or twenties from progressive heart failure. Along with severe cardiomyopathy, other DD-related manifestations can include skeletal muscle weakness and intellectual impairment. There are no specific therapies available for the treatment of DD and medications typically utilized for the treatment of CHF are not believed to modify progression to end-stage CHF. Patients with end-stage CHF may undergo heart transplant, which currently is available to a minority of patients, is associated with significant short- and long-term complications and is not curative of the disorder in the long-term. RP-A501 is in clinical trials as an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">therapy for DD, which is estimated to have a prevalence of 15,000 to 30,000 patients in the U.S. and the EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DD is an X-linked dominant, monogenic rare inherited disorder characterized by progressive cardiomyopathy which is almost universally fatal in males even in settings where cardiac transplantation is available. The causative mutation has been identified in the gene encoding for lysosome-associated membrane protein (LAMP2), and in particular the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LAMP2B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> version of the gene which is primarily expressed in heart, skeletal muscle and brain tissue. This results in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to heart failure. DD predominantly affects males early in life and is characterized by absence of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LAMP2B</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expression in the heart and other tissues. Preclinical models of DD have demonstrated that AAV-mediated transduction of the heart results in reconstitution of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LAMP2B </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expression and improvement in cardiac function.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have one AAV program targeting DD, RP-A501. We have treated seven patients in the RP-A501 Phase 1 clinical trial, which enrolled adult/older adolescent and pediatric male DD patients. This includes a first cohort evaluating a low-dose (6.7e13 genome copies (gc)/kilogram (kg)) in adult/older adolescent patients aged 15 or greater (n=3), a second cohort evaluating a higher dose (1.1e14 gc/kg) in adult/older adolescent patients aged 15 or greater (n=2), and a pediatric cohort at a low dose level (6.7e13 gc/kg&#894; n=2).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously disclosed, a patient receiving therapy on the high dose cohort (1.1e14 gc/kg dose) had progressive heart failure and underwent a heart transplant at month five following therapy. This patient had more advanced disease than the four other adult/older adolescent patients who received treatment in the low and high dose cohorts, as evidenced by diminished baseline left ventricle ejection fraction (35%) on echocardiogram and markedly elevated left ventricle filling pressure prior to treatment. The patient&#8217;s clinical course was characteristic of DD progression. The patient is doing well post-transplant.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the initial efficacy observed in the low dose cohort and to mitigate complement-mediated safety concerns observed in the high dose cohort (thrombotic microangiopathy) and in agreement with the FDA, we have moved forward with the low dose (6.7e13 gc/kg). Additional safety measures were implemented and are reflected in the updated trial protocol for Phase 1 and the protocol for our ongoing pivotal Phase 2 study. These measures include exclusion of patients with end-stage heart failure, and a refined immunomodulatory regimen involving transient B- and T-cell mediated inhibition, with emphasis on preventing complement activation, while also enabling lower steroid doses and earlier steroid taper, with all immunosuppressive therapy discontinued 2-3 months following administration of RP-A501.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted a variety of efficacy assessments in the Phase 1 clinical study to measure the prospect of benefit for patients. These assessments included the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NYHA Functional Classification is the most commonly used heart failure classification system. NYHA Class II is where a patient exhibits a slight limitation of physical activity, is comfortable at rest, and ordinary physical activity results in fatigue, palpitation and/or dyspnea. Class I is where a patient exhibits no limitation of physical activity and ordinary physical activity does not cause undue fatigue, palpitation and/or dyspnea. Class III and IV are considered more severe or advanced heart failure.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BNP is a blood-based evaluation and a key marker of heart failure with prognostic significance in CHF and cardiomyopathies. Elevations in BNP are strongly associated with worsening heart failure and poor outcomes in cardiovascular disease.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">High sensitivity troponin I is a blood-based evaluation and a key marker of cardiac injury, one that is (like BNP) frequently elevated in DD patients and has been shown to be markedly elevated in patients with advanced stage disease.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Echocardiographic measurements of heart thickness, most notably, left ventricular mass and maximal left ventricular wall thickness, indicate the degree of hypertrophy present in the heart.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KCCQ is a validated, patient-reported outcomes assessment that measures a patients perception of their heart failure symptoms, impact of disease on physical and social function, and the impact of their heart failure on overall health status and quality of life. Assessment scores range from 0 (very poor health status) to 100 (excellent health status). Changes in KCCQ score of +/- 5 points are considered meaningful and have been shown to correlate with heart failure outcomes.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Histologic examination of endomyocardial biopsies via hematoxylin and eosin histology and electron microscopy is used to detect evidence of DD-associated tissue derangements, including the presence of autophagic vacuoles and disruption of myofibrillar architecture, each of which are characteristic of DD-related myocardial damage.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LAMP2 gene expression in endomyocardial biopsy samples is measured via both immunohistochemistry and Western blot and confirms the presence of LAMP2 protein in DD cardiac tissue following RP-A501 treatment.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced positive results and presented long-term safety and efficacy results of the Phase 1 study at the American Heart Association&#8217;s 2024 Late-Breaking Science sessions and simultaneously published these data in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The long-term safety and efficacy results from the Phase 1 RP-A501 study showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months (sustained up to 60 months) and reduction of left ventricular (LV) mass index by &#8805;10% at 12 months (sustained up to 54 months) after treatment.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img173888082_1.jpg" alt="img173888082_1.jpg" style="width:720px;height:405px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The safety and preliminary efficacy of RP-A501 was evaluated in a single-arm, open-label, multi-center Phase 1 study in male patients with Danon disease. Five patients [pediatric (n=2) and adult/adolescent (n=3)] were treated with the low dose (6.7 x 1013 GC/kg), and 2 adult/adolescent patients were treated with the high dose (1.1 x 1014 GC/kg). Data from the Phase 1 study (cut-off April 19, 2024) showed that RP-A501 in conjunction with a transient immunomodulatory regimen was generally well tolerated. Evidence of sustained clinically meaningful improvement was observed in pediatric patients followed up to 24 months and adult/adolescent patients followed up to 60 months.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img173888082_2.jpg" alt="img173888082_2.jpg" style="width:720px;height:405px;"/></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All evaluable patients in the Phase 1 trial demonstrated:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cardiac LAMP2 protein expression at 12 months and thereafter;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduction or stabilization of LV mass index &#8211; the median reduction from baseline to most recent visit of 24% (for the ongoing pivotal Phase 2 trial, a 10% reduction in LV mass index and positive protein expression of Grade 1 or more are co-primary endpoints);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preservation of normal LV ejection fraction (LVEF);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduction or stabilization of cardiac biomarkers (median cTnI and NTproBNP reductions of 84% and 57%, respectively);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvement in New York Heart Association class from Class II at baseline to Class I at most recent follow-up visit; NYHA Class I reflects the absence of clinical signs of heart failure;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements in Kansas City Cardiomyopathy Questionnaire quality-of-life (median improvement of 27 points) scores that persisted up to 54 months of follow-up; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary long-term follow-up assessments for Patient 1001 were positive for immunohistochemical staining and appear to show Grade 3 expression in the heart at the five-year timepoint. These are preliminary results with a formal update to be presented at an upcoming medical conference in 2025.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img173888082_3.jpg" alt="img173888082_3.jpg" style="width:720px;height:405px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results from the Phase 1 DD trial represent one of the most comprehensive investigational gene therapy datasets for any cardiac condition. RP-A501 was generally well tolerated with evidence of durable treatment activity and improvement of DD for both pediatric patients with up to nine months of follow-up and four adult/older adolescent patients with up to 54 months of follow-up. All adult/older adolescent and pediatric patients who received a closely monitored immunomodulatory regimen showed improvements across tissue, laboratory, and imaging-based biomarkers, as well as in NYHA class (from II to I) and KCCQ scores with follow-up of 24 to 54 months.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced that alignment was reached with the FDA on the global Phase 2 pivotal trial of RP-A501 for DD. The global, single-arm, multi-center Phase 2 pivotal trial will evaluate the efficacy and safety of RP-A501 in 12 patients with DD, including a pediatric safety run-in (n=2), with a natural history comparator and a dose level of 6.7 x 1013 GC/kg.</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support accelerated approval, the study will assess the efficacy of RP-A501 as measured by the biomarker-based co-primary endpoint consisting of improvements in LAMP2 protein expression (&#8805; Grade 1, as measured by immunohistochemistry), and reductions in left ventricular mass.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key secondary endpoint is change in troponin. Additional secondary endpoints will include natriuretic peptide, KCCQ, NYHA class event free survival to 24 months and treatment emergent safety events. These endpoints could support full approval with longer-term follow-up.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A global natural history study will serve as an external comparator and run concurrently to the Phase 2 pivotal trial.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-house manufacturing has been completed with sufficient high-quality drug product produced to fully supply the Phase 2 pivotal study. Potency assays have been developed and qualified in accordance with FDA guidance.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we received CTIS approval to include clinical trial sites in certain EU Member States. The global Phase 2 study is ongoing in the U.S. and EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug product for the Phase 2 study is being produced in-house in our GMP manufacturing facility in Cranbury, NJ. We have successfully produced multiple commercial-grade Danon AAV cGMP batches since 2022. These batches have superior specifications to Phase 1 material in both titer and full versus empty particles. We believe the improved quality of our in-house manufactured product will allow for full dosing with lower total viral particles, potentially further optimizing the safety profile of RP-A501. Furthermore, we have reached agreement with the FDA on the continued utilization of HEK-293 cell-based process through commercialization, our comparability approach and our potency assay.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Achieved Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023, we announced that RP-A501 received RMAT designation from the FDA, and in May 2023, we received PRIME designation from the EMA. In September 2024, we announced completion of enrollment of 12 patients in the Phase 2 study across sites in the U.S. and EU. Dosing and follow-up is ongoing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Arrhythmogenic cardiomyopathy (ACM) is an inheritable cardiac disorder that is characterized by a high propensity for arrhythmias and sudden death, a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, and fibrofatty replacement of the myocardium. Most commonly, the cardiomyopathy initially manifests in the right ventricular free wall, so the disease was termed arrhythmogenic right ventricular dysplasia/cardiomyopathy. However, since left dominant and biventricular forms have also been observed, this has led more recently to the use of the term ACM. Mutations in the PKP2 gene comprise the most frequent genetically identified etiology of familial ACM. PKP2 encodes for the protein Plakophilin-2, which is a component of the desmosome, an intercellular complex involved in cell-cell adhesion. PKP2 is also involved in transcriptional regulation of calcium signaling between cardiomyocytes. Patients with mutations in PKP2 are typically heterozygous and demonstrate reduced expression of PKP2 in the myocardium. Mean presentation is at the age of 35, and patients have a very high lifetime risk of ventricular arrhythmias, structural ventricular abnormalities, and sudden cardiac death (SCD).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no specific available medical therapies available that have been shown to be highly effective for ACM, and current treatment protocols follow standard ventricular arrhythmia and cardiomyopathy guidelines, which involve lifestyle modifications (i.e. exercise limitation) and include drug treatments such as beta blockers, anti-arrhythmics and diuretics. The use of these therapies is driven by the arrhythmia burden and severity of cardiomyopathy. These therapies do not modify the course of the disease, and generally provide only symptomatic and/or palliative support. Upon diagnosis, a substantial percentage of patients receive an ICD for primary or secondary prevention of ventricular arrhythmias and SCD. Of note, ICDs are not curative, and breakthrough life-threatening arrythmias may persist with ongoing risk of death. Furthermore, ICDs do not prevent the progression to end-stage heart failure. ICD firings, although lifesaving, are physically and emotionally traumatic events. Patients whose condition progresses to end-stage heart failure are considered for cardiac transplantation which, while curative of underlying disease, is itself associated with significant morbidity and mortality. Hence there exists a high unmet medical need in this population. PKP2-ACM is estimated to have a prevalence of 50,000 patients in the U.S. and EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have one AAV program targeting PKP2-ACM, RP-A601, which is a recombinant AAVrh.74 vector expressing PKP2a. PKP2-ACM is typically caused by heterozygous pathogenic mutations in the PKP2 gene resulting in reduced PKP2 expression in the myocardium. A once-administered gene therapy that addresses the root cause of the disease (PKP2 deficiency) early in the disease course, could mitigate the early electrical remodeling and diminish the risk of life-threatening arrhythmias and SCD associated with ACM, potentially impeding the development of irreversible cardiac structural changes. Prevention of syncopal episodes, life-threatening arrythmias, SCD, ICD shocks and the resulting anxiety, discomfort and hospitalizations is anticipated to result in a vastly improved quality of life and survival benefit. Furthermore, such an approach could spare patients the need for lifelong adherence to multiple arrhythmia and heart failure drugs that are nonspecific for PKP2-ACM and are associated with their own side effects, enabling patients an opportunity to live without exercise restrictions and with diminished concern for arrhythmias, palpitations, ICD shocks and progression to end-stage heart failure.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we presented preclinical efficacy data for RP-A601 at the American Society of Gene and Cell Therapy 26th Annual meeting. Nonclinical studies of RP-A601 demonstrated efficacy in altering the natural history of PKP2-driven ACM. 100% of PKP2 conditional knockout (cKO) animals treated with the study drug exhibited extended survival to the longest timepoint measured (5 months), reduced cardiac dilation and fibrofatty replacement/fibrosis of the myocardium, preserved left ventricular function, and mitigation of the arrhythmic phenotype. Untreated PKP2 cKO mice had a median survival of approximately one month. These results were published in January 2024 in the journal Circulation: Genomic and Precision Medicine.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated a multi-center Phase 1 study for RP-A601. The multi-center Phase 1 dose escalation trial is evaluating the safety and preliminary efficacy of RP-A601 in adult PKP2-ACM patients with ICDs and overall high risk for arrhythmias. The study will assess the impact of RP-A601 on PKP2 myocardial protein expression, cardiac biomarkers, and clinical predictors of life-threatening ventricular arrhythmias and sudden cardiac death. Patients in the dose-escalation trial will receive a single dose of RP-A601. The starting dose will be 8 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8239;GC/kg.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Achieved Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, we announced receipt of FDA Fast Track and Orphan Drug Designations. In May 2024, we announced receipt of Orphan Medicinal Product Designation from the European Commission. Enrollment in the U.S. Phase 1 study is completed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BAG3 Dilated Cardiomyopathy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DCM is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. A familial association of DCM can be identified in 20-50% of DCM patients, with up to 40% of familial patients having an identifiable genetic cause. Mutations in the BAG3 gene (BCL-2-associated athanogene 3) are among the more common pathogenic genetic variants observed in familial DCM and these variants are highly penetrant, with approximately 80% of individuals with disease-causing genetic variants in the BAG3 gene developing DCM at &gt; 40 years of age. BAG3 protein is associated with a variety of cellular functions including cardiac contractility, protein quality control (as a co-chaperone), cardiomyocyte structural support and anti-apoptosis. BAG3 associated dilated cardiomyopathy (BAG3-DCM) leads to early onset, rapidly progressing heart failure and significant mortality and morbidity. We estimate that the prevalence of BAG3-associated DCM in the U.S. to be as many as 30,000 individuals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, DCM patients with a BAG3 mutation are treated with the standard of care for heart failure, which include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, neprilysin inhibitors, beta-adrenergic receptor antagonists, or beta-blockers, aldosterone antagonists and/or diuretics, along with certain lifestyle changes, and do not address the underlying cause of disease. Patients who meet specific parameters may also undergo placement of an implantable cardioverter defibrillator, a cardiac resynchronization device or a combination of the two. There is no current therapy directly targeting the underlying mechanism of BAG3 associated DCM, and patients diagnosed with BAG3 associated DCM appear to progress to end-stage heart failure and death more rapidly than patients with DCM not associated with BAG3 variants. For example, approximately 19% of patients with BAG3-DCM require mechanical cardiac support, heart transplant, or have heart failure related death at 12 months after diagnosis, nearly twice the rate of similarly staged non-BAG3-DCM patients.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, we completed our acquisition of Renovacor which provided the Company with Renovacor&#8217;s recombinant AAV9-based gene therapy program designed to deliver a fully functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes and slow or halt progression of BAG3-DCM. Initial proof of concept for AAV9-BAG3 has been demonstrated in studies of BAG3-knockout mouse models, which show treated mice have improved ejection fraction versus untreated knockout mice and comparable ejection fraction to walk test controls at timepoints 4- and 6-weeks post injection.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Achieved Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonclinical, IND-enabling studies are ongoing. Submission of the IND is anticipated in the first half of 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hematology Programs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Introduction to Hematology Programs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our hematology programs utilizes third-generation, self-inactivating LV to correct defects in patients&#8217; HSCs, which are the cells found in bone marrow capable of generating blood cells over a patient&#8217;s lifetime. Defects in the genetic coding of HSCs can result in severe, and potentially life-threatening anemia, when a patient&#8217;s blood lacks enough properly functioning red blood cells to carry oxygen throughout the body. Stem cell defects can also result in severe and potentially life-threatening decreases in white blood cells, which may result in susceptibility to infections, and in platelets responsible for blood clotting, which may result in severe and potentially life-threatening bleeding episodes.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fanconi Anemia Complementation Group A</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FA, a rare and life-threatening DNA-repair disorder, generally arises from a mutation in a single FA gene. Patients with FA have a genetic defect that prevents the normal repair of genes and chromosomes within blood cells in the bone marrow. An estimated 60% to 70% of cases arise from mutations in the FANCA gene, which is the focus of our program. FA frequently results in bone marrow failure, developmental abnormalities, acute myeloid leukemia, and other myeloid dysplastic syndrome types of blood cancers, often during the early years and decades of life. Bone marrow aplasia, which is bone marrow that no longer produces any or very few red and white blood cells and platelets leading to infections and bleeding, is the most frequent cause of early morbidity and mortality in FA, with a median onset before 10 years of age. Leukemia is the next most common cause of mortality, ultimately occurring in about 20% of patients later in life. Solid organ malignancies, such as head and neck cancers, can also occur, although at lower rates during the first two to three decades of life. The average lifespan of an FA patient is estimated to be 30 to 40 years. The prevalence of FA in the U.S. and EU is estimated to be approximately 4,000 patients in total.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although improvements in allogeneic (donor-mediated) HSCT, currently the most frequently utilized therapy for FA, have resulted in frequent hematologic correction of the disorder, HSCT is associated with both acute and long-term risks, including transplant-related mortality, graft failure, and graft versus host disease, a sometimes fatal side effect of allogeneic transplant characterized by painful ulcers in the GI tract, liver toxicity and skin rashes, as well as increased risk of subsequent cancers. Our gene therapy program in FA is designed to enable a minimally toxic hematologic correction using a patient&#8217;s own stem cells early in the disease course and administered without conditioning. We believe that the development of a broadly applicable autologous gene therapy can be transformative for these patients. In light of the efficacy seen in non-conditioned patients, the addressable annual market opportunity is now believed to be 400 to 500 patients collectively in the U.S. and EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have one </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> LV-based program targeting FA, RP-L102. Our Phase 2 registrational enabling clinical trials treating FA patients with RP-L102 at the Center for Definitive and Curative Medicine at Stanford University School of Medicine, Great Ormond Street Hospital in London and Hospital Infantil de Nino Jesus in Spain has completed treatment. The trial has treated a total of 12 patients from the U.S. and EU. Two additional patients were treated in the U.S. Phase 1 study at Stanford such that a total of 14 patients have received RP-L102 on Rocket-sponsored clinical trials. Patients received a single intravenous infusion of RP-L102 that utilizes fresh cells and an improved process which incorporates a modified stem cell enrichment process, transduction enhancers, as well as commercial-grade vector and final drug product.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resistance to mitomycin-C, a DNA damaging agent, in bone marrow stem cells at a minimum time point of one year post treatment is the primary endpoint for our ongoing Phase 2 study. Per agreement with the FDA and EMA, engraftment leading to bone marrow restoration exceeding a 10% mitomycin-C resistance threshold could support a marketing application for approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we presented updated clinical data for RP-L102 at the ASGCT 26th Annual Meeting. As of the data cut-off (April 17, 2023), RP-L102 conferred sustained genetic correction in 8 of 12 evaluable patients and comprehensive phenotypic correction in 7 of 12 evaluable patients with &#8805;12 months of follow up as demonstrated by increased resistance to mitomycin-C in bone marrow-derived colony forming cells and hematologic stabilization. The safety profile of RP-L102 has been highly favorable, and the treatment, administered without any cytotoxic conditioning, has been well tolerated. No signs of bone marrow dysplasia, clonal dominance or insertional mutagenesis related to RP-L102 have been observed. Polyclonal integration patterns have been observed in each of the seven patients with phenotypic, genetic, and hematologic evidence of engraftment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we provided an incremental clinical update at the ASGCT 27th Annual Meeting (data cut-off September 11, 2023). RP-L102 continued to demonstrate sustained genetic correction, phenotypic correction, and hematologic stability in 8 of 12 patients with greater than 12 months of follow-up. RP-L102 continued to be well tolerated with no significant safety signals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anticipated Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pivotal trial enrollment and treatment have been completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 2, 2024, we announced that the EMA accepted our MAA for RP-L102. Submission of a BLA on a rolling review basis was initiated on September 26, 2024.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LAD-I is a rare autosomal recessive disorder of white blood cell adhesion and migration, resulting from mutations in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ITGB2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene encoding for the Beta-2 Integrin component, CD18. Deficiencies in CD18 result in an impaired ability for neutrophils (a subset of infection-fighting white blood cells) to leave blood vessels and enter tissues where these cells are needed to combat infections. As is the case with many rare diseases, accurate estimates of incidence are difficult to confirm&#894; however, several hundred cases across the spectrum of severity have been reported to date. Most LAD-I patients are believed to have the severe form of the disease. Severe LAD-I is notable for recurrent, life-threatening infections and substantial infant mortality in patients who do not receive an allogeneic HSCT. Mortality for severe LAD-I has been reported as 60 to 75% by age two in the absence of allogeneic HCST.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have one </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> program targeting LAD-I, RP-L201. UCLA and its Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research served as the lead U.S. clinical research center, and Hospital Infantil Universitario Ni&#241;o Jes&#250;s (HNJ) and Great Ormond Street Hospital (GOSH) served as the lead clinical sites in Spain and United Kingdom, respectively for the global registrational clinical trial for LAD-I. This study has received a $5.9 million CLIN2 grant award from the CIRM to support the clinical development of gene therapy for LAD-I.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The open-label, single-arm, Phase 1/2 registration-enabling clinical trial of RP-L201 has treated 9 severe LAD-I patients to assess the safety and tolerability of RP-L201. The first patient was treated at UCLA with RP-L201 in the third quarter of 2019. Enrollment is complete in both the Phase 1 and 2 portions of the study.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we presented additional follow-up data at the ASGCT 27th Annual Meeting, which included 18-45 month follow-up data (data cut-off July 24, 2023). We continued to observe 100% survival in the absence of allogeneic transplant, and all patients enrolled at less than 12 months of age had surpassed 24 months without allogeneic transplant. When compared with pre-treatment history, data showed substantial decreases in the incidences of significant infections requiring hospitalization or intravenous antimicrobials, combined with evidence of resolution of LAD-I-related skin and periodontal lesions and restoration of wound repair capabilities. Furthermore, RP-L201 continued to be well tolerated with no new safety events related to the treatment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Achieved and Anticipated Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A BLA filing for RP-L201 was accepted by the FDA with priority review in September 2023 with an initial Prescription Drug User Fee Act date of March 31, 2024. In February 2024, the review time was extended by three months, to June 30, 2024, to allow additional time to review clarifying CMC information submitted by us in response to FDA information requests. In June 2024, we announced that the FDA issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Red blood cell PKD is a rare autosomal recessive disorder resulting from mutations in the pyruvate kinase L/R gene encoding for a component of the red blood cell glycolytic pathway. PKD is characterized by chronic non-spherocytic hemolytic anemia, a disorder in which RBCs do not assume a normal spherical shape and are broken down, leading to decreased ability to carry oxygen to cells, with anemia severity that can range from mild (asymptomatic) to severe forms that may result in childhood mortality or a requirement for frequent, lifelong RBC transfusions. The pediatric population is the most commonly and severely affected subgroup of patients with PKD, and PKD often results in splenomegaly (abnormal enlargement of the spleen), jaundice and chronic iron overload which is likely the result of both chronic hemolysis and the RBC transfusions used to treat the disease. The variability in anemia severity is believed to arise in part from the large number of diverse mutations that may affect the pyruvate kinase L/R gene. Estimates of disease incidence have ranged between 3.2 and 51 cases per million in the white U.S. and EU population. Industry estimates suggest at least 2,500 cases in the U.S. and EU have already been diagnosed. Market research indicates the application of gene therapy to broader populations could increase the market opportunity from approximately 250 to 500 patients per year.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have one clinical stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> LV-based program targeting PKD, RP-L301.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting a global Phase 1 open-label, single-arm, clinical study with 2 adult patients and 2 pediatric patients (age 8-17) currently enrolled in the U.S. and Europe for assessing the safety, tolerability, and preliminary activity of RP-L301. Stanford serves as the lead site in the U.S. for adult and pediatric patients, HNJ serves as the lead site in Europe for pediatrics, and Hospital Universitario Fundaci&#243;n Jim&#233;nez D&#237;az serves as the lead site in Europe for adult patients. Both adult and pediatric enrollment is completed in the Phase 1 study.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we presented positive updated clinical data at the ASGCT 26th Annual Meeting (data cut-off May 3, 2023), which included up to 30 months of follow-up from the two treated adult patients and early clinical data from the first pediatric patient treated with RP-L301. Robust and sustained efficacy was observed in both adult patients at up to 30 months post-infusion evidenced by normalized hemoglobin (from baseline pre-treatment levels in the 7.0-7.5 g/dL range), improved hemolysis parameters, and red blood cell transfusion independence. Furthermore, both adult patients reported improved quality of life with documented improvements via formal quality of life assessments. The safety profile continues to appear highly favorable, with no RP-L301-related serious adverse events in either of the adult patients. Insertion site analyses in peripheral blood and bone marrow in both adult patients through 24 months post-RP-L301 demonstrated highly polyclonal patterns and there has been no evidence of insertional mutagenesis. The first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, hospital discharge less than one month following infusion, no RP-L301 related serious adverse events and early signs of efficacy. There were no red blood cell transfusion requirements following engraftment. Both adult and pediatric enrollment is completed in the Phase 1 study.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we presented further clinical updates at the ASGCT 27th Annual Meeting (data cut-off February 5, 2024), which included 36 months of follow-up on the two adult patients and 12 months of follow-up on the two pediatric patients. Sustained and clinically meaningful hemoglobin improvement was observed in all patients including hemoglobin normalization in three of four patients. No patients have required red blood cell transfusion following neutrophil engraftment. Improvements in hemoglobin supported by improved markers of hemolysis and quality of life have been observed. RP-L301 remains well-tolerated, with no drug-related serious adverse events. Insertion site analyses in the peripheral blood and bone marrow for both adult patients through 36 months post-RP-L301 continued to demonstrate highly polyclonal patterns with no clonal dominance or insertional mutagenesis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Achieved Milestones</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we announced receipt of FDA RMAT designation and in August 2023, we announced EMA PRIME designation for RP-L301 based on the robust efficacy observed in the Phase 1 treated patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have reached agreement with FDA on study design of Phase 2 pivotal trial of RP-L301. Based on positive safety and efficacy data from the Phase 1 study, we have aligned with the FDA on the pivotal study design to support accelerated approval with a 10-patient, single-arm Phase 2 pivotal trial with a primary endpoint of &#8805;1.5 point Hgb improvement at 12 months.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">cGMP Manufacturing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a 103,720 square foot manufacturing facility located in Cranbury, New Jersey. This facility supports clinical development of our growing pipeline of LV and AAV gene therapies from discovery through pivotal trials, with space for potential future expansion and commercialization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Opportunities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the programs specified in this Annual Report, we are also conducting exploratory preclinical research and development to expand potential applications of proprietary LV and/or AAV program platforms. Research focus areas include the development of new candidates for the treatment of additional monogenic rare genetic diseases.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy that may be important for the development of our business. We additionally intend to rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity, and patent term extensions where available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing its future products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and in-licensed numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of gene therapy products. Our proprietary intellectual property, including patent and non-patent intellectual property, is generally directed to gene expression vectors and methods of using the same for gene therapy. As of February 21, 2025, our patent portfolio includes both owned and in-licensed patent families relating to our product candidates and related technologies, discussed more fully below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fanconi Anemia</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our FA patent portfolio includes granted patents in Australia, Japan, South Korea, and Russia and pending applications in the U.S., Europe, Japan, China and other countries with claims directed to polynucleotide cassettes and expression vector compositions containing FA complementation group genes and methods for using such vectors to provide gene therapy in mammalian cells for treating FA. These applications were exclusively in-licensed from CIEMAT, CIBER, FIISFJD, and FIBHNJS. We expect any patents in this family, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2037, absent any patent term adjustments or extensions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our PKD patent portfolio includes granted patents in Europe, China, Hong Kong, Japan, Mexico, South Korea, Australia, India, Russia, Singapore, and the U.S. and pending patent applications in the U.S., Europe, Japan, China and other countries with claims directed to polynucleotide cassettes and expression vector compositions containing pyruvate kinase genes and methods for using such vectors to provide gene therapy in mammalian cells for treating pyruvate kinase deficiency. These applications are exclusively in-licensed from CIEMAT, CIBER, and FIISFJD. We expect any patents in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2037-2038, absent any patent term adjustments or extensions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Danon Disease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our DD patent portfolio includes both proprietary intellectual property and a patent family in-licensed from the University of California, San Diego, which includes granted patents in Europe, India, the U.S., and Hong Kong, allowed patent applications in Japan and Russia, and pending patent applications in the U.S., Europe, Japan, China and other countries with claims directed to the treatment of DD. We expect any patents in this portfolio, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2037 absent any patent term adjustments or extensions. We also own granted patents in the U.S. and Russia and pending patent applications in the U.S., Europe, Japan, China and other countries with claims directed to gene therapy vectors for the treatment of DD; the U.S. patent issued in 2020. Any patents, if issued, arising from these patent applications, are expected to expire in 2039, absent any patent term adjustments or extensions, if the appropriate maintenance, renewal, annuity, or other governmental fees are paid. We have also filed additional patent applications directed to methods for treatment of DD. Any patents, if issued, arising from these patent applications, are expected to expire in 2040-2041, absent any patent term adjustments or extensions, if the appropriate maintenance, renewal, annuity, or other governmental fees are paid.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio includes a granted patent in Russian and pending patent applications in the U.S., EU, Japan, China and other countries with claims directed to transduction of allogeneic HSCT, which may be relevant to our LAD-I program. We expect any patents arising from these patent applications, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire in 2039, absent any patent term adjustments or extensions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Objectives</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our objective is to continue to expand our portfolio of patents and patent applications in order to protect our gene therapy product candidates and manufacturing processes. From time to time, we may also evaluate opportunities to sublicense our portfolio of patents and patent applications that we own or exclusively license, and we may enter into such licenses from time to time. The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing the non-provisional application. In the U.S., a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration of a U.S. patent as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug was under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. When possible, depending upon the length of clinical trials and other factors involved in the filing of a BLA, we expect to apply for patent term extensions for patents covering our product candidates and their methods of use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and third parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of its premises and physical and electronic security of its information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 12, 2023, the Company filed an action in the U.S. District Court for the Southern District of New York against Lexeo Therapeutics, Inc., Kenneth Law, and Sonia Gutierrez, Case No. 23-cv-9000 (PKC). The Company asserted claims for trade secret misappropriation, breach of contract, tortious interference with contract, and unjust enrichment. The defendants have moved to dismiss all claims. The Court denied the motions to dismiss as to the trade secret misappropriation, breach of contract, and tortious interference with contract claims.  On August 28, 2024, Lexeo Therapeutics, Inc. asserted counterclaims against the Company for trade secret misappropriation, breach of contract, correction of inventorship, and tortious interference with contract. The Court has not set a trial date. The Company intends to vigorously pursue this action and vigorously defend against all counterclaims.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 31, 2024, the Company filed an action in the U.S. District Court for the District of Oregon against Brian C. Beard and Little Whiskers, LLC, Case No. 3:24-cv-02170-SI.  The Company asserted claims for trade secret misappropriation and breach of contract. The Company intends to vigorously pursue this action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Contracts</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements for PKD with CIEMAT Group</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, we entered into a license agreement with CIEMAT Group, granting us worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human PKLR gene solely within the field of treating PKD. Under the terms of the agreement, we are obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least two uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, we are obligated to pay CIEMAT Group an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. We are responsible for prosecuting and maintaining the licensed patents at our expense, in cooperation with CIEMAT Group. We also have the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT. For five years following the effective date of the license agreement, we had a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group at market value. We are obligated to license (without charge) to CIEMAT Group for non-commercial use any improvements to the licensed intellectual property that we create.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, we paid CIEMAT Group an initial upfront license fee of &#8364;0.03 million (approximately $0.03 million) which was expensed as research and development costs. We are obligated to make aggregate milestone payments of up to &#8364;1.4 million (approximately $1.5 million) to CIEMAT Group upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the PKD license, we are obligated to pay a low to mid-single digit percentage royalty on net sales, subject to specified adjustments, by us or our sublicensees or affiliates. In the event that we enter into a sublicense agreement with a sublicensee, we will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate this agreement at any time by providing CIEMAT Group with 90 days advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for FA with CIEMAT Group and FIBHNJS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2016, we entered into a license agreement with CIEMAT Group and FIBHNJS granting us worldwide, exclusive rights to certain patents, know-how, data and other intellectual property relating to LVs containing the FANCA gene solely within the field of human therapeutic uses of VSV-G packaged integration component LVs for FA type-A gene therapy. This license is only sublicensable with the prior consent of CIEMAT Group and FIBHNJS, not to be unreasonably withheld. Under the terms of the agreement, we are obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least two uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, we are obligated to pay CIEMAT Group and FIBHNJS an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, regulatory and financing milestone payments, and sublicense revenue payments. We are responsible for prosecuting and maintaining the licensed patents at our expense, in cooperation with CIEMAT Group and FIBHNJS. We also have the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group and FIBHNJS. For five years following the effective date of the license agreement, we have a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group and FIBHNJS at market value. We are obligated to license (without charge) any improvements to the licensed intellectual property that we create to CIEMAT Group and FIBHNJS for non-commercial use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, we paid CIEMAT Group and FIBHNJS an initial upfront license fee of &#8364;0.1 million (approximately $0.1 million), which was expensed as R&amp;D costs. We are obligated to make aggregate milestone payments of up to &#8364;5.0 million (approximately $5.5 million) to CIEMAT Group and FIBHNJS upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the license, we are obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by us or our sublicensees or affiliates. In the event that we enter into a sublicense agreement with a sublicensee, we will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate this agreement at any time by providing CIEMAT Group and FIBHNJS with 90 days&#8217; advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for LAD-I with CIEMAT Group and UCLB</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into a license agreement in November 2017, effective September 2017, with CIEMAT Group and UCLB, &#8220;Licensors&#8221;), granting us worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human LAD-I gene solely within the field of treating LAD-I. Under the terms of the agreement, we are obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least two uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, we are obligated to pay Licensors an up-front payment, royalty payments in the mid-single digit percentages based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. We are responsible for prosecuting and maintaining the licensed patents at our expense, in cooperation with Licensors. We also have the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with Licensors. For five years following the effective date of the license agreement, we have a right of first refusal to license any improvements to the licensed intellectual property obtained by Licensors at market value. We are obligated to license (without charge) any improvements to the licensed intellectual property that we create to Licensors for non-commercial use.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, we paid Licensors an initial upfront license fee of &#8364;0.03 million (approximately $0.04 million), which was expensed as research and development costs. We are obligated to make aggregate payments of up to &#8364;1.4 million (approximately $1.5 million) to Licensors upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the LAD-I license, we are obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by us or our sublicensees or affiliates. In the event that we enter into a sublicense agreement with a sublicensee, we will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may terminate this agreement at any time by providing Licensors with 90 days advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for DD with UCSD</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2017, we entered into a license agreement with The Regents of the University of California, represented by its San Diego campus, under which UCSD granted us an exclusive, sublicensable, worldwide license to certain intellectual property rights for the treatment of lysosomal storage diseases, including DD. In exchange for the license, we became obligated to make an up-front payment, certain clinical and commercial milestone payments, royalty payments (on net sales of products covered by a valid claim within the licensed intellectual property), maintenance fees and sublicense revenue payments. We paid an upfront license fee of $0.05 million and are obligated to make aggregate milestone payments of up to $1.5 million to UCSD upon the achievement of specified development and regulatory milestones for the treatment of DD. A reduced schedule of milestone payments applies to achieving the same milestones for additional indications. With respect to any commercialized products covered by the agreement, we are obligated to pay a low single digit percentage royalty on net sales, subject to specified adjustments. If we enter into a sublicense agreement with a sublicensee, we will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances. We are also subject to certain diligence milestones for development of a product using the intellectual property licensed from UCSD under this agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the license agreement with UCSD is through the expiration of the licensed patents, some of which are still in the pending application phase.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for DD with RGNX</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2018, we entered into a license agreement with RGNX, pursuant to which we obtained an exclusive license for all U.S. patents and patent applications related to RGNX&#8217;s NAV AAV-9 vector for the treatment of DD in humans by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene therapy using AAV-9 to deliver any known LAMP2 transgene isoforms and all possible combinations of LAMP2 transgene isoforms, as well as an exclusive option to license all U.S. patents and patent applications for two additional NAV AAV vectors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted to us under the license agreement, we made an upfront payment to RGNX of $7.0 million which was expensed to research and development costs in the 2018 consolidated statement of operations. A fee of $2.0 million per additional vector would be due if we exercise our option right to purchase additional vectors. The license agreement provides for royalties payable to RGNX in the high-single digits to low-teens on net sales levels of licensed products incorporating the licensed patents during the royalty term. If successful, we will be required to make milestone payments to RGNX of up to $13.0 million for each licensed product upon the achievement of specified clinical development and regulatory milestones in the U.S. and EU. In addition, we shall pay RGNX 20% of the payment fees received from a priority review voucher issued in connection with or otherwise related to a licensed product. These royalty obligations are subject to specified reductions if additional licenses from third parties are required. We must also pay RGNX a portion of all non-royalty sublicense income (if any) received from sublicensees. We paid a $1.0 million license fee payment under the RGNX agreement upon the dosing of the first DD patient in 2019 and a $2.0 million license fee payment upon initiation of a Phase 2 pivotal trial in 2023. There were no additional milestones achieved or related payments made during the years ended December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for BAG3 with Temple University</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 1, 2022, we acquired Renovacor, including a license agreement for BAG3 with Temple University. The license agreement provides for royalties payable to Temple University in the low-single digits on net sales of licensed products during the royalty term. If successful, we will be required to make milestone payments to Temple University of up to $19.25 million upon achievement of specific clinical development and regulatory milestones.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2022, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;), with Cowen with respect to an at-the-market offering program pursuant to which we could offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.01 per share, having an aggregate offering price of up to $200 million through Cowen as our sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024 after three years in accordance with the Commission&#8217;s rules. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to us. We may consider reactivating the at-the-market offering program in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sold a total of 4.2 million shares under the at-the-market offering program for gross proceeds of $65.8 million, less commissions of $2.0 million, for net proceeds of $63.8 million. We did not sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023, we sold 0.9 million shares for gross proceeds of $17.8 million, less commissions of approximately $0.6 million, for net proceeds of $17.2 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries, including in the field of gene therapy, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products and novel therapies. While we believe that our experience and scientific knowledge provides us with competitive advantages, we face potential competition from many different sources, including larger and better-funded pharmaceutical and biotechnology companies, new market entrants and new technologies, as well as from academic institutions, government agencies and private and public research institutions, which may in the future develop products to treat the indications targeted by our pipeline that have not yet been conceived. Any product candidates that we successfully develop and commercialize will compete with existing therapies such as bone marrow transplantation and new therapies that may become available in the future. We believe that the key competitive factors affecting the success of our product candidates, if approved, are likely to be efficacy, safety, convenience, price, pharmaco-economic value, tolerability and the availability of coverage and adequate reimbursement from governmental authorities and other third-party payors. In addition, we intend to develop single treatment curative therapies for clinical indications that address mortality or high morbidity, which could differentiate us from potential competitors developing alternative competitive therapies that may require chronic or repetitive treatment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other early-stage companies may also compete through collaborative arrangements with large and established companies. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of companies developing gene therapies. These companies also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will face intense and increasing competition as new drugs and therapeutic modalities enter the market and advanced technologies become available. Our commercial opportunity could be reduced or eliminated if our potential competitors develop and commercialize products that are safer, more effective, have fewer adverse effects, are more convenient or are less expensive than any products that we may develop. Our potential competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our gene therapy platform has two main components: the production of LV and AAV vectors and the target cell transduction process, which results in drug product. We commenced GMP manufacturing at our facility in Cranbury, New Jersey in 2022. We plan to supplement our own direct manufacturing capabilities with third-party manufacturers for our AAV programs. For our LV programs, we currently rely on third-party manufacturers to produce the plasmids, vectors, cell banks and final drug product for our clinical trials. We manage such production with our vendors on a purchase order basis in accordance with applicable master service and supply agreements. We have long-term agreements with these manufacturers. Whenever possible, we procure materials from redundant and multiple sources to mitigate risk. If any of our existing third-party suppliers should become unavailable to us for any reason, we believe that there are a number of potential replacements, although we might experience a delay in our ability to obtain alternative suppliers. We also do not have any current contractual relationships for the manufacture of commercial supplies of our product candidates if they become registered. With respect to commercial production of our product candidates in the future, we plan to pursue multiple options including direct manufacturing as well as outsourcing production of the active pharmaceutical (drug substance) ingredients and final drug product manufacturing (drug product) to contract manufacturing organizations if these products are approved and registered for marketing authorization by the applicable regulatory bodies.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to develop drug candidates that can be produced in a cost-effective manner through direct manufacturing or at contract manufacturing facilities. Should a supplier or manufacturer on which we have relied to produce a product candidate provide us with a faulty product or such product is later recalled, or should we experience such problems for our own products produced through direct manufacturing, we would likely experience delays and additional costs, each of which could be significant.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Regulation and Marketing Approval</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, and biologics under the Public Health Service Act, the regulations promulgated under both laws and other federal, state, and local statutes and regulations. Failure to comply with the applicable U.S. regulatory requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions and non-approval of product candidates. These sanctions could include, among other things, the imposition by the FDA of a clinical hold on trials, the FDA&#8217;s refusal to approve pending applications or related supplements, withdrawal of an approval, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, restitution, disgorgement, civil penalties, or criminal prosecution. Such actions by government agencies could also require us to expend a large amount of resources to respond to the actions. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, approval, manufacture, distribution and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate R&amp;D activities and the testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, post-approval monitoring, advertising, promotion, sampling and import and export of our products. Our drug candidates must be approved by the FDA as biologics through the BLA approval process applicable to gene therapy product candidates, before they may be legally marketed in the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the FDA, the FDA&#8217;s Center for Biologics Evaluation and Research regulates gene therapy products and has published guidance documents with respect to the development of these types of products. The FDA also has published guidance documents related to, among other things, gene therapy products in general, their preclinical assessment, observing subjects involved in gene therapy studies for delayed adverse events, potency testing, and chemistry, manufacturing and control information in gene therapy INDs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a biologic may be marketed in the U.S. generally involves the following:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to GLP, or other applicable regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission of an IND, which allows clinical trials to begin unless FDA objects within 30 days;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug or biologic for its intended use or uses conducted in accordance with FDA regulations and Good Clinical Practices, which are international ethical and scientific quality standards meant to ensure that the rights, safety and well-being of trial participants are protected, and that the integrity of the data is maintained;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation and submission to the FDA of a BLA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission of a user fee for FDA review of the BLA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of pre-approval inspection of manufacturing facilities and clinical trial sites at which the product, or components thereof, are produced to assess compliance with cGMP requirements, and if applicable, the FDA&#8217;s cGTP requirements, and of selected clinical trial sites to assess compliance with GCP requirements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA approval of a BLA which must occur before a biologic can be marketed or sold.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data, or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IND and Clinical Trials</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Prior to commencing the first clinical trial, an initial IND, which contains the results of preclinical testing along with other information, such as information about product chemistry, manufacturing and controls and a proposed protocol, must be submitted to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA within the 30-day time period raises concerns or questions about the drug product or the conduct of the clinical trial and imposes a clinical hold. A clinical hold may also be imposed at any time while the IND is in effect. In such a case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin or re-commence. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence or continue.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the U.S., certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, as set forth in the National Institutes for Health Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA or IND so long as the clinical trial is conducted in compliance with GCP, and the FDA is able to validate the data from the study through an onsite inspection if the agency deems it necessary.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A separate submission to the existing IND must be made for each successive clinical trial to be conducted during product development. Further, an independent Institutional Review Board for each site at which the clinical trial will be conducted must review and approve the clinical trial before it commences at that site. Informed written consent must also be obtained from each trial subject. Regulatory authorities, including the FDA, or Institutional Review Board, or the sponsor, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk or that the clinical trial is not being conducted in accordance with FDA requirements. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access to certain data from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials for BLA approval typically involve a three-phase process, although some phases may overlap or be combined. Phase 1, the initial clinical evaluations, consists of administering the drug and testing for safety and tolerated dosages and in some indications such as rare disease, as preliminary evidence of efficacy in humans. Phase 2 involves a study to evaluate the effectiveness of the drug for a particular indication and to determine optimal dosage and dose interval and to identify possible adverse side effects and risks in a larger patient group. When a product is found safe, and initial efficacy is established in Phase 2, it is then evaluated in Phase 3 clinical trials. Phase 3 trials consist of expanded multi-location testing for efficacy and safety to evaluate the overall benefit-to-risk index of the investigational drug in relationship to the disease treated. The results of preclinical and human clinical testing are submitted to the FDA in the form of a BLA for approval to commence commercial sales.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All clinical trials must be conducted in accordance with FDA regulations, GCP requirements and their protocols in order for the data to be considered reliable for regulatory purposes. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period of time and impose costly procedures upon our activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure of Clinical Trial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved up to a maximum of two years. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The BLA Approval Process</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to obtain approval to market a drug in the U.S., a marketing application must be submitted to the FDA that provides data establishing to the FDA&#8217;s satisfaction the safety and effectiveness of the investigational drug for the proposed indication. The application includes all relevant data available from pertinent non-clinical or preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators that meet GCP requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the End-of-Phase 1 or 2, and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice and for the sponsor and the FDA to reach agreement on the next phase of development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of product development, non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product for its intended indication. The FDA reviews all BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept a BLA for filing. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. The FDA has 60 days from its receipt of a BLA to conduct an initial review to determine whether the application will be accepted for filing based on the Agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA reviews a BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA has agreed to specific performance goals on the review of BLAs. Specifically, FDA under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, as amended, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process may be extended by the FDA for three additional months to consider certain late-submitted information or information intended to clarify information already provided in the submission. After the FDA completes its substantive review of a BLA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate that the BLA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, non-clinical or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability of the application or the timing of any such approval, if ever. If or when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA may issue an approval letter. FDA has committed to reviewing such resubmissions in two to six months depending on the type of information included. The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA may inspect one or more clinical sites to assure compliance with GCP. For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with the cGTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the cGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through appropriate screening and testing. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the BLA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 or post-approval trials may be made a condition to be satisfied for continuing drug approval. The results of Phase 4 trials can confirm the effectiveness of a product candidate and can provide important safety information. In addition, the FDA has authority to require sponsors to conduct post-marketing trials to specifically address safety issues identified by the agency. See &#8220;Post-Marketing Requirements&#8221; below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also has authority to require a REMS, from manufacturers to ensure that the benefits of a drug outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the BLA submission. The need for a REMS is determined as part of the review of the BLA. Based on statutory standards, elements of a REMS may include &#8220;Dear Doctor letters,&#8221; a medication guide, more elaborate targeted educational programs, and in some cases distribution and use restrictions, referred to as elements to assure safe use. Elements to assure safe use can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. These elements are negotiated as part of the BLA approval, and in some cases the approval date may be delayed. Once adopted, REMS are subject to periodic assessment and modification.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution or use, or post-marketing trial requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product, including safety labeling or imposition of a REMS, the requirement to conduct post-market studies or clinical trials or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for our products, or obtaining approval but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign governmental action.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Hatch-Waxman Amendments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, a portion of a product&#8217;s U.S. patent term that was lost during clinical development and regulatory review by the FDA may be restored by returning up to five years of patent life for a patent that covers a new product or its use. This period is generally one-half the time between the effective date of an IND (falling after issuance of the patent) and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, provided that the sponsor acted with diligence. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended and the extension must be applied for prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Exclusivity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Affordable Care Act, or ACA, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-approved reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reference biological product is granted four and twelve year exclusivity periods from the time of first licensure of the product. FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four (4) years after the date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was approved in the U.S. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously approved product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Orphan Drug Act, FDA may designate a biologic product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the U.S., or more in cases in which there is no reasonable expectation that the cost of developing and making a biologic product available in the U.S. for treatment of the disease or condition will be recovered from sales of the product). Orphan product designation must be requested before submitting a BLA. After FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by FDA. Orphan product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, meaning that FDA may not approve any other applications to market the same drug or biologic product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval of different products for the same indication than that for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan medicinal product status in the EU has similar, but not identical, benefits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the U.S. and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rare Pediatric Disease Designation and Priority Review Vouchers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, the FDA incentivizes the development of drugs and biological products that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the U.S. or affects more than 200,000 in the U.S. and for which there is no reasonable expectation that the cost of developing and making in the U.S. a drug or biological product for such disease or condition will be received from sales in the U.S. of such drug or biological product. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biological product application after the date of approval of the rare pediatric disease drug or biological product, referred to as a priority review voucher. A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a priority review voucher upon approval of its BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a priority review voucher upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a priority review voucher is received, it may be sold or transferred an unlimited number of times. The rare pediatric disease priority review voucher statutory provision expired on December 20, 2024 and, unless extended by Congress, priority review vouchers may only be granted to BLAs that received a rare pediatric disease designation no later than December 20, 2024 and that are approved no later than September 30, 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA is authorized to expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a biologic product candidate may request FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Biologic products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with FDA, FDA may initiate review of sections of a Fast Track BLA before the application is complete, a process known as rolling review.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product submitted to FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as regenerative medicine advanced therapy designation, priority review and accelerated approval. To qualify for RMAT designation, the product candidate must be a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations; is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such disease or condition. A gene therapy product may meet the definition of a regenerative medicine therapy for purposes of RMAT designation. A BLA for a product candidate that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A product candidate with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical studies, patient registries, or other sources of real-world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate including one that received Fast Track or RMAT designation is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition compared to available therapies. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a biologic product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials intended for dissemination or publication within 120 days of marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Marketing Requirements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling, or off-label use, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. Although physicians may, in their independent professional medical judgment, prescribe legally available drugs for off-label uses, manufacturers typically may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, who may or may not grant approval or may include a lengthy review process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prescription drug advertising is subject to federal, state, and foreign regulations. In the U.S., the FDA regulates prescription drug promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the U.S. Drug Supply Chain Security Act and the Prescription Drug Marketing Act, both of which are part of the FDCA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., once a product is approved, its manufacturing is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Additionally, manufacturers and other parties involved in the supply chain for prescription drug products must also comply with product tracking and tracing requirements and notify the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the U.S. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such product or may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall, withdrawal of the product from the market, or refusal of importation. In addition, the manufacturer and/or holder of an approved BLA are subject to annual product and establishment fees. These fees are typically increased annually.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require post-marketing testing, also known as Phase 4 testing, to monitor the effects of an approved product or place conditions on an approval via a REMS that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, withdrawal of approval, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and may also require the implementation of other risk management measures. New government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government healthcare program administrative authorities, managed care organizations, private health insurers, and other entities. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our products. Therefore, our products, once approved, may not obtain market acceptance unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our products.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, or otherwise subject it to a health technology assessment. In either case, payer coverage rules might exclude certain FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular drug product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The containment of healthcare costs has become a priority of federal, state, and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for drug products and medical services, examining the medical necessity, and reviewing the cost effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Recovery and Reinvestment Act of 2009 provided funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our product candidates, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our product candidates, once approved. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be significantly lower.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-Kickback and False Claims Laws and Other Regulatory Matters</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., among other things, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation and enforcement by various federal, state and local authorities in addition to the FDA, including the Department of Justice, Centers for Medicare &amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, state Attorneys General and other state and local government agencies. Our current and future business activities, including for example, sales, marketing, and scientific/educational grant programs must comply with healthcare regulatory laws, as applicable, which may include the Federal Anti-Kickback Statute, the Federal False Claims Act, as amended, the privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act, as amended, physician payment transparency laws, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended, which requires special pricing to both the Veterans Administration and other Federal agencies, as well as to certain safety net providers, referred to as 340B covered entities. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully, directly or indirectly, in cash or in kind, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of, any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the intent standard under the Federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care Education and Reconciliation Act (collectively, the &#8220;ACA&#8221;), to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the Federal False Claims Act. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, many states have adopted laws similar to the Federal Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth of these federal and state anti-kickback laws, and the potential for additional legal or regulatory change in this area, it is possible that our future business activities, including our sales and marketing practices and/or our future relationships with physicians and the medical community might be challenged under anti-kickback laws, which could harm us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal false claims and false statement laws, including the civil False Claims Act, prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent. Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, knowingly providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been found liable under the Federal Civil False Claims Act in connection with their off-label promotion of drugs. Penalties for a civil False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the Federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the Federal Civil False Claims Act and certain states have enacted laws modeled after the Federal False Claims Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. For example, there are federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs. In addition, as discussed below, a similar federal requirement under the Physician Payments Sunshine Act, requires certain manufacturers to track and report to the federal government certain payments provided to physicians and teaching hospitals made in the previous calendar year, as well as certain ownership and investment interests held by physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and their immediate family members. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities. Effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, imposes specified requirements relating to the privacy, security, and transmission of individually identifiable health information on certain types of individuals and organizations. Although we will not likely be a &#8220;covered entity&#8221; under this law, our customers may require us to become a &#8220;business associate&#8221; to them for various purposes, which will require that we make ourselves amenable to lawsuits for any data breaches we may incur. In addition, certain state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other and from HIPAA in significant ways and may not have the same effect, thus complicating compliance efforts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with regulatory requirements subjects us to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, refusal to allow us to enter into supply contracts, including government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the law and program requirements to which we will or may become subject because we intend to commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs. However, we cannot guarantee that this program will work effectively with respect to every federal and state law at each and every moment where such compliance is necessary.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in law or the interpretation of existing law could impact our business in the future by requiring, for example: (i) changes to our manufacturing or sales arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; (iv) increases in our governmental rebate liability; or (v) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Legislative Reform</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D (which ended December 31, 2024); and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for deficit reduction of at least $1.2 trillion for the years 2013 through 2021. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction, which triggered the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of, up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless Congress takes additional action. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional action is taken by Congress.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2032. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Trump administration may reverse or otherwise change these measures, President Trump has not rescinded this executive order and both the Trump administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs and are examining legislative and executive proposals that would provide for a comprehensive overhaul of U.S. health care laws if enacted or implemented.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Most recently, on August 16, 2022, President Biden signed the Inflation Reduction Act which provides for (i) the government to set or negotiate prices for select high-cost Medicare Part D (beginning in 2026) and Medicare Part B drugs (beginning in 2028) that are more than nine years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval, (ii) manufacturers to pay a rebate for Medicare Part B and Part D drugs when prices increase faster than inflation beginning in 2022 for Medicare Part D and 2023 for Medicare Part B drugs, and (iii) Medicare Part D redesign which replaces the current coverage gap provisions and establishes a $2,000 cap for out-of-pocket limits costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for 10% of costs up to the $2,000 cap and 20% after that cap is reached. Implementation of the Inflation Reduction Act has occurred, but the results of its impact on the market for drugs, including our products, remains uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private third-party payors.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union Drug Review and Approval</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Approval</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, an applicant for authorization of a clinical trial must obtain prior approval from the national competent authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the relevant independent ethics committee has issued a favorable opinion in accordance with the laws of the Member State(s) concerned. In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022. It overhauls the system of approvals for clinical trials in the EU. Specifically, the new legislation, which is directly applicable in all EU Member States (meaning that no national implementing legislation in each EU Member State is required), aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure through the EU CTIS via a single-entry point (instead of submitting applications for a multi-jurisdictional trial with several sites separately to each national competent authority and ethics committee in the Member States in which the trial will be conducted) and strictly defined deadlines for the assessment of clinical trial applications. The Clinical Trials Regulation also makes it more efficient for EU Member States to evaluate and authorize applications together, via the EU CTIS portal.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transitory provisions of the new Clinical Trials Regulation offered sponsors the possibility to choose between the requirements of the previous Clinical Trials Directive and the Clinical Trials Regulation if the request for authorization of a clinical trial is submitted in the year after the new Clinical Trials Regulation became applicable i.e. until January 31, 2023. Since January 31, 2023, all applications need to be submitted under and in accordance with the Clinical Trial Regulation. If the sponsor chose to submit under the Clinical Trials Directive, the clinical trial continues to be governed by the Directive and the relevant implementing legislation in each EU Member State, as required, until three years after the new Clinical Trials Regulation became applicable. If a clinical trial continues for more than three years after the Clinical Trials Regulation became applicable, the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The implementation of the Clinical Trial Regulation may require us to take additional steps and procedures to ensure that our clinical trials comply with applicable laws.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, medicinal products can only be commercialized after obtaining a marketing authorization. There are two types of marketing authorizations: (1) the centralized authorization, which is issued by the European Commission through the centralized procedure based on the opinion of the Committee for Medicinal Products for Human Use, a body of the EMA, and which is valid throughout the entire territory of the European Economic Area, or EEA (comprising the EU Member States plus Norway, Iceland and Liechtenstein); and (2) national marketing authorizations, which is issued by the competent authorities of the Member States of the EU and only authorize marketing in that Member State&#8217;s national territory and not the EEA as a whole, including the harmonized issuance of marketing authorizations in several Member States upon the initial application (&#8220;Decentralized Procedure&#8221;) or subsequently after the issuance of the initial national marketing authorization (&#8220;Mutual Recognition Procedure&#8221;) in accordance with the procedures set forth in Regulation (EC) 1234/2008.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy medicinal products (i.e., gene-therapy, somatic cell-therapy, and tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific, or technical innovation or which are in the interest of public health. Gene therapy products are a type of advanced therapy medicinal product (&#8220;ATMP&#8221;) in the EU. The scientific evaluation of marketing authorization applications for ATMPs is primarily performed by the committee for advanced therapies (&#8220;CAT&#8221;), a committee of the European Medicines Agency (&#8220;EMA&#8221;). The CAT prepares a draft opinion on the quality, safety, and efficacy of the ATMP which is the subject of the marketing authorization application, which is sent for final approval to the CHMP. The CHMP recommendation is then sent to the European Commission, which adopts a decision binding in all EEA Member States. The maximum timeframe for the evaluation of a marketing authorization application for an ATMP is 210 days from receipt of a valid application, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of an application considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. The development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines, and the EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">National marketing authorizations are for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EU, this marketing authorization can be recognized in another Member States through the mutual recognition procedure. If the product has not received a national marketing authorization in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which an authorization is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). If the RMS proposes to authorize the product, and the other Member States do not raise objections, the product is granted a national marketing authorization in all the Member States where the authorization was sought. Harmonization throughout all concerned Member States is achieved through procedures set forth in Regulation (EC) 1234/2008, including in cases of differences on the assessment between the relevant authorities of Member States.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the above-described procedures, before granting the MAA, the EMA or the competent authorities of the Member States of the EU make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory exclusivity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, innovative products authorized for marketing (i.e., reference products) may qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, however, another company may market another version of the product if such company obtained marketing authorization based on a marketing authorization application with a completely independent data package of pharmaceutical tests, preclinical tests, and clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that a product will be considered to be an innovative medicinal product or qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product and qualifies for the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials. Following the expiry of regulatory exclusivity for a product (or if a product does not qualify for regulatory exclusivity), a generic or biosimilar version of the applicable product may be authorized and marketed in the EU. Therefore, we would need to rely upon enforcement of any surviving European patents covering the applicable product to protect against generic competition in the EU.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:8.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan designation and exclusivity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an orphan medicinal product in the EU, are similar in principle to those in the U.S. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if the following criteria are fulfilled: (i) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in its development; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Otherwise, orphan medicine marketing exclusivity may be revoked only in very select cases, such as if:</span></p><div class="item-list-element-wrapper" style="margin-left:0.19999999999999996in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.6613173332785385%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a second applicant can establish that its product, although similar to the authorized product, is safer, more effective, or otherwise clinically superior;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.19999999999999996in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.6613173332785385%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.19999999999999996in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.6613173332785385%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PRIME designation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation, where the marketing authorization application will be made through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need, i.e., there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicine will bring a major therapeutic advantage, and they must show potential to benefit patients with unmet medical needs based on early clinical data. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the EMA&#8217;s CHMP or Committee for Advanced Therapies are appointed early in PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reform of the Regulatory Framework in the European Union</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines, including those for rare diseases and for children. The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. In October 2023, the European Parliament published draft reports proposing amendments to the legislative proposals. In April 2024, the European Parliament initially debated the draft legislation. Once the European Commission&#8217;s legislative proposals have been initially voted on by the European Parliament and the European Council, reviewed, negotiated and discussed among those bodies, the final text of these legislative proposals will be adopted into EU law.</span></p><p style="margin-left:8.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.K. formally left the EU on January 31, 2020. The EU and the U.K. have concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of U.K. and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework currently continues to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns with EU regulations in many ways, however it is possible that these regimes will diverge more significantly in the future now that Great Britain&#8217;s regulatory system is independent from the EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MHRA in the U.K. established a new medicines approval pathway following Brexit, known as the Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;), which aims to accelerate the time to market and facilitate patient access to certain types of medicinal products in development which target a life-threatening or seriously debilitating condition, or where there is a significant patient or public health need. The first step in the ILAP is receipt of an Innovation Passport, which allows for enhanced engagement with the MHRA and its partner agencies. Once an Innovation Passport has been granted, the next step in the pathway is the preparation of a target development profile (&#8220;TDP&#8221;) document by the MHRA and the U.K.&#8217;s health technology assessment agencies. The TDP sets out the regulatory and development milestones, identifies potential issues and creates a roadmap to achieving early patient access in the U.K. The TDP also gives access to a toolkit where a number of tools can be selected as needed for a particular medicine or stage of development. These tools include rolling review of an MAA, whereby data can be submitted for review on a rolling basis as it becomes available.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2024, a new international recognition framework was put in place by the MHRA, under which the MHRA may have regard to decisions on the approval of marketing authorizations made by the EMA and certain other regulators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 27, 2023, the U.K. government and the EC announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the U.K. In particular, the MHRA will be responsible for approving all medicinal products destined for the U.K. market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single U.K.-wide marketing authorization will be granted by the MHRA for all medicinal products to be sold in the U.K., enabling products to be sold in a single pack and under a single authorization throughout the U.K. The Windsor Framework was approved by the EU-U.K. Joint Committee on March 24, 2023, so the U.K. Government and the EU will enact legislative measures to enact it into law. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January 1, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 1, 2025, the MHRA has been responsible for approving all medicines intended to be marketed in the United Kingdom, and the EMA is no longer be involved in approving medicines intended for sale in Northern Ireland.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 299 full-time employees, of whom 288 were located in the U.S., 8 in Spain, 1 in Italy, 1 in the UK and 1 in the Netherlands. Of these employees, 210 were primarily engaged in research and development activities and 89 were primarily engaged in general and administrative activities. We also engage the services of independent contractors and consultants as needed for special or temporary projects or specific expertise. None of our employees are represented by a labor union or covered by a collective bargaining agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation and Benefits Programs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, attracting, recruiting, retaining, incentivizing, developing, and integrating our existing and new employees, advisors, and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We provide employee wages and benefits that are competitive within our industry, and we engage a nationally recognized outside compensation and benefits consulting firm to independently evaluate the effectiveness of our compensation and benefit programs and to provide benchmarking against our peers within the industry.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Talent and Culture</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that developing a diverse, equitable and inclusive culture is critical to continuing to attract and retain the top talent necessary to deliver on our growth strategy. As such, we are investing in creating and maintaining a diverse, inclusive and safe work environment where our employees can feel inspired to deliver their workplace best every day. We regularly assess our benefit programs, employee engagement and turnover, recruitment initiatives, workforce diversity and other workplace culture matters relevant to human capital management, and review those results with our board of directors on a periodic basis. All employees are responsible for upholding certain standards of behaviors and adhere to a Company code of conduct, which form the foundation of our policies and practices.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Development and Training</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development, recruitment and retention of our employees is a critical success factor for our company. To provide a meaningful experience for our employees, we offer training and development programs to increase our organizational learning and support the promotion and career development of our current employees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in Delaware in 1999 as Inotek Pharmaceuticals Corporation (&#8220;Inotek&#8221;). In January 2018, Inotek merged with Rocket Pharmaceuticals, Ltd. and changed its name to Rocket Pharmaceuticals, Inc. Our principal executive offices are located at 9 Cedarbrook Drive, Cranbury, NJ 08512, and our telephone number is (609) 659-8001. Our internet address is </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.rocketpharma.com.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We use our website as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. We make available on our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our SEC reports can be accessed through the Investors section of our website. The SEC maintains a website that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov. The information found on our website is not incorporated by reference into this report or any other report we file with or furnish to the SEC. Our common stock is listed on the NASDAQ Global Market under the symbol &#8220;RCKT.&#8221;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1_a_risk_factors"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. R</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">isk Factors</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We operate in an industry that involves numerous risks and uncertainties. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Annual Report, including our financial statements and related notes hereto. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. The risks and uncertainties described below may change over time and other risks and uncertainties, including those that we do not currently consider material, may impair our business. In these circumstances, the market price of our common stock could decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Needs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Operating History</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development efforts, we could be forced to delay, reduce, or eliminate our product development programs or commercial development efforts.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late-stage gene therapy company with a limited operating history on which to base your investment decision. Gene therapy product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations to date have been limited primarily to organizing and staffing our company, business planning, raising capital, acquiring, and developing product and technology rights, building out our R&amp;D and manufacturing capabilities, and conducting preclinical and clinical R&amp;D activities for our product candidates. We have never generated any revenue from product sales. We have not obtained regulatory approvals for any of our product candidates and have funded our operations to date through proceeds from sales of our stock.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses since our inception. We incurred net losses of $258.7 million, $245.6 million and $221.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, we had an accumulated deficit of $1.22 billion. Substantially all our operating losses have resulted from costs incurred in connection with our R&amp;D programs, buildout of our manufacturing capabilities and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we intend to continue to conduct R&amp;D, clinical trials, regulatory compliance activities, and internal and external manufacturing activities. If any of our product candidates are approved, sales and marketing activities, together with anticipated G&amp;A expenses, would likely result in us continuing to incur significant losses for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any of our product candidates, we may not be successful in commercializing those product candidates if and when they are approved.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited sales or marketing infrastructure and have no Company experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved candidate for which we retain sales and marketing responsibilities, we must either continue to develop our sales and marketing organization or outsource these functions to third parties. In the future, we may choose to continue to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenues or the profitability of these product revenues to us may be lower than if we were to market and sell any medicines we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The amount of and our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal net operating losses generated in taxable years beginning after December 31, 2017 generally may not be carried back to prior taxable years, and while such federal net operating losses generated in taxable years beginning after December 31, 2017 will not be subject to expiration, the deduction for such net operating loss in any taxable year will be limited to 80% of our taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself. However, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) repeals the 80% limitation on the utilization of such federal net operating losses for taxable years beginning after December 31, 2017 and beginning before January 1, 2021 and allows for federal net operating losses generated in taxable years beginning after December 31, 2017 and before January 1, 2021 to be carried back to each of the five taxable years preceding the taxable year in which the loss arises. This change in law temporarily allowing for the carryback of federal net operating losses is not expected to produce any material benefit for the issuer. As described above, we have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our net operating loss or tax credit carryforwards. Additionally, new tax laws could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws, including changes in corporate tax rates, which collectively may impact the utilization of our NOLs and other deferred tax assets, the deductibility of expenses, and the taxation of foreign earnings. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. The impact of changes under the Tax Act, the CARES Act, or future reform legislation could limit our ability to utilize our NOLs or increase our future U.S. tax expense and could have a material adverse impact on our business and financial condition.</span></p><p style="text-indent:3.733%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses, or net operating losses or tax credits, or credits, (including federal research and development tax credits) to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. As described below, we have experienced numerous &#8220;ownership changes&#8221; within the meaning of Section 382 of the Internal Revenue Code. Future changes in our stock ownership, many of which are outside of our control, could result in one or more additional ownership changes under Sections 382 and 383 of the Internal Revenue Code and further limit our ability to utilize our net operating losses and credits. Our net operating losses or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our net operating losses or credits if we undergo an ownership change prior to the utilization of all such net operating losses or credits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Capital Needs</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our licensing activities, product development efforts or other operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to require substantial future capital in order to expand our gene therapy platforms, advance preclinical and clinical development for our current product candidates and other future product candidates, if any, and potentially commercialize these product candidates. We expect our spending levels to increase in connection with our preclinical and clinical activities. Also, if we obtain marketing approval for any of our current or future product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing, and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, limit or terminate our product development efforts or other operations. Furthermore, to the extent we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. Additionally, recent volatility in capital markets, rising interest rates and lower market prices for securities generally may affect our ability to access new capital on terms favorable to us, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations have consumed significant amounts of cash since inception. As of December 31, 2024, our cash, cash equivalents and investments were $372.3 million. Our future capital requirements will depend on numerous factors, many of which are outside of our control. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory and marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never generated any revenue from product sales and may never be profitable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory, pricing and reimbursement approvals necessary to commercialize our product candidates. We do not anticipate generating revenues from product sales for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing research and preclinical and clinical development of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking and obtaining regulatory and marketing approvals for product candidates for which we successfully complete clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing a sustainable, commercial-scale, reproducible, and transferable manufacturing process for our vectors and product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support preclinical and clinical development and the market demand for our product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales force, marketing and distribution infrastructure;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining a favorable market protection for our products, e.g., obtaining (and maintaining) orphan designation with market exclusivity in the EU, which in turn may depend on activities of third parties and other factors on which we have no influence;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining sufficient pricing and reimbursement for our product candidates from private and governmental payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining market acceptance of our product candidates and gene therapy as a viable treatment option;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any competing technological and market developments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying and validating new gene therapy product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if one or more of the product candidates that we will develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the EMA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if we generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Clinical Development and Product Regulatory Matters</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Clinical Development of our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in commencement, enrollment or completion of our clinical trials or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing our current and future product candidates on a timely basis, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of our current and future product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical trials are expensive, time-consuming, and outcomes are uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our experience with clinical trials has been limited. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A clinical trial may be delayed or halted at any stage of testing for various reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of patients to enroll in the studies at the rate we expect;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ineffectiveness of our product candidates;</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients experiencing unexpected side effects or other safety concerns being raised during treatment;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in governmental regulations or administrative actions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to conduct studies in accordance with required clinical practices;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspection of clinical study operations or study sites by the FDA, the EMA or other regulatory authorities, resulting in a clinical hold;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insufficient financial resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insufficient supplies of drug product to treat patients in our ongoing and planned clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">political unrest or natural disasters at domestic or foreign clinical sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a shutdown of the U.S. government, including the FDA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public health crises such as pandemics and epidemics.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, to the extent we seek to obtain regulatory approval for our product candidates in foreign countries, our ability to successfully initiate, enroll and complete a clinical study in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty in establishing or managing relationships with Contract Research Organizations and physicians;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">absence in some countries of established groups with sufficient regulatory expertise for review of LV and AAV gene therapy protocols;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to locate qualified local partners or collaborators for such clinical trials; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate planned clinical trials, the occurrence of any of which would harm our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. We may not be able to identify, recruit and enroll enough patients, or those with required or desired characteristics, to complete clinical trials in a timely manner. Patient enrollment and trial completion is affected by numerous factors including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease under investigation and size of the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eligibility criteria for the study in question;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceived risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proximity and availability of clinical study sites for prospective patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of competing therapies and clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ability to monitor patients adequately during and after treatment.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, each of the conditions for which we plan to evaluate our current product candidates are rare genetic diseases with limited patient pools from which to draw for clinical studies. The process of identifying and diagnosing patients may prove costly. In some cases, potential patients may be located outside of the U.S., and immigration related issues, including government policy changes, may introduce additional delays into the enrollment process. Finally, the treatment process for our LV programs requires that the cells be obtained from patients and then shipped to a transduction facility within the required timelines, and this may introduce unacceptable shipping-related delays to the process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary, interim or topline results in our ongoing clinical studies may not be indicative of results obtained when these studies are completed. Furthermore, success in early clinical studies may not be indicative of results obtained in later studies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule. Study designs and results from previous or ongoing studies and clinical trials are not necessarily predictive of future study or clinical trial results, and initial or interim results may not continue or be confirmed upon completion of the study or trial. Furthermore, our product candidates may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical studies. We cannot guarantee that any of these studies will ultimately be successful or that preclinical or early-stage clinical studies will support further clinical advancement or regulatory approval of our product candidates.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercial viability of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gene therapy is still a relatively new approach to disease treatment and adverse side effects could develop with our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction soon after administration which could substantially limit the effectiveness and durability of the treatment. If certain side effects are observed in testing of our potential product candidates, we may decide or be required to halt or delay further clinical development of our product candidates. The FDA or other regulatory authorities may require us to halt or delay clinical development of our product candidates for reasons unrelated to new drug-related safety events being observed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to side effects caused by the product candidate, the administration process or related procedures associated with a given product candidate also can cause adverse side effects. If any such adverse events occur, our clinical trials could be suspended or terminated. Under certain circumstances, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Moreover, if we elect or are required, to not initiate or to delay, suspend or terminate any ongoing or future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if undesirable side effects caused by our product candidate are identified following regulatory approval of a product candidate, such as in long-term follow-up studies, several potentially significant negative consequences could result, including reputational harm and regulatory authorities suspending or withdrawing approvals of such product candidate, requiring additional warnings on the label or requiring that we change the way a product candidate is administered or that we conduct additional clinical trials.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our gene therapy product candidates are based on novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Currently, relatively few gene and cell therapy products have been approved in the U.S. and the EU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our R&amp;D efforts to date on a gene therapy platform, and our future success depends on the successful development of viable gene therapy product candidates.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical study requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Currently, relatively few gene and cell therapy products have received marketing authorization in the U.S. or the EU, including Zolgensma (developed by AveXis), GlaxoSmithKline&#8217;s Strimvelis, Spark Therapeutics&#8217; Luxturna, Vertex Pharmaceuticals&#8217; Casgevy, Bluebird Bio&#8217;s Lyfgenia, Pfizer&#8217;s Beqvez, Sarepta Therapeutics&#8217; Elevidys and Orchard Therapeutics&#8217; Lenmeldy. It is therefore difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the U.S., the EU or other jurisdictions. Approvals by the EMA may not be indicative of what the FDA may require for approval. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approvals necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue and our business, financial condition, results of operations and prospects could be materially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements governing gene therapy products have evolved and may continue to change in the future. For example, FDA&#8217;s Center for Biologics Evaluation and Research may require us to perform additional nonclinical studies or clinical trials that may increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our gene therapy product candidates or lead to significant post-approval limitations or restrictions. Additionally, the FDA continues to develop its approach to assessing gene and cell therapy products. In January 2020, FDA released its final guidance with recommendations for long-term follow-up studies of patients following human gene therapy administration due to the increased risk of undesirable and unpredictable outcomes with gene therapies that may present as delayed adverse events. The final guidance advises that patients treated with gene therapies that incorporate integrating vectors, such as LVs, undergo long-term safety and efficacy follow up of fifteen years post therapy while patients treated with gene therapies that incorporate AAV vectors undergo long-term safety and efficacy follow-up as long as five years post therapy. We cannot be certain whether such guidance, or others that FDA may issue, will adversely impact our gene therapy candidates or the duration or expense of any applicable regulatory development and review processes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the U.S., certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the EMA&#8217;s CAT and other regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of certain of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate product revenue, and our business, financial condition, results of operations and prospects would be materially harmed.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even though we have obtained orphan designation for certain of our product candidates, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the U.S., EU and other major markets, may designate drugs intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. The FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, the European Commission, based on the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition and either (i) such condition affects not more than 5 in 10,000 persons in the EU; or (ii) without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biologic product. In either case, the applicant for orphan designation must also demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product must be of significant benefit compared to products available for the condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received orphan designation from the FDA and the European Commission for RP-L102 for the treatment of FA, for RP-L201 for the treatment of LAD-I, RP-A601 for the treatment of PKP2-ACM, and for RP-L301 for the treatment of PKD, and FDA orphan drug designation for RP-A501 for treatment of DD. To date, we have not requested orphan drug designation (or the foreign equivalent) for any other product candidates, and even if we do in the future there can be no assurances that the FDA or foreign regulatory authorities will grant any of our product candidates such designation. Additionally, the designation of any of our product candidates as an orphan product does not mean that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or foreign regulatory authorities from approving another marketing application for a product that constitutes the same drug (or &#8220;similar medicinal product&#8221; in the EEA, which is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication) treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), or if in the EU a &#8220;similar medicinal product&#8221; is approved before we obtain a market authorizations for our product, we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the U.S. and 10 years in the EU. The exclusivity period in the EU may be extended by an additional two years if the applicant enjoys the incentives and rewards granted for including the results of additional pediatric studies in its product information. On the other hand, the exclusivity period in the EU can be reduced to six years if a product no longer meets the criteria for orphan drug designation, such designation is revoked by the sponsor or expires, including if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition in the U.S. Even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Additionally, the U.S. federal courts may interpret the orphan drug statutory or regulatory provisions in way that reduces or eliminates any exclusivity that may attach to our product candidates. The FDA may further reevaluate its regulations and policies related to orphan designation and orphan drug exclusivity. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A Fast Track or regenerative medicine advanced therapy, or RMAT, designation by the FDA, or a PRIority MEdicines, or PRIME, designation by the EMA, even if granted for any of our current or future product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our current product candidate and any future product candidates will receive marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product candidate is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for FDA Fast Track designation for a particular indication. We have received Fast Track designation for RP-A501 for DD, RP-L102 for FA, RP-L201 for LAD-I and RP-L301 for PKD. We may seek Fast Track designation for future product candidates, but there is no assurance that the FDA will grant this status to any of our proposed product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company may request RMAT designation of its product candidate, and FDA may grant such designation if the product meets the following criteria: (i) it is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. We have received RMAT designation for RP-A501 for DD, RP-L102 for FA, RP-L201 for LAD-I and RP-L301 for PKD. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion of trials to additional sites.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRIME designation is a scheme provided by the EMA to enhance support for the development of medicines that target an unmet medical need. To qualify for PRIME designation, product candidates require early clinical evidence that the therapy has the potential to offer a therapeutic advantage over existing treatments or benefits patients without treatment options. We have received PRIME designation for RP-L102 for FA, RP-L201 for LAD-I, RP-L301 for PKD and RP-A501 for DD. Among the benefits of PRIME are the appointment of a rapporteur to provide continuous support and help build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has broad discretion whether or not to grant Fast Track or RMAT designation, and the EMA has broad discretion whether or not to grant PRIME designation, so even if we believe a particular product candidate is eligible for such designations, there can be no assurance that the FDA or EMA would decide to grant it. Even if we do receive Fast Track, RMAT or PRIME designation, we may not experience a faster development process, review or approval compared to conventional development, review, and approval timelines, and receiving a Fast Track, RMAT or PRIME designation does not change the standards for the product approval. In addition, the FDA may withdraw Fast Track or RMAT designation and the EMA may revoke PRIME designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated approval by the FDA, and conditional approval by the EMA, may not lead to a faster development process or regulatory review and does not increase the likelihood that our product candidates will receive marketing approval. If we are not successful with this process, the development or commercialization of our product candidates for which we seek accelerated approval or conditional approval could be delayed, abandoned or become significantly more costly.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek approval of our product candidates using the FDA&#8217;s accelerated approval and the EMA&#8217;s conditional approval pathways. While we may utilize trial designs to support accelerated approval, such product candidates may not be subject to faster development or regulatory review timelines.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product may be eligible for accelerated approval by the FDA if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of accelerated approval, the FDA may impose specific obligations with defined timelines, including to perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of a product. If the FDA or the EMA do not approve our product candidates for which we seek accelerated approval or conditional approval, but instead require the completion of a full Phase 3 clinical trial or trials prior to the filing of marketing applications, the development and commercialization timeline of such product candidates will be delayed. Even if we do receive accelerated approval or conditional approval, we may not ultimately receive full approval from the regulatory agencies. The additional data generated through post-marketing clinical trials may not confirm that the benefit-risk balance of any of our product candidates that receive accelerated approval is positive or the burden to further complete the obligations may become too high. Additionally, the Consolidated Appropriations Act of 2023, enacted on December 29, 2022, contained revisions to the accelerated approval process that provide FDA with additional authority to enforce the post-market study requirements and withdraw approvals more rapidly when holders of accelerated approvals fail to comply with post-approval clinical study requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the conditional marketing authorization is subject to an annual renewal procedure that assesses the marketing authorization holder&#8217;s compliance with the specific obligations of the authorization. If conditions are not complied with, the EMA may decide to extend the timeline for the existing obligations, change the scope of such obligations or add new obligations, which may require additional financial resources and time. We may not be able to comply with such changes or additional obligations and may need to withdraw the marketing authorization. The EMA may also decide not to renew the conditional marketing authorization, although such measure is rarely applied in practice. An analysis of reimbursement decisions for conditionally authorized medicines in the EU has shown some delays in the timeline for reaching a positive health technology recommendation. If this happens for any product candidate for which we seek conditional approval, it may delay the timing and success of the commercialization of such product. Finally, if new data obtained from fulfilment of the conditions of the conditional authorization or otherwise show that our product&#8217;s benefits no longer outweigh its risks, the EMA can take regulatory action, such as suspending or revoking the conditional marketing authorization.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have received rare pediatric disease designation for RP-A501 for DD, RP-L102 for FA, and RP-L201 for LAD-I. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received rare pediatric disease designation for RP-A501 for DD, RP-L102 for FA, and RP-L201 for LAD-I. Designation of a biological product as a product for a rare pediatric disease does not guarantee that a BLA for such biological product will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the Federal Food, Drug, and Cosmetic Act, we will need to request a rare pediatric disease priority review voucher in our original BLA for our product candidates for which we have received rare pediatric disease designation. The FDA may determine that a BLA for any such product candidates, if approved, does not meet the eligibility criteria for a priority review voucher.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The authority for the FDA to award rare pediatric disease priority review vouchers for biological products after December 31, 2024 is currently limited to biological products that receive rare pediatric disease designation on or prior to December 20, 2024, and FDA may only award rare pediatric disease priority review vouchers through September 30, 2026. However, it is possible the authority for FDA to award rare pediatric disease priority review vouchers will be further extended by Congress.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we successfully complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. We have not received approval from regulatory authorities in any jurisdiction to market any of our product candidates. Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, issue a complete response letter, or ultimately, we may not be able to obtain regulatory approval. In addition, we may experience delays or rejections if an FDA Advisory Committee recommends disapproval or restrictions on use. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative actions, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of data obtained from preclinical and clinical testing could delay, limit or prevent the receipt of marketing approval for a product candidate.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or other labeling changes. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. Regulatory authorities may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a Risk Evaluation and Mitigation Strategy, or REMS, or equivalent requirement. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may never obtain FDA or EMA approval for any of our product candidates in the U.S. or the EU, and even if we do, we may never obtain approval for or commercialize any of our product candidates in any other jurisdiction, which would limit our ability to realize our full market potential.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to eventually market any of our product candidates in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy on a jurisdiction-by-jurisdiction basis. Approval by the FDA in the U.S. or the EMA in the EU, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, preclinical studies and clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. While the foreign regulatory approval process involves similar risks to those associated with FDA or EMA approval, regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory obligations and continued regulatory scrutiny.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval in a jurisdiction, we will remain subject to ongoing regulatory obligations and continued regulatory scrutiny. The applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions once a product candidate is approved. Additionally, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA and must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. FDA guidance advises that patients treated with some types of gene therapy undergo follow-up observations for potential adverse events for as long as 15 years. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and cGTP, as well as adherence to commitments made in the BLA. For certain commercial prescription biological products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the U.S. If we or a regulatory agency discover previously unknown problems with a product, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product or the manufacturing facility. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may take a variety of actions, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuing a warning letter asserting that we are in violation of the law;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking an injunction or impose civil or criminal penalties or monetary fines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspending any ongoing clinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusing to approve a pending marketing application, such as a BLA or supplements to a BLA submitted by us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seizing products; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusing to allow us to enter into supply contracts, including government contracts.</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s policies, and those of comparable foreign regulatory authorities, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative actions, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval which we may have obtained and we may not achieve or sustain profitability, which would materially harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If approved, our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and, as a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section entitled, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business &#8212; Government Regulation &#8212; Healthcare Legislative Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The United Kingdom&#8217;s withdrawal from the EU, or Brexit, could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe and/or the United Kingdom.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have clinical trial sites in the United Kingdom, contract laboratories in the United Kingdom conducting testing for our global clinical trials, and other collaborators and potential collaborators in the United Kingdom and throughout Europe. Pursuant to Article 50 of the Treaty on EU, the UK ceased being a Member State of the EU on January 31, 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. Initially, the EU and the UK concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. However, the UK has implemented legislation on the marketing, promotion and sale of medicinal products, application for marketing authorizations and the application for clinical trials. Accordingly, the regulatory regime in Great Britain no longer aligns with  EU regulations as regards regulations and administrative processes for pharmaceutical processes, including the process for obtaining marketing authorizations in the UK (through a national marketing authorization or an IRP as described above) and, for clinical trials through the application of the UK Clinical Trial Regulation and the implementation of the combined review process by MHRA and HRA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the EU and/or the United Kingdom. It is possible that there will be increased regulatory complexities which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Noncompliance with Applicable Laws or Regulations</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are successful in commercializing any product, our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain regulatory approval. Our arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain regulatory approval. See the section entitled, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business &#8212; Government Regulation &#8212; Anti-Kickback and False Claims Laws and Other Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent laws, rules, regulations, policies, industry standards and contractual obligations regarding data privacy and security and may be subject to additional related laws and regulations in jurisdictions into which we expand. Many of these laws and regulations are subject to change and reinterpretation and could result in claims, changes to our business practices, monetary penalties, increased cost of operations or other harm to our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory framework for privacy and personal information security issues worldwide is evolving rapidly and likely to remain uncertain for the foreseeable future. The U.S. federal and various state, local and foreign government bodies and agencies have adopted or are considering adopting laws, rules, regulations and standards regarding, the collection, distribution, use, disclosure, storage, security and other processing of personal information. For example, HIPAA imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. We may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA and its implementing rules and regulations. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the U.S., relevant legal requirements continue to evolve. For example, the collection and use of health data and other personal data including data collected in clinical trials is governed in the EU by the GDPR, which imposes substantial obligations upon companies and new rights for individuals. The GDPR also forms part of the law of Great Britain (England and Wales, Scotland and Northern Ireland) by virtue of section 3 of the European Union (Withdrawal) Act 2018 and as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (SI 2019/419) (&#8220;UK GDPR&#8221;). Failure to comply with the GDPR may result in fines of the higher of (i) &#8364;20,000,000 or (ii) 4% of the preceding fiscal year&#8217;s total annual global revenues of the noncompliant company, among other administrative penalties. The GDPR has increased our responsibility and liability in relation to personal data that we may process, and we may be required to implement additional measures in an effort to comply with the GDPR and with other laws, rules, regulations and standards in the EU and United Kingdom relating to privacy and data protection. This may be onerous and if our efforts to comply with GDPR or other applicable laws, rules, regulations and standards are not successful, or are perceived to be unsuccessful, it could adversely affect our business. Further, following the July 2020 Court of Justice of the EU decision invalidating the EU-U.S. Privacy Shield, there remains uncertainty regarding the appropriate mechanism for transferring personal data to the U.S. The Court of Justice of the EU&#8217;s decision and other regulatory guidance or developments may impose additional obligations with respect to the transfer of personal data from the EU to the U.S., all of which could restrict our activities in those jurisdictions, limit our ability to provide our products and services in those jurisdictions, require us to modify our policies and practices, and to engage in additional contractual negotiations, or increase our costs and obligations and impose limitations upon our ability to efficiently transfer personal data from the EU to the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., a variety of data privacy, protection and security laws, rules, regulations and standards potentially may apply to our activities, such as state data breach notification laws, state personal data privacy laws (for example, the CCPA of 2018 as amended by the California Privacy Rights Act effective January 1, 2023, state health information privacy laws, and federal and state consumer protection laws. The CCPA requires covered businesses that process personal information of California residents to disclose their data collection, use, sharing and retention practices, provides California residents with data privacy rights (including the ability to opt out of certain disclosures of personal information including for certain advertising purposes), imposes operational requirements for covered businesses, provides for significant civil penalties for violations as well as a private right of action for certain data breaches and statutory damages (that is expected to increase data breach class action litigation and result in significant exposure to costly legal judgements and settlements). Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities, depending on their interpretation. Other state legislatures have enacted or are currently contemplating, and may pass, their own comprehensive data privacy and security laws, with potentially greater penalties and more rigorous compliance requirements, and laws in all 50 states require businesses to provide notice to customers whose personal data has been disclosed as a result of a data breach. Finally, federal, state and foreign laws, rules, regulations and standards may apply generally to the privacy and security of information we maintain, and may differ from each other significantly, thus complicating compliance efforts and potentially requiring us to undertake additional measures to comply with them.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With HIPAA, GDPR, CCPA, and other laws, regulations and other obligations relating to privacy and data protection imposing new and relatively burdensome obligations, and with substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in addressing their requirements and making necessary changes to our policies and practices and may incur significant costs and expenses in an effort to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may make public statements about our use, collection, disclosure and other processing of personal data through our privacy policies, information provided on our website and press statements. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. Any failure or perceived failure by us or our vendors or service providers to comply with our applicable policies or notices relating to privacy or data protection, our contractual or other obligations to third parties, or any of our other legal obligations, laws, rules, regulations and standards relating to privacy or data protection, may result in governmental investigations or enforcement actions, litigation, claims and other proceedings, harm our reputation, and could result in significant liability.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As with other companies engaged in similar activities, we face a risk of environmental liability inherent in our activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing, Commercialization and Development of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Products intended for use in gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have development, manufacturing, and testing agreements with third parties to manufacture supplies of certain of our product candidates. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, public health crises such as pandemics and epidemics, disruption in utility services, human error or disruptions in the operations of suppliers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates require processing steps that are more complex than those required for small molecule pharmaceuticals. The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of certain of our product candidates. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities and we may need to find alternatives, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to attractive development programs. Problems in third-party manufacturing processes or facilities also could restrict our ability to complete our clinical trials in a timely manner or meet market demand for our products. Additionally, should our manufacturing agreements with third parties be terminated for any reason, there may be a limited number of manufacturers who would be suitable replacements and it could take a significant amount of time to transition the manufacturing to a replacement. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. Changes to the manufacturing process or the transfer or setup of new manufacturing facilities could require that we conduct bridging studies before being able to proceed with either clinical or commercial manufacturing activities. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. Further, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require approval before selling any products manufactured at that facility.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience in manufacturing, and there can be no assurance that we will be able to manufacture products at the scale our business may require.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have historically relied on third parties to manufacture supplies of our product candidates. We have completed a build-out of a manufacturing facility in Cranbury, New Jersey, and have since completed a limited number of DD AAV cGMP batches.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although some of our employees have experience in the manufacturing of biopharmaceutical products from prior employment at other companies, we as a company have very limited prior experience in manufacturing. As a manufacturer of pharmaceutical products, we will be required to demonstrate and maintain compliance with cGMP requirements related to production processes, quality control and assurance and recordkeeping. Furthermore, establishing and maintaining manufacturing operations may require a reallocation of other resources, particularly the time and attention of certain of our senior management as well as potentially significant capital expenditures. Any failure or delay in the development of our manufacturing capabilities could adversely impact the development or commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must comply with cGMP requirements, as set out in statute, regulations and guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the potential commercialization of any products that we may develop.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face inherent risks of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater product liability risks if we commercially sell any approved products. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization of our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to successfully develop and commercialize our product candidates will substantially depend upon the availability of reimbursement for the costs of the resulting drugs and related treatments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be covered and paid by government authorities and other third-party payors, such as private health insurers and health maintenance organizations, which we cannot guarantee. We have not commenced efforts to have our product candidates reimbursed by government or third-party payors. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize our products. If coverage is provided, but only at limited levels, the reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. See the section entitled, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business &#8212; Government Regulation &#8212; Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the principal decisions about coverage and reimbursement for new medicines are typically made by the CMS, an agency within the HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow the CMS to a substantial degree. It is difficult to predict what the CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Factors payors consider in determining reimbursement include whether the product is a covered benefit under its health plan, whether the product is safe, effective, and medically necessary, whether it is cost-effective and whether the product is experimental or investigational.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors are increasingly limiting both coverage and the level of reimbursement of new drugs. They may also impose strict prior authorization requirements and/or refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly approved drugs. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important to successful commercialization of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. In some cases, the reimbursement price of one Member State may have impact on the pricing level in other Member States, which may result in an incentive not to market products in some markets to prevent price reductions or erosions in other markets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are engaged in gene therapy for severe genetic and rare diseases, which is a competitive and rapidly changing field. Although we are not currently aware of any gene therapy competitors addressing any of the same indications as those in our pipeline, we may have competitors both in the U.S. and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our potential competitors may have substantially greater financial, technical and other resources, such as larger R&amp;D staff, more robust manufacturing capabilities and more experienced marketing and manufacturing organizations. These competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than us. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against those of our competitors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if our patent rights were to expire or be successfully challenged, we could face increased litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize, thereby causing harm to our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of any of our product candidates will depend upon the degree of market acceptance of gene therapy by physicians, patients, third-party payors and others in the medical community.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even with the requisite approvals from the FDA in the U.S., the EMA in the EU and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance of physicians, patients and health care payors of gene therapy products in general, and our product candidates in particular, as medically beneficial, cost-effective and safe. If any products that we commercialize do not achieve an adequate level of acceptance by physicians, patients, health care payors and others in the medical community, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and our product candidates, if approved for commercial sale, will depend on several factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety of such product candidates as demonstrated in preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of product candidates over alternative treatments, including the prevalence and<br/>severity of any side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of our treatment relative to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the product candidate is approved by the FDA or the EMA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient and physician awareness of, and willingness to seek, gene therapy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians to undergo specialized training with respect to administration of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of competitive products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity concerning our products or competing products and treatments; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient third-party payor coverage and reimbursement.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is approved and launched and is subject to change over time if adverse long-term follow-up data become available after approval. The failure of any of our product candidates to achieve market acceptance could materially harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ethical, legal, and social issues may reduce demand for any gene therapy products for which we obtain marketing approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to receiving certain gene therapies, patients may be required to undergo genetic testing. Genetic testing has raised concerns regarding the appropriate utilization and the confidentiality of information provided by genetic testing. Genetic tests for assessing a person&#8217;s likelihood of developing a chronic disease have focused public attention on the need to protect the privacy of genetic information. Concerns have been expressed that insurance carriers and employers may use these tests to discriminate on the basis of genetic information, resulting in barriers to the acceptance of genetic tests by consumers. This could lead to governmental authorities restricting genetic testing or calling for limits on or regulating the use of genetic testing, particularly for diseases for which there is no known cure. Any of these scenarios could decrease demand for any products for which we obtain marketing approval.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Development of our Pipeline and Research and Development Activities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to expand our pipeline of additional product candidates for development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business model is centered on applying our expertise in rare genetic diseases by establishing focused selection criteria to develop and advance a portfolio of gene therapy product candidates through development into commercialization. We may not be able to continue to identify and develop new product candidates in addition to the pipeline of product candidates that our efforts to date have resulted in. Even if we are successful in continuing to expand our pipeline, any potential product candidates that we identify may not be suitable for clinical development. If we do not successfully identify, develop and commercialize product candidates, we will not be able to obtain product revenue in future periods, which would likely result in significant harm to our financial position and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The success of our R&amp;D activities, clinical testing and commercialization, upon which we primarily focus, is uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary focus is on our R&amp;D activities and the clinical testing and commercialization of our product candidates, and we anticipate that we will remain principally engaged in these activities for an indeterminate, but substantial, period. R&amp;D was our most significant operating expense for the year ended December 31, 2024. R&amp;D activities, including the conduct of clinical studies, by their nature, preclude definitive statements as to the time required and costs involved in reaching certain objectives. Actual R&amp;D costs, therefore, could significantly exceed budgeted amounts and estimated timeframes may require significant extension. Cost overruns, unanticipated regulatory delays or demands, unexpected adverse side effects or insufficient therapeutic efficacy will prevent or substantially slow our R&amp;D efforts and our business could ultimately suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Third Parties</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business, financial condition and results of operations could be substantially harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have relied upon and plan to continue to rely upon third parties, including CROs, medical institutions, and contract laboratories for certain aspects of our ongoing preclinical and clinical programs. Nevertheless, we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our vendors are required to comply with the current requirements of GMP, GCP, and GLP, which are a collection of laws and regulations enforced by the FDA, the EMA or comparable foreign authorities for our drug candidates in clinical development.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators, preclinical study and clinical trial sites, and other contractors. If we or any of our vendors fail to comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with GMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the development and regulatory approval processes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our relationships with these third parties, medical institutions, clinical investigators or contract laboratories terminate, we may not be able to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our ongoing preclinical and clinical programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Switching or adding additional CROs, medical institutions, clinical investigators or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work replacing a previous CRO. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, we cannot guarantee that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition or results of operations.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in finding strategic collaborators for continuing development of certain of our product candidates or successfully commercializing our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek to establish strategic partnerships for developing and/or commercializing certain of our product candidates due to relatively high capital costs required to develop the product candidates, manufacturing constraints or other reasons. We may not be successful in our efforts to establish such strategic partnerships or other alternative arrangements for our product candidates for several reasons, including because our R&amp;D pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate efficacy or market opportunity. In addition, we may be restricted under existing agreements from entering into future agreements with potential collaborators.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to reach agreements with suitable licensees or collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay our development program, delay our potential commercialization, reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to independently fund development or commercialization activities, we may need to obtain additional expertise and additional capital, which may not be available on acceptable terms or at all. If we fail to enter into collaboration arrangements and do not have sufficient funds or expertise to undertake necessary development and commercialization activities, we may not be able to further develop our product candidates and our business, financial condition, results of operations and prospects may be materially harmed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages, Executive Orders, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Recent Executive Orders issued by President Trump may significantly reduce the federal workforce and could adversely affect FDA&#8217;s ability to attract and retain qualified scientific reviewers which could result in longer review times for our marketing applications. Disruptions at the FDA and other agencies may also slow the time necessary for biologics or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our rights to intellectual property for the development and commercialization of our product candidates are subject to the terms and conditions of licenses granted to us by others.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to license our platform or develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories not included in our licenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses to additional third-party technology that may be required for our licensing or development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could materially harm our business and financial condition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that we license from third parties. If our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be impacted.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government. As a result, the government may have march-in rights, or other rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for products and related technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products may be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our product candidates and our manufacturing technology. We and our licensors have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to many of our novel technologies and product candidates that are important to our business and may continue to do so.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex. Certain patents in the field of gene therapy that may have otherwise potentially provided patent protection for certain of our product candidates may expire prior to commercial launch of our products; though we can mitigate this risk by pursuing and receiving 10 years Biologics regulatory exclusivity from the FDA, which would grant protection in later years where patent expiration may not exist. It is possible that we will fail to identify patentable aspects of our R&amp;D output before it is too late to obtain patent protection, in part because the work of certain academic researchers in the gene therapy field has entered the public domain, which we believe precludes our ability to obtain patent protection for certain inventions relating to such work.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we believe our intellectual property allows us to pursue our current development programs, several companies and academic institutions are pursuing alternate approaches to gene therapy and have built intellectual property around these approaches and methods. We may not be aware of all third-party intellectual property rights potentially relating to our technology and product candidates. Publications of discoveries in the scientific literature often lag the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any owned or any licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the patent applications we license or may own in the future do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may avail themselves of safe harbor under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) to conduct research and clinical trials and may be able to circumvent our patent rights by developing similar or alternative technologies or products in a non-infringing manner.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patent rights may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of is technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we breach our license agreements, it could have a material adverse effect on our commercialization efforts for our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to intellectual property license agreements with several entities, each of which is important to our business, and we expect to enter into additional license agreements in the future. Our patent portfolio includes a number of patents and patent applications in-licensed pursuant to those license agreements, and those agreements impose, and we expect that future license agreements will impose various diligence, development and commercialization timelines, milestone obligations, payments and other obligations on us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our licensors breach any of the agreements under which we license intellectual property relating to the use, development and commercialization rights to our product candidates or technology from third parties, we could lose license rights that are important to our business. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other intellectual property rights to third parties under collaborative development relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of is product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. In addition, if disputes arise as to ownership of licensed intellectual property, our ability to pursue or enforce the licensed patent rights may be jeopardized. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our contractors, collaborators, employees and consultants. Nonetheless, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the contractors, collaborators, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets. Enforcing a claim that a third-party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming and the outcome is unpredictable. In addition, courts outside the U.S. are sometimes less willing or unwilling to protect trade secrets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our trade secrets could otherwise become known or be independently discovered by our competitors. Competitors could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for our development pipeline through acquisitions and in-licenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have intellectual property rights to develop our gene therapy product candidates, through third party licenses and our owned patents. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently, and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies with greater cash resources and clinical development and commercialization capabilities are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to the institution. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents and/or applications. We and, to our knowledge, our licensors have systems in place to remind us and them to pay these fees, and we and, to our knowledge, our licensors employ outside firms and rely on our and their respective outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We and, to our knowledge, our licensors employ reputable law firms and other professionals to help us and them comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or one of our licensing partners initiated legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our or our licensing partners&#8217; patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Such prior art and prior art we have disclosed to the USPTO could impact the scope or validity of certain of our patent claims. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming, and inherently uncertain. Congress may pass patent reform legislation that is unfavorable to us.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. Supreme Court has ruled on several patent cases in recent years, narrowing the scope of patent protection available in certain circumstances and weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, recent court decisions raise questions regarding the award of patent term adjustment for patents in families where related patents have issued without patent term adjustment. Thus, it cannot be said with certainty how PTA will/will not be viewed in the future and whether patent expiration dates may be impacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, changes in patent laws and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or how they are enforced may weaken our ability to obtain new patents or to enforce patents that we have licensed or own in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system took effect June 1, 2023, which significantly impacts European patents, including those granted before the introduction of the system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct R&amp;D activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot ensure that any patents issued to us, or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents or intellectual property rights of others may harm our business; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may have in the future, ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As identified </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">supra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on October 12, 2023, we filed an action against Lexeo Therapeutics, Inc., Kenneth Law, and Sonia Gutierrez asserting claims for trade secret misappropriation, breach of contract, tortious interference with contract, and unjust enrichment. Subsequently, on August 28, 2024, Lexeo asserted counterclaims against Rocket that included, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter alia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an allegation of correction of inventorship of Rocket&#8217;s issued patent, US Patent No. 11,883,506. The Company will vigorously defend against all counterclaims.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Personnel and Expansion of our Company</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Personnel</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business could suffer if it loses the services of, or fails to attract, key personnel.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent upon the efforts of our senior management, including our Chief Executive Officer, Gaurav Shah, MD;  our President, Head of R&amp;D and Chief Operating Officer, Kinnari Patel, PharmD, MBA; our Chief Financial Officer, Aaron Ondrey; our Chief Business Officer and Senior Vice President, Raj Prabhakar; and our General Counsel, Chief Corporate Officer and Senior Vice President, Martin Wilson. The loss of the services of these individuals and other members of our senior management could delay or prevent the achievement of research, development, marketing, or product commercialization objectives. Our employment arrangements with the key personnel are &#8220;at-will.&#8221; We do not maintain any &#8220;key-man&#8221; insurance policies on any of the key employees nor do we intend to obtain such insurance. In addition, due to the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified scientific and technical personnel and consultants. There is intense competition among major pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions for qualified personnel in the areas of our operations, and we may be unsuccessful in attracting and retaining these personnel.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, consultants, and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the U.S. and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation or could cause regulatory agencies not to approve our product candidates. We have a code of business ethics and conduct applicable to all employees, but it is not always possible to identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we endeavor to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Expansion and Growth Plans</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As our business activities expand, we may expand our full-time employee base and hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational setbacks, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected our ability to generate and/or grow revenues could be reduced and we may not be able to implement our business strategy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may fail to realize the anticipated benefits of potential acquisitions or business combinations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of acquisitions or business combinations will depend on, among other things, our ability to combine our businesses in a manner that allows us to achieve developmental and operational synergies. It is possible that the integration process could result in the loss of key employees; the disruption of our ongoing business; or inconsistencies in standards, controls, procedures, or policies, in each case, that could adversely affect our ability to achieve the anticipated benefits of the acquisition. Integration efforts between the two businesses will also divert management&#8217;s attention from our core business and other opportunities that could have been beneficial to our shareholders. An inability to realize the full extent of, or any of, the anticipated benefits of the acquisition, as well as any delays encountered in the integration process, could have an adverse effect on our business and results of operations, which may affect the value of the shares of our common stock after the completion of the acquisition. If we are unable to achieve these objectives, the anticipated benefits of the acquisition may not be realized fully or at all or may take longer or cost more to realize than expected. In particular, the acquisition or business combination may not be accretive to our stock value in the near or long term. In addition, any acquisition or business combination may impact the market price for shares of our common stock, which could result in substantial losses for our stockholders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in connection with any potential acquisition of businesses, technologies or products in the future, we could, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue equity securities that would dilute our current stockholders&#8217; percentage ownership;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur substantial debt that may place strains on our operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assume substantial actual or contingent liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reprioritize our development programs and even cease development and commercialization of certain of our product candidates; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash or shares of the other company on terms that certain of our stockholders may not deem desirable.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we intend to evaluate and consider acquisitions, reorganizations and business combinations in the future, we have no agreements or understandings with respect to any acquisition, reorganization or business combination at this time.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future formations of strategic alliances or joint ventures with third parties could disrupt our business and harm our financial condition and operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such strategic alliance or joint venture, we will achieve the expected synergies to justify the transaction. The risks we face in connection with any strategic alliance or joint venture, include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management time and focus from operating our business to addressing integration challenges;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coordination of R&amp;D efforts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in relationships with strategic partners as a result of any product acquisitions or strategic positioning;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural challenges associated with integrating employees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the need to implement or improve controls, procedures, and policies at any joint venture;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">liability for activities of any partnered company prior to any strategic alliance or joint venture, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities, and other known liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated write-offs or charges; and</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation or other claims, including claims from employees, customers, former stockholders or other third parties</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to address these risks or other problems encountered in connection with our past or future strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future strategic alliances or joint ventures could result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or operating results.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Given our commercial relationships outside of the U.S., in particular in the EU, a variety of risks associated with international operations could harm our business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage in various commercial relationships outside the U.S., and we may commercialize our product candidates outside of the U.S. In many foreign countries, it is common for others to engage in business practices that are prohibited by U.S. laws and regulations applicable to us, including the Foreign Corrupt Practices Act. Although we may implement policies and procedures specifically designed to comply with these laws and policies, there can be no assurance that our employees, contractors, and agents will comply with these laws and policies. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results could be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be, and to the extent we commercialize our product candidates outside the U.S., expect to be subject to various risks associated with operating internationally, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for approval of drugs and biologics in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires, public health crises such as pandemics and epidemics, or from economic or political instability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with foreign laws, regulations, standards, and regulatory guidance governing the collection, use, disclosure, retention, security and transfer of personal data, including the GDPR and UK GDPR; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">greater difficulty with enforcing our contracts in jurisdictions outside of the U.S.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and related risks could materially harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners, however, may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of our collaborators&#8217; or partners&#8217; support for our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of our product candidates. Any of these developments could harm our product development efforts.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of our Common Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is performing well.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception or the perception that such sales may occur, could reduce the market price of our common stock. Our outstanding shares of common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or to the extent such shares have already been registered under the Securities Act and are held by non-affiliates of ours. In addition, certain of our employees, executive officers, directors, and affiliated stockholders may enter into Rule 10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the employee, director or officer when entering into the plan, without further direction from the employee, officer, director or affiliated stockholder. A Rule 10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information. In addition, in the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to regularly publish reports on us, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price is likely to be volatile. The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their shares of common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of clinical trials of our product candidates or those of our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commencement or termination of collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license additional product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative publicity around gene therapy in general, or our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">macroeconomic conditions, including inflation and rising interest rates, capital market volatility and global conflicts, including the Russia-Ukraine war, the Israel-Hamas war and the conflict between China and Taiwan;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.2798611111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.712835907716918%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RTW, our largest stockholder, may have the ability to significantly influence all matters submitted to stockholders for approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RTW Investments, LP, in the aggregate, beneficially owns approximately 17.1% of our outstanding shares of common stock. This concentration of voting power gives RTW the power to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, RTW could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. In addition, this may prevent or discourage unsolicited acquisition proposals or offers for our capital stock that you may believe are in your best interest as one of our stockholders.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be stockholders&#8217; sole source of gain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be stockholders&#8217; sole source of gain for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult for us to evaluate the success of our business to date and to assess our future viability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations to date have predominantly focused on organizing and staffing our company, business planning, raising capital, acquiring our technology, administering, and expanding our gene therapy platforms, identifying potential product candidates, undertaking research, preclinical studies and clinical trials of our product candidates, building out our R&amp;D and manufacturing capabilities, and establishing licensing arrangements and collaborations. We have not yet obtained marketing approvals, manufactured a commercial-scale product, or conducted sales and marketing activities necessary for successful commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history. We are currently a drug discovery and clinical stage company and at a later point we will need to transition to a commercial stage company. We cannot guarantee that we will be successful in this transition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Pursuant to Section 404 of the Sarbanes-Oxley Act (&#8220;Section 404&#8221;), we are required to furnish a report by management on the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. Preparing such attestation report and the cost of compliance with reporting requirements requires significant management time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules governing the standards that must be met for management and our independent registered public accounting firm to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. In connection with our and our independent registered public accounting firm&#8217;s evaluations of our internal control over financial reporting, we may need to upgrade systems, including information technology, implement additional financial and management controls, reporting systems, and procedures, and hire additional accounting and finance staff.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us or our independent registered public accounting firm conducted in connection with Section 404 may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. We could become subject to stockholder or other third-party litigation, as well as investigations by the SEC, NASDAQ or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions, payment of damages or other remedies. Further, any delay in compliance with the auditor attestation provisions of Section 404 could subject us to a variety of administrative sanctions, including ineligibility for short-form resale registration, action by the SEC and the suspension or delisting of our common stock, which could reduce the trading price of our common stock and could harm our business.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">permit only the Board of Directors to establish the number of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Any of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, or those of our third-party collaborators or other contractors, may fail or suffer security breaches, which could result in a material disruption of our development programs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internal computer systems and those of our current and any future collaborators and other consultants and contractors are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, data breaches, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident, attack or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable national or global economic conditions or political developments could adversely affect our business, financial condition or results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the national or global economy and financial markets. For example, governmental statements, actions or policies, political unrest and global financial crises can cause extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, political unrest or additional global financial crises, including those resulting from the COVID-19 pandemic and the ongoing Russia-Ukraine war, Israel-Hamas war and the conflict between China and Taiwan, could result in a variety of risks to our business, including weakened demand for our products, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate, further political developments and financial market conditions could adversely impact our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1b_unresolved_sec_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresol</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ved SEC Comments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div><ix:nonNumeric id="F_4464e2de-fa6b-4e6f-9a73-822d4dd8f09a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_4464e2de-fa6b-4e6f-9a73-822d4dd8f09a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90f96cca-1eef-4515-ba45-5398b1cd3526" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a cybersecurity risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The program is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96f17f83-bc7c-48e5-bdb5-c305062fe1fe" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within the Company&#8217;s enterprise risk management framework and addresses both the corporate information technology environment and the external ecosystem</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4464e2de-fa6b-4e6f-9a73-822d4dd8f09a_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe206939-d834-4e99-9c81-8ffd590b169b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The underlying controls of the cybersecurity risk management program are based on recognized best practices and standards for cybersecurity and information technology. The Company has a third party perform an annual assessment of the Company&#8217;s cybersecurity risk management program. The Company has a Cyber Security Operations Center monitoring our global cybersecurity environment and coordinates investigations and remediation of alerts. We are enhancing our programs for staging incident response drills to prepare support teams for a significant incident. The cybersecurity risk management program includes administrative, physical, and technical controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28884b5f-7f9e-48f5-bec6-f58f8514093a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61ab65b2-e352-429d-b6e5-74b15d16f8cd" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our VP, Head of Information Technology is the Company&#8217;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e5c027e-70fa-49b6-b102-97d80c35f9d4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All employees are required to complete cybersecurity training at least once annually and have access to more frequent cybersecurity training through online and live events. We also require employees in certain roles to complete additional role-based, specialized cybersecurity training that is documented in our quality management system. Employees outside of our corporate information security organization also have a role in our cybersecurity defenses and they are immersed in a corporate culture supportive of security, which we believe improves our cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e57ef899-817c-4e68-9fc0-842c8a3905fd" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6ba43e8-76f2-437a-bb99-b9885517b27c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#8217;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team collectively has decades of experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes around the world, and relies on threat intelligence as well as information obtained from governmental, public, and private sources, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edc7717d-758f-43f3-861f-3bfe14e5abdc" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including external consultants engaged by the Company on a real time basis.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea456853-8a29-4bd2-8d4a-43afb69a9ff3" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d6b0d55-58ba-4b73-8fe3-c034474c55f8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76afe941-c355-402c-be5f-cae9a47a2a88" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af962807-7246-4849-a685-0d57a71cb671" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, in addition to the Company&#8217;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#8217;s cyber risk management program, generally on a quarterly basis.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, cybersecurity risks will be reviewed by the Board of Directors, at least annually, as part of the Company&#8217;s corporate risk mapping exercise.</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a935c1b5-e5a6-40b7-b0a3-43ede6228591" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not experienced any material cybersecurity incidents to date, and, by default, we believe no cybersecurity events have occurred that have materially affected the Company or its business strategy</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, results of operations or financial condition. We continue to invest in cybersecurity and the resilience of our infrastructure and the enhancement of our internal controls and processes, which are designed to help protect our systems and data, and the information they contain. For more information regarding the risks we face from cybersecurity threats, please see &#8220;Risk Factors.&#8221;</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Prop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">erties</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Headquarters, R&amp;D and GMP Manufacturing Facility, Storage Facility</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket&#8217;s corporate headquarters is located in Cranbury, New Jersey, in a leased facility consisting of 103,720 square feet of space including areas for offices, process development, research and development laboratories and 50,000 square feet dedicated to AAV cGMP manufacturing to support our pipeline. The NJ Lease Agreement has an initial term ending in 2034, with an option to renew for an additional two consecutive five-year renewal terms. In addition, we lease space in New York, New York at the Empire State Building, which consists of approximately 6,600 square feet of office space under a lease that expires in July 2027. Rocket leases an additional 4,666 square feet storage facility in Dayton, New Jersey.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Facilities in Hopewell, New Jersey</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the acquisition of Renovacor, we added lease agreements for approximately 15,463 square feet of space in Hopewell, New Jersey that expires in March 2033. The Company intends to sublease these facilities and signed the first sublease agreement for one of the Hopewell, NJ facilities in January 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be subject to other various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any other claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">afety Disclosures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item5_market_registrant_common_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Re</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lated Stockholder Matters and Issuer Purchases of Equity Securities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is traded on the NASDAQ Global Market under the symbol &#8220;RCKT&#8221;. On February 21, 2025, the last reported sale price for our common stock on the Nasdaq Global Market was $10.47 per share.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The graph set forth below compares the cumulative total stockholder return on our common stock between December 31, 2019 and December 31, 2024 with the cumulative total return of (a) the NASDAQ Biotechnology Index and (b) the NASDAQ Composite Index, over the same period. This graph assumes the investment of $100 on December 31, 2019 of our common stock, the NASDAQ Biotechnology Index and the NASDAQ Composite Index and assumes the reinvestment of dividends, if any.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img173888082_4.jpg" alt="img173888082_4.jpg" style="width:636px;height:340px;"/></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 21, 2025, there were 31 stockholders of record, which excludes stockholders whose shares were held in nominee or street name by brokers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be made at the discretion of our Board of Directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 9, 2024, the Company entered into a Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with RTW Innovation Master Fund, Ltd. (the &#8220;Investor&#8221;) pursuant to which the Investor agreed to purchase in a private placement pre-funded warrants representing the right to purchase 0.4 million shares of our common stock, at the offering price of $12.49 per pre-funded warrant (which equals the public offering price per share of common stock in the Offering (as defined below) less the $0.01 per share exercise price of each such pre-funded warrant) (the &#8220;Private Placement&#8221;). The Private Placement closed on December 12, 2024, concurrently with the closing of a public offering of approximately 15.2 million shares of our common stock at a public offering price of $12.50 per share (the &#8220;Offering&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants issued in the Private Placement were offered and sold in reliance upon the exemption from the registration set forth under Section 4(a)(2) of the Securities Act, and the regulations promulgated thereunder relating to sales by an issuer not involving any public offering, and in reliance on similar exemptions under applicable state laws.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds from Public Offerings of Common Stock and Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, we completed the Offering of approximately 15.2 million shares of our common stock at a public offering price of $12.50 per share and Private Placement of pre-funded warrants to purchase 0.4 million shares of common stock at a price of $12.49 per warrant. The gross proceeds from the Offering and Private Placement of pre-funded warrants were approximately $194.7 million, net of $12.2 million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of pre-funded warrants of $182.5 million. The Offering and sale of the shares was registered under the Securities Act pursuant to a prospectus supplement, filed with the SEC on December 12, 2024  to the Company&#8217;s effective registration statement on Form S-3 (Registration No. 333-281606), which was previously filed with the SEC, and declared effective on August 16, 2024. There has been no material change in the planned use of proceeds from the Offering and Private Placement as described in the prospectus supplement related to the Offering.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no repurchases of our common stock during the year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Re</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">served</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7_management_discussion_analysis"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Fin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ancial Condition and Results of Operations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements, related notes and other financial information included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties such as our plans, objectives, expectations, and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in &#8220;Risk Factors&#8221; included elsewhere in this Annual Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unless otherwise indicated, references to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rocket,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">we,&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">us</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> refer to Rocket Pharmaceuticals, Inc. and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have two clinical stage and one pre-clinical stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adeno-associated viral (AAV) programs in the U.S., which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The DD program is currently in an ongoing Phase 2 trial (RP-A501). </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601).</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. Our program utilizes recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to slow or halt progression of BAG3-DCM. </span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced our alignment with the FDA on our pivotal study design for RP-A501 in DD. Completion of enrollment in this study was announced in September 2024, and dosing and follow-up are ongoing. The Company has received FDA clearance of an investigational new drug (IND) application for RP-A601, and has initiated a Phase 1 study for this program. For the BAG3 program, nonclinical and IND enabling studies are ongoing. Submission of the IND is anticipated in the first half of 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have three clinical-stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lentiviral (LV) programs, which include programs for:</span></p><p style="margin-left:8.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102) and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for RP-L201 for the treatment of severe LAD-I. In June 2024, we announced that the FDA had issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025. With respect to RP-L201, treatments in the FA Phase 2 studies were completed in 2023 and submission of a BLA on a rolling review basis was initiated in September 2024. In April 2024, the European Medicines Agency (EMA) accepted our Marketing Authorization Applications (MAA) for RP-L102. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. With respect to RP-L301, we have reached agreement with the FDA on the study design of the Phase 2 pivotal trial for RP-L301, our ex vivo LV-based program targeting PKD. While the Phase 2 RP-L301 study is ready for patient enrollment, we are currently focusing our resources on other programs and have not initiated enrollment in the Phase 2 RP-L301 study.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have global commercialization and development rights to all of these product candidates under royalty-bearing license agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Developments</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2022, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen with respect to an at-the-market offering program pursuant to which we could offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.01 per share, having an aggregate offering price of up to $200 million through Cowen as our sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024 after three years in accordance with the Commission&#8217;s rules. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to us. We may consider reactivating the at-the-market offering program in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sold a total of 4.2 million shares under the at-the-market offering program for gross proceeds of $65.8 million, less commissions of $2.0 million, for net proceeds of $63.8 million. We did not sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023, we sold 0.9 million shares for gross proceeds of $17.8 million, less commissions of approximately $0.6 million, for net proceeds of $17.2 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Offering and Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company completed the Offering of approximately 15.2 million shares of its common stock at a public offering price of $12.50 per share and Private Placement of pre-funded warrants to purchase 0.4 million shares of common stock at a price of $12.49 per warrant. The gross proceeds from the Offering and Private Placement were approximately $194.7 million, net of $12.2 million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $182.5 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to organizing and staffing the Company, business planning, raising capital, acquiring, or discovering product candidates and securing related intellectual property rights, conducting discovery, R&amp;D activities for our product candidates and planning for potential commercialization. We do not have any products approved for sale and have not generated any revenue from product sales. From inception through December 31, 2024, we raised net cash proceeds of approximately $1.2 billion from investors through both equity and convertible debt financing to fund operating activities.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the near future. If our development efforts for product candidates are successful and result in regulatory approval or license agreements with third parties, we may generate revenue in the future from product sales.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our R&amp;D program expenses consist of both internal and external costs incurred for the development of our product candidates. These expenses include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with research institutions and consultants that conduct R&amp;D activities, including process development and preclinical and clinical activities on our behalf&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to process development and production of preclinical and clinical materials, including fees paid to contract manufacturers and manufacturing input costs for use in internal manufacturing processes&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consultants supporting process development and regulatory activities&#894; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to in-licensing of rights to develop and commercialize our product candidate portfolio.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize external development costs based on contractual payment schedules aligned with program activities, invoices for work incurred, and milestones that correspond with costs incurred by the third parties. Nonrefundable advance payments for goods or services to be received in the future for use in R&amp;D activities are recorded as prepaid expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our direct R&amp;D expenses are tracked on a program-by-program basis for product candidates and consist primarily of external costs, such as research collaborations and third-party manufacturing agreements associated with our preclinical research, process development, manufacturing, and clinical development activities. Our direct R&amp;D expenses by program also include fees incurred under license agreements. Our personnel, non-program and unallocated program expenses include costs associated with activities performed by our internal R&amp;D organization and generally benefit multiple programs. These costs are not separately allocated by product candidate and consist primarily of:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries and personnel-related costs, including benefits, travel, and stock-based compensation, for our scientific personnel performing R&amp;D activities&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities and other expenses, which include expenses for rent and maintenance of facilities, and depreciation expense; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and equipment used for internal R&amp;D activities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We allocate salary and benefit costs directly related to specific programs. We do not allocate personnel-related discretionary bonus or stock-based compensation costs, costs associated with our general discovery platform improvements, depreciation or other indirect costs that are deployed across multiple projects under development and, as such, the costs are separately classified as other R&amp;D expenses.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents R&amp;D expenses, in thousands, tracked on a program-by-program basis as well as by type and nature of our expense for our product candidates for the years ended December 31, 2024 and 2023, and 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:46.66%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.780000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.780000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.780000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years Ended December 31,</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Direct Expenses:</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Danon Disease RP-A501</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,677</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,992</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,524</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy RP-A601</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,595</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,171</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,724</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I RP-L201</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,725</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,617</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fanconi Anemia RP-L102</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,749</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,276</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,917</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency RP-L301</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,145</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,808</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,744</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Infantile Malignant Osteopetrosis RP-L401</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other product candidates</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,768</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,501</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,580</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total direct expenses</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,310</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,473</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,377</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unallocated Expenses:</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,040</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,867</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,274</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation expense</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,784</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,509</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,465</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,023</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,375</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,037</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory and related expenses</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,170</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,618</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,405</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,831</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,927</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,601</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expenses</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,086</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,573</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,411</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other research and development expenses</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,934</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,869</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,193</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expense</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,244</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,342</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,570</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Effective December 2021, a decision was made to no longer pursue Rocket-sponsored clinical evaluation of RP-L401; this program was returned to academic innovators. Costs to close out the study were incurred in 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot determine with certainty the duration and costs to complete current or future clinical studies of product candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs, and timing of clinical studies and development of product candidates will depend on a variety of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress, and expense of ongoing clinical studies as well as any clinical studies and other R&amp;D activities that we undertake in the future&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future clinical study results&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties in clinical study enrollment rates&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changing standards for regulatory approval; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and receipt of any regulatory approvals.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect R&amp;D expenses to increase for the foreseeable future as we continue to invest in R&amp;D activities related to developing product candidates, including investments in manufacturing, as our programs advance into later stages of development and as we conduct additional clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of R&amp;D projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future R&amp;D expenses will depend on the clinical success of our product candidates, as well as ongoing assessments of the commercial potential of such product candidates. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect our R&amp;D expenses to increase for the foreseeable future as we seek further development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, outcome and costs of our clinical trials and other R&amp;D activities&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and potential advantages of our product candidates compared to alternative treatments, including any standard of care&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market acceptance of our product candidates&#894;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining, maintaining, defending, and enforcing patent claims and other intellectual property rights&#894;</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt, and terms of any marketing approvals.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of our product candidates that we may develop could mean a significant change in the costs and timing associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing beyond those that we currently contemplate for the completion of clinical development of any of our product candidates that we may develop or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and related benefit costs for personnel, including stock-based compensation and travel expenses for our employees in commercial, executive, operational, finance, legal, business development, and human resource functions. In addition, other significant general and administrative expenses include professional fees for legal, consulting, investor and public relations, auditing, and tax services as well as other expenses for rent and maintenance of facilities, insurance and other supplies used in general and administrative activities. We expect general and administrative expenses to increase for the foreseeable future due to anticipated increases in headcount to support the continued advancement of our product candidates and our progression to commercial operations. We also anticipate that as we continue to operate as a public company with increasing complexity, we will continue to incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense in 2024 and 2023 was related to our financing lease obligation for our Cranbury, NJ facility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and Other Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and other income related to interest earned from investments and cash equivalents and reduced fair value of warrant liability.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024 and 2023</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations, in thousands, for each of the periods presented:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.071%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.603%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.603%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.722000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,244</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,342</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,098</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,961</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,317</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,644</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,205</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,659</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,546</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(273,205</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(259,659</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,546</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,886</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,875</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,267</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,288</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,979</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount on investments, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,651</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,573</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,459</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,064</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">395</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(258,746</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(245,595</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,151</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses decreased $15.1 million to $171.2 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. The decrease in R&amp;D expenses was primarily driven by decreases in manufacturing development and direct material costs of $19.9 million. The decreases were partially offset by increases in the costs for professional fees and consultants of $4.0 million, non-cash stock compensation expense of $1.3 million, and depreciation expense of $2.2 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G&amp;A expenses increased $28.6 million to $102.0 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. The increase in G&amp;A expenses was primarily driven by increases in commercial preparation related expenses, which consisted of commercial strategy, medical affairs, market development and pricing analysis expenses, of $17.6 million, legal expenses of $4.8 million, non-cash stock compensation expense of $3.2 million, and compensation and benefit expenses of $2.1 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, increased by $0.4 million to $14.5 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. The increase in other income was primarily driven by an increase in interest and other income, net, of $3.0 million partially offset by a decrease in accretion of discount on investments, net, of $2.6 million. The increase in interest and other income, net, of $3.0 million was primarily due to decreases in warrant liability of $1.9 million and increased interest income of $0.7 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations, in thousands, for each of the periods presented:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:55.071%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.603%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.603%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.722000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,342</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,570</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,772</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,317</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,773</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,544</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,659</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,343</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,316</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(259,659</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(224,343</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35,316</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development incentives</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(500</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,875</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,862</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,288</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,889</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,399</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,651</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(47</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,698</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,064</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,480</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,584</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(245,595</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(221,863</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,732</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses increased $20.8 million to $186.3 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. The increase in R&amp;D expenses was primarily driven by increases in costs for compensation and benefits of $16.9 million due to increased R&amp;D headcount, clinical trial costs of $14.5 million, non-cash stock compensation expense of $5.0 million, and license expenses of $2.2 million. Increases noted were partially offset by decreases in manufacturing and development costs of $17.0 million and direct materials of $3.5 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G&amp;A expenses increased $14.5 million to $73.3 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. The increase in G&amp;A expenses was primarily driven by increases in commercial preparation related expenses of $8.4 million, non-cash stock compensation expense of $3.4 million, and legal expenses of $3.0 million, which were partially offset by a reduction in acquisition related expenses of $3.0 million due to the closing of the Renovacor acquisition in 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net increased by $11.6 million to $14.1 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. The increase in other income was primarily driven by an increase in accretion of discount and amortization of premium on investments, net, of $10.7 million and interest and other income, net, of $1.4 million. The increase in interest and other income, net, of $1.4 million was due to increased interest rates of $1.6 million, partially offset by increased fair value of warrant liability of $0.4 million.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not generated any revenue and have incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, those related to drug candidate development, technology and data security, patents and proprietary rights, our lack of commercial manufacturing marketing or sales experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional R&amp;D efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug candidates are in the development and clinical stage. There can be no assurance that our R&amp;D will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate significant revenue from product sales. We operate in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Rocket has incurred net losses and negative cash flows from its operations each year since inception. Rocket incurred net losses of $258.7 million, $245.6 million, and $221.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. We have experienced negative cash flows from operations and have an accumulated deficit of $1.22 billion as of December 31, 2024. As of December 31, 2024, we had $372.3 million of cash, cash equivalents and investments. We expect such resources would be sufficient to fund our operating expenses and capital expenditure requirements into the third quarter of 2026. We have funded our operations primarily through the sale of equity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 18, 2024, CIRM awarded the Company up to $5.8 million under a CLIN2 grant award to support the clinical development of its AAV-based gene therapy, RP-A501 for the treatment of DD. Proceeds from the grant would help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients. As of December 31, 2024, the Company has received RP-A501 grants of $2.3 million from CIRM, which were recorded as a reduction of R&amp;D expenses for the RP-A501 program for the year ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the longer term, our future viability is dependent on our ability to generate cash from operating activities or to raise additional capital to finance our operations. If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation, or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Our failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Offerings and Private Placements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company completed the Offering of approximately 15.2 million shares of its common stock at a public offering price of $12.50 per share and Private Placement of pre-funded warrants to purchase 0.4 million shares of common stock at a price of $12.49 per warrant. The gross proceeds from the Offering and Private Placement were approximately $194.7 million, net of $12.2 million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $182.5 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, we enter into contracts and commitments that obligate us to make payments in the future. Information regarding our obligations relating to income taxes and lease arrangements are provided in &#8220;Note 12. Income Taxes&#8221; and &#8220;Note 13. Leases&#8221; to our consolidated financial statements contained in &#8220;Item 8. Financial Statements and Supplementary Data.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any off-balance sheet arrangements that are material or reasonably likely to become material to our financial condition or results of operations.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows from operating, investing and financing activities, in thousands, for each of the periods presented:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51.95%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.017000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.017000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.017000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(209,724</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(194,916</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(178,142</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by/(used in) investing activities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,706</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,066</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(69,326</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,739</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,401</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">155,288</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,721</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(84,581</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(92,180</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, operating activities used $209.7 million of cash and cash equivalents, primarily resulting from our net loss of $258.7 million offset by net non-cash charges of $47.1 million, including non-cash stock-based compensation expense of $43.9 million, depreciation, amortization expense of $9.4 million and change in fair value of warrant liabilities of $1.9 million, partially offset by accretion of discount on investments of $8.1 million. Changes in our operating assets and liabilities for the year ended December 31, 2024 included an increase in accounts payable and accrued expenses of $6.1 million, decrease in other liabilities of $3.7 million, and an increase in our prepaid expenses and other assets of $0.7 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, operating activities used $194.9 million of cash and cash equivalents, primarily resulting from our net loss of $245.6 million offset by net non-cash charges of $37.2 million, including non-cash stock-based compensation expense of $39.4 million, depreciation and amortization expense of $7.1 million, impairment of acquired intangible asset and write down of property and equipment of $0.9 million, partially offset by accretion of discount on investments of $10.2 million. Changes in our operating assets and liabilities for the year ended December 31, 2023 included an increase in accounts payable and accrued expenses of $10.1 million, and a decrease in our prepaid expenses and other assets of $2.7 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2022, operating activities used $178.1 million of cash and cash equivalents, primarily resulting from our net loss of $221.9 million and net changes in our operating assets and liabilities of $6.1 million, partially offset by net non-cash charges of $37.6 million, including stock-based compensation expense of $31.0 million and depreciation and amortization expense of $6.3 million. Changes in our operating assets and liabilities for the year ended December 31, 2022 consisted of an increase in accounts payable and accrued expenses of $9.7 million and an increase in prepaid expenses and other assets of $3.6 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net cash provided by investing activities was $131.7 million, primarily resulting from proceeds of $383.5 million from the maturities of investments, offset by purchases of investments of $245.9 million, and purchases of property and equipment of $5.9 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, net cash used in investing activities was $98.1 million, primarily resulting from proceeds of $309.3 million from the maturities of investments, offset by purchases of investments of $390.9 million, and purchases of property and equipment of $16.4 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2022, net cash used in investing activities was $69.3 million, consisting of proceeds of $272.9 million from the maturities of investments and proceeds of $42.7 million from the acquisition of Renovacor, offset by purchases of investments of $376.3 million, purchases of property and equipment of $8.4 million and purchases of right of use assets of $0.3 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During year ended December 31, 2024, net cash provided by financing activities was $185.7 million, consisting primarily of proceeds related to the December 12, 2024 public offering of $182.5 million and $3.2 million from the exercise of stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During year ended December 31, 2023, net cash provided by financing activities was $208.4 million, consisting primarily of proceeds related to the September 15, 2023 public offering of $188.9 million, $17.2 million from issuance of common stock through our at-the-market offering program and $2.2 million from the exercise of stock options.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2022, net cash provided by financing activities was $155.3 million, consisting primarily of proceeds related to the October 6, 2022 public offering of $108.1 million and issuance of common stock through our at-the-market offering program of $46.6 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in conformity with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We periodically review our estimates as a result of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of our significant accounting policies, refer to &#8220;Note 3. Summary of Significant Accounting Policies&#8221; included in the notes to our consolidated financial statements appearing elsewhere in this report. We consider the most critical accounting policies to be those related to our Accrued R&amp;D Expenses, Stock-Based-Compensation, Goodwill and Intangible Assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business combinations are accounted for under the acquisition method. The total cost of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, asset lives and market multiples, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has one segment and one reporting unit and as such reviews goodwill for impairment at the consolidated level. When testing goodwill, the Company has the option to first assess qualitative factors for reporting units that carry goodwill. The qualitative assessment includes assessing the totality of relevant events and circumstances that affect the fair value or carrying value of the reporting unit. These events and circumstances include macroeconomic conditions, industry and competitive environment conditions, overall financial performance, reporting unit specific events and market considerations. The Company also considers recent valuations of the reporting unit, including the magnitude of the difference between the most recent fair value estimate and the carrying value, as well as both positive and adverse events and circumstances, and the extent to which each of the events and circumstances identified may affect the comparison of a reporting unit&#8217;s fair value with its carrying value. If the qualitative assessment results in a conclusion that it is more likely than not that the fair value of a reporting unit exceeds the carrying value, then no further testing is performed for that reporting unit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company performed the qualitative assessment of its goodwill and determined that it is more likely than not that the fair value of a reporting unit exceeds the carrying value of the reporting unit. As a result, the Company has determined there was no goodwill impairment as of and for the years ended December 31, 2024, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets consisted of IPR&amp;D assets and a mice colony model. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&amp;D intangible assets which are determined to have had a drop in their fair value are adjusted downward and an expense recognized in R&amp;D expenses in the Consolidated Statements of Operations. These IPR&amp;D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&amp;D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. If a triggering event occurs that would indicate a potential impairment, the Company will perform a quantitative analysis to determine whether it is more likely than not that the fair value is below carrying amount. The annual impairment assessment for the IPR&amp;D asset was performed as of December 1. No impairment of the IPR&amp;D asset was recorded for the years ended December 31, 2024 and 2023. The mice colony model was impaired and written off during the year ended December 31, 2023.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued R&amp;D Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued R&amp;D expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued R&amp;D expenses include fees paid to:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CROs in connection with performing R&amp;D services on our behalf;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigative sites or other providers in connection with clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors in connection with non-clinical development activities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vendors related to product manufacturing, development and distribution of clinical supplies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage non-clinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We issue stock-based awards to employees and non-employees, generally in the form of stock options, RSUs, and PSUs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. The cost of stock options and RSUs is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The vesting condition for PSUs is performance based and the cost of a PSU is recognized when it is likely that the performance goal associated with the PSU will be achieved and the award will vest.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as expected volatility and expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify stock-based compensation expense in our Consolidated Statements of Operations in the same manner in which the award recipient&#8217;s payroll costs and services are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Not Adopted as of December 31, 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09: Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update was required to be effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the effect that ASU 2023-09 will have on its financial statements and disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASU 2024-03: Disaggregation of Income Statement Expenses (DISE). This update requires disaggregated disclosure of income statement expenses. This update is effective for the Company for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the effect that ASU 2024-03 will have on its financial statements and disclosures.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Adopted as of December 31, 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update is effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. The adoption of ASU 2023-07 resulted in a new footnote disclosure for Segment Reporting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7a_quantitative_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ive Disclosures about Market Risks</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risk related to changes in interest rates. As of December 31, 2024 and 2023, we had cash, cash equivalents and investments of $372.3 million and $407.5 million, respectively. The Company&#8217;s investments are primarily in U.S. Treasury Securities and Corporate Bonds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will fall in value if market interest rates increase. If market interest rates were to increase immediately and uniformly by 100 basis points, or one percentage point, from levels at December 31, 2024, the net effect on the net fair value of our interest-sensitive marketable securities would have resulted in a hypothetical decline of $0.8 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item8_financial_statements_supplementary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Supplementary Data</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements required by this Item 8 are included in Item 15 of this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9_changes_disagreements_accountants"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accountants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on Accounting and Financial Disclosure</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Contro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ls and Procedures</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive and our principal financial and accounting officers, evaluated, as of the end of the period covered by this Annual Report, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of December 31, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13a-15(f) and 15d-15(f)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and interim principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13(a)-15(f) and 15(d)-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of management, including our principal executive and financial officers, we assessed our internal control over financial reporting as of December 31, 2024, based on criteria for effective internal control over financial reporting established in Internal Control &#8212; Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Our management&#8217;s assessment of the effectiveness of our internal control over financial reporting included testing and evaluating the design and operating effectiveness of our internal controls. In our management&#8217;s opinion, we have maintained effective internal control over financial reporting as of December 31, 2024, based on criteria established in the COSO 2013 framework.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by EisnerAmper LLP, an independent registered public accounting firm, as stated in their report which is included herein.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inherent Limitations of Internal Controls</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Othe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of our directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ce55352-d99e-45a7-b868-1094dfde8ed4" contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_ad284b4c-a8db-4684-a6d6-d59c950d8b0d" contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted </span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4de3d90c-6d83-47bf-b044-804dc4fd12b9" contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_fcc7b562-cbdf-40ab-8872-488afe1fef7c" contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Ju</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risdictions that Prevent Inspections</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="partiii_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III. &#8212; OTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ER INFORMATION</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Office</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rs, and Corporate Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information with respect to this item will be set forth in the Proxy Statement for the 2025 Annual Meeting of Stockholders (&#8220;Proxy Statement&#8221;) under the headings &#8220;Nominees for Election as Directors,&#8221; &#8220;Information about Our Executive Officers,&#8221; &#8220;Information about the Board and Corporate Governance&#8221; and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information with respect to this item will be set forth in the Proxy Statement under the headings </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Compensation Discussion and Analysis,&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Compensation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; &#8220;Director Compensation&#8221; and &#8220;Equity Compensation Plan Information&#8221; is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item12_security_ownership_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ers and Management and Related Stockholder Matters</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information with respect to this item will be set forth in the Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item13_certain_relationships_related"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Party Tra</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nsactions, and Director Independence</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information with respect to this item will be set forth in the Proxy Statement under the headings &#8220;Transactions with Related Persons&#8221; and &#8220;Information about the Board and Corporate Governance&#8221; and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item14_principal_accountant_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accountan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t Fees and Services</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent public accounting firm is EisnerAmper LLP, New York, New York, PCAOB Auditor ID </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc28ea72-c130-4103-a09c-3cd4993d3e3c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">274</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information with respect to this item will be set forth in the Proxy Statement under the heading &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference. The Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T IV</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item15_exhibits_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15.  Exhibits, Financial </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements and Schedules</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following documents are filed as part of this Annual Report:</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements:</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:94%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#audit_report"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 202</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_comp_loss"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_equity"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_stmt"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statement Schedules:</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits:</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312517283239/d421363dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2.1</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger and Reorganization, dated as of September 12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (incorporated by reference</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on September 13, 2017)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036122034038/brhc10042060_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2.2</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated September 19, 2022, by and among Rocket Pharmaceuticals, Renovacor, Inc., Zebrafish Merger Sub, Inc. and Zebrafish Merger Sub, LLC (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on September 20, 2022)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312515114201/d893535dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.1</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Seventh Amended and Restated Certificate of Incorporation of Rocket Pharmaceuticals, Inc., effective as of February 23, 2015 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on March 31, 2015)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518004435/d516098dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.2</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of Amendment (Reverse Stock Split) to the Seventh Amended and Restated Certificate of Incorporation of the Registrant, effective as of January 4, 2018 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on January 5, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518004435/d516098dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.3</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of Amendment (Name Change) to the Seventh Amended and Restated Certificate of Incorporation of the Registrant, effective January 4, 2018 (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on January 5, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036118029797/ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.4</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Seventh Amended and Restated Certificate of Incorporation of the Registrant, effective June 25, 2018 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on June 25, 2019)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036124030718/ef20031374_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.5</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of Amendment (Authorized Shares Increase) to the Seventh Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the Commission on June 20, 2024)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518107593/d564113dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.6</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated By-Laws of Rocket Pharmaceuticals, Inc., effective as of March 29, 2018 (incorporated by reference to Exhibit 3.2 to the Company&#8217;s registration statement on Form 8-A/A, as amended (001-36829), filed with the SEC on January 11, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518004435/d516098dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.1</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate of Rocket Pharmaceuticals, Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on January 5, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036121006677/brhc10020974_ex4-8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.2</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description of Securities (incorporated by reference to Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on March 1, 2021)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036123044141/ny20010507x5_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.3</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on September 15, 2023)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518143310/d535515ddef14a.htm#toc535515_57"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.1#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Second Amended and Restated 2014 Stock Option and Incentive Plan (incorporated by reference to Appendix A to the</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Company&#8217;s Definitive Proxy Statement (001-36829), filed with the SEC on April 30, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036118036347/ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.2#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Incentive Stock Option Agreement (Employees) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on August 14, 2018)</span></p></td>
    </tr>
   </table></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036118036347/ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.3#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Non-Qualified Stock Option Agreement (Employees) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on August 14, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036118036347/ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.4#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Non-Qualified Stock Option Agreement (Non-Employee Directors) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on August 14, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036118036347/ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.5#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Non-Qualified Stock Option Agreement (Consultants) (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on August 14, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036120005056/ex10_61.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.6#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.6.1 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on March 1, 2021)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000156459018004621/rckt-ex103_200.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.7#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Ltd. 2015 Share Option Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on March 7, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036119014585/ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.8**</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amended and Restated Lease Agreement, dated as of June 26, 2019, by and between the Company and Cedar Brook 12 Corporate Center, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on August 8, 2019)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000156459018004621/rckt-ex1010_755.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.9#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. Amended and Restated 2014 Employee Stock Purchase Plan (incorporated by</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">reference to Exhibit 10.10 to the Company&#8217;s Annual Report on Form 8-K (001-36829), filed with the SEC on March 7, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518004435/d516098dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.10#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement, to be entered into between the Registrant and its directors (incorporated</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on January 5, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000119312518004435/d516098dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.11#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement, to be entered into between the Registrant and its officers (incorporated</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on January 5, 2018)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036123038855/brhc20057098_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.12#</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severance and Change in Control Policy, effective as of February 14, 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on August 9, 2023)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.13</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">#</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Form of Proprietary Information, Inventions and Non-Solicitation/Non-Competition Agreement, to be entered into between the Company and its officers (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on February 27, 2024)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036119004603/ex10_26.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.14&#134;</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License Agreement, dated as of November 19, 2018, by and between Rocket Pharmaceuticals, Ltd. and REGENXBIO Inc. (incorporated by reference to Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on March 8, 2019)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036121006677/brhc10020974_ex10-23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.15</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant to Purchase Shares of Common Stock, dated as of December 21, 2020, by and between the Registrant and Neptune Consulting, LLC. (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on March 1, 2021)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036122007036/brhc10034550_ex10-26.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.16</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant to Purchase Shares of Common Stock, dated as of December 17, 2021, by and between the Registrant and Neptune Consulting, LLC. (First Indication) (incorporated by reference to Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on February 28, 2022)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036122007036/brhc10034550_ex10-27.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.17</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant to Purchase Shares of Common Stock, dated as of December 17, 2021, by and between the Registrant and Neptune Consulting, LLC. (Second Indication) (incorporated by reference to Exhibit 10.27 to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on February 28, 2022)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036121029648/ny20000237x2_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.18</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated as of August 27, 2021, by and among Rocket Pharmaceuticals, Inc., and each of those persons listed as an Investor on the Schedule of Inventors attached as Schedule A thereto (incorporated</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on August 30, 2021)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036122007127/ny20003042x2_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.19</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales Agreement, dated February 28, 2022, by and between the Company and Cowen and Company, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on March 1, 2022)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000114036123008393/brhc10048715_ex4-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.20</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assignment, Assumption and Amended &amp; Restated Warrant Agreement, dated January 16, 2023, by and among Rocket Pharmaceuticals, Inc., Zebrafish Merger Sub II, LLC, as successor to Renovacor, Inc., and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form 8-A (001-36829), filed with the SEC on February 24, 2023)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001281895/000114036123043736/ny20010507x4_8k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.21</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Sales Agreement, dated September 12, 2023, by and between the Company and Cowen and Company, LLC (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K (001-36829), filed with the SEC on September 13, 2023)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.22</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">#</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. General Compensation Clawback Policy (incorporated by reference to Exhibit 10.23 </span><span style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">to the Company&#8217;s Annual Report on Form 10-K (001-36829), filed with the SEC on February 27, 2024)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000095017024054465/rckt-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.23</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">#</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated March 25, 2024, by and between the registrant and Aaron Ondrey (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (001-36829), filed with the SEC on May 7, 2024)</span></p></td>
    </tr>
   </table></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:89%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Index</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="rckt-ex10_24.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.24#*</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. Non-Employee Director Compensation Policy</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="rckt-ex19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">19*</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. Insider Trading Policy</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="rckt-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">21.1*</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">List of Subsidiaries</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="rckt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">23.1*</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consent of EisnerAmper LLP</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1*</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Power of Attorney (included in the signature page)</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rckt-ex31_1.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rckt-ex31_2.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="rckt-ex32_1.htm"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="https://www.sec.gov/Archives/edgar/data/1281895/000095017024021096/rckt-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">97</span></a></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. Nasdaq Rule 5608 Compensation Clawback Policy</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Certain portions of this exhibit have been excluded because they are both not material and would likely cause competitive harm to the Company if publicly disclosed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The certification attached as Exhibit 32.1 accompanying this Annual Report on Form 10- K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Rocket Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item16_form_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K Summary</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:48%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ROCKET PHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gaurav Shah, MD</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gaurav Shah, MD</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Aaron Ondrey</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Ondrey</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:0.12%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> OF ATTORNEY AND SIGNATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each person whose individual signature appears below hereby constitutes and appoints Gaurav Shah, MD and John Militello, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gaurav Shah, MD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gaurav Shah, MD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Aaron Ondrey</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Ondrey</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Militello</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VP, Finance, Senior Controller &amp; Treasurer</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John Militello</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Elisabeth Bj&#246;rk</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Elisabeth Bj&#246;rk</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carsten Boess</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carsten Boess</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mikael Dolsten</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mikael Dolsten</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Pedro Granadillo</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pedro Granadillo</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gotham Makker, MD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gotham Makker, MD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Fady Malik</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fady Malik</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Piratip Pratumsuwan</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Piratip Pratumsuwan</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David P. Southwell</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">David P. Southwell</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Roderick Wong, MD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roderick Wong, MD</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ R. Keith Woods</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R. Keith Woods</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:0.12%;font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="margin-left:32.133%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:31.981%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index to Consolidated Financial Statements Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:94%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#audit_report"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(PCAOB ID 274)</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 202</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_comp_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_stmt"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Board of Directors and Stockholders of</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0754171-9047-4989-a89d-2ed7524c20c8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:AuditorOpinionTextBlock" escape="true" continuedAt="F_a0754171-9047-4989-a89d-2ed7524c20c8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="audit_report"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Rocket Pharmaceuticals, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).  In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated February 27, 2025 expressed an unqualified opinion.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management.  Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.  We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.  We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment assessment &#8211; In-process research and development</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Notes 3 and 6 to the financial statements, as of December 31, 2024, the Company had an indefinite-lived intangible asset of $25.2 million which is related to in-process research and development (&#8220;IPR&amp;D&#8221;) acquired from Renovacor, Inc. in December 2022. Management reviews the IPR&amp;D for impairment by performing a qualitative assessment of impairment indicators. If a qualitative assessment indicates that the Company&#8217;s IPR&amp;D is impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the asset is less than its carrying value, the asset is written down to its fair value. As of December 1, 2024, management performed its qualitative assessment of impairment indicators for its IPR&amp;D based on indicators including progress of research and development activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. Management made significant assumptions regarding the likelihood and extent of preclinical and clinical study timeline and related costs, probability of regulatory approval, commercialization, and sales projections.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal considerations for our determination that performing procedures relating to the impairment assessment of the IPR&amp;D is a critical audit matter as there was significant judgment by management in its impairment analysis. This in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence relating to preclinical and clinical study timeline and related costs, probability of regulatory approval, commercialization, and sales projections. In addition, the audit effort involved the use of professionals with specialized skill and knowledge to assist in performing these procedures and evaluating the audit evidence obtained from these procedures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. We obtained an understanding, evaluated the design and implementation and tested the operating effectiveness of controls relating to management&#8217;s IPR&amp;D impairment assessment. We evaluated the reasonableness of management&#8217;s assumptions which involved consideration of whether these assumptions were consistent with (i) the Company&#8217;s public announcements and filings, (ii) external market and industry data, and (iii) evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the reasonableness of the discount rate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ EisnerAmper LLP</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2016.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a664076d-fdbd-4a7b-a623-2d448e2151da" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EISNERAMPER LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3695472-7ee4-4369-aea7-b82ed7b5de6e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Iselin, New Jersey</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Board of Directors and Stockholders of</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a0754171-9047-4989-a89d-2ed7524c20c8_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited Rocket Pharmaceuticals, Inc. and Subsidiaries&#8217; (the &#8220;Company&#8221;) internal control over financial reporting as of December 31, 2024, based on criteria established in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;).  In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) issued by COSO.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of Rocket Pharmaceuticals, Inc. and Subsidiaries as of December 31, 2024, and the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes and our report dated February 27, 2025 expressed an unqualified opinion.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting.  Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit.  We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.  Our audit also included performing such other procedures as we considered necessary in the circumstances.  We believe that our audit provides a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An entity&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  An entity&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the entity; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the entity are being made only in accordance with authorizations of management and directors of the entity; and (iii)  provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the entity&#8217;s assets that could have a material effect on the financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ EisnerAmper LLP</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f82508f6-6726-41ee-ad21-2a0e54a43f22" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EISNERAMPER LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9700c82-ec89-47b8-9bfe-ec86438ac898" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Iselin, New Jersey</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.872%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:17.063%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:17.063%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7372f7a-9076-4541-836b-c27c9dd17f7f" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,635</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a4ab1c4-8a2a-401c-8325-96925abae580" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,904</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e473563f-2f2f-4de9-86e7-b42c30da9cab" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,701</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_865b19dd-3571-4e29-85a3-c5384f9eecca" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">317,271</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2fe9d36-657d-401c-bdbd-24f5c6fcd9ea" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,847</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddd799d3-b3fc-4723-a897-f408c4eb2234" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,047</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91cfbda-b972-48f6-baf8-3ed34339844b" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">378,183</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cf8937f-a796-4ca3-849d-2368baae93d1" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">378,222</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bf3b110-042d-47ea-89eb-3d58da384493" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,786</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d99e3dec-a198-4802-a6e4-dba824c195c1" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,172</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e454198c-e051-404e-af1b-576d30077070" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca33475f-5dd5-44ae-8d9e-3c4187e5c6ed" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d9f0af1-bf9a-4f41-adcc-543ddde92f32" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,150</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e5b97e3-1b1c-4329-84d2-c6eb2d4cacd1" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,150</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12c96d3b-ff99-4d78-9d2c-efbb9f1a450f" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,362</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7de6332-35dc-469f-94db-345d77dace62" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7cda09e-c0c2-497a-b29c-285b5f0cbbe3" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ca70b7c-680f-4b7d-b103-988d0059bb07" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">533</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b18c04b-14f5-44e0-a1ea-bef016c871af" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa479b1f-d290-4fb5-b164-174d6b06142f" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,320</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets, net</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0beb781d-4c74-45d2-992f-81419fb3f0b8" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0235947-0f7d-4684-a8cc-a1a02313c138" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,901</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease right-of-use asset, net</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6558c87e-8f67-405e-b878-af2b05af5374" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,363</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c469ab6c-d895-40d0-ac28-3c2319de237a" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,517</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60787076-7602-4bda-8aac-6be768e83443" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e73990a6-6b82-49e6-879b-9ba6dcb4d295" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">566,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f545ccb7-577f-4802-bc6a-9b9647c54e17" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,827</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_071695c1-6c30-4464-a274-49a3d393ed37" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,789</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af8764e7-e0eb-4855-915e-64ef7957c7db" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,001</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f86e41f-2a0c-4f57-8be1-fb7f1f2d78a5" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">925</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liability, current</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7ba4acb-c7c4-4716-a2ed-c04dd105cf65" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,856</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d12652a4-ecf9-49b8-84be-d20d56f43aeb" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,791</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a947204c-a606-4c31-9645-f47d632a48b6" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,684</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92b04728-859b-4670-a12e-6c47e73aa2cf" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,505</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, non-current</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c63abb43-2ac0-4c94-8178-4c2ff98727c8" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,258</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_155e0d25-0e70-4505-b2da-65f3ea43d460" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,973</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liability, non-current</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e6a2a87-8ce3-422a-af6a-926887c461b8" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,383</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5005a81-5f01-4beb-9c3e-860a6ac0177f" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,353</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9b4c68a-0279-4acd-85af-c9d728a8d084" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b0d8a24-7ef9-4047-a6d4-9c9b3e02f0c4" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,936</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19b5c2b3-5262-4063-a515-9abfbc952efc" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,466</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70f1030d-83d8-4f52-8e75-0a287ecbf7a2" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,767</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_63f0a92f-a65a-4c84-b222-33d614db54c3;"><span style="-sec-ix-hidden:F_76b723fc-c65f-451e-978b-806aac96cad9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 14)</span></span></span></span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1dc9ecf-8546-4b5e-9915-fb958122f7f0" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2edf3808-01f2-44b1-96a7-2bf165465f59" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, authorized </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0dcb5fa-d778-4055-82dc-ed8f6c455573" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_14954af7-97a9-4a10-9e0f-f55960458dbe" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares:</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series A convertible preferred stock; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1e74c20-35d1-463a-994e-63b8ed85923a" contextRef="C_6562543d-3991-4041-aff9-088643ccce60" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8d42fb03-fa26-4ade-ba72-ca26f4714201" contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares designated; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3726097-48e8-443f-8e44-4ffd797039e5" contextRef="C_6562543d-3991-4041-aff9-088643ccce60" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dc090e66-695f-4a8f-b147-cfb4f4e55ede" contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_32d8a654-13d9-4e38-b3a4-9b814c28407b" contextRef="C_6562543d-3991-4041-aff9-088643ccce60" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_01ed6932-b4a5-43f7-9305-45996bfd0334" contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_dc034d90-1564-4b13-80cc-fb23b4f1b2e2;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_fc42e5ab-9c8c-4f21-a12e-b9264001c1d4;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Series B convertible preferred stock; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abf3af6d-1986-45c7-9b12-04f3a9dbe1fc" contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_41198bd1-f12c-493b-8d3c-4252d14c5fd5" contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares designated; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f3c4307-b7ce-4905-8d7f-1dae5ceea5f3" contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_43473417-cfe0-41e8-80b5-be2fac0ec8d3" contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_052a55bf-d6f6-4562-a7ee-e567a9aadcae" contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_41f4c2bf-6cce-403e-8e5a-3597a62e06f0" contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ccfdc9a8-1b03-4d0f-b432-45e689b2bcfb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4bf39ad5-2046-4fcd-9234-2456d6001b5f;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f81b38d-c7b6-40e6-bc89-602a2535253a" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_28337d0f-3632-4b47-b4a2-715d98348b11" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_503974f1-3248-42b3-9d95-8e3d70e07435" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1cd5b126-84d3-4d79-98ae-2dd75ac66cc9" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">180,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1339b06-6303-4553-9409-1e98d793373e" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4d9a1779-9550-4b74-892f-3fba446a005e" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,453,818</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_178078bd-bde9-4a9c-919b-f6b446ce86a4" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dbca314e-569a-45a3-b8b3-aefd8a358262" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">90,282,267</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d142dd-b2b9-4b8e-81c3-9cfc55db3d42" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,065</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd6acbf4-eaeb-446e-955c-597afaa4ab84" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">903</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7662410-e195-489c-8808-1874a28fed89" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,680,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72bb9757-1d40-480e-bfc8-4722db17c75c" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,450,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cf90265-9f35-4c76-8d32-2b113ac2f0d0" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6f012eb-9743-4bfe-b260-1fa3f8103005" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_199c984d-d28a-4fbe-9677-9f00d2c0f1c6" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,218,116</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eee087d4-d316-4b8c-a05d-521b09f4bc94" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">959,370</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10ba6980-cdc1-44ea-bef9-623057870b16" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463,234</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fbcc647-162e-42ea-be62-cced41deed2c" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">492,574</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae57d85d-4bf6-49a5-a927-e83c82fa4319" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5434f35-d172-4eb7-98ce-5b9a718bb20f" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">566,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.652%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.782%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52907c47-3a52-4c89-8925-f7fcfcbab2e1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bbde882-726b-4248-a9d1-4e2fb2b92d32" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93f62f68-3922-4892-abcc-211779f06219" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0052a38-9cc0-4f96-a45b-084972697f52" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,244</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b13bfdd-d611-4a12-bab6-53f0bfd7ece9" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,342</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92190900-dcb2-42ce-821a-a342bebae210" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,570</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ae962d-0f4b-42a2-ac6a-cfd8ce3e308a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1f0d40b-458a-435b-93b9-5fc37f3fe881" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,317</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0e97ae-6648-4fe9-98af-be971230606d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,773</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa6784c4-0253-4fbf-a7e9-db8bd93a2a69" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,205</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_910d9a9b-1d19-4929-acc7-ca5c909358b1" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,659</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e723e27c-e0b7-49e2-85ea-c009c1856a7c" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,343</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d5fe501-bad1-498e-adb7-3f7731743c01" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">273,205</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6d98b0-e305-4231-bdb4-bd9301291a87" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">259,659</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6825238-66cd-4432-b2e1-8d3c238c9f07" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224,343</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development incentives</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96f4d280-6207-4622-93a4-7a6b63b69495" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:ResearchAndDevelopmentIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef2677cc-5d7a-4fbc-b4d2-1dc36fac7171" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:ResearchAndDevelopmentIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5689f36-aa13-4123-a300-395662f52580" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:ResearchAndDevelopmentIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7504b384-b0fc-452f-b73d-0896d62f816e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,886</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d69791-ca9a-46c5-8f2e-9be493d9b87b" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,875</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b235095-4c02-4038-b085-b2d93646df85" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,862</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96fc89f7-b6b8-4ff8-bc0e-5956fec5a0b2" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,267</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54164b7c-c023-440a-b4c4-7f279fdff8db" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,288</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81cfd0f2-47eb-4c1b-8466-82a909561288" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,889</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acb2ae89-539b-443c-8759-6a905cf3d18d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,078</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c35526-5894-4f8b-8520-8b0820883067" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,651</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92496749-359c-4762-8ca3-4ca6c6062f41" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b010e0d6-fa86-46d1-b8ba-e8724a4d95f9" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f836b2c6-7aef-4290-8e58-3a6b374cfec6" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73ab652a-681f-4e9f-aa8f-e6ac92cef05f" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8d0222f-8766-448b-90d4-7582c0367466" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2b12eb4f-3c45-4ed5-a46e-e47720dff843" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.73</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68ab32c6-6264-4845-87a9-46604324603b" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2bc10fca-321e-4a4d-b67a-e44693792848" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.92</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56f784da-92d5-4c9f-8ad9-8ec71a3c0252" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0728dc6c-d1fd-4b72-850a-92f05e6e09c1" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.26</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ede6654-d5cc-4228-bfce-798867586906" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_831e4dbe-308a-4b03-b048-9d555d214295" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">94,807,773</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d576af7-ca2e-43e4-bae2-f592448eaf72" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_90b1b612-570b-4c77-bbee-1f45810339da" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,009,004</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3bc7c78-cfbf-440c-8770-6a75d578af46" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d3fad02d-9c7e-494f-9661-5766e75a213a" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">68,148,925</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:0.12%;font-size:10pt;margin-top:2.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_comp_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:32.133%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:31.981%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:52.969%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.677000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.677000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.677000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d23fe1d6-1b5e-41d6-b3aa-f551feaf2633" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fedbe1cd-1819-4382-babf-1139836652ed" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b3f2423-f3c5-4bee-ad22-3ceb15bab8ee" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized (loss) gain on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47ba9e1c-0c92-485a-8bfb-1f0cb33864a4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d970939-f4b8-43d3-a72b-ba226d09de84" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3172a91e-d2a7-47a8-87ab-5035f21b5b30" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97dce9ad-7b9f-4fd1-b407-6d0cb2b946d1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb012ce1-1c5b-43ee-b1c2-7dc18037b140" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">244,919</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb0a6e14-fcdc-44c0-b909-3e20cd2fa978" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">222,059</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements o</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f Changes in Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.092%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.938%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.539%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:5.959%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.979%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.979%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.979%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.539%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Income/(Loss)</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f52f00a8-f4e7-4eb0-a514-7074b5a2b82f" contextRef="C_b57bb250-c7e3-4d28-a381-947cb29c01f5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">64,505,889</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e10deb3e-1877-44ab-b10c-c3f726268f78" contextRef="C_b57bb250-c7e3-4d28-a381-947cb29c01f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">645</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f07c320-ff35-4705-846a-cfab63cc1476" contextRef="C_9b1dc6b9-f15b-42c3-88cc-60968fdcd0ff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">946,152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a68fac39-b781-4a12-8ce1-503ec795cef3" contextRef="C_c05bc945-3f19-4133-993a-f7a7c46cf63f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e71ebc0c-ff1e-42c9-8dd7-51dcf7916bbe" contextRef="C_5579d6c9-7175-4d28-8d03-b3467227e674" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">491,912</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee84757b-514d-405d-9868-d4eb25997e19" contextRef="C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">454,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5c7b00e-e5bd-4e20-aeb3-76c46fb6fd84" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,820,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70069f56-433e-4bab-8cdf-436c3e642958" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06e4a98c-a057-4cc7-98e7-04bff506f325" contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,060</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12284021-d8be-4870-807d-2764aae41ce3" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,138</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b95e3fe-c4e0-494e-a968-0de8a11c34d1" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,887</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f01bd5-75ef-4394-983a-3e069c8ad121" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14bdbf06-0a1e-43ea-b63f-4078fa324d5e" contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">630</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16340594-3b25-47fb-8128-d572b633a23c" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0a092e-6c8a-4d22-85d6-9a926796fd64" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,168</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to acquisition</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b795b90-5744-4ee8-bb31-93bfaeb5f98f" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,420,774</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e1ef674-24f9-496f-a108-dd7a5d3242ef" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a983c426-be25-4633-b75c-9a7a69b6a1e7" contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b821b39-63a8-4665-95da-13e95f386f7d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to earnout restricted stock units settlement</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_117ed893-fa10-4287-9495-d0b03b5345ce" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_610152ae-4f4d-45f2-ae4d-7a163788941f" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="rckt:StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,291,922</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211f2281-03e1-4bbb-904d-09f22cb7edfe" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d487e7b4-0297-40a3-b32d-868b6cc38bac" contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120" name="rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,533</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42406da9-3417-4ad0-88ff-04c61b765087" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,566</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c8848c5-5aa1-4023-8401-7fd84a6d746c" contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,571</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b04a279-7383-40a8-8101-8014538b0cea" contextRef="C_c72bc269-579c-4d57-ac72-5d5633259ea5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4143e41-381d-4dd5-bd0e-844f3df8dcc5" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized comprehensive loss on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d19fee2-fcf3-4587-8623-a363fec2bc82" contextRef="C_c3286afb-2e4a-4c4c-99a2-97e9d815732a" name="rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0864d817-32cb-49c9-a6eb-f40db56916f9" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56813cb2-3903-4bd1-b652-5b71004ff0ac" contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,009</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6406081b-ad3a-4853-ad7b-c79e405a606e" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,009</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cce3f6e5-f880-426e-aa57-df0114e14bbf" contextRef="C_2c3ff4eb-7ecb-4647-a320-5c43c59dd844" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_017a7178-cc3c-40cb-9606-436b42dac906" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ede8d5a-0715-4620-a2a6-d7c34958b120" contextRef="C_74f8d0f8-a7bf-4f11-928f-7f1a09f755c1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">79,123,312</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b67d8320-a00c-45c3-9511-68a8e4dd67e6" contextRef="C_74f8d0f8-a7bf-4f11-928f-7f1a09f755c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">791</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97c3b59b-ede7-4723-b437-1a64380b0af7" contextRef="C_2f0b3d23-92ac-4213-bd74-31dcf6bf23dc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d21eb6b-3af2-4a71-b038-be1f829dc70b" contextRef="C_df19c97a-a904-4e39-bf6b-380f08b81962" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,203,074</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c1a947d-eac5-4fbb-804b-8eb639f269ea" contextRef="C_79626284-c57a-465a-9017-f3638fa6a020" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">357</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cc4c15a-7ab4-4d11-9c8b-672c755c0bad" contextRef="C_58974243-708a-4a81-a595-749260b730ad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">713,775</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7de3afc-077b-4813-972c-bad50133f565" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">489,686</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7acd4d2-ac8b-404f-90c6-f572f703e899" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,453,418</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11ed4d26-15ac-457d-bd41-7e36aae88923" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f4d2e8e-53d3-41ff-a28d-5337f6d0ef20" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,790</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_405f634d-f00f-47a7-b76a-7e752f183a91" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,885</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b277c0e-9bdf-4a69-abbf-9c7c2443acde" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a138133f-fd20-4498-aedd-80383b482761" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76867a89-e6b3-4ffc-8301-c00a9d31e524" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,229</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07c61760-a56f-4c67-b517-1baff06a8a16" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2342ab0-27ce-439d-97e5-12a3de586c1a" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">407,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef898ab2-c13a-473e-92e2-6ec3c0a59374" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51228714-df5f-45d7-bee2-1d3cc9f56197" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74e3fe1a-851b-4489-9d6e-94ed3b143c39" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="rckt:StockIssuedDuringSharesCommonStockWarrantExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">126,093</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44a94317-de54-4fb1-a257-a25368549d38" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0934ab05-546a-4427-a4ed-0e2ac0f94170" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2160f12-14a1-422c-9842-7ee3014e90c1" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa15753a-87d9-4893-8438-65910cc22a40" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="rckt:StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">948,300</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8005ae70-0cb4-4339-8ee6-4bb758405abe" contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39" name="rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8da073b-df68-4d04-8aa6-eb7ae303a540" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,212</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4b09172-05f9-427e-be0e-26a42f6fb6bb" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,222</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized comprehensive gain on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f9550c1-62f4-45e9-b37d-26f63f2c7a3c" contextRef="C_95348ff1-8262-49b2-97f9-9288584683e3" name="rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05651522-ec5d-4378-a2f5-9a00bbc7b885" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale of treasury stock</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e25641-f1ad-4caf-b9c9-be34963f21ce" contextRef="C_46f31250-5670-4e2c-961d-6755291c25a1" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d1d820-c484-4fba-ba2f-5d59c2071449" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bc346a4-657b-4220-afae-510ca316b423" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4ddaab3-62bc-41c8-a974-77f4e24334c1" contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,406</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d61f858b-e56b-4db2-ba5d-de57aa1b19d2" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,406</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c6021c-6ba4-4328-9662-e48c97f27d58" contextRef="C_053815b6-adc7-4370-b942-f77a4c14f8b7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fbb1786-0137-48b4-aaba-7e1b165521c1" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a228f9b3-c09f-4dfd-9294-8264aec6738e" contextRef="C_0ea9594b-03e6-487e-a61a-c1acf9b39205" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">90,282,267</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_810281cb-6b72-45c9-8d3b-65b2bc53dbb5" contextRef="C_0ea9594b-03e6-487e-a61a-c1acf9b39205" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">903</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0ec4bc7-1282-4c14-a77a-27884596d9c5" contextRef="C_1f827aab-8c58-4267-acb7-76cf53e8db5b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,450,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10a229f9-64b0-43ab-b209-45f37453f669" contextRef="C_c9cbcf73-650e-4bae-b575-14bb681c7fcb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_796b60da-8cfb-4d18-bf87-01f5c397a76e" contextRef="C_c3c68b77-90ed-4616-a582-7d53b5f05ebe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">959,370</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cddbed12-8009-438e-aeba-caaef0a1e287" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">492,574</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4515e27-1256-40cf-9723-3b0e0e88893b" contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,180,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7958580e-9337-4a82-9edc-b54ae2dba8b1" contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_916d6376-5adc-49e2-ab7e-b5fe06296592" contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,376</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2725c73-d935-4a9f-a324-1eb25bd9efbc" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,528</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a8ab8a5-e0dc-45be-bf13-315c85882fc5" contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">269,080</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c36175a-1820-498f-8ed8-7d80ca8147c5" contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55279587-bab4-46c8-9765-2f663b8a4925" contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,208</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3444da97-c2d8-4f81-8312-35b2a0902aac" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to vesting of restricted stock units</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ef9a5c-07b8-4160-a65d-3e734a382bd4" contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427" name="rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">722,471</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57338723-659f-4411-a28e-6a4b849a6401" contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427" name="rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5498880-0999-47f5-9f4a-299b6d2ba908" contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2" name="rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized comprehensive loss on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88a85eca-e1d2-4d7f-94f1-426612aba76a" contextRef="C_b75d21e1-b615-445e-a851-9927373017c8" name="rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd12b83-2240-487c-9766-657bd9a60f48" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cffd1c15-9b4b-429a-8153-dc3573a05de9" contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,920</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d0cc8e-8fc8-4650-88aa-c529cebe51d6" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,920</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe0b1f07-bfb0-4301-b5f5-08ce614b5fd1" contextRef="C_2401d799-1468-4c2d-8db7-16420132a1ab" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_895536d9-de1d-4b1f-8b22-706116e405c1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cadd7ce-7f2c-4f7c-add7-294e39a21e95" contextRef="C_4610418f-69ff-4383-8d4b-b7f932f3e7ca" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,453,818</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18df1ef-12d1-4dfd-97af-6d3641b4a72e" contextRef="C_4610418f-69ff-4383-8d4b-b7f932f3e7ca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,065</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69c05045-91e2-4ca1-aa43-bca593895775" contextRef="C_c0a9f08c-83d5-4fde-9bc3-f69654e05e5c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,680,219</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85859f69-1243-4edb-977d-a6d64452720a" contextRef="C_d6baac6b-72b3-4bad-a3e9-4bd2c34ab5f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a035ce33-fd04-4f1a-9a51-cc7c4629f7d0" contextRef="C_f68555a5-2282-4a77-abe9-8ff2dee0202d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,218,116</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc3e3055-65da-41bf-ab8a-10c8c575fb33" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">463,234</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Stat</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.271%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.242%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eef2905-01b8-4e8e-a2b3-e813a03d4dae" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0f5b38-ae38-46b6-9eef-d7881e9a499a" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc34f49c-f035-4622-b6d1-bab838fb955d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4bc3070-5228-4b08-92fa-f34e980430c3" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OtherDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,221</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f842cd0-a08d-47bd-bf85-33084fd5b401" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OtherDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,944</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b122579e-d872-49ac-8688-506b6ed5756a" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OtherDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,932</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of finance lease right of use asset</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42758cf6-a905-4a1a-9672-9825c7e11c40" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:AdjustmentOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2444005f-6093-4c22-992f-eeb069dc1675" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:AdjustmentOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7ae06b-7e7c-4636-9dce-a70598c31e6e" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:AdjustmentOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,334</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of acquired intangible asset</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac5e9a3f-d77d-445e-844e-8423cba642bc" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfeddd31-b689-4d90-add7-ea146ec77307" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">574</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6210009e-8ae5-409e-b230-673f8c7896d8" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Write down of property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f838ae9-96a0-4de9-b355-5fc649723c54" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:PropertyPlantAndEquipmentWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55cd6be5-0c81-45ea-8b82-98bb67accd7c" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:PropertyPlantAndEquipmentWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0233c7ae-1542-4352-8a0a-d46883ad0ba3" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:PropertyPlantAndEquipmentWriteDown" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e82682e5-b250-46e9-84b4-589f73ae4fc9" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,920</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a85937ed-9035-4fae-8fbc-a081e57dccbb" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,406</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe5481ed-3c54-479a-be23-9302b8b670a1" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,009</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd190fbd-7036-4406-b855-0b3061017a93" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,068</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4335d8b1-efb9-4c04-8d7a-27e8e6a0f0fe" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,168</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_739cf89d-7c96-44a4-86b8-b25e02a4caaf" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of warrant liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82fb787d-1827-4742-8e98-30a4aa8f0434" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c01acbf4-6c4d-420d-9e4e-08ae29d7c392" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">364</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_759d787f-0155-4f19-8c50-7a521d4951f8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0800ca1b-4a05-44f3-bf5a-7003aa06b384" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,694</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10dc9bea-8c52-4588-8fd6-86fa4adefc12" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,593</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bb44ce3-4712-48c1-902e-c3f797d85d8a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,067</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb3ebb2-74af-4655-9fe9-45dd0e667bd9" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,147</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0fd32d1-aa35-4756-8f75-a42f2ddcfb9d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,674</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities and right of use assets, net</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_430a6c17-6091-4e8b-839c-7d67dcb5a7a9" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8aa22c77-80f0-433d-acbe-6cd59609afcb" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ad5a55c-fb31-4289-ba96-025b93d5f55b" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liability</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e48f85f-254c-45fd-88bd-feb6b25b5c17" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:IncreaseDecreaseInFinanceLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e09d5dc9-f114-4f77-9b8c-5b2c57785335" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:IncreaseDecreaseInFinanceLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4461df21-15b8-44a2-bd8d-68ee677d1e1b" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:IncreaseDecreaseInFinanceLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7a0729-9d6b-4cb2-a67e-9ad8e3e5a9b4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,671</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eff91db-5000-4a59-91b9-9a3c46df16db" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c63d5da2-720d-4033-a840-dba7f3393f3d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cdcca1d-405f-49ed-8b56-b13b5ee99403" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_361f857b-027a-4bed-aef8-37a12a75e6a1" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">194,916</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e51d61c-44b2-4dd4-abbd-aacf5f5d1186" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">178,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54e1dbec-f61d-4daa-8879-de82843caafe" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,886</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_857d82ec-e147-4c09-8477-0a7536e0cf22" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">390,920</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32b7bd80-abb5-4338-bc56-d8b973a23097" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">376,327</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef9a7782-52ff-4737-8c91-6d0b260484c8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383,454</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d44e2698-95cb-4a2d-98c9-b06e9c5b5461" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309,326</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f26502fb-63ad-4a56-a833-fa12da9a9ad6" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,894</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash proceeds from acquisition of business, net of cash paid</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1663eac9-53e4-42e0-a68b-0fc21b5fb476" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83b451d1-44a6-4e97-9963-9731b9b0ccb9" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6eea194-1171-4880-a57e-f4b2963dc04f" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,726</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments made to acquire right of use asset</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5381ba4-88e3-4b5f-8607-05a99da2e977" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:PaymentsToAcquireRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c0e532e-8a92-4c04-aaf3-71cc2460c4f1" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:PaymentsToAcquireRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1d6a2d1-2758-49b1-8050-eb22e6cd43f4" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:PaymentsToAcquireRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ae7f50-08b3-404d-93b7-66ff4d6bd2ec" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,862</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3e1ca6d-e9b1-4631-8cb3-69629d9858c1" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,436</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fff3ccae-f98f-4df3-a7f5-cade43912842" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,358</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by/(used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c1e85b-3df4-4c75-8b44-bbb6c5dd49b7" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,706</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7a81177-c3c8-41ee-b603-0ac806c5ded4" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,066</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ae2ac65-cc94-4bcc-b65a-44769ffb78ba" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,326</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21d6868b-d25c-4364-9ea9-eeec318383fc" contextRef="C_8248820b-9b6e-4904-9222-9f0abb8fa0d0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,528</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68e43aa-7dea-4385-a657-12176e6a0ac5" contextRef="C_81130365-ff4b-4a54-b76d-5c0eadb8eb25" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,885</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc0e7d9-adf0-4aa9-85e9-444bba68c889" contextRef="C_25bb15f2-0efc-482c-a2c6-da231c955822" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,138</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, pursuant to exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c62eb6b-b857-4807-8ea1-e71167a9a6e4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,211</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90ecbf95-1480-4cb9-8b14-a8dcb0abebca" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f739f78d-b4b0-4e68-b66a-ecfe4de2b5e8" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Treasury stock repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b40bab02-0b8d-4e85-a981-702ebb7b674d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:PaymentsForRepurchaseTreasuryStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b022d2-d523-4817-bd09-96a512a997b2" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:PaymentsForRepurchaseTreasuryStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e642702-ac6e-4588-a4bb-96118cd45a43" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:PaymentsForRepurchaseTreasuryStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, pursuant to sale of treasury stock</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aebad3c-6055-4f90-9289-500fbb30a66f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ProceedsFromSaleOfTreasuryStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25bf31d4-9937-4af1-a5f9-4de81a1a4328" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ProceedsFromSaleOfTreasuryStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca82feba-6662-4cb4-8569-fe5dc97e442a" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ProceedsFromSaleOfTreasuryStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, pursuant to the at-the-market offering <br/>&#160;&#160;&#160;program, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28a39841-1ef7-42c7-b31c-7e27465d4077" contextRef="C_e289c72e-5a2f-4c23-8a80-507c89a70c8e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c9b74d5-e36f-429d-a4bd-cb9b6d30da46" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,222</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da80f227-645f-4126-97de-471361705abb" contextRef="C_a7d9a7dd-fff1-4380-9e5f-b878d0a03f2b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,566</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, pursuant to exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebd21725-55c3-4afc-a0ec-6f4060486a60" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9ea2646-605c-4050-9387-0498eefa0e1b" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1bfd75-7a95-4bbf-a146-ea4a0942ae05" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25865acf-2a7b-4787-93d9-f25eba6206f0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,739</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa794b92-b690-4b30-9a9b-aa331e1b74ae" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,401</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a3df9e-fbce-4773-8157-1e6623be14a5" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155,288</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net change in cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47555fbd-2e57-444d-89b1-aedcbb238bd5" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,721</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13dd2da2-d141-427c-ac4f-a8792c61f7e3" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,581</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20e483a0-8648-42d5-9795-312184c8aaf8" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,180</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ca62b47-db58-4468-b0c2-ce29d159ec29" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,276</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbd65eeb-3804-4614-9f63-8b1c5c771b9b" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,857</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9733d198-441a-4371-bd0b-df6ec50481db" contextRef="C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec42e24c-8607-4406-b48e-70abc121d781" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,997</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_546d9a41-41a1-470d-99c5-3cc86791cb3b" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,276</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e15d5b6-7c89-4610-805d-1f49e487df6d" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,857</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash financing and investing activities:</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued purchases of property and equipment, ending balance</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4ae6074-27f1-4a76-9a59-32af0bcd720b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b29a5cff-d426-4640-bebc-b8516e07e498" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f64f9914-feec-4b08-9769-6b862f4e93fa" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,095</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Receivables from sale of property and equipment, ending balance</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb01ab6-0c0a-44ce-97f7-d10ed3882fb8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4ecf003-8be1-488b-ab26-8c8a2daab1db" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7850730-da5e-4c3a-a496-023139137469" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6265c391-c8f6-4324-8b79-a23ebd75b5ce" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:NonCashOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a8477f3-b997-4fc7-b2b4-831c5ebfca78" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:NonCashOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,929</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75ece17b-63b1-4c41-a550-3b5092e75cac" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:NonCashOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right of use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbd34ddf-043d-4761-b1ee-a17852584e5e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:NonCashOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7374f306-ae56-4955-8ed3-79a635429e56" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:NonCashOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,958</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f859d59-6b97-4e69-aaac-03b0cfb584a3" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:NonCashOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized (loss) gain on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79ac9655-06dc-4d5e-940d-90290600f15e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b424849-9d93-491f-8d4c-e4101335fb66" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">676</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a80af70-0fa8-4f28-9a29-83f21a088dcd" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock related to acquisition</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd76f69-eaa8-427a-9d19-1596bd484e06" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd9b3cd-7c01-422d-b3b7-a1f1f16a93d8" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89632d08-91ac-46df-a070-adb3636c9148" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,724</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of construction in process from finance right of use asset</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f95108e-80ec-45e9-ae2b-508ecd58d9c1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd567073-629a-4925-9335-5d7d0bd92a4d" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55802080-5aa7-41ec-b41d-09badc325a20" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial_stmt"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inancial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_846fcb70-bf5d-42ed-ba65-b4f31d360cad" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of Business and Basis of Presentation</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c26c7b1e-322a-4ba5-9f7c-5de8e7a430c4" contextRef="C_479a9661-05cc-4e37-ac7c-06504e617691" name="rckt:NumberOfClinicalStagePrograms" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical stage and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7ea95ba-3a5c-4c1e-ad3e-9b4856a241db" contextRef="C_479a9661-05cc-4e37-ac7c-06504e617691" name="rckt:NumberOfPreClinicalStagePrograms" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-clinical stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> adeno-associated viral (AAV) programs in the U.S., which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The DD program is currently in an ongoing Phase 2 trial (RP-A501);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. The Company utilizes recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to slow or halt progression of BAG3-DCM.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company announced its alignment with the FDA on its pivotal study design for RP-A501 in Danon Disease. Completion of enrollment in this study was announced in September 2024, and dosing and follow-up are ongoing. The Company has received FDA clearance of an investigational new drug (IND) application for RP-A601, and has initiated a Phase 1 study for this program. For the BAG3 program, nonclinical and IND enabling studies are ongoing. Submission of the IND is anticipated in the first half of 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d612c735-bb24-48ca-b897-8414bc665954" contextRef="C_5d1d40da-cfd2-4824-a96b-b4971b74b346" name="rckt:NumberOfClinicalStagePrograms" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical-stage ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lentiviral (LV) programs, which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201)</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for RP-L201 for the treatment of severe LAD-I. In June 2024, the Company announced that the FDA had issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025. With respect to RP-L201, treatments in the FA Phase 2 studies were completed in 2023 and submission of a BLA on a rolling review basis was initiated in September 2024. In April 2024, the European Medicines Agency (EMA) accepted our Marketing Authorization Applications (MAA) for RP-L102. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. With respect to RP-L301, the Company has reached agreement with the FDA on the study design of the Phase 2 pivotal trial for RP-L301, our ex vivo LV-based program targeting PKD. While the Phase 2 RP-L301 study is ready for patient enrollment, the Company is currently focusing our resources on other programs and have not initiated enrollment in the Phase 2 RP-L301 study.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has global commercialization and development rights to all of these product candidates under royalty-bearing license agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_61da8605-0af8-417c-9ab0-8ce3641eee70" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:RisksAndLiquidityTextBlock" escape="true" continuedAt="F_61da8605-0af8-417c-9ab0-8ce3641eee70_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Liquidity</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development, technological uncertainty, uncertainty regarding patents and proprietary rights, having no commercial manufacturing experience, marketing or sales capability or experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_61da8605-0af8-417c-9ab0-8ce3641eee70_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s product candidates are in the development and clinical stage. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c71f63a3-5da5-4f9c-96b4-349d39029ced" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="9" decimals="-7" sign="-" format="ixt:num-dot-decimal">1.22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion as of December 31, 2024. As of December 31, 2024, the Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_846e3175-57dc-438c-b617-82c31f18beb1" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">372.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash, cash equivalents, and investments. The Company expects such resources will be sufficient to fund the Company&#8217;s operating expenses and capital expenditure requirements into the third quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2022, the Company entered into a sales agreement (&#8220;the Sales Agreement&#8221;) with Cowen  with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ce0be6-46e2-4535-9102-bc7c448eae47" contextRef="C_a1502da7-9920-4457-8a72-b7448a4ac6aa" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d1a96fa-2802-436c-9731-834f8a456050" contextRef="C_39d4c570-76ba-4c52-80e3-dde4aa7b4c66" name="rckt:SaleOfStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through Cowen as its sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to the Company. The Company may consider reactivating the at-the-market offering program in the future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31de9a02-1197-46a7-861b-7ff5ac44269e" contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a027eb7-0c9a-4187-8bef-09ed4ad9ab0c" contextRef="C_6f626844-ba06-4567-931e-02c5cb0a1650" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pursuant to the at-the-market offering program (see Note 8 &#8220;Stockholders&#8217; Equity&#8221;). The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bbcbeaa-de46-4fbe-bcc2-3e980fcde1dc" contextRef="C_e289c72e-5a2f-4c23-8a80-507c89a70c8e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b1baab8-686f-40b4-85db-ea539a622c11" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares under the at-the-market offering program for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4bf333f-f53e-4d4d-92c4-2c262367ef64" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="rckt:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less commissions of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4b03894-b162-447c-b6f6-0a7b639dfd08" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="rckt:StockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5015ee7-ff9d-463d-8236-8f4579eeebd1" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company completed the Offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d003e0ae-dfce-42e4-99dc-bde1c3606bd2" contextRef="C_abe62c65-86b2-4c28-a166-de2d40714fe1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50397ede-c048-4a15-a79e-c23b78de3567" contextRef="C_b7504ddd-7215-4a12-a2a7-05b47998068b" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and Private Placement of pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bfabda7-38ad-4a6d-be73-0b5088227bd3" contextRef="C_69408d2a-0545-4d3a-a4f7-3c54eb9825f9" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_124ab93a-d303-42a1-bd3d-3a3e8faf1ff3" contextRef="C_3abe252d-55ed-4732-a04d-1b253a82ba3b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant. The gross proceeds from the Offering and Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c911a5c-4494-4721-8a00-77e744cb787f" contextRef="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8" name="rckt:GrossProceedsFromSaleOfStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">194.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f37505d-09c3-4260-8702-94b5eeb5d005" contextRef="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8" name="rckt:SharesIssuanceCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62fdb304-3b5d-4a12-ad0c-11ba3fac072d" contextRef="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">182.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(see Note 8 &#8220;Stockholder&#8217;s Equity&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the longer term, the future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_432aaf86-0f7f-45fa-aa99-92a59ecbfff9" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with U.S. GAAP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All intercompany accounts have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_517e2007-9033-4c9f-92c6-ba9f5882790e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of R&amp;D </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses, the valuation of equity transactions, and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_314c077c-c6c5-4a39-8bee-442f501e61cc" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_314c077c-c6c5-4a39-8bee-442f501e61cc_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company&#8217;s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_1" continuedAt="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_2"><div><ix:continuation id="F_314c077c-c6c5-4a39-8bee-442f501e61cc_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bb08086-29a2-4113-bdf0-70db0eba2eb1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#8217;s operating leases (see Note </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13 &#8220;Leases&#8221; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#8217;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:65.633%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:15.183%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:15.183%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79f46501-a359-4575-814e-2a0a804ec480" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,635</ix:nonFraction></span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71d985a2-39ff-4523-a52d-bf994cfba6e8" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,904</ix:nonFraction></span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_516ccdb5-7587-4673-9c6b-45d0f10575e3" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,362</ix:nonFraction></span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9507a363-61f3-46d3-bf2b-66b6e46c6786" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9c95b8c-94eb-43be-94ee-125f54a6801a" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,997</ix:nonFraction></span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1c657a-a84d-4d94-b96d-5a22ecf2b2ea" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,276</ix:nonFraction></span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></ix:nonNumeric></div></ix:continuation></div><p style="margin-left:403.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3b57f01-f704-4bab-adee-1b8cd62ac141" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:GovernmentGrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Grants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense was presented net of reimbursements from CIRM (See Note 16 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIRM Grant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for additional disclosure).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea593b77-55bd-49e4-9e66-82420bfd0ce0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk and off-balance sheet risk</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of U.S. Treasury Securities, and Corporate Bonds. The Company&#8217;s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AA-/Aa3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rated, thereby reducing credit risk exposure.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c0b41c5-3729-4c75-80e4-95fb16ba2be2" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments consist of U.S. Treasury Securities and Corporate Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to ASC 320, Investments&#8212;Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company&#8217;s Consolidated Statement of Operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb44dc7c-8a44-42cf-b483-3bcd0fe566bf" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f50521ca-7d30-4804-85fb-2d0b15be9917" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0fedd2d9-5dba-4f8f-8250-46e543dc5ef3" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses on investments for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022. For the years ended December 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 and 2022, there were net unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aaa599e-0aea-4409-bd12-29ff61e40627" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net unrealized gains on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52425483-8a18-45c8-a2de-69fe67d66403" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and net unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b03c4dc7-1d20-4e6a-aa33-d60b50b6185b" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4fc7d47-9874-4af9-b1e5-290cbe58eb19" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets consisted of an indefinite lived intangible IPR&amp;D asset and a mice colony model. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&amp;D intangible assets which are determined to have had a decrease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in their fair value are adjusted downward and an expense is recognized in R&amp;D expenses in the Consolidated Statements of Operations. These IPR&amp;D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&amp;D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. If a triggering event occurs that would indicate a potential impairment, the Company will perform a quantitative analysis to determine whether it is more likely than not that the fair value is below carrying amount. The annual impairment assessment for the IPR&amp;D asset was performed as of December 1. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cc5a08c-63d7-46f3-a258-faf597ff6e6c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4345ba6f-c1e0-41c9-9985-14b27deda8b7" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment of the IPR&amp;D asset was recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded an impairment of the</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intangible long-lived asset </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related to the mice colony model of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_769e2ecc-97c0-4cd8-a681-61c50b7eb123" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_2" continuedAt="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e11f1a60-7aff-43f6-b019-179865f62041" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business combinations are accounted for under the acquisition method. The total cost of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, asset lives and market multiples, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_546a459d-d911-4740-8d24-f8be78c16cd8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17db49ed-b127-494b-a0c9-fabf2d9d8763" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reporting unit and as such review&#8217;s goodwill for impairment at the consolidated level. When testing goodwill, the Company has the option to first assess qualitative factors for reporting units that carry goodwill. The qualitative assessment includes assessing the totality of relevant events and circumstances that affect the fair value or carrying value of the reporting unit. These events and circumstances include macroeconomic conditions, industry and competitive environment conditions, overall financial performance, reporting unit specific events and market considerations. The Company also considers recent valuations of the reporting unit, including the magnitude of the difference between the most recent fair value estimate and the carrying value, as well as both positive and adverse events and circumstances, and the extent to which each of the events and circumstances identified may affect the comparison of a reporting unit&#8217;s fair value with its carrying value. If the qualitative assessment results in a conclusion that it is more likely than not that the fair value of a reporting unit exceeds the carrying value, then no further testing is performed for that reporting unit.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company performed the qualitative assessment of its goodwill and determined that it is more likely than not that the fair value of a reporting unit exceeds the carrying value of the reporting unit. As a result, the Company has determined there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9a6e43e-61f3-4e42-9581-ab023265fd01" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d8dff593-a267-4821-adf4-4066e7424daf" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bdc135a4-00f3-44c8-8887-89ec09239a9b" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> goodwill impairment as of and for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e40884d1-38e3-4fe1-9a51-0525cd63aaf0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful lives of the asset which are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0694d6e1-d557-4d2f-9915-e0723669ef60" contextRef="C_65579abf-153c-44b1-82d0-fd8168b17b2d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifteen years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company capitalizes purchases of laboratory equipment, machinery and equipment, furniture and fixtures and leasehold improvements in relation to the facility at Cranbury, New Jersey, since it has been determined these assets have alternative future uses to the Company. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. Costs incurred in connection with development or purchase of internal use software and cloud computing arrangements, including in-substance software licenses, are capitalized. Amortization is computed on a straight-line basis over the estimated useful life of the asset, which is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6350954-56e9-42cb-a2bf-0b8deb1cb4b7" contextRef="C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Capitalized software is included in property and equipment in the Consolidated Balance Sheets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17873ccb-cba9-4667-8606-db7fc5b10abf" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. The Company conducted its impairment analyses of long-lived assets to be held and used in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.  The Company also recorded write downs of property and equipment in each of the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_3" continuedAt="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac6df31e-6a76-4925-9d6d-a1076032d795" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 - Valuations that require inputs that reflect the Company&#8217;s own assumptions that are both significant to the fair value measurement and unobservable.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company&#8217;s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae6b0738-7067-4637-a87b-b0aaf765095a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DerivativesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity and/or ASC Topic 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company&#8217;s Consolidated Statements of Operations. Warrants classified as equity instruments are recorded within additional paid-in capital at the time of issuance and not subject to remeasurement</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d424b1e1-79a8-4db2-b213-956236221aca" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses, which include salaries and staff costs, license costs, manufacturing and development costs, clinical trial expenses, depreciation and amortization expenses, regulatory and scientific consulting fees, as well as contract research, and stock-based compensation expense, are accounted for in accordance with ASC Topic 730, Research and Development. Accordingly, R&amp;D costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_847080ca-ffb9-41d2-9449-169b446d3bf8" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain foreign currency transactions during the years ended December 31, 2024, 2023 and 2022 were primarily denominated in Euros and British pounds. Gains and losses on foreign currency transactions were not significant for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e437bb2-8ff2-425c-bdfb-d8a975d890b0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:TreasuryStockPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records treasury stock at cost.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_6e163df6-4f41-4b29-92db-8286f408c73d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_6e163df6-4f41-4b29-92db-8286f408c73d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issues stock-based awards to employees and non-employees, generally in the form of stock options, RSUs, and PSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. The cost of stock options and RSUs is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The vesting condition for PSUs is performance based and the cost of a PSU is recognized when it is likely that the performance goal associated with the PSU will be achieved and the award will vest.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_4" continuedAt="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6e163df6-4f41-4b29-92db-8286f408c73d_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as expected volatility and expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations in the same manner in which the award recipient&#8217;s payroll costs and services are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6c9a1fe-82c1-4483-8c75-681cd6c967ee" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet differences. In accordance with ASC 740, Income Taxes, the Company recorded a full valuation allowance to fully offset the net deferred tax asset because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2024 and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d289cb8-396e-48e8-a47e-f0832fc22af0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates net loss per share in accordance with ASC 260, Earnings per Share. Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Warrants that meet the definition of equity classification and that requires the holder to pay little or no consideration to receive shares upon exercise are considered outstanding in the context of basic earnings per share. Diluted net loss attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, outstanding options are considered potential dilutive common shares.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87629888-3be2-480b-a9ed-d339f77a5cef" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86d09636-9f2f-4276-9186-0467bcc8836b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e4e33013-0944-4e5f-ae6a-24eab71a59cf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the senior leadership team. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e9b8c7e-d69c-4398-8ee2-51b60f066351" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Included in these expenses are R&amp;D expenses by program.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d4a8f8a-7c30-40c4-bb2e-72ef7810d0ef" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources and consists of net loss and changes in unrealized gains and losses on investments.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c33bf18e-185f-42ff-84c8-007279746032" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company&#8217;s Consolidated Balance Sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company&#8217;s lease agreements contain renewal options&#894;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company&#8217;s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company&#8217;s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10d736da-8224-4483-a5e5-5f1aeb329898" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Not Adopted as of December 31, 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09: Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This update standardized categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update was effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the effect that ASU 2023-09 will have on its financial statements and disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2024-03: Expense Disaggregation Disclosures. This update requires disaggregated disclosure of income statement expenses. This update is effective for the Company for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the effect that ASU 2024-03 will have on its financial statements and disclosures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Adopted as of December 31, 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update was effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adoption of ASU 2023-07 resulted in a new footnote disclosure for Segment Reporting.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:nonNumeric id="F_6fba30f3-71cf-4243-955b-778148ec6be1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true" continuedAt="F_6fba30f3-71cf-4243-955b-778148ec6be1_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee2b0b97-80c1-4b43-8661-4b740b93f460" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Items measured at fair value on a recurring basis are the Company&#8217;s investments. The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.87%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.282%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.282%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.282%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.282%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements as of December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_155568d5-f023-41d0-8130-0b5a5fde31cd" contextRef="C_0037c99e-c1ca-4b23-b24c-81e17fdc512c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,948</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c45a8dbe-92ad-4885-bdc6-7f04ea187e09" contextRef="C_20f6fd52-2ba1-4fa6-be1d-d13c170008e6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b708602-18ed-4112-94c6-1595cbfeb20c" contextRef="C_614d6896-e6d5-492d-9c77-ffb84b0406db" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be178e25-e741-442d-9597-c960cdca6303" contextRef="C_56deae45-2475-4724-92a9-1a0f1898168d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,948</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa98b77-ba3e-4552-80c6-d6a29e434118" contextRef="C_dc209532-0fd3-44e9-9598-91da8bb7ea6a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c2ce38-6a5a-48ae-be75-f096d41925d8" contextRef="C_8fde949d-0acd-44a3-9e91-5d4c632ff5be" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e66d55-0fea-44c2-97d2-5d36c64f4662" contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,948</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b46da520-095a-4044-9f80-da21cc7d22be" contextRef="C_78dca576-a930-4462-aa00-b27c81826e49" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,453</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1d4fe19-04fc-4a6b-a84d-38e03289df16" contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fef7da7-9ef2-4ac6-9ae1-dde45995d275" contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,401</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd8f859-2362-438a-9f00-5611c83dcc5c" contextRef="C_5bed0892-88b1-4193-a2a6-7964d153c972" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5d92689-1cb2-4525-a4d6-2f386b644b16" contextRef="C_dc209532-0fd3-44e9-9598-91da8bb7ea6a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,701</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b9e7dfb-245e-4482-b79c-79f3bbcbe340" contextRef="C_88bd68f9-d4e7-4d24-ad5b-0cfd4a8572fd" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_232a7646-abf6-45ca-82fc-b5a8174ef8b5" contextRef="C_8fde949d-0acd-44a3-9e91-5d4c632ff5be" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,701</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d2558ca-824a-4b3a-a20e-275549f77b08" contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c39a5f-d7a1-4e45-841f-26dfba1c1584" contextRef="C_78dca576-a930-4462-aa00-b27c81826e49" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,701</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ae89525-3220-48ad-8acc-d8a2bc71232e" contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af138a1d-6dd4-4836-890f-3c1ea8d632fc" contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,701</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f26dcb8d-2bd6-487a-a8a2-c5c87e31ee2e" contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,948</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bda94bb-2227-473a-b3f7-a65972856b17" contextRef="C_78dca576-a930-4462-aa00-b27c81826e49" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">216,154</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1048046-1b02-4893-b9be-07051c10a201" contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7842cc84-496a-4502-9c05-604ce9215178" contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">356,102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a20af349-e3cf-477c-8b27-a6099698d828" contextRef="C_1e1369d9-110a-42d0-b7c0-84ac9ece8089" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc012807-5227-4227-a896-1326dd464ebd" contextRef="C_ec6889e5-cd60-493d-a8e3-c53b58b5fa3d" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a0fbfbc-66b2-4099-ade1-de7a6ecf1e53" contextRef="C_a20e6031-eb30-4c47-8d1b-adc6495a52e1" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c684803-9fbf-4100-9fac-acd3cb18d9bc" contextRef="C_07c3747f-e2f3-42a9-89ac-9acfd5f74970" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5db80b78-44a4-4ee7-937d-e131791f6fb1" contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d914df-426e-4aab-82d1-45bf9ac2ecfb" contextRef="C_78dca576-a930-4462-aa00-b27c81826e49" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc45900f-1167-4a46-a4a1-09da43cd27d4" contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_213b2921-5880-4dd7-b6eb-0b8a0c9aa902" contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements as of December 31, 2023 Using:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43dd3c7f-7ad2-4bdf-a4ef-56681a613a84" contextRef="C_e1b43b69-998d-4796-b42a-aea9aafdd667" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,737</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb6cf75e-038a-4ef4-af8d-63b47e1ce34a" contextRef="C_7192b875-69fe-4a97-bfab-df69481b623d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f31d11e-a30e-48e6-a5a1-94522ae42906" contextRef="C_f8197a09-186b-424a-b44f-83d44b69c54d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cd17a7e-5819-44f9-a2b3-38b2ea32fa2e" contextRef="C_e1c16979-17a8-4d46-9822-2b46b4a8cb39" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,737</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11479cac-f252-4b31-8e9d-9d9f4d68ccd7" contextRef="C_37654162-418a-45b1-acc3-24642763a46c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d20950f-693a-4876-8323-151cceca22a3" contextRef="C_bfe02d27-19e3-433a-95db-5d94f0827b20" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887a721e-99fa-4abc-8f1d-87a07ea90936" contextRef="C_943dc870-40c2-4855-8570-af751ebf236a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0715a01-a92c-4501-b3b9-0ff4610cbcf1" contextRef="C_d48d3908-3513-4784-ae1b-75c7c67ca6e0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_212c003f-a9a3-4d86-887f-defb34d75a67" contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,737</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9d42055-613f-4185-a5af-55add2deaba8" contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,487</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_803eb681-441c-44ae-a675-b4397d26fdaf" contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f32b771-b4c3-4dfa-9a09-125b08e3f63d" contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f915b451-2cc8-48c9-9602-95f21a36b1a0" contextRef="C_37654162-418a-45b1-acc3-24642763a46c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c072ba-fe80-49da-b910-6fb7f6a9e0e7" contextRef="C_bfe02d27-19e3-433a-95db-5d94f0827b20" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,696</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e70835d-61e9-470f-b8e9-878dcd057d0d" contextRef="C_943dc870-40c2-4855-8570-af751ebf236a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09b6bc1b-b806-44c8-ae52-a23c5457fdd7" contextRef="C_d48d3908-3513-4784-ae1b-75c7c67ca6e0" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,696</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3a718ae-ac10-4265-b91b-b1454c1c36fc" contextRef="C_8cfc4f1d-1cde-40f3-8c46-dd26d0bccc8c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a2ed78f-050b-4446-9d4c-42cba76405c4" contextRef="C_a6f9948b-434e-4c07-bdf1-b761c191b422" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,895</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71f341fd-a265-403a-a782-68825d0d565b" contextRef="C_3a2dd3b1-3fb8-410c-ab6a-47d3ffbd35f8" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7849f05-1ea8-4787-b15d-1ea67d20adc4" contextRef="C_522afc24-fadc-4b87-92bc-1830764fccf5" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,895</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bde57f0-a4af-4e81-873e-4022873d1da3" contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32ef690e-2da8-4cfb-b1c3-1d8f349bf051" contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f928e70d-2056-45d9-8e3d-68320ccd2f33" contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb1eecf-4e4a-4964-88b1-8cb6d3b5f1d7" contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">351,591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_505db33e-5f05-4946-87a6-6311d8372bc6" contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,737</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74b41d2d-5173-4b6f-ace1-90d5be7907bd" contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354,078</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90abf815-df90-479e-a8c7-2e8732b146a2" contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28976b5d-d1a3-41ff-89f3-a12488815767" contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404,815</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_047cd4b7-22d7-41e1-bc17-6671c296c14a" contextRef="C_92d0c82e-65b5-4c8a-8b1c-a545c812be74" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47948316-9b0a-4c7b-a33d-749840f3b009" contextRef="C_6d0adb09-8317-454a-af5e-3df33b3384e2" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850995f0-8fa1-40ef-bde3-96e8541083a9" contextRef="C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03cf6f2b-3ca9-427c-974b-f01e466fa688" contextRef="C_991c71a4-2d8b-4a30-b81d-b081fa3aa360" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f9254f9-ec31-4292-834c-b8d889995550" contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ccb5be9-cd8a-42b2-9824-570f568905db" contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73dbf0bf-d331-4c7e-a144-301693208811" contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_829107d2-da70-4506-a405-ee6f861540e1" contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its money market mutual funds as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its U.S. Treasury Securities and Corporate Bonds as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87b3373a-02c3-4c8f-8b4d-ff407424f121" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of the Company&#8217;s warrant liability, which is recorded as part of Other Liabilities in the Consolidated Balance Sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.439999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed4c600f-8f2a-4df4-903e-6546fccc6a47" contextRef="C_1d96ec30-1174-441b-a600-2e0b2c261eb0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13138c0f-4757-4ae8-8d6b-0640aa85b8bb" contextRef="C_8e233e0a-2ea3-41c0-89a4-fc2fd285a9ab" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">364</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47af7ef5-e0df-424c-acaf-07d84cdc3dcb" contextRef="C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b71596e-00f8-4361-beec-b06b184fa114" contextRef="C_23045695-c17e-4d48-ab1f-bb772f60c66e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5e8c367-fbc2-4d24-8152-eaabb5d4edd7" contextRef="C_a20e6031-eb30-4c47-8d1b-adc6495a52e1" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_6fba30f3-71cf-4243-955b-778148ec6be1_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes a Black-Scholes model to value the warrant liability (see Note 10 &#8220;Warrants&#8221;) at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in an options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the expected volatility of its common stock based on historical volatility of its common stock, considering the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the valuation date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e49cd440-b95b-4530-a06c-b253abebbdef" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_e49cd440-b95b-4530-a06c-b253abebbdef_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the warrant liability has been estimated with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.572%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.864%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.563%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b29c55a-a984-43d1-aec6-e50da918abae" contextRef="C_f7122f45-e86b-4832-8a3c-08b89787f233" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">12.57</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92802939-9270-4965-9bd2-cc9e54c23609" contextRef="C_88e568be-e56e-4e25-9251-014e7a901a92" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">29.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd6ebbed-4f65-48db-bc96-4d222419fc5d" contextRef="C_6949dc0c-ac58-42f1-b238-512744e2f55a" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">65.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30318837-b4df-44bd-bd32-ebc4bd7738a8" contextRef="C_546e10b4-ff00-4699-b1d3-6c11db3121d3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" scale="0" decimals="2" format="ixt:num-dot-decimal">65.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb910d0-4b00-4523-b1f0-d6e890dbfa61" contextRef="C_5de73c69-3b3e-412b-a788-62510c450a86" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" scale="-2" decimals="4" format="ixt:num-dot-decimal">52.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6e7ca3-d261-4865-a622-7abdeed54c63" contextRef="C_9ca4967a-2d36-4cf3-813a-a556cf2894e6" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">68.83</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_befb0d17-279f-4c8a-9f51-663ff34b2c0f" contextRef="C_5788384e-0e15-4c14-b7f3-ea8098caef5a" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9c9af6c-cee6-40bf-8e6a-48b845b53fa9" contextRef="C_231c38bb-1d40-4602-a048-1a166b10048d" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.70</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e4dd22-d324-459b-9dba-bf3e2f28e03d" contextRef="C_3f829c1c-8313-4171-8476-384337e26d5d" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2c4865c-7419-48de-9aed-7690221c62d7" contextRef="C_956a0bae-50e5-4afb-9e3f-ce6ad3fb91df" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (years)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_124e40b1-01ad-4598-af79-5c6fd71fb8a2" contextRef="C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e87d8582-c398-4c3f-9667-df1edc319ba0" contextRef="C_df02e688-dcfc-497e-8173-c2fefd94643a" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.31</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value per warrant</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82622006-8c4f-463a-a843-07fcdf84af9d" contextRef="C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5ae67f3-f76a-42d0-a7c4-27704527e890" contextRef="C_df02e688-dcfc-497e-8173-c2fefd94643a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_e49cd440-b95b-4530-a06c-b253abebbdef_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_250be423-6fde-4b43-861f-602a64663a79" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_731dc541-43f1-4a57-8718-f1fc8dd32ede" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s property and equipment consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.113%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.442999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.442999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5a603b4-d33d-4159-b71e-12f0d1080de9" contextRef="C_8b46be80-cf70-47f1-91fb-b0731982128f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,205</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0b4af88-16f3-419d-b8a7-1832d016a2cc" contextRef="C_a111d06c-dc8e-4e3a-8e0d-78a1e5369023" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,232</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb4bcf83-1e84-45c2-9993-493d654f53b7" contextRef="C_906a09af-a884-4b84-bbef-d07f25a1fe78" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,857</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecf626ea-712f-4866-8156-1a5d8c778c9b" contextRef="C_dab486eb-7044-4902-b0e7-0bf059248bfa" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,325</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0ec35db-93ba-4394-b002-8627e1971468" contextRef="C_b579542c-2ebf-4d4c-99f6-66f0c8bde726" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,015</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea4bf9fb-559f-4a16-b337-43a337f94b28" contextRef="C_3c6df573-5d38-4acd-8c24-1b20574901cf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fa56bc-8649-4cfa-ad73-c8997600b9d1" contextRef="C_600a0f88-6bde-40ff-97bd-99954442846a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7e66c9e-2ab9-4c52-a73a-a97c80171e97" contextRef="C_f89a9364-484a-44e7-a942-5ef3c5798d0a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,777</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833e1249-7c77-4b65-a5c2-1b43580e0553" contextRef="C_427ef717-f6ba-4ddc-87e2-99ea816b4e39" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,282</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0402796-a048-4ac8-a771-e1b908395c31" contextRef="C_0cfac2e7-eea8-42c7-88ef-e2f0746599fd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,723</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7bc0f31-016c-4df9-add1-7fa749ab2c91" contextRef="C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,903</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_514889c8-abbe-4f2f-9a4f-1dbbfefba741" contextRef="C_c0e3b9f1-cd58-4ddc-8dac-3bce6794b077" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,903</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27bfbdc9-896c-4826-b6b9-0bc5d751f42a" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,039</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd5bc54-63e7-4267-8fa9-4e2766680690" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94297495-36ff-41b6-abee-a993fe8f99c8" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,253</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ae0ee3d-2454-4a44-ba89-e9a9638209ba" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,032</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e177889-e3e9-4919-9988-0da01c2afcf9" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,786</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0766487f-f0a3-4107-abda-ad2512335699" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,172</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization during the years ended December 31, 2024, 2023, and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d774c14a-5ce9-41c4-b18a-e559548b6656" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1c40040-1146-4fcb-941a-7afc19d34558" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c80041a-e4a6-4f9e-82a8-86eaf92b514d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:nonNumeric id="F_f2d3a8c5-46d3-420b-818b-f864647566fc" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible Assets and Goodwill</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s intangible assets consisted of an acquired IPR&amp;D asset received in the acquisition of Renovacor. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4730d440-9a76-44c3-8d0e-759e731ac846" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" escape="true" continuedAt="F_4730d440-9a76-44c3-8d0e-759e731ac846_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 are summarized as follows:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_4730d440-9a76-44c3-8d0e-759e731ac846_1"><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.872%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.063%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.063%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross carrying value</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dc36083-813e-46e4-b396-cc3aeb4379ae" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a7af20-f3d7-4f45-9a8b-2b0b450986ab" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a05fe374-b919-4494-b825-0152ebdf72b2" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42417453-9797-4a8d-b4a3-ff0e3670b73e" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying value of Goodwill as of December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cb63c48-1276-4729-9f72-e06c4f462e63" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e870b8c0-06cd-4c7e-80fe-5efe5cef14b9" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_27fd6e68-326a-4127-bd8c-ce4b0d34a2f3" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.2</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8054cee3-c41f-4d2d-ae95-4f76eb3a3b14" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Payable and Accrued Expenses</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_105c032d-199b-4550-8dbb-d0836658ebf6" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s accounts payable and accrued expenses consisted of the following:</span></p><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.872%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.063%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.063%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c754cf-230f-4035-a098-2b72a21bc6a1" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="rckt:ResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,768</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55e35a16-1c2e-486f-b4ba-65209b53b691" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="rckt:ResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,867</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment payable</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_797aa44f-58fd-459d-9d1c-207149af6012" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="rckt:InvestmentPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_091bf55e-f7cc-46e5-b605-b88184b66420" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="rckt:InvestmentPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,137</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e86d53a-b344-4406-875e-70aab6a0badd" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,944</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_400b8fe7-d411-461f-903d-0ba73d53aee8" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,930</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46f4c5f0-a04e-4229-a4a7-fda2c3565aae" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:ConstructionPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82020e1b-a357-40ad-aa58-2e655c90765c" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:ConstructionPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,077</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3835782-01fe-4484-a507-ed48bebadc7b" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,305</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8caf370e-25f6-4322-9ea5-92ea59b14e26" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,006</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40949ab4-2439-45bd-b5c3-41eaffa0c58a" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93a3c4a8-c14c-44ea-93b8-6aad310b3596" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,772</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accounts payable and accrued expenses</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f65dd54-8b73-4589-b72a-cd4a37be39e1" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,827</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95c376c5-24b8-45ed-97f1-6a720f573dc7" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,789</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f5e61ce-5021-4da8-8340-09d3e02ba2e8" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="rckt:InvestmentPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million investment payable was related to investment purchases of available-for-sale securities in 2023 that settled in 2024.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_20933eeb-f050-484d-81a5-2448b3a7ab3f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_20933eeb-f050-484d-81a5-2448b3a7ab3f_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is currently authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a18ec170-711e-49eb-bca2-c8ea1e7d6c1b" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">180,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a7521f0-a10b-45ba-85b3-0bafe1e8f255" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock. All issued shares of common stock are entitled to vote on a 1 share/</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_218d6fa4-9e1e-4f79-a450-dd8c71b00ba4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:CommonStockVotingRightsNumberOfVotesPerShare" unitRef="U_Vote" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe9654f-0d03-47c5-af43-4b2395420701" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ProceedsFromSaleOfTreasuryStock" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> treasury stock transactions were recorded for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the year ended December 31, 2023, the Company recorded sale of treasury stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bb773ee-0699-4823-84eb-ccf62febacd2" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ProceedsFromSaleOfTreasuryStock" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. During the year ended December 31, 2022, the Company recorded a repurchase of treasury stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_539cfeb4-19ff-4b31-b701-375c2a263ea4" contextRef="C_c72bc269-579c-4d57-ac72-5d5633259ea5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for shares withheld to pay the payroll tax liability of the vesting of RSUs. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_757a7ae5-e5c5-45ba-b4f5-abb979673460" contextRef="C_e0a89db5-ae0b-4a17-b75d-9c2a60a086ec" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a73fa87d-e66d-4cdd-b224-6d08ff38b8ad" contextRef="C_63ad2220-d8b8-479c-b35d-56ecb8208ca7" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> treasury stock as of December 31, 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering Program</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2022, the Company entered into a Sales Agreement with Cowen with respect to an at-the-market offering program pursuant to which the Company could offer and sell, from time to time at its sole discretion, shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of its common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1bff23d-72b4-46a0-b540-d1b660fda2d1" contextRef="C_a1502da7-9920-4457-8a72-b7448a4ac6aa" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c67babc-00ca-452d-ae15-13926213e838" contextRef="C_39d4c570-76ba-4c52-80e3-dde4aa7b4c66" name="rckt:SaleOfStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through Cowen as its sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to the Company. The Company may consider reactivating the at-the-market offering program in the future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85fa8956-9137-4554-83c8-029fd7894fb8" contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares under the at-the-market offering program for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_620d1968-ee20-4fe0-af0b-02bfceb04ae3" contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c" name="rckt:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">65.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871e77ed-f7e5-4f10-9ffe-748338a852fa" contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c" name="rckt:StockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15df0372-6f25-424e-bba4-6bf1d09f2c3c" contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">63.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company did not sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd8c3bc-0da7-4b07-83d1-7fc14092a5c0" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares under the at-the-market offering program for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05f1f3df-e359-46aa-b21d-b67a3500a58f" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="rckt:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less commissions of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42602293-8b56-4cd4-9fac-566dd9a39d6e" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="rckt:StockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c3a2972-c4aa-4467-903e-b527018dc41a" contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_20933eeb-f050-484d-81a5-2448b3a7ab3f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Offerings and Private Placements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 6, 2022, the Company completed a public offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efdc2032-43a8-4b66-973b-03ed53b3362b" contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">7.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of our common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6a29afc-f906-4462-a830-15fc194f8798" contextRef="C_15399861-ccb4-4e70-8bbd-0ddf51277dc0" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The gross proceeds from the public offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_092ee70c-bad7-4a58-96d2-835cb6f00fb1" contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897" name="rckt:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">115.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d345396e-c255-46c9-9812-d03583687ba1" contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897" name="rckt:StockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, commissions, legal and other expenses for net proceeds from the offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e521351d-3084-47b2-8c11-7444646af68b" contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">108.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 15, 2023, the Company completed a public offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_171a1372-a285-4051-a9cb-0221b83b99a6" contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab898071-0bcc-4a41-a3dd-1959179686ab" contextRef="C_bf567e9b-5f3d-4efa-a215-8c9b02dd65f3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d97a30a-f49b-464f-a0ee-3e5b6b2fb5c4" contextRef="C_2c62f640-e90d-405f-b768-464bdc8fe131" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4677ab4a-128f-4702-a24a-567682222ee5" contextRef="C_9b231eaf-1cc1-439b-be3b-21ff07a55616" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant. The gross proceeds from the public offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47ffa997-f4f4-451c-9884-8d370331d77d" contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa" name="rckt:GrossProceedsFromSaleOfStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">201.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_342aaa1f-afb7-4635-a4ad-f09588e75864" contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa" name="rckt:SharesIssuanceCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52ca63fd-3d54-4b2b-8aa2-0f053f3dafbd" contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company completed the Offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a904c72b-618a-4fcc-ade2-5e8837bc1491" contextRef="C_abe62c65-86b2-4c28-a166-de2d40714fe1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baa55436-7597-451e-8a62-10b5199b5c49" contextRef="C_b7504ddd-7215-4a12-a2a7-05b47998068b" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and Private Placement of pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7187ea24-bc44-4db8-88f9-1b92aac51eae" contextRef="C_69408d2a-0545-4d3a-a4f7-3c54eb9825f9" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_997a05ec-6aa5-462f-a766-a4fcf163fb62" contextRef="C_3abe252d-55ed-4732-a04d-1b253a82ba3b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant. The gross proceeds from the Offering and Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97998005-9ae6-4012-9577-aaf2039cbfc9" contextRef="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e" name="rckt:GrossProceedsFromSaleOfShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">194.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce5fa866-24e0-47a0-b60f-aadf2e2adff1" contextRef="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e" name="rckt:SharesIssuanceCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b005407-fca2-4bb0-b2b6-76b6036537fa" contextRef="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">182.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_afa84c9c-a8e6-4ccb-a29a-f937e66e4db3" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_afa84c9c-a8e6-4ccb-a29a-f937e66e4db3_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Awards</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Valuation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17fb3ef9-0536-4837-afa3-f5990ac1849f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of the stock options granted to employees, non-employees and directors were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.851%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.049999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.049999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.049999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_130128b0-a39e-4d5a-8166-37f3ba820647" contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0adc538-e1c6-4181-aa21-099c60cd3744" contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d318e65b-be83-492a-96f2-ffe53595396b" contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_859eb9a5-3529-429b-a209-7946fbd977ee" contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.81</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ec608e8d-f8e6-4aa8-bd3e-7162308a3e13" contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.82</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d02ea096-c5ba-4187-ab32-83eabfe6367b" contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.09</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87c8d435-5953-4b86-836c-46867f05f0e2" contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">73.72</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5888fdec-6c10-4afe-84e0-8bc589d1e57a" contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">73.32</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6f5637d-5bb1-440a-ba73-6ece99c0856a" contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">64.12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f68e134-789f-43a0-87da-eebceeb35263" contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc860aa-8518-429f-ac47-433d5f4db9de" contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52ea96ec-6d00-43a4-b524-76b3f1a8c4e5" contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d47ae418-83ef-4d94-bc47-58410c19b477" contextRef="C_ab8144ca-12d4-48b2-a36b-ecea9a99ea61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4988dd9-3fd7-4d71-82dd-85f7378f8b93" contextRef="C_d7da2197-3558-4b5e-baa6-7e95259215a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba28f151-b9b3-45a7-8b4b-d81ec2ae9a3a" contextRef="C_5f849fe8-09d4-4c36-86ef-cef05c3dbc49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.56</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f44f034-6ff4-4f68-8a7b-3da2486c44e8" contextRef="C_ab8144ca-12d4-48b2-a36b-ecea9a99ea61" name="rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd563ded-1dec-485f-93ab-85d9b604e1f4" contextRef="C_d7da2197-3558-4b5e-baa6-7e95259215a5" name="rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c7e9a73-9b07-49cf-a0b3-2a0878b691ea" contextRef="C_5f849fe8-09d4-4c36-86ef-cef05c3dbc49" name="rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.56</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13af6ab7-e5d1-4faf-a7a3-b63c9d3db948" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.189%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.302%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.362%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.302%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.842%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (Years)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a22a10b-fa50-47b0-a048-60e5e75e4275" contextRef="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,138,870</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_facf2ce4-f1e9-43a1-a641-9801118d0ecb" contextRef="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.52</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fdc2b33d-e011-4dab-8e50-8f786213c5da" contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.46</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f74a1cc-1827-46e2-b322-716e80d0115c" contextRef="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,767</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e27ea38-ee93-42f4-a661-f50bbf5b008a" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,370,862</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95fb2ff5-8e75-4a84-9462-1250ea133c52" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2e0c1139-2681-4d61-bfa9-775507472dad" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="rckt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.76</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8547e0e1-213a-44fb-bf31-b9c7da09d784" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">223,145</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8a7c081-8f12-42cb-a351-52a1b8b10d80" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa05c240-5e6a-4925-868c-ea253f588a19" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,318</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_380f0e6b-5421-43b7-8572-696ca2b7e278" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">422,591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf36c100-c52d-47bb-a7e7-edebb1ace9da" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">29.82</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fda207e-c17c-41d4-88dd-7ea15e3943ba" contextRef="C_e6d96dee-383b-4648-a425-7febaa2eae01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,863,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c33bbc7-ec2e-43e1-ac36-5893e6f4dd82" contextRef="C_e6d96dee-383b-4648-a425-7febaa2eae01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.07</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2dcffce3-0ec2-4bb0-9202-322a65642de2" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a7bf947-de20-471d-bb34-d61681774dc2" contextRef="C_e6d96dee-383b-4648-a425-7febaa2eae01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,602</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc2a611e-c79c-47a1-ae5e-518c4c4241c9" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,767,674</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2770d90-58fa-4cea-9ed7-61ebd5b7edb2" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9143d83d-f211-4e6e-a3e0-24759653f531" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="rckt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.94</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_687bcd0d-e93c-4f4f-b055-b3b60819cb8f" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">269,080</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f44f4b8-4b29-41fd-8573-8af0fe300035" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f051c307-6d1b-4de3-bd6d-57f6f71d5d55" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,412</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7d072e2-ddc2-4ca2-b3b3-402d87f3181a" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">317,904</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a375358-8dde-40c5-9434-52285f107c79" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a1bf0b0-6209-427d-b949-8ed37205ff36" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,044,686</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b1d48e0-af34-46f7-9a1a-054352882208" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ea906107-3ba6-4ae3-ae3b-6e8170257efb" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.67</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7edc9f16-0f4c-4cb2-86c2-95c8116f8b35" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,295</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0086dcf4-0d25-4945-b62e-d7eda47c1d7b" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,255,024</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3bbc050-ec07-4ee8-a4ce-d17199d6dd70" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.55</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e2d6f00a-e5e5-48f9-b43a-8a678ebf0060" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56e484f1-b1e1-4c46-9ea1-885c660676f2" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,285</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d1d70c1-7e0d-4f00-8629-62304d7fa413" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,789,662</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50c24be-b94c-42de-bb61-4df12cb071e5" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.96</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f11a4094-fd36-4807-92f7-62d3a37c5822" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.72</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaf4a415-ee06-405b-bec0-17641724af44" contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca" name="rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8b1fe30-881a-4084-bbe7-3712036b67de" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_283336b8-db48-42ac-8739-8ff72b67ce4f" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eefdcd2-1bd8-4d3e-8c65-32e78200a9cb" contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of options vested during the years ended December 31, 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d539977b-4764-4086-b07a-6bbc6c3255de" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc07b70e-d9ed-4eac-b7b7-862b4d8604b8" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2733809-43fd-42dc-9161-2dfa32d74601" contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_afa84c9c-a8e6-4ccb-a29a-f937e66e4db3_1" continuedAt="F_afa84c9c-a8e6-4ccb-a29a-f937e66e4db3_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ca792ba-6c54-4ce6-a63f-fe7bf76617d5" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.28%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.6%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.119999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006c05b9-251e-41b7-8f5b-14dc51a0d953" contextRef="C_d4b68ab5-2b41-4121-b8f8-df6a4d864157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">992,874</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c7ae17b-8945-413d-9c8e-2fca22ba6153" contextRef="C_d4b68ab5-2b41-4121-b8f8-df6a4d864157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.49</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fb5be14-adb7-41c4-abb9-85a9f89649c6" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,018,322</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24bb6f89-1daa-4b0d-875b-265c416f1104" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.67</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7b045bd-0e24-4eb9-a94e-cb86d4a50eda" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">408,119</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8906689b-6302-4a9d-a115-a193dd40e522" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.61</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6833653b-d32c-4b1f-9de7-63153ec4e7e0" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">112,720</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a0f3654-8438-47c5-a99f-3b1787531d76" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.92</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e111cf5f-6ddc-420b-b703-c8ca21082aff" contextRef="C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,490,357</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7321c3-5e1a-40e9-b8a0-06139ba5bae9" contextRef="C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.53</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e418830-bb72-4e5c-8902-57014af22778" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">760,423</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e802832-9284-4a31-840d-72dab03de861" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.45</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaa84127-03c1-4f92-9208-e55d15a848bb" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">722,471</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8c6f170-889d-4b86-8a85-87f50f029514" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.69</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3374e609-dac2-4789-975a-9a4f5e1455bb" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">114,099</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5874d6-7135-4dd3-84e0-db51d9098e0b" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">21.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908951b7-4041-4648-ba96-15e29dd7e79b" contextRef="C_ebdeda00-9ced-49ab-96a0-78c4cdd5ca46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,414,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c7e431c-3841-4188-a992-2b8a84a99d14" contextRef="C_ebdeda00-9ced-49ab-96a0-78c4cdd5ca46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.02</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Common stock issued is net of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32f8d582-919b-41f9-8549-3da361832569" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">120</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares related to taxes.</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of RSU&#8217;s vested during the years ended December 31, 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be5e9755-65eb-4519-9ea8-efda08aed205" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90846133-095c-4e4c-9580-3c62f6ba1641" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e46a3e2b-aa6d-4aac-b61a-e0e7b049e2a9" contextRef="C_f889aac3-200d-4251-9867-6d16afb64a27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9971d52c-7ed5-4e3e-9f49-230ef56de406" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company began granting PSU awards in 2024. The following table summarizes the PSU activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e22d16-a33b-4f56-b6de-2632d9664790" contextRef="C_ae6b3516-7a34-414f-a317-8b7d0434e4e3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b227dd84-8120-4340-a03b-b540f1253bae" contextRef="C_ae6b3516-7a34-414f-a317-8b7d0434e4e3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_469839f1-e0ca-44db-b127-08f3ce204e03" contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">156,738</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51fca5e-4f02-4847-8aaf-b64d6e08d6aa" contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a52988-9a6e-4599-9e89-fcb115d05f8b" contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59b16d0f-4a16-4c71-b58e-9dcc9f2e0a80" contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf89067-ea25-4030-9f04-8aee38ac42ab" contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">87,077</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0efadcc5-f332-4a03-b1eb-eea186eb657b" contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.31</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_203d9a99-6ae8-46e0-9896-e51610e0ae26" contextRef="C_af781e94-ac4a-4e0a-b76d-1f546fae593e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">69,661</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76de9950-f7e3-4320-8802-89d8a8945bd9" contextRef="C_af781e94-ac4a-4e0a-b76d-1f546fae593e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.71</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU vesting and expense recognition is based on achievement of specific performance goals within certain time periods. PSU awards that are not achieved within specific time periods are forfeited. No performance goals were probable of achievement and the time periods for 3 performance goals had expired as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9f8912d-9f62-4893-9fe4-44a124ce5bdf" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized by award type is as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42bfeba7-c2e8-4b1f-8abf-20cf40fab0bd" contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,054</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1611338-87a1-46a9-8f6b-28717659f855" contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,091</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b1099cb-f70c-494f-95d0-796b6bb9f573" contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,620</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_632666f1-b655-42a3-a63d-87b3e1aaacf9" contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,866</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48af0aaf-9346-4575-bc7a-25aa8226bc98" contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,315</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7db32b19-fb0b-4582-96a0-36f68ed2d1e3" contextRef="C_f889aac3-200d-4251-9867-6d16afb64a27" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,389</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8173570-ac46-40d2-bbd0-da9598d7286b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,920</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7496a8-a539-4804-a2cd-052e2a410d34" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f5dba7-6fc2-49c2-96ce-ab8c56c0d089" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,009</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_afa84c9c-a8e6-4ccb-a29a-f937e66e4db3_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76487ade-f415-46ea-acbd-1e37505bdc1e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9774f910-678e-4a32-a2ab-4712849b34d6" contextRef="C_a24c8827-54a1-427b-bed0-b964f5520e1c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,784</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f4fbdd1-d426-4197-ba00-f22cea316892" contextRef="C_fadd17aa-74ce-41d1-ba1c-01a9d30e8d5b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,509</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b47b1294-d6d9-4492-ac97-ece022b29d75" contextRef="C_a3a9b56e-e418-462d-87f6-73709057c6a8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,466</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d768a853-652b-4487-9c9f-c13eceb71dbb" contextRef="C_7d36cd7b-896c-4b98-9546-ea32bed606cf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,136</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a520e15-2d4f-4648-b7c2-e4c4490673f3" contextRef="C_34f5602a-7c3f-4806-8c95-b68c3340e325" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,897</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e59cddcc-bc30-4458-83c5-7769cedfe4ff" contextRef="C_08780583-41ea-448f-ad3c-a32d151f99de" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,543</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b35114dc-4a63-413e-a448-48064335c91b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,920</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f3706d-19cc-4c26-83d5-be1cf9359127" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57405bd-cd2f-4342-9478-ef82602fbc48" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,009</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had an aggregate of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56911c4a-f8bc-4439-a05c-f3df45f983b7" contextRef="C_69c35b9b-2ef7-4ee6-b016-6923857d4819" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">58.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over the weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18ff41eb-329b-4506-bd4f-6b338fe4ee9a" contextRef="C_775eb4a6-0d31-417a-ac1c-4d459d9a1b5c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_ebf51842-8c4d-4617-964d-0d6ca7ba66b0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DerivativesAndFairValueTextBlock" escape="true" continuedAt="F_ebf51842-8c4d-4617-964d-0d6ca7ba66b0_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b91002c8-2688-43a2-96c5-4d64dbd4eaa5" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s outstanding warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:21.14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:35.86%;box-sizing:content-box;"/>
         <td style="width:25.16%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant/Assumption Date</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bcb8018-2ea4-4964-83cd-ed02026e2566" contextRef="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">57.11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68b36fa1-af6f-4cb8-91ab-bf4ba0304e19" contextRef="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">603,386</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d7a83c9e-99f6-4683-bd60-3d79c17b0ee6" contextRef="C_63ca01b0-e7b0-45e5-aa8a-17201501dd48" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 21, 2020</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_16b1f5c0-53f4-4be5-87b3-e3a3ec9d94d5" contextRef="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 21, 2030</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5c9e304-a7c5-4685-a81c-bb18ad4c2981" contextRef="C_192b6914-1bac-4600-8f9d-77f09fef2c75" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">33.63</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_767f7cfc-2dda-46fc-a89f-939fffa7d257" contextRef="C_192b6914-1bac-4600-8f9d-77f09fef2c75" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">301,291</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e5845706-0c1f-457b-a657-4af76a1009b1" contextRef="C_51821ea0-ebf2-416d-b94b-558384084f5c" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2021</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a9ae022f-ebf0-49d9-bbe1-39b8c82c2072" contextRef="C_192b6914-1bac-4600-8f9d-77f09fef2c75" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2031</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02e7e77c-ea5f-487d-8b0b-0f22660e660d" contextRef="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7b34ba-71e1-4d27-a624-4adb87817c22" contextRef="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">153,155</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_80cd9325-2e78-4191-b477-02515e910ecc" contextRef="C_6e010d18-1522-44a9-b62f-331c4708e6ee" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2021</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c0f8abd7-7d03-46bb-8f97-5468c7abcc71" contextRef="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2031</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04b3caf5-9ff7-44f5-bbbd-f8988410288e" contextRef="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.51</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa431f05-b940-4071-84f4-ba84a6893faa" contextRef="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">153,155</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a09f1133-e096-49ce-8a1b-ae9f770f361d" contextRef="C_a0c2517b-dc96-4c54-8ca8-8365a9a71c1e" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2021</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0c382776-4a59-4dc6-a3db-2b4c8b092031" contextRef="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2031</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00744670-8eff-4ab9-a867-04100a5f800a" contextRef="C_2b8daae2-1c08-437a-af18-31fd63828d53" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">65.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_670f9a5e-f20e-412c-9f91-844791d9e7a3" contextRef="C_2b8daae2-1c08-437a-af18-31fd63828d53" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">617,050</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_edd411ad-c975-4bc9-8c17-9bad4b0a6515" contextRef="C_8cae4c49-ba69-493e-87c2-811bf32aab54" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2022</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1552ebe2-7d22-4bef-8b4d-d14fe5eca5f8" contextRef="C_2b8daae2-1c08-437a-af18-31fd63828d53" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 23, 2025</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44d0866-7b2a-4df6-ae4c-fd68b1584f30" contextRef="C_2c739877-da67-4ce9-9177-ac7aba511326" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">65.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_679c07bc-fd19-4f8f-8746-d230a4cab2b7" contextRef="C_2c739877-da67-4ce9-9177-ac7aba511326" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">760,086</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3c73b93b-3f81-4338-af96-f106497d0735" contextRef="C_07a7dd6a-45bf-41e3-812c-421cdda9cc6b" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2022</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_59d33346-af47-41a9-a095-667ba4225b2c" contextRef="C_2c739877-da67-4ce9-9177-ac7aba511326" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2026</span></ix:nonNumeric></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbbb0cb8-d460-4d32-92ef-7a893bbb705a" contextRef="C_0b068067-3bc4-428c-8a9a-66ff44763c0b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26a391fe-23ab-4c34-ad17-20383d7a5bb3" contextRef="C_0b068067-3bc4-428c-8a9a-66ff44763c0b" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,126,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_10507d8e-66ee-4ffa-94da-74e394b6b460" contextRef="C_a62b5264-3059-4dbe-b8df-0bb7b813db23" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 15, 2023</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df5a2a15-8109-40a8-8b42-1183a56e6461" contextRef="C_ad2fb098-5ecf-47f9-9732-d89dedec0a31" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d692a41c-e52b-489c-bc0e-782074b7aea3" contextRef="C_ad2fb098-5ecf-47f9-9732-d89dedec0a31" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_307a2f34-0070-4311-905d-4124ab2dd9e7" contextRef="C_84c34b9d-6390-46b6-8bd7-a209b92ac32e" name="rckt:ClassOfWarrantOrRightGrantDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 12, 2024</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76e39a8a-0332-4a75-b3ec-b0014a5e33f5" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,115,078</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table below is the summary of changes in the Company&#8217;s warrants to purchase common stock for the years ended December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.939%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:26.919%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.041%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.082%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Warrant Shares Outstanding and Exercisable</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price per Share</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bae73696-d50c-4f18-ad1b-b4ac344d9f44" contextRef="C_61647b0b-b5df-4485-8420-e20842c8ff39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,721,267</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0764471c-f123-4c12-8c09-808d72f16790" contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,126,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a2a32da-3e1e-4652-94c6-54171f8daa29" contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_992a4e48-869d-4661-9817-433881d69364" contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">126,093</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_611c8370-0735-4bfb-97c2-5a135226a8bd" contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.06</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f05b47de-22c8-4335-a6a1-29cc1bfdac5a" contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,051</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df378ebe-c5eb-4f62-b7f5-d630f3ca0687" contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.42</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c91baa9-8540-4087-aeaf-2dc78c4622bb" contextRef="C_55db9cf5-dacb-451e-bc48-da645969b76a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,715,078</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03464235-cfc4-4c7b-8f76-2bf3351971ee" contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3f1325-e5f9-4baf-8576-e1a8feb632c7" contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19304011-8756-49a8-905e-aa97e87dbe63" contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a2ac6f-3ee7-4801-b2e9-17b7c9caa4e8" contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca05ac39-adba-458f-8c39-d45bce74fcd7" contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fec4c5e-b767-46a7-92ed-2d5b34cc557e" contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fae8166-0488-4bc1-924e-097274306dc5" contextRef="C_a2ac1bfa-acd2-4922-9ccd-25d39d1ed512" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,115,078</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants Issued in Public Offerings</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued warrants to a related party during the years ended December 31, 2024 and 2023. For the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company sold pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f893811a-6847-4256-84ca-66b03c7991bb" contextRef="C_a589b03e-fb9c-4bfa-83f1-f8a8d07ed1fa" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3889022f-64ed-4fcc-89ee-951f8c4a3496" contextRef="C_2752ee0c-715c-4d1f-bee7-73f449628989" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,126,955</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common shares, respectively at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2738496-35d3-4892-b384-db9177a913d5" contextRef="C_594c6d62-c2cf-41a3-886a-1934d4223d53" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_21824dad-afc0-441e-b8fb-0283457624e7" contextRef="C_2c40b128-241d-4c5e-acaf-fed48f581245" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (see Note 8 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Stockholders Equity&#8221;). The pre-funded warrants were acquired by funds affiliated with RTW (see Note 17 &#8220;Related Party Transactions&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assumed Renovacor Warrants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the acquisition of Renovacor, Rocket assumed outstanding public warrants, which were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">converted into warrants with a right to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98814ce0-875d-4d42-809b-0e98243c1c2e" contextRef="C_c72cfefa-5df0-4873-ad35-93e437d2fecc" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">760,086</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Rocket common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd516057-2876-4ad0-98f5-e64a8c06f6ea" contextRef="C_c72cfefa-5df0-4873-ad35-93e437d2fecc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">65.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ebf51842-8c4d-4617-964d-0d6ca7ba66b0_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the acquisition of Renovacor, Rocket assumed outstanding private warrants, which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were converted into warrants with a right to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70beb675-fca2-4cc1-acfc-96ec8670abd8" contextRef="C_e9d92f5a-8151-4cab-ad6d-17971fdc56a0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">617,050</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Rocket common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_672c08af-627b-4d8c-9640-a8187f17a99b" contextRef="C_e9d92f5a-8151-4cab-ad6d-17971fdc56a0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">65.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the private warrants did not meet all of the criteria for equity classification. Accordingly, the Company classifies these as a derivative liability in other liabilities in the Consolidated Balance Sheets. The Company measures the fair value of these warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company&#8217;s operating results for the current period. See Note 4 &#8220;Fair Value of Financial Instruments&#8221; for discussion of fair value measurement of the warrant liability.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the acquisition of Renovacor, Rocket assumed pre-funded warrants, which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were converted into warrants with a right to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c06f5208-2552-414c-ba3e-974e9606cd4d" contextRef="C_b27c603f-0be6-4a87-b784-35a6acc0b66b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">126,093</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Rocket common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da2b0545-7d7a-4733-99e6-fe3b55d4bd91" contextRef="C_b27c603f-0be6-4a87-b784-35a6acc0b66b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. These warrants were exercised in January 2023.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_870f9bb6-4763-4fb1-a2fa-ec0aa2cefd9e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2230b44a-64dc-4f31-af45-68cc5efdf5be" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_2230b44a-64dc-4f31-af45-68cc5efdf5be_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f86278e9-85c2-4904-9e65-dc89ba198c2f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a96ceef-c2eb-4127-ba4d-3d23e3f92fa6" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6693e76f-ab7c-4711-b577-16da81f9a936" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b22d10a0-acb3-4514-b6ae-70658c8dd40d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_de46ca60-1875-47ec-85e8-b70d78fb9d6d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">94,807,773</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7947c0e-def2-423d-bb17-61613823b8e8" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0397c179-04d5-4e63-bb6c-c13cc45b42f5" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">84,009,004</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_657efa99-7f53-4eeb-a2de-13d2f2f0fd8a" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9dab512d-b613-49de-b3af-050b15db750e" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">68,148,925</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eea573e-54de-42dd-ad3a-c58a93852cc6" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_16814a50-9648-4cdd-b19c-4f5861f3a16e" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.73</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed758b21-9fb9-4df8-afb4-68193d816d42" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2bc47205-80de-4b16-86e8-2558807c5c60" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.92</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df83faa5-df99-490d-98fe-9bdc8807d9c1" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3cf0904a-f150-48ab-a9b6-f103e47e5e2c" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.26</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_2230b44a-64dc-4f31-af45-68cc5efdf5be_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, </span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023, the Company included the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68110d64-aa6c-4a14-823e-f9c82de6394e" contextRef="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,126,955</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential shares from the pre-funded warrants acquired by RTW in 2023 in the basic weighted-average common shares outstanding as it only requires the holder to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bb5b11d-0a39-42fc-beae-44d30718ae47" contextRef="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share upon exercise.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company included the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da976d8f-bb9d-49b6-8df0-a419daadd4ba" contextRef="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,126,955</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential shares from the pre-funded warrants acquired by RTW in 2023 and the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41347a42-2759-4f26-a153-397dae1b5738" contextRef="C_845cdb5d-eeb4-4f91-b37f-77626c44f34b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential shares from the pre-funded warrants acquired by RTW in 2024 in the basic weighted-average common shares outstanding as it only requires the holder to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27048268-e719-4726-8a6b-718dd688a07e" contextRef="C_845cdb5d-eeb4-4f91-b37f-77626c44f34b" name="rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share upon exercise.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9285cdf-8d75-4e30-90d3-a13bc3a733f5" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_e9285cdf-8d75-4e30-90d3-a13bc3a733f5_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8704df7-d6b3-4a8c-a990-d418ea649654" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,588,123</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e795506-6b30-40a6-a70f-a59d237113a6" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,588,123</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9435701c-3143-4fc9-b7f0-5f4c9ee09c49" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,721,267</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b20cf0a-1520-43ae-b3ff-43a22fac3d09" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,414,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f01396f-312b-4a26-a429-9238bb3958ab" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,490,357</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_782251ac-ce4f-459e-b932-fe8a880aac0c" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">992,874</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance stock units</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17680a45-dabc-4742-9679-183718f1c6a0" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">69,661</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a00b67ce-32db-437f-a13c-f59bd998c6d8" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd1fabf5-2493-49d8-9b24-243937515cc1" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a352d276-3b11-4ac0-9967-027d7eb56415" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,044,686</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95f1dded-b09e-4791-8dc9-d3d7a2df2fcc" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,863,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b44991b9-888d-4d49-a7a8-c9c76c990c79" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,138,870</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total potential shares excluded from diluted net loss per share</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e458d8d-d017-45fd-a8d3-8c9d82237044" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">20,116,680</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13a4f01b-2d7a-4d5d-a43d-0cbc92cd8798" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">18,942,476</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fd9a3bd-dd21-4761-8c26-db12414d17bb" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,853,011</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_e9285cdf-8d75-4e30-90d3-a13bc3a733f5_1"></ix:continuation></div><p style="margin-left:67.28%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div><ix:nonNumeric id="F_0668cb6c-7ba9-44b7-999a-6b16fba3ff24" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_0668cb6c-7ba9-44b7-999a-6b16fba3ff24_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d151c9be-dabe-4283-b0d0-b39c6c97e225" contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_82666f1e-3d72-4895-8773-aa7a2e9f4147" contextRef="C_fe613fec-8a94-4877-8745-1c95fb74dd4e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b2a371b8-b8e7-4d1d-8128-960153415518" contextRef="C_1bae87d0-dd44-44ba-9b20-91cc4df8a8be" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for federal or state income taxes was recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, as the Company incurred operating losses and maintains a full valuation allowance against its net deferred tax assets.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_0668cb6c-7ba9-44b7-999a-6b16fba3ff24_1" continuedAt="F_0668cb6c-7ba9-44b7-999a-6b16fba3ff24_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f31d0b2-9168-421f-9d72-9e9a0e804859" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.26%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal tax at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86df5d8d-f1e5-49c2-a9ab-76903b6527cb" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_394d7642-5e38-4273-bdf5-d88d3b654b82" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d0a5610-f2db-4b50-bf8f-38ac60255537" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c32228e-f364-43ef-9cd4-ac4a196f610b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f202b0f-7e34-4cfd-aa98-edbfcdd19caf" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">17.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71fff192-d71f-43bb-9334-d61c7db13572" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">16.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state tax apportionment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e611e06-d86f-4870-b435-f4f84da484fb" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f89349bc-e79f-432c-bead-ebd58d55d0e4" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_102ea39e-a29f-4231-b1db-b7553acf9373" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52060f2e-eff7-4825-aacc-8b5fe142289d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c599d835-2884-4e1d-9fdd-c782e0a968ca" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f442d8a3-c2d4-452f-8125-15ef13d82b59" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Return to provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5da87bbe-d219-440b-88b9-30e0c341df2b" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af5c56e-3b72-4f07-bd3a-f9bf1fc5c34e" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cf3b5b2-b415-4b2b-927c-939084023808" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_437e5f45-784b-4e6f-a0a9-d694767e5190" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc7aad79-34be-4001-b00f-3487b4799b16" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83a1d9f2-f3ca-49a1-a2c0-fe0912eaf1c4" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e29b193-fe1c-4a29-8b83-17d728b603a2" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22211293-c965-4a97-99a6-43c0cc48fd70" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45974880-b793-4822-8e8f-c5f116af363b" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_841d782a-a34e-4698-9df7-71592a05724c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a192d399-a3ed-41cb-bca7-1a1328b8f9bf" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba5776c0-2331-433b-a296-bb2a30116e6a" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae567a03-ac91-4cd3-b5c7-b9ba52a01427" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b50ad4b1-11cc-4ebc-843d-99bbe6278968" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ee1f433-624f-412c-94f6-7625dca9049f" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2023, the Governor of Massachusetts signed into law a bill that included the adoption of a single sales apportionment factor effective on January 1, 2025. As required under ASC 740, the Company has accounted for the deferred tax impacts of this tax law change in the period the tax law was enacted, which has the impact of reducing its state deferred tax assets. The impact of the tax law change is offset by a change in valuation allowance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property rights in different jurisdictions are reflected in the Company&#8217;s effective tax rate.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43ea8552-ba78-445a-9837-145cf4556594" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of the Company&#8217;s deferred income tax assets and liabilities after applying the enacted corporate tax rates are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.26%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.66%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47020e5f-76ee-4942-bf78-cd45ff54e178" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,410</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4553ca3-31f2-4983-bd1c-bc81d7760205" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0b0d145-acf5-43a4-8b40-62e18e377093" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses and credit carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05ea0911-db48-478e-9352-8452870bbb7e" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0faa64f-38bd-46ec-9732-e8b0672043f3" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,313</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94af28b5-0604-40b2-9000-0ad3593cca0b" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,718</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ac09dbb-7b77-4bee-9531-109071d955f7" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,787</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a197367a-fa87-4aa1-80ea-eb2ab1556e97" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,205</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6abe1a3-4915-4d15-bffc-6ddcff2ba0f3" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,085</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11b72695-dce1-42eb-b836-798e2a815bd4" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,041</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea1729f-b13e-4b71-bdd4-4bbd58cd1253" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,499</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1e6f06-3e32-4532-a982-9d24da063673" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,781</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5154927f-b9f8-4648-81a3-f960d571db3a" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="rckt:DeferredTaxAssetsWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,713</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_956f85d9-b176-4dee-bdce-05336c43563e" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="rckt:DeferredTaxAssetsWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,283</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_026d1d06-3654-4b06-ae97-2ed1a4a84732" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="rckt:DeferredTaxAssetsWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,390</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cecf0200-0376-4bf7-93c7-51c67b1725bc" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,697</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da85fd21-ba6e-4576-87bf-121ebf00ef53" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,787</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd0275f-3814-4441-b8e0-6622b6294a33" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,424</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3031b860-ab33-4b5a-8a96-1833f67e4132" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,829</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee969a6d-49cc-4bfa-9fc1-aed3d2357a84" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,086</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2243b72-142c-4578-a74f-8445579c4b35" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,332</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21fcb97b-3b83-42ca-98e4-a2d843503736" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,077</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdb375e1-1361-4d71-aa69-a79fad722820" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,472</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2b3b3d8-09ea-48eb-9676-a6dd56a6dfe7" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,263</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax asset (liability)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fa98e66-6564-429e-969e-8ed75f5b0829" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02ce30c0-df9a-421a-95f4-ba56eb59a36f" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b97eea29-3e04-4c07-8bf3-ef3466bd468f" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal and state net operating loss (&#8220;NOL&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ec042d6-4f0a-4f46-972b-d521b466b15b" contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">303.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b27e110-9e03-4261-a243-6e08c00b6ac5" contextRef="C_4aa60fef-eb52-492b-9a6b-0ce93d49fb48" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">78.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The state NOL begins to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0a395aa8-c4ae-4063-a1b7-e3d080e5ffcf;"><span style="-sec-ix-hidden:F_f8ada714-1a3a-4a7f-a2c0-3691e7ff6012;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Additionally, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98e16cf6-c13c-443b-a667-f9daf4aca5da" contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">303.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the federal NOL can be carried forward indefinitely. The Company has federal R&amp;D credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c38e81f1-9838-40b5-8b8d-d1816eb9a3f8" contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1" name="rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_476f0015-4836-4e88-9984-744d464250a3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by ASC 740, Income Taxes, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOL carryforwards and capitalized research and development costs. As a result of the fact that the Company has incurred tax losses from inception, management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state net deferred tax assets and, as a result, a full valuation allowance has been established against its net deferred tax assets as of December 31, 2024, 2023 and 2022. The Company has offset certain deferred tax liabilities with deferred tax assets that are expected to generate offsetting deductions within the same period. During the years ended December 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 and 2022 the valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a55beb85-786d-4bf0-8a18-01b53781e03a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bada1cbe-ff49-4a81-9618-b9a2b1c1b044" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_509c6230-c386-42f8-8703-fc76b513bbfa" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Realization of deferred tax assets is dependent upon the generation of future taxable income.</span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0668cb6c-7ba9-44b7-999a-6b16fba3ff24_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Internal Revenue Code Section 382, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. The Company has completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company became a &#8220;loss corporation&#8221; as defined in Section 382. The Company experienced multiple ownership changes occurring in 2005, 2007, 2015, and 2018. The ownership change has and will continue to subject our pre-ownership change net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of our stock at the time of the ownership change multiplied by a specified tax-exempt interest rate. As a result of the merger on January 4, 2018, the Company is limited to an approximate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_103545b0-7606-4b1d-9f50-7199415c5edd" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="rckt:AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million annual limitation on our ability to utilize the NOL&#8217;s and R&amp;D Credits prior to the ownership change. Due to this limitation, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8399c9a-ea56-4e0e-ac7a-032e017dbba5" contextRef="C_e74a48a3-05d2-4751-8cd8-1f14b04dcc09" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">91.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acb12e16-ce01-4362-972d-b04b0bb6273b" contextRef="C_e74a48a3-05d2-4751-8cd8-1f14b04dcc09" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">127.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pre-merger Federal NOL will expire unutilized as the cumulative limitation amount over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3354e879-8a43-4eb3-bbda-8ab4ff0426d2" contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2" name="rckt:OperatingLossCarryforwardsCumulativeLimitationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> carryforward period is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35a775cf-d157-4aaf-8833-928f98875c97" contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1" name="rckt:DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_019201e8-bf12-4b8a-80bf-07d447b41990" contextRef="C_bf12f724-78e9-4689-a9d8-6cfcdb16921d" name="rckt:DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal R&amp;D credits will expire unutilized. As a result, the Company has reduced its deferred tax assets related to the Federal NOL and federal R&amp;D credits by an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9ff68b0-dd8c-4d1b-9118-0949110c8baa" contextRef="C_bf12f724-78e9-4689-a9d8-6cfcdb16921d" name="rckt:DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which is offset by the corresponding decrease in the valuation allowance. In conjunction with the acquisition of Renovacor, the Company acquired Renovacor&#8217;s federal NOL&#8217;s of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd2132f1-2950-4969-b377-95c3b08b1f30" contextRef="C_1a9df4ee-5889-42bf-97e5-3fe2409b390d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company has completed a study to assess whether an ownership change has occurred as a result of the transaction. The Company experienced ownership changes occurring in 2021 and 2022. As a result of the ownership changes, the Company is limited on our ability to utilize our Renovacor NOL&#8217;s. As a result of the Company&#8217;s study, any limitation under IRC Sec. 382 would not result in NOLs expiring unused.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2024 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8cf2b6b-73f1-4e98-9a32-162a9f42d85d" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4d5006bb-909a-4bc8-92d9-96f4641412cc" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any uncertain tax positions in its financial statements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcf9e0d9-a44e-44f9-ba2b-ffc110eb9aa4" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c495d38e-322c-4226-9a92-4ee1bcf06330" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the Consolidated Balance Sheets.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_fac00edd-f0c0-4e8b-a4f0-e07196f1ea75" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:LessorSalesTypeLeasesTextBlock" escape="true" continuedAt="F_fac00edd-f0c0-4e8b-a4f0-e07196f1ea75_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance Lease</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a lease for a facility in Cranbury, New Jersey, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7cd6f49-ef3d-431a-933f-f3ebf1d77849" contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603" name="rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">103,720</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space including areas for offices, process development, research and development laboratories and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea2de813-2eaa-4cad-8477-89d37acee9b4" contextRef="C_f9abc263-c852-40e4-bb93-fffa5f59bb9a" name="rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet dedicated to AAV </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cGMP manufacturing facilities to support the Company&#8217;s pipeline (such lease, as amended, the &#8220;NJ Lease Agreement&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The NJ Lease Agreement has a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9968b89f-48c1-4fa2-aefa-3d3da6c3d9d3" contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year term from September 1, 2019, with an option to renew for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75e7b8d4-1b21-4b25-a5f1-5f39887d73ad" contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603" name="rckt:NumberOfOptionsToRenewLeaseAgreement" unitRef="U_Leaseagreement" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27e92c54-8227-45af-8b2b-76c68d6d326e" contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewal terms.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated rent payments for the NJ Lease Agreement are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d9f8ad1-5e23-4110-b434-02da9a7fad65" contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603" name="rckt:FinanceLeasesEstimatedRentPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per annum, payable in monthly installments and subject to annual base rent increases of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea714bbf-308a-467b-b2b2-3292f6491d37" contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603" name="rckt:PercentageOfAnnualIncreaseInBaseRent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The total commitment under the lease is estimated to be approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beda2212-6286-4566-930b-65628f6dfae4" contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcc2ee31-7191-4d5a-9c2e-43ad5fb39b30" contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year term of the lease. The Company paid a cash security deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06fb45d0-5e10-4a0b-afb8-d584e97e8a29" contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the landlord in connection with the NJ Lease Agreement which has been reflected </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as part of deposits in the Consolidated Balance Sheets as of December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 7, 2018, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a63cc39-c47b-4c59-8b00-f9dfb86efce7" contextRef="C_05d3269a-9c6d-44e5-9b7c-99c1bf950fb2" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ESB Lease Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the ESB Lease Agreement, the Company established an irrevocable standby letter of credit </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_178ba56e-1bfa-4272-b987-ce9fc7befa29" contextRef="C_05d3269a-9c6d-44e5-9b7c-99c1bf950fb2" name="us-gaap:LinesOfCreditCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On March 26, 2021, the Company entered </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">into Amendment No. 1 to the ESB Lease Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that extended the term of the lease agreement to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20039975-5c75-4a58-a2a0-6bc96dd09d5c" contextRef="C_76dc7d6c-2561-4ef0-81f4-82f6593b6052" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On March 29, 2024, the Company entered into Amendment No. 2 to the ESB Lease Agreement that extended the term of the lease agreement to July 31, 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The letter of credit serves as the Company&#8217;s security deposit on the lease in which the landlord is the beneficiary and expires </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3bc2e57-495b-451d-8524-07b498eb3f62" contextRef="C_842fddb4-2c73-4db6-a334-14dfdfb8754b" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 30, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a certificate of deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_147ff651-01ac-4e8d-a0b6-3fe1ae6d8471" contextRef="C_71fbe897-d128-4353-aa54-ac82b0209669" name="us-gaap:CertificatesOfDepositAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8bbd8264-8e16-4e01-847c-83f75aef81cd" contextRef="C_f6f45e22-281d-462c-89e9-34ded8f15e53" name="us-gaap:CertificatesOfDepositAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with a bank as collateral for the ESB LeaseAgreement letter of credit which is classified as part of restricted cash in the Consolidated Balance Sheets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, and 2023.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_fac00edd-f0c0-4e8b-a4f0-e07196f1ea75_1" continuedAt="F_fac00edd-f0c0-4e8b-a4f0-e07196f1ea75_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 1, 2022, in connection with the acquisition of Renovacor, the Company added </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating leases for spaces at facilities in Hopewell, New Jersey and Cambridge, Massachusetts with remaining lease terms of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cc9bf31-3ca9-4869-8ef9-b9ec5e9cc8d2" contextRef="C_2765a887-d17f-45bb-83df-c1b045d9460d" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.25 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34364d6c-a3bd-4b88-99de-3ba3da3ea782" contextRef="C_f6793c34-d860-442e-be6e-737f243f3d98" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.3 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years, respectively. As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of December 31, 2024, lease commencement dates had occurred for all leases and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company recognized total right-of-use assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ffcbd43-79cc-4ca9-92ed-0be5afce3158" contextRef="C_f6793c34-d860-442e-be6e-737f243f3d98" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with corresponding total lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae54cdac-9e2e-40fa-8d66-cc0897032590" contextRef="C_f6793c34-d860-442e-be6e-737f243f3d98" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at lease commencement dates. The Company intends to sublease the facilities in Hopewell, New Jersey and signed the first agreement to sublease one of these facilities in January 2024. Rental income received under sublease agreements for the facilities in Hopewell, New Jersey totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4afdbd1-7998-469f-b97b-94d0d4431dc0" contextRef="C_c182ea63-0464-4304-ac90-99a8af5eefc8" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc4b7ebb-cffe-44f1-a81f-35979814c937" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cd7c6bb-3002-4feb-8d17-d7bd3ef626a0" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6775b515-c106-44ca-ba55-2fabb8877832" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total restricted cash balance for the Company's operating and finance leases as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_407486b2-c1fa-45e8-abd7-f3b2b2cffe2f" contextRef="C_c8dbc4c6-e882-4412-ac54-add80894cf82" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c8004df7-9e42-4c4b-b93c-37c419d550cd" contextRef="C_c12614f0-c656-4035-8e89-9961453df24f" name="us-gaap:RestrictedCashEquivalentsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9925d38f-08c0-48c2-aeb6-fd1977591b08" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes lease cost for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years ended December 31, 2024, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c14a9e8-4412-4977-94ba-9e4f4e5a003d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,247</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e711a7-6cac-4f82-b56c-823f0d2c796a" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d19f195c-c484-491a-a877-d0b83da7d35e" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">818</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease cost:</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of right of use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ab10d0f-ce37-4071-bacf-fbc9df988969" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee0b8e66-4b6b-4a53-8a5d-259129f1ec3c" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f27b9192-0596-467f-aa95-423f5b650478" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,139</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9769384-6312-4edf-ad81-1a08f7029703" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,886</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9744bdc8-729b-45d4-b446-e1d065a4cbb0" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,875</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46a52d9d-1d2c-4671-b375-28d6bb6cd1cb" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,861</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8f3a9f9-e22c-4fea-baba-720cecccbafc" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6782ce2d-c58e-43ad-b765-261d11c7597f" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,406</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3f4a71-1ca9-4352-a1e6-ca1506e13cc6" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,818</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f9a4a40-ca5d-473e-bde1-8d7653ce9958" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturity of the Company&#8217;s lease liabilities on an undiscounted cash flow basis:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3669699e-2f9a-4a4a-a0f0-8e5979bc13d8" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,001</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60fa7977-95d8-4471-9a19-d4e0fed4d195" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d95ef2c-a2ee-43e9-928e-50bad8a183a7" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f8b1eac-772f-4acc-bad4-0a322d852f67" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27787b45-c3c2-4c82-86e1-0692240a33bc" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16aa04e2-9e3a-41dd-97d2-4559545c4e0f" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,881</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0230fd4-6476-485e-b7de-259c2c209c04" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,707</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_325b4414-6e9e-4653-bfd4-501e02c78a33" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f72c4e3-915c-4cf7-99d5-bf2494d37f58" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,259</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a3c13e5-4e8d-44b6-845c-29d21666c2f5" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:22.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76a5a4bd-41a1-4001-ba3d-d3325fc9e1ce" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,856</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc05b8f5-025e-495a-ad0a-721fffc5e625" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,911</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f5e2872-38d7-4b15-9535-bcd0f06e3bdb" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,969</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a5e6cd6-c4c0-4a8b-8689-650c505da05c" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e98d6a7f-58c4-4093-9f44-712fbc8644d6" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,089</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85b2bb59-fac6-4a28-bca4-953c04a3ce82" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,915</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdc62a43-0776-477b-82dd-056a0907f0c3" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,768</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bdc40a0-b88b-43ae-b5de-28c58a88dcda" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,529</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deadf0c3-fd4e-45e5-9a3d-dba6dd2b5db9" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_fac00edd-f0c0-4e8b-a4f0-e07196f1ea75_2"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bd6e2ca-4df5-49e5-b79c-8f6f8e248625" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:LeaseBalanceSheetInformationTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the operating and financing lease liabilities and right-of-use assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.752%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.122999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.122999999999998%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b803def2-6ca1-4352-8cb6-6a7dae928ebb" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,173</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8204a373-75bf-418c-9f74-b856e2b9a9eb" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,901</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating current lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4954460-8552-4a46-a73e-3d14e848b71c" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,001</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce214a22-e5d9-44c9-a8f6-88d65c1062e2" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">925</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating noncurrent lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32bb8694-77f1-455c-b1a2-7d939d4585bb" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,258</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6d6100-6cef-4bfa-8fd9-60b4da2cd7af" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,973</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fabba31c-9909-4152-8b06-c94166831a01" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,259</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02592ad2-dde8-46dc-ad3e-c7bf17d2b53e" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,898</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50fa84a9-3931-4ce2-b425-882571f78ab7" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,363</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec12c819-294f-43d7-a745-177aec8eb2fe" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,517</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance current lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98ca5d2a-1511-4285-95f1-06a82106a416" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,856</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e6c525e-8f07-44b9-aa6c-75d9168ece89" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,791</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance noncurrent lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_008a9f32-a6c4-4828-81d7-c36d3432d11b" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,383</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9decadda-f4ff-4a07-a4a1-556dbf4b5287" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,353</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50913dc-1ee8-4eae-b299-e15fb5ea167d" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,239</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c50d338-d5f1-490a-b557-f44e8ecf8563" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,144</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eaf59830-f779-4d1d-9c50-761bea5a97d4" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:LeaseSupplementalCashFlowInformationTableTextBlock" escape="true" continuedAt="F_eaf59830-f779-4d1d-9c50-761bea5a97d4_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.915%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.225%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.225%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.636%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Information</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dba69599-785b-42a5-bcbd-7b5fcbd60e6c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4dd8b7b-789b-4a16-aab1-ed4a46e3e4bb" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23edd121-68d5-45f1-945c-a544a07fbe28" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">938</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f039fbd-7020-4460-b97b-9192856d639d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,791</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d53ef118-bb7d-4462-ba57-217c685c9c9f" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da0fc314-e69b-4bfb-8b3d-04bd80ff7724" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,689</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Information</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4b21efa4-ba30-4a38-b16d-637fb15a97ac" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1914f0be-e1a1-47c0-821e-2fa30bce412a" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4bd448d5-6df4-4c9a-a940-ff345413cd93" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fccc39ab-bdf5-419b-a4c9-0038ca770035" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b73942fb-99f5-4de7-a8aa-310519812489" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b4a0c927-56fe-4cfd-8918-6104e04b7337" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_815b5301-6f89-4dd6-ac16-444fde6bcb3a" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.82</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f413963d-2c11-4564-89d9-d170e8a999e1" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a6fabfa-f7c2-4e46-85de-e70d5c23deeb" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.44</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd75fe98-831d-4b39-92ec-27836e05b0fc" contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.96</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb3f8c4d-13ed-488a-9e6b-0cf581a41e57" contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.96</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d44feed1-3735-4b65-86c5-5ffc09e177b9" contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.69</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_eaf59830-f779-4d1d-9c50-761bea5a97d4_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_030c5143-60b9-48ae-a0cd-c1e586d81df7" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Arrangements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to its bylaws and as permitted under Delaware law, the Company has indemnification obligations to directors, officers, employees or agents of the Company or anyone serving in these capacities. The maximum potential amount of future payments the Company could be required to pay is unlimited. The Company has insurance that reduces its monetary exposure and would enable it to recover a portion of any future amounts paid. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Throughout the normal course of business, the Company has agreements with vendors that provide goods and services required by the Company to run its business. In some instances, vendor agreements include language that requires the Company to indemnify the vendor from certain damages caused by the Company&#8217;s use of the vendor&#8217;s goods and/or services. The Company has insurance that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:AgreementsRelatedToIntellectualPropertyTextBlock" escape="true" continuedAt="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements Related to Intellectual Property</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, directly and through its subsidiary Spacecraft Seven, LLC, has various license and research and collaboration arrangements. The transactions principally resulted in the acquisition of rights to intellectual property which is in the preclinical phase and has not been tested for safety or feasibility. In all cases, the Company did not acquire tangible assets, processes, protocols or operating systems. The Company expenses the acquired intellectual property rights as of the acquisition date on the basis that the cost of intangible assets purchased from others for use in research and development activities, has no alternative future uses.</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3_1" continuedAt="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for PKD with CIEMAT Group</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, the Company entered into a license agreement with CIEMAT Group</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, granting Rocket worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human PKLR gene solely within the field of treating PKD. Under the terms of the agreement, the Company is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0f41fdbb-616b-4390-91ca-6c0083fedb69;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, Rocket is obligated to pay CIEMAT Group an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. The Company is responsible for prosecuting and maintaining the licensed patents at its expense, in cooperation with CIEMAT Group. Rocket also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group. For five years following the effective date of the license agreement, the Company has a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group at market value. Rocket is obligated to license (without charge) to CIEMAT Group for non-commercial use any improvements to the licensed intellectual property that it creates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, Rocket paid CIEMAT Group an initial upfront license fee of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_188986a9-4cc8-4bdd-9c03-98c44d17473a" contextRef="C_62e99bbf-513f-4f99-b0ea-bcc4f892c8d2" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_EUR" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de89f22a-1ce0-4f0d-b9bf-3be672c7f4bd" contextRef="C_62e99bbf-513f-4f99-b0ea-bcc4f892c8d2" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) which was expensed as R&amp;D costs. The Company is obligated to make aggregate milestone payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63755f65-40e1-441d-a11a-20fe01112b37" contextRef="C_3ffc89cd-c5e5-47b4-9f7d-0851382b9894" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_200d6794-713f-4f54-86e1-11d6efc964ed" contextRef="C_3ffc89cd-c5e5-47b4-9f7d-0851382b9894" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) to CIEMAT Group upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the PKD license, Rocket is obligated to pay a low to mid-single digit percentage royalty on net sales, subject to specified adjustments, by the Company or its sublicensees or affiliates. In the event that Rocket enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket may terminate this agreement at any time by providing CIEMAT Group with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d133dfec-81e6-450c-9c50-21040d118d6a" contextRef="C_392358ca-cf5c-43db-9d21-66153965d64c" name="rckt:AgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for FA with CIEMAT Group and FIBHNJS</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2016, Rocket entered into a license agreement with CIEMAT Group and FIBHNJS granting it worldwide, exclusive rights to certain patents, know-how, data and other intellectual property relating to LVs containing the FANCA gene solely within the field of human therapeutic uses of VSV-G packaged integration component LVs for FA type-A gene therapy. This license is only sublicensable with the prior consent of CIEMAT Group and FIBHNJS, not to be unreasonably withheld. Under the terms of the agreement, Rocket is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_df646047-6e29-47e2-b2b5-6f058df99877;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, the Company is obligated to pay CIEMAT Group and FIBHNJS an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, regulatory and financing milestone payments, and sublicense revenue payments. The Company is responsible for prosecuting and maintaining the licensed patents at our expense, in cooperation with CIEMAT Group and FIBHNJS. Rocket also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group and FIBHNJS. For five years following the effective date of the license agreement, the Company has a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group and FIBHNJS at market value. Rocket is obligated to license (without charge) to CIEMAT Group and FIBHNJS for non-commercial use any improvements to the licensed intellectual property that it creates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, Rocket paid CIEMAT Group and FIBHNJS an initial upfront license fee of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caac466b-0cdb-494d-8842-4fa25127e414" contextRef="C_f7e81d9b-0896-4ad4-ba24-d00ff70c5380" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48a79660-7c68-4ac1-92de-827d306d8fdf" contextRef="C_f7e81d9b-0896-4ad4-ba24-d00ff70c5380" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), which was expensed as R&amp;D costs. The Company is obligated to make aggregate milestone payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af23534-8b27-456a-845d-87ac2c019614" contextRef="C_9db51dfa-02b3-4033-8f63-ae0680935120" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a4f4b3f-525d-4b66-b4c6-b6bf34c4b6fe" contextRef="C_9db51dfa-02b3-4033-8f63-ae0680935120" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) to CIEMAT Group and FIBHNJS upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the license, Rocket is obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by Rocket or its sublicensees or affiliates. In the event that the Company enters into a sublicense agreement with a sublicensee, the Company will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><ix:continuation id="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3_2" continuedAt="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3_3"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket may terminate this agreement at any time by providing CIEMAT Group and FIBHNJS with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2fa6dcd-ac41-4841-ac2c-fa7e83d11413" contextRef="C_d25d260a-f7e7-4db6-8072-fa02e589a560" name="rckt:AgreementTerminationNoticePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for LAD-I with CIEMAT Group and UCLB</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into a license agreement in November 2017, effective September 2017, with CIEMAT Group and UCLB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, granting the Company worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human LAD-I gene solely within the field of treating LAD-I. Under the terms of the agreement, Rocket is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_51fd1836-2c76-4d4a-89af-503fa040d252;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, the Company is obligated to pay Licensors an up-front payment, royalty payments in the mid-single digit percentages based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. Rocket is responsible for prosecuting and maintaining the licensed patents at its expense, in cooperation with Licensors. The Company also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with Licensors. For five years following the effective date of the license agreement, Rocket has a right of first refusal to license any improvements to the licensed intellectual property obtained by Licensors at market value. The Company is obligated to license (without charge) to Licensors for non-commercial use any improvements to the licensed intellectual property that it creates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, Rocket paid Licensors an initial upfront license fee of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee4c081d-995c-4a6e-beed-b19ad5d86af5" contextRef="C_f58025d4-77f4-4bb3-a4eb-7fe3d5f5ebf7" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_EUR" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf079268-bc8e-4ef4-ba60-b854c39937a6" contextRef="C_f58025d4-77f4-4bb3-a4eb-7fe3d5f5ebf7" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), which was expensed as R&amp;D costs. The Company is obligated to make aggregate payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7b7e9b1-71b0-42c0-ab17-1aa8331d1f0f" contextRef="C_648e9485-2de4-4dbf-b7be-6f5b0c53d513" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09d0953f-6d1c-4914-bcdb-85e46bed11ca" contextRef="C_648e9485-2de4-4dbf-b7be-6f5b0c53d513" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) to Licensors upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the LAD-I license, Rocket is obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by the Company or its sublicensees or affiliates. In the event that the Company enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket may terminate this agreement at any time by providing the Licensors with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89b6b2ea-a918-48f1-9249-cfa870ddeb8d" contextRef="C_743963e7-e2f3-4156-9218-0e77929607dc" name="rckt:AgreementTerminationNoticePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for DD with UCSD</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2017, the Company entered into a License Agreement with The Regents of the UCSD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under which UCSD granted us an exclusive, sublicensable, worldwide license to certain intellectual property rights for the treatment of lysosomal storage diseases, including DD. In exchange for the license, the Company became obligated to make an up-front payment, certain clinical and commercial milestone payments, royalty payments (on net sales of products covered by a valid claim within the licensed intellectual property), maintenance fees and sublicense revenue payments. The upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e06297f5-f341-4904-94c5-7f662179eb8f" contextRef="C_3d43c909-ed76-4cd3-8437-c11a815217b6" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was expensed as research and development costs in 2020. The Company is obligated to make aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b28ace5-1e06-4ccf-a0d3-9462a7c000c1" contextRef="C_cc91e4ce-92d4-493e-b585-ed3ef5272e3c" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to UCSD upon the achievement of specified development and regulatory milestones for the treatment of DD. A reduced schedule of milestone payments applies to achieving the same milestones for additional indications. With respect to any commercialized products covered by the agreement, the Company is obligated to pay a low single digit percentage royalty on net sales, subject to specified adjustments. If it enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances. The Company is also subject to certain diligence milestones for development of a product using the intellectual property licensed from UCSD under this agreement. The term of the license agreement with UCSD is through the expiration of the licensed patents, some of which are still in the pending application phase.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for DD with RGNX</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2018, the Company entered into a license agreement with RGNX, pursuant to which the Company obtained an exclusive license for all U.S. patents and patent applications related to RGNX&#8217;s NAV AAV-9 vector for the treatment of DD in humans by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene therapy using AAV-9 to deliver any known LAMP2 transgene isoforms and all possible combinations of LAMP2 transgene isoforms, as well as an exclusive option to license</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> all U.S. patents and patent applications for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfa66298-6aca-49b4-9dc9-f3b653ccadf9" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:LicenseAgreementNumberOfPatents" unitRef="U_Patent" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional NAV AAV vectors in the Field</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3_3"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market, promote and sell licensed products incorporating the licensed patents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless the license agreement is terminated earlier as provided below, the license from RGNX expires on a country-by-country, licensed product-by-licensed product basis until the later of the expiration date of the last to expire of the last valid claim of the applicable licensed patent or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0df930b9-fc40-4f63-9dcb-136deed3612c" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:ResearchAgreementInitialTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the first commercial sale of a licensed product in such country. The license agreement provides that RGNX may terminate the agreement upon a material breach by the Company if the Company does not cure such breach within a specified notice period if the Company commences a challenge against RGNX or certain of its licensors to declare or render invalid or unenforceable the licensed patents or upon the Company&#8217;s bankruptcy or insolvency. The Company may terminate the agreement in its entirety or terminate one or more of the licensed vectors at any time upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02e6c1a0-699a-4d17-b92e-d4a581e12d4c" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:AgreementTerminationNoticePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; notice. The Company&#8217;s option right expired </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4c6b54f-23b8-4dd4-86cb-4cd66a0f019b" contextRef="C_50276bb0-33c1-4f8f-878e-9cd8590b54aa" name="rckt:LicenseAgreementOptionsRightExpiryTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of the license agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted to the Company under the license agreement, the Company made an upfront payment to RGNX of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e48535e-3be5-42bf-9fda-9a8c8032e48c" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:ResearchAndDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The license agreement provides for royalties payable to RGNX in the high-single digits to low-teens on net sales levels of licensed products during the royalty term. If successful, the Company will be required to make milestone payments to RGNX of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a4635e1-7c87-47c6-9b11-a894f0c26a4a" contextRef="C_c0959b18-8b8a-48d0-97a6-aefc2f4ade16" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each licensed product upon the achievement of specified clinical development and regulatory milestones in the U.S. and EU. In addition, the Company shall pay RGNX </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce9f0cb-3bc1-4565-98dc-813d71eb2424" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:RoyaltiesPayableOnFeesReceived" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the payment fees received from a priority review voucher issued in connection with or otherwise related to a licensed product. These royalty obligations are subject to specified reductions if additional licenses from third parties are required. The Company must also pay RGNX a portion of all non-royalty sublicense income (if any) received from sublicensees. The Company paid and expensed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43cee9b5-7d4a-4566-98e3-c75631ba9e7c" contextRef="C_308b60bc-adf6-4c0d-98f7-6dd8faf1845b" name="rckt:PaymentAndExpensesForLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million license fee payment under the RGNX agreement upon the dosing of the first DD patient in 2019 and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_240958aa-4f8a-4a93-a28d-53b9f420c8eb" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:PaymentAndExpensesForLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million license fee payment upon initiation of a Phase 2 pivotal trial in 2023. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15dac136-0307-4b8d-b137-da895b72843a" contextRef="C_c7874f61-2268-4af4-888a-25b614890494" name="rckt:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b8b4e19f-408f-4db9-892b-e041fe7eb066" contextRef="C_fe041e39-6da1-43a6-9419-34b2d437cff8" name="rckt:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_382a8fd2-ef96-4dea-b66d-70b2a615fff3" contextRef="C_58582e6a-472e-48eb-b983-e4e33afabbd1" name="rckt:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional milestones achieved or related payments made during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for BAG3 with Temple University</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 1, 2022, the Company acquired Renovacor, including a license agreement for BAG3 with Temple University. The license agreement provides for royalties payable to Temple University in the low-single digits on net sales of licensed products during the royalty term. If successful, the Company will be required to make milestone payments to Temple University of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_915139c6-58ce-423d-a088-9100c1f827dd" contextRef="C_59178516-f6c7-4b30-a565-d0b9d51d21d3" name="rckt:ResearchAndDevelopmentCostsPotentialFutureObligation" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">19.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of specific clinical development and regulatory milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f409fb0-4fb2-4d5d-8aea-7ad86faa9ac2" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIRM Grants</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LAD-I CIRM Grant</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 30, 2019, CIRM awarded the Company up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8790e37f-a711-419a-8aed-de5aea36f385" contextRef="C_a067d039-439e-4ceb-af2b-1cde0cbe0191" name="rckt:GrantAwardForClinicalDevelopmentSupport" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy, RP-L201. Proceeds from the grant helped fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients enrolled at the U.S. clinical site, University of California, Los Angeles Mattel Children&#8217;s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edy the Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. As of December 31, 2024, the Company has received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1884790a-bd71-47e5-acba-b9a248859e35" contextRef="C_6b479ce2-ba9e-4e7a-9b6e-64a21f473b06" name="rckt:ProceedsFromMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in total RP-L201 grants from CIRM. These were recorded as reductions of R&amp;D expenses. The Company received a final milestone grant of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b83a5076-b55f-4e1b-b5fe-c8098d88c5d4" contextRef="C_ad45b344-bcc3-4fab-a36c-d35bf9065472" name="rckt:ProceedsFromMilestonePayments" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on January 2, 2024 and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2203c09a-2413-4c5c-b82f-51943c52d168" contextRef="C_6b479ce2-ba9e-4e7a-9b6e-64a21f473b06" name="rckt:AdditionalPaymentsAvailableUnderGrantAwardsProgram" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional payments are available under the grant awards program.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DD CIRM Grant</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 18, 2024, CIRM awarded the Company up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78b23da4-7c36-4358-a697-88e09ed42f22" contextRef="C_4e8fe46b-7cf9-4f88-b35f-815f319dccc5" name="rckt:GrantAwardForClinicalDevelopmentSupport" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under a CLIN2 grant award to support the clinical development of its AAV-based gene therapy, RP-A501 for the treatment of DD. Proceeds from the grant would help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients. As of December 31, 2024, the Company has received RP-A501 grants of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae069295-f82d-46e2-baf5-27752d872003" contextRef="C_7132f227-a70e-41d6-9438-433555a0c26d" name="rckt:ProceedsFromMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CIRM, which was recorded as a reduction of R&amp;D expenses for the RP-A501 program for the year ended December 31, 2024.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_a0c31432-64fa-4592-9de4-9daaf781917d" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" continuedAt="F_a0c31432-64fa-4592-9de4-9daaf781917d_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the Company entered into a consulting agreement with the spouse of one of the Company&#8217;s executive officers for information technology advisory services. The Company incurred expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dafcda54-97f8-4761-aa4c-f2218e1ce458" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-3" format="ixt:num-dot-decimal">0.002</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fded40e9-b4bd-4320-aad1-286e8b9c58fd" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="U_USD" scale="6" decimals="-4" format="ixt:num-dot-decimal">0.02</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively, relating to services provided under this agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 15, 2023, in connection with the Company&#8217;s public offering, the Company sold approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1057749c-8917-43a6-a1fe-9959c0e502ce" contextRef="C_c85f9ea7-c5e2-4223-8d66-d75ebaec1617" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pre-funded warrants to purchase shares of the Company&#8217;s common stock to funds affiliated with RTW, the Company&#8217;s largest shareholder (see Note 8 &#8220;Stockholders&#8217; Equity&#8221;).</span></p></ix:nonNumeric></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a0c31432-64fa-4592-9de4-9daaf781917d_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, in connection with the Company&#8217;s public offering, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1255b7d2-7800-42e8-92d5-6fbe33e9b72c" contextRef="C_1adde562-4738-4477-bfc6-f6adc114c4a6" name="rckt:NumberOfStockWarrantsIssuedToPurchaseShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pre-funded warrants to purchase shares of the Company&#8217;s common stock to funds affiliated with RTW, the Company&#8217;s largest shareholder (see Note 8 &#8220;Stockholders&#8217; Equity&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, the Company enter into a consulting agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with one of the Company&#8217;s board members, effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca96f9bc-a1f2-42a7-bb8d-7b9585a1db66" contextRef="C_f241f631-e65d-4cb2-96fd-2e31846e930f" name="rckt:ConsultingAgreementEffectiveDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 3, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for services related to the Company&#8217;s research and development activities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation for services rendered, the consultant will receive $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e45e994-e31f-4789-9a3d-577143a39c02" contextRef="C_f241f631-e65d-4cb2-96fd-2e31846e930f" name="rckt:ConsultingFeeMonthlyInstalment" unitRef="U_USD" scale="6" decimals="-3" format="ixt:num-dot-decimal">0.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to be paid in equal monthly installments and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21988e6a-ee2e-4cff-b1eb-d98d5b26bd9e" contextRef="C_a390a215-8672-44fe-88df-66981bedc86b" name="rckt:ConsultingFeeMonthlyInstalment" unitRef="U_USD" scale="6" decimals="-3" format="ixt:num-dot-decimal">0.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of RSU&#8217;s valued as of the closing price on March 3, 2025 which will cliff vest on December 31, 2025.  The agreement will terminate on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52d9b42f-a8be-44f5-ac53-3af46adfb745" contextRef="C_069e4998-345d-4f31-93a6-b24211692b71" name="rckt:ConsultingAgreementTerminationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless terminated earlier by the Company for cause or voluntarily by consultant.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fd7d3b7-bfb7-41a5-be50-cac49197dc06" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k) Savings Plan</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a defined contribution savings plan (the &#8220;Plan&#8221;) under Section 401(k) of the Internal Revenue Code of 1986. This Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the Plan may be made at the discretion of the Company&#8217;s Board of Directors. The Company has elected the safe harbor</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> match of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dff296d-a569-4725-9d8f-1e41c676bac1" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employee contributions to the Plan, subject to certain limitations. The Company&#8217;s matching contribution for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_3d4decc2-8c3a-4229-8ef5-7287b54caf72" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_867794a6-d6eb-461f-b044-95fc13137c88" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44d1edc5-5695-4b8a-a412-a5972fdfb633" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bfd94744-829e-4cc8-ba6b-fdcedb4e4a06" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Reporting</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9158b7b-34e9-4db2-8436-4ad1d5293f7f" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment related to R&amp;D and commercial readiness of its gene therapies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_451a042b-eab6-4290-938a-8e09ce736c2b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the senior leadership team. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3fc3dd3-7cf5-4c32-be07-c2e8bd6aea0a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Included in these expenses are R&amp;D expenses by program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99f9a9e2-470a-49ed-bb41-1e6e506bc8fb" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment loss, including significant segment expenses:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.851%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.623000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.903%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.623000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae247529-45ad-45dd-b50f-47d6120480e2" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb5f16c3-144b-45f8-a5fd-9d91bb7953cd" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96514368-8b25-4bf4-8ef8-5c1ae43e278d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a066d385-78ba-4e1f-8ba4-bddff62ec9ca" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,244</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_165c2ddd-295f-42db-9c10-59a7f9c0d8cf" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,342</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a664d614-dfc9-4f65-ab04-bc1130d22285" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,570</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-commercial general and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47e87829-ab21-412d-8235-e2fcdea0c35a" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:NonCommercialGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,878</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8a6bf20-b505-4b61-bfd4-f72ff3e9677b" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:NonCommercialGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,805</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e9ade3c-0270-4877-951b-77090948896d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:NonCommercialGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,211</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial general and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a29ceb0-f60a-47fe-a37b-0aff8f7ed86c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:CommercialGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,083</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fd6bc0f-9b6e-4efe-9a13-adf78bf7b865" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:CommercialGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4499068-abb5-4696-93c2-de48277960db" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:CommercialGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,562</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6a3568a-cb6e-4fcf-bda8-489eac87fbd5" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,205</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62ce5953-c948-4daf-b2a2-5b35803ff6f4" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,659</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ce3956c-c6ca-461c-8c3a-028c0aaf932d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,343</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e765de2-9b59-4c01-a8f2-c4e808363887" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">273,205</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_746871bc-f3fd-4962-b979-8d77850d8314" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">259,659</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b171a371-9752-43cf-a487-2266db5ad96f" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224,343</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development incentives</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4321a462-d872-4d5e-93b1-25b86741f91c" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="rckt:ResearchAndDevelopmentIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c5cfd7f-558f-4d30-b043-e2ee745ddb2f" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="rckt:ResearchAndDevelopmentIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11f7cc78-14f4-41b1-add6-882e64a99b6a" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="rckt:ResearchAndDevelopmentIncentives" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cefb3ea9-4f66-490b-af62-5aeb4101ce13" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,886</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdc2f9c8-c593-41fb-9c08-8393f427f564" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,875</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53cbed1b-ace3-40a2-a822-b3ed90f6ff3d" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,862</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08a96fe1-d710-4c8a-83c1-915b6cdfa709" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,267</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ea9d04-0cea-4834-b972-ec9eb239144a" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,288</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_724d07f8-4b6d-4e0a-9298-1ef3aeb5954b" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,889</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7246bf03-03fa-460e-b266-91509c085d51" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,078</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cace42a2-8109-424f-905d-cc61d66d082f" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,651</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_206ec1f3-a4d1-49f9-b3ff-7118ca81b218" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Segment loss and Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a5062e-66b1-45f8-8395-48daeba1e177" contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">258,746</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274a76d8-fc8f-462b-85b2-28e1f041f3b4" contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">245,595</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a821f65-593a-4a27-9d60-06e33827c501" contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">221,863</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM uses net loss to evaluate past spending and to guide decisions of future spending. Net loss is used to monitor budget versus actual results. The CODM also uses net loss in analysis of programs and along with the monitoring of budgeted versus actual results in assessing performance of the segment and in establishing manager&#8217;s compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>rckt-ex10_24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html>
 <head>
  <title>EX-10.24</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="z-index:-3;min-height:1.26in;position:relative;"></div><p style="font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.944444444444445E-4in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">											Exhibit 10.24</font></p><p style="font-size:10pt;margin-top:3.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.944444444444445E-4in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROCKET PHARMACEUTICALS, INC.</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.944444444444445E-4in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p><p style="margin-left:0.05pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:6.944444444444445E-4in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Effective as of September 26, 2024)</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.95pt;text-indent:35.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07777777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) believes that compensation of the members of the Company&#x2019;s board of directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; and any committee thereof, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including equity compensation, represents a powerful tool to attract, retain and reward members of the Board who are not also employees of the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and to align the interests of the Directors with those of the Company&#x2019;s stockholders. This Non-Employee Director Compensation Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) documents the Company&#x2019;s Board-approved practice regarding cash and equity compensation to its Directors.</font></p><p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:2.75in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.2in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.890040973325529%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Compensation</font></div></div><p style="margin-left:42pt;font-size:10pt;margin-top:12.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors will be entitled to receive cash compensation for their services as follows:</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Director, other than the Chairperson of the Board, will receive an annual cash retainer of $40,000. Directors will not receive additional meeting fees for their Board service.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committee Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Director, other than the Chairperson of the Board, who serves as a Committee chairperson or a Committee member will receive an additional annual cash retainer as follows:</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee Chairperson: $20,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee member: $10,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Committee Chairperson: $15,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Committee member: $7,500</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee Chairperson: $15,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee member: $7,500</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee Chairperson: $10,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee member: $5,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D Committee Chairperson: $15,000</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0798611111111112in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:8.680370014130835%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D Committee member: $7,500</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6pt;text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13055555555555556in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Director may elect to receive their cash compensation in the form of an equivalent equity award instead.</font></p><p style="margin-left:6pt;text-indent:36pt;font-size:10pt;margin-top:12.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07916666666666666in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Director who receives an annual cash retainer as a Committee chairperson will not receive an additional annual cash retainer for service as a member of such Committee. Directors will not receive additional meeting fees for their Committee service.</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:12.55pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chairperson Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Chairperson of the Board will not receive any cash compensation and will instead receive compensation for service on the Board entirely in the form of automatic equity awards set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All annual cash retainers will be paid quarterly, in arrears, or upon the earlier termination of the relevant Director&#x2019;s service on the Board. Annual cash retainers owing to mid-year appointed Directors will be annualized, meaning that for Directors who join the Board mid-year, such retainers</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="margin-left:5.75pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will be pro-rated for the number of calendar days served by such Director.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Travel Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Director&#x2019;s reasonable, customary and documented expenses related to such Director&#x2019;s Board or Committee service will be reimbursed by the Company in accordance with its policies.</font></div></div><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:2.529861111111111in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.2in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.64023867711937%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Automatic Equity Awards</font></div></div><p style="margin-left:6pt;text-indent:36pt;font-size:10pt;margin-top:12.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.0125in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All grants of equity awards to Directors pursuant to this Director Compensation Policy will be subject to the Company&#x2019;s then current equity compensation plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) in all respects.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Type of Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Awards granted pursuant to this Director Compensation Policy will initially be nonqualified stock options (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and, except as otherwise provided herein, will be subject to the other terms and conditions of the Plan. Commencing with awards granted for the Company&#x2019;s fiscal year ending December 31, 2026, an award granted pursuant to this Director Compensation Policy will be two-thirds in the form of Options and one-third in the form of restricted stock units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such quotient based on the grant date fair value thereof as determined under generally accepted accounting principles (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Date Fair</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Value</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and, except as otherwise provided herein, will be subject to the other terms and conditions of the Plan. All Options granted to a Director will have an exercise price per share equal to the closing price of the Company&#x2019;s stock on the date of grant.</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No person will have any discretion to select which Director will be granted an Initial Award or an Annual Award (each, as defined below) under this Director Compensation Policy or to determine the terms and conditions of an Initial Award or Annual Award.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Number of Shares covered by Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The aggregate number of shares covered by an award will be based on the Grant Date Fair Value thereof and the award&#x2019;s dollar value specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 4 and 5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, rounded down to the nearest whole share.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each person who first becomes a Director on or following the effective date of this Director Compensation Policy will be granted, automatically and without necessity of any action by the Board or any Committee, an initial award having a dollar value of $360,000 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections B(1) and B(3)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on the date on which such person first becomes a Director. A member of the Board who was an employee of the Company or any subsidiary of the Company and who ceases to be an employee, but remains a member of the Board, will not receive an Initial Award. Notwithstanding the foregoing, no Initial Award will have a dollar value that is more than twice the dollar value of the Annual Award made to a Director in the year in which such Initial Award is granted.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each Director will be granted, automatically and without necessity of any action by the Board or any Committee, an annual award having a dollar value of $360,000 (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections B(1) and B(3)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on each date of the annual meeting of the stockholders of the Company. Notwithstanding the foregoing, the Annual Award to be granted to the Chairperson of the Board will have a dollar value of $360.000, determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections B(1) and B(3)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on each date of the annual meeting of the stockholders of the Company. If a Director joins the Board mid- year, the Director will be granted, automatically and without necessity of any action by the Board or any Committee, an Annual Award having a dollar value of $360,000, determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections B(1) and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B(3)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on the date such Director joins the Board, prorated for the number of days between the grant date and the next annual meeting of the stockholders of the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:12.6pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The terms of each Initial Award and Annual Award granted pursuant to this Director Compensation Policy will be as follows:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5798611111111112in;text-indent:36pt;font-size:0;margin-top:3.9pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.475426673368152%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Initial Award will vest as to [1/36] of the shares covered by the Initial Award on each monthly anniversary of the grant date, rounded down to the nearest whole share and such </font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><div class="item-list-element-wrapper" style="margin-left:0.5798611111111112in;font-size:0;margin-top:3.9pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fractional share will remain unvested until one share can vest and such whole share will vest on the next applicable vesting date (if any), provided that the Director continues to serve as a Director through the relevant vesting date.</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.5798611111111112in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.475426673368152%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Annual Award will vest on the date of the next annual meeting of the stockholders of the Company, provided that the Director continues to serve as a Director through the relevant vesting date.</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.5798611111111112in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.475426673368152%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Annual Award and Initial Award will otherwise be on the form of award agreement attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A (for Options)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B (for RSUs)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as may be updated to reflect changes in applicable rules and regulations.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.0798611111111111in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.4813016027197667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation Limit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Director may be paid or granted compensation for Director services in any fiscal year that, in the aggregate, exceeds $1,000,000, increased to $1,500,000 for such Director for the fiscal year in which he or she joins the Board as a Director. Notwithstanding the foregoing, no Director may be paid or granted compensation in any fiscal year for Director services that exceeds the 75</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percentile of the compensation paid or granted to similarly situated non-employee members of the boards of directors of the companies comprising the peer group used by the Company for purposes of determining Director compensation for such fiscal year. For this purpose, equity awards will be valued based on their Grant Date Fair Value. Any awards or other compensation paid or provided to an individual for his or her services as an employee, or for his or her services as a consultant (other than as a Director), will not count for purposes of the limitation under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section B(7)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Consistent with the Compensation Committee&#x2019;s charter, the Compensation Committee will annually review, and reassess the adequacy of, the Company&#x2019;s peer group based on discussions with such consultant and a review of all relevant factors, including, but not limited to, market capitalization, stage of development, therapeutic focus, and employee headcount.</font></div></div><p style="font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:2.3999999999999995in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.2in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.504560019719004%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment and Termination</font></div></div><p style="margin-left:6pt;text-indent:36pt;font-size:10pt;margin-top:12.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.   </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment and Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Board may at any time amend, alter, suspend or terminate this Director Compensation Policy. No such amendment or termination will adversely impact any award previously granted under this Director Compensation Policy.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.83in;width:6.84in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.83in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>3
<FILENAME>rckt-ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html>
 <head>
  <title>EX-19</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.2in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">													Exhibit 19</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222217in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.30000000000000004in;text-align:left;"><font style="color:#171717;white-space:pre-wrap;font-size:16pt;font-family:Arial Narrow;font-kerning:none;min-width:4.032593584786954%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font></div></div><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:8.2pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy is designed to prevent insider trading or allegations of insider trading and to protect the Company&#x2019;s reputation for integrity and ethical conduct. It is your obligation to understand and comply with this Policy. Should you have any questions regarding this Policy, please contact the Company&#x2019;s Compliance Officer (the &#x201c;Compliance Officer&#x201d;).</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222217in;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.30000000000000004in;text-align:left;"><font style="color:#171717;white-space:pre-wrap;font-size:16pt;font-family:Arial Narrow;font-kerning:none;min-width:4.032593584786954%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scope</font></div></div><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:8.2pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1388888888888889in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Insider Trading Policy (this &#x201c;Policy&#x201d;) applies to all employees, officers, and directors of Rocket Pharmaceuticals, Inc. and its subsidiaries (collectively, the &#x201c;Company&#x201d;) and to any consultant to the Company.</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Persons Covered. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a director, officer, employee, or consultant of the Company, this Policy applies to you. The same restrictions that apply to you apply to: (1) your family members who reside with you, (2) anyone else who lives in your household, (3) any family members who do not live in your household but whose transactions in Company securities are directed by you or are subject to your influence or control (such as parents or children who consult with you before they trade in Company securities), (4) any corporations or other business entities controlled or managed by you, and (5) any trusts of which you are the trustee or otherwise have investment control over. You are responsible for making sure that the purchase or sale of any security covered by this Policy by any such person complies with this Policy.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Companies Covered. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prohibition on insider trading in this Policy is not limited to trading in the Company&#x2019;s securities. It includes trading in the securities of other companies, such as partners, collaborators, licensors, licensees, manufacturers or suppliers of the Company and those with which the Company may be negotiating major transactions, such as an acquisition, investment, or sale. Information that is not material to the Company may nevertheless be material to one of those other companies.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transactions Covered</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Trading includes purchases and sales of stock, derivative securities such as put and call options and convertible debentures or preferred stock, and debt securities (debentures, bonds, and notes). Trading also includes certain transactions under Company plans, as follows:</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.0597222222222222in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.6201388888888889in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:9.555162626215626%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1.3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Exercises. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy&#x2019;s trading restrictions generally do not apply to the exercise of a stock option (whether in cash or through a net exercise). The trading restrictions do apply, however, to any sale of the underlying stock or to a cashless exercise of the option through a broker, as this entails selling a portion of the underlying stock to cover the costs of exercise. In addition, this Policy&#x2019;s restrictions do not apply to the withholding of shares to satisfy a tax withholding obligation upon the vesting of restricted stock or restricted stock units (if applicable, and to the extent permitted under the Company&#x2019;s equity incentive plans). However, the sale of shares,</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.56in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:120.7pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including a broker-assisted cashless exercise, to satisfy tax withholding obligations is subject to the restrictions set forth in this Policy.</font></p><div class="item-list-element-wrapper" style="margin-left:1.0597222222222222in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.6201388888888889in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:9.555162626215626%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1.3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy also does not apply to purchases of Company stock under an Employee Stock Purchase Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ESPP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). However, this Policy will apply to any sales of Company stock acquired pursuant to the ESPP.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transaction Not Covered. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you own shares of a broad mutual or exchange-traded fund (e.g., NASDAQ Biotech Index or Russell 3000 Index) that invests in the Company&#x2019;s securities, there are no restrictions on trading the shares of the mutual fund at any time.</font></div></div><p style="font-size:10pt;margin-top:6.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222217in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.30000000000000004in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:16pt;font-family:Arial Narrow;font-kerning:none;min-width:4.032593584786954%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font></div></div><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Background</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s board of directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has adopted this Policy for our directors, officers, employees, and consultants with respect to the trading of the Company&#x2019;s securities, as well as the securities of publicly traded companies with whom we have a business relationship.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and state securities laws prohibit the purchase or sale of a company&#x2019;s securities by persons who are aware of material information about that company that is not generally known or available to the public. These laws also prohibit persons who are aware of such material nonpublic information from disclosing this information to others who may trade. Companies and their controlling persons are also subject to liability if they fail to take reasonable steps to prevent insider trading by company personnel.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is important that you understand the breadth of activities that constitute illegal insider trading and the consequences for such activities, which can be severe. Both the U.S. Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the NASDAQ Stock Market investigate and are very effective at detecting insider trading. The SEC, together with the U.S. Department of Justice, pursues insider trading violations vigorously. Cases have been successfully prosecuted against trading by employees through foreign accounts, trading by family members and friends, and trading involving only a small number of shares.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties for Noncompliance with this Policy</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Law. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal law imposes heavy penalties on those who, in violation of law, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">either</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> buy or sell securities while aware of material nonpublic information, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pass such material nonpublic information along to others who use it to buy or sell securities (known as &#x201c;tipping&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Civil and Criminal Penalties.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential penalties for insider trading violations include</font></div></div><p style="margin-left:75.9pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) imprisonment for up to 20 years, (2) criminal fines of up to $5 million, and (3) civil fines of up to three times the profit gained or loss avoided.</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Controlling Person Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Company fails to take appropriate steps to prevent illegal insider trading, the Company may have &#x201c;controlling person&#x201d; liability for a trading violation, with civil penalties of up to the greater of (1) approximately $1.5 million (adjusted for inflation) and</font></div></div><p style="margin-left:75.9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) three times the profit gained or loss avoided, as well as a criminal penalty of up to $25</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.71in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.56in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:75.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million. The civil penalties can extend personal liability to the Company&#x2019;s directors, officers, and other supervisory personnel if they fail to take appropriate steps to prevent insider trading.</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Failure to comply with this Policy may also subject you to Company- imposed sanctions, including dismissal for cause, whether or not your failure to comply with this Policy results in a violation of law.</font></div></div><p style="margin-left:80.2pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these consequences, and even an investigation that does not result in prosecution, can tarnish the Company&#x2019;s reputation and irreparably damage you and the Company.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Policy</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Trading on Insider Information. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not trade in the securities of the Company, directly or indirectly, including through family members or other persons or entities, if you are aware of any material nonpublic information relating to the Company. Similarly, you may not trade, directly or indirectly, in the securities of any other company if you are aware of material nonpublic information about that company, including material nonpublic information that you obtained in the course of your employment with the Company.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time due to certain developments relating to material nonpublic information, the Company may implement special blackout periods during which the Company may notify particular individuals that they should not engage in any transactions involving the purchase or sale of Company securities or the securities of another company. If you are subject to a special blackout period, you should not trade in the applicable company&#x2019;s securities during such time and you should not disclose to others the fact that you are prohibited from trading. However, it is not the Company&#x2019;s policy to impose special blackout periods every time that material non- public information exists, or every time that a Company employee may be in the possession of material non-public information. Thus, the absence of a special blackout should not be interpreted as permission to trade.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Tipping. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not pass material nonpublic information of the Company or any other company on to others or recommend to anyone the purchase or sale of any securities of the Company of any such other company when you are aware of such information. This practice, known as &#x201c;tipping,&#x201d; also violates the securities laws and can result in the same civil and criminal penalties that apply to insider trading, even though you did not trade and did not gain any benefit from another&#x2019;s trading.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Exception for Hardship. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The existence of a personal financial emergency does not excuse you from compliance with this Policy.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Material Nonpublic Information</font></div></div><p style="margin-left:39.7pt;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note that inside information has two important elements: (1) materiality and (2) public availability.</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information is material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to buy, hold, or sell a security. Any</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.71in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.56in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:75.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information that could reasonably be expected to affect the price of the security is material. Common examples of material information are:</font></p><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial results and clinical trial status (e.g., completion of enrollment);</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending FDA or other regulatory action;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negotiations regarding an important license, distribution agreement, or joint venture;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impending stock or other securities offerings by the Company;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant new product candidates or discoveries;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a pending or proposed merger, acquisition, license or sale of all or part of the Company&#x2019;s business;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">current, proposed or contemplated transactions, business plans, financial restructurings, acquisition targets or significant expansions or contractions of operations;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in management, directors or auditors;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impending financial problems;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or threatened major litigation, or the resolution of such litigation;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new major contracts, licenses, collaborations, or the loss thereof; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2402777777777778in;display:flex;margin-top:0.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.961853252285454%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the status of any of the Company&#x2019;s activities which may have an adverse or favorable impact.</font></div></div><p style="margin-left:12.85pt;font-size:10pt;margin-top:6.1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note that other types of information may also be material; no complete list can be given.</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both positive and negative information can be material. Because trading that receives scrutiny will be evaluated after the fact with the benefit of hindsight, when in doubt, questions concerning the materiality of particular information should be resolved in favor of materiality, and trading should be avoided.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonpublic Information. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonpublic information is information that is not generally known or available to the public. One common misconception is that material information loses its &#x201c;nonpublic&#x201d; status as soon as a press release is issued disclosing the information. In fact, information is considered to be available to the public only when it has been released broadly to the marketplace (such as by a press release or an SEC filing) </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and the investing public has had time to absorb the information fully. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a general rule, Company information is considered nonpublic until the second full trading day after the information is released. For example, if the Company announces financial earnings before trading begins on a Tuesday, the first time you can buy or sell Company securities is the opening of the market on Thursday (assuming you are not aware of other material nonpublic information at that time). However, if the Company announces earnings after trading begins on that Tuesday, the first time you can buy or sell Company securities is the opening of the market on Friday (assuming you are not aware of other material nonpublic information at that time).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An exception to this rule is trading in compliance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to a contract, instruction, or plan established at a time when you were not aware of material, nonpublic information that meets specified conditions (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10b5-1 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Any 10b5-1 Plan is required to be reviewed and approved by the Compliance Officer prior to entry into such plan. In addition, all amendments, modifications and terminations of a 10b5-1 Plan must be reviewed and</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.71in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.56in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:75.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.14027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approved by the Compliance Officer prior to effecting any such amendments, modifications or terminations.</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than transactions pursuant to 10b5-1 Plans, there is no exception to this Policy, including for transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure, as noted above).</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Restrictions for Directors and Section 16 Executive Officers</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Persons Subject to Special Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To help prevent inadvertent violations of the federal securities laws and to avoid even the appearance of trading on the basis of inside information, the Board has adopted certain procedures that apply to directors, executive officers subject to Section 16 of the Exchange Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16 Executive Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and certain designated employees and consultants of the Company (including its subsidiaries) who have access to material nonpublic information about the Company. The Company will notify you if you are subject to these special restrictions, described below.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Blackout and Pre-Clearance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each director, Section 16 Executive Officer and anyone else specifically designated as subject to these special restrictions must contact the Compliance Officer in advance of effecting any transaction in the Company&#x2019;s securities and obtain his/her prior approval of the transaction. All requests must be submitted </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at least forty-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eight (48) hours prior to making any transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (purchase or sale) involving the Company&#x2019;s securities. The Compliance Officer will then determine whether the transaction may proceed. If the transaction is approved, the transaction must be executed within five business days after approval is obtained, but regardless may not be executed if you subsequently acquire material nonpublic information concerning the Company during the time. If a transaction is not completed within the period described above, the transaction must be approved again before it may be executed. If a proposed transaction is not approved under the pre-clearance policy, you should refrain from initiating any transaction in Company securities, and you should not inform anyone within or outside the Company of the restriction.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 16 Reporting. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For directors and Section 16 Executive Officers, if the Company pre- clears the transaction and you proceed with it, the Company will assist you in complying with your reporting obligations under Section 16 of the Exchange Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Under Section 16, directors and Section 16 Executive Officers are required to a file a Form 4 within two business days after certain changes in beneficial ownership occur (including the exercise of options or other derivative securities). Form 4 requires that you provide detailed information relating to any purchase, sale, or exercise, including the price of the shares acquired or disposed, the transaction date, and the amount of securities beneficially owned following the transaction. As such, you should promptly report the details of any transaction that you engage into the Compliance Officer.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 144. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are a director or Section 16 Executive Officer, you may be deemed to be an &#x201c;affiliate&#x201d; of the Company. Consequently, shares of Company common stock held by you may be considered to be &#x201c;control securities,&#x201d; the sale of which are normally subject to compliance with the safe harbor established under Rule 144 under the Securities Act of 1933, as amended</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.71in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.56in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:75.85pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(or any other applicable exemption under the federal securities laws) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 144</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). If this is the case, note that Rule 144 places limits on the number of shares you may be able to sell and provides that certain procedures must be followed before you can sell shares of Company stock. Contact the Compliance Officer for more information on Rule 144.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Guidance</font></div></div><p style="margin-left:8.2pt;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.1388888888888889in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers it improper and inappropriate for those employed by or associated with the Company to engage in short term or speculative transactions in the Company&#x2019;s securities or in other transactions in the Company&#x2019;s securities that may lead to inadvertent violations of the insider trading laws. Accordingly, your trading in Company securities is subject to the following additional guidance:</font></p><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Short Sales. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You may not engage in short sales of the Company&#x2019;s securities (sales of securities that are not then owned), including any &#x201c;sales against the box&#x201d; (a sale with delayed delivery).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hedging Transactions. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company prohibits hedging and monetization transactions that transfer, with respect to equity compensation received by a director, officer, or employee or other equity securities held (directly or indirectly) by a director, officer or employee, all or a portion of the risk of a decline in the market price of shares of Company common stock. Instruments that would be considered to be a &#x201c;hedge&#x201d; include prepaid variable forward contracts, equity swaps, collars, and exchange funds. For the avoidance of doubt, 10b5-1 Plans providing for future sales or purchases of securities are not prohibited by this Policy.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Publicly Traded Options and Other Derivative Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You may not engage in transactions in publicly traded options on Company securities, such as puts, calls, and other derivative securities, on an exchange or in any other organized market.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Standing Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Standing orders should be used only for a very brief period of time. A standing order placed with a broker to sell or purchase stock at a specified price leaves you without control over the timing of the transaction. A standing order transaction executed by the broker when you are aware of material nonpublic information may result in unlawful insider trading.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.6.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Margin Accounts and Pledges</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Securities held in a margin account or pledged as collateral for a loan may be sold without your consent by the broker if you fail to meet a margin call or by the lender in foreclosure if you default on the loan. A margin or foreclosure sale that occurs when an insider is aware of material nonpublic information may, under some circumstances, result in unlawful insider trading, as the SEC deems the forced sale of stock on a margin-call as a voluntary sale, even if the stockholder did not have the financial resources to avoid the forced sales. Because of this danger, you are prohibited from entering into loans or other arrangements during the term of this Policy where Company securities are pledged as collateral, except as may be approved by the Board.</font></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.71in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="padding-top:0.56in;z-index:-3;min-height:1.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:2.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.7</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font></div></div><p style="margin-left:8.2pt;font-size:10pt;margin-top:7.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy continues to apply to your transactions in Company securities even after you have terminated employment or other services to the Company (including a subsidiary) as follows: if you are aware of material nonpublic information when your employment or service relationship terminates, you may not trade in Company securities until that information has become public or is no longer material.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.8</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unauthorized Disclosure</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:7.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintaining the confidentiality of Company information is essential for competitive, security, and other business reasons, as well as to comply with securities laws. You should treat all information you learn about the Company or its business plans in connection with your employment as confidential and proprietary to the Company. Inadvertent disclosure of confidential or inside information may expose the Company and you to significant risk of investigation and litigation.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5499999999999998in;display:flex;margin-top:5.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.14027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:7.143396429919647%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing and nature of the Company&#x2019;s disclosure of material information to outsiders is subject to legal rules, the breach of which could result in substantial liability to you, the Company, and its management. Accordingly, it is important that responses to inquiries about the Company by the press, investment analysts, or others in the financial community be made on the Company&#x2019;s behalf only through authorized individuals.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.9</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Responsibility</font></div></div><p style="margin-left:8.2pt;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should remember that the ultimate responsibility for adhering to this Policy and avoiding improper trading rests with you. If you violate this Policy, the Company may take disciplinary action, including dismissal for cause.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.10972222222222228in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.4in;text-align:justify;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Arial;font-kerning:none;min-width:5.376114950226795%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.10</font><div style="width:100%;display:inline;"><font style="color:#171717;white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Assistance</font></div></div><p style="margin-left:8.2pt;font-size:10pt;margin-top:7.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.13958333333333334in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your compliance with this Policy is of the utmost importance both for you and for the Company. If you have any questions about this Policy or its application to any proposed transaction, you may obtain additional guidance from the Compliance Officer. Do not try to resolve uncertainties on your own, as the rules relating to insider trading are often complex, not always intuitive, and carry severe consequences.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.49in;width:7.55in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.46in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.71in;min-height:0.83in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>rckt-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:78.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2.564%;box-sizing:content-box;"></td>
     <td style="width:41.026%;box-sizing:content-box;"></td>
     <td style="width:34.615%;box-sizing:content-box;"></td>
     <td style="width:21.795%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiary</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jurisdiction of Incorporation</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rocket Ownership</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Ltd.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cayman Islands</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Foundation, Inc.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spacecraft Seven, LLC</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zebrafish Merger Sub II, LLC</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals Incorporated</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NJ</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, B.V.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Netherlands</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, GmbH</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals UK, Ltd.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals Spain, S.L.</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spain</font></p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>rckt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statements of Rocket Pharmaceuticals, Inc. on Form S&shy;3ASR (No. 333-281606) and Form S&shy;8 (Nos. 333-236946, 333-204501, 333-212308, 333-216892, 333-268908 and 333-223488) of our reports dated February 27, 2025, on our audits of the financial statements as of December 31, 2024 and 2023 and for each of the years in the three-year period ended December 31, 2024,  and the effectiveness of Rocket Pharmaceuticals, Inc.&#x2019;s internal control over financial reporting as of December 31, 2024, which report is included in this Annual Report on Form 10-K.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/s/ EisnerAmper LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EISNERAMPER LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Iselin, New Jersey</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 27, 2025</font></p><p style="margin-left:63pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.7pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.27in;min-height:1.25in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:5.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>rckt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="margin-left:0.65pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certifications under Section 302</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Gaurav Shah, MD, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Rocket Pharmaceuticals, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57%;box-sizing:content-box;"></td>
     <td style="width:43%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gaurav Shah, MD</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gaurav Shah, MD</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>rckt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="margin-left:0.65pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certifications under Section 302</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aaron Ondrey</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Rocket Pharmaceuticals, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57%;box-sizing:content-box;"></td>
     <td style="width:43%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Aaron Ondrey</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Ondrey</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Financial Officer</font><font style="color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>rckt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;min-height:0.5in;position:relative;"></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the annual report on Form 10-K of Rocket Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2024, as filed with the United States Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned officers hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his knowledge:</font></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:44%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gaurav Shah, MD</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gaurav Shah, MD</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:51%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:44%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Aaron Ondrey</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Ondrey</font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:20.15pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Rocket Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img173888082_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173888082_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 62#$P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWBCP_K<ET\CZ#I-YKOCKX4WN@3R2ZAH]PW@&XM9?"^HVL^E6-UX?U[088],
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6=T ?I'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;/7M;AOO%^IC3[:_;3[[5M%B?2]*B6YU35GAO)+\6%G.FEZ?JFIR6FG772_
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M-Q)9VDD\2,$F>UMWD5F@B*]I_P &GO\ R03]K?\ [*]X"_\ 4,OZY'_@[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?SH
M_P#!S_\ \HW?#_\ V<U\,/\ U$/B=7]%U?SH_P#!S_\ \HW?#_\ V<U\,/\
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M!H5?Q4_\&Z?_ "E;^!G_ &)_QL_]5'XOH _HN_X.I?\ E'O\'?\ L\KX>_\
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MG4I=6N+2RTW2M$^)FE^#+SQ!KPO+2YT7PI_PD5U&]W;M=Z5J7^F+7^0+\6O
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MF?#WP5^UW^S!XP\?:WJAT31O _A;X^_"GQ!XOU?6E:16TC3/#6D^++O6K_5
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M6C:)HVE6LM]JFKZOJE_+!8Z;IFFV,$]Y?W]Y/#:V=K#+<7$L<,;NNG7YD_\
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M*-,UBTAU"PN+>^L9;BSC2[LYX;F!I(94=O4?AI\6?A7\:?#$?C?X._$OX?\
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MKFXO;V]\$>%+N\O+N:2YNKNZN=!L)KBYN;B9GFGN)YG>6::5WDED=G=F9B2
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M2K66^U35]7U2_E@L=-TS3;&">\O[^\GAM;.UAEN+B6.&-W7S/]H3XM6_P"^
M?QP^.UWHDWB:U^"OP@^)?Q:N?#=O?)I=QX@M_AQX,UKQC-HD&IRVM]'ITVK1
MZ,UA%?265XEH]PMP]K<+&8G_ ,Z?]M/]OC_@H;_P5>T_XD^,I/"7C/2?V6/@
M]9V?B?Q5\/?AG9:X/@I\-K;3H+ZYTG6OB?XRN8[?3]?\9ZCY5Z^B/XJOH;C4
MK^*6U\"^&K&0-9$ _P!#'X8_M=?LH?&WQ*?!?P9_:>_9Y^+GC%=.NM8;PG\,
M?C3\-O'WB5=(L7MXK[5#H7A7Q+JVJ#3K.2[M8[J^-K]FMWN;=)I4::,-]#5_
MFY_\&Z?_ "E;^!G_ &)_QL_]5'XOK_2,H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_.A_X.4/\
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M-KZZ;K7@/Q-X7UB*'6#X;T+^T+=K][>Y73+99(BJL& /P:_X-2?^32?VE/\
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MZ/HZS?O77R9^UC^PS^RM^W'H'A'PS^U)\)K3XI:1X#U?4-=\(H_BGQUX-O\
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M_P!,AT6[UT17EY>R7\VDV]YJ$.G^9+>2*EJE]=^5&B*UQ*VYS]'T4 ?SQ?\
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M.EZ!/K]Y:I'+=6'AK3;NX75/$NHVT$T=Q<:=H-EJ-]!;,;F6W6!6D'YY7_\
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M;RO!<6]Q!\%?&TL,\$T3+)#-#(JR12QLKQNJNC!@" ";_AX1^P/_ &A_9/\
MPV_^R#_:OVS^SO[,_P"&E?@Q_:']H>?]F^P_8_\ A-/M/VS[3_H_V;R_/\_]
MUL\SY:^MK2[M;^UMKZQN;>]LKVWAN[.\M)H[FUN[6YC6:WN;:XA9X9[>>%TE
MAFB=XY8W5T9E8$_XYVFZ!K6LV7B#4=+TR[O['PII$.O^)+JVB:2'1=%N=?T/
MPM!J>H..(+27Q%XET#1DE;Y6O]6LH/O3+7]Y7_!M;_P4!G^//[/^K?L=_$CQ
M"VH_%']FO1K6\^'<FIW]W>:SXA^ 37MII&G6B":T,:V/PGU?4-'\&6P_M*46
MGAK6_!6D6EC:VFEAY0#^C7XC_%'X9_!WPK>>._B[\1? OPL\$:?<65I?^,OB
M/XN\/^!_"MC=:E<QV6G6UYXA\3:AI>D6UQ?WDL5I90S7B275S)'! LDKJAR_
MA;\;/@U\<M%NO$GP4^+?PQ^,'AVQNSI][K_PM\>^%?B!HMG?A2QLKK5/">JZ
MO8V]V%5F-M-.DP4$[, U^)O_  <M_P#*,3Q!_P!EL^$?_I=K%? __!IA_P B
M!^VW_P!CA\"__3+\3Z /Z^*\2^+/[2_[./P#NM%L?CK^T!\$O@M>^)+>\N_#
MMG\6?BMX$^'-UK]KITD$.H7.BV_C#7M&FU2WL9KJUBO)K%)X[62Y@2=D::,-
M[;7^;-_P61^-OC/]O7_@JOXS^&'PYO;CQ9IOA?XC>&OV4/@?X>@O[V33;CQ+
M8:U8^"]>_LX7,AT\2>*OBY>:\Z:KIEK!::AI/]AE9M3AM(-3NP#_ $,OA/\
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M_P"C[OV-?_$G_@E_\W%?@Q^U#_P;%6_[1O[1WQR^/UM^V_J7A"/XT?%/QO\
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MW.H/Y:^*_P#@NY_P2=\&ZU<Z#J_[8'AR\OK7!EG\*?#;XV^.]%?+.H^S>)/
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MM+NZ@T[0-:(OO$FEZ(T>FW]A!K6[6M%T;79]3TVV /U5HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !7^6O\ \%A_^4G?[:G_ &6S7/\
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M.ZBE#>*C]H33($33K'^BS_@E7_P44L_!?_!"?]H_7-8\0VVG?$']B'PU\2_
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MO6?#G@2PTW4?[6\!?#SQ3H:_:;O1M2B^QOJ:W\/V;S+BUBBFMWE\A_X.O_\
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M4M)Y[:+6-*OHH)YHD21OX$/^#E#_ )2A>-/^R0_!_P#]1^XH _;_ /X)2_\
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M';YVE"W"ZEXH\+>%]2TI8H,;I(7M?"&LF>4$"%TMT()G4CR?_@TP\;6L=_\
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MZ!\-=5@O?%@TK2K33;?2=$^)%NJ>-=#LK;3;;3M+&IW_ (9LI[Z3PY=W+/\
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MO[0FD_ V+QUKVD7MK\+_ -K?0?@AX;/CVST[0I]?ED\&ZE\:/ %Q-J;Z;>:
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MG3 ^J:1I]S%]V_\ !M?_ ,I0O!?_ &2'XP?^H_;U^E__  =%_L->7/\ #O\
M;X\":1\EQ_9?P@^/'V.'I/&DO_"K_'%]M<D^9"EYX#U6^D143[/X%L$)>7D
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M?^GOQ[0!_4[_ ,&_/_*(K]DG_NO7_K3?QGK]E*_&O_@WY_Y1%?LD_P#=>O\
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M_P"#FC]B+X0?LX?![X877P;_ &J=<\<?"_X(_#[P%<K;^$_A'9>%-8\5^"?
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MTE]+8V+:]X=OK)=:T^T;4]0^S:5XGL]=TF%[HS1V"W,%I-;@'Q)X._X.-_\
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M.KQV]K;1Q>5?LT_\$GO^"?G[(/Q)M_B_^SS^SOIW@/XDV6G:CI.G^*[OQ_\
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MXGO:SQQ6]]\/O FHRVOA#POJ$&]Y+JRUOX@QQ^*CF*'[-J7PWTIXYY!+<0@
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M&/VZ?VI_!7[,?B/]F5?@5=?$+2O%3^%/&$OQO;XA07_B?PWH5WXFA\,3:/\
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M-Z3XF\*^%+^/3KWP?\3?'5P^IPZIXRT1A:WME8PRVKW,L5T[V[1' _XA^?\
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M.V\$_#G5O&(\1_%+Q46N;O1X'BT#2-4OAI5C'=V5UK.KRZ5H>F;=1U.SB/\
M7O\ \'4O_*/?X._]GE?#W_U27[0]?N+^S#^QO^S'^QEX3U;P5^S+\'_#7PHT
M'7[ZTU'Q"=)FUC6-<\17FGVS6>G2^(?%GBG4]=\5ZZNFV\MRNFPZMK5Y!I[W
MVI36<<$VIW\ES>_:=_9+_9Y_;+^'MA\*OVEOAO9_$_P%I?B>U\9Z=H-YKOBK
MPY]A\466B:_X<L]:M=4\':[X=UF"\MM&\4:]9P-'J*QQ_P!H-<)&+N"UG@ /
MY(_^#33_ )*E^VA_V('P=_\ 4B\=5^OG_!?#_@FKJW[<W[..E_$OX0^'IM;_
M &COV=H=<UKPEHNF1I_:GQ&^'^JK9W7C3P!!!!:2WFM^(8#I-IX@\ ::9F<Z
MO#K.A:5!]M\8SLWZ2_LF_P#!/_\ 9 _8;B\8Q_LM?!C2_A=+X_DTM_%VH#Q-
MXZ\::UK$>BK<KI=D^N_$/Q1XMUJTTNS:\NYXM(T^_M-+-W<2WCVCW;M,?L:@
M#_-&_P""3_\ P5)^(O\ P2N^-'BWPOX\\&:[XB^!_C778M(^.WPL_LJUTOXC
M>&/$7AB6\TE/$WA./7GT>2P\<>%9'OM,U7P?XAO]+T?Q#:BYT;5YM#U>VTGQ
M'H/]=]A_P<8?\$I[SP3%XKN/C7XVTO79+1[E_AI?_!3XJ2>-H)DNGMUT^6_T
MSPQJ/PX:[EA5;Y'@^($U@+61$DO8[T26:?5_[6__  2<_8-_;6U&X\3?&OX&
M:./B%<>3YGQ0\ W^H?#[Q]<F.ZAN)'UK5?#4]G8>+I)X(Y=/\SQKI?B22TLK
MJ8Z8UC>):W=M^9T__!K3_P $[9M36_C^)/[7%K:B:WE.BP?$?X4MIC) (A+;
MM+<_ ZXUD0WAC=KAEU9;A3/+]DGM5$*P@'\//[5_Q5\/?'7]J7]I7XW^$;/6
M=.\*?&/X_?&/XJ^&-/\ $=O8VGB&P\/?$/XB>(_%VBV>O6FF:CJ^FVNLVNFZ
MO;0:I;Z?JVJ6,%\D\5IJ-[ L=S+_ *A'_!1C_E'O^W=_V9K^T_\ ^J2\<5\M
M?L^_\$-O^":/[./B;0?'7A/]G]?%WCSPQJL&M:!XM^*/C+Q?X\GTO4++4+'5
M=*N[3PSJ6L1^ 8KW1M0TZVN=*U4>$?[9M'\T#462:16_4/Q]X%\*?%#P+XT^
M&GCS1X?$7@;XB>$O$?@7QGX?N)[RUM]=\*>+='O- \1://<Z?<6E_;PZGH^H
M7EE+/8W=K>1).TEM<0S*DB@'^>;_ ,&U_P#RE"\%_P#9(?C!_P"H_;U_H"_'
M?X*> OVCO@S\3?@1\4-,_M7P%\5_!FN>"O$D$<6GR7]I::U926\.MZ'+JEAJ
MEEI_B?PY>FU\0>%=9DT^ZET+Q)IFEZS:Q?:["!E^4OV8_P#@E;^P-^QQX^D^
M*7[.7[/FG?#_ .(,FG7.D)XIN/'GQ4\;ZE::;>P7%M?6>G'XA^.O%D&EPW\%
MS)'?C3H;4WPCM3=F9K*S,'Z#4 ?Y$W[3O[/'Q!_9.^/_ ,5OV=/BC:PV_C;X
M3^+;WPUJ=Q:+<IINMV/EP:CX<\6:+]MAMKUO#WC+PS?Z/XL\.RWMK:7DVAZU
MI\MW:6MP\EO'_7#_ ,&F'_(@?MM_]CA\"_\ TR_$^OZ"_P!J;_@F9^PQ^VIX
MHTCQO^TM^S]H'Q$\9:)ID6BV7BNV\2^/O ?B.31[>2YFM-+U36OAOXL\(:CK
MFGV,MY=R:?::W<:A!8-<SFS2 ROGU3]EO]CC]FC]BSP1J?P[_9C^%&C?"SPM
MK>LR>(-<@LM3\1^(]8US5WB$$=UK?BOQGK7B/Q7K"V< -OIEKJ6MW5II-N\L
M&F06D,TJ. ?YRW_!8/\ :3US]LG_ (*0?';Q'HEUK'B?P]X8\9I\!/@]H]M;
MS7K_ /"+?#B_N/"MI:^%["V-U>36GC3QNWBCQQ868#7MUJ'C2X;[%937 TVU
M_LF^#?\ P;T?\$SM(^$/PJTGXO\ [-4/B[XM:7\-_ VG?%'Q9;_&?]H318/$
M_P 1;+PQI=MXV\0P:/H'QCAT+28=:\2Q:GJ4>F:+%%I-@ERMKIL:6<4*CZ*\
M#_\ !$S_ ()@?#GXG>'OC%X4_99TN#X@^%O%=OXWT/5]9^*'QO\ %FG6OBFT
MOCJ=IJTWA7Q9\3-<\):A)::CMO[6VU+0KRRMKN*"XAMDEMX&C_5*@#\"OV@_
M^#>3_@G!KGP+^+VE_ G]G&X\&?&NZ^'/B_\ X5)XFM_C7\;]3_LOXD0Z)>7'
M@MKO3_'7Q2UKPG=Z9<^(8M/LM7@UK3VMGTJYO!'=:;<^1J5I_&%_P2A_:0D_
M9!_X*'?LX_$_7IUT7PU'\0(_AI\3/[5MKT0:;X*^),=Q\/\ Q1J.J6=MY>H[
MO""ZTGBQ+>&.6X34O#EL'L=05)-.NO\ 4RK\G/&7_!#7_@E;X^\=^(_B3XH_
M9-T6Z\6>+/$NH>+M=FT[XG_'#P[H5WKNJW\FJ:A/!X.\.?$W2?!VFV-S>RRR
MMHNEZ#9:(J2/;QZ<ENQBH _6.O\ /._X.<_^4E5I_P!FZ?"S_P!/?CVO]#&O
M@;]J;_@E]^PE^VIXWTCXD?M+? '2_B)XZT30(O"]CXGMO&OQ-\!ZI)H-O=W%
M[::=JDOPW\:^$$UV.QN+NZ;3Y=;CU&XT^.YGM[*:"WE>)@#YD_X-^?\ E$5^
MR3_W7K_UIOXSU^RE>6?!3X)?"O\ 9S^&'A7X,?!/P;IOP_\ AAX)AU.#POX1
MTF;4+BQTE-9UO4O$>K-'<:K>:AJ-Q-J.NZQJFJWEQ>7MS<3WE]<2R2DOQZG0
M!_D=?L??\G;?LM_]G%_!+_U9?AFO]47]JK]GKPO^U?\ LX_&?]G+QC<_V?H?
MQ>\ Z[X0_MI;234)?#.LWEL9_#'BZVTZ._TO^TKSP?XFMM(\466FS:A:VFH7
M>DPV5[+]DGG4_%O@7_@B7_P2[^&WQ)\*_%OP;^RAX?TSQSX*U_2O%'AF]N?B
M'\9-<T/3=>T1X9M)U$^"]?\ B+JG@F]DL;FW@O8(M1\/7=N-0BCU!H6O46X'
MZI4 ?Y2NAW?[1_\ P2D_;ITK5=7\/1^'?CI^S'\19Y7TG55UV#PUXLTTV][I
M-X;:[MV\/ZOK/PZ^)O@S5+V*RU2RDL!K_A#Q"L\>R.[:(?V\_"G_ (.1?^"9
M?C;P%9>(_B'\0/&_P7\:+H=A>:Q\.?$/PP^(OC"[CUZ33OM&J:)X?\4> /"G
MB'P[K%I9ZBDFG6&LZS<>%/[2C>TOKC3M*66Z@L?U*_:>_8D_91_;,T72]#_:
M:^!_@SXK0Z%]I70-6U6+4=&\7>'X;U2+ZT\/^.O"VH:%XUT.POV$4]_IVE:_
M9V-]=6EA>7=O-=:?8S6_XP:Y_P &MO\ P3JU:_DO+#X@_M9>&+=]^W2M#^)'
MPQN+"+=--*/+D\2_!3Q#JA\M)$MD\W4I<PV\+/ON&GN)P#\./^"VG_!;30_V
M[]#TS]FS]FS3-?T?]G31]?L/%/C'QCXIL'T3Q-\5O$VB/>)H=G9Z&EY.^C_#
M[1WG36[>WUM$U[7=>33+V]TSP^OA^"#4_P!>_P#@V]_X)J>*OV>_ 7B;]LKX
MX^%9O#OQ)^-/AZ#PU\)/#&OZ=?:?XH\&?"H:F]YK&O:SI>K:=:7.D:E\2-0T
MW1;_ $98GDD;P7IVFZ@)Q!XHGM8?T=_9A_X(;_\ !.+]E;Q;9?$#PG\%I/B-
MXZTG[%)H7B7XW:U+\2_^$>O;&>SO(-9T/PSJ-M:^!]/\1PZE86FIV'B:+PM_
MPD&AWD;GP]J6D03W$$OZZT ?QK_\';G_ #C^_P"[K/\ WVVOTH_X-I/^48GA
M_P#[+9\7/_2[1Z_3S]K7]@/]DC]NFW\!VW[5'PBA^*<?PRF\23^!F;QI\1O!
M5QH+^+TT./Q(L5W\._%_A*ZO8=57PUH1GM]2FO;='TRWE@BBD#N_JO[/?[-_
MP2_93^&FF?![]G[P#IWPV^'&D75Q?67AO3;[6M40:A>16T5[J-WJ?B+4]8UK
M4M1OA:027^H:EJ5W>7UPKW5W/-<S32R 'X7?\'(_[!K_ +1G[*=C^T_X T.&
MZ^+'[*$.KZ[XE-I;V\>I>)?@#J:)<^/;:>2WTJ6_U2;X;7]I8_$/2DU+6K#1
MO#GA2/XKW-I;7>LZ_!#-_GWU_LD7=I:W]K<V-];6][97MO-:7EG=PQW-K=VM
MS&T-Q;7-O,KPSV\\+O%-#*CQRQNR.K*Q!_):_P#^"$?_  2=U+Q3+XQN/V/_
M  Y'JTVKQZV]I8?$GXVZ5X6%[%<)<K#%X&TSXEV?@F#2#)&JR>'X/#T>@RVY
M>TETU[622%P#,^+'[4GCK]BS_@BW\./VF_AKX6\/>-/&?PO_ &7_ -D:XTKP
MYXJ@UBY\/WMOXH/P<\$:U/J<6@7^EZKY.EZ#XEU/5DEMK^W2">QBGNV>SCN(
MW^1OV:O^#FO]@WXF>%]#7]H6W^('[-?C\6,@\4P7?A'7_B;\.X]2@,Q1O"_B
M/X>:=KOB_4+&_A2WD1=:\ :'<:??7,VG2-?6=FFNWW]!VM?#[P%XD\$7GPS\
M0^"/"&O?#?4- 7PI?_#[6O#6C:IX(OO"ZVB6"^&[SPI?64^@W.@+8QQV2Z/-
M8/IPM(TMQ;"%50?AO\7/^#;#_@F9\3M:U#6_#_A_XQ_!)]2FDN9M,^$?Q+B7
M18+F>XCN;B73]-^)OAOXF0Z9#*ZS1QZ;8&WTBQM[J2WTS3[&&"Q2T /PW_X+
MR_\ !9+]GW]MSX6^!_V8_P!EP:_XN\%Z-\1=/^)_C7XLZWH.J>$;#5+SP[H_
MBKP[H'A3PMX;\3Z;8^)I;.Z_X22?Q#J^M:MIWAZXMFL-&TVSM+Q;S65L_O3_
M (-:_P!D7QI\/OAC\:OVN?&VD:AHVE_&^/P[X$^$*736T4>M^#O!>L>()?&?
MBE;>.[FNWL]1\6K8:'I+WUEIKH?"^KW5H=1L-6MKB'[Y^!'_  ;J?\$R_@EJ
MMMKFL?#_ ,??'O5+&2:6QD^._CA->TJ"2;>F;GPIX&T3X>^#M:CBADDAAM_$
M/A[5[5-R71@:_@M[N']RK2TM;"UMK&QMK>RLK*WAM+.SM(8[:UM+6VC6&WMK
M:WA5(8+>"%$BAAB1(XHT5$554  %BBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBOQ[_X+M_M,2?LR_\ !-;X
MXW^E7UQI_B_XU1Z?^SOX-GMTM6/VSXH0:C%XQW2W+>9:21?"K2/B%<V%[8PS
MZC:ZK!82VAL74ZK8 %6X_P""_P#_ ,$C;6XGMI?VN(6DMYI8)&M_@=^TG>6[
M/"[1NT%W:?!V>UNH2RDQ7%M--;SH5EAEDC97/ZM?#GXC>!?B[X%\*_$WX9>*
MM&\;^ ?&^C6?B#PIXK\/WB7VD:UI%\F^"ZM9TP592'@NK6=(KNQNXI[*]@M[
MRWG@C_R9--_9I^*.J?LP>*?VM[71;B3X0^%/C3X7^!6H:O':7LH_X3+Q)X/U
MWQG(S7"0&SAT_1K#3=$L]3GDG_T?4O&7A>TE$,NKZ>MY_:Q_P:Z?M,I\1?V0
MOB3^S1J^H0R>(/V<?B)-K'ARQ+W"2I\-/C!+J7B6S6**X+PW#6GQ$T_XB7%_
M+ITBQ6L>M:1'?65K/=P7FK '].]?DMXZ_P""Z/\ P2J^&_C3Q5\/_%G[6.EV
M_BCP7K^J^&/$-OHOPH^/'B[2K;6M%O)M/U*VL?$WA'X6Z[X8URWM[N":%=2T
M+6-2TRY*%[6\GC(<_K37^17\6=+M]<_:B^)>BW;S1VNL?'SQEI=S);LB7$=O
MJ'Q#U*TF>!Y8YHUF6.9FB:2*5%<*7C=05(!_HC6__!?_ /X)&W5Q!;1?M<0K
M)<3101M<? []I.SMU>9UC1I[N[^#L%K:PAF!EN+F:&W@0-+-+'&K./T$_9^_
M:X_9F_:JTW5-5_9V^-_P[^+EOH<Q@UNV\(>(;6\U?1FR@CDU?0)C;ZYIMK<&
M1!:7E[IT%I>$D6D\Q1]O\_GCG_@U._8TU#PW?VOPT_:'_:;\)>+Y(W&EZYXY
MN_A7\0_#=G*89EC>_P#"N@?#GX8:IJ4:7#02O%;^,M*:2&.:!98GG2YM_P"/
MO0/&'Q^_X)M_MCZ]/X'\47'A7XS_ +-/Q=\2^"]4NM.N=3@T'Q-/X$\5W&CZ
M[H.MVEE>:=-XA^'OC-=(:#5-(FNEL]?\/7J@2A9H;A #_6$U/4]-T73=0UG6
M=0L=)TC2;&[U/5=5U.[@L--TS3;""2ZOM0U"^NI(K6RL;*UBEN;N[N98X+>"
M.2::1(T9A^/UQ_P7_P#^"1MK<3VTO[7$+26\TL$C6_P._:3O+=GA=HW:"[M/
M@[/:W4)928KBVFFMYT*RPRR1LKG[R^*?B^#XA?L9_$;Q]:V4VFVOCC]F/Q?X
MOMM.N)4GGL(/$OPJU'6H;*>:-4CFFM8[U8))8T5)'C9U55( _P N?]BSX+>%
MOVC?VM?V<_@-XWO]?TKPA\7OC!X%^'WB74O"MUIUCXDL=&\3Z[::7?W.AWFK
MZ5KFEVVIPV]P[V<U_H^IVL<P5IK*X0&-@#_0@_XB!O\ @D5_T=M_Y@7]IO\
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M:O\ +^_:$U/XC?\ !6S_ (*K?$.W^$S2:YK'Q_\ C+JWA7X4/?Q1Q0:?\+/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_
MFN?\'!WQCU+XM_\ !4CXYZ=<7:W6A?!S1OA[\'/"29!>RTW0?"6G^*/$5I*T
M=]?0%E^(WC'QQ<1B#[&4M[B&.\L;?4DO2_\ I1U_E7_\%6+BXN?^"DO[;\ES
M/-<2+^TI\5+=9)Y7E=;>T\3WUK:0*TC,PAMK6&&VMX@0D-O%%#&JQQJH /\
M28_8%^%B?!/]B3]E'X6Y9KKP?\ ?A=8:M(]J+(R^(;GPCI>I>))Q:?9[:2V6
M?7[W4IDAN8C?1HZK?S7-Z)[B7^,7_@ZE_P"4A'P=_P"S-?A[_P"KM_:'K^]K
MP]HMKX:T#0_#MC)<2V6@:/IFBV<MV\<EU+:Z5906-O)<O#%!"]P\,"-,\4$,
M;2%BD4:D(O\ !+_P=2_\I"/@[_V9K\/?_5V_M#T ?T/_ /!N1_RBL^$'_8__
M !H_]61KM?@1_P '5.D>"]/_ &RO@-J&D6^EVOC;7OV>(+[QFMG9V5MJ&H:?
M:>/_ !;I/A+6-8N(+2*[U">6+3]:T:TN;Z[NVBL=!@LK=+:"U E^(/V-?^"[
M?[8'[#7[.NB_LT_!SP)^SOJ?@WP_J'BW5-*\1^//!WQ#UKQK!?\ C#5[W6[Z
M=[O1_BMX=\-S?8+Z^D;3(IO"[PI%%#'?QZ@!*9<CP/\ L6?\%1/^"P'[0]S\
M6O&_@SQW>7OQ O;&#Q)^T#\6O">K?#WX0>&M$TW29O[.LM%GMO#UKI]SI>EZ
M=816.G>&OAYHFJSQWVH6$^IV]L^M7&L2@']4?_!L=!J47_!-2XDOFF-K<_M$
M_%2?1A+<"9%TU='\"VTJV\8ED-I"=8M]59K=EA+7#3W7E%;E9I?P;_8P_P""
M\/\ P4T^+G[<7[+W@#Q_\;O#FN?#/XL_M&?"'X:^+OATGP>^$VEZ&_A?XC^.
MM!\$ZO!IVN:1X.L?'UE>:=9ZW-JNC7@\92R1:Q:6;:D-3TH7>DW?]MG['_[+
MGP^_8Q_9R^%_[-_PT\ZY\-_#C0OL,^N7EM;6NJ^+/$6H74^J^)_%VL1V@\I=
M2\1:[>WVI2PJ\R6,,UOIMO*UI96^/\P[_@G/_P I"/V$?^SROV8/_5V^!Z /
MZ[?^#A+]OO\ X*!_L+_$[]G:[_9F^*D/PN^$'Q,\!^+;>_N8OA]\)O'$^K_$
MGPEX@M9=<@OIOB#X*\7W^D0VGACQ'X1DTJ*T;3;34GGUAXUO9M-NS9_H?_P0
M]_;L\;?MY?L4V?C7XP>)K'Q3\=OAK\0/%GPY^*>LPV?AK0KO7Y//@\5^#O$\
MGA/PMH^@:1H%E>^$?$FF>'87T_2X].U75_">O7EO-]K&H65AY_\ \'#'[,?_
M  T-_P $X/B)XITC3/MWC7]F[6](^.V@O:Z3]NU-_#FA)=:%\3+,7T)^V:;H
MEIX!U[6O&>LE4N+">7P5I<NHV\2V<&J:7_//_P &N_[3$GPW_;&^(?[-FK7U
MPGA[]I3X<W.H:!8(EK+')\3/@[!JGBS3'+7#1W-G!+\.KWXFO>/ISR->75CH
MT=]8W,-K!>Z2 ?O7_P ' '_!1;XT_L$? ;X-6'[./BS3? WQD^-7Q$U>WM/%
ME]X<\->+;K2/ 'P]T>TO_&!T?0/%^E:YX<DU&_UOQ/X'TR74=5T?5(K'2+W5
M(K6TAU2]T[5=+YK_ (-[/VQ?VU/VVOA1^T;\4?VL/B?'\3_#WAWXA>#/ /PP
MU ?#[X>^!Y=,UG3O#>H^(?B+9O-\//"GA.QU>.6Q\3_#N>*/4+2ZN]-8RM'<
M"'41$O\ .A_P<C_M,-\;_P#@H7J?PNTF^DN/"'[,7@G0OAG:PK%$ME-XXUZ)
M/&_C_5+>3<]W).DVMZ%X.U 3_9X$N?!)^QVAC9]1U/\ HW\&_#7Q-_P3M_X-
MZ?%UAH$,^A_%>']E3QAX]\37IO#'J^@?$CX]6LEWJ5TMYIXCA36_AQ#XTLM&
MTF2T\VU$_@_3?,NM2'GZA> 'X\_\%2/^#AOXZ^./BWXB^!G_  3_ /%H^'OP
MI\*:[/X6N/C'X=TS1?$/C[XQZW87=YIM[>>"M2O(-<T_PY\.[Z^-LWA*[\.6
MD?C'Q'!9VVN2>(=.TS79?"=M\K>+/A9_P<A_"+X?O^T?XL\8?MZ:;X)TNTO/
M%NIR7/[2&L^+;[0M*M[#4=8U+4O%?P3M_B?KWB70-$TK3[&]NM3@\3?#ZQTK
M1(8H4O8++?9QOY-_P;U_#3PE\2?^"H_P3;Q?8?VI;_#[P_\ $3XEZ%8R>0UD
MWBWPQX5O8O#5_>QRP2O)_8.I:E%XBTS[-+:3P:]I&D7;3O;V\]I=?Z3E '\>
M?_!%+_@O1\4_BQ\5_!W['O[:^JQ^-M8^(%Q!X<^#7QXCTZRT[Q))XNV6]MH?
MP\^)&EZ%IEGIVN6_B2&.2UT+X@Q0VVOV_B.*TLO&$7B:/Q/<>*O"MG_@XM^-
MO_!2WPYXY\8_"7X4>'/B@?V"O$G[.OA.Z^*VM>%_@1I7C#X=2ZE>^,?%R>))
M_&/QEF\!^(M1\#ZK"VG>'+.?2H?&OA06>EP:#J":7%_;[ZIK?\N/[6G@FU_9
M8_;M_:"\$?#P16^F? O]ISX@V7P]2\\N^%KHO@KXC:E<>"8=25+33K>ZN+72
M[+2H=3C@M+:TDN8KF.W06YC8_P"BW_P67_Y1>_MH?]DAN?\ U(-"H _SL?V%
M/BA^VM\(_CA)XL_8(TSXB:M\=F\%Z_I<EK\,?A#8?&WQ+_PA%Y=:1)XAE/@O
M4O!7CZW73DN[;1Q=:Q_80DL7:WB6^MQ=LDW]Z/\ P1)^,_\ P4:^,_PD^-6J
M_P#!1?0/B=HOC#1OB-HVG_#>3XJ_ W2_@/KUWX:F\,PW.L)8^'=+\"?#V/6-
M(M=4,+0ZU+HER_VVYOK%=4G%K]DL?Y@?^#8S_E)5=_\ 9NGQ3_\ 3WX"K_0Q
MH _A:^.O_!6K_@KO_P % OC5\2_@I^P/\._'_P -/ WAG5M;\.S:)\)_"UC>
M?$2'3/#GB:2Q&N^//BYKMCN^'^LW<T^D0ZA:^&-9\'VNG@Q:0;W5(I]0N]4^
M-/CO/_P<$?\ !/\ TS2?BW\>OB_^V1X*\+R:C9Z/;>)O$'[29^._@.#5-3:Y
M:PL->L]/^)/Q0\'V-U>MILZ6D7B2R@>5MD$63?01W']'O[4?_!=[_@GC_P $
M_?&GC7X'?L__  CC^*?C:T\9>(->^*.G_ ?0?!?PW^%=G\2]4DO$\7R>)?&L
M-G#'XJ^)-SJEAI*>*]6T#PMXIM6,]S;ZQXM/B;P_?>'$_%+]OW_@XJTS]N']
ME/XR_LKM^QM-X"T_XI0^&+>S\=W'[09\1W&B/X/^(/A?Q[I.I3^$[7X,^'5O
M9I;KPK:12Z>GBR"WA>=C)=:A;PO;W8!^\/\ P0?_ ."K'Q!_X*%?#OXE_#G]
MH#^QKCX_?!!?#%_=>+-"T6S\.V/Q,\!^(X+G3K;Q)?:+IL_]E6'C#2/$6CWT
M/BY-#TGPWX7DMO$'A:3P_HMLQU:WM/P,_P"#J7_E(1\'?^S-?A[_ .KM_:'K
ML/\ @U-_Y/)_:(_[-EN?_5I_#NN/_P"#J7_E(1\'?^S-?A[_ .KM_:'H _I>
M_P"#?G_E$5^R3_W7K_UIOXSU^,W_  =C_"K34G_8Z^-]I"R:O=1?%+X5:_.?
MLY2XTVP?POXN\(PK\Z72M9W6H^-G?$=S;R"_3<]E)&JZA^S/_!OS_P HBOV2
M?^Z]?^M-_&>OSV_X.MO^32?V:_\ LXNY_P#5:>+Z /9O^#83XO3>//\ @GEK
M_P -M0U*.>]^!OQX\<^&=)TOSII9M/\ !OC/3/#OQ(TVZ9'C6&WM]1\8^)_B
M L,,$DF9K&ZN) C7 W?T;U_(;_P:97%PWPY_;7M6GF:UA\;?!*XAMFE<V\5Q
M<Z%\1X[F>*$L8XYKB.TM8YY54/*EM;K(S+#&%_KRH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ JO=VEK?VMS8WUM;WME>V\UI>6=W#'<VMW:W
M,;0W%M<V\RO#/;SPN\4T,J/'+&[(ZLK$&Q7R'^WW\>?$/[,/[%W[2_QZ\(0P
MS>,?AK\)/%>M^#FNH(+NSM/&%Q9G2?"NIW]E<@P7^G:1K^HZ=JFHZ=)M&H6-
MG<60>-IPZ@'YG?#KX#?\$3_^".%S+X?\8^._A3H/Q:UJSUK5Y_$'QVUS0_B7
M\=G\)Z[=+>V]C!X?T/PZ;_0/""QZ/%I?A]]*\%Z0FO'2YTGO_$&O2:K=W7Y5
M_P#!<_\ X*(?\$M?VX/V1'TGX'_%?P]\1/VDO"/CWP)K/@6^;X(_&7PIXK/A
MNUO-8TWQ/H<7CKQA\-_"=C;^'DTGQ/JVLS^'M3UR?2KW4K:WO+;2)M<@TV]L
M_P -?^"<G[%WCK_@K3^V=XA\ ^.OC!K6B:A?^&O%_P =?C'\5=:M7\;^,M5T
M^Q\1^'-*U::VAU76=+.J>)/$OBCQIHFGG4;[4)H])AOKO7)=.U>/3#I%Y^NW
M_!6'_@A9^Q_^P%^Q/XB_:#^'GQ:^/GB'XFZ7XK^'?A/1]+^(OB[X7OX0\07_
M (FUJ"TUU++0-#^%OASQ!+=Q:+!K.LZ?I]KXIN9K&UT^XNKQ]0M+&ZD8 ]$_
MX-,==U9/&W[:_AI;Z;^PKGPM\$M=ETQMCV_]K6.K?$BPM[Z+>K203?8]1N;>
M?R'B2[3[/]K6=K*R-O\ GE_P<H?\I0O&G_9(?@__ .H_<5][_P#!II_R5+]M
M#_L0/@[_ .I%XZKX(_X.4/\ E*%XT_[)#\'_ /U'[B@#^GW_ ((#?L9? 3X+
M?L,_!CX_>&_!>F7_ ,;/CQX8NO&7C;XF:U8V=]XIM[>[U?5M.L/"/AK498&N
M/#GA33M,M8(YM,TR6$:SJ#W6J:N]U)):PV/\IO\ P<(_ GX:_ ;_ (*1^-M,
M^%GAC1O!GA[XA_#OP#\4;_PSX<TRVT;0=.\3>((M6T?Q#/IFF60CL[1=;O\
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MZ'=:GX'\!_$'2O%]Q9127%I=:_\ 9/"1N_LEO=KH<+WLUO9?NY_P1M_X)?\
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MY2$?!W_LS7X>_P#J[?VAZ_H1_P""4W_!$O\ X=C?&7XB?%O_ (:9_P"%W?\
M"??#*7X<_P#"/_\ "F?^%;?V3YGBKP[XF_MG^U?^%K^/OM^W^P/L7]G_ -FV
M>?M?VG[</(^SS0?\%5_^"'6D?\%-/C;X ^.,/[2>H_!#7O!_PKL_A1J6CR_"
MBV^)VD:UI&C^+?%?B_1-3L2GQ#^'=YHFHPWGC;Q!:ZJ)[C7+;4;9-'-I#I,M
MC>OJH!ZI_P &_/\ RB*_9)_[KU_ZTW\9Z_+W_@[&\;6EA\%/V/OAR_\ Q_\
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M\+/&W]KW^@:UXLN]7@\GX=^./%UQI_V2WU.QD\W5(K*&?S]EM),\<RQ_+/\
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MJGAS0=$UUD\76WB'Q/=K*OB7QEXK@T[^P[?4;G68AKVNK;:/>?WP_$OX?_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"$M_X2W^T_[:_X2G_A)/\ A$?[9_X2/^V?^)M_;?VW^T_[3_T_[5]J_>T
M?4]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5\&_P#!2K]B;2/^"@/[(?Q'_9VN=5LO
M#?BK4FTOQ;\,/%NHI=RZ?X7^)/A2Y:]\/WNI160EF;1M8MI=3\)>(98[+4KJ
MR\/>)-5O],T^XU>TT_;]Y44 ?SW_ /!$7_@EM^V#_P $U]>^.=E\<?BS\$O%
M'PO^)^D>&+K2/!?PIU'QEXCNH_'NAWEU%_PE&HZKXR^'7@*;1K>W\/75UI)T
M_3&U>+7)+VVN;U=/?0+,WW]"%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7\>_A7_ (-U?VG/BU^WMJO[3O[:'Q8_9_\ %7PH\6?'
M'7OC1\0/!O@;Q!\2?&'B;QE:77BV;Q3I_P ,;BR\4_#/P'HVF>$-2MC;^$]6
MN+/76DT3PM&^G^']-)6SDLO["** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(7_$AWT@O^A9PO\ ^)-A/_E1_9317\:X_P"#B3]LW//PJ_9B(]O"7Q5!_/\
MX7(?Y4[_ (B)/VR>_P *?V9>G_0J?%,<^O\ R6 \>WZT?\15X1_Y_P"._P#"
M&I_F+_B0[Z0?_0KX8_\ $GP?_P K/[)J*_C9_P"(B3]LG_HE'[,O_A*_%/\
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MG_0HX:_\2? ?_(G]CU%?QQ_\1$_[7G_1(/V;_P#P0_$[_P">E2_\1$_[7?\
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M_P"@_$?^$&,_^5!_Q(W](O\ Z)3*/_$KX>_^;_ZMZ7_KEHK^1S_B(W^.7?\
M9T^%'_A2>+Q_[.:7_B(W^.'?]G/X4_\ A3>+A_4T?\10X._Z#\1_X08S_P"4
MB_XD<^D9_P!$GE/_ (E?#O\ \\#^N*BOY'Q_P<<?&[O^SE\*S]/%'BX?T-+_
M ,1''QL[_LX?"S_PJO%H_P#9#1_Q%#@W_H88C_P@QG_RG^K/RNO^)'/I&?\
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MA[_LAZ,?I\;;X?\ O+#2_P#$21K_ '_9"T?_ ,/?>C_WE1H_XB9P7_T-Y?\
MANS/_P"8Q?\ $E'TE/\ HWU'_P 3#@C_ .B,_JDHK^5W_B))US_HT'2?_#XW
MG_SJ*=_Q$DZW_P!&@:5_X?.[_P#G34?\1,X*_P"AQ+_PW9I_\Q"_XDI^DK_T
M;RE_XF' _P#]$A_5!17\L'_$25K/?]C[3/\ P^MT.?\ PTA_+]:</^#DK5^_
M['NG'Z?':Y'_ +R(T?\ $3."O^AQ+_PW9I_\Q!_Q)3])7_HW=+_Q,.!O_HE_
MJWI?^IVBOY8Q_P ')6J]_P!CS3S]/CQ<C_WD!I1_P<EZGW_8[L#]/CS<#_WC
MQI_\1+X*_P"AP_\ PW9I_P#,7]6]!?\ $E7TEO\ HW5/_P 3#@7_ .B4_J;H
MK^6;_B)+U'_HSJR_\/Y/_P#.;IW_ !$F7_\ T9S9_P#A_9O_ )S-'_$2^"O^
MAR__  W9K_\ ,(O^)*OI+?\ 1N8?^)AP)_\ 1,?U+T5_+2/^#DR][_L;VI^G
MQ_E'_O%S2_\ $29=_P#1FUM_XD#+_P#.5H_XB7P5_P!#E_\ ANS7_P"81?\
M$E?TEO\ HW$?_$QX#_\ HG/ZE:*_EL'_  <FW/?]C6 _3]H*0?\ O$S2_P#$
M2;<?]&:0_P#B0C__ #D:/^(E\%?]#E_^&[-O_F'^K/RN?\26?27_ .C;Q_\
M$QX"_P#HH_JWI?\ J2HK^6\?\')TW?\ 8SC/T_:&8?\ O#S3A_P<G/W_ &,5
M/T_:((_]X::?_$2^"O\ H=?^8[-O_F'^K>@O^)+/I+_]&V7_ (F/ /\ ]%)_
M4=17\N7_ !$G-_T9B/\ Q(D__.+IP_X.3QW_ &,"/I^T5G_WA0H_XB5P3_T.
MO_,=FW_S +_B2WZ2_P#T;7_S<> /_HJ/ZBZ*_EU_XB3E_P"C,6_\2)'_ ,XR
ME'_!R='W_8R<?3]H=3_[PX4?\1*X)_Z'7_F.S;_Y@%_Q)=])?_HVK_\ $PX!
M_P#HI/ZB:*_EY_XB38._[&DW_B0B'_WB(H_XB38._P"QI-_XD(A_]XB*?_$2
MN"O^ATO_  W9K_\ ,(?\27_27_Z-K+_Q+^ O_HI/ZAJ*_E['_!R;:XY_8VN
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M7_T.X?\ A#F?_P Q!_Q)K])3?_B&=?\ \2?@K\O]9+G]-U%?S)_\1(WA;O\
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M_P!T44_^(C<%_P#0[I_^$>8__,8?\2<_22_Z-EB__$CX._\ HB/Z8:*_F?\
M^(D/P-_T:EXL_P##KZ/_ /,-2C_@Y"\"=_V4_%H^GQ5T8_\ ND"C_B(W!?\
MT.Z?_A'F/_S&+_B3KZ27_1LL7_XD7!__ -$)_2_17\T7_$2%X"_Z-4\7_P#A
MU-&_^8JE'_!R%X![_LJ^,!]/BGHI_GX,%'_$1>#/^AW3_P#"/,?_ )C%_P 2
M=_21_P"C98S_ ,2'A#_Z(#^ERBOYI?\ B)!^'W_1J_C+_P .AHG_ ,Q]+_Q$
M@_#S_HUCQG_X<_0__F0H_P"(B\&?]#NG_P"$F8__ #(+_B3SZ2/_ $;+&_\
MB0<(_P#T0']+-%?S4#_@Y ^'7?\ 99\:CZ?$W0C_ #\)K2_\1('PY_Z-:\;?
M^'+T+_YE*?\ Q$7@S_H>4O\ PDS#_P"9 _XD]^DA_P!&QQO_ (?^$O\ Y_\
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MF'_\$XO_ .9_Z^3%_P 2D_2+_P"C7YQ_X<.'_P#Y[G]%E%?SJ_\ $1I^S_\
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MK,_H=HK^>,?\'&'[-G?X$?' ?2?P$?\ W9A3O^(B_P#9J[_ GXY?]_? )_\
M=H%'^O\ P?\ ]#W"_P#@O$__ "@/^)3OI$?]&MSS_P *LE_^>A_0U17\\W_$
M1?\ LT]_@5\<_P#OOP"?_=J%._XB+_V9O^B%_'7\_ '_ ,UM'^OW!_\ T/<+
M_P" 8G_Y1_7R8O\ B4_Z1'_1K<]_\*<F_P#GF?T+T5_/3_Q$7?LR_P#1#/CM
M_P"8_P#_ )KJ</\ @XN_9B[_  .^/ ^B_#X_^[B*/]?N#_\ H>X3_P  Q/\
M\H\_S[,7_$J'TA_^C6Y]_P"%&3__ #R/Z%**_GL_XB+?V8?^B'_'G_OW\/?_
M )LJ</\ @XM_9?[_  0^/8^D/P]/_NZBG_K[P?\ ]#W"?^ XC_Y2+_B5'Z0_
M_1K<_P#_  ?E'_SR\_ZLS^A&BOY[_P#B(M_9<_Z(C\?/_ ?X>?\ S;TO_$19
M^RWW^"7Q]_\  ;X=G_W>!1_K[P?_ -#W"?\ @.(_^4A_Q*E](?\ Z-9G_P#X
M.RG_ .>/G_5F?T'T5_/E_P 1%G[+/_1$_C__ . GPZ_^;NE_XB+/V6._P4_:
M _\  /X='_W?!1_K[PA_T/<)_P" U_\ Y3_7R8O^)4_I#?\ 1K.(/_!N5?\
MSQ/Z#**_GU_XB*_V5>_P6_:"_P# 'X<G_P!W\4[_ (B*_P!E/O\ !?\ :$_\
M%_PX/_O013_U]X0_Z'N#^ZO_ /*?Z^3%_P 2I_2&_P"C6<0_^#,K_P#G@?T$
M45_/P/\ @XJ_91[_  8_:%'TTWX;G_WH8IW_ !$5?LG_ /1&?VA__!7\-O\
MYXM'^OG"'_0]P?W5_P#Y4+_B53Z0O_1K.(O_  /+/_F\_H%HK^?O_B(I_9.[
M_!K]HC_P5?#4_P#O1Q2_\1%/[)?_ $1O]HG_ ,%'PU_^>31_KYPA_P!#W!_=
M7_\ E0?\2J_2%_Z-9Q%_X%EO_P W^?\ 5F?T!T5_/]_Q$4_LE?\ 1'/VB_\
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M^)8O'_\ Z-3Q=_X0P?Y5C]UJ*_"K_B(2_8?_ .A+_:/_ /"$\ __ #U:</\
M@X1_8>/7P=^T:OU\"> _Z?%,T_\ 7?A+_H?Y=_X.?_R(?\2Q^/W_ $:CB[_P
M@B_RJG[IT5^%W_$0?^P[_P!"A^T6/^Y#\#?T^*)H_P"(@_\ 8=_Z%']HL?\
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M3\_Z&;XG?^&SU?\ ^2:/]<>%?^B@RG_PMH?_ "8O^)=O';_HTG'W_B-9E_\
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M#_@NM_P3V/\ S._Q"'U^%_B;^D1H_P!;^%O^BARC_P +\/\ _)B_XEY\=/\
MHT?B#_XBV;?_ #-_PW4_8BBOQX_X?J_\$]?^AX^(/_AK_%'_ ,8IP_X+J?\
M!/0_\SWX_'U^%WBK^EL:/];^%O\ HH<H_P#"_#__ "S^ODQ?\2]>.G_1H_$+
M_P 17-__ )E/V%HK\>Q_P73_ .">9_YGWQ\/K\+O%G]+4TO_  _1_P"">?\
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M_P##AA?_ )9_7R8O^)?O'+_HT7B+_P"(CG?_ ,QGZ]45^0__  _)_P""=O\
MT4[QE_X:OQY_\IJ=_P /R/\ @G9_T5#QC_X:KQ[_ /*6G_K;PO\ ]%#DW_AQ
MPO\ \M#_ (E^\<O^C1>(W_B(9Y_\Q>?]69^NU%?D4/\ @N/_ ,$ZS_S5+Q>/
MK\*OB!_30S3O^'XW_!.K_HJGB[_PU7Q!_P#E#1_K;PO_ -%#DW_AQPO_ ,M%
M_P 2_P#CE_T:+Q&_\0_/?_F(_7.BOR-'_!<7_@G4?^:K>+!]?A3\0_Z: :=_
MP_#_ ."=/_16/%?_ (:GXB__ #/4?ZV\+_\ 10Y-_P"''"?_ "T7_$ /''_H
MT7B/_P"(=GW_ ,PGZX45^2 _X+A?\$Z#_P U9\4CZ_"CXC_T\.&G#_@N#_P3
MG/\ S5WQ./K\*/B5_3PT:/\ 6WA?_HH<F_\ #EA/_EO]?)B_X@#XX_\ 1H?$
MC_Q#<_\ _F _6VBOR3_X?@?\$Y_^BO>)O_#4?$O_ .9FG#_@M_\ \$YCU^,'
MB4?7X3_$W^GA<T_];.%_^BAR7_PY83_Y:+_B 7CA_P!&A\2?_$,X@_\ F#S_
M *LS]:J*_);_ (???\$Y?^BQ>(__  T_Q/\ S_Y%7_Z_M2C_ (+>?\$Y#_S6
M3Q$/K\)OBC_3PH:/];.%_P#HH<E_\.>#_P#EP?\ $ _'#_HT/B3_ .(7Q#_\
M[S]:**_)D?\ !;O_ ()Q_P#19O$ ^OPF^*?]/"1Z?_JS2_\ #[K_ ()Q?]%H
MU\?]TE^*G]/"!H_ULX8_Z*')?_#G@_\ Y<+_ (@)XW_]&A\2O_$)XB_^=Y^L
MM%?DX/\ @MS_ ,$X3_S6O71]?A+\5_Z>#C2_\/N/^"</_1;-<'_=)?BQ_3P;
M1_K7PQ_T4.2_^'/!_P#R[^ODQ?\ $!?&_P#Z-!XE_P#B$<1__.X_6*BOR?'_
M  6V_P""<!_YK?K0^OPD^+?]/!9I1_P6U_X)OG_FN&LCZ_"3XN?T\$FG_K7P
MQ_T462?^'3!?_+A?\0&\;_\ HT'B9_X@_$G_ ,[?/^K,_5^BORA'_!;3_@F^
M?^:Y:P/K\(_B]_3P0:=_P^S_ .";O_1==6_\-'\8?_F%H_UKX8_Z*+)/_#I@
MO_EP?\0&\;O^C0>)G_B#<2__ #M/U<HK\I?^'V7_  3=_P"B[ZI_X:/XQ?\
MS"4O_#['_@FY_P!%YU/Z?\*B^,G_ ,P6/UH_UJX8_P"BBR3_ ,.N!_\ E_\
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M'/>&/_"3^)7_ ,Q=.'_!7+_@G0?^;GO"WX^%?B0/Y^#!3_UCX>_Z'V3?^'3
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MA'\9)_X-XOVV1_S4;]F,_3QO\3_Z_!H4W_B'D_;:_P"BA_LR_P#A;_$W\_\
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MP)^WA_S]? X_]U#U?^O@T=?_ -=?VPT4?\0FX4_ZF?\ X60_^9P_XG\\>_\
MJBO_ !'*_P#\]?ZOZ'\3A_X(#?MXC_EO\$#]/B'JG]?!XI#_ ,$!_P!O(?\
M+;X(GZ?$34_Z^$17]LE%'_$)N%/^IG_X60_^9Q_\3^^/7;@G_P 1W$?_ #V/
MXFC_ ,$"/V\A_P M/@D?I\1-1_KX2%-/_! G]O,?Q?!0_3XBW_\ 7PH*_MGH
MI?\ $)>%.^:?^%D/_F?^KORL_P#B?WQZ_DX(?_=NXG],W/XE_P#AP5^WI_U1
M7_PXM[_\RU-_X<%_MZ_W?@O_ .'%O/\ YEZ_MJHH_P"(2\*=\T_\+*?_ ,S#
M_P")_O'G^3@?_P 1W%?_ #X_J_H?Q)G_ ((&_M[#_EE\&3]/B-<_U\-"D/\
MP0._;W'_ "P^#1^GQ&G_ *^&Q7]MM%'_ !"7A3^;-/\ PLI__,P_^)__ !Y_
MY]<#?^([B_\ Y\_U=^5OXD3_ ,$#_P!O<?\ +M\&S]/B/+_7PZ*;_P .$/V^
M/^?3X._^''?_ .9^O[<**/\ B$O"G\V:?^%E/_YF#_B?_P >?^?/ W_B.XS_
M .?1_$<?^""/[?(_Y<_@\?I\1V_KH IO_#A+]OK_ )\/A!_X<@?_ "BK^W.B
ME_Q"7A3^;-?_  LI?_,W]7?E9_\ %0#QX_Y\<"_^(]C?_GT?Q%_\.%/V^O\
MH'?"'_PY"_\ RDII_P"""O[?@_YAGPC/T^),7]=&%?V[44?\0DX5_GS7_P +
M*7_S*/\ XJ >/'_0/P)_XCV._P#GV?Q$?\.%OV_/^@5\)/\ PY,/_P I^_\
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M;_\ A7A__F,?_%03QU_Z /#_ /\ $?S7_P"B$_AS_P"'$W_!0?\ Z$WX<_\
MAS_#O^--_P"'$_\ P4(_Z$OX=_\ AS_#G_Q=?W'44?\ $(^%O^?V;_\ A7A_
M_F,?_%07QU_Z%_A]_P"&#-O_ *(C^&__ (<4_P#!0G_H2/AZ?^ZH>&?ZRBD_
MX<5?\%"O^A'^'W_AT/"__P >K^Y&BC_B$?"W_/[-_P#PKP__ ,QC_P"*@WCI
M_P!"[P]?_= S?].(T?PV_P##BO\ X*%_]"+\/_K_ ,+0\+?_ "1G]*;_ ,.+
M?^"AG_0A> ?_  Z/A/\ ^2J_N4HH_P"(1<+?\_LW_P#"O#__ #%_5_2Q_P 5
M!O'3_H6^'K_[H&<?IQ(OZ?H?PU?\.+?^"AG_ $(/@+_PZ/A+_P"3*:?^"%__
M  4-'_-/O AYQQ\4O"'Y\WHX_7VK^Y>BE_Q"+A;_ )_YQ_X5X;_YB'_Q4'\<
M_P#H6>'C]<@SG].)4?PS_P##C#_@H=_T3SP+_P"'2\'?_)])_P .,?\ @H?_
M -$[\#?^'2\&<_\ E1_GBO[F:*/^(1<+?\_\X_\ "O#?_,(_^*@_CG_T*_#M
M_P#= SG].)D?PQ_\.,O^"B'_ $3CP3_X=/P3S[_\A/\ G@^U'_#C/_@HA_T3
M?P3_ .'3\$?E_P A3_ZWO7]SE%'_ !"+A;_G_G'_ (5X;_YA'_Q4(\<_^A5X
M=?\ AASO_P"B?^KORM_#"?\ @AK_ ,%$?^B:>"S[CXJ>!N?SU8'\P*3_ (<:
M_P#!1+_HF7@P_P#=5/ G]=8%?W/T4O\ B$/"_P#T$9S_ .%>%_\ F$/^*A/C
ME_T*?#I^N0YY^G%"/X7C_P $-_\ @HF/^:8>#C]/BIX"_+G61_A[TW_AQQ_P
M44_Z);X0_P##J^ /_EY7]T=%'_$(>%_^@C.?_"O"_P#S"/\ XJ$^.7_0H\.7
MZY#GOZ<4(_A;_P"''/\ P44_Z);X1_\ #J_#_P#/_D.__7]J0_\ !#K_ (**
M_P#1*O"1_P"ZK?#S^NOBO[I:*/\ B$/"_P#T$YS_ .%>$_\ F ?_ !4*\<?^
MA/X</_N@Y[^G%*/X6/\ AQW_ ,%%O^B4>%/_  ZWP[_^:"D/_!#S_@HN/^:3
M>%3]/BO\.?Z^(A7]U%%'_$(>%_\ H)SG_P *L)_\P?U?T#_BH5XX_P#0F\./
M_##GW_T5'\*O_#C[_@HQ_P!$C\+_ /AU_AM_\TE)_P ./_\ @HQ_T2+PQ_X=
M?X:__--7]U=%'_$(>%_^@G.?_"K"?_,']7]+/_BH7XX_]"7PW_\ #%G_ /\
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M '5OX1?U\;"C_AR7_P %(/\ HANCG_NKGPA_KXW%?W=44?\ $(.&/^@O._\
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M'N&O^@_//_"C ?\ SM'_ ,5$_&GKPKX7_P#AGXK_ /HT9_!$?^"-7_!2<?\
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M'X#_ .=P_P#BHIXR]>$_#+_PU<5+_P!_!G\"Y_X(\?\ !2$=?V9M7_#XA_"
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MN)O_ *)S_/\ _P#ATG_P44_Z-?\ %W_A1?#[_P":^F_\.E?^"B8_YM?\8?\
MA0> 3_+Q=7^@%11_Q!WA[_H8YS_X-P/_ ,PC_P"*BWBYUX.\.?\ PBXF7_OS
M,_S_  _\$E_^"B8_YM?\8_\ @^\!G^7BRFG_ (),_P#!1(?\VO>,_P -<\"'
M^7BLU_H"T4?\0=X?_P"AEG/_ (,P7_S$/_BHMXM_]$;X=?\ A'Q-_P#1+Z_U
MO_G\?\.F_P#@HC_T:]XU_P#!SX'_ /FJI/\ ATY_P40_Z-=\;?\ @X\$?_-3
M7^@112_X@[P__P!#+./_  9@O_F+U_I:G_%1;Q:_Z(WPZ_\ "3B7_P"B3U_K
M?_/V_P"'3W_!0_\ Z-=\;_\ @U\%?_-133_P2@_X*'#_ )M<\<_AJ?@T_P O
M$QK_ $"Z*/\ B#F0?]#+./\ P9@O_F,?_%1?Q9_Z(SP[_P#"7B7_ .B,_P _
M/_AU#_P4._Z-<\=?^#+P=_\ --33_P $H_\ @H:/^;7/'GX7_A _R\2&O] Z
MBC_B#F0?]#+./_ \%_\ ,8_^*B_BQUX+\//_  FXD_\ HB9_GX?\.I?^"AG_
M $:WX]_\#?"7_P T=-_X=3_\%"_^C6_'_P#X%^%/_FBK_01HI?\ $',@_P"A
MGG'_ ('@O_F/U_I:O_BHOXK_ /1%^'O_ (3\2?\ T0^O];_Y]G_#JG_@H5_T
M:U\0?_ GPM_\T%'_  ZJ_P""A7_1K7Q!_P"__AC_ .:"O]!.BC_B#F0_]#/-
M_P#P/!?_ #('_%1?Q6_Z(KP]_P#"?B3_ .B _P ^H_\ !*S_ (*$C_FUKXA_
MA+X:/\M>--/_  2N_P""A _YM9^(OX/X</\ +737^@O11_Q!S(?^AGF__@6#
M_P#F0?\ Q47\5?\ HBO#[_P1Q'_\_P _SYS_ ,$K_P#@H./^;6?B-^!\/'^6
MN&F_\.LO^"@W_1K'Q(_[YT#_ .7=?Z#5%'_$',A_Z&>;_P#@6#_^9!_\5&/%
M3_HB?#__ ,$\1_\ S^/\^3_AUG_P4&'_ #:Q\2?7[F@G^6M?IUIO_#K7_@H+
M_P!&L?$O_OSHG_RXK_0=KD/B#?7>E^ ?'&IZ?<26E_IWA#Q+?6-U$0);:[M-
M%O;BVN(R00)(9HTD0D$!E&01Q2_X@YD7_0SS?_P+!_\ S+Z_TM7_ ,5&/%/_
M *(C@#_P5Q%_\_?7^M_X$#_P2W_X*"#_ )M7^)G_ (#Z,?Y:O3?^'7'_  4#
M'_-J_P 3O_ 72#_+5J_T(**/^(.9%_T-,V^_!_\ S*'_ !48\4O^B(X _P#!
M?$7_ ,_#_/>/_!+K_@H&/^;5OB?^%II)_EJM(?\ @EY_P4"'_-JWQ0_"RTL_
MRU0U_H144?\ $',B_P"AIFWWX/\ ^9A_\5&/%'_HA^ ?_ .(O_GV?Y[?_#K[
M_@H#_P!&K?%+_P %^G?_ "SI/^'7_P#P4 _Z-5^*?_@MT_\ ^65?Z$M%'_$'
M,C_Z&F;??@__ )F]?Z6K_P"*C'BA_P!$/P%_X#Q#_P#/H_SV/^'8/[?_ /T:
MK\5?_!78_P#RPIO_  [#_;^_Z-4^*_\ X*;/_P"3Z_T*:*7_ !!S(_\ H:9K
M]^#_ /F;U_I:O_BHSXG_ /1#<!_=Q#_\^3_/5/\ P3%_;^'_ #:I\6/PT>U/
M\KXTW_AV-^W[_P!&J?%K_P $MO\ _)M?Z%E%'_$',D_Z&F:_^6G_ ,SA_P 5
M&?$[_HA> _\ S8/_ )\>O];_ .>E_P .R/V_/^C4_BW_ .".'_Y,IO\ P[*_
M;[_Z-3^+O_@@C_\ DJO]"^BC_B#F2?\ 0US7_P M/_F<?_%1GQ-_Z(7@3[^(
M/_GL?YY__#LS]OK_ *-2^+W_ (3Z_P#R333_ ,$SOV^1_P VI?&#\/#F?Y7!
MK_0RHH_X@YDG_0US7_RT_P#F?U_I:O\ XJ,^)G_1"<"_?Q!_\]C_ #S/^':'
M[?/_ $:C\8?_  FF_P#C]-_X=H_M\?\ 1J/QC_\ "8D_^/5_H:T4O^(-Y)_T
M-<T^["?_ "CU_I:O_BHSXE_]$)P-_P"!9_\ _/7U_K?_ #R3_P $T_V]QC_C
M%'XR<^GA:8_GB0X_&F_\.U?V]O\ HU#XS?\ A*7'_P 77^AQ11_Q!O)?^AKF
MGW83_P"4!_Q4:\2O^B#X&_\  \__ /GGZ_UO_GC?\.UOV]A_S:A\9_3_ )%.
MY/\ )_UZ?F*;_P .V?V]/^C3_C3_ .$?>?XU_H=T4?\ $&\E_P"AKFGW83_Y
M0/\ XJ->)/\ T0? _P#X,S[_ .>9_GAG_@FU^WH/^;3_ (U?AX.OC_*FG_@F
MY^WF.O[)_P ;/3CP9J!_DI_/I7^A]12_X@WDO_0VS3_P'"?_ "D:_:->)'7@
M+@A^E7/E_P"])G^>!_P[=_;R_P"C3OC;_P"$5J7_ ,12'_@F_P#MY#K^R=\;
MOP\$:F?Y1G/X5_H@44?\0;R;_H;9G_X#A?\ Y2/_ (J->(__ $0/!'_@[/O_
M )X^O]+7_.]_X=P_MX_]&F_'#_PAM6_^-4G_  [B_;P_Z--^./\ X0FK_P#Q
MFO\ 1#HH_P"(-Y-_T-LS_P# <+_\I#_BHUXC?]$#P3_X/SW_ .;_ %_K?_.Z
M/_!.7]N\=?V3/CG^'@'6C_*W-)_P[F_;N_Z-,^.G_A :W_\ (]?Z(U%'_$&\
MF_Z&V9_^ 87_ .5#_P"*C?B+UX X*_\ "C/5_P"[S/\ .W/_  3G_;N'_-IG
MQV_#X?:Z?Y6QI/\ AW3^W;_T:7\=_P#PWFO_ /R)7^B312_X@WD__0WS+_P#
M"_\ RL?_ !4;\1/^B X+_P#"C//_ )M/\[7_ (=U_MV#_FTOX\?^&Z\0G^5G
M3#_P3M_;K'_-I7Q[_#X;^)#_ "LC7^B;11_Q!O)_^AOF7_@&%_\ E8?\5&_$
M3KX?\%_^%.>+_P!W6?YV/_#N_P#;J'_-I7Q\_P##:^)3_*QI#_P3P_;I'_-I
M7Q]_#X9^)S_*P-?Z)]%'_$&\G_Z&^9?^"\+_ /*Q_P#%1OQ#_P"C?\&?^%6>
M?_-A_G7?\.\_VZ/^C2?C_P#^&Q\4_P#RNI#_ ,$]/VZ!_P VD_M ?A\+_%9_
MEIIK_12HH_X@WE'_ $-\R_\ !>%_^5C_ .*CGB#_ -&^X-_\*\[_ /FH_P Z
ML_\ !/;]N<?\VD?M!?A\+/%I_EIAII_X)\?MS#_FTC]H3_PU?B\_RTNO]%:B
ME_Q!O*/^AOF/_@O#?_(>O]+5_P#%1SQ _P"C>\'?^%F=_P#S2?YU!_X)\_MR
MC_FTC]H7\/A3XQ/\M*--_P"'?G[<G_1H_P"T/_X:;QG_ /*BO]%FBC_B#>4?
M]#?,?_!>&_\ D!_\5'./^OA[P?\ ^%N=+_W89_G2G_@G[^W(/^;1_P!HC_PT
MOC4_RT>FG_@G_P#MQCK^R-^T5^'PB\;M_P"@Z,:_T7**/^(-93_T.,Q_\%8;
M_P"1#_BHYQ]U\/.#_P#PNSI?^YV?YT7_  P#^W%_T:-^T7_X:#QS_P#*6D_X
M8"_;A_Z-&_:,_P##/>.S_+1*_P!%ZBC_ (@UE/\ T.,Q_P#!6&_^1'_Q4<X]
M_P"C=\(?^%^<_P#RX_SGO^&!?VX!_P VB_M'_P#AF_'Q_EH5'_# O[<'_1HO
M[1__ (9KQ]_\HJ_T8:*3\&LIZ9QF/SI89_\ MJ'_ ,5'./?^C=\(_P#A?G/_
M ,M]?ZW_ ,YP_L$?MOCK^R)^TC^'P8^(+?RT TG_  P3^V]_T:)^TE_X9;XA
M?_,_7^C)11_Q!K*O^AQF'_@G#?\ R(?\5'>//^C=<(_^'#.?_EGK_6_^<R?V
M"_VW1U_9$_:4]./@I\1&]^WAX_GT[=:;_P ,&_MN?]&A_M+?^&1^(_\ \SE?
MZ-%%'_$&LJ_Z'&8?^"<-_D/_ (J.\==?#KA+_P ..<+_ -O9_G+G]@[]MP=?
MV0_VEOP^"/Q';^7APTP_L(_MMCK^R%^TS^'P-^);?R\-&O\ 1KKD+*^NY/'W
MB73'N)&L+3PAX(OK:U)'E0W>HZU\0;>^N$&,B2YATO3XY"205M(L $$E?\0:
MRO\ Z'.8?^",/_EZ_P!+5_\ %1WCKKX<\)_^'+./_DF?YX7_  PE^VUS_P 8
MA?M-<?\ 5#/B9^G_ !3//X=>U(?V%/VV0,G]D']IO\/@5\3B?R'A@FO]&VBC
M_B#65_\ 0YQ__@C#C_XJ.\<_]&YX4_\ #GG'^?K_ $M?\Y#_ (86_;8'_-H/
M[3O_ (8?XHG^7A:D/["_[; _YM!_:>_#X#?%$_R\+&O]'"BC_B#65_\ 0YQ_
M_@C#C_XJ/<<?]&XX4_\ #IF_]=_Z6O\ G&G]AG]M<?\ -H'[4'X? /XJ'^7A
M0TG_  PW^VM_T:!^U#Z?\D!^*W_S)_KTK_1SHH_X@UEG_0YQ_P#X3X?_ #]?
MZW/^*CW&_P#T;?A6_P#V-<W_ "MZ]?\ @_YQ1_8<_;5'7]D#]J+_ ,,!\5S_
M "\)&D_X8?\ VT_^C0?VHO\ PP'Q8_\ F2K_ $=J*7_$&LL_Z'6/_P#"?#_Y
M^O\ 2U?_ !4>XVZ^&_"W_AVS;_Y%G^<0?V(/VTAU_9"_:A'U^ /Q7'_NITT_
ML1_MGCK^R)^T^/K\ OBL/_=3K_1YHH_X@UEG_0ZQW_A/A_\ ,?\ Q4>XU_Z-
MMPO_ .';-O\ Y _SA/\ AB7]L[_HT;]IW_PP?Q5_^92D/[$_[9@Z_LD?M.#Z
M_ 3XJ#_W5*_T?**/^(-9;_T.L=_X3X?_ .2'_P 5'N-/^C;<+_\ AWS7_P"5
M^O\ 2U_S@?\ ABG]LK_HTG]IK_PPWQ4_^92D/[%?[9 Z_LE_M,CZ_ ?XIC_W
M5:_T?Z*/^(-9;_T.L=_X34/_ )+U_I:G_%1_C/\ Z-KPQ_X>,U_^4^O];_YO
MW_#%O[8W_1IO[3'_ (8CXI?_ #*TG_#%_P"V)_T:=^TM_P"&)^*/_P RU?Z0
M5%+_ (@SEW_0[QO_ (34/_DQ_P#%1_C+KX:<,_\ AYS7_P"4L_S>S^QC^V$.
MO[*/[2@^OP+^* _]U:D/[&?[8 Z_LI?M)CZ_ OXH#_W5J_TA:*/^(,Y=_P!#
MO&_^$U#_ .3'_P 5'^,?^C:<-?\ AZS3_P"9S_-Y/[&O[7PZ_LJ?M)#Z_ WX
MGC_W5Z;_ ,,;_M>#K^RK^T@._P#R0[XG=/7_ )%>O](BBC_B#.7?]#O&_P#A
M-0_^3'_Q4?XP_P"C9\-_^'O-/_F;U_K?_-U_X8Y_:Z_Z-7_:/_\ #'_$W_YF
M*3_ACO\ :Y_Z-9_:-_\ #(?$S_YF*_TBZ*/^(,Y=_P!#O&_^$M#_ .3]?Z6I
M_P 5'^+_ /HV?#?_ (?,S_\ F7U_K?\ S<O^&/OVMAU_9;_:+'_=$?B7_P#,
MQ2']D#]K0=?V7?VBA]?@G\2Q_P"ZS7^D=12_X@SE_P#T.\9_X2T/_E@_^*D'
M%W7PRX<_\/N9_P#S(S_-P/[(/[68Z_LO?M$CZ_!3XE#_ -UFF_\ #(G[6'_1
ML'[0_P#X97XD_P#S-5_I(T4?\09R_P#Z'F,_\)*'_P L'_Q4@XM_Z-EP[_X?
MLS_^8S_-M/[(O[5XZ_LQ?M##Z_!;XDC_ -UJF_\ #)'[5O\ T;)^T)_X9?XC
M_P#S-U_I*44?\09R_P#Z'F,_\)*/_P L'_Q4@XL_Z-CP]_X?\R_^8O7^M_\
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MX@#_ -UZF_\ #+G[3/\ T;K\=?\ PT?Q _\ F?K_ $HZ*7_$&<#_ -#W%_\
MA'1_^7>O]+4_XJ0\3_\ 1KLA_P#$CS#_ .=OK_6_^:V?V7OVF!U_9W^.@^OP
MD\?C_P!U^F_\,P?M*_\ 1O'QR_\ #2^/O_F?K_2FHH_X@S@O^A[BO_"*C_\
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M8/\ Z'V)_P#"&E_\T!_Q4BXC_P"C69)_XD^._P#G3Z_UO_FG_P##-_[1 Z_
M3XT#O_R2WQQT]?\ D!4W_AG']H;_ *(/\9O_  U_C?\ ^4=?Z65%'_$&,'_T
M/L3_ .$-+_YH'_Q4BXB_Z-7DO_B48[_YT'^:9_PSG^T)_P!$(^,O_AL/&_\
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MAWB__H5?$G_@CU/_ .1::?"'BP=?"_B(?71-2'_MM7^GM11_Q!>G_P!%'/\
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MG>%_"&JVRA )1=ZSJWC>SOF>3.7C:'0=/$:$ 1LLK DRG'44?\06C_T4DO\
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M(+2_Z*2/_AH?_P \_7^GH_\ BI12Z^#53_Q8,?\ Z"4?Y?%%?Z@W]BZ/_P!
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M?]"+X._\)C1/_D&C_B"];_HHJ?\ X:Y?_-X?\5)LO_Z-!C/_ !-Z'_T*^O\
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M:1_F445_IK?\*D^%/_1,OA[Z_P#(E^&^OK_R#:0_"'X3GK\,/AV?KX*\-?\
MRLH_X@OB/^B@H_\ AMG_ /-H_P#BI+E/_1I,Q_\ $RPW_P!#9_F545_IIGX0
M?"4]?A=\.C]?!/AH_P#N,I#\'?A&>OPL^')^O@CPR?\ W&4?\08Q'_104?\
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M. _\*\/_ /+/-?>>Q_J/QK_T1_%/_B/YM_\ ,GFOO/J.BOES_AN+]BK_ */
M_9<_\2 ^$_\ \UM'_#<7[%7_ $>!^RY_XD!\)_\ YK:/[4RS_H8X#_PKP_\
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M\4_^(_FW_P R>:^\^HZ*^7/^&XOV*O\ H\#]ES_Q(#X3_P#S6T?\-Q?L5?\
M1X'[+G_B0'PG_P#FMH_M3+/^AC@/_"O#_P#RSS7WA_J/QK_T1_%/_B/YM_\
M,GFOO/J.BOES_AN+]BK_ */ _9<_\2 ^$_\ \UM'_#<7[%7_ $>!^RY_XD!\
M)_\ YK:/[4RS_H8X#_PKP_\ \L\U]X?ZC\:_]$?Q3_XC^;?_ #)YK[SZCHKY
M<_X;B_8J_P"CP/V7/_$@/A/_ /-;1_PW%^Q5_P!'@?LN?^) ?"?_ .:VC^U,
ML_Z&. _\*\/_ /+/-?>'^H_&O_1'\4_^(_FW_P R>:^\^HZ*^7/^&XOV*O\
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MO/J.BOES_AN+]BK_ */ _9<_\2 ^$_\ \UM'_#<7[%7_ $>!^RY_XD!\)_\
MYK:/[4RS_H8X#_PKP_\ \L\U]X?ZC\:_]$?Q3_XC^;?_ #)YK[SZCHKY<_X;
MB_8J_P"CP/V7/_$@/A/_ /-;1_PW%^Q5_P!'@?LN?^) ?"?_ .:VC^U,L_Z&
M. _\*\/_ /+/-?>'^H_&O_1'\4_^(_FW_P R>:^\^HZ*^7/^&XOV*O\ H\#]
MES_Q(#X3_P#S6T?\-Q?L5?\ 1X'[+G_B0'PG_P#FMH_M3+/^AC@/_"O#_P#R
MSS7WA_J/QK_T1_%/_B/YM_\ ,GFOO/J.BOES_AN+]BK_ */ _9<_\2 ^$_\
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MYA1VD@CO+5Y55;B$OV?_  W%^Q5_T>!^RY_XD!\)_P#YK:/[4RS_ *&. _\
M"O#_ /RSS7WB_P!1^-?^B/XH_P#$?S;_ .9/-'U'17RY_P -Q?L5?]'@?LN?
M^) ?"?\ ^:VC_AN+]BK_ */ _9<_\2 ^$_\ \UM']J99_P!#' ?^%>'_ /EG
MFOO'_J/QK_T1_%/_ (C^;?\ S)YK[SZCHKY<_P"&XOV*O^CP/V7/_$@/A/\
M_-;1_P -Q?L5?]'@?LN?^) ?"?\ ^:VC^U,L_P"AC@/_  KP_P#\L\U]X?ZC
M\:_]$?Q3_P"(_FW_ ,R>:^\^HZ*^7/\ AN+]BK_H\#]ES_Q(#X3_ /S6T?\
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MS7WA_J/QK_T1_%/_ (C^;?\ S)YK[SZCHKY<_P"&XOV*O^CP/V7/_$@/A/\
M_-;1_P -Q?L5?]'@?LN?^) ?"?\ ^:VC^U,L_P"AC@/_  KP_P#\L\U]X?ZC
M\:_]$?Q3_P"(_FW_ ,R>:^\^HZ*^7/\ AN+]BK_H\#]ES_Q(#X3_ /S6T?\
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MS7WA_J/QK_T1_%/_ (C^;?\ S)YK[SZCHKY<_P"&XOV*O^CP/V7/_$@/A/\
M_-;1_P -Q?L5?]'@?LN?^) ?"?\ ^:VC^U,L_P"AC@/_  KP_P#\L\U]X?ZC
M\:_]$?Q3_P"(_FW_ ,R>:^\^HZ*^7/\ AN+]BK_H\#]ES_Q(#X3_ /S6T?\
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M#_\ RSS7WA_J/QK_ -$?Q3_XC^;?_,GFOO/J.BOES_AN+]BK_H\#]ES_ ,2
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M7/\ Q(#X3_\ S6T?\-Q?L5?]'@?LN?\ B0'PG_\ FMH_M3+/^AC@/_"O#_\
MRSS7WA_J/QK_ -$?Q3_XC^;?_,GFOO/J.BOES_AN+]BK_H\#]ES_ ,2 ^$__
M ,UM'_#<7[%7_1X'[+G_ (D!\)__ )K:/[4RS_H8X#_PKP__ ,L\U]X?ZC\:
M_P#1'\4_^(_FW_S)YK[SZCHKY<_X;B_8J_Z/ _9<_P#$@/A/_P#-;1_PW%^Q
M5_T>!^RY_P") ?"?_P":VC^U,L_Z&. _\*\/_P#+/-?>'^H_&O\ T1_%/_B/
MYM_\R>:^\^HZ*^7/^&XOV*O^CP/V7/\ Q(#X3_\ S6T?\-Q?L5?]'@?LN?\
MB0'PG_\ FMH_M3+/^AC@/_"O#_\ RSS7WA_J/QK_ -$?Q3_XC^;?_,GFOO/J
M.BOES_AN+]BK_H\#]ES_ ,2 ^$__ ,UM'_#<7[%7_1X'[+G_ (D!\)__ )K:
M/[4RS_H8X#_PKP__ ,L\U]X?ZC\:_P#1'\4_^(_FW_S)YK[SZCHKY<_X;B_8
MJ_Z/ _9<_P#$@/A/_P#-;1_PW%^Q5_T>!^RY_P") ?"?_P":VC^U,L_Z&. _
M\*\/_P#+/-?>'^H_&O\ T1_%/_B/YM_\R>:^\^HZ*^7/^&XOV*O^CP/V7/\
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M\^HZ*^7/^&XOV*O^CP/V7/\ Q(#X3_\ S6T?\-Q?L5?]'@?LN?\ B0'PG_\
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M8J_Z/ _9<_\ $@/A/_\ -;1_PW%^Q5_T>!^RY_XD!\)__FMH_M3+/^AC@/\
MPKP__P L\U]X_P#4?C7_ *(_BG_Q'\V_^9/-?>?4=%?+G_#<7[%7_1X'[+G_
M (D!\)__ )K:/^&XOV*O^CP/V7/_ !(#X3__ #6T?VIEG_0QP'_A7A__ )9Y
MK[P_U'XU_P"B/XI_\1_-O_F3S7WGU'17RY_PW%^Q5_T>!^RY_P") ?"?_P":
MVC_AN+]BK_H\#]ES_P 2 ^$__P UM']J99_T,<!_X5X?_P"6>:^\/]1^-?\
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M_8B_#O\ ]2#XHUW5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU \<]M=6T\<<UO<0R)+#*B21NKJ&']B7_!)C_@K+9?M V6B?LY?M&:W;:?\
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ME:-8_'/]GS6Y/%_C*32[W5K[3]<^%WAKP_-)>FUUG4K/Z=_X/=_^33/V)O\
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M?"3X<^ OC!\3-0T^]:6^ET#Q#I.IPKH=E)#JFI=Y_P &=W[46L:=\'_VL?\
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ME,:_RY_\.1/A+_Q$+?\ #F7_ (79\1?^%6?]%D_L/PU_PG__ "9#_P -5?\
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M;WP5H3:IXIE\0Z)K-E>:9J.BV>D7.I6UY:W$+VP>&0* ?SD?"/XZ_P#!0/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MERPJT*L*N%Q5*ABZ%>A3****]<^ "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ#\1:=-K&D6FH7.H6_\ '3^Q+_P7PC^"_P#P;9?M%?!J^\9W$W[7?P)U6/\
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M_P .>'_L&H1Q:>GVF69&H S?^#U;_E%E\ _^S_\ X6?^LZ_M55Z3_P $Z?\
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M)II'D=F/YK?\'2__  3>_;(_X*/?LW_LQ>#?V,_A-!\8?%_PU^-WB'Q-XO\
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MQ[^T[#X5\=^ _"GPJ_9#^$7PV^(GP-UCP;I_A73_ !AK/PZN/$@O-!'Q%O\
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M(OQE\:^;X/\ $OBS2/&_B'_BB/$FEW&D?\(AX<\0?;]0DET]_LTL+M7[ ?\
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MM=1BGMJ^5>A]%AJ+P^'I47/VCIP47-JW,UULV[>6KT"BBBN4W"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .%T_P#Y
M*9XN_P"Q%^'?_J0?%&NZKA=/_P"2F>+O^Q%^'?\ ZD'Q1KNJ "BBB@ HHHH
M**** "BBB@ HHHH **** "O(OC];_&^[^"'Q8LOV:KGX?V'[05_\/_%.G_!G
M5?BK>ZO8?#?1/B1?Z1=6?A+Q!XVDT#PSXPUBZ\.^']8FM=:U+2M/\.W\^MP6
M#:,'L%OVU&T]=HH _%7_ ((C?\$C=)_X)4?L[>(-*\>^)= ^+?[7?QS\0R>/
M/VF_CII8UN_/B?Q!)-=7.E^#="\0^*HX/%&M^$/"$VI:M<V^N:YI^BZMXO\
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M_P"'WB/Q+XC^'VJ_#>^L?B1I7B/6-#BT/6/$?A3Q/<W=I;>&/%?@^_35DO\
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MYUL3E&"K8B&&S&E7J/%8+&TL-.<J6%QU/#U84\3&M[)0KJ<_ZF/A1X&^!O\
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M_LLZA)X'_81_9 \,:MX;LWECO_B%/;6?PBMM?N8W\E;VPL8_"NM^/O%%M>6
MC1=:\<WGAC7H/+%E-H<MK%#*?A\LR7+\1]=GF^?X/):6#KK#.+H5\?C*]6\U
M)X?!8=PJ3HP<+3K2E"$7**?6W]-<9^)7%F5+ANAX?^%7$/B/C>),JEG5.M#-
M,MX5X>RO!<N&G2IYOQ'FL<1A,-F&(AB?:8?+J="OB*T*-65-2LK_ ,P=%?V8
M?LB_MQ_LZ?\ !76?Q_\ LZ_M!_LP^&-,\46'A.]\8:5;:A<6WCC3[[18X;/P
MCKGB#PYXME\/:!XB^'_C?1)/$UM#I&HZ3,FJ0:?J#S:7K\%S9S12?RQ_MA_
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M3HP<JT8JBFM?SW!_2<XEXDX@X^X/X"\%\]XSXJX"XTXFX;Q^'P_%&69-D/\
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M\0:0MY?1R7FD^-]!M'MEG!-NGV 2QJS*\T@"[?SG_P"" G_)^%U_V0[XA_\
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M>]\?$DOP_P!2L_&MKHOA>?XB?#37#:^(;?Q!X"U=-.FTB_&JBWBTO4O^$/\
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M+"UU70?A*=4U"Q\,_#KPSJS7=CH/B[XD7>BVEYJVH7OB#6(%MO"GPVT)]/\
M$/B2RAOM4O=;\*Z<V@7?B( _HHHK^&WPYXD_X/3/VH["7XH^'9/@K^QQX>UJ
M_O;[0_AKXC\$?LS>'[^+3KR0)':Q>%_BGX5^.WQ0\/V&C2VDT%G:_$/6-+\5
M7$=V;NZ_M>RFL+V/RWP1_P '%/\ P5S_ ."8'QX^'OP5_P""YO[*"W'@#QOI
MEL(OB7X*\+>#?#WQ&>QT,Q:)XB\<>$M8^&GB34?@!\6VM-1>QU#QAX/\+R^%
M+C3&UBTO-.OM&TW4= T34 #^^2BN)^&OQ(\"?&+X?>"OBM\+_%6C>.?AS\1O
M#&B^,_ _C'P]=K>Z+XE\+^(K"#5-&UG3;E0IDM;ZQN89T$B1S1%C%/%%,DD:
M]M0 4444 %%%% 'B'Q0_::_9N^"'BKP!X%^-'[07P0^$/C;XL:B-(^%G@[XH
M?%?P'X \5?$O5CJ.F:.-+\ >'O%>OZ3J_C+43J^MZ-I8LO#MGJ5R=1U?3+$1
M?:;^TBE]OK^!;_@Z^_Y2F_\ !';_ +">@_\ K17@6O[Z: "BBB@ HHHH ***
M* "BBB@ HHK_ #K_ -F+_@H!_P '*?\ P4M_; _;5^"G[%W[<GP=\$:?^SI\
M2?&\J^&?B9\'?V<M%TS2O DOQ0\5^$_#&D^'=9D_9>^(NMZS_8<&D6VGSR^)
MM5EUB>W-K=7.I:O=O?7* '^BA17\1?Q$\5_\'F7[&_AZ;XEZ]<?L[_MX^&_#
M_P#Q/_$/A7X=_#KX2^*?$,>F6=S8R2Z/#X ^&W@C]G'XK>,?MB64EI_9?PPL
M/$OBV2VUN^ELWAFM;6\T7]7/^"*/_!P'\&O^"KHUKX+>.?!#?LZ_MH?#W0&U
M7Q?\'[[4Y]1\,^/=.T5X-+\4^+?A3JNI6MAJ\2Z3J[I/XC^&_B6V?Q5X,L]2
MM([;6O'FG:7KOB>S /Z&**** "BBB@ HHHH **** "BBB@#B/B/\3/AO\'/!
M.O\ Q+^+OQ!\$?"OX<>%+:"\\4_$#XC^*]!\#^"?#5G=7MMIMM=:_P"*_$]_
MI>A:-;7&HWMG803ZC?VT4M[=VUK&[3SQ1O8\ _$'P%\5?!OA[XB_"_QOX0^)
M'P^\7:=%K'A/QUX!\2Z-XP\&^)])F9TAU3P]XG\/7NHZ)K6G2O'(L5]IM]<V
MTC(ZI*2K ?QP_P#!V3^T#X\^-?C#]A'_ ((Q_ X3_P#"Q_VP_BW\/OB#X]GA
MNS"G_"-7WCF\^%?P:\/ZE:"[AMKWPKJ_Q$E\7>._$]WJ[Z99Z#<_"#PSJ$6H
MO;/K$NF?U\_ WX,?#[]G3X.?#'X$?"C0[;PY\./A'X(\.^ ?!VD6UM86OV?1
M/#6FV^FVL]VFFV>GV4^JZAY#:CK-]%96[:EJ]W>ZC-&)[J4D ]4HK^0O_@U6
M_P""IW[<_P#P4RO/V_KG]L_XSVWQ7A^#]S^S'/\ "[3[/X:_"GX>V?@R+XER
M_M&2>+K.U?X;^"/"=_K=M?IX&\)P0/XMOO$-Y8Q:.AL[J&:_U6:__KTH **_
MDC_X**?\%5_VW/@1_P '#W_!/_\ 8*^%7Q/T;PO^RW\6[#X +\4OAX?AU\/]
M;N_',WQ3^)/Q#\,^(KN_\:>(O#FK>.-#GM-*T;2H]'3P9XB\,VMM-8I->6U^
M\]Y]I_H _P""BW[=/PR_X)N_L>_%_P#:_P#BMI>H^)=!^&6G:1!HO@C0]0TW
M3O$'C_QMXLU[3?"G@WP?HUSJD@B@.HZ[J]I<Z[J4%KJMSX=\)6/B'Q2NBZM#
MH<UA. ?;E%?PJ_L^_M6_\'7?_!63P+)^U)^R5KW[,7[%W[.7C#6=3'PKM_$?
MA'X=R1>)=$\.W]YH-PVBS?%7X<?'SQSXAMGOHYH=6\7WVD>%=!US7M$U"7PE
M::/I0?1J_4S_ ()._'+_ (.#;+]L'6?V7?\ @JS\&/ .L_!?3?@KXS\<Z-^U
M3X.\"^'8+7Q+XT\->(?ASH^B:!%X\^%'B'2?A19W'B"R\::M?CP;JWPR\.>-
MM43P]JFIZ)8VVC>%O%#P@'] /Q7_ &@?@+\!O^$0_P"%Y?&[X1?!G_A87B*#
MP?X!_P"%K_$GP9\._P#A./%MSY?V;POX0_X2_6M'_P"$E\17'G1>1HFB_;=3
ME\V/R[5MZY]=K^<?_@Z=_8[_ .&J_P#@DC\7?%FAZ0-1^(/[)>NZ'^TWX7DM
MM+-WJ1\,^$8K[P_\7K-M0@_TW3]"L_A5XF\5>.-70)<Z==7?@719=2MX18VV
MK:3]?_\ !"?]M_5?^"@'_!+[]F;XZ>,O$1\3?%O2/#E[\(?C?J<ZRC5;WXH_
M"B^D\*:GX@U]VS;2Z[X_\/VOAKXFZE)I["P,OC4+!;:8RR:38 'Z\T444 %%
M%?P^_P#!8K_@I-_P6"\/_P#!;7X<_P#!-K_@GE^U!X.^".F_%+X;?"R+P9H?
MC#X5?!3Q'X:F\=^)M)\8>(=5U;Q%XP\=_!?XK>,++^TH=*@TR"+3U;1[7[+8
M%=-M'FU/4IP#^X*BOXBOB'X4_P"#TS]GWPYJ'Q*7XZ_L\?M66/A^PO=4U3X9
M?#SP/^S->>([C3M($.J7LVGZ'+\!?@;XA\37\]E:75E9>'?!WB/5?%&LF>:P
MT#0KSQ!<:,M?JK_P02_X+I67_!6KP9\1/AK\8O .D_!_]LOX%P_VK\3?!/A3
M3]?L?AYXK\&WNN2Z/9>,O MGXFU?Q#XE\.3:%JCVGACQKX.\3ZYJVH:5JL^E
M:KI^M:E::[<:9X: /Z(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3P]\/_!=CH6B^'-0L]8T+S-2FU5[6:6PL-$OO"'AV6VTV\G>UN-'_*3]D/\
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M9M@,FP,L75SK#5*6&CB\RQ&&P\L15IT:TZ=%5'4G"E4E&+C"37\R%?V5?\$
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M&&HVGB2*YNCJ$&J:7\"?!MQ%H=[H]Q8W>CW6FW6PZ*\<>FZ]YNN/'<3^O?\
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MC^&_Q+F$,;&V\+K)X@M=2^&/Q7:VNIWMA:Z8->\8P:3I[C2[S0=*_>G\6O\
M@H?_ ,$J?BG^PG!I_CZU\26?Q2^"&OZZ^@V/C2RT]]'U[PMJURD]WI&C^-]
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M5R_L]^ (/BY\'-8UK5-6\$S^'?$6C:?KWA70;RZBGL/"GB71_&7B.WU:XO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^??_  4 _P"#B;]J+_@GG_P7!_:_^!/C+6=9^*_[*7PE^$?@72O@E^RWX3\
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M^&?&7Q+T#6/BK\8?BC/K=E\%O@3X9U2'P_J7C67PW'82>(M>\2>+[O3-:LO
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M^%_Q1^)'A;XB^%OB1\4?%WQ8M;ZQNOA/X1\=ZKH^NZ/JOCO6M"U/3-=T72;
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M\26$UWXUGC^'GC'3 #_18\?^"/#OQ-\">-?AOXOLAJ7A/X@^$O$G@CQ1IYV
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MY\0/$^B>#/!GAC3%\%_$"!M1\0^*/$=]INAZ+8+//#";S4KZVMQ+-%&9-\B
M_P"@U7^=9_P6"_9[^%'[5O\ P=:_LU_LZ_''P[<>+/A-\6_ _P "O"?CCP_:
MZWKGANZU'2+CP9X]N@EMKGAO4-*UK3KB"\M;6ZAGL;^%C) L<XFMGF@E /ZY
M_C__ ,%V?^"2'[.WPXUWXD>(OV]/V;?B/#H^GWEU9>"O@!\6/ _Q[^(_B;4(
M$066@Z%X.^%FO>);^/4-7O)K:PL]0\0/H/A>Q>9]0\0>(=%T.PU75K#^8_\
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M$4^LVFJ7&B:-< ']OU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!6L/$G@SQ#I'BC0+U7ABN%:TUC0[R^TZY#03P3J8;EP89HI!E)$9NJK\7O\
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MPH4L/FF8T*>%56.&IT<=B:4,/&NVZ\:$(58QI*LVW55-151MN?-<^/S#P]X
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MP.(IU,+7PTZ?N2H5:4J4H>ZX..A^HW_#Z+_@I;_T<G_YAWX!?_.LH_X?1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>:=6O5G5Q6*JU\77KUZA1117KGP 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'X0_\ !S+X3\5>./\ @B+^VOX6\%>&O$'C#Q-JG_#-_P#9GASP
MMHVH^(-=U'[%^UO\!=1O?L.D:3;7>H7?V33[2[OKK[/;R?9[.UN+J79!#(Z_
M=_\ P2STG5= _P""8W_!.;0M=TS4-%UO1?V$/V0])UC1]6LKG3M5TG5=._9^
M^'MGJ&F:GI]Y'#=V&H6%W#-:WME=0Q7-K<Q203QQRQLH^[Z* "BBB@ HHHH
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M"?/B?2?A[^QIX ^-/@OQ/X$;XY^//AOJ"75C\3=%\$^/X=-U63X<:MXW%_\
M&./Q?8>%=(L?$UF/A9X&O+G5]0\+^-HK#^ON@ K^"7]O32]3D_X/)/V&/+TZ
M_?[7X=^!NJ6FRTN&^U:9IW@;XI_VAJ-OMC/G6%C_ &7J?VR[CW6]K_9U]Y\B
M?9+CR_[VJ* "O\[W_@FEIGB__@B+_P ','QF_8*OAKZ_LW_MEWFI^&OAKI6B
M6NNZCX?O_"/C:XU#XI_LN>,IM,L[71XM1UOX72GQ1\"?$OBD:+-H/A>]UCXL
MW-FL/AY)-:M_]$*B@#^(C_@YF_8X_:X\'_\ !07]@'_@L-^S_P#!7Q#^TMX!
M_92;X#:3X_\ A5X!TO6]3\6:'K?[/W[0OC#]H+PYJWB"'P]IOB#7+?P%\0D\
M6W7A*]\6:5X;U.U\"ZAH2SZ_G_A(]"MYO0K_ /X.U3^U-X(;X6?\$R?^"=G[
M6?QM_;-\66$VCZ)X;\4^%O#6L?"_X>:QJEM=P:;XSUB_^&?BOQAXD\5^'?#]
MQ&=6U6U\0Z/\)M#?3+#4+C5O&GA_3K.[OXO[-:* /X0O^#1+P?\ %OP;^VY_
MP6C\-_&[2;73_B[X*\?_  _\'_&>'1'M;[P]I'Q;TWXM_M'V'C32;#4]*FN]
M'FM?^$GT;Q(ND/8WL]K?6.GS7&GS7%K"THPO^#K;2]3N_P#@J;_P1H^R:=?W
M7]J>(M$TO3/L]I<3?VCJ<?[17PY\S3K'RXV^UWZ?VCI^^TM_,N%^W6>Z,?:H
M-_\ >U10 5_(C_P<>_\ !*[]KCXL_'+]E/\ X*J_\$X?#^K>,?VL_P!E"Y\,
M:;XH^'^B?\(_=ZSK7AKX:>+]3^*7PM\=^$_"^LFQMO&NK>%?%&I^*?#OCCP5
M)-XBU;X@^%_$7A71])\/36/AG6+/5?Z[J* /XC/AS_P><_#[0/#VF^$OVIO^
M">G[1/@+]H2.QL=-N_"7PYU/1-2\/>)O%"^=I%S<Z;IGQ%3P/XW\)V.L>);.
MXM['PY)IGCK4-#WS:/)K_B6_TQ[O4/U[_P""4_\ P4I_X*,_\%%/VC/BWXK^
M*O\ P3XU+]C/_@GSX>^&5XOPD\5?&#3/&^G?'SXB_&!O%_A6+0+BVN_$UQX-
MT/6OA]JOP_E\9ZMK47A+X5ZII/A7Q18Z3H"_%KQ%.+F"[_?BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK^/74_\ @Y6^
M.*ZEJ"Z-^SK\*9='%]=C2I=3UGQ?!J4FFBXD%B^H06NJ7%K#?/:^4UW%;7$]
MO'<&1(9I8PKM1_XB6/V@_P#HW'X-_P#@^\;?_)U?0+AC.&K^PIZ]Z]*_S]X\
MC^W,N_Y^S_\ !53_ .1/[&*_*7_@MY_RB_\ VG/^Z+_^M"_">OQ!_P"(EC]H
M/_HW'X-_^#[QM_\ )U?-?[7W_!<+XQ?M@?L[?$/]G3Q5\%?AIX2T'XB?\(E]
MO\0^']6\4W6KZ?\ \(EXY\,^.;7[)!J-W+9/]KO?#-O8W'G(VVUN9GCQ*L9'
M5@>'<UH8W!UJE&FJ='%8>K4:K4FU"G5A.324KMJ*;LM7LC#%9S@*N&Q%*%2;
MG4H5J<$Z4TG*=.48IMJRNVM7HC]I?^#;S_DQWXJ?]G6^./\ U4/P,K^@>OY^
M/^#;S_DQWXJ?]G6^./\ U4/P,K^@>O*SS_D;8_\ Z_O_ -)B=^5_\B_"?]>E
M^;"BBBO*.\**** "BBB@ K_-9_:<_P"3COCS_P!E@^(W_J6ZM7^E-7^:S^TY
M_P G'?'G_LL'Q&_]2W5J_&O&7_D5Y-_V'U__ %'/]&/V<O\ R77B+_V2>7?^
MKB!X;1117\^'^N 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/PO^*$VM7.M3?%#3X[6UCT_2XK2+2[R::\E>6" _S\?\&,?_ #E%_P"[)O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY9_T+L!_X28?_P"5^2^X/]>.-?\ HL.*?_$@S;_YK\E]Q\N?\,._L5?]&?\
M[+G_ (C_ /"?_P"9*C_AAW]BK_HS_P#9<_\ $?\ X3__ #)5]1T4?V7EG_0N
MP'_A)A__ )7Y+[@_UXXU_P"BPXI_\2#-O_FOR7W'RY_PP[^Q5_T9_P#LN?\
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M)A__ )7Y+[@_UXXU_P"BPXI_\2#-O_FOR7W'RY_PP[^Q5_T9_P#LN?\ B/\
M\)__ )DJ/^&'?V*O^C/_ -ES_P 1_P#A/_\ ,E7U'11_9>6?]"[ ?^$F'_\
ME?DON#_7CC7_ *+#BG_Q(,V_^:_)?<?+G_##O[%7_1G_ .RY_P"(_P#PG_\
MF2H_X8=_8J_Z,_\ V7/_ !'_ .$__P R5?4=%']EY9_T+L!_X28?_P"5^2^X
M/]>.-?\ HL.*?_$@S;_YK\E]Q\N?\,._L5?]&?\ [+G_ (C_ /"?_P"9*C_A
MAW]BK_HS_P#9<_\ $?\ X3__ #)5]1T4?V7EG_0NP'_A)A__ )7Y+[@_UXXU
M_P"BPXI_\2#-O_FOR7W'RY_PP[^Q5_T9_P#LN?\ B/\ \)__ )DJ/^&'?V*O
M^C/_ -ES_P 1_P#A/_\ ,E7U'11_9>6?]"[ ?^$F'_\ E?DON#_7CC7_ *+#
MBG_Q(,V_^:_)?<?+G_##O[%7_1G_ .RY_P"(_P#PG_\ F2H_X8=_8J_Z,_\
MV7/_ !'_ .$__P R5?4=%']EY9_T+L!_X28?_P"5^2^X/]>.-?\ HL.*?_$@
MS;_YK\E]Q\N?\,._L5?]&?\ [+G_ (C_ /"?_P"9*C_AAW]BK_HS_P#9<_\
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M/_PG_P#F2H_X8=_8J_Z,_P#V7/\ Q'_X3_\ S)5]1T4?V7EG_0NP'_A)A_\
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M\E]Q\N?\,._L5?\ 1G_[+G_B/_PG_P#F2H_X8=_8J_Z,_P#V7/\ Q'_X3_\
MS)5]1T4?V7EG_0NP'_A)A_\ Y7Y+[@_UXXU_Z+#BG_Q(,V_^:_)?<?+G_##O
M[%7_ $9_^RY_XC_\)_\ YDJ/^&'?V*O^C/\ ]ES_ ,1_^$__ ,R5?4=%']EY
M9_T+L!_X28?_ .5^2^X/]>.-?^BPXI_\2#-O_FOR7W'RY_PP[^Q5_P!&?_LN
M?^(__"?_ .9*C_AAW]BK_HS_ /9<_P#$?_A/_P#,E7U'11_9>6?]"[ ?^$F'
M_P#E?DON#_7CC7_HL.*?_$@S;_YK\E]Q\N?\,._L5?\ 1G_[+G_B/_PG_P#F
M2H_X8=_8J_Z,_P#V7/\ Q'_X3_\ S)5]1T4?V7EG_0NP'_A)A_\ Y7Y+[@_U
MXXU_Z+#BG_Q(,V_^:_)?<?+G_##O[%7_ $9_^RY_XC_\)_\ YDJ/^&'?V*O^
MC/\ ]ES_ ,1_^$__ ,R5?4=%']EY9_T+L!_X28?_ .5^2^X/]>.-?^BPXI_\
M2#-O_FOR7W'RY_PP[^Q5_P!&?_LN?^(__"?_ .9*C_AAW]BK_HS_ /9<_P#$
M?_A/_P#,E7U'11_9>6?]"[ ?^$F'_P#E?DON#_7CC7_HL.*?_$@S;_YK\E]Q
M\N?\,._L5?\ 1G_[+G_B/_PG_P#F2H_X8=_8J_Z,_P#V7/\ Q'_X3_\ S)5]
M1T4?V7EG_0NP'_A)A_\ Y7Y+[@_UXXU_Z+#BG_Q(,V_^:_)?<?+G_##O[%7_
M $9_^RY_XC_\)_\ YDJ/^&'?V*O^C/\ ]ES_ ,1_^$__ ,R5?4=%']EY9_T+
ML!_X28?_ .5^2^X/]>.-?^BPXI_\2#-O_FOR7W'RY_PP[^Q5_P!&?_LN?^(_
M_"?_ .9*C_AAW]BK_HS_ /9<_P#$?_A/_P#,E7U'11_9>6?]"[ ?^$F'_P#E
M?DON#_7CC7_HL.*?_$@S;_YK\E]Q\N?\,._L5?\ 1G_[+G_B/_PG_P#F2H_X
M8=_8J_Z,_P#V7/\ Q'_X3_\ S)5]1T4?V7EG_0NP'_A)A_\ Y7Y+[@_UXXU_
MZ+#BG_Q(,V_^:_)?<?+G_##O[%7_ $9_^RY_XC_\)_\ YDJ/^&'?V*O^C/\
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M\U^2^X\6_P"&'?V*O^C/_P!ES_Q'_P"$_P#\R5'_  P[^Q5_T9_^RY_XC_\
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MY_XC_P#"?_YDJ/\ AAW]BK_HS_\ 9<_\1_\ A/\ _,E7U'11_9>6?]"[ ?\
MA)A__E?DON#_ %XXU_Z+#BG_ ,2#-O\ YK\E]Q\N?\,._L5?]&?_ ++G_B/_
M ,)__F2H_P"&'?V*O^C/_P!ES_Q'_P"$_P#\R5?4=%']EY9_T+L!_P"$F'_^
M5^2^X/\ 7CC7_HL.*?\ Q(,V_P#FOR7W'RY_PP[^Q5_T9_\ LN?^(_\ PG_^
M9*C_ (8=_8J_Z,__ &7/_$?_ (3_ /S)5]1T4?V7EG_0NP'_ (28?_Y7Y+[@
M_P!>.-?^BPXI_P#$@S;_ .:_)?<?+G_##O[%7_1G_P"RY_XC_P#"?_YDJ/\
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M1_\ A/\ _,E7U'11_9>6?]"[ ?\ A)A__E?DON#_ %XXU_Z+#BG_ ,2#-O\
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MT+L!_P"$F'_^5^2^X/\ 7CC7_HL.*?\ Q(,V_P#FOR7W'RY_PP[^Q5_T9_\
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M_P!ES_Q'_P"$_P#\R5?4=%']EY9_T+L!_P"$F'_^5^2^X/\ 7CC7_HL.*?\
MQ(,V_P#FOR7W'RY_PP[^Q5_T9_\ LN?^(_\ PG_^9*C_ (8=_8J_Z,__ &7/
M_$?_ (3_ /S)5]1T4?V7EG_0NP'_ (28?_Y7Y+[@_P!>.-?^BPXI_P#$@S;_
M .:_)?<?+G_##O[%7_1G_P"RY_XC_P#"?_YDJ/\ AAW]BK_HS_\ 9<_\1_\
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M_P UGBW_  P[^Q5_T9_^RY_XC_\ "?\ ^9*C_AAW]BK_ *,__9<_\1_^$_\
M\R5?4=%']EY9_P!"[ ?^$F'_ /E?DON'_KQQK_T6'%/_ (D&;?\ S7Y+[CY<
M_P"&'?V*O^C/_P!ES_Q'_P"$_P#\R5'_  P[^Q5_T9_^RY_XC_\ "?\ ^9*O
MJ.BC^R\L_P"A=@/_  DP_P#\K\E]P?Z\<:_]%AQ3_P")!FW_ ,U^2^X^7/\
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MS_\ 9<_\1_\ A/\ _,E1_P ,._L5?]&?_LN?^(__  G_ /F2KZCHH_LO+/\
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MK\E]P?Z\<:_]%AQ3_P")!FW_ ,U^2^X^7/\ AAW]BK_HS_\ 9<_\1_\ A/\
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M\+ZM#A@AO-%URTO;&2:!F,MI<^2+FSG"7%K-#.B2+_GB?\$1?VO? 7_!OO\
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MC3PW/;WFFZMH^LZ=>:+XIU>W>PU2""]>QU>VU+2[$ ^]:_D"_P"#U;_E%E\
M_P#L_P#^%G_K.O[55?U^U_(%_P 'JW_*++X!_P#9_P#\+/\ UG7]JJ@#X=_8
M^^-O_!W)/^Q9^REX*_9D_8^_9BL_V?5_9H^ ?A[X _%[4/$W[.S>+7^"UO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJNF7-G>S:II%[J$$VHZ;-9W.E-?SZ;<:39:4 ?T145_,!_P4K_X*P?&KP_\
M&?Q;\!_V;O$?_"N/#_PUU._\)^-O&-G8^'=7\4>*/%^G7$]KKMCIFI72ZY;>
M'M#T2YC33XAIL6F^*?[7L]2&I7MI$1I,'2_\$I?^"F_QI^(?QITO]G/]H3Q3
M=?$2S\>VVK_\*]\8:CI]DGB70O$FE65_X@FT35;[2K&U?6-#UC3[74_L]YJR
MW5_I%_;Z?90WB:-((+  _I:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?C;_ #1[I17A?_"](>_PG^-P]<^ &X^N-4-'_"](!_S2CXV_3_A 'S_Z<^]
M<R[_ -:?=NCW2BO"O^%ZV_\ T2CXV>__ !0+<?7_ (FGX\9I?^%ZVW_1*_C6
M/^Y!DY'K_P A+I0%UW_K3_-'NE%>%?\ "];;_HE?QJ/T\ O_ %U,4O\ PO6U
M_P"B6?&GV_XH&3GZ?\3*@+KOV_&W^:/=**\+_P"%[6G_ $2WXT'_ +D*3^NI
M"C_A>UG_ -$O^,X],^ I>?RU$T!==_/\O\T>Z45X7_PO:R_Z)A\9O_""EX]O
M^0A1_P +VL?^B8_&4?\ <A3?3'&H&@+KOO\ \#_-'NE%>%_\+VL?^B9?&4>N
M? 4W'U_XF%'_  O>P_Z)G\9/K_P@<V/I_P A#//3IWH"Z[[_ / _S1[I17A?
M_"]]/_Z)I\8Q['P'/T]?^/\ Z4?\+WT[_HFOQB'_ '(<_P"?_'_0%UWW_P"!
M_FCW2BO"_P#A>^G?]$W^,.?3_A Y\_\ I=1_POC3?^B<?&#_ ,(.X_\ DZ@.
M9;7_ *=O\_ZLSW2BO"_^%\:9_P!$X^,'_A"7'_R=_G-'_"^-+_Z)U\7Q_P!R
M)<]?3_C]ZT!==U_5O\U;N>Z45X7_ ,+YTOO\._B\/8^!+C\O^/VC_A?.E?\
M1//B[[_\4)<\?7_3* NN_G^7^:/=**\+_P"%\Z3W^'OQ='L? ESG_P!+*/\
MA?.D=_A_\6Q]? MUQ_Y-T FGLU_7_#_?H>Z45X7_ ,+YT?\ Z)_\6_\ PA;K
MIZ_\??2C_A?6C?\ 0@?%KW_XH6ZX'J?]+Z?X&@%)/9_UI_F>Z45X7_POK1O^
MA!^+/M_Q0MWS]/\ 2J/^%]:+_P!"%\6/_"&N_P#Y*H#F7?\ K3_-'NE%>%_\
M+ZT3_H1/BOST_P"*&O.?I_I-'_"^]$_Z$7XK#Z^!KSKZ?\?/7].#S0',N_\
M6G^:/=**\+_X7WH?_0C?%4>Y\#7G7TXN>O\ A1_POO0O^A'^*ON?^$&O./K_
M *1^% 77=?U;_-'NE%>%_P#"^]!_Z$CXJ#Z^![W_ .2*/^%^:!_T)/Q3]_\
MBA[W@>I_TCI0%UO=?U_PZ]#W2BO"_P#A?GA_OX*^*0^O@>]Z>O\ K^GZ\=*/
M^%^>'\X_X0OXH_7_ (0>^X'J?W^<#Z4!==U_7_#GNE%>&?\ "_/#W7_A#?BA
M[?\ %#WW/T_?=J0?'WP[_P!";\4!]?!%]S^4QZ?UH"Z[K^O^'/=**\+_ .%^
M^'/^A/\ B=_X1%__ /':7_A?OAOOX0^)H]CX(O\ @^G^MZ_3/0T!==U_5O\
M-'N=%>%_\+^\-_\ 0H_$T=LGP3?XSZ?ZVC_A?WAKOX1^)@/H?!.H9'U_>X_6
M@+KNNGX[?F>Z45X7_P +^\,]_"?Q+'J3X)U#CV/[SOQ^8I?^%_>&/^A5^)7T
M_P"$)U'/U^_C]: NKVNOZ_X<]SHKPO\ X7]X8YSX5^)(QZ^"=1Z>O#GC_ TO
M_"_O"_'_ !2WQ)Y_ZDG4>GK]_I0',MK_ -.W^?\ 5F=SI_\ R4SQ=_V(OP[_
M /4@^*-=U7S#9_&[PW'XY\1:JWAWQ\8+WPGX,T^.%?"&H->1RZ9K'CRYFEGM
M@=\5M,FK0):SM\MQ+!>1IS;/75_\+_\ "O\ T+/Q&]O^**U+GZ?-0',MKH]S
MHKPO_A?_ (4_Z%KXC'W'@K4L?3EA1_PT!X4_Z%OXBC_N2M2Z^GWNO^% 77=?
M>>Z45X9_PO\ \)_]"[\1/_"*U/@^GUH_X: \)?\ 0N_$/_PB]4_SS0%T^J_K
M_ASW.BO#/^&@/".<?\(]\0AZY\%ZIQ]>_P#^ND_X:!\(_P#0O_$+'K_PA>J8
MQZ_2@+KNOO/=**\,_P"&@?"'_0!^((_[DO5.GKTZ4?\ #0/@_P#Z 7C_ /\
M"+U7GZ?+^% <R?5'N=%>&?\ #0/@[_H!^/\ _P (S5?_ (G_ #FC_AH'P;_T
M!?'OU_X0S5N?_'.U 76]U_7_  Y[G17AG_#0/@S_ * OCW_PC-6_^(H_X:"\
M%]]&\>#Z^#-6Z^GW.M <RWNOZ_K7MU/<Z*\,_P"&@O!?_0'\=C_N3-7_ /C=
M'_#07@K_ *!/CH>N?!NK\?7]W_G- <RWNOZ_K7MU/<Z*\,_X:"\$_P#0*\<_
M^$;J_P#\:[T?\-!^"/\ H%^.??\ XHW6.!ZG]UT_P- 77=?>>YT5X9_PT'X'
M_P"@9XW_ /".UC\_]5_]?VH_X:#\#_\ 0-\;_P#A':Q_\9_SB@+KNOO[GN=%
M>&?\-">!O^@=XV]O^*.UGGZ?N:/^&A/ O_0/\:_^$=K/_P 9H"Z[K[SW.BO#
M/^&A/ G_ #X>-!_W)VL]?3_4=:3_ (:%\!CK9>,Q]?!^L_E_J* NMKK^OZ^9
M[I17AG_#0O@+K]C\98]?^$/UK&?3_4=>WUH_X:%\!?\ /IXR_P#"/UKCZ_Z/
M_G- 77=?>>YT5X9_PT+X!_Y]?&(]?^*/UOCZ_P"C4?\ #0W@ =;;Q@/KX0UO
MIZ_\>W2@.9=U]Y[G17A?_#0_P^[P>+A[GPAK?3U_X]NG^%+_ ,-#?#__ )X>
M+^>G_%(:WS]/]&H"Z[K[SW.BO#/^&AOA]_SQ\6_^$AKG_P BTG_#0_P\'6/Q
M8,],^$=<Y^G^B]J YEW7WGNE%>&?\-#_  \_N>*__"1US\O^/3_ZWO2?\-$?
M#L_P^*L^G_"(ZYG/3'%IUH"Z[K3S/=**\,_X:(^'8ZCQ4/7/A'7>/K_HGT_,
M4G_#1/PY]?%'_A):[_\ (?>@+KNOO1[I17A?_#1/PX'5O% /<?\ "):]Q]?]
M#_&C_AHGX<==WB?C_J4M>_/_ (\__K^U 77=?>>Z45X9_P -$_#?O)XF'U\)
M:]T]?^/+IU_(T?\ #1/PW_YZ>)O_  DM?Y^G^A?SQ0',NZ^\]SHKPL?M%?#4
M])O$A^GA/7__ )"H/[17PT'6?Q'CU_X1/7\9]/\ CQZ_X4!==U]Y[I17A?\
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M]&_\G/\ Y%H"Z[K[T>MT5Y)_PO?X0_\ 0]Z-_P"3G_R+1_PO?X0_]#WHW/\
MU]_K_HO'XT!==U]YZW17DO\ PO;X1?\ 0]Z+^=W_ /(U+_PO7X1?]#YHG_?5
MU_\ (U 77=?>CUFBO)O^%Z_"+_H?-$_[[N?_ )'H_P"%Z_"/_H?-$]/OW/\
M\C_KTH"Z[K[T>LT5Y/\ \+T^$?\ T/FA_P#?RX_^1Z/^%Z?"/_H?-#_[^7'_
M ,CT!==U]Z/6**\H_P"%Y_"/_H?-"_[^S_\ QBC_ (7E\)/^A\T+_O\ 3?\
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M^#FS_P#CM+_PN'X5_P#10/"?_@ZLO_CM 77=?>>D45YO_P +A^%G_10/"?\
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M2BO._P#A;GPN_P"BA>#_ $_Y&#3/_DG]>E+_ ,+;^%W_ $4+P=_X4.F?_)-
M77=?>>AT5YY_PMOX7?\ 10O!W_A0Z7_\DTO_  MKX7_]%"\&_P#A1:5_\E4!
M==U]YZ%17GO_  MKX7_]%"\&_P#A1:5_\E4O_"V?A?\ ]%"\&>O_ ",>D_\
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M?'FL7L.C^-O&?B3P[X/@U#Q;XIUK6+G2_ NC^&=(>2>UM18BQTK2;6Q^FO\
MA:7PS_Z*)X&_\*S0?_D^C_A:7PS_ .BB>!O_  K-!_\ D^@+KNOZ_P"'7WGR
M=^U/_P $S_V(/VU_BG\#_C7^T]\"K#XH_$W]G#4XM7^#OB:X\;_$WPK_ ,(O
M>0^(]$\61+?:-X&\:>&?#_C&PC\0>'M+U!-)\<:5XDTI=EY:BR^Q:KJMM>_:
MOB#P_H/BS0=;\*^*M$TCQ-X8\3:1J7A_Q'X<\0:;9:SH/B#0=9LYM.UC1-;T
M?48;G3]5TC5=/N;BPU+3;^WN+*^L[B:UNH98)71N<_X6C\,_^BB>!?\ PK=
M_P#EA1_PM'X9CK\1? H_[F[P_P#_ "PH"Z[K^O\ AU]Y^/\ JG_!N#_P1,U?
MXB3?%"[_ &!_AW#XEGU"'4GTS2_'GQKT3X=K<06<5BD</P@T7XFZ?\)K;3VA
MB5YM)M_!,6EW%X9=0N+.6_FFN9/L5/\ @E_^P1;?M)_ /]K?2/V:?!/A?XZ?
MLN?#9_A!^S_K?@J_\6>!O!/PM^&[)\2%3POX;^#'@_Q%HGP5%K:M\7/B#<6%
MY?\ P]O=3TZ\UY+ZPOK:\T;09]+^NQ\4?AF>GQ$\"GC/'B[0#QZ_\A#I2_\
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M47_!2GXK^$_AAX7\ 6D$%UK:?#;PGXM\-ZYK.J6%S<ZE9Z1X<U;Q-\1C\-_
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M/Q?_ &%INA?\)?XE_L[1O#?]D:1;_P!KW6VQ_P!5Y9^VQ_P3-_8=_P""B_\
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M^L>&]=TG5%MY+JQ-V;&^O;:X_(;_ (A<?^"%'_1C/_FS/[8?_P!$%7[H?\+
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M "'M*Z^G_'W0!TU%<S_PFG@[_H;/#/\ X/M+_P#DJE_X33P=_P!#9X:XZ_\
M$]TOC_R:H Z6BN:_X3/P>.OBOPT/^X[I?_R52_\ "9>$#T\5^&__  >Z7_\
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M/4M%F<E]=\-:=80VJ2K;REM$UO4=6^TV%K'J-O?:H ?O%1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7SU^USXNUGP!^RC^T[X[\.7M[IO
MB'P3^SU\:?%VA:CIUV]AJ%AK/AOX;^)=9TN]L+Z)7DLKVUOK*">UNXT=[:>-
M)D5F0 _0M<UXT\):-X^\'>+/ OB.%[CP]XT\-:[X2UVWC9%DGT;Q'I=UH^J0
MQM)'-&KRV-Y.BM)%*@9@6C=05.E*485:<YKFC&I"4H[WC&2;6NFJ31,TY0FH
MNTG&2B^S::3^3U/Y+?\ @VB\!^#-6^*/[4?Q&U-+>;QWX)\&?#/PQX129[%I
M+?0/'NK>-+WQG?VEM- ]^+B.Y\#^$K!M0L;B"&VM=3NK*]2?^U+;ROZ]Z_SO
M?A/\7_VC_P#@D#^V;XSLHM$BF\2^"[[4?!'CKP-XK&IZ?X:^)7@6]GAO=+U0
M)H^J#RUU73#IWBOP1K\-SJUOI5U<6=S-:ZS8-J6DW_\ 4'\%?^"__P"P5\2=
M/C_X6/J_CSX!:^I$4VG>-O!FM>*]&N;AY84C&D^(?AK9>+3):,D^Y[SQ!I/A
ME86MKSSHDA2UN+SZKB'+,;B<9+'X:G/%X;$4J,J<J"=1PC&G"-N2-YN,FG44
MHQ<??=[-,\#)\;AJ.&6$KSCAZ]*=1357W%)N;=^:5HJ2NH.+:?N['[?U\(_\
M%.O!7A;QU^P%^UCIWBR+1GM-$^"?COQKI$^M6EK=Q6?BGP/H5YXI\+RV!NIH
M!:ZS<:WI5GIVE7<$HNHKR^C6"&[9S97/COB#_@M7_P $TM TF]U0?M(VNN36
MUO<2VVC^'_AU\5]0U;5+F&VGN(=/LHW\#VUC!<7K0_9;>ZU:_P!,TF*YFA6_
MU*RA<S+_ #Z?\%0?^"V47[7GPVUC]G3]G_P+K_@CX0>)+W29_'GC+QV=*3QQ
MXYL]$U'3=<T[P[IWA_2+G6-/\&Z!!XBTNVU*^U"/Q'JVN>);6UTZQFB\,Z<=
M=TC7/.RS)\SJXS#S6&KX>%*M2J3K5J<J*A&$XR;C[11<Y67NQ@FVVKVC>2[<
M=F."AAJT77I595*4X1ITYQJ.3G%I)\C:C'764FE;:[LG]H?\&R_BR_O/!/[7
MG@62.(:9X<\4_!SQ99R@#SGO_&FD_$/1]1CD.P-Y4=OX"TIH@78!Y9L(A+&3
M^HNOY\?^#=K]GCQ'\,/V6_B%\;/%&F_V5+^T/XTTVX\)P301+>ZA\/\ X;6V
MK:+I&O3RK>R3Q6VI^*==\;P:9I][IMA/]@T^'7[:?4=*\1Z;+%_0=66?SIU,
MWQLJ;3C[2$&UJN>G1ITZGS52,T_.Y>4QG#+L*IIJ7)*2OORSJ3G#[X2BUY!1
M117CGHA1110 4444 %<+\+O^29_#O_L1?"/_ *C^GUW5<+\+O^29_#O_ +$7
MPC_ZC^GT"ZKT?YQ.ZHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 <+I_\ R4SQ=_V(OP[_ /4@^*-=U7"Z
M?_R4SQ=_V(OP[_\ 4@^*-=U0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5POQ1_Y)G\1/^Q%\7?^H_J%=U7"
M_%'_ ))G\1/^Q%\7?^H_J% '=4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )@>@_*C:OH
M/R%+10 FU?[H].@Z>E)L3^XO_?(_PIU% #=B?W%_[Y'^%)Y<?]Q/^^5_PI]%
M #/+C_YYI_WPO^%)Y47_ #SC]?N+U]>E244 1^3%_P \H_\ OA?\*/)A_P">
M47/7]VO/Z5)10!%Y$/\ SQB_[]I_A1Y$'_/&+_OVG_Q-2T4 0_9[?_GA#_WZ
M3_XFC[-;_P#/"'_OTG_Q-344 0?9K;_GW@XZ?NH^/_':/LMM_P ^\'_?F/\
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MNT4 4O[,TW_H'V//7_1(.?\ R'2?V9IO_0/L?_ 2W_\ C=7J* */]EZ9_P!
MZQ_\!+?_ .-TG]EZ9_T#K#CI_H=OQ_Y#J_10!0_LK2_^@;8?^ =O_P#&Z3^R
M=+_Z!NG\=/\ 0[;C_P AUH44 9_]DZ5_T#-/_P# *V_^-T?V1I/_ $#-._\
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M_0?^@)I'_@MLO_C-:]% &/\ \(]H'_0#T?CI_P 2RRX_\@4?\(]H'_0#T?\
M\%EE_P#&*V** ,?_ (1WP_\ ] +1O_!99?\ QBD_X1SP]_T M&_\%=C_ /&*
MV:* ,;_A'/#W_0!T;_P5V/\ \8I/^$;\._\ 0!T7_P %=C_\8K:HH Q?^$;\
M._\ 0 T7_P %5C_\8H_X1KPY_P! #1/_  56/_QBMJB@#$_X1GPY_P!"_HG_
M (*K#_Y'H_X1GPW_ -"_HG_@JL/_ )'K;HH P_\ A&/#?_0O:'_X*;#_ .1Z
M/^$8\-?]"]H?_@IL/_D>MRB@#"_X1?PS_P!"[H7_ (*-/_\ D>C_ (1?PS_T
M+NA?^"C3_P#Y'K=HH P?^$6\,?\ 0N:#_P""C3__ )'H_P"$5\,?]"YH/_@G
MT_\ ^1ZWJ* ,'_A%?"__ $+>@^G_ "!]/Z>G_'O2?\(IX6_Z%K0/_!/IW_R-
M7Y0?\%ZOVH_CM^Q=_P $GOVK/VE_V:/'/_"M?C;\-?\ A1G_  A7C7_A&?!W
MC'^Q?^$Q_:3^#O@#Q'_Q3GC_ ,/>*O"6H_VCX2\5:]I/_$VT&_\ L?V_[?8?
M9=3M;*]M_K__ ()[?%+QW\<?V!?V'OC7\4M=_P"$H^)OQ@_9 _9I^*7Q%\3?
MV9H^B?\ "1>._B!\%_!7BSQ=KO\ 8WAW3](\/Z1_:_B#5]0U#^S-"TK3-'L/
MM'V73-/LK**"VB /J#_A%/"W_0M:!_X)M._^1J3_ (1/PK_T+/A__P $VG?_
M "-7044 <]_PB7A0=/#/AX?]P73?_D:C_A$?"G_0L>'O_!+IO_R-70T4 <]_
MPB/A3_H6/#W_ ()=-_\ D:C_ (1#PG_T+'AW_P $NF__ "-70T4 <Y_PA_A+
M_H5O#G_@DTS_ .1:/^$/\)#./"WAP9Z_\233.?K_ *+71T4 <Y_PA_A+_H5O
M#G_@DTS_ .1:/^$.\(_]"KX<YX/_ !(],Y'I_P >M='10!S?_"&^$/\ H5/#
M?_@CTO\ ^1:0^#/!YZ^%/#1^NA:7_P#(M=+10!S7_"&>#_\ H5/#7_@BTO\
M^1:3_A"_!W_0I^&>>3_Q(=+Y/K_QZUTU% ',_P#"%>#?^A2\,]<_\@'2NOK_
M ,>G6C_A"O!N<_\ ")>&,^O]@Z5G_P!)*Z:B@#F?^$*\&GKX2\,'_N Z5_\
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MD/\ A7O@'_H1_"'_ (36B_\ R%2?\*]\ ?\ 0C^#_P#PF=%_^0J["B@#C_\
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M_A3WPL_Z)]X3Y_Z@EC_\:X_"O2** LNR^X\W_P"%/?"S_HG_ (3_ /!+9?\
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MU?Y%ZDAFFMIHKBWEE@N()8YH)X9&BFAFB</%+%*A5XY8W57CD1E9'4,I! -
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU7"Z?_R4SQ=_V(OP[_\ 4@^*- '=4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PNG_\
M)3/%W_8B_#O_ -2#XHUW5<+I_P#R4SQ=_P!B+\.__4@^*-?Q+W'[?G_!=S]K
M+_@IC^V]^Q_^Q+^T?X0T:T^ OQ9_:-E\->$O$OPU_9LTW2M"^$WPG^.D7PGT
MNVB\3^,_A#XBUO6=4MSKWA>.5M4U2]O[YI;Z]>X"Q&, ']T5%?R"_P#"K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW<,EM=VEW;?L\_#N&XMKFWF5)H+B"9'BFAE1)(I$9'564@ 'WO1110 4444
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M6L,:>9*\MQ.X:>YFFGDDE?\ B$_X+5R)^SW_ ,'"O["'Q[\0:A_9W@W5[_\
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M3L?M%C+K>I6$$D.AR3VP!^I'_!P9_P %(?VE_P#@GUXT_P""?_\ PHGXG_\
M"MO!'Q7\:_%ZZ^.7D> ? 'CC4?$7@[X=:M\!MFFV7_"<^%_$LFE;-(\<>+-\
MGA[^R]5NIY[3;J$;6L./CA/VT?\ @XA_X*)Q^)?VG?\ @G?\.?#OP)_9*M_$
M>HV?P9\)>-M-_9]3QM\9-!TJX@T^XO;G5?C59ZL=0F6[TR[.HZMX>O\ P/X*
MLK_6-4\*Z%XK\7:CX5O]5L/./^#Q/_G'7_W=S_[[%7]I'ACPUH'@OPUX>\'>
M%-)LM!\+^$]#TGPUX;T+38A!IVBZ!H5A;Z7H^DV$ )$-EIVG6MM9VL0)$<$,
M: X6@#\%O^"]?[;G[7?[#7_!/CX'_&#X)>-=$^$WQX\8?'GX6?#KXAZOI/A+
MP=XXTBQAUKX.?%OQAXQT7P]I?Q%T?QKHJ63>+/!FFQ6.HW%I?ZC'I=N\45^7
MN9;AOAGP9_P4-_X+:?\ !3O0X#_P33^&7A#X%_!#PEX?\/Z-JO[77QU\.^%+
M/4?BO\0-(L].LO&=WX/TWQ7H7BOP5)IU_P"*=(\4V7]E>#OAEXLA\-:>\2^*
M]>\%Z_J.D:#9>P?\':__ "CC^"O_ &>S\./_ %1/[2-?M5_P3)M+6R_X)O\
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M;_P5X_X*S?\ !+[]KGX8? ?_ (*WV_PP^*?PA^*]YH5Q+\4/#ND^ -(U?1_
MUSK.I:!J?Q%\":Q\)--\(Z/-9^&M5U&&?Q?X0^(?PY@\2:GI/A.TAT ^&O[;
M'B37/V,_X-R-,TVP_P"".O[)]U8Z?8V5UK=]\?\ 4]9N;2TM[:XU?4HOVE/B
M]HT6H:G-#&DE_?1:/I&E:5'=W32W":;IFGV*R"ULK:*+\J_^#OW0-.N?@O\
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M7WA[Q)<_9?%ESJ.GRZM<^"/V&_X+,_M(?&']D;_@FM^TI^T'\ _%$'@OXM^
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M\1:UN+0C3?B9K>M_$C1E$5RJR.J:/XKL46Z4?9[U5%[:LUK<0L0#^5[]CO\
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MBUW^(K[5I%^R>>CK<W%U--^T/_!0_P",'CSX ?L*_M:_&GX6ZK;Z%\1_AI\
M_B5XL\#Z]<Z9IVM1Z#XHTSPS?R:-KBZ1K%M>Z-J=QH]\8=2M+'6K#4M&N;JU
MAAU;3-2TY[FQN/YBO^#9*YMU_;D_X*MVC3PK=S^)M*N8;9I4%Q-;VOQ>^+<5
MS/%"6$DD-M)>6D<\J*4A>ZMDD96GB#?T3_\ !7;_ )1A?MW?]FR?%7_U&KN@
M#Y=_X(!_MB?M#?MO_L(WWQA_:;\=0?$;XE:=\=/B%X&7Q1%X4\'>#9+GP[HN
MB>"M6TJVN=&\":#X9\.>?9S>(+^!;NVT>VGGMEMQ=O<3QM/)\-?M=_\ !5/]
MOK]IW]O+QW_P38_X)%Z'\/= \9_!6S\52?&SX^_$6+PGK8T?5?!>H:=X=\7#
M0+;Q"?$WA+1_"G@WQ3X@TCP=K,FJ>"_%_C'6?'ES'IMIH?A[2=%U"?7_ $G_
M (-4_P#E&-K_ /V='\5O_40^%U?CA^RA^V;\"_\ @D#_ ,%P?^"B?A7]H#Q$
MVJ_![XM_$+QUHTWQ3\"HWCY?AW>>)O'UO\6_#0\6:9X5CN]3U$^'=+\3:AX+
M^).G>&='U/Q-X>\=:7/IJ>'"]AJEG:@'7?\ !1']I+_@Y=_X)H:#X1\;?'']
MKCX=^-OAIXPO8]#M_B=\&?@[^SUXG\'Z'XMG74KBV\'>)QXL_9A\"^)-&UR]
MTW2[C5-.N)?#LGA[4[7?;Z=KMUJMGJ6G6/\ 37_P2=MO^"AES\!-:\8_\%!O
MCI\,/CUKWQ"UKP_XT^"7BGX8Z%X7T;3U^$FO^#-#U33;F]/A/X:_"NQF&LWM
M[+J-A!?^&Y=9LX&E-[J+PW-I8:?_ #C_ /!;'_@JS\#?^"H7P\^$7_!/C_@G
M=X=\5?M-_$#XG_&'PKXFN/%5OX"\7>%+>SNO#VFZS'I/AOP5H_CW2/"?B-M<
MO+C5[J^\6>,=:TO2/"7A#P7HNMM=7>H6>LWFL^%O[ ?V2OA/JWP$_95_9F^!
M>OWL.I:[\%_V??@S\)]:U&VB2&WO]6^'/PY\-^#]2O8(8[F]2&&ZO-'FGBB2
M\NTC2146YG $K@'T%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_!5^W_ /L\6W[,'[5_
MQ5^%NCVMS;>#EU.U\5^ &GADBB?P;XOLH=<TVRLI926O+;PW=W.H>$'O<DW-
M[X=NV;#A@/C2OZ4/^"]WP:U/7?%O[,WQ&\)^&=3UWQ%XDM?%OPGO5T32=6U3
M5-1GT^\T[Q-X(T.WAL8[J*YNIY=;\<SZ?80P0ZC<,+UX1J$,,@T[Q#]FO_@A
M7\9/'UMI7BC]H;QMIGP=\.WMM9:@/!F@VP\5?$J:*:17FT[6#*UGX7\'7+V3
MK)#<B]\87EI=;K/4_#MK-%(J@'X/5_3S_P &^6B+;^"OVG/$86(/JOBGX8Z(
MS"28S%?#^D^,K]%DA8?9TB4^)G,4D1,TKO,LX"0V^?N?X=?\$>/V#O -I:1W
MWPOUCXCZG:QQH^N_$7QIXCU&[O'CNGNO.N](\/7GAGPBTC_N;>00^&H(7M;=
M(?*'VB_:\^\?A?\ !7X1_!/3=3T?X1?#;P9\-],UF^CU+5[/P=X?T[0H=3OH
MH%M8;J^%A!";J6&W010&9G$*M)Y00RR%P#X8_P""PNKS:5_P3Z^-L, E5]9O
MOACI#317#0/!#)\4_!M]<$[%)FBN;>PEL)K<O&LD-W(79T5H9?XE:_LR_P""
MV<\T7["GB2.*:6-+GXC?#F"Y2.1T2XA75I[E89U4@2Q+<6\$XCD#()H(90-\
M:,O\9M !7T?^R+\"=2_:5_:/^$OP:T^&*2V\6>*K63Q)-.\\<%EX+T**;Q!X
MTO9'MKFRG\V#POI>J_8;>&_T^>_U)K+3K:^M;J\@F3YPK^AW_@@)\'K75?'G
MQR^.NI6T4C^#_#V@?#CPK)-#:7 %_P",+NYUWQ1>VS-<-=Z;?:9IWAK0K!+D
M62"]L/$VI6EO>A(]1MI0#^G73-,L-%TW3M'TJUBL=,TFQM-,TZR@!$-G86%O
M':V=K""6(BM[>*.*,$DA$ ))YK^,/_@K]^T[<_M ?M7:YX0TF]\[X>? /^T/
MAQX7@BN$GM+SQ,EQ"_Q&\2!8I)X4N=0\06<'AQ7@G:&ZT7P?H5T\-M>37<0_
MK(_:M^,L'[/G[.7QC^,<C[+KP1X'U6]T0>=IUOYOBK4%CT3PA;>;JR36 ^U^
M*=3T>UVS6NH/)YWEV^EZK<O#IMU_GU7M[>:E>7>HZC=W-_J%_<SWM]?7L\MU
M>7MY=2O/<W=W<SO)/<7-Q/(\T\\SO+-*[R2.SL20"M5FRLKS4KRTT[3K2YO]
M0O[F"RL;&R@ENKR]O+J5(+:TM+:!))[BYN)Y$A@@A1Y9I72.-&=@#6K]C?\
M@BS^S%;?&K]IF3XK^)K+[5X+_9ZMM/\ %UO#-;R26NI?$K49YX? -N\A18T_
ML"6RU3QI%+%<BYM]8\.Z#&]M/97MT8P#]@/^":O_  3 \#_LZ>&/!_QK^+VB
MQ>)/VA]9TBVUN"QUFU632_@^FKVUE>V^AZ5IMU&R'Q[I2 VVO>*&'G:?>S7^
MB^'FCL(;C5==_9.N?\6>*_#G@7PQX@\9^,-9L?#WA7PMI&H:]XAUS4I?)L=*
MTC2[:2\O[ZZDPS"*WMXG<JBO+(0(XHY)71&_AF_:T_;U^-?[3/QU?XL6?B_Q
M=X!T3PCKEW=?!?PUX=\0ZAHT_P --.-O:Z?'?Z9J&CW5O<P^+M9MK&"_\2Z]
M;W7GW&HW%Q:Z?)::';:;IMF ?W<T5_/-_P $Z?\ @L+_ ,)[JOA7X#_M47&F
MZ7XDNK:ST'PA\:)+C['9>)]60K;6.E_$&";%IIFMZFICAM_%-M-;Z9J5_LAU
M.QL+JX.H77]#- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?
MS??M.?\ !QA\#/!4>M>'/V8?AOXD^+WBBTN-2T^T\;>-T'@WX8B2UNHX++5]
M-L(+NX\;^*=.O(TN[G['>V'@.<0FP9;XO<W,5E^ G[0'_!6K]OO]IF:\T?7O
MC7KW@GPSK$NI6<?P^^"L$OPYT22SU]E@N?#\]WH$S>-?%&E36_EZ9#IOBWQ3
MXDWVC30,99-0U%[WZ+!\,YEB4IU(PPE-Z\U=M5+=U2BG)/RJ.GWOW\?$9W@J
M#<82EB)]J23C?LYR:7_@//Z']ROQ\_;=_9+_ &8%GC^.GQZ^'W@35;9[9)O"
MDFJ2>(?'B+=V1U&VN/\ A7OA.WU[QPUE+9F*=;]/#[60%U8JUP)+^R2X_!;]
MIG_@Y&\-:;Y6C_LB_!BY\2W:Y:^\<_'6.;2-"1T^T(+71_ G@WQ#_;>K6TX:
MTN1J^J>,?"]S;-#=6)\.W*SPZE#_ #O:Q^PY^UWI/P4\9?M,>,_@AX\\(?"'
MPG;^%]6USQO\0;1/!\VIP^//$FE>'/#E_H.B^*KC3?%/BVWUC5M=T^0ZKH.D
M:GI\-I=1:C>WT%M=6LMQ^F__  27_P""17PR_;P^&/B+XY_%?XK^-/#WA;PI
M\5M>^&<_P\\"Z/HUAJ^KR:)X,\%^*HM9;QYK4FNV]C;75QXUM[*YTB+P3-<"
MUTFX:#6X9]4BDTKV89-D>74)XO&8B6-C1FJ4^1WI*LXIJG[*@Y24VI1?+4JN
M*3BY63U\V699IC*L</AJ,<*ZD74AS*TW23:Y^>HE%QO%J\*=WJE=H_H5_P""
M-_[8'QG_ &U?V7_&GQ0^.=]X?U+Q?X;^.GBGX>V-[X=T&W\.VTWA[3/ GPT\
M3V?VNQM)7MGOH]0\7:I$US"ENLEHEG&\330R3S?K+7SK^S!^RI\$/V//AI_P
MJ?X">%;CPKX2N-:F\4:PM]KNN>(M3\0>++S1]$T/4_$VJZAKE_?2+J.J6'A[
M24N;73$TW1+8VJII>DZ?;_N!]%5\=C:E"MBZ]3"T_98>=1NE3Y8PY(:67+%N
M,>]DVE<^CPT*M/#TH5Y^TK1@E4G=RYI=7S-)OM=K4****Y3<**** "BBB@ K
M^17Q_P#\CQXO_P"QDUG_ -.%Q7]=5?R*^/\ _D>/%_\ V,FL_P#IPN*_/?$+
M_<LO_P"PJK_Z9/ZT^B5_R4O%G_8CPG_J>CD:***_*3^[ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]C^!WQQ\;_ /QO9^-
M/!=Y_P \[;7="N9)/[(\2Z1Y@>;3-3A0_62RO8Q]JTZZVW%NW^LCE\<HK6A7
MJX:K3KT*DJ5:E)3IU(.TH26S3_!IW33:::;1Q9CEV S? 8O+,SPE#'9?CJ$\
M/B\)B(*I1KT:BM*$XOY.,DU.$U&<)1G&,E_5K\#OCCX(^/G@BS\:>"[S_GG;
M:[H5S)'_ &OX:U?RP\VF:G"A^LEE>QK]FU&UVW%NW^LCB]CK^4OX'?''QO\
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M9XNUW^QO#NGZ1X?TC^U_$&KZAJ']F:%I6F:/8?:/LNF:?9644%M$ ?7]%%%
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M)'Q2^%6B_ 'X27MIJ"^*=%^!7@#XGW_B2TU'Q-'J=GIOB+4+Q]6\:^)M1O\
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M6Y.GS3B)]2T:;3=8CB6VU&W+?05 !1110 4444 %%%% !1110 4444 %%%%
M!1110!_EM>,/ /CCX,>.;KPC\5OAUJWASQ/X>O)XM7\%>.],U[0I9C:W5S8R
MK<1VEWHNJ2V#W5K<1PW^DZE%!=-;LUK>RQ EOZ)/V ?^"LW_  3G^ @TS3-?
M_8=TO]G;Q-%+>J/BU\-8%^,-^/M5@EG+)J'B7QW,/C%HNE7%D;K3WTC3]?\
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MQ]>_L&6=K??M9?"."\MXKF%+GQ?>)',@=%NM.^'_ (LU"QN K @2VE[;6]U
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M\=/"/Q3^#FHQZ5)KEKX?@-E)=Q6NHW>@WWB'2[R;PCXJBM'>WN+3R=;TV_2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^"/_  <\Z3JNN?\
M!#;]M[2M$TS4-8U.Z_X9K^S:=I5E<ZA?W/D?M>_ &YF\BSM(YKB;R;>&6>7R
MXV\N&*25\(C,/O?_ ()46EW8?\$O/^";MA?VUQ97UE^P1^Q[:7EG=PR6UW:7
M=M^SS\.X;BVN;>94F@N()D>*:&5$DBD1D=592!][T4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"Z?
M_P E,\7?]B+\._\ U(/BC7=5PNG_ /)3/%W_ &(OP[_]2#XHUW5 !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO>6T<D=JL%^Z:9QU^&\UPDE5PSCB(Q=XU,-4<*J7?DDXROY4Y3>VN]NBEG6
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M]4A@/JD/J,[05#VE3G=)U(RFKVYN=M))I'\^\#\&^+V%\/%D>'PGAM5RSBO
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M2Y=+UVXFU6"6QC$=O++=.OVV2-KZ&&WM[F&WBM_$[]E3]D?PK\//&7B3P?\
MM0Z'XE\4:'X>U/4]!\/1^/?AMJ4FMZG9V[S6NEQ6.D%M2NI;V11;Q168\UI'
M7E5#,/S+HIK-<O6'5'^P<"ZBHJE[?VV*]HY\BC[:WM+<_->=MN9]EKG+@;BR
M6;2S#_B*/$JPCS%XS^REEN2+"K#O$^W_ +/4UA%46'5+_9N96G[/56D?4'['
M'PKN/BW^T)X"T1K1KG1/#VH1^./%3;HUBAT'PO<6UYY=TKGS)+;5=8?2- D2
MW1I\ZNK@P1K)=0?HS_P4*^%?Q[^-/B_P/H7P[^'VM^(?!?A'0[R_FU&TO]'M
M;2[\3:_=B.\B-M>:E:RS?V9I>E:8L%S(C;)-1U"&!8U,SW"?\$P_ 5KX5^&O
MQ'^,VN[;*+7]0.CV-Y<$>7;>&/!UM+?:OJ,7EJSK;W>J7T]O<B0M(7\.J8X8
MT^>Y^)_$O_!0C]IZ_P#$>OWWASXBMHGAZ]UK5;O0M%;P7\/+IM(T:XOIYM+T
MMKJ\\+WUW<MI]B\%H9[J]O+F8Q&2>ZN)6:5_H*$<MRSABA0S.6.@\]K2Q4E@
M8X=UO88:5/V,9O$2C%4I>Y6BTI2<JC2]U-'Y1F=7C+C/QIS/,>"Z7#%>EX89
M?2R6C/B>MFM/+EFF=4,1_:-:@LKHUZT\?3_VC 5(R=.E3IX2$FG4E!OZO_8&
M^#W[0_P1^+.KQ>-_AQK^A^!?&OAJYT[5;Z2X\-7%E8ZWH[_VKX?U*^:#5I=2
M2)81K.C0K8QW"R7>NP&ZM3%&+RQ^8/\ @HA\*9?A[^T#JOB:TLX[?P[\4K6/
MQ;ISV]I#:6R:Y''!8^+;4F&5OM5]+JJ)XBO[IX;9Y9/$D?F+/,LMW/SUG_P4
M%_:RMKNUN9_B;;:C#;W,$\VGWG@;X?):7T44JR26=T^G^%[&_2VN44P3M97M
MG=K$[&VNK>8),GZ/_MY^'-'^-_[*_A[XP^$4_M)?"TFB>.])NX=*FN-0G\(>
M*(+?3=<M4,D=OJ&F6L/VS2=>UEY(-D,'AIFO[6)8!=66BCE>:<-8[ 99+'SJ
M91-9E1CF"P\:JA+G^L1I+#SDI4E#VTY1:356I#XFXVY9U>-^"O&3A?BCC.CP
MMA\-Q]AY<'8^KPK/-ZN!EB:/U?\ LNMCGFV&I3HXZIB7EU"C4C.<)8'"XF*]
MFJ=5RXC_ ()2?\B/\7/^QK\._P#IHO*^2_C1^WE^TO<_$'Q9I.C>*K/P!I.@
M:]K7A^VT'PWHVBW C32-8O+5+B^U?6+36-2O-3DC@ABO9[6\M-+F>$R6.F64
M<\T<G;_\$OOB1IGACXI>,O &IW:6C?$?0],ET@2BV2.[UOPC)JES!9+<2SQS
M+<2Z9K&KR06T$,YNF@;>8VACW\1^U[^R'\6O"WQ?\:>*_!W@KQ#XV\#^-_$.
MH^*M+U#PEHMUK,ND77B*\N-3U+0=4TG1K:>ZTM=+U&>YMM/N6MVTZ[TQ]+9+
MT:C+=Z?9Q4Q&8U.$LIGE=7%0^JXC$X?'1P<YJI%^TG4I2J.C:HH<KC)ZJ*=6
M*E>\6=.&RKA##^/G'=#C? Y'B'G64Y)FO#%7B'#X:IA:JIX/#87'0PBS!2P<
ML5[:E4IQTE7E'!U947!*M ^H?V"_VNOB?\4?'^I?"?XK:O#XM@U#P_JVM>']
M<N=,L;;5[>]TZ6Q:YT6\?3+>RL[O2KC3YM1NXYKRUEOH+J".T6ZDLYX8+3YN
M^*_PO\._!S_@H!\.='\-6L>E^%M4^*OPA\9Z9ID,44=KH]OK/B[2)-1L+&&U
M)6+3;;5K74O[-M$M[<65@;>PA@>*VBN+CWW_ ()W?LQ_$3P9XMU'XT_$30[S
MP9IT7A[4=#\-:+XBL#8:]?RZA=1IJ&M7%A>M%J&@V5C;:?+!;-?V=O/JT.H_
M:[0C3%6>^^'_ -JCXV?\+!_:;\1_$3PQ?QWVD^%-=TC2_!-V%@%K-8^"I(5@
MO[6YTR99;S3=6UV#4M<L+Q[S[;)8:E JR6:QP6MHL97KT^&\IK9O[6>.CFRJ
MX-XB[Q7U.FN:;DYR]JZ<FDESZRO0=N7DD'#V6Y5B_&3CS+^ G@,/PU5X#E@.
M(891R1R2/$6*J*CAH4:>%A]1CC*<)5)25&T:<H9I!SC7EB*3^T?^"LD4@O\
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M9;Q?QSGV=Y9/$7I1EE-.M4<,7*=14XJDJL\31E.486EA:DI)1M;[<_X)O_\
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MGE)UZU6O";3M:%J<U%**3M9:WN_/].XDX0XDSK,Y8W*_$//N&\*Z%*DLLR_
MY37PT9TU+GK*IB\/4K.=9M.:E-I-)1LK)>P_'KP1X%^'?Q2\1>$OAMXWLOB%
MX.TZ+19-*\46.HZ?J\=V]]H>G7VH6\FI:/#'HUW+9ZC<7=N6TN2Y@AC2.VN9
MEU*"^MK?]G_V+OA[XI^$7[(NL^+M%\.W&J_$7X@:;KGC_0-#22R^TZ@9])%G
M\/;#S976SBL=0M[>TUT-<22O;V^O7!N5\Q#8P_B!\*/ 5Y\4/B5X'^'UCYJR
M^+?$NE:/-/"4$EEI]Q<H=5U$&177;IFEI>:@X\N5BELP2&9RL;_MG^WI^T5X
ML_9Y\.?#'P9\(-9B\*>(=5EN[N6>'2-$UE;#PAX=L8M*L]+^R^(K#5;2.+4;
MZ^A>WGBM&NU&@31_:H(I)([OZ#AJ6&PW]L\15Z<\-AL-%T,/3PR4Y4JN-J)<
MN&]M)*4Z$)4X1]I.W+5;E=+3\G\9:>=9O_Q#SPDRK%X?.,YSFK3S/-\9G+J8
M>CCL'PYAO:*MFZR^C*5'#9IB:6*Q-?ZK0<E6P4:=%QE)<WY<7'[%G[5UU/-=
M77PD\1W-S<RR7%Q<7&K>'9IYYYG:2::::37&DEEED9GDD=F=W9F9BQ)K]?OB
MO\-?'/QO_8FA\/>-/#M[8?%S1?"&DZV=/U6RT>ZU9_&_@7=!?3V::;>OIUK<
M^,]/LM6MK"XL;N V]CXG42V<0-SI%?DU_P -_?M;_P#16?\ RP_AG_\ ,97Z
M'?L _M8>/_C+X@\<>!/BWXIMO$/B&WT_3_$?@^X&@:5HUU)IUM)-9>);29O#
MVEZ9I,L5I+<:%<V:W$$>H$W6HLLUY;1K'8=?#];AR6(Q&6X:IG'_  KX>IA*
MBQRP4:#?).4)*5"HYJLO?C1=FN>IRZ2:9X/BQE_B_2RC*>,LYPOAZO\ B'V;
M83/\+/ABKQ'4S.,%B,/1KT72S+"1PT\NDUAZ^80]I3:P^%<VY4X3A+\?_@5<
MQV?QN^#EW*(VBM?BI\/;F194,L31P>+M(E<2QK\TD952'1>77*CDU^LG_!5O
M1YY_ WPCU];BY6VTSQ9XAT>6T29ULYY]<T>TO;>XG@$1CDN;6/P]<Q6DS31O
M!%>7J)%,MQ(\'YF_M5_#+_A4GQ]^(_A"WM/LFC'79=?\,I%IW]F6"^'?$JKK
M>F6FF0H3;RV.BK>R>'O/M"MLUUI%U&L-I)%+9V_[->&]3\#_ +?W[+3^'=2U
M&#2_&$$&EVNN3C3X+B_\'?$C0+:UF&OZ;8WTMQ-)H>LK<3)'<6M\MQ=^&];U
M;0#J]GJZ:B;/FR3#RJ8/B3AN?+''SM*A"4E%5JV#J/GIQ;LK\].FXMR:<9N;
M7)"3?L^)>;4<'Q#X/>,-"-:OPMAU.CFF(HT9UGE^7\18.G]6QE6$(SJ./L,9
MBU4BJ49QK4*="#>(Q%*"_G?HKZ?\?_L;?M(_#W5SI=Y\+?$_BF%WF6TUGP!I
M6H^-=(O(X%@9YQ)H=G<WVG(YN$6&/7+#2KFX:.?R;>06\Q3U7X2?\$[_ (]_
M$+4T_P"$PTR/X4>&4+_:M:\2K;W^KR%-R^3I7A6QU"._NIQ(8F+ZK=:#I[6Q
MEEM]0N)XEM9?F*>2YO6KO#0R[&.LI*,HRH3A&#>SJ5)J-.G%K53G.,&FGS6:
M9^TXSQ'X"P.5K.L3Q?P_'+ITG6I5Z69X;$U*\8_%'#87#5*V+Q-:+O&6&P]"
MKB%-2@Z2E%I<C^P#_P G;_";_N?/_59^,Z]._P""E%Y=Z=^T[IVH:?=7-C?V
M/@/PA>65[9SRVUW9W=MJ>N3VUU:W,#)-;W-O,B303PNDL4J+)&RNH(X']AC3
M9]&_;,^'.CW3Q27.E:A\2--N'MV=H'GL?AYXWM9GA:2.*1HFDB8QL\4;E"I:
M-&)4=K_P4T_Y.2@_[)UX6_\ 2[7Z]NES1X+Q6\91X@CY-26$P_5;-,_-\:Z=
M;Z1N2R7+4I5?":HU=7C.G//\U:NFK.,HO9K5.S1]O_M%0V7[6G[$&E_%;1/+
ML]5\,Z<?B6]H9Y?*MKWPE::OI'C_ $*:5]+2>YCM(%UU[&2.TL(KZ]TW2[I;
MJ+3)G>;P'_@F+\*DM[_QW\??$9-AHWA[2KKPMX>N;R)H;)Y9UBU/Q5KGVN58
MT6/1M.L[73EDB>:%UU;54N!#+9Q%^D_X)=?%%]3L/B)\#==O%NK."V7QIX6T
MZX%Y(ZV%Y(FC>,[*.=W>TAL!<7/AZ\M]-B^RR&\U+6]01+HW%Y):^N_M6W'A
MO]D_]D$?"/P$DJ#QK>ZMX(TTW4K2WHTOQ+<:MKOC#4;R;>DMT/[.GGT*-GDD
M>+^U-.0QR6MN\:_34HX?&1P'&%=QE]2RRL\93TBZF982U&A[JO;VDISG#9QY
M</=.,M/Q?&U<VX=K<4?1\RR%>F^)>,LO7#V,2=2G@^#<]4LPS1>UFHNH\%AZ
M%"A7TFJWMLV<90G0BI_EUX@^*5[\9?VN])^(-S<O/9ZS\8?"47A^-D>);/PM
MIOB?3-.\-6:P.J>2\6C6UH]X1%"USJ$EY>S1+<7,V?N3_@K/_P T!_[JI_[S
MBORX^#__ "5KX7?]E%\$_P#J2Z97ZC_\%9_^: _]U4_]YQ7SN#K5,1PSQ3B*
MLN:K7Q>7U:DG?WIU,;2G)ZW>LF^I^O<09?A,I\9_ [*\#25'!9;D/%V!PE&*
M25/#83AO%T*,%9)>[3IQ6B5VKV/QSHHHKXT_H<**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHK8\/^'];\5:WIGASPYIEYK6NZU>0V
M&EZ780M/=WMW.VV.&&-?Q9W8K'%&KRRND2.ZN,92DHQ3E*348QBFY2DW9)):
MMMZ)+5O1$5*E.C3J5JU2%*E2A.I5JU)QA3ITX1<IU*DY-1A"$4Y3G)J,8IMM
M)-AX?\/ZWXJUO3/#GAS3+S6M=UJ\AL-+TNPA:>[O;N=ML<,,:_BSNQ6.*-7E
ME=(D=U_HJ_8V_90MOV=/#%UJVO7C:C\2?%MG:KXDDMKJ5M(T>TB;[1;Z#I\*
MLL%VUK,Q>\U26-I+BYW+:F&T55EI?L>_L>Z)^S]HD?B?Q/'9ZS\6=:LPNI:D
MH6>T\+VDZJTF@Z#(R_>Z+JNJJ%DOY%,,)2Q1$D^XZ_7>%>%EERAF.803QTHM
MT:+U6$C)--RZ/$2BVI=*2;BKR;:_@#QT\<)<73Q'"/"M=PX7HU5',<PA>,\_
MK4*BG&-)NTH951JPC.FM)XVI"-:=J,:<)%%%%?='\PA1110 4444 %%%% !1
M110 5PNG_P#)3/%W_8B_#O\ ]2#XHUW5<+I__)3/%W_8B_#O_P!2#XHT =U1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!^2/_  76_:P^-O[#O_!*S]J7]J/]G/Q'I_A+XR_##_A2/_"'
M>(=5\.Z'XLL-/_X37]HSX1?#SQ#Y^@>)+'4M%O\ [7X5\6ZY8Q?;;*;[+-<Q
MWMOY=W;02Q_6_P"P#\6/&_QZ_8/_ &*/CG\3-2M]8^(_QG_9(_9O^+'Q U>T
MTZQT>TU7QO\ $7X.>#/&'BO4K;2=,@M=-TNWOM>UB_NH=.T^VM[&RCE6VM((
MK>*.-?RX_P"#H[_E!1^W-_W;-_ZV'^S[7W__ ,$G?^467_!-/_LP#]C?_P!9
MU^'- 'W_ $444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <+I_\ R4SQ=_V(OP[_ /4@^*-?S2_\%VOVO/C=
MXI_:G_88_P""8'['OQP\>_!WXN_&WXE>&/$GQD\;?"CQEXB\">)_"7A/Q9KD
M7@WP)IUYXP\&:A!KEGIB:>WQ#^(/C7PV$^UC1O#O@?6&L-2M-6LH9OZ6M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYI/Q"N;>"QD#3W^F@'P7_P &X/@_7OVM_P!LW_@H1_P53^(FC"&Z\9^-M?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /P!_X.CO^4%'[<W_ ';-_P"MA_L^U]__ /!)W_E%E_P3
M3_[, _8W_P#6=?AS7W_10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <+I__ "4SQ=_V(OP[_P#4@^*-
M?Q[_ /!4>";_ ()K_P#!>W]CS_@H)81G0/@[^TB?#OAWXR:NE[=Z3H@O+6RA
M^"/QAGUIKB-_#K6ND?"S7/A_\1+6SFGM8]2\4:-=ZQ=QZ7J5HOB>?^PC3_\
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M0O'/]I:C!J^H_P#"8^--%T6R\2>)OM^K6UMJE[_;6I7OVK4;>"]G\RYBCE4
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M4*B]54C)/L[HG*%*.7852O?DFU?3W95)RA\N1QMW6H4445XQZ04444 %%%%
M!7\BOC__ )'CQ?\ ]C)K/_IPN*_KJK^17Q__ ,CQXO\ ^QDUG_TX7%?GOB%_
MN67_ /855_\ 3)_6GT2O^2EXL_[$>$_]3T<C1117Y2?W8%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY8Q?;;*;[+-<QWMOY=W;02Q_6_[ /Q8\;_'K]@_]BCXY_$S4K?6/B/\ &?\
M9(_9O^+'Q U>TTZQT>TU7QO\1?@YX,\8>*]2MM)TR"UTW2[>^U[6+^ZAT[3[
M:WL;*.5;:T@BMXHXU_+C_@Z._P"4%'[<W_=LW_K8?[/M??\ _P $G?\ E%E_
MP33_ .S /V-__6=?AS0!]_T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <+I__ "4SQ=_V(OP[_P#4@^*-
M=U7"Z?\ \E,\7?\ 8B_#O_U(/BC7=4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT2;_ ,OSXF?_ #9T?\, _LD?]$F_\OSXF?\ S9U]C44?V+DW_0IRS_P@PO\
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M_P#-G7V-11_8N3?]"G+/_"#"_P#RH/\ B)'B)_T7O&G_ (E.>?\ S<?'/_#
M/[)'_1)O_+\^)G_S9T?\, _LD?\ 1)O_ "_/B9_\V=?8U%']BY-_T*<L_P#"
M#"__ "H/^(D>(G_1>\:?^)3GG_S<?'/_  P#^R1_T2;_ ,OSXF?_ #9T?\,
M_LD?]$F_\OSXF?\ S9U]C44?V+DW_0IRS_P@PO\ \J#_ (B1XB?]%[QI_P")
M3GG_ ,W'QS_PP#^R1_T2;_R_/B9_\V='_# /[)'_ $2;_P OSXF?_-G7V-11
M_8N3?]"G+/\ P@PO_P J#_B)'B)_T7O&G_B4YY_\W'QS_P , _LD?]$F_P#+
M\^)G_P V='_# /[)'_1)O_+\^)G_ ,V=?8U%']BY-_T*<L_\(,+_ /*@_P"(
MD>(G_1>\:?\ B4YY_P#-Q\<_\, _LD?]$F_\OSXF?_-G1_PP#^R1_P!$F_\
M+\^)G_S9U]C44?V+DW_0IRS_ ,(,+_\ *@_XB1XB?]%[QI_XE.>?_-Q\<_\
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MIRS_ ,(,+_\ *@_XB1XB?]%[QI_XE.>?_-Q\<_\ # /[)'_1)O\ R_/B9_\
M-G1_PP#^R1_T2;_R_/B9_P#-G7V-11_8N3?]"G+/_"#"_P#RH/\ B)'B)_T7
MO&G_ (E.>?\ S<?'/_# /[)'_1)O_+\^)G_S9T?\, _LD?\ 1)O_ "_/B9_\
MV=?8U%']BY-_T*<L_P#"#"__ "H/^(D>(G_1>\:?^)3GG_S<?'/_  P#^R1_
MT2;_ ,OSXF?_ #9T?\, _LD?]$F_\OSXF?\ S9U]C44?V+DW_0IRS_P@PO\
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M>\:?^)3GG_S<?'/_  P#^R1_T2;_ ,OSXF?_ #9T?\, _LD?]$F_\OSXF?\
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MIRS_ ,(,+_\ *@_XB1XB?]%[QI_XE.>?_-Q\<_\ # /[)'_1)O\ R_/B9_\
M-G1_PP#^R1_T2;_R_/B9_P#-G7V-11_8N3?]"G+/_"#"_P#RH/\ B)'B)_T7
MO&G_ (E.>?\ S<?'/_# /[)'_1)O_+\^)G_S9T?\, _LD?\ 1)O_ "_/B9_\
MV=?8U%']BY-_T*<L_P#"#"__ "H/^(D>(G_1>\:?^)3GG_S<?'/_  P#^R1_
MT2;_ ,OSXF?_ #9T?\, _LD?]$F_\OSXF?\ S9U]C44?V+DW_0IRS_P@PO\
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M_P#-G7V-11_8N3?]"G+/_"#"_P#RH/\ B)'B)_T7O&G_ (E.>?\ S<?'/_#
M/[)'_1)O_+\^)G_S9T?\, _LD?\ 1)O_ "_/B9_\V=?8U%']BY-_T*<L_P#"
M#"__ "H/^(D>(G_1>\:?^)3GG_S<?'/_  P#^R1_T2;_ ,OSXF?_ #9T?\,
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M,_\ HHG@7_PKM _^6%'_  M'X9_]%$\"_P#A7:!_\L*/^%7?#/\ Z)WX%_\
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M[X9_]$[\"_\ A(Z!_P#*^C_A5WPS_P"B=^!?_"1T#_Y7T!KY?CY?\'\/,/\
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M0&OE^/E_P?P\P_X6C\,_^BB>!?\ PKM _P#EA1_PM'X9_P#11/ O_A7:!_\
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M#/\ Z)WX%_\ "1T#_P"5] :^7X^7_!_#S#_A:/PS_P"BB>!?_"NT#_Y84?\
M"T?AG_T43P+_ .%=H'_RPH_X5=\,_P#HG?@7_P )'0/_ )7T?\*N^&?_ $3O
MP+_X2.@?_*^@-?+\?+_@_AYA_P +1^&?_11/ O\ X5V@?_+"C_A:/PS_ .BB
M>!?_  KM _\ EA1_PJ[X9_\ 1._ O_A(Z!_\KZ/^%7?#/_HG?@7_ ,)'0/\
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M O\ X2.@?_*^@-?+\?+_ (/X>8?\+1^&?_11/ O_ (5V@?\ RPH_X6C\,_\
MHHG@7_PKM _^6%'_  J[X9_]$[\"_P#A(Z!_\KZ/^%7?#/\ Z)WX%_\ "1T#
M_P"5] :^7X^7_!_#S#_A:/PS_P"BB>!?_"NT#_Y84?\ "T?AG_T43P+_ .%=
MH'_RPH_X5=\,_P#HG?@7_P )'0/_ )7T?\*N^&?_ $3OP+_X2.@?_*^@-?+\
M?+_@_AYA_P +1^&?_11/ O\ X5V@?_+"C_A:/PS_ .BB>!?_  KM _\ EA1_
MPJ[X9_\ 1._ O_A(Z!_\KZ/^%7?#/_HG?@7_ ,)'0/\ Y7T!KY?CY?\ !_#S
M#_A:/PS_ .BB>!?_  KM _\ EA1_PM'X9_\ 11/ O_A7:!_\L*/^%7?#/_HG
M?@7_ ,)'0/\ Y7T?\*N^&?\ T3OP+_X2.@?_ "OH#7R_'R_X/X>8?\+1^&?_
M $43P+_X5V@?_+"C_A:/PS_Z*)X%_P#"NT#_ .6%'_"KOAG_ -$[\"_^$CH'
M_P KZ/\ A5WPS_Z)WX%_\)'0/_E?0&OE^/E_P?P\P_X6C\,_^BB>!?\ PKM
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MHNK2[M?"^AV]U:W5OH=]-!<VUQ#8I+!/!*B2PS1.LD4BJZ,K*" />\OQ\O\
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M ,)'0/\ Y7T!KY?CY?\ !_#S#_A:/PS_ .BB>!?_  KM _\ EA1_PM'X9_\
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MAG_T3OP+_P"$CH'_ ,KZ U\OQ\O^#^'F'_"T?AG_ -%$\"_^%=H'_P L*/\
MA:/PS_Z*)X%_\*[0/_EA1_PJ[X9_]$[\"_\ A(Z!_P#*^C_A5WPS_P"B=^!?
M_"1T#_Y7T!KY?CY?\'\/,/\ A:/PS_Z*)X%_\*[0/_EA1_PM'X9_]%$\"_\
MA7:!_P#+"C_A5WPS_P"B=^!?_"1T#_Y7T?\ "KOAG_T3OP+_ .$CH'_ROH#7
MR_'R_P"#^'F'_"T?AG_T43P+_P"%=H'_ ,L*/^%H_#/_ **)X%_\*[0/_EA1
M_P *N^&?_1._ O\ X2.@?_*^C_A5WPS_ .B=^!?_  D= _\ E?0&OE^/E_P?
MP\P_X6C\,_\ HHG@7_PKM _^6%'_  M'X9_]%$\"_P#A7:!_\L*/^%7?#/\
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MB=^!?_"1T#_Y7T!KY?CY?\'\/,/^%H_#/_HHG@7_ ,*[0/\ Y84?\+1^&?\
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MAG_T3OP+_P"$CH'_ ,KZ U\OQ\O^#^'F'_"T?AG_ -%$\"_^%=H'_P L*/\
MA:/PS_Z*)X%_\*[0/_EA1_PJ[X9_]$[\"_\ A(Z!_P#*^C_A5WPS_P"B=^!?
M_"1T#_Y7T!KY?CY?\'\/,/\ A:/PS_Z*)X%_\*[0/_EA1_PM'X9_]%$\"_\
MA7:!_P#+"C_A5WPS_P"B=^!?_"1T#_Y7T?\ "KOAG_T3OP+_ .$CH'_ROH#7
MR_'R_P"#^'F'_"T?AG_T43P+_P"%=H'_ ,L*/^%H_#/_ **)X%_\*[0/_EA1
M_P *N^&?_1._ O\ X2.@?_*^C_A5WPS_ .B=^!?_  D= _\ E?0&OE^/E_P?
MP\P_X6C\,_\ HHG@7_PKM _^6%'_  M'X9_]%$\"_P#A7:!_\L*/^%7?#/\
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MB=^!?_"1T#_Y7T!KY?CY?\'\/,/^%H_#/_HHG@7_ ,*[0/\ Y84?\+1^&?\
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MAG_T43P+_P"%=H'_ ,L*/^%H_#/_ **)X%_\*[0/_EA1_P *N^&?_1._ O\
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M$CH'_P KZ U\OQ\O^#^'F'_"T?AG_P!%$\"_^%=H'_RPH_X6C\,_^BB>!?\
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M,_\ HHG@7_PKM _^6%'_  M'X9_]%$\"_P#A7:!_\L*/^%7?#/\ Z)WX%_\
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M[X9_]$[\"_\ A(Z!_P#*^C_A5WPS_P"B=^!?_"1T#_Y7T!KY?CY?\'\/,/\
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M#/\ Z)WX%_\ "1T#_P"5]'_"KOAG_P!$[\"_^$CH'_ROH#7R_'R_X/X>8?\
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M_P!6N?\ F;?_ ,4='_#]#_JUS_S-O_XHZ/\ B%''_P#T(/\ S*Y+_P#/$/\
MB=KZ,7_1S?\ S3/$'_Z%#^@"BOY__P#A^A_U:Y_YFW_\4='_  _0_P"K7/\
MS-O_ .*.C_B%''__ $(/_,KDO_SQ#_B=KZ,7_1S?_-,\0?\ Z%#^@"BOY_\
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M@"BOY_\ _A^A_P!6N?\ F;?_ ,4='_#]#_JUS_S-O_XHZ/\ B%''_P#T(/\
MS*Y+_P#/$/\ B=KZ,7_1S?\ S3/$'_Z%#^@"BOY__P#A^A_U:Y_YFW_\4='_
M  _0_P"K7/\ S-O_ .*.C_B%''__ $(/_,KDO_SQ#_B=KZ,7_1S?_-,\0?\
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M_-,\0?\ Z%#^@"BOY_\ _A^A_P!6N?\ F;?_ ,4='_#]#_JUS_S-O_XHZ/\
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M?_H4/Z **_G_ /\ A^A_U:Y_YFW_ /%'1_P_0_ZM<_\ ,V__ (HZ/^(4<?\
M_0@_\RN2_P#SQ#_B=KZ,7_1S?_-,\0?_ *%#^@"BOY__ /A^A_U:Y_YFW_\
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M $<W_P TSQ!_^A0_H HK^?\ _P"'Z'_5KG_F;?\ \4='_#]#_JUS_P S;_\
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M:^C%_P!'-_\ -,\0?_H4/Z **_G_ /\ A^A_U:Y_YFW_ /%'1_P_0_ZM<_\
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M%'_DF?Q$_P"Q%\7?^H_J%=U7"_%'_DF?Q$_[$7Q=_P"H_J% '=4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<+I__)3/%W_8B_#O_P!2#XHUW5<+I_\ R4SQ=_V(OP[_ /4@^*- '=44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?E!_P7"_:\^,O[!W_  2[_:>_:N_9^O?#^G?%WX5?\*6_X1*\
M\4Z#!XFT*'_A.?VAOA-\-]>^W:)<RPP7OF>&/&&M16N^5?LUX]O=KN>W53]8
M?L&?%[QE^T'^PU^QC\>_B-/I]S\0OC?^RA^SK\7O'=SI-A'I6E7'C+XE?"#P
M?XS\43Z9ID3/%IVGRZWK5])96$;O'9VS1VZ,RQ@G\L/^#H[_ )04?MS?]VS?
M^MA_L^U]_P#_  2=_P"467_!-/\ [, _8W_]9U^'- 'W_1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PN
MG_\ )3/%W_8B_#O_ -2#XHUW5<+I_P#R4SQ=_P!B+\.__4@^*-=U0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3Z'NX*-*.%H1H3=2BJ:]G.2:<HW>K346GOHXI^04445PG4%%%% !1110 5_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=_V(OP[_ /4@^*- '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3EBYX9YKC<#3Q=>G&I&<<%A9UL;6@ISHX>I&E4</S)HHHKU3XP**_4#]F_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJQ:7=U875M?6-S<65]97$-W9WEI-);7=I=VTJS6]U:W$+)-;W%O,B2P3Q.DL
M4J+)&RNH(KT4-)III--6:>J:>Z:ZICC*4)1G"3C*+4HRBW&491=U*+5FFFDT
MTTTU=']//_!.;_@HQ:_&RTTKX)?&W5;>R^,%C;):>%O%-V\5M:_$ZTMH\+;7
M+?NX8/'%O$FZ>!0D?B*-6N[-%U!;FVD_8>OX![.\N]/N[6_L+JXLKZRN(;NR
MO;2:2VN[2[MI%FM[FVN(62:"X@F1)89HG22*1%=&5E!'].?_  3G_P""C%K\
M;K32_@G\;-4M[+XP6-LEKX7\473QVUI\3;2VCPMO<L=D-OXW@B3=/ NR/Q#&
MK7=FBWZW-M)_,WB;X9O+W7XBX=P[> ;E5S++:,;_ %%OWIXK"PCK]3;O*M1B
MO]D=YTU]5;CAO]??H?\ TOX\41RSPJ\5,SC'B:$:6!X2XLQU51CQ%&*C3P^2
MYS7J-)9_%)4\!CZDK9VE'#XB7]L*G4S;]A:***_"#_2H*X7XH_\ ),_B)_V(
MOB[_ -1_4*[JN%^*/_),_B)_V(OB[_U']0H [JBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA=/_ .2F
M>+O^Q%^'?_J0?%&NZKA=/_Y*9XN_[$7X=_\ J0?%&@#NJ*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X73_ /DIGB[_
M +$7X=_^I!\4:[JN%T__ )*9XN_[$7X=_P#J0?%&NZH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVA6/B..\TF[N)[>PMQI]GXBT*>:70+'P[K&FZ7/_ "PU^SO_  1*\1:C;?M
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MB)_V(OB[_P!1_4*[JN%^*/\ R3/XB?\ 8B^+O_4?U"OQ$_T2.ZHHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#SCXG?![X4?&KP]+X3^+WPV\#
M_$SPW*DR?V/XY\,:/XFLH&G\HO<64>K6ET=/O5D@MYH+^Q:WO;:YMK:YMYXK
MBV@EC_%#]IK_ (-[OV2_BG9:MJ_P"UCQ/^SIXWGDDN[&SMKN]\>_#&>XEDBF
MN;>^\+>(M0/B33H[EHY8K&3P]XRT_3=!-[++%X=U2SM;+2(N]\!_\%L_AO\
M%S]M#3?V2?A!\!_B%\1]-U3X@2^ K3XKZ)KVC"RDBTJ]:U\4^/%\*-922?\
M"O/#UI::MXADUR3Q%%J-YX:TX:BFB07=U'IJ_MS7J*>:Y/.E:I6PDJD%6A3]
MI&490D])3H\TX:M-<M2"E=--:,X'# 9C&;Y*6(49.G*?(U)22U4:MHRT36L)
M-;:G\"?[0G_!#[]OGX%-?ZCHOP[L/COX4M'NWCUWX*:C)XEU9K6*/[1;>?X
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M/@N]TZ:9[:%-+N]5FBN&EEBMKC^9VOZ./V)/VD_@_P#&#]A[Q3^SS^T!\7?
M/P\U;2-"\3?!ZRG\8^-_"/A#4]0\!ZMX>6'PGKNC1:Z-,M9)_#45_-H,!2WU
MIXY/#-AJ.K2SS:G]G/\ .==6\EI<W%I*T#RVL\MO(]K=6U[;-)#(T;M;WME+
M<6=W S*3%=6D\UM<1E98)9(G1VT\,J>.RK"YYPKCX5N;A[-JT,%7J1G&GB,N
MQLIUJ$Z$I1C&HG5A7K3Y'[BQ-.$H0=E+C^F!B>'.-,Y\._&CAG$9>Z?BGP3@
ML1Q#EN$K4*F+RKBOA^GAL!F5#,:-.M5JX:<<)7R_+Z"Q$5]8EE6)K4:^)@W*
MG_3K^Q+=VO[87_!-[Q+\#_$,Z3ZWX<T;Q7\&?[0U?2].N[>QNM.M+?Q#\+=>
MM;"&:"*ZM_"5MJ/A6"PGG;3=1DU3PG-.UPMTD6L7'%?\$M_ ]G^SC^RQ\<?V
MD/B)IEQHUWJ%[XIO+ZVU"WNK+4[;PE\&+76+*YTUK:[@%Q9:M/XR'C#2;G3H
M;1[F:\T[3K>9;B\BBL[3\^O^"47[1.A_ _\ :#U7P]XY\5Z?X3^'?Q4\)WFD
MZQJ>O:CHVB^%]-\4>%UGU_PIK6OZUK%U8QZ=#%9KXG\.6#)<M'/J7BNU@GM7
MWQ75C]T_\%1/VL_A1%^S]IWP5^ ?Q)\!>*)_B7XKNK_QJOPZ\3:-XIM=/\)V
MVHW7BG6+6[O_  _>7]MI%WXF\9W>F7+P/=P37NF0:W9?8Y=.O)]GP6=Y'F]+
MB3-N"<'AJ[R/B_/,KSVIB:5.I'#X3!\U?$9M3<H4W3A-XBA!TXN:C&&#H148
M^V2C_3'AWXB\"XSPEX)^D+G^:Y:O$7P)\.>,O#?"Y1C<9A:F:9[GSI99EG!&
M+C1KXB.*Q%".6YEBH8JM&A*K/$9[F%652LL!*57^?;Q?XIU?QQXL\4>-?$$R
MW.O>,/$6M^*=;N$#A)]7\0:E<ZMJ4RB2260++>W<SJ))9' 8!I';+'G:**_H
MJ$(4X0ITXJ%.G&,(0BK1A""48QBEHE&*22Z)'^5.(Q%?%UZ^*Q-6=?$XFM4Q
M&(KU9.=2M7K3E4JU:DW=RG4J2E.<F[RDVWJPK^I#Q1_RATM?^S;_  A_Z4:)
M7\M]?U'_  -^*?[*'Q>_8#\ ? [XC?M!?#SP"-7^%FF>!?%>G:E\2/ O@_QM
MHE[H-TMI=-'I?BRZDDMUDO-+6XLKBZTJ:WU'3)X;JU)CN8IE_*O%2-6%/A'&
M0P^)Q%' <48+%XKZKAZN(G3HT5*K.7)2C*5W&G+E6G-)<J=V?VI]"VI@J^,\
M;\AKYKE&68_B7P;XAR3)_P"V,SPF5X?%9ACZM'!T*2Q&,JTJ:2K8FBZK3DZ=
M.3J27+%L_EPK^GO_ ((Z>,?%7CW]FCQSX*\:K_PD/@_P;XWN_"_A<ZPL-_;_
M -@ZWH%CJ6L^#I+>='6YTC3Y[Z2\C@O%G7R?$DVGJW]GVUK:V_SE_P ,!?\
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M?59C'H_C#1XM;URYM+ 2:C$OAS4M.T?[7"PEL_$%_:VT\EW?RQ\'&G!>.RG
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M]@/^"*7_ "=/X^_[-_\ %7_JQ?A57U?XJ_96_P""1GQ4N[OQ!H'Q]\(?"_\
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MOYB_\$M_^3[?@9_W4W_U3OQ!KUG_ (+'?\G>6_\ V2;P5_Z<O%%>,?\ !/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<+I_\ R4SQ=_V(OP[_ /4@^*-=U7"Z?_R4SQ=_
MV(OP[_\ 4@^*- '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?@#_P '1W_*"C]N;_NV;_UL/]GVOO\
M_P""3O\ RBR_X)I_]F ?L;_^LZ_#FON_5=)TK7+"?2M;TS3]8TRZ\K[3IVJV
M5MJ%A<^1-'<P^?9W<<UO-Y-Q#%/%YD;>7-%'*F'16%BTM+2PM;:PL+:WLK&R
MMX;2SL[2&.VM;2TMHUAM[:VMX52&"W@A1(H88D2.*-%1%55  !8HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH X73_ /DIGB[_ +$7X=_^I!\4:[JN%T__ )*9XN_[$7X=_P#J0?%&NZH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[2VF@>_%Q'<^!_"5@VH6-Q!#;6NIW5E>I/\ VI;>5_7O7^=[\)_B_P#M'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X73_ /DIGB[_ +$7
MX=_^I!\4:[JN%T__ )*9XN_[$7X=_P#J0?%&@#NJ*** "BBB@ HHHH ****
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M-0N;#1X]9UR]73+*XU"^GM;(002WES)&TS_E1_P='?\ *"C]N;_NV;_UL/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.MH[/3],TS3[..&TL-/L+2&&ULK*UABMK6VBC@@CCBC51^8'_!:W]LGXN?\
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M#_B!/C?_ -&;\5?_ !7G%W_SG/S_ **_0#_AUO\ MV_]$,_\R;\'?_G@T?\
M#K?]NW_HAG_F3?@[_P#/!H_UOX3_ .BHX=_\/>6__-(?\0)\;_\ HS?BK_XK
MSB[_ .<Y^?\ 17Z ?\.M_P!NW_HAG_F3?@[_ //!H_X=;_MV_P#1#/\ S)OP
M=_\ G@T?ZW\)_P#14<._^'O+?_FD/^($^-__ $9OQ5_\5YQ=_P#.<_/^BOT
M_P"'6_[=O_1#/_,F_!W_ .>#1_PZW_;M_P"B&?\ F3?@[_\ /!H_UOX3_P"B
MHX=_\/>6_P#S2'_$"?&__HS?BK_XKSB[_P"<Y^?]%?H!_P .M_V[?^B&?^9-
M^#O_ ,\&C_AUO^W;_P!$,_\ ,F_!W_YX-'^M_"?_ $5'#O\ X>\M_P#FD/\
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M3?@[_P#/!H_UOX3_ .BHX=_\/>6__-(?\0)\;_\ HS?BK_XKSB[_ .<Y^?\
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MBK_XKSB[_P"<Y^?]%?H!_P .M_V[?^B&?^9-^#O_ ,\&C_AUO^W;_P!$,_\
M,F_!W_YX-'^M_"?_ $5'#O\ X>\M_P#FD/\ B!/C?_T9OQ5_\5YQ=_\ .<_/
M^BOT _X=;_MV_P#1#/\ S)OP=_\ G@T?\.M_V[?^B&?^9-^#O_SP:/\ 6_A/
M_HJ.'?\ P]Y;_P#-(?\ $"?&_P#Z,WXJ_P#BO.+O_G.?G_17Z ?\.M_V[?\
MHAG_ )DWX.__ #P:/^'6_P"W;_T0S_S)OP=_^>#1_K?PG_T5'#O_ (>\M_\
MFD/^($^-_P#T9OQ5_P#%><7?_.<_/^BOT _X=;_MV_\ 1#/_ #)OP=_^>#1_
MPZW_ &[?^B&?^9-^#O\ \\&C_6_A/_HJ.'?_  ]Y;_\ -(?\0)\;_P#HS?BK
M_P"*\XN_^<Y^?]%?>4?_  3)_;?EU.[T>/X);M2L+#3M3N[;_A9/PC'E66K7
M&J6NGS^<WCX0/]HGT74X_+CE>:+[-NGCC2:W:6]_PZW_ &[?^B&?^9-^#O\
M\\&C_6_A/_HJ.'?_  ]Y;_\ -(?\0)\;_P#HS?BK_P"*\XN_^<Y^?]%?H!_P
MZW_;M_Z(9_YDWX.__/!H_P"'6_[=O_1#/_,F_!W_ .>#1_K?PG_T5'#O_A[R
MW_YI#_B!/C?_ -&;\5?_ !7G%W_SG/S_ **_0#_AUO\ MV_]$,_\R;\'?_G@
MT?\ #K?]NW_HAG_F3?@[_P#/!H_UOX3_ .BHX=_\/>6__-(?\0)\;_\ HS?B
MK_XKSB[_ .<Y^?\ 17Z ?\.M_P!NW_HAG_F3?@[_ //!H_X=;_MV_P#1#/\
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MG_T5'#O_ (>\M_\ FD/^($^-_P#T9OQ5_P#%><7?_.<_/^BOT _X=;_MV_\
M1#/_ #)OP=_^>#1_PZW_ &[?^B&?^9-^#O\ \\&C_6_A/_HJ.'?_  ]Y;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_DIGB[_L1?AW_P"I!\4:[JN%T_\ Y*9XN_[$7X=_^I!\4:[J@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA
M?BC_ ,DS^(G_ &(OB[_U']0KNJX7XH_\DS^(G_8B^+O_ %']0H [JBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KA=/\ ^2F>+O\ L1?AW_ZD'Q1KNJX73_\ DIGB[_L1?AW_ .I!\4:
M.ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM/M5[9^9):S)<0-]HL+BUNE\N:-'PDRAL;7#*2I\L_X9J^"G_0E_^7'XL_\
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M#;Q;W).R&*.-<X5%'% 2BY6M;2^_R/%OV-?^19\9_P#8=L/_ $WM7J_[2O\
MR13QI_W+G_J6Z#7H/@SX?>$/A]:WMGX0TC^R+;4)X[F\C^WZG?\ G3Q1^5&^
M_4[V]DCVQG;MB9$/5E+<UK>)?#6B>,-$O?#OB*R_M'1M1^S?;+/[3=VGG?9+
MN"^M_P#2+&>UNH_+NK6"7]U.F_9L?=&SHP5;W;>5OP/Q,K]P=*_Y!>F_]>%G
M_P"D\=>-?\,U?!3_ *$O_P N/Q9_\OJ]PBBC@BCAB7;%#&D4:Y+;8XU"(NYB
M6.% &6))QDDGF@F,7&][:V_4_,3]JS_DKEY_V M$_P#1$M=9^QS_ ,CQXH_[
M%0_^G?3:^P_%?P9^&OC?5WUWQ1X;_M/59((+9[K^V-?LLP6RE84\C3]4M+8;
M%8C<(0[9R[,:M^#?A/\ #_X?WUUJ7A'0/[)O;VT^PW,W]JZU?^;:^='<>5Y>
MIZE>Q)^]AC??'&DGR[=^TLI <6Y7TM=?A8VO'G_(C^,_^Q4\1?\ IHO*_%JO
MW%O[&UU.QO=-OHO/LM0M+FQO(=\D7G6MW"]O<1>9"\<L?F12.F^*1)$SN1U8
M!AXM_P ,U?!3_H2__+C\6?\ R^H"47*UK:7W^1N_ S_DD?@/_L!1?^CYZ^7_
M -L[_D*> ?\ KP\0?^E&E5]PZ%H>E^&M(L-"T2U^Q:5ID MK&U\^XN?(@5F8
M)Y]W-/<RX9F.Z::1^<%L 5R_C3X8>!OB%+I\WC#0_P"UY=+CN(K%O[3UC3_(
MCNFB>==NEZA9++YC01',PD*[<(5#,"#:;C;K9?A8_.']FK_DM?@O_N8__42U
MZOU<KRCPU\#_ (7^#];LO$7AWPQ_9VLZ=]I^QWG]M>(;OR?M=I/8W'^CWVK7
M5K)YEK=3Q?O8'V;]Z;9%1U]7H"*:5GW_ ,C\3/%'_(S>(O\ L.ZO_P"G"XK]
M%/V2/^25W'_8UZO_ .D>E5V5U^SI\&KVZN;RY\'>;<W<\US<2?\ "0^*D\R>
M>1I97V1ZXD:;Y'9MJ*J+G"JJ@ >B^$?!GAKP)I3:)X5TW^RM,:[FOFM?ME_?
M9NITBCEE\[4KJ\N!O2"(;!*(UVY5%+,2"C%IW=MO\CYY_;"_Y)GH?_8]:9_Z
MC_B>O@CP'_R/'@S_ +&OP[_Z=[.OUZ\8^!_"_C[3(-'\6Z7_ &MIMM?Q:G!;
M?;=1L-E[#;W5K'/YVF7=G.VV"\N8_+>5H3YFYHRZ1LG V'[/'P>TR^LM2L?"
M'D7NGW=O?6<W_"0>*)?)NK29+BWE\N;6Y(I/+EC1]DL;QOC:Z,I*D!Q;E?2U
MU^%CVFOR4_:#_P"2Q^./^O\ L?\ TS:;7ZUUY)XA^!?PK\5:S?>(->\+?;]7
MU*2.6]N_[;\1VOG210QVZ-]GLM7M[6/;##&F(H8P=NX@L68@Y)M67?\ S/G+
M]BW_ )J5_P!R=_[M5?0?[0?_ "1SQQ_UX6/_ *>=-KJ_!7PU\$_#S^T_^$.T
M7^Q_[8^Q_P!H_P#$QU;4/M']G_:_LG_(4O[WR?)^VW7^H\KS/-_>[]D>SH?$
M/A_2/%6C7WA_7K3[?I&I1QQ7MI]HNK7SHXIH[A%^T64UO=1[9H8WS%-&3MVD
ME2RD!)J-NMG^-S\2*_;/PO\ \BSX=_[ 6D?^F^WKRC_AFKX*?]"7_P"7'XL_
M^7U>VVMM!96MM9VR>5;6D$-M;Q[G?RX((UBB3?(SR/LC15W.S.V,LS,22"C%
MQO>VMOU/SD_;"_Y*9H?_ &(NF?\ J0>)ZH?LD?\ )5+C_L5-7_\ 2S2J^Z?&
M/PB^'GC[4X-8\6^'O[6U*VL(M,@N?[6URPV64-Q=74<'DZ9J=G VV>\N9/,>
M)ICYFUI"B1JD?A'X._#CP)JK:WX5\._V5J;6DUBUU_:^NWV;6=XI)8O)U+4[
MRW&]X(CO$0D7;A74,P(#BW*^EKK\+'7^*/\ D6?$7_8"U?\ ]-]Q7XF5^Y-U
M;07MK<V=RGFVUW!-;7$>YT\R">-HI4WQLDB;XW9=R,KKG*LK $>)?\,U?!3_
M *$O_P N/Q9_\OJ E%RM:VE]_D7_ -GS_DCG@?\ Z\+[_P!/.I5X7^V=_P @
MOP#_ -?_ (@_])]*K[ \/>'](\*Z-8^']!M/L&D:;')%96GVBZNO)CEFEN'7
M[1>S7%U)NFFD?,LTA&[:"%"J,+QI\.?!OQ"BT^'QAH_]KQ:7)<2V*_VAJNG^
M1)=+$D[;M+OK)I?,6"(8F,@7;E I9B0;3<;=;+\+'Y>? S_DKG@/_L.Q?^B)
MZ_7FO(="^ WPH\-:O8:[HGA7[%JNF3BYL;K^W/$ESY$ZJRA_(N]8GMI<*S#;
M-#(G.2N0*]>H"*:5GW_R/Q:\>?\ (\>,_P#L:_$7_IWO*^]_V/?^29ZY_P!C
MUJ?_ *C_ (8KT6__ &>/@]J=]>ZE?>$//O=0N[F^O)O^$@\41>==7<SW%Q+Y
M<.MQQ1^9+([[(HTC3.U$50%'?>#O _A?P#ID^C^$M+_LG3;F_EU.>V^VZC?[
M[V:WM;62?SM3N[R==T%G;1^6DJPCR]RQAWD9P48M.[MM_D>,_M6?\DCO/^P[
MHG_H^6OS/TK_ )"FF_\ 7_9_^E$=?L[XK\(>'?&^D/H7BC3_ .T]*DG@N7M?
MM=]99GMF+0OY^GW-I<C8S$[1,$;.'5A7F<7[-_P7@ECFB\&;989$EC;_ (2+
MQ6VV2-@Z-M;72IPP!PP(.,$$<4!*+;NK;?YGN%?E'^TK_P EK\:?]RY_ZB6@
MU^KE>4>)?@?\+_&&MWOB+Q%X8_M'6=1^S?;+S^VO$-IYWV2T@L;?_1['5K6U
MC\NUM8(OW4";]F]]TC.[ Y)M67?_ #/E_P#8Q_Y"GC[_ *\/#_\ Z4:K7U=\
M8O\ DE?Q _[%36?_ $CDJWX+^&'@;X>RZA-X/T/^R)=4CMXKYO[3UC4//CM6
ME>!=NJ:A>K%Y;3RG,(C+;L.6"J!UFLZ1IVOZ5J&B:O;_ &O3-5M)K&_M?.G@
M\^UN$,<T7G6TL-Q%O0D;X98Y%SE74\T#BK)+^MS\0:_9;X7?\DS^'?\ V(OA
M'_U']/KA?^&:O@I_T)?_ )<?BS_Y?5[-I>F66BZ9IVCZ9!]FTW2;"TTS3[;S
M)IOL]E86\=K:0>=<22SR^5!%''YD\LDS[=TDCN68A,8M.[MM_D?G7^V%_P E
M,T/_ +$73/\ U(/$]87[*?\ R5RS_P"P%K?_ *(BK[+\2_#7P3\0_B9K?_"8
MZ+_;']C^!? _]G?\3'5M/^S_ -H>(/B-]K_Y!=_9>=YWV*U_U_F^7Y7[K9OD
MW])X4^#/PU\$:NFN^%_#?]F:K'!/;)=?VQK][B"Y4+,GD:AJEW;'>J@;C"77
M&4930#BW*^EKK\+'J%?A?7[H5X7_ ,,U?!3_ *$O_P N/Q9_\OJ E%RM:VE]
M_D4/V7O^2.>'_P#K_P!?_P#3S>5YO^V5_P BSX,_[#M__P"F]:^JO"_A70?!
MFC6_A_PU8?V;I%K)<2P6GVJ]O/+DNIGN)V^T7]Q=73>9-([X>9@N=J!5 49O
MC/X?>$/B#:V5GXOTC^U[;3YY+FSC^WZG8>3/+'Y4C[],O;*23=&-NV5G0=54
M-S0-IN-NME^%C\J_@[_R53X?_P#8UZ-_Z61U^P]>.Z-\ OA+H&JZ?K>D>$_L
MFIZ5=PWUA=?V[XEG\BZMW$D,ODW.LS6\NQP#LFBDC;&&1AQ7L5 132L^_P#D
M?CQ\8O\ DJGQ _[&O6?_ $LDKZ\_8U_Y%GQG_P!AVP_]-[5[3K/P"^$NOZKJ
M&MZOX3^UZGJMW-?7]U_;OB6#S[JX<R32^3;:S#;Q;W).R&*.-<X5%'%=?X,^
M'WA#X?6M[9^$-(_LBVU">.YO(_M^IW_G3Q1^5&^_4[V]DCVQG;MB9$/5E+<T
M"C%IW=MO\CR_]J'_ )(YX@_Z_P#0/_3S9U^65?M?XH\*Z#XST:X\/^);#^TM
M(NI+>6>T^U7MGYDEK,EQ WVBPN+6Z7RYHT?"3*&QM<,I*GRS_AFKX*?]"7_Y
M<?BS_P"7U 2BV[JVW^9[I7Y@?M6?\E<O/^P%HG_HB6OT_KR_Q7\&?AKXWU=]
M=\4>&_[3U62""V>Z_MC7[+,%LI6%/(T_5+2V&Q6(W"$.V<NS&@J2NFOZW/CS
M]CG_ )'CQ1_V*A_].^FU]L_%'_DF?Q$_[$7Q=_ZC^H54\&_"?X?_  _OKK4O
M".@?V3>WMI]AN9O[5UJ_\VU\Z.X\KR]3U*]B3][#&^^.-)/EV[]I93V^J:99
M:UIFHZ/J<'VG3=6L+O3-0MO,FA^T65_;R6MW!YUO)%/%YL$LD?F02QS)NW1R
M(X5@"BFE9]_\C\/:_8?X._\ )*_A_P#]BIHW_I''7*?\,U?!3_H2_P#RX_%G
M_P OJ]BT;2-.T#2M/T32+?[)IFE6D-C86OG3S^1:VZ".&+SKF6:XEV( -\TL
MDC8RSL>:!1BT[NVW^1\-?MG?\A3P#_UX>(/_ $HTJO&OV:O^2U^"_P#N8_\
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M_E]7NE!,8N-[VUM^I^67[4/_ "6/Q!_UX:!_Z9K.O2/V-?\ D9O&?_8"L/\
MTX-7UEXH^"GPR\9ZS<>(/$OAG^TM7NH[>*>[_MGQ!9^9':PI;P+]GL-5M;5?
M+AC1,I"I;&YRS$L=+P9\*_ ?P^NKV\\(:%_9%SJ$$=M>2?VIK-_YT$4GFQIL
MU/4;V./;(=VZ)4<]&8KQ0"BU*^EKO\;D_P 4?^29_$3_ +$7Q=_ZC^H5^--?
MN%JFF66M:9J.CZG!]ITW5K"[TS4+;S)H?M%E?V\EK=P>=;R13Q>;!+)'YD$L
M<R;MT<B.%8>,_P##-7P4_P"A+_\ +C\6?_+Z@)1<K6MI??Y'5_!W_DE?P_\
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MKZ;))+97?]M^([KR9)89;=V^SWNKW%K)NAFD3$L,@&[< &"L/6Z BFE9]_\
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M5R!7KU 132L^_P#D?C3\4?\ DIGQ$_['KQ=_ZD&H5]L_L<_\B/XH_P"QK/\
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MMJ$\=S>1_;]3O_.GBC\J-]^IWM[)'MC.W;$R(>K*6YH%&+3N[;?Y'GW[2O\
MR13QI_W+G_J6Z#7Y1U^V?B7PUHGC#1+WP[XBLO[1T;4?LWVRS^TW=IYWV2[@
MOK?_ $BQGM;J/R[JU@E_=3IOV;'W1LZ-Y1_PS5\%/^A+_P#+C\6?_+Z@)1;=
MU;;_ #/9=*_Y!>F_]>%G_P"D\=?F?^U9_P E<O/^P%HG_HB6OT[BBC@BCAB7
M;%#&D4:Y+;8XU"(NYB6.% &6))QDDGFO,_%?P9^&OC?5WUWQ1X;_ +3U62""
MV>Z_MC7[+,%LI6%/(T_5+2V&Q6(W"$.V<NS&@J2NFOZW/CS]CG_D>/%'_8J'
M_P!.^FU]T>//^1'\9_\ 8J>(O_31>5B^#?A/\/\ X?WUUJ7A'0/[)O;VT^PW
M,W]JZU?^;:^='<>5Y>IZE>Q)^]AC??'&DGR[=^TLI[J_L;74[&]TV^B\^RU"
MTN;&\AWR1>=:W<+V]Q%YD+QRQ^9%(Z;XI$D3.Y'5@& **:5GW_R/PZK]>?@9
M_P DC\!_]@*+_P!'SUA?\,U?!3_H2_\ RX_%G_R^KU[0M#TOPUI%AH6B6OV+
M2M,@%M8VOGW%SY$"LS!//NYI[F7#,QW332/S@M@"@48M.[MM_D?#W[9W_(4\
M _\ 7AX@_P#2C2J\:_9J_P"2U^"_^YC_ /42UZOT>\:?##P-\0I=/F\8:'_:
M\NEQW$5BW]IZQI_D1W31/.NW2]0LEE\QH(CF82%=N$*AF!QO#7P/^%_@_6[+
MQ%X=\,?V=K.G?:?L=Y_;7B&[\G[7:3V-Q_H]]JUU:R>9:W4\7[V!]F_>FV14
M=0'%N5]+77X6/5Z_$SQ1_P C-XB_[#NK_P#IPN*_;.O$KK]G3X-7MU<WESX.
M\VYNYYKFXD_X2'Q4GF3SR-+*^R/7$C3?([-M151<X554  "47*UK:7W^1QO[
M)'_)*[C_ +&O5_\ TCTJJ'[87_),]#_['K3/_4?\3U]#>$?!GAKP)I3:)X5T
MW^RM,:[FOFM?ME_?9NITBCEE\[4KJ\N!O2"(;!*(UVY5%+,2SQCX'\+^/M,@
MT?Q;I?\ :VFVU_%J<%M]MU&PV7L-O=6L<_G:9=V<[;8+RYC\MY6A/F;FC+I&
MR VFXVZV7X6/R%\!_P#(\>#/^QK\._\ IWLZ_:6O%K#]GCX/:9?66I6/A#R+
MW3[NWOK.;_A(/%$ODW5I,EQ;R^7-K<D4GERQH^R6-XWQM=&4E3[30$4TK/O_
M )'Y*?M!_P#)8_''_7_8_P#IFTVOH/\ 8M_YJ5_W)W_NU5]&^(?@7\*_%6LW
MWB#7O"WV_5]2DCEO;O\ MOQ':^=)%#';HWV>RU>WM8]L,,:8BAC!V[B"Q9CT
M/@KX:^"?AY_:?_"':+_8_P#;'V/^T?\ B8ZMJ'VC^S_M?V3_ )"E_>^3Y/VV
MZ_U'E>9YO[W?LCV E%J5]+7?XW.4_:#_ .2.>./^O"Q_]/.FU^2E?MOXA\/Z
M1XJT:^\/Z]:?;](U*..*]M/M%U:^='%-'<(OVBRFM[J/;-#&^8IHR=NTDJ64
M^2?\,U?!3_H2_P#RX_%G_P OJ E%MW5MO\SU?PO_ ,BSX=_[ 6D?^F^WK\^O
MVPO^2F:'_P!B+IG_ *D'B>OT;M;:"RM;:SMD\JVM((;:WCW._EP01K%$F^1G
MD?9&BKN=F=L99F8DGS[QC\(OAYX^U.#6/%OA[^UM2MK"+3(+G^UM<L-EE#<7
M5U'!Y.F:G9P-MGO+F3S'B:8^9M:0HD:H%25TU_6Y\+?LD?\ )5+C_L5-7_\
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M?,:"(YF$A7;A"H9@0;3<;=;+\+'YP_LU?\EK\%_]S'_ZB6O5^KE>4>&O@?\
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MJPCR]RQAWD9P48M.[MM_D?*/[4__ ![^)O\ KP^$G_IT^,U?$OA?_D9O#O\
MV'=(_P#3A;U^J.O>#/#7COQOXLT3Q5IO]JZ8OA#X:WRVWVR_L<74&N_%:.*7
MSM-NK.X.Q)Y1L,IC;=ED8JI%2U_9T^#5E=6UY;>#O*N;2>&YMY/^$A\5/Y<\
M$BRQ/LDUQXWV2(K;75D;&&5E)! <6Y7TM=?A8]MK\H_VE?\ DM?C3_N7/_42
MT&OU<KRCQ+\#_A?XPUN]\1>(O#']HZSJ/V;[9>?VUXAM/.^R6D%C;_Z/8ZM:
MVL?EVMK!%^Z@3?LWOND9W8')-JR[_P"9\O\ [&/_ "%/'W_7AX?_ /2C5:^H
M/CG_ ,DC\>?]@*7_ -'P5L^"_AAX&^'LNH3>#]#_ +(EU2.WBOF_M/6-0\^.
MU:5X%VZIJ%ZL7EM/*<PB,MNPY8*H'4:[H>E^)=(O]"UNU^VZ5J<!MKZU\^XM
MO/@9E8IY]I-!<Q995.Z&:-^,!L$T#BK)+^MS\1:_:7P'_P B/X,_[%3P[_Z:
M+.O-O^&:O@I_T)?_ )<?BS_Y?5[386-KIEC9:;8Q>19:?:6]C9P[Y)?)M;2%
M+>WB\R9Y)9/+BC1-\LCR/C<[LQ+$)C%IW=MO\C\]_P!L;_D>/"__ &*@_P#3
MOJ5<G^RG_P E<L_^P%K?_HB*OOKQE\)_A_\ $"^M=2\7:!_:U[96GV&VF_M7
M6K#RK7SI;CRO+TS4K*)_WLTC[Y(WD^;;OVA5%3PI\&?AKX(U=-=\+^&_[,U6
M.">V2Z_MC7[W$%RH69/(U#5+NV.]5 W&$NN,HRF@'%N5]+77X6/0=5_Y!>I?
M]>%Y_P"D\E?A]7[F2Q1SQ2PRKNBFC>*1<E=T<BE'7<I##*DC*D$9R"#S7A__
M  S5\%/^A+_\N/Q9_P#+Z@)1<K6MI??Y!^S5_P D4\%_]S'_ .I;KU>4?ME?
M\BSX,_[#M_\ ^F]:^KO#7AK1/!^B67AWP[9?V=HVG?:?L=G]IN[OR?M=W/?7
M'^D7T]U=2>9=74\O[V=]F_8FV-41<GQG\/O"'Q!M;*S\7Z1_:]MI\\ES9Q_;
M]3L/)GEC\J1]^F7ME))NC&W;*SH.JJ&YH&TW&W6R_"Q^5?P=_P"2J?#_ /[&
MO1O_ $LCK]AZ\=T;X!?"70-5T_6](\)_9-3TJ[AOK"Z_MWQ+/Y%U;N)(9?)N
M=9FMY=C@'9-%)&V,,C#BO8J BFE9]_\ (_&GXH_\E,^(G_8]>+O_ %(-0K[9
M_8Y_Y$?Q1_V-9_\ 31IM>L:I^S[\(=:U/4=8U/PC]IU+5K^[U/4+G^W_ !/#
M]HO;^XDNKN?R;?6HH(O-GEDD\N"*.%-VV.-$"J.V\&^ O"?P_L;K3?".E?V3
M97MW]NN8?MVI7_FW7DQV_F^9J=Y>RI^ZAC39'(D?R[MFXLQ!1BT[NVW^1Y7^
MU#_R1SQ!_P!?^@?^GFSK\LJ_:_Q1X5T'QGHUQX?\2V']I:1=26\L]I]JO;/S
M)+69+B!OM%A<6MTOES1H^$F4-C:X925/EG_#-7P4_P"A+_\ +C\6?_+Z@)1;
M=U;;_,]TK\LOVH?^2Q^(/^O#0/\ TS6=?J;7EGBCX*?#+QGK-QX@\2^&?[2U
M>ZCMXI[O^V?$%GYD=K"EO OV>PU6UM5\N&-$RD*EL;G+,2Q!R3:LN_\ F?)O
M[&O_ ",WC/\ [ 5A_P"G!J^R_BC_ ,DS^(G_ &(OB[_U']0J#P9\*_ ?P^NK
MV\\(:%_9%SJ$$=M>2?VIK-_YT$4GFQILU/4;V./;(=VZ)4<]&8KQ79ZIIEEK
M6F:CH^IP?:=-U:PN],U"V\R:'[197]O):W<'G6\D4\7FP2R1^9!+',F[='(C
MA6 .*LDOZW/P]K]A_@[_ ,DK^'__ &*FC?\ I''7*?\ #-7P4_Z$O_RX_%G_
M ,OJ]BT;2-.T#2M/T32+?[)IFE6D-C86OG3S^1:VZ".&+SKF6:XEV( -\TLD
MC8RSL>:"8Q:=W;;_ "/@S]LK_D9O!G_8"O\ _P!."UYO^R]_R6/P_P#]>&O_
M /IFO*_0SQG\*_ ?Q!NK*\\7Z%_:]SI\$EM9R?VIK-AY,$LGFR)LTS4;*.3=
M(-VZ57<=%8+Q6;X7^"GPR\&:S;^(/#7AG^S=7M8[B*"[_MGQ!>>7'=0O;SK]
MGO\ 5;JU;S(9'3+PL5SN0JP# !Q;E?2UU^%CU.OP^U7_ )"FI?\ 7_>?^E$E
M?N#7A\O[-_P7GEEFE\&;I9I'ED;_ (2+Q6NZ21B[MM770HRQ)PH &<  <4!*
M+E:UM+[_ ".>_93_ .21V?\ V'=;_P#1\5<G^V-_R(_A?_L:Q_Z:-2KZ9\*>
M$/#O@C2$T+POI_\ 9FE1SSW*6OVN^O<3W+!IG\_4+F[N3O90=IF*+C"*HJIX
MR\!>$_B!8VNF^+M*_M:RLKO[=;0_;M2L/*NO)EM_-\S3+RRE?]U-(FR21X_F
MW;-P5@#:;C;K9?A8_)CX7?\ )3/AW_V/7A'_ -2#3Z_9:O&M+_9]^$.BZGIV
ML:9X1^S:EI-_::GI]S_;_B>;[/>V%Q'=6D_DW&M2P2^5/%')Y<\4D+[=LD;H
M64^RT!%-*S[_ .1^0WQS_P"2N>//^P[+_P"B(*^H/V,?^07X^_Z__#__ *3Z
MK7O>N_ ;X4>)=7O]=UOPK]MU74YS<WUU_;GB2V\^=E52_D6FL06T6551MAAC
M3C(7)-=1X+^'/@WX>Q:A#X/T?^R(M4DMY;Y?[0U74//DM5E2!MVJ7UZT7EK/
M*,0F,-NRX8JI )1:E?2UW^-S@?VE?^2*>-/^Y<_]2W0:_*.OVS\2^&M$\8:)
M>^'?$5E_:.C:C]F^V6?VF[M/.^R7<%];_P"D6,]K=1^7=6L$O[J=-^S8^Z-G
M1O*/^&:O@I_T)?\ Y<?BS_Y?4!*+;NK;?YGLNE?\@O3?^O"S_P#2>.OS=_:W
M_P"2J6__ &*FD?\ I9JM?I;%%'!%'#$NV*&-(HUR6VQQJ$1=S$L<* ,L23C)
M)/->;^+O@[\./'>JKK?BKP[_ &KJ:VD-BMU_:^NV.+6!Y9(HO)TW4[.W.QYY
M3O,1D;=AG8*H 5)737];GQ3^Q[_R4S7/^Q%U/_U(/#%?>_CS_D1_&?\ V*GB
M+_TT7E87@[X1?#SP#J<^L>$O#W]DZE<V$NF3W/\ :VN7^^RFN+6ZD@\G4]3O
M(%W3V=M)YB1+,/+VK($>17[V_L;74[&]TV^B\^RU"TN;&\AWR1>=:W<+V]Q%
MYD+QRQ^9%(Z;XI$D3.Y'5@& **:5GW_R/PZK]>?@9_R2/P'_ -@*+_T?/6%_
MPS5\%/\ H2__ "X_%G_R^KU[0M#TOPUI%AH6B6OV+2M,@%M8VOGW%SY$"LS!
M//NYI[F7#,QW332/S@M@"@48M.[MM_D?%O[:7_--?^YQ_P#=5KY\_9\_Y+'X
M'_Z_[[_TS:E7Z8^-?AKX)^(?]F_\)CHO]L?V/]L_L[_B8ZMI_P!G_M#[+]K_
M .07?V7G>=]BM?\ 7^;Y?E?NMF^3?SWA[X%_"OPKK-CX@T'PM]@U?39));*[
M_MOQ'=>3)+#+;NWV>]U>XM9-T,TB8EAD W;@ P5@ XMROI:Z_"QZW7XF>*/^
M1F\1?]AW5_\ TX7%?MG7B5U^SI\&KVZN;RY\'>;<W<\US<2?\)#XJ3S)YY&E
ME?9'KB1IOD=FVHJHN<*JJ  !*+E:UM+[_(XW]DC_ ))7<?\ 8UZO_P"D>E4?
MM;_\DKM_^QKTC_TCU6O=_"/@SPUX$TIM$\*Z;_96F-=S7S6OVR_OLW4Z11RR
M^=J5U>7 WI!$-@E$:[<JBEF)/%W@SPUX[TI=$\5:;_:NF+=PWRVOVR_L<74"
M2QQ2^=IMU9W!V)/*-AE,;;LLC%5(!M-QMULOPL?CIX7_ .1F\._]AW2/_3A;
MU^V=>)6O[.GP:LKJVO+;P=Y5S:3PW-O)_P )#XJ?RYX)%EB?9)KCQOLD16VN
MK(V,,K*2#[;0$4TK/O\ Y'Y*?M!_\EC\<?\ 7_8_^F;3:^@_V+?^:E?]R=_[
MM5?1OB'X%_"OQ5K-]X@U[PM]OU?4I(Y;V[_MOQ':^=)%#';HWV>RU>WM8]L,
M,:8BAC!V[B"Q9CT/@KX:^"?AY_:?_"':+_8_]L?8_P"T?^)CJVH?:/[/^U_9
M/^0I?WOD^3]MNO\ 4>5YGF_O=^R/8"46I7TM=_C<POCG_P DC\>?]@*7_P!'
MP5^0U?MUKNAZ7XETB_T+6[7[;I6IP&VOK7S[BV\^!F5BGGVDT%S%EE4[H9HW
MXP&P37D/_#-7P4_Z$O\ \N/Q9_\ +Z@)1<K6MI??Y'I/@/\ Y$?P9_V*GAW_
M --%G7P1^V%_R4S0_P#L1=,_]2#Q/7Z+V%C:Z98V6FV,7D66GVEO8V<.^27R
M;6TA2WMXO,F>263RXHT3?+(\CXW.[,2QX+QC\(OAYX^U.#6/%OA[^UM2MK"+
M3(+G^UM<L-EE#<75U'!Y.F:G9P-MGO+F3S'B:8^9M:0HD:H#:;C;K9?A8^%O
MV2/^2J7'_8J:O_Z6:57Z1:K_ ,@O4O\ KPO/_2>2N"\(_!WX<>!-5;6_"OAW
M^RM3:TFL6NO[7UV^S:SO%)+%Y.I:G>6XWO!$=XB$B[<*ZAF!](EBCGBEAE7=
M%-&\4BY*[HY%*.NY2&&5)&5((SD$'F@(II6??_(_#.OU<_9J_P"2*>"_^YC_
M /4MUZC_ (9J^"G_ $)?_EQ^+/\ Y?5ZOX:\-:)X/T2R\.^';+^SM&T[[3]C
ML_M-W=^3]KNY[ZX_TB^GNKJ3S+JZGE_>SOLW[$VQJB*"C%IW=MO\CY#_ &SO
M^07X!_Z__$'_ *3Z57R_\#/^2N> _P#L.Q?^B)Z_4/QI\.?!OQ"BT^'QAH_]
MKQ:7)<2V*_VAJNG^1)=+$D[;M+OK)I?,6"(8F,@7;E I9B>7T+X#?"CPUJ]A
MKNB>%?L6JZ9.+FQNO[<\27/D3JK*'\B[UB>VEPK,-LT,B<Y*Y H!Q;E?2UU^
M%CUZOQI^*/\ R4SXB?\ 8]>+O_4@U"OV6KQK5/V??A#K6IZCK&I^$?M.I:M?
MW>IZA<_V_P")X?M%[?W$EU=S^3;ZU%!%YL\LDGEP11PINVQQH@50!*+E:UM+
M[_(\G_8Y_P"1'\4?]C6?_31IM?7M<AX-\!>$_A_8W6F^$=*_LFRO;O[=<P_;
MM2O_ #;KR8[?S?,U.\O94_=0QILCD2/Y=VS<68]?04M$EV2"BBB@84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5POPN_Y)G\.
M_P#L1?"/_J/Z?7=5_&3_ ,% /^#@#]LC]A[]I[Q+^S'\)_AK^S-XA\!?#GX>
M_ :;1-7^(?@WXIZMXONF\9? CX;^.]4&JW_AOXS>$M&G6#5_$U_;6 M- L3%
MIL-I#<&ZNHYKRX^BX9X7S7BS'U<MR>%">)HX2IC9K$5E0A["G6H4)-3DFG+V
MF)I6CU3D^A$I*#3>VJ_+_(_LVHK_ #^?^(K+_@H;_P!$;_8Q_P##>?'#_P"B
M)H_XBLO^"AO_ $1O]C'_ ,-Y\</_ *(FON/^(*\<_P#0/EO_ (<:?_R!/MH>
M?W'^@-17^?S_ ,167_!0W_HC?[&/_AO/CA_]$31_Q%9?\%#?^B-_L8_^&\^.
M'_T1-'_$%>.?^@?+?_#C3_\ D ]M#S^X_P! :BO\_G_B*R_X*&_]$;_8Q_\
M#>?'#_Z(FC_B*R_X*&_]$;_8Q_\ #>?'#_Z(FC_B"O'/_0/EO_AQI_\ R >V
MAY_<?Z U%?Y_/_$5E_P4-_Z(W^QC_P"&\^.'_P!$31_Q%9?\%#?^B-_L8_\
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MO/CA_P#1$T?\05XY_P"@?+?_  XT_P#Y /;0\_N/] :BO\_G_B*R_P""AO\
MT1O]C'_PWGQP_P#HB:/^(K+_ (*&_P#1&_V,?_#>?'#_ .B)H_X@KQS_ - ^
M6_\ AQI__(![:'G]Q_H#45_G\_\ $5E_P4-_Z(W^QC_X;SXX?_1$T?\ $5E_
MP4-_Z(W^QC_X;SXX?_1$T?\ $%>.?^@?+?\ PXT__D ]M#S^X_T!J*_S^?\
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M/] :BO\ /Y_XBLO^"AO_ $1O]C'_ ,-Y\</_ *(FC_B*R_X*&_\ 1&_V,?\
MPWGQP_\ HB:/^(*\<_\ 0/EO_AQI_P#R >VAY_<?Z U%?Y_/_$5E_P %#?\
MHC?[&/\ X;SXX?\ T1-'_$5E_P %#?\ HC?[&/\ X;SXX?\ T1-'_$%>.?\
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M - ^6_\ AQI__(![:'G]Q_H#45_G\_\ $5E_P4-_Z(W^QC_X;SXX?_1$T?\
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M.?\ H'RW_P .-/\ ^0#VT//[C_0&HK_/Y_XBLO\ @H;_ -$;_8Q_\-Y\</\
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M -$31_Q%9?\ !0W_ *(W^QC_ .&\^.'_ -$31_Q!7CG_ *!\M_\ #C3_ /D
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M?[&/_AO/CA_]$31_Q%9?\%#?^B-_L8_^&\^.'_T1-'_$%>.?^@?+?_#C3_\
MD ]M#S^X_P! :BO\_G_B*R_X*&_]$;_8Q_\ #>?'#_Z(FC_B*R_X*&_]$;_8
MQ_\ #>?'#_Z(FC_B"O'/_0/EO_AQI_\ R >VAY_<?Z U%?Y_/_$5E_P4-_Z(
MW^QC_P"&\^.'_P!$31_Q%9?\%#?^B-_L8_\ AO/CA_\ 1$T?\05XY_Z!\M_\
M.-/_ .0#VT//[C_0&HK_ #^?^(K+_@H;_P!$;_8Q_P##>?'#_P"B)H_XBLO^
M"AO_ $1O]C'_ ,-Y\</_ *(FC_B"O'/_ $#Y;_X<:?\ \@'MH>?W'^@-17^?
MS_Q%9?\ !0W_ *(W^QC_ .&\^.'_ -$31_Q%9?\ !0W_ *(W^QC_ .&\^.'_
M -$31_Q!7CG_ *!\M_\ #C3_ /D ]M#S^X_T!J*_S^?^(K+_ (*&_P#1&_V,
M?_#>?'#_ .B)H_XBLO\ @H;_ -$;_8Q_\-Y\</\ Z(FC_B"O'/\ T#Y;_P"'
M&G_\@'MH>?W'^@-17^?S_P 167_!0W_HC?[&/_AO/CA_]$31_P 167_!0W_H
MC?[&/_AO/CA_]$31_P 05XY_Z!\M_P##C3_^0#VT//[C_0&HK_/Y_P"(K+_@
MH;_T1O\ 8Q_\-Y\</_HB:/\ B*R_X*&_]$;_ &,?_#>?'#_Z(FC_ (@KQS_T
M#Y;_ .'&G_\ (![:'G]Q_H#45_G\_P#$5E_P4-_Z(W^QC_X;SXX?_1$T?\16
M7_!0W_HC?[&/_AO/CA_]$31_Q!7CG_H'RW_PXT__ ) /;0\_N/\ 0&HK_/Y_
MXBLO^"AO_1&_V,?_  WGQP_^B)H_XBLO^"AO_1&_V,?_  WGQP_^B)H_X@KQ
MS_T#Y;_X<:?_ ,@'MH>?W'^@-17^?S_Q%9?\%#?^B-_L8_\ AO/CA_\ 1$T?
M\167_!0W_HC?[&/_ (;SXX?_ $1-'_$%>.?^@?+?_#C3_P#D ]M#S^X_T!J*
M_P _G_B*R_X*&_\ 1&_V,?\ PWGQP_\ HB:/^(K+_@H;_P!$;_8Q_P##>?'#
M_P"B)H_X@KQS_P! ^6_^'&G_ /(![:'G]Q_H#45_G\_\167_  4-_P"B-_L8
M_P#AO/CA_P#1$T?\167_  4-_P"B-_L8_P#AO/CA_P#1$T?\05XY_P"@?+?_
M  XT_P#Y /;0\_N/] :BO\_G_B*R_P""AO\ T1O]C'_PWGQP_P#HB:/^(K+_
M (*&_P#1&_V,?_#>?'#_ .B)H_X@KQS_ - ^6_\ AQI__(![:'G]Q_H#45_G
M\_\ $5E_P4-_Z(W^QC_X;SXX?_1$T?\ $5E_P4-_Z(W^QC_X;SXX?_1$T?\
M$%>.?^@?+?\ PXT__D ]M#S^X_T!J*_S^?\ B*R_X*&_]$;_ &,?_#>?'#_Z
M(FC_ (BLO^"AO_1&_P!C'_PWGQP_^B)H_P"(*\<_] ^6_P#AQI__ " >VAY_
M<?Z U%?Y_/\ Q%9?\%#?^B-_L8_^&\^.'_T1-'_$5E_P4-_Z(W^QC_X;SXX?
M_1$T?\05XY_Z!\M_\.-/_P"0#VT//[C_ $!JX73_ /DIGB[_ +$7X=_^I!\4
M:_@S_P"(K+_@H;_T1O\ 8Q_\-Y\</_HB:R8?^#IK_@H)!KFH^($^#W['!O-3
MTG1='GB;X??&PVJ6NA7FO7MI)"@_:$$JSR2^(KU;EGFDC>.*U$44+),\Y_Q!
M7CG_ *!\M_\ #C3_ /D ]M#S^X_T'**_S^?^(K+_ (*&_P#1&_V,?_#>?'#_
M .B)H_XBLO\ @H;_ -$;_8Q_\-Y\</\ Z(FC_B"O'/\ T#Y;_P"'&G_\@'MH
M>?W'^@-17^?S_P 167_!0W_HC?[&/_AO/CA_]$31_P 167_!0W_HC?[&/_AO
M/CA_]$31_P 05XY_Z!\M_P##C3_^0#VT//[C_0&HK_/Y_P"(K+_@H;_T1O\
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M >VAY_<?Z U%?Y_/_$5E_P %#?\ HC?[&/\ X;SXX?\ T1-'_$5E_P %#?\
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M#S^X_P! :BO\_G_B*R_X*&_]$;_8Q_\ #>?'#_Z(FC_B*R_X*&_]$;_8Q_\
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M?[&/_AO/CA_]$31_Q%9?\%#?^B-_L8_^&\^.'_T1-'_$%>.?^@?+?_#C3_\
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MY_P2 _X+XZ!^W7XIN/@'^T]I'P_^#_[1NI7MQ<?#:;P8FMZ-\-?BGIVSS/\
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M_:*\*Z[>Z1%KNCW]O97NH^'M)FO(8EN4M%AEC9O%O^(U;_@EE_T0/]O_ /\
M#6?LZ_\ T55 ']?M%?S"_LH_\'8__!./]K_]I#X,?LP?#WX1?MG>%_'7QT\>
MZ)\./"&N_$#X;_!:P\&6/B/Q%,;32/\ A(;[PK^T+XPU^SL+J],-F;K3_#>J
MM!+<12W$,5HMQ<P_T]4 %%%% !163K^NZ1X6T+6O$WB"_@TK0/#NDZEKNMZI
M=%EM=-TC2+.;4-2O[ED5V$%G96\UQ,55F$<;%58X!_"/_@G-_P ''/\ P3__
M ."F_P"TC>?LL_ S0?VA? _Q+?POXF\6>%;CXS^!/ _AOPU\0++PBT4^M6/A
M._\ !OQ0^(&IIJT.B-<^)HK+Q3HWAD2Z'IVH.)AJ5O\ V:X!^^5%<UXS\6:1
MX"\'^+/'/B![B/0?!GAK7?%FMR6L#7-TFD>'=+NM8U)[:V4JUQ<+96<S0P*R
MM+(%C!!;-?R3_P#$:M_P2R_Z('^W_P#^&L_9U_\ HJJ /Z_:*_D"_P"(U;_@
MEE_T0/\ ;_\ _#6?LZ__ $55?HA_P3+_ .#BG]B'_@JM^T+K7[-/[/WPX_:?
M\#>/M&^%WB/XL'4?C7X'^%V@>%=1T/POX@\(^'M1TG3]0\ _&;XE:F/$#R>,
M;/4;6'4-%T_2)=.TW5?,UF'45TW3M3 /WMHK^;[]L+_@Z2_X)N?L3_M9>/OV
M0/BIX3_:E\0>-?A=XFT/PGX_\>?#[X8^!=5^&7AS5]4L=+U#4UDNO$GQ9\)^
M/=5M_"EOJB?V]/H/P_U47,EK=KX77Q(/LK77]"7P^\?>#?BKX"\$?%'X=>(=
M.\7?#[XD>$/#7C[P+XLT>5IM)\3^#?&&C67B'PQXATN9TC>73M:T34;'4K*5
MHT:2VN8G9%)*@ Z^BBOP$_X*2_\ !R!^P)_P2^_:&'[,7QL\*_M'?$GXHVG@
M[0/&?B2W^!?@;X=^(-%\'6_BA9[K0=%\1:E\0OBW\,9/[?U#1H[7Q MKHEIK
M5E!I&J:9)=:A!>7$EE" ?OW17C/[.OQW\!_M0_ 7X._M&_"Z35Y/AW\</AOX
M0^*/@P>(-._LC7H?#WC31+/7=.M=;TP3W<=CJ]G!>+::E;V]Y?6D=[#,+._O
MK3R;N;^;/XS?\'A7_!+OX+_%OXE_"&^^%G[:WC;4/AAXY\4> =2\6>"/A7\'
M1X1U_4_"6L7>AZEJ/AP^-?V@_!?BQM(FOK&X%E)KWA30-1EA59)M-M]P6@#^
MK*BOYG?V8?\ @[,_X)%?M(^.M(^'^M>+?C)^S#J?B#6;70]&UW]I[P+X5\(>
M!9KR]"+;W.L>/? 'Q$^)WA+P7HWGN+>Z\0>/=7\+:'IA5[K5-0LM/4WE?TMV
MMU:WUK;7UC<V]Y97EO#=6=Y:S1W%K=6MQ&LUO<VUQ"SQ3V\\3I+#-$[1RQLK
MHS*P) )Z*** "BOEC]MC]L+X/?L"?LM_%W]KOX]/XG_X57\&M'T?4_$5KX*T
M-/$?B[5[WQ-XIT'P-X4\.^'-(GOM*L+C6/$WC'Q/X?\ #]A/K&L:)X?T^XU-
M-1\1:[HFAVFH:K9_S4_\1JW_  2R_P"B!_M__P#AK/V=?_HJJ /Z_:*_ O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O\ +^_X+E?\I*OC'_V3C]EG_P!93^"M?Z@-?Y?W_!<K_E)5\8_^R<?LL_\
MK*?P5K]K\!_^2PS#_LG,9_ZLLH,*^T?5_D?DA1117]:G,%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*4)*5*I&%6$X1[(R4E=;?BGV?G_6P4445XA04444 %%%% '"Z?\ \E,\7?\
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M?_*(3^T/^03]G^P?\?\ _IW_ ![_ /'Y_I/^N^>O]!JOX _^=Z[_ #_TAXH
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M  JSX8_]$X\!_P#A(>'O_E=7\_7_  :O_MGVG[5W_!)SX4>!-9\0VVJ?$_\
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M ,(Q_P (YH/_  C?_0O?V/I_]A_\HA/[0_Y!/V?[!_Q__P"G?\>__'Y_I/\
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M;>+OBGX)AGFA>\6VT_Q%XHT'5KE]*U P:<\(LY;S\3/^#SK_ )*[_P $9_\
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M*WMK:WB1$1!P222 =?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWEGIMG=74/U=^UG_ ,$T?VW/V&O#/A3QE^U)\$)_AAX9\;:[=>&?#.L+X_\
MA7XXMK_7;/3WU6;395^'/CCQ?-IDYT^*:ZMSJL5C%>1V]R+22=[:X6/^@O\
MX-[OV8?AS^S?\ /CK_P6"_:5TV"S\-?#?PWX\TOX&7>H64SW]EH'A;2]1TGX
MI^//"PDW6M[JOC#5+BZ^"WA)[,?VJVI:?X^\/F/R==@%Q]E_\%M]=O/VUO\
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M[ZIX6\7_ !4T+Q3X>OGM+B)[G1_$.C:7K.GREK;4+"UNHY(4YWXF_P#!$/\
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M$Y;Q.&3L\103]@\39U::?U963Q%G*_L$VDZO\-75Y:A9]O+Y]CR>BO=?BO\
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MU;4HM-BU+5M*T^2^>V6U2^U/3[1I1<7EM')TOCC]FO\ :+^&/C+PK\.OB3\
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MVS^W?^&;_C'_ &-]DSM^U?VG_P (;]B^S[OE\_S_ "L\;LU\D5C0Q>$Q7/\
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M\%]/^5IK_@BO_P!XY/\ UXI\9*_O"T__ )*9XN_[$7X=_P#J0?%&ODSXZ_\
M!,W]AW]I?]J#X(?MG?&_X#Z;X[_:6_9R_P"$/_X4W\3;CQI\2M$G\(?\*_\
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M?%GPC\7;K/4=(N)H/#/Q(T/PSJVI:8=4L;/7]'MM1\.ZO,VC:OJ,,L_[2?\
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M/H5_JEEI!\9^-I(#8>!/ =A=WMQ;H=3\9^+KK1_#MG% TMVTE^7MK>XEC$3
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M/A7P=\4T\)_&WPKXO@^SZY;Z/=^ =/M/$>HVVH6VH>$KS4-,\3Z+?:M^$?\
MP:4R:+%_P4"_X*UVO[)D7C"[_P""=DVKQW/PHU/Q%;Z[96]HD?Q=\7?\,_Z;
M/;>)]6O-=EU^3X/W?B]+R]UB&3Q/>:=I6FWGB]-"U2[M]*D_H1\8_P#!MO\
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M_2'BO[_*^$O^'9O[#O\ PW%_P\C_ .%#Z;_PVI_9O]E?\+M_X33XE?:OLO\
MPK7_ (4[YO\ P@O_  F?_"L?[2_X5C_Q1O\ ;/\ PA7]K_V1\GV[S_W]?=M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5_E_?\%RO^4E7QC_ .R<?LL_^LI_!6O]0&O\O[_@N5_RDJ^,?_9.
M/V6?_64_@K7[7X#_ /)89A_V3F,_]664&%?:/J_R/R0HHHK^M3F/[J?^#67_
M ),=_:Y_[+CJ/_JH?"M?PK5_=3_P:R_\F._M<_\ 9<=1_P#50^%:_A6K\NX+
M_P"2X\3_ /L/X?\ _4'&FL_@I>DOT"O[COC%K4G_  5>_P"#<&#XJ:Q=Z5X@
M^.W[+.B-XS\4:C?>(YKR_L/''[,POM(^(6M>()=!L[=H_$?C_P#9TU/6/'D/
MAK6M);3TU/QOX?FN)?(@TOQA#_#C7]>'_!JC^T7$/&_[3_[%OBN6ZO\ PW\0
M_!UG\;/"&DS6FFC1+?5/#LMEX ^*%I/>I)#K,VI>+_#OB3P%)!9.E[ID>F^!
M=4GBETB\ED37.CQ.PU6EDV"XDPE/FQ_"6:X/.:7*W&=3"1K0HYAA>9)I4:U*
M4*M=.RE3P]M?@DJ;U<7M--?/H_D?SE?L#_LW7'[7G[97[.?[.:023Z;\3/B;
MH=CXM$,EU%/!\/-#\_Q7\2[VVDLBMRMUI_P^T'Q+?VICFM?](MHP][8QE[R#
M]V?^#I+]IP>+_P!ISX1_LB>$]1^R^"?V<OAY9>)O%'AW2[U;72+?XE?$RVMK
MW3;&_P! LMEF)_"_POL/"%SX;N+Q3<:;8>.]<M=,M;"RU&ZGU;[O_P"",?\
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MX1> OACI\ GL_P"S_)^,?C#4_$U]>36DEC)?OJ4'_"DK6UL+RTU&TM[6SO\
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M@\.\B@U4IXO/YYY546I0GA\CPZQ*YK/EE3JPK54G=IJ+LI.R,H:1J2[1Y?\
MP)V_ _B5K^B/_@V%T#5=8_X*:-J.G7%W!9^%/V>/BOK^O16X<PWFE7.I>"?"
M\-O?E;B$"T77/$FC7:&2.[3[=:V8%NKE+JV_G<K^[_\ X) _LY:)_P $?O\
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M  C'A?QCHOP)\.ZQ%<ZKIUS<Z>]UX;\-Z=J<5G<:3=1Z(9ETZ.PN+>QC@?\
MH)_X.R?'6L^&OAE^PY\#-$B_L_X?:YXD^+OCJ_T]()EM'UGX7^'_ (?>#_!,
M5E,+CR3_ &+HGQ,\80W,$MM+-'%JFGO#<1(\\<_TV:T\9C,!X8\!5L57I4\[
MP%&KGU2G5E3KUL%D^54,37P+K1;?)B6JL)/63=&FY-IR4I5DZE1):/W>UV]]
M^GW:Z'QA\._^#J/]L&R^*<6H_%KX-? KQE\$M3U^[_M[P%X<T7Q-H'C33?"%
M[/=B/3_#7C.\\6:EI-SJVF6L]M')<>)O">IV6NPV4MI)!HTVH_VI8?J1_P '
M+_C3PY\'O^"<?P:^!_P_\*VO@/1_C#\>=,U*7PA:Z>VDVFB>'/#^D^+/B-XB
MTZ+3M'NAHVGWB^/M<\,7#Z:)+S2;8?;X]+LLVUE>:=_+%_P2'_8R\;?MK?MS
M?!;P1H6F7C> ?A_XP\.?%?XT>)T66+3_  U\./ ^MV6MW]I-?Q?/:ZUXVO+*
MU\$>%5@2YN$US7;?5)K4Z+I&LWEE^OW_  =@_%N'Q#^U#^S-\%+>XDF7X7?!
M3Q#X\O(Q&@M[34_B[XQ;2I;83BZ:1[QM+^%&CW=Q"UC;QPVMWI\D=Y>O<S0:
M?GC^'.&\+XE\'97D6!P^!J8.AC,YSBCA)5/9\N$HR_LB5:ASNE"O'$*J_:22
MK2IUX2FW&5/G%*3IS<G>[25_57U_I71])_\ !IA\'M23P_\ ME_'>[@M8--U
MG4?AE\'O"VKQ(LFKP:EH5EXE\8^.((S<026L%JEOXF^'=TB.EXM[=(/M$$,=
MC&+SQ3]J#_@X,M/V1/'%A^S'_P $MOA5\&+?]GSX(:OJV@ZI\0/'=GKGCZU^
M-OB6UU&/^W_%.E:GH7C'1-1UC2/$&KPZOJ&K_$[6/%'B/QG\6+S4V\:3:YIL
MET+C4_H_]B_5_P#AB#_@V7^.'QZT8^+O!GCWXV:=\7=<LM=T6>;2_%UEXP^*
MOCVP_9=^'7BKPU=RZMI&H:-:Z7I.F>%?%=AJVD7=M?:=807WC'P]9ZC>R6QU
M+^)*NC(^&\NXPXOXXSW.*7U_+\)G-/),)@*DI_4JF*RC!PPE;$UZ,9\E>="G
M4Y<*Y\T:;Q6(JJ*J3@X$I.$(1B[-KF;ZV;NM?S]%J?TU?\$"F\:?MF?\%E?'
M_P"UA\2["WU#Q+HOAOXZ_M#>);ZRM];'AK0_&/Q,OXO =CHNB?;M5U!K"QL;
M/XEZQ9^#="UC4=9>P\/: ZV2RSZ%%J=A^IG_  5,_P""L'P4_P""8_QN^,7A
M3]C7X?> ?B)^W-\;O$6A^*OVF_BQ\0[;5_%6G^"=-T_P?HV@>!? MU=Z?K.A
M:G?ZEH'A+3M ;PIX#TW5[/P5X'LE;6-<TO6O$GB368;CP?\ X-5_ >D>!?A1
M^W+^U9XE1ETK39O"'@.WOOL]E#]@TCX?^&_$7Q'\>I!J-W?PHS7EMXA\'37%
MO=#3;*T_LRUGFO[D7+C3/Y _BS\4?&GQM^)WCWXO?$75[C7?'/Q)\6:YXR\4
M:I<SW=PUQJ^O7\U_<I ]]<WEU'8VIF%GIMK)=3"RT^WM;.-S% @"I\.X'BOQ
M%S^.+4IY'PME629,LNISG2PV,G4A+'4L+B(P:=7!X.NJE2>&;C">)IX:4E.$
M&I',X4XVWFV[[M;+[W^5^I_H-?\ !/K]KWQ#_P %=?\ @ES^U5K/[8/@3X?6
MT&CWGQ?^#_B6]\)6NI^'_#>LZ/IOPE\.>,H/%$,6M:IK$GACQ+H*>,%9]2T_
M63%93V%CK-K%IAD\D?Q ?\$\/V)O''_!0']JOX=_LY^#KG^Q],U>X?Q+\2_&
M##>G@7X5>'KFR?QGXHCA\BY6ZU9;:[MM%\*Z?-''9ZKXQUKP]I>I7NE:9>7F
MK6/]4W[/%S/^Q)_P:^?$GXCFSNO"/C?XY^"_B5JRR:0VGZ5XCO=7_:&^(\7P
M,\#>)H+Y[Z5KV\_X5A+X0\41W]B;37-.\*Z<@L;>VU/14N:\+_X-(/!V@7WC
M;]N;X@7.EZ;-XI\,>%O@!X.T?6I;""35]/T#QUJWQ<UOQ)I=CJ;?Z39Z;K&H
M_#OPI=ZK81?N-1NM#T:XN/WFE6U>/EF/7"F2>+&=Y)2AA\!@\^65Y1AX7GAL
M-C*-2EEU7$T:<I2@Z:K8_#UDDW"<*,(6=.,8E-<[I1EJW&[?=/6WX/\ K4[/
M]NO_ (*L> O^"5?BD_\ !.3_ ()/? +X<^$_$/@36M-M?BGXVO?#M[XR;4?B
M!K^AV447A_2;)-1;7_B3\3(8;GPW9:]XY\=:SXBNK6[TV/P#;Z%>)I<<NF_I
MY_P2N^-G[9_[>O[.?[1OA7_@JG^S1IF@?">ZCT[0O#^N_$7X;WGPGM_B=X9U
M?3-3OO&^G:KX$\1O8W3:)X.BA\.ZCHOQ(TK3='TIK_4+NWT[5KGQ#X3U"YTW
M\1/'?_!UQ^UM;7'B32?#7[*/P*\%ZW9ZM=V=E9^.]0^)GB>X\/?8]5\NYTGQ
M)IEAK?P^N]1U:SM(KC3;N2*7PYY6JK]LDTV**%])?\KOVPO^"X'_  4)_;2\
M*ZO\.O'_ ,3]%^'GPJ\1Z-#HOB?X8_!?PW'X)\.^*+=9KI[T^(=;OKWQ%\0=
M5M-8@N(K'6?#MSXU;PA?V5G;Q/X<5Y;^6]F'A]GV:Y9ALOJ\-Y3DV83JX;$Y
MAQ?C\]J9SG]7$TZM*O7QN%EA*$)1K5I1G&G0J8J5&$&X^TC-0Q#/:13;YG):
MI02Y8VMHG?HO3Y6T,_\ X)X_M7?'O]E+]L[4/A/^PO\ %33+;PY^TK\:/!OP
M"T;QAXP^&6D>,)?$?A/5?BJOAKX;>-7\+^(8/#VJ6FM1V/B!M4;1$O\ PTMV
MVJW6GZK!;7$-E-I?]3/_  7X_P""LW[1?[ 'Q)_9T^&7[,/B[P1H_B3QCX'\
M<^._B7I?B7P?I/BZ^70YM>T7P_\ #N_A34I6.FVEY?Z'\1+=&AAC%[-I\X>6
M8V:I!_,M_P $"/@[)\8?^"J/[-:7&@V.N^'OAC=>,_C%XF.H1:+=0:+'X#\%
MZW<>#M>CL=9D!N[ZP^*-[X"73)=)M[O6M&U*XM/$=E';+HT^I6'HG_!QO\7)
MOB?_ ,%3?BQH)M((+'X*>!?A;\(]+N89XYGU*&+PK!\2-3N[I8EV03V_B/XD
M:WI(@,L\BV^F6\DS03226=K])G&191G7BAE&!Q. P>-C@.&<7FN;2KX?#5)8
M^=6I#*L&LP:IQ=>I04:5:C":_=)PG2A"#9$9.-*33M>22WTZO[_QU/D'QS\5
M/VQ_^"R_[9GPHT/QIK&@^./CM\1(/#?P:\"K;Z'IG@SPEX5\):1=Z]XCN)KZ
M'P[I<US;>&O#C:OXR\>>*-6EM=>UN*REUF2SBNX+73-'A_I3_;#_ &POV>_^
M#?;P!X3_ &,OV#OA!X$\2?M7^*? G@KQ/\:/C9XVTJ>_:Y@@:XM+/7?'IM=7
M'B+Q%XF\4SV_B;7/#'PZA\2Z/X)^&.G>(4U;2=/GLM:72M0_-7_@UM\':!XG
M_P""DGBO6]8TO3=0U'X=_LM?$[QCX4N[ZP@O+K0]?OO'7PF^']SJFC7$O[S2
MM2F\+>.O$FBRW]M^_DTC6-5TQO\ 1M1N*_0/]LW_ (.8OVE?V>?VE_VD?@!X
M1_9=^$=O#\'?BK\1_A?X7USQ]K'C[4-1U6+P9KNI>'=$\::QI6F7/A);G3/%
M"6-KXMM=)T^XL%.B:I:V%IX@O (]?NN#B>EC,QXJP7"65</T,TX>X=RG#YAB
M<@AFE'(L#B<1B:SCA98FU*JL3A,'&%.=/"1H6E7G5G6E*+C";C90<G*TI.RE
M9R=E:_S\[['W-_P1C_;1_P""G?[9OB[XK^%?VZ/V<]G[.]W\-FO=(^)_BKX.
M7GPJT[5=?UB^M-+B\!V&D>((;/2/BCX<\4^&9_$=[K;:/HVIQ>'1IUA#X@U&
M"T\4:/97O\E/Q?\ V-O!GQN_X*\_$C]BS]D34[/_ (03QA^U-XH^'O@[4H+,
MMHGP^\/VFL7FH?$8V%IJ5WHTNN>%?@M:6'C*#31;:C)<^*_#O@NVDT+4M:N-
M5T^]O_;/VE_^#A;_ (*5_M)^%[KP4/B'X,^!'A?5M/UC2_$>G_L_>$KKPCJ?
MB&QU?R%$%SXR\5:_XZ\>:'_9]O'<6EG)X.\4>&9;BVO[M-8?57%I):_3?_!K
M)\,K#Q=_P4$^(7C_ %?P]8ZK;_";]FWQGJ?AW6KN/3IKCPOXX\7^,_ /A"QO
M=+2YWZA;7VI>!=1^(^C2:CID2>5IE[J.G7EW%!JRVM]KA<IS/@C!<8\8UL+E
M.2>UR>-/ \/9/4J5\OHXNC^[PV,QDJU.A1GB'B)02AA:<:<J-:JFG6FT#:FX
M0NY6>LGHVGNEN_O/U<_;X_;W^#W_  05^$7PP_85_81^%?@^_P#C?JG@_0/&
MOC+Q?XTT9WL;>U6"P\*CXG_$M/#]OX;3XC_%?XGIX4U572UU72-.\,0:;;7<
MNG1:%_PCGAJ=G_!(K_@KAXJ_X*I_%NZ_9:_;._9\^%_C7Q%X+@TK]H+X9?$3
MP-X:FTW2/"VK_"7QCX=U_3]4\6:/XD\5:S=6&K:=XHN/"R^&]?\ !DMNERRI
MH/B+P]>:=J&IZLW\N/\ P6%\?^)/B5_P4]_;:\1>*M)N-%U/3?CMXH\ 6MG=
M"Y$DWAOX3I9_"SP;JRBZM[:7[/K_ (0\&Z'KMH5C:V-IJ4)L[B[M#!=3?TB_
M\&MG[$7BKP#H/QD_;H^)_A7_ (1RQ^(?AG3_ (6_ G4M:EU;3]3U'P-!JH\2
M_%/Q?'I5U%;:,?">N:SHG@+2O#/B8R7M_=3^%O&4%M_9.CN9_$GBY]PUP]DG
MAO+.\SI_6>*,?A,)C8YQ4Q%1YG6SO,O8UE'#UXUHN5+#1G/]W3?LY87#U*TJ
M<IRFY.,I2J66D5=<O3E6FOK^O8_%;_@XG^+.H?$__@JG\;](N%M1I/P>\,_"
M[X3>&GAAO8;J73['P-I/CC66U(7=]=PRW4?C;QWXLM[:;3H--LI=(ATQFL7O
MOMNHW_\ 5Y^S_P"&OV</V,_^"&O[-GB3]K3PO'>?"[X7?"SP%^T9XG^&^H6M
MLUYXU^)GB_Q#/\:/!W@R[\.^*M0MX=<\4S?$GQ;H;Z9X8UC4-/TR/Q1I&EVV
MI0Z?X;TRZTN'^"SX@ZI/^V7^W!XWUKPO'J5A<_M6_M5^)=4\.Q7NFV0U>RG^
M.?Q=O;O2([O1[75WTX:E;R>*+=;C3;;7GLA=(]K#J[0;;T_U+?\ !U-\5+OX
M>_#?]BS]DCP-J,VB^ Y[+QIXU\3^&;.X-O!=Z;\/K+P9X+^%%M<VUG?1)/I^
MFK?>-Y/LVH:2;0WUKI=UIEPMQIUU'#ZG$F22Q$?"W@*%:IADDL7CZE%RI5J<
M,DRN"K582BVZ5>NZN,C1J1<G3KRYDU9-J+M[2I:_1?\ ;S[=MOEH?F5^U3_P
M<;?MB_M*_#WXZ?!*S^&WP.^'7P4^-7@_4/A]'X=L]'\4Z[XV\%>#=7T^#3-6
MLM*\<1^)O#VEZGJ6J6*WEG>7NH^!SIZ6FHW$.GZ+8-';RP_IM_P2$_9/_9O_
M ."</[!VM?\ !8C]LCPMJ6M>.[OP\/$WPETN31[;7]3\#^ /$NLZ?X1^'LOP
M^\/2[;2/XG?&O6]5L?L7C74]0M;;P]X$U_14_M'P9H5W\0]2U;^+VO[J/^#F
M9KCX'_\ !.G]D7]G3P''J/ASX?0_$SP=X0NM,\/FXM/#;^&/@_\ "?5M,\*>
M$=4DMI+.&XTR&YETW6='T2\L9+2XO?"EIJZ0VUYX>LF7NXKR?+\LGPMP1D.'
MCDN!XMS:K_;$\#*=*OB,MRK#8>6,P[KRE.I[3%4:E.$JDG.51P:J\\:E6-0C
M)OFG+WG%*U]DV]'9>?I_E^;NC_\ !U9^VI9_%:_\2:O\%?@'K/P@NM=U.:T^
M%J6OB[3?%.F>%I[QY=)TNV^*,&NS13^)=/L4M[.\\37W@*ZTC4YFO[R/P9IH
MN;*VTO\ 7K_@O7\3_ 'P[_X(V:5I'@?X5W7PGT[]KWXF_"'44^'<6EZ+H-UX
M,U[QEJ5S^U#XQE\7:7X:U"[\-0^()=?\&7L/BQ=%OM6M=0\;:U=:Q#<:EYMW
MK(_C/_X)]?L<^,/V[_VL_A/^SEX5MM2CTSQ-K2ZO\2/$FGI<1IX)^%7AUH]2
M\=^*+G5$T;7K'1KI-)0Z)X5NM;T]](U'QYK?A/PY</Y^N6T<G](W_!V3\5XK
M?6?V,_V=-&UZ.*ST/P[\1OBOXE\'Q.DDJQ:C=>'O OPWUZ^:5Y;SRX8O#_Q-
MTO2GS$DS/K!G>\ECB-GYV<<,\-8/Q X$RC(L!0P.(IU<1G&9T\-.NH?5LJI?
M6,KJ8FG[2=.56>)H8F,*TX^VE)VJ5)1J(%*3A-MW5E%7MN]]=]K:'@7_  ;V
M?\$\?@OXW\.?%W_@I!^U[IF@7WP,_9UDU^+P%I'C.PGO_"7]N^ _#4?C;XD_
M%CQ9HUQ926FM>'?AMX=N--B\,Q"'7-.O?$TWB6[N+*UUGP-I?VF?XX?\'4_[
M66I_%O5]5_9U^$GP=\(_!FQNY[3PQX7^+6@>(/&7B[7M.MK^_%GKOB_4_"WC
M;PI!I&IZQITEA+>^&_#MY=66@W,+V-MXDUY5?5;S[[^.%E<?LX?\&LO@G3/A
MG8S:!)\2?@Y\%[WQ7J$#I=W<EO\ M _%3PYXM^(-]>7)CN%DA\46OBC4/#*I
M=,'TS1-:M=)LY+633[".'^+7X)_!KXB?M#?%GP!\$_A-X<O_ !7\0_B5XET_
MPOX8T73[6\NF>[O7+7.HW_V&VNYK+0M"T^*\UWQ)K,D#6>@^'M-U/6]1>'3]
M/N9H^_(LMRGC7,N+.)^)J5+'X++LVQN1Y3AL;4E]3RW+LKI4YXC$JDIJE"IB
MG4C7K59N4J<H3<)1BTVFW!0C&Z;2D[+5M[+N[;6^^Y_H-?%_]K/X7>,O^")W
M[4W_  42\%?!J?\ 9T\9_M5?L^:YI'C=(=,BM_%.J?$GQ-?7O[,GAKQ--K7A
MA],OO$$4?B3Q!#_P@7Q&U*TTG6;WP>?#7B35],L;&"'2K;^,'_@E#_P3_P!>
M_P""BG[6_A3X0F6?2OA?X4@C^(GQN\2)!>L+#X<Z)JFG07V@:?=6KP+;>)?&
M]Y=VWAC0)&NX9; WM_XC2"^M_#UW9R_TW_\ !?'1-+_8M_X(Y?LJ_L8>#KBQ
MFM[CQI\)/AEK%U+%!++KNB?"KP+KWBOQ9XDMBTUE<V^K:]\2M/\ "VN7UW;Z
M4;+RM6U6TD@TPWMC">6_X-5O"VB^%/V:_P!M?XXVNBQZOXOF\=^'?"S0QK.F
MH7>B_#SP%?\ B_3]%M+LM>I:QZKJGC2]69;+2UGFG@LY;UM4%IIMOI_S&0YB
M^&_#KB[B/)_:0GFF?XC"9%.K.56>'P"K8;*LM<JE>4IN6"I/$.DZLYQ3I4H2
M7+S7MKFJ0C*WNQ3EYO=_>_\ ,\J_;3_X+)#]ASQ_<_\ !.G_ ()#_ 3P#X.\
M/_ W6G\*^)_%^G>%9/']SXC\<^';"XB\<:)X7\,V]QJ>H>*=2T8Z;;V7CKXH
M^/-1\0>-?$?B'1?$JWMLD.FP>*M;_6/]B;XC?'_]O/\ X)X_M'1_\%BO@)X;
M^&'PT;3]:?\ X2'QYX)U+X50ZY\*=#\'0^)=6^)NL>#_ !!J*Z[X1O\ X?ZM
MILOC#0/B1ID7A6S=ET[6/""6=SX:?5Y_PKUW_@[$_:VN-*NH?#7[,W[.FDZV
M_D?8M0UV\^)?B+2K?;<PM<_:M'L/%OA>[O/-M%G@@\K7;'[/<RPW4GVF*![.
MX_*#]LW_ (++_M\_MRZ!<>!OBQ\5K7PK\+;R1);[X5?"+18_ /@[5I!#=VTD
M?B*Z@NM1\:>+--G@NR)?#WBOQ=K?AI9[:TOX='AU&!;L]</#W.\RPF!P4N',
MJX=Q='$X;%8[BO$9Y4SCB.OB:-2%:OB\-6P^'IN.(Q-5.2IUZ[HTKRY.5JG)
M+VD5=J3EI91Y>6*6FEO*W^6A!_P18^#Q^-O_  5 _9 \+RZ6^J:9X;^)T?Q7
MUC,%Y-96-I\'=&U3XFV=YJ;VDUNL%H^M^%])T^$WLW]GW>I7]AIEW;W\=_\
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M?#GBGPS/XCO=;;1]&U.+PZ-.L(?$&HP6GBC1[*]^&?VS?^#F+]I7]GG]I?\
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M/#X":O\ #W_@I+^V/\/--^(7CCX&^'?$'PS^$7P]GTK1-1M_BY\0/%$B>(/
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MY(=4MKFT@2YU/5/MS1I_*=_P5C^%OA+P#_P4V_:V^&GPAT/9H1^--RV@>&=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%T'Q!\076M?\(KXV\7_ &OQ'?\ PZ\4>%_"FG?V=\/]+UOQ'!LUWQ!9ZO\
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MIRJ1JU:\,76IXAO$5FG&I6J0G)PDXPY$H<B<FY<SLWV>J]+=C^[K]C3]K?\
MX-KOV"?'7BGXD_LV_'/6/#'C3QAX3/@?6-<U_P"&_P"V)XQNAX7DUC3=>NM*
MT\^(OA+??V;!?:KHNCW=^+/ROMLFEZ>;C?\ 9(=GPU^W1XP_X-P_C%X-_:L^
M-W@SXP?$;XB?M>?$CPI\7/&W@>ZN=,_:YL(M;^.WB71=;O?!LDEKXH\!>'_
MFE:!:>,;K2BND7MQIGAC2= M%TJTM(M-M;;3Z_DJHKYC"^&F$PN9/-X<5\:S
MQ]3V$<17J9SA74Q=##3C.GAL34CEL*M7#>XHRI>T2<;I-.S5.HVK<D+=-'IY
M[[_TS[*_X)\?LTZM^UU^V?\ LZ? :S\(:GXT\/>,/BIX.D^)VFZ9=/IIL?@Y
MH^O6&J_%G7+S5DU#29-+M-(\!6NNW0GMM3L]4NKP6FEZ UQXAU#2;.Y_=O\
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M\._#'X6ZHVOH^H>._ FE:,LMS\7(/"NJQOX0\1ZAJ3KI<T$FIZGHU[J4U_\
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MPKKJA'2E&O.K"-E>$K(;FVFN6"ONU'7^O0_4[_@CI^W3X)_X)[_MJ^'/C?\
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M;/6G>-8Y;8R:O\0+Q#'/<L+^246EQ#\E_P#!7/\ X+-_#O\ :E^#OA;]A_\
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M\%0-+U/POX>\!>$-.^'VE^*X_"WCKQAX4\:^"_"]S!<?#O4=.N/AGI6N^/?
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MO@3\+?C1!\;_ (JZ#XD\._$K]HGQ#H?PO\=_#/PS8_$'PA\*+CP==W=GI_Q
M\(>&IO(\5>(_B!XTOM$TWPI>:QI>DZ?I5W!K,T;/X>ENOY<:*X\'X=9-A<TR
M[.JV/SS-,TRVO*M#'9MF$,=B,1^XJ4:%'$5)X:+CA\+[6I6H4L(\*I5Y<^(=
M=1A&(ZDFFK))]$K):I_C;6]S[Z_X)A?M?Z%^PE^V]\%?VF?%^E>+/$'@;P1/
MXQTWQSX<\%2V8\0:WX8\:> _$W@VYBLK+4]6T+1]7GTB]URP\366DZQJUAI]
MUJ>A6)DO+.:*&[@_I'_;I_:I_P"#;7]I/Q)X_P#VJ/&H\9?'7]HC6?!PTU/!
M?AG0/VI?AL?'.O\ AKPI=>'?!%SXEN#:?#?PG!)9VVG^'-(EU6+Q9:SC2M,T
M>.[M+Z*SO+=_XOJ*]#.N"\!G.<8;/7F.>97F.'P:R^=;)LQ^H/%8)5Y8E8;$
MRC1J573]K.3;HU*$W>/-)NG2<!3:3C:+5[ZJ]GM='WE_P39_;G\5_P#!/#]J
M_P $?M%>'M'/BK0K6QU;P9\3/!*S6MG)XT^&_B=;8:WH]IJ5Q;7+Z7JVGZC8
M:+XJT&\@,"-K_AS3+34WGT*ZU6QO/Z4_CM^T9_P;-?M^>-U_:1_:#\4?%+X4
M?&3Q0-!;QMI\O@W]H70_$FOQ:!I%EI6GVGC*U^$_AKXF?#>XN(]*MK/1;K5O
M"VO)K-Q!I,"'67BAMKB;^+JBC.^"\OSK,J6<0Q^<Y+FU/"O!2S#(L=' XC$8
M3G=18?$\]#$4ZM.,WS)NFIW4$Y-4J2@1FTK64E>]I*Z3[K;_ "^\_K)_:2_X
M+C?LF?LJ_L^ZY^R'_P $9OA!?_#/2];^U1:]^T/J>C77AE[>YO=&T"QN?%G@
MW3O$LVJ?$7QQ\0M2TR*;0+KX@?%3_A&M5\)S^'[.30M&\36TVCZMH?\ *#87
M]_I5_9:II=[=Z;J>FW=M?Z=J-A<S6=_87]G,EQ:7ME=V[QW%K=VMQ''/;7,$
MD<T$T:2Q.KJK"I17?D'#.5\.4,12P,:]:OC:BK9CF&/KSQF89C62E%5<9B:F
MM1QC*2A",:=&'/.4*<95*DIJ4G*U]EHDM$EY(_ND^/W_  4Z_P"""?\ P4S^
M#?PGU/\ ;>U7Q[X1\<_#J#7M=TGX?W7@KXY6GC3PEKVN6\6F>+?#NE>,/@_H
MOB+P?J^@^*Y?#6@:I8->^*(8KJSM_"MWK47AS6+76=(TO^/C]I[QO\#9/VIO
MB+XZ_8K\.>*/@Y\$=*\;V&H_ O3)/$'BM_%WABQ\-6VE1:;XEAU_7O$_B3Q=
MI^M:CK^F7/B^SDN?$UUJ.B7.HPVUK-9"Q@M;7YBHK@X:X+R_A:5:&7YCG=?!
M5(5J='*L?F'UG*\%"O76(J_5,)&C2C&<IIKVM:5:KRSJKVEZU5S<IN>ZC?NE
M9OIJS^TF3_@K1_P2#_X*@_L^_"KPI_P5<\):I\+_ (R_#"[O+V75?#?A?XL7
M_AZ/Q!=V,.GZ]K'PT\7_  CM/$_CC2?"'CVULM)OM?\  'BFV-K8ZSIFDVMW
M=>*7\(^'O&,_S_\ \+!_X-=?V6[?_A8GP[\%?%+]M#Q]H<W]J^%/!'BG0_C+
M<:#-K$:>58Z?XBT3XM:1\*OAAJOAPS@3:NGB?P[XZ2*RFN+BV\/ZW>6]GI3?
MR;45Y5'PVRS"^TH8#/N+<NRNI5J5?[%P&>2P^60C6G*I5H4H1P[Q=*A4E.7/
M&&+4I*3YIMMMOVCZQ@W_ #.-W\^E].Q]!^"_%7PP\8?M5^$_&WQ%TC0OAI\&
M/%/[0>A>*O'6@Z'H)U?PSX ^&&M_$>UU?Q/I&C^&--T>Z;4]"\*^%+J^LM/T
M'3_#]R;W3["'3[71YC+'9-^U_P#P<0_\%&/V</V]/B3^S-I7[,'C^[^)G@'X
M/>!_B%J&K^)W\'>+_!5A#XP^)>O>';;4-!MM.\?^%O"?BJZN]/T7X<^']0O;
MW[!<>'VAUFP@TJ\?48->A@_G-HKZ;$\.X'%9UDV>5*F*^LY#A\;A\!152#PJ
M6/HK#UZM6,Z4Z\ZWL8J$9K$05M9QF]25)J+CI:5K]]-C]>O^"'OQ\_9?_9<_
M;X\)_'_]JWQ\_P ./!7PX^'7Q*N?"'B-?#OC_P 5#_A8/BK0U\ VEA)HGPZ\
M,>+-8NDNO!_BSQHP?4-.AT>VDA2XEO8]0CTV"X\<_P""LO[3WA;]L+_@H#^T
M/\=_A_XGG\7?#3Q'KWA[1?AKK,EIXBTNWN/!/@WP;X=\)Z3/8Z)XITO1-;T*
M#4I-'NM:N=+O='TZ:/5-4U"YF@DN+J:ZN/SHHIQX?P4>(ZO$[JXJ>85,IADT
M:4YTGA*.#AB5BW[&FJ*K0JSK7E.3KR@TY6IQ<FQ<SY>72U^;SO:WY']0W_!
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M\UK<UO>_RO\ +0_3S_@D]_P4@\1_\$T?VFH_BO\ \(_?>.?A5XZT%?A_\9_
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M'B/QCXHU3QS/#:^./"?A3QA/'<>'[3X>6)6]@N-&AETB6;1O*GO-6>Y^X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPG"/7&2DKK;\4^S\_P"MCA=/_P"2F>+O^Q%^'?\ ZD'Q1K^>S_@LA_P<,_\
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MJVM:;J%KJXT< _2W_@LS^TS\7?V.O^"8?[7_ .TC\!=<T_PQ\7_AG\.M+N_
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M%R_\)O\ \+,_X5)\=Q\$_M?_  @7_"J?"'_"&?\ "09_X2;[/_PFGBO^RO\
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MTO?'7PW^(\GA?09[#3K";QM8>&?'7AKXHM8Z3::%XUG.F'Q2;CQ!XMU:X\2
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M?V-9!X=T_2Q:ZU>,OB/4/#UM=?V%JEN=1M?L=W/; ']I%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45EWFN:+IVHZ1I&H:QI=CJWB&6\@T#2[S4+2VU'7)
M].LY=1U"'2+*>9+G4I;#3X9K^\CLHIWM;.*6ZG"01LXU*5T[V:=G9^3LG9]G
M9I^C3ZC<9146XM*:YH-II2BI2@Y1;^)*491NKKFC);II%%%%,04444 %%%%
M!1110 4444 %?Y?W_!<K_E)5\8_^R<?LL_\ K*?P5K_4!K_+^_X+E?\ *2KX
MQ_\ 9./V6?\ UE/X*U^U^ __ "6&8?\ 9.8S_P!664&%?:/J_P C\D****_K
M4Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUCDJ./M,1B:BNW6K^S@W1C-T:$8QIPYYJI6J]=."@N[>[Z>B\E][_!<+I_\
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MEEM[72"FBV7H_P#P:8_\I O^"V__ &4WPQ_ZNO\ :+KRO_@K9H7QJ_X(G_\
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M%NMZ)IZV]_XUT>V\*6=SXD\(2^(-3M;DZGX#U'PY*WA/5;D:;::QK6EPOJ<
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MW'QG_P#42^%% 'Z@_P#!>W_E#E_P4+_[-V\2_P#IPTFOCK_@U"_Y0D?LV_\
M8^?M$_\ J]?'E?KA_P %$?V<K_\ :[_83_:X_9HT4 ^)?C/^S_\ $_P3X,+W
M<5C GCW4/"VHR> 9;RYN)[6W33X?&<&A2ZBES=6MO-8I<07%U;PR/,G\2_\
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MM];L/"FJ3^&WNS>>)-(T[5=&T6QUC7[S2M%U  \'_P""$?\ P5A_X)7>!/\
M@E5^RC\)M:_:U_9D_9V\;_!#X26GASXI_"[XI_$WPC\(O$%IX_\ [9\2ZIXU
M\0:5I/CJ\\,OXUN/'WB0ZUX_N[SP4OB/SKWQ7$E_,-7OU@E_-K_@A%\0;?\
M; _X.+O^"I?[;_[*VA^(HOV*_%7P]\;:#J'CB\T?4]!\.^,/$WB;QQ\(#X/U
M,:1K=E;:O8:_\4=4^'?C_P"+>AZ=K.FZ+XGT3PQ-JUKXEM?#^IZA<>'KW\M_
MAO\ M^?\&I/Q,^&GP+T?]J#_ ()0_M"^#?BUX.^%'@OP+X[UOX1ZGJ>C> ;O
M7/!WA+3?#]SKU]K_ ,+?VK/@_P")OB/J_B5]"M]0U/QMXN^%R^,M;\0ZMJ&J
M^)[N]O[[6-?O?ZW_ /@D'_P5V_X(H_&R33/V._\ @G]::#^S'K,UQ?Z_X3^
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M5&D\))Q<).5'VZQ$8Q<W24/>!QDDVUHG9[:/TW_0_,NBOI[]C#]F#Q+^V?\
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M8>K-TI5TY8BG"=&C2=&+J>WKU*=#E7\357E1;;23;2NUU[;'\\E%?U[^%_\
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MQJDL]R;'4+%]$FY*'&O"^)IY76P^;4JU+.<=++,OG"ABY1JYA%4V\'6?U?\
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MB\,AO-+^#/PI\"?"_3KLS3"YF-S8^"-!T.VG,MP!<2&6)]\P$K9D&ZO;:**
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M]B#QW_P2J_9_U?PI\+/V5O'/P;\>_M&_M4V_PROOAKX:U6U\#?%"3XROXO\
M%-GH'A^VO= U>/2O"NL^"_A5J/C^ZT/Q;\2/'=P/#R0:%X?T.T\0'^YSQ3_P
M3._X)O\ CG5I=?\ &W_!/S]B/QAKMP)!/K7BG]E+X$>(-6F$MS<7LHEU+5O
M5W>2"2\N[N[D#S-ON;JXG;,LTCM]7^"/ '@3X9>';+PA\-_!7A+X?>$].&-/
M\+^"/#>C>%/#M@-D<>++1-!LK#3;4>7%%'B"VC^2.-?NHH !UM%%% !1110
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M8_\ LG'[+/\ ZRG\%:_U :_R_O\ @N5_RDJ^,?\ V3C]EG_UE/X*U^U^ _\
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MU^%GQA^$_@#XOZ7<? BXU/Q]XN\+Z#\1]"\/^(M"TGQ5\/3HND^.9-=M-/\
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M!XN\*^-1I>F:3HU[JVAR>*-!N+?7=%T_3]/UK3]6MIAI.DW<-W8Q?V.^)_\
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MCB:=%S>(KS<I)O#2:OW?9P]UR6M[-JSOUM??IY?(_N3_ &!?^";WQ!_8Q_8
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M/''B*673&>[N/C!K%IJ6G6G@U]<M_P"SO!/@33=,L_#=_K]UX70:%C_L2_\
M*KK\?_\ LE_[6O\ ZEWB:I/^"7_[6GPI_P""SO[$_CS_ ()E_MOZF][\:/!_
M@[2+7P9XYN-4MX_&OCSPOX3M;3_A#/BEX=UC5M6N]<UKXU?##5-,6?Q_/<6<
MMIXO\.W%I?>)3XDL/$_Q"T^/\SKT,12S?B7.L;0EFG"F4>(F85^(,FA%W:FH
MT\-FLXQ?^V4L!.?/4P=7]S)*U1>SJU:E'6_NQBG:3IKEE]WN^5^_3Y(_B_\
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MZ/UBOB*?+&TZM!7DI4HQ)).FG%WY'9MJSL_^#M_P]_T*_P""D_C/Q1_P3?\
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MOB?6=,\'W%GKFL:;J5M-K'\G/[+'_!);]NS]JCXQ:/\ "C1/V?/BI\-+)[R
M^-/B/\6_AYXP\ ^!?A]H@NTMK_4];U3Q+I&E)?:G @N&TWPEI#7?B?79;6ZC
MT[3GM[+4KNQU\.\=DF$R#B>EGU?+Z..I\09U+B6GF,J*G5E*K9RQ-&O[U:A.
M'/3A#V<H3JJM3A!U'-,J*3<+)VY8\MMODUY_IY'].?\ P<G^+M5^('_!+7]B
MGQYKJVB:YXV^,?PC\7:REA"]O8KJOB3]G;XE:SJ*V5O)+/)!:+=WLPMH9)YG
MBA"(TLC*7;Y=_P"#2;_DJ7[:O_8@?!K_ -2+Q[7U;_P<O^%+7P'_ ,$QOV._
M =EK=OXEMO OQV^&?@J/Q#:P1VL&M?\ ")? /XH^'GU-+2*]U&.S^V2:<\[6
M2ZA>_8W=K8W=PT1E;Y2_X-)O^2I?MJ_]B!\&O_4B\>U\CA73?@;G[HI*D\QK
MNDDG%*F\_P %R)1DDXKEMHTFMFDQN_MHWWM&_K;4_#'_ (*O_M??'?\ :S_;
M-^-4WQB\:7^M>'_A)\5_BK\-?A/X*A<6OA/X>^#- \<:GHUO8Z#H\ BM!JVJ
MVFB:7+XI\2W$4FN^)KNQL6U2]EM-,TBRT[^HO_@@[JVM_M,_\$7?VLO@9\7-
M7N_%_@_P[X@^/?P:\*0:ZQOD\-_#OQ+\$/!WB"'PYIY@:PU%;30O%'BKQ+KV
MCS?VLNH:9-J<-IH]]I5KI.DI:?QL?MC?\G=_M4?]G'_'#_U9WBBO[&O^#9S_
M )1C_MC?]EQ^*/\ ZS]\,:^P\1,+AL%X=95'!X>CAHX'&</U<&J-.%-8:JZD
M+U*/*ER5)>TJ.<XVE-SG*3;E)N:3;J:ZW3OY^I_/Q_P;_P#P%T'X]?\ !3[X
M&V_BFS@U+P]\);'Q9\<+W3;FTL[N"\U3P#I6/!CR+>S*D0TOQ_J_A37%EAM=
M0N"VEK#';VPF?5=._IH_X*N_\$8?VS/^"DO[15Y\08/VJ_ASX/\ @?X<T7PY
MH/PH^#^MVOCZZL_#":=I3/XA\1:KI^EP#P[?>,/$7B?5?$=S-XBBLSJJ^&)?
M#WA>>^NK+P_9D?RW?\$+OVF?#W[+G_!2GX%^*O&NM:;X=\ ?$-?$WP8\::UJ
M=K<W$.GVOQ#T>6T\)S+<6L<S:5'_ ,+*L? Z:CJ]Q"UA8:*VIRZE-8:?]IU*
MS_1S_@X=_P""9O[3:?MK>+/VL?A3\,_'7QC^%7[0=CX,N;U_AMX*U[Q7J?PV
M\;^#O WASP#J?AOQ1I^@G7M3%AKUMX5LO%NB>*+BQTG2+FXUZ_\ "L-NMUX>
M2ZU7GXFIYC+Q1R]0SW"</.IPM*&3X_&Y90S*A4Q$<=-XS!T(8JOAJ-'&SIN5
M65=5?:K#QA05_K$8MQM[-^ZY>_JDVG:RM>VZOT^>Z/V+_P""0G_!%[]IS_@F
M9^T7XF^)NO\ [0GPY^('PO\ B%\.M4\"^.? /A<^.]%-UJ$&I:=KW@[Q>NEZ
MEI[Z#K6M>&K_ $_4-%T^;4&L;W2M"\9>*VTS4D%[>Z7K'\P__!0;6OA=^RQ_
MP74^)WQ$TC0[?7_AS\*_VQ_A9\=?%/AK1'AUQ-8OAJO@#XQ?%30+:WU?5Y+&
M2]OO%E[XLTR?0KK4]/TG3M0DFT-(-"TVT2PL/BCX%?\ !.G]N?\ :4UU_#_P
M9_99^,GBJY@D2&\U6^\)7G@SPCIL\K1"*VU?QWXZ/AKP3H]U,LRS0VNJ>(+.
MXFMDGNHXVMK6YEB\J\)?LO\ QV\=?M&C]DOPGX"GUK]H,_$/Q%\*O^%>V^O>
M%HI!X[\)7VJZ=XCT9O$UUKD'@U8-)N=$U7[3K;>(AX?^S64M]%JLEB4N']W)
MN'XX7/\ /,XSCC/+LZQ.)R!X'-<-A\'@\H>'P<9PG3S#&*AF6)5-4:%.K1A7
MJ4J2C3E)^UM!IRY7C%1@U[UT[MW=MEHKWT?_  #^T/\ X+"?\$V?%7_!8/2_
MA1^VW^P/\=_AS\9=.\+?"NZ^'^G_  U;Q7#8>&O%]MHGB7QAXEN+[P'XKDDE
M\/:+\3;S6=>C\)>)?#/CT>#;".'1-*.M^*=$NM#.FW7\<G[1?P2_:X_9,N&_
M9L_:.\*_%7X4Z7!XA/Q"L?AGXDU2_E^'6J^*+K0=/TJ?Q[X7CTO4]1^'GB?6
M1H$MAX?U#Q=X9NM4NK6"'_A'+[489;*;3X/;O!'P]_X*C_L'?%8P_#OP%^V%
M^SS\2(O$VFQ36?A/PC\2](TSQQJG@[6)5TJVN['3-.N?!OQ>\+"_O)XK.TNH
M/%_@KQ+IFL3PQQ:MHFNRI??U>?\ !4SQ!\2OC3_P;U:'\5?VZOAM:_#;]J]=
M3^$GB/2O"NL:2NAZYHGQ#NOC3!X4M=330$0S>$O$'BWX W_B3Q'KW@[4$L=0
M\*G6M5\.:S8V.LZ/-I\'CY?C<PX&K\,9$LPR?B?AG-,UHY5E-2E[*CGF72QE
M24J%:4:%2KAL;@\,YU/;8J%.%3WHN52C[2G2=-*:E*THR2NT_A=K?.[TT]#S
MG_@V3_Y1Y?MP?]E0\5_^J/\ #U?A!_P;]? #P]\?O^"G?P6B\6+8W6@?!W2_
M%7QUN-'OK..\36=8\!6=O;^#8(1,LD$$VD>.M=\,^*?/FAE!@T">W@\BZN+>
MZM_W?_X-D_\ E'E^W!_V5#Q7_P"J/\/5_/W_ ,$(_P!IGP[^R]_P4J^"'B+Q
MKJ6AZ'X%^)\7B'X'>+/$&O)>B#08_B+91P>$M1@O;6>.VT<-\1M,\%V.K:UK
M4-SH6E^&KW7+K4SID"?V]I/+&.,GBO&^.7J;QDJ&#5%4TW4DWDV-YHTDDY.K
M*'-&DHKF]HX\MI68WM0OW_6)]3_\'*'[6_Q6^*W[>OC7]F.]\3ZG;?!+]G"S
M^'UMX8\#6=]<0^'M6\=>*?AMH/C7Q#\0-:TOR;=+WQ3:KXZNO!6EW=XU^FDZ
M#I4YT.2R'B37QJ'QY_P15_:^^*'[*/[?WP"LO!WB#5H?A]\>OBC\._@C\8?!
M,>H"#P]XL\-^/O$]MX1T?6M5L9=-U>.75OAUK'B5?%_AZ^L+2TU[;:ZOX8LM
M:TO2/%WB%;S]3O\ @XB_X)?_ +2-[^V)K_[7'P+^#OQ-^,/PR^-OA[P=/XXN
M/A]H6H>/]2\"?$?PEX9A\&7]KJ'A?POI5WXDT/PAJ?A7PEX:UJV\1ZE;W^B_
M\)'J6LZ9)K.G--HFC#YS_P"")'_!)[]J?XE_MI_!'XZ_%?X)>/?A5\"/V?\
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M[6'_  S+_P ++\7>-]*\=W?Q-TG_ (7[^TYXY^ ^H_\ ""ZGH/CS0/"VD?\
M".:/X4MM>LO[?\(^*OM^I74]O/\ 9[58\?TV4 %%?A5_P<'_ /!4/XX_\$F/
MV*OA]^T5^S[X)^%'CKQ[XW_:7\$_!*33OC)I7B_6_".G:#XB^&GQ@\>ZCJZ:
M9X)\9^ =9N=72?X:V.FV6[Q%!90PZG=W$]M=/%#%7Z4?LF_%"?\ ; _8=_9H
M^-'Q*\,Z#:W/[4?[*7P:^*'C_P ':2+YO"]M/\;?A#X<\5^*O#.F+?W=UJ;:
M##)XFO\ 2[,7M]<7QT]8Q<7<UQOF8 ^K:*_BK_X-X_%7B/\ X)[_ /!4;_@I
ME_P0^\8:SJ%Y\/?!OC#7_P!H3]F9=4N);Y[/P\6\(75M9SWUTUG<CQ!X^^!G
MCSX1^,=1T^UTJ71X=3\%>+KRVU0M=PSZY_:I0 4444 %%?S-?\''?_!;+]H?
M_@CUX?\ V1[;]G'X7?!CQ]XJ_:-UCXUSZYK/QMLO'&O>'_#GA_X.67PNC;3-
M*\,^!/&?P[U&YUCQ)J/Q6L;I==O/%ALM&LO#-WIY\.ZM/X@AU+P_\'>(_P#@
MJ7_P=I_#72YO%_CW_@CE^S[XB\+:8LK:EI'PN\#?$GQKXUN@UM<& :3H'@#]
MK_XF^)[MH[A8Y9EL?!FK--&C6B"WGNH+B, _M6HK\#O^"*G_  7E^#W_  5R
MLO&OPQU/X<:Q^S]^UO\ !_PW'XD^)WP:U;5(]>T+5_#T'B!?"NI^-?AOKTMM
MI.NWFCZ/K=YX>LO&.@>)_#FC:MX'UKQ?H7A]+_Q?;L/$MW\M?\'!?_!<']K;
M_@EU\9/V2_@3^R+\%?@C\3O&?[1&C^(]6O+OXS:7X^\4"ZU"/Q3H?@[PIX4\
M*>'_  +\0/A>]CJ-[JNH3R76K:KXAU>"\^U65E!I6FFUFOKP _J6HK^*'Q9_
MP5B_X.NO@OH[_$;XO_\ !'+X#>(?AQH%Q;R>*=*^$?@GXF>+O'<^G3/Y+2:5
MIWP^_:O^,7B*T@M79;G4=:'P\U_3='T^*XO=4CM;*.6\@_9S_@BU_P %Q/@?
M_P %B/ 'CA?#O@?6O@O\?OA!!H=Q\5/@_J^I/XGTR/1M?5X-)\;>!O&\&DZ1
M9^(?"VHZK::EI4UE?:?I'B?0-0LA%JNDG3=0T/6M9 /W"HK^9/\ X.,_^"V'
M[1__  1X_P"&,?\ AGOX9_!'XB?\-#ZE\=I?'7_"Y=*\=ZI_9VD?!_\ X4M]
MBL?"?_"$>// W]G:EK?_  M#4?M6JZQ_PD%K9_V99>5HTWF3[OZ,?BEXV_X5
MK\,OB+\1O[,_MK_A / GB[QM_8WVW^SO[6_X17P_J&N_V9_:'V2_^P?;_L'V
M7[;]AO?LOF^?]DN/+\EP#NZ*_P ^']A;_@\'_:V^*'[5_P "O!?[7G[._P"S
M9X0_99^-?Q9M/@_<_$?X9:#\5_!FN> =5U[6/#&E0^)K_P :^/OBQXU\$^(M
M'^&T7C+PUK?Q.TBU\.:-JB>&M6M]:LYM*DGTS2]5_P!!Z@ HK!\5>*?#O@;P
MOXD\:^+]9T_PYX2\'Z!K'BGQ1XAU:X2TTO0O#OA_3KC5M;UG4KJ0B.VT_2],
MM+F^O+AR$AMX))&.%-?P)?"K_@[:_;N^*_[;'P*\$Z5^R_\ LUZ7^QQ^T-^U
MWI'P2^'6O:KX8^,=O\6-6^&^H_$SPEX.OKVV\=3?%B#PA<>-M#T+QMX?U+4]
M17X2IH,6KW9TS^PP\%TD !_H%T5\7?\ !1;]J/7OV*?V&OVH?VK/"OA;2/&O
MB?X&_"/Q+XX\.>%_$%[>V&@ZKKUG'%::/'K<^G+_ &@^D6^H7EO>:E96$UE>
MZC9VTVGVNJ:3/=)J=I_(1^RO_P %Q_\ @Y[_ &V?A/;?'+]EW_@FO^Q=\6?A
M3>:]K7ABT\9:9X7\?Z#8W6N>'I((M9LK>T\7_MP>'M4F%A-<102W4=@UF\_F
MPQ7$DL$Z1@']Y%%?RT?L5_MK_P#!SC\2?VI_@MX'_;!_X)J_LO?"#]F;Q%XL
M-G\9/B5X2AO;;Q+X0\(1Z5J5W/JNBRW?[9_CV#[>+VWLK:&-O!WB%YS<&"'3
MI9I(V3^I>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\825IPA5GS5*<9K2<:<HJ:LI)V13G*6CDVNQ^F/[,W_!5;]HG]E7]CK]H/\
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MWJ=2*E**J4W&?).<+\LY)I-Q=TVGY'[:?M&?\' /_!0[]I34?""^(O$OPZ\
M>"/"OB_PAXTO/A9\*_"NM^&_!/CC4O!7B/0_%.CV'CJ^U7Q;XB^(6L^'I=6T
M&VDU/P_:>.],TR_BN+E);<,MD]E\9_\ !0/_ (*!_&7_ (*0_&7PS\<?CCX9
M^&7A7Q9X5^&6C?"G3]/^%.C>*M#\.S>'=#\5>-/%]I>WMIXO\:>.=2DUJ34O
M'6K07%Q!JUO8O8V^G11:=#<0W-S=_"]%<> X8X?RJIAJV6Y1@<%5PD*]/#U,
M-1C2G".*Y%B+RC9U)5E2IJ=2KSU&H0CS6BDFY2=[MN]M_+8_4SX4?\%=?VE_
MA!^P?XY_X)Y>'O"/P5U7X)^/-(^(6AZAXC\0^&/&D_Q.TK3OB5<S7FOQ:-K>
MD_$/1_#"/;WEU=W.E2ZKX-U9[=[EX[HWMO';P0_GK\*/BM\1?@9\2/!GQ>^$
MGBW5O OQ(^'NO67B7PAXKT62);_2-6L7)1S#<Q7%CJ%C=0O-8ZMH^J6E[HVN
M:5=7NCZS87^E7UY9S^>T5V8?*,LPG]H?5\#AZ:S6O5Q.915-2AC:]>/)6J8B
M$^:%1U87C437+--J2=V)MNUV]%9>21^H'_!0?_@J[\<O^"D^C_#NR^//PE_9
MP\.>(/AG=WDFA_$+X5^!O&GA_P ?7VE7]K)%>>%]:UOQ/\2?&EO=>%YKUUUM
M=(M=.L8[;6H_M=G);I/>07.9^PY_P5L_;7_X)]Z=>^%O@5X_TG4?AIJ-_>:Q
M=_";XD:$OB[P"NMWWV1;K6=,MH[S2?$7AZ^N4LXTNQX;\1Z/::@SO/J5K>72
MPSP_FE17*N&\A65+(WE6"GE$92E#+ZM)5L-"4IRJ.5.%7GY)*I.4XR@XRA*3
M<'%L.:5^:[OWZG]'7CO_ (.C/^"D_B[PU?Z%X?\ #W[,/PMU2\1DM_&G@3X7
M^,-0\2Z4S12QB6PM?B;\4?B-X.D='D2=1JGA/4HS+!$'C> S0S?@!\3?B?\
M$3XT>//$OQ0^+/C7Q+\1/B'XQOUU+Q/XR\7:M=ZWK^LW<=M!8VQN]0O9)9C!
M8:?:6>F:991F.RTO2K*RTO3K>UT^SM;:+A**,HX:R#(75ED^4X'+YUDHU:N'
MH1C6J0335.=9\U65-22DJ;GR*7O*-]0<I2W;?J?3W[*'[9/[1O[$GQ)'Q4_9
MM^)&I?#_ ,3W-I#I>O6T=M8:OX<\7:%%?6]^^@>*_#>KVU[I.LZ;+/;J4::V
M34-/9Y+C2+_3KUA=+^V+_P#!T[_P4<;2(M-7P!^R9'>1Q&-]?3X:?$PZO.QC
MD032PR?&J301*&D64"#1(8?,AC!B,1FCE_FPHK'->$^&L[Q$<5FN29?CL3&*
M@L16P\76E".D83J1Y9U(16D8U'*,4VHI78U.4=%)I=CVOX__ +1OQR_:G^(^
MH?%K]H3XF^*/BM\0=1M+?37\0>*+R.4V&D6DUU=6FA:#I=G#::+X:\/6=U?W
M]W:>'_#NFZ7HMK>:A?W=O81W%]=2S?KM_P &XOP[^,?C#_@IW\-/%/PQU"[T
M7PK\,O"'Q \2_&G5&AU*?1;OX<ZKX8U#PK%X5U2ULK_3+34KSQ'XOUOPT= L
M]3O)8=*U;2X?'$.E:S+X+_L^;\'J_27_ ()Z?\%2/V@?^":7_"Y9O@%X.^#'
MB'4_C;I_@W3M>UKXJ^%?%/B/5?#</@?_ (2]]+;P?+X<\<^#K>R^VW'C&YN]
M9M];MM?L-0N=&\/L;2)+&>.\QXGRS%8CA7-<GR'"8)8C$Y?/+L)A:BIX?!TJ
M.)Y<-5<8QA[.FL/AJE6K1@J?+[2G"*C9V"+7.G)O1W;W>FJ_$_0G_@Y>_:Y'
MQ\_;KM?@3H1+>"?V1O#3^"4N/M#3Q:K\2_'MMH7BSXD:G:("BVEOI]M;^#/
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MLEK9*[&VW:[O967D@HHHKO$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !117Z:?\$Q?^"8OQD_X*3?&2
M+PIX4BN_"7P>\)7=E<_%_P"+]S9-+I?A72Y6$HT/0Q*%M]9\<ZS;JZZ-HRNT
M=I&QU;5C#IT*K<\699E@<HP6)S',<13PN#PE-U:]>J[1C%:))*\IU)R:A3IP
M4JE2I*,(1E*23:3;22NWLA?^"8O_  3%^,G_  4F^,D7A3PI%>>$O@[X2O+*
MY^+_ ,7[FQ:72O"NERL)1H>AB4+;ZSXYUFW5UT;1E=H[2-CJ^K&'3H56Y_TO
M?V9/V9/@W^R'\&_"7P*^!?A*S\)>!/"5F(XHH@LNJ:[JLJH=3\2^)=3*K<:U
MXCUJX4W6IZG=%I)9"L,2PVD-O;Q'[,G[,GP;_9#^#?A+X%_ OPE:>$O GA*T
M$<448675=<U254.I^)?$NIE%N-:\1ZU<*;K4]3NB9)9"L,2PVD-O;Q>_5_&7
MB#X@X[C/'>SI^TPN1X6HW@<"Y6E5DKQ6,QBBW&>)G%ODA>5/#4Y.G3<I2JU:
MO7"FH+O)[O\ 1>7Y]>EBBBBOSDT"BBB@ HHHH X73_\ DIGB[_L1?AW_ .I!
M\4:_B-_X.0M6E_:J_P""W?\ P1>_X)ZW6B0^+? UCXK^&7Q&\?\ AR:"SUG0
M]4T'XZ_M":;X5\?VWB?06O+==1@\.?"_X#:IK5]I^I&$GPWX@O5L)%36+KS?
M[<M/_P"2F>+O^Q%^'?\ ZD'Q1K^%?]ORZNKC_@\@_86BGN9YXK'1?@':V44T
MTDL=G:OX/^)MZ]M:H[,MO UY>7=VT,(2-KJZN;@J99Y78 _OBK^!;_@U!_Y2
MF_\ !8G_ +">O?\ K17CJO[Z:_@=_P"#4NUNK'_@JO\ \%D;*]MI[.\L]:\1
MVMW:74,EO=6MU;_M'>/(9[:YMYE26">"5'BFAE19(I%9'564@ ']\5?P+?M[
M_P#*Y)^Q!_V#/@#_ .H-\1:_OIK^!7]N@C5?^#RW]BZSTLC4KO3--^!(U*UL
M"+RXT\VGPQ^(.N70OH+?S);0VVB31:Q<"=8S#I<L>H2;;1UF(!^J'_!WI^S+
M\5OV@_\ @E98>+_A;IE[K\'[,?Q^\*_'WXGZ';:AY*Q_"G3?AW\4/ GB7Q9;
MZ3Y$C:SJ/@W4?'.@ZK<E9K?^R/!C^-=7<RQ6DD9[O_@@'_P6L_82_:J_9-_9
M@_9/MO'/@;X!_M4?"#X3_#SX*7_[/7BJZLO!B>.]4\!>%],\+6WB;X&7E]%I
MV@>/++QLFDW/B0>!/#U]J/Q"\)3-J]IK^B7>DV.G>,?$?]+]?R\_\%&/^#4K
M_@GM^V;-XG^(/P(@O_V+OCEK/VO4%U;X7:59ZG\&=<UZ[O=4U.ZO/%7P;N9M
M.L[/^T;K41#+)\/?$'@>&RAM;.1--O1#-:W8!_4-63K^NZ1X6T+6O$WB"_@T
MK0/#NDZEKNMZI=%EM=-TC2+.;4-2O[ED5V$%G96\UQ,55F$<;%58X!_A9_X-
M[_V]?V_?V4O^"DGC?_@A5_P4$\4:K\19?"6C>+]%^$>H^+/$DWBWQ'\.]>^&
MW@2/XE^']*\%>-]?N;/Q#XG^!GC[X(6<_BCP+H&J6E[J7AC1X/!A\.:1X0\/
M-XFTJ#]H_P#@Y_\ VRK#]DG_ ()(_'?P_I^MZ=8?$C]JQ;3]E[P'I=T;F>ZU
M/1_B+%<'XPW$=C8RQ70L[3X,:?XYT]M6N98-&TW7M;\-6VI27<VJ:?HFL 'Y
M%_\ !O3X;L_^"F7_  5W_P""E_\ P6J\<^&9KKP[X>\=7'PI_98OM7AAA;1X
M_%6A2>#;"_%E)<W^J6?COP%^R_X4\ ^!]<NVNK/19[3XO>(X=.TZ<2)!X;VO
M^#W?_DTS]B;_ +.)\<?^JUFK]Z?^"#'["\/_  3]_P""8/[.7PAU/3!IGQ-\
M>^'K?X^_'".2UTVWOX_BS\7=*TC7-6T+5I=+,MOJ.H?#_P .0>%OA@=3^V:@
M+VU\$6LEO>O8_9(H?P6_X/=_^33/V)O^SB?''_JM9J /W8_9Z_X+%_\ !*GP
MM\ O@=X9\0?\%#/V0]*U_P ._!_X::%K>EW7QT\!+=:;J^D>"]%T_4K"Y5-9
M=1/9WMO-;S!691)&P5F&"?TE_9[_ &G_ -G;]K+P7J?Q%_9F^-7PV^._@/1?
M$][X*U;Q=\+?%FD^,?#^G>+M.TK1==O_  Y>:GHUS=6L&L6>C>(]!U.XL))!
M<166L:?<,@CNHF;\'_@)_P &R_\ P1#\:_ OX+^,?$W[$_\ :7B3Q;\)OASX
MF\0:C_PTA^UQ9_VAK>O>#]'U35;W['I_Q[M;"U^U7]U<3_9K*UMK2#S/*MK>
M&%$C7]H/V,/V%/V4_P#@GM\)]3^!_P"Q[\)K;X._"_6?&^K_ !'U;PW!XM\?
M>-Y=1\;:]I'A_0-5U^\\0?$GQ5XQ\37%S<Z+X5\.Z8L$FLM96MGI-K#:6T"J
M^\ _BY_X+Z?\K37_  17_P"\<G_KQ3XR5_?Y7\!G_!?>SO$_X.C_ /@BAJ#V
MMREA=7/_  3NL[:^>"5;.XO+#_@H?\5Y[ZU@N2@AFN;.'4=/FNX(W:6WBO[.
M29$2Z@+_ -^= '\@7_!ZM_RBR^ ?_9__ ,+/_6=?VJJ_?[_@D[_RBR_X)I_]
MF ?L;_\ K.OPYK^?K_@]8NK5/^"7G[/MB]S;K>W'[?'PUNK>S::-;J>UL_V>
M?VGX;RYAMRPEEM[66^L8KF9$:."2\M4E9&N(0_\ 0=_P2JL[S3O^"7O_  3>
MT_4+6YL+^P_8)_8^L[ZQO();6\L[RU_9Z^'<%S:W=M.B36]S;S(\,\$R)+#*
MCQR(KJ0 #^3S_@M=J]]^QI_P<X_\$G/VP=&NK6#2/BSH_P '_AYXO1M6FBU*
MWM]0^)GCKX"?%+4'2[M[32=/T>7X/?%C18=,C.KLE_JFG^(!JPTBTD@O+K^[
MFOX*/^#OJZU5_P!N#_@CK9>$KF!O&EOXE\<76A6BS:<UU!JMY\7?@1#X<N9K
M?4&-I%!=:M8RQ6TVI(NG3R6=TDK-%;W(3^]>@ HHHH _@#_X/G/^<77_ '>S
M_P"^CU_?Y7\ ?_!\Y_SBZ_[O9_\ ?1Z^IO$7_!*?_@Z_^+FF3?#_ .+7_!8O
M]G[0/AWXB$EAXJU3X6^*OB#X?\;6^DW%M/;W*Z1=^#/V2?A+K=PTT<QAELH_
MB!X>AGC<O)=[HHT(!\5?L86.A^)O^#SW]H'7?V8+G0S\)-&\0?M#>(_C'+X0
MU+3]0T/5+B]_9O'A_P"+%S<7>F6,5G<WM[^UQXAL=4UV%=D]MXH^UQWNI:E>
MVUQ/J'H7_!U]_P I3?\ @CM_V$]!_P#6BO M?T7?\$;/^"&G[.'_  1^\&>)
M-1\&>(O$7Q>_:,^*6@:)H_Q<^-GBF&TTR">PTLP7K^#/AGX1L4:'P5\/FUR+
M^VYK/4M2\3>*];U1+6X\0>*KZPTGPWH_A_\ F5_X/$? =G\4_P!O_P#X)>?#
M'4+^YTJP^(WA;4? =]J=G'%->:=9^+_C5X5\/W-_:Q3_ +F6YLX=0>X@CF_=
M/+&JR?(30!_>_P#%CXO_  I^!'@/7OBC\:OB/X(^$_PX\,6QN_$'CCXA^)]'
M\(^%])APQ07FM:Y=V5C'-.RF*TMO.-S>3E+>UAFG=(V_@H_X-HK"+]I/_@O)
M_P %2/VY/@9I?B;2OV6=;A_:8OM#UJ_TF\TZVU,?M$?M,>&_B#\-/"E];V]C
MI6FZ+-J'AOPMKOC*+PK="ZO?#D.@Z;I<D>I36S:]&W_@H;_P9L>$/A#^S/\
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M;:OI6L^$/A#K5A.;C5-0T[XQ2)HFG23PW.KZ)_-]_P %#OV(]-_X)X?M+?\
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MB5XXT[3+:\UWPOX>U&[GTJSLKVXETBSCFN7@C\H_IM0 4444 %%%% !1110
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M "#V#_F7W,_R7:*_UHO^'</_  3R_P"C#?V,?_$7?@?_ /,-1_P[A_X)Y?\
M1AO[&/\ XB[\#_\ YAJ/^(_9/_T3^9?^%6%_R#V#_F7W,_R7:*_UHO\ AW#_
M ,$\O^C#?V,?_$7?@?\ _,-1_P .X?\ @GE_T8;^QC_XB[\#_P#YAJ/^(_9/
M_P!$_F7_ (587_(/8/\ F7W,_P EVBO]:+_AW#_P3R_Z,-_8Q_\ $7?@?_\
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M_9/_ -$_F7_A5A?\@]@_YE]S/\EVBO\ 6B_X=P_\$\O^C#?V,?\ Q%WX'_\
MS#4?\.X?^">7_1AO[&/_ (B[\#__ )AJ/^(_9/\ ]$_F7_A5A?\ (/8/^9?<
MS_)=HK_6B_X=P_\ !/+_ *,-_8Q_\1=^!_\ \PU'_#N'_@GE_P!&&_L8_P#B
M+OP/_P#F&H_XC]D__1/YE_X587_(/8/^9?<S_)=HK_6B_P"'</\ P3R_Z,-_
M8Q_\1=^!_P#\PU'_  [A_P"">7_1AO[&/_B+OP/_ /F&H_XC]D__ $3^9?\
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M*L+_ )![!_S+[F?Y+M%?ZT7_  [A_P"">7_1AO[&/_B+OP/_ /F&H_X=P_\
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M_L8_^(N_ _\ ^8:C_AW#_P $\O\ HPW]C'_Q%WX'_P#S#4?\1^R?_HG\R_\
M"K"_Y![!_P R^YG^2[17^M%_P[A_X)Y?]&&_L8_^(N_ _P#^8:C_ (=P_P#!
M/+_HPW]C'_Q%WX'_ /S#4?\ $?LG_P"B?S+_ ,*L+_D'L'_,ON9_DNT5_K1?
M\.X?^">7_1AO[&/_ (B[\#__ )AJ/^'</_!/+_HPW]C'_P 1=^!__P PU'_$
M?LG_ .B?S+_PJPO^0>P?\R^YG^2[17^M%_P[A_X)Y?\ 1AO[&/\ XB[\#_\
MYAJ/^'</_!/+_HPW]C'_ ,1=^!__ ,PU'_$?LG_Z)_,O_"K"_P"0>P?\R^YG
M^2[17^M%_P .X?\ @GE_T8;^QC_XB[\#_P#YAJ/^'</_  3R_P"C#?V,?_$7
M?@?_ /,-1_Q'[)_^B?S+_P *L+_D'L'_ #+[F?Y+M%?ZT7_#N'_@GE_T8;^Q
MC_XB[\#_ /YAJ/\ AW#_ ,$\O^C#?V,?_$7?@?\ _,-1_P 1^R?_ *)_,O\
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M]:+_ (=P_P#!/+_HPW]C'_Q%WX'_ /S#4?\ #N'_ ()Y?]&&_L8_^(N_ _\
M^8:C_B/V3_\ 1/YE_P"%6%_R#V#_ )E]S/\ )=HK_6B_X=P_\$\O^C#?V,?_
M !%WX'__ ##4?\.X?^">7_1AO[&/_B+OP/\ _F&H_P"(_9/_ -$_F7_A5A?\
M@]@_YE]S/\EVBO\ 6B_X=P_\$\O^C#?V,?\ Q%WX'_\ S#4?\.X?^">7_1AO
M[&/_ (B[\#__ )AJ/^(_9/\ ]$_F7_A5A?\ (/8/^9?<S_)=HK_6B_X=P_\
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M "#V#_F7W,_R7:*_UHO^'</_  3R_P"C#?V,?_$7?@?_ /,-1_P[A_X)Y?\
M1AO[&/\ XB[\#_\ YAJ/^(_9/_T3^9?^%6%_R#V#_F7W,_R7:*_UHO\ AW#_
M ,$\O^C#?V,?_$7?@?\ _,-1_P .X?\ @GE_T8;^QC_XB[\#_P#YAJ/^(_9/
M_P!$_F7_ (587_(/8/\ F7W,_P EVBO]:+_AW#_P3R_Z,-_8Q_\ $7?@?_\
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M_9/_ -$_F7_A5A?\@]@_YE]S/\EVBO\ 6B_X=P_\$\O^C#?V,?\ Q%WX'_\
MS#4?\.X?^">7_1AO[&/_ (B[\#__ )AJ/^(_9/\ ]$_F7_A5A?\ (/8/^9?<
MS_)=HK_6B_X=P_\ !/+_ *,-_8Q_\1=^!_\ \PU'_#N'_@GE_P!&&_L8_P#B
M+OP/_P#F&H_XC]D__1/YE_X587_(/8/^9?<S_)=HK_6B_P"'</\ P3R_Z,-_
M8Q_\1=^!_P#\PU'_  [A_P"">7_1AO[&/_B+OP/_ /F&H_XC]D__ $3^9?\
MA5A?\@]@_P"9?<S_ "7:*_UHO^'</_!/+_HPW]C'_P 1=^!__P PU'_#N'_@
MGE_T8;^QC_XB[\#_ /YAJ/\ B/V3_P#1/YE_X587_(/8/^9?<S_)=HK_ %HO
M^'</_!/+_HPW]C'_ ,1=^!__ ,PU'_#N'_@GE_T8;^QC_P"(N_ __P"8:C_B
M/V3_ /1/YE_X587_ "#V#_F7W,_R7:*_UHO^'</_  3R_P"C#?V,?_$7?@?_
M /,-1_P[A_X)Y?\ 1AO[&/\ XB[\#_\ YAJ/^(_9/_T3^9?^%6%_R#V#_F7W
M,_R7:*_UHO\ AW#_ ,$\O^C#?V,?_$7?@?\ _,-1_P .X?\ @GE_T8;^QC_X
MB[\#_P#YAJ/^(_9/_P!$_F7_ (587_(/8/\ F7W,_P EVBO]:+_AW#_P3R_Z
M,-_8Q_\ $7?@?_\ ,-1_P[A_X)Y?]&&_L8_^(N_ _P#^8:C_ (C]D_\ T3^9
M?^%6%_R#V#_F7W,_R7:*_P!:+_AW#_P3R_Z,-_8Q_P#$7?@?_P#,-1_P[A_X
M)Y?]&&_L8_\ B+OP/_\ F&H_XC]D_P#T3^9?^%6%_P @]@_YE]S/\EVBO]:+
M_AW#_P $\O\ HPW]C'_Q%WX'_P#S#4?\.X?^">7_ $8;^QC_ .(N_ __ .8:
MC_B/V3_]$_F7_A5A?\@]@_YE]S/\EVBO]:+_ (=P_P#!/+_HPW]C'_Q%WX'_
M /S#4?\ #N'_ ()Y?]&&_L8_^(N_ _\ ^8:C_B/V3_\ 1/YE_P"%6%_R#V#_
M )E]S/\ )=HK_6B_X=P_\$\O^C#?V,?_ !%WX'__ ##5QEC_ ,$Z_P#@GV_Q
M"\463_L*_L<-9V_@SP'=06C?LQ_!-K6"ZO-<^(\-W<PVY\$&**>ZBL;**YF1
M%DGCL[5)69;>$(?\1^R?_HG\R_\ "K"_Y![!_P R^YG^4A17^M%_P[A_X)Y?
M]&&_L8_^(N_ _P#^8:C_ (=P_P#!/+_HPW]C'_Q%WX'_ /S#4?\ $?LG_P"B
M?S+_ ,*L+_D'L'_,ON9_DNT5_K1?\.X?^">7_1AO[&/_ (B[\#__ )AJ/^'<
M/_!/+_HPW]C'_P 1=^!__P PU'_$?LG_ .B?S+_PJPO^0>P?\R^YG^2[17^M
M%_P[A_X)Y?\ 1AO[&/\ XB[\#_\ YAJ/^'</_!/+_HPW]C'_ ,1=^!__ ,PU
M'_$?LG_Z)_,O_"K"_P"0>P?\R^YG^2[17^M%_P .X?\ @GE_T8;^QC_XB[\#
M_P#YAJ/^'</_  3R_P"C#?V,?_$7?@?_ /,-1_Q'[)_^B?S+_P *L+_D'L'_
M #+[F?Y+M%?ZT7_#N'_@GE_T8;^QC_XB[\#_ /YAJ/\ AW#_ ,$\O^C#?V,?
M_$7?@?\ _,-1_P 1^R?_ *)_,O\ PJPO^0>P?\R^YG^2[17^M%_P[A_X)Y?]
M&&_L8_\ B+OP/_\ F&H_X=P_\$\O^C#?V,?_ !%WX'__ ##4?\1^R?\ Z)_,
MO_"K"_Y![!_S+[F?Y+M%?ZT7_#N'_@GE_P!&&_L8_P#B+OP/_P#F&H_X=P_\
M$\O^C#?V,?\ Q%WX'_\ S#4?\1^R?_HG\R_\*L+_ )![!_S+[F?Y+M%?ZT7_
M  [A_P"">7_1AO[&/_B+OP/_ /F&H_X=P_\ !/+_ *,-_8Q_\1=^!_\ \PU'
M_$?LG_Z)_,O_  JPO^0>P?\ ,ON9_DNT5_K1?\.X?^">7_1AO[&/_B+OP/\
M_F&H_P"'</\ P3R_Z,-_8Q_\1=^!_P#\PU'_ !'[)_\ HG\R_P#"K"_Y![!_
MS+[F?Y+M%?ZT7_#N'_@GE_T8;^QC_P"(N_ __P"8:C_AW#_P3R_Z,-_8Q_\
M$7?@?_\ ,-1_Q'[)_P#HG\R_\*L+_D'L'_,ON9_DNT5_K1?\.X?^">7_ $8;
M^QC_ .(N_ __ .8:C_AW#_P3R_Z,-_8Q_P#$7?@?_P#,-1_Q'[)_^B?S+_PJ
MPO\ D'L'_,ON9_DNT5_K1?\ #N'_ ()Y?]&&_L8_^(N_ _\ ^8:C_AW#_P $
M\O\ HPW]C'_Q%WX'_P#S#4?\1^R?_HG\R_\ "K"_Y![!_P R^YG^2[17^M%_
MP[A_X)Y?]&&_L8_^(N_ _P#^8:C_ (=P_P#!/+_HPW]C'_Q%WX'_ /S#4?\
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M]C'_ ,1=^!__ ,PU'_$?LG_Z)_,O_"K"_P"0>P?\R^YG^2[17^M%_P .X?\
M@GE_T8;^QC_XB[\#_P#YAJ/^'</_  3R_P"C#?V,?_$7?@?_ /,-1_Q'[)_^
MB?S+_P *L+_D'L'_ #+[F?Y+M%?ZT7_#N'_@GE_T8;^QC_XB[\#_ /YAJ/\
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M7_1AO[&/_B+OP/\ _F&H_P"'</\ P3R_Z,-_8Q_\1=^!_P#\PU'_ !'[)_\
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M*L+_ )![!_S+[F?Y+M%?ZT7_  [A_P"">7_1AO[&/_B+OP/_ /F&H_X=P_\
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M'?67A#Q#XCU/XH?%+5=/\5?#_P"(7Q,@L/#GC'QM>^"M(T[PE?ZY::EI=O\
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M_B#5WW7GB7QGXAF3)OO%'C/Q!<:CXE\17[LQN-5U*Y,0BME@@B^E* /X%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_\ ]]Z NN_]:?YH]THKPO\ X7E_U1[XZ?\ AO\ _P"^]'_"\O\ JCWQT_\
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MR:Y_T1?XK?\ @EL__DZC_A<FN?\ 1%_BM_X);/\ ^3J NN_]:?YH]THKPO\
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M_P"(H_X67\4/^B$Z]_X5WA[_ .(H"Z\_N?\ D>Z45X7_ ,++^*'_ $0G7O\
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MKS^Y_P"1[I17A?\ PGWQK_Z(#_YE3PG_ /(='_"??&O_ *(#_P"94\)__(=
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M .%5<_\ QF@+^OW/^NOY]F>Z5POQ1_Y)G\1/^Q%\7?\ J/ZA7"_V_P#M _\
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M_@I\1_\ Q=']G_M&?]##\*?_  4^(_\ XN@+^3^[T_S_  ?8]THKPO\ L_\
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M?_CU ?)_A_G_ %9^5_=**\+_ + _:!_Z'_P+_P"$K<__ !ZC^P/V@?\ H?\
MP+_X2MS_ /'J ^3_  _S_JS\K^Z45X7_ &!^T#_T/_@7_P )6Y_^/4?V!^T#
M_P!#_P"!?_"5N?\ X]0'R?X?Y_U9^5_=*X73_P#DIGB[_L1?AW_ZD'Q1KA?[
M _:!_P"A_P# O_A*W/\ \>KE+/1/CB?'/B**+QOX,754\)^#)+VZ;PU<-:S:
M?+K'CQ=,MX8/-W1SVUS%J\ES*21-'=VJ  P-D"_D_P /\SZ?HKPO^P/V@?\
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M^8K\)_\ R91_P@/QK_Z+]_YBOPG_ /)E 7?9_A_F>Z45X7_P@/QK_P"B_?\
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M5 ?)_A_G_5GY7]THKPO_ (5/XV_Z+?XZ_P# 72?_ (U1_P *G\;?]%O\=?\
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M?%;_ ,+F\_\ D:C_ (4)H?\ T/7Q6_\ "YO/_D:@+OM^/I_F_N\SW2BO"_\
MA0FA_P#0]?%;_P +F\_^1J/^%":'_P!#U\5O_"YO/_D:@+OM^/I_F_N\SW2B
MO"_^%":'_P!#U\5O_"YO/_D:C_A0FA_]#U\5O_"YO/\ Y&H"[[?CZ?YO[O,]
MTHKPO_A0>@-Q+XV^*<T9XDAE\<7IBE0\/%(%MU8QR+E7"LI*D@,#S1_PSYX)
M_P"@MXZ_\++5O_CE :]K?/T_X/W>9[I17A?_  SYX)_Z"WCK_P ++5O_ (Y1
M_P ,^>"?^@MXZ_\ "RU;_P".4!KY??\ \#U_IZ>Z45X7_P ,^>"?^@MXZ_\
M"RU;_P".4?\ #/G@G_H+>.O_  LM6_\ CE :^7W_ / ]?Z>GNE%>%_\ #/G@
MG_H+>.O_  LM6_\ CE'_  SYX)_Z"WCK_P ++5O_ (Y0&OE]_P#P/7^GI[I1
M7A?_  SYX)_Z"WCK_P ++5O_ (Y1_P ,^>"?^@MXZ_\ "RU;_P".4!KY??\
M\#U_IZ>Z45X7_P ,^>"?^@MXZ_\ "RU;_P".4?\ #/G@G_H+>.O_  LM6_\
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MFKX*?]"7_P"7'XL_^7U'_#-7P4_Z$O\ \N/Q9_\ +Z@->R^]_P"1[I17A?\
MPS5\%/\ H2__ "X_%G_R^H_X9J^"G_0E_P#EQ^+/_E]0&O9?>_\ (]THKPO_
M (9J^"G_ $)?_EQ^+/\ Y?4?\,U?!3_H2_\ RX_%G_R^H#7LOO?^1[I4,UQ!
M;*'N)X8$+! \TB1*7()"AG906(5B%!R0I., UXC_ ,,U?!3_ *$O_P N/Q9_
M\OJFA_9Q^"\#ET\$PL2I4B;6_$MRN"0<A+C694#948<*' R P#,"!KV7WO\
MR/7_ .U=+_Z"5A_X&6__ ,<H_M72_P#H)6'_ (&6_P#\<KRG_AGSX.?]"/8?
M^!VL_P#RRH_X9\^#G_0CV'_@=K/_ ,LJ U[+[W_D>K?VKI?_ $$K#_P,M_\
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MH/A_X6(50H+Z3:NQ"@ %G=&=VP.6=F9CDL2233O^%._"O_HG_A3_ ,$UG_\
M&Z U\OQ\O^#^'F;W_">>!_\ H<_"G_A1:1_\F4?\)YX'_P"AS\*?^%%I'_R9
M6#_PIWX5_P#1/_"G_@FL_P#XW1_PIWX5_P#1/_"G_@FL_P#XW0&OE^/E_P '
M\/,WO^$\\#_]#GX4_P#"BTC_ .3*/^$\\#_]#GX4_P#"BTC_ .3*P?\ A3OP
MK_Z)_P"%/_!-9_\ QNC_ (4[\*_^B?\ A3_P36?_ ,;H#7R_'R_X/X>9O?\
M">>!_P#H<_"G_A1:1_\ )E'_  GG@?\ Z'/PI_X46D?_ "96#_PIWX5_]$_\
M*?\ @FL__C='_"G?A7_T3_PI_P"":S_^-T!KY?CY?\'\/,WO^$\\#_\ 0Y^%
M/_"BTC_Y,H_X3SP/_P!#GX4_\*+2/_DRL'_A3OPK_P"B?^%/_!-9_P#QNC_A
M3OPK_P"B?^%/_!-9_P#QN@-?+\?+_@_AYF]_PGG@?_H<_"G_ (46D?\ R91_
MPGG@?_H<_"G_ (46D?\ R96#_P *=^%?_1/_  I_X)K/_P"-T?\ "G?A7_T3
M_P *?^":S_\ C= :^7X^7_!_#S-6;XD_#NV<)<>/O!<#E0X2;Q3H<3E"2 P5
M[]25)5@& P2I&<@U#_PM'X9_]%$\"_\ A7:!_P#+"H8?A1\,(%*)\//!; L6
M)F\,Z/<OD@# >XLY7"X480,$!R0H+,3-_P *N^&?_1._ O\ X2.@?_*^@-?+
M\?+_ (/X>8?\+1^&?_11/ O_ (5V@?\ RPH_X6C\,_\ HHG@7_PKM _^6%'_
M  J[X9_]$[\"_P#A(Z!_\KZ/^%7?#/\ Z)WX%_\ "1T#_P"5] :^7X^7_!_#
MS#_A:/PS_P"BB>!?_"NT#_Y84?\ "T?AG_T43P+_ .%=H'_RPH_X5=\,_P#H
MG?@7_P )'0/_ )7T?\*N^&?_ $3OP+_X2.@?_*^@-?+\?+_@_AYFSHWBWPIX
MCEF@\/>)O#VO36T:RW$.C:UINJ2V\3ML22:.QN9WBC9_E5Y JLWR@D\5T-<]
MHWA+PIX<EFG\/>&?#V@S7,:Q7$VC:+INERW$2-O2.:2QMH'EC5_F5)"RJWS
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M5H1R^E6Q+HSG0I5L3+#Q<:E"K")1117V1^!!1110 4444 %<+\+O^29_#O\
M[$7PC_ZC^GUW5<+\+O\ DF?P[_[$7PC_ .H_I] NJ]'^<3NJ***!A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'"Z?_P E,\7?]B+\._\ U(/BC7=5PNG_ /)3/%W_ &(OP[_]2#XHUW5 !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7"_%'_DF?Q$_P"Q%\7?^H_J%=U7"_%'_DF?Q$_[$7Q=_P"H_J% '=44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,5OA;X5\=ZSI.AC4KJ^U$:/IVHZ]<V>F"_O;R]%E# +JZN)_,F< ^EZ***
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M/6-?\1RV%YJC6.C^$/ASX9\8>,=1AL["QGN=4U.TT&72M(C:U&JWMFU]8K<
M'V+17R#^Q=^WK^R3_P %#/ACK/QC_8[^,.G_ !E^'GAWQ??> M>UFV\,>.O!
M5_H_BS3M,TG6;G2=2\,?$CPOX/\ %EF6TO7-+OK2]GT--.U&WNM^GW=UY%P(
M?KZ@ HK\NKO_ (+2_P#!,2P_;&7]@2^_:O\ "]G^U<_Q&L_A"GPVN_!/Q8M]
M)?XH:C# ^G^ U^*<W@%/@^WBB_OKJV\.6>DCQ\;JZ\:7$'@2!'\9S1Z$WZBT
M %%?B5\8_P#@XQ_X(S_ 'XL?$GX'_%?]LNV\-?%#X1>-_$WPX^(GANU^ O[3
M_BF+P[XV\&ZO=Z!XHT!_$'@_X*:_X9U.YT76K&]TR\GT76=1LEO+6>%+EVC;
M'FW_ !%'?\$*/^CYO_-9OVP__H?: /W^HK\6_@1_P<-_\$>/VF/C#\._@'\%
M?VP[?Q?\6/BOXFL?!WP_\+77P*_:9\(Q>(/$VIEUT[2%\1>-_@QX;\+:;<7\
MJ?9[-M8UO3X+B[>"SBE>ZN((9/VDH **** "BH+JZM;&UN;Z^N;>SLK.WFNK
MR\NIH[>UM;6WC::XN;FXF9(H+>")'EFFE=8XHU9W954D?F5^Q_\ \%F/^"9_
M[>WQ;USX$_LG?M3>'OBK\5_#^@:KXHN_"#> _BWX#N+_ $'0[^UTW5]0\,ZG
M\2_ '@W0_&26$][;3W$/A'4];N5TQWUH0MH\,U]& ?IY163K^NZ1X6T+6O$W
MB"_@TK0/#NDZEKNMZI=%EM=-TC2+.;4-2O[ED5V$%G96\UQ,55F$<;%58X!_
M!?\ XBCO^"%'_1\W_FLW[8?_ -#[0!^_U%?@#_Q%'?\ !"C_ */F_P#-9OVP
M_P#Z'VOKC]B__@M'_P $S_\ @H3\5]5^!_[(/[3%O\6?BEHW@?5_B/?^%9OA
M+\=OAU(O@[0=9\.Z!JVJ6NK?%7X8>!]!U*XL]3\5:'&VC:;JEWKLMK<W.I0:
M;+IFEZK>60!^HU%?D9^T#_P7@_X),?LL_'_7?V7OCO\ MB^%O OQL\+:OH6@
M^*?# ^'GQI\4:+X7UCQ%;6%W86'B7XA>#?AMXA^&^@3VMMJ=G+X@_M?Q=9IX
M45YAXH;1VM+L0?K)I6JZ9KFF:=K>B:C8:QHVL6%GJND:OI5Y;ZAIFJ:9J%O'
M=V&HZ=?VDDUK?6%]:S17-G>6TLMO<V\L<T,CQNK$ OT45^77[9G_  6C_P""
M97_!/OXH:;\%_P!K?]J/1_A;\4=4\+V/C.'P;8_#?XS?$W5+/PYJEU>V>F7V
MN/\ "3X<^/+/PY-J,FGW4UAIGB"ZTS5;NP6+4[>RDTZYM;J8 _46BN!^%7Q2
M^'_QO^&?@'XQ_"CQ1I_C;X9_%'PAX>\>^ O%VE"Y33_$7A/Q5I=MK.A:M;PW
ML%K?VHO-.O()7LM0M+/4;&5I+34+2UO()[>/\>?B=_P<C?\ !%3X/?$7QO\
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M_A;GG?9_M'AK^SO^$?\ +\Z__M;S-- /W:HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***_/W_@I?^W!H?[!/[+/B_XOO#::I\0M89O!/P>\-W31
MO#J_Q%UJPO7TJ_U*U,T,]QX;\+06UQXD\1I \3W5CIPT>&ZM+[5[&8<^*Q-'
M!8:OB\3-4Z&'IRJU9OI""N[+=R>T8K64FHK5H]7(LDS+B3.,MR')\-+%YGFV
M,H8'!8>+M[2O7FH1<Y/W:=*";J5JLK0I4H3JS:A"37Y,_P#!<W_@KCJG[/UM
MJG['G[-/B(6'QE\0:-%_PM[XD:/> :E\*/#VMVBSVWA+PU/ _FZ=\1/$FDW,
M%_=ZV"ESX/\ #E]:7&C;?$NL66K>%OXF&9G9G=BS,2S,Q+,S,<EF)R222222
M22<FND\9^,?%'Q$\7^*/'WC?6[[Q+XR\:^(-8\5>*O$.IR";4=<\0Z_?W&J:
MQJM[(JHK7-_?W4]S-L1(P\A$:(@51S5?SEG^>8G/L?/%5W*-&+E#"8>]X8>A
M?2*2T=2:2E6J;SGM:$81C_L1X5>&>2^%O"V%R++:=*KF%6%+$9]FZA:OFV9\
MEJE64I+GCA*#E.EE^%ORX?#ZM2Q%7$UJQ5BUM+F]GCMK2"2XGD.$BB4LQ[DG
MLJ*/F=V(1%!9V"@D/L;*YU&[@LK2,RW%PX2-!P.A+,S=%1%!=V/"HI8\"OHG
MPWX:M/#UILC EO9E!N[LK\TC#GRX^Z0(?NIG+'YW);&/F,9C(82"TYZDK\D+
MV_[>EVBG\Y/1;-K]OX=X<Q&?5Y/F=# T9)8C$\MWS635&BGI*M)--W]VE%J<
M[MPA4X[1?AM BI/KDS3R%<FRMF:.*,G'RRSC$LA'(81>4JL/EDD7D]O%X7\.
MPH(TT;3V49P9;=)WY]9)A)(V.VYC_.MZBOG*N,Q-:3E.K-=HPDX07DHQ:7S=
MWW;/V/ \/Y/E])4\/@,.VE:56M3A7KS[N=6K&4M7KRQ<8)_#&*T/.->^'NG7
M4,DVCJ+&\4%EB+N;6X('*,KEOL[-_ \6V)3PT1#;T\1DCDADDBE1HY8G:.1&
M!#)(C%71@>0RL""#R""*^M:\&^(VG+::VEU&H5-1MEF< !1]HA)AEP  /FC$
M+L>K.SLW)R?3RS&5)S="K)SO%RIRD[R3CO%MZM-7:O=JUMGI\/QOP]A,/AHY
MK@:%/#.%6-/%TJ,5"E*-7W:=:-.-H0G&IRPFH12J>T4I>]%N7(:3JVJ:!JNF
MZ[H>I7^C:UHVH6>JZ/J^EW<]AJ>E:IIUQ'=Z?J6G7UK)%=65_8W<,5S:7=M+
M'<6UQ%'-#(DB*P_TG/\ @E/^VU%^W5^R'X,^)>M3VW_"U/"$[?#CXQV4"I K
M>.?#]C8S'Q%;6PV-'IWC+1;W2_$<9B@CL;75+W6-#LWG71)93_FIU_13_P &
MVG[0]Q\.?VR/%GP$U"]E7P]^T3\/=273;'S'\IOB#\+;;4/&6C76PL8E \%?
M\+#MY2$66:62R'F[81%)^H<"YM/+\ZI8:4G]6S)K"U(-^ZJ[O]5J)?S^U?LK
M_P M:6C:5OX?^E#P%A^+O#;'YU2H*6=<&0JYW@J\8IU)9;!0_MO"3ENJ#P,'
MCVK-^WR^BDXQE-O^Z>BBBOWP_P J HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "L'Q/X5\+^-]!U'PMXS\-Z#XN\,:Q%'!J_ASQ/H^GZ_H.J013
MQ744.HZ/JMO=Z??11W,$%Q''<V\J)/#%,H$D:,-ZBDTFFFDTTTTU=-/1IIZ-
M-:-/<J$YTYPJ4YRIU*<HSA.$G&<)Q:E&<)1:E&49).,DTTTFFFCXI\0?\$WO
MV!/$^HMJNK_L<_LZ&^D5EFETWX4>$-"2X=YYKF2XNK?0M,TVVNKV6:XE:>^N
M(9;V<>7'+.\<,*Q^E_"_]D+]E7X*S07?PF_9R^"7P]U*VN(+J/6_"WPS\(:5
MXA-U:37D]E<S>(K?25UVYN+![^\73YKG4)9+"&XDM[-H+<B(?1=%<T<%@X35
M2&$PL*B=U4CAZ49I]U)04K_,]:MQ%Q!B<.\)B,]SBOA6K/#5LSQM7#M+9.C.
MO*FTNW+8_$?XQ_\ !9C2_A!_P4BT+_@GU=?L]7^N1ZQ\3/@A\,9OB[;_ !/M
M[%[35/C=HG@75-+U&/X?R> KA;JPT.Y\>Z;9Z@&\<6EQ<P6=]>6\0D%O93_M
MQ7\./[:W_*Q]X-_[.V_8"_\ 46_9PK^XZO$R#,,7CL5G]/%5?:0P6;XC"X9>
MSIP]G0A4J1A3O3A%SLHKWJCE-ZWDS]%\3N%LCX=R?PRQ>3X)X2OQ#P-E><9O
M-XG%XA8O,L1AL+5K8E1Q->M'#\\ZT_W.&5'#Q5E"E&P4445]*?D04444 %%%
M% !7\4?AW_@[7_X17P_H7A?_ (8 ^W_\(WHVF:#]N_X:K^R_;?['LH-/^U_9
MO^&;KC[/]H^S^=Y'VB?R=_E^=+MWM_:Y7^,!>_\ 'Y=_]?,__HUZ^2XIS/'9
M=]1^I5_8^V^M>T_=4:G-[/ZOR?Q:=2UO:3^&U[ZWLK?O/@AP7PSQA+B;_6++
M?[1_L^.3_4_]LS#">Q^MO-/K'^XXK"^T]I]6H?Q>?DY/<Y>:?-_9W_Q%[?\
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M_P"(O;_K'K_YME_^317\7=%'^L^>?]!W_EM@_P#YG#_B"WAG_P!$U_YF<_\
M_GJ?VB?\1>W_ %CU_P#-LO\ \FBC_B+V_P"L>O\ YME_^317\7=%'^L^>?\
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MZSYY_P!!W_EM@_\ YG#_ (@MX9_]$U_YF<__ /GJ?VB?\1>W_6/7_P VR_\
MR:*/^(O;_K'K_P";9?\ Y-%?Q=T4?ZSYY_T'?^6V#_\ F</^(+>&?_1-?^9G
M/_\ YZG]HG_$7M_UCU_\VR__ ":*/^(O;_K'K_YME_\ DT5_%W11_K/GG_0=
M_P"6V#_^9P_X@MX9_P#1-?\ F9S_ /\ GJ?VB?\ $7M_UCU_\VR__)HH_P"(
MO;_K'K_YME_^317\7=%'^L^>?]!W_EM@_P#YG#_B"WAG_P!$U_YF<_\ _GJ?
MVB?\1>W_ %CU_P#-LO\ \FBC_B+V_P"L>O\ YME_^317\7=%'^L^>?\ 0=_Y
M;8/_ .9P_P"(+>&?_1-?^9G/_P#YZG]HG_$7M_UCU_\ -LO_ ,FBC_B+V_ZQ
MZ_\ FV7_ .317\7=%'^L^>?]!W_EM@__ )G#_B"WAG_T37_F9S__ .>I_:)_
MQ%[?]8]?_-LO_P FBC_B+V_ZQZ_^;9?_ )-%?Q=T4?ZSYY_T'?\ EM@__F</
M^(+>&?\ T37_ )F<_P#_ )ZG]HG_ !%[?]8]?_-LO_R:*/\ B+V_ZQZ_^;9?
M_DT5_%W11_K/GG_0=_Y;8/\ ^9P_X@MX9_\ 1-?^9G/_ /YZG]HG_$7M_P!8
M]?\ S;+_ /)HH_XB]O\ K'K_ .;9?_DT5_%W11_K/GG_ $'?^6V#_P#F</\
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M;_K'K_YME_\ DT5_%W11_K/GG_0=_P"6V#_^9P_X@MX9_P#1-?\ F9S_ /\
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M .>I_:)_Q%[?]8]?_-LO_P FBC_B+V_ZQZ_^;9?_ )-%?Q=T4?ZSYY_T'?\
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M ":*/^(O;_K'K_YME_\ DT5_%W11_K/GG_0=_P"6V#_^9P_X@MX9_P#1-?\
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M]HG_ !%[?]8]?_-LO_R:*/\ B+V_ZQZ_^;9?_DT5_%W11_K/GG_0=_Y;8/\
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M\7=%'^L^>?\ 0=_Y;8/_ .9P_P"(+>&?_1-?^9G/_P#YZG]HG_$7M_UCU_\
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M[?\ 6/7_ ,VR_P#R:*/^(O;_ *QZ_P#FV7_Y-%?Q=T4?ZSYY_P!!W_EM@_\
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M]O\ K'K_ .;9?_DT5_%W11_K/GG_ $'?^6V#_P#F</\ B"WAG_T37_F9S_\
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M_@B/\2]4NH-&\._$GQS\7?@)+K\VC&^\1ZEX'N="\-:AJ,=W83VGV_6OBU\
MI?A9\3;33+;185L]"\!Z_<WD&@74,VESYO\ P<V_\IF?^"&7_93?AI_ZU5\-
M:M?\'0/@SX@_L!_\%!/^"<__  6X^#ND'4QX(\8>%O@W\4=#&JV>DV7B77O
M]UXK\;Z!X6O+N;0M8NM-/QG^#FH_%GX;ZWX@MX=3?1=$\):?=:;IEGJL:7>H
M ']TM?P&_P#!5W5[G_@L=_P7*D_8]T:#5_$/[)7_  2U_9\^,WQ&^.2LLLGA
M74/BIX7\#:CXS\87$D44^F2S6^K?$-O@K^S]>V&H2&[MI_#7Q UW1TU30+B:
M.\_KQ_; _P""@?PK_9D_X)R?$K_@HGI=Y:^,OAKHOP)\._%[X:3V;VE]IWCB
MX^*5IX>LO@K:I-;ZQ86MQI7C+Q1XV\&64MS8:RK-I^JR3Z;<7$WV=9?YN_\
M@W,_9$\4^#/^"57[=W_!0WXXOXH\0?M%?\%#= ^/GCC4?&GCB6&\\0ZY\+_"
M>@_$)=/\3R37ULWB*'5OBA\4==^)WCCQ+J]Y?I:^.]&'PZUVWTYK2PT[6M8
M+G_!DQ_R8!^U7_V>'>?^J5^%%?U._MH_M1>#?V*/V4/V@?VKO'MH=4\-_ CX
M7>*?B _A]+YM+G\7:UI5@Z>$_ UEJHT_54TO4?'7BNXT3P?INIW&G7=GI^H:
MW;7E[$;."<C^6+_@R8_Y, _:K_[/#O/_ %2OPHKK/^#NS]I'7]:^!?[*_P#P
M2^^#-U+J_P <_P!NCX]^ FO_  9IEY>O?:KX"\,^*++1_ V@:II%A;32SP>.
M?CMJ_@:Z\.RRF?SK_P"&NL1V6E7]Y;I<Z8 ?R*^/OV#?VFM/_P""9GAC_@X
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M?"*/QM9)HVD7=M=:QK\'ALK!JL]C:Z5=@'[I_P#%,>.?#'_,!\8>#?&&@_\
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M;G2IXO '[0GQC@BT"+PTVIW>H2:UI&D3'48]%72M1D0ZI;/[#^U#_P $</\
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M;?1?"OB?7/&=]->>&-2UWPP?!9NX[W3-&AUU)@#^]"O@3]L7_@J1_P $_OV
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M:[C&M"$FE=:I6U0ZBBBM#D"BBB@ HHHH **** "BBB@ HHHH **** /YA?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!_4!_P0U_X+E:C^R?J/AW]DW]K+Q%>ZK^S'JM[%IOP\^(>I2SW
MVH_ #4;Z?$=A?R'S;F\^$EY<RE[NT023^!YY)-3TR-]%>_L(/[^]-U+3M9TZ
MPUC1[^RU72=5LK74M+U33;J"^T[4M.OH([JQO["^M9);:\LKRVEBN+6ZMY9(
M+B"2.:&1XW5C_C"5_4!_P0U_X+E:C^R?J/AW]DW]K+Q%>ZK^S'JM[%IOP\^(
M>I2SWVH_ #4;Z?$=A?R'S;F\^$EY<RE[NT023^!YY)-3TR-]%>_L(/M>'>(O
M8<F Q\_W&D</B)O^#T5*JW_RZZ0F_P"%\,OW=G3_ )O\7?")9FL3Q3PMADLR
M2G7S;*:$;+,4KRJ8W!4XK3'K66(P\5_MNM2FOKG-'%_Z!%%4M-U+3M9TZPUC
M1[^RU72=5LK74M+U33;J"^T[4M.OH([JQO["^M9);:\LKRVEBN+6ZMY9(+B"
M2.:&1XW5C=K]#WV/Y(::;3333:::LTUHTT]4T]T%%%% @HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .%T__ )*9XN_[$7X=_P#J0?%&OX/?
M^"^G_*TU_P $5_\ O')_Z\4^,E?WA:?_ ,E,\7?]B+\._P#U(/BC7YF?M:?\
M$8OV3_VR_P!O/]EO_@HE\5O$WQNTSXX_LE?\*K_X5YH'@CQ=X1TCX9>(/^%-
M?%?Q!\9_ G_"=:%J_P /_$'B34/L/C;Q-J<U[_PCGC#PM_:6FF#3[O>D/F,
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M?^4S/_!#+_LIOPT_]:J^&M?T^?\ !8?]A^U_X*'_ /!.;]IK]F. 7">-]?\
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MM=-T;3+V]N)[FX@MXHH7DFFBC5G7MJ^8?VSOV4O _P"W%^S!\7_V4/B7XO\
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M1_B=;^*/#>DZ]IFK#7=!&IZ',EE^!7_!J'\3O%'@7]M;_@IO^PK\*/C7XO\
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MB=?B5'?1Z%>^!-.DUG^X"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _J
M_P""&O\ P7*U']D_4?#O[)O[67B*]U7]F/5;V+3?AY\0]2EGOM1^ &HWT^([
M"_D/FW-Y\)+RYE+W=H@DG\#SR2:GID;Z*]_80?W]Z;J6G:SIUAK&CW]EJNDZ
MK96NI:7JFFW4%]IVI:=?01W5C?V%]:R2VUY97EM+%<6MU;RR07$$D<T,CQNK
M'_&$K^H#_@AK_P %RM1_9/U'P[^R;^UEXBO=5_9CU6]BTWX>?$/4I9[[4?@!
MJ-]/B.POY#YMS>?"2\N92]W:())_ \\DFIZ9&^BO?V$'VO#O$7L.3 8^?[C2
M.'Q$W_!Z*E5;_P"772$W_"^&7[NSI_S?XN^$2S-8GBGA;#)9DE.OFV4T(V68
MI7E4QN"IQ6F/6LL1AXK_ &W6I37USFCB_P#0(HJEINI:=K.G6&L:/?V6JZ3J
MME:ZEI>J:;=07VG:EIU]!'=6-_87UK)+;7EE>6TL5Q:W5O+)!<021S0R/&ZL
M;M?H>^Q_)#33::::;335FFM&FGJFGN@HHHH$%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '"Z?_R4SQ=_V(OP[_\ 4@^*-=U7"Z?_ ,E,\7?]B+\.
M_P#U(/BC7=4 %%%% !1110 4444 %%%% !1110 4444 %?(7[+'[!?[)7[%6
MK?&_Q#^S-\'=.^&WB7]I'XA3_%/XX^*'\3>.?&WBGXC>-I[G6+Y=1USQ-\0_
M$_BS7DTZQO\ Q%XDU'2/#.G:A8^%M$U'Q+XDU#1]%L;SQ!K$][]>T4 %%%%
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M6K/"S<84JN.ITJ=>E2K.T95(4)U*47=>T:N^R_;&_8F_:,_80^+=Y\'/VC_
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M=O/'O19$WPR_M.I(F^-T==RC<C*PRK GYS_:7_X-5/VHOA?X,UCQ9^SU\=/
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MQ5#+O[7K4\77AA_99;]96#6,J5*KC3C2>*:H1;FI2JM1C%MGY)45_1G\0_\
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M2JXK$4Z>&I9)[&%*I7RN51U:D?9X*$HU)S<J5"$)WIT:,>;F\\HK^BOX8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0:#K-G#J.CZWHFL:=-<Z?JND:KI]S;W^FZE87%Q97UG<0W5K-+!*CM^+?\
MP40_X.$?^":G_!-7QAJOPK^,GQ'\6_$OXX:"-.;Q!\#_ ( ^&+'QYX^\-IJ:
M:7=6R>*=0UWQ!X,^'7A74#I&K6^OC0O$GCS2O$4VB@7MKI%P;O38KX ^N/\
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MM!>Z?X&\$:2EQKWB(Z3%?V=UK^H6ULNC^';.ZM;K7M2TV"ZM7F /MNBOY1?
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MMX,U;QO:>,_%/C'PO)INNZE>7N@?#G7/L5C;6=G%XC_H]_X)Z?\ !'S]A_\
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M?K=UX-\&033P?VAJ=AX \8^"_']EIMQ<ZC?KX>\)Z]X,\%6-MHWA[P]X=LY
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M/?VLOA-^U'HFFF'0?VB?AX?"_BZ\M[%?+?XF?!X:?H_VW4]0@PJW&L?#G6?
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M7#F/<L-.K[>O1QUYK,(8FLU&5:LL7[7][*%-5*7LITZ5*BZ5./VU_P %U/\
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M!EFF5<18?,%A*5/#PQ=+"9;BJ]#VT*,81J2A44&IS3DU2HQ;M2IJ)_P:$_\
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M7=WK&L?"C]FC2/#.O>(?$\M_I5OI6B67B+4_B=!\*;N\DO;6"#5(=3\1C1M
M!MIKS0/C?_@T_P#VGF\,_&K]H3]DC7+]UTKXH^#M-^,7@.WF6,6MOXQ^'=S'
MH/B^PLW1EN&U'Q-X2\1Z7JDR31S6PL?AV[136,Y:+4_TK_X*6_&K_@WS_:&_
M:%O?#?[='[0/BC5?B_\ L_V^I?"&^\+^%$_:NNO"?@O4M.UN_P!2\3:7$OPJ
M\$ZQ\/Y_%D>L7C:/XQU+2[ZZU<77A_3_  QX@N%NO"<&GZ=\O_LY?%3_ (-<
M_P!E+XT^!?V@?@C\>?'GA;XH?#J\U2\\+ZW/X<_;?U>WMFUO0-6\+ZO!=Z7J
M7PNN+"_L]2T#7-5TR\M;J&2&:VO)49>01]M6CRY]1QU/,LHIX?"^RPT:,\?3
MC5AAH0]E6A*#32FG.K*,&U:5DVFKG\U9=6]MX79APQB>#N/\7F^>_6\YK9E1
MX5Q5; XC.,17AC,!BZ>)C.,Y8>4,/@:=2O"E*4Z2JSA"4)QIO^=+_@LS^S"W
M[)W_  4>_:4^'EA8/8^#O%?C&7XQ?#OYHS:/X.^+2GQE'8::$5)4T[PKX@U'
MQ!X'MTNHQ<@^%W+S7R&/4;S]+_\ @U#_ .4B/QF_[,N^(G_J\?V=*_2;_@ZI
M_92T;QO\$O@9^W%X/LX=1USX>ZUI_P '_'.MZ9/:3VVH_"KQU_;'B/P+K%S<
M*K"[TSP[XY>\T[2I+&[8//\ $^6;[+=6[-=V'YL_\&H?_*1'XS?]F7?$3_U>
M/[.E>6L']1XKHTDK4YXN->C;;V592G%+R@W*GZP>^Y]M5XA7$O@5F..G-RQ>
M'R-Y9F',[S^NY?.AAZLZFKM/$0C2Q36FE=:+8]W_ ."]/_!8KX_>#/CO\0OV
M$OV5=6U_]F_P-\+]8C/Q6\=?#Z_B\)?$+XE>-_%9TSXD:L^C>)?#3VVL^"_#
M+ZEKK76M2Z#J6G>(O'FJZCXA?Q;>SZ-JMUHMSZE_P;1_\%(_VG_C'^T'\1_V
M3_V@?B_X\^-'A"Z^#^J_$CX=ZQ\2_$%_XS\5^$O$?@_Q5X=T_5-%M_%6MB]\
M3W^@^(="\77-PUIK>O7UAH4WA/2;/P_96$6IWXD_"7_@N;_RE@_;._[*!X:_
M]5GX'K[1_P"#77_E)I>_]FW?%;_T_?#^BAF&,J<314L15Y?K\\,J:G)4E0C4
MG25-4TU#E45>UM9^^[SO(>9<*\/8?P5JSI93@HUY<*X3.YXN5"$\9+-*N#PV
M,J8R6+G&6(]M.LW%OVB2H/ZM%+#VIKX-_P""T7P>\*_ C_@J%^V%\._!.DV^
M@^&4^(FD>.-/T:RCA@T_3)/BUX#\(_%G4;/3+2V9K;3])@U3QO>II6F6JP6N
MEZ<+;3[:ULX+:.UA_K_^,^A?$_\ X(T?\$>?AI\,/V(OA)KWC']IWX@S^%_#
M/B+Q1X-^%6K>+_$MC\2_'7A74_$GQ1^.'BGPQ8V%_J%[<^%H-%'@WP0OBV'5
M[#PU=2_#K0M7TS5_#^B3:)/_ "P_\'#'_*8+]KS_ +H#_P"LO_!2O[3O^"Q7
M_!0G]H+]@_\ 8Z^&G[3G[-GP]^'_ ([F\3_$[P5X<\9'XE>&?&_BCPQX6\$^
M,_!/BS6M/URZC\&^+_ .IZ3)/XGTWPWX?MM8UB]&D_;-:MM(FLEU?6-*4=>7
M4Z%'$\45N>6&>&J5:5.M1ASU</1J8G$QJ2I1333BJ=-)IIQ2O=6/!XOQ.99A
MD_@AERP]'-HYQA,%CL7EV88IX;!YKC\)E&35,)2QU=QJ.5.<\9B7*$XSC6E+
MDE&3DFOX<](^*O\ P6XT+XBP_%?3==_X*0Q>.8?$,7B=M2N-*_:"O],O-2BU
M&+4S:ZIX6U#3;KPGJ_AV>XAC@O?"&JZ'>>$[_2U.B7VB7&C.]@W]/?\ P6/\
M$3?MO?\ !#7X7?MB?$[X=3>%_P!I'X0>&O@[\4M:L;+P1>Z!XA\/>(/%.N>'
MOA5\>O W]F^(].U/QGX>^'D>KZ_?>-;_ $*;4[9X#\/?">KZSJ^H6NA2/>_D
MG_Q%>?\ !1'_ *(S^Q=_X;OXX_\ T1=?.O[6/_!Q/^W)^V!^SY\2/V;_ ![X
M"_9F\'>"OBGIEAHOB?6OASX$^(]EXN&D6FLZ;K-QI^FWOC+XO>-]#M(]4.FI
MI]_<2>'KB^CL+BY.F76G:A]GO[?DI8W*\/A,PH?VAC<8L7AJD(TJ^':C'$)<
MU*JI.K-*2G:[LKM)M^ZK^_C>'..,VSWA+,UPIPUP]+(,YPN)K8W+,VIRK5<K
M<X4\=@)TZ>"HRG1J8?G48)RY5SPA%>U;/HK_ (-0_P#E(C\9O^S+OB)_ZO']
MG2O<O^"]G_!87X^>#_CUX\_84_97U?Q'^S=X(^%&N)-\4_'/P[U4^#?'_P 3
M/'/BR*Q^(6KMIGB+PK-9ZMX3\*/?^(Y;O61I.H6>N^.]:U#7+OQ9=3:;?/I,
MWAO_  :A_P#*1'XS?]F7?$3_ -7C^SI7YW?\%S?^4L'[9W_90/#7_JL_ ]1]
M9KX;A>@J%25)ULPK4JDH/EFZ?)*;@I+WHJ4H1YN5KF2Y7[K:>O\ 8V69QXX9
MI_:>#HXV&7<*8',,)2Q$?:4(8R%?"X>GB)497I59TJ6(K>R]K&:ISDJL$JD(
M3C_2'_P;"_MZ?M$_M!W'[1W[/7Q^^)_COXR6W@+0?!OQ)^''BSXB>(]1\8>*
M?#UGJ&JZIX<\7^&;WQ5XAN]0\1ZMI%W-+X5O?#>GWM]/:^'?L.N068CM]2@M
M[?\ /7_@MG_P5P_:%\ ?'SQC^P'^QSXEO/V5OV<?V:K30/A5)!\&"G@'Q7XM
MU;0M(\/7EU:67B/0+32]=^'O@;P;-&W@GP[X0\!ZGI-EKNDV>K:EXJOM>TSQ
M!I7AOPKV?_!I5_R<U^U;_P!D)\,?^K LJ_%W_@L;_P I0OVW?^R[>)O_ $38
MUKB,=BX\,X!QKU%.IBJ]"=52?M71BZDE2]I?GY&U%22?O1A&#?(G%\64\-9%
M6\:^*:57*\'/#8/),NS3#8*5"F\#3S&K2R^D\:L'R_5WB(QK5Y4YRIOV=:O5
MQ$4J\E4C_5?_ ,&R_P"W3\;OVI_AK^T;^SK^T9XT\4_&:3X0-X0\2>"_&GQ'
MU>;QGXCN?!GQ(D\5Z=XB\">)M>UY[K7/$&F:1JFAPWGAU]?N]=N(M+\0:GX<
M6ZT_P]H'AS28_P"*;]K7X7Z-\$/VJOVF?@OX<W_\(]\(?V@OC-\+]"\R>>YD
M_L;P!\1_$GA32_,N;IGN;A_L.DP;I[AFGE;,DS-(S$_U!?\ !HW_ ,E4_;8_
M[)_\&/\ U(_'U?SF?\%(O^4B/[>W_9Z/[4G_ *O'QU7-F-2=?A_)JM:3J58U
ML9252;<I^SC-I1<GJTHPA%7Z1BNA[7".&H9;XL^(N P%*GA,%5R[(,;/"T(J
MG0^M3PM&I.M&E%*$93J8K$5)62O.M4?VK']@G[5?_*J3X7_[-N_8V_\ 6@_@
M;7\<O[$'[:7Q5_8%^/6F?M$_!G1? >O>.M(\,^*?"UE8_$?2=>UKPTMEXLTX
MZ9?W;V'AWQ-X3U"2_M82)=/=M6^R). ;NSO(LPG^QK]JO_E5)\+_ /9MW[&W
M_K0?P-K\#_\ @WZ_X)X_#/\ ;T_:R\5WWQUTJW\4?!/X >"K?QKXF\#37U_9
MQ^//%WB349-$\">'M5?2[S3=17PS:26VO^*M8:UOE2^NO#>D>'-2L[W1?$.I
MI'U9K1Q%?-,CI827)B)Y7@/95+V5.49XB7M&TFTJ:BYNR;M%V3=D_%X'Q^49
M9P3XF8[/J+Q&44>-^)UCL,H*I+%4JM#*J"PL8.=.,IXFI4A0@IU*<.:HN><(
M7DOC?7_VW?\ @J?^V!XZUWQ);_'[]KSXI^*;R33)=3T/X0ZU\0=+\.Z4]OI4
M]IIXTOX:?!R+1?!/A-)[#2M1NFBT'POI$6HW46MZS<I<ZC<ZO>S?V-_\&]/Q
M4_:[^-G[.?[2/P$_;MT7X[>(K?P'JWARR\(:Y^T9X8\967B#Q/\ #OXNZ/XT
MM/$?@M?&GC5;;Q/XXL=!O_#6H-(FI27M[X6TKQ5I.BV>LG0O["T70/C?]NW_
M (.-(OV,OB[\1_V0/V&/V7O@]9:!^SSXFG^$S^*/&6GZUH?@"R\2> ;S_A&O
M&GA;PK\'/ "_#MM/T#PKJ6E7OA'1M3@\8VME>/I7]IZ=I<NA?V<+W]#O^"$W
M_!5[]HG_ (*>_P##4W_"_/!GP6\(_P#"D/\ A2'_  B?_"H/#OCG0/[0_P"%
ME?\ "WO[=_X2'_A,_B-X_P#M?V3_ (0#1O[)_LW^R?(^TZG]L^W^=:_8N[*(
MX6AF\**SC$X[%2^L4ZU-T:BP]64:5252,JM2K/GY)0<U.THSE!-6YKGS7']?
M/,QX Q&/?A]DO#61THY1B\OQ<,PP;S; 4JF,P5+"5:&#PF"H+#_6(8B.'EA^
M>E4P]&K44XMTTI?YW7Q/\,V'@KXE?$/P;I4UW<:9X2\<^+?#.FSZA)#+?SV&
M@Z_J&E6<U[+;6]I;R7<EO:1O<R06MM"\S.T5O"A6->&KUOX_?\EW^-?_ &5O
MXD?^ICK->25\)-)3FEHE*22\DW8_I_"RE/"X:<FY2G0HRE)[N4J<6V_-MML*
M***DW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'TFN5GC@TC4-;TGXFS16L0MX39VYU[XBZW,ULTEVS74US=_:%6Z6UMOYX/\
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MPM\%_&7]I35_#J66E>&-)U7Q+XRLO"_@[P]X\U1_"VJ>+8=5\3>)KW0F\/\
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MH[C6K_P5XPU3?X=\1^ -3O([R7PKJD^LVVN_9?LNG^(M'TG79$LI@#^B>O\
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M44UWPOIVK^(_$FOZ+?.Y\+^*O'?B/P^L:7-A>W%V ?SM?\%D_P!D7P+^W?\
M\'47[/W[)WQ.UOQ!X>^'GQ>^&GP;L?&>H^%7M(?$;^'/"WP_^(GCK5-*T:[O
MH;FUTV^U^U\+R:##J\MI?#1SJ1U1=/U![-;*?^^3X;?LK_LR_!RQ\#:;\)_V
M>O@I\.+3X9"\_P"%=IX+^%_@OPY+X)EU+0I_#&J77A>ZTO1;:ZT6^U;P[=7>
MAZQJ%A/#>ZMI=W=V.HW%U;W5Q')_&5^UE_RNB?L8?]DR\(_^L]?'*O[KZ /\
M[C_@KI^RI\,OVW/^#KO]F[]E_P",PUF7X5_%#X=_!J/QU8Z!J,ND:GK7A[PA
M\//B/X^O/#<>K6Q2^TNU\3CPJGA[4M2TN:TUBQTW4[NZT>^L-4BM+R#^W:[_
M ."<_P"PC?\ [.J_LFWW[)GP*O/V>4\+V?A%/AI=_#_0[C3DTW3M-@TO3]37
M5YK9_$J^-+"*UMK^S^(@UH>/[7Q!;P>*(/$R>)(8]67^&'_@M5^USI?[!_\
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M!^V]?P!_\%]/^5IK_@BO_P!XY/\ UXI\9*_O\K_/<_X.*_&OA'X:_P#!S/\
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MT^'PIX4BU&6[T_2](_X2U[K60#]S:*** "BBB@ HHHH **** "BBB@ HHHH
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MR3_\'2G_ #8O_P!W-_\ OOE?<G[(7_!&?_@FS\4?V3?V7OB9XZ_9P_MSQO\
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M=P7OB#4HUN+9(])T2VU#4[FXN[.TM;2:ZN[:&7UIY/D5*$JE3*LHIPBKRG/
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M[J/B9^V+^QQ_P4W_ ."%4_@[X]?M#_ SPO\ M7^"?@W_ &UIOA#XD_%KX.^
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MZQ\<$^!?[+/AF7X,Z?\ %+P5=?%B#7?"'QV^$NI>)]-N/AS%K3>,;:XT33-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEV7.5I5)*\?KV.Y6XU,74BVH03E3PE.3HT7*4J]>N4445[A^8A1110 4444
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M)O\ A"O!7_"3>,?&/]B_\)CXQ\0^/_$?_%1^/_$/BKQ;J/\ :/BWQ5KVK?\
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M=2&M8'P\=L P!#$;))S@ R;5Y$*L?._A]HHU/6?MDRG[)I"K=MR!ON]V+*(
MLA;$H,S;"65(22I7(KWPDDDDDDG))Y))ZDGN37S6;8IJV&@[72E5:>MGK&#\
MFK2??W5W1^U\!9'%J6=8F"DTY4<#&2ORN+Y:V)5]+WYJ--[Q:JNVL&BBBBO"
M/U **** /G?Q[&$\4:@1_P M%LY"/0FS@4_GMW=_O?@./KJ?&MPMSXFU5T.5
M26&#Z-;VT,$@_"6-ZY:OL<,FL/AT[W5&E>^]^2-_N/YSSN499SFTH-.,LRQK
MBULT\34U7KOVUTT#^G^?\_C1116YY9]5:9=+>Z=8W:L&%Q:P39'^W$K$$=F!
M.&!Y#9!Z5>KR?X?>)H1 NA7TR1/&S'3I)#M$JRNSO;%R<"19&)A!YE$GE)@Q
MHK^L5\?BJ,J%>I"2:7,W!VTE!N\6NFS2:N[.ZZ']%9)F='-<MPV*I3C*;I0A
MB()IRI8B$4JL)K=>]>4&TN>FXS2M)!12$A068@*H)))P  ,DD]@!R37G?B3Q
M]9Z>KVND/%?WI4J;A&WVEL3QG>O%Q(O9(R8@>7DRIB>*-"K7FH4H.3ZO:,5W
ME+9+UU>R3=D;YCF>!RJA+$8VO"C!)\L;IU:LE]BE37O5)/R5HKWI.,4VKWC+
MQ5'HEJUI:2*VJW*$1 $-]DC/!N9!S\W40(PP[Y<ADC96^?V9G9G=BS,2S,Q+
M,S,<EF)R22222222<FI;BXGNYY;FYE>:>9R\LLC%G=CW)/8# 4# 50%4!0 (
M:^IPF%AA:?(O>G+6<[6<GV7516R7J]VS\,X@SW$9[C/;U$Z6'I*4,+A[W5*F
MW=RDUI*K4LG4EMI&"]V""OL[]@+]D#Q?^W!^U!\._@7X:M[Z/1+[4(/$'Q-\
M1V0A'_"%_"_1[ZQ'B[Q,TES!<6GVN&WN[?3-"M;J/R=4\2ZIHVDN\*WQGB^2
M/#_A_7?%>NZ-X7\,:-JGB+Q)XBU2PT30- T2QN=4UC6M9U2ZBLM-TK2M-LHI
MKN_U"_O)H;6SL[6&6XN+B6.**-W=5/\ HF_\$@/^"=&G?L"_L[0'Q=8V=Q^T
M1\78-*\3_&'5T:*XD\/A+8R^'_A;IEW!)+;/IG@F.\O!JEW9R31ZUXKO];OX
M[V[T>+P_#I_V7"F05,]S*$9Q:P&%<:N,J6=I13O'#Q>WM*[3CO>--5)[Q2E_
M.7COXKX7PNX/KUL-6I3XISJ%; \.8-N,ITZTH<N(S:M3O?ZKED)JK=IQK8R6
M%PSM"K4G3_4SPEX4\.>!/"OAGP/X/TBS\/\ A+P;X?T;PIX6T'3D,>GZ)X<\
M.Z;;:1HFD6,;,[1V>FZ99VME;(SL4AA12S$9/0445_0Z2BE&*48Q248I)))*
MR22T22T26B1_D34J3JU)U:LYU*M2<JE2I4DYU*DYMRG.<Y-RE.4FY2E)MR;;
M;;84444R HHHH **** "BBB@ HHHH XKQ]\2OAU\*?#\GBWXH^/O!7PV\*PW
M"6LWB;Q]XJT+P=X?BNI(9[B.VDUKQ%?Z=IL=Q);VMU.D+7(D:&VGE52D,C+^
M%W[37_!Q5^QW\'KNZT#X)>'/&'[37B2U:'?J.@S1_#[X9[7@E>: >-?$6FZE
MX@N[V"?[+$#I/P_U31YHY+F6/6O,M4MKKXR_X.DIYU@_8;MEFE6VFE_:5GEM
MQ(X@EGMT^ <=O-)$#Y;RP1W5RD,C*7B2XG5"JS2!OP#_ &+?A3^Q%\4O&4.F
M_M@_M-^/_@!HHU+28((?#?PI/B+3O$-O>75REY#_ ,+&M-3\2'P1<0Q0VD(U
M+7/A=J^B6LNJ"^O;N*PTJ\:;\ZX@XIS/#YM6R7+E@\-.G[%/&8JK2CK5P]*O
M=2Q,H8:DHJKRVJ*JYN/NI-J)_5OA?X,\'YGP3@?$#BNIGV<4,5''SCD&38/&
MU6HX+-,9EO*Z>4T\1FV-G5>$]K?#2P<*$:C]K)PINJ?9_P"T3_P7U_;_ /CC
M'>Z1X0\6>&?V>?"MW;QVLFF_![1#:^)+B**Z:[6XN/'_ (GN/$/BO3]2=_)@
MFN_!][X1AFL[:.U:SV7&I&__ "HM;+XQ?M%?%_PSX<O-2\5_$WXR_%[QAX9\
M+:%<>-O%$U]XC\7>+?'^L6=CX<AU#Q3XUU6*-6U_5M<M)%UC7=7MM/ U#^T;
MV_AM7ENA_?-^Q+_P3P_X)3>%_#&F>.?V;_!?P?\ VA)([7RW^*OB7Q-HGQZU
M5KBYNWGCGD2_N-4\)^#]>M39OIA7PYX8\*:G:)9WUC=PK=RZS]I_GB_;6_Y6
M/O!O_9VW[ 7_ *BW[.%?/YSDF:1PV!QV;YN\=]<S##82-*C5G6I4X8B%6<JE
M*K+EHQ<53Y5&E0=-N3DIM*TOT_@#Q#X,JYKQ'P[P/P*N&UD7"^;YW5QN/PF'
MP.-Q.(RRM@,/3PN+PE'VN.JPJO%JI.MB\RCB8PHPINC&4[T?I7]@;_@WR_:*
M^'_QF^"?[0/[0?Q/\ ?#C_A5'Q)\"?%>S^&OA.*[^(GBO5=3^'OC;1_$EEX9
M\1:S#/H/A'P[;ZQ_9#O+K&@:OXZ^RVLMM']A-W<7*Z;_ %\T45^H93DV!R6A
M.A@85(JI)3JSJU)5)U)QCRJ4KVA%VZ4X0CUY3^-^-^/^)/$#,*&8\18C#U*F
M$I3H8.AA,+2PN'PE"I4=6=*FHJ5:HG/7GQ->O5LDO:65@HHHKU3XL**** "B
MBB@ K_& O?\ C\N_^OF?_P!&O7^S_7^,!>_\?EW_ -?,_P#Z->O@^-O^99_W
M._\ NH?U%]&OX^,_\/#WYYV5J***^#/ZF"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYX?[)3P_H]O:6\%I+;ZIJ=U?/968!_0Q17\5'B+_ (.U/VE/A58P^,OVAO\
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MPWTQ-*U+5+CQ)K5CK'['W@32Y["W&GB&87WB_0+>,3B5[]-@CD_J7H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K^:;_@YS^(KZ'^RA\"_AE!>O;3?$'XXR>([JWBD"MJ.D_#
MWP;K4-Q;7";@9+*+5?&FAWSC:P6]M-/8[< U_2S7\D7_  =/R3BP_8;B4_Z,
M]W^TC),.,&>.'X$+;'UXCENNG')SVKYCC.K*EPSFLH[NE0I.W\M;%X>C/_R6
MH[^1^V_1QP=+'^-7 M"LDX0QN9XQ)VM[7+LAS7,*#UOJJ^%IM=4TK6=F?R&4
M45)%&TTL<2_>ED2-<]-SL%&?Q(K^=C_7Q)MI)7;:27=O1(^AO U@=/\ #5F&
M#+)?L^HS G@^< ML0,#&+5(CR2<NV,#KUU0V\2000PQ#$<44<<8/9$4*OZ 5
M-7Q=:HZM6I4=WSS<M>S>B]$K)+HE8_I/+L)# 8'"8.FDHX?#TJ5U]J48)3FW
MU<Y\TF^K;T6P4445F=@5!=7$=I;7%U*=L5M!-<2'N$AC:1\=1G:IQGC.,\5/
M7G7Q&UI;/2TTF%A]IU-@T^"0T=C"ZL?NR @W$ZK& Z,K1Q3 <GC;#T77K4Z2
M^U)<S[06LG\E>WG9'FYOF$,KR[%XZ=OW%)NG%_;K2]RC#SYJDHIVVC=[)GB=
MU<27EU<W<N/-NIYKB3'3S)Y&E?'MN8XJ"BBOL4DDDM$E9+LD?SG*4IRE.3<I
M2DY2D]6Y2=VV^[;;9][?L%?L&>/_ -OC7?CMX+^&MY%9^,?AA\#M5^)_A&VO
M3%;:3XL\7V'C'P=HVF> +_5K@K;:-/XHT/5O$\NBZA<O#:)K>D6":E<V.D/J
M-_:_$GB7PUXA\&>(M<\)>+=$U3PWXH\,ZK?Z%XA\/ZW97&FZQHNLZ7<R66HZ
M7J>GW<<5S9WUE=PRV]S;3QI+%+&R.H(-?V>?\&QOP'O/"OP"^//[0FK6TL,G
MQ;\?:%X%\,"YC 9O#GPNTV^O-0U;3W )^Q:QXA\;W>E7!+JTMWX0PT*QP037
M'Z _\%)/^"/OP&_;_M9/&]K<1_"']H?3[%(-/^*>@Z3:7%KXNAL[=8-/T3XG
MZ,@MY?$=E;P1QV6G:_;7=KXET.W2UC2ZU71]/A\.S?H=#@BMF'#F S'!.V8U
M(UJM3#5)*,,30E6G[#DG)J-.JJ2C)<UJ=2,TG*#BG+^1<T^DSEO"GC!Q1P?Q
M''VG!^%KY?@<+G&$I.M7R?,Z67X;^U%BJ%*,JN*P#QLZM&JJ49XK"5L/.=.G
MB*=9PH_YT]=%:>+/$=E'Y5OJUR$P !-Y=R5 SA5:YCF=4&>$5@H]*^X_VLO^
M"7G[:O[&M_J<GQ7^#VM:OX&TY9IX_BY\.+>^\<?"ZYL8" U]=>(].L([KPJK
MGS##8>.]*\*:Q-%!/<Q::]I']H/Y]D%258$,"000000<$$'D$'@@\@U\%C,#
M6PU1X?'82=&K!ZTL31<9*SW4:D=4[)J2O%Z--JS/ZJX>XHR_-\'3S;A?/L-C
M\%B(KDQV39C"K3DFKNG.KA*KY9QO:=&HXU*<KPJ0C)-+5O\ 7M9U,,M]J5U/
M&V-T)D,<#8Y!-O%LA)&!@^7GBLFBM;0M!USQ/J^GZ!X;T?5/$&NZM=16.EZ-
MHMA=:IJFHWLYVPVEC8644UU=7$I!"0P1/(V#A3@UC""C:%."5VDHPBE=O1)1
MBMWHE9>1Z.(Q-2JYXC%XB=1QBY5*V(JRFXPBG*4IU*LFU&*O)N4K)7;ZF374
M^"? _C'XD^+-!\!_#_PQKGC/QIXIU&'2?#GA;PUIMUK&NZWJ4X8Q66FZ;91S
M75W<,J.^R*-BL:/(VU$9A^RG[(/_  02_;;_ &D[K2]<^)/AMOV8OAG<S(;W
M7_BQIUU:^/9K+]XD[:#\)]UKXHDOX7\B2*#QD_@72[VV>62TUJ22(12?V%?L
M-_\ !,K]EO\ 8'T%D^$_A1]?^(^I6OD>)?C+XWCL-7^(6K)*B_:M-TR_CL[>
MW\)^&9)%&WP]X=@LX+F.*U?7;G7=1MEU)_M,CX)S;-9PJXBG/+\$VG*MB(.-
M:I#=JAAY6G)M;3J*%*SYE*=N5_SAXF_26X#X$H8G!Y1C,/Q=Q+&,X4<NRG$0
MK9?A:VJ4LTS6E[3#4HTY)JIA<++$XWGC[*I2PZG[:'P1_P $=_\ @CAI?[&6
MFV?Q_P#VA]-T;Q%^U+K5E,FAZ1%-::UH7P-T74('@N=.T:^A,UAJ?Q U6SED
MM?$OBJPDFM-,LII_#/A>[ETZ;6]9\3?T 445^W9;EN#RG"4\%@J2IT::NV[.
MI5FTN:K6G9<]6=ES2LDDE&"C",8K_,WC/C3B#C[B#&<2<2XUXO,,6U&,(J4,
M+@L+!R]A@<!AW*:PV#PZDU3IJ4ISG*I7KU*V)K5JU0HHHKO/E0HHHH ****
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MX>'OSSLK4445\&?U,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/^5IK_@BO_WCD_\ 7BGQDK^_ROX _P#@OI_RM-?\$5_^\<G_ *\4^,E?W^4
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MD_7;]H2XD_X+9?\ !SO\+OV;[)O#_C3]D'_@DNNK>+OB5;:IIE_>^&M;\:>
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M!E.&4A@1U!!R#^!K^:6KIKNFOO/]H*<_9U*=2U^2<)V[\LE*WSL?6PP0".A
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M %-RO_G_ (__ ,&X?_YE/O\ _B8GC;_H5\+?^$6;?_/L_P QG_B'G_X+!?\
M1H?_ )G[]E__ .?71_Q#S_\ !8+_ *-#_P#,_?LO_P#SZZ_TYJ*/]3<K_P"?
M^/\ _!N'_P#F4/\ B8GC;_H5\+?^$6;?_/L_S&?^(>?_ (+!?]&A_P#F?OV7
M_P#Y]='_ !#S_P#!8+_HT/\ \S]^R_\ _/KK_3FHH_U-RO\ Y_X__P &X?\
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MK_3FHH_U-RO_ )_X_P#\&X?_ .90_P")B>-O^A7PM_X19M_\^S_,9_XAY_\
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M1_Q#S_\ !8+_ *-#_P#,_?LO_P#SZZ_TYJ*/]3<K_P"?^/\ _!N'_P#F4/\
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M *%?"W_A%FW_ ,^S_,9_XAY_^"P7_1H?_F?OV7__ )]='_$//_P6"_Z-#_\
M,_?LO_\ SZZ_TYJ*/]3<K_Y_X_\ \&X?_P"90_XF)XV_Z%?"W_A%FW_S[/\
M,9_XAY_^"P7_ $:'_P"9^_9?_P#GUT?\0\__  6"_P"C0_\ S/W[+_\ \^NO
M].:BC_4W*_\ G_C_ /P;A_\ YE#_ (F)XV_Z%?"W_A%FW_S[/\QG_B'G_P""
MP7_1H?\ YG[]E_\ ^?71_P 0\_\ P6"_Z-#_ /,_?LO_ /SZZ_TYJ*/]3<K_
M .?^/_\ !N'_ /F4/^)B>-O^A7PM_P"$6;?_ #[/\QG_ (AY_P#@L%_T:'_Y
MG[]E_P#^?71_Q#S_ /!8+_HT/_S/W[+_ /\ /KK_ $YJ*/\ 4W*_^?\ C_\
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M_P#GV?YC/_$//_P6"_Z-#_\ ,_?LO_\ SZZ/^(>?_@L%_P!&A_\ F?OV7_\
MY]=?Z<U%'^IN5_\ /_'_ /@W#_\ S*'_ !,3QM_T*^%O_"+-O_GV?YC/_$//
M_P %@O\ HT/_ ,S]^R__ //KH_XAY_\ @L%_T:'_ .9^_9?_ /GUU_IS44?Z
MFY7_ ,_\?_X-P_\ \RA_Q,3QM_T*^%O_  BS;_Y]G^8S_P 0\_\ P6"_Z-#_
M /,_?LO_ /SZZ/\ B'G_ ."P7_1H?_F?OV7_ /Y]=?Z<U%'^IN5_\_\ '_\
M@W#_ /S*'_$Q/&W_ $*^%O\ PBS;_P"?9_F,_P#$//\ \%@O^C0__,_?LO\
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M6"_Z-#_\S]^R_P#_ #ZZ/^(>?_@L%_T:'_YG[]E__P"?77^G-11_J;E?_/\
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MG[]E_P#^?77^G-11_J;E?_/_ !__ (-P_P#\RA_Q,3QM_P!"OA;_ ,(LV_\
MGV?YC/\ Q#S_ /!8+_HT/_S/W[+_ /\ /KH_XAY_^"P7_1H?_F?OV7__ )]=
M?Z<U%'^IN5_\_P#'_P#@W#__ #*'_$Q/&W_0KX6_\(LV_P#GV?YC/_$//_P6
M"_Z-#_\ ,_?LO_\ SZZ/^(>?_@L%_P!&A_\ F?OV7_\ Y]=?Z<U%'^IN5_\
M/_'_ /@W#_\ S*'_ !,3QM_T*^%O_"+-O_GV?YC/_$//_P %@O\ HT/_ ,S]
M^R__ //KH_XAY_\ @L%_T:'_ .9^_9?_ /GUU_IS44?ZFY7_ ,_\?_X-P_\
M\RA_Q,3QM_T*^%O_  BS;_Y]G^8S_P 0\_\ P6"_Z-#_ /,_?LO_ /SZZ/\
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M_/L_S4_^(>?_ (+!?]&A_P#F?OV7_P#Y]='_ !#S_P#!8+_HT/\ \S]^R_\
M_/KK_3FHH_U-RO\ Y_X__P &X?\ ^90_XF)XV_Z%?"W_ (19M_\ /L_S&?\
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MO^C0_P#S/W[+_P#\^NO].:BC_4W*_P#G_C__  ;A_P#YE#_B8GC;_H5\+?\
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M /P;A_\ YE#_ (F)XV_Z%?"W_A%FW_S[/\QG_B'G_P""P7_1H?\ YG[]E_\
M^?71_P 0\_\ P6"_Z-#_ /,_?LO_ /SZZ_TYJ*/]3<K_ .?^/_\ !N'_ /F4
M/^)B>-O^A7PM_P"$6;?_ #[/\QG_ (AY_P#@L%_T:'_YG[]E_P#^?71_Q#S_
M /!8+_HT/_S/W[+_ /\ /KK_ $YJ*/\ 4W*_^?\ C_\ P;A__F4/^)B>-O\
MH5\+?^$6;?\ S[/\QG_B'G_X+!?]&A_^9^_9?_\ GUT?\0\__!8+_HT/_P S
M]^R__P#/KK_3FHH_U-RO_G_C_P#P;A__ )E#_B8GC;_H5\+?^$6;?_/L_P Q
MG_B'G_X+!?\ 1H?_ )G[]E__ .?71_Q#S_\ !8+_ *-#_P#,_?LO_P#SZZ_T
MYJ*/]3<K_P"?^/\ _!N'_P#F4/\ B8GC;_H5\+?^$6;?_/L_S&?^(>?_ (+!
M?]&A_P#F?OV7_P#Y]='_ !#S_P#!8+_HT/\ \S]^R_\ _/KK_3FHH_U-RO\
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M )G[]E__ .?71_Q#S_\ !8+_ *-#_P#,_?LO_P#SZZ_TYJ*/]3<K_P"?^/\
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M3QM_T*^%O_"+-O\ Y]G^8S_Q#S_\%@O^C0__ #/W[+__ ,^NC_B'G_X+!?\
M1H?_ )G[]E__ .?77^G-11_J;E?_ #_Q_P#X-P__ ,RA_P 3$\;?]"OA;_PB
MS;_Y]G^8S_Q#S_\ !8+_ *-#_P#,_?LO_P#SZZ/^(>?_ (+!?]&A_P#F?OV7
M_P#Y]=?Z<U%'^IN5_P#/_'_^#</_ /,H?\3$\;?]"OA;_P (LV_^?9_F,_\
M$//_ ,%@O^C0_P#S/W[+_P#\^NC_ (AY_P#@L%_T:'_YG[]E_P#^?77^G-11
M_J;E?_/_ !__ (-P_P#\RA_Q,3QM_P!"OA;_ ,(LV_\ GV?YC/\ Q#S_ /!8
M+_HT/_S/W[+_ /\ /KH_XAY_^"P7_1H?_F?OV7__ )]=?Z<U%'^IN5_\_P#'
M_P#@W#__ #*'_$Q/&W_0KX6_\(LV_P#GV?YC/_$//_P6"_Z-#_\ ,_?LO_\
MSZZ/^(>?_@L%_P!&A_\ F?OV7_\ Y]=?Z<U%'^IN5_\ /_'_ /@W#_\ S*'_
M !,3QM_T*^%O_"+-O_GV?YC/_$//_P %@O\ HT/_ ,S]^R__ //KH_XAY_\
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M>?\ X+!?]&A_^9^_9?\ _GUU_IS44?ZFY7_S_P ?_P"#</\ _,H?\3$\;?\
M0KX6_P#"+-O_ )]G^8S_ ,0\_P#P6"_Z-#_\S]^R_P#_ #ZZ/^(>?_@L%_T:
M'_YG[]E__P"?77^G-11_J;E?_/\ Q_\ X-P__P RA_Q,3QM_T*^%O_"+-O\
MY]G^8S_Q#S_\%@O^C0__ #/W[+__ ,^NC_B'G_X+!?\ 1H?_ )G[]E__ .?7
M7^G-11_J;E?_ #_Q_P#X-P__ ,RA_P 3$\;?]"OA;_PBS;_Y]G^8S_Q#S_\
M!8+_ *-#_P#,_?LO_P#SZZ/^(>?_ (+!?]&A_P#F?OV7_P#Y]=?Z<U%'^IN5
M_P#/_'_^#</_ /,H?\3$\;?]"OA;_P (LV_^?9_F,_\ $//_ ,%@O^C0_P#S
M/W[+_P#\^NC_ (AY_P#@L%_T:'_YG[]E_P#^?77^G-11_J;E?_/_ !__ (-P
M_P#\RA_Q,3QM_P!"OA;_ ,(LV_\ GV?YC/\ Q#S_ /!8+_HT/_S/W[+_ /\
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MKH_XAY_^"P7_ $:'_P"9^_9?_P#GUU_IS44?ZFY7_P _\?\ ^#</_P#,H?\
M$Q/&W_0KX6_\(LV_^?9_F,_\0\__  6"_P"C0_\ S/W[+_\ \^NC_B'G_P""
MP7_1H?\ YG[]E_\ ^?77^G-11_J;E?\ S_Q__@W#_P#S*'_$Q/&W_0KX6_\
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M)>SA*=9PI0YE1ITW4JRJ%%%%>N? A1110 4444 %%%% !1110 4444 %%%%
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MKN6^AU22ZEUO3_ MOJ4EQ)J5O;ZB\[W)E>^@ANV8W$22+]IT ?B?_P %G?\
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M[P9\+OA_X3UN.U_9]^.=S:IJ_AWPGI.CZDEM<KX"5;BW6]LYEAG5566,+(
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M7?\ 9NG?:K[1_L=U<?8++S97^RP>7[=0 5_ M_P=??\ *4W_ (([?]A/0?\
MUHKP+7]]->(?%#]F7]F[XW^*O 'CKXT?L^_!#XO>-OA/J(U?X6>,?BA\*/ ?
MC_Q5\--6&HZ9K U3P!XA\5Z!JVK^#=1&KZ)HVJ"]\.WFFW(U'2-,OA+]IL+2
M6( ]HNK6UOK6YL;ZVM[RRO+>:UO+.ZACN+6ZM;B-H;BVN;>97BGMYXG>*:&5
M&CEC9D=65B#_ )[7_!*#4['_ ((B_P#!QS^TY_P32UC5[GPW^S5^UKJVF^$?
MA/J/B_996EQ>:AI=]\5OV1E/BC6M4C?Q'J45EXV\5?LZ6VHZ:^IS^+_BKXF3
M39-)T[5A=6FB_P"A97A'C3]EK]F3XD?%CP9\>OB)^SG\"/'OQS^'-MI%G\/?
MC1XT^$7P_P#%/Q8\!V?A_5]3\0:#:^#/B+KGAZ^\8>%[;1->UO6=;TB#1-8L
M8M-U?5]3U*R2&\O[N:4 _AZ_X/G/^<77_=[/_OH]?W#?M2?\FR_M%_\ 9"?B
M[_ZK_P 0U8^,O[,_[.'[1G_")_\ #0G[/WP1^.__  @6I76L^!?^%R_"GP)\
M3_\ A"]7OOL7VW5?"?\ PF^@ZY_PCFI7?]FZ=]JOM'^QW5Q]@LO-E?[+!Y?L
M]U:VM]:W-C?6UO>65Y;S6MY9W4,=Q:W5K<1M#<6US;S*\4]O/$[Q30RHT<L;
M,CJRL00#^,W_ (,F/^3 /VJ_^SP[S_U2OPHKY1_X.I/AQ\4/^"?W[?/[#'_!
M:#]EK0].\.^.9=17X;?$?Q3+H&EWGA#4_BS\.-*NKGX>Q?$6SBCT_5M?U'XM
M_!&^\;?#749QJ_VY_AW\'[;2]*U#PQ>:3IM_=?W#_!3]GKX!?LU^%=0\"_LY
M_ [X/_ 'P3JWB"Z\6:IX.^"GPT\%_"OPKJ7BJ^T[2M'OO$VH>'O NBZ#I%YX
M@O-(T+0]+NM9N+.34;C3M&TJQFN7MM.LXH=GXL?!SX1?'KP1J7PS^.?PK^''
MQG^&^LW&G76L?#[XL>!_#'Q%\$:M=:/?P:II-SJ7A3Q?I>L:#?7&EZG:VNHZ
M=-=6$LEE?VT%Y;-%<0QR* ?S%?\ !I3^QAJ_PD_8<\<?ML_%G3[>_P#CK^WE
M\2M>^(B^++^#3IO$<GP;T._GT_PQ%>W<=FM[9S^,O'9^('Q O[:"^_L[5-)U
MCP9=2:=:WNGLS_!G_!S;_P IF?\ @AE_V4WX:?\ K57PUK^YCP_X?T'PGH.B
M>%?"NB:1X9\,>&=(TWP_X<\.>']-LM&T'P_H.C6<.G:/HFB:/IT-MI^E:1I6
MGVUO8:;IMA;V]E8V=O#:VL,4$2(OG'CO]GSX"?%+QQ\.?B=\3?@A\(?B+\2O
M@]J$VK?"3XA>._AKX,\7>./A;JEQ=6-]/J7PY\6>(-%U#7_!&H3WNEZ9=S7G
MAG4-,N)+K3K&X>1I;2W>, _.C_@O;_RAR_X*%_\ 9NWB7_TX:37\O/\ P;T?
M\%XO^"9O_!/S_@FOX*_9U_:?^-?B;P=\6=-^*/Q8\6:CX?T;X/\ Q6\8VMEI
M'BGQ&MUHCR:YX8\(ZEHLUQ=6< NG@M+^Y:WCFBCN#%<B:"+^]3QKX(\%_$KP
MCXC\ ?$7PCX8\?> _&.CW_AWQ=X)\:Z!I7BKPCXJ\/ZI ]KJ>A>(_#>NVE_H
MVN:/J-K));7^F:G975E>0.\-Q!)&S*?B?_AT[_P2R_Z1I_L ?^(;_LZ__.YH
M ^+?V=?^#C__ ()(?M3_ !O^&G[/'P?_ &A?$NJ?%'XN>)K7P=X#TK7?@M\7
MO"VFZOXFU"*=]+TB77M=\&V6D:?<:K<0KI^GM?W=O!/J-S:VIE1IU-?NC7Q3
MX(_X)K?\$Y_AGXO\.?$#X<?L!_L4_#_Q[X.U>R\0>$?&_@C]E?X%^%/%_A;7
MM-F6XT[6_#GB70? EAK.AZO83HL]EJ6F7MK>VLRK+!-&X##[6H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,4J<N:,Y83"UZ<:E.=*4XU(N)_2-^VW_ ,$Z_P#@FA\5_"&N>,/VC?!_PI^
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M2^&7_11? G_A7>'_ /Y84!==U_7_  Z^\[NBN$_X6E\,O^BB^!/_  KO#_\
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MW7]?\.OO.YHKAO\ A9_PT_Z*'X&_\*W0/_EA1_PL_P"&G_10_ W_ (5N@?\
MRPH"Z[K^O^'7WG<T5PW_  L_X:?]%#\#?^%;H'_RPI/^%H_#/_HHG@7_ ,*[
M0/\ Y84#NNYW5%<+_P +0^&?_11/ O\ X5V@?_+"E_X6?\-/^BA^!O\ PK=
M_P#EA0*Z[K^O^'7WG<T5PW_"S_AI_P!%#\#?^%;H'_RPH_X6?\-/^BA^!O\
MPK= _P#EA0%UW7]?\.OO.YHKAO\ A9_PT_Z*'X&_\*W0/_EA1_PL_P"&G_10
M_ W_ (5N@?\ RPH"Z[K^O^'7WG<T5PW_  L_X:?]%#\#?^%;H'_RPH_X6?\
M#3_HH?@;_P *W0/_ )84!==U_7_#K[SN:*X;_A9_PT_Z*'X&_P#"MT#_ .6%
M'_"S_AI_T4/P-_X5N@?_ "PH'==_Z_IH[FBN%_X6C\,_^BB>!?\ PKM _P#E
MA1_PM'X9_P#11/ O_A7:!_\ +"@5UW7]?\.OO.ZHKA?^%H_#/_HHG@7_ ,*[
M0/\ Y84?\+1^&?\ T43P+_X5V@?_ "PH"Z[K^O\ AU]YW5%<+_PM'X9_]%$\
M"_\ A7:!_P#+"C_A:/PS_P"BB>!?_"NT#_Y84!==U_7_  Z^\[JBN%_X6C\,
M_P#HHG@7_P *[0/_ )84?\+1^&?_ $43P+_X5V@?_+"@+KNOZ_X=?>=U17#?
M\+/^&G_10_ W_A6Z!_\ +"C_ (6?\-/^BA^!O_"MT#_Y84!==U_7_#K[SN:*
MX;_A9_PT_P"BA^!O_"MT#_Y84G_"T?AG_P!%$\"_^%=H'_RPH"Z[K^O^'7WA
MI_\ R4SQ=_V(OP[_ /4@^*-=U7B5C\1OAZGQ"\47K^//!BV=QX,\!VL%VWBC
M0UM9[JSUSXCS7=M#<&^$4L]K%?64MS"CM)!'>6KRJJW$)?L_^%H_#/\ Z*)X
M%_\ "NT#_P"6% 77=??_ %W1W5%<+_PM'X9_]%$\"_\ A7:!_P#+"C_A:/PS
M_P"BB>!?_"NT#_Y84!==U_7_  Z^\[JBN&'Q/^&AZ?$/P,?IXMT _P M0I?^
M%G?#;_HH7@?_ ,*S0?\ Y84!==U_7_#K[SN**X?_ (6=\-O^BA>!_P#PK-!_
M^6%'_"SOAM_T4+P/_P"%9H/_ ,L* NNZ_K_AU]YW%%</_P +.^&W_10O _\
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MX&_\*W0/_EA1_P +/^&G_10_ W_A6Z!_\L*!77=?U_PZ^\[FBN&_X6?\-/\
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M[K^O^'7WG;T5Q'_"S/AO_P!%!\$?^%7H/_R?1_PLSX;_ /10?!'_ (5>@_\
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M5:%_\GT#NN_]?TT=M17$?\+,^&__ $4#P1_X5>@__)]'_"S/AO\ ]%!\$?\
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M56A?_)])_P +*^'(Z^/_  2/^YJT+_Y/H&=M17$_\++^''_10/!/_A5:%_\
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MZ_Z'[P5_X56A?_)] KKNOZ_X=?>=K17%_P#"R?AT>GC[P4?^YIT/_P"3Z/\
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M_P"'7WG9T5QG_"Q_AY_T/G@S_P *C0__ ).I/^%D?#O_ *'WP7_X5.A__)U
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MUW7]?\.OO.SHKC/^%C_#S_H?/!G_ (5&A_\ R=1_PL?X>?\ 0^>#/_"HT/\
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M<TI8.69PJSHSPLL#CJ>,S/&9ARSIUJU!R5...]C5H356FW3C4;O-1I_Q_?\
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MJ[X9_P#1._ O_A(Z!_\ *^NZHH"R[+^O^&7W'"_\*N^&?_1._ O_ (2.@?\
MROI/^%7?#/\ Z)WX&_\ "2T'_P"0*[NB@++LOZ_X9?<<+_PJ[X9C_FG?@7\?
M"6@'^>GT?\*N^&?_ $3OP+_X2.@?_*^NZHH"R[+^O^&7W'"_\*N^&?\ T3OP
M+_X2.@?_ "OH_P"%7?#/_HG?@7_PD= _^5]=U10%EV7]?\,ON.%_X5=\,_\
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M/_E?7=44!9=E_7_#+[CA/^%7?#,_\T[\#?\ A): /Y:?1_PJWX9_]$[\#?\
MA)Z#_P#(%=W10%EV7]?\,ON.$_X5;\,_^B=^!O\ PD]!_P#D"C_A5OPS_P"B
M=^!O_"3T'_Y KNZ* LNR_K_AE]QPG_"K?AG_ -$[\#?^$GH/_P @4?\ "K?A
MG_T3OP-_X2>@_P#R!7=T4!9=E_7_  R^XX7_ (5=\,Q_S3OP+^/A+0#_ #T^
MC_A5WPS_ .B=^!?_  D= _\ E?7=44!9=E_7_#+[CA?^%7?#/_HG?@7_ ,)+
M0/\ Y7TG_"K?AG_T3OP-_P"$GH/_ ,@5W=% 679?U_PR^XX3_A5OPS_Z)WX&
M_P#"3T'_ .0*/^%6_#/_ *)WX&_\)/0?_D"N[HH"R[+^O^&7W'"?\*M^&?\
MT3OP-_X2>@__ "!1_P *M^&?_1._ W_A)Z#_ /(%=W10%EV7]?\ #+[CA/\
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M&7_1._ __A*:%_\ (-'_  JSX9?]$[\#_P#A*:%_\@UWE% 679?=_79'!?\
M"J_AE_T3SP1_X2VA_P#R#1_PJOX9?]$\\$?^$MH?_P @UWM% 679?U_PR^XX
M+_A5?PR_Z)YX(_\ "6T/_P"0:/\ A5?PR_Z)YX(_\);0_P#Y!KO:* LNR_K_
M (9?<<%_PJOX9?\ 1//!'_A+:'_\@T?\*K^&7_1//!'_ (2VA_\ R#7>T4!9
M=E_7_#+[C@O^%5_#+_HGG@C_ ,);0_\ Y!H_X57\,O\ HGG@C_PEM#_^0:[V
MB@++LOZ_X9?<<%_PJOX8_P#1//!'_A+:)_\ (-'_  JOX9?]$\\$?^$MH?\
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MAB/^:>>"?_"6T0_SLJ[ZB@++LOZ_X9?<<%_PJOX9?]$\\$?^$MH?_P @T?\
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M_P#"6T/_ .0:/^%5_#+_ *)YX(_\);0__D&N]HH"R[+^O^&7W' _\*J^&/\
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M3&C?_(==_10%EV7W?UV1P'_"J?AA_P!$\\%?^$QHW_R'1_PJGX8?]$\\%?\
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M?_(='_"J?AA_T3SP5_X3&C?_ "'7?T4!9=E_7_#+[CS_ /X5/\,/^B>>"_\
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M_P *G^&'_1//!?\ X36C_P#R)7H%% 679?U_PR^X\_\ ^%3_  P_Z)YX+_\
M":T?_P"1*/\ A4_PP_Z)YX+_ /":T?\ ^1*] HH"R[+^O^&7W'GW_"I_AA_T
M3WP9_P"$WI'_ ,B4?\*F^%__ $3WP9_X3>D__(E>@T4!9=E_7_#+[CS_ /X5
M/\,/^B>>"_\ PFM'_P#D2C_A4_PP_P"B>>"__":T?_Y$KT"B@++LON//_P#A
M4_PP_P"B>>"__":T?_Y$H_X5/\,/^B>>"_\ PFM'_P#D2O0** LNR_K_ (9?
M<>?_ /"I_AA_T3SP7_X36C__ ")1_P *G^&'_1//!?\ X36C_P#R)7H%% 67
M9?U_PR^X\_\ ^%3_  P_Z)YX+_\ ":TC_P"1*3_A4WPO_P"B>^#/_";TG_Y$
MKT&B@++LOZ_X9?<>??\ "IOA?_T3WP9_X3>D_P#R)1_PJ;X7_P#1/?!G_A-Z
M3_\ (E>@T4!9=E_7_#+[CS[_ (5-\+_^B>^#/_";TG_Y$I?^%3_##_HGG@O_
M ,)K1_\ Y$KT"B@++LOZ_P"&7W'G_P#PJ?X8?]$\\%_^$UH__P B4?\ "I_A
MA_T3SP7_ .$UH_\ \B5Z!10%EV7W(\__ .%3_##_ *)YX+_\)K1__D2D_P"%
M3_# _P#-/?!G_A-Z0/Y6E>@T4!9=E_7_  R^X\^_X5-\+_\ HGO@S_PF])_^
M1*/^%3?"_P#Z)[X,_P#";TG_ .1*]!HH"R[+^O\ AE]QY]_PJ;X7_P#1/?!G
M_A-Z3_\ (E'_  J;X7_]$]\&?^$WI/\ \B5Z#10%EV7]?\,ON/#+'X8_#E_B
M#XGL'\"^$FLK;P;X$N[>T;0-+-O!=7NM_$6&\N(H3;>7'-=16%C%<2JH>5+.
MV5RRPQA>R_X5-\+_ /HGO@S_ ,)O2?\ Y$J?3_\ DIGB[_L1?AW_ .I!\4:[
MJ@++LON_KLCS_P#X5/\ ##_HGG@O_P )K1__ )$H_P"%3_##_HGG@O\ \)K2
M/_D2O0** LNR^X\^_P"%3?"__HGO@S_PF])_^1*/^%3?"_\ Z)[X,_\ ";TG
M_P"1*]!HH"R[+[OZ[(\^_P"%3?"__HGO@S_PF])_^1*/^%3?"_\ Z)[X,_\
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M_A-Z3_\ (E'_  J;X7_]$]\&?^$WI/\ \B5Z#10%EV7]?\,ON//O^%3?"_\
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M\)S2O_D6C_A4OPO_ .B>^#?_  G=*_\ D6O0J* LNR_K_AE]QYY_PJ3X7?\
M1/?!W_A/:7_\C4?\*D^%W_1/?!W_ (3VE_\ R-7H=% 679?U_P ,ON.'L/AG
M\.]+O+;4=.\#^%+*_LIDN+2\MM"TV*XMKB,[HYX)4MP\4T3 /'*A5XW =&5@
M".XHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\ZRORYHH_L;)_P#H59;_ .$.%_\ E0?\1:\5?^CF>(/_ (F?$?\ \\C]1O\
MA]%_P4M_Z.3_ /,._ +_ .=91_P^B_X*6_\ 1R?_ )AWX!?_ #K*_+FBC^QL
MG_Z%66_^$.%_^5!_Q%KQ5_Z.9X@_^)GQ'_\ /(_4;_A]%_P4M_Z.3_\ ,._
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M_P P[\ O_G64?\/HO^"EO_1R?_F'?@%_\ZRORYHH_L;)_P#H59;_ .$.%_\
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M%+?^CD__ ##OP"_^=91_P^B_X*6_]')_^8=^ 7_SK*_+FBC^QLG_ .A5EO\
MX0X7_P"5!_Q%KQ5_Z.9X@_\ B9\1_P#SR/U&_P"'T7_!2W_HY/\ \P[\ O\
MYUE'_#Z+_@I;_P!')_\ F'?@%_\ .LK\N:*/[&R?_H59;_X0X7_Y4'_$6O%7
M_HYGB#_XF?$?_P \C].(_P#@L?\ \%((M3N]8C_:,VZE?V&G:9=W/_"H?@0?
M-LM)N-4NM/@\EOA@8$^SSZUJ<GF1Q)-+]IVSR2)#;K%>_P"'T7_!2W_HY/\
M\P[\ O\ YUE?ES11_8V3_P#0JRW_ ,(<+_\ *@_XBUXJ_P#1S/$'_P 3/B/_
M .>1^HW_  ^B_P""EO\ T<G_ .8=^ 7_ ,ZRC_A]%_P4M_Z.3_\ ,._ +_YU
ME?ES11_8V3_]"K+?_"'"_P#RH/\ B+7BK_T<SQ!_\3/B/_YY'ZC?\/HO^"EO
M_1R?_F'?@%_\ZRC_ (?1?\%+?^CD_P#S#OP"_P#G65^7-%']C9/_ -"K+?\
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M^ 7_ ,ZRC_A]%_P4M_Z.3_\ ,._ +_YUE?ES11_8V3_]"K+?_"'"_P#RH/\
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M/B/_ .>1^HW_  ^B_P""EO\ T<G_ .8=^ 7_ ,ZRC_A]%_P4M_Z.3_\ ,._
M+_YUE?ES11_8V3_]"K+?_"'"_P#RH/\ B+7BK_T<SQ!_\3/B/_YY'ZC?\/HO
M^"EO_1R?_F'?@%_\ZRC_ (?1?\%+?^CD_P#S#OP"_P#G65^7-%']C9/_ -"K
M+?\ PAPO_P J#_B+7BK_ -',\0?_ !,^(_\ YY'ZC?\ #Z+_ (*6_P#1R?\
MYAWX!?\ SK*/^'T7_!2W_HY/_P P[\ O_G65^7-%']C9/_T*LM_\(<+_ /*@
M_P"(M>*O_1S/$'_Q,^(__GD?J-_P^B_X*6_]')_^8=^ 7_SK*/\ A]%_P4M_
MZ.3_ /,._ +_ .=97Y<T4?V-D_\ T*LM_P#"'"__ "H/^(M>*O\ T<SQ!_\
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M^B_X*6_]')_^8=^ 7_SK*/\ A]%_P4M_Z.3_ /,._ +_ .=97Y<T4?V-D_\
MT*LM_P#"'"__ "H/^(M>*O\ T<SQ!_\ $SXC_P#GD?J-_P /HO\ @I;_ -')
M_P#F'?@%_P#.LH_X?1?\%+?^CD__ ##OP"_^=97Y<T4?V-D__0JRW_PAPO\
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M0?\ $6O%7_HYGB#_ .)GQ'_\\C]1O^'T7_!2W_HY/_S#OP"_^=91_P /HO\
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M_B9\1_\ SR/U&_X?1?\ !2W_ *.3_P#,._ +_P"=91_P^B_X*6_]')_^8=^
M7_SK*_+FBC^QLG_Z%66_^$.%_P#E0?\ $6O%7_HYGB#_ .)GQ'_\\C]1O^'T
M7_!2W_HY/_S#OP"_^=91_P /HO\ @I;_ -')_P#F'?@%_P#.LK\N:*/[&R?_
M *%66_\ A#A?_E0?\1:\5?\ HYGB#_XF?$?_ ,\C]1O^'T7_  4M_P"CD_\
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M\%+?^CD__,._ +_YUE'_  ^B_P""EO\ T<G_ .8=^ 7_ ,ZRORYHH_L;)_\
MH59;_P"$.%_^5!_Q%KQ5_P"CF>(/_B9\1_\ SR/U&_X?1?\ !2W_ *.3_P#,
M._ +_P"=91_P^B_X*6_]')_^8=^ 7_SK*_+FBC^QLG_Z%66_^$.%_P#E0?\
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M:\5?^CF>(/\ XF?$?_SR/U&_X?1?\%+?^CD__,._ +_YUE'_  ^B_P""EO\
MT<G_ .8=^ 7_ ,ZRORYHH_L;)_\ H59;_P"$.%_^5!_Q%KQ5_P"CF>(/_B9\
M1_\ SR/U&_X?1?\ !2W_ *.3_P#,._ +_P"=91_P^B_X*6_]')_^8=^ 7_SK
M*_+FBC^QLG_Z%66_^$.%_P#E0?\ $6O%7_HYGB#_ .)GQ'_\\C]1O^'T7_!2
MW_HY/_S#OP"_^=91_P /HO\ @I;_ -')_P#F'?@%_P#.LK\N:*/[&R?_ *%6
M6_\ A#A?_E0?\1:\5?\ HYGB#_XF?$?_ ,\C]1O^'T7_  4M_P"CD_\ S#OP
M"_\ G65]\_L!?\%S/BK9?$Y/!7[;OC&U\9?#_P 975I9:7\38?"?A'PM?_#7
M5'(@AEUJP\#^'_#VGZKX/O79?[3O)=/FU?1),7ZW%SIRSVL'\X%%88GA_)\3
M0J4'EV#H^TBXJKA\-0H5J;W4Z=2G34HRB[.VL9?#*,HMI^SP_P".?BQP_G.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?D9_P %
M7_\ @F!=?\%(]!^"B:)\5H/A;XG^#6K^.6M+C5?#TGB30=9T'XA6?A<:W#<6
M=I>Z9J$.KV>H>"/#KZ7<Q7PLUL[C6HKNTN)Y;&:T_%[_ (A?/B=_T=SX#_\
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M*[S_ (BE/^K%_P#S9O\ _)\H_P"(I3_JQ?\ \V;_ /R?*\KE\-_^?D_NSO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP[_]2#XHUW5<+I__ "4SQ=_V(OP[_P#4@^*- '=4444 %%%% !1110 4444
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MO"?P?\,'7/#.HSW&OFPT#X=@'UC_ ,'=7_*&CXA?]EV^ W_J4W-?R3_\$?\
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M+;+Q#/=0:.D\/A[1_P#69K^!;]O?_E<D_8@_[!GP!_\ 4&^(M?WTT ?QJ?\
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ML7BSQ=X?\#>!M;NK4S2:CX:\4:UX>EA%IK=Q/#\D?\$P?^#>O_@@_P#M9?\
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M5^QG_P 11G_#J;_A'O'?_#(?_0!_X3S5?^$W_P"4>/\ PT?_ ,CQY?\ :?\
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M?&KX?Z8?&_P?4Z;8:R&^*/A3XZ^$->^'X.D:K'+I>J@^++#20=-U**2POO\
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M/#D4Z7']F:'IGVBTO/&WC:\M+C1_!NCW$,\\.IZYJ?AOPYKX!_H(?&_]J_\
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M28-/^&OC/3/!FD? ;P;XQ\.V5[\/M!T^VO?">M6%UXQ\)Z%=V)B\-'33\*_
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M[OPIJUU#\3--URY\%2V^E^*;"^\-:C.FMM%9:_97>C7+1:C;36R8WP0_:O\
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MP]C1E-U)0A&A2I0]Z;YI2<7)Z)R:22****[CYL**** "BBB@ K_/]_X*L_\
M)[GQ!_[)W^SE_P"LX?"BO] *O\_W_@JS_P GN?$'_LG?[.7_ *SA\**^UX#_
M .1QB/\ L75O_4G"'\>_38_Y-5D/_9?95_ZS_%!^=-%%%?K9_ER%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#L=]VWA^Q^-7P/M#\5YK?7&2V_L?X8Z;&EY8>(+R:R\0_P!^E?RL_P#!3?\
MX(1?M+?'O_@K-^S)_P %2_V#?B=\ O@_X^\#ZC\+=9^/=O\ &'5/B1%=>+?$
MOPEUC3]'T?Q7H6D^%O!/C;3_ !))XB^#D%E\,?$OAF\UGX=::^D^#="^RZB-
M1\0Z[KED =E_P=U?\H:/B%_V7;X#?^I3<U]L_P#!$?P=X9^(G_!$']B#X?\
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MFU.$:LMMIUI>:M_3'0 45_G^?\%$-$\9_P#!0/\ X.S/V1_A3^S=XPU_5O\
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M)V_!/_@EY^R=X,_96^"+W^L66EW]]XP^(GQ UJVM[/Q#\5?BKXAL],M/%7Q
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MI:MXHGCL]-6**YF864M[<?+/_!CM_P DB_X*&_\ 91_V>?\ U&/BK7T=<?\
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M@OAO^T=X[^#'CCQ5\7/B[HOC?0Y/@EK?CCQ%X?TWP_HO@VQT%4U74O'?P_\
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MC^V!\$?'_P"SK^T5X T?XE?"3XE:/)H_B;PSK$;J05=+C3=:T74K=XM1\/\
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MKP'_ ,CC$?\ 8NK?^I.$/X]^FQ_R:K(?^R^RK_UG^*#\Z:***_6S_+D*]/\
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M\NVB13<W5Q,7F>M117T_]=_S/YS;;;;M=MMV2BKMWTC%**79))):))']3O\
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M1E4YU,KRVI4G*I4J8#!SG.<G*<YRP].4ISE)N4I2DVY2;;;;;;;/G_$G"X7
M^(O'V!P.&P^#P6#XUXIPN#P>%HT\/A<+A</GN/HX?#8;#T8PI4,/0I0A2HT:
M4(TZ5.,80C&,4E^R/_!-/_@FU\,OVH?A[X__ &F?VC_B_9_##]GGX5>+I/">
MLP6NJ:;X?U+5]6TG2/#WB/6I?$'B[Q"G]B^#_"T%AXI\.V,%S!%J6KZY>:CJ
M%I;2>'9M.LKO5?T.\+^!_P#@W)\2^*+;X;6.JZ9#KDMS/IL/B_Q1XZ_:A\(^
M%[B\L1)-<2W7CGQ%K>A_#S3[:5()X8-5O9].T.^*HFFWDTUYI[7/\OY\6>*3
MX63P,?$OB ^"8_$$GBQ/!YUG43X63Q3+IT6CR^)4\/FY_LE?$$NDPPZ7)K(M
M!J+Z=%%9-<FVC6(4='T?5_$.KZ7X?\/Z7J.N:]KFHV.CZ)HFCV-SJ>KZQJ^I
MW,5EINEZ7IME%/>:AJ.H7D\-I8V-I#-<W=S-%!!%)+(B'S\5E&*Q=:O6K9UF
M&&IW?U:C@*JPE*A!15G6:4I8B7,G*3DX))N*T2:^\X:\5>&N%LIR3*,J\(.
M^(,;&$/]8<VXURZKQ/F6=8RI7DY1RJ%2I1HY'1C1E##8>E0I8KFG"->I"=25
M2-3]T?\ @J?_ ,$C=&_9-\(Q?M#_ +/6NZQK_P $&U&UL?&_ACQ9JUAJ6O\
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MU'XL/!8VOG.8=-TBP$K0:5HFFQ6FD:19B.QTNQM+.&*!/Y[OVXO^3U?VP/\
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MMNG'YQ@LNJ4Z->56>(JQ<Z>'P]&I7K.FFTZCA3B^6',G%.37,T^5/EER_/\
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M:)X7L=;\6S^&=%?5];U/Q'XB@D\7ZV_B7QCJ5]K<KV&G0>'_  _X?_8*BB@
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MSU#^R-2U#0;B\TW[?9VE[]CFA^U6T$^^)/I:B@ HHHH **** "BBB@ HHHH
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M )#_ .U[_P!@?X(?^EOQ4K\+OVXO^3U?VP/^SH_V@/\ U;'BVOW1_P"#;?\
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MCC[/X9^(/AQK".."6+2]%\03Z7J)O$GNI;JY^(5[;S/8QV5@MU[=^Q;\"?\
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M_P")_BT^G7UMJ.CZYKGBWQ;Y5GY4D$NG6VJ^.EU6VMVLM*@L6_F2\*?M:?\
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M)MKKQ +=/RE_X;B_;5_Z/ _:C_\ $@/BQ_\ -;7FX#!9SB\DPU"AC,J6!Q&
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MC\LK8'$8*4<(E3KX#+,+"EA<5BZ]*%?"\U=6IT<3!4V[J'\]G_!(W]HOP/\
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MI83&YECL7A<'S1G]4PV)Q56M0PW/",(R]A2G&ES1A",N2ZC%-)?O3_P;N_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:6QL1JWASQ%I,]KJVA:Q;V]W/]@UC2KNTU/3;ADO-/NK:[AAGC_CA_X)1_\
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MFA>'-%M2ZZ1X5\+:6TUP-)\.:);N8+&T,]S=W,KW6JZQ?:IKNHZIJM]]@?\
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MJY57P^8X&C3PSH5\FP^&PV"K4Z24H.<8X6G.K[15(UINHJD73FZ:_JS\3?\
M!:3_ ()J?$?6/#OQ/^)O[&/C/Q;\9?#5G8KHNO\ B#X5_ SQ;>Z%/I5_/J.D
MVFE>/M;\9Q>(5L](O[B;5-(N!H%L^E:I<7%YI]E;W4LES)_,YXG^*.IZC\:?
M$/QI\&VG_"OM8OOBCJWQ1\*6.CW0NO\ A"-3N?%EQXLT*TTN]EM;<7/_  C5
MT]K#8W4EE )OL44SVL6XQ+Y?1667Y-@LL]K]659JK"--QK5ZE:$:<7)JG"$V
MXQC>3NK-OJ][^IQWXM\8>(G]G2XAJ95"KEN*JXZGB<IR? Y3BL1CZU.A2GCL
M9BL'3A7KXE0P]/DESQA3:O"":AR_TN_#S_@NG\&/BM\,[;X=?M^?LLV?Q4FT
M_P#LV2;6?!OA[P9XP\.>*KZUO;AQK%[\.?B)?Z/9^%-7LK.'3)))])\4:Q9Z
MSJLFI3V>G^$M-^RZ6LEM_P %4_\ @E)\)YD\6? ;_@GG/)\0--W7VA:AXE^&
MOP5\%3:;J]HC)ISZ9XOL-=^)FM>'?/6ZO$O=1T?21<QHD -KJ *BU_F>HKC?
M#&5<T^2.*HTJDG*>&H8S$4L-)RMS+V4*B23M\,6DMHI122^LA])#Q.='"_7,
M1PYFN9X&A3P^$XAS?A/(<QS^C"B[T)K,<1@I.K6HJRC6KTZM6I).K7E5KRG5
ME]-?M??M1^,_VQOCUXO^._C?2-$\.:AXC32M,TOPUX>6X;3/#WASP_I\&E:+
MIBWEX\E]JM\+:#[9J^K731#4-7N[Z>PL-&TIM/T33?F6BBO=HTJ="E3H48*G
M2HPC3IPC>T(0BHQBKMMV22NVV]VV]3\5S7-,PSO,\PSG-L54QV9YIC,1C\?C
M*W+[3$XO%U95\16FH1C"+J5)RER4X0IP34*<(P48KV/]G;XBZ1\'_P!H'X%_
M%KQ!9ZCJ.@_"[XQ_#'XBZWI^CI;2:O?Z1X)\;:)XEU*STN.]N;*SDU&ZL],F
M@L4N[RTMGN7B6>Y@B+RI^CO_  5K_P""A/PD_;UU_P""%U\(_"7Q&\-:7\+M
M'\=V^K3_ !'L/#.E7^HW_C&]\+211:=8>&?%'BVW^QV%OX85Y+NYU*&:XFOV
MA6QB2T%Q=?C_ $5S5<OPU7'8;,)QD\3A*=6G1DIM04:T91GS06DG:4DF]KWW
M2/H<NXZX@RK@[B'@3!UL-'A_BC&9=CLVHSPM.IB:E?*Z]#$X3V.*E^\H05;#
M495(P^-0Y6U&4E+V7]G_ ./?Q*_9E^+7A#XT?";65T?QCX/O_M-NMU')<Z/K
M>FSJ8-6\-^(K"*>V?4?#^O6#S:?JEI'<VMT(91=:=>Z?JEM9:A:_KW_P4P_X
M*4?LC?MX? GP;I6C_"'XO^&_VAO!.M:=J/A[Q7K-CX$LO"ND:;J,?D^.?#=Q
MK-AXJ\0>(/$'A_4TCM;O3; ^'_#]U'K>G:3JCZI:6EMJNC:]^#]%1B,LPF)Q
MF%Q]2$HXK"-^RJTYNG)Q>].KRV]I3UE[DM+3FMI23ZLB\1N*.'^%>)."<'B<
M/7X:XIC#^TLLS#"TL=0I8BFH\N/R]5KK X].G0E]:H)3<\+A*CO4PU"4/W6_
MX)N?\%0_@;^QM^R=\7_@7\1?!7Q7\1>,O''C[QUXR\.W_@K2O"%YX96W\3?#
M;P3X/T^QUJ_UWQIH&JZ?-%JOA:XFO);'0]82+3[J&:!;FY1[2OPIHHJ\-@,/
MA,1C,314E5QU2%7$.4W).5-2C'EB](JTI72WOY(Y.(..,_XFR3A/A[-:N&J9
M;P7@<7E^1PHX:%&K2P^-J4*M=8BK'WL1-RPU%1G.W*HM)7E)O]UO^"K?_!4/
MX&_MU_";X6^ /A/X*^*_AO5/!_CZX\9:]>?$/2O"&EV!MSX:U#18;'2&\-^-
M/%=Q?3/<:G)+++>6^E)%#;(469[ADM_PIHHHR_ 8?+,-#"852C1A*<HJ<W.5
MZDG*5Y/5ZO3L@XYXXS[Q#XBQ/%'$M7#5LUQ=#"8>K/"8:&$H>SP6'AAJ*C1I
MMQB_9P3F[MRDV]%9+]UO^"D?_!4/X&_MD_LG?"#X%_#KP5\5_#OC+P/X^\"^
M,O$5_P"-=*\(6?AEK?PS\-O&W@_4+'1;_0O&FOZKJ$TNJ^*;>:SEOM#T=)=/
MM9IIUMKETM*^7?\ @F[_ ,%)/&G[ WB_Q%:R^'Y?B!\'OB'=Z)+XW\%#5)+'
M4-*OM+F:W'C#P7+/YVG6_B*/2+JZL[_3[F*UL_%4%MH]CJFI6/\ 9&EZAIWY
MET5ST\ER^G@*F6>Q=3!U9SG.G4G*3YIS4[J=U*+C)*4&FG%I-,][,/%_CO'\
M<8#Q$_M6G@N*LMPV%P>%QV PE"A26'PN&G@U2JX24:N'KTZ^&J5:6*IU83IU
MX5)QE"S27]/>L_\ !5G_ ()+2>*)/BQIW[ VM:G\7QK4_BF/6=4^$'P+TI+K
MQ7)>7&H_\))>Z[:>--8G?Q!+J<HU:7Q!+X:O-735W.JK<2:A;0W+<9XS_P""
MZ?A7XV?LP?M5_"SXN_#+QCH?Q ^+^B^/_"'PEL/ MIX<UCP+X0\'^*/AUHWA
MG2+'Q=XIUGQ%X>\2:AJMMXI'B?7]6U.R\(7:SVNJ6EI8VMM#;16=M_-O17''
MA?*HNG*4<35G2G3E2J5L56JRI*E-5(PI\\G&$'**YDHIM+ENDW?ZRO\ 20\3
MJD,70P^)X?RS"9CAL?A\SP64\-Y5EN'S.>8X2K@ZV+S#ZM0A7Q6*A1K5'0G5
MK.G3JR57V4IP@X_:_P"P1^VIXD_80^.DWQD\/^"M'^(-IK'@O6/A_P"*?"NJ
MZI=Z#-J/AO6-6\/^()#HOB"UM-470]8@UKPMHDT=_=Z'KUHU@FH63Z9YMY#>
MV7[)W7_!3W_@CSXGOF\<>,O^">M_<_$+4[F;5=?1?@G\ ]:T:^UF\NYKC4+V
M]U"[\;:4FOW-Y)/->WFI:KX3CN]0O9'>\1Y#]IK^96BNK&Y)@<=7^LU%B*5=
MPC3G5PV)K8>52G&_+"HJ<U&2C=V?*I6=N:R27S/"/C%QGP9DW^KV7O(\RR2G
MBZV/PN7<0</93G=' 8[$*FJ^+P4\;AIXBA4K*E3YX*M*A>+G&E&I*<Y?K7_P
M49_X*M_$#]N&UTSX:^$O#-Q\(?@%H%\U]_PA<>LQ:IK?CW5-/O;E= USQK?6
M=AIMI:6.F::+*XTOP)IRW^D:/KCW>HWNM^*;JS\-WFA?#O[+?[47Q7_9 ^+N
MD_&?X/7VE6_B;3["^T;4-,\06$NJ>&_$WAW4WMI=1\.^(K"VN].O9]+O)[*Q
MNF;3M3TS4;:\L;2[L=0M;FWCE'SM1730RW X;!O 4L-36$E&<9T9)S513^-U
M'-RE4E+K*;<M$DTDDOGLZ\0>,N(.*X<;YIG^.K<44:^&Q&%S6C.&$JX&6#:>
M$A@*6%A1H8*AAVKTZ&&I4Z7-*I.<)3JU93_J$UK_ (+*_P#!.S]H32]$U?\
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MU6^R;1 U[;?J5_P6C_X*(?#;]KG5OA+\+OV?/%W_  F'P;\%65WXZ\1>(/\
MA'_$OAMM:^)>JRZCH-EICZ3XU\+^']>MX?!GAB&XGM=0LS_9VKS>.]1M[F&6
M;0K.9/.SW+Y9IFV2X=X6I*AAY5<3BL4Z<O8*BG!K#.IRNFYU94;.FWSQ4XR2
M4929]]X*\<T?#;PN\7<^CQ+E^'SG.Z.6\/<-<,1QV&_MFKFKI8FG4XBIY?[>
M&-I83+</FWM*>-IP6&K5<+B*-2<Z^&H4G^%%%%%?6G\MA1110 4444 %%%%
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M+O\ L1?AW_ZD'Q1KX _N8[JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:E9>-_A]I3^(M(TJ#2_#VE^%M-T+PMX2U_Q_=_#*STW^I[_@U ^"GB/X/?\
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M?@KJ'CR]AM++3K"RU;X@2_#O_A-]:TS3+"STC2]7U^^TW2+>+3;6U4?S _\
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M^)_#6M_V3/(D<G]@6^IZ=<VOAZ%U+VNAP:?:L\AA,C:7_!/O_@@=_P $U/\
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M ">Y\0?^R=_LY?\ K.'PHK_0"K_/]_X*L_\ )[GQ!_[)W^SE_P"LX?"BOM>
M_P#D<8C_ +%U;_U)PA_'OTV/^359#_V7V5?^L_Q0?G31117ZV?Y<A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_)3/%W_8B_#O_P!2#XHT =U1110 4444 %%%% !1110 4444 %%%% !1110
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M?V5_97^@_;O[2L_H#]D[XZ?\-0?LL?LT_M+_ /"+?\(/_P -$?L__!OXZ?\
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MTUNT\:^!+?X>>*O#FJZA?IK/@#5[:W35Y;W[,^*G_!:?_@NY^UC\/?%7P/\
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MO'^TV^RW$C>?#CS%_D8_X(4?L4_M-?M ?\%,?V[_ /@M=^W/\ _B[^SMXO\
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M[POJ<TM]?'2?$?AW5H+75M"UBWM[N#[?H^JVEIJ>FW#/9ZA:VUW#-!'^G]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^)6/ ?\ Z(3_ ,V?C+_Z(3^7/_B&P_ZO/_\ -=/_ ,>U'_$-A_U>?_YKI_\
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M %>?_P":Z?\ X]J_J,HH_P!;N(?^AA_Y:8'_ .9@_P")6/ ?_HA/_-GXR_\
MHA/Y<_\ B&P_ZO/_ /-=/_Q[4?\ $-A_U>?_ .:Z?_CVK^HRBC_6[B'_ *&'
M_EI@?_F8/^)6/ ?_ *(3_P V?C+_ .B$_ES_ .(;#_J\_P#\UT__ ![4?\0V
M'_5Y_P#YKI_^/:OZC**/];N(?^AA_P"6F!_^9@_XE8\!_P#HA/\ S9^,O_HA
M/Y<_^(;#_J\__P UT_\ Q[4?\0V'_5Y__FNG_P"/:OZC**/];N(?^AA_Y:8'
M_P"9@_XE8\!_^B$_\V?C+_Z(3^7/_B&P_P"KS_\ S73_ /'M1_Q#8?\ 5Y__
M )KI_P#CVK^HRBC_ %NXA_Z&'_EI@?\ YF#_ (E8\!_^B$_\V?C+_P"B$_E6
MM_\ @W*\_P 3:OX=_P"&QMG]E:%X=UK[9_PSUN\_^W]0\46/V;[/_P +P7RO
MLG_"->;YWGR>?]MV>5#]FWS[O_$-A_U>?_YKI_\ CVK^E+3_ /DIGB[_ +$7
MX=_^I!\4:[JC_6[B'_H8?^6F!_\ F8/^)6/ ?_HA/_-GXR_^B$_ES_XAL/\
MJ\__ ,UT_P#Q[4?\0V'_ %>?_P":Z?\ X]J_J,HH_P!;N(?^AA_Y:8'_ .9@
M_P")6/ ?_HA/_-GXR_\ HA/Y<_\ B&P_ZO/_ /-=/_Q[4?\ $-A_U>?_ .:Z
M?_CVK^HRBC_6[B'_ *&'_EI@?_F8/^)6/ ?_ *(3_P V?C+_ .B$_ES_ .(;
M#_J\_P#\UT__ ![4?\0V'_5Y_P#YKI_^/:OZC**/];N(?^AA_P"6F!_^9@_X
ME8\!_P#HA/\ S9^,O_HA/Y<_^(;#_J\__P UT_\ Q[4?\0V'_5Y__FNG_P"/
M:OZC**/];N(?^AA_Y:8'_P"9@_XE8\!_^B$_\V?C+_Z(3^7/_B&P_P"KS_\
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MH_UNXA_Z&'_EI@?_ )F#_B5CP'_Z(3_S9^,O_HA/Y<_^(;#_ *O/_P#-=/\
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MY:8'_P"9@_XE8\!_^B$_\V?C+_Z(3^7/_B&P_P"KS_\ S73_ /'M1_Q#8?\
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M )F#_B5CP'_Z(3_S9^,O_HA/Y<_^(;#_ *O/_P#-=/\ \>U'_$-A_P!7G_\
MFNG_ ./:OZC**/\ 6[B'_H8?^6F!_P#F8/\ B5CP'_Z(3_S9^,O_ *(3^7/_
M (AL/^KS_P#S73_\>U'_ !#8?]7G_P#FNG_X]J_J,HH_UNXA_P"AA_Y:8'_Y
MF#_B5CP'_P"B$_\ -GXR_P#HA/Y<_P#B&P_ZO/\ _-=/_P >U'_$-A_U>?\
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M %>?_P":Z?\ X]J_J,HH_P!;N(?^AA_Y:8'_ .9@_P")6/ ?_HA/_-GXR_\
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M/_\ -=/_ ,>U'_$-A_U>?_YKI_\ CVK^HRBC_6[B'_H8?^6F!_\ F8/^)6/
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MV(OP[_\ 4@^*-=U7"Z?_ ,E,\7?]B+\._P#U(/BC7=4 %%%% !1110 4444
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MG*!2X:-B05]LN(4N8)[=RP2>&2%RA <)*C(Q4D, P#$J2K '&01Q0$4TM?\
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MG9V<$-K:6EKXHURWM;6UMXUA@MK:WAODB@@@B1(H88D6.*-51%55 '[!>)=
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M^A^+_%&C6"Z-I$JV.E:_JVG6BRRPR&21;:SNX81)(0"[A-SD L217Z+UX/\
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MEV4VR",QM$ "^X.2"O->!_V;? W@'Q1I?BW1]5\67.I:3]M^S0:G?:/-9/\
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M[)/%9Z[I.HZ/=RVK1I=1VNIV<UE/);/-%/$DZ13NT+2PS1K(%+Q2*"A^9_\
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MF:TO+:430@26]S;O'-#( 2 \;JP!(S@FJGPP^#WAGX3_ -N?\([?:[>_V_\
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M+?$VMV(\,ZI<"SU?7M5U*T$\=UIJQS"WO+N:$2HLCJD@3>JNX5@&.?I[XD_
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MMOYWB?1;>;R+NUDBGB\V"66"3RY%WPR21ME'93^9W_"T?B9_T43QU_X5VO\
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M=)U'1[N6U:-+J.UU.SFLIY+9YHIXDG2*=VA:6&:-9 I>*104(.*:23W/Q_\
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MBFN8=/O]&BLT>&V@M5$$=SH-W.JF.!&827$I+EB"%(5>Q^&'P>\,_"?^W/\
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M/^CL?_,$_LT?_.;H_P!3<T_Y_P" _P#!N(_^90_XF#X,_P"A9Q/_ .$65?\
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M/^CL?_,$_LT?_.;H_P!3<T_Y_P" _P#!N(_^90_XF#X,_P"A9Q/_ .$65?\
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M/^CL?_,$_LT?_.;H_P!3<T_Y_P" _P#!N(_^90_XF#X,_P"A9Q/_ .$65?\
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M/^CL?_,$_LT?_.;H_P!3<T_Y_P" _P#!N(_^90_XF#X,_P"A9Q/_ .$65?\
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M/^CL?_,$_LT?_.;H_P!3<T_Y_P" _P#!N(_^90_XF#X,_P"A9Q/_ .$65?\
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M_P""MG_1V/\ Y@G]FC_YS='_  _Y_P""MG_1V/\ Y@G]FC_YS='^IN:?\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KA=/_P"2F>+O^Q%^'?\ ZD'Q1KNJ
MX73_ /DIGB[_ +$7X=_^I!\4: .ZHHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD>-U8_DG_P %7_\ @K3X0_X)=Z!\));OX52?&OQQ\7[_ ,4KHO@FV\>K\/\
M^S?#_@^/0AK'B/4];_X0OQR(;=KOQ#IUAIMK)I44NIW/VS[)))%INI268!^O
M-%?A[_P2A_X+4>&_^"G?CSXI_#.;X!:I\#/%_P ._".F^.M/C7XCP_$[1?$G
MAN76;?P_K#S:I_P@OP^N-#U32]4U30UMK#^S-5AU.TO[JX^W63Z<;>Z_<*@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#A=/_Y*9XN_[$7X=_\ J0?%&NZKA=/_ .2F>+O^Q%^'?_J0?%&NZH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!PNG_\ )3/%W_8B_#O_ -2#XHUW5<+I_P#R4SQ=
M_P!B+\.__4@^*-=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRSNX8[FUN[6YT".&XMKFWF5X9[>>%WBFAE1XY8W9'5E8@_YU_P"U3\,?%?\
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MD%6HEFF+HU(T)2QN'I\_-*A3=9IOV;A:A7YJD)1IPJ_B;11178?/A17]R/\
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M)7E6HQ5Y3P<Y-RQ.&BFXMRQ&'C[3VE/$?Z>%%>)_L\?M#_"/]JCX1^$OC?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"Z?\
M\E,\7?\ 8B_#O_U(/BC7=5PNG_\ )3/%W_8B_#O_ -2#XHUW5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUO1M-T'0A_:6OZYIMSJ7AC3?$?WA_P '/OA_3]%_X*(^!]2LH((KGQ;^RO\
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M_:Z2&*.%&\0_#:9DB18U,MQ\$_AI//*50 &2>>22:9R-TDLCR.6=V8_T+?\
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MN80R;ZQS5\/AHRKU)1^LU,1;$5?<PU.:CRTU/VDH5'#DEX'>_P#!!S_@F/\
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M?%W_ *C^H5W5<+\4?^29_$3_ +$7Q=_ZC^H4 =U1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M34JCASS_ $?_ .#F3_E)':?]F[_"[_T]^/*^.O\ @B=_RE+_ &/?^Q]\1?\
MJN/&M5_^"O/[<'PQ_P""@7[7+?'GX1>&O'GA;P7!\,/!?@2UL/B/8^'],\47
M%]X>N->OM0O;C3_#'B/Q9I-K:23ZW]GLUCUV\FEBM?M,ZVSS_98?!/\ @GQ^
MT;X1_9'_ &R_@)^T9X]T;Q'X@\&_"[Q;>:QXBTCPA#IESXFNM,U'PWKGA^8Z
M+;:SJ>BZ5=7UL=76[BM;[5],M[GR&@>^M?,$R;8?#UXY!'"RIR6(_LV=+V3M
MS>TE0E%0WMS.32WT>YQ9IFV75O%*>=4L72GE7^M^$QWUV/-[%X2EF-"K/$*\
M>9TXTX2G=1NXJZ3T/V%_X.E/^4@7P?\ ^S.OA_\ ^KK_ &@Z_9O]E'3?$'[;
M7_!NE+\+? %K_;GQ*C_9\^)WPETOPO8WUI%>WGC/X2>*M=7P5X9^U7&GV5A#
M?^*]&\/^$9[:&Y$<$:>([2UO]=CD%UK:?S!_\%FOV^/A'_P45_:C\$?&OX+^
M&/B-X5\)>%?@/X6^%=S8_%#2_#.C^(KK6]$\??$[Q=>7\%EX4\6>,],72GM/
M'&GVMM))K NY+FTO#+:01>0TJ?\ !*K_ (*Q_$C_ ()G^,/&-K#X3'Q5^"OQ
M/GT.X\<_#BXU^XT.[TS6=&DEM[;QKX(U"2UU/3],\1C2+NZT[5[2?31:>+;.
MVT2SU:\M6T+1;_3?.J99BZN19;3I4U''X"=#$TZ-1J/-.DY<U*3<DHW4E+5J
M[@HWC=M?783C/(<%XF<78K%XJ57AGBC#9AE&(Q^%C.HJ-#&4Z'L\;3IQI3JU
M(PG1E1:C3DXPKSJJ%1TU"7Y.7]A?:7?7FF:G9W>G:EIUW<6&H:??V\UG?6%]
M9S/;W=G>6EPD<]K=VL\<D%Q;SQI-!,CQ2HKJRC_00_X-_OV9?C3^S9_P3X^)
M"_&SP7J/P_U;XO?$CQ?\4O"GAG7XIK#Q1!X,O/AQX,\,:9J'B+0[F&*\\/W6
MJ7GAK4;RRTS45CU$Z5)8WUS;6RWL*'\^_''_  70_P""/&I>(+GXZ:3_ ,$V
MM8\8?M*V]W!XRTWQ/XR^"7[-WA^ZO?B/IZ_VEI>M:G\6+'Q3XT\60:E::]#:
M26WCG_A"M6\1V'D6VL6NG&^L+2R'*?LQ?\',MG_;/[2FK?MG>"/B5J&G^/=0
MT)?@%X.^!7A_P+K/AOX9>%+?2?$>GZOX:UN;Q=XO^'^L:CJ,UW<:+K-]XPNK
MSQ)J'B74;W5X8M-\'^']#\->'EQS:6;YI@71AE4\/&,Z4ZJJU83JU)QG%*&'
MA!W<8N3G.I.R<(M*TE9]O M+@3@GB../Q7&N%S6M7H8W#8&6"PF(HX+"4*F'
MJSEB,UKUX-0JU53CAZ&&P[J2C7JJ523@TX_S.?LA?\G9?LO_ /9Q'P4_]65X
M9K^HS_@[*_YL$_[NH_\ ?<:_DY^"7CNQ^%OQG^$?Q-U.RN]3TWX=?$_P#X[U
M#3;!H4OM0L?"/BO2?$%W96;W#) EW=P:?)!;M.Z0K-(AE94#$?LW_P %O?\
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M:Y#[+,E5AB\(G]8QN$HX&,89C6Q"TI2G-MJ-.5X5ZV(IK[$_X+1:-\3/#O\
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MK_#;Q#_:7@ZZGN_/N@NKQZ1;Z_ITEY<WFC:MIFHR"\6C^R7^V%\0/V3OVN/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<+I_P#R4SQ=_P!B+\.__4@^*-=U7"Z?_P E,\7?]B+\._\ U(/BC0!W5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:RWUQ;QWMFT_\N?[!/\ P1=\<?\ !4SX?Z!^VO\ M_?'WXGZ=H7CG0K/PO\
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M^P>'_IP_G?Z1'_(EX=_[&F*_]1$?-%%%%?HA_)X4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %<+I__ "4SQ=_V(OP[_P#4@^*-=U7"Z?\ \E,\7?\
M8B_#O_U(/BC0!W5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'X _\'1W_ "@H_;F_[MF_];#_ &?:^_\
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M6D>+/ VM:_-'XD\,:FOB;2[K25\0^)'BN_$&DGP]I&D 'L/_  =AQZ:/CO\
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MNK6)+F]70O">CWFMZC%IMF\L'V_5;JWLWM=)TU)4FU+4IK6Q@)GN(P?YZ?\
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M_KH^+_[5GC+]B+_@BQ\-OVG_ (?^'?#'BSQ?\,?V9?V/O[(T#QBNJOX;O_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PNG_\
M)3/%W_8B_#O_ -2#XHUW5<+I_P#R4SQ=_P!B+\.__4@^*-=U0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?YT/_  <H?\I0O&G_ &2'
MX/\ _J/W%?T^?L"?L.?LE?ME?\$JOV']-_:8^!'@;XJ2:1\&X+71M?U2UOM%
M\;:)8R>(?$KS:;HGQ \*WVA>.=&TJXFNI;JYTK3/$-KIUS?+!?3VLEY:VL\/
MJ7[=7_!#K]C[_@H#\:H_CW\6O%/QX\%>/7\*:-X2U4_"GQGX-TK1M=M/#[W2
MZ5J&HZ=XX^'/Q :VU.VLKE--+:)<Z1I\]K:6TMQITNHM=7UU^EO[/OP+\!_L
MS?!CX>_ ;X81:K!X ^&6A+X<\+0ZYJ+:OJT>F)=W5ZJ7VI-% UY,LUW*/.:)
M&*;%()4L0#Y[_9D_X)I?L+_L<^(&\7?LY?LZ>#OA]XP-C?Z9'XRN-1\6>-_&
M-KIVJ,AU&RL/%?Q"\0^+/$.G6MZL:PW,-CJ5O'+:@VC*;5FA/W/110!\V7?[
M&?['U_X^N?BM??LI?LV7OQ1O=?F\5WGQ)N_@7\+[GQ]=^*+F=KJX\27/C&;P
ML_B*?7Y[IWN9M8EU%]1EG=IGN6D8L?I.BB@ K\TOC1_P1V_X)G_M >);_P 8
M?$O]D;X=S>)=6U*ZUG6-7\#ZAXT^$=SK6KW[R3:AJFM+\(_%/@>'6-1U&YFF
MO=1O=3BNKG4-0FEU"\EGO9'N&_2VB@#X%_9X_P""6_\ P3^_95URU\4? W]E
MWX=^%O%=A*MQIGBW7&\0_$?Q9H]REY!?Q7.B>*/B;KGC'7M%NH+NV@FM[G2M
M1LY[;RD2"2.,;*^@/VJ=2^)>C?LO_M(:Q\%K/5=0^,>E? 7XP:E\)K#0K&75
M-<OOB78_#WQ%=>!+/1M,A5YM1U6Y\4Q:5#IUC$C2W=V\-O&K/( ?>J* /\KC
M_@F/\=_V;OV?_P!MCX8_&S]KWP9JGQ'^&/A:X\0:U,D.DIXMO=(\>MIUS/X.
M\;7/AZ^U&Q@\1R:'XC\B_,=Y+>26EX\.OVMG>:II=FE?V6_M0_\ !?'_ ()!
M>(?@WXV\/76OM^UC'JGAK78K;X.3_!/XCZ7I/BO4Y-/>PL-%U76/BS\/?#N@
MZ#;:I_:,\%QX@@35+O1M-34[RVL+R_73],U/Z._:=_X(0?\ !.+]J7QQJ_Q*
M\1_"G6OAAX[\27=QJ/BG7O@EXGE\!VOB75+EK%YM6U+PE-8ZWX%@U>YDM;JX
MU/5M'\+Z7J/B#4=9U?6?$EUK&M7$.HVWR7X<_P"#7+_@G/HFIK?ZGXY_:M\8
M6JPRQ'1?$?Q*^'%KICO( $N&E\(_!OPMK FMR"T2IJR6[%CY\$RX  /Y1O\
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M^$/B#\9?A]I&PW-S=[AX?\ _$?PUH(F\V[E07(TT7 MDMK(2BSLK."#]:Z*
M/F3]G3]C+]EC]DFPU'3_ -G+X&> ?A0-7R-6U/P]I33>(]4A:'3(&M-1\5ZO
M-J7B:^L&_L;3KAM.N=7EL3?V[:D;<ZA<7-S-]-T44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7^3=^V?_ ,G>?M0?]E_^+O\
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M_P HZC_6?(_^@[_RVQG_ ,SA_P 0;\2/^B<_\S&0_P#ST/XZZ*_L4_XA-?\
MJ_O_ ,U7_P#RCJ/^(37_ *O[_P#-5_\ \HZC_6?(_P#H._\ +;&?_,X?\0;\
M2/\ HG/_ #,9#_\ /0_CKHK^Q3_B$U_ZO[_\U7__ "CJ/^(37_J_O_S5?_\
M*.H_UGR/_H._\ML9_P#,X?\ $&_$C_HG/_,QD/\ \]#^.NBO[%/^(37_ *O[
M_P#-5_\ \HZC_B$U_P"K^_\ S5?_ /*.H_UGR/\ Z#O_ "VQG_S.'_$&_$C_
M *)S_P S&0__ #T/XZZ*_L4_XA-?^K^__-5__P HZC_B$U_ZO[_\U7__ "CJ
M/]9\C_Z#O_+;&?\ S.'_ !!OQ(_Z)S_S,9#_ //0_CKHK^Q3_B$U_P"K^_\
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M_H._\ML9_P#,X?\ $&_$C_HG/_,QD/\ \]#^.NBO[%/^(37_ *O[_P#-5_\
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M(37_ *O[_P#-5_\ \HZC_6?(_P#H._\ +;&?_,X?\0;\2/\ HG/_ #,9#_\
M/0_CKHK^Q3_B$U_ZO[_\U7__ "CJ/^(37_J_O_S5?_\ *.H_UGR/_H._\ML9
M_P#,X?\ $&_$C_HG/_,QD/\ \]#^.NBO[%/^(37_ *O[_P#-5_\ \HZC_B$U
M_P"K^_\ S5?_ /*.H_UGR/\ Z#O_ "VQG_S.'_$&_$C_ *)S_P S&0__ #T/
MXZZ*_L4_XA-?^K^__-5__P HZC_B$U_ZO[_\U7__ "CJ/]9\C_Z#O_+;&?\
MS.'_ !!OQ(_Z)S_S,9#_ //0_CKHK^Q3_B$U_P"K^_\ S5?_ /*.H_XA-?\
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ME?9/^$:\WSO/D\_[;L\J'[-OGW?^(37_ *O[_P#-5_\ \HZC_6?(_P#H._\
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MZRA/,<QG!+$8[$);O=T\/3;DL-AE)QI1;;<ZTZM6H4445YA]D%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_%'_DF?Q$_[$7Q=
M_P"H_J%=U7"_%'_DF?Q$_P"Q%\7?^H_J% '=4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+I_\ R4SQ
M=_V(OP[_ /4@^*-=U7"Z?_R4SQ=_V(OP[_\ 4@^*- '=4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.'
M[7'[)_P2_;B_9Z^(/[+G[1GAS4/%OP:^)_\ PBG_  F/A[2O$6N>$[_4/^$*
M\;^&OB'X>\C7_#=]INM6'V3Q5X2T.^E^Q7L/VJ&VDLKCS+2YGBD]'^#?PG\$
M? 7X0_"OX&?#/3;C1_AQ\&/AOX'^$_P_TB[U&^UB[TKP1\.O#&E^#_"FFW.K
M:G/=:EJEQ8Z#H]A:S:CJ%S<7U[)$US=SRW$LDC?-'_!1[]M[PK_P3B_8Q^,O
M[9OC7P/X@^)'AGX-_P#"O/[3\%^%M1T[2==UG_A8?Q6\#?"JR^PZAJROI]O_
M &=J'CFTU:Z^T*?-L[&X@BQ/)&1[?^S)\;]*_::_9M_9\_:1T+0]0\,:)^T'
M\#_A/\;]'\-:M<VUYJOA[2OBOX#T#QYI^AZG=V8%I=:AI-IK\-A>W-J!;3W-
MO)+ !$RB@#W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#A=/_P"2F>+O^Q%^'?\ ZD'Q1KNJX73_ /DI
MGB[_ +$7X=_^I!\4:[J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *X7X7?\DS^'?\ V(OA'_U']/KNJX7X7?\ ),_AW_V(
MOA'_ -1_3Z!=5Z/\XG=4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .%T__DIGB[_L1?AW_P"I!\4:[JN%
MT_\ Y*9XN_[$7X=_^I!\4:[J@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KA?BC_ ,DS^(G_ &(OB[_U']0K
MNJX7XH_\DS^(G_8B^+O_ %']0H [JBBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>7?&GXT_#3]GGX:>)?C#\8?$O\ PB'PY\(?V-_PD7B+^QM?U_\
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M5'BE_P"'OA/_ .@@_O2_X?1?\$TO^CD__,._'W_YUE'_  ^B_P"":7_1R?\
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MG_YAWX^__.LK^"VBC_B,/$W_ $ Y%_X39A_\\P_XIV>"G_14>*7_ (>^$_\
MZ"#^]+_A]%_P32_Z.3_\P[\??_G64?\ #Z+_ ()I?]')_P#F'?C[_P#.LK^"
MVBC_ (C#Q-_T Y%_X39A_P#/,/\ BG9X*?\ 14>*7_A[X3_^@@_O2_X?1?\
M!-+_ *.3_P#,._'W_P"=91_P^B_X)I?]')_^8=^/O_SK*_@MHH_XC#Q-_P!
M.1?^$V8?_/,/^*=G@I_T5'BE_P"'OA/_ .@@_O2_X?1?\$TO^CD__,._'W_Y
MUE'_  ^B_P"":7_1R?\ YAWX^_\ SK*_@MHH_P"(P\3?] .1?^$V8?\ SS#_
M (IV>"G_ $5'BE_X>^$__H(/[TO^'T7_  32_P"CD_\ S#OQ]_\ G64?\/HO
M^":7_1R?_F'?C[_\ZROX+:*/^(P\3?\ 0#D7_A-F'_SS#_BG9X*?]%1XI?\
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M5'BE_P"'OA/_ .@@_O2_X?1?\$TO^CD__,._'W_YUE'_  ^B_P"":7_1R?\
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M"G_14>*7_A[X3_\ H(/[TO\ A]%_P32_Z.3_ /,._'W_ .=91_P^B_X)I?\
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M )AWX^__ #K*_@MHH_XC#Q-_T Y%_P"$V8?_ #S#_BG9X*?]%1XI?^'OA/\
M^@@_O2_X?1?\$TO^CD__ ##OQ]_^=91_P^B_X)I?]')_^8=^/O\ \ZROX+:*
M/^(P\3?] .1?^$V8?_/,/^*=G@I_T5'BE_X>^$__ *"#^]+_ (?1?\$TO^CD
M_P#S#OQ]_P#G64?\/HO^":7_ $<G_P"8=^/O_P ZROX+:*/^(P\3?] .1?\
MA-F'_P \P_XIV>"G_14>*7_A[X3_ /H(/[TO^'T7_!-+_HY/_P P[\??_G64
M?\/HO^":7_1R?_F'?C[_ /.LK^"VBC_B,/$W_0#D7_A-F'_SS#_BG9X*?]%1
MXI?^'OA/_P"@@_NGL_\ @L?_ ,$WXO'/B+6)/VC-NFW_ (3\&:9:7/\ PJ'X
M[GS;W2=8\>76H0>2OPP,Z?9X-:TR3S)(DAE^T[8))'AN%BZO_A]%_P $TO\
MHY/_ ,P[\??_ )UE?P6T4?\ $8>)O^@'(O\ PFS#_P">8?\ %.SP4_Z*CQ2_
M\/?"?_T$']Z7_#Z+_@FE_P!')_\ F'?C[_\ .LH_X?1?\$TO^CD__,._'W_Y
MUE?P6T4?\1AXF_Z <B_\)LP_^>8?\4[/!3_HJ/%+_P /?"?_ -!!_>E_P^B_
MX)I?]')_^8=^/O\ \ZRC_A]%_P $TO\ HY/_ ,P[\??_ )UE?P6T4?\ $8>)
MO^@'(O\ PFS#_P">8?\ %.SP4_Z*CQ2_\/?"?_T$']Z7_#Z+_@FE_P!')_\
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MP^B_X)I?]')_^8=^/O\ \ZRC_A]%_P $TO\ HY/_ ,P[\??_ )UE?P6T4?\
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M_A]%_P $TO\ HY/_ ,P[\??_ )UE?P6T4?\ $8>)O^@'(O\ PFS#_P">8?\
M%.SP4_Z*CQ2_\/?"?_T$']Z7_#Z+_@FE_P!')_\ F'?C[_\ .LH_X?1?\$TO
M^CD__,._'W_YUE?P6T4?\1AXF_Z <B_\)LP_^>8?\4[/!3_HJ/%+_P /?"?_
M -!!_>E_P^B_X)I?]')_^8=^/O\ \ZRC_A]%_P $TO\ HY/_ ,P[\??_ )UE
M?P6T4?\ $8>)O^@'(O\ PFS#_P">8?\ %.SP4_Z*CQ2_\/?"?_T$']Z7_#Z+
M_@FE_P!')_\ F'?C[_\ .LH_X?1?\$TO^CD__,._'W_YUE?P6T4?\1AXF_Z
M<B_\)LP_^>8?\4[/!3_HJ/%+_P /?"?_ -!!_>E_P^B_X)I?]')_^8=^/O\
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M^8=^/O\ \ZRC_A]%_P $TO\ HY/_ ,P[\??_ )UE?P6T4?\ $8>)O^@'(O\
MPFS#_P">8?\ %.SP4_Z*CQ2_\/?"?_T$']Z7_#Z+_@FE_P!')_\ F'?C[_\
M.LKE/'G_  6/_P"";^M>!O&>CZ9^T9]IU+5O"?B+3-/MO^%0_'>'[1>W^CWE
MK:0>=<?#"*"+S9Y8X_,GECA3=NDD1 S#^%BBC_B,/$W_ $ Y%_X39A_\\P_X
MIV>"G_14>*7_ (>^$_\ Z"#^]+_A]%_P32_Z.3_\P[\??_G64?\ #Z+_ ()I
M?]')_P#F'?C[_P#.LK^"VBC_ (C#Q-_T Y%_X39A_P#/,/\ BG9X*?\ 14>*
M7_A[X3_^@@_O2_X?1?\ !-+_ *.3_P#,._'W_P"=91_P^B_X)I?]')_^8=^/
MO_SK*_@MHH_XC#Q-_P! .1?^$V8?_/,/^*=G@I_T5'BE_P"'OA/_ .@@_O2_
MX?1?\$TO^CD__,._'W_YUE'_  ^B_P"":7_1R?\ YAWX^_\ SK*_@MHH_P"(
MP\3?] .1?^$V8?\ SS#_ (IV>"G_ $5'BE_X>^$__H(/[TO^'T7_  32_P"C
MD_\ S#OQ]_\ G64?\/HO^":7_1R?_F'?C[_\ZROX+:*/^(P\3?\ 0#D7_A-F
M'_SS#_BG9X*?]%1XI?\ A[X3_P#H(/[TO^'T7_!-+_HY/_S#OQ]_^=91_P /
MHO\ @FE_T<G_ .8=^/O_ ,ZROX+:*/\ B,/$W_0#D7_A-F'_ ,\P_P"*=G@I
M_P!%1XI?^'OA/_Z"#^]+_A]%_P $TO\ HY/_ ,P[\??_ )UE'_#Z+_@FE_T<
MG_YAWX^__.LK^"VBC_B,/$W_ $ Y%_X39A_\\P_XIV>"G_14>*7_ (>^$_\
MZ"#^]+_A]%_P32_Z.3_\P[\??_G64?\ #Z+_ ()I?]')_P#F'?C[_P#.LK^"
MVBC_ (C#Q-_T Y%_X39A_P#/,/\ BG9X*?\ 14>*7_A[X3_^@@_O2_X?1?\
M!-+_ *.3_P#,._'W_P"=91_P^B_X)I?]')_^8=^/O_SK*_@MHH_XC#Q-_P!
M.1?^$V8?_/,/^*=G@I_T5'BE_P"'OA/_ .@@_O2_X?1?\$TO^CD__,._'W_Y
MUE'_  ^B_P"":7_1R?\ YAWX^_\ SK*_@MHH_P"(P\3?] .1?^$V8?\ SS#_
M (IV>"G_ $5'BE_X>^$__H(/[TO^'T7_  32_P"CD_\ S#OQ]_\ G64?\/HO
M^":7_1R?_F'?C[_\ZROX+:*/^(P\3?\ 0#D7_A-F'_SS#_BG9X*?]%1XI?\
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M5'BE_P"'OA/_ .@@_O2_X?1?\$TO^CD__,._'W_YUE'_  ^B_P"":7_1R?\
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MG_YAWX^__.LK^"VBC_B,/$W_ $ Y%_X39A_\\P_XIV>"G_14>*7_ (>^$_\
MZ"#^]+_A]%_P32_Z.3_\P[\??_G64?\ #Z+_ ()I?]')_P#F'?C[_P#.LK^"
MVBC_ (C#Q-_T Y%_X39A_P#/,/\ BG9X*?\ 14>*7_A[X3_^@@_O2_X?1?\
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M^@'(O_";,/\ YYA_Q3L\%/\ HJ/%+_P]\)__ $$']Z7_  ^B_P"":7_1R?\
MYAWX^_\ SK*/^'T7_!-+_HY/_P P[\??_G65_!;11_Q&'B;_ * <B_\ ";,/
M_GF'_%.SP4_Z*CQ2_P##WPG_ /00?WI?\/HO^":7_1R?_F'?C[_\ZRC_ (?1
M?\$TO^CD_P#S#OQ]_P#G65_!;11_Q&'B;_H!R+_PFS#_ .>8?\4[/!3_ **C
MQ2_\/?"?_P!!!_>E_P /HO\ @FE_T<G_ .8=^/O_ ,ZRC_A]%_P32_Z.3_\
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M^@'(O_";,/\ YYA_Q3L\%/\ HJ/%+_P]\)__ $$']Z7_  ^B_P"":7_1R?\
MYAWX^_\ SK*/^'T7_!-+_HY/_P P[\??_G65_!;11_Q&'B;_ * <B_\ ";,/
M_GF'_%.SP4_Z*CQ2_P##WPG_ /00?WI?\/HO^":7_1R?_F'?C[_\ZRC_ (?1
M?\$TO^CD_P#S#OQ]_P#G65_!;11_Q&'B;_H!R+_PFS#_ .>8?\4[/!3_ **C
MQ2_\/?"?_P!!!_>E_P /HO\ @FE_T<G_ .8=^/O_ ,ZRC_A]%_P32_Z.3_\
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M_P#SK*_@MHH_XC#Q-_T Y%_X39A_\\P_XIV>"G_14>*7_A[X3_\ H(/[TO\
MA]%_P32_Z.3_ /,._'W_ .=91_P^B_X)I?\ 1R?_ )AWX^__ #K*_@MHH_XC
M#Q-_T Y%_P"$V8?_ #S#_BG9X*?]%1XI?^'OA/\ ^@@_O2_X?1?\$TO^CD__
M ##OQ]_^=91_P^B_X)I?]')_^8=^/O\ \ZROX+:*/^(P\3?] .1?^$V8?_/,
M/^*=G@I_T5'BE_X>^$__ *"#^]+_ (?1?\$TO^CD_P#S#OQ]_P#G64?\/HO^
M":7_ $<G_P"8=^/O_P ZROX+:*/^(P\3?] .1?\ A-F'_P \P_XIV>"G_14>
M*7_A[X3_ /H(/[TO^'T7_!-+_HY/_P P[\??_G64?\/HO^":7_1R?_F'?C[_
M /.LK^"VBC_B,/$W_0#D7_A-F'_SS#_BG9X*?]%1XI?^'OA/_P"@@_O2_P"'
MT7_!-+_HY/\ \P[\??\ YUE'_#Z+_@FE_P!')_\ F'?C[_\ .LK^"VBC_B,/
M$W_0#D7_ (39A_\ /,/^*=G@I_T5'BE_X>^$_P#Z"#^]+_A]%_P32_Z.3_\
M,._'W_YUE'_#Z+_@FE_T<G_YAWX^_P#SK*_@MHH_XC#Q-_T Y%_X39A_\\P_
MXIV>"G_14>*7_A[X3_\ H(/[TO\ A]%_P32_Z.3_ /,._'W_ .=91_P^B_X)
MI?\ 1R?_ )AWX^__ #K*_@MHH_XC#Q-_T Y%_P"$V8?_ #S#_BG9X*?]%1XI
M?^'OA/\ ^@@_O2_X?1?\$TO^CD__ ##OQ]_^=91_P^B_X)I?]')_^8=^/O\
M\ZROX+:*/^(P\3?] .1?^$V8?_/,/^*=G@I_T5'BE_X>^$__ *"#^]+_ (?1
M?\$TO^CD_P#S#OQ]_P#G64?\/HO^":7_ $<G_P"8=^/O_P ZROX+:*/^(P\3
M?] .1?\ A-F'_P \P_XIV>"G_14>*7_A[X3_ /H(/[TO^'T7_!-+_HY/_P P
M[\??_G64?\/HO^":7_1R?_F'?C[_ /.LK^"VBC_B,/$W_0#D7_A-F'_SS#_B
MG9X*?]%1XI?^'OA/_P"@@_O2_P"'T7_!-+_HY/\ \P[\??\ YUE'_#Z+_@FE
M_P!')_\ F'?C[_\ .LK^"VBC_B,/$W_0#D7_ (39A_\ /,/^*=G@I_T5'BE_
MX>^$_P#Z"#^]+_A]%_P32_Z.3_\ ,._'W_YUE'_#Z+_@FE_T<G_YAWX^_P#S
MK*_@MHH_XC#Q-_T Y%_X39A_\\P_XIV>"G_14>*7_A[X3_\ H(/[TO\ A]%_
MP32_Z.3_ /,._'W_ .=91_P^B_X)I?\ 1R?_ )AWX^__ #K*_@MHH_XC#Q-_
MT Y%_P"$V8?_ #S#_BG9X*?]%1XI?^'OA/\ ^@@_O2_X?1?\$TO^CD__ ##O
MQ]_^=91_P^B_X)I?]')_^8=^/O\ \ZROX+:*/^(P\3?] .1?^$V8?_/,/^*=
MG@I_T5'BE_X>^$__ *"#^]+_ (?1?\$TO^CD_P#S#OQ]_P#G64?\/HO^":7_
M $<G_P"8=^/O_P ZROX+:*/^(P\3?] .1?\ A-F'_P \P_XIV>"G_14>*7_A
M[X3_ /H(/])3]G3]JKX"_M9^%]<\9_L_>//^$_\ #7AO7SX8UK4O^$7\9^%?
ML6N+IUEJIL?L?C7P[X;O[C%AJ-G/]IM+6>S_ 'WE"X\Z.6-/H2OY[?\ @W2_
MY-?^.'_9>I?_ %7O@NOZ$J_=.&<TQ&=9#EN:8J%&GB,90=6K##QG"C&2JU(6
MIQJ5*LTK03M*I)WOK;1?Y<^-O ^4^&WBKQGP-D6(S'%Y3P[F=+!8+$9M6PU?
M,:M*> PF*<L56P>$P&&G453$32='"4(\BBG!R3E(HHHKW3\K"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img173888082_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173888082_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +0!0 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***\@^/WQJ\*_LZ?!KXA_&[QM:ZO?>%_AQX>
MN/$.JV&@6]M=:U?I'-!:6MAID-Y=V-FUW?7MU;6L+7=[:VL33>;<7$4*.XSK
M5J6'HU:]:<:=&A3G6JU):1ITJ<7.I.3_ )8PBY/R1V9=E^-S;,,#E66X:KC,
MQS/&8;+\!A**YJV*QN,KPPV%PU*+:4JM>O4ITJ:;5YR2NCU^BOY[?^(BW]F#
M_HA_QZ_[]?#W_P";2OT*_8Y_X*:_LO\ [;.HWOA;X9:QXA\,_$73M,;5[GX<
M_$+2[/1/$EUID'EI>ZAH4^FZGK6A>(+2QED NH]-U>74[6W*7E]IEI:N)*\#
M \7\-9EB883!9S@ZV)JNU*CSRISJR_DIJK"FJDWK:$&YNSLF?K'%'T>_&G@O
M)L5Q!Q+X=<0Y;DN!BIXW,?8X?&8?!4FTO;XQX#$8J6%P\7**GB*\:="#:4ZD
M6TC]"**_-S]N?_@IS\%_V#/$7@3PE\1/!_Q$\9^(/'FBZGXBL[7P19^'VMM+
MT;3KY-,6XU.\U_7M&4SW][]ICL[:QBO"L=C=2WLEH&LUO/C#PQ_P<.?LA:MK
M-II_B+X9_'GPGIETZQ2:_+H?@K6K/3W:1!Y^H66E^-FU0V21F1Y9--L]3O0R
MQQQ:?,)&>(QG%W#67XRI@,;G&$P^+HRC"K1J.HG3E.,9Q4YJ#IQ]V<6[S2C>
MTK--)</?1\\9^+.'<'Q7PYX>Y]G&09A1KXC YA@X86:QE'#UJN'JSPV&EBHX
MRM:M0JTX1IX>4JKA>E&<7%O]\J*\^^%WQ5^'GQJ\!>&_B?\ "SQ7I7C7P)XM
MLC?Z#XBT>222TO(HYY;6YADBFCAN['4-/O;>YT_5-+O[>UU+2]1M;K3]1M;:
M\MIX(^_WKZ_H?\*^@IU*=:G"K2G"K2J0C4IU*<HSIU(32E"<)Q;C.$HM2C*+
M:DFFFTS\DQ>$Q6 Q6)P..PV(P6-P=>MA<9@\71J8;%83%8>I*E7PV)P]:,*U
M"O0JPG2K4:L(5*52,H3C&46DZBJ&IZIIVC:;J&KZK>06&EZ597>I:E?73B*V
MLK"Q@DNKR[N)6^6."VMXI)I9&X2-&8\"OPU^%/\ P7P_9N^*'QG\(?"I?A=\
M4?"^D>.?&&D>"]"\=ZU/X6:PMM0\0:I:Z/H^H:_I%OJK7&E:/+>7<1OKN&]U
M&;3K9A<36KHLX@\S,L\RG**N$HYECJ.$JXZ;IX6%7GO5E&5.,K.,9*$8RJTT
MYU'""<E>6]OM>#?"_C_Q!P6?YAP9POF/$&"X7PU/&9[7P7U=1P%"M3Q5:DW&
MO7HSQ%6I2P6*G##X2-?$2C1DU2?NW_=FBF[U]?T/^%?CE^U-_P %I_V?OV4_
MCKXW^ ?BKX9?%WQ5XD\ GP_%K.L^&;;P@FA3W/B#PQHWBN"'3VUCQ1IVH3"T
ML=<M+:ZEGL;93?17*6XFMDANI],TS?+<EH0Q6:8NE@Z%2M&A"I54VI5I0G4C
M!*$9RNX4IRVM:+N]K\G _A[QGXDYKB,CX&X?QO$>:X3+ZN:8G!X*6'C4HY?1
MQ&%PE7%3EB:U"DJ<,3C<+2:Y^=RK1M%I2:_8^BOP]^"?_!=K]G7XX?%[X:_!
MW0OA#\:]'UOXG>-/#_@?2-4U6V\$R:7I^I>)-1@TNQNM273_ !9=7JV$-S<Q
MO>2VUM/+#;B2989/+V']5_V@?VA/A5^S#\+?$'Q@^,7B-?#O@[P^(86>*"2]
MU76=6O2T>E^'O#^EQ8GU37-5F1H[2TC*1111W%_?W%EI=E?7UMA@>(<ES+"X
MG'8+,</6P>"YOK6(YI4Z5!1A[23J2JQIJ,8T_><MDMV>IQ1X1^)7!F>Y+PQQ
M+P?F^6\0<1JG_864>SI8S'9JZV)^ITH8.A@*N*E6J5,5^YA27[R4VDH6:9[7
M17\Z,7_!QK\!6\4_8YOV>OBY%X+,FW_A(4UWP=+XG$7GA?,/A W46E[Q;9F,
M0\;,/. MQ(4/VD?NK\$?CA\,OVB?AEX8^+OPD\2V_BCP/XLM9)].U"**:VNK
M:YMIGM=1TG5M/N$2ZTS6-*O8IK+4=/NHTE@GB+(98)(9Y<\IXFR+/*M:CE69
M4,96H1YZE*"J4ZB@I*+J1A6ITY5*:E*,74IJ<$Y13DG*-^OCWP5\4_##!8#,
MN.^"\UX>R[,ZJP^#QU>6#Q6#GB94Y5HX2MB<NQ6,HX3&3I0J5*>$Q<Z&)J0H
MUI0I25&JX>LT5^5W[97_  5W_9=_9!UH>!Y+N_\ C%\3[>\^S:[X'^'%[I=P
M/!Z1EQ./%_B*[G&D:1J:,AC7P["U_P"((I&CDU'3M.LYH;N3[5_9@^/VB?M0
M? ;X<_'GP_H6J>&-'^(NEW^I6>@ZS/:W6I::-.UW5=!GAN;BQ+6LQ>YTF::*
M2(C=!+$72.3>B].'SO*<7F&(RK"X^AB,?A:;JXC#T9.HZ,(SA3ESSBG24H3J
M0A.FINI"4K2BFG;R,X\,^/>'N$LHXZSWA;-,HX4S[&0P&3YMF%*GA89AB:F'
MQ&+I+#X6M4CCY4*^&PN(KX?%O"QPF(ITW*C7FG'F]\HIN]?7]#_A7Y9?MK_\
M%9O@5^Q!\4M'^$7CGP+\3?&OBC4_!VG^-KF?P9:>&ETG3--U;4]7TO3K.>ZU
M_P 0Z1<3ZE*^B7EU/';6DEK;VLMD1>2W$UQ;VFN8YG@,HPSQF98JGA,,IPIN
MK5YN7GJ-J$$HQE)RE9Z)/1-NR39Y_!O!'%?B#G4.'>#,DQG$&=5,-B,7' 8+
MV2J_5<*HRQ%>4Z]6C1ITZ?/!.4ZD4Y3A"-YSC%_J?17X.^!_^#A']CCQ'K]G
MI'BOP-\;_A[IMY-%"WBC5/#OAC7M%TT.Q$EQJUMX:\6:EXA2UB7#%M)T/6;E
MN0+48!/Z3_M*_M-0?#G]C?XF?M1?!B_\'_$"'0?AJ_COP#J%S+=:OX,\0K</
M:1Z==73:+J.EWMYII^U>9<6]GJFG79:)[5KFTF#F/@PG$V19AAL9BL!F6'QE
M/ 4*F)Q4:$FZU.C2A*<INA)0J\K49*,N7EE)<JE?0^JS_P $O%+A3.N',AXI
MX-S;A[&<5YI@\FR.MFE*%/+L;F&.Q-'"T</#,Z,Z^!52-2O2E7I>W=:C2E[6
MI34+-_7=%?F=_P $K/VS_B9^W)^SSXO^+/Q8T#P)X<\2^'?C)XB^'5K9_#S3
M?$.EZ'/H^D^"_A]XFM;R>U\2>)O%E_\ VD]WXNO[>>2/4TM7M[:T$=I%*LTD
MWZ7[U]?T/^%>CEN88;-<#A<QPCG+#8NDJU%U(.$W!MI<T'=Q=T[JY\CQEPEG
M' ?%&=\'\04\/2SKA_&SP&8T\+7CBL/'$0A";5+$02C5ARSBU));M6T'44W>
MOK^A_P *-Z^OZ'_"NT^9'44W>OK^A_PHWKZ_H?\ "@!U%-WKZ_H?\*-Z^OZ'
M_"@!U%-WKZ_H?\*H:KJ=MI&F:CJUT)6MM+L+S4;A84#S-!96\ES,L2NT:-*8
MXF$:M(BLY 9U!+!-I)MZ)*[?9(J$)5)QA"+E.<HPA%;RE)J,8KS;:2-&BOS+
M_8/_ ."GOPP_;U\5_$;PEX'^'/CSP->_#_2;#Q USXKN/#]U:ZMHVHZE)IEL
MR_V/J%S-9:FLJ))/8F.[M$C9O+U.5D"O^F6]?7]#_A7%EV98'-L)3QV78B&*
MPE5SC3K04XQDZ<Y4YI*I&$ERSBXN\5M=75F?2\8<&\3\ Y]BN&.+\HKY'GV"
MIX6KBLNQ-3#U:M&GC<-3Q>&G*>%K5Z$E5P]:G47)5DXJ7+-1FI13J*_*;]M7
M_@KQ^SA^QEXSE^%FI:7XK^*?Q4LK:PO-<\*>"O[+MM.\*0:E MY9P>*/$>JW
M<4%EJMW82P7]OI&G6&KWJ6ES:7&H)IT-W:23^<_L:_\ !:OX(?M9_%CPU\$;
MSX8^/OA=\0/&DVIP>%&N[W2?%WA/4;C2])U#6IK*ZUS3UTG5--O9]/TVY>U$
MWAN33WE0PS:E [0^=Y<^+.'*>9QR>>;859C*LL,L.O:2MB)24%0E6C3="%9U
M&J?LI55-3]QQYDT?<X;P"\8\7P74\0J' &>2X/I9;4SF6;S6$I.644J$L5/-
M*67UL53S2OERPL)8I8VA@JF&EAE]8C4=%J;_ &?HKP[XU_M+? ?]G*RT#4?C
MC\4/"_PTL_%-U?67AZ;Q+=36_P#:]SID-O/J$5E'!;W$LOV.*[M7N7V".+[3
M KN&EC#>M:#K^C>*-#T;Q+X?U&VU;0?$6DZ=KNB:K9N9+34](U:SAO\ 3=0M
M9,#S+:]LKB&Y@? W12JV!G%>Y'$8>=:IAX5Z,\114)5J$:L)5J4:BO"52DI.
M=-333@Y12DG=71^85LHS;#9=@LXQ&5YCA\IS*IB*.79I6P6)I9=CZN$FZ>*I
M8+'5*4<-BJF&J)PQ$*%6I*C-.-11:L:]%-WKZ_H?\*-Z^OZ'_"MCSAU%-WKZ
M_H?\*\Y^,7C>[^&WPC^*?Q$TVTM=1U'P#\.?&_C2PT^],RV5]>^%O#.J:Y:V
M=VT#).MK<SV$<%PT+I*(G<QLK@$14J1I4ZE6;M"E"=2;2;:C"+E)V6KLD]%J
M^ATX+"5\?C,)@<-%3Q.-Q-#"8>,I*$95\35A1I1E.348IU)Q3E)I13NW9'I%
M%?D+_P $F/\ @H'\7/V\O#/QKU7XN^%OAQX9O_AKK_@W3]%/PYTSQ/I5G>V/
MB?3_ !!<SKJ=OXF\5^+9I+JUFT1?*N+6[M(7BN61[0/$)7_7C>OK^A_PKARK
M-,)G.7X;,\#*<L+BE4E2E4@Z<VJ=6I1GS0>L;5*<DNZ2:T9]/Q[P/G_AMQ;G
M'!/%%+#4<]R.IA*>/IX/$PQF&C+&X#"YE0]EB::4*BEA<90E)I+EFY0:YHL=
M13=Z^OZ'_"C>OK^A_P *]$^/'44W>OK^A_PKYY_:<_:E^#O[(GPNOOBU\:->
MN-)\.P7UMH^EZ=I=H-2\2>*-?O4FEL] \-:29K87^IS06UU=.9[JSL;*RM+J
M^U&]L[*WFG3'$8BAA*%7$XJM3P^'H0E4K5JLU"G3IQ5Y2G.3222[OR6K/1RC
M*,TS_,\#DN29?B\US;,\32P>7Y=@*%3$XS&8JM)0I4,/0I1E4J5)R>T5HDY2
M:BFU]$45_.99_P#!QM\"Y/$T5I??L[?%>U\'M*RRZ_;^(_"-YXCBB\YE25?"
MCO9Z;(QM]LKQ?\)BFR4M DDJJL[_ +Z?"WXE^%/C%\-_ OQ6\$7-U=>$?B)X
M5T3QAX<GOK.6POGTC7K"#4;-;VRFS):W<<4ZQ7,!9UCG214EE0+(WDY3Q)D>
M>SK4\IS&CC*F'2E6IPC5ISA%OE4^6M3IRE#FLN>"E"[2O=H^^X_\&/$_PMPV
M6XSCWA#,.'<)FU2='+\5B*V Q>'KUX4W5EAW6R[&8RG0Q*I)U/JV(E2KN$9S
M5-QA)KOZ*;O7U_0_X4;U]?T/^%>X?F ZBF[U]?T/^%&]?7]#_A0 ZBOGC0/V
MLOV</%/QAU+X >'OC!X.U?XRZ/=ZUI^I?#VRO9I=?L[[P[;S7>NVDL7V<6_V
MG2K>WGDOH4N&D@$$RNH>*15^A=Z^OZ'_  K&CB,/B5.6'KT:\:=25&I*C5A5
M5.K"W/2FX2DHU(77-"5I1NKI71Z.991FV35,/1S?*\QRJKB\'0S#"4LRP6)P
M-3%8#%<WU;'8>&*I4I5\'B.2?L,324J-;DE[.<N5V=13=Z^OZ'_"C>OK^A_P
MK8\X=17XN?L._P#!6#Q'^U[^U9\0_P!G;4_@*/ 6E^%])\:ZUIOB.#Q/?ZOJ
MVG0^#=?TS06L?%VE3^'M/M[6XU&;4#NN(+JU33M0$&E&UOFF^V+^T.]?7]#_
M (5YF4YQE^=X66,RVLZ^'C7JX=SE2JT6JM%I5(\E:%.=E=-2Y;-/1W32^TX\
M\/>+/#3.Z?#O&66PRK-ZN68#-X8:GC\OS&+P.94Y5,+5=?+<5B\/&4N2I&5)
MU54A*#;CR2A.;J*;O7U_0_X4;U]?T/\ A7IGQ8ZBF[U]?T/^%&]?7]#_ (4
M.HIN]?7]#_A7X@_\%,_^"F_QI_8M_:"^"7PE^&?@KX7>(_#_ ,0/"^E>)?$U
M_P".M.\67VL(-0\;:CX:>QT*;0/%WARRTXQV6F23+=:A8ZT#=7*,;?RK=H;C
MR\XSC!9'@I9AF$ZD,-"K1I-TZ<JL^>O45."4(ZVYGJ]DDWV3^Y\._#SB7Q1X
MFH\)<)T,+B,XKX+,,?3IXS%T\%0^KY;A9XO$RE7JWBI*E3:A"S<YM+17DOW
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MKR^U_MA_\%#_ -KKQE^W+:?L!_L3W?@?X>^*+;4]/\/ZA\2_&&G:/K-SJ'B
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MW'B'Q;XCPF-G3OST,JI\29EBLYQ<;:WP>4X?&XI;7]C;FCNOPJ^!?[*/BO\
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M^,M5TG4+OQ;I-]XBT]]'L_#PU6SETH:7KNCQ@W,LT<INFENDD@6/R0JNS/\
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MEUIMKK*0ZG9S:3<:AJ$ME?Z/>2)=/:75HJ?I?7\Q7_!MXS#0_P!KP G']K?
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MP!,$[:?XKM&EC/9S;75Q"3_<F<=Z^@/^"/;M_P .X?V:.2<:3\0QSSP/B_\
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ML]8T&^@TR]UCPMJUXL7B>PN)8]+N=%U3P^T:V^KZ5<G4H9;/]F_V9/B[XF^
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M,1PGD=#-YY;]<S7,LIPF*PLL=2F\?&CAJ=;$0A3KTI*,H2K.<-7]E'_@K?\
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MC'-J\&IQ_BG_ ,$&KR"P_;E_:7T>\F6UU2Z^%OC-H+*8&.>4Z9\6O!Z7Z(K
M RVK7,1DBR)=I=U0I%*R>A_\'(%KKAUW]DJ_E\Q_#@TGXRV=GM5S%;ZV;SX;
M3:EYC@>7')>6*Z5Y*G:\RV-P5WK VSR\@Q..X?\ #W-<]P6/Q52NJU3"T,+5
M=*I@\#5GF=/#3Q=.DZ=_;N-;G?M'.$I\G-3Y&T?=>+&2\+>+'TNN _"[B3A3
M(L'E3R_!Y[FF>X&.-PG$'%&"PO!>+SBAP_C,=#%QA++*=?+E@Z;PD,/BJ>%^
ML>RQ4:\$SL=3_;4_X+6>&?@Q:_MAZY\(/@RWP-NM&T_QG/X6_P"$>M5N]/\
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M+,M^]FMELM%O+OY7_:/_ ."15Y\6/VT=$_;$^%OQVM_@_KL/B7P)XUUG0O\
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M_&W[<?Q$^-</Q'U'5O%7Q \6>#_!:^!9='?0;[QK%J6DZ2E]KEQXLU:*YMO
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MV,NHK\7_ !%:V=K'<:NFI31-H%_'=-:F I"\XNX/W'\\_P![_P!"H\\_WO\
MT*O/P_ '"F$Q5'&X?*JE/%8>M3KT:O\ :.;3<:M&I&K3DXU,=*$U&<8R<)QE
M"5K2BTVCZW./I8>/N?9'F7#>:\<T,5DF;Y?C<JS# +@[@3#PK8',,+5P6+HP
MJX7ABCB,/.KAJU2FL1AJU'$TN;GHUJ=2,9K0WMZ_H/\ "OQ[_;,_X)677[6/
M[6'PU_:6M_C=!X&M?!>F>!M,U3PC/\/Y/$5Q?+X$\4:EXEMY[#68_&&BQ1-K
M U)M/FAN--8:8;<7R2ZEYYL8/UT\\_WO_0J///\ >_\ 0J^@S3*,#G.&CA,R
MP[Q&'A7I8F,%4K4;5J$G*G+GH3ISTNTX\W*TW=;-?D_ W'_%GAOG-7B#@W-%
ME&;5\LQ^3U<4\#E^8*67YE3C3Q=#V&987&8=.:A"4:L:2JTY03A.*<E+0WMZ
M_H/\*\'_ &G_ (*M^T=^S_\ %;X&_P#"2?\ "(M\2_"=YX:3Q+_9(UP:-+/+
M!<17KZ1_:&DG4(TDMT62W74K)GC9MLZ, :]H\\_WO_0J///][_T*NROAZ>)H
M5L-7IN='$4JE"M"\X\]*K"5.I'F@XSCS0DUS1E&2O>+3LSYW*<TQV29IEN=9
M77^K9EE&88/-,NQ/LZ5;ZOCLOQ%/%X2O[&O3JT*OLL12IU/9UJ52E/EY:E.<
M'*+^%O\ @G/^Q5>?L'_ WQ#\(K[XBV_Q+O/$GQ/UWXDW&MVGAB3PK;6#ZOX8
M\&^%TT:&RFUS7Y;Q8(?!T5^^H/<6A>749+06*I9K=7?A'P[_ ."7]WX#_P""
MBOB+]NP_&>WU+3]9U[Q[XE@^&H\!R6M[!>>//">K>%I[";Q2?%L\#6VEC6)M
M0BO$T 2WI@CLWM+3S&NT_6#SS_>_]"H\\_WO_0J\C_5K*/JV4X3ZG+V&1XBC
MB\LA[?%7P]?#MNE-S]MSUN5R;<*\JD)/XHM:'W[\9/$5YSQ_G_\ ;\?[5\3\
MHS'(>-L3_9.36S?*LUC3AC<+"A_9_L,N]K3IPIQKY93P>(IQ3=.M&;<C\7_V
MW/\ @D,_[1/QX_X:?^!?QRU;X"_&*\&D7.N7,-CJT]K>Z_H&F0Z/I7BO0/$&
M@:[HVO\ @[6TTNQTW3[YM/2_M[L6JZA#'97[WSZE\^_$S_@@UXH^+.C6?B+X
M@_MH^-_B)\=;W78I/$_Q*^(7A?5O$^GOX/AL98[+POH>D:AX^N-8MY-,U">6
MX2]O/$D]A<6@M[+3M%\.1Q7!OOZ(O//][_T*CSS_ 'O_ $*O.Q? O#.-K8RO
MB,ME.>/JNOB81Q>.I49XB3O/$K#TL1"C#$3=^:K"$9^])IISFY?89%]*#QOX
M:RSA[*LGXRAA\/PM@J65Y+B*W#W#.-S+#910A&&'R:>:X[)\1F.)RFA&,%3P
M&(Q-3#I4J$90E'#8:-+X2_;8_8>F_:W^$OPU\$:'\7_$?P>\<?"'Q!I_BCP/
M\0/#VGS74L6J6/AR[\/2)=65EK>A:G:"[AN$FAO]+UZWO-,EC+(+Z-Y()/S>
MT?\ X(F?%OXJ^-?!_B#]M3]M;Q]\>O"_@R8BS\)27/C'6;^\T\S6<UQI=OXN
M\:^*M3G\.6FM?9$BU^72=$DU2]BCC,.J6]Z(;ZU_H.\\_P![_P!"H\\_WO\
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M/XUN?#WV^&[M/"^JW=CXPTWPYKQ$4:B;7;G2[.S%];P7Z>$6!^RP_97[-/\
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M\FSC'8M8ZOCJ&9X;#4LSJUEC%]8H_6,76CAYO]S&$8PC'^=+2O\ @B3^TO\
M"2\U'1_V<O\ @H?\1?AMX UG5+B]O-&TI?'W@B\C@F"Q1MJ-MX%^(EGHOB?5
M([2*"VN-0EL]!2\$*LMK:1!+>/\ 4C]@S]B6Z_8N\*?$"PUWXS^*_CCXT^)_
MB/3/$OBSQAXGL9M.W76E:;)IUI!9VM[KGB?4Y&V3SF[OM0UZ[FO,6X6&T6'R
MV^Y?//\ >_\ 0J///][_ -"KS\MX0R+*,53Q> P=:E6H*I'#J>-Q]>CAXU8.
M%14*%?$U*-/GC*46U"Z4FHM)V/K>-/I!^*OB!D>+X>XIS[ 8W+\RG@ZF;3PW
M"_"V5YAG%3+Z]+$X*>9YIE>38/,<5]7KT:56,7B8TZDZ<)UH5)137X$_M-?\
M$+=)^(WQKUWXU_L\_':\^!M]XN\0W7B76_"\_AS4=4M=&UW7+RXNO$FL>#?$
M.B^)M#U/2+2]ENKB[M_"\MG-:V]Q<7%I8ZSIFD&TTZQYS7O^#?GP;)8_"R]\
M,_M$:['\0/#_ (JU7Q%\6/'?BOP5/K\OQ':^OM$OM.&CZ+%XYLH?"B:"VEZE
MLAN[_P 2:CK=UXDO;S5/$'EZ?I]D/Z&?//\ >_\ 0J///][_ -"KCJ< <*5:
MN)K3R>#GBJGM:BCB,9"$*GM8595*%.&(C##3G.$5.5"--NGS4E:E.I"7T&"^
ME?X_9?@,ER["^(&*CA\BPOU+!SJY/P]B<57P<<%7P%'"YKC,3E-7%9S0P^'Q
M%65"GFM7%J&*]ECGS8[#87$4=#>WK^@_PKX%_P""AO[#-G^WO\)O"?PTG^)5
MQ\+;SPCX^M/'%CXBB\)Q^-(+@0Z#KNA76E7.AMXC\*.1<1ZRES#?1ZRAMI+/
MRVM;E+@F+[J\\_WO_0J///\ >_\ 0J^FQ^7X;,\'B,!CJ#KX3%0]G7HN52GS
MPNI6YZ4J=2+3BFI0G&2:T9^+<*\4Y]P3Q#E7%7#&/>5Y_DF)^N99CXX?"8MX
M;$>SG2Y_JV/H8K!UTZ=2I"5/$8>M2E&34H,_F-_XAN_^KS/_ #7?_P#'G7TC
M\4_^")VJ_%EOV6O#?BG]I^YU'X;_ +.WPTT/X<:AH5Q\-KD:EXIM[+QAKOBC
MQ%J&EW ^(,L/AV7Q18:GIOA>))&U4^'M-T'2YT?6?LJV;?O#YY_O?^A4>>?[
MW_H5?+TO#SA*C3K4J642A3Q"I*O#Z_F<HU8T:T*].$U/&23BJM.$FM+V2=T?
MN6-^EU](3,L5E^-QW'T<1BLIEC:F68C_ %4X)H5<#6S#+\1E>*Q&'J8;ARA*
M%>6!Q>(HPJ-MTU4E*'++4M6T,-G;P6EI#%;6MK#%;6UO!&D4%O;P(L4,$,2*
MJ1Q11JL<<: *B*%4  "OQE_;G_X)*77[5W[1WAG]I7X>?'*#X+^,=,TKPC:Z
MPC^ I?%4EWX@\%:C/<:#XSL;^#Q;H#0ZI::<NCZ6-/FM6@:/0;&=;Z-I)8Q^
MR'GG^]_Z%1YY_O?^A5]!FN2Y?G>%6"S+#/$8>-:G7A"-2M0E"M1O[.I"KAZE
M*K"45*4;QFO=DT]&?D? ?B+QAX9Y]/B7@O-O[)SBK@,9E=>O4P67YG1Q.7X]
M4_K>$Q6"S7"XW!8BE5E2I5&JV'FXU:5.I%J44S\K?^"D?_!,[4?V_M3^#>JV
M_P 9K/X8W/PQLO%&E:BMQX"F\5PZU;>*KCP]<S7]FL7B_P /-87&G2:$XCT^
M9[N*^6^4-J-B;,F\^T/VC/V;_#W[1O[-'C?]F[Q)JK:=IOBWP=8>';/Q+_9B
M:E+H>N:#)I^H>&?$Z:2;VQ%Z^D:]I&FZJ^FKJEC]MC@DL?[0MEG:=?H+SS_>
M_P#0J///][_T*H60Y8J^;8GZIS5<\HTJ&:.52O*.*HT:$L-3@X2J.%)*A.4&
MZ,:;E?FDW))KJGXI<=3RS@#)UGLJ>!\+LPQN:\"PHX#+*%7(LPS#-*&=8G$P
MQ-+!PQ.-F\RPU#$TXYC5Q=.A[-4J,(47*F_RR_X)L_\ !,/2_P!@34?B7XIU
M/XE6WQ5\:_$'3]%T"VU6V\&MX2M_#'AK2;R]U"\TVT$WB/Q%<7[^(;]]*O=2
MD=K&.!M$L((H9]CW+Y?[07_!+Z[^./[>7PF_;/B^-%OX;L?AUXC^$7B2^^'\
MG@.35KO5)_A'XAL_$%M9VGB-/%NG0VT/B)K&*RGN)M%F?1P\EW'#JQ"VM?K#
MYY_O?^A4>>?[W_H5<L>%<CCEF$R>. Y<OP6*AC</05?%)PQ5.I.K&M*LJWMJ
MKYZDVXU:DX-24>7EC!1]RIXZ^*57C;/_ !$J\3NIQ=Q/D>)X:SC-)Y3DDH8C
M),5@\+@*F HY>\N>6X."PV"PT85,'A*%:-2FZWM76K5YU?RR_P""E/\ P30O
M/^"@&J_"'5['XQ6WPMG^&5MXJTNZ@O/ TGB^+5[#Q5<Z#=27<#P>*O#;V=WI
MCZ$$2TD6XAU!;TEKS3S: 7?Z;>"?#W_"&^#/"/A!;TZ@OA7PQH/AM;]K=;5K
MY=#TJTTP7C6PEN!;FY%J)C )YA"7\L32;=[:_GG^]_Z%1YY_O?\ H5=V'R?
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M;XE25?GBFH17L(R5!+:DGJ?:T_'CQ3I9O@<]AQ-%9IEWA]'PNP>)_L7(&J/
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MN!R+!Y=AUF'M4ZD<?4A4Q=-RE&E6A"3@?S9ZY_P0!\9>%O%^LW7P"_;%\0>
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M2R?BKCG.L6\ZQ^ KYI/AC%<38;!XS#Y;@L[SS'RJ8+!0I8/#8>-:G_0P+A&
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MO$6LZ=<W\0N 8#):QRIYP,6[>-M?D7\/SX!_9[_X*%?ML>(/A!HFB>#?A/\
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MK974/$L.I7NGK/<-ID-BRM;W#V_GPQN<^QE3Q>*Q]:OC^*9X65/+8\]7"X+
M9;]9Q^%P+A%2]A2S"C5P/MG^\G3M5G+GE.1]76X7\/)8ZEBL@R'A? Y;PKX(
M8;.:6+XRJRH8'/.)>)^,8Y/POG7$RQ%2=-YCCN%,PP7$CRZG?"X;&.I@\/!X
M:A2@?;O[-G[5WQYU?]I;XA?L@_M2>!?AGH_Q4\)_#JS^+GAKQU\%M1\3R?#O
MQEX&O=8T_1#Y>C>,I[SQ%H^I65_J4-K*UWJ,JW5W::I''9P6MM9WNI<?\<OC
M3_P4Z\&^'_B-\6O!?P7_ &3_  ]\+OAO;>+?$$W@;QYXW^(OC'XR^*?!OA":
M]NY-9TR[\$'1?A[I6I:]X=L'U:PT.YU34KG3I+A+&YDO+V$VUQZG^S#^R]XB
M^%OCGXD?M ?&_P ?6/Q7_:3^,-MI.F^*O$^CZ,?#_@WP5X3T:.,Z9\.?AQI$
MT\]]!X;L)HK?[5JNI2)J?B%].TV_U&TM]02\FO? ?VFOC!XD_;%USQ-^Q'^R
MQJ8NM+NYO^$?_:L_:!M[22^\#?"CP1<#;KWP[\-:MD:;XH^*WBFU9M);2=.F
MNK?1[1]3L[V>SO8-<U+P;ZM>.8T,C7U['YI0S"OB<;#*,%0K8-YKB?:U)O+,
M)B9PH5(5:]"DHU,3.%14*%%U*F/K584)UE\/EL>$LR\2G/AOA7@;,N%,NR?A
MBMQ_Q#F> XB7!.2/!8;#0XTSS)L+B<QP5?!9;FF.G5PF48?%82699CF$<)A>
M&<#@<1F6'P$_O[]F/X[6'[2/P"^%?QQL-'F\/1?$7PK:ZW<Z#-=&\.C:K'-<
M:;K>F17OEVQO[2RUBQO[>ROVM;5[ZSC@NWM+5YFMX_2=6^(W@+0=:'AK7/&W
MA'1?$9\.ZAXO&@:MXET?3M:/A/2;B*UU7Q.-*O+^&^/AW3+J>"VU#6O(_LVR
MN)HH;FYCDD13RGPP\!>%/A!\._!?PN\#6)TSPCX"\-Z3X6T"S9UDG73](M([
M6*>\G18A=:C>&-KS4KUHUDOK^>YNY1YLSD_DOK7P=\,?MA?\%/\ XQ2?$(2>
M)O@_^S-\'OA9X)USP+=2SCPWXP\:^*KZ^^(.E:)XEL]\<>M>&],G/_"0:QH$
MAFTK5-:T/PL-9M[RUM#:R>UB\7F678+)Z+IT,=FV.KX/+ZBE4>'H3Q/U6KB,
M;B7*%*<H4:=/#8BL^2C)J"2C3D[0?YSD/#/"7%W$GB%F$<9F7#/ ?#>6<0<5
M865/"QS7-,-D_P#;N!RKAS*%2Q&+H4\1F&*Q.=95EREB,=1ISKS<ZV*IPYZ\
M?V ^'OQ@^%/Q<T^^U?X4_$SX?_$[2M+O%T_4]3^'OC3P[XTT_3K]X4N%L;Z]
M\-ZIJ5M:7C6\B3K;7$L<S0NDH0HP8X^N_M _ OPO!JMSXE^-'PG\.VVA>)O^
M$*URXUWXC>$-)@T;QE]GMKO_ (1+59;_ %NWCT[Q-]EO+.Y_L&\:'5?L]U;3
M?9/+GB9_R_\ @7X8\ ?#S_@J/^TQ9_!WP]X8\!?#;PQ^R[\/4^*>@>#=$MO#
M_ABW^)5_XC36M&NCI>D"UT6RU+_A"XYKF?[+8Q-<&6^N' O)M1EN_+_^"</[
M*OPE^-_A;XH?M=?&_P ':'\5+SXZ?&SXP>-OAQH7C_3H?$GA?P7X7U'QG<VE
M[KVB>&-:6YTJQ\5^*-2T&$WWB,Z>-9&C>'_#4-E=6R)<FZ\VCGF:XFIA,#A\
M'@)X^KB\[P^(J2Q%98*E0R6O2PU7%PY:4J\HSKUZ%#V+C>->4J;J*,757U^.
M\+>",HPN>\1YMQ#Q-A^%\#D7AOFN58.CE675.(\;F?B)E>+SC!Y#B?:8RCEM
M&KALMRW,,Q_M",_9U<LA1Q<,(ZU6G@JG[4>/?B_\*OA5IEGK7Q0^)GP_^&^C
MZA-]GL-6\>^-/#O@_3+Z?:C^19W_ (AU33K6YFVR(WEPRN^UT.W# F:T^+'P
MQO\ P-/\3['XB^!;WX:6NFW6LW/Q#M/%^@7/@:VTBQ1I+W59_%L.I/H$.FV<
M:.]U?2:@MK;HC--*BJ2/R7_8F^&W@/\ ; UCXS?ME?'SPQX6^+NI>,_BEXR\
M _!G0O&^E:;XP\(_#+X/_#_4SH.C6/A/P[KMM>Z/I.K:Y=V]W>:YJ]K:"[OW
M7[7'+;RZOK)U#*_8KTOX;^!_'?\ P5'T_1=&T)/V5?"OQ2MTLO LNEQWGP_T
M_6_#W@/4;SXRV&F^'KA;K0TTM;N#3["XTFSTS[+'8:?I5C'"]C:Z?:V]T,]Q
MM>>6U_J^#IY?G+QJP$Y5ZKQ5.EAL'B<90Q^+@J:I+#8FEAKRITINI06(PZE4
MG.4XQYLR\*>',MPW%^6O.,_Q?%OA[#ANKQ3AJ.68*&2XO&9QG^3</YGPQD>)
MEBJF-EG648O.7&CC,7AHX;-)93FLJ>#PU&E0JUOL']G3_@H?\#OV@_B#\5_
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M8[)<RS7..%<PS[*,MRWBJC+.<!1RZGF./Q^2YEA<N>/Q=:AF-(_<N_\ C?\
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M;PGJ#/HVO7F@6^H2Z=X4DU6PO;/2Y_$'BF[M(OMTMO<VWKW_  2YTOP_9_\
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M%8[-N(\PXDPW#:RO*Y96\/PQ6S+,LERK(,9Q1A\1C(YTLMXCS#-:F!PN:X'
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MEX8\*>(9H[I-0FT>?QY:WEQXCTV6Z=;JZ.E7+M]NL[2[M:OQ_P#@-^SK;?\
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MZSX\\<>)?&UT)_$7B*ZU*Z2VO]:M=2N[O18;F[LOLMA;_8-'MX?7OVO/A_\
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M/_Q5'GKZ_P#CQ_\ BJP?M7O^O_V5'VKW_7_[*CD?=?C_ ) ;WGKZ_P#CQ_\
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M?A\5@J[HU8QJ1AB</6I.44Y0=C\Q]7_86_:0^*NE2>"?VEO^"A?Q-^)OPKO
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MORL'4?;%_O?S_P :/MB_WOY_XUR_VQ?[W\_\:/MB_P![^?\ C1[/RE^/]?\
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M-\5O^"B;'/\ P[8P?7_AL;X'?_*__/7K7Z\45R_6*W\__DL?_D0/R";XH_\
M!15O^<;>/^[Q/@=U]?\ CPZ_Y]:A/Q-_X**D8/\ P3=_\W"^!W_R#7[!T57U
MJNMII?\ ;D/_ )$#\>A\2O\ @HJ.O_!-[/\ W>%\#A_[94A^)/\ P43/_.-S
M\1^V'\#_ /Y"K]AJ*/K5?_GY_P"2P_\ D0/QW_X6/_P44_Z1O?\ FX7P/_\
MD.C_ (6/_P %%/\ I&]_YN%\#_\ Y#K]B**/K5?_ )^?^2P_^1 _'?\ X6/_
M ,%%/^D;W_FX7P/_ /D.C_A8_P#P44_Z1O?^;A? _P#^0Z_8BBCZU7_Y^?\
MDL/_ )$#\=_^%C_\%%/^D;W_ )N%\#__ )#H_P"%C_\ !13_ *1O?^;A? __
M .0Z_8BBCZU7_P"?G_DL/_D0/QW_ .%C_P#!13_I&]_YN%\#_P#Y#H_X6/\
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M )^?^2P_^1 _'?\ X6/_ ,%%/^D;W_FX7P/_ /D.C_A8_P#P44_Z1O?^;A?
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M'R_/NP/Q^_X2+_@I/_T93\//_$E?!_\ \@T?\)%_P4G_ .C*?AY_XDKX/_\
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M_#S_ ,25\'__ "#1_P )%_P4G_Z,I^'G_B2O@_\ ^0:_8&BCZU7_ .?C_P#
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MR_\ @IY_T;I^SQ_X>;4O_D"OU[HH^LU_^?C^Z/\ D!^0GE_\%//^C=/V>/\
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MC\WG02Z'8>1%$ 0ACF_>EU+#Y"*_7BBCZS7_ .?C^Z/^0'Y%?\(M_P %4/\
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MEY?GW8'Y%?\ "+?\%4/^A _8T_\ "W^*?_R!1_PBW_!5#_H0/V-/_"W^*?\
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MW_!5#_H0/V-/_"W^*?\ \@5^NM%'UFO_ ,_)?A_EY?GW8'Y%?\(M_P %4/\
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M_P _S'6O&;:X((!.#Q_G].WICJ/EZJ#=2G)R=WS-)V5]%'MZ@=A"_3/7M_\
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MWC'05;6-+\$>'="TZ_TV233=6^U6C7*:D ?L/_P7M_X*[W_P/_X)RZO\?O\
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MMC^T%-'!'9Q07=Y)]=_\&\ZJG_!3W_@X[1%"JOQ[UU550%557XT_M.@*H&
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M:QXEGLO'OBS2_"&K?WKQQI$B11(D<4:+'''&H1(T0!41$4!515 554 *
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M,]]X@\-0_$'Q'X2\41W<K6/C$^!=%@\=:/J$FCVMC9_I!_P;E_LG_LS? ?\
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M2P0^(O!^JZSI$LT9!#Q)>,Z$8917\-7P6_9A^"O_  6[_P"#A_\ X*<>&_\
M@H3/XJ^)'PS_ &.+/7OAQ\$/V=[KQWXU\!Z<WAGP9XZ@^&<.IZ;<^"=?\/\
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M&F>*]%@U>R26XCM=3@T_5;>&_MXKBXABNTE2&XGB"2O_ !)_\%#_ (G?$/\
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M#*Z^%_[1\/ACP[+9:1\%_@1:G6-.UBU\3W5[.?!,TSP:C9J^NWZHEM8?4O\
MP2,GTSP3_P '8/\ P55\._&B?3[+XG^+K/\ :7_X5(WB"6VMK_4++5_BM\-/
M'FAZ9X:CO6M)[O5;KX)Q6^L6J:=9W-S)X2TC6KM+AM-2[N+D _;O_@G-^VA_
MP74\9_M-Z1\#_P#@J+_P3;^%OP-^'7C7P=XO\1^&OCS\ ?$7]O\ @_PIJ_A.
MTM[FW\,^.CX<^-/[2&@VU]XKDG:UT,:UXN\!7,DL$GV"RUU@T4?V1_P6<_;<
M^*W_  3K_P""=/QV_:Z^"?A_X>^*/B3\,+KX:0:!HGQ3TKQ)K?@>\3QG\4?!
MW@G5#K&F^$O%G@C7KAH-*\0WMQ8&R\2Z>(M0BM9;@75LDMI/^I-?SX_\'2G_
M "A#_:]_["'P&_\ 6@OAC0!]Y_L>?MY^%_B/_P $W/V9OV[/VNO'OP/_ &>K
M/XM?!WX=^._B)XH\0^+=.^%?P:\,>)O' MK2WTW3]>^)OBVZBT:QU'6;NWT[
M0['7/%FHZA<W5S;6*7M[=2IYGT7J7[9'[(6C?$?P9\'-8_:J_9NTKXN_$:RT
M#4OA[\*]2^.7PQL?B/X\T[Q7;_:O"VH>#/ ]UXHB\3^*++Q+:D7.@76B:7?0
M:S;_ +[3I+F/YJ_C^_;T_P"5,O\ 9^_[(I^Q1_ZM[P%7Y=?\%%_^"1/[(O[/
M7_!O]^R3_P %$_"4'Q3UG]LSXJ0_LO?$KQ_\;/%GQ2\5ZYJ7B*3X[^!U\3:M
MX6F\.7%[_P (G8:%X/N;BRM_!NI:1HFG^,X(=)LCKWBO7BURLX!_HK:I^UE^
MROHGQFTO]G+6OVE_V?\ 2/VA=<-N-%^ ^J?&7X<V'QFU@W=K<WUJ-+^%]WXC
MB\;Z@;FRL[R\MQ::',9K6UN;B/=#!*Z:/QJ_::_9N_9LT[3=7_:*_:#^"'P#
MTG69)8M'U/XU?%?P'\+-.U66!X(YX]-O?'.OZ%;7TD,ES;)*EK+*T;W$"N T
ML8;_ #O/^"NW_!(C]E_]CK_@C1^QI_P4$^%VI?%:[_;9\=>-?V>?B#\7OVA_
M%'Q/\<Z]XI^)GB?XX?#C7OB=XAU&ZTS4?$-SH7AK4/#_ (X33M3\*:]X>L+7
MQ3';6!3Q-KWBC5[N?7*^Z?\ @IU/^P+^U-_P41\!^ +G_@G3^T]_P5[_ ."A
MDG['_P !Q\3?A!X6_:/U;]FKX!_"GPQ!H!\:Q^(+CQG\/K*#QA:^-[VV^).F
MZKXMBUB1/AC8P:_X-M--NK'Q3JGB&SH _N%^%OQ?^$WQR\'6'Q$^"?Q0^'?Q
MA^'^J230Z9XY^%OC;PU\0?!VHS6^S[1%8>)O"6IZOHMY)!YD?G1V][(T7F)O
M"[US\^_$?_@HG_P3\^#OC#5_A[\7/VZ?V.?A9X^\/S?9M>\#_$?]ISX*>!_&
M&B7&2/(U?PSXF\;Z7K6FS95AY5Y90OE2-O!K^(3_ (-X]1\<_ GXW_\ !?+X
M)Z7I6J?L,>'_  /\!/&/C2Q^&?C_ .*TOQ*L/V4O&?A"3XBZ;HU[K_Q+MK"W
MMO$DGPNT[6&BUGQNN@OJ^I:;H%G/=K=W-F5F_+7]GC]G/4_VJ?\ @E'X=_9S
M^#__  1$_:6^-/[;7QQ^*EYXA^'G_!3"Q\)>)K7X1ZEI3_%2X>^U_5?CEX@M
M]-\+:/:6>AZ-KOPNU;P?XKU_2? 4=PTOQ"U?6;;Q*R6S@'^IQ\._CI\$OB]\
M-X_C)\)_C%\+/B?\(9H-:N8?BK\._B#X2\:_#>6V\-W%W:>(KB/QSX:U?4_#
M$D&@W=A?6NM2KJACTNXLKN"^:"6VF5. ^#W[9?[('[0WB76/!GP!_:L_9M^.
M7C#P];R7?B#PI\'OCG\,/B9XET.UAG:UEN=8T+P7XHUO5-,MXKE'MY)KVU@C
M2=6A9A(I4?Q(?\%_?A1J_P#P34_X)1?\$N_^"8?P:TSQ/X6^'WQA^(+P?M0:
M9\$];\2>)-7^+?COPSI/@K6?'F@>'QXMU6[\1>);;XB?%7QYK7C7PYX6N[2+
MP_)K'A[PEIT6DZ%I^G:7H8_/#XS?LQS> ?BM^Q?\9O\ @D1_P11_X+-_L:?M
M"? ;XQ^$-:\8>.OC'\$/VA?%GA#X@^'[.6S6?5O$SZG<^+DTC5KF\MC8^)M-
MT*+P;\.=;\&^(?%NEZUHBV;64$(!_I"?&7]L/]DC]G/6]$\,_M"?M2_LY_ C
MQ)XF@^T^&_#_ ,9?C=\,_AAK?B"V\];;[1HFD^-_$^AW^JP?:76W\VPM[B/S
MV6+=YC!3[YI.K:5K^EZ=KFA:GI^M:+K%C:ZGI.L:3>VVHZ7JFFWT*7-EJ&G:
MA9RS6E]8WEO)'<6MW;32P7$,B2Q2/&ZL?\ZG_@IY_P $^/'O[+'_  4F_;$_
M;H_X**?\$WOB%_P4_P#V#OCSXAE\<:7\7OA#\;?BCX+\9?LR^%K>VCN)7\0:
M/\)/$>AWNFZ7\*_!MA'X0$7Q3T?3OA=J&D:-X5FTKXIZ9J)UZT?^S_\ X)!>
M)?V4O%'_  3A_99NOV)/$/CSQ'^S-IG@2\\/_#6;XI_V</B9H]MH?B;7-/UK
MPKX]32;2RTQ/$_A3Q#%JOA^_;3X[BPN!I\5W8ZGK-G<6^L7X!^D]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!R7CEMOA;5&]/L/_IRLQ_\ KKPV
MVE##.>0.#G^?/_UP,G@FO;O'QQX2U8_]>'ZZG9CGV]?:O ;23'!_7I_]?/\
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MN5FN?%.KI&87+F3^J;X&_L!_!KP#_P $X?AU_P $Y_''AVQ\7?"'3?V:=,^
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M#^;W]JC_ (-\A^TS_P $I?V-_P#@F*?VN#X*'[)7BOPQXF/QN'P%_P"$C/Q
M'ASP_P#$+038CX;'XT:$/"AO1X\^U"Z_X3WQ+]F_LKR/L]Q]N\VS_5']N?\
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M\4>,-?\ B-I_C:]M_'-UXC\37.KZE!9OX(\-7>G6=[;6>HZUXAU"TNM:U/\
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M3TCPU<^)#\1O C^$[T6?PFM[&[\0OH_BQ[NYUN?4Y=+,MH;>]_>BB@#^;?\
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MPZ%WH6EV^N^&_ 'PK^%HU_2]/T^PEN[06S33_IS\=?\ @D0GQK_X+ ?LN?\
M!5Q_V@F\-C]FOX72?#=?@*OPI&K_ /"9N^G?%ZQ76S\4C\2-,_X1Y5/Q5$S:
M8/ASKA<:#Y0U%#JGF:=^S:JJJJJH55 554 *J@8"J!@     # ' I: /SH_X
M*=?\$QOV=O\ @JQ^SFW[/?[03>)M"31/$MGXZ^&WQ)\"7=A8^./AOXYTZSO=
M.BUC2)-5L-4TK4]*U32]1O\ 1?$WAO5["XL-8TJ\:6UDTGQ'IWA_Q%HGXL?!
MG_@VH^/^C_$KX8:O^U-_P6Q_;A_:L^!WPD^('@'XB^%OV>M<N/'F@^$+K5OA
MCXJTGQ7X-TW73X[_ &@OC3X9N-$LKK0].MKFWT?P'H5\(8FDT?4=$F%N]O\
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MAWP1^W+H>CS:Q>VFG:?:W>IR6;7MQ;V-G!-.\5K J?U;_L6_ ?XC?LQ?LO\
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M1O\ P<*?L9_L\_%WXS?"RS^#G[:_[0FB?LSZ_#X7_:D^.G[-/[.5U\2_V?\
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MSX ZO<>*_&VA7&N>+?!/B?Q5H$?_  K?PUKZPCP9J_AF]D#7;)?Q:BVGWM@
M?UKT5_-A_P %3O\ @JY\6S^Q3^Q'JO\ P3=\<:?X-_:-_P""BFFVWQ1^$OC'
M6O#/A'QG)\,O@+\./A'<_'WXZ^+M4\+>+=(\7>&KK6?#'AFRL/"&HZ?JGA[5
MX;:?4]>^RR6>L:98WD/R7\2?^"AW_!6+4O\ @WL^"W_!13X8?'?X&^$O'FF_
M '7/'_QZ^+OB;X3:-XH^,/C#QK#\<5^&?A+2OAK\-[;P_I'[/W@_3+S19)M3
M\7^)]>\-^)%2ZL[73_#_ ,/[7[9<:O;@']@=%?FQ+<_MN?M&_P#!/[]F#5_V
M;_CU\,?@K^T%\8OA%\!_%'Q._:"^)/PHMOB=-X3TGQA\)[+Q#XZ\9_#WX2:9
M>>$_ >N_$>Z\67NER:)H/BB32_AY9Z=>:TTU@WV32].D_-'_ ((F_MO_ +=O
MQ:_;*_X*8?L,?M>?&7PK^U]HG[$7CKP_X:\+?M;>&/A+X3^"\VM^(-0UCQ!H
MVL> O$?@_P"'EE:^!X+^!=%GFATVS$VM>&=6\.^*M.U'Q!XPL;S2KW2@#^E6
MBDR/4?F*_C-_X*@?\%<_^"@_[''_  5N^(5CX#^*%A/_ ,$_OV1/ 7[(WQ4_
M:?\ @;'\+_AKK&L:W\*?C9X\T+X9^/?%6D>.+SP9<_$JWU[2=<\=:!=:;::?
MXYT;2HIX-.\RW-BNK6^I ']F=%?RF_\ !PI_P5+_ &NOV=S\/_@[_P $X/BU
MH?P\^(OAC]G3XB_MT_M!?$[_ (0KX=?$J'2/V<?#-]HGP^^'6C:5IGQ#\*^.
MO#BM\3OB)XI$2:DNAVNH6HTC19;/5DTZ_P!4MKC*_P""I_[>O_!5#X _L2_L
M._M9_!SXW? WX6_#GXLP?L0:!XWN=,^%FG>/?CG\2/B)\=/"G_"1?$Z;45\>
MZ+>_"#X9_#VSCM4BT6P\+>$O$_BO5+O4[R6/7O!]K86=G< ']8]%?@3_ ,%V
M/VWOVH/V0=$_9#\.? _XJ^'/V2OA3^T'\9=9^'G[07[?OBWX-'X]^'OV4=+M
MM,TB?P))=_#V^BF\)O/\2M<U#4-*@UWQHC:#IL.@W<<TFG_:GUK2JG_!"[]K
MO]L']IFZ_;5\+_'SXXZ%^VK\!O@?\7O#7@S]F+_@H)X;^".A_ #P]^TU%-IN
MO1_%C3?#W@WPG';^"]8T+X6>)M*TO0K3Q;X1BU'2-4NM2OS%XI\36IL+JV /
MZ :*3(]1^8K^,W_@J!_P5S_X*#_L<?\ !6[XA6/@/XH6$_\ P3^_9$\!?LC?
M%3]I_P"!L?PO^&NL:QK?PI^-GCS0OAGX]\5:1XXO/!ES\2K?7M)USQUH%UIM
MII_CG1M*BG@T[S+<V*ZM;ZD ?V9T5_*;_P '"G_!4O\ :Z_9W/P_^#O_  3@
M^+6A_#SXB^&/V=/B+^W3^T%\3O\ A"OAU\2H=(_9Q\,WVB?#[X=:-I6F?$/P
MKXZ\.*WQ.^(GBD1)J2Z':ZA:C2-%EL]633K_ %2VN+'_  4+^-W_  5Z\#?\
M$\XO^"E/PP_X*$_ []F[X:_#+]E/]G+XN6GP=L/V6? ?Q&\3?M!^,?B!X&^&
M%SX[B^)OQ)^)K:GI?PUU36?B-XHU?1/ASX:^$_@>33KO2[S1[35=4T[5+UKS
M2 #^JJBOY]_B%_P54_:!TS_@E#^QI\8O#_PST-/^"EG_  4+\#?#+X??LT_
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MN_'G@_Q?<Z!:Z5\+?#FI>(I[[PQ>>%=6=]8UJWN+J:YL=$N;/8_X*[_MP?\
M!2+]COQY\1?B%\%O^"L7[(&K_%[P]\<? WA/X1?\$=/AE^S]\+_BU\9OB)X
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M^$]0UC2M=^%_B.SLM.F\6:IXJUB_UO\ X1V"">*\EU>\U  _M!HK^-SXV?\
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MC?7O#=EX]M])L-<D_M6RL]"T+4]4EL/M\&FOI$UV ?O?129'J/S%&1ZC\Q0
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M !%/_J1?^93_ /!Q^Y-%?AMD>H_,49'J/S%']D_]1'_E+_[H'_$4_P#J1?\
MF4__  <?N317X;9'J/S%&1ZC\Q1_9/\ U$?^4O\ [H'_ !%/_J1?^93_ /!Q
M^Y-%?AMD>H_,49'J/S%']D_]1'_E+_[H'_$4_P#J1?\ F4__  <?N317X;9'
MJ/S%&1ZC\Q1_9/\ U$?^4O\ [H'_ !%/_J1?^93_ /!Q^Y-%?AMD>H_,49'J
M/S%']D_]1'_E+_[H'_$4_P#J1?\ F4__  <?N317X;9'J/S%&1ZC\Q1_9/\
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M1'_E+_[H'_$4_P#J1?\ F4__  <?N317X;9'J/S%&1ZC\Q1_9/\ U$?^4O\
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M,)\TDZG+!Q7/S+[FHI,CU'YBC(]1^8KS3]%.(^)'_(EZS_W#O_3K8U\WV@!
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M;_XCMX;UY5\<Z]HHCL_!VC6$%EH?%K]D#_@JWX4_X-_OV>/^"5?PO_X)X?\
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M,&5BI!K^87X.?L<_&C]LSQM_P55^$^G_ +5*_!C]G'QC^W[\1?#OQB^&>B_
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M)_")T;Q1>:=8>#=7U6?P=H5O O\ PCN@:1)JGB237> _X* ?#;XC^ OVH_\
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M\UI0W?I^J Q;KHWT/\EKE[KHWT/\EKJ+KHWT/\EKE[KHWT/\EKKI=/\ $OT
MY>ZZ-]#_ "6O2_A!][Q'_P!P?^6IUYI==&^A_DM>E_"#[WB/_N#_ ,M3K7%?
M[I5]8?\ I< /:J_F$_X<N?\ !9'_ *62_C__ .(?:%_]$S7]/=%>(!_,)_PY
M<_X+(_\ 2R7\?_\ Q#[0O_HF:/\ ARY_P61_Z62_C_\ ^(?:%_\ 1,U_3W10
M!_,)_P .7/\ @LC_ -+)?Q__ /$/M"_^B9H_X<N?\%D?^EDOX_\ _B'VA?\
MT3-?T]T4 ?S"?\.7/^"R/_2R7\?_ /Q#[0O_ *)FC_ARY_P61_Z62_C_ /\
MB'VA?_1,U_3W10!_,)_PY<_X+(_]+)?Q_P#_ !#[0O\ Z)FC_ARY_P %D?\
MI9+^/_\ XA]H7_T3-?T]T4 ?S"?\.7/^"R/_ $LE_'__ ,0^T+_Z)FC_ (<N
M?\%D?^EDOX__ /B'VA?_ $3-?T]T4 ?S"?\ #ES_ (+(_P#2R7\?_P#Q#[0O
M_HF:/^'+G_!9'_I9+^/_ /XA]H7_ -$S7]/=% '\PG_#ES_@LC_TLE_'_P#\
M0^T+_P"B9H_X<N?\%D?^EDOX_P#_ (A]H7_T3-?T]T4 ?S"?\.7/^"R/_2R7
M\?\ _P 0^T+_ .B9H_X<N?\ !9'_ *62_C__ .(?:%_]$S7]/=% '\PG_#ES
M_@LC_P!+)?Q__P#$/M"_^B9H_P"'+G_!9'_I9+^/_P#XA]H7_P!$S7]/=% '
M\PG_  Y<_P""R/\ TLE_'_\ \0^T+_Z)FC_ARY_P61_Z62_C_P#^(?:%_P#1
M,U_3W10!_,)_PY<_X+(_]+)?Q_\ _$/M"_\ HF:/^'+G_!9'_I9+^/\ _P"(
M?:%_]$S7]/=% '\PG_#ES_@LC_TLE_'_ /\ $/M"_P#HF:/^'+G_  61_P"E
MDOX__P#B'VA?_1,U_3W10!_,)_PY<_X+(_\ 2R7\?_\ Q#[0O_HF:/\ ARY_
MP61_Z62_C_\ ^(?:%_\ 1,U_3W10!_,)_P .7/\ @LC_ -+)?Q__ /$/M"_^
MB9H_X<N?\%D?^EDOX_\ _B'VA?\ T3-?T]T4 ?S"?\.7/^"R/_2R7\?_ /Q#
M[0O_ *)FC_ARY_P61_Z62_C_ /\ B'VA?_1,U_3W10!_,)_PY<_X+(_]+)?Q
M_P#_ !#[0O\ Z)FC_ARY_P %D?\ I9+^/_\ XA]H7_T3-?T]T4 ?S"?\.7/^
M"R/_ $LE_'__ ,0^T+_Z)FC_ (<N?\%D?^EDOX__ /B'VA?_ $3-?T]T4 ?S
M"?\ #ES_ (+(_P#2R7\?_P#Q#[0O_HF:/^'+G_!9'_I9+^/_ /XA]H7_ -$S
M7]/=% '\PG_#ES_@LC_TLE_'_P#\0^T+_P"B9H_X<N?\%D?^EDOX_P#_ (A]
MH7_T3-?T]T4 ?S"?\.7/^"R/_2R7\?\ _P 0^T+_ .B9H_X<N?\ !9'_ *62
M_C__ .(?:%_]$S7]/=% '\PG_#ES_@LC_P!+)?Q__P#$/M"_^B9H_P"'+G_!
M9'_I9+^/_P#XA]H7_P!$S7]/=% '\PG_  Y<_P""R/\ TLE_'_\ \0^T+_Z)
MFC_ARY_P61_Z62_C_P#^(?:%_P#1,U_3W10!_,)_PY<_X+(_]+)?Q_\ _$/M
M"_\ HF:/^'+G_!9'_I9+^/\ _P"(?:%_]$S7]/=% '\PG_#ES_@LC_TLE_'_
M /\ $/M"_P#HF:/^'+G_  61_P"EDOX__P#B'VA?_1,U_3W10!_,)_PY<_X+
M(_\ 2R7\?_\ Q#[0O_HF:/\ ARY_P61_Z62_C_\ ^(?:%_\ 1,U_3W10!_,)
M_P .7/\ @LC_ -+)?Q__ /$/M"_^B9H_X<N?\%D?^EDOX_\ _B'VA?\ T3-?
MT]T4 ?S"?\.7/^"R/_2R7\?_ /Q#[0O_ *)FC_ARY_P61_Z62_C_ /\ B'VA
M?_1,U_3W10!_,)_PY<_X+(_]+)?Q_P#_ !#[0O\ Z)FC_ARY_P %D?\ I9+^
M/_\ XA]H7_T3-?T]T4 ?S"?\.7/^"R/_ $LE_'__ ,0^T+_Z)FC_ (<N?\%D
M?^EDOX__ /B'VA?_ $3-?T]T4 ?S"?\ #ES_ (+(_P#2R7\?_P#Q#[0O_HF:
M/^'+G_!9'_I9+^/_ /XA]H7_ -$S7]/=% '\PG_#ES_@LC_TLE_'_P#\0^T+
M_P"B9H_X<N?\%D?^EDOX_P#_ (A]H7_T3-?T]T4 ?S"?\.7/^"R/_2R7\?\
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M8QA5I0C0K02K.I/#RC.51PH<E&,ZE2,(5*M:=*FF\/4E+] :***U/*"BBB@
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M,PUV>-U+*\I9[;3BAC\RU:XGD66*>R=/F?X$_"B;XF>*%>_BD3PIH;Q76NW
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M-W97UE=PI<6MY9W5N\D%S:W,$D<UO<02/#-"Z21NR,K&U7QE_P $[+;7[/\
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M:U^L8?\ Y_T?_!L/_DCR_P#5_/O^A)F__AMQO_RD\-HKW+_AFWXT_P#0F?\
MEQ>$_P#Y>T?\,V_&G_H3/_+B\)__ "]H^L8?_G_1_P#!L/\ Y(/]7\^_Z$F;
M_P#AMQO_ ,I/#:*]R_X9M^-/_0F?^7%X3_\ E[1_PS;\:?\ H3/_ "XO"?\
M\O:/K&'_ .?]'_P;#_Y(/]7\^_Z$F;_^&W&__*3PVBO<O^&;?C3_ -"9_P"7
M%X3_ /E[1_PS;\:?^A,_\N+PG_\ +VCZQA_^?]'_ ,&P_P#D@_U?S[_H29O_
M .&W&_\ RD\-HKW+_AFWXT_]"9_Y<7A/_P"7M'_#-OQI_P"A,_\ +B\)_P#R
M]H^L8?\ Y_T?_!L/_D@_U?S[_H29O_X;<;_\I/#:*]R_X9M^-/\ T)G_ )<7
MA/\ ^7M'_#-OQI_Z$S_RXO"?_P O:/K&'_Y_T?\ P;#_ .2#_5_/O^A)F_\
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MTB[NM-MH8K.XEA?ZU_X9M^-/_0F?^7%X3_\ E[1_PS;\:?\ H3/_ "XO"?\
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M  ;#_P"2#_5_/O\ H29O_P"&W&__ "D\-HKW+_AFWXT_]"9_Y<7A/_Y>T?\
M#-OQI_Z$S_RXO"?_ ,O:/K&'_P"?]'_P;#_Y(/\ 5_/O^A)F_P#X;<;_ /*3
MPVBO<O\ AFWXT_\ 0F?^7%X3_P#E[1_PS;\:?^A,_P#+B\)__+VCZQA_^?\
M1_\ !L/_ )(/]7\^_P"A)F__ (;<;_\ *3PVBO<O^&;?C3_T)G_EQ>$__E[1
M_P ,V_&G_H3/_+B\)_\ R]H^L8?_ )_T?_!L/_D@_P!7\^_Z$F;_ /AMQO\
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M .7M'_#-OQI_Z$S_ ,N+PG_\O:/K&'_Y_P!'_P &P_\ D@_U?S[_ *$F;_\
MAMQO_P I/#:*]R_X9M^-/_0F?^7%X3_^7M'_  S;\:?^A,_\N+PG_P#+VCZQ
MA_\ G_1_\&P_^2#_ %?S[_H29O\ ^&W&_P#RD^2_B7\)/A3\:/#J>#_C%\,O
MA[\6?"4>I6NLQ^%OB7X+\-^._#L>KV"3QV.JIHGBG3=5TQ=2LX[FY2UOEM1=
M6Z7$ZPRHLL@;0UCX<_#WQ#XG\%^-=?\  G@W7/&7PW.MM\._%NL>&-$U/Q/X
M";Q+IT>C^(SX+UZ]L9]5\+'Q!I,46EZV=#N[$ZKIT<=C?^?;(L0^I/\ AFWX
MT_\ 0F?^7%X3_P#E[1_PS;\:?^A,_P#+B\)__+VE[?#;^VH7=K_O*>MG==>C
MU79[%K).(DHQ649THQY^5++\<E'VL>6IRI4;+VD4HSM\<5:5UH?%'@[]G/\
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M3M+TJ.\O9$1[NZ2T$]RZJTSNR@CZP_X9M^-/_0F?^7%X3_\ E[1_PS;\:?\
MH3/_ "XO"?\ \O:/;X6_-[:AS/>7M*=_OO<3R;B25*-&659XZ,7>-)X''NE%
MZN\:;I<B=VW=*^K[L\-HKW+_ (9M^-/_ $)G_EQ>$_\ Y>T?\,V_&G_H3/\
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M2C"+=VH)T6HIO5J-E<\-HKW+_AFWXT_]"9_Y<7A/_P"7M'_#-OQI_P"A,_\
M+B\)_P#R]I_6,/\ \_Z/_@V'_P D1_J_GW_0DS?_ ,-N-_\ E)X;17N7_#-O
MQI_Z$S_RXO"?_P O:/\ AFWXT_\ 0F?^7%X3_P#E[1]8P_\ S_H_^#8?_)!_
MJ_GW_0DS?_PVXW_Y2>&UT'A;PSJWC'7],\-Z);FXU'5+E8(@=PBA3EI[NY=5
M8QVMI"LEQ<R;6*0QN55FVJ?4O^&;?C3_ -"9_P"7%X3_ /E[7V1^S[\&I/AQ
MI%QK/B*VB7QEK*F&XC62"Y&C::DFZ/3H;FW>:&2:Y=$NK^6"9XG9;:!&9;4R
MS8U\91I4Y2A4IU)[1C&<9:O9OE;M%;O:^U[L]?(^#\US+,:-#&8#'8#!Q?M,
M5B,3A:^&7L8-<U.E*M3BI5JEU""7,XW=1Q<(2/6_ '@?2?A[X7T[PSI"AH[5
M/-O;QD5)]2U&8*;N_N,9)>9U"QH6?[/;1P6J,8X$KLZ**^<E*4Y.4FW*3;;>
M[;W9_0M"A1PU&EAZ%.-*C0IPI4J<%:,*<$HQBEV22\WNVV</\2/^1+UG_N'?
M^G:QKYPL^GXG^1KZ/^)'_(EZS_W#O_3M8U\X6?3\3_(UZV!_W:?_ %]?_I-,
MU.HL^GXG^1KJ+/I^)_D:Y>SZ?B?Y&NHL^GXG^1IU?M?+] .CMNW^?[U;\'0_
M0_R:L"V[?Y_O5OP=#]#_ ":N.IT^?Z 33=#]?Z)6'/U'U'\UK<FZ'Z_T2L.?
MJ/J/YK2AN_3]4!BW71OH?Y+7+W71OH?Y+74771OH?Y+7+W71OH?Y+772Z?XE
M^@'+W71OH?Y+7I?P@^]XC_[@_P#+4Z\TNNC?0_R6O2/A$2&\18/_ $"/Y:G6
MN*_W2KZP_P#2X >VT5#O;U_0?X4;V]?T'^%>(!-14.]O7]!_A1O;U_0?X4 3
M45#O;U_0?X4;V]?T'^% $U%0[V]?T'^%&]O7]!_A0!-14.]O7]!_A1O;U_0?
MX4 345#O;U_0?X4;V]?T'^% $U%0[V]?T'^%&]O7]!_A0!-14.]O7]!_A1O;
MU_0?X4 ?._[5_P"R3^SY^W!\$O$G[.?[4/P__P"%G_!KQ??^'=3\1>#O^$K\
M;>"O[0OO">NV'B7P_/\ \)#\//$GA+Q5:?8-;TRQO?*L=<MH;KR/LU['<VDD
MT$GR#^Q__P $5/\ @F/^P5\0O%'Q3_94_9AL_AKXW\:_#O7?A/XKU+4?BO\
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MF$8>UI<\Z-:C6HS57#XK"XBDXU,/B</5C&I2J0=G9TZL:E&I5I3_ (YO#O\
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MTW^8<OG+[_\ @'A__$0;_P $U?\ H[G_ ,P)\>__ )RU'_$0;_P35_Z.Y_\
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M/2A))8B4U["E6<H1NHRG3C4G2^)-SIN3I[6E472+YCBO^(@W_@FK_P!'<_\
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MM?\ 7LKN,5=[*[DEJUKIU*C3YOM2[+6]^IYA_P 1!O\ P35_Z.Y_\P)\>_\
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M]/Q/\C3J_:^7Z =';=O\_P!ZM^#H?H?Y-6!;=O\ /]ZM^#H?H?Y-7'4Z?/\
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M22E+EWBG[KLDU-WJ[V:U32MNTTK:W<;[];+0_&SQS\8?VM_@1_P42_:B\1_
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MY_#G]EWP3^RKX\_:(UCX*?M4_#_]GSP_\2_CSXVT_7=<T+XN>+O'5_J]I/\
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M6I:QXT^)4OBZ+7]:\0"UL]OB>6XFAT2\BN]%@D;4;/\ LWRK.UA^?T_X)_\
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M+S6OIZ:L_*G3O^4[#_\ :)9O_6PTK]?@2"""00000<$$<@@CD$'H:_('3O\
ME.P__:)9O_6PTK]?:R:L_P"OT;_,I[_)?DCZ,\.:H-7TBTNRV9PGD70[BYA
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MZ-]#_):ZBZZ-]#_):Y>ZZ-]#_):ZZ73_ !+] .7NNC?0_P EKT?X1_>\1?\
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M/PV!K>WK*$:D(RI5Z&(AA*].G3K?LI2,RJK,S!54%F9B JJ!DLQ.   "22<
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M6>&EBZ,J^"Q5&K4P^%JRPV,ITZSIQK8:C5ISHU(VJTO8XBM\#^,O^1O\5?\
M8R:Y_P"G2ZKFZZ3QB<^+O%1]?$FN'_RIW5<W7B'["%%%% !1110!^D%%1^9[
M?K_]:CS/;]?_ *U '^93_P '"?\ RE__ &NO^Z!?^LP?!6OQAK]G?^#A$Y_X
M*_?M='_L@?\ ZS#\%J_&*OQ;-?\ D:9E_P!A^,_]2*A_H_P-_P D3P?_ -DM
MP_\ ^JG"!7ZS?L:?$;]EGX;_  :^%7_"[?!?[/\ XR\,_$']KSQ!X'_:R7XA
M^%M(\6_&31_V<;CX8>"QX$U/X3W%E::M\8/ASI5AXBU'XMZ[K?CSX(VFD>(9
MO%N@> ]!\0ZW=Z;<6/AO6/R9KZL_8L^)/@KX2_'W3O&OQ!UK_A'_  Q!\,OV
M@?#TNI_V=JVJ[-8\;_ #XG>"?"]G]BT2PU+4&_M/Q/XAT?3/M"VC6ME]L^VZ
MC/::?;W5W!E@ZGL\13?[M*<H4W.JE*%-2J0YIR3<4X\J<:D7**E3E.+DE)M=
M_$&#^N97B8I8J;HTJV(C0P=2=+$8F=+#UE2HTITXU)PKJI*%;"U(4ZDJ.,I8
M>O&G4E24)>H?M6_$GX;?&CX(_ CXI0^#?@)\/_CEJOQ'_:'\/^+O#/P \'>
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M\-O=?9)([F$2&*4V]TNX(XC8EHI$C='C9E5CN.QC\V+Q3<4=7)\J-@J^81&
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MBMHMGX3UR34;+1=7\-6T.DOK<5C<Z;/K=@9KG3KJT%L377E*6,I3Q%&D_P"
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M_):]#^$_WO$/_<)_EJ5>>771OH?Y+7H?PG^]XA_[A/\ +4JUQ7^Z5?6'_I<
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MM]9\;^)_&$>L^/KO7(;'1?#$-K_PE+Z9/?Z_J%KI%OI6GVT]S=6\2N%_7/\
M:?\ ^",OQ*T?]B7]GW3_ (0B/QM\>_@E#XPU[XE>']+DLK6X\8GX@2Z=XCUV
MR\'7\TMF=1N_AWJ6D1Z9X9L7*:CXKT^ZU&ZM%CU9],T*;^HNBO>Q'&&,G4PD
ML'AJ.#I86O/$.BI3K*O5JJHJBJR:@_9R5:K:$4G%SNIWC#E_$,B^BCPIAL!Q
M+0XJXASCBS,N(LHP>14\VG0P^55,FR_+IY?5P$LMP].>,@L=0J95EWM,5B*E
M:%>GA?8SPZIXG&+$_P"?9+J'[6WCWX7_  Z_96TSX/?&N\\2>#?B'X[\<V;V
M6@_$2?QAJW_"PM-\(:'-H^I:,^G"6WTC29?"2W%M=R.MNDNI:@;D1*K2'^LO
M_@DU^Q/XG_8O_9VOM,^)!BA^+'Q1\0+XQ\<Z):W.GZA9>$X[2T_LOP]X5AU3
M3I+BVU6ZL-/674-6O+>[N+!-6U:\L-.DN;2R34=0_4BBN?-^)JV9X7ZE3PE+
M!8>=5UZZA.565:HYNIK*48J$/:2=1Q46^91M)13B_?\ "[Z.^5^'G$O^MV8\
M3YGQ=G>%RR&39-5QF#H9=ALJR^&%HX!<F'H5\3+$XM8"A#!1Q,ZT(?5Y5N?#
MSK5(UJ97X2_\%JOV"?B5^TMX:\ _'3X%Z3?>*/B;\(['4=#USP3I6W^W_$W@
MB[N_[9M;[PH \<U[XB\*:P+VYBT"W+7VMV.M7C:1OU?3+/2]9_=JBO%R['U\
MLQE'&X?E=2DW[LU>%2$DXSIS2:?+.+:NFFG:46FDS];X]X)R;Q$X5S7A'/?;
MQP&:4Z7^T86<:>+P>*PU:GB<'C,+.<9P5;#8BE3J*,X3I58J=&K"=*I.+_S]
MAI7[7_[0/A;X,_LN^&_@U\6K_P 2?"J]^(&E2F/2_&=OJ6JQ?%/Q#8:T\/CT
MZQ!::;X>TO1I+>>WBOM<N[32X]/N[B6\DMT6623];_VC_P#@C#\4=%_8A^ E
MK\*H;;Q?^T'\'9/&OB?XF^&M&FM+>Y\7Q_$"33-;U*Q\*ZA<7,":EJWPYET&
MQTG0[")DN/%5O<:K<::#J;:7I-Y_4U17T>(XQQDZF%EA,-1P=/#XBIB94E*=
M98BK5]I[559-4W[.?MJK4(I.+FFI7A#E_ LB^B=PIA<#Q%0XIXBSCBS'Y[DN
M!X>PV93H8?*JF29;E;RYY;++J%.>-@\?AO[(RR$L77G4A7I8:5*KAW#%8M5_
M\^R74/VMO'OPO^'7[*VF?![XUWGB3P;\0_'?CFS>RT'XB3^,-6_X6%IOA#0Y
MM'U+1GTX2V^D:3+X26XMKN1UMTEU+4#<B)5:0_UE_P#!)K]B?Q/^Q?\ L[7V
MF?$@Q0_%CXH^(%\8^.=$M;G3]0LO"<=I:?V7X>\*PZIITEQ;:K=6&GK+J&K7
MEO=W%@FK:M>6&G27-I9)J.H?J117-F_$U;,\+]2IX2E@L/.JZ]=0G*K*M4<W
M4UE*,5"'M).HXJ+?,HVDHIQ?T7A=]'?*_#SB7_6[,>)\SXNSO"Y9#)LFJXS!
MT,NPV59?#"T< N3#T*^)EB<6L!0A@HXF=:$/J\JW/AYUJD:U,K\0_P#@L_\
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M6;1O ^LQ_P!L:#XRL]4TO6)M,AL_#_C"]U"UT*;Z[_X.$/\ E+[^UU_W0/\
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M/<Z;))>V"&$O'")%OHHI7=)K=)=J0SE0DMQ&%"@ .:VB6FJZ'IVC:+J-W?\
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M=D4"!2D9/\/D_N7?((.%8C[HK2OO/^UHL%M$4NK"53?(ZL5E2*4Q+-"5622
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M.)PYNC.MNT@A*LYB\^7=(XS $+2%EBRU0Z[K376I7&GVR-BPM9I%++^ZGO%
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M5D7_ %9.6B#<OA</M!-0Z9;VR6\MC%:);Q3 F>)( B/]HBPRS0(?W)=%"A%
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M[/I^)_D:ZBSZ?B?Y&G5^U\OT Z.V[?Y_O5OP=#]#_)JP+;M_G^]6_!T/T/\
M)JXZG3Y_H!--T/U_HE8<_4?4?S6MR;H?K_1*PY^H^H_FM*&[]/U0&+==&^A_
MDM<O==&^A_DM=1==&^A_DM<O==&^A_DM==+I_B7Z <O==&^A_DM>A_"?[WB'
M_N$_RU*O/+KHWT/\EKT'X4MM;Q!QG/\ 97\M1K7%?[I5]8?^EP ]DHJ/S/;]
M?_K4>9[?K_\ 6KQ )**C\SV_7_ZU'F>WZ_\ UJ )**C\SV_7_P"M1YGM^O\
M]:@"2BH_,]OU_P#K4>9[?K_]:@"2BH_,]OU_^M1YGM^O_P!:@"2BH_,]OU_^
MM1YGM^O_ -:@"2BH_,]OU_\ K4>9[?K_ /6H DHJ/S/;]?\ ZU'F>WZ__6H
MDHJ/S/;]?_K4>9[?K_\ 6H DHJ/S/;]?_K4>9[?K_P#6H DHJ/S/;]?_ *U'
MF>WZ_P#UJ )**C\SV_7_ .M1YGM^O_UJ )**C\SV_7_ZU'F>WZ__ %J )**C
M\SV_7_ZU'F>WZ_\ UJ )**C\SV_7_P"M1YGM^O\ ]:@"2BH_,]OU_P#K4>9[
M?K_]:@"2BH_,]OU_^M1YGM^O_P!:@"2BH_,]OU_^M1YGM^O_ -:@"2BH_,]O
MU_\ K4>9[?K_ /6H DHJ/S/;]?\ ZU'F>WZ__6H DHJ/S/;]?_K4>9[?K_\
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M#YW_ &V+2)/V,OVKUMHX[>*V_9@^.Z0K!&D0CMU^%?BIC;HBH%2!V*DQ*$Z
M]0:^:?V<?@I<_$G]EG]D#7+GQGK?A:S\-_LZ?L_7FFZ5:B-]*GU&S^'7@[4%
MUMTC6"XBNIVW6LV)+F*YA5%<*0RU]&?MEZD-2_8I_:HO+:,Q07'[,'QZ=TNH
MY+>X57^%7BT1H(6R5E4;/-BEP8C\I59%VBK^Q_8RVW[&O[)-Q*)GTR3]F'X
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M]/#8F%'$5/W.%K*BZ>+K_N,-*K6]P^QZ*_ KX<?\'!?[,_BCQK;>'_'GPO\
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ML#9:OI&H16SNL?VN/3]=T_3+RYM$D>.*6[MH)K:&:6**:5))8U;UJ@ HHHH
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M6E]9I4N>IA^6:K1@X2M],T445Q'V!\(^+_\ D;?%'_8Q:W_Z<[JN=KHO%_\
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M$[2OB/\ %7X:V/C6WUY_BY>0>$OAEXM-EI?@:]\'ZCXNTFQ\5ZQ>3WWZ,?\
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MKDM2C_\ !-W_ (*FK=!HI(G7]CN_:.)\_OEP_C'+J%RL3[%?#,3L.#7]%?\
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M[4_X*GVY6 VQ&G_L>:C'&D.YF"PF7QR9(R69I3C"K*[E%53BOZ(O^$.\1_\
M0._\F[#_ .2J/^$.\1_] [_R;L/_ )*JU4DHN"?NMQ;6MFXII-J]GHWTTYGR
MV3L2YR;NX[;:/1.U[>MORO>VO\W]Y^WEXJO)[>=O^";_ /P5+$FG2R76G/\
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M]ILB4?:99#+&TK!FG=D_I=_X0[Q'_P! [_R;L/\ Y*H_X0[Q'_T#O_)NP_\
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M",H.+BB8QY;6@THR4XQ2M&,U;WTDM)6YHWOK&3B[IN_\UEG^W#XJM;QYH_\
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M]/UVRO[2UUS0M1BBO]&U:"%+_2[V..ZL;B"=%D'\9O\ P30N?%-G_P &U/\
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M0WBSPTRZMI^M_&SX'ZSHX25(?MD=WH-[<VT#RON2VE=F6WF\P'[-,'6508V
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M@G_K,7P6KQ1/#_P8_9Z_9(_9S^,.J_LC>'/VE_$'[0D_Q!U#Q+\4/C1XM_:
MT;X3_#O5O ?C[QAX*MO@KX'TC]GSXJ?!"63QW)X>T;0?B9XNU3QQXT\47,NB
M^+O#=KH'A?0[.WOM4U;VG_@X+_Y2\_M<?]T$_P#68_@O7EO[.7C#X?\ P ^
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M_P ^VF?]^;K_ .3:/^%@:S_S[:9_WYNO_DVN&HK]6/X0YI=W_7_#?GW9W/\
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M_GVTS_OS=?\ R;1_PL#6?^?;3/\ OS=?_)M?B4?^"4R]O^"E?_!7#_Q,\?\
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MJ-V].:2;2T3=VE)V2;M&3V5S6%.K/X5+X>:[32Y5RIN[LFKNV^KT^T?TE_\
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M410FYNK:W\QU\Z>&/=(OP=_PV]\0O^D=?[?/_A.?LN?_ $5=>(!]]T5\"?\
M#;WQ"_Z1U_M\_P#A.?LN?_15T?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%?
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M$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ"_Z1U_M\_P#A.?LN?_15T?\
M#;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;WQ"_Z1U_M\_^$Y^RY_\ 15T?
M\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ"_Z1U_M\_P#A.?LN?_15
MT?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;WQ"_Z1U_M\_^$Y^RY_\
M15T?\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ"_Z1U_M\_P#A.?LN
M?_15T?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;WQ"_Z1U_M\_^$Y^R
MY_\ 15T?\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ"_Z1U_M\_P#A
M.?LN?_15T?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;WQ"_Z1U_M\_^
M$Y^RY_\ 15T?\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ"_Z1U_M\
M_P#A.?LN?_15T?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;WQ"_Z1U_
MM\_^$Y^RY_\ 15T?\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ"_Z1
MU_M\_P#A.?LN?_15T?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;WQ"_
MZ1U_M\_^$Y^RY_\ 15T?\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\ #;WQ
M"_Z1U_M\_P#A.?LN?_15T?\ #;WQ"_Z1U_M\_P#A.?LN?_15T ??=%? G_#;
MWQ"_Z1U_M\_^$Y^RY_\ 15T?\-O?$+_I'7^WS_X3G[+G_P!%70!]]T5\"?\
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M+*WVZUMTFGT])XYG%IF06EZEMNW0&Z(D@C5GB662!FV[LN8+JYGD$2VTUO\
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M_LT7Q[_ZN7X!U\N_\%.M+^*LOPG_ &7?&GQDF_X*&>$O&OB77OCAIMQ\&?\
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MLEAN898KN1E%[&;B-'.W:ZM:7NBZ5J]HR:>FJV]O=V-KJ!>U:]>>WDN8]/*
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MG33;;;)*TDAEF40!)9&=I69<RDN>?W7Y].3_ )'X#G).#Z#D"OPA^**VJ?\
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M$EM.D@L;3ZH\7_\ !1;]E'P%\./V;/B3XH\?:^]C^UQX4M?&?P!\,^ ?A?\
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M%'QG\ ?"I/V:OAS\5?B%-)#XETSX4ZMXS\(:]#IOB7PY<6/A:STCQ#X;-_\
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M.'B;X%:1;_M'W$6I1:WXW\+_ +.,7[5?B?X_:3\)1X"U+XD7MQIT6O\ B?\
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MTV^97M"7Q.3M*,;KV:O%RT44O=481=Y1]U-)VT46]U:R5[-VUNI6O?O=[7+
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M\C3XE_[#^L?^G&YK K?\5_\ (T^)?^P_K'_IQN:P* "BBB@ HHHH ^^****
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M917+*4XN5249RJ\U9ROJTXPDH\UG)P=IR:3<D^5R<E[B;NE&Z46N2T5$\/\
M@-*)O^"VVN-'?)J$"_\ !+Z]2"X2&*,!4_:NT(2Q/)#(ZW,L5SYZSS[8,3"2
M!85CA1F_=VOQ.^%&OZ!XM_X+->$/%OA: VWA[Q3_ ,$<],U_2H6L?[,FBMM1
M_:Y@E\FZT\JC6=Y;R>9;7=NRJT-Q#)'C"@U^V-8UI^TJ3GM=]+6T27V4H].B
M2[)(YFK;=EOYI'8^#K#[1?27KKF.S3"$C@W$H*K['9'O;V8H>#BO3ZQ/#UA_
M9^EV\; ":8?:9^.=\H!"GWCC"1GMN4D=:VZS-8JR7GK]YR?CG_D5M4_[<O\
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M&OQ,\7WJ*[R&Y\0^/OB-X@\5>.O%>IRO(S7&L>*/$6L:M<D@W%[+M7'1T44
M%%%% !1110!]XY/J?S-&3ZG\S244 ?YI/_!P)_RET_:U_P"Z#?\ K,OP8K\;
M:_9+_@X#_P"4NG[6O_=!O_69?@Q7XVU^+9K_ ,C3,O\ L/QG_J14/]'^!O\
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M3+U)-13_ /!'/PY<HT5S_P %$?\ @JI<1NCQO'/^UO8RHZ2\2(R2?#!E9)
M'4@A\?,#1"48M)IJ#LIJ%DY133TOHG>*UTO;75ML=5/76_2^J7]:>EG;H?2E
MW(]K/#]EMKF[BNIK87L\<L,$5E':P2EI97D8M*DKN R6P5VV@[BBDUJV/GH+
MII &@8P-:RQ;2LD;Q*2/,#.S[')S+A Q=5C5@-Y^6A_P1ZT-4$8_X*+_ /!5
M@("2$'[75F$!;J0H^&6 3W..>]2K_P $@=)0 )_P4<_X*NH!P O[7ULH '
M ^&8 P/2CGW=DW913?11<6FE=ZVBHZ6]U:W;N+VD?/>[\]/TNW_GI?Z>O;.:
M]BBCDD,*2.\5VR"6&8Z?+NE$%LT$J/!=%UA;[2)%D"QLK'YMM44"6LJ//<6]
MM:6,,UHD+2EE\RZG1+29K^Z*S+.UJL<,B8!:XFF_>2KY3'YO_P"'0&D'.?\
M@HY_P5=.3N/_ !E];<MZG_BV?7WZU6D_X(Z>'9ED2;_@HE_P54E6619I5D_:
MWL7665-NV616^&!#R+L7:[ LNU<$8&*51Z)W45LEK:]T[)V2;3WMT["YX^>O
MEZ;][:_CY7^E[/SI9)WF0^;-.\$,1NOM$;V\*Q+9SPJ&86XO(PMP(V8R2,[R
MN["4"J>G7WG:=%?7]_I5TOF7 AOM-ESI-RTTUQ!#'YDCLMR1"T=O-RT1NDD,
M:*3&H^<_^'.7AO:Z?\/$/^"J>R4AI4_X:VL-LC*%56=?^%88<JJJH+ D!5 X
M Q#+_P $:_"DUO#:3?\ !0K_ (*FRVMO+#/!;2_M9:;);P3VT@EMYH87^%YC
MCE@E59(9$57BD4.A5@#3]I%W;4DW.#5MHP47&25VVW+W;:VM'5NZL^=>=K-/
MO>ZMY66MTE=OK:R,']L*_F/[*_[:.F3Z'?Z8L7[,7QHN+;5+J6UDL=>\WX3>
M,%N1I:PNTD7]G-;B.ZAF"2[F241[,N+_ .QYJNF:=^Q=^RSJVHW$EIIMC^S#
M\"XM2$ULT;PP0_"#PFTFH*Y81?94"L\-Y*50(LO0@5/KG_!%_P $^)]$UCPU
MXE_X* ?\%1?$/ASQ#IFH:)K^@:Y^U7I.K:)KFC:O9S:?JND:QI5_\++BQU/3
M-3L+BXL=0L+V">UO;.>:VN8I8971JVE_\$4OA[H>AZ+X9T7]O7_@IYH_AOPW
MIVG:1X=\/Z7^U)HFGZ'H&DZ/8II>D:7HNDVGPJAL-+T[2],C33M.LK&W@MK&
MQ1+2VBBMU$8YZ\547[F,*,E32@WSU8QJQIJ/M'&52,I*<DY3@Y\JYI*'+%1B
MM:=>*DG/GE&Z4E%QC)QYDU%-QDERJZ3Y6[I-W>K^@Q;VNGW,/B&TUA-7M=6M
M=.@L5O)XWTZ">W8VL#6$=O P%Q?_ &D"[N)KHF4"&*(B)Y<[,T\SFS LYHWO
M#Q%_K3:3K$)FBGD4FV3 61$)E=&G\M(OF.3\[#_@C;X76-81_P %#/\ @J>(
MED258A^UGIPC66(JT<BH/A?M$D;(C(X&Y"BE2"HQ,?\ @CKX>9E=O^"B?_!5
M5G1S(C']KBQ+*YX+JQ^&.5<C@L""?6L(4+0Y9*+OK+E;LIN[E*'.IRB^9\RY
MI3TC""Y4KFDL7%N]I:62NEK%<J2DH\L7:*:?+&*;<I.[DK>\2*UI?QRS31VM
MH [6Y8*T?VHK()GG,RN)]ZLODA51;=(")"48$L$HNVGTN]6&[ACBCFU&>YB"
MP7$<RS/'MD$9CEMT=8Q+"DT3QM)&W*_,?"9/^".GAV92LW_!1+_@JI*IR"LG
M[6]BZD,-K AOA@0<C@Y'(X/%#?\ !'/PXR&-O^"B/_!51HRH0QM^UO8E"BC:
MJ%3\,"NT#@+C ' &*:P\(\RLY1:EI*4I)RG-2DI1=XN'*N6,;+E3:7NNPGBD
M[-Z27*DU%)Q44DN5JS4KW;?5J]KV;^@%M[.ZMWCN+.>ZAN4EC>U8?9[66.)O
M*$.UI 8U+1;]T#!7C97E7>[DY-L;!;S5[S0XUM9WU&%-0&FM=0)=W-FJP[+]
M0BK<%9YCO2W0V]PBJ[^;(/E\5_X<Z>'0% _X*)?\%5 $7:@_X:WL<*O]U1_P
MK#Y5]A@4+_P1T\.J6*_\%$?^"JBE_OE?VM[$%N"/FQ\,!NX)'.>"16G+)1G&
M,N52ND[7<+J*NK_:M"*NW:R6Y+Q$&U)QDVK7N[*6J=G;IO;?6[WU?OT%AIFF
MRO(;"U2XN9_M 2&-A&]Y)Y4CR2D\1"-+=)5AM_)0B ><CN(P+ U&1_.\Z9(#
M$<2*QB4%)'<128!=UCFF5E0E5\UXR$5@A ^>E_X([>'TC6)/^"B?_!558D 5
M(U_:XLEC51T"H/AB%4#L  !2#_@CIX=#!Q_P42_X*J!PH4./VM[$,%7.U0W_
M  K#(5=S8&<#)P.32E"HVFJLM%97;=WHESO>2459)./1725@C7IKXH7NTWIL
MM+I7V;[V>JN[O?Z%/VFWMK/48;VXCT])&U>^@LX[=X=0>X2*-=-MHXXD8Q22
M(UU(\[*0US)-(TC!%C\;^VZQ\0;C7K;Q):W?AVSLO$:6NF/Y<9CUO2%L[>XO
MQIA,_G16<\TPTJ:6:-&N&MKPI#]FE^?FF_X(W^&'C>%_^"AO_!5!XI23)$W[
M6FGM'(3&(270_"\JY,2K$2P),8"'Y0!5>'_@C)X.MTBCM_\ @H)_P5(@CAC6
M&&.']J[2XDBB3;LBB5/A:JQQKM7:B@*NU< 8&/.S++ZV8SP\)8CEPD(S6(P_
MO0CBG.*C^^=/EJ.,;RE%*K&TU%RYM3KP>84<+&K)4FZ\W'V5;1RH*,DVX)MQ
MYI)<DN:$ERN2C;0]SM;J:TO3:PZ=%#I<5E;BTO(-TKR2;WBGMDLTA8 11;2'
M638X=HT11'@3VEC<ZGJ$O[N>QG@5X;2=;MX[6\$[2.J'3FS*3:)&CRO=1$[R
MYMFEB#/7AI_X(W^&&V;O^"AO_!5!O+=94S^UIIYV2( $D3/PO^5U  5QAE
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MT&FKHUOKMSNM]*EO5GN=&6'S5BN;F[@B=Y&2:T$UQ;VK,$#&.VFF)+/7@O\
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MT3QS;WD'PNNVB\:BR/A)HM,D\2KH_P#8T.L:9/X;GU*/Q$LVE( ?UX_M>?\
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MPXAJXO+<%+$4*>*Q>6SP\YJ<(I584<IH5)0M)Z0JTW>WO']_G_"3Z'_S_?\
MDM>?_(]'_"3Z'_S_ '_DM>?_ "/7DM%?>G\LGK7_  D^A_\ /]_Y+7G_ ,CT
M?\)/H?\ S_?^2UY_\CUY+7\__P ,O^"Q/[67QR\):7\2?@O_ ,$PKCQI\-?$
MUUKJ^$?%&H_MH_"?PA=ZM8Z'K^M>';BXU#0-=\ QWNAWJW^@ZC%<6%S-<1QR
M0%[.^U&PEL]0N]*=&K6;C1I5*LHQYG&G"4VHW4>9J*;4>:48W>EY);M!_7W)
MM_@F_1-G]+7_  D^A_\ /]_Y+7G_ ,CT?\)/H?\ S_?^2UY_\CU_/G+_ ,%&
MO^"B4+2*W_!))6,/E&40_M[_  +N/+$RJR%C;^")0%^=1(WW878)*4?Y:J)_
MP4H_X*%R7(LT_P""2,QN2YC$9_;K^"ZAFVR-\COX!6-U*1.ZNKE'1=ZL4*DZ
MK!8QIM83$M)7;5"K9+35ODVU6OFNXKKNOO/Z%_\ A)]#_P"?[_R6O/\ Y'H_
MX2?0_P#G^_\ ):\_^1Z_GJ3_ (*2_P#!0MU#K_P24^4NJ G]O/X(+EV4LJ@-
MX%!.5&3@8 (R1N7+XO\ @I%_P4-F57B_X)*+(C;MKI^WK\#F5BK%&4,/ V-X
M<%"F=V\,N-RD 6"QCVPF)?72A5>G?X/)_<%UW1_0E_PD^A_\_P!_Y+7G_P C
MT?\ "3Z'_P _W_DM>?\ R/7\^9_X*,_\%%%0NW_!(YE4'!)_;S^!P/\ WR?
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MBG:]FU"RTU]-0YH_S+[T?T/?\)/H?_/]_P"2UY_\CT?\)/H?_/\ ?^2UY_\
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M^]'NA^UI_P#/R&]OCCN[V6^^C^YG]$G_  D^A_\ /]_Y+7G_ ,CT?\)/H?\
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MQX@NO"HEF_;H^$4=LVO637*7-A'=O\.%M9"C6=TJW,<S6<K02"&XD(K=M_\
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M9M'L-$T>36=/BD G-GXCO=9BN'_=W@N;;]Q7Z/\ Q$^#?PL^+/P\O?A/\1?
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MPMD.5Y#@ZU3VU:CEF#HX58BLH\JJXB=.*J8BHH^Y&I6G.48^ZFHZ'RC\2O\
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M'"5E2Y6UG\]KC"W$98IFQHMGKVJ^*O&%FL^GV?AIM.T&QEM-[K!KFK2S7]E
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MW7\*?A+X=\=>(_V>K+XC3?&_X/?"B]^'_CQ_V!OV^OV5?@=^S=^T;\6_B?\
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M?0_R6NG\ ?>UC_N'_P KVN8NNC?0_P EKI_ 'WM8_P"X?_*]K7%?[I5]8?\
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M&.O?"R_\5ZN]Q<ZEXNL]!TSP_K>CZWJ%_<,\FIZE%I'B6RT74M3EEEO-1O\
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MBZUX+\-ZKK^N:'H&E>))?&B:,GC26^U#0-?T^Q?3$TQ]/U'3M0DT^2UNG_L
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MUK2_#6DZ=HMMK'B*\U'48].M(+1+A;>)(U](HH **** "BBB@ HHHH ****
M"BBB@#[@HHHH _S5?^"_W_*7#]K/_N@__K,_P9K\<:_8[_@O]_REP_:S_P"Z
M#_\ K,_P9KSS_@GCX'^'WBWP'\?&\:_"O]F?XGRW'C7]G3PJQ_:K^)Y_9_\
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MJL8T:2A*,)23CDDFGS244G[CLT_@Y6VU>/)9Z72?,VT[(XJU\+V=Q=ZA=W4
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M,(+*VACB\]E>1]E+19+W4;;PQK%YX0U=3KNF6_C%-%UC29-.CMM4BO[6X?\
MM"6:WFCLM?DN;*=I-/AO#- UPSF&6 Q7-1>(-#6[U[6+Z/5?%>BQ>(4U&SN/
M#-M<P2>&K+31L:^\/01G3@L%[?Q:BPFUJ.XEO9F23[+Y-O;#R_;C4P\ZD:2G
M5=.$*\JM6+7L>6C*G&.'A*DYQ4J=J]5RI>UA*3E&\9<S)Y)QBVU!R;AR1=N9
M2G=N<HOE;4KPB^=1:235XVB;$&F?VF4NKF68Y2$ZJBQ)!%K&HK*BO>E9&GN8
MD(0C[$)7@=%S&IE;(XJ#0==T;7/$%EIFCZK-H>HZKJ_BA-1O+^XU[6!KNO3?
M99CI%C,O]F67A?3K>QCNM-T(7#7MO++N\E+8R1'T>:STKPAX;BT^&*YL])T'
M16G#0QWL\&G:;X>M8+AUBG@,MS)):VMNZ6ZR3BZU#]X42XEDG!J)XINM2T[0
M-6TBVU&QAUNTL]9N'URS2V'AG3I(;/4WM-=T]IXKNSU'4;6>XTZT2V^T+::@
M)!>*(X6W9PNXSM#GI3Y5[6I#V4)1H\U6#M&;;E!1E*<5[1IRWJ2G%2=W=--*
M2UY5+G<7/E35VM.:]HOW4TM%%+3QSQ[#HFI^'_#5M<^()KNQT#Q9]ITC??AM
M0UWQ-X<?4+)]"%S:H\LEO8W$LTU[9QO;"799VLBR311()_ASIVI/KVH>+KRX
MU7^TM6EL;"VNII9C#X:\B\N3<>&H+.2::*\FUU/*GU][>*.YM98&M(I6CC4A
M^L>5<:KIUC96EG8W5S>76L+E;:+1](6>874\L$\$>S^U9=1DGU"]U@ 37UZ4
M,7G^5$[>AZ,UIX4L X^U1RV]W+<V9LYH9)MELL5T)H[1(KEX(;^XAFA7[0&O
M+N&1OFADE'E>+4J2KXI.=6I+"X6K4E0C7]^-.4^5R<$N:$I-0M)TTXZ)).:M
M+T%%4\/RQC%5JT8JI[/1RBGHI.R:5WIS--J^BAHM_4M7C5M3V:A)-,SS6ME?
M(P6<W5O%))=1Q/L+&R5TE412J9/)5<O$^7&7JWBBTET9K?\ M2SL=:UB]%GH
MMJ!>2R7.JZ=;7,VJ1"2%938DV N%GU"Z+16L<BRB*2=X%;FM-L[_ %F6QO=3
ML[JTDUG3[_6-070[X:-JUG<?:[:XE,4-X98[6WUO3X1%<2.S7(LC>P^4BRPF
M7*\*>-_#GC*\\06NG:;9C2=)U"[\/:0QCU#3=(EUBY4W-]!9ZAJIB7Q"8F:.
MVGU&RDN8Y;N,VT)(B&VE*M%QKT[XG#TXOGE&%Z<8S35"522A*,%6G&LWAYQC
M*5*#2Y74<H1R0:=.2]G4]S>24G*+7.H1E).7+'V;]HKIS;;;44I=)I<,.N32
MQ-<NVGF".22V;4;J:*(Z7:! 1OE@DD>6<B_N)99'MF<*\D+EE88>O:B/%<4,
MOA:]MV@T*.\DU+4VM9)-*U"TC:*SL[:WUFV62(&UN$D:Y(B9)(V4B3:KX[32
M='TG5-(U.]T\QM;PNL.L0QR^?/J=Y8AXK^$S&*W%O&;!Q9PQ0 Q,T)$\DC23
M3&.P_LF]LHK6T@M[32H5C5/#^@)!:6.GP312-)=W\[,1-<06Y67[0\CQ1NY2
M ,<*,'2<\.Z>*P\XUZOLTHRJ.C-4XM:N3A[12:]E&'Q<B<VXMM&JFHU.>C-.
MG"]VHJ:YFDFDD^65WS/HG9>]=6?'66G^(K&*V6PM=)U%'2>&^D1[-[6T< 75
MQ'=7TI$+QF65Q (H!--*KNJR.=U&B0^9-J>G7VD6MD=1LIEO+>ZEBL-.GM+=
M#(L=M=ES!#J%R3(\%Z&61YTC\O;(PB/J-KI4LUM=:)!?6^E0:U;R1VUY;7,.
MIZC:69*R2MIL<L,$5DR)+'$MS<V]VJ2S13;4<KMHQG1S<76AZ9X@TVYM=*TY
M;7Q ;UM.MKM+CSU6VM]4ECNH8;3^T_+=GFB^RE[F(ADBBD5SSTL!)QC4I3JJ
M5&4E*$X.MR1E:$)MSC3BXU.94XP<U*4K0Y)2FKU/%I2E&<:;51)J7,X7:LVG
M*+D[Q>MTN5)?%&USQ35[?PEK<$%K=6\VDW]O%#-I.NV7VB:ZL;Z*TN[&TN-9
M;3XQ=0B*WN9H&O+<OYMM<3K>:;(@%:6A1Z9H&B:5J4NO:3X7O9M3N--BL[6"
MW72=8O=1W"2]T^>T::UF?5)8TLKJVDM;%8Q.D4U@)Y#%7>W7PUMKZ+4_#SR7
MVAS6EA =.M;VZ9O+MWL9;:?S99_,O=06>"%TFEU"YNHX+N42V=SM24US_@_P
M(NAVM_X;U34]'U[0-0C9+O0[Q+?5HD:Y>14GN;V5!"&FM2N!;!A:C*%GQNJ\
M1+'*C2H?7*E?#2:<8+DA3A:,W%.FZKG"')SQG2I04:$YRO[1*',Z;PKE*HJ2
MA4C9MM.I)I\MVI>S<7+G::E.7O\ *K2@VS\__P!O;1_%&D>(_P!AJ62#3(_!
MES^WY^S?*]C83W\=OI/B7^T_&$HM9;:[D:8?VAILD[O-9M!;Q/I\JPVMF)8E
M;],[W6M-M/LFB7-WIHU'Q2]UH>B)<PW,T5UK$NE:CJ<5J8<1RWULNGV-U-(6
MG02P>;"]Q;MM8_GQ_P %!M(N=*;]AS27NKV;0[7_ (*%?LM):"[B60V+W3?$
M&.ZLH]5^TR76H+;I:)<1_;('G@@NH?\ 2YB[HGZ%6>E-9S2:D\5Y<W%E>_:+
M%9'AEBM[8 V-U=Z?+':K<69:SFDA$!EF<1O<*\FR<JG=E,?8U<0\13E&-.-*
M;5.LG/FE1<Z,_@J0G3YY04XJ,)>RT2A45UP8B7M'>G-2E)J*;B^62YE&::;C
M*,[<VK;7/K>4=ZEL5G::X>'4;%'T^S@'VCRX?,D:.=[^.?2PTC6FZ.=K66S>
M$VQMEWQ3R(RNDMS9HTS36::-91VXAN?LEOIT=NUQ>Z/#'&]S<7 +"YE:"&%(
M+ /F"*0PJI <U2LE\1KJVNWNO#1%T>.ZTCP]X5,=Y-++9V]]<:A<0+K4'VA8
MYM:U&<D:?.UO<1(EI+']O*,EM%9NUTRYN)-6COVNK+S(K*U@M8+N=[?4K::9
M908H4WR,Y</?M<+/!%)''/,$\DK%V1P\9SK.RA&DVHRIRJR4[J+E"51RDTU)
MWG&;_=58RBH\KASOVC3@K\SDDVK1;AMRV2LG>*W2]Z+O=M2:SR7261KZ\>UO
MY](-U%!J4%O9S#1[I#)#/#&P#FQEM9X)'N& _>K$YQLC(QI]<O$6T0W4$-KH
M5XL,MG,\\UL+Y[!;NUFTR5I!';_--]I<R1.6MXY8DE!=7-2XO(M=\27,J:M=
MQ77AK3--N+BWNK&Z1]3CF#QV=@VH:C;I;R:-<0>6T=UI,LMM9MI:V4R1S22Q
MA$@L;*SDN%M$E@@2"5!*SSVLTJVN%N;@PNKW>TSO%*LA>,Q1JXCD9%%8RIJ"
MI0JPDZBC%N"@W3E'%4Y3IN$JL5RWHSA4A)7C*,FXN%WS;1ES<THM6OHUI)2I
MRC%Q:O9VDI1>MTTE[S5EK^(),7:3",ZFTEEH]W<W,,\US<:4MQ97-Q=Z7=)*
MI?4+OR)$GN9'2)%6$[<-(]<9!I]D]K=-IDEU:(9YKK4=6@U*&>\BO;W3K5]+
MNK.S>:XBTXF&ZBBM(XK-+.^NLW=T)B3(MB&XUVUTR*2+2=,;7?$%FD9M+749
MK_9+Y+W=W"^H7B!([*[A_P!'LM0188H4*H$?:(FVKVP-Y.BWJ)#:@26L:V\)
MA22[%A.)H-L0M;B0I:R"-9XY5CDGQ<(T/DBLI4/J\9R53F7M(4XRBHSBXTY4
MY2DZ<;PK1;II)*=2E*M3;2E*/M'<*G-RQY=XMN[:DVXN.C;4H22DVKQBU%QD
M]-#,1M.&J112HFJZG90V95%E!>6TOH9+?[3=V\.QI&,X+J401"0W#1KL@VCM
MM)\+^!;WQCI?B/68Y;'Q39K:75KI-G.%TK75M-)\K2M:U_3!:M"FNZ#;P3V>
MDS)-YL\<4%P(I74HW$[O">C^(A>W3:/IFKGPI8S7T]S-?V&FVNA>'YWM[34;
MN9_+^SQZ;J&IW$UY*DJ;XV>:Z$MM'MC[6PBD:U.JBQT,SF[EU3_A,'LEGNM3
MS;64%A#?^1);G6+"W5$ETR*5X7-O-)''(L!DC&G+[*<9\DU2JNC.-2=)TZ:D
M_92K224E>$'SRA)<THKV;Y(.;Y(E)S349VDH3@U&=Y-.ZBG=?:LE-7LVY6E+
ME5^>U.:23QKXH>34[BYCU&ZT^>WL3B:UT^X6"S2>UTB[,5A/%8_)=:EJ#7T<
MT]SJ=_J+@992M9SI.F">ZUFTU?4KAV=%N+2<6QT]6:]AN;NRL(7MY9;Z"22!
M](2<M9O9_:YYOGBMU.9K%EFPTJ#3-/TZZCL+=$DU6^GG:XM[B=DMS,T%K#)>
MW<3QGRKE9'2YCMY?,C+XEB?4^)=I'X>TC1KY-8TR[\/7-AINO66OVUR?LYE7
M5+?PS?6T[N3(MI'J=^=,LKI9(S.\BR)&6F\IL<1*-63BZ[G+%2;II0:FG1YJ
M5.DH47*<93IQIOD<E4J-WE"HH*<]*:Y?9KDY%!1A*\DHM6A*4N=M)V;DWH^5
M)V:NU'E]/TE?$.O6NB?V]<SRZO/:6GV4F22*"ZNI#((8(F>-)K3S[1;J6W^2
M**\6<Q,C2 1=5X3GTC3M8C;7=(BU:[MM=UFRT9M"MKFW\07\EMH<VA6/A^UT
MV28VMO$LMWIVOPAFMV$-MKBK<R-<O;39_@30H=;\6:@;'4M5\/VGA[39-:GU
M>(60L="+1NL<45]>2DRP%I;S[+)]D+,PE>1+6.1&?KTUG3-1^)7A_P 3>%D6
MPN]%N(?%NB3ZOIHL+_Q O^G07DWA^2[@>V"3:0S-#=:A++#-+:1?9XHV:9I>
M:4%54N:K"$HTI.#I58)U94Z<J=*$)KE3YTHJ5G*?LU.JU-\LGM*3BW",9RC:
M+DI1DE!S:G+G:3Y4[NS^%.T;I7MQU@U]=MI\+Z#'+>Z+IVJ+J%BD$IO(9-/D
MG?6M0^RVL,-U!ITL,%U->[I!):W5S<"WB3!6+HM*M+^^T5KSPWIVCB'4,7,-
MQ9ZM/>3R:5##) S:5<M=-';_ &;48A;W<0C6(6;R[I;F<3JGI=MXOU-O$5QX
MC\'06=TFN:D((8+R)I[ZZLO#LLGD?VA<*\-O/#?RSQ7?B.^C:6!=5EFA5IH&
M=2UH[PZ GEW=G:ZA;W6H:EJC:!:+8:KIJZB72XTW1+!H+J,W=]<K,D1>PG\O
MS#+:V3RM B=N P\JCE&O1=/GA"<*T:K48N<?WEX1I.3J1J1Y5*"E=JI"TG*'
M+R5J[33BH:-)TVKNZNTFI3^#7K?3E::;:/S2_:;5_#_[:?\ P3'U;Q#I^H^)
M[9%_;*U&+POIPC,5SJEK\%/"#V5OIB;U2WCO[I-'>[F>4".&,WCHB_?^\M=U
M:XOF&L_%#6K?3YY='BNM0\,^'H8[_6],2Y$C1065W&PALM'T.QMIHFN;9K:1
MYH[B6=S(]M$_QM^U/IFC:M^VW_P3(TK2=,;4K83_ +=4ESHT+1&]>^M?@1X-
MO[NWO(4DC\J_2YA<WD)\O=/'*D>X;4'WFS+HW@O4=.\6_P#"/^'[6UU#37TB
MQO)GT^XT6PO("6N_$,VVXU*6XNOEE>UED>Z2%5N;>&-;B-A\-GZA#,<PP_U:
ME94HR>)J*<U3M1HV]O!WH\D9-N,TE65:NU"<8R;.[!-RC3J>TDINO&*HP<(R
MDFDFJ-[S4GHY77(X4TVY22MYK\,?A_XDTKQY<:MKGBY6\.ZO;Z]%-/?O"UI=
M?V79F#1['3=-O8KBPO9H+@18%R8S81I'(\H>^ KDAI]WXPUBP%WXKBTK1=/\
M7V$EI>+>27NNRV\45Y.(;2UTXM?W%A/?W-O;7.GZC<-9*MBL=FRQ%H3Z%\<?
M%[7%EI?AKP,+SQ/INF^&-)UJ:VC630FN[N]+ZE'J]_\ 9C')J*WFGAM371M2
MMK9%MK5;YVN'P)/$/#NJ:W"EG/XBFT:WU"WUN_OHH-+L((]/":A>07$MM<^4
M\,T LY+.+3K>.^&^QV&."4+,N/E6\/AXS>&Q#2R_$T^:&)KSE6Q53'*I"H\,
MHTW2=##0PS5>$\1S*52#I_Q'&/L15>LXSKTES8JBTG3IQC&A##<CA*K=\ZJ5
MG52A*-%1Y(._-R\S]+^%>LF/3_'[^*IM0?0])U4S^'[&-7L;;4]?-P;:^GNK
M1)3<6-F\#VEV;6XE\X0[D&7\P/K^%=;O-8\9?VO;WD211:1JVJZW;6=NEKI<
M4(F-FC::BJBJ8H!:1R-<J)P6GC,4;&-TQO!9U;QO\/?%OB/Q(=,\(ZSXDU<_
M\(WX0LX4+:%X<TJYN9Y&\2W,$I%[J]Z\EK8+''O;34-L\Z.7:,;W@:V\$6WB
M32]*N3KJ7L>F:5J7BYET])%O;S5'D:UAAGA2*&.W-S'*;BW1I$=8TCF=W9(Z
MZ:<\3CJE%X3#<F'C_M?L82J.E1]OBH4%.-*I*;HTW*KAHJ-2_+SQC!0;A1CE
M45&A&O[:JYUG^X<[1<Y>RH*<DYP4%4E^[JMRA\4H-R;BO:/5\?W.J>$_AFVO
M:?*VCZ]XSUS3_ W@UXY(UFL5\1R1?VUK&HS70F?3]*T;PM97URQDFAAQ-*+8
MK&RN_GOQG7Q3=ZA-;>&]-NY_A[X3TG2_AM-J2+;O::C9_8L>=;B8>9=+J.OM
M':6\]C&QCD@C,\J2D ?67B7PG9^,=3UG2O'EC;6$&M7<>B^'=+M]4@DL/,TG
M3+A;)["U6R2:>[U;34EM-;NH4QI6GNU@KQND;U\WM'KFB7VH>$->GT>\O_#-
MGJ6OFT\.RW,B:IXGO[JX&E6$FN7,)L](;1[F:XU"XM'GMX%>TM;>4_;3'GIK
M\U%T8K#N=.K1Q-*<ZT'6YZM6CB*,JTJ"A'V;HRFL71CSSJ3J82$YQ5O9F.&F
MI\\O:*-2G5I55&#4+4XU,/44(5>9\UU3^KU).,806)G;23DN4^$>E:AX;U'Q
M*J7^HVCZ[<O#JK/>.4BE\+Z7]AO;!3.&0VL%_?AS]HC^P_;;=GDX5VCY#15\
M4>&]=\0V]C;SOH%P\N@>*K9Q;74-C9'4_%,=A<223-);R23&&U_M$0*S'S+1
MC'*%\Y+'A[49IM#U+PWI>I:GK/BLVDWB*?6+6/[%8HWB3QE<R^)=/0%Y[A-2
MC'D6-Y;@R1R0M<74'^CLXCZ/6KR\T'2E\7:WH+_V;>V&L:O-IXSI$-WJE]I^
MFPZA9VME923W<\FFZE.8;2YN)4FNYX]0D%D%FLG/B4L/*IAZ$*:G!4DL1!K^
M)-8R=.ERPMS<Z56S<(<TI0J\\5*"<H>K5J<E6LYN$W5_<R3MRWP\?:*4DW'E
M;IZ1E/EY9T[.S]V4OA+4H/$4>D3MINH:9<6K1Z#H[V:?98]-NKZ&8W<'EQ!5
MNIHM+NI0(7B+174DL\CSRB0L:SXAN[#XAZ3\,-:T<2Z2PU.XT&^UNPDN8'\2
MVMFQL-4@GM0^IW4GG"XT>WV0Q+<36["T@::V\QO1/A'IUO>^$?"VM6ER;2.]
MU>XU!M+>Q6\GT]M0M@UOJ'FWXMMFISV$F%E5R]EOWK!<2D^1ISQ:#I/QK\-P
M7EQ>2W^FZ%X@NK"\N(9KQ$EMM+O+N2[MP!-MN5DPEB';=-<6\T4"DSL&]O#T
MX4XS>(PD*GUJ7LH48U:D'A:N(J0AA_WKYI5G2DZ<5":G]8IQC&;BY<]/RZM1
MSJ-4JLTZ$)U)3<%+VL:4'*H^710YUS/FCR^RE-RBFERS^=M3\!7/B#3=1O/$
MVK&+Q1>:GI/@[0;FPU6T\^>)+VUG\265K+>2?V3:6<%O.^D0:K>W%A.9+AY)
M68Q9#_$6D:3IOBE[TWU[_9$.CBYU2>Z8RV>FV\X9%;4I(X[AYKE(;3:@LP&F
MDBD;S)I"JUZQH/A34'TF#4+^;PYJMMI&KW>I0Z/<F2WDCTJ^\C3;&1=)>*,>
M<^LV5Y-/=SDVJ"TO1Y,DD\,==#;:)I;6,&HZE9I)I%II5R=:EG:'[+)-=7EU
M/;MK$D<F[3[.*"2XFA6)5>XGMC:VS&X24+RUJ&*4XPKTZD*M&E"BI8F$JM;V
M/)*'LIRK+EC3C"I5C04(P]G"+E3C&KRS73"O12<J<HSA.<I<M&484U4;A+F@
MH/F<FZ=-S4N92J22DW3;B9S:-9-_;FC^$_[50Z=X<T"_36[(17%FBVZ/-J-Q
M]LN(K2/3M/M+>ZE2ZTPK-=SQ&,WC,)6C)HDUGI^L3:-9RP71O4LO.\17X6*Z
MM-*O85&IK9G!&G,")(VNIFN'5"4,4:.P/$:+XGM];\8ZIK&L7^L6^A&UNY!<
M.+NWT:>)X;;^PO"^EQZC,L0T>5T:YATJWMFN[NXC-S?16Z96-SZO#KU]+9^$
MM O;FQO+^SM;-[\3L=4N;:VCDWLE^SP64.ER+=*;J>X1'L(GN$@*I,8^KFI4
M*JY*RBL/7G2O"GR593I33FL/0E+G:A4ER1F^12G3E+W6I<V#IU*D'&4'^]I0
MJ/GDG3BJD59U:UK7<8\_(N:T)ZIJUO,_V-M!T_0/^"VGQ<AT_6I=>&I?L%>-
MM:NK^>-XY1<:E^U7X0F6U8LBQS"TLQ:01S0%XI(EC)83>=''_1=7\^_[*>N6
M^M?\%F]7CM+TZE!H?_!,&\T(:D(UBMM0GL_VI?#,][=:>H1&.FO?W=TMA+*7
MEGM4CF9AY@1/Z"*[:^(>*K3Q#J.JZK4G4DXMR=DG\,*<;)KE2C!1222NDI/P
MW3=)^S<>3DTY;-65M-&VU=6;N[W>MGHBNR\(I-OO),D0;8T([--DLI!SU1-P
M;CGS%YXKC:]5T>S^PZ?!$5Q(R^;-Z^;( 2#[HNV/Z)WZG$1F>,?^1<U'_MS_
M /2^UKR:SZ?B?Y&O6?&/_(N:C_VY_P#I?:UY-9]/Q/\ (UZ^!_W:?_7U_P#I
M-,#J+/I^)_D:ZBSZ?B?Y&N7L^GXG^1KJ+/I^)_D:=7[7R_0#H[;M_G^]6_!T
M/T/\FK MNW^?[U;\'0_0_P FKCJ=/G^@$TW0_7^B5AS]1]1_-:W)NA^O]$K#
MGZCZC^:TH;OT_5 8MUT;Z'^2UR]UT;Z'^2UU%UT;Z'^2UR]UT;Z'^2UUTNG^
M)?H!R]UT;Z'^2UTG@,D-J^"1_P >'3Z7E<W==&^A_DM='X$^]J__ &X?RO*U
MQ7^Z5?6'_I< /0\GU/YFC)]3^9I**\0!<GU/YFC)]3^9I** %R?4_F:,GU/Y
MFDHH 7)]3^9HR?4_F:2B@!<GU/YFC)]3^9I** %R?4_F:,GU/YFDHH 7)]3^
M9HR?4_F:2B@!<GU/YFC)]3^9I** /G;]JK_AK-O@IXE7]B4_L\?\-$->^'U\
M)?\ #4Y^)7_"E_[,.MV(\5_\)'_PJ7/CG[?_ ,(U_:?_  CW]F?Z/_;GV'^T
MO] ^T5^!W_!-;_@DS_P4/^!7[,G[5W[ O[9GC#]B#5?V1?VF_!_[1.H7?B7]
MGC4OCOXC^/\ H7Q?^/EMX>T">Z1_B9X-\%?#A_AWX?T"'7M1L+!]'NO$J>(H
M-!2?4[[3GO\ R_Z>J* /Y5_A9_P1C_X*.>.M"_8E_9&_;?\ VAOV0O''_!/O
M]@7XG^&?B5\/+7X.^%/BU:?M$?'AOA?!K-A\)O#/QD@\7P6_P]\*Z)X?TK6)
M-(N!X*U/5;I]$$VGZG-XEU::'Q-9^>:3_P $)_\ @H_HW[/.K_\ !*ZV_:G_
M &59_P#@E+KWQR7XCZCXJG\'?%&+]MA?AJWQ$T[XHW7P?L]+M[9/@O!IUQXH
MTV.[?Q#_ &RVKKJL]QJL,D&A-'X'B_KKHH _ ;_@H1_P3^_;N_:,^+.DZ?\
M ;P/_P $@[[X):/X%\-^"/AQ\7?VMOV9?%OQ;_;!_9DBLM/M;/5=0^".J76C
M^)_ASJ\VFZI;GQ9X2M_$@T:UM=9,,%]$XMDU!_T^_8+_ &/_  ;^P1^R-\$?
MV2_ >NZCXJT3X/\ A>?2[OQ=JMG%INH>,/%&N:SJ?BOQIXLN=+@NKZ+2?^$D
M\7:[K>L0:0NH:D=*MKN#3GU/4GMFO[CZ[HH 7)]3^9HR?4_F:2B@!<GU/YFO
MQ@\6_L&_M?\ A/5?VH_A_P#L[?%SX&:3^S[^U[XL\2>+/'@^(^A>-9/B=\.+
MCQ[%<67CFU^'T'AR&3POK,>I:;=RV,4OB.\M&-E#90VZ:7J$-QK5Y^SU%=F#
MQU?!.HZ/LI*JH<\*U*%6#E2J1JTI\LTTITZD5*+7FI*46T_D^*N#,FXPI8*&
M:RS&A5R^>,>%Q>59CBLLQE.CF.#JY?F6%=?"SA*6%Q^"K3H8BG)-VY*U&5+$
M4J5:'G/P>^&>B?!?X5_#SX3>&99YM"^'7@_0/"&F7-SA;J\M]#TZ"Q-_=*A*
M+=7\D+WER$)03SR!/EQ7H^3ZG\S245RSG*I.4YR<ISE*<Y/>4I-RE)^;;;9]
M)A<+A\#A<-@L)2A0PN#P]'"X:A35J='#X>G&E1I03;M"G3A&$5=VC%:BY/J?
MS-&3ZG\S245)T'PO_P % _V*]&_;@^"0^'[ZY!X3\=>%]83Q5\.?%EW;37NG
MZ=K:6TME?:3K=K;NEU+H'B'3II+*^DM"]SIMY'IFMPVNI'2CI-__ #GV?_!(
MS_@H]XATCPM\"]>\/> ]%^%GAGQQK_C+3/$]YXX\%7.B:7K7CFP\+Z%XJU@#
M1IKKQ_J$)TKP7X>;^S;G0S'&UJ#IT4<]W?$_V,45[V6\1YCE>'>&H?5ZM)3E
M5I+$4G4>'J2BXRG0:G!Q<E)W4N>%W)J*<Y\WXCXA> ' 7B3G<>(<Z>>9?F=3
M!T<NS.ID.90P%//,!AJU*OA\)F]*KA,7&O"C4HTN2I0^K8AQHX>,Z\UA<*J/
MS3^R)^S/X7_9&^ W@[X)^%KZ36/["CNM1\2>))8)+.;Q3XMU>47.NZ\UB]W>
MC3X;B81VUAIZ74ZV.F6EE:M/<2Q27,WTOD^I_,TE%>+6K5<15J5ZTW4JUIRJ
M5)RWE.;<I2=K)7;V226R222/U[*<JR_(LKR_)LIPM/!99E6#P^7X#"4N;V>'
MPF$I1HT*47-RG+DIPBG.I*=2<KSJ3E.4I-<GU/YFOYN_^"KW_!+#XJ?%?XHZ
MU^TW^SGI<7C/4O%T&A1?$;X:17EM9^(CK>FV%KX?A\4^$TO!9Z9?Z==:3IVF
M?V_I4E_%JT6J1W.KV<>J0ZC>1:5_2'17;E>:8K*,4L7A7'FY73J0J)RIU:4G
M&4H32:=FXQDG&2DI133W3^1\2/#?ASQ2X:J\,\2PQ*POUFECL'C,%5A1QV79
MA0IUJ5+&86=2G6HN:HXBO1J4Z]&K1JT:U2$H<SC.'\8&@?\ !.;]O_\ ;"^*
M_A^[^*7POG^$6EZ1X;\$_#_6?'GC?3HO#&E:5X5^''AC2_".CR6/A[[9/KOB
MC6)-"T:TMK9]'LCIFIZGMGOM3TFQEN-0M_KS_@H1_P $9O%UE/X>^(O[(.CS
M^+](TOP?X)\&^*OAG=ZK"?&,MWX3T+3_  G9^,-!GOEL=,U:+4M)TK3;CQ1I
MIN[34(M:-YJVEVEY9ZA<6NC_ -0=%>W+C'-/K.&K488>A1PT)4XX2G"?L*D)
M\O,JEYN;:Y(J#C*/L[>ZE>?-^/X;Z)_ALL@S[*<TQ.?9WFO$&,H9AB>*<=B\
M-_;>#QF&^L>QJ9?*GA(X6C"3Q6(>+A7H8EXUU7]8G)4L,L/_ !@:!_P3F_;_
M /VPOBOX?N_BE\+Y_A%I>D>&_!/P_P!9\>>-].B\,:5I7A7X<>&-+\(Z/)8^
M'OMD^N^*-8DT+1K2VMGT>R.F:GJ>V>^U/2;&6XU"W_K]^$OPR\+_  6^&?@;
MX3^"8;JW\*?#[PSI7A;0UO;EKN^DL]*MDMQ=7]R0@GOKV19+R]E2.&)[J>4P
MP01%(D]"HKSLWSW%YO&A2JPHX?#X9/V.'P\91IIM*/-+FE)RDHKECM&$;J,4
MY2<OOO"[P6X9\+:V<YCEV,S7/,_X@G%YKGV>5J%;'5:4:DJWU:BL/0P].A1J
M5I>WQ#:J5L374)UJTX4:%.BN3ZG\S1D^I_,TE%>(?L!\Y>&O@A.FJ?M!1>,I
M-*U#PU\9-8BN;2UTVYNY+^UTW[#>VLAOA=:?;P6FHPRW$5Q9/:2W\<4T*R^:
MK1JK>#1?LI_%"?P1XW\.Z[XH\':YJ_B;QUX#UN'4+FYUE;>[T#P9:76G,=8#
M:#*XUB_L9+?S+:.&\M))EF,VHMYFX_H-10!@>'O"GA?PC;36?A3PWH'ABSN)
M1/<6GA[1].T6VGF"[1--!IMM;12RA?E$CHSA>,XXKH,GU/YFDHH 7)]3^9KS
M'XSQVG_"J_B!J-WX6TGQI-X?\'>*/$>E>'-;TJQUJSU'6=%T#4KW3;<6&HVU
MW;237%Q&+5"T#MB=T *NRMZ;2,JLI5@&5@596 *LI&""#P01P0>".#50ER3A
M.U^6496NU>S3M=:J^UUJCGQ>'^M87$X;F4/K%"K14W"-14Y5(2C&I[.:<)N#
M:FHR3BVDGH?PD_L%_!OX<_'S]HGX>:A\6?BG\+M.;4/C#X:M]1^$?C+1O%CZ
MI\5K/5;^.ZU'2] B\,^$[SPA8P:B\LFE6]IJ>K:!;0SND4"6UJL3CD9O"7AS
M]GW]ISX4ZA\-/B;\,OC[$_Q*LVN_#?@_1?%4FCI:-XKM]*O/AWXHTKXA^%/#
M\&I6_B72+RYT2Y@MX-1TZXLKBZADN4;::_6C]HK_ ((P?'CX<?&ZW^,7[#?B
M30QI=MXAF\;>%_#6J:S;>%_$_P ,-?M=0&H:=I7AW4M8^V:/X@T>SD8'1;W4
MKO3KVSAA33M3M[TP#5K_ -$_8*_X(S>.O 7Q<T+X\_M9:KX3O+SPGK*>*?#7
MPNT&Y_X2-=2\6*9KNSUOQIK,<%EI%O#X?U9K?5K#1-%_MJVU74H('U"_M=.M
M)M,U?]<JY_E:IU\P_M-5*%7!1IPRNU/VWM;54Z+I*DJD%>I%>TYU&Z;E4E2C
M!K_+;+?!#Q)>.R7@=^&]3 9WEG%U;,,9XD>TQTLJ_LZ53*9PS.CFE3,)X#%R
MC3P6(J?4/J<ZRC.G&A@:6:5<8I?T.>'/"_AGP=I<&A^$?#NA>%=%M@%MM'\.
M:1I^AZ7;J!@"#3],M[6TB    CA4 #'2M[)]3^9I**_(FW)N4FY2;NVVVV^[
M;U;]3_4ZG2IT:<*5&G"E2IQ4*=*G"-.G"$5:,80BE&,4M%&*22T2/EWXC?\
M(Y:Q_P!P_P#]-5C7$UVWQ%_Y'+6/^X?_ .FJQKB:184444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'VSD^I_,T9/J?S-)10!_FM_\%_/^4MW[67_=
M"/\ UF?X-5V_[+D]G^R/\&]/_:#O/V(/VAOVC?A#XM\'Z5'^T%?^#/VO_P!F
MWXS?L?>)X;>?2-;T'0_VA_A3X6_8W^.]O\$_$/A_4O$/AO7/#?@CXV?$#1?B
MCX3\0S0WFG36-S->6PXC_@OY_P I;OVLO^Z$?^LS_!JOEN]\#_$/]FKX%_LH
M_M@? 'Q=\</ _B?XCI\6M&\6?&[X=^+=3\*>'_ ?CK2_&'B7PCIGP>T/Q1X+
ML]&\0>%/'=U\-=%?QUXET[5_%UU-XJ\(^.])DTC2;+2]*U>74/R/$5)4LVS:
MK!2YJ6+Q<^>,:,W3B\8Z;E[.M2J1J+]XE*"E2YHN2E4Y6T_[^RC#4L=P%P'@
M:TZ7L\;D/#]!8>M5Q^'ABJD.'X8N%#ZUE^.PE7"R:PLY4Z\J6-]G5C3G3PLJ
MD8RCYW^UY^T)IO[3?Q8/Q0LH?C9!<76A6FEW\'QO^,?@SXQ:E8O97^IS66D>
M!I?A]\"/V>/!OP[^&NBZ;>6FF>%/A?X9^'\'A[PE';746@RVFDW5GHVE]/\
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M]8U>RL]*NO!GB@*D7A#Q+X7;4M#UNZ@NAHVI311NB[US\6_ FF:IJ-Y:^+?
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M (=<_P#!._\ Z,Y^ O\ X0FF?_$4 ?>E%?FIXP_8 _X)>> M1\!:5XL_91^
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MO#^O/X6\,P/&S:QXT\3+I'@[P[$4G\0:]ID$L4C]-_PZY_X)W_\ 1G/P%_\
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M?B5X[^'.@V/@KP59ZCI3ZM:Z)JOB#Q[JTVJ6=IX-\#^*+P75O; 'U'17.?\
M#K#_ ()S?]&8?L_?^&^TC_XU1_PZP_X)S?\ 1F'[/W_AOM(_^-4 ='17.?\
M#K#_ ()S?]&8?L_?^&^TC_XU1_PZP_X)S?\ 1F'[/W_AOM(_^-4 ='17@OP;
M_81_X)@?'#PMKGB[PG^Q%\&]/TW0/BC\9OA+>0>(?AKX8M+Z7Q'\#?BSXS^#
MGBR]MHM-O]6MWT34?$_@?5K[P[<RW,-_=Z#<:==:EIND:A-<Z7:>K_\ #K#_
M ()S?]&8?L_?^&^TC_XU0!T=%<Y_PZP_X)S?]&8?L_?^&^TC_P"-4?\ #K#_
M ()S?]&8?L_?^&^TC_XU0!T=%<Y_PZP_X)S?]&8?L_?^&^TC_P"-4?\ #K#_
M ()S?]&8?L_?^&^TC_XU0!T=%<Y_PZP_X)S?]&8?L_?^&^TC_P"-4?\ #K#_
M ()S?]&8?L_?^&^TC_XU0!]]T5C>'?#VA^$?#^A>%/#&E66A>&O#&C:7X>\/
M:)IL"6NG:/H>BV4&FZ3I6GVT8$=O9:?86UO:6L" )#!#'&H"J*V: /\ -;_X
M+^?\I;OVLO\ NA'_ *S/\&JYK]GS7M,_9+\-?LQ?$0_M'_MA_ WP-^TO\(_V
MAOB-\9]2_9K^-_B+X.1>,/%?P<UKXQ^#/@5\'=$UGP=X \8G3?$EQXV\*Z)%
MXJ\0>,="^(%AX;T/XS:3J\>C>$],2]U?4^E_X+^?\I;OVLO^Z$?^LS_!JO*O
M@EHG_!07X1_ ?6+_ ,!Z-\.M4_9_\16\7QGD^'OQKTW]DCXT^$YM9TSP9KFM
MQ>-?"7P)_:-@\>2Z;\4[SX7:'JWB)6\&> [/XH>(_A18VGB 6^I^ AI5\WY%
MB&XYQF<U"K)PQN+E&5&FZLJ<HXQSYI04Z;<)QC*E/]Y#W*DM7\+_ +^RJG"M
MX>\%8>IB<#1IU^'<@IU*./QD,#3Q<*F04Z*IT\1/#XM1Q&'K5:..P]L+6O7P
MM)6@VJL/(OVW/"OA>+7_ (+_ !G\-W_QMFN/VH/@X_QS\2Z=^T7\3M/^,GQ>
ML/$5W\6?BG\/;G4O$?Q+L/A[\+7\86/C&S^']CXVT'6[_P %:=?7FE^(87DN
MM4B$-_-J_LR?MZ^)OV7_ (1?%+X.:!\!O@+X]TCXQW-Q#X[\:>+9?CYX+^+&
MJ^#KW2['2]1^%+_$[]GWX\_!'Q;-\(=8%E]O\0?#>^U&]\,^(]1N9Y_$%EJ<
M<=G#:?+_ ,8_C1\5/V@OB'XA^*_QG\<Z]\0_B#XHN%GU;Q'X@N4EF\F%?*L=
M*TNQMH[;2_#_ (=T:T6/3O#WAC0+'3/#GAS2;>UT?0=+T[2[2VM(O7?V3OV?
MK']H[7/B[X+LX?$?B'XG:+\#_%WC+X'_  P\'ZOH>D>*OB[\4-'USPI:0>#=
M!CUO3-8E\37VD>#=3\8_$=O 'AG3Y/&OQ"M/ EUX,\(7%AKNM6E_;<,:M26+
M<\*W&=3FC'FA"\[PM-NG:<>:M:3]E%3]Z?LX<VE_IZV"PM'(:=#/5&KA\+[&
MK55/$8CV>&]GB5/#1CC'+#5I4<!>E#Z[B'0;IT/K>)]E^\Y//OB]\5/ OQ*3
M05\&?LU_!3]GUM';4FU"3X0Z]^T9K3^*A?"Q%JFO#X]?'[XW1VZZ,;2=M-/A
M>/PV\IU.^_M=]56/31I_[A_\&R'_ "?G\6_^S1?'O_JY?@'7PO\ M#>&_BY^
MSA^Q-^S_ / _XX?#Y/ GC;QQXK^.7B!?@Y\:_A3\-])^-'PY\-6?B3X9W'A;
MXV>$-<B\!^$?VC/A;I7Q+U6S\=?#RY\!_$_Q;XE\(>-K/P#?^,M&T!K&7PQ-
MX>^Z/^#9#_D_/XM_]FB^/?\ U<OP#KT<KA*GGF7J>DW4H3G'V,:')*=)2Y/9
MP]U636MHN3O*48R;/C^.<33Q7AEQ;.A[V&AALPH8:M]?KYE]9HX?'^Q]N\5B
M+U9.<X3]QU*T*:2A3K5*:BS^Z*BBBOUH_@H*_F*_X).Z?-=?\$_?V?KZ*#4X
M+F&3XH:=8W-GJMTUD\@^,WQ5O?M>HZ0CQVL<<27%U;?:[B.:-WCME9Q,+80_
MTZU_+C^R;\,/^"H_[*?[/?@+]GY/^":*?$(_#Z?Q6!XXLOVR_P!G'PC!XE_M
M_P ?>*_&<$\N@W2Z[?P6UFGB7^SH(+K6)&E2T%ZUO8RW<ME#[N08W#X'%8BI
MB*CI0JX.I04XQJR:E4JT):*E>7P0F]?=T_FY2)Q;Y6DFXS4K.UM+VW3ZV/TK
M6)W\76=IK/B*[M-.M%TN2ZU.V33$ENM4N[;598/"5]%(@N+ZS>W4ZM%'9M9S
M)&_ER74V2M6DA-OYNBOJ9U:2ZDU75].OVL)42RTM9[9=/L$CDB,5O);6LJQR
MP7]P;V:[\YH!- CF+Y+N/%/_  4^NKFUNKC_ ()+-++9,7M'E_;K_9HEEMY&
MR&:&:317= 48QC!WJIVI(H)!QM1U3_@J)J&K6FM-_P $K];@NK&VU.VMK>']
MOO\ 9P73B=3%@'GNK'^R!'<SVGV!/L$C,C6GVB[\HC[3)GZ1YUD\YR<L2XPG
MAW2G3^JU7&4X1DU*ZI*2E6GR*4M5!<R:EI(2YU:VZFI)W6FJLUIIRZZ)V>FU
MCZBM/$MU;77BC0K6PCCU_P !-:Z3/=>*-VEZ+K4U_:Q:M!_8LMDU_=/&]G+;
M>:D<<R1,WE(6D218/L/X::=J'A?P_)X^U2VO-5U#7;&VLM.\.^'4;4"D+S;H
M4GD!18KF6^#I=3S&.'2X4:.Z(=)MOY5Z=J/_  47C/AV\US_ ((_76L:WX8U
M2>^L]6MO^"@'[-FCG5K1K@75CI_BNVA\.W)\1'2)2XTV_N+B&\MX6$ ?R_,6
M7USQ?^T#_P %6O$6CPZ+I'_!)2X\+6WVVTEOFT[]OO\ 9M=KS3+>7S)]&C6/
M0+-;2TOAF*Z:,.7B)0* 3G@Q^<X#%1P^%P[^KT*OLECZDZ=62_=PIPFJ?(I5
M'2JRI*M&,*=.I3Y_8<_+'G':5VVW.SERMV5XN3E'2^C7-9[K2ZLV?4FO:_KD
MWB:/7-6G@\1ZI;PW=JNG6#0S:3X<U';'MA:UE9(]1.GR7*V]LR&XMKVYMVO;
MEI/+C6NDT'Q=J_A7P_JOAR+2=#L)I[=[I[>&Q.GK:1O Z/->V,%W&/.O$C)B
M(M=/@6*/[3']H68A?S4\(^(_^"J?AG0K32KW_@ESKOB2_@FO[FXUW5?V]OV:
M%O[N6_O[F^9"(=$"0VML+D6EG;(62"TACB#-C(UK;Q=_P4ZLYQ<6W_!)*6&2
M26>>]D7]O+]FPS:C+<0^5))>W#:*9YY,+'L>21FCBB2WB,=N!&-I8[([RHSQ
M<:]&C)*DX87%0IUE1DW2DJ<H1]E!ZRA!T^:]1JHE[SD-S:BU"S:7-JDULVKK
M1M;-IZ\O71GZ9R?&CQ/+H;ZG;:'9B6:TTVXTN'35_M%I"S12FVN&FGMT:WNH
M95B>[B++IJ![R-+P$15VFB:[X=^*S6"Z[HW]E:K;:?<W#>'-0O)&U>UN8[N-
M)Y(;NR(T[4-+GM%0N!,\X66-9[:(*[#\E['QC_P5&LM1OM5/_!*76+B\U&UL
M[2X2;]OW]FXV,,-@KK;I8:>-#%O8H6=I;D1 M=3,SRN5V(G2Z5\4?^"H.FZW
M8:\__!(ZZNKS2UF>PC;_ (* ?LZV]O%>21/%'<21V^CH9XXQ*YDMG81W!V"1
MMJ;6Y,56X?=*I]4J2H5X\TZ-:A#%J7-*FE[&7M4DZ;DDI3:C-6YX<O-4A.%&
M:UMKMNOOTZM=+O\ )GV[K_PZL?AGJ.KWMW<R3:-XGOVU>;59A.-*T^]MTAL[
M/3!:SSW-IHZK"D36D-F(H)VBDN%5;CS&;GM7US1[&[T33=0D6QG\07"VVC17
ML\5@NKRWMC>7EM:6MG,1)?O>6=I/=11-"56W'VS_ %:L!XC%^U!_P51DMHX=
M3_X(]0ZA(I1Y''[?G[-\5O)-"XD@F6UG\/7@CDB95=6$K;95$D?ED!1S>N?'
M#_@I?XEMM0MM:_X(V17;WEP9;>^3]OW]F>UU/3(%C1(;:QU*V\)Q7D1A/VDK
M<B87!6\GC+[-H#PW$-+]W''4YUG"*IRKTJDHRG&FHPH2C3=-*U*,5>#E",H1
M4(QA=H.271)/?9=7[U[-:O76^[NU=L^B-3U]-&B^TI$(WTZP>Y.E6PMK6.:T
ME=K2VM/[0N9(;.S:WFCB26;E$0*X46[*1RNN175C#J'B+2[=[G7+:UC?0;34
M ;JWANM9\LZE!9Q65O<WD\UZL$%M<V6F1/?WYM;:.UDCEN&F7Y<LO&7_  4M
M36+74M4_X) C4K6UM6M!IL?[>W[-]FKPQHR6$#WAT6[NGM[$22MME>6YNI/*
M:XNW6,I);T+QU_P4NT7Q3%KS_P#!(6\U+2]+D6X\->'K[_@H'^SC<6^D7ZK;
M21ZM=7EWH%U+J6K6-W!)<:1>)#I_]FI</$D4TBI<#U:?$>5X><I4W*;C1YW:
ME5C&O/FO+#._*XJ:7(Y3CRJC5G!U9**IRETI2C9MWNK:K1)*S3Z-.[T2U2LE
M=M?KW\/?"4'@_P /16H(DU/5)%U?7+PQM&\^HW4$680K9E2VL(E2SM89"6BC
MC.=K.XKN",8^F?\ /^3_ $'Y:G]J?_@J:23_ ,.>9LD]3_P4)_9P)_7POR??
MW^E5[K]J+_@JE-:W$-O_ ,$?Y;6>:&2*.Y_X>"?LWRM;F1=IE2/_ (1J,&1
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MU"^U%83:WVHWHM;O4))-(N4FNK"WL9M/LQ+/B6W=8E!ZF;7?^"I[W5M>0?\
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MKK\,/[??_!,V)= UCPQ=Z'XI_;D\/WEWJEE99U+4KCX ^!K:*YT:WMKB?SK
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M/XBOP#Y,_P""6W[-WC/]FJ[^-WA@?LE67[/?PEN?"OPXMO"'Q ^*'PQ_8O\
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M]E^T]-\)U_9MGUGQ+=:A8>'M%TU/BN;O4?&E[:^!+:*3QI<1:"P!_.I\./\
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M1KCX ?M(^&M.^-OA#P%'';7WBCX">(=:^#]KIW[07P]M]7U'PXFN?$3X!O\
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MTN[BQ\6>&;C5@#X;^&G[(GQ6L_!_BN+X2_LLG]C/X<:]^W3\#/C#\,/V;?\
MA(_@C9?\*?\ !7@CX?>&/#OQ&^)G_")?!/X@^-_@EX$_X2GQMIVH>*O^%?\
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M/AQKGA1_BG^SI_P3^UG]JWP[X+\1? +Q'X\_:6^.'PO^*OC+Q%^USI_B&?\
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M '\@_P#C%'_"-:=_SUO?^_D'_P 8KG/[<U3_ )^O_(%O_P#&:/[<U3_GZ_\
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MG/[<U3_GZ_\ (%O_ /&:/[<U3_GZ_P#(%O\ _&: .C_X1K3O^>M[_P!_(/\
MXQ1_PC6G?\];W_OY!_\ &*YS^W-4_P"?K_R!;_\ QFC^W-4_Y^O_ "!;_P#Q
MF@#H_P#A&M._YZWO_?R#_P",4?\ "-:=_P ];W_OY!_\8KG/[<U3_GZ_\@6_
M_P 9H_MS5/\ GZ_\@6__ ,9H Z/_ (1K3O\ GK>_]_(/_C%'_"-:=_SUO?\
MOY!_\8KG/[<U3_GZ_P#(%O\ _&:/[<U3_GZ_\@6__P 9H Z/_A&M._YZWO\
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MIW_/6]_[^0?_ !BN<_MS5/\ GZ_\@6__ ,9H_MS5/^?K_P @6_\ \9H Z/\
MX1K3O^>M[_W\@_\ C%'_  C6G?\ /6]_[^0?_&*YS^W-4_Y^O_(%O_\ &:/[
M<U3_ )^O_(%O_P#&: .C_P"$:T[_ )ZWO_?R#_XQ1_PC6G?\];W_ +^0?_&*
MYS^W-4_Y^O\ R!;_ /QFC^W-4_Y^O_(%O_\ &: .C_X1K3O^>M[_ -_(/_C%
M'_"-:=_SUO?^_D'_ ,8KG/[<U3_GZ_\ (%O_ /&:/[<U3_GZ_P#(%O\ _&:
M.C_X1K3O^>M[_P!_(/\ XQ1_PC6G?\];W_OY!_\ &*YS^W-4_P"?K_R!;_\
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MW** /RO\&?\ !.NY\%_LP_%'X Z7X(_X);:3??%#Q;X;UK7[#PA_P2X/@_\
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MS^TZ2/%A;5CX@'@C!\-:+_PDF= ^Z** /S4_; _85^*G[1/B/XV:G\+/VDM
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M!VE_"FY^.OQ&\'?#[XR>(!I&MW'CJ\^!7P;D\0>*-0?4O!FA>-/#<WC7X?\
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M[K0/^&7/CA_TD?\ VS__  AO^">'_P! 91_PRY\</^DC_P"V?_X0W_!/#_Z
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MQ:>%]?BT6ZN+ZSOM473(YM8/:2[4_P#P52_^0\OS[L/J%#_GYC?_  Y9C_\
M-1^^B?LO_&V1%DC_ ."D7[9KHZJZ.G@?_@G>R.C ,K*R_L&$,K @JP)!!!!P
M:=_PRY\</^DC_P"V?_X0W_!/#_Z RO9/ ?\ PO?_ (6/XY_X3'_A4G_"A_\
MA&? '_"G/^$9_P"$Q_X6Y_;O]E7'_"PO^%E_VI_Q1O\ 9/\ :']G_P#"&?\
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MM_PRY\</^DC_ .V?_P"$-_P3P_\ H#*/^&7/CA_TD?\ VS__  AO^">'_P!
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MC?\ PY9C_P#-1]"_\,N?'#_I(_\ MG_^$-_P3P_^@,H_X9<^.'_21_\ ;/\
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M_#+GQP_Z2/\ [9__ (0W_!/#_P"@,I#^R[\;U!9O^"D'[9P4 DD^!O\ @G@
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M7RRQ+B[22=I)I[--:'V?1116)ZX4444 %%%% !1110!_FP_\%^?^4MG[6/\
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MPO?*?#LNB_"O0/'FF_#VZAL?!4-MH1@UF^CTL27%SJ89M1E60?J9\,O&^G>
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MJ[_L?0-.FU&XBTZV:6%;S4;Q81:Z;:>=$+N^GM[<2IYH<8'LGI%%?G%\4/\
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M8U=K>VBM+F],S6<=_)%<^3$Y>/?D-;NK&*_TZ#3Y(?MD5S8VT=S;ZW&C27,
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MY=T,-.I[6K)RHJCBJ=64J,:TZDJ,%*%6@XKVKG%5:JDHJ].I3E.$U=02[O\
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M]7US7=4U#4[UX8;2QADN?LNFV-AIT%K9P>Z4 2>9[?K_ /6H\SV_7_ZU1T4
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MXXT6PM[3]F/PSI4/Q2^-OBRQ^'7Q'L?B/\1/$^N^+_$4'@KPRGA"+3_Z:J*
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M&Z_':OV(_P""^W_*6K]K'_NA/_K-/P;K\=Z_%LU_Y&F9?]A^,_\ 4BH?Z/\
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MQ@_\$N?V8P1G+?&KK_V<-\6*N&[]/U1$]OG_ )GW[\3I+;5+Q=(L+^YM-?\
M#V@:EXINH;.2U@;4-(<+:+I-[<3H9H;62X":H&BFCM_.L+>.]BN4N8HQXEIN
MJPC^S_#]L9[O5[,M-?SWUI?Q6MYH<]G-<VMU::LENEA=ZS +*>:XM42!8+8J
MLX5RHKZ4OO!%M>:]XWUNZCBN8/%7A+1-!:TA>XCOVET(ZO,,7&\)!#=->V<<
M<, 4/+;&6Z+AU5?G%S>QZ3;Z5=3:A:2>'M42R::S"SZA)'?WEK>-I6HP&*=8
MYK;46O=)U2[@/ERV=N)DDA)<#] R2K0GA?JM&4I^Q>'E)MQAR5,30E*M+1.=
M6%/%3E0C22A)MPJ1JN,73AQ5%+FYMKIKU47%)7O[K<4I-MM?%&R;NY@PT>+7
MM1CT^TU2#4U@O7LM#ACBUC4[VZ^SZ9()OM-[::/J0:WBMV2?[5;226ZR6[1R
M-&&FETO1M+M]3&GZ/X7$.F6OA^*S3599V>5+59;A;;0X+617EN;& _;'>X$Y
M33E2TAE017-NPJZ=9Z78131VVIWOB"+2YKNZ72(KVWU6?_3GD8636D862XAL
M+NWG&B0W4L;V+L(('6&)0F[IBWBW=^7A&GZ7%+%;Z;:9A.888D*W6G) (_LJ
MWDQVW%A<*[><I9G>&4(/3J2<8U.2<_AM>4JE-2M[.%).E&<7.I3IV<5;EM.:
M<II6>:5^6Z2UTLE*V[DT[:*3TWULM$WI)K.HZY8W,>KZ+I\&J0"P2WU#2FNI
M+.\>_6W6RL[VTN9W^PV]LBQ-=7\#Q*U[.L*X+7,LR<;%KFJIJ/@S0[>YU/7;
MY@MQXFN)M(M]$N+?PO<6NH30:Q?Z%>W\$UA"VJVUII"3:;%JEQ;7KM R""XG
MN$[)KFZL[3Q+<ZO;:?!H]K'#)I$^G&YOKV\LE-MYPO-*2V#6]\ET)[=;:W:Z
M$]M&DZE-Y1:-R=:FU**QT^2T62"RMGU._NF@EN)+:[F8-';Z3;R"2&5FMP6G
MOD6T6"2YFLQ<30/&)H\D8.+I49*,'"-637+_  5R<\ESN4J"Q-O9TY0G[1TX
MUXU52A&!.[=U*:NXWBM7:Z;LKKE4^2[D[I1YN5Q;N[6G7FHV=H)]?D\NXEOK
MHW!B<8M(;RXD_L6QG)B)N)@9++3KEHG5$G:2Y5VCCV-HZ&=1A;28M8O(+JY6
M>:WDOX;"*S#6MU>RF.(0"2=@MO;S6]L\HD5I)4N)"B*^!#-)<37.D2VAT:ZT
MI;BWN-=36=S*^BP6DY0:<54P'4X]2%HT3WBI;B%92'AGCB<.U2]MM&M'U&^A
MO+FULX[9V33[6YN[N9+JYCMX=T5INN&,MW=0/<31C=;VKRW#E(HG(YI?O/<5
M."G7]Y0IPBY1E+GIQIPC)<T))S?N*7+*$J-TY*Y:LK2N[0ZR=DU:+;;O:2LM
M)-7B^;H]7>.X$\+>'-0OKG69[>#4'GALM2TN*&>]L4O(A%:2.MQ%)8PO!=,H
MBN[J&;3B,374?D"1:X/P+K4WB&QU*\L=#UBWOHM4A\/SSZGIEM++>VEG:3PR
M>)$OT:UBLX+AC!!)&@^UVP:.3^RUAFCF;TNZUG4[">[\-W^GZ9JV@3:3#<RK
M>6;W=J$E8M?V\FM/<*(O,62.73#;P1W%O):SWB7BH@A/!Q^%].GETN2V&MKX
M=CU>[US1[6_N+IKC3](GT=+7^S=09[N:6:*%[2TE\Y9&N0EE$(Y2)I2^N$DE
MA*E+$13G.2JT\5'EG"I248S5-TH^S:J3Y$G"<W#W93A+FCRR4N;VD91;LERR
M@[IIWM?F=[*SW2OK9Z/33CN[:V66+5'T^S2Z$=E*7E607;33&WBL[9YE4B>2
M21%CC!$AWR&/<@8"C:0Z7;R0Z(-+A\/:9I\UK:Z$\3B5-3>XLW62Z@B(@7[7
M96\,MAY4DDKBUMXF1D&%I;/3;?0](L;"2)Q:V44.HW=Q9JD$RM97'VQ[V"$.
MUS:65N$ OVMA)$+:]GAE<173*;R_9]0T&]\411QQV6C231:BVHRC2AH^;J..
MQU,V[0374L=S!)<)O*+;*D:;G"7*RQ[RE"+GRN;A.I&G&:DXQ]K*T,/)0;<5
M4J:TXPJNH^6HH4U&I**%9MI^ZI*-VK*3MIS*_9.TKJVUW:*9V-UXZU.2PTC2
MKZ+3]<O[,W\EYKEUI7_$L1$M)/LGV.*6ZFN;:[BC<1/-/'/#=744Y,8A:$OP
MVO6FJ-%!J$RJ-4TB6>];2['3X(_[7T?6/L]KH^EQ7+,(M*LE,YNIM6BD<S6(
M>UNH&C40RQ$6TWBB6RG63_A&Y=.M;C4];L=1ADO=.N+AGLVTU-&A:6ZTB]?3
M?+UN/4&,MO=M((RJS ,^E=12:G-;Q:;I>F:8/#EOI_AG29K[Q++=23^&='%T
M^J2:CJ-X9+2\O[ 8U2PRD=S?0"^LY99)TM#)S4J-'"SI>RIPIQE%UJU1JDH*
M-64FX-<Z44_:34X4J2>'AR5[T94X)MOF33;>O+O*ZY5%7O;5Z+WF[2:<7S)L
M^2OVR=(&A_L<?MEW,VJ7%^FJ?LU?%I[/0EN+5]/\-QP_"CQ%IA@T<2B&0V\D
MEPMUJ4DC":6Z1Q:H6EAMG^8_V0-&\;ZG^S3^S+KNE)-';>'_ (!?!N&70$N9
M&LO%NCR?##PY+/>Z=?)92G3?$.F0PSK_ &?]I^R75P((9T6>?$?T7^V&G@+Q
M+^Q_^U_XETVQL]5O;G]ECXQK-JRQ73V=W]F^'7B6XTN:*0YL);G3-0TB&1TA
M5;JRU&QM3>K'-#&#\V?L164>@?LZ? V]T353!=^(OV=/@9I=SHD6O:G!8VM[
M?> ='O+;5M0TSS;B/3I=3NKC4$^W:=%$U^(L7,$L-LB-EC8S^MS]M[:,HX*$
M:\IQ6'E2FZ^%I4](S:<(SM&<ZKIRJ0DY3BY5)\N^$:4?=Y)>_>G'^*II*;FK
MZ--QNTH)\LDN5KE5_HF\^+]CH5IJNJ>.9WT$Z/;PVNH/!IFKW*Z? TTL=@ER
MJV\]P8[JXN!NGEL4E,\<GDQJ6V)W,=Y9WFF0:A>ZQ91:+9Q6.N-K6JSG2["U
M@$1NXM66[2+_ (EUO9PRM(\-S"CV[11-+- PG#)+_9]]JM^FH/!::_IHM8+&
MW5+L6]J+BVE2&]U:*U2#S+1[A+L3SE9],%]'E98KV8E,U]&N[2ZAL+:RDO="
MU3^TY-6CTZPANK+4I)1:B]DU*TN)GO+B.XOUNUMA# #<VK,VIN]J&D?GJTJU
M*JIU92<7)56J=&:G3I3YTITU.O-<D(.,Z:C"-I2;A*4>63ZXU*4X*-.*B[6Y
MIU(N,IQ4'9M4X>]*2E&5Y.Z2BXQDF=3IOBC3=>M=/UN"].K:+=VMO<V6NZ9,
M);"[M[A72.]5K=EM)K6]N(7:"ZA39&R2?P31$^?KHL^LV6J-KVGW6GZ-J3ZY
MIPT*^L-%GL[IK;5(WL/%=Q=P6K['NH8)%M;4R2^3:7#7#Q+=^85ETVT\0ZOI
M^K6?A73=&U_3HY1X<DTG6)I])T/3]-TQVN5N[.73M'>73M;@E-MYUM:0_8;N
MVB6UBG@E5I6[[6[Y+."W\V+4;VYEN;'1+.'1A)YS27B/'/=O'%<A#I\443_V
MC>NC_98',4:+),4E*T*=JJ=/WZDYQH+$0I>U7LX)+VU.2A!>W;A*ISX:*<5'
MV3?/4IP4&XN"C/X>1U.24N7WI*_)/WFN1WMRU=-6[.*D^6TK2M,6*R<WUQ_:
M=A'J.J:/(WD7AM[1[B2(Z+!.(_M,UC;2217-M;QR2-<SP)+,5$2J=;2/#4>G
M>.M9\6/IRC5;[0A_:ES<7*_:=1=4MY]%U"72YL^5'?1W-^YO+:(36HM )T9W
MA58=*TFXU!H4MK:ZLKW3;74K6^=H$:.PFGFDETZ:TMY!&;RW-O*'EFV!'<+^
M\CV EOA*'7;K1AJ>LVMI!?Q6U[#+>VMY,+FXO&NYHDLW)MSNL+?]Y,;E\2E@
MJFU5BTHXZ+G*-%3IQYX>TY/:<T%[DHSO+GG",9.-53C)N3F_9V2A&*J:U%&+
MJ2C.\6HPFHM2;4TTDDHMN-X*ZTY;MZMOEP/%NA0ZU!;-+!/J<MY=-%+<WLHN
M+_2=2TBY^VL+%K^*-Y!)JEK%!:S1HD<H@M7A=[=UD78.A2:G>0W5Q$UC"FF/
M)+.UM!J &L7DUK)=VSV,[-'$;$V[I.+B"=)/M3-9-"\#N]J/Q''XAU6X\.N9
M+/4+2"(VFI3PQ7?]K0!D\Z5K6.1FDM(&BDLY7NY[:[=S(H@>T1;B2"2S;5[V
M+3[&RN[.70I=1TLZTUYJT5[:2SO9ZGID\,%S&]EXCBO,6D-VKSQV=NL#QV\D
MT[74;==&*YW*,(J"I.<9MTZ\HJM355MQG5CAU4JU*\<.XTX^T;4/W2K.'-G-
MRC&,6VI*:324J:]V2@FFH^T<8QI<]Y-JS:YN7FMS>OWL>IV>DZEI>CZ?/Y$R
M7+WEC)96H33YQ<0IJ,%R\D0-JD8>1!)YT-W&H6T7S )(H[_4=)U&QTW2X-]]
M#I5FNN.ULM]?7T=TMV-/TN2W%HHM[N6:Y>>)+*XF_=M$;BY22T5Y5ZG4-+GA
MLK4+)%!! U]9ZUYUL9)[^Z$0AMGL)6E\B*PL_P!\T,(MY%$:I WEM'(S<)+9
M0:3%#X<L1J2V&)-,2XMS"SW]UJVER3Z;?2HP^V7.FVT%M,EQLDBMWU*XBLA'
M=/O$3AR4<1:<>:$8?O)\]2%2-)SIJ,:K]GRN=.495&J,5)P4^9M1:IUK4I+D
MERR4VXQLI1<DG?EO*_*U)13FW'F<6DDWS]1=Z;_:\TL5Y+(VF:?>VTB6%M<S
MPWDGB#1;N&ZM]4FGTJX@7[&R%$N=,DC:&Y=O+NHDA3R6BUM?%2WMW<QPVT=O
MJEU;QP7FCBQBOM*#"7S=:O9;\"";4+669U2P$E[&R,[06R++/ .JOK#2]<32
M=,M_^$DT)?#=[8W%YJ&G7$<)OXM%>RE&FSZB)+F[O-.U:69EO"BF6^AM+JUN
M)+?S S48;/4]4NX3>75]9:=<Z\P2YBBT^WNR+:5[N32Y(@&1;!K9HHKF6W66
M0^9&3,DDA2M:U3V/L8.K3G!S<(X>*J4Z,7+D?MW&,[R=65XSIWJ<E)14V^:/
M+G27/SRY.5J*E*I+EE/W;KV:?*TN1>]%^ZYRNTK73MW-I>WEYX:TZ<7^O0+$
MJ:O=V4MAH]L\(6-QK=W%$(A,ZW212"PTF1EEEFCE:U^SP#83ZD8)?"NIW5[X
M>DM!H^H&]%U8ZRM[]DEO=.*ZAI,<:W,L4=NC117\%Y:/,)9(&%S;1K,XL6EQ
MX@M;JYT?[/>VNGV<T]K#/J-I9V-QJP:\,D=[93V%Q-;'2)=/G@L85,%OJ:M;
M3F]ABG.VM339-1:ULW\566B:=<RPF'5[>[U"*\M])BDRIBM]0:UB.I)//!$T
MAG2S6/>HVS+'&K=M!PC4E%M5(TY2I3E"T9U%555R5.+@GR2IIVG[-*,O91J?
MO)4XG/-R:C)JW,E.*O=1<7%)RY7923:]U2NXJ5KI-O\ .;_@HE%>Q:M^P8EE
M=0MI<?\ P42_9D,2>0'NH=1FNO&3Q26SK-Y5Y;-&DKS-*R/).8423RU=J_3;
MPC<:=K4@O$U72KW4_#%Q>>&;W4;W3;G3Y8]0Q:W.I6T*,'$=K._DW*3QFX,D
MBHR3EXF)_.?_ (*.1QQ:E^P%;02M9K+_ ,%&_P!EZ5Y$BMU: _:?&L4-W'YQ
MF=^DSKFWFM-\3"0 ".)_TGU'Q!%H#Z8M@);N74X[J);'3+ :IJ=Y=P6T4[0H
MZ!(1.@DS&DD*"=7+((E 8_/8J:I8C$J<W3DZ=%1=&7(Z<53<'"?[J<ZBJP;I
MNFJD(.HU.K%Z)=%.+J*T8<RO?WU?FU3YKN24>5IOFY9244^5]3IXK#38O[0N
MK8SMJ=ZT!;[ M_=6=P]JA0---/($BD8'";8(8RIW/N8!C6GN;6SOA;)ILMQJ
M&HP27!G@T][6SFDTV$;8+C444[;IHR\5C%(0LDSRL,$NKSZ8)KV&)8C=VM_J
M\L=P;>_E21].FFBB6>U:UP'M(8F #Q1[X893+DEND L;R:;4[2"6_8^5,D.H
M%U$$E\3);1MI]FSM+<Z? R07B.QA@NT:6-,2+(JY1NTW&3G%0CSM5%2M%1A"
ME>-W*2I-0M!1;E&#4>6+7*W:]I:/F=KQ<[N]Y:K1*2;U;6KW>M^<U$SRZKX=
MG6UMK2U'VR:^4KI,D]JZVV+5#:WUG-<W<HEF9)9;.ZL7MY$+N[PR%*NWOB2]
MT\2-'<W#&VL91_9EMIL2Q:BMXZH?*\]+:QNI3Y",4EN'DM_+)0HK@O3:TN_#
M&B))XFGNM<U6)46_;2]-ACO;B1KD1)J$]C#*\=K:K"WG20QO))Y".V&=61='
M3YX]4FW6(GU9;J,VUI! ':?=')^^^P0^1&0+A8W@DEE@=8E8G>DH!55/<E!N
M,)4Z4YT%7INI&G7M7E4G.;M&JZ<J=3E5H4:DJ2A9*I":-(6DFU>[49<DE%N-
MX**C&Z<%)--W<IQ3;ULTR235;F2;3TN(M,M-$AMIY+FSM;6:*YU.Y>!O+M+?
M49[L)I:^:4DOH+:TG>5XP!<QP;XI<VVUEHM.&NRZ)KMO-=6RC4= M+ZW\0,8
MHY"9_P"S)K5;$WS*BJWDO:S/-&/*RLAR-77]1LKJ]BLM*\-Q>&KZ)XW:TCO6
MN9M4$;[]@TZ51.ES(@>-IX6F"H1A0S*QQ;6R87]YJ.D6NIW,.K".\OH9;E6D
ML9TC6)(K>T:W:2WMY5 :X(C3=<Y\_P N4YK%QE4H-U81IJ,8RI5/9N%16G)V
M<J4X4ZBG[2=7VDU6K/V4:490@VGHN5323=YWYH.:E"WNWNI.;B_=C&T7&*4K
MOWK6\<T7XSP>)QJ+:GX(\3^!2FIZ9IF@RZI;S^';SQ-<3:C.[,L&IBXU#1;B
M^L_L49TZ[T\AY))X;:Z8R%4]FM_%.EPZG+X=\'>$GT^UG_TW5-?E,=M+!=DB
M^ELC"I$Z733+YE]YWDHZM)'*_F2@-G>(=%O[$V_BW7=2L-.\.VUY:2))XPO[
M:#1_#DES]GTBWN+6>1)A'>7=[<PK%=72.EK<RHT4UGY;3IN6GAO5M9UF6XT&
M32Y+" P0ZM#--]JDOT2W,L5UIMYITYA@,SE)(_MD<[-M9 CI+YZY4:TJ2IJT
MJLXW]JYTU2J2;<U1E&-.I[.:I07-&;HQDYNK&JJR5Y:U8TY\TDU3A)>XE5E4
MA%I4E.,G*"FI2DU>*G*-N5Q<$XVL+\0])U*6.XLM1&LW$BW"?VG]DD^S6+VQ
MD@F\YI8HK:"2(B2)X$+I%)M?RPRHX\XTZS\-Z_XGLO%/@^ST^ZFL7U.6\U<)
MK%LDEU/##H^HZ9!926]N9)=NFV974';8(EC33LVSSF=[WGB.Z\0Z):Z1\*]8
MNO!][;RZGKGCG5-?M]%T+0XH;FYM[]+S3]7M(M4N;EO*$M@EO$+67]_]KN+.
M*'S6P/BE\1/#?PL72XM:U7Q=87VH>)+NQ\.CP+X=?Q'+J=GI*Z;?:F+BPM'O
M9Y=.DAO[6'4+V_,,%E'>$6'VPEF6Z]L/357'JG"3DW1FJN'2I2A*M3JT*F%E
MS5:%>=:"4(3G0JTHM552G"M0J$T4IS]GA>=N4;2CRSES*7))352G[LZ<82<I
M6C.$K.+DI0J1/IC1[35Y])5M1N+J/6!JLU]IL^A[-)2UL'8I9Z=/"_FQW5G
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MJ+_LS']@W_U>'_!1ZO,A\-;_ *]K_P!.TCBQ7\?+?^PVI_ZKL>?9U%?SY_\
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M8=8NQ=Z5: '[KT5^ '[-_P 4OC=\6O\ @LEIGB3]H#]FO5_V6?'\'_!-/7;
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MI=)]GFM]0@26*Z7A/LS],:*_!7X_Z7XJ^ 'Q,^#7PE_8,\<?M5S_ +27PY^
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M\B['_P#8%BO_ $Q4/LZBBBLSM"BBB@ HHHH **** /\ -G_X+[?\I:OVL?\
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M-3>XL]-T'5K+3M,GN;^:6YN;G2[2RNY979_M"L<UU/@_]D_X ^ M9M]<\*^
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M!K6ASZ@DAL7U*WMI[66UU!8,R)8:M9W-S8WK0J\L,4Y>)24P?PS_ &@_A?\
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MW'QETSQ;I^NS:OXIC?4['5;'4K72IM:U.+?;0=CI6I_M66&G>/\ X@1)K%U
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MDM/[.OYKB*9;BPVRM&T8GDF\RX>*+^DL D@ $DD  =23P /<FOY\_P!D2^^
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MWBK_ (1[4M(OY6\/^*],@GD3R/$6D27-UKUK??9VG_\ !+KX8^%?COJ'QO\
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MA?\ PG/_  4-_P"C7?V,?_$\OCA_]+AH_P"$Y_X*&_\ 1KO[&/\ XGE\</\
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MS6CEN9^TR_$XW!UL/1Q<.3#PJ7H5*D:C=*=.JE%NE4IU.6<?Y*]2T[P9\!/
M_P "?C[\!_C[K@^.4VK^)]7BN--\->*=+U'7K_2_%>FV1MKEKS4+K3[&STZT
MFNK/5=,U*WNK'QM;2W-O<PWEG=-$WK?CV]T_]JW]H+]JGQ;^U=\3]7\%>-?
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M&=.L-$\0Z5I=QH/C.TU>WN;;POJ;6VL:%;ZI#=W/AQ-6L=*LYH;;1]/M[/\
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M.49-TIULVKTXSO%:SI5%:_NG!_V+J?\ S[?^1K?_ ..T?V+J?_/M_P"1K?\
M^.UWE%?2GXV<'_8NI_\ /M_Y&M__ ([7R;/_ ,$[OV*;J>:YN?V)?V3;BYN)
M9)[BXG_9Y^"\T\\\SF26::63PFTDLLLC,\DCLSN[%F)8DU]W44 ?!G_#N?\
M8B_Z,?\ V2/_ !'7X*?_ #)4?\.Y_P!B+_HQ_P#9(_\ $=?@I_\ ,E7WG10!
M\&?\.Y_V(O\ HQ_]DC_Q'7X*?_,E1_P[G_8B_P"C'_V2/_$=?@I_\R5?>=%
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M"G_S)4?\.Y_V(O\ HQ_]DC_Q'7X*?_,E7WG10!\&?\.Y_P!B+_HQ_P#9(_\
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M/_$=?@I_\R5'_#N?]B+_ *,?_9(_\1U^"G_S)5]YT4 ?!G_#N?\ 8B_Z,?\
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MT]?\XS@U9KK>_P M ,*XCY]><_YY_P#U9]JR)XCR0/KUY]1WZY]^O'09Z:=
M>1_^K]>G.?H>V.,J:(YSV[@=#_3!YQQWQQQ6\)):=W^.BL!S$\(()QZ]<?Y[
M^I'/ID5#9!(6G+,J!O+P68+G;OZ9(S]X=^,\\]=F:'.64'&?S_F._OU]<@YT
MMMN!P/TYZ#ZY_,^^.16SM.#A)V3MKZ-.WX;_ -,)OM-N.3/#CU\U/_BJ:;RT
M'6ZMQ]9XA_[-61+:$9Z@?Y_SGWX[9SGMAR"#G\.GISZ?C[XK-86'\\K>27]=
M_P"MQ_Y?G^ATQO[$=;RT'UN(?_BZ3[?8_P#/[:?^!,/_ ,77(/:C/W>O'(_0
M8/3W]_Q,#6><D<?3K],#_/?UJEA*;_Y>27JD)M+?KM_7S.V.H6 ZWUF/K<P_
M_%TG]HZ?_P _UG_X$P?_ !=<&;)N_P"I/^-)]C/M^9_QI_4Z?_/U_<OZ_KR8
MSO3J.GCK?V0^MU!_\<I/[2T[_G_LO_ J#_XY7 FQ)ZG]?_KU\8_&G4O!]E\1
M_%6G>(_BKXC\$>)[3X6^#]2^%^@:!\4/$?AO4M:\6W6O?$6,?\(_\-M,UH:5
M\2M:O;_3O#VG'1-0\'^+QJ9^Q:/)I=U%=BTGF6$IQ5_:-ZV^RNC>_?2R[NRN
M!^AG]I:=_P _]E_X%0?_ !RC^TM._P"?^R_\"H/_ (Y7Y:?$']H3XIZ-XLUO
MX>Z/J_@BT\26GA#5);VS?PMX?N=;\+^(=.^$M]XZN+Z.RE^/TOC'6]/&J64=
MK87EQ\%=.\+R)J-M&?$&I&S']K]-X'_:'U_7_C#X0^'<'C/X:?$'1M<*VU_J
M?A#0/#^@S$MX#O?%B:UI4<O[1OC/QG<Z3)=V]I:K=R?"A/#THO6MH/%;7%O'
M+=S]7HWM[2?Q<NT=W\[V\[ ?I+_:6G?\_P#9?^!4'_QRC^TM._Y_[+_P*@_^
M.5^>NL_M'7%AI7BVWLKWP'=^-?!>A_'?6?$7A9[R?[?H$7PXUU[/P6_B/3H=
M8DU+0K;Q#HYAU&ZEU"*%M3A=K_1EM[-2@V=-^)7C3Q-\*_C5K?AOQK\.O%>I
M>"]&U"[\)?$OX?\ AZYO?!-_=1^%EURXTZ+2)?'7BR#4=:\/7"O:WTL/BBXL
M?.O-/>ZTN-X+S2Y7]6I7M[26U]H]K]7\GT3T;3: ^\?[2T[_ )_[+_P*@_\
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MZF?5J7N_O)/FVLHVW:MK9[K=I+S _0[^TM._Y_[+_P "H/\ XY1_:6G?\_\
M9?\ @5!_\<K\M_$7[1GQ>\(>'?"^I^(HOAPC>.?#G@KQ/9:U8Z+;Z=H/@BV\
M0V/BNZN]/\1W'Q'^./PV\.ZW)>3Z!8V6CZA)XY\#NMUJ4MO#H^NW5O;6]_L:
MQ^TCXRLVT/[/?_"J+6[GX>?#3QE8_#075IXB\:_%O5/&.L:]IFK>'OA=JGA[
MXF2Z&'@BT:"YTO4=-@^(NGJ^J1+?71LK9M2N#ZO1_GFO6,?SO:_E>[>BN] /
MTP_M+3O^?^R_\"H/_CE']I:=_P _]E_X%0?_ !ROS2L/CIXIU[PS<W;Z]\./
M&DL=Y\%-1OI/AU_PE&BP> -7\7_%+PYX?U/X>>,[JQ^(&I:C>^);"TNYIC!<
MR^%5OET[4+'Q1X(DTF\FTNYGN_BQ\8Q\.T\2ZMXH^%WA.XU#PO\ !KXD1>((
MO!>NS:)X4\+>-_%Z:3XDTKQ';ZQ\0 NK6^F:<([RZ\3P7_AA4T\:G"FFZ;<F
MTUJR/J]+^>;T<M%#97\[=-+-];VLP/TF_M+3O^?^R_\  J#_ ..4?VEIW_/_
M &7_ (%0?_'*^%/C+\7]7^']WX.T^P\>_"'PXGB'P'XK\66^O^-[*]N]-\7Z
MQX<?PK'IOAOP;8VGC_PX[7'BE=?N;C3S!JOB6]@BMX%M=-UHRNX\YU_]H'5?
M$OPZ\6Z3;:AH/A[XC6?@/XYZGXF\,:7JMU9^,_A_<>#KXV7@XZK!;:I-JOAN
M^OM.GBO9+J^M8I-1D4ZCHL5O:+Y8'AJ*;7M)72OM%WO;:S?=?C:]F!^F/]I:
M=_S_ -E_X%0?_'*/[2T[_G_LO_ J#_XY7Y7^//C#XMNO!,^K6/C/PCXWL_#?
MB?Q=!;^,_A9<^)/#'@SQ?!:_LX?%7Q9+X:NY]$^(?B#4Y+SP]KVFV$NJ7.C>
M-H)H+Q=(O;/^Q-:L%>WV?B=\8/&TOCV_^&OAGQQX!L]1B\1?"]?#^GZ-;G7=
M:TV6]\;^ ;#4D^(-[X?^+R>*M/L0=5O$U7P_K7PS\):-K>EZEINB67Q#NM3O
M9(YCZO2LWSRTT6D=;IO>]MU96;N]M /TW_M+3O\ G_LO_ J#_P".4?VEIW_/
M_9?^!4'_ ,<K\S_B3^T1\1OA]I7A^SNXO <>NR:O\1]*U7Q/J,'AGPWX*UJ]
M\#>(K?1M/TG38?B5\>_AE#X=O]>M;M=0F6'QC\0-4TN*SNIH?#VK69DNK/?^
M&GQ4\2?$3XQ>&;2\\5^$4MUT'XJC6?A=X:DO&\1^ +W1O$/AO2](M/B5=P^+
M=:TO6M5U"UBO+_0;P>'?"44<']J/H:>(-.GDU.$^KTK\O/._N[J*7O6ZWL[7
M6BOY:78'Z(_VEIW_ #_V7_@5!_\ '*/[2T[_ )_[+_P*@_\ CE?G+H'Q5^)L
M^M>+XM,7P9!X7\$>-9+?6K35[/QGKOB+7K3Q'^T!\1/AU]GTK7;[QLUOX;;3
M=,\-0ZC;B72]=TF.XG.CZ3H>@Z);65M:^F_&:_\ $.G^(O#-SH5_J]I:^ ="
MUWXI^)K33+RYAM]9T;1-4\/:7=:'JEA;SQC5X]1\-ZAXRN=,LKF*XMTUO3-.
MOD07EE;2(_JU*S?M):6Z1ZNVG71I[V>FUF@/LW^TM._Y_P"R_P# J#_XY1_:
M6G?\_P#9?^!4'_QROS*\(?&[QY>^,_AWX T./1 _C+38?B'=M\0=6T@:_K.A
M^/=0\0^-%L_#=CJOQ0T#QO96?@[PJ(;.Q'AWX:_$?1IKN!O#US)X+LM O;^/
ML_AW\=_&?Q#UKPUHMCX>T2U/BKP]X+US2M26UUFZM9+;3;J]A^-6IW$7VRV%
MGI&C:C;0>#/"#F[N+AO%%]:WFI"_TF>!95]7HZ?O):NWPK>R?ZI:VU\FKA^@
M7]I:=_S_ -E_X%0?_'*/[2T[_G_LO_ J#_XY7YG^(O'2O\9?BY?VGB/0M7U#
MX:Z;';>&_!$7[0'CGP[X@76M'\)6&HH;GX#:$+/PUXMT+6?%'B>RTG4?$7B#
M5(BGV?R(;6;[#;&XZSQ!\8_&G@_2M3M/&/B[X2>&=0C^)%YX.MO'^I^'O$4/
M@JPM=.\ 67C6^TYO#,GCV+4O$?BEM3GE\'Z39V7C+1)];NTNM3M-'2XTP^']
M1/JU+6]26C:V5M.[=DKV?5I=6@/T$_M+3O\ G_LO_ J#_P".4?VEIW_/_9?^
M!4'_ ,<K\V[7XR>,+/P[8^*->\1^#O!>H>.O$.@^&X=6\8Z;XAN_!OAJ;2OA
MI:>+M5L=(\%Q>*M)U#5_%&N>(;^\\*:;X>M_%NG:OJ-[;M=(=5N-)BT"ZV?
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M_$GB[4-,635K:PTW6DOF^S'U>E9OGGI;=16[2ZOSOVZ7OH!^FO\ :6G?\_\
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M>*-;L_B#IJ:QXI/Q&U_Q"_E^&M!B^/OCEOB!X6\-VGP\CCT74O'7[.QBM_"
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M/_CE']I:=_S_ -E_X%0?_'*_+R#X[:#XT^#^N:_\5O&^G^'!:?$-_!WA34O
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MTG3])M1;^'-(<VRD^KTKM>TEHVGHKZ=4FM>[2O9-.]] /TL_M+3O^?\ LO\
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MSS["_I_/_&C["_I_/_&CZE3_ .?K_P#)0/0_[2T[_G_LO_ J#_XY1_:6G?\
M/_9?^!4'_P <KSS["_I_/_&C["_I_/\ QH^I4_\ GZ__ "4#T/\ M+3O^?\
MLO\ P*@_^.4?VEIW_/\ V7_@5!_\<KSS["_I_/\ QH^POZ?S_P :/J5/_GZ_
M_)0/0_[2T[_G_LO_  *@_P#CE']I:=_S_P!E_P"!4'_QRO//L+^G\_\ &C["
M_I_/_&CZE3_Y^O\ \E ]#_M+3O\ G_LO_ J#_P".4?VEIW_/_9?^!4'_ ,<K
MSS["_I_/_&C["_I_/_&CZE3_ .?K_P#)0/0_[2T[_G_LO_ J#_XY1_:6G?\
M/_9?^!4'_P <KSS["_I_/_&C["_I_/\ QH^I4_\ GZ__ "4#T/\ M+3O^?\
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MX;T.U\JSAN)E^W:UJVGV7GM&+:V^T?:;R:WM(IIX_D/QC^R9J=IXHL;[X<>
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MQW/X8T-/#_P<\&Z%KV@:[X0UFU\*:KI\&D_#O1)(=&M-+;P[-H4OV>V/:O\
MDMWN_1;J+O\ Y*_H'WS]C/M^9_QH^QGV_,_XU\F)^R/_ &#I?B"/X>0>#?A]
MX@US0OCGX=_X2#PY:O97L&C>//$4.J?#S1D*:.8QHOA/3K>*SBT=H9=(\,.7
MC\/Z;?6S2K-YWX0_8FU1+35+?QIH'P]FLQX8^(UMX;\/_P!K>&==\/:!XV\3
M67@:U\-^+M$TCP7^SM\!_#/AV^TX^'-2DNM3LO"5]X@LKN:'4[#5+FYO[N.S
M/:RT]S?^]HOG;]/2X'W9;O97<]];6E[9W5QIEQ'9ZE;V]S%-/I]W+:6U_%:W
MT4<C26EQ)8WEG>QP7"QRO:75M<JIAGB=\75?$GAK18Y9=0UBSC6#Q!H/A:Z2
MW:6_GL_$'B>[TNRT+2[ZWT]+JXL;C4)M;TEX_M<4,<5IJ%M?W$D-C)]I'C/A
M_P"$ESX(^+M[XCD^$OPX\2?\)]XHT+5F^)%@D4?CCPG?Z5\-I=*UW5=;>[\%
MX>UN-5TN>#2[^T\7G5]4O_'>HF?3;6(:I=3YGBK]F,>(_$OQ1<^"OA3_ &!\
M2?'/PJ\6ZIKKB>V\5:[I/A;5O!=UXQ\&^*+"V\(&&_TC4XO#6I:E8M+XGO;;
M5M3UJYM=6TNQBGN=1D;J.SLM;M:WMM==%O\ )>; ^D))(8M1M-+:.]-S>VE]
M>PRQZ;J4VG)#I\MC#.EWJ\5J^DV%W(^HVYL;"^O;>_U.*.^GTVVNX-+U.2TO
M?8S[?F?\:^.O&_[*NOZAI%AH'AW0/AY?^%])M?B[IND>#K_7F\,:#I&G>./B
M3\/O&WA.'3["]^$_Q1\)O8>&X?"-W+-X9UCP+K/AC[>=/LTTZ[L6EN;39^(G
MPG\77/@;]G+P5<?#/X:?$2Y\.^)!;^*/!=ZMSH'P?BLK/X8^-K*-=4DTGX<^
M(].M=%T_4)=-CTR23X<Z9H^I>((],DLO#_A9KJPL-,7M7K>+Z6U[VNMNEWMN
M!]17IM--L[O4=1N[33]/L+:>\OK^]N(K6SLK.VB::YNKNZGDC@MK:WA1Y9YY
MG2**)&DD=54D1136\VH7&FQK=F>VL;'47G;3M233)+;4)KZ"W6TUE[9='OKM
M7T^=[S3K*^N-0TZ"2PNM0M;6VU33);O\]9OV'_'^HZLJZK;_  @FTM?"6L:
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MBKP9IWB5?#\^CR> ;KP1\++*WO&\.7>D:BEG:ZRUAJQA\1ZK*_BZ3*VC_/\
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M742I-+I]F[F".]]D?U_\>/\ C5>T79_U;_@_T] Y[[&?;\S_ (T?8S[?F?\
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MOKQGGCMGWQVTEMQW4G/L#_7(_7OQ4RVYR,<#^?7J.OYY_"LW-/>7]:=OE_2
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M9,+8_P _T.:9Y1]?_'FIJ2Z/^M/^!]WD!D_9O;_/_?5'V;V_S_WU6MY1]?\
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M?\+DN+A?'VF)=>"K35;B2:[L8?!?V2[TJPN[<^/++7)7M+/Q+PK^UW\2$O\
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MWT35O NH:MJNHV\=K&UI9RW<L,/V-K/Q@^$/AV?1[;Q!\5_AMH5SXATZ#6-
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MEAH$M]9^.-2%WK>M^&H_LUJT.J>'-8YGP9^U+XX^(?A#Q1JNHVG@[S-(\5?
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MF&WN[>:UG$4TUM*8;B-HI1%<VTL-S;R%';9/;RQ3Q-B2*1)%5@*ZW;Z?DO\
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MX#-^S>W^?^^J/LWM_G_OJM+R6_SC_&CR6_SC_&B[[O\ K_AE]P&;]F]O\_\
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M&^'$NB7OABQDO)?'_C'Q_KD]C;W&B7B:7&--T"_\*>*_!G@U?'T,5K';^(-
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M:!\>P>-IKE/,UN4E?#4<']CRVRM&/$*-]K>;2%7[&<+Q/^TYXR\':5+I^O\
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M4^U_[WZFC:_][]31=]W_ %_PR^X"#[.?0?D/\:/LY]!^0_QJ?:_][]31M?\
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M@[QMX1T_3+N[^)7Q^^*/AS2Y+8>,/[5CE\#>$/!6FPW-K>VMMHMO8ZC:P:0
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&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img173888082_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173888082_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +0!0 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW)PCC^+/%&B>"/"OB7QIXFO8],\-^$/#^L^*/$&I2_ZK3]$T#3KG5M5O9/\
MIG:6%I<3O_LQFOYF_A'_ ,'"WB/QG\:O OA'QS\"_!OA+X8^+/'FD^&]6\2V
MGBO6KK7O"WA[7M6CTN#7[M9[-=.O6T.*ZM]1UB**"!;JVM;Q+,02O#M^\_\
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MO#0KK$YT\+DE-XB.)5+,Z.#@J4*-:NZG]MM?SR?MM_\ !:7XI?LS_M5?$?\
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M_P##RKXI? [QI\!?V)[VR^&_P]L?B7K7Q"\??%VXNX?#-S<^)=?\(^#]!M?
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M,LPV)AA:^;O#T8X2,YU(TE5IPG7C7K8;GDDJ\*=IO2G&;<>;\CX&^CEBO$+
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MK6]S<Z/>0:A8G[)J^@:VECJ:Z1JJQ6-Q<3:5J4%WIEC-:F-OPB\!_P#!8O\
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M=3+\@X>R_A[%SP>.Q^-Q4*&(J^RG5@WA84J-25:GS5[PPM*OB*7]-5%?B/\
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M-JVE:C:N)+6_TW4;G1[RQO;:0<2075K-%/"XX>.16'6OS+_X(H_\HP?VKO\
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M\6W'@_\ :S_9NT#P[XK3QQX-TK3;&Y\?>"8&N->N+B/3'M[JTL_%NJ:3X/\
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M6VC1:E;6GB+4[$Z/IKVNF075[XCT^YN=.&G65[IK_GKXP^&G_!9OP!^SC/\
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M&;!QC/XU&S;C3:"< GTH *_/G_@JM_RCU_:C_P"Q!L__ %*_#M?H%YGM^O\
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MZO$ME?V5S80W;0-I]S):S)8W4Z0N5^7_ (9?\$K_ -G7X0_M7WG[7_@3Q/\
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M8C5I>ETG_@WM_9#L?$4&IZC\2OCUK>@P7S7+>&;K7O!-FEY:B1GATZ]U?3O
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MITL9@\/EF)IPS1U/886.(P]2KB:3]@I5:L84FXTG&*E+3F77Z?B?BWZ.N)\
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M&N>'1\1O&RLNRY_X2CX@,/$<]G?@#!O- TJ[TGPO(5RNS0HP&<#>W.?ME?\
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M[&IV&L6U[::7/I^G:9XAM-0T6X_LUK>RO5UN/3=-M+'X$_X)+_M'?M(_#/\
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M_)LZX/R;PXX<XECF6<9;AJF&JX[(>)L;6HRR[#YC%QBJ6-DU1I*WLZ,G-5/
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MAGE\0P:IX;U2*\BUC3];DU0SMJD6L+J%_P#VC'< P3+=S0I#';E(4_)C4O\
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M3/ /A<_"GP GA+XAV.O^*-&T.Z\*:IX1DN+34+G6[;4K^*6S@U2V2WU^SNI
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M8;#YCE4\UKY>\'CZ"@G5PN+I)QJX=J+BHS3;NVXIM2/-X \<^!.'_#W'^%.
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M9WN!,^QE_G+_ ."_-QX.\<_M<_!'X?\ @/1I-3^,<7PZTS0/%D]C/$_]I?\
M"5^*[IOAMX4>T$:-'KEF]UK.HO-+,3/IGBO0X\+' F.+C#*WD_"63X["T,+D
MN:9+F"GA,-@J]7%0B\QK5(5\)0K5HJK6J5(RIUZSDDG[&M&%X\K/I?H\<;T_
M$3Q_\1N&,[S;._$G@CQ(X2]AG^=\2Y;@,DQ5:'!V!P-?*\]S3+<!6E@LMPN"
MJTL9E> A2G.I!9C@*N)M7]NE]V_\&^'P$'@S]G[XD?M :MIXCUCXR>,$\-^&
MKJ6/+GP+\.A<V;W-G*R[HHM4\9ZGXCL[Z*,[)V\,Z=)(SF&)8OZ#O,]OU_\
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MG_LPG&/^*"^(0_\ +A\/5^U/PG_X)H? +X._M9>-/VQ_"_B/XKWGQ.\<Z_\
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M GTH)P"?2H&;/)X '^?Q/^% #R^0>,?C4+-@XQG\:;O)X P3QUZ?I3& 7O\
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M=22IUL'@J]&<H0BY5(QJ.5.*O-1-N'?#7BGBG)\9GV43X6669?*"Q]7-N/\
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MX2E7PD%EF,J8?&5*N-P:C2Y,1"H?;?G^WZ?_ %Z//]OT_P#KUE>:/[P_(?\
MQ5'FC^\/R'_Q5>W[/S_#_@GYH:OG^WZ?_7H\_P!OT_\ KUE>:/[P_(?_ !5'
MFC^\/R'_ ,51[/S_  _X(&KY_M^G_P!>CS_;]/\ Z]97FC^\/R'_ ,57%?$7
MQE>^!/!>O>*]+\&^*?B'J>DVT+:=X*\$VMA=>)O$-]=WEO8VMCIJZIJ.F:9
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M^/APMG^8<,9CFV*R[,N)\BXNS.>99OC\DH8+#YOEF"I3Q$<SS3$UYGPWX@^
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M@1I>^$?A/X'TO5!#D1-K0T&RN-;D0,$;;+JT][+\ZASOR^6R3^:OB'XOZ_\
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MY?BLJR7#JIRSJ1P_L:F$Q6(HTTZ<*]'F<*DU%OYG*O%GAG#9?@>%\VJYKF/
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ME+**U?)\CX]H<(XVB^-\PP+QLLMS_$2\1\1#BJ%6GA,1F%;*IRP=:5"6#PV
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M-3\2ZOJ.LWVGV&D65S=W&I:M<X:VTVSBCMU@A6+]WN;7*.'\1A<?3Q-3!8/
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M$_@WC'(^'L=@*F$RGP]X.X7>94O]5<JP53&8BC4S/,\)F<,/GM?*Z>&P./\
M['P^,K8K,<9F%1Y?^?OQQ^*>D_'#]H/0/$]E.VL_!']@;X4ZE^U9\3(K-!/:
M>(/C-KO@:_UKX2>#BSQ,IO\ PMX0CU;QO(]E=3)$^K65G=".Z,)C^'-)^&'Q
M!_:H^#%_XV\0_LD_M+>/OVS?BKIUOXD\._M%_$KQGH_PI^$_P;;Q+?#4O!NJ
M?!^X'Q7.LZ-X&\ :)<VNKV>AZ%X E\1^)[BU:WUA;AM1M4M?VF^"7[+'P:^
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M6/BSX6.C^*]1U#3SJ/C/QM+X6U76VO5D;0C]@MI8KOZ#M? GQ7\;^)_V._\
M@G;\<?B+K>M:5X2_9ZUKXW?M32Z'XCUJWNOBQI&D^(H_!?@?X87GC&VN=/U_
M4/#-GJMY]D\6.D\$_B73M*AEE>*XDM;RV^G=)_8%\$>%+V\M?AW\?OVKOA;\
M.KO7-3UY/@S\.?C(OAOX::5+K6H3ZMK&G^&HH_#<_C3PII.HZE=75[+8^&?&
M>DK;W-S<2V+VC3S%_3/CE^RAX+^-_C;P7\3!\0OC'\(OB-X'T/5O"EEXX^"W
MC:V\(>(=8\':W+'=7_A+Q%<ZGHOB.WU/1&OXDU*W5;6VU"TU)5O;;4(ITC=.
M7#<,9E##U*V)H.OF$ZF$IY@OK&$IT\XP[QM'%9A&56CAJ5:K&LZ4*=)9E5G;
M!RJX&%+#TJU7VON9MXQ\'XC-L)@<GQ[RKA;#8?/<7PE4_LG/<9C> ,V7#>+R
M/A2K1P6/S?%Y;@*N!CCJ^)QDN#\%A>;/Z6!XDQ&-S7&X# +!?%O[._P.^$/@
M3_@IS\0="^!JWFD?#?\ 9^_9SLK;4O *>)_$.N^%? GQ;^,WB:WOM43PEIFM
MWVH6_AJ36O!/AS3K_P 1V>ESQP75]/;S.JS+/;P?7'_!2?X@7/@7]B']H*[T
M]6FU7Q1X.7X:Z1!'*L4LVH_%'5M.^'\2Q,VY6>*/Q%-<F,@"5(&CR"P-=+^S
MW^R;\(/V9-?^)_B3X8Q^)AJ?Q;N_"][XMG\3:_)XCN9KKPKIEW8P7*:K?0?V
M[?WNL7VI:QXB\0:GXAU77-4U/7]8U"Z-[#:M;6-MV?QS^"'A']H+0_!OAOQM
MJOB6RT3P=\3/!7Q1&G>'KS2K6V\2ZGX$U!]5TGP]XIBU72-934/"EW?F&YU3
M3[(:;J$\EI:FVU6S,;;_ &<-DF,PW#V;8*AA\+@\?F-3-ITJ.$G_ +)A?K<Z
MF'P:I3=.FN6A@UAI-*C33E%QC3@FHK\[SGQ X?SCQ9X#XDS#-,]S_ACA'#<!
MT<7F.>8>3SW.EP_A\'FN?O&T8XO&3]MFO$-3-X1E+'XN:I8FG5JXO$24Z\_A
MZV_9/_:^^+GP>^'G[+WQW\4?L\_#?]FOPIX=^'_A_P 6Z7\#KGXD>*/B7\1_
M#WP^71%T_P &W>M^-=&\(:)X*TG5QHUO-KFJ:/I^LZBTL2VEI!%937$<G'Z'
M\ ?#G[67[>O[5FK>.]1U6[^ GP6\(_"3]GN#X<^'=>U+PYH'CK4K#08O'.H^
M'/%MSX9U#2]2U+PCX0UG6)I[[P;/>2:-K>M7&CMKD%Q%X<ATVOU^^U>_Z_\
MV5>&_"7X$^#O@S#\6U\*ZKXHN[[XT?%#QC\6O%^L:[J&G7FJ1>)O&<-G;7-M
MHTEGI6GVMEHFC6MA:VV@6-Q:7LUI%&?M=Y?R.[M5;A7"RK9?'V=3&8>GB(5<
M=+&UY5IU\/@L%C,/EV!]FU&D\)3KXV59T(TX49R4W651U9J4Y=XT9Q2P'%E=
M5\-D&:XS*\1@N&:/#N61P.'RW-.).(^'<TXLXF6*52IC8Y[BLMX<P^ AFE;$
MXC'T85,/#+ZF$C@L.Z'Y@_ KXLZC^RM_P3X_;/\ BSX$%Q;^#O"G[0'Q[L?V
M:M"O;NZU[2_"7AJ;QEI/PU\#66GIJE[?ROX<TWQQ)?:HUG=/ME7[;-/'(+IY
MIO/?VQ?V./A1\(/V3/#>I7'B#Q7?_MH?&[Q'\-?A5=_&RX^(GCF/QC\4_'/Q
M5U[1K'XB:)KL,&O2Z?JW@*[\+GQ#9GPK=6$FDVF@:=I\7[W4U%Q>_J+X;_8_
M^#7A_P#98;]C^>/Q)XB^$LVB:UHE[-K>K6L7BN_.N>(KWQ7<ZM<:OX?T[0;-
M-8@U^^;4;6XM-)M;<2V]NMQ:7,?GI/Y/I?\ P3J^#ZZ]\+/%GCCXF_M!?&/Q
M;\&_&7ACQ?X&\2_%WXE6GB[4-,3PDDCZ5X8CM5\-Z=HUGX>FU(:?K6L3:1I>
MF>*-=U/1=(;5_$MY9VC6<OAXGA?,JV7X; 3P."Q4?["PV!INMB$J.3XZM6K2
MS3$X2E[&2E4C1JX:EEM6@J<J*PG)S4J<TJGZ-D_C)PCE_%F;\48;B+B/):O_
M !$W-^)L9_9V53ECO$#AG+\NRVEP5E&>8I8^BX8.KF."S?&<78#,9XJAF,\^
MAB94<;BL.YX;P[]N+X57.B>/_ 7C_P",?P8\5_M(?L,?"SX(/H/B+X<>!_&%
MQINI_"GQAHUW,MY\6]0^'-MKOA)?B-IT'@^.RTM)1JU]/X2LH-9\01V>D_V9
M#<:EQW[0_CW19M>_9A_9+^$GA#]I/XH_LNS_  7?XY_$'0?@9J6OZW\3/'7P
MRUW49M*^&'A+5O&?C#QQX6\46/@&]U.6[D\46D_BBS\17&E1Z/H=N]M#;S+!
M]B?$;]AGP5\4/$GC*_\ $7QS_:D@\!?$/4YM3\;?!#2/C/=V7PDU\7T:QZSI
M3Z7)H]SXLTKP_KQ#/JV@:!XQTG2)A));V]I;6;FVKK?BO^Q_\-OB7KW@?QAX
M>\6_%'X%>.OA[X/_ .%=>'?&_P !O%MIX(UX_#E9;>XM_ .JPZCHWB/0M8\*
M65W;0WNG:;J&BS_V?>H+FRF@E56'3BN'LSJU,VJ8;"T*$<9B,'*7/4PM7&XG
M#T<1!XK"T<3]6A_PG5\/1PW+@LPE53;KX:]##2C%^7D?BCP;@L-P)A,WSC,\
MRJ\/Y;Q!&A[#!YY@N',HS7'Y35ADN=X_)%G.(_XR[+<US+-Y5N).%:.#G'ER
MS.'#,LWIUJJ\._8<^ _B[X8_&KXQ^/\ PS\&-<_99_9S\5^#?".@^#_@1XC\
M<:=XHUC6O'.F7<][K7Q6O/#N@>*O&?A_P#)/IUPOAC^QK;Q#/?ZJ+7^UK^WA
M+PY_0GXG_%OX??!CP/KWQ(^*/BS2O!G@KPU:->:OKNK32+#$HR(;6TM;=9[_
M %35+V7;;:9HVE6M[JVJWLD-CIME=7<T4#\3\(/AI'\(O"\_AO\ X6)\5/B?
M=7FJW&L7_BOXO^-;GQKXHN;JXMK.T,$$_P!GTW1]%TJ&&RB:WT3PYHNC:/%<
MRWE\+'[=?WMQ/X'^U)^Q7X(_:P\2?#CQ/XQ^+'QV\!W7PKNGU7PC8?"KQEX=
M\.Z3:^(S<I<0^*YK/7?!OBEF\36:(MG9:K;S6TEM8F2WC0">=I?<P^!Q>49&
MZ.58*-?'<U2K3PN)K4*5&E5Q5=U*B?U6EAL-&CA_:.4<-AJ=&$U%4HU5*;Q#
M_,<US[A_C_Q*AF7'&?8C+^&_98+ XS.LHR_-<=F.,P.2972P>%DO[:QV<9Q7
MS'-'A:5&MF^<8K,<10E7EC:N"JT:%+*5PWP8\"^./VG/VA-!_;3^,/A?5? '
M@;X=^'];\.?LG?"3Q)$+7Q;9Z=XJC$'B7XT_$&P4J^B>(O&.E"'3_#_A&YDN
M)-$T7R[B^C34(;6_O?H_]LCXYZQ^SU^S)\7_ (N>&[(:EXI\+^&DM_"-DUI)
MJ$<WB_Q+JFG^%?"AGL8766\MXO$&MZ=-<6T9#3P1R1 @O7*_!#]FNZ^"OB?4
M/$US^TI^U)\91?Z)-HJ>'OC?\3M(\8^&-.,][97AU?3]*TKPAX::+6XQ9?8X
M;V>YN4BLKN]B2 /<>8GK_P 6OAGX&^-_PY\6?"KXDZ.FO^"O&FF'2];TTSS6
MLK(D\-Y9WEG>6\L=Q9:EIFH6UIJ6F7L#K-9W]I;7$9W1@$PF78VGDV80I0EA
M<YQM/&598K$5J=6=3,JN'5*ABZL\-&5*G3@XT*=*E3A*.'PU&E2C&:@N8SOB
M7AK%^(7"F*QM2EG7A]PYB>'<%2R;*LOQF#P^$X1P.9_7LRR+!8;-JU+%XK%8
MF.(S+$X['8RO2J9MF^8XW'5:E)XF3A^(>C?LU^._B7IOPNU+X<_LT_M-^"/V
MK8/'_@+Q1\4OVV?VCO'>C>$M7T>;3+^SU;Q[=Z-H.E?%7Q3K'BCPYJUI#<^$
M_#GP_P!(\':;X<M]+U"*2]6&>QO[F?ZP^.WPYE_:F_X*.>$?AGJ/BOQ-H_PN
M^!?[-&H^(?B-9>"_$E[X7UG7M0^+GC'[!'X#N_$.A7%GXBT73?$FD>$M)O\
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MKW_7_P"RK\XO^'H?[#O_ $6\_P#AM?B__P#,%1_P]#_8=_Z+>?\ PVOQ?_\
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MCFI?\_J?_@4?_D@/T=^U>_Z__94?:O?]?_LJ_.+_ (>A_L._]%O/_AM?B_\
M_,%1_P /0_V'?^BWG_PVOQ?_ /F"HYJ7_/ZG_P"!1_\ D@/T=^U>_P"O_P!E
M1]J]_P!?_LJ_.+_AZ'^P[_T6\_\ AM?B_P#_ #!4?\/0_P!AW_HMY_\ #:_%
M_P#^8*CFI?\ /ZG_ .!1_P#D@/T=^U>_Z_\ V5'VKW_7_P"RK\XU_P""GW[%
M,Y$.G_%^^U6]D.VWT[3OAC\6Y;V[D[16T<O@>&-Y",L TJ# /.>#-_P\H_9>
M_P"@U\1/_#0?$S_YFZ.:E_S^I_\ @4?_ )(#]%OM7O\ K_\ 94?:O?\ 7_[*
MOSI_X>4?LO?]!KXB?^&@^)G_ ,S='_#RC]E[_H-?$3_PT'Q,_P#F;HYZ/_/Z
MG_X%'_/S_/LP/T6^U>_Z_P#V5'VKW_7_ .RK\Z?^'E'[+W_0:^(G_AH/B9_\
MS='_  \H_9>_Z#7Q$_\ #0?$S_YFZ.>C_P _J?\ X%'_ #\_S[,#]%OM7O\
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MZ#7Q$_\ #0?$S_YFZ.>C_P _J?\ X%'_ #\_S[,#]%OM7O\ K_\ 94?:O?\
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M'E'[+W_0:^(G_AH/B9_\S='_  \H_9>_Z#7Q$_\ #0?$S_YFZ.>C_P _J?\
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M'_G]#[U_F!^B'VKW_7_[*C[5[_K_ /95^=__  \-^#__ $(7[1'_ (8SQO\
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M8SQO_P#(M'/1_P"?T/O7^8'Z(?:O?]?_ +*C[5[_ *__ &5?G?\ \/#?@_\
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M[U_F!^B'VKW_ %_^RH^U>_Z__95^=_\ P\-^#_\ T(7[1'_AC/&__P BT?\
M#PWX/_\ 0A?M$?\ AC/&_P#\BT<]'_G]#[U_F!^B'VKW_7_[*C[5[_K_ /95
M^=__  \-^#__ $(7[1'_ (8SQO\ _(M'_#PWX/\ _0A?M$?^&,\;_P#R+1ST
M?^?T/O7^8'Z(?:O?]?\ [*C[5[_K_P#95^=__#PWX/\ _0A?M$?^&,\;_P#R
M+1_P\-^#_P#T(7[1'_AC/&__ ,BT<]'_ )_0^]?Y@?HA]J]_U_\ LJ/M7O\
MK_\ 95^=_P#P\-^#_P#T(7[1'_AC/&__ ,BT?\/#?@__ -"%^T1_X8SQO_\
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M _Z-L_;,_P#$=_$?_P L:/:4?^?T/Z^?G^?9@?H5]J]_U_\ LJ/M7O\ K_\
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MV]^GKGVS7YRK^W]X; P?V:_VS^F/^3=O$/'_ )43@^_-3Q_\% O#"'G]FO\
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M7O\ Q*#1O_G'T?\ $7UIW_2/+7O_ !*#1O\ YQ]?Q:T4?ZW9O_U"_P#@E_\
MRS^KORL?\0"X!_ESK_PY1_\ F;^KORM_:5_Q%]:=_P!(\M>_\2@T;_YQ]'_$
M7UIW_2/+7O\ Q*#1O_G'U_%K11_K=F__ %"_^"7_ /+/ZN_*Q_Q +@'^7.O_
M  Y1_P#F;^KORM_:5_Q%]:=_TCRU[_Q*#1O_ )Q]'_$7UIW_ $CRU[_Q*#1O
M_G'U_%K11_K=F_\ U"_^"7_\L_J[\K'_ ! +@'^7.O\ PY1_^9OZN_*W]I7_
M !%]:=_TCRU[_P 2@T;_ .<?1_Q%]:=_TCRU[_Q*#1O_ )Q]?Q:T4?ZW9O\
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M/IE]]H_:@TSS5M1H&NZDK61B^!Y070O=.M WV@>2;0W:@K.T#+O?\1?6G?\
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MM._Z1Y:]_P")0:-_\X^C_B+ZT[_I'EKW_B4&C?\ SCZ_BUHH_P!;LW_ZA?\
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M#_+G7_ARC_\ ,W]7?E;^TK_B+ZT[_I'EKW_B4&C?_./H_P"(OK3O^D>6O?\
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M*/\ \S?U=^5O[2O^(OK3O^D>6O?^)0:-_P#./H_XB^M._P"D>6O?^)0:-_\
M./K^+6BC_6[-_P#J%_\ !+_^6?U=^5C_ (@%P#_+G7_ARC_\S?U=^5O[2O\
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M+7O_ !*#1O\ YQ]?Q:T4?ZW9O_U"_P#@E_\ RS^KORL?\0"X!_ESK_PY1_\
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M"V+PU_P@]G_PD-MHNB:7IVEVGBH:_H ^RVD*+X8B"@5]'?"__@MCX"T[P?\
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M)M]&5XEA_-+]HW_@KU_P3S_:X^),OQB_:-_X(Z_\+(^)UUX?\/\ AF^\4_\
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M &-WBS_T^WM==7(^#?\ CSUK_L;O%G_I]O:J'^[U_P#'0_\ <ICB/^1QE?\
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M[P?!HNE^9X(\!:WXBE^P:MX/M-8^VV?BO3(KKSO[/N]-FMHY3=> ?%G]K/\
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M-0HPITX%<CJ?_(Y^%/\ L$^*_P#T/P]775R.I_\ (Y^%/^P3XK_]#\/48?\
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M$+XO_P#!+[X1_P#!-A_A@- M_AX?!^D^*?C&/B =2F\?>"/ &IZKJGA+PB?
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M  B;_#1O \6W6+*UO/[8A\-1Z^?*^SMJIM7D@?\ $[_@J3_P57\1?\%/[?\
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M\-WX=TX%9?"/B(VORG^R[XH^/?A#]B__ (*8:Q^S=^U7^SS^QM\2U_X+(_M
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MN+N]T^YT/7=+TP!="?4='UMQK4FO?!O_  59_P""=WB7P-_P4L^.?P0_8O\
M@/\ $OXA>';OP[X3^-NF?"[X-_#CQ9X]O?ASH'Q TK3+_6--CT'P;I&KW6D^
M$M'\5:A<V.BYM;?2](T^_P!&T*%T\F!'^O/ /_!P[\--(U[Q/\6_B7_P3)^#
M_P 0OVD?B3H/@32/C%\3]*^,FO>$O /Q1U+X:WD=[X*\8:_\"]6^&_COP>OC
M?P],K/I/C,ZC=>*],!BM-.UNUTBUM]+C_,3]L+_@H?\ $/XH_MN?&7]L#]E[
MXR?M*?!'4_C;IWAU=<>P\<7/PU\;:!:6>@^'M-NOAG#XC^$WB:Q3Q1\/O#<_
MAO2[?PQ?:A'H][JUCIVFWVNZ!!K<$UY<ZX[$X.OAY^TQ\\;SXV%6E2A2G2J8
M'#-8A2I4G7C&#C*+H1E1I7HTY0O&ZM.7G<+Y+Q!EF:87ZKPMA^'/JW#5? X_
M'5L=A,9A.)LYC5R>5/'8Z&65JN)56E.&;5*./Q]L?BJ6)Y:JIMSHTOV6_P""
M%6F?![X0^._CQ^S]XV_98^*?@C]N73_V7/VB/%WQ9^(WQQM+WPGJ'PY\(06/
MAR#PA\//AM\+]7TVRUG0CXM\.>)=+\1^*_%OB6UTWQ#/\^E:4VH>%=8C^S_E
M!_P2R_:S^,?[/NM_$SX6_L@?LYV/Q+_;B_:27PI\/_@#\:E;P]KWB3X*0VFH
MS7_BS_A'? _B[P1XD\,:A:>(=%^VR^*==UW7/#N@>']-TFU\0>)I+K0/#]];
MS<+^Q3_P4L^(7[+G[17Q;_:3^*FE>,_VI/'GQ=^!/CKX*:[K'Q ^+VMVWBZ1
MO&%MX9L;'Q1JWCCQ'X?^(FL^(&\.Z=X9M-.M-'O(X3-9"VMH=6L(+**)_2_^
M"5G_  4[^&W_  35F^,OB#5OV3#\>_B)\6-$LO!UC\0;;XXWGP=U_P  ^!!#
M>-KWA[PIJ.D?##QGK^EWGB;49['4=2\0Z%XAT#4HI=!T'[+Y5QIL-W6=+&8>
M2RNFL4L$L+5QRG6CAVZM&A5C1C2G^ZHS4L35C&:5:"E.E5:J7CRP.['\/9M2
M7&N)GD?^L=7.<+PS4P^7U<U4<%F&8X.KC:F+HOZ[F&&E2R? U:M"<LNKSP^'
MQF#A+"*G6]M7O[?_ ,'#'B/X8:Q^V'\/-&T:X\":[^T5X,_9_P#A_P"&/VS?
M&WPR@T^U\&^*?VB+!+L>(]D.G);QR>(='MO)LM9FNK*TU&TM&T7P[J,-M>>'
MYM/L/H[_ (-._P#E(3\??^S-/$/_ *N[X.U^(7[8'QK_ &8_CAXP\.^(OV9O
MV1;C]D?2;72M1B\:Z%=_M$_$G]HRZ\=>);[5);Y?%-SXD^)>G:?JFC7$=M(;
M.:PLQ/!>2;K^>4W$C"OV]_X-._\ E(3\??\ LS3Q#_ZN[X.UV9/66(XHA6C*
ME)5)8F2E1]IR-/"U+-.M2HU92_Y^3G2@YU.:=O>N_G?$++YY5X)U\NJTL91J
M82CDU&=+'/!_682CGF#<HRCE^,S#!TJ2;_V:AA\9B*>'PWL:"J7IM+^]_P >
MG;X3U8^GV'_TY68_/T]Z\$M)<CD]1_D_X>IYYKWCX@G;X0U<^AT__P!.ED/S
M]/>OGJUDY'.,@?S//T';Z>W'[!@E>C)/9U'_ .DP/XO.NM'P0,]>?_K]> ,<
M<^A^G10. <9ZCGGGDG^G3W(XKD[5AD<^A^HR<?TQ726V6VMGH0#[]?Z_ICTH
MFMG]X'26Q(QS].W]?7&/PK81N1WX'Z$D?ABL*$\@@]OZL?\  UL1=03Z ?JP
M_J*Y9?$_ZZ 2R#/)/3'YY_\ U?6LBX.#GT(/Y;:V7.$8^@S^M8EP<Y_SW&/T
M%$5=KRU^X##N7!+?0#\#_D9_SCF+QB&Z^A^IX_I71W7 )]OY8KE[PDDG/ Y
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M\6Z+X*\(:;>ZE8Z/9W6N:[>1V5DEWJFI36]E8VJO)YEQ<3R@)$CE%DDV1O\
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MX:,:-#+YX3!YA5K8&K"AE^)QM;$8F2HT/9X=8R&*H?BC^QW_ ,$O?B=^V/\
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M/BBZ;6+_ ,/>'_%.L6\4FGZ'=PV[66@Z@[WDEO'(D4#RW$/SC7Z]_P#!!?\
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M?2_"NI^#-2\.Z3>Q:X-0U%_'5G*(/"WB&YM+2[@MK-[_ /KGTSQ?^PE\1O\
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M2G4QN7X:KCX8187!5,?"G4Q&%P&+Q&'Q&(:<Z>'G)J_X^>)_^0GX&_[&Y_\
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M5X>UFK?C#1117 ?3A7(^#?\ CSUK_L;O%G_I]O:ZZN1\&_\ 'GK7_8W>+/\
MT^WM;P_W>O\ XZ'_ +E/*Q'_ ".,K_[!,T_]*R\ZZE!((()!!!!!P01R"".0
M0>AI**P/5/LN#_@HU_P4)M;>&TMOV[_VR[>UMX8[>WMH/VH/C=#;P6\*".*"
M&&/QPL<4,4:K''$BJB(H15"@"O$O!'[0?Q[^&?C[6_BM\-_C?\7OA]\4?$R:
MM'XD^)/@CXE>,_"GC[Q!'KU_#JFN)K?C'0=:L/$6JIK6IVUOJ.K+?ZC<+J-_
M!#=W@FN(DD7*^#7PTU?XT?%[X6?![0)H[?7/BK\1?!/PXT>XF1Y8K?4_&WB3
M3?#5C<2QQ@R2107.I1RR)&#(Z(RH"Q K^@_]H/\ X)S>!/VO?^"I_P 7/V/?
MV?YOA3^RS^SC^PS\!?"^C?$WXO)X+T1GM?"_PQ\(Z#<>-?B5XZL] ;PG>_$_
MXHZYXP\4W5GKFN>*/$5GJ%UI^C7%YJGB..+28+6?TJ%''8R"JPK59SCB:6'H
M0=67-*M5A4G>$I34::ITZ+E.<I144XW=KM?(9EF/#>08F6#Q.!P6%H5LIQV:
M9E7A@Z*HTL!@L1@L-&.(I4:$ZN*J8K%8ZG2PN&ITZM2K*%51BYJ$)_AU\2_V
MS/VP/C1X4NO GQB_:M_:3^+'@>]NK*^O?!OQ+^.?Q/\ '?A2[O=-G6ZTZ\NO
M#OBGQ3JND7%U87*K<65Q+9O+:SJLT#QR -7F/PO^,'Q;^"'B?_A-?@M\4OB-
M\(?&7]GW6D_\);\+_&_B;P!XG_LJ^,37VF?V]X4U/2=5_L^\:W@:ZLOM?V:X
M,,1FC<QIM_3[]K#_ ()@_";X%?L5:+^W%\#_ -MOPK^U5\,/%7[0MO\  SPS
M#X8^#/BKX;SM"_A#Q%XBO-;\4KXS\52Z[X4\3Z=?^&KG3Y_ T_A>_AETC4-&
M\1VWBZ:'4%T^/]*?$O\ P23^"_Q6_9(^$<.O_&?X:_LB:A^QI^R%\&_CU^U+
MX_U3X#R>+_$_C'7/VM?$WC+XA:A;>/O$WA*[\/>/=8U3X2^ /#ND:9X%\+S:
M9XWGU&[UFU\(:1)X<AE?4Y]8Y=F-6K/FE>O1H4Z].3Q-*?/"3<H.GB%6=**5
M*%:LI>U2Y:<N762//J\7\'X' X;V5%1RO'9GB<LQ5*&2X[#O#XFDJ5"K'$Y1
M++X8VI4EC<1EV72IK!N2KXRDIM0ISY?YT_ W[67[5'PPU'QCJ_PT_:7_ &@?
MAYJWQ$U6ZUSX@:IX&^,OQ&\):CXYUN]DEFO=8\8WN@>)-/N?$VJW<TTTMUJ&
MM2WUW<22RO+,[2.3@_#;X+?M ?M(^)/$-M\'_A-\8OCWXOMHYO$OBNW^&W@/
MQK\4O$EO#J%Z5N/$'B&+POI6NZG%'?:C.1-JNI*JW-[,0\[SR'=_06?^#=;P
MI<_%70_@]I'_  4:^%.I^-_C-\'+CXU?LG^'?^%(>.X-?^-7A#3O#:Z_JNL^
M,K1/%-UH_P &_#R/<6MOHVHWGB#QIK6OVL6M7MCX86;0;_3A\R_\$</V*_BE
M^T3KGQA\=>)O&GQVT']CW]G;6_ _Q!^.WPY^ L'COQ;XP^/OQ#\#:O/XC^%_
MPS\)_#'P4E])XO\ $EOJNGS:JNOSZ'J-SX-L9EN-.ET>[UB/7=*:RS'O$8?#
M8FG4:J3K1A&->E44'3C&I6;E&=6%&,8SA5J2E&[I252,9J4;S+C7A997FV<9
M-B<)&I@Z&75<15KY5C\).M3QE>>$P$(4JN%P5?'U*U6AB,#AJ-*IRPQM&>$K
M5,/.E54/RYM=+_:X_:9\1>$O@?9:=^T;^T%XM^%&@:IX6\"?""UM/B9\5_$7
MPU\+^'GA@UKPYX2\ 11Z]J?@[0-#>RMX=4TC1])T[3M,>TACN[> P($Z?]IF
MS_;K\*2?"[0?VR+7]K3PW-X5T*>S^"NB_M,P?&+1Y/#GAG3&TFRNK7X7:=\4
MTMFT?0M/;3]#M)X/"<-OI]HUCI,$B1FVLT3[4^+_ .S7^TA^VE^WAI7QC^)O
MP)\2? /P;^VK^WCJ?P6AT379M.T#Q?X*\4W7B+PU<^,/#&O>#-7FD\=:'XD\
M)^"O$NFZUK.KZ_X+L=)U/5);J?38;@F33H?T8^$FL?";_@H__P %$/VXOV(/
M$7PX\$Q_#/6?@%XY_9Z_8<U)?"?A[4M9_9N'[(=S?/\ "*_^&WB"]A.K^#]%
M\5Q:=XG\2_$33-!U_2;+QO=ZW)IGB">ZLI8V@=/!.JZE+VM>%6MB88;#2J.4
M(XGW)5*+G2E%3C%J-%0;G)*5>FU%1A)N,7Q+2P*PF-6"RRM@LOR>MG&<T\(J
M.(K9+S8BCA<?'#8VC6E0K5(SJYA4KTZ>'IRK4\MQ495?:5Z<3^:OXJ?&GXQ_
M'3Q!:>+?C=\6?B9\8_%5AI-OH%CXF^*GCSQ3\0O$%EH5I<7=Y::+::UXMU75
M]2M])M;N_OKJWTZ&Y2SAN+V[GCA66XF9_,ZFN+>:TN)[6X3RY[::6WGCW*^R
M:%VCD3<C,C;75EW(S*<95B"#4->/*4I2<IRE*3>LI-N3?FW=M^I^@4:5*C3A
M2H4Z=*C"*5.G1A&G3A'=*$()1C'6Z44EJ%<CJ?\ R.?A3_L$^*__ $/P]775
MR.I_\CGX4_[!/BO_ -#\/5MA_P")+_KQBO\ U&K'G9S_ +I1_P"QKD7_ *O,
MN.NK5T+7M<\+:WH_B;PSK.J^'/$GA[5+#7/#_B#0M1O-(UO0]:TJZBOM+UC1
M]5T^:WO],U33;Z""\L-0LKB"[L[J&*XMYHYHT<95%8)M.Z=FM4UNGW/4:4DX
MR2E&2:E%I---6::>C36C3T:/LF[_ ."B_P#P4'O[6YLK[]NW]LF\LKR"6UN[
M2[_:>^-MQ:W5M.C13V]S;S>.'BG@FB9HY8I4:.1&9'4J2#XW\)/VC?VA?@#<
MZ_>? GX[_&7X*7?BI+&/Q1=?"3XH>-_AQ<^)(],DNY=-CU^?P=KFC2ZPFGRW
M]])8IJ+7"VDE[=O (VN9B_C5>D_!KX::O\:/B]\+/@]H$T=OKGQ5^(O@GX<:
M/<3(\L5OJ?C;Q)IOAJQN)8XP9)(H+G4HY9$C!D=$94!8@5NJV)J5*=JU:51/
MEIOVDW).=HVA)RO'FT3LU=:/0\Z67Y1A,+B4\!E]#"2I^UQ<(X/#PHSIX=.H
MI5J<:?+45+E<X\T9<K5XV9V'Q:_:G_:>^/NE:5H7QV_:.^//QJT/0M0?5M$T
M;XM?%_X@_$?2M'U66VDLY-3TK3O&/B'6;33]0DM)9;5[VTAAN7MI)(&E,3LI
MY_X6?'SXZ_ N3Q#+\$OC3\6O@[+XML(=*\5R?"SXC>,/A[)XFTNW:=H--\0O
MX2UG2&UJP@:YN6AL]2-S;QM<3E(U,LF[^B7XV?\ !-7X._MF?\%+/VG?V0?@
M;XK^&O[)7PO_ &"?V6/#EGIWBFT^%6D:K:_$'4_AEHGA"/Q;XC^+FK^&M4\&
MZM>^*]7\1>,]4D\8_$_6$\:>)%L_#\:2:5JIB@ACY#1_^"!WP0U^[_9F\1:5
M_P %0OAG<?"#]L"%_#O[/'C5_P!G'XDVWC/XE?%>.[O()?!FE?#&[\703:1X
M8M(["X34?'WC'Q7X7&GZM-IFB3^&!>ZM8^;Z<LJS.5:I*E+VSIU9T%B/K5&G
M*4Z52.'FX^VK0J\D:LHTE-I1;G!77/%/XJEQSP72R_#8?&4_[/ABL#A<QEE2
MR3,,72HT<;A)YMAHUE@,NKX-XF>"I5,;+#PE.K%8?$3M)8:K./X4>"/VIOVG
M?AGX+U;X;?#?]HWX\?#_ .'>O-?OKG@'P1\7OB#X4\%ZT^JHT>J-JWA;0?$-
MAH>HMJ4;NE^UY8S&\1V6X,BL0?" 2"""00000<$$<@@CD$'H:_:_]GG_ ((\
MV/Q03_@H)/\ &?\ :P\(?L]:7_P3R^(MEX'^)WBB[^&/B/XC>%==TZW\4>+M
M \5>)--GT/Q%HWB>!]-MO!]Y=>&O#]EX2U[4_%VIW^F:$6T.2X:]C^O3_P &
MZWA2Y^*NA_![2/\ @HU\*=3\;_&;X.7'QJ_9/\._\*0\=P:_\:O"&G>&UU_5
M=9\96B>*;K1_@WX>1[BUM]&U&\\0>--:U^UBUJ]L?#"S:#?Z<,HY5FE>G3DJ
M3G#X*:GB:"<;U)T5%4ZE92AS5:4J4%RKGJ)0C>4HI]U;CK@G+,5BZ4L;&AB$
MHXC&5,/DV:5(5$L%A<P=6IBL+EU2A7=++\=AL96DJU1X?"U)UJSITJ5:5/\
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M?$71M,U86\UH-4T_2_&'B+6+&SU$6MQ<6PO;:".Y%O/-")?+E=6[7PK^WO\
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MY+\R_&?[4G[37Q'\!:;\*_B'^T7\=O'GPPT;[!_9'PX\9_%WX@>*/ 6E?V4
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M>//%7A?X@W%UXD%P/$5S/XST/5;'Q'+<:^+N[&M32:DTFJBZN/MS3^=)NUO
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ME\29I;Q/.OKI4_F[_;;^*?PS^-/[6'QX^)/P7\ >#OA?\(?$'Q!UB/X8>!_
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MQKYOLR,=?4_ASS7T3\1_^1,UKZ:?_P"G2QKYOL^GXG^1K]OP/^[S_P"OK_\
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MBLC_ (2#0?\ H-Z1_P"#*R_^/4?\)!H/_0;TC_P967_QZOG_ &-7_GU4_P#
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M_P!!F$_\**/_ ,GYK[S7HK(_X2#0?^@WI'_@RLO_ (]1_P )!H/_ $&](_\
M!E9?_'J/8U?^?53_ , E_D'U_ _]!F$_\**/_P GYK[S7KD?!O\ QYZU_P!C
M=XL_]/M[6O\ \)!H/_0;TC_P967_ ,>KE/".N:+'::P)-8TN,MXK\4R*'U"T
M4M')K=X\;J&F&4=2&1AE64@J2#FMX4JOL*_[NI\='[$O^GOD>5B,=@GF^6-8
MS"V6$S--_6*5DW++[)OGLF^G?H>A45D?\)!H/_0;TC_P967_ ,>H_P"$@T'_
M *#>D?\ @RLO_CU8>QJ_\^JG_@$O\CU?K^!_Z#,)_P"%%'_Y/S7WFO7[>_\
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M:K'%4Z$8X3)<9FF(R:A*DJM12GA*.:U,/6JJ45BG"%7V=%-4H_TI:S_P6?\
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M5Q)'/(\DFD>)=)OK<K#J#//^+%>>^)-<T1]1\$LFL:6XB\5O)*5U"T81Q_\
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MQB2_7P+XPT?Q.]E&TJM$LETFF-!&TBM&KR*75E!!\&_X2#0?^@WI'_@RLO\
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M!</5>5WT;RW X>,7TK*575SL?O?_ ,$.-<M?A+^T7^TQ^W9XCF.E?#']C_\
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MT5D?\)!H/_0;TC_P967_ ,>H_P"$@T'_ *#>D?\ @RLO_CU<WL:O_/JI_P"
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M/EC+EE4Q$H<SC'E7)&-.E2IQC>5N5RYO>Y5[^7X3 8',LQS*6;4,56QV$RG
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MB1\./'WQ3T#0?"?P)\4_''Q1IOB"+P7:MXAN9]=\;^*[OP5=:[9:%XAAO(/
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M/B)\1+.TO'WW5CIGBSQ5JFLZ5IT[ E=^G:9=VEB5C"Q(+<)"D<2HB^#5D?\
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MKG]C5_Y]5/\ P"7^1ZOU_ _]!F$_\**/_P GYK[S7HK(_P"$@T'_ *#>D?\
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MX-/O^4A'Q]_[,U\0?^KM^#U?RY?\)!H/_0;TC_P967_QZOZ>O^#3C6M&N/\
M@H=\=[:WU;3)[BX_8V\2B"WAO[66:<P_&KX/2S"&))6DD,47[R0(K;(_G;"\
MUZO#%.I'.L(Y0G%<N(U<9)?[M5ZM6/AO&K%X6KX<9["EB</4FZN46A3K4YR=
MLXP#=HQDV[+5V6BUV/[Y?B1_R)>L_P#<._\ 3M8U\X6?3\3_ "-?1_Q(_P"1
M+UG_ +AW_IVL:^<+/I^)_D:_;,#_ +M/_KZ__2:9_"QU%GT_$_R-=19]/Q/\
MC7+V?3\3_(UU%GT_$_R-.K]KY?H!T=MV_P _WJWX.A^A_DU8%MV_S_>K?@Z'
MZ'^35QU.GS_0":;H?K_1*PY^H^H_FM;DW0_7^B5AS]1]1_-:4-WZ?J@,6ZZ-
M]#_):Y>ZZ-]#_):ZBZZ-]#_):Y>ZZ-]#_):ZZ73_ !+] .7NNC?0_P EKTOX
M0?>\1_\ <'_EJ=>:771OH?Y+7I?P@^]XC_[@_P#+4ZUQ7^Z5?6'_ *7 #XN\
M0_"7X5?$O_@J9XH_X6/\,_A]\0/L/[ 7PU:R_P"$V\&>'/%7V-A^T1\6E#6O
M]NZ;?_9R%EE4&+8<22#H[9^P_P#ADW]EC_HVC]G_ /\ #-?#K_YG*^?=*_Y2
MF>,O^S ?AK_ZT5\5Z_0*O$ ^?_\ ADW]EC_HVC]G_P#\,U\.O_F<H_X9-_98
M_P"C:/V?_P#PS7PZ_P#F<KZ HH ^?_\ ADW]EC_HVC]G_P#\,U\.O_F<H_X9
M-_98_P"C:/V?_P#PS7PZ_P#F<KZ HH ^?_\ ADW]EC_HVC]G_P#\,U\.O_F<
MH_X9-_98_P"C:/V?_P#PS7PZ_P#F<KZ HH ^?_\ ADW]EC_HVC]G_P#\,U\.
MO_F<H_X9-_98_P"C:/V?_P#PS7PZ_P#F<KZ HH ^?_\ ADW]EC_HVC]G_P#\
M,U\.O_F<H_X9-_98_P"C:/V?_P#PS7PZ_P#F<KZ HH ^?_\ ADW]EC_HVC]G
M_P#\,U\.O_F<H_X9-_98_P"C:/V?_P#PS7PZ_P#F<KZ HH _(O\ X)T?LR_L
MW:U^S_\ $.\UC]GSX(:M=P_MW_\ !4O28;K4_A1X#O[F+2M _P""G'[7>A:%
MID4]UH$LL>GZ+HFG:?HVDV2,+;3M*L++3[..&TM8(8_NW_AD_P#99_Z-J^ '
M_AF_AU_\SE> _P#!-;_DW?XC_P#9_P#_ ,%8?_7IO[9%??M '@'_  R?^RS_
M -&U? #_ ,,W\.O_ )G*/^&3_P!EG_HVKX ?^&;^'7_S.5[_ $4 > ?\,G_L
ML_\ 1M7P _\ #-_#K_YG*/\ AD_]EG_HVKX ?^&;^'7_ ,SE>_T4 > ?\,G_
M ++/_1M7P _\,W\.O_F<H_X9/_99_P"C:O@!_P"&;^'7_P SE>_T4 > ?\,G
M_LL_]&U? #_PS?PZ_P#F<KX1_P""?W[,O[-VL?#_ /:$FU;]GSX(:I-9_MW?
MMS:39RZC\*/ =]):Z5I7[3?Q%L=+TRV>YT"5H-/TVQAAL["RB*6UG:PQ6]O'
M'#&B#];:^ ?^"=O_ "3O]HW_ +/^_;V_]:E^)5 'O_\ PR?^RS_T;5\ /_#-
M_#K_ .9RC_AD_P#99_Z-J^ '_AF_AU_\SE>_T4 > ?\ #)_[+/\ T;5\ /\
MPS?PZ_\ F<H_X9/_ &6?^C:O@!_X9OX=?_,Y7O\ 10!X!_PR?^RS_P!&U? #
M_P ,W\.O_F<H_P"&3_V6?^C:O@!_X9OX=?\ S.5[_10!X!_PR?\ LL_]&U?
M#_PS?PZ_^9RC_AD_]EG_ *-J^ '_ (9OX=?_ #.5[_10!X!_PR?^RS_T;5\
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M_P -#\/O_F>H_P"&6/V8O^C<O@/_ .&A^'W_ ,SU>\44?6,1_P _ZW_@V?\
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M9B_Z-R^ _P#X:'X??_,]1_PRQ^S%_P!&Y? ?_P -#\/O_F>KWBBCZQB/^?\
M6_\ !L__ )(/:3_GG_X$_P#/R7W'@_\ PRQ^S%_T;E\!_P#PT/P^_P#F>K\(
M/V(/@+\#-5_95^#>H:G\&/A/J-_<Z!J3W-[?_#KPA>7=PZ^)=<17GN;C1Y)I
M6"(J!I'8A550<  ?TKU^ '["/_)I/P5_[%[4_P#U*-=KI^L8C^S\2_;UK_7<
M"K^UG>WL,Q=K\W=)^J78_D[Z7F,Q>&X&X;EA\5B*$I<64HRE1KU:4G'^Q\U?
M*W"46U=)V;M=+LCU3_AG;]G[_HA?P<_\-CX)_P#E)1_PSM^S]_T0OX.?^&Q\
M$_\ RDKV.BO.^LXG_H(K_P#@VI_\EY+[C_/?^V,V_P"AIF/_ (6XG_Y:>.?\
M,[?L_?\ 1"_@Y_X;'P3_ /*2C_AG;]G[_HA?P<_\-CX)_P#E)7L=%'UG$_\
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MB*^&]OA9.ABGA'B/J[QV&BL%C94I8C!MT9J,=:BBBN0\,*\J\'?\I&/V2_\
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M7Q7K]!:_/G1_^4IGC/\ [,!^&G_K17Q8K]!J\0 HHHH **** "BBB@ HHHH
M**** "BBB@#\]?\ @FP3_P ,\?$CD_\ )_\ _P %8>__ %E,_;'K[[R?4_F:
M^ _^";'_ ";S\2/^S_\ _@K#_P"O3/VQZ^^Z /S7_P""Q7@7QQ\3O^"7G[<7
MP_\ AMX.\5_$/QYXM^ 'C'1O"O@CP/X>U?Q9XN\3:Q=1VXMM*\/^&]!L]0UG
M6=2N"K""QTZRN;J4J?+B;!KCO^"D'PM^(.IZ+^PQ^T7X&\ ^*_B9/^Q/^UCX
M ^//Q"^'O@70=3\4_$K6/A+?_#/XA?"'XFWOP_\ !6F7$>K>-?%_@S1?B/\
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MY@?\$[_@3\2OA+XO_:6\52?!C7/V1?V:_B)J_P ,H_V<_P!BK6?&GP]\01_
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M_JQ#]N6O<?B2GQ%D^'OCA/A!<>"K3XK-X3\0#X;7/Q)L]=U#X>P^.O[*NO\
MA%7\<67AB^TSQ)<^$QK?V(>((]!O[76#I1NCILHNQ$#X;^WK_P E._X)H_\
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M<RQ-K?C'Q/HFDF_NQ;:5IBWAU#5[^PTVVNKR'^85M;L-2\;7OP]L_C);Z?\
M'N3_ (+!#Q3X@_X([2VT4^@WG@ZT_::AUZ+]H-_"E_>C]IR.UN_AE'I7[=LG
MQ5\._$_3_P!AF[\1A+NY^ ]W!-K2ZC^L?_!:GP#\+/&?[%$&M?&'P5X \7>!
M?AM^TM^R#X]\3WOQ'\-^'?$7ASP9X)LOVF_A7H_Q-\5:D?$EE>V.D:!!\,=:
M\8:7XVU-UAM!X#U/Q/9ZW(?#UWJ\;U7RK"0QV5X;][3IXO$*A4<>9U)4W*A&
M%2*K*,9U*CJS7ML.Y8*JE!X:4W&HASPU)5L-3]Z*JSC"7+=R<6X)27-92E+F
M?OTVZ,M/9MM21^M58GB;Q-X;\%^'-?\ &/C'Q!HGA/PCX4T;4_$?BCQ3XFU:
MPT'PYX;\/:)93ZEK.O:_KFJ7%KIFCZ-I&G6US?ZGJFHW5M8V%E;SW5W/%!%)
M(O\ +=^U9=_LQWB?\%"9O%G_  B,_P"V],?AC=?\$?M0L9O"TWQ;O?AO=? K
MX6/^RXW_  38DT.>35)/"0_:!7Q[-XUE^!D:12WMQJK?%F:?PC_9HB_I_O/#
M.G>,_!)\*_$OP_X<\5V&OZ!;Z9XT\-ZUI-AKOA;6FN;.)-8T^]T?5+>ZT_4=
M*N+CSE^R7MO-!+#M62-AQ7G8S+HX.GA*LZE2<<0USQ=%4I**H86O*5&3J5%5
MC;$NESM02JTIQ<>W/5H*DJ4I2DU-ZKE46ER4YMQ;DU)6J<MVE:<6FM#X8^'?
M_!0W]D7Q%^R1XZ_;C^&T&MW7P2N_B?XV\,6=_P"$? UI=>,/CE\1]%^)P^ O
MA^Z\">'/#EU=7GC36?C#XRTGPYH'PTO=:GTW5=:TW5/#$GB5?#%I#=)I7M_P
M!_:IT7XX>+?B)\,-=^%/Q;_9_P#C1\+=.\'^(_%WP<^-D'PTD\71^!_B"FLK
MX'^(&C:_\&/B;\8_A=XD\*^(]1\,^+-"1]!^(>H:WH>N^%M8TOQ3HF@W!TX:
MA^*&OR3Q?\$EOVHI3X<35=%M_P#@I1^T9>>,O%W]G>/M7N/@9X#T_P#X*=^(
M=0\;?M+Z?IOPN\1>$_'EQJ7[./ANUU'XSV%QH7B'3H=)N?!D>M^(1?>%=,UW
M3;SZ<_8"\:^#9?VHOVZOBUI?[4&B_MD_ S3/A'^SF9/V^?$NL_#&6SL;GPA8
M_%O5/&WP"U#XE_!2P^'_ .RSJ_A;X-Z1=:;\5-2OOAG\,O VK>%KGXO:E!\8
M-:\5ZQ_8^H:?Z6*RO#0PV9U:4*KEAL9B*-!SG.I-1I8C+J5"FYQA&C)NGBJ_
MM%44*M24:$L/!0C63Z*F'I^SQ$XJ5X5:D87<I.T:F'C"+DHJ#;C5GS7492:@
MX))21]]_'3]L#1?@[XRO/AOX3^"_QK_:0^(OA[P##\6/B!X'^ L'PDGU_P"&
MWPOOK_6])T7QKXH7XO\ Q<^$&G:E%XDU7PQXGT_PQX1\"ZAXQ^(WB"?P[J\F
ME^#+FUMA<2?0/PN^)O@;XT_#?P)\7?AEK\'BGX>?$SPEH'CCP3XCMK:]LXM:
M\,>)M-M]7T;4!8ZG;66IV#W-C=0O-8:E96>HV,QDM+ZTMKN&:%/PW^.B_L\^
M&_VZ/VD_B/\ M>_M:^//V?\ X&?'']G?]F'Q)^S'XH\'?M/>*/V4O ?Q3U3P
M+9_&#3/%6G^"_C-\&_'?P[\??%GQWX-D\5:;XCTWX+IXTUKPGK.C_%C2/%D?
MPV\8ZHNC:SX<_63]BCQ%\;O%W[(O[-WBC]I.QNM-^//B#X-^ M7^*MEJ.A'P
MOJT/C&_\/V5QJAUWPU]EL!X>\12O(LWB+0TT[3(M)UN2_L(=+TR*W2PM^#&X
M*C0P>'JTXRYI+#.=67/%598C#>WJ0IJ2<*WU6JI4*LJ2I?5YJ-.HL1.KSTL:
MU&$*-.44[OV=Y/F2DZE/GDHW]V?LI)PFX\OLW:,N=RO#Z@K\ /V$?^32?@K_
M -B]J?\ ZE&NU^_]?@!^PC_R:3\%?^Q>U/\ ]2C7:X?^9=B?^PW ?^F,Q/X^
M^F%_R0G#7_96TO\ U3YJ?6]<#\4?BE\.O@IX \3_ !2^+/C/P]\/OA[X-TXZ
MIXE\6^*=3MM)T;2[5IX;2V66ZNG19;S4+^YM-,TG3K<3:AJ^K7MEI6F6UWJ-
M[:VTO?5Q_COP_H/B+PQJ-OX@T32-=M]-5?$&G0:SIMGJ<-AKV@'^U-"UNRBO
M89TM=7T74[:VU'2=2@6.\TZ_MX+RSFAN(HY%X:2@ZM-55-TW.*J*#49N',N9
M0E*,HQDXW492C))V;C)*S_SXP*PTL9A(XV->>#>)H+%0PM2G2Q,\.ZD56AAZ
MM6G6I4JTZ?-&G5J4:T*<VIRHU8Q=.7S4_P"VS\,9_P!GWX%?M Z!X4^)OBRW
M_:7'@>U^"'PJ\/:'X=E^+'CK7?'^BW/B;2/#L%CJ?BS2_ NAWFF^&-.UGQ)X
MFUGQ1X^T3P=X<T/0M5U#5?$]O%!%Y_JWP.^._AWXYZ5XNDL/#7C'P!XP^'/C
M&\\ ?$WX8_$2TT"U\;_#_P 76NF:7K]OI>M2^$/$?C+P7JUOK'AC7O#_ (HT
M/7O!?C'Q5X:U71=;LI+767O8M0LK+\:(]1L=(_X)R?\ !)75O$?B,?"+P+I>
MM? ._P#&G[4<?GQ7G[,%FGP7\:6VA>/;74KJ<^!O#J^-/%5UHGP;O?$OQDT3
MQE\%]-L?B/<6WC_P5XBM=1LK9/L#_@GUXO\ #.DV'[1>N:M\4_#GQ(\+_$K]
MKK4]*^$W[3^NZAHFCZC^UI<WOPV\"6]I>Z=?:;>:?\.?&^K^$[[1-?\ A+H-
MW\#?#'@[X<:YI7PQDE\*^"+&\L/$5Y>?0XO*\/2P>*JTH5'*EBL1"G*]2;M2
MQLL/&DYJ/U9J-"+J3I.2QW/:NH?4[R/UGB#@?*<!D.?XS X;%RKX#/,WPF#J
MN6+K5)+!<35<HI8)UHTO[)J4Z>5TI8NO@)5(\2O$<F9K#K('*J>T/^WA\-T\
M9W>E#X<_&1OA1I_QFB_9YOOVF/["\%1_ ^V^,LVN0>#E\';)O'\7Q@NK)/B+
M=6_PRG\?V/PCNOAA;>.I'TFX\;16UK>W]M]O5_-<VK65_P"+;OP3;?%.&R^,
MS_\ !4 >(M;_ ."74D$<VC77A:V_:!BUF/XV-X<O+L?M I;W/P^33OVQG^(^
MA_$&Q_9 N=="W-Q\&[F&75A?_P!*-<N<8&C@OJWL8RC[15$U+VGO0IJER57[
M2*4Y5'.;=;#.6!JQ4?JTVXU;>'X@<,Y;PZLF^H4JM&6+CC83C5EBKU\/A8X'
MZMC)_6Z<%B*V*EB,2YYCD[J\-8ZG"@\FKU94<;R^=^#OBIX*\>^*OB?X-\+Z
ME/J&N?!WQ/I/@SQ_"^G7UE!I/B;6?".@>.K/2X+F]M[>/5"/"_BGP_J4U[II
MNM.1M26R%X]_::A:VGHE?SK?$;PK\*OA_P"/?^"G6B^'O"?AWPMXLUK]J3]E
MSQW\<-'^%VC:!H'Q@U_]B3Q)HO[.&I?M!^))HO#46G^/=2^$6M37?Q2O/B3J
MGA^5XYK^^\>W%S<+K][JLDOW%^P[_P *>_X:+_:C_P"&0/\ A ?^&-_^$)^
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M./!?[.^AZ3\+=*^,?AWP;HN@V.N^)_$WQ'/CKXL>#OA=X&TSPL=:\-:#K/\
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M2HU%2JJ,YX'BC&SH590E&CC,/A*M:CB\*L1@L1^>G["OA+QLWC#]LOXZ^(_
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M!X7^-EW\ /#'[5.K^'?AY)\%_P#A>][*G@B^\$>$M3D\=W'Q=M9[[Q;J%_\
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M\.V?V=_^BB_M^?\ BU__ (*E_P#T8]??5% 'P+_P[9_9W_Z*+^WY_P"+7_\
M@J7_ /1CU\1?L(_\$_O@1XH\!_'JZU+Q[^V[;2Z7^V[^VOX:ME\._P#!3/\
MX*1>$+:73O#?[2/Q!T?3[G4K/PE^U?HEIK'B"XM+2*;7_%FKP7WBGQ7JKW.N
M^*-9UC6[V\U"X_=>O@/_ ()W_P#)._VC/^S_ #]O7_UJ7XET ._X=L_L[_\
M11?V_/\ Q:__ ,%2_P#Z,>C_ (=L_L[_ /11?V_/_%K_ /P5+_\ HQZ^^J*
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M:LUB]\%Z_P#VAX>L+<^+/!UQH/BEM!N-=\+-K)\,>*/$VCZO]*_\.YOV?O\
MHH7[=_\ XM,_X*<?_1>5Z'^WE_R4_P#X)H_]G]7?_K"/[<M?5E?B'B9BL50S
MO!PH8FO1B\JI2<:5:I3BY/%XQ.34))-V25VKV271'QG$=6I#&45"I.">&BVH
MSE%7]K5ULFM=%KY+L?"'_#N;]G[_ **%^W?_ .+3/^"G'_T7E'_#N;]G[_HH
M7[=__BTS_@IQ_P#1>5]WT5^=?VCF'_0=C/\ PIK_ /R9\_\ 6*__ #_K?^#)
M_P#R7DON/A#_ (=S?L_?]%"_;O\ _%IG_!3C_P"B\H_X=S?L_?\ 10OV[_\
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M374_\,G^"?\ HL_[=_\ XLS_ ."C/_T4]'_#)_@G_HL_[=__ (LS_P""C/\
M]%/7T[17)_:68_\ 0?C?_"JO_P#+#F_XBOXI?]'*X_\ _$QXB_\ GCY+[CYB
M_P"&3_!/_19_V[__ !9G_P %&?\ Z*>C_AD_P3_T6?\ ;O\ _%F?_!1G_P"B
MGKZ=HH_M+,?^@_&_^%5?_P"6!_Q%?Q2_Z.5Q_P#^)CQ%_P#/'R7W'S%_PR?X
M)_Z+/^W?_P"+,_\ @HS_ /13T?\ #)_@G_HL_P"W?_XLS_X*,_\ T4]?3M%'
M]I9C_P!!^-_\*J__ ,L#_B*_BE_T<KC_ /\ $QXB_P#GCY+[CYB_X9/\$_\
M19_V[_\ Q9G_ ,%&?_HIZ/\ AD_P3_T6?]N__P 69_\ !1G_ .BGKZ=HH_M+
M,?\ H/QO_A57_P#E@?\ $5_%+_HY7'__ (F/$7_SQ\E]Q\Q?\,G^"?\ HL_[
M=_\ XLS_ ."C/_T4]'_#)_@G_HL_[=__ (LS_P""C/\ ]%/7T[11_:68_P#0
M?C?_  JK_P#RP/\ B*_BE_T<KC__ ,3'B+_YX^2^X^8O^&3_  3_ -%G_;O_
M /%F?_!1G_Z*>C_AD_P3_P!%G_;O_P#%F?\ P49_^BGKZ=HH_M+,?^@_&_\
MA57_ /E@?\17\4O^CE<?_P#B8\1?_/'R7W'S%_PR?X)_Z+/^W?\ ^+,_^"C/
M_P!%/7Q7^P_^QM\)/%7[*/P5\0ZKXR_:OAU'5?"]Q=7<>@_MY?MQ^%-(68Z[
MJR,;+P]X6_:)T;P_I<;! S0:9IEG TK23-&9I9'?]<:^.?\ @GY_R9M\ _\
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M_P"+$_\ @H'_ /1.4?\ #"WP4_Z'?]L;_P 6)_\ !0/_ .B<K[&HH_M',/\
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M/_@H'_\ 1.4?\,+?!3_H=_VQO_%B?_!0/_Z)ROL:BN+^T<P_Z#\;_P"%5?\
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M?'/_  PM\%/^AW_;&_\ %B?_  4#_P#HG*/^&%O@I_T._P"V-_XL3_X*!_\
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M_&_^%5?_ .6>2^X/];^+/^BHXB_\/>9?_-)\<_\ #"WP4_Z'?]L;_P 6)_\
M!0/_ .B<H_X86^"G_0[_ +8W_BQ/_@H'_P#1.5]C44?VCF'_ $'XW_PJK_\
MRSR7W!_K?Q9_T5'$7_A[S+_YI/CG_AA;X*?]#O\ MC?^+$_^"@?_ -$Y1_PP
MM\%/^AW_ &QO_%B?_!0/_P"B<K[&HH_M',/^@_&_^%5?_P"6>2^X/];^+/\
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MOVPPTFDZ=(PC_P""AW[?\,89[.%B(X8?VF4BB0$D)'$B1HN%1%4 #K_V\/\
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M%/\ H=_VQO\ Q8G_ ,% _P#Z)ROJWPY_R+V@_P#8&TO_ -(8*V:Y7F.87?\
MM^-W?_,57[_]?/)?<>/5XOXL56JEQ1Q%;VD_^9WF7\S_ .HD^.?^&%O@I_T.
M_P"V-_XL3_X*!_\ T3E'_#"WP4_Z'?\ ;&_\6)_\% __ *)ROL:BE_:.8?\
M0?C?_"JO_P#+/)?<9_ZW\6?]%1Q%_P"'O,O_ )I/CG_AA;X*?]#O^V-_XL3_
M ."@?_T3E'_#"WP4_P"AW_;&_P#%B?\ P4#_ /HG*^QJ*/[1S#_H/QO_ (55
M_P#Y9Y+[@_UOXL_Z*CB+_P />9?_ #2?'/\ PPM\%/\ H=_VQO\ Q8G_ ,%
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MH<#_ +M/_KZ__2:9_KL=19]/Q/\ (UU%GT_$_P C7+V?3\3_ "-=19]/Q/\
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MWNO$6CW_ ($T>UTZ+0]?DDU$QQ:2^K^(![AXX_9@_:%^)MS^W'X8^(/[7/\
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MU:\UU/"/C+X1>/[W1-!U6]TG5-0O+C0]9FU5XK M92RZ3=WFB>'KS2?V0HH
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M%>]N[GQ-XV/A.]O(-%TB]N]'\'ZSK<^F^&K[Y*_:K^$/[=>HP>,?B)\1+?\
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M6:^QJ^.?^"?G_)FWP#_[$^?_ -2#6:[:?_(NQ7_8;@/_ $QF1]%A?^22SO\
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M3C&-6A&O-8.A!SC6G-QA.?[W@>!.#I\09;EBP*Q."Q62\*8K$8^6,S7-L%'
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M2E*491C5I\\Z7M*3:2J4_:4ZE/GC>//3G&_-&211112,PKXY\$?\I _VG/\
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MH+ 5:<:E&O"$JBG4IR7[S@^"N#L3@\FQ-;"8C#SKY=]8P.$C@^)8YCQ'7H<
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M*T8>+_%'C/4K;PAX/TJW^(^HP:Q>WNE7-_?Z(EW=P:;\(_#+]K#]F?\ ;_\
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M/P1KNI6$-WJ'A=_%,>B^'H==N-$GE;3[O4;?1;"VGNH)C;1/ (YI.[KF-?\
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MWQ8\+:/XZ\':A\._#&FZSJ.J7L=E9Z5:W]_H>GVFOS36']S7BCX9_#CXQ?\
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MU;4]%TF_OX+BZTVSEA^BJ "BBB@ HHHH **** /SJ_X)N.1^SY\2@,?\G_\
M_!6#_P!>E_MC^]??&\^@_7_&O@7_ ()N_P#)OGQ*_P"S_P#_ (*O_P#KTK]L
M:OO>@#\@/^"Z7P]\ :Y_P3%_;7^)&M>!?!NK_$3P-^R[\6=&\$^/M3\,:+?^
M-?!VD>+X-%3Q9I7A7Q3=V4VN>'M-\4)I&DIXBL=(OK2UUM-,T]=2BN196PBH
M?\%-C_87BS_@DK\4=>F@L?AI\,_^"B7PDE^(>MW\.GKH?AL?$3X*?&/X3?#[
M6]?U34+B"+1+!_BAXX\':!:ZBS")=:U_2HFD2XDM%D_63QQX%\$?$WPCX@\
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M?VEU97#V=Y,L-W;7%M(5FAD1?Q->YFB_:0^%OPF\<>'O"-MKVE_\%0-+U/\
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M2?(HO$2A4QM2E.O22I4GA+3@GB(\GU.:<%Y?AN&\WQ^%S3$365U)XF.73Q>
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MU))YKX$M/%/Q1^!7Q!_X*0^*/"'QHUN7Q!\1/VZ_V9O@=H%[\1-%^%UUX/\
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M-2_:(_\ 50^,*^E/#G_(O:#_ -@;2_\ TA@K"?\ R+\/_P!AF,_],8$\VO\
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MUO0->T;4O!]E::CI&M:/J<%UIVJ:9J%I++:WMA?6T]K=6\DD,\4D;LI_G?\
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M9#IEG!\7_P#E+)^Q3_V:?^V-_P"I7^SY7Z)^#O!?@[X=^&-%\$_#_P )^&O
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M?QB\/WFN>%?#MG\2+/0))M.UFUT'4+/PAIVL:OH6M3PS+X1U5+34;'X5L_\
M@@/^UE\?O#G_  6)TO\ ;A_:*^ FH^,O^"E;_LF>,O ?Q(_9\\,^/-,L/AQ\
M2OV<H]:UR"#7?A=XNM[-(O ^BZY-X?\ !NBQV_Q+\7:_XR\':;J'B77KKPMX
MKU".RM0#[I_9<_X+)?%[QQ^TW\"?V8?VYO\ @GC\2O\ @G[XB_:\\(>)?&/[
M'_BWQ'\:_ GQS\*_&*/PEHL'BG6O"?BB?P5X>\.7/PA^(D7A:[M=57P1XJBN
M]6M[F:#1M6&EZGJ6@PZQ\+_L!_\ !467]DW]A[_@L3^U_P#MC_$WXQ?&GPS^
MSS_P5B_:F^&/P[T'Q)XXUKQUXK31/[3^&/A[X9?!;X;2^.==N+3PQX6MM:UY
MQINAV5U8>&O"NES:UJ\&GI#!<Q3?3'P+_P"":G_!2?XV?MC?L@?M.?\ !5;X
MX?LA>+O#_P#P3WT#QM%^S?X'_9&\-?%"TU#XE?$/QQX>TKPG?_%?X\:[\5-*
MTMM.UR#3=#TG7#X;\ 1CPQ+XGL-/FT^UT73X-4MM?\MTW_@@I\4?'/\ P3Z_
MX*=?L;_&+XI?"_1/%?[8'_!0CXP?ML? ;QMX%E\4>-/#W@N/7->\ ^)_AGI7
MQ0T3Q1X0\'_:[Z2]\'WVB>/-!TJU\3Z)::1K!O-(U?7;R".W4 ZC]DG_ (.1
M_A+\:H/VG-)^/_P)T+X*_$']G7]F#QI^V%8>%/@#^UM^S_\ MX:#\3O@Q\/[
M61_%6G:1\1/@-J-KX6\*_&'3;S[(L_PH\5266JV>C7]OXDU74M-TA+J6W]8_
MX)=_\%M?BC_P41^)OAKPQXI_X)]>.O@M\*/B9\/M4\>_"G]HCX:?'?P7^UW\
M*3)I4DLS^!_C[K7PA\'Z=8?LN_$;4-+@GFTKP)\6=3LO%-QK5I=^&[O2;#46
MTTZGY9^PK_P2(_;-^%&I_M!_$/XS:[_P2\_94^*?B_\ 9VU3X!_ :X_X)M_L
M!? :PTGP/XEUJULSJGQ_^(WBKXN? GPW\1_'.N:M=Z;:6GB7X%'7T^"?B/3)
M]1D73=%OCHKZ'X/^P'_P0G_;!^#'_!0;X!?MB_M"ZC_P3F^#NE?LU>#_ !_X
M:BG_ ."=GPK^(OP;\8?M:7?C#PYJ7A"WU7]I#P =#^'_ ,"_!D\=O?\ _"7:
MG;_"/PA'HUUK*OX>CT1-.CTO6]* /JSQ1_P70^,6N_&KX[Z=^RA_P2V_:2_;
M+_9(_95^.<?[.O[0W[3/P:\<>&[GQ_I7Q1TK4+#3/'ND?!W]E)?"^I_$SXY6
MW@6YU73SJE[X<UO2(DLGGUO5AH7AT6&LZET/_!3/_@O+X*_8-^-_@#]F7X9_
M!+PE\=_COXJ^%%O\<O%.A_&?]K3X'?L&> / 'PVU*^N=,T2WU/XF?M)26FF:
MA\4=9N[6:YLOA+!I5KXI.C0W&IMAK>:S7Q+2_P#@E]_P5X_91^*W[5?@;_@F
M[^V'^R-\)/V4?VQOVFO$/[5GB?XC_&GX5^+/B#^UC^S_ /$#XC7NFW/Q+T7X
M4>%9M UOX#_$?P[J4.@Z9IVGO\3C:72:3<2V]C%X>UNP?Q-K-O\ X*9?\$7O
MVA?C[^USX(_;9_9=7]@7XY?$ZY_9QM?V;_C#\./^"H'P07XM?"?6UT&\GU#P
MO\<O!.G^$?AYXIL_#7Q9L;B\GCFL=)\*^'?"A2'RWM[S1-3U;PY< &]XQ_X.
M)O"6I_#C_@F=\1?V8/V/_B9^U%-_P4CU3XZ>#?#OPX\.?$CPCX+^)GPS^)WP
M/3P_I6K^";W3M;T?4?!OB2";Q?K<]IJ_BK4/'7@G0_#_ (&TR7XBQR:W87,&
MDUZ?^SI_P6 _:+_::^%W_!1KP5:_\$]O%/PA_;Z_8 LO#=KXF_91UG]HWX8>
M(]$\2ZC\0]%UW5_!MUH7[0$OA72? ,;Q:/X=UGQ'=_:_#6H>'[FR@T=-*UG6
MX]<#6G Z'_P1J^./@WXB?\$3_$^C?$#]F_4[+_@G=XS_ &DO'W[2^H^$?A%X
M*_9@T_XA>(_CWX>T*%)O@I\$?V=_@YX?^$=C!I&KV5UIMV^L1>!M1U/1K#3=
M>UC4-=\3ZEJ[+]4_LL_\$\?B_P#!G]O/_@KS^TUXU\6_#:X^&W_!00_L]P_"
M73_"VI>*-6\<>$[?X6?"GQ9X"\43?$71=6\)^'=!L)KC4]?MKS0+?PUXL\4)
M?V,,YU&YT:X$<#@'SQ_P;6_M;_MC_MB?\$[/#?Q*_:[\(^(=2O9/%7CN?P'^
MTQXH^*?A#QEJW[2MMJGQ7^)[>*;W_A7?AW3=.U+X-Z=\)-6L;7X9:/X<UE!8
MZOI6E6>I>%+33O#\5M9Q_P!"%?B__P $//V(?VS/^"<W[*$W['?[4'BO]F/Q
MS\._A+XF\0?\,Y>+/@++\56\::UX4\:>./'/C[Q9=?&R#XA:/HVAV?B%M<\4
M6B^'=.\"V\VFZ5I4=SIVI:IKUY!%K-Y^T% 'YT?\$W?^3?/B5_V?_P#\%7__
M %Z5^V-7WO7P/_P3>8#]GWXE G_F_P#_ ."K_8_])2OVQJ^]MZ^OZ'_"@!U%
M-WKZ_H?\*-Z^OZ'_  H =13=Z^OZ'_"C>OK^A_PH =13=Z^OZ'_"C>OK^A_P
MH =7P)_P3P_Y)W^T7_V?W^WG_P"M1_$JOOG>OK^A_P *^!/^">++_P *[_:+
MY_YO[_;S['_HZ/XD^U 'W[13=Z^OZ'_"C>OK^A_PH =13=Z^OZ'_  HWKZ_H
M?\* '44W>OK^A_PHWKZ_H?\ "@!U%-WKZ_H?\*-Z^OZ'_"@!U%-WKZ_H?\*-
MZ^OZ'_"@#X&_:V_Y.@_X):_]G>_&'_UWA^VQ7WW7P%^UJR_\-/\ _!+;GI^U
M[\8>Q_Z1X_ML>U??>]?7]#_A0 ZBF[U]?T/^%&]?7]#_ (4 .HIN]?7]#_A1
MO7U_0_X4 .HIN]?7]#_A1O7U_0_X4 .HIN]?7]#_ (4;U]?T/^% 'YW_ +=_
M_)4?^":'_9_5Y_ZPA^W+7UE7R9^W<P/Q1_X)HX/_ #?U>>O_ $8A^W+7UG7X
M3XH_\CW!?]BFC_ZF8T^)XE_WVC_V"P_]/5@HHHK\U/G0HHHH **** "BBB@
MK\)/V;O]=^TY_P!GR_MI?^M$^/:_=NOPD_9N_P!=^TY_V?+^VE_ZT3X]KIC_
M +AB_P#K_@__ $G%'\P_2W_Y-5@_^RTR7_U5<0G0_&[]G+X4_M#P>"8OB?9>
M-99_AQXHF\:>!]5\!?%SXN_!SQ#X;\43Z%JOAF76;#Q-\'?'/@/Q#]I;P_KN
MLZ2%GU.:!;/5+^)(E^TREN67]D+X*2> [_X=:J/B_P"*M!O/$VF^,[+5?'?[
M2W[2?Q ^(7A/Q7H\(MM,\0?#GXL^-_BUX@^*GPNU2SMS/!#=?#CQEX6D$-_J
ML3%DU?5%N_INBN>&,Q=.$*4,5B84Z;YJ=.%>K&%.7,Y\T(*2C!\[<[Q2?,W+
M?4_SLH\09]AL-AL%A\[S>A@\'4]MA,)1S+&TL-A:JK2Q*JX:A"M&E0J?6)RK
M\]*$9>VE*K?GDY/YJ_X9"_9];X7W?PAG\%:G>>%;_P 76_Q#O-9U'XA?$O4O
MBK<?$>RNK6[T[XF2_'2_\87/QM;XF:2UAI]IHWQ%_P"%@_\ ":Z-I6G:;HNE
MZ[::1I]G8P=7X,_9[^%?P\^'=[\+_!.E>)?#?AK5=?N?%FN:EIOQ(^)<?Q"\
M2^*[_6+77=3\4^*_BX_B^3XK^*_$FLWME:P:[KWB/QIJFK:[H\">'=7N[WP^
M#IA]JHI2Q>+FG&6*Q$HNJJ[C*M4:=962K-.33JI))5'[^BU%5S[/:]*=&MG6
M;5J-3&K,ITJN8XRI2GF*22Q\Z<ZSC+&I1BEBFG72BDJFB/D+7OV&O@#KWCKQ
M[\2!/\?_  MXM^)^O6OB?Q[<_#3]L/\ :^^$ND>)/$%EH6D^&+35;OPI\+OC
MIX0\)PW=MX>T+1]'A>RT2U6/3]-M+95$<*@>W_$WX._#WXQ?#;4OA)\1]'U#
MQ%X&U:'08[RR'BGQ9H^N"X\+ZOI?B#P[JUGXUT'7-+\;:9XBT77M$TG6].\3
M:9XBM/$-KJ]A;ZE%J:WJF<^G442QF+E*C*6*Q$I8=P>'E*O5<J#IJ"INBW)N
MDX*G!0<.7E4(*-N56=;B#/L14R^K7SO-Z]7*7AY955K9EC*E3+)82-&&%>7S
MG6E+!/#0PV'CAWAG3=&.'HQI\JI4U'Y5\5_L4?LW>./$MGXL\5^"?$&LZI'I
M_@?3?$-K<?%;XOQ^&OB?;_#9XG\#3?'7P9;>/(/!_P"T%J7AQH(19:Q\<-"^
M(.KLD,4=S?3QQHJ_55%%15Q%>LH1K5ZU6-)<M*-6I.HJ<;17+!2DU!6C%6C9
M6C%=%;GQF:9GF-/#4LPS''XZE@X.G@Z>,QF(Q-/"TY1IPE##0KU)QH0E"C1B
MXTE&+C2IQ:M"*7BUE^SO\&M/^'/BWX36W@FV_P"$ \;^*?&7CCQ'H-QJWB"]
M>Y\8>/?&5_\ $/Q'XET_6+S5KC7=!UH^.-1N/%6@ZAH&IZ7<>#]:CL+[P@^A
M2Z5I9L^6T;]DCX$:-X*\=^ Y/#?BCQ1I7Q+M].M/&NN_$?XL?%WXJ_$G6+;0
MY);GPO#'\7_B7X[\6?%?28_!&I3W.O?#Y=%\::=_PKWQ/=WOBGP3_8'B*\NM
M4F^DJ*M8O%KF2Q.(2G45:25:HN:LI1DJLK2]ZHI0A)3=Y*4(M.\5;>.?9Y!5
ME#.<VBL1BX9AB%',<9%5\?3J4JU/&UDJR57%PJT:-6&)GS5HU*-*<9J5.#7A
MGP^_9S^%OPQT7QCH_A2#Q[)<^/[)-,\6>,_%OQE^,OQ%^*^J:9;V=_9:7IJ?
M&;XA^/O%/Q:TS3O#J:KJ]SX2L-)\:V-IX/U/6-8UCPM#I&K:MJ-[<Y_Q%_9>
M^$'Q2GT"^\4VOQ$M-8\.^'[?PG#XD\"_''XX_"OQ=KOA:U=I;;PUX\\7_"_X
MB^#O$_Q*T"&YEN[Z/1_B'JWBC3UU+4]9U,6_]H:WJ]S>_0=%"Q>*51UEB<0J
MKU=55JBJ-\JA=SYN9^XE#?X4H[)(2SW.XXR681SG-8X^3<I8Y9CBUC)2=*-!
MREB56]LVZ$(46W._LH1I_!%163H.@Z'X5T/1_#/AG1]+\/>'/#VEV&B:!H&B
M6%KI6C:)HVE6L5CIFDZ3IEC%!9:=ING64$-I96-I##;6MM%'!!&D:*H^3_BA
M_P GN_LB_P#9'?VO/_2_]FROL:OCGXH?\GN_LB_]D=_:\_\ 2_\ 9LK7!-NO
M4;;;>$S%MMW;;P&*;;;U;;W9W\-3G4S7&3G*4YSX?XQG.<Y.4YSEPGG;E*4F
MVY2DVW*3;;;;;N?8U>;_ !3^$?@'XT>&8_"?Q#T>\U+3;75M/\0:1?Z)XC\3
M^"?%OACQ%I+R-IOB3P9X\\#:SX<\<>"/$EDD]U:V_B'PCXBT764L+[4-.%]]
M@U&^MKCTBBN2$YTYQJ4YRIS@U*$X2<)QDMG&46G%KHTTSP</B<1A*]+%82O6
MPN)H3C4H8C#U9T:]&I%WC4I5:<HU*<XO6,X24D]F?-7_  R%^SZWPON_A#/X
M*U.\\*W_ (NM_B'>:SJ/Q"^)>I?%6X^(]E=6MWIWQ,E^.E_XPN?C:WQ,TEK#
M3[31OB+_ ,+!_P"$UT;2M.TW1=+UVTTC3[.Q@ZOP'^SW\*_ACX8T?PCX$TKQ
M+X>TG2/&]W\2+BZM_B1\2[GQ-XO\<:B]T^J^(OBAXUU#Q?=^,OB]>:PUUC6T
M^*>O>,;76DL](CU6WNTT/1EL/:J*VEB\7.,H3Q6(E&51U91E6J2C*JX\KJ2B
MY-.HX^ZYM.3CHW8]"KG^>UZ-7#U\ZS:M0K8J6.K4:N8XRI1JXV</93QE6G.L
MX5,5.E^[EB)Q=64/<<W'0X+4_AAX&UCXD>$OB[J.A_:?B'X&\+>,/!?A;Q#_
M &GK$/\ 9?AKQ]?>%M2\6Z;_ &3!J$6AWW]K7O@KPS-]LU'3;O4+#^S/+TRZ
MLXKS4([NO\6?A/X"^.'@'7/AC\3=%GU_P9XB?2)]2T^SUWQ#X7U&.\\/ZWIO
MB70=4TGQ+X2U;0O%'A[6=#\0:/I>M:/K?A_6=,U;3-3L+6\LKV">%''HM%9Q
MK58RI3C5J1G0Y70G&<E*BXS=2+I23O3Y:DG4CR-6FW)6DVSDIYACZ5; XBEC
M<73KY8Z;RVM3Q-:%;+W1Q-3&47@:D9J>$=+%U:N*I^PE3Y,34J5XVJSE)_*O
MBO\ 8H_9N\<>);/Q9XK\$^(-9U2/3_ ^F^(;6X^*WQ?C\-?$^W^&SQ/X&F^.
MO@RV\>0>#_V@M2\.-!"++6/CAH7Q!U=DABCN;Z>.-%7U#XU_ _X;_M"^!9?A
MO\5M+US5_"4NO>&?$XMO#GCKQ[\.=7M_$'@S7;'Q/X6U6R\5_#;Q-X1\6:?=
MZ)XATS3M8L7L=;MUCU"QM+EE>2WB*^M45H\9BW*C-XK$.>&:>'DZ]5RH-<MG
M1ES7I-<D+.#C;EC;X5;K>?Y[*ME^(EG6;2KY1.-3*J[S+&.MEDX>RY)Y?5=;
MGP4X>PH<LL-*DX^QI6:]G"WRK#^Q?\!7\%^/_AWXCM/BW\2O!/Q-T>ST3Q9X
M<^-7[2O[2OQUT\VVG7G]I:9?^&E^,GQ;\=2^ _$>E:JEMJ^D^+O DOAOQ5I>
MLZ=I&KZ?K-MJ6C:5=6?8?#C]FCX1?"C2?'FF^#-/\;1W_P 3HHK?QUXX\3_%
M_P",'Q ^+?B"WM-)ET32;:X^-7C_ ,>>)_B[:VWAO3KB[3PA;:?XVM(/!MS>
MW^H>%8]'U&_O+J?WJBG+&XR<90GB\3.$Y*<XRKU91G./L^64HN;4I1]E2M)I
MM>SIV?N1M=;B/B'$4:^'Q&?9S7H8JK3Q&)H5LTQU6CB*])894JU>G.O*%6K3
M6#PBIU*D93@L+AE&2]A2Y?G3XE_LI_!;XMSZ#?>,M,\>1ZQX?\,?\(3'XD\%
M_&OXV_##Q=K_ (,WI*?"/CWQ?\,OB'X0\3_$SPRUR);Y]!^(FK>*-*DU*^U7
M4WM6U#5]4N;SW70=!T/PKH>C^&?#.CZ7X>\.>'M+L-$T#0-$L+72M&T31M*M
M8K'3-)TG3+&*"RT[3=.LH(;2RL;2&&VM;:*.""-(T51K45G.O7J0A2J5JM2G
M3NZ=.=2<H4W+63A"3<8W>KY4K]3DQ&9YEB\-A\'BLPQV)P>$<Y87"XC%UZV&
MPTJK<JDL/0J5)4J+J-MS=.$7-MN5VPKXY_X)^?\ )FWP#_[$^?\ ]2#6:^QJ
M^.?^"?G_ "9M\ _^Q/G_ /4@UFNBG_R+L5_V&X#_ -,9D>IA?^22SO\ [*+A
M?_U6<7GV-7SE+^R=\"IOB-_PL^3PSXC.MGQ/'XX?PN/BC\5T^#LWCN&Y348O
M'UQ^S^GC=?@3<>/8M;CB\41^-Y_AS)XI3QC!;^,UU8>*K>'6(_HVBN>G6K4>
M;V-:K2YXN$_9U)T^>#WC+E:YHOK%W7D>3@\QS#+W6> QV,P+Q-*6'Q#P>*KX
M9UZ$OBHUO8SA[6E+[5.?-!]8L^:=._9 _9YTKXN77QOLO EVGCNZ\67_ ,05
MMIO'/Q$O/AUI_P 2-5T*'PSJOQ.T/X,7GBRX^#GA[XHZKH4<FG:I\2]"\!Z=
MXZU&+4-9>]\03S:[K,M_[EI/A32=&M-=L;:;7KRV\1ZOK.M:DFO^+/%7BATN
MM><OJ%II,_B76=6G\/Z$F2FE^&- ETSPWH,)-OH>E:= 3&>DHIU,1B*W+[6O
M6J\D(4X>TJSGRPIWY(1YI/EA"[Y(JRC=V2NS3%YMFN/5)8[,\PQJP]"AA:"Q
M>-Q.(5'"X9R>&PU)5JL_9T,.Y2="C#EITG*3IQBV[\1\-?AQX,^$'P_\&_"W
MX=:-_P ([X$^'_AW2O"?A'0O[1U75O[)\/Z+:1V.F6']IZ[?:GK-_P#9K6*.
M+[5J>H7M[-MWW%S+(6<^5^(_V3O@%XOU[XP^(O$O@:?6;KX^Z#HWA[XN:5>>
M,O'C^#_&,7ARQTC3/#VO3^ E\3IX'TGQYH.GZ!H5IHOQ*T#P]I7Q#TN'1M*6
MQ\3P?V?:>5]%T40Q.(IU)U85ZT*M1WJ5(59QJ5'[2-:\YJ2E-^UA"K>3?[R$
M9_%%-.CF^;8?%8G'8?-,QH8W&2<\9BZ.-Q-+%8J;Q=''N6)Q$*L:M>3QV'H8
MURJSFWBZ%'$7]M2A./C7P?\ @#\+O@7%XG/P]TGQ -5\:ZE8ZKXR\7^.OB#\
M1/BY\1/%EUI.GQZ3HL?B3XE_%KQ7XW^(.N:?H&F1FQ\.Z1J?B6YTGP]:S7<.
MBV5@E[>"?J/&/PP\#>/];^'/B+Q=H?\ :VL_"7QC+X_^'UY_:>L6'_"/^+9_
M"WB3P5+JWV?3-0LK75=WAGQ=XATS[!K<&I:8O]H?;%LAJ%I8W=MWM%*5>O.I
M*M.M5E6DG&5652<JDHN'LVI3;<FG3_=M-V</=?NZ$5<SS*MC*F85LQQU7'U:
M<Z57'5<7B*F,JTJF&>#G3J8F51UITYX1O"SA*;C+#-T&G2;B?-/C3]D#]GGX
MA?% ?&#Q=X$N]3\933>#+O6[>#QS\1-(\!>-M1^'-Y<ZA\/M9^)?PET3Q9IW
MPH^*.O\ @:]N5N?"'B#XB^"O%&M^&YK#17T>_LSH&A_V?[#K_P ._"/BNYU^
M3Q3IMQXET[Q5X,N_A]XD\)>(-9US6?AYKOA/4)+Q]2T[5/AIJ6I7/P^O;G58
M;^[T[5=9G\,OKFJ:+*-!U#4KG18H;"/M:*<L3B9JFI8BO)4H*G24JM22IP7+
M:%-.3Y(+DA:,;)<L;+W5:ZN<9O7CA85\TS&M# T8X; QJX[$U(X/#P5)0P^%
MC.JUAZ,50H*-*BH4XJC22BO9PM\W_!;]DOX%?L_ZK)KOPV\.>*5UP>%--\!:
M;K7C_P"+'Q=^,FK^&/ 6DSK=6/@/P-J?QC\=>/+[P!X'CNHK6YF\'^"9] \-
MWEQIVD3WFF7$NCZ6]G](445-:M6Q$W5KU:M:HTDZE:I*I-I*R3G-RDTEHKO1
M:(RQ^8YAFN)GC,TQ^,S+&5%&,\5C\57QF)G&"Y81G7Q$ZE62@M(IS:BM%9'Q
MS\:?^3M_V*/^[D/_ %6>E5]C5\<_&G_D[?\ 8H_[N0_]5GI5?8U=.*_@9;_V
M!5/_ %8X\];._P#D6<(?]D[BO_6MXH"O _BO^S/\)/C1KVE^*?&=GX\T_P 2
M:5H\_AS^WOAE\9_C/\$=7UKPU/>#4!X8\8ZA\%_B!X NO'?AFTOFNKS3/#OC
M677]%TBYU37)M+L;.37M::_]\HKFI5JM":J4:M2C42:4Z4Y4YI-6:4H-22:T
M:OJM&>1@L?CLMKQQ678W%X#%1C.$<3@L36PM>,*D7&I&-:A.G449Q;C.*DE*
M+:DFG8\L\5?!+X5>,_ /A[X6:YX+TL?#SPEJOP\UGPQX1T22^\*Z-H%Y\)_$
M>@^+/AY'I-MX6N]&-CIOA?7?#&A7-EHMNZ:/-;:='I=[876DR3V,NMXQ^&'@
M;Q_K?PY\1>+M#_M;6?A+XQE\?_#Z\_M/6+#_ (1_Q;/X6\2>"I=6^SZ9J%E:
MZKN\,^+O$.F?8-;@U+3%_M#[8MD-0M+&[MN]HH5:LK6JU%9U)*U22M*M%0K-
M6>CJP2A4:UJ12C*Z214<RS&"BH8_&P4)XVI!1Q5>*A4S*C##9C.-JBY9X_#T
MX4,;)6EBJ,(4J[J0BHKYI\:?L@?L\_$+XH#XP>+O EWJ?C*:;P9=ZW;P>.?B
M)I'@+QMJ/PYO+G4/A]K/Q+^$NB>+-.^%'Q1U_P #7MRMSX0\0?$7P5XHUOPW
M-8:*^CW]F= T/^S_ '+QEX0\-?$+PAXJ\!>,](MO$'@_QMX<UOPEXJT*\,RV
MFM>'/$>FW.CZWI5TUO+#<+;ZAIMY<VDS030S+'*S12QR!77I**J6(Q$_9<]>
MM/V"C&AS59R]C&/*HJE>3]FHJ,5%0LERQMLK76S;-<1]1^L9GF%?^S(4Z>6^
MVQN)J_V=3I*FJ4,#SU)?5(4E1HJG'#^SC!4J:BER1M\B>(_V%_V:_%>@^#_#
MVN>&OB#<6_@GP7J'PUTW6+7X_P#[0FD^--=^&NJ7PU&]^&_Q&^(.D?%*Q\=_
M%KX>R7>7C\#?%/Q'XQ\+6T3RVUKI,-K+)"_TP?!WA%O"1\ 'PMX=/@0^'?\
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M_P!(8*WG_P B_#_]AF,_],8$]6O_ ,DEE7_919__ .JSALV:***XSYT****
M"BBB@ KY2_;P_P"3'?VS/^S4OVB/_50^,*^K:^4OV\/^3'?VS/\ LU+]HC_U
M4/C"NO ?[]@O^PO#?^GH'O<*_P#)3\.?]C[)_P#U88<^E/#G_(O:#_V!M+_]
M(8*V:QO#G_(O:#_V!M+_ /2&"MFN66[]7^9XM;^+5_Z^3_\ 2F%>;_%/X1^
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M$@XX>5&K4INFX3E%E%%%8'FA6+^S+_RDW\+?]F(_'7_UH']F:MJL3]F8@?\
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M?PT_]:(^*]?HA7YW^'/^4I/C;_LP/X:?^M$?%>OT0KQ "BBB@ HHHH ****
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M_A37_!1;_H^KX!_^():G_P#1<U]]44 ? O\ PIK_ (*+?]'U? /_ ,02U/\
M^BYH_P"%-?\ !1;_ */J^ ?_ (@EJ?\ ]%S7WU10!\"_\*:_X*+?]'U? /\
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M(Q^Q=^V1>-KNIVK?M0:L?$FGMX>L_$&AC04N-#=;_6['7?[7*Z(VDZK]0?\
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M^#X$?^(.:G_]%E7W?11]?K_\^\%_X;LO_P#F7R_/NP]M/M2_\$4/_E9\(?\
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M[KX._P#B(=__ /1)U]C44?7Z_P#S[P7_ (;LO_\ F7R_/NP_UHS+_H&X=_\
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MSB=!3I8_!8JDI4I5*G)4A"-2*J3BI<LY)T/^%7_MN?\ 1W7P=_\ $0[_ /\
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M_P#^9?+\^[/\[_\ 6C,O^@;AW_Q$.$__ )R'QS_PJ_\ ;<_Z.Z^#O_B(=_\
M_1)T?\*O_;<_Z.Z^#O\ XB'?_P#T2=?8U%'U^O\ \^\%_P"&[+__ )E\OS[L
M/]:,R_Z!N'?_ !$.$_\ YR'QS_PJ_P#;<_Z.Z^#O_B(=_P#_ $2='_"K_P!M
MS_H[KX._^(AW_P#]$G7V-11]?K_\^\%_X;LO_P#F7R_/NP_UHS+_ *!N'?\
MQ$.$_P#YR'QS_P *O_;<_P"CNO@[_P"(AW__ -$G1_PJ_P#;<_Z.Z^#O_B(=
M_P#_ $2=?8U%'U^O_P ^\%_X;LO_ /F7R_/NP_UHS+_H&X=_\1#A/_YR'QS_
M ,*O_;<_Z.Z^#O\ XB'?_P#T2='_  J_]MS_ *.Z^#O_ (B'?_\ T2=?8U%'
MU^O_ ,^\%_X;LO\ _F7R_/NP_P!:,R_Z!N'?_$0X3_\ G(?'/_"K_P!MS_H[
MKX._^(AW_P#]$G1_PJ_]MS_H[KX._P#B(=__ /1)U]C44?7Z_P#S[P7_ (;L
MO_\ F7R_/NP_UHS+_H&X=_\ $0X3_P#G(?E%^VE\./VQ+/\ 8Y_:RO/$/[4O
MPHUS0+7]FCX[W.N:)8?LL7NAWVL:/!\+?%4NIZ79:VW[0>K+H]WJ%DL]I;ZJ
MVE:FNGS3)=G3[T0_9I/H'0?AA^VRVA:*T7[6_P 'HXFTG3C'&W[(U_(T<9LX
M2B-)_P -()YC*N%+[$W$;MJYP.O_ &\/^3'?VS/^S4OVB/\ U4/C"OI3PY_R
M+V@_]@;2_P#TA@KLGCJWU"@^3!W>+Q:_Y%^ MI1P35E]6LGKJTKO1-M)6^@K
M\39BN%<LG]6X?YI<09[!I\)\*N%HY=PZTU3>3>SC)N;YIQBIS2C&<I1A!1^4
MO^%7_MN?]'=?!W_Q$.__ /HDZ/\ A5_[;G_1W7P=_P#$0[__ .B3K[&HKC^O
MU_\ GW@O_#=E_P#\R^7Y]V?/_P"M&9?] W#O_B(<)_\ SD/CG_A5_P"VY_T=
MU\'?_$0[_P#^B3H_X5?^VY_T=U\'?_$0[_\ ^B3K[&HH^OU_^?>"_P##=E__
M ,R^7Y]V'^M&9?\ 0-P[_P"(APG_ /.0^.?^%7_MN?\ 1W7P=_\ $0[_ /\
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M7Y]V>/5XHS+VM7_9N'?XD_\ FD.$W]I]7DESXY_X5?\ MN?]'=?!W_Q$._\
M_HDZ/^%7_MN?]'=?!W_Q$.__ /HDZ^QJ*7U^O_S[P7_ANR__ .9?+\^[,_\
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M_P ^\%_X;LO_ /F7R_/NP_UHS+_H&X=_\1#A/_YR'QS_ ,*O_;<_Z.Z^#O\
MXB'?_P#T2='_  J_]MS_ *.Z^#O_ (B'?_\ T2=?8U%'U^O_ ,^\%_X;LO\
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M_P#3U8GHKX\^%G[>O[+7QD^)NB_"#P3X[\41>.O%_A_Q#XL^&]MX[^#/QO\
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M&@6<VOO8)X>N-:NK+29]2N_#UGJMSKVD:3>:'J^L:;8:9XE\.W>J?E!^UO\
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M.CF.:XG(XY57:Q4*SRS.*N.65XR?L_W$HHHKYX_)0HHHH \?T_\ Y/X_8?\
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M /2:9_L>=19]/Q/\C746?3\3_(UR]GT_$_R-=19]/Q/\C3J_:^7Z =';=O\
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M!WASX'?!OX'^!Q?>/]:TOP_>^/\ QSXE\+>)/B/XKC\+>&]+U+Q@^B:3!IA
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M/V>/%'PM^($\\'C_ .)?B^>U\(>,]&^+?B_XO>"_A-XODUG2M$T'PY\,-$\
M>'_#NH:K^S-?.7P&_95^!O[-ESXUU;X6^'?%#^+?B1<Z+/X_^)'Q/^*?Q8^/
M7Q>\9P>&+*;3O"NC^)OC'\=_'/Q)^*>L^&/"-I=:A'X0\)7_ (PG\,>%'UC7
M9_#VD:;<:]K,M]]%;QZ']/\ &@!]%,WCT/Z?XT;QZ']/\: /@G]K3_DY_P#X
M)<?]G=_&'_UWG^VK7WS7P'^UHX_X:>_X)<]>/VN_C!Z?](\_VU1ZU]\[QZ']
M/\: 'T4S>/0_I_C1O'H?T_QH _/C_@I#^VKX6_8S^"WA^:X^)/PJ^%OQ2^/7
MC>Q^"/P3\9?&WQ9X>\$_"CP;XS\0:;J6I:I\3?B-XC\4ZMH6B6O@OX4^$M*U
MWQYJFEW.KV%YXTU#1]'^'>@S_P#"2^,M%1_RM_X(N^!_V9?B/^S;_P %1OV-
M?@K^U4WQ'\/:W^UI\?M!OOBU\+/CGX/\>?'+4O!'QA^$?P\\,O\ M"V7C6"Y
M\:1C7OB%XFMO'>O^'OB'-I6H^&[WQCIVN?V)%<)H<]A:?TL[QZ']/\:^)%_8
M7^'=C\*OVROA3X9^)GQM\%6W[;GQ#^*/Q,^(_C?PEXF\)Z7\0O OB/XN>$/#
MG@GQ,/A%KC^![JP\,6UGHOAFT;0)]>T;Q9J^F7]W>WAU6YD^Q"R /S2^$7P^
M^%?Q]_;,_8:T7]A'P/X<TG]D7_@DWI?Q;\!>+?VH= LM$MO#?C[Q7XD^%>I_
M"";]DKX/:SI^F6LOQ'M-*O\ 5;3XH_'WQSH<ES\.;7QKX>TC16U#4/B9%>)H
M']!=? 7[-/[#WBC]E^R^%WA'PE^V]^U/XI^#7PDT&R\*^&?@)XG^'W[ 'AWX
M7S>&=+T:71M'T.^G^#W[#WPK^)%M::4&M]3@G\/_ !"T+4;S5+*&;5[[4K:Y
MU*TO_OK>/0_I_C0 ^BF;QZ']/\:-X]#^G^- 'Y[?MT?\E3_X)H_]G\7O_K"/
M[<E>*?\ !8N?Q);_ /!*_P#;]E\*2W<.LK^RU\6UWV,C17']DR>%[V/Q$N]&
M6002>'7U6.[$3"9K1IUA_>E!7M/[<[!OBI_P31 S_P G\7O7_LQ']N2OK/4-
M/L-6L+[2M5L;/4]+U.SN=/U+3=0MH;VPU"PO87MKRQOK.Y22WN[.[MY)(+FV
MGCDAGAD>*5'1V4_B/B-76&XGRG$N"J+#X'!UW3;LIJEF&+J<C=G92Y>6]G:]
M[,^-X@G[/,L+4MS>SHTI\KVER8BK*S];6/PUL1\6/@'\6O\ @E1K'Q#^)FD_
MM3Z5^T1XUU;X::=X'O?@G\!-/^'W[+^MZQ^RW\0?B)I_Q#_8T\4^"?AEHWQE
M\$>$?#WAOP=KGPSO[?XJ?%3XTZQXC^#OBB[75_&$>K65WJVK<K\5?!_C[]BG
MX ?\%#/V_?@!^WK<_$^7P_\ &/\ :"_:>\0_!+PSX _9MU+]GKQ-XL\)3:;X
M=U;X$_%;7%\(>-OV@[KQYX8T'P5I_P (-5USP;^T3\,I=#UG0?#\B?#/2+K2
M]>\.^)?U,^#O[#W[-7P'\7Z=XV^&_@[Q9:ZOX=T;4_#?@'3O%_QF^-OQ1\%_
M![PSK/V6/4?"_P !/AQ\4?B+XR^'O[/WA>XL+#3=!'AKX*>%_ 6AP>%M*T?P
MG;V$/AG2--TFUS];_8)_9:\0_$+5_B/J7@/Q,+SQ+XLB\?>+_A_IOQD^-VA_
ML_>._'D<EG<MXX^(7[+^B?$;3OV;OB#XRNM1TW2M:U'Q3XT^%6NZ]JGB+1M$
M\1ZC?W6NZ+I6HVGQZS7!JM3;C.5!0A'$0^H8%+&1CC:N)=*=!SE3PR=.I&G[
M>C-U'.'M)PDW%Q\CZS2YTVFX*,547L**55*M*HX.',XTU:2CSP?,VG)IMZ>G
M?$Z'7/B;^S?XS&D:SXQ^%7B#QM\(=4O+/5/#UCX6O?''@R_UGPK)?>19:?X\
M\)>,?"L^M6$DS:?+;^(/!VL6AF$JOIOG"/R_PK_8Q\6?&[X)_P#!,7_@DM\*
MO!/[1'CR'Q5^VO=_L_\ PFTGX@^.O"7P*U*\_9B\!-^SWXP^*GBK0O@KH.D_
M"/POHGB'6VT?X7W?A+X>WOQ\L?C1=Z-XC\40^(_%\GCW3M#'A#6/Z198HKB*
M6">*.:":-XIH9462*6*12DD4L;ADDCD1BCHX*LI*L""17Q1H_P#P3K_9'T+X
M)W?[.MC\/_%\WP=/BWP_XZ\,^$=7^.OQ_P#$$GPH\5^$;^VU7P=K'P \2Z]\
M4=2\6_LY3>#=2M8;_P '0? ;7OAS9^$[L2S^'K?39+BX:7EP..PU##U</B*3
ME">,H8F*6'H5TE3HXJE[SK2A*3I3K4JL:+;I8A4YT:KIPJ3<LZ->G"G*G4C=
M.M"HE[.G/2,:D7=S:?NN49*&L:EI0FXQDV_-?V7OB/\ '#PG^V'^TO\ L;?%
M7XM>)/VC_#7PX^$/P%^/_P //C/XX\)?#+PI\2]%L?C#J_Q0\%:W\*OB./@I
MX#^%WPLUQ['7/A)>^,/ >N:-\./!VLR>'_$&IZ'KT7B*;P_;^(+GR_Q?^S5X
MC?\ :,_;G_:C^#G_  4+USX?>.KCPY\*](\5?"KX6> ?V8O%>G_#J7X+_"2[
MUWPCX%_:(N_BMX)^,'CZ_P!&UF;Q5JOQ$L]"\$:U^S;KD7A3X@ZJ4U;4KF^\
M/^--*^^O@7^S+\&/V<8/%Y^%?AO6[?6_B%JVGZW\0O'OCWXA?$CXR_%CX@:C
MHVF1Z)X?D\=_&'XR^+O'WQ4\96_AC1(H]$\)V'B7QAJ>G^%-&!TGP[:Z9I[-
M;'AOBI^P]^S;\9/'.K?$;QGX5\:V7B?Q1IVD:/\ $$?#GXX?';X->&OB_H^@
MP366D:/\=O WP>^)7@7P/\>=(LM'N;KPW'I?QD\.^.;!O"-[?>#Y;>3PO>W>
MD3...PT<76J4^:C0K87#T*BC@,#45:5)X6=64\'4E]7I1JUL.ZJ]E-2C/E=V
MI5(L5:FJLY*\82ITX22HT9*;BZ3DW2D^2*E*#E[LDT[.]G)/\U/#'B+]HO\
M:2B_X)4?\%9O!_[/%]\5=5'[+GCS1?C#^S?X(\5>"_!OCG0K7]J#PI\,?$R_
M$SX+7'QP\>?#GX>:O%H7B#X?1:7<:#XX^(_A_4+[X<^,QJ&CZOK>KZ<+6_\
M2/\ @DL?BK??$G_@J9XD^)/A;3?!%MXI_P""@6KZYHG@W2O$J^+(/"=]J'[/
MWP,OO$'AG4]:TZ-/"=YXST W>D:3\36\$W6O>%;/XH6GC/1]%\7^,-.TJT\1
M:A]^_&;]CS]GOX\6_P +D\<^#M=T;4?@DVI+\(?%7P>^)WQ6_9W\??#73]:\
M/IX6USP_X,^(W[/WC?X8^/= \(Z]X>@LM*U[P9I_B.#PIK=MI6B?VIHUW)H6
MCR6/IGP=^#/PQ^ 'P]T'X5_"#PAI_@KP-X=6[>QTFRFO]0N[W4=3NYM2USQ'
MXD\0:U>:EXD\8>,O%&L75[K_ (Q\;^+=7UOQ?XR\2:AJ7B/Q3K>KZ[J5]J%Q
M=?,\/4P5;#TZ/+.K#ZO2BZ;2PN$CF%3'4Z4:_P!:FJ[@Y*"D\)0G:<U*I)4X
M^TJ>(IRHSA&%I27)%<KM3I>WE7C'G]JU.UU&_L8/5WD^5<WIU?A)^S=_KOVG
M/^SY?VTO_6B?'M?NW7X2?LW?Z[]IS_L^7]M+_P!:)\>UYD?]PQ?_ %_P?_I.
M*/Y4^EO_ ,FJP?\ V6F2_P#JJXA/I.BBOA__ (**>,?'_@7]E+QKKW@'7/%W
MA"$^)OACH_Q,\?> +2ZN?''PV^!?B#XD^%M#^.?Q(\*36$5S?:+K'@;X57_B
MOQ)%XKLK2YNO!D&GW'BV$6KZ*-0L^7"T)8K$X?#1E&$L16IT8RE?EBZDU!-I
M)MI-[)-O9)MG^=&2Y74SO.,JR>C6I8>KFN88/+Z=>MS.E2GC,13P\*DU3C*I
M*,95$W"G&52=N2$93:3^X**_GF\9?M1#P]HW[:'PP_99_:,\4^.O@5X(^%_[
M*OQ+\-_&BZ^/"_%'7-!T_P")WQF\3_#C]H?PS\%/VG?C=XY\3P>-/%FK^$/#
M/V;X76VI>/==;PQ\9[C6O!?@[4+/Q%!IWA?0_MS]AOQY8ZY\=OVFO GPT\9_
M&O6/@9X&\-_!*[TKP;^T_P"(OC+J'QW\'_%/Q39>,[OQM=#P[^T_>3?M.^'_
M (8^(_#-CX#NO#DWQ(L[3P=J_BFS\8S?"IKC3;?Q$R>IB,DKX;#5\3.4E&C&
MG4Y)T9TY*G4C@)159.3]A7DLPI*-%\ZDZ.)M4M3@ZOV^;>&N8Y3D^9YQ7Q%2
M-+ 4L+BHT,1E];#5XX7%T>&*]*GF4959K+,SJ1XKP4:. D\3"O/ 9SR8ODP>
M'GC?TJUK1]-\1:-JWA_6+;[9I&NZ9?Z/JMIYT]O]JTW4[66ROK;[1:RP74'G
MVL\L7G6TT,\6[?#+'(JN.,\)_"7X?>!OA-X?^!OA;P__ &7\+?"O@#3OA?H/
MA?\ M76[W[!X%TG0(O#&GZ'_ &WJ.I7?B*Z^SZ'#'8_VG>:O<:Q+M^TSZA)>
M%K@_FC^W1X,\4> K/XF?%EOVE?CG>_M _$SQ!X+\$_L#?!;X5^/_ !_\-?#G
MA[XBZ1IEG<Z%X0U#X2^$_'D?P^_:!L]>\9QZ]X\^-GC+XU>#]>T31OA0;S1K
MVST+PGX2AN+GWO\ ;_\ BG\?_A!^SIX2\3_!F'P@WC_4OC9^S;X*\37&M>++
MWPCI\>D>//C#X&\(>(--TF]B^&WQ,F-OXHN=83PC?WPTO3]4\+^&==U;QCH=
MWJ/B+P]I?AW6LH8&K-9?2P^+4EC\2H1C/VF'HPQ$(T5[1.HUSQI2Q,J'MU"+
M]M2Q%.DIQ49U.+"\+XW%PX4P64Y]"I#BK-Z>&HTL0\3E. P^;8:CEZ>+4L5.
M"Q-' U,WK97_ &G'#TF\PP6:X7 K$4(T<3BOL;X<?#WP?\)?A_X(^%OP^TC_
M (1_P)\.?"?A_P #^#-"_M#5-5_L;POX6TJUT70M+_M/6[W4M9U'[#IEE;6W
MVW5=0OM1NO*\Z\N[BX>25^(U[]G?X->*/AGXT^$'B#P3;:M\/_B%KGB#Q1XN
MTB\U;Q"]_J?BCQ+XHD\:W_B>'Q.-67Q7I/B2P\5M!KOA?7]%UO3M7\%7^F:'
M+X-O-!'A_0UT_P"4OB7^W#X_\!CXW^+-)^ &F^+/@]^RA)H>G_M-^-D^+-[H
MOBO2=</@_P -_$/XA6?P)^']S\*;N#XQ:;\,O _BS1-;U;5_&'C'X)#Q#/-=
MZ-X6LM4U.PNH$] _;\\>>+/!W[(?Q$\:_#KQJW@N=9/AXNI^,-)\3>$?"7B:
MU^'?B+XA>$=)\??\*W\1^.;[3?#%C\3M8\!ZIKFF_#!KN]@O[OQO?Z#9^'2_
MB2YT>-U#"9@L1A%.K*C/'XJC[.O]9C-JO)TJD*M:5*I.I"K!8FG63J*-5*IS
M15VV98;(.*XYOD,:^-J9?B>)\\R_ZIFCSBG6E'-:U3 XO#X_'U<!B\1BL-C<
M-#.L)F$:F*C3QT(8OV])<TY,ZK6OV8](\-?!BV^#_P !]0\0?#B*?XG>&/'N
MK^+IOBI\7;KQU>W)^).D>-OB#XAU_P"(DWBO4OB/\1_%'BBPM-2TN[MO'WB_
M4](\20WL&C>+9-1\*V\FB3_5M?D5^S!'X2^-7Q*_:I^"?AOXA_M0R?LY^%M
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M+I.I^-?''Q.\%?MG^ ?V3?A=\!?'_P"T=IWPO^*?C#7=0T']IOX4?$'QY=>
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ME>+?CPGB_6OV@-8\7_V[J"ZQ<^,6\>3^-Y5L;+3;#Q%IEO;6,MA]-^&=)N-
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M4OJ7B#0?AC9>(?\ A;4=G;6?B\1??_QD^,WQV\(?MY?LY?#/0;3P:WP$\1?
M?X^_$'X@C4O&^JZ3KL]WX$U[X56-UXAB\/Z?\(_$DVH7G@K3/%"1^&?#\7CO
M3-+\9/XL\0W.N2>&[WP5X;?Q+W8C YEA\31PT<=5<J&%Q>(H.=:K0]E#"K$4
M:JPZG4?+&M'"R6'E3<?;T)4I.,$W"'TV:\,\8Y5G6!R2GQ/C:E?*LCS_ #?+
M9XC,L;ET<%A<BCFV Q]/*85L3)PI9A2R*M'*)X1TO[2RRM@:M6CAH3J4,/\
M77PN^#_P[^#'@[_A!/AOH,N@:!+J6MZYJ,MQKGB+Q#XE\0>(_$M[-J7B/Q9X
ML\;^)]6UGQKXP\8Z_J%Q+?:UXP\4^(-8\3:K=L+B^U6>5(W7BO%/[+OP.\8_
M"OP;\&-9\'WL/@7X=7GAW5?A^/#OC3Q[X.\9^"-<\+1S0:-XE\)?%#PAXGT+
MXG^'?%D=M=ZC::AXLTGQA:>)-;LM8UZRUO5-1M=?UF&^^>?A5^VQXQ\:^(?V
M?-1\<_ JU^'?P;_:Z?68OV<O'5O\3V\5^.;V>#P5K?Q0\(6_QI^&;_#WPUI7
MPLN/B%\-/#6N>)/#T'ACXE?%B33M2M[7PMXJ70-8O0L/2_ME>)/$=UXA_91^
M!.A>)O$W@W2OVD/V@YO _C_Q%X*\1:WX-\8I\/? _P '_BG\9=>T#PSXU\+Z
MAI7BKP;J/BR\^'6D>';OQ)X7U'3O$-EH.H:U!HVK:+J5U:ZQ8\BPV8T\;"%:
MO4H5JCJXR=>.(562^JK$.O7]I1JRYJ]%4<3&SFJJFI0;BY-G@0RCBW"<14</
MC\RQF79CBGCL_KYG2S:..K162PS:699D\5E^.K>VS+ 1P&<4>26)AC(XB-;#
MSG1=:4GZ;XO^ %M8_ [P?\#O@;=7'PGT'PAKOPQCT.[\/^,O'OAG4/#_ (3\
M'^-="U_7T@UGPSJ]OXD\5:KK>C:=JEEJ%AXKUNYTGQK?ZQ=R?$&;7K"^U>TU
M/Z4KX/\ V-M<\0Z'\0/VPOV>-4\6^-?'7AO]GKXW>&-.^&WB'XB>)O$OCGQG
M9>!/BI\&OAW\6(/!FM^/?%][K7BKQL?!_B7Q1XFL=(U[Q5XDU[Q1_P (W<:)
MI>JWCQ:;8W%UQ6J:_P#M%Z?_ ,%./A?X>\7?$;0HO@-XI_9__:'U#X=_"/P9
M9^(;(F;P=K'[-L%QXZ^+&LW^L#3/%OC.[UGQ3XET[POI>G^&K'2? 7A:%!8:
MKK&L>*_$EQ&IX6M4K5L//$PE[+#ULSA4J\_M,1&OA:6,72<O;5:"ISE&I)0A
M)5+U)2MSF)R/'X['YCE.(SC#55E^4YEQG0QF-6)^MYO2S#(\%Q"K>[B*O]HX
MW+8X;$UJ6)KK#X:I#&-XJM6<?K7Z2T5_.KJ7[4%U\.M9\4_$?Q7\>?BBW[;F
MF?\ !0+2/A;XI_99O?B3XVF\-Z-^S5XG_:%\-?"'PK::?^RN_B8^!-%^&7B/
MX"Z]X-^(/AG]HJ/P4NJZU\3_ !/I=U;?$O5KCQ'_ ,(UJO\ 156>89;5P"HN
M<N>-5U(1ER2A&4Z,:4JDJ3E_&P[5:#HXB-HUHWDHQMKQ\5<'XWA:. J8FJZ]
M''2Q>'IUGAJN&IU<3@*>!JXNI@956_K^4U(9CA9Y=FU+DI9C2E.I3HTE"S^4
MOV\/^3'?VS/^S4OVB/\ U4/C"OI3PY_R+V@_]@;2_P#TA@KYK_;P_P"3'?VS
M/^S4OVB/_50^,*^E/#G_ "+V@_\ 8&TO_P!(8*RG_P B_#_]AF,_],8$XJ__
M "265?\ 919__P"JSALV:_G3^,G_ "0[_@XQ_P"PQJO_ *Q=\*Z_HLKXO\3?
ML+?"3Q5X5_;2\(:AXB^(T.F_MUW-Q=?%R>RU?PS'?>'9+GX8^'_A0Z_#F6?P
MC<6^D(/#OARQO4'B:V\7L-:EN[DLUB\.G0=N38VA@:M6==R49O M<L7)_P"S
MYI@<74T7:C0J-=Y)1W:/H/#WB3+.&\;CJ^9SK0IXB?#,J;HT76;65\;<,Y[B
M[I-6ME^5XN4/YZJA25G-->V^#-+OM;_9_P#!^CZ9XCUKP?J.J?"+PW86/BOP
MY!X>NM?\.75UX/LH8-;T6V\6Z#XI\+SZGILCK=V47B'PWKVC27$4:ZCI&H6A
MEM9/PQ_8!\3?',? 3_@G1^RG\/\ X^^-O!>G_&CX*?&GX]^,_B@WA/X*ZYX_
M\!>!OA5XC\$^%=)^$?P;L]8^$]]X"M;'7?%7CB+7=:\3?%CP7\5/$]OI9UW3
M=,U>"2[T*7P[_0MX>T&R\->'-#\+V,ES/I^@:)IF@V<MX\;W<UEI5A!I]O)=
M2016\3W,D$"-.\,$$;2EFCBB4A%^#?#?_!.+X;>"O!7PK\+>"OC+\>_">O\
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M9]/Q/\C7+V?3\3_(UU%GT_$_R-.K]KY?H!T=MV_S_>K?@Z'Z'^35@6W;_/\
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MB@ KX'_X)Y_\D\_:)_[/X_;Q_P#6HOB37WQ7P/\ \$\_^2>?M$_]G\?MX_\
MK47Q)H ^^**** "BBB@ HHHH **** "BBB@#X'_:S_Y.>_X)=?\ 9W7Q@_\
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M>/V7:]5KRKP=_P I&/V2_P#LW[]LS_T\?LNUOEW^\3_[ \Q_]5V*/USZ-_\
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MLFU&*3=F[Z:MMN[;;_.WXJ?L??'K4_C1XD_: ^ '[2_@'X/_ !'^+OP"\&_
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M*E@,#A7[+#4*-*A0IN\*5"G"A!1I14%XC^S5\&_^&>/V?_@W\"_^$C_X2_\
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M-6P>*HUL-BZ5?#5Z-?"UZU&K2K4:D)0J23C>S7S'\%/@%XD^ WP[\/\ P_\
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M:#I?BW2]%\0^%;W3_%_@Y-=\*7GBKP=XD\(^+?$WAW7]%TSQ?X1U=X-2BO\
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M_%WC6'XC_%3XV?$J^^*OQ3\9:=X8;P1X;O?$,GAOPUX(T31O!?@J;Q%XQO\
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MKK64\%_"[PGXV\66GAR"Y1[)_$NH:-:>'QJ _LX:D;XBW/U[\+/BG\.?C?\
M#KP;\7/A%XT\._$7X9_$+0;'Q/X+\;>%-2@U;P_XBT+48_,M;_3[ZW9D=<AX
M+FWD$=U97D-Q8WL%O>6T\$8!^''[!/Q:_;RL/@E\0X/#'[&?P3\0Z=)^V_\
M\%,KV[O]1_;/U'P]<6WB34O^"C_[5FH^,=!BL$_9=UH7.G^%O%UUK?AG2=>-
MY _BK2](L_$[Z/X>?5VT#3?M+_A<_P#P43_Z,6^ G_B=FI__ $(]2?\ !.C_
M )()\3O^S_\ _@J[_P"O1_VQ*^[Z /@S_A<__!1/_HQ;X"?^)V:G_P#0CT?\
M+G_X*)_]&+? 3_Q.S4__ *$>OO.B@#X,_P"%S_\ !1/_ *,6^ G_ (G9J?\
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MI#_GQ2^^O_\ +CX0_P"%P_\ !0K_ *,?^!'_ (G'J?\ ]";1_P +A_X*%?\
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M7_B1<4__ #[/QB_X0[_@HO\ ]&E_L_?^)F:Q_P#0NT?\(=_P47_Z-+_9^_\
M$S-8_P#H7:_9VBCV^&_Z%N"_\&9C_P#-_P#5WY6/^):_!?\ Z(Z7_B1<4_\
MS[/QB_X0[_@HO_T:7^S]_P")F:Q_]"[1_P (=_P47_Z-+_9^_P#$S-8_^A=K
M]G:*/;X;_H6X+_P9F/\ \W_U=^5C_B6OP7_Z(Z7_ (D7%/\ \^S\8O\ A#O^
M"B__ $:7^S]_XF9K'_T+M'_"'?\ !1?_ *-+_9^_\3,UC_Z%VOV=HH]OAO\
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M_$O+_P#^ALH_X6A^VY_T:+\'?_$O+_\ ^ALK[&HH^M4/^A=@O_!F8?\ S?\
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M_$O+_P#^ALH_X6A^VY_T:+\'?_$O+_\ ^ALK[&HH^M4/^A=@O_!F8?\ S?\
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MXOVS_P#HQGX3_P#B:=S_ /0NUL44?7*7_0OP7_@>8?\ S=_5WY6/^)LO%/\
MY\\+?^&C%?\ SS,?_AN+]L__ *,9^$__ (FG<_\ T+M'_#<7[9__ $8S\)__
M !-.Y_\ H7:V**/KE+_H7X+_ ,#S#_YN_J[\K'_$V7BG_P ^>%O_  T8K_YY
MF/\ \-Q?MG_]&,_"?_Q-.Y_^A=H_X;B_;/\ ^C&?A/\ ^)IW/_T+M;%%'URE
M_P!"_!?^!YA_\W?U=^5C_B;+Q3_Y\\+?^&C%?_/,Q_\ AN+]L_\ Z,9^$_\
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MBF]]I.W<V,G6_P"%H?MN?]&B_!W_ ,2\O_\ Z&ROJWPY_P B]H/_ &!M+_\
M2&"MFN5XJA=_\)V"W?\ R\S#O_V'_P!7?E;QZN=Y;[6K_P 8APZ_WD]?K/%G
M\S[<46/CG_A:'[;G_1HOP=_\2\O_ /Z&RC_A:'[;G_1HOP=_\2\O_P#Z&ROL
M:BE]:H?]"[!?^#,P_P#F_P#J[\K9_P!MY;_T2'#O_A3Q9_\ 10?'/_"T/VW/
M^C1?@[_XEY?_ /T-E'_"T/VW/^C1?@[_ .)>7_\ ]#97V-11]:H?]"[!?^#,
MP_\ F_\ J[\K']MY;_T2'#O_ (4\6?\ T4'QS_PM#]MS_HT7X._^)>7_ /\
M0V4?\+0_;<_Z-%^#O_B7E_\ _0V5]C44?6J'_0NP7_@S,/\ YO\ ZN_*Q_;>
M6_\ 1(<._P#A3Q9_]%!\<_\ "T/VW/\ HT7X._\ B7E__P#0V4?\+0_;<_Z-
M%^#O_B7E_P#_ $-E?8U%'UJA_P!"[!?^#,P_^;_ZN_*Q_;>6_P#1(<._^%/%
MG_T4'QS_ ,+0_;<_Z-%^#O\ XEY?_P#T-E'_  M#]MS_ *-%^#O_ (EY?_\
MT-E?8U%'UJA_T+L%_P"#,P_^;_ZN_*Q_;>6_]$AP[_X4\6?_ $4'QS_PM#]M
MS_HT7X._^)>7_P#]#97:_L0^+?CQK_\ P4Z\.K\6?@SX*^&D$?[#7QS2TF\+
M_&>X^)CW,!^.W[-TCS2PS?"_P(+9UNDMK80B6<-%/)<^:I@$$WTC7,?LY_\
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MM^#H?H?Y-7'4Z?/] )INA^O]$K#GZCZC^:UN3=#]?Z)6'/U'U'\UI0W?I^J
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MG\<^+/&7]&'A$@_\%1O'!'_1@OPT_P#6A_BM7Z-UX@'YH?M+?&W7OCA\,/\
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MBQ^P0O[(>L>)=4_9V_:WM+GQ_P#MZ>#=5^%GC#]DCQ;K&I_'S2-5TS6_A/\
M'?P]X@U]/B]\:M7TCQ!H?P[U'P=X$BGGT+X3P7/B;Q%XKLK33+OPC/\ ZF1
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M$Z[<+_ S+_L"I_\ JQP!]%DG_(LXO_[)W"_^M;PN?8U%%%<1\Z%%%>)_%?\
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MDE\+_"RRL?BA+HHC\#-JNN0W6CSR:='>0S?V'JJJJJJA54!550 JJ!@*H&
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M'^'GA'1;(0>'?"6G7-]J]WJ/T30 4444 ?!/[67_ "<[_P $O/\ L[CXP?\
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MWA70?"_Z34 %%%% 'Y^?MO?\E7_X)I_]GZWW_K"?[<5>>?\ !6KQ[XW^&/\
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MA\#_  J\1> OVA_$7PX^ O@;]J#XP6OQOUOQE\.?$WQ5TK2/$WAOQ]IOPO\
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MO$7CK6?&MEJFM^.9_BCX&\50:=\'/A:OPVAL?%.F_#5_!/B;4+KXA2-)\0M
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M\=[?]O+Q#=_M.^./#MYXUT[XK'7-#MO@W?:3XGT;QKX>LO'.C:7)!JVF^&M
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M3<KU*LJE5KFG)OXY^-/_ "=O^Q1_W<A_ZK/2J^QJ^.?C3_R=O^Q1_P!W(?\
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M,OVCO@%\8_!@\&W_ (<\(_#_ ../P<^*.D>)_%&M^%M;M?!?QHNOAA?-XN\
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MM^#H?H?Y-7'4Z?/] )INA^O]$K#GZCZC^:UN3=#]?Z)6'/U'U'\UI0W?I^J
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M_P!$Y_;_ /\ Q4[_ ,%3?_H-Z/\ AY9^SK_T3G]O_P#\5._\%3?_ *#>OO\
MHH ^ /\ AY9^SK_T3G]O_P#\5._\%3?_ *#>C_AY9^SK_P!$Y_;_ /\ Q4[_
M ,%3?_H-Z^_Z* /@#_AY9^SK_P!$Y_;_ /\ Q4[_ ,%3?_H-Z/\ AY9^SK_T
M3G]O_P#\5._\%3?_ *#>OO\ HH ^ /\ AY9^SK_T3G]O_P#\5._\%3?_ *#>
MC_AY9^SK_P!$Y_;_ /\ Q4[_ ,%3?_H-Z^_Z* /@#_AY9^SK_P!$Y_;_ /\
MQ4[_ ,%3?_H-Z/\ AY9^SK_T3G]O_P#\5._\%3?_ *#>OO\ HH _GL_8/_;^
M^!7A?X+?$73=3\!_ML75Q>?MO_\ !3#Q-%)X=_X)J?\ !1KQA8)IWC/_ (*.
M_M5^,-'MKK5?"7[*VMZ78^(+/2==LK3Q9X3O;RW\5> _%,&L>!_'.C>'?&OA
MWQ!X?TS[._X>0?L]?]$[_;U_\55_\%0/_H/JM?\ !.W_ )(/\3_^S_\ _@JY
M_P"O1OVPZ^ZZ /@K_AY!^SU_T3O]O7_Q57_P5 _^@^H_X>0?L]?]$[_;U_\
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MW^WK_P"*J_\ @J!_]!]1_P /(/V>O^B=_MZ_^*J_^"H'_P!!]7WK10!\%?\
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MJ^?9?E4L-C,7.C2C3Q."S3$NM&='#N?/"6"C%1:<7&H[V<5?[#_X>I?LD?\
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M/^@7&?\ A=1_^=WK_2U/^)R,^_Z(C*/_  [8W_YF.P_X>I?LD?\ 0-_;&_\
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M_P! W]L;_P 5J?\ !2+_ .A.H_X>I?LD?] W]L;_ ,5J?\%(O_H3JX^BCV^
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MOAC_ (:P\$_]$8_;O_\ %9G_  49_P#H6*/^&L/!/_1&/V[_ /Q69_P49_\
MH6*_>6BN3_A._P"@;&_^%U#_ .=Q[G_$H7A;_P!#?C__ ,//#O\ ]"/K_2U_
M!K_AK#P3_P!$8_;O_P#%9G_!1G_Z%BC_ (:P\$_]$8_;O_\ %9G_  49_P#H
M6*_>6BC_ (3O^@;&_P#A=0_^=P?\2A>%O_0WX_\ _#SP[_\ 0CZ_TM?P:_X:
MP\$_]$8_;O\ _%9G_!1G_P"A8H_X:P\$_P#1&/V[_P#Q69_P49_^A8K]Y:*/
M^$[_ *!L;_X74/\ YW!_Q*%X6_\ 0WX__P##SP[_ /0CZ_TM?P:_X:P\$_\
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M_H%QO_A?0_\ G=Z_TM3ZSPG_ -"3B+_Q*,M_^A ^.?\ ANGX*?\ 0D?MC?\
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M@?\ ]#'7V-11[3+_ /H%QO\ X7T/_G=Z_P!+4^L\)_\ 0DXB_P#$HRW_ .A
M^.?^&Z?@I_T)'[8W_BNS_@H'_P#0QT?\-T_!3_H2/VQO_%=G_!0/_P"ACK[&
MHH]IE_\ T"XW_P +Z'_SN]?Z6I]9X3_Z$G$7_B49;_\ 0@?'/_#=/P4_Z$C]
ML;_Q79_P4#_^ACH_X;I^"G_0D?MC?^*[/^"@?_T,=?8U%'M,O_Z!<;_X7T/_
M )W>O]+4^L\)_P#0DXB_\2C+?_H0/CG_ (;I^"G_ $)'[8W_ (KL_P""@?\
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M_P#.[U_I:GUGA/\ Z$G$7_B49;_]"!\<_P##=/P4_P"A(_;&_P#%=G_!0/\
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M"_\ @GN^/A[^T/Q_S?K^W<>OK^U!\2#Z5]X5\%_\$^/^2>_M#_\ 9^G[=O\
MZU!\2* /OCS/;]?_ *U'F>WZ_P#UJCHH D\SV_7_ .M1YGM^O_UJCHH D\SV
M_7_ZU'F>WZ__ %JCHH D\SV_7_ZU'F>WZ_\ UJCHH D\SV_7_P"M1YGM^O\
M]:HZ* /@_P#:P?\ XR<_X)?<=/VM_B^>O_6/G]M >GO7WIYGM^O_ -:O@?\
M:P_Y.<_X)?\ _9VWQ?\ _7?/[:%?>E $GF>WZ_\ UJ/,]OU_^M4=% $GF>WZ
M_P#UJ/,]OU_^M4=% $GF>WZ__6H\SV_7_P"M4=% $GF>WZ__ %J/,]OU_P#K
M5'10!\"_MLMN^+/_  33&,?\9Z7QZ_\ 5B?[</M7VE7Q5^VQ_P E:_X)J?\
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M#0JU,5B*E.$)QHK%8>4_T>HK^??XG_'GQ]\+;_\ X*3?LJ_"'XR_$3Q%X9^
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MRCX_97_[)K'_ .GW6J\UKTK_ ()9?\H^/V5_^R:Q_P#I]UJO0H?\B_%_]AF
M_P#3&8G]O_0R_C^(O_7KA3_TOB(^_J***YS^Z0HHKY(_;'_:M\/?LG_"7Q7X
MSU#PW\5/$7B9?A_\2/$/@B'P%^S=^T9\?/"\7B#P7X:?5;)/B3J7P%^'?C.S
M^'?ANXU"XTY9M5\>:[X(T^^TY-8N-/UI(M%UB\TS2C1JXBK"C1A*I5J2480A
M%RDWZ)-V2NV[:)-O1,J$)5)1A!.4I.R23;?R5WIN^RU/K>BOSV_8_P#VT=>_
M:_\ V5O#'Q%\ >!/$EK\?M0_9_\ A_X]U'0_BU\"?VI?V:?@1JWQ0\;>!X]7
MATOP?\3_ (J?!^]M_%_PX_X2E;B"7Q)\*KSXQSZ;X7DT_6$EUN+4](NM5\5_
MX)3>,OVF_$ES_P %#-#_ &J?B]I_QF^*GPY_;N\3>#(]3\,Z1K'A;X9^$]'_
M .&=OV=O%%E\/OA-X,UOQ#XEOO"OPZ\+7_B74++1[>\UJ[UG7[EM0\9^*KJZ
M\7>)=>O)^R66UZ<,=*M*%&I@94XU,/4YU6GSU84N>,7%)4XNI"7/-QYU*/LU
M-<[AJ\/.,:SFU"5!Q4J<N93?-*,;I6LHKF3O)J]URIJ[C^N=%?RT?L?_ +9?
MQ.\!^(O!_BU?BE\0?VA_C)XD^ OQK/[>'P&\4_&?QKXRL/A)^WEK7[2'A/X?
M?LO? K3/ ?BWQ!XN\._LE:]XI\7^*?BA\,M*^'7@73? /A;7?AEX,D^(^H^%
M==T?X?6'B6#]C_V"_P!I_P" GQ4\(6OPB\!?M">)_CS\4O"7AZ_\>^-O&GC7
MPG\8_"<7Q2'B7QSXDLO%GQ2^">H_%[P_I&G_ !$^ *_$B'Q!X9\#ZU\%];\;
M?"7P/H,'A;P1X?UVVTB+PY;W.^.R;$X*-6;4ZU.E)1E4IT:CC&TJD)SJM)JC
M!SA&5"51Q^L4:U*K!)N<*=UL)4H\SM*48M)R4)66LDW)ZJ$6TG3<FO:0G&:2
MUC']"****\@Y0HHHH _*G]OC_DYW]@/_ +"G[3?_ *JC2*O51_;X_P"3G?V
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M/90P7%XL$S6D%U<26=M/<K&Q@AN+N*UOI;6"24(DUQ%97DD$;-*EK<,HB?\
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MU<:CJ+1:=9W<\7YB>+O^",'PBT#XQ?L#^(/V?=<^-/@3X._LJ_$[QOXF\7>
M]>_;R_;VU4:;X-U'X*^/?!7@[0_@AH>K_&KQ;HW@RXM_'&OZ _BJRT#4/AY8
MZ_\ #T>)?"NM7GB+P]K&I>#];^SO&?[*VK_M4CQ#I/[:VF^&KO0OA=^TGJ/Q
M._9$U3]F+XU_M0_ GQ[X4\$VO@!/"?A;Q)\2O&7PX^(?PV\1Q_&2"3Q7\4-*
MU6/PCK<O@5/#.KZ.;"W&JOJ,B@'A/_!*7XM_M8?$C2OVTO"7[8GQ0T3XI_%+
MX&_MD:U\++:_\,>"O"G@CPMX3T2Z^ WP%^)MS\/_  K9^&-+L+O6/"W@[Q9\
M1?$^C^&_$?C&]\1>.-8T2"PN/$GB'4+SF+]8*_,C_@G_ /\ !/\ F_8Q^(_[
M:/C.\\7^,_$ME^T'^T5>_$+X<V_B#]I#]I+XV2Z=\,&^&7PJ\-6,?Q L?C=X
MMUW3[OXN'Q9X1\4-J?C[?XM\8ZCX,D\)^';_ .(E]HFCZ;X9\/\ Z;T %%%%
M 'P7^UA_R<Y_P2__ .SMOB__ .N^?VT*^]*^"_VL/^3G/^"7_P#V=M\7_P#U
MWS^VA7WI0 4444 ?('[9B_M<ZMX&^'_@7]CN;2O"?C+XD?%KPKX/^)/QPU2U
M\$Z]-^SK\%IK'6]6\=_%KPSX%\>7L>B?$'QU;G2=*\(>"O#-WH_BG3(O$'BR
MT\0^(?#>J^'="U6V?YL_8<^-?QEOOVL/V[/V2_B%\<M3_:I\$_LSR_ ;6O!_
MQZ\1^#OA9X4\=:%XA^+OACQ7J/C7X ?$R[^"/A;X=_"GQ%XJ^'B^%M \765]
MX?\ AKX*U_3M"^(EKI7C'3[F>WT;5-1]+_X*.Z[^V?:_!OPSX0_8I^'/C[Q3
MXO\ B+\0=%\*_%'XA_"S6O@!9?$WX)_!AH+N^\;>-OA?H?[1_P 4OA-\.?$O
MQ.U2&UMO"'@I=7\13:=X7O\ 7IO&M_INJ?\ ".VNCZGYS^SM^SUX>UW]E#XM
M?L;:%^S!^V!^P/X)\6^$?$&D:]\6_%OQ(_9,USXY_$SQ7\4K74+'XD?%B+XF
M?!SX^?M5:IKOQOUET;5O&/Q(^*VB6NHZC?ZM8SZ/-J!L!;:* >/?LY?MX?'#
M]HO_ (*I>-/A?HCZ1IO["Z?LH^/O%?P*N(;#3;C6OC;XV^&GQR\$?#/QO\=%
MUBYT5-:L/ $GB#5/%?@#X96>EZ[+X?\ &>A>&;KXE+;W^F^)_"E[#^UU?B;\
M&_\ @GI\>?@C_P %'?@Q\4]._:(^/_Q#_9L^%?[#WB'X*:?J'C#1?V&O#.DV
MM_!\2_"<WA3X!?\ "'_!G]F?X1^(++P!:>&M,7QM9ZYX9\/:3K-GK?A?2-%D
M^),.@7.H^"]:_;*@ HHHH ^ OVV/^2M?\$U/^S\[[_UA3]N"OK7Q7X:T[QGX
M8\0>$M7N?$%GI7B71]1T/4;OPIXL\5> _$]M9:I:RV=S/X?\;>!M9\.^,O">
ML113.^G>(?"NO:-K^D70BOM)U.RO8(;B/Y*_;8_Y*U_P34_[/SOO_6%/VX*^
MU:_"O%!N.?8&46U)951::;336-QK336J:>J:U3/B>)6UCJ#3LUA8--;I^VK:
MGX.? ;X*0>,_^"H_CJQ^"OQI_; TC]G3]@7PGHOAWXK:-XQ_;B_;/^.'@[X_
M_M2_&?PV?$5CX%\0:5\;/C]\2O"-UX2_9Z^&4^A^(]<T+3]*L-1N_B%\1M$@
M\1/=6/AV&Q.;_P %$/VI/CQK_P"TO^RI\/\ ]G+Q]JO@;X%_!?\ ;T_91^&?
M[5_C'PW=ZCI]Y\5?B1\6?%FER:3^S3I&MZ7J5EYOAOP=X"O)/&_QXL)HKVPU
M"Y\7_"_P7*)F'C73[']&/V$?V;?'?[-W@'XSP?%74_"VM_$WXW?M6?M&?M$^
M+-8\'ZWXA\0:/<6GQ3^(FHWOP_TT7WB;0?#>H0WGACX5Z?X%\*7^FV^EII.G
M7FASVVD7-]8K%>W'QI^TU_P1N^$GQ L?A?#\!M:^,?P^?2_VSOA]^TK\3M&U
M/]N?]NO2?!5]HY^)&J_$/XRZK\/O!.D_&;Q!X1\'?%GQ3JNLZEK'AKQ-X5\/
M^"=5TCQ#>W5_I/C+PK/(;P_.T<=@'FD98RK.M2PV'I8/#UITH8FE-JFUBL56
ME5K0G-U*LJ\\.Y*K*FZU-Q<%AJ47P1K4/K*=:3G"G3C1IS<55BWRM5*DG*46
MW*3G*FWS./-&S2IP1^L?Q>\9ZY\._A;\0?'?AKP9K?Q$\0>$?".O>(-'\$>&
MY_"UMK?B6_TO3Y[NWTS3Y_&WBWP'X5CDFDC#2'6_&/AZT,*2K_:4,QB#?FQ^
MR_\ \%,=?\>?L(?L[?M1_M!_L]_$OP;\3/CSIWPC\-_#KX9^ K/X5ZM=?M)_
M%3XH^%HO$&F6O[.F@:=\??'<WA_P=J*0:[JD5U^T3XQ^%-]X*\)>'=>\6?$N
M?PQX7T/5/$$'ZH:KH-MJGAK4O##R3"SU'0[S07EN9[N^N!;7=A)I[27%U<7)
MOKR;RI"TL\]X;NXDW22W)F=I:_&/X<_L+?M@>#_V2/V*OA9(W[.&E?&O_@G%
M\2/AWKWP.N+#XG?$SQ'\*_VB/!7@KX9>+?@UKVG?%:]OO@5X=\7? +7_ !C\
M/O'WB3^S9O".E?'ZT\#^*K71M9GE\<Z8+W0)/-P$<#4P]2GB51C4^MT)1JSG
M.G5]C['$W@FI\JI3Q"P\*TE3G*E"I*KHH*4.:BJ,J<HU%!2]K!\TI2C+DY)W
MBFI6Y7-04WRR<8R<M$KK]#?V>_VLO#/QZ\7_ !2^%FJ?#3XK? 7XW_!D>$;_
M .('P2^-MI\/D\;:?X2^(.GWM_X#^(&B:[\(_B+\6_A9XS\#^*WTCQ%I%IK7
M@OXC>(&TCQ)X7\1>&O%%IH.NZ:^GO^=__!67X::/I/A;P_#\(_'_ .U+X>_;
M#_;,^+O@3]FSX"'P-^W+^W%\/?A_X#\5^*+!T\4_&5?@A\*OVC/!GPTMO#7P
M1^%OAKQ3\4O$-IIG@B+0M8UK0[)O%MIJ#^(M2EOOL;]F_P#9\^,]E^T=\<_V
MP?VD(?A5X:^*/Q9^''PC^"7A7X5_!CQ=XQ^)/@SX<?##X1:IX_\ $XN=1^*G
MC3P%\(-6^(7B[QYXQ^).MZOJ,H^#_@?3O!^B:3X?\-:=_P )#<)K'B35MCXJ
M?LV^._B5^W7^R=^T5=:GX6/P?_9J^%?[1MG%X=N-;\0P>+[CXS_&6/X=^%O#
M_B:Q\/VV@R>&-1T30OAWHWQ T>XU#5?$EMJEA>>*HUTO1[B.:[NX=,/5P^#S
M-5:-;V=*EAO;3A3K3=*IBJ>#5=X-5%)NMAIX^,:#3E4C.G>U6LE&K.J<J='$
M*<)\L84^=I2;BZL:*FZ7,G>=-UTH;M..TII*<OB3]N!/$G[._AS_ ()R_ '6
M?CE^T3KG[/-SXVU/P!^T9J_P[^+/Q:U3]O?X\0^"?A-?WW@34O"VH?"77?\
MAK;XG65S\1;2T\6?'RV_9K&K?%&U\/FUO]0L[7X/VGQ ^S^Q?\$HOB-XY\?>
M _VGM/U?QSXQ\;_"?X=_M<_$_P !_LZ+\9/&6H>,/VD?"'PBL='\):Q;^"OV
M@E\7ZQJWQH\+>+=%\4ZUXD?PKX2_:6CTK]H_1_AM>>#U^*6EV]Y-IQ?T[]JS
M]F?XR>*_VBOV8_VPOV=[CX9^(/BO^SAH/QB^'MU\)?C5XG\5> _AU\1?AY\<
M[3PC#XDEL_B9X-\"_%;7OAIXY\+:GX(T+5=%UR#X5>/++Q!IC:QX2U.QTB'5
M(=?TS>_8]_9R^*WPR\>?M1_M"_'O4OA[#\:/VL_B)X.\5>)/ 'P?U#Q'KWPM
M^%WA+X6> M,^&'PZ\*:-XS\7>'_!GB3XF>*9_#NDG6_''Q(U3P#\/!K.J:G;
M>']+\$Z1H?A32I[_ &JXG#3RCDE.E*O*ESR^'VCQLLQJU)KV"BI*J\'-2EF'
M-[*5"-/ J'M$W&I5(2PMG*+FXMO5<WMGB)2E^[2NI.D[NO?D<%&C;F6GW57X
M2?LW?Z[]IS_L^7]M+_UHGQ[7[MU^$G[-W^N_:<_[/E_;2_\ 6B?'M>/'_<,7
M_P!?\'_Z3BC^4_I;_P#)JL'_ -EIDO\ ZJN(3Z3HHKXW^+O[9W@KX7_M*? #
M]EVS\,>)_%_C[XU>)ETW7-5T_2M>L_!GPM\.W?@;XG^+M U;Q+XR/AZ^\+77
MBCQ9=_"[6]-\,_#M-:L/$E_I-EKWBN?['I6C6J:WR4,-7Q4Y0H4Y590I5:\U
M&UH4J,'4JU)-M*,8PBW=M7=HQO*48O\ SFRS*,RSFO6PV5X.KC*V&P6-S+$1
MI<J5# Y=AJF+QN*K5)RA3ITJ%"E*3E.<>>HZ=&DIUZM*G/[(KA/B/\+?AE\8
MO"USX'^+OPZ\"?%/P5>W5G>WG@_XC^$?#_CCPM=WFG3BYT^[N?#_ (FT_5-)
MGNK&Y5;BSN);1Y;6=1+ Z2 -7SQ^UK^V%X5_95A^$^GW?AK4/'OC3XO?%+X?
M_#_0?".D7W]G2Z3X=\5_$+P9X!\2_$SQ'J(T[5AI7A#P5>^.?#MI+<36136O
M%OB+PCX/AN;"Y\21ZE8P_%W]L[P5\+_VE/@!^R[9^&/$_B_Q]\:O$RZ;KFJZ
M?I6O6?@SX6^';OP-\3_%V@:MXE\9'P]?>%KKQ1XLN_A=K>F^&?AVFM6'B2_T
MFRU[Q7/]CTK1K5-;Z*&!Q\E1Q%"C52E#$XBC5A)0:A@4IXBLI<RE"-&Z2J/E
M4I^Y3<JGNGK9;PSQ35IY?FN5Y?C8QKT,XS/+\;AJL*$XX?AJE#$YMCX556IU
M,-2P"E!+$S=*-7$VPV%G6Q2=)9=Q\'/C'^S[XAM(_P!C'X>_LTVOP.O/"[:;
M>?LSZK)9_LO^"O"'C[^V[S5;[XM>%?&7P@_9\^+>IZ[J/BW3+NV\/>)O!>N^
M%M.TV(Z)I7B+2?$,%Y-JVG:A\[0?\$\O'G@[X ?L^Z+X(\?>$=;^/?P!_:;\
M1_M@1KXKM=:T3X,^.OB9\0M6^(>K?$/X>^1I-MKVO^ _ <T?Q/\ $&E^!?$]
MIHGB[6_!]QI^C^([KPSXAN3?Z5<?J+XL\2:?X.\*^)O%VK.L>E>%?#^L^)-3
MD9Q&L>GZ'IUSJ=X[2$,$5;:UD8N58*!N(.,5\[_LT?%;]HSXP^&_"WC[XK_
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MAH8W"8;$U<9ETL70HUJ^$CC\/AGBJ-*I5PZJTX2DO3J]*_X)9?\ */C]E?\
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M^Q_^Q;<_L8? W4?AUXQ\:@_%;P1!XTT#Q1=?%OXUZ)XA^'?A?1/A'X@?P_\
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M?'/@C_E('^TY_P!F<_L+?^KK_P""B=/"_P #,O\ L"I_^K' !DG_ "+.+_\
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M&ZEG%QX1XW_:%^,WPK\">"4^(?P;^&)^/7Q=^+6F_"+X0?"[X?\ QU\5^+/
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MF/A'_LQ;XZ_^K^_9HKL:X[]GW_E)CX1_[,6^.O\ ZO[]FBOM?#S_ )*W+?\
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M;Z'^2UT?@3[VK_\ ;A_*\KG+KHWT/\EK?\#_ 'M5_P"W'^5W6N*_W2KZP_\
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MM6M"G#Y4X1@G\U&[\V?E3^WQ_P G._L!_P#84_:;_P#54:15ZJ/[?'_)SO[
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M.-%^)WQ&UOQQ\._C1^SE^U1X[^*UOXS\+^._$'[0G@-OB_\ !KP9J?C3XL>
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M6H8;,<90PU+-<9G<E3S3$X58NC*IF>88NHWA7AD\/*EAZBJ^Q]K,KXY\$?\
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M_D7M!_[ VE_^D,%;-8WAS_D7M!_[ VE_^D,%;-<LMWZO\SQ:W\6K_P!?)_\
MI3"OBW]M?P5\,?%WACX3WGQJ_9QOOVD?A5X.^+=CXE\7:'I6E^._'^I>!$F\
M&>-/#&E^/$^ OP_\,^+=9_:"TM=3\16_@_Q'\/7T'6+;3_#WB[4O'-SHVJ6?
MA.[A3[2HK;#5GAZT*T>>\&_X=6=&HE*+A)PJTVI0FE)N,O>CS6YX5(<U.7=E
M&95,HS'#9A2>(4\/*HN;"8W$Y=BXPK4:E"I+#8["3A6PV(C3JSE1J6JT5445
MB<-B\,ZV&K?A7I7PI\4>!_$/@S]H3X6_!SX@>'OV6?A!^W#I_P 3?A9\!O#7
MP6\6^"O%/@;X$^+?V1=7^ WQ:\7^!/V8QX8T;XG^';)OC?XR\2>/9_AAI/P]
MTKQAKR'Q9\0]%\#ZQ/XHBG\0_='['7A_Q'J_Q!_; _:&U;PGXQ\#>&_VA_C5
MX5U;X:^'OB!X?U_P9XRO/ 7PP^#'PZ^%5MXRU[P'XJM=(\4>!I?%_B/PQXEO
MM,\.>+?#F@>+8O#MOHNH:U80KJ%E;6OW917?B<VJ8FE.G*E%3G0AA/:N<I3>
M$IUZ>*C&IHE4Q$L12C5K8EV=64JEZ:<[KZO.>.\3G&!Q.%J8"G#$5\MPV0_7
MIXF=:O/(L+F6%SFG2Q:]G3CB\WKYM@Z>-Q^<MTGBZE7%7P5.5?GA^$_ACPOX
MX\'6'@2^\4_!;XO^)-!_9D_X*:?M,?%_XL>&K/X3_%#5I[_P#\7_ !%^T/+\
M(OC)\*_#UGX/O8?VAM/\(:I\1/!?C.XLOA-%XV\5>#I$?5H='MO$>B16R?=O
M[$?A[Q!'J/[6'Q.F\&^*OA[\/_CI^TYK'Q,^%/A/QMX7UGP)XJE\-)\+_A=X
M)\0>-]8^'WB>QTCQ9X#N/B'X_P#!_BWQ1'X<\6:'H/B6:VNX/$NLZ/97OB.5
M6^ZZ*,5FLL32JP]@H2K+DE)5)2BJ<L0L9-1IM)*H\3S.-2[<:#5%J4DZLC.^
M.JN=8/'X>66T\/6S&+H5ZRQ=6K1CA:F;KB#$1I825.$(8J><RJRHXSVCG2RN
M<<MG3KU(RQU3XD\&^#?$GBS]O;XU?%7Q9X7UFT\,_"7X&_"SX.?!;6]6T.]L
MM'U"]^(&K^)?B/\ '#6/">JWMNMMK#7C:9\(O#6M7NCS-#8S^%#I-PYNOMD4
M9X-\&^)/%G[>WQJ^*OBSPOK-IX9^$OP-^%GP<^"VMZMH=[9:/J%[\0-7\2_$
M?XX:QX3U6]MUMM8:\;3/A%X:UJ]T>9H;&?PH=)N'-U]LBC^VZ*YWCIOVEH1C
MS8&E@86;_=0A['VLX=I8CV=;VJT3^LUM[Z^14XFQ,OK7)AZ5+V_#. X9P_).
MHOJ.&PO]F_7,1AOY*N:_4\=]>@K4ZG]LYC?F]J^8HHHKA/F0KCOV??\ E)CX
M1_[,6^.O_J_OV:*[&N+^ '_*2_PA_P!F+_'7_P!7]^S17VOAY_R5N6_X,=_Z
M@8D_I'Z)7_)^>#O^P;B?_P!9?.#]@/%W_(O:A_VZ?^EUM7EEGT_$_P C7IOB
MS_D7[_\ [=?_ $MMJ\RL^GXG^1K^JL#_ +M/_KZ__2:9_L>=19]/Q/\ (UU%
MGT_$_P C7+V?3\3_ "-=19]/Q/\ (TZOVOE^@'1VW;_/]ZM^#H?H?Y-6!;=O
M\_WJWX.A^A_DU<=3I\_T FFZ'Z_T2L.?J/J/YK6Y-T/U_HE8<_4?4?S6E#=^
MGZH#%NNC?0_R6N7NNC?0_P EKJ+KHWT/\EKE[KHWT/\ ):ZZ73_$OT Y>ZZ-
M]#_):W_ _P![5?\ MQ_E=U@771OH?Y+6_P"!_O:K_P!N/\KNM<5_NE7UA_Z7
M #XA\;_!WP9^T+^W!^T;\"OB)'J<G@;XN_\ !,OPW\._%1T/49-'UR#1/%GQ
MO^,.C7UWH>K1)))I>M6,5V;S2-12*4V.HP6UUY4OE>6WS;^Q5_P0K\3_ +./
M[1/[.7QK_:%_;W^*G[8GA+]A;X?^+/A=^P3\)/$_PH\$_"W2O@!X.\8:1>^$
M[Y/&'B7PMKFM7_QIU_3_  1-I_AO1M=U?3O"SZ>NE6$BVDFFZ5X;T7P_]'^/
MOC%X9_9X_;4_:>^/OC6QUW5/!WP1_P""6UC\6_%>F^%[73[WQ+J'AOX=?%WX
MU^+];LO#UGJVIZ)I=WK=UIND7,&E6VI:SI-A/?/!%=ZE8V[27,7QUX?_ .#G
M']DZX\*?#[XL_$?]B+_@JI\!/V:_B-J/AJSTK]K7XR_L?Z?I'[,]A8>+KE+3
MP_XBO?B7X2^*WC--3T#4IY$6RN?".E>)[N_!SIUC>;6QX@'ZM>./V8/VA?B;
M<_MQ^&/B#^US_P ))\"OVH/A!+\+/@;\&_\ A0?@C1_^&6)]<^&^M^"/'7B3
M_A8>B>(+#QC\</\ A+M8U>/Q7_8_B^X\/IH'V/\ L+1]1AM;AKN+\G_V1_\
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MFU5XK M92RZ3=WFB>'KS2?O_ .%G[1W_  M+XX_M$?!#_A0W[2/PZ_X9YO?
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M0K*XU;5_"UY?S6FBZ!I>F:'I-M)<-#IND:=8:;9I#96=O!']B?\ # 7["/\
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MX>_^6-'_  M7X7_]%(\!?^%AX>_^6->#?\,!?L(_]&4_LD_^(X?!S_YC:/\
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MP%_X6'A[_P"6->#?\,!?L(_]&4_LD_\ B.'P<_\ F-H_X8"_81_Z,I_9)_\
M$</@Y_\ ,;0![S_PM7X7_P#12/ 7_A8>'O\ Y8T?\+5^%_\ T4CP%_X6'A[_
M .6->#?\,!?L(_\ 1E/[)/\ XCA\'/\ YC:/^& OV$?^C*?V2?\ Q'#X.?\
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M_P#S\QO_ ((H?_-'K_2U+4/YJO\ X+A_\L/=_P#A:?PQ_P"BC^ __"O\/?\
MRQH_X6G\,?\ HH_@/_PK_#W_ ,L:\(_X8'_85_Z,L_9,_P#$<O@]_P#,=1_P
MP/\ L*_]&6?LF?\ B.7P>_\ F.HY<O\ ^?F-_P#!%#_YH]?Z6I:A_-5_\%P_
M^6'N_P#PM/X8_P#11_ ?_A7^'O\ Y8T?\+3^&/\ T4?P'_X5_A[_ .6->$?\
M,#_L*_\ 1EG[)G_B.7P>_P#F.H_X8'_85_Z,L_9,_P#$<O@]_P#,=1RY?_S\
MQO\ X(H?_-'K_2U+4/YJO_@N'_RP]W_X6G\,?^BC^ __  K_  ]_\L:_#/\
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M[\&_^%/HG_R=7CO_  QE^Q]_T:C^S7_X8OX7_P#S+4?\,9?L??\ 1J/[-?\
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M_"Q?A]_T/?@W_P *?1/_ ).K['_X8'_85_Z,L_9,_P#$<O@]_P#,=1_PP/\
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MM0_FJ_\ @N'_ ,L/=_\ A:?PQ_Z*/X#_ /"O\/?_ "QH_P"%I_#'_HH_@/\
M\*_P]_\ +&O"/^&!_P!A7_HRS]DS_P 1R^#W_P QU'_# _["O_1EG[)G_B.7
MP>_^8ZCER_\ Y^8W_P $4/\ YH]?Z6I:A_-5_P#!</\ Y8>[_P#"T_AC_P!%
M'\!_^%?X>_\ EC1_PM/X8_\ 11_ ?_A7^'O_ )8UX1_PP/\ L*_]&6?LF?\
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MFS@EFS4I>TY5:3BN1RE?F2C+]%?^%B_#[_H>_!O_ (4^B?\ R=1_PL7X??\
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MO_A3Z)_\G4?\+%^'W_0]^#?_  I]$_\ DZO'?^&,OV/O^C4?V:__  Q?PO\
M_F6H_P"&,OV/O^C4?V:__#%_"_\ ^9:CER__ )^XW_PGH?\ S3Z_T]#V7"?_
M $&\1?\ AKRWR_ZG'K^'F>Q?\+%^'W_0]^#?_"GT3_Y.H_X6+\/O^A[\&_\
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M6^7_ %./7\/,]B_X6+\/O^A[\&_^%/HG_P G4?\ "Q?A]_T/?@W_ ,*?1/\
MY.KQW_AC+]C[_HU']FO_ ,,7\+__ )EJ/^&,OV/O^C4?V:__  Q?PO\ _F6H
MY<O_ .?N-_\ ">A_\T^O]/0]EPG_ -!O$7_AKRWR_P"IQZ_AYGL7_"Q?A]_T
M/?@W_P *?1/_ ).H_P"%B_#[_H>_!O\ X4^B?_)U>._\,9?L??\ 1J/[-?\
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M>A]S^'?B)\/U\/Z$K>.O!P8:/I@(/B?1 0190 @@WV00>"#R#6Q_PL7X??\
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M_P#FGU_IZ'LN$_\ H-XB_P##7EOE_P!3CU_#S/8O^%B_#[_H>_!O_A3Z)_\
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MZOQ7_P"";WQ=\5_M6VWQK^.?A?Q;^T1\'?A)\7]+^'VH)'^R[H7Q<^('QU\
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M'_[/S_;L_P#6GOB/0!]YT444 %%%% !1110 4444 %%%% 'P9^UA_P G-_\
M!,#_ +.W^+W_ *[Y_;1K[SKX,_:P_P"3F_\ @F!_V=O\7O\ UWS^VC7WG0 4
M444 %%%% !1110 4444 ? G[:O\ R5S_ ()I_P#9^=__ .L)_MPU]MU\2?MJ
M_P#)7/\ @FG_ -GYW_\ ZPG^W#7VW7X3XH_\CW!?]BFC_P"IF-/B>)?]]H_]
M@L/_ $]6"BBBOS4^="BBB@ HHHH **** "OPD_9N_P!=^TY_V?+^VE_ZT3X]
MK]VZ_"3]F[_7?M.?]GR_MI?^M$^/:Z8_[AB_^O\ @_\ TG%'\P_2W_Y-5@_^
MRTR7_P!57$)])T445YQ_FJ%%%% !17P!_P %&/VQ_&W[&G[/_B[XA?#+X*>+
MOC)X_M/"OB7Q!I31:)=Q?"7P'IGAJ&REUCQG\8/'$FH:'IVE:+I<-_%)H_@G
M1]9;XA?$;4U&B>%-.@L8O$'BGPQ]"_&OQ%\>[3P=X1MOV>_!OA+Q!X[\9>*_
M#6A:IXH\>72MX!^$OA*^AN+_ ,3?$OQ+X6M?%/A+Q7\0H=&M+3^S-$\ >#_$
M&DZSXA\0ZQI$5[X@\-Z!!K/B#3^Q8&NZ6%KR=*G1Q=6O2HU*M:G"-\,J3K2J
M)RYH0BJT.5RC>HU*-)3DN4^AI\,YG+ 9+FE66!P>79_CLSP& Q>,S#"8>FJF
M3PP-3,*V)C*JZV&P]*./H*E4J4U+&5(U:."AB*U/V;]ZHK\G]:_;C^,WP_\
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MXPKKP'^_8+_L+PW_ *>@>]PK_P E/PY_V/LG_P#5AASZ4\.?\B]H/_8&TO\
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MP%\1/'-S\6_BYXT\%Q?$;3OA_P"%[GP5\2OAK!\,O#FA^%KSPY;ZUX_OM/\
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MP,TW]J3P[^UW\&K/X6?'']F7P5\*_B5;?#;X._%2/XX>&?CMX)^.NOW'P_\
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M]X&U+Q+\ KOQ9<I^EGQ&_:T\3Z+\$?VO?B'X'_9H_:3U;QS^S;KGC;P!X&\
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MP';>&/A5>?$OQ)\,OV9_A/<2Z_:_#7PO?:;KGB77TC\2ZKK^K:SX@UO5KFS
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MK9_JQOL:-?GG_P % O\ @FS^SI_P4!^%/C?PKX^^&OP5M/C%K_@_3?!?@O\
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M&GQY\.)X&^%/C'3_ !'\?O$?C'Q=^T'\14\9_%VY^$GA#X:Q^'_"?A?XR?\
M"&?#Z]\3ZA\#/A]^T+^T_H,'A?X&:WXY\"^#?!OQBUWX0^)/C?XMA\<KJ6CW
MZZY^K=>:?&+XQ_#+]G_X9^+OC#\8_&.E> OAOX%TP:IXE\3:O]JEAM8I;F"P
MT^PL-.TZWO=8U_Q!KNK7EAH/A?PMX?T_5/$OBOQ'J6E^'/#>DZKKNJ:?I]SH
M\QKSQD:N$CB*<JE-8:GAH5G.-FVJ-"E3H4:"=&$W"4,,Z<U4JQYJCJ.I).GB
M)RJJ5)5(N4?9QIJ?,K/2$(1A""Y(R:<:;C)2DO>YFW?^?_\ 9&_9Y^)/@_\
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M[\K=NIS.$XQC.4)*,[\LG%J,K;\K:L[=;-V-JOA#_@F-_P F&?LT?]B)<?\
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MW_P*^+WA+5_A;\&?'^H?#WP+X?LO^%"+X.D\=?!/X?\ B'XSMX[\::9HFM^
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M[-2_:(_]5#XPKZ4\.?\ (O:#_P!@;2__ $A@K>?_ "+\/_V&8S_TQ@3U:_\
MR265?]E%G_\ ZK.&S9K\Z?&7[?G_  B7@?\ X*,>,_\ A4_]H?\ # -Y=VG]
MF_\ "=_9/^%L_9?@OX5^+_F?;/\ A#;G_A ]_P#PDW_"/;/LOC/;]B_M;<WV
MG^S+?]%J_G3^,G_)#O\ @XQ_[#&J_P#K%WPKKOR3!X?&5JL,13]I&,LO45SU
M(65?-L!AJNM.46^:A7JPU;Y>;FC:<8R7TWAOD&4Y_C\PHYMA/K=*A/A94H^W
MQ-#E69<=\+9-C5S8:M1E+VV6YEC<-[S?L_;>VI>SQ%.E5I_O=;?$7P[;?#&S
M^*WB_4]&\$>%5\#V?CSQ%JWB+6['3M!\*Z+)H<6NZE>:SXAU,Z9IUIIFCVCR
MO>ZM?&PM(K>"2ZN/LT08)\N?L_?\%!/V;/CA^R]H'[5NJ_%3X3_"SX=ZA?OH
MOB:Z\9?%WP%;Z9\._$LU^8M*\&^.O$]SJFFZ'X>\:W^EW6AZK)X8U">WOX%U
MRQBMA?V\]I?WGTQ\* 3\'_AJ "2?AMX.  &22?"^G   <DD\ #K7\ZO[(7Q"
M^&'@?P[_ ,$K/B;\7_%?A33?@U\ OA+^T_\ !SX@^+_$.N:4G@?]F[]K36-8
M\"R>&M'^-6HW-XFE?!SQW?> 1XU\+Z-/X_?1+VUO?$D.@1BTO_$^GQWNF R[
M#XRACKTZ\JV'Q5-4_8SO*5)83,\0\/&FX3O4Q%3"4J,*LN=PE*+A3J-.E6[.
M%N$<IS_+.)W/"9E4Q^59YA(8.67U^:K5P,,@XVS6>4T,+/#UHSQ>:XO(<!E^
M'Q=1UZM"MB*,Z&%Q4U/!8_\ I.\'>-/!WQ$\,:+XV^'_ (L\->.O!GB2S74?
M#OB[P=KNE^)O#&O:>[O&E_HNOZ)=7VE:I9O)'(BW5C=SP,Z.H<LK >$>,/VC
M?^$4_:R^"G[+W_"&_;_^%P_"?XQ_%#_A.?\ A(?LO_"._P#"I=6^'NE_V'_P
MC/\ 8=S_ &O_ &__ ,)WY_\ :?\ PD&F?V5_97E?V?J7V[S+/YJ_X)V7$'B'
MQ/\ MO\ Q(\!V<UO^SO\3OVJ]1\5? 74K0747@WQK8?\*U\ :;\3_B3\.8IX
MH;.]\%^//BS9>+]:M/$^@K+X;\8ZJVK^)-'O=1AOY-0NH/B__P I9/V*?^S3
M_P!L;_U*_P!GRLH8"C3Q^+PM12J0HY?C<1&,VX5*=:&65,73IU53DK5L+6M3
MK0ORNK2G&4.6\#@H<+Y?A>*<]R7%*IBZ& X5XBS6E3KRGA\5@\?A^#<7GF%P
MN-CAJL.7,,FQ_L\)F%!M498W!5Z-:A[-SH+].*^4OV\/^3'?VS/^S4OVB/\
MU4/C"OJVOE+]O#_DQW]LS_LU+]HC_P!5#XPK@P'^_8+_ +"\-_Z>@?,<*_\
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MT/Z?XU\$?M7_ /)S7_!,'_L[;XO?^N^OVT*^\J )=X]#^G^-&\>A_3_&HJ*
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M_A.'@'A>./PV(6UTQC0(TT<+_9RK;CT+Q[\/_ 7Q4\'Z_P##SXH>"/"/Q(\
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M5E@\+^%?$.K>&?!LOC3Q)]Z_#29=9_X*[?M5:EX6N;6[\/\ AC]A?]D7P?\
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M.D\1>+_ FNW9\*>%I_M/A?1/@KQ7!+^S]XO_ ."N'C3P1\4?B_\ "Z\\;_\
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MQ7^T_P"$_B?IWQD^+>OPI\"/ RZU\++'1? 7@[2Y;B^\;^'?#GQ>^)MUH_\
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M_B5XK@^"'[2OQJ6WL/B+JFKWGA[X9>&_#]WXA3X>^$?AY:^!-3M?!G@[P_\
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M$F+=/.\W>,HXBE1S2E!26:0YJTOYS?CAHGQ'_:$\=6>A?'[QE\%?AWX(T_\
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MZ6(A#VO/A:^71PT88Q9CAOPQ_9:F\:RZ'_P2 U'Q!XJ\$^-?@#XI\0>-]0^
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MR:[JNKK<R_7W[9\J:?\ &#_@G;KNM2Q0^"]-_;)DL=<FN65+.#Q%XH_9O_:
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MZPIU,35S2AAG+ABBY)1JY)3I5G5H2:RZE_/O)=>+[SX;WVN:=KWA.7]EV_\
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MP_\ $K]JG]OS1-:^-_Q&T?X4?#+3=._:^_;.\677B#QOKH;[!9W:>#O$VO\
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M+>3Q9ID&D:I+'>ZGXMOM;TQVLK=8R?#^K:*+Q6:'5AJ5JL-O%J_\.L/V?_\
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MZ&F7_P#@&(_^5^O]/0_XD4XX_P"BUX4_\)\W_P#F7U_IZ<117;_\.L/V?_\
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M^9N=2^&3<'2RZK32C=^TJ4VUR\S4-%=O_P .L/V?_P#HJW[:/_B:_P"TG_\
M/#H_X=8?L_\ _15OVT?_ !-?]I/_ .>'7/\ \0IS3_H:9?\ ^ 8C_P"5^O\
M3T\O_B13CC_HM>%/_"?-_P#YE]?Z>G$45V__  ZP_9__ .BK?MH_^)K_ +2?
M_P \.C_AUA^S_P#]%6_;1_\ $U_VD_\ YX='_$*<T_Z&F7_^ 8C_ .5^O]/0
M_P")%../^BUX4_\ "?-__F7U_IZ<117;_P##K#]G_P#Z*M^VC_XFO^TG_P#/
M#H_X=8?L_P#_ $5;]M'_ ,37_:3_ /GAT?\ $*<T_P"AIE__ (!B/_E?K_3T
M/^)%../^BUX4_P#"?-__ )E]?Z>G$45V_P#PZP_9_P#^BK?MH_\ B:_[2?\
M\\.C_AUA^S__ -%6_;1_\37_ &D__GAT?\0IS3_H:9?_ . 8C_Y7Z_T]#_B1
M3CC_ *+7A3_PGS?_ .9?7^GIQ%%=O_PZP_9__P"BK?MH_P#B:_[2?_SPZ/\
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MM'_Q-?\ :3_^>'1_PZP_9_\ ^BK?MH_^)K_M)_\ SPZP_P"(4YI_T-,O_P#
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M_GAUB_"G-&V_[4P&K_DQ'_R'K_3TX)_06XWE.<EQKPJE*4I)/#YO=*3O_P!
MOF_Z>G$45V__  ZP_9__ .BK?MH_^)K_ +2?_P \.C_AUA^S_P#]%6_;1_\
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MBBNW_P"'6'[/_P#T5;]M'_Q-?]I/_P">'1_PZP_9_P#^BK?MH_\ B:_[2?\
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MCX>^&OB/X,^(_A/\8_B)XS^!_A=/"&I:SX9\2^&?$7@?XA?#[X-_'J?P]?\
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MHG@'Q*GCVV^/FE^/_BQXOUCXZ?L7?!?]HC3/B#X1LM+^$FO:M#;^%/@)\/\
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M-\4)_@Q'<WFBZ%X1U>^^*.C6OCF]^+5UW/Q9^'?[26J?%RP_:5;2_%=O\9_
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M2^(][K.O^,/'OMW[0GQW_:ITO]M7Q'\-/@;XH^+GB&^\,>$/@SJ_@'X%:9\
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M#XXZ9\%O@5X@TWQ?^T/\%;;Q$+.]^-'C?]ES]G&/]H[XV>$M9NOAQ?ZAX?\
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MG\:_A_\ M#:);_'+7-4\4ZE\;OBW8?%WX5)X*^'7[._QR\+S_"J[T+3?@/\
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M.FO^,?"6A>$?A]X1^DOVH?V6O%W@F^_:!_:/U&TU7Q7J%MK>L_$KX Z/\&/
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MTOQ[I?A^'0[3PX =+J__  2(\,>/9=5\4?%?X:?LW^/_ (A^+KOQY;^.M?\
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MP!&Y65L$9&58!E/JK ,#P0#Q0 M<G_PGO@7_ *'3PG_X4>C_ /R9765^>_\
MPH[XH_\ 0K_^5OP[_P#+:OD^*,ZSG)_J/]DY+6S?ZQ]9^L>QH8JM]7]C]7]E
MS?5J=3E]M[6K;GM?V3Y;VD?A'C9XC^(?A]_JS_J'X<YCQ_\ VO\ VS_:OU#+
M<\S#^R?J']E?4?:_V-A<3['Z_P#7<9[/ZSR>T^I3]CS<E7E^W/\ A/? O_0Z
M>$__  H]'_\ DRK=CXN\*:I=16.F^)_#VHWL^_R+.QUK3;NZF\J-YI/*M[>Y
MDFD\N&.25]B'9&CNV%5B/AC_ (4=\4?^A7_\K?AW_P"6U>A?"KX5>/?#?CW0
M=:UK0?L6F67]J?:;G^U-&N?*^TZ-J-I#^YM-1GN'WW$\4?[N)]N_>^U%9A\]
M@.+N*\3CL%AL3PEB\-A\1B\-0KXF6#S*,</1JUJ=.K7E*I04(QI0E*HY3:@E
M&\FDFS\FX6\??'7.>)^',HS?P%S[)\IS7/LHRW-,WK9!QA1HY5EV.S##X7&Y
ME5K8K+:>&I4\#AJM7$SJXB<*%.-)RJSC34FOK2^UG2-,N=(LM2U73=/O/$&H
M2:3H-I?7UK:7.MZK#IFHZW-IFD07$L<NI:A%HVCZMJ\EE9)-<IIFEZC?M$+2
MRN98M*OGCX]^"_&?BW5/@I?^#;":ZF\%_$7QAXCU:[M]3L-,GTBSU#]GOXW>
M"M)U""6\OK*:69_%WB[PUIT:Z>9[NV>_74)(X=/L[V\M?A_0?V<?C]\.+?1?
M%S^/?VBM7O\ PQHGPOUW57\8?M0^/_%VD#6M:^%_BS2/VC[K4_#&I?$J\\-Z
M]:_VY8^#]0T/0KO1=2\,^"=<^TZY\#M&\+7%]K]U<_II_:!^L]%?C-\!/A/^
MT[X_\#_"_6UU+]I'P%X>N;7PUXY:?XK_ +3.J>+M=\2?$ZV^!>OSK\2=3U+P
M;\9/&FH7OP#\9_%&\^'.J:7\$)9] T(S>'_$G_"4? _POX9\1ZKHVL^C^"O
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ME']I:=_S_P!E_P"!4'_QRN _L_W_ %H_L_W_ %H^I4_^?K_\E [_ /M+3O\
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MK9V=K#%;VUO%'##&D:*HX_\ L_W_ %H_L_W_ %H^I4_^?K_\E [_ /M+3O\
MG_LO_ J#_P".4?VEIW_/_9?^!4'_ ,<K@/[/]_UH_L_W_6CZE3_Y^O\ \E [
M_P#M+3O^?^R_\"H/_CE']I:=_P _]E_X%0?_ !RN _L_W_6C^S_?]:/J5/\
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MH_M+3O\ G_LO_ J#_P".5P']G^_ZT?V?[_K1]2I_\_7_ .2@=_\ VEIW_/\
MV7_@5!_\<H_M+3O^?^R_\"H/_CE<!_9_O^M']G^_ZT?4J?\ S]?_ )*!W_\
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M_P _]E_X%0?_ !RC^TM._P"?^R_\"H/_ (Y7 ?V?[_K1_9_O^M'U*G_S]?\
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M"=9US3],.MW^C:5XJT/4=5L=&658&U>\TZTU":[MM,69EA-_-"EJ)66,R[R
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MXD\5Z>+>^GL_AYK&BZ'8WFCVEO9^#VTK1Y?B9K-[!I&FB77+SQ)IMYKE_?\
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MQH]HNS_K^G_3T#GOL9]OS/\ C1]C/M^9_P :Z'[(_K_X\?\ &C[(_K_X\?\
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M\?\ &CVB[/\ K^G_ $] Y[[&?;\S_C1]C/M^9_QKH?LC^O\ X\?\:/LC^O\
MX\?\:/:+L_Z_I_T] Y[[&?;\S_C1]C/M^9_QKH?LC^O_ (\?\:46K9Y/ZG^I
M(H]HNS_K^G_3T#G?L9]OS/\ C2BS(.?Y'_Z_Z5TGV;V_S_WU1]F]O<]3_(DU
M/.^R P1:$_\ U\_X_P JD6S]N?SQ[\'(_6ML6^/7'L?\3@U*(0>,'^?\F-'/
M+R_K^OQ]+!C+;!2 1D^V#C^O/I@\?6KL< QPO/;CIUZ=?RY'KBM%;=>!CG\#
M_(Y_G4XMSD8R/QZ^_'/X'./:LW-/>7]:=/N_I,"DD & 03GG'4=_7/Z9_"KD
M<.2, X_GUY[Y^F3^'(JXD SR,D_B3_/]2>G:K:Q $<?D,_J3D].@_&LW-O;0
M"**$=<?_ *_UZ>IS[>UQ$SC&<=/K[?0>OM^4@CSC P.X]?QS[=L].*M11=./
M_K^P] .Y_P C-M+=@+%&>/KGZGV]ACD_Y%U1M'OG/XTL<8 SQ@=?H.P]O\^U
M28W'(&%'']>@^M8MW;?<"PR]QCIR*@((.X< =1TSC].G^<U;J-E[C'3D4@*C
M;6Z#CTQ^HJ%XP>@_#O\ A_G_  JTR9/&!3> "K#GL1C_ .L>O^<4; 9;PY]Q
M],_IU!^G^-0-$<YY(].OY9Y_G^E;&P$$X'OZ_P OQJ$Q9ST_D?Y=:T4^^O\
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MOAEKVF>"O%=CX6O;?Q)"NM:QIME++<S3RZ5K.@Z%8:-I:^._$W[2VG_&&_\
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M[IO@KXY6OPJL;#X.Z)-XHTKPYXTUO4?%/Q33P/X[\4W.M77B#P],_@[P%:^
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M6RN:UY^U'\%]/CC.HZQXTT^[8:O+/HFH?"#XRV7B?3+'0+;1[S6=:USPG=>
M8O$WA_PYIUGK^CWEUXEUS2=/\/QVE_#<_P!I& 22()K35:+KOT=_Z_0#PSP/
MH?Q-@^+FI^*OB/X2UN_T+7-:TR31['2O"QTU_"'Q0?X)?#Z+4O%NI:9;>*O'
MN@76C:@MAKW@G1M<M/%WB#1/ 'B&WOM&G\1>(HO$UQKVD^=?#/Q+^U%X[\16
M?AS4/$7Q@\)>&-6\1>'TO/%^M?#S2V\4^'].?PG\4M4UC3X[GQK^R9\%/"EB
M1J^B^ [&ZO?^$/\ B'H\%WJ7V/3?&%W+JMO#!]?S?M*?"^U\4:YX0O!X_@U?
M1O%%EX0MF@^%/Q.UC3_$^M7WAJW\6QP^#]2\/^%-6L_$:Q:%+<:E<"PE>>'2
MM/N]?:#_ (1LV>LW>KH'QS\$ZUK4GAD7.H7GB"+6_%NEW,7A3PK\2?%FAZ+!
MX8\5^*?"Z7'B[Q3:^ [+0_!EU?3^$M65;?Q)=:?I]SJ%E?6OAK6/%&FP6FMZ
M@M+WYK6;ZVUT=OEV\^@'R9X6\??':2]\7KXAF^-FLW5I\']1U*"PT7X6'P?I
MFB>,=)T#2HI38?\ "6_LX75AK_B34=12?4=+D\*?$KXIPW^J:K?:?!\%8]+T
MA(X.6\(?$7]HN>7PD/$6H?&NXA/Q-;36TS3OA7X@BU7Q/X0N[+P*R7>M>*_$
MG[$?@;P[8Z=IFM7'B33OL6O^&?V?_,TZXU#46^*%]!HUK>G[;\2_'#PGI7AO
M1/$6@.WB==?;X27^GVB)JVDO-X5^+OC[1/ VC^(U>ZT>9]ULVK7&I#19+>+5
M+@V L;B/3C=QW<=*/]I#X4-/'9377C_3]6GU/3=(L_#NL?!CXUZ)XKU.\U>S
MU[4+!M'\)ZQ\/['Q+K-A)9>%O$=U-JVE:5>:59P:)J4E[>VZVLI5WV]Y^6KU
MU6VNNVF_W: >00>&O"EM\;/%5]X]^&'BSQ%\3KWQUI5_\+OB+I_@#Q-K5EH_
M@(>&]"M+6QTSXJ:=8-X=^'VA:1>P>+4\7>"-8\5Z%/XGDN-;G/A[Q%%XVL+'
M6?'/AIK/Q<^'/P]\1^*?%&M?%&TF\&>'_@YX]U7X?Z]\,]#\.?#ZS^'EMX%\
M$#XE>'_ TNE_#30K/1O$.DM'XNM[7P'I/B"WNM-U31=,6XT.S?5-3U/4/L34
M_C7;Z'\:;_X6ZUH*Z=X?L?AS#XX;X@2ZXOV5=4DF\17+>%KC0FT])H)#X;\*
M>(O$<&K1:G<QR6^BZE;3V5J\5O-=<1H7[1?@KQ7\,;?Q5\4/ ?BKP]H^LZOX
MQTV^T*/X>_$+XK:5I6G>#->ELGU#QS?>%/A_J6D^$08(+;5+VW\51Z=:Z5,E
M]%'J%_%H]W?JKJ][VLWW6JMOWMI]X'->/=$U_6_A]\%M2^,_A/4?'7AP:T=?
M^-'@;1?"%YXZBAEUKPSK\_A_3K_P#X8TO5]1\=^&O _BS4=&TMM.LM!UV[-W
M8:+XSU&"<:'?ZG#YCXO\4_$SPUXK^%N@_ _PQ\7?"_P\:#P=Y'A.\\#ZS%X6
MC\-ZCXZU"RU2%],F_9N\?ZCX333?"L;WMOX7\6?'/X*W7A'0V\/:=8^$-.^Q
M2://]=Z[\>/AMX=U37](O[CQK<7/AJXTZQU.XT+X4?%KQ1I$NJZJ^C1V&A:+
MK_AGP3J^A>)?$DYU_2V/AOPWJ.K:]!%+<S7&G10Z=J3VD>O_ !K\->&]2\-M
MK%O?Z3X3UKX7_$'XJ:EXDU[3_$/A_4/#FB^ +OP)#=0:KX-U?0;;Q):W%S:^
M-7N[JWU"UT[4]*;27M9]*GFNV^QN]OM/IK?LTOT^^X'Q'K2_'?6=(\%:)XX\
M1?&W5]6UNW^ 'C*#P[I_P:T6;PEJFIWOC'1]9^)ND>-/$/A_X51-X$B^'T>E
M_:]$T?5?&/A77DC1?[1O?'4UT-*A[;7M9^,&@:9Y,$OQ,\!:;)XD_:+OM*?X
M6_ ^P\6:EXE\60_%[6_^%=:5XJTFW^&GC&'0_"GB/PU,=;F\8RZ5X=?Q;-=O
MK>I_$2TNYFN]6^H$_:%^%<NA-K\.H^+ID&O_ /",)H$?PN^*[^.Y]:.BIXD6
M"W^&Z^"C\0;FT;P\ZZZNK6_AB72#HV[5!?&R1YUY?PG^U/\ ##7_  SX=U[5
MIM=T2;6O#%OXDO!9^#_B%XF\,:0\WAU_%<FA2^/](\&GPE<>(H?#T9U<>'/[
M0M_$DU@\-RFB[+B#S#3^9^6KU^'K??:UK;Z(#PR/3_VJ-2T>'6K[XD?$'PWK
M6I>$OC9X@U'PMHOPW^&U]I/A_P 2>"/%%G9?#CPMH5QJGP]U75I[+Q1I=S<O
M='6-3US5/&%G9C4/"=WH*F2>G0>._C_J>C>,[&XO=?T]OAKK'A?P;XO\3>$?
M ^G^)_%MX?$?BQ?$6M>*O#/@Z/PYK;ZGX@\*?!Z^\$NVD6'A?6;)=?\ %7B8
M'PUXAN?#EE9U]U>'/$>A>+K&;5/#>HIJVF0ZA>Z8NI6T=V-/N[K3IC;7K:9>
MRPQVVK6<%TLMJ=2TN6\TY[NWNK6.Z>XM;F.+QWPG\4=.EN-(DA\%V7AS2?&/
MQ2^,G@G4]8LKZ+9'XL^'>O\ B71;/5M7C@T:R2YE\;:=X'U:\DO;JY2;2[N#
M3=%:;6&N8KR,O;[3UMU?DM+?+7_+0/E+Q!\2OBW:IX4T.3QM\;M*_M?P[\9]
M7\(:GHOP&M]9^)GCF7PMXC\&Z?\ #VX^(7@UO@UJL7@33K]-=U6SU:6[\%_#
MBWGMET:^N-0\-S7+>?1^)WB7]IS5/&_B/PGX=D^+GA^UNO!VM0:A%H&@+=Z)
MIFKCX-ZCKD-WX$\11?LQSZ)^]\>QZ;HMA>3?M*:]XC&H7-[:P>$;&=K,:1Z#
MX@_:S^R^+/"K:;\-/AO>^(->\#^'_$'@ZU\2?%N/PW\4?%GAOXE>/O$/A[1-
M)^&?AD_#36;SQ/+J-AX-\/>,?%.E1:[I$&E1:CIL%P=1?2HKZ;U./]J'1976
M1?"VHI82_ C_ (7);W4VJVT-S-K26\-[<?"_^S'@%Y#XIMM/NK*ZDDG6-'^U
M)%!:3213^6KK;F>O+WVTTU[Z;:]]@/%/A9X<^+D6MZ]XHTCQW\83HGC/XHV6
MDW%CX\^%?AOPY>WVCWOP.T.WD^)6NZ;J/PP\+>(M.UO2/%FFV.F0RV\.@^"_
M-T@:9J'AG4+NZN[NY[30M<^,7Q0^"'Q9U.XM;R'Q%'I]QX#T'1O#]Q%HM_J>
MO^"M,BT3XGZQX;UJ"XT>_M+S7O'2>+]!\*7$NJ:9;0VGA_0=5LY-+_M&ZNY/
M3H?VF? #>+K'PQ>W/]BV,'AKQMKWBWQEXCB\0^%O WA^7P)>^']+UNUTCQKX
MG\.:-X.\;V%AJVLW6F:SKGAGQ%=6.@7NG1V^J+#/J,$4>SX,^+_PPU_Q7X4\
M#?"75? ?B[POK'A[XBZX^O\ PZ\4:!J^@:%JG@W5OA\+W0GM?#0O=.^WZK_P
MLF+5[HF_L[BT\I)I;.[_ +76XMVG;2_XMZNVVKTV[]-0/C_2]?\ "7@7QQKG
M_"@O GBWX7^'Y?#_ ,*M1UCP>GP0\=> ;OQS;Z5\34B^).L>!_A?XA\%:3K?
MC/7O"_P[O!:^.=:\)^%]7\1S6NM^$XX+R>[L;-H='XG?$_\ :*GTGP_JG@73
M?'^AZ+K&O_%&>VU:?X<>-[+7HK;3?$EG:_#O2?$7@S3OV7_CWXPLO#]_X?FO
M-2F&I^#/ 6JW\=K#%)XZT_4@UA>>_?%;]JWP1\/K*^MM"TKQ5XQ\6KXAT[PM
MHNDQ^ OC%:^%]=UBZ\2:?X9U(:=X\\/_  M\9:7K-IX>O[_[/K3>#;+Q=?V^
MJ1Q>'H]-FUZ\M-/DZK3OCSI>O?#GQIX_\/>$_&%P?A]J6JZ=XET77_#/C'P;
M+*OAC6;C3?%EYX;N_$GA>R/B:WTVST[5M2LETZS^T7,MK!HNM0^'-9GN;.P+
MK:]K*^EUIH^C\EY]@/D%/$?QMUKQG;7&K>,_VC[7PWHWQ.TR74KOP=\'KNP\
M,IH.N:/XWM(M$A\)^,OV6?#_ (XU'1--UT:)I=[?6^N_&+1(-",/B[6_%7A?
M69-&DM]_0]>^.6D:/\*--V?$3POJD7PS^"8\.^ O"WP4L?\ A ?$OB.^9;?X
MCZ3\4-:L_AOJ-G\)K70+9+>UMM(MO$'PHM]%LPUS8_VNV=.L/K*^^-_AC2=7
M\6VVHVNKS:+X:U+PUX=LM0\,:)XK\>:[XE\5ZYX?E\6ZAHNB>"O!'AO7_$=_
M'H/A>XT36;[4=.M]0C2UU"^EO(-.M='GNYZ^E?M'?![7-9BT'1O$6M:GJ$T4
M9C>R\!?$:?2S?3^%1XVMO#[:\GA0Z#%XON_"[#5;3P9+J2>++N,_9K?1I+T&
MV!?^\^V[Z<O2]^BMJ]^H'S5K$W[3R-IEYI_C'Q^I\;?$+Q5X9O-.C^&/@ZXL
M_AOX2TWXW>'O#6@^(]$#>"6U$7%[\-[C6-6?5?&]_P")-#O[=1XAL].M[*RD
M$N'\7?%G[1_A'PKHFG>%K_XM:YXJT_6?BK86^OV'@BRF@\76F@:_#;^"'\6V
M'A#]ECXQ6:WVK:?/ ;.ZL8O@AX2UFP2_N8_%$$^)]+^B=,_:K^&'B'PEJ/B+
M0AXMM;^Q^'-]\3)])\:?#KXK^%+71_#]OI&L:K9WWBW6X? &NVN@Z3J?]@ZM
M!IFK6D&N)X@;3KX>#K;Q3<01VL_H.G_&SX=:D]^+?4M=^S:;K^C>%9=;E\#?
M$&U\*7_B'7?$<?A"QTSPYXQO?"UKX8\5NOB:0:/?S^&]5U2WTBY64ZQ)I\4,
MSQFZTD^BOS/I;SM?1?@!\I75Q^T+::)>OX/L-?T"ZTR+]J7QC%H&D^ O#.C6
M/BSQ%H_Q@*_#71M8N-0\%:H8+3Q5X<U34];-QH]M;>+?'!0>(8-8U.\DOKC4
M>O\ V<O&?CK7;M-*^)_B_P 5OK]S/XJNO"OAWQ!X3\0Z+J.N^']*L_!"ZQJ>
MO77BG]EO]FVY=?#&K:S;0:'=>'O#.FZ7<1>*+JQU6^\3ZEI\!T;V<_'3PRGB
MSX@:"-.\0:CIGP\T#PMJ>IZGX7\->-/&>MW6J^(/&'CWP9?Z):>"/"GA;5_$
MMX-"U#P.TMQJFEVVIVMQ;ZA+<LEK8:;)?7%[PG\8/A9XY\46.F>&9]8O_%=U
MHES<R"X^'7C_ $K4-!TB'6-<TR6R\6WVL>%+ >!Y9]>\*:]8VVA^+[C0K_4-
M4T:Y@L["XN8E4E[6]Y^5WO\ #MKY?>P/C;XQ_##Q@_B?XL:QIO@C6?%_A7XI
M?&/X/^#O'OA<Z!=ZS::GX5TG3_@]=Z5X\M-,G$EGJ'A_0KJ#QAX6\<2065Y!
M=Z5J(N-3N([;P3+;-ZY\"/A9<?"[0[U_AW\%_AOX;NM>^+_Q5M?&%Y>H_P +
M];B^']I\6_&1\(7ND6VA_#G7Y/&%M9>&+FWE\(Z-JE]X:T3^QWT]=+UNVTZZ
M26+[1\H^O_CS4>4?7_QYJ+6=^O\ PWZJ_JV!D_9O;_/_ 'U1]F]O\_\ ?5:W
ME'U_\>:CRCZ_^/-57?=_U_PR^X#)^S>W^?\ OJC[-[?Y_P"^JUO*/K_X\U'E
M'U_\>:B[[O\ K_AE]P&3]F]O\_\ ?5'V;V_S_P!]5K>4?7_QYJ/*/K_X\U%W
MW?\ 7_#+[@,G[-[?Y_[ZH^S>W^?^^JUO*/K_ ./-1Y1]?_'FHN^[_K_AE]P&
M3]F]O\_]]4?9O;_/_?5:WE'U_P#'FH\H^O\ X\U%WW?]?\,ON R?LWM_G_OJ
MC[-[?Y_[ZK6\H^O_ (\U'E'U_P#'FHN^[_K_ (9?<!D_9O;_ #_WU1]F]O\
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M^-?#7BR5=,\0:=H6O37.I>'M+LM5L)-*A6/Q!I3W4,5\7?=_U_PR^X#H]<^
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M3PAX/\1Z#K7B+X6^&/ /C=?"NM>(/%F@:3J>L^-_"=YXFLM1DN-2U>1AX/\
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MO@WJVGVWAW0+.]U.ZDU#XJ^+8[*WLI8+BS\0WC0ZY9 '1Z7\"OV;-"\?:O\
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ML-C=:?\ ;O$L%M>Z?X'T^Y@TA/!OA>P'_"'0V>G:A<V6B>$O!N@^']'E\?\
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M_B6;5/@%>R^.M/>*P<_V7\0'\5:1:7=_>:IIFG6&KII]_8_86U_[WZFC:_\
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M@R6[\)?#CPQ/K7A37=-E2Q\16WB!]6U;4(+:W:'6+.<2S2_4.U_[WZFC:_\
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M,?2]6\-W-Y9ZK#>:?=W9DO)KC3KW3IDMG@Y_6?V9_!VK:7\,K"'Q%XST6_\
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M?>(=-ATB]\9ZI9:9)X0\0>&;V73+?3+?6KO6)K);E_?MK_WOU-&U_P"]^IH
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MW;P?IHT6WTG3M,\,Z-;376G6/AR+3(M,LM.^@=K_ -[]31M?^]^IH \0\4_
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M]>?YTN!Z#\A2 KX'H/R%* N>F/H!FK(3/0+^(_\ K4OE>R_E_P#6H @QN^Z
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M^0HP/0?D*DV'U'Z_X4;#ZC]?\* (\#T'Y"C ]!^0J38?4?K_ (4;#ZC]?\*
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M"I-A]1^O^%&P^H_7_"@"/ ]!^0HP/0?D*DV'U'Z_X4;#ZC]?\* (\#T'Y"C
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+\A2T4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img173888082_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173888082_3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +0!0 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BD9MHIGF>WZ_\ UJ )**B9LC&,?C3* +%%5Z* +%%5
MZ* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +
M%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z
M* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%
M%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z*
M +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%
M5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z* +%%5Z*
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M."QYGM^O_P!:CS/;]?\ ZU5_,]OU_P#K4>9[?K_]:@"QYGM^O_UJ/,]OU_\
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MPKK#8*G5ERRQ->4H15*DOM2<JD(]%S3BKWDD_J.'^"N*^*L#Q#F7#N0YCG&
MX3RNIG7$F+P5'VM')\JI4Z]:IC<;.Z5.C"EA<35;7-+V>'K5%'DI3<?T^\SV
M_7_ZU'F>WZ__ %J^6_VMOVLOAU^QI\))/C+\4-%\;Z[X73Q)HWA8V/@#2-+U
MG7/[1UQ+U[.:2'6M<\-Z7;6""PF6>[N]7MU$TEM;1+-<7,,3Y?['_P"V=\(/
MVV_AQJOQ+^#\7BG3],T'Q-<^$M<T+QMIVEZ1XFTG5H--TW5D-U8Z/K?B&P:R
MO++5('LKVUU2X@N)(KR %9K2=$3S3+UF"REXNBLQE0^LQP;E:M*AK^\4;6<?
M=D]'>R;M9-EQX'XNGPC4X]AP_F4^#J69+)ZO$4:/-EM+,G[.V$J55)N%1NK3
MBG**@YU(04^>2B_KCS/;]?\ ZU'F>WZ__6JA=7UM8VMS>WL\-I9V=O-=7=U<
MRI#;VUM;QM-/<3S2%8XH88D>265V5(T5G8A037YM?LJ?\%5_V</VQ?C)JOP4
M^$?AOXOQZ_I?AW6O%1\0^*?"OAS2_"5[HFA7NFZ?<W5M=:=XSUG7+87%QJUB
MMF-6T#3!(TZ12M!</'"[Q.98#!XC!X3%8NC0Q.83E3P5"I*U3$SAR<\:4=6^
M7G@F]$G**O=HSR3@OBOB/*>(L^R/(LPS/)N$L+1QO$F986CS83)\+B/;^PJX
MVJY1C!55AL0X17-.4:-62CRPDU^FGF>WZ_\ UJ/,]OU_^M5?S/;]?_K5^6?[
M0_\ P6%_9 _9I^+7BCX+^-Y?B5KGC+P8]C;>)6\%>$;#5M&TW4;[3[75!I1U
M+4_$.B?:KZUM+VU-\+*"XMK6YD>QDN?MMM=V]NLQS3+LIHQQ&98S#X*A.HJ4
M*F(J*G&=64934(WUE)QA*5DF^6+;T3+X0X&XPX^S&ME'!?#F;<39EAL)/'XC
M!Y1A*F+K4,%3K4:$\564%:E1C7Q%"C[2;C%U*M.";E)(_53S/;]?_K4>9[?K
M_P#6KYN_9B_:J^#?[7GPTC^*?P5UVZUCP_'JMUH&L6&JV$ND>(/#>OV4%K=W
M&C:[I<K2BWNQ97UC>PRVMS>6%W:7<$UI>SJ7V?0[S)&K.Y5$16=W=@JHB@EF
M9C@*J@$LQ(  ))Q73A\30Q="EB<+6IXC#UX*I1K49QJ4ZD);2A.+::?D]'=.
MS31X^;Y/FN09ICLDSO+L9E.;Y;B:F$Q^6YAAZN%QN$Q-)VG1KX>M&-2G-:-*
M4?>BXRBW&46[7F>WZ_\ UJ/,]OU_^M7XO^*_^"[_ .PGX7\2ZYX=@N/BSXKB
MT34KK3!XC\+>!]-NO#FL-:2M#)>Z+=:KXHT>_N].ED5OLUU/IMJ+F,">!7MY
M(I9/UG^'GC_PS\4O 7@OXE>#+R34O"/C_P +:#XR\,W\MO/937F@^)-,M=7T
MJXFL[J.*YM)I;*[A::UN(TGMY"T4J*Z,!P8#/,GS6K6H9;F6$QM7#J]:&'K0
MJRIQ<G!2?*W>/,FN:-XWMKJK_4\6>&/B%P)@<MS+C+@WB#AK YO)T\NQ.<9=
M7P5/%58T88B5&#K1BX5HT9QJ.C44*JBIWA>G44>Y\SV_7_ZU'F>WZ_\ UJK^
M9[?K_P#6H\SV_7_ZU>J?"%CS/;]?_K4>9[?K_P#6JOYGM^O_ -:CS/;]?_K4
M 6/,]OU_^M1YGM^O_P!:J_F>WZ__ %J/,]OU_P#K4 6/,]OU_P#K4>9[?K_]
M:J_F>WZ__6K'\0^(-.\+Z!KGB75WDBTGP[H^IZ[J<L4;SRQ:=I-E/J%[)'!&
M#)-(EM;RLD2 O(P"*"Q%)M13E)I1BFVV[))*[;?1):METZ=2M4IT:4)5*M6<
M*=.G!.4ZE2<E&$(15W*4I-1BEJVTD=!YGM^O_P!:CS/;]?\ ZU?FS^QY_P %
M2/V=?VW/B3XG^%GPDT#XK:-XE\+^$=2\<7$WCWPWX;TC2M2\.Z7KWA_PY=76
MEW6A>,?$TYF-_P")M):*UU*TTVX>VEED**\$D0_1[S/;]?\ ZU<>7YC@<UPZ
MQ>78JEB\-*<Z:K49<T'.#M.-VD[Q>^G5/9GT7%G!W$_ N<5,@XOR3'\/YS2H
M8?%5,NS&DJ.)CA\5#VF'K.*E).%6%W%J3U4HNTHM*QYGM^O_ -:CS/;]?_K5
M7\SV_7_ZU'F>WZ__ %J[3YHL>9[?K_\ 6H\SV_7_ .M5?S/;]?\ ZU>'_M+_
M !:U#X%?L^?&?XR:1I%EKNJ_#+X;^+/&FFZ/J,\]OI^HW^@Z1=7]I:WTUL/M
M*6DL\48N?LY29H=Z12Q.RRIE7K4\-0K8BJW&E0I5*U623DXTZ4'.;48IMM1B
MW9)M[)7._*\MQ><YGEV3Y?3C5Q^:X_!Y;@J4JD*4:F+QV(IX7#4Y5:CC3IQG
M6JPBZDY1A!-RDU%-GO'F>WZ__6H\SV_7_P"M7Y!?\$J/^"B_Q&_;XMOCHGQ%
M\!>"?!EY\)Y_ALVFS^"IM=%MJUMX\C\=B:&^M-=U#5989]-E\%J\5Q;WHCN8
M]1,3VL+6@EN?UU\SV_7_ .M7'E.:X/.LOP^9Y?.53"8GVOLISISI2?L:U3#U
M$X32E'EJTIQU5FES)M--_0\>\"\1>&O%F;<$\68:A@^(,D>!6/P^&Q=#&T(?
MVCEN#S;".GBL-.=&JJF!QV&J/EDW"4W3FHU(2BK'F>WZ_P#UJ/,]OU_^M5?S
M/;]?_K4>9[?K_P#6KT3X\L>9[?K_ /6H\SV_7_ZU5_,]OU_^M1YGM^O_ -:@
M"TK9.,8_&G53\SV_7_ZU2 Y&?6@"Q14*MM-.\SV_7_ZU $E2!\#IG\:C!R,^
MM% %@'(SZT5"K;34BMDXQC\: &,V>!TS^?\ ];_ZU,HI&;:* !FVBHV;(QC'
MXTTG))]:A=LY'8=_7_ZU $C-M%?(_P"WNV?V(_VMQC'_ !CG\8N__4A:[7UC
MV_Q_KTKY(_;U?/[$G[6P_P"K<_C%S_W(6N]L5Y^;?\BK,_\ L7XW_P!1JI]=
MX?\ _)><$_\ 97<-_P#JYP1_,;_P0U_9P^!O[1?Q ^/^F?&_X:>&_B3I_ACP
M=X*O] M?$<%Q/%I=YJ&M:U;WMQ:BWN;<K)<PV\,<A8L"L:X .2>4_P""V/[*
M/[/?[+OQA^$Z? ;1K'P4OQ$\'>(-;\6_#[3M6U#4+/1[G2=;MK/2?$=E9:K?
M:A=Z/8^)5NM3L(;&WEAT@3^%[IM.M+=Q>!OEG]@/X#_MD_'/7/BA:_L=?%76
MOACK_ACP_H>H^,CH?Q7\6_"J[\1Z;>7NH0Z/IZWWA=HH]5>"\M[MXH-8N;6S
MM'G\U9D,LC+H? SPOX-U#]NNQ^'_ /P4OO/B[>ZDOC*U\)>,K[Q#XSDU'4T\
M:PWME:Z':?$GQ+K$FL:QJGP]U-6AM;S7/#GB"UF72+RQUC3-8;17:[7^::-:
MAB>$,JR:60TL/B<QS&5'#<48R%.AA8S^O3G.*QD:,ZMXPOAJD)S48TE.=FJ:
M/]J<?EF:91](/CGQ&H^*V/S?)N$N$:>8YSX&\/XK&9CG=2A_JOA<-0K/A^OF
M5# *-?$J&=82OAL,ZM7&2PN'E4C4Q<W+^G:W\4>,/&/_  11UOQ'X\DOKCQ3
MJ?["7C)]0OM3EGFU'58+?X8ZS::3K5_<77^D75WK>C6^GZM<7<S.]W+>O<F2
M7S?,;\2?^"&_[./P-_:*\?\ Q_TSXW_#/PW\2M/\,^#_  3?:!:^(X;B:+2[
MS4-:UNWO;BU%O<6Y62XAMX8Y"Q8%8UP <Y_I9_;@L]/TG]A?]J;2-*LK33M+
MTS]FCXL:=INGV,,5K96%A9?#S6;6SLK.UA5(;>UM;>*."WMX46*&*-(XU5%
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MKC6AQ#D^:9KE&45)XY8O%8B67XC#O,YU'!8;!XAU\-"4JM>E7G3H?9W[5?\
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M_AOXN?M*_#BUMVFE??X>T#PM\5-,TZ"65FWS>1_8^GW :7<7FMHW<;N1M_\
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M@Q\)]0^+>NWWAWP]K'B?4-0\7P^%O"/A;5=8TNSU2_\ "]CJ-MH&NW_B[5-
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M;ZX_8AU.[U3_ ((EP7-[,9)HOV>_VI]-1BS9%IH_B;XRZ181_,S'$-C8VT0
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M7$RKIX+#8.G1AE]6-.G)4Z%?D6(JJE*O02J5JDU4BZL904E"J?B^,\/OH_\
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M @]^O;O]/\__ %Z6LY)??CZY'Y]JE\SV_7_ZU?K?)+M^1_G\75;!]>Q'^?\
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M>)P>'S7#)X*4*>*PN&C4]I&,I/\ '?X9?M*S?M/?\$9/C)XOU:]DO_&O@_\
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M2=+U"^$TWVB47E[96L%S="6?]]()Y'WS?O&R_P U?*<4<+2XF>44*N,C1R_
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MM<_%8>%VN9_%O@C3=6>\A\,K\-_$)6VL%\0)'!NU_=J4=L+C_0EN%2/^?_\
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MD8*,*L^1SIPK58VJ1FIW@U*G*',_C_#;Z0V09-P7Q]P!XI\!5?$;A[CKBO\
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MO%&O7.C7UKJVE^&_"^BZ-H5BT$C^(;:TF;4%DOK[4;:U2TBTVQ^UW 'ZV_\
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M2W7AW4I?LTEQHVN6UEKCZ--8S:;%>>T_ME?\%&?CO_P44^#OBSP+\)O@7?>
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M,J>6U,3'&5,)"=.E3C2GBHT,-&M)*GS.4:%-7E9)VN_XS?BXQ_X?>Z2YR/\
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MP.T:TT^UM[&PM;>RLK2&.WM+.TBBMK6UMX5"106]O"$BAAB10D<4:*B* JJ
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MKHRH\N H8:>&IX6/-6K2Y53J2C=2BE"-*"C:FCT?'CZ3N*\6<^X$S3AGAV7
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MPZ+JY\16OCSP+=P7=\EAJ-S83:;_ ,)#->-&;&5WGLA:2"(2-+'_ 'G?;?\
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MS7VCIWPD57_G3_X.+I#*/V/#R0I_:"!/4 M_PI$@$Y(!(4D#C.#CH<?>6M^
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MO[2!\/#7_B9\;_AU_P (8-5^R?\ "F_B3??#W^V/^$B_LS[1_P ))]BL[O\
MM?\ L_\ L*'^R/-\O^S_ +;J@3?]M?;;TBY-72MI>U]4M_Z[>@>R/,5.2><?
MET_(^O3N.:HR7)]?\\?3^GXU\@_\.QOAW_T<O^V]_P")):Y_\IJ/^'8WP[_Z
M.7_;>_\ $DM<_P#E-25=+[&G;FM_[:!]<M-D [O_ *W3W_J/QJJT^>-W^?Q(
M(KY0_P"'8WP[_P"CE_VWO_$DM<_^4U'_  [&^'?_ $<O^V]_XDEKG_RFJHXF
MS;Y-_P"]_P#:M@?5QNMHP#^O_P!<C/>H3=>_Z_X,*^5_^'8WP[_Z.7_;>_\
M$DM<_P#E-1_PZZ^"UUSKWQE_:W\5.G%M)XA_:(\67#V2M_K4M3906 1)B$:4
M2+(28TVE0""?68_\^O\ R=__ "('U1]J]_U_^RH^U>_Z_P#V5?*__#K#]G;_
M *'C]I3_ ,/_ ..?_DFC_AUA^SM_T/'[2G_A_P#QS_\ )-'UB/\ SZ_\G?\
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MGVW_ #N_^O1]M_SN_P#KU\M_\.L/V=O^AX_:4_\ #_\ CG_Y)H_X=8?L[?\
M0\?M*?\ A_\ QS_\DT?68_\ /I?^!_\ VOE^?=@?4GVW_.[_ .O1]M_SN_\
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M'_\ :^7Y]V!]2?;?\[O_ *]'VW_.[_Z]?+?_  Z$_P""=O\ T;U_YEGXX_\
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MG;_T;U_YEGXX_P#SS*/^'0G_  3M_P"C>O\ S+/QQ_\ GF4?68_\^E_X'_\
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M_.[_ .O6%)XU\,PR212^(M"BEB=HY8I-9T])(Y$8J\<B-<AD=&!5E8!E8$$
M@BOGC_AT)_P3M_Z-Z_\ ,L_''_YYE=%%_P $J_V (8HXD_9P\.E(HTC4R^*_
MB-/*510JF2:;QC)--(0 7EED>61LO([.2Q7UE?\ /I?^!>G]WR_J[N'L7_"=
M>%?^AF\/_P#@[T[_ .2J/^$Z\*_]#-X?_P#!WIW_ ,E5Y!_PZO\ V O^C</#
M7_A3?$'_ .:ZC_AU?^P%_P!&X>&O_"F^(/\ \UU'UE?\^E_X%Z>7E^/K</7_
M /A.O"O_ $,WA_\ \'>G?_)5'_"=>%?^AF\/_P#@[T[_ .2J\@_X=7_L!?\
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ME_#_ /\ "T\.?_+.L7_AVW^PM_T;+\-?_ '4?_EC1_P[;_86_P"C9?AK_P"
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M>'/_ )9T?\+F^%?_ $4OX?\ _A:>'/\ Y9UB_P##MO\ 86_Z-E^&O_@#J/\
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M&^\/_P#R'1]9_P"G<?O?^7E^?=@<G_PTI\ /^BY?![_PYW@K_P"7E'_#2GP
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M;1M,\1:L!]AT#7_B)9^&KGX:>'-;>1H[:?2M?\8:;?V=[<6MC>V]O>7=M!*
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M_P 5].\2Z[#_ ,)E?^,+7X?S_8=$@EO?,MO%<T5SL^S6;W%VRP&M_P %&/\
M@GI^U;\<?@%_P3&N?AW\+O"GQPNOV.]/^'%Q\;/V0?&/CWPYX1TCXI7>G>%O
MAGIFKZ6WBK5=67X>WXTD>%/$GAB_FU'4[BT_LCQ%J%SH9UVVNKS2=3 *_P#P
M3^_;]_:*NO\ @I+XL_86^*'[8_P3_P""AWPL\0?!^X^)WP^_:.^$OA7X6>$)
M-"UK1[2RNM0\+7UI\&;N_P#!>%7^V;75M)N=4\2ZO;RKX;U:#7--@O-1T%/%
M_P!F+]I3_@KK^V_H/[>6F_"W]K7X9?"&V_9:^.7Q;T_PAXUUWX$?#?QGXY\8
M#33J8\$?!:.P?P[I?@7PIX$TBQ\,W=UJWQ*U?PSXX^(%UJ?B.VB$=_8:;*B=
MY^Q7^PE^UMX4_P""K?AC]L;QE^PS\"_V,/@+JGP#\6>%%^&?P'\;_"+5=(^'
M6NSP7.E:?I/C2Q\#?\(O!XE\>>(9X&UG4?$W@7P;=>%!HE]H%E>:I'K%AJL$
M'TU_P2A_8T_:2_9JTC_@H]:_&SX<?\(7/\>OVA/'OCCX3Q_\)AX"\1_\)7X6
MUJU\4QZ9JF[PEXHUY-"^TOJ-DOV+Q(VCZC#YV;BTB$<IC /D,_\ !:_]HFZ_
MX(P>&OVQ-.\)^$%_:0U/XXVO[,.K>+KS0I&^&VBZ[B?4I/BYJV@07_E6%O<^
M%X[*T>REE30K?Q_J2RQ:1)X=%OH$U'4/BA_P56^%_P#P4F_8V_8V\4_\%/-$
M^+GA;]H/P7%\7O$>M>"OV1OV<X9=(T#P]!XF\0ZOX5U+1+#1QJ=OX/\ %^G>
M$;C1M"^)]GXNT^_%OJ=UK%OX<2XT9+>^_.WXX? /X]?L6_\ !&+X1_LA_M :
M3??"?XY?&K_@H#!JOA_X4W'B+P-XH\!?$[PG'IWAMUTGXI^.O!7Q"E\/>%_
M\>LQZ7KD\O\ PD%WJ0U?1=)CNM'L+"6?Q3X=^J?@?9>-/^",?[8O[-7@?XI?
ML<_\$]8KS]L_Q=IGPLTOQ?\ LE?$/]I?Q=\9/!-KKGBCPUX:FOE/[4GC?QQK
M=CX7N=1\0Z;-=Z/X.L="T+Q,^F26M[KZ:AI]C;D ^F/C7_P4N^,_Q]_;M_:!
M_9;^$W[>W[,W_!-/X)_LN2#PSK?QI^,.D?!_QIXZ^,/Q,AN6TW7?#WAKPO\
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MJ$NL?9?%_B;0+W7MEGH&KS?V?X9MM9U1OLGEK8M+/;),G_!1+]D+]HGXZ_\
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M*M8\+_$7PTE]/I%MIVH>&(E2P\1SQV,^O^,Y=0UFU\%:-I?AU=9NVN+#P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7+;7M/\ AS?:G\.[+7=#G\;>&+1[3PU<(FE:I;>)M$OKW79]/AU)O.OV\_\
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M_!*_PO\ L,_&S]G/PK^RW\3OV3H?A3J'P!\?>(?C_P"#?B5H'QNUSPO9^+-
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M?TP/RK:MSTS_ )ZC]<"L"W]"?RY]?7V&.WUK:@8].XR/Y]/Q'Y4IMZ+O>_X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ_D&Y-O#T7PE\2>/_&'PT\$^*/BG\-?^%._$77?#UAJ/C+X6_P#"8Z+\0O\
MA!->N(]U]X;_ .$W\.06NA>)_P"SI/W7]L:5;PV5W]^&-5XKT2@"?(]1^8HR
M/4?F*@HH GR/4?F*,CU'YBH** )\CU'YBOSK^-G[?.I?"']L;]G7]E*/]G3X
MB:OH?QW\97G@B?X^:[JNG>#?AUI>MP>!+[QZNG>!;&>PUK7OBC?6&G6:6WB:
M:VM_"WAK0;R\AL(O$^JZU;ZEH]A^AM?A#_P43TK_ (*%>,?VP/V5_&O[/W[
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M/B/+<PIH]QJ][;2>"Y)S<:60FG&/Q@P!]CZG_P %E;NU^+%[/IW[('Q'U/\
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M"?'/B2?X;2^,O!ND>&6?4KOPO\.-5-I%\3DD%UJCV'C#2+E-"O-%M'TKQO\
MGS\<O@M\=_V;OV3OA=8>"_\ @I5XB\3^-(&\)_#_ /X):_LY?LC:=X7\->"?
MVG_ LNOZ!<0ZK\<_AKHND?V?\:]2\0^'?$6_XC:M>WLGPP\.65O%XA\0:IXL
MU;QMJFE:B >Z?\$YO^"DWQ!\ ?M!?##_ ()\^./%5I^U/\&-?U2#P[\$/VU[
M>_\ $TNJV>EZG\'YOBKX+^ _Q2.F^$-<\,>)_C=X6TPZ1H?B:=/&>F#1=,EG
MNM?O+G4=+>WN/Z<:\1_9]^"'P]^ 7PC\$?#/X??#7P)\+]'T"R74KCPC\/\
M319^%]+\6ZS#)=^*[S2#/YE].+O5;[4U34;Z:749[&589YC'^['MU !1110
M45#<3I:PR3R+,R1@%EM[:XNYB"P7]W;6D4UQ*<D9$43D+EB JDC(_P"$BT__
M )]]=_\ "7\3?_*B@#=HK"_X2+3_ /GWUW_PE_$W_P J*^8O^&_/V(O^CL?V
M?_\ PZ?A#_Y:UA6Q.&P_+]8Q%"ASWY/;5:=+FY;<W+SRCS<O-&]KVNK[H]'
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MY#X-_P#A>^'_ /Y-H ^GJ*^8?^&U?V1_^CD/@W_X7OA__P"3:/\ AM7]D?\
MZ.0^#?\ X7OA_P#^3: /IZBOF'_AM7]D?_HY#X-_^%[X?_\ DVO4?!/QE^&'
MQ+TJXUWX<>,=,^(&AVFH2Z3=:SX)6\\5:5;:K!;6EY/IEQJ.A6M_:0ZA#:7]
MC=2V4DRW,=M>VD[Q+%<PLX!Z;16%_P )%I__ #[Z[_X2_B;_ .5%'_"1:?\
M\^^N_P#A+^)O_E10!NT5A?\ "1:?_P ^^N_^$OXF_P#E17F_Q1_:'^"/P/\
M#]GXL^-7Q-\*?"#PMJ&L6_AVP\2_%'41\/\ P_?>(+NRU#4K70[/6?%B:3IU
MSK%SIVDZK?V^F0W+WLUEIFH74<#065S)'I2HU<14A1H4JE:M4?+3I4H2J5)R
M_EA""E*3\HIL&TM6[+NSV6BOB'_AY=_P3S_Z/;_9;_\ #W_#S_Y?T?\ #R[_
M ()Y_P#1[?[+?_A[_AY_\OZ]+^P<\_Z$V;?^&[&?_*?-?>1[2'\\/_ E_GYK
M[S[>HKXA_P"'EW_!//\ Z/;_ &6__#W_  \_^7]'_#R[_@GG_P!'M_LM_P#A
M[_AY_P#+^C^P<\_Z$V;?^&[&?_*?-?>'M(?SP_\  E_GYK[S[>HKXA_X>7?\
M$\_^CV_V6_\ P]_P\_\ E_1_P\N_X)Y_]'M_LM_^'O\ AY_\OZ/[!SS_ *$V
M;?\ ANQG_P I\U]X>TA_/#_P)?Y^:^\^WJ*\R\ _&7X8?%;PEI/C[X7>,=,^
M)/@77OM_]A^-/ *WGC'PEK7]EZG>:+J?]D^(_#MKJ.CZC_9VL:=J&DW_ -CO
M)OLFIV%Y87'EW5K/$G8?\)%I_P#S[Z[_ .$OXF_^5%>94ISI5)TJL)TZM.<J
M=2G4BX5*<X-QG"<))2C.,DXRC))Q:::31:::NG=/5-;-=S=HK"_X2+3_ /GW
MUW_PE_$W_P J*/\ A(M/_P"??7?_  E_$W_RHJ -VBO(/'GQ^^#/PL_LK_A9
MWQ&\-?#G^W?MW]B?\)Y>-X0_MG^R_L?]I?V5_P )!%IW]H_V=_:.G_;OLGG?
M9/MUG]H\O[3!O\]_X;9_9#_Z.3^#'_AP/#O_ ,G5V4LOQ]>G&K0P.,K4I7Y:
ME+#5JE.7+)QERSA!Q=I)Q=F[233U5CY_'<6\*Y9BJN!S+B;A_+\;0Y/;8/'9
MSEN$Q5'VM.%:G[7#XC$TZM/VE*I3JPYX+GISA.-XRBW]0T5\O?\ #;/[(?\
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MY!^P!_T>?^S+_P"'H\!?_+RM_J&._P"@+%_^$U;_ .0/-_UCX>_Z'V2_^'3
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M'B"PM]4T77=%U2W>UO\ 3=2L+I)(+FUN8)'CDCD0XR&4JZJP /Y@O@1^QO\
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MFF!Q&"QF(H9'.E0J_&,BHLCK&_F(KLJ2;2GF(&(5]C<KN&&VGE<X/(K]U/\
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M"XK#T*M\;CZRI86A"ICJ\E*W]?'_  :G?\WY?]VN_P#OQ-?U\5_(/_P:G?\
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M/\A78_#_ *ZO]-._E>5QUW]P?\!_D*['X?\ 75_IIW\KRMJW^[S_ ,,/_2X
M>CT445YH",2%8J-S $A<@;B!P,G@9/&3P.M?ES\-?VROCOJ/[15O\,O'NA?L
M]^(O!=[X4^(?BSQ';? ?QMJ_Q \:_ F#P/;S3-I'QCUH7LGA<:Y)J$4?AEK'
M2]-TU+G6KM'M9U6W-G/^G]W'/-:W,5K<?8[F6WFCM[OR4N/LL[QLL-QY$A$<
M_D2%9?)D(23;L8A6)K\I_!?[#OQKU+X_>%?BE\4K[]FOP;HW@VV\>V>IZO\
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M1?PS_P!"[H7_ (*-/_\ D>@#=HK"_P"$7\,_]"[H7_@HT_\ ^1Z/^$7\,_\
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MNA?^"C3_ /Y'H_X1?PS_ -"[H7_@HT__ .1Z -VBL+_A%_#/_0NZ%_X*-/\
M_D>C_A%_#/\ T+NA?^"C3_\ Y'H W:*PO^$7\,_]"[H7_@HT_P#^1Z/^$7\,
M_P#0NZ%_X*-/_P#D>@#=HK"_X1?PS_T+NA?^"C3_ /Y'H_X1?PS_ -"[H7_@
MHT__ .1Z -VBL+_A%_#/_0NZ%_X*-/\ _D>C_A%_#/\ T+NA?^"C3_\ Y'H
MW:*PO^$7\,_]"[H7_@HT_P#^1Z/^$7\,_P#0NZ%_X*-/_P#D>@#=HK"_X1?P
MS_T+NA?^"C3_ /Y'H_X1?PS_ -"[H7_@HT__ .1Z -VBL+_A%_#/_0NZ%_X*
M-/\ _D>C_A%_#/\ T+NA?^"C3_\ Y'H W:*PO^$7\,_]"[H7_@HT_P#^1Z/^
M$7\,_P#0NZ%_X*-/_P#D>@#=HK"_X1?PS_T+NA?^"C3_ /Y'H_X1?PS_ -"[
MH7_@HT__ .1Z -VBL+_A%_#/_0NZ%_X*-/\ _D>C_A%_#/\ T+NA?^"C3_\
MY'H W:*PO^$7\,_]"[H7_@HT_P#^1ZL6NA:)8S+<V6CZ59W"!@D]KI]I;S*'
M4JX66&%'4,I*L P#*2#D&@#5HHHH **** "BBB@ K_,7K_3HK_,7K\7\7O\
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M\K:M_N\_\,/_ $N 'H_F>WZ__6H\SV_7_P"M4=%>:!)YGM^O_P!:CS/;]?\
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M4=% $GF>WZ__ %J/,]OU_P#K5'10!)YGM^O_ -:CS/;]?_K5'10!)YGM^O\
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MU1T4 2>9[?K_ /6H\SV_7_ZU1T4 2>9[?K_]:CS/;]?_ *U1T4 2>9[?K_\
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M;/\ D5Y'_P!A^)_]1XG^EO[-/_DN/$S_ +)3*/\ U;R/:_[:O_\ H5]<_P#
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M_8W_ +"\3_Z>F?Z_<-_\D[D'_8ERK_U!H#;>X>:%)9+6:T=P2UO</;M-$0Q
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M75?II_\ *\K:M_N\_P###_TN 'H=%%%>: 4444 %%%% !1110 4444 %%%%
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M-U?]I=2CAX/ UYRJUZ=*4J/+7I4ZE'FFOXB/^& OV[O^C*?VMO\ Q'#XQ_\
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M=W_Q\\83W4;?;Y(/&T5I%X%@GN)O]*D0?#W3?#.IO!/M%MJNKZN53?---/\
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M@-KHWAKPMX'7P_X?TBU:62=K;2]&TG7;33K"!IYI9C#:6T49EEDD*[W8G?\
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M/R? KPWI=W9ZOX'TG2KJYU'PUXUMTUB/1+FVM8K:;]D/L_B/_H*Z)_X3]_\
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ME-J#B\_LV"T%Q'%(&B3U7[/XC_Z"NB?^$_?_ /S34?9_$?\ T%=$_P#"?O\
M_P"::NFA@</AZLJU)252<.23E)RYKN#G.3>LIS<(RDY-KFYYQ495*KGX^9<3
M9KFV!HY=C*E*6%P^(]O0ITZ2IJBH1JTZ&'HPB_9T<-AJ5>I1H4Z4(-4%0H5)
MU*.$P<,/T=%<Y]G\1_\ 05T3_P )^_\ _FFH^S^(_P#H*Z)_X3]__P#--78?
M/G1T5SGV?Q'_ -!71/\ PG[_ /\ FFH^S^(_^@KHG_A/W_\ \TU '1T5SGV?
MQ'_T%=$_\)^__P#FFH^S^(_^@KHG_A/W_P#\TU '1T5SGV?Q'_T%=$_\)^__
M /FFH^S^(_\ H*Z)_P"$_?\ _P TU '1T5SGV?Q'_P!!71/_  G[_P#^::C[
M/XC_ .@KHG_A/W__ ,TU '1T5SGV?Q'_ -!71/\ PG[_ /\ FFH^S^(_^@KH
MG_A/W_\ \TU '1T5SGV?Q'_T%=$_\)^__P#FFH^S^(_^@KHG_A/W_P#\TU '
M1T5SGV?Q'_T%=$_\)^__ /FFH^S^(_\ H*Z)_P"$_?\ _P TU '1T5SGV?Q'
M_P!!71/_  G[_P#^::C[/XC_ .@KHG_A/W__ ,TU '1T5SGV?Q'_ -!71/\
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M)_"]]=[[&XF@^SWUS<VB[_-6!9E61?S\_:[_ &4?^"@_C[X\?L\>+/V9;O\
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MM1$)2_EF$I* 'S[\-OVB_P!K>"Y_9L^,/C/Q]X/\:^!_VK]?\4^'=&^!^D^
M-.T:+X=7,VCZUJ/@9]'\>0O%XAUJ22[TJTAUY_$LDME86MQ?*)KI3%J^G='X
M3_:F^/?@W3-2T/XBW^HMXW\8>"/!%QX>O?CCX/T?X/>&?AM\1"FOM\<-7U.\
M;PYX$34?@/\ "2U_X1>YL_$[CQ./%&MZOH_A/2?B#JVJ>(H1IWK7PB_80U+X
M=>,OAI?>*OC_ .,/B5\,?@1?:[J/P+^%FH^%M T"W\&7VM+>6Z7?B3Q1IES+
M?^.[C2;2^N(])DO+#2?[/F*BS6WTUI]+F].\4_LJMXQT_P =ZQKOCR.^^+'C
M#QSX)\7V'C^Y\*RSZ1X9TCX7^,=.\7?#GX>:;X/?Q1]HB\#Z3<::DGB*QTWQ
M7H^H^*];U+6_$=QJ>GWU[:1:< ?2'PXU.RUCP)X4U#3_ !_8?%2VFT6R0_$;
M3)O#D]CXSN;:,6M]K]NWA&.'PRBWU[!<2/;Z+$EA:R;[6%0(37:UXS\#OA6W
MP<\#S>%Y]=A\2:MJOB[QMXY\1:U::+_PCNG7OB'QWXIU3Q3JW]DZ =4UR31M
M)M;C4S9Z?83ZUJUS';6\;W.HW5P\DK>P;V]?T'^% %*YUO1K*9K>\U?3+2X0
M*6@N;^T@F4. REHI94<!E(925 (((R#5?_A)O#G_ $,&B?\ @UL/_DBM7>WK
M^@_PHWMZ_H/\* ,K_A)O#G_0P:)_X-;#_P"2*_-[_@K7^UGI'[,7[ WQ\\<Z
M!XCTT>.?%/AIOA1\/$L=1MI;\>+OB4)/#2:G8"*23;=^%M!N=>\8Q&0>6?\
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M@_PH RO^$F\.?]#!HG_@UL/_ )(H_P"$F\.?]#!HG_@UL/\ Y(K5WMZ_H/\
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M#_@/\A72^"NNI_2Q_E=5S5W]P?\  ?Y"NA\&]=2^EE_*YK:M_N\_\,/_ $N
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M2/!GBWX>^-?@_P#%C7_!_CG]F#6_B7XIT.]\&636FK^'O$6FW.D:Q\![@#Q
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M .&9_P"0_P#\E[_ZIW_Y6*/^&F_#W_1-OC%_R03_ (7S_P B=8_^&9_Y#_\
MR7O_ *IW_P"5B@#Z<HKYC_X:;\/?]$V^,7_)!/\ A?/_ ")UC_X9G_D/_P#)
M>_\ JG?_ )6*/^&F_#W_ $3;XQ?\D$_X7S_R)UC_ .&9_P"0_P#\E[_ZIW_Y
M6* /IRBOF/\ X:;\/?\ 1-OC%_R03_A?/_(G6/\ X9G_ )#_ /R7O_JG?_E8
MH_X:;\/?]$V^,7_)!/\ A?/_ ")UC_X9G_D/_P#)>_\ JG?_ )6* /IRBOF/
M_AIOP]_T3;XQ?\D$_P"%\_\ (G6/_AF?^0__ ,E[_P"J=_\ E8H_X:;\/?\
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M *IW_P"5B@#Z<HKYC_X:;\/?]$V^,7_)!/\ A?/_ ")UC_X9G_D/_P#)>_\
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M_)!/^%\_\B=8_P#AF?\ D/\ _)>_^J=_^5BC_AIOP]_T3;XQ?\D$_P"%\_\
M(G6/_AF?^0__ ,E[_P"J=_\ E8H ^G**^8_^&F_#W_1-OC%_R03_ (7S_P B
M=8_^&9_Y#_\ R7O_ *IW_P"5BC_AIOP]_P!$V^,7_)!/^%\_\B=8_P#AF?\
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M9).E*EF.68W+L7F>6XW.\3EN*P_/@>,,CK3PE2AE>95Y?;7[-/\ P7<_8?\
MCC?1^#_B9KFN?LK_ !2@N#IVJ^#_ (Z6JZ'H%OJT4IAN[2V^(<(_X1NUBM9"
ML4A\:_\ "#ZBTWF(FE%86>OV3TC6-(\0:78:YH&J:=KFBZK:PWVEZQI%];:E
MI>I65P@DM[RPU"REGM+RUGC(>&XMYI(94(9'92#7\U_Q]_9]L/A28/ O_!1#
M]G_P]^UC\ 9FMM \'_M.>'M.GTSXS^ ;':EMI.FR_$#2[O3?&EO;V<:0"#P;
MXH\2/ITSPI::%KVNZ9I@T=N6\#_\$POCC\*=#?XU?\$:_P#@H9KUKX,U.ZFU
M%?@Q\5=1BU7P;<WN%N;G2]5QHNI>&?[?@BF%G:Z7XY^$UAKEC'+"U_XI@>9[
M]O@?;9S@OX^'I9K17_+[!VPV+25KRGA*LW1JR?:C6B]/@/Z:_L_PZXCURS-<
M=P/F53;+^(5/-^'YU):1IX?/<#0688*DFG>68Y=7C%-<V)?3^HJBOYM]'_X+
M+?M9_LC:CI_@[_@J-^Q!XV\#637<6EQ_';X+6D6I^"=3F,BP1R?8;G6=6\%:
MM<LA6^U)O#/Q/2\CC8BT\&QO+!:#]D_V:_VZ_P!DK]KK3X+KX _''P3XWU22
MV^TW/@QK]M ^(6F1I$TD[:EX!\11:5XMMH+?RYD;4!I,FE3F":2SO[F!/-/5
MA<VP&+G[*%;V6)6DL)B8RP^*B^SH55&<K=7!3C_>/$SO@3B;(<.L?B<O^N91
M.[I9YE%:CF^2UH+:<<QP$Z]"DI7O&&)E0K=Z:LSZUHI,CU'YBC(]1^8KTCY
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MU0/\5_V/O'?B2X\"BX$L8U_X3:EX@,-_<Z)]ID>YN=#TOQ/J5GXCTN><1_\
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M^5]'_L^_\%[OV1?B+KH^'?[0VB^//V.?BW9SQZ=K7AGXR:3=GPG8ZP_+Z?\
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MY9- \-6O@TWJQ?VA&!_3A7;Q)DM3A[/,RR>I5A76#KKZOB:;C*GB\%7IPQ.
MQM-Q;BZ>,P5:AB8--KEJJS/SMPK025:C4HU+SC*G5A*G*-2E4G1K0<9I-2I5
MJ=2E-;QJ0E"5I1:11117AB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBOP?_P""['_!0_5?V1/V>[#X9? SXJZ/
MX3_:8^*VOZ58I8Z5(+OQ]X.^$DMEKTWB3QSI"QPW5MX:OK_5M.TCPGH>KZH+
M:_DCU?7-2\(_\3CP^^J:-[G#G#^/XHSK 9%EL4\5CZ\:49SC4='#T_BJXG$.
ME"I.%"A34JE62@VHQLDVTG%2I&E"4Y;15^EWV2O;5O1>9^\%%?S[_P#!O?\
MM#_MA_M"? #XM:I^TSK'BKQYX&\.^,- M/@I\5O'+7%]XI\627\?B5_B1H$O
MB&]E-]XFT;P?J%GX8.F:G>I<SVEWX@U?0DU6YM=(MM-T7^@BJXGR#$<+9]F6
M08K$X7%U\MKQHU,1@YNIAZCG1IUERN48RC4A&JJ=>E)*5&O&I1E>5-MJE456
MG&HDTI*Z4E9[M?=I=/JK,****\$T"BBB@ HHHH **** "BBB@ HHHH ****
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MT[PSI^G:'?:WY-O*BC3[]/#7A_P#?W:1@.EWXV\01/AIYS* ?E9-^V[^V/\
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MEMXF\/7FG:1I*7VI7]OJEI):V4ZR8K@_^")?[4_[.'[%GP$_;B^"?[8'Q/\
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MVH]'@CAFM##XB\;WGQ&\#:O9((,:!?:7/YP33X[&?],/VC?A)X=^ G_!6O\
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MZ^\<ZEK7C76]0T;2O",/B#4-//B+5]6L?$N@W>F:1I/VO4K^#5;.2UM95DR
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MK7X5_P#!5SXY:U^UO^Q9_P $HOVU_!FNR?#GX5:9\4;"Z^,FO:%X'/Q%\*_
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M_P"$*_X1WXE>$M>_X63_ ,)'_P *Z_L758=4_P"$^_X0[S?^$N_X0K[#Y_\
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M  E/_"+>1/\ \)'_ &%]O_L/R9?[3^R^6^#1?CW\&/$G_"%?\([\2O"6O?\
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M_P"%D_\ "1_\*Z_L758=4_X3[_A#O-_X2[_A"OL/G_\ "4_\(MY$_P#PD?\
M87V_^P_)E_M/[+Y;XT]%^$?PG\-_\(5_PCOPN^'.@_\ "MO^$C_X5U_8O@GP
MUI?_  @/_"8^;_PEW_"%?8=-@_X1;_A*?/G_ .$C_L+[!_;GG2_VG]J\Q\FB
M_"/X3^&_^$*_X1WX7?#G0?\ A6W_  D?_"NO[%\$^&M+_P"$!_X3'S?^$N_X
M0K[#IL'_  BW_"4^?/\ \)'_ &%]@_MSSI?[3^U>8^2/USW>;ZM]CGY?:_\
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M#G0?^%;?\)'_ ,*Z_L7P3X:TO_A ?^$Q\W_A+O\ A"OL.FP?\(M_PE/GS_\
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MT7X1_"?PW_PA7_"._"[X<Z#_ ,*V_P"$C_X5U_8O@GPUI?\ P@/_  F/F_\
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M_4/S?\O H?ZZ?[-]9_U7_P"8+ZW[#^UO^J;_ +1^K>T_[N_ZE[7_ *IOV_\
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M_5-^W_YFAF:+\>_@QXD_X0K_ (1WXE>$M>_X63_PD?\ PKK^Q=5AU3_A/O\
MA#O-_P"$N_X0K[#Y_P#PE/\ PBWD3_\ "1_V%]O_ +#\F7^T_LOEO@T7X]_!
MCQ)_PA7_  COQ*\):]_PLG_A(_\ A77]BZK#JG_"??\ "'>;_P )=_PA7V'S
M_P#A*?\ A%O(G_X2/^POM_\ 8?DR_P!I_9?+?%[2_A5\(?"</A"XT;X9_#7P
MS;_"^+Q/-X!GTOP9X8T:'X=P^+%F?QG+X0EM-.MD\(Q>)4EN'\3R:*VGKK*R
MS-JIN0\A/\X?[3O[9^L?M1?%GPY^P;_P1[^%7P[E\3_#YO%6EZ]^UAX9\(>'
MM#\$?L^:#XQFN+'XCS_!CQ5I6C26W@;3_$/GWMKXJ^)/AR..]\57,D^G?#S3
MO$FMWVE:\OT/#?#.>\2XJ='"_4,/A,)3AB<VS7%U*F'RS*<&GAU6Q6,Q,URT
MXV6,5"DN:OB)K#PI4YR5:V<*G&5-8;ZW_JPW)X)8F&&_M9RF_P#C&_[16%53
M_N[_ *FZNB_XQKZPU_PIGUK^W3_P5]M/"UW8_LZ?\$]=!_X:H_:P\>_8=+TF
M[\":=+XS\ ?"[^W8)IK'6-=U"P631]=\1M90W.HZ=H4E]#H&C65K<^(_&^I6
MNDZ;_8VM\3_P3._88^"'PE\4^%_VL/VFOCAX2_:A_;A_:$N?$WB'PKXSGUZ/
MQMH>FW_AZ-_^$TL?@S*8IAXY\4>#X()-.\7>,="@FA\(6%E_PCWAJQ\-Z':W
MUSKOVU^P#_P3%^!?["WA2SOK>VA^+'Q^U/[-J'C7X^^-=.AU#Q?<ZLFC7>AO
M8^"I=0:_NO!'A>UTK4M3TBVL-,O6U/4=,OIX?$.K:LK0Q6WW1HOPC^$_AO\
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M?]A?8/[<\Z7^T_M7F/DC]<]WF^K?8Y^7VO\ U#^TY;_]S?)?_J'YO^7@4/\
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M^$I\^?\ X2/^POL']N>=+_:?VKS'R1^N>[S?5OL<_+[7_J']IRW_ .YODO\
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M %3?]H_5O:?]W?\ 4O:_]4W[?_F:&9HOQ[^#'B3_ (0K_A'?B5X2U[_A9/\
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M_A"OL/G_ /"4_P#"+>1/_P )'_87V_\ L/R9?[3^R^6^#1?CW\&/$G_"%?\
M"._$KPEKW_"R?^$C_P"%=?V+JL.J?\)]_P (=YO_  EW_"%?8?/_ .$I_P"$
M6\B?_A(_["^W_P!A^3+_ &G]E\M\:>B_"/X3^&_^$*_X1WX7?#G0?^%;?\)'
M_P *Z_L7P3X:TO\ X0'_ (3'S?\ A+O^$*^PZ;!_PBW_  E/GS_\)'_87V#^
MW/.E_M/[5YCY-%^$?PG\-_\ "%?\([\+OASH/_"MO^$C_P"%=?V+X)\-:7_P
M@/\ PF/F_P#"7?\ "%?8=-@_X1;_ (2GSY_^$C_L+[!_;GG2_P!I_:O,?)'Z
MY[O-]6^QS\OM?^H?VG+?_N;Y+_\ 4/S?\O H?ZZ?[-]9_P!5_P#F"^M^P_M;
M_JF_[1^K>T_[N_ZE[7_JF_;_ /,T,S1?CW\&/$G_  A7_"._$KPEKW_"R?\
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MZ^&W^+'PQ\$_$5O#ZZJ;0ZHNB-XOT/6#I*ZD;"Q-^+ VXO#96AN!(;:'9/\
M"K]G[X"_ F'5+?X(?!'X1?!NWUR2*76H/A5\-O!GP\AU>6!0L,FJ1>$=%TA-
M0DA4!8GNUF:-0 A XKUC>?0?K_C1O/H/U_QH \:\4?LV?LZ>-_B!I?Q9\:?
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MT^QF:4R6D#1^A;SZ#]?\:-Y]!^O^- 'F_BCX*?!KQQXV\(?$OQK\)/AEXO\
MB/\ #U@_@'X@>*/ 7A7Q!XV\#N+@W8?PAXKU;2KO7?#3"[)N@VBW]D1<$S9\
MPEJF\0?!SX1>+?'?A+XH^*OA7\./$WQ,\ Q7$'@3XB^(/ _AC6?'?@J"[\_[
M5#X2\7:EI=SX@\.17/VJY^T1Z/J%FDWVB?S WG2;O0MY]!^O^-&\^@_7_&@#
MR#XJ_LZ?L^?'9]*D^-_P)^#7QDDT%9UT-_BK\,/!/Q#?1ENBIN5TIO%VAZPV
MG+<%$,XLS")2J^9NVC'9)\.?A['X('PSC\">#4^&XTDZ /A\GA?1%\$#0F!5
MM%'A06(T'^R64D'3OL'V,@D&'!-=;O/H/U_QHWGT'Z_XT >0?"K]G7]GWX$M
MJC_!#X%?!OX-OKBQ+K;_  J^&/@GX>-K"P$&%=4;PCH>CG4%A*J8A=F81E04
M (%+XG_9U_9]\;?$/0?B[XS^!7P;\7?%?PJ^ER>&/B?XG^&/@G7_ (A^')-#
MNGOM%?0?&NJZ'=^)-'?2+V62\TMM/U.W;3[J1[BT,,KLY]>WGT'Z_P"-&\^@
M_7_&@#(\3>&/#7C7P]K/A'QEX>T/Q;X4\1Z;=Z/XA\,>)M)L->\/:]I%_$T%
M]I6LZ+JMO=Z;JFFWD#O#=V-];3VMQ$[1S1.C%3S?AWX3?"OP?\/_ /A4WA+X
M:?#_ ,+_  K_ +,U31/^%9^'?!OAS1/A_P#V-KANVUO2/^$,TS3;7PY_9FL&
M_OCJEA_9OV34#>W9NXIC<3;^[WGT'Z_XT;SZ#]?\: /-?"_P1^#'@?X>W7PC
M\%?"+X8>$/A3>Q:K;WOPQ\+^ ?"GA_X>W<&NO))K<-UX+TG2;3PW<1:S)--)
MJL<NFNFHO+(UVLS.Q/-?##]E[]F?X):Q?>(O@Q^SM\"_A'X@U.V-GJ6N_##X
M2> / .L:C9ES(;6^U/PIX?TF]N[8R,TA@N)Y(BY+;-Q)KV_>?0?K_C1O/H/U
M_P : /$?'7[+_P"S3\4/%MGX_P#B7^SQ\#/B)X[T]((K#QKXZ^$G@'Q;XML8
M[952VCL_$FO^']0UBV2W556!(;U%B55$84  >C>-O '@/XE^&-0\$_$?P3X1
M^('@S5EA35/"/C;PWHWBOPQJ26TJ3VZ:AH.NV5_I5XMO/%'-"MQ:2"*6-)(P
MKHK#J-Y]!^O^-&\^@_7_ !H \=^&_P"SA^SS\'--U_1OA%\!O@Q\*]'\5PO;
M^*=)^&_PN\#^!]-\2V\D#6SP:_8^&-#TNUUB%[9WMWBU&*Y1H':(J8V*FWX?
M^ 'P'\)_#75O@SX6^"?PC\-?!_7X=6MM=^%'A_X;^#=&^&NM6^OIY>NP:MX%
MT[1K;POJ4.M1_N]6BO-+F34D^6\69>*]7WGT'Z_XT;SZ#]?\: .4\)_#SP!X
M"\&Z?\.? O@;P?X+^'NDV%UI>E>!/"?AG1?#G@W3-,O9;B>]T[3_  QH]E9Z
M)96%W/>7<UU:6UC';W$MU<22QN\\I;DOA5^S]\!O@2FNQ_!#X)?"+X-Q^*);
M*X\2I\*OAMX-^'B>(I]-%TNG3:ZOA'1='75Y;!;Z]%E)J N'M1>70@:,7$V_
MUC>?0?K_ (T;SZ#]?\: *VIZ9INM:;J&C:SI]CJVD:M8W>F:KI6IVD%_INIZ
M;?P26M]I^H6-U'+:WMC>VLLMM=VES%)!<0220S1O&[*?-/A3\!/@7\![/6-.
M^!WP7^$WP:T_Q#<VM[K]C\*?ASX/^'=GKEY8Q2P65WK%KX0T;1X-3N;.">:&
MUGO4GEMXII8XG1)'!]4WGT'Z_P"-&\^@_7_&@#SUO@[\(G^)D?QI?X6?#A_C
M'#HA\,Q?%EO _AEOB9%X;*NA\/Q^/#I9\4IHA2613I2ZJ+ K(Z_9\.P/%:-^
MRG^R[X<^(,GQ:\/?LV_ /0?BK+>SZE+\3=&^#WP\TOX@R:C=8^TW\GC.Q\.P
M>(WO;G \^Z;4C/-@>9(V!7N^\^@_7_&C>?0?K_C0!YZWP=^$3_$R/XTO\+/A
MP_QCAT0^&8OBRW@?PRWQ,B\-E70^'X_'ATL^*4T0I+(ITI=5%@5D=?L^'8'#
M\3_LZ_L^^-OB'H/Q=\9_ KX-^+OBOX5?2Y/#'Q/\3_#'P3K_ ,0_#DFAW3WV
MBOH/C75=#N_$FCOI%[+)>:6VGZG;MI]U(]Q:&&5V<^O;SZ#]?\:-Y]!^O^-
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M "%;/A7K?_2S_E<5M6_W>?\ AA_Z7 #KZ***\T HHHH **** "BBB@ HHHH
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M"^C01E$A?Q!HFAZ=\/O"GA2SMH]2C\5>#]8TG2KO77NM4.IZ!K5WXH$NM?W
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MA5Q6<X'+JV64?]JS"M4IM3?]K?F>WZ__ %J/,]OU_P#K5^1OP>_X+,?LI_$
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M_7_ZU'F>WZ__ %JCHH D\SV_7_ZU'F>WZ_\ UJCHH D\SV_7_P"M1YGM^O\
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MMJS_ .>.K?\ @@UW_P"5U=9X9M>9[?K_ /6H\SV_7_ZU8O\ ;5G_ ,\=6_\
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M2_S\U]Y]J>9[?K_]:CS/;]?_ *U?%?\ P\<_8 _Z/5_9;_\ #Z?#?_YHJ/\
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M]I3X ?!#^P_^%T?&'X>_"'_A)_[3_P"$:_X6AXGTSP!_PD/]B_V?_;/]A_\
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M,/B/_P!B'XO_ /4>U&N\K@?BFRGX8_$89_YD/Q?V/_0OZC[5WF]?7]#_ (4
M.HIN]?7]#_A1O7U_0_X4 .HIN]?7]#_A1O7U_0_X4 .HIN]?7]#_ (4;U]?T
M/^% ' ?%#X3_  S^-?@W5/AY\7/ ?A3XD>"-951J/ACQEHEAKVD3RQJZP7:6
MM_#,MKJ-F9'DL-3M#!J&GSD7%C<V\ZK(OX#_ !-_X(S_ !O_ &6?%^K?'/\
MX)(_M$>)/@SXCE<WVL?L\^/M>GUCX<^+H;?S)5T:QUG7(M8T_4(PBBUTG1_B
M?I'B"..[N6O!X^\.K#'+'_1OO7U_0_X4;U]?T/\ A7TN0<6YYPY[6EE^*C4P
M&*TQV3X^E3Q^3X^#LI1Q>78E3P]1R24?;1C#$07\.M!ZF=2E3J6<E[R^&<6X
MSCZ25FOR\C^>[X&_\%P+SX<>-[;]G_\ X*A_ SQ-^R+\8H62UC\?P:%K-[\(
M_$V)$MEU8PK)K6K:+IEW<N([;7_#VH^/_!,P6XOKKQ+HED@C7]4OV@OV<OV6
M_P#@HG\"8/#/CN'PO\4_AWXBM)M7\ _$GP/K6D:IJ/AO4;F$P0>+OAQXWTLZ
MG:6U[$459O)>^T;5HH3IFO:=JFG-/8OZU\<OV?/@?^TMX)N_AU\>/AEX3^*'
MA"Z$K)IGB?3%N+C3+F5/*;4?#VL6[6^N>&-86/Y(M:\.ZEI>K0*2L-[&"<_@
M=XM_X)0_MC_L'^)=6^+?_!)G]H?7+CP[/=OJ_B']E'XOZM9:AX=\2J'1I=/T
MF^U<6G@W7IY( -/L;GQ+#X/\7Z1I<<OV+XF7.I3AG^AJX+@/C.G.E2E1X(SF
MO%QJ8#,)U<9P?CYRWC1QLU5QV1N<G*3AC(XO TDH0AB*25UM@L=F648O#X_
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M#X.R.JU.GB>)LNCB\1CZ::<HY+DN!GEV;YA-Q:E&?-##2B^9XN,=5]9EG$7
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M@3_R>)\2?^S:?&/_ *M'X-U^'M?N#_P0*('[8GQ)S_T;3XQ_]6C\&ZY^#/\
MDJ<D_P"PV'_I$SU/I#?\F4\1_P#LG:W_ *D8<_KOHIN]?7]#_A1O7U_0_P"%
M?U2?XBCJ^2/V_O\ DQ#]M?\ [-(_:0_]4YXSKZUWKZ_H?\*^2/V_F7_AA#]M
M?G_FTC]I#L?^B.>,_:N?%_[IBO\ L'K?^FY'K\/_ /(^R3_L;Y;_ .IM$_S
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MU8L9X_\ A(/!VNJ97!V,LHE@"@%(4?+G]E**X*G"G#57XLBRM7_Y]X.C1_\
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MA%!;6FO:@_AVX\1^#H[K58XQ#<V]A-?276G6FGIK#R-#%86?U,OP!_X+<^'
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M?5+WI=WV9_9W@%BM*/%/BKE4FOBQ_!_"^94HO6SYL#Q;A:DTO=;7L8/>*O\
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M_P#Q(LW_ /FPS]A0_P"?-+_P7#_(_(W_ (<2_P#!*G_HUC_S-_[1W_SWJ/\
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MZ/\ @F#_ ,F-? __ +J7_P"K?\?U_(O7]='_  3!_P"3&O@?_P!U+_\ 5O\
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MZ_[8?^E,-<C;=O\ /]ZNNUS_ )!=U_VP_P#2F&N1MNW^?[U>AA?X3_Z^2_\
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M% %'^VK+_GEJG_@CUO\ ^5]']M67_/+5/_!'K?\ \KZO44 4?[:LO^>6J?\
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MVK+_ )Y:I_X(];_^5]']M67_ #RU3_P1ZW_\KZO44 4?[:LO^>6J?^"/6_\
MY7T?VU9?\\M4_P#!'K?_ ,KZO44 4?[:LO\ GEJG_@CUO_Y7T?VU9?\ /+5/
M_!'K?_ROJ]10!1_MJR_YY:I_X(];_P#E?1_;5E_SRU3_ ,$>M_\ ROJ]10!1
M_MJR_P">6J?^"/6__E?1_;5E_P \M4_\$>M__*^KU% %'^VK+_GEJG_@CUO_
M .5]']M67_/+5/\ P1ZW_P#*^KU% %'^VK+_ )Y:I_X(];_^5]']M67_ #RU
M3_P1ZW_\KZO44 4?[:LO^>6J?^"/6_\ Y7T?VU9?\\M4_P#!'K?_ ,KZO44
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M,5!17]4G^(I/D>H_,5\D_M^$?\,(_MK<C_DTG]H_N/\ HCOC*OJ^ODK]OO\
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MZKINGZG#%/!#J-C:7\4-TBQ74,=Y!'<)%<QJ\BQSQK($F19)%20,H=@ QO4
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MF'!!_P"2T]/^Z35^!]?O9_P6^_YMB_[K3_[R:OP3K^NO"_\ Y(;(_P#NI_\
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MK_H(:7_X)[O_ .7E'DZU_P!!#2__  3W?_R\K4HH R_)UK_H(:7_ .">[_\
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M_H%^S?\ ^3X<5?\ 9J<\_P#6OX&/N+R=:_Z"&E_^">[_ /EY1Y.M?]!#2_\
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METVYT;Q'HVE:_H]XACO-*UO3K/5=-NXR""ES8WT,]K.A!(*RQ.I!(QS7P?\
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MS1D^I_,T 3T5!D^I_,T9/J?S- $]%09/J?S-&3ZG\S0!^#7_  6^_P";8O\
MNM/_ +R:OP3K]Z?^"W9)_P"&9,DG_DM'7_ND]?@M7]=>%_\ R0V1_P#=3_\
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M\_?TW?\ E)_Q._[LO_UWO"84445]\?RF%%%% !7];G_!,;_DQWX(_P#=2?\
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MALII33C4S*M3A@X23C*LGH?"/_#H']D?_HJ7QG_\+?X9_P#SLZ/^'0/[(_\
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M/_ ^U_\ CM:61ZC\Q1D>H_,4 9O]M:-_T%M,_P# ^U_^.T?VUHW_ $%M,_\
M ^U_^.UI9'J/S%&1ZC\Q0!F_VUHW_06TS_P/M?\ X[1_;6C?]!;3/_ ^U_\
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MO[>O/&$NK6VMQ^)U\7#61XML]=L-2LK";1M4L=;MKS0HM.TVST66PLM.LK>
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M= 3Q7<_;KK_H#:E_W]T?_P"6M<O\4?\ DF?Q$_[$7Q=_ZC^H5W5 &;]NNO\
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M32&WM[>%$BAAB1(XHT6.-550!=ANIY9 CZ;>VRD$F6:33FC7 R 1;W\\N6/
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MI!_*2MJW^[S_ ,,/_2X ;=%%%>: 4444 %%%% !1110 4444 %%%% !1110
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MU)RC[>K*<Y5:UO:5)3FYR;DV]*BLWS=8_P"?'3?_  :W7_RFH\W6/^?'3?\
MP:W7_P IJU.,TJ*S?-UC_GQTW_P:W7_RFH\W6/\ GQTW_P &MU_\IJ -*BLW
MS=8_Y\=-_P#!K=?_ "FH\W6/^?'3?_!K=?\ RFH TJ*S?-UC_GQTW_P:W7_R
MFH\W6/\ GQTW_P &MU_\IJ -*BLWS=8_Y\=-_P#!K=?_ "FH\W6/^?'3?_!K
M=?\ RFH TJ*S?-UC_GQTW_P:W7_RFH\W6/\ GQTW_P &MU_\IJ -*BLWS=8_
MY\=-_P#!K=?_ "FH\W6/^?'3?_!K=?\ RFH TJ*S?-UC_GQTW_P:W7_RFH\W
M6/\ GQTW_P &MU_\IJ -*BLWS=8_Y\=-_P#!K=?_ "FH\W6/^?'3?_!K=?\
MRFH TJ*S?-UC_GQTW_P:W7_RFH\W6/\ GQTW_P &MU_\IJ -*BLWS=8_Y\=-
M_P#!K=?_ "FH\W6/^?'3?_!K=?\ RFH TJ*S?-UC_GQTW_P:W7_RFH\W6/\
MGQTW_P &MU_\IJ -*BLWS=8_Y\=-_P#!K=?_ "FH\W6/^?'3?_!K=?\ RFH
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MDN1E0/8?R&/\:71>'O!Z&#_VK6M1WP]3R45_Y4A^@&[1117G %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <+\4?\ DF?Q$_[$7Q=_ZC^H
M5W5<+\4?^29_$3_L1?%W_J/ZA7=4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"(YP__ /.P^0_^&9?BI_T??^UA_P"$E^P]_P#09T?\,R_%3_H^_P#:P_\
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M5>_9N_;0_9B_:[M_$L_[/'Q7TKXAOX/FM(O$FGKHOBKPKK>EI?HS65Y+X?\
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MG[&5&KB(U?8YS[.5"A"%6M74^3E=&C3J4ZE6HGR4X3A.<E&46]?]8Z/-R_\
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MB_\ :[\0:D?%?Q.^+_A"#X=>)/B+JWCWQROPZOO$6A^ K*&SN/"OA/5-)O\
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ML$M[:?V2T5Z6&\5ZT(5/KV0X7'U,7C,\Q&8R>+G0I8S"YQ.MB896J2P]25'
MX?,*L,77@JU2IC?J^'IRJ4)0=:6$\ABVO98J=*-.GA844J:E*E/#J$'7YG-*
M56=&+IP?+%4N>;M--17\GG[</[,^H?L@_#;_ ()G?!G6?B/<?"GX*_#OQ!XW
M\;_&#]H&#X57WQQ\':!^T1<IHFOV/B7Q)\.9;.2W\3VLNJRZKHO@O2]:MY7N
M_#LFHYTR\72=2M9OK_X#?#VW\0_LX_M]?MA_!/XQ?&C]J3]I'XJ?"7Q1\/\
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M/VTI3G-4E:$7.3DHIV7.X1:@ZC2=1Q<VE>R****\LW"OB;]D(G_A5GC?D_\
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MW?CVVUG]H#QKX:L8+>W\+0VO@_3?",>L^(]9CL/UOT/X;?#KPQX@UGQ9X:\
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M_P &ES_\IZT:9++%!%)--)'###&\LLLKK'%%%&I>2221R$2-$!9W8A54%F(
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MUK3]0\,Z9IVDZEY">%[VYTBU7Q-%=6\=['X;U66/2F /V/\ -U;_ )\M._\
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MO)M9U'7_  3X$^'MF)UT[1-,32='2V\03V\FIZD^NS:-HD<5M-K8U+XI\&_
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MSY;F;]I6]OEV(]WVU.E[#$KE7L,50YI\_P"2_P#PYM_9B_Z'KX\?^%/\/O\
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MI5HKPS]./Y9/'?\ P3;_ &R-$^!G[.?ASQM^S=\.?VS?"=]\6?VB/C]^TO\
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MXO\ _P!'?1_Q#KB[_H60_P#"_+__ )J#ZOE?_1291_X3<0__ #B/LRBOC/\
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MN_Z%D/\ POR__P":@^KY7_T4F4?^$W$/_P XC[,HKXS_ +(_;F_Z.!_9/_\
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M0==B\BZA^PZL^DZ7KBVF^XBBCN<Z7K.FW7GV;W%L/M/D&87$-Q#%LFW !)X
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MNY[&=DCNHX)3&+FVF6*;R_*N(U6XMWEMY8I77U6/\[^Y>5_Z\U\PZO[1;_\
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M4:?X0OM=T36/$&GZ/HGBSP]X;UO4K6#Q5J_A'4M=MM 611?F.:6WAF/JU/\
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M(M_H7B&RTO6]*N0/]99ZII]G>1'B6!#Q2^K0O;VCNMUI?IT_K=?,.J^T6_\
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M1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\
MQ59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__
M #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_
M]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:
MAK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5
M(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU
M1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\
MQ59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__
M #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_
M]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:
MAK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5
M(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU
M1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\
MQ59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__
M #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_
M]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:
MAK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5
M(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU
M1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\
MQ59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__
M #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_
M]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:
MAK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5
M(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU
M1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\
MQ59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__
M #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_
M]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:
MAK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU1]F]O\_]]4?5
M(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\ Q59/V;V_S_WU
M1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__ #WA_P"_J?\
MQ59/V;V_S_WU1]F]O\_]]4?5(_SR^Y?UW_I:AK?:+?\ Y[P_]_4_^*H^T6__
M #WA_P"_J?\ Q59/V;V_S_WU2BV!//'XX_J1_*CZI'^>7W+^N_\ 2U#5^T6_
M_/>'_OZG_P 52^?!_P ]HO\ OXG^-9GV1/7_ ,>'^-/%L.@Q^!']&J?J]/\
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M/')K6FBE'6UULF].EFEK?RZ.^VVB"A\&_@[8:/XDUO78?"^D3>(/AWX \/\
MPG\%^,=>\"7WA*\76](E\8WWBA?"<FNZ0NM6GPY@?Q%HOAWPQ=Z+/JNC3>'-
M,.GZ5J&K6MHT]SC1?LK>*$TF_P##,OB+P]/X<N-#\$LMJYU0/=^.?^$6\.?#
MKXB^+=0@:"2U(3P)H5Z/!VGHLD<_B'Q-J>IZH^F7MEINJ1X-I\9/BOXQM_ _
MCKP3XU\#74ME\)OCQXG\41WGA+4I? VOOX#\3>!8H-/T?2/!7QS\:>&KG5HU
MFFTJ#Q[HWQ1\?:)IIFUJ&WTZYNY[_1]-W=#_ &D/B/K[^('T27X6^)-?MM ^
M(WB"3X.Z)8:N_P 1/AG#X#U%&TNS^(VHGQS.MW<>.M,A>PT:5O!O@BV@UK6-
M(N].D\3:-!/+='-'9]/Q32OHGTT3W>BWW I^)?V9/B'KOQ-^*_CV35-#N;_7
M?#WB'3_AKX@;Q?%H>JZ(FJZ)8:%:>$[E="^#D/C[P[X<@TZ37(FN++XU^*M!
MM=;O#XULOALGB2YC?2K&@?LT>-=&T_QY<:-IGPJ^'=]KWAGQKIOA3PC\.K_5
M])\*>'+OQ7IO@73DL$UJQ\'Z#J=DL4'A/5#-XKTC0[:_CU3Q3JWB"T\.174K
M69TE_:<\9ZEHGQ"U70] \+SKX9\!^,_C!X:NYX=<?2]:^&$UDB_""_OIA>VT
MEMJ?C/4;?7KF^-L)H5TGPW>-9VL1OK.['<^(?%OQ%@^$/[1=KXNUKPTGBOP#
MX9UG['XM\#:%K'ANQ@M-5^'5CXD@OX]$UKQ-XPO+;4O#\FHW2F]&N3V]\MG;
MWPL-.)EM%$XZV;UN][;ZZ;?Y=^@'*Z-^SA.^F:MI\O@?X4_#'1/$EY\-[36?
M 7PSU":Z\+Q^'O!GBW5O%&OB&]C^'O@)[_5/&)GTRPU0SZ#8B2R@:VEOI/LD
M,]SPWA/]D?Q#HOQ6\'^(M3A\(2?#_P *:KJFN>'/#^@:WI.DP?#F>?Q3XM\4
MV6D^"]!NO@IJ6M6VGS7>J:%!K,G@_P"*OPJL=8T^S31_$'A[Q'I6D1VVMW_&
M7[1VL^ ?$_C7PEHOBWX06NG_  ZU-?#%E\-T\.ZAK_Q/C\)VGPFTSQDGQ-FL
MX_BQX5MT\)>&[N[:'5;&[T31M'FT;2[AI_'_ (>GF\ZTS?#'[1WQ$\8^$_"O
MBB;X@?"CP=I5O\>E^'7B'Q5>>&O#>J^$O$&@ZA\-CXBTFUCN?!?[1WQ&\-Z+
M>W'B:Z3P]!>Z9\5=6GGUHZ0EQ::=)#J?AK53FCI>]UII:VC3\E:^O1;O<#V'
MQ_\ #GQ5XB^('BJZT&+3K:];0/@[XN\':KK%KJ$GAV_\3_"SQQXOU>^\*>);
MZQBF;3K+5+76M*BM;V!+[4=.;4+OQ!I^C:K+X>>RN>2MOV?/&?BN2S/Q(M?#
M+:1'\4]2\;/X/U/XG^/_ (YZ-IVFW'PQUCPU:#3K_P")?AG0Y)7A\<:E#XFM
M/"?]DZ?X:T%+.&\TBX6^@MK>'S8_M5>.O#\7P(T*TTSPG9IXL^%WPC\3WL7B
M[7_#$5QXONO&F;;5M.\*>)OBI^T9X+\:7-WX?AM=[W%CX4^-VNZOJ&H65IJL
MEIJ-Q!)J?5WGQI^-P^&2>*M9\7?"3P;=:EX3^!OQ1B\1P^!/$%QH'@[PEX]\
M;)HWBG1_$]MK7Q)"ZS;Z5I@2]N_%EOJ/A-$TU=5A32M+NC9Z]8'/%J[;[_\
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M\7?V5?B+\0/BAXX\8:-'\,=)LO$'ASQAHFGZXK>&=*\17\/B+X0ZWX#L]/\
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MX4ULFUKMH]HQMO?I9+?S MV?[+_C*\E\,Z=K&F>'-)L3K&FZQXI\1Z!\=?C
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MFTFWUB]UO2;;6="N$\1ZI]NMDNM?M(Y[WP\MM 0JYWC?X^^,_"5GX)\7:/\
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M(?B1J7B:_6YO-.&I1#5[O2%\1".ZE;4+%M;GM)+ISIQO#%;BFNO;MKT_6_X
M0:;^T-\/8-,UG4/B7<1_ B;0M;TW0+_3_C)XG^'7AYS>ZSH<7B+1OL>M:%XZ
M\3>$[XZGI+S75O9VOB*75(ELKS[9I]JL2L^M9?'KX1ZU=:WIOA7QYX1\7ZQX
M;U?PAI&N:1H/BOPM]MTX^-M0T#3]#U%GU?7M*L;K3)W\2:<T,^GWEW+JEUYV
M@:!;ZQXJ$.@3XOC7]G6SG\ Z/X"^#&I:!\#=,T_Q$->U*R\&:!XJ\*:'KIDT
MJZT^Z2\MO@O\2/@EXGM[N>X>PU!KJT\9QVMS)IT-OK&FZO#Y MN1T?\ 97U?
M3/!EY\/9/B7:W'A6ZN?@;JJLG@V^3Q)!KOP=D^'4-[=KKUUXZOXY['Q5I?PZ
ML;>"TN]+GU'0-1OI]4GUKQ"D?V"8Y_G\O2WZW=NFP'J<OQW^!D-EK6IS?&?X
M31:=X;U5=#\0ZA+\1/",=EH.MO\ :MNCZU=MK0@TO56^PWNW3[Z2"[/V.ZQ"
M?L\NR#3_ !S\%M;^*=MHVF^,O!^J_%7_ (0.RU'2]*M_$,%[J\O@+Q#<-J\5
M_H%B+V2TN+#5CIUIJ>I7>C127-SI]OX=O-6D;33X?D;Q?X6_L=7/@#Q5X)\1
M:W\0H/&"?#^\T_\ X1\7]G\7-3U9]'TKPAXU\)V&F7=U\2/C[\3_  [IDEN/
M%_\ :D<O@?PCX+TZ&YM;VUMM&M['4+:#2/9?A_\ !G5_A[K_ (>OM-\7Z7=>
M']/^&VA_#_7=$G\(SQ7^IR^&-4\0ZGH.LZ-K,'BM;;P_%"WB;4+?4=)NM#\0
M+>Q):FUO]->)S*<^U_GOY>GGWM;9[@9VJ_'CPYIFK^-/#Z>$_B#J.N>$+GPC
MI]II=OX<AL+OQMJOC75->T71;#P<OB#5M%2XA.I>&]6CN?$'B!_#WA)+&W.N
M0^(+CP^'U5.>N?VE-&CTMKFR^&/Q6UC7=,C\57/C3P7IFF^"V\2?#ZP\%WL=
MCKU]XFN+WQ[9>%;Y%DFMYM)LO!GB;Q;J_B.SG^U^'=-U6WM[V2U3Q-\!/B9X
MA^(7B;QY'\5? ^FO=OX)N?!EC'\(-8O+GPW??#S6_$&I>'GUW4+KXOM;^)[2
M_P!-\7>)M"\4P:;I7A"\U&VO;.ZT+4O"]W8R/>P/^SKX\M9+[6]#^+NCZ=XU
M\967BK3/B?KMW\,Y=2TO6['Q1>VES"W@?14\?V&H>"+[PK!;26'A6;6?$?CZ
MPA@NII=?TOQ#=+#/&<_Y_A]^_P" 'IO@GXJ^'/'_ (C\3>'=!L/$D9\-:3X8
MUL:QK&AW.BZ3K^E^+'UV+3;_ ,.KJ,L&KWUB)O#NHH=0N=)LM/OH_LUYHMWJ
MNGW"7=4M;^/?P(\-7NL:;XC^-?PCT#4?#U_!I6OZ?K?Q'\'Z5>Z'JEU'<2VV
MFZQ:WVMP3Z9?W$5G=R06=['!<2QVMP\<;+!*5I_#WX0^,/!'Q#USQ+<>./"V
MJ^#;[P7X3\"Z-X5M/A_K.E>(M+TCP)-K3>%Y[_QE<?$K6=/U>^6V\0ZI#KDL
M/@K2(=4E73Y[&WT5;:Y@O^ UW]G7XH7?AN3P3X>^-6D^'/"-CXNU;Q)H%K9>
M$/BAH7B0V6NZCXFU?4M'\7>,_AG^T/\ #37O$?EZIXABNM/N]%F\'6[G3D_X
M233/$TUPUQ$U-==^OWK]/RV ]@F^+WPCMTU22?XI?#B%-#T&S\4ZT\WC;PU&
MFC^&-0%F;#Q'JC/JJC3]!OAJ%@;/5[LPZ?<B^L_)N'^TP[^.TS]H[X1ZCI$'
MB>?Q;X=T3P5<R>-%@\<^(?&'@31_"MQ;^"O$^B^$Y]2LM0NO%PFU/1M=U+7M
M/?0M;TNTO=):"XLXM9O-&U#5]!L=6Y;PO^RW=>#?AO-X-T+QY9-XAM_&/PT\
M<Z)XEU?P?>:GID.M?#7PI\/_  O8Q^(?#_\ PFEMJ?B2RU%/ OVN<GQ;I>IV
MS:E"(-4-[I4.HW.1??LJ>+9]*LFL/C!%HOBZ(_%BZU'7=#\(^)O#>FW]_P#%
MWXF>!OB/K\=I;>$?BKX;\::#H]N_A*^T*&#1?B):>(Y[36HKJY\5M/8WJ:VN
M=::>OKIMKZ_@![C8_%[X1ZG=^%+#3?BE\.-0OO'EO<7?@:RL?&WAN[N_&=K:
M2W-O=7/A2V@U62;Q%;VT]G=PW$VCI>1PRVMS'(RO!*J\L/CWX(CUSXSZ#?6G
MB#2I?@=IUAJOB>_U#3[2/3-:LK[05U]W\)7,.J3R:K-I\,EK8ZE:7D&EW=MJ
M-_IL0@DMM2L;J?F/@U^SMXR^#6II=:7\3-#UVPUYII_B);Z_X+\9ZUK6N7(\
M1^,_$=D_A/Q9XA^,NO>(/#T<,OC*XM[S_A-+KXHWE]]C6\%]:WE]?33:6N?L
MUP:WX[_X31O&M_8177Q,_P"$XUW1;+2(%A\0^'4\+^ ["'P)J=W/?S,;%?&?
MPT\'^,I=5M[:&XFM["Z\,_9([34KV_D.?;\?Z_'\/,#*M/VG?#M\GA"]MOAW
M\2WT'Q1X;^'/B?4O$;0> 8M.\#V?Q2\1ZCX5\*VOBNQF^(<?B.XOWUG3+B#4
M(_!NA>+K>RC:*<W4D;.4]6TOXG^#;[PCKWCK4]4MO"7A7PSXB\9^&];UKQA>
MZ9H.FZ?<^!O%^K>"M7O[O4;C4GTZTTNXU?1[B33[J[O+>26SGM&N8+2ZE>TB
M\?L/V1_#]D_A+6CK6F3^// '@_X:>&/ WCQ_!]N-<\-7'@'Q!XGUC4[JRN#K
M3WRZ-XXL/$LOA_Q)X9BU&WM+K3(9%NKN^:>$67;W?P,OT\ 3^%=%\7V5GK]M
M\7==^,&@:_JOA:?5]&LM8U7XJZO\3;/2M9\,6_B?1[C6]-L3JS:+,]MXDT2[
MNG@BUFSFTJ[2&" 4UU_IZ;?CO]_0"#2_VD?@;?Z-INOWWQ/\!^&=)U_7_$GA
M_P *WOBGQIX1T6W\92^&-8.BWNH^$+B;7WMO$.D75PUM/I]YILTS3V=_82RP
MV[W4<5);?M-_LX73/&OQW^$5M-'KNJ>&3:ZE\0?"^DWC:[HU\=.U#38K+5-5
ML[N>>.Z\OR###)%>V]Q:7MC)<V5[:7$WE/BW]DGQQXH\%P^$$^-JZ0FJ:M\4
M];\;'1_#OQ)\+Z+KFH_%/7GUZ_GTO1/A]\>/ TT4>C2WFJV6GZ;X]U?XF:%=
M6=ZAU72+Z]6^N]3=X[_9/^(?C'2M5\+6OQSAT/P9J.L_$6_CT2Q\,_$_1+N.
MR^(^IG6-0AU74?A]^T%\/K7Q5?Z7>W>L1:9_PE.D:OX5;3M02TO_  ;>3P7-
MY?G/Y?UI?]?P ^N]2O\ 3M'LY-0U>_L=*L(7MXY;[4KJ&QLXI+NXBM+6.2YN
M9HH4>YNYX+6W1G#37$T4,8:21%/G/COXR_#;X=Z)_P )#XC\5:'%I<?BW3O!
M=[<1:WH4::7K5YJMCI=^FJ2W^KV-O91>&4OAJWBE99Q=Z-HMM>7\UJPA$;Z5
MWX1UKQ]X3^)W@?QW9V.F^&_$']K^$?##:>SG6'\)7'AK3]*?7-5EAU.\MHM7
MN/$+:[JNB_89+*6RT4Z M[;6NM0W^/"+#]CZ*._L-2UCQ]'K,\=_X)\5:O _
M@VVM=/UCXBZ5X]\,>./B%XV>R&O3K;W7Q!'@SPUHUK9/)=GPI;6-Q=+>Z_-?
MW2LW-=+_ -?U_6X'M4WQA^&<-CI.O?\ ";>#9/!>L>&_$'BJW\?IXV\%)X-3
M1O#>IZ%H]_=G5)_$L,UY9B_U^UMGU;2K+4="TVXB:SUW5=)O[_1+75L>R^/_
M ,'K[QCIO@F+X@>$$U3Q%H?AC7_!=U+XJ\,+IGQ!M/%=YKEEIT'@&==<>X\6
M7D$NA2M>Q:3:3Q1QZAI1@FN6NV2'B_%7[+]QK6N:%XGT7QS9:+K?A7Q'\1/%
MWA];_P &R:SHHU[QO\2? ?Q&LCK>EVWBO0Y]5TS1[CP4^G7EI:ZEI-[JTFJK
MJUGJN@7VFPB?K+[X%ZAX@O\ Q#K_ (H\4Z%>^)O%'AWX0Z-JE_HW@JXTG3HK
MKX5^-]:\:O>:;I^H^+_$.H6MEKEQJZVMOIMSKE])HDEJ+XZCJLDHAB7/M^.G
MY:]_\_(#J/$_Q5^'_@?4M3L?'/BSPMX(M-+TK0M5FUOQ=XO\'^'],D7Q!=^(
M;2RM1%J7B*#6+68-X:OY5N=2TFQTG4$WQ:+J6J7>FZ[;:0[6/'?PJNY=&\':
MUXW\"37GQ(T2>;PSX9N_%.AKJ7CK0+^RE,UQX;TM]22\\1:;=V#3,+G28KJ"
M2W+2++L!8<]X@^!%MX@^-OAWXQ3Z_"H\/6OA>&+PW-H*70EF\-:1\9M*2ZCU
M=]53[++<_P#"W3.A72Y'M?[ ,2R3?VN9--SO GP.\2?#?6M*N/#'CCPZWA^;
MPIX7\+>--)UCP#?WNJZO%X/BUZ+1KGPCKEAX^TFU\'QLFNR?;K#5-!\:VLC6
M_FV TZ:[O))GSK\?PTZ??U\_("Y\'M=^%6I^$=,\6> [B#2K/XBR>&-7GT_6
M-?%[K_\ ;^I^ ?#DNCZ/K$-SKVM&V\4+X'T[09[C2;:]FEGM(/[8/VLW<^HW
M-./]I7X$R:IXGL_^%I> (])\'6.D7/B3QC+XW\()X*TG4=:U;5=&MO#6H>(?
M^$@-M8>)XKO29&N=&OTM9XX;RP,;2R7#11^>^"?V3_$'@VS\,^%T^*.E7W@+
M1I_#>KZMIB_#Z^L?%VK>(M!^$EC\));BR\71_$.?3-%T2\TZP@UJ'2O^$/U+
M5+'4MT9\27=J0@Y75?V,_&VM3>'-7O?C7IEIXC\%>'?!W@[PE=^%O!/Q%^'V
MG)X8\&Z9XSTBQC\2/\._C_X3\;:KK-S9^-M2,]UH'C[PCX?$]O;JGA7[#-J%
MC>+GV_'\/^#WZ=] ^J#\3?AF-?\ #GA0_$3P(/%'C#2H-=\)>&SXMT$:_P"*
M=$NH;FXMM8\.:.=2_M'6]*N+>SO)X-0TRVNK2:&TN98YF2"5DHZA\8?A!I-G
MXAU'5?BK\-M,T_PCJ-IH_BN^U#QQX9L[/PQJVH22PV&E^(;FYU:.#1=1O98)
MXK2QU)[:YN9(94AB=HW"^=^&/V?/%/A;Q/\ #/5-)^(&AZ+X>\"^&]-T#6]&
M\.^'OB=;ZIXT2PL;^![?5M3\3?'CQ?H&I:2UY>+/IC>-O!GCSQIX>LS?6NB>
M.[.^U ZO;T?%W[,-YKG@CP_X:T#XA77AK6O#7Q.^('Q)T_6[2+Q[HME<2_$'
M6?&VHW^EZC#\,/BK\+?&3FRM?&MQ;17NF_$+2XKVZL_M6IZ==V=Y/I(?.OZ^
M7Y:].B ].M_C-\&[S7'\,VGQ9^&5UXDBTC_A()/#UOX[\+SZY'H/]CIXA_MM
M])BU=K]-(_L"6+7/[2:W%G_8\B:GYWV)UG/+:;^TI\"M2TWQ#X@/Q2\ Z?X.
M\/\ B33_  F/'FI^-O"%IX&UW7-1T&V\0Q67ASQ1_P )!)I>J3PVLT]M<VPF
MAO([[3=4A6V>.S><^$ZA^Q%XBUAM+L=2^,\O_",Z'HK66B^'K:P^,=Y8:5J!
M^'U_X+1H-'\6?M&^*_!%YHD>HZG?>(&BUGP5JOC:]AN)=&U;XA:B)[K4KGOM
M8_9N^).L:?XJO)/BOX(L_'?C+QKIWC+4O%NC_#'XA^&8]$FTGP;I/@JR@\'0
M^$/VAO#GBS2+B73M%LWU>;6?'?B73=<BEOM)U+1)]$N(].MUS]U_77KZ^OD!
MZ'XQ^/7PY\$?$#P5\-=7U?3SXB\:Z)K?BB$GQ)X(TJTT+PIH5N;BZ\3:ROB7
MQ;H6HW&E7"1W9L1X:T[Q%J%Q!I>M:@;"/2M$U:_LYKWXB_ 35]<^'5_>_$OX
M87NMZFVI7GPN1_'_ (?>37I[[[1X=U#4/"&G+KGV?Q#>*%U#0DU#3K6_NK+S
M]6TRVGM_MNI03GQ,^!A^)%O=0WOBV2"2\^#GQ ^$UW<WN@VNH2WC^/)?"<L_
MB6[AM+W1K%I+1O##M/HUK9VEI?-J3B&XTV&U6&;#^(G[/VK^-->\17&E>-M&
MT'PQX^T?P1HGQ!TN^\#W6N^);RS\!ZI?ZCI/_"%^++?QIH-MX1><:A-'<C5/
M#/C&*WN =1TF/3;Z:XEF.??\/Z_X??RLPZBQ^/'P+U34;32-,^-'PFU'5K_6
M(?#MCI=C\1?"%WJ-[X@N-I@T*TLK?6I+FYUB<.IATR&)[V3<NR!LC.UXG^*?
MPN\$ZI9Z'XS^)/@#PCK>H0-<V&C^)_&'A_0-4OK95F9KBST_5=3M+NY@5;>=
MFEAA>,+#,2V(W*^?6G[->DV6DV.FPZQIZ2:?\./@C\.X+N+PM;Q/':_!GQ7>
M>*HKN%$U7,%OKT]TD,>F)+Y>BS0+>K<ZDY$2=3XQ^".F>,=:\4:Q>7]DO_"3
M_P#"EUGM[G0(-0\NW^#_ (_U+QY#;332WT7VR'6I]1>RB1XHDT:57U%$U!YF
MME.?RU_KS[_T[:A<NO$7PF^)'A-HF\7>"_%?@WQ+HFJ:R9]-\6:;>:+KOACP
M]?6T'B"_6_TK5?L^H^&M.O'M].\2R+<3:0$N6TG6MUO>RVLW"3_M._!FPM"-
M1\6:-HNLSM\3X] \+:_K_A3PYJ_BA/A+XDU7PKXBFT*[UWQ'IOAE+:]U'2+F
M709]8\0:1#>::);^Z>PM]-UIM+H>+/V<?$>H-J%SX,^(>A>&;[6H?C+H^L2Z
MY\/;OQ3:MX:^,VO:7K^K6^DV>G^/O")L/$>D7.DVZ66NWUSK&FW(EN9+OPR[
MR)Y>'K/[*FM77@EO!NB?$O3=,6_TS]H?P_KNH:EX!N=9^V>'_P!H#7[GQ%=0
M:;:6WCK13I>K>%KW^SDMM3N+K5;358+2Z2;2+)KZ-K(Y_P"ONV_'?R ]0\:?
M'?X3>!(?$L.L>./"UQXH\+>%->\8WOP]TWQ-X:G^(5YI/AS0;KQ)J*Z9X5GU
MRUOKJX&DVDMS$7,%H8]L\UW#:[KA>N7XA> #XLM/ +>-O",7CZ^TU=8M/ DW
MB/1H_&<^EM!)=?VA%X8.H?VU+9+;PSS-=QV;VXC@FD\W9&[#Y=\4_LP^/?B7
M>?&_PYKGBSP]X1^'7C7QA<ZUH<5KX)DU;QEJ.I2?!'PY\/;+Q-)XH@^(T%A;
MZ'9ZG'>)=>%;KP99:YJ,&D2V@\26NE:K')7>VW[,M]9_&L_%%/'DE[X>E\2V
MOC";P;JLWQ==[7Q!;>#K7P>MSH\&C_'/0_A1!&MK90S12:W\%O$6JK%/>VDV
MKW.^PN--.?RZK[NO_  ]/\0_&'X0>$;O5[#Q7\5?AMX8OM AM+G7;+Q#XX\,
MZ+=Z+;W\\%M83ZO;:EJUM-IL-[<75M;VDMXD*7,]Q!%"SR31JUW7/B1X)T3P
MIK7C)O$GAV_T;1-,MM3FGMO$_A:SMKA=2TZ#5-#MH]9UW7M'\-V4WB*TN["3
M1+G6=;TK3+R+4+*Z;4(;&<70\@^(O[,-YXQFU_4]!^(5UX5U[5/BNOQ0LKRU
MB\>Z5:VSR?##2?AA=:-J=S\,/BK\*O&FI Z?ILFH6M]I_CC088Y;B.PU#2]5
ML()8KOF_$7[&UEXAT.PT+_A-8])LH_A!=_#K5;"QT/Q#J&E:EXGMO#?C7PSX
M1\<J/%'Q"\1>(7B\+6?Q'\93?V#KWB;Q)J&KW,_AV>Z\5PW/AFTGN#G\OZT_
MX/W; >R:[XQ^"]IXZT_3?$GCSP)I/Q'@\,7]EIWA_4_'>E:5XI@\-^*KK2I[
MV6UT Z[!=B'4KO1-+$.KP6;3;[-8K&^5))5EZ;1-1^'_ (=TBQ\/:#K'A72]
M&\-)<^%;'3+/5M.CMM(/A+3!)?:$L8NS]GN/#VDVOGZC92$7.G64+7%XD42M
M)7SKXM_8Z3Q?XZ\4Z[J?CV>[\&>,)KW4-2\)7\_Q>:ZTW6KWP!'X"_M/P]'H
MWQUT#X56DUG;007UA<ZQ\&=?UFW=KF!]:F?^SKO3+UE^R)$-,\:6.L?$6_O9
M_'7PYUOPWK%YI6@CP\P^(GC7R#\0_BC;K::[/<0WGBI=(\-VL&BPW<4^B6.D
MW<4'B&[NM8N+V$Y]]/Z\_P"O+S ]CTKXT_!G7H=$N-#^+?PQUFW\2ZM+H'AR
M?2O'GA;48=?UVW^S^?HNB2V>KS)JNK0_:[3S=.L6GO(_M5OOA7SH]V;=?&[X
M<WGA"]\7^!?%GA/XE6=MXF\.^"XSX)\4:3XALO\ A+/%6NZ-X=TC1[_4M"N-
M7ATR3[=KVG7&H&6*2>QTUY+]K62-%5_/?A3^S!J?P^\57?C77/&^D^+/$5UX
M;\8^'9;BXTOXLZQ'>IXH_P"$"%M<:K=_%WX^?&7Q%<1:9'X'BM)]-T_Q!I.G
MZG8W=O"(+";3S=7LUA\$/B'X6^'.H:*_C2U\;ZQ:?$GX?^//#NBZ7IGB/1-
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MKQLMY<%KJQ!T"\22_MIKW3IA<6MQ=6\GC"?LH?$2XN_AQ;ZO\<H;WPK\.9/
ML5EX=TWPS\3_  U!>:=\/O%47B+1X[C3-!_:"LO .JZIJ%K9:7IFMZMXS^'W
MC(22V/\ :&BV.A*T%C:>W>*O@C9^*/$WC+Q+)K%O;7'BW1_A+I"QOH4=W-IJ
M?"SQSK7C9)!>-J4+W2:S/JZVJ0".U&E2VHOU>_>46\1S^7]6UZ]_P^X#E(OB
M[^S5\'-)O_",GQ<^'7A^'P3J%OI_B'3-6^)%IKOB;1-6\2:ZL+77C.;5M>U;
MQ7_:6J:]JS7>M:[XIGDNGN+J\U?6]0$:WEXGJE_XX\-:;>:5#=ZGI<.FZMX7
MUWQA#X@FU[PW;:/%H.@2>'UNM0;[7KMOJMWI\D7B.RN1K.EZ7J&@6$"C^V]6
MTJ;4="AU;Y]U/]EKQ5>16VGVGQ/\.:?I'A#7M=\5?"Z)?AC?2ZMHOB#7OB!I
MGQ!N9OB#JB_$J"W^(.G1W]A+9FRTC2OA]=WBW$6H:EJE[J=HEU)Z9\4_@;-\
M5$5M3\46FGW,WP>^*'PKU P>&WN;&YG^)K^!I+K7X;*X\0>9;VFER>#9!'H,
M]Y>O>PZJL<NM0M8M)>G.NW:R^ZZOY>G0#3B^./P2N-/TC5X/C%\*YM*\0:[+
MX6T'4XOB#X3DT_6_$T!MA-X=TB]366MM2UV$WEH)=(LY9M0C-U;;[<>?%NO>
M%OBCX+\5V6MWEKJUII9\/>(]=\,ZO9:W?:797]E=Z)XX\0?#V&]N+:/4[DVV
MF>(?$GAK5+?PS<73P2ZLL8B2WBOTN+*#BY?@3X@TCXLW_P 6? GC3PWH>H:W
M:V.AZ[HWB+X?WWB73I?"UMI_@ZRN+/1I-)\>^#I](U^9_"$+P:Y,=4TZ*UN8
MK2]\-ZF=,L;E.+C_ &7/$VFZQK]QH'Q/T6ST3QIXI'B+QGI^J?#F]U75KFWL
MOC7XT^,FC:;X:UFV^(FD6>@-#-XTNO#NKWVJ:!XH.IV]G#J5A:Z'-(ULAS]_
M/;Y6Z]=0/5A\:_AC-\0)/AGI_B[P_J_BNPTOQ'JWB6RTC7M OSX)@\,G2OML
M/C6W@U@ZEX;N;I-5673X[^P1)HK#4GEDMQ:CS.*\2?&W]F[2=,M?C;/\3?AQ
MK2:5H_B[PMX9UG0OB)X:OO\ A(9"NC>(/$'@OPM$OB:WT/Q!XHO)M%T!H=+2
M2358IFLX8Y;2"_E\_F+W]E#6-8CU?1=9^)EE_P (FGA3XR^$O!UKH/@>]T/Q
M;HME\9]>L_$6KW7B'QB?'FH?\)%>Z3?:?:Q6=QHFA>"I;VV-S+J3W&J26^IV
MG)6W[&WC2TM/%AA^+OAMM:^(/A7Q5X \;ZQK'@OXP^/GU+P;XHL-!L7&DO\
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MIOA+2]/O]-T35_'_ (SU&.ZTVV\-3+JRW'B&Y/B!;^V@2;1K32;>VG],\'^
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ME%% $Y (P:8R8'&34E% %>BIB@))YYJ,J03P3^% $90$D\\U&5()X)_"IJ*
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M_::<EUX9NO&]II/C^XTF+P*WB*R\.:W/J&E:"/&6IZI:W:PV^I64_P!EU 1
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M]Z;\%+GP3)I=Q\.?%6K6%\NE?"SP)J5]XCETO5OLGPR^&GBOQ1XE31M*L_\
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=% # @QSG/?I1L'J?T_PI]% !THHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img173888082_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img173888082_4.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 42"7T# 2(  A$! Q$!_\0
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M/?\ YUU?K710!^2G_#FK]F'_ *'OX\_^%/\ #W_YUU'_  YJ_9A_Z'OX\_\
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M4?\ #FK]F'_H>_CS_P"%/\/?_G75^M=% 'Y*?\.:OV8?^A[^//\ X4_P]_\
MG74?\.:OV8?^A[^//_A3_#W_ .==7ZUT4 ?DI_PYJ_9A_P"A[^//_A3_  ]_
M^==1_P .:OV8?^A[^//_ (4_P]_^==7ZUT4 ?DI_PYJ_9A_Z'OX\_P#A3_#W
M_P"==1_PYJ_9A_Z'OX\_^%/\/?\ YUU?K710!^2G_#FK]F'_ *'OX\_^%/\
M#W_YUU'_  YJ_9A_Z'OX\_\ A3_#W_YUU?K710!^2G_#FK]F'_H>_CS_ .%/
M\/?_ )UU'_#FK]F'_H>_CS_X4_P]_P#G75^M=% 'Y*?\.:OV8?\ H>_CS_X4
M_P /?_G74?\ #FK]F'_H>_CS_P"%/\/?_G75^M=% 'Y*?\.:OV8?^A[^//\
MX4_P]_\ G74?\.:OV8?^A[^//_A3_#W_ .==7ZUT4 ?DI_PYJ_9A_P"A[^//
M_A3_  ]_^==1_P .:OV8?^A[^//_ (4_P]_^==7ZUT4 ?DI_PYJ_9A_Z'OX\
M_P#A3_#W_P"==1_PYJ_9A_Z'OX\_^%/\/?\ YUU?K710!^2G_#FK]F'_ *'O
MX\_^%/\ #W_YUU'_  YJ_9A_Z'OX\_\ A3_#W_YUU?K710!^2G_#FK]F'_H>
M_CS_ .%/\/?_ )UU'_#FK]F'_H>_CS_X4_P]_P#G75^M=% 'Y*?\.:OV8?\
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MI_PYJ_9A_P"A[^//_A3_  ]_^==1_P .:OV8?^A[^//_ (4_P]_^==7ZUT4
M?DI_PYJ_9A_Z'OX\_P#A3_#W_P"==1_PYJ_9A_Z'OX\_^%/\/?\ YUU?K710
M!^2G_#FK]F'_ *'OX\_^%/\ #W_YUU'_  YJ_9A_Z'OX\_\ A3_#W_YUU?K7
M10!^2G_#FK]F'_H>_CS_ .%/\/?_ )UU'_#FK]F'_H>_CS_X4_P]_P#G75^M
M=% 'Y*?\.:OV8?\ H>_CS_X4_P /?_G74?\ #FK]F'_H>_CS_P"%/\/?_G75
M^M=% 'Y*?\.:OV8?^A[^//\ X4_P]_\ G74?\.:OV8?^A[^//_A3_#W_ .==
M7ZUT4 ?DI_PYJ_9A_P"A[^//_A3_  ]_^==1_P .:OV8?^A[^//_ (4_P]_^
M==7ZUT4 ?DI_PYJ_9A_Z'OX\_P#A3_#W_P"==1_PYJ_9A_Z'OX\_^%/\/?\
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MK]F'_H>_CS_X4_P]_P#G75^M=% 'Y*?\.:OV8?\ H>_CS_X4_P /?_G74?\
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M/?\ YUU?K710!^2G_#FK]F'_ *'OX\_^%/\ #W_YUU'_  YJ_9A_Z'OX\_\
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M4?\ #FK]F'_H>_CS_P"%/\/?_G75^M=% 'Y*?\.:OV8?^A[^//\ X4_P]_\
MG74?\.:OV8?^A[^//_A3_#W_ .==7ZUT4 ?DI_PYJ_9A_P"A[^//_A3_  ]_
M^==1_P .:OV8?^A[^//_ (4_P]_^==7ZUT4 ?DI_PYJ_9A_Z'OX\_P#A3_#W
M_P"==1_PYJ_9A_Z'OX\_^%/\/?\ YUU?K710!^2G_#FK]F'_ *'OX\_^%/\
M#W_YUU'_  YJ_9A_Z'OX\_\ A3_#W_YUU?K710!^2G_#FK]F'_H>_CS_ .%/
M\/?_ )UU'_#FK]F'_H>_CS_X4_P]_P#G75^M=% 'Y*?\.:OV8?\ H>_CS_X4
M_P /?_G74?\ #FK]F'_H>_CS_P"%/\/?_G75^M=% 'Y*?\.:OV8?^A[^//\
MX4_P]_\ G74?\.:OV8?^A[^//_A3_#W_ .==7ZUT4 ?DI_PYJ_9A_P"A[^//
M_A3_  ]_^==1_P .:OV8?^A[^//_ (4_P]_^==7ZUT4 ?DI_PYJ_9A_Z'OX\
M_P#A3_#W_P"==1_PYJ_9A_Z'OX\_^%/\/?\ YUU?K710!^2G_#FK]F'_ *'O
MX\_^%/\ #W_YUU'_  YJ_9A_Z'OX\_\ A3_#W_YUU?K710!^2G_#FK]F'_H>
M_CS_ .%/\/?_ )UU'_#FK]F'_H>_CS_X4_P]_P#G75^M=% 'Y*?\.:OV8?\
MH>_CS_X4_P /?_G74?\ #FK]F'_H>_CS_P"%/\/?_G75^M=% 'Y*?\.:OV8?
M^A[^//\ X4_P]_\ G74?\.:OV8?^A[^//_A3_#W_ .==7ZUT4 ?DI_PYJ_9A
M_P"A[^//_A3_  ]_^==7XQ_M/^$KW]DW]HGXG_![X0>//B)I?A?06\%M'=S^
M)FM-:U-M6\">'?$TC:Q/X:M/#NGWC6E]X@U""P*:9 8+(QQ,99O.N)O[!Z_D
MI_X*;?\ )\'QM_[IM_ZJ+P#0!^M?_!&K_DV'QW_V7GQ/_P"J]^%U?K77Y*?\
M$:O^38?'?_9>?$__ *KWX75^M= !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\E/_!3;_D^#
MXV_]TV_]5%X!K^M:OY*?^"FW_)\'QM_[IM_ZJ+P#0!^M?_!&K_DV'QW_ -EY
M\3_^J]^%U?K77Y*?\$:O^38?'?\ V7GQ/_ZKWX75^M= !1110 4444 %%?F/
M\9O^"O\ _P $_/@1^TC\)/V:/B#^U!\ M&\3_$W3/BK?:[XGO_CO\'-*\)?!
MR]^&-GX:N;30OC!>ZMXVLKGP3K/Q%GUZ^TWX>V>J6T+:_JGA?Q%80XN;(1O^
MAG@CQ[X&^)GAK3O&?PW\:>$_B!X/UB,RZ3XK\$>(]'\5^&M4B&,RZ=KN@WE_
MI=[&,C+VUU*HR.>: .LHJK?7UEIEE>:EJ5Y:Z?IVGVMQ?7]_?7$5I96-E:1/
M<75Y>75P\<%M:VT$<DUQ<32)%#$CR2.J*S#XB\#_ /!3S_@G!\3/B%:_"?X>
M_MY_L@>-?B1J.J66AZ-X,\,_M%?"?6=>\1:YJ#K%::+X7L['Q7,WBG6)9F%N
M=+\.G4[^*YW6TUO'.K1@ ^YZ**9))'#')++(D442-)++(RI''&BEGDD=B%1$
M4%F9B%5022 ": 'T5\8^"_\ @HU^P!\1_BQ_PHKX?_MK_LK^-?C&^HMHUM\-
M?"WQY^&6N^+]0UQ)OL\V@Z3HVF^);FZUC7[6X#6]YH6EI>:M97$<T-W9PRPR
MHGV=0 45E:YKNB>&-&U3Q'XEUG2O#WA[0["ZU76M=US4+32=&T?3+&%[B]U+
M5-4OYK>QT^PL[>-Y[J\NYX;>WA1Y99$12P^6/@E_P4!_87_:5\;:A\-OV>_V
MPOV:?C7\0--2[FN/!?PO^-?P\\;>)IK2PCEEOM1TW1?#_B"_O]8TJSBADENM
M6TF"]TVWC7?-=(I4D ^O**** "BBOCWXQ?\ !0G]A#]GKQ_9?"GXZ_MD_LQ_
M"#XEWQM-G@+XC?&_X<^$/%EK'?A&T^YU;0M;\0V>HZ'9:@'!L+[68+"SOL.+
M6>8QR;0#["HJAI6JZ7KNEZ;K>B:E8:SHNLV%GJND:OI5Y;ZAI>JZ7J%O'=V&
MI:;?VDDUI?6%]:3175G>6LLMO<V\L<T,CQNK&_0 45\7>(O^"CW_  3\\(_%
MIO@/XI_;;_94\/?&:/4O[$N/AIK/Q[^&.G>,+'7C)Y2>'=3T:Z\3176E^))I
M"B6_AW44MM:N&E@$%A)Y\._[1H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#'(]PGBZZ$T]M('GFMX[1[E9+54@ /[&/A7_ ,$>?V"OAS^PSH_[!6H?L_\
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M&GB#[98VMP+2>?SO"_AS6[>W\NX(C\JZE@F;[Z1LGS5XK_P\V_8?_P"BV_\
MF-OB[_\ ,#0!]Y45PWPY^)7@;XM^$=+\=?#KQ%:>)_"VL1F2QU.UBN[5B0JN
MT%YI^HVUGJ>F7:))%(]CJ5E:7B12PRO L<T3/W- !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME> /@_KOBFPTWXD_%/0/'WB?X?>%+B.\%]XIT/X7/X13Q]>Z=.EL^G@^&_\
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MKK\E/^"-7_)L/CO_ ++SXG_]5[\+J_6N@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY
M*?\ @IM_R?!\;?\ NFW_ *J+P#7]:U?R4_\ !3;_ )/@^-O_ '3;_P!5%X!H
M _6O_@C5_P FP^._^R\^)_\ U7OPNK]:Z_)3_@C5_P FP^._^R\^)_\ U7OP
MNK]:Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _)3_@C5_P FP^._^R\^)_\ U7OPNK]:Z_)3_@C5
M_P FP^._^R\^)_\ U7OPNK]:Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OY*?^"FW_ "?!\;?^Z;?^JB\ U_6M7\E/
M_!3;_D^#XV_]TV_]5%X!H _6O_@C5_R;#X[_ .R\^)__ %7OPNK]:Z_)3_@C
M5_R;#X[_ .R\^)__ %7OPNK]:Z "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)3_@C5_R;#X[_ .R\
M^)__ %7OPNK]:Z_)3_@C5_R;#X[_ .R\^)__ %7OPNK]:Z "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY*?^"FW_)\'
MQM_[IM_ZJ+P#7]:U?R4_\%-O^3X/C;_W3;_U47@&@#]:_P#@C5_R;#X[_P"R
M\^)__5>_"ZOUKK\E/^"-7_)L/CO_ ++SXG_]5[\+J_6N@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/R4_X(U?\FP^._\ LO/B?_U7OPNK]:Z_)3_@C5_R;#X[_P"R\^)__5>_"ZOU
MKH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_DI_X*;?\GP?&W_NFW_JHO -?UK5_)3_ ,%-O^3X/C;_ -TV_P#51> :
M /UK_P""-7_)L/CO_LO/B?\ ]5[\+J_6NOR4_P""-7_)L/CO_LO/B?\ ]5[\
M+J_6N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /R4_P""-7_)L/CO_LO/B?\ ]5[\+J_6NOR4_P""
M-7_)L/CO_LO/B?\ ]5[\+J_6N@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K^2G_ (*;?\GP?&W_ +IM_P"JB\ U_6M7
M\E/_  4V_P"3X/C;_P!TV_\ 51> : /UK_X(U?\ )L/CO_LO/B?_ -5[\+J_
M6NOR4_X(U?\ )L/CO_LO/B?_ -5[\+J_6N@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R4_X(U?\
M)L/CO_LO/B?_ -5[\+J_6NOR4_X(U?\ )L/CO_LO/B?_ -5[\+J_6N@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBXUG4D6\N;O5M<U#4-6U*[NKRZ>0?%'_ !!M_P#!(_\ Z&/]K_\ \/+X)_\
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M2?%FCV]IX;L_%5]_;>GZMJ\>EZ%KGB34='\/W.O:W<6]O<HGABW\+ 'Y=_\
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M^%=,O4#I?:E'\6]/^)7Q1TRZLR+&/3_ :O+=,+_31JFQ_P '9O[.OBSX*?M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K^2G_ (*;?\GP?&W_ +IM_P"JB\ U_6M7
M\E/_  4V_P"3X/C;_P!TV_\ 51> : /UK_X(U?\ )L/CO_LO/B?_ -5[\+J_
M6NOR4_X(U?\ )L/CO_LO/B?_ -5[\+J_6N@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R4_X(U?\
M)L/CO_LO/B?_ -5[\+J_6NOR4_X(U?\ )L/CO_LO/B?_ -5[\+J_6N@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJEJ6IZ;HVG
MWFK:QJ%EI6EZ=;RW>H:EJ5W!8Z?8VD"EYKJ\O+J2*WMK>% 7EFGD2.-06=@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAX>N3;ZGHVJPB.50PW07=I/&TEKJ.F7L6VYT[5+">YT_4+5X[JSN9X)$D/\
M4^"S'@GQHR.>#Q=%4,TPU-SGAIRIQS7*JLE&+Q6 Q'+_ +1A)3Y5*2@Z-7]W
M#%X>G4=."_GK%8'BOPLS:.)PU5UL!7FHQKQC-Y=F-.-VJ&+H\S]AB8Q<FHN2
MJT[SEAJTX<\G_H'V]Q;WEO!=VD\-U:W4,5Q;7-O*D]O<6\Z++#/!-$S1S0S1
MLLD4L;,DB,KHQ4@F:OY*_P#@GA_P4Y\1?LWWFE?";XS7NJ>*?@/<SQVFF:@?
M/U+7_A4TSA1=:/'F2ZU/P<K-YFI^&8O,N=/CWZCX:B:Y2YT76OZN/#/B;P]X
MS\/Z/XK\)ZUIOB+PUK]A;ZIHNN:/=PW^F:GI]T@D@N[.[MW>*:*13U5LJP9'
M"NK*/Y?XWX%SC@?,?JN/C]8P->4GE^:4H2CAL936KBTW+V&*IJWML-.3E#XZ
M<JM&4*L_W_A3B[+.+,%]8P<O8XNBHK&Y?4DG7PTWIS*UO:X>;3]E7C%*27+.
M-.JI4X[E%%%?$GU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,UU<MLM-/LHWD:ST;1;!"+;2=$TY97CL-,LTCMX TDA#W$T\TOZ'_P#!/O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK^2G_@IM_P GP?&W_NFW_JHO -?UK5_)3_P4V_Y/@^-O_=-O_51> : /UK_X
M(U?\FP^._P#LO/B?_P!5[\+J_6NOR4_X(U?\FP^._P#LO/B?_P!5[\+J_6N@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /R4_X(U?\FP^._P#LO/B?_P!5[\+J_6NOR4_X(U?\FP^.
M_P#LO/B?_P!5[\+J_6N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_-7_@H/_P %
M!_"O[(7A5_"WA9].\3_'KQ/ISR>&?#,CBXL?"=C<!XHO&'C"*)U>.RC=7.BZ
M*7BN_$%W$RJT&F07M[#ZN2Y+F7$.98;*<IPT\5C<5/EA".D(06M2M6J/W:5"
ME&\ZM6;48175M)^=FN:X')<#7S',:\</A</'FG.6LI2>D*5*"]ZI6J2]VG3C
M>4I/M=H_X*#_ /!0?PK^R%X5?PMX6?3O$_QZ\3Z<\GAGPS(XN+'PG8W >*+Q
MAXPBB=7CLHW5SHNBEXKOQ!=Q,JM!ID%[>P_R!>-O&_BWXD>*]=\<^._$.J>*
MO%OB6_EU/7->UBY:ZO[^[EPNYW;"100Q+';6=G;I#9V-G#!964%O:00PQM\:
M>-/%7Q$\5:]XX\<:]J/B?Q;XGU&?5M>U[5IS<7VHWUP1OEE?"I''&BI!:VL"
M16EE:106=G!!:P0PI^['_!,W_@E\WB@^'/VB_P!I'0BOAC-OK7PW^%>L6I#^
M)<>7/IOB[QK93CY?#9XNM$\-W$6[Q"!!J.K(/#YBL->_L'*LJX6\%^&*N89C
M6AB,SQ,%#%8J,8_7,SQ:CSPR[+J<VI0PM.2NDW&*2>*Q4E:*A_,^8YCQ!XIY
M_3P6"I2HY?0DY8?#RD_JV PSER3QV.G&\9XB<79V4I7:P^'B[MSX3_@G+_P2
MSU#XMMH?QR_:-TF\TGX69@U/P;\/+L366K_$9 5EMM7UY0T5UI/@B3"O:VP\
MG4_%,9$\;66A-;W6M?U :?I]AI%A9:5I5C9Z9I>FVEO8:=INGVT-E86%C:1)
M;VEE96=LD5O:VEK!''#;VT$<<,,2)'&BHJJ+8 4!5 55 "J    ,  #@ #@
M< 4M?RQQEQKG'&N9O'9E4]GAZ3G' 9=2E)X7 T9->[!.WM*]1*+Q&)G%5*TD
MDE"E"E1I_P!"<+\*Y9PK@%@\!#GK5%&6,QU2*^L8RK%?%-J_)2@W)4:$7R4H
MMOWZDZE2H4445\@?2A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#,,#S7GAZS7QPO[T\-6M*5"K;5*5.5JE.:5RBBBOASZT**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_GV_X*$^(/VBOB/_ ,%%O@3^RW\)OVB_B1\"M!\<_"C3KY+KP3XH\5:%IT&M
M3:A\3]2U#5]6TWPKK_AV?7+BXL?">GZ; +N^Q9QHCV_E[KA9^O\ ^'87[=W_
M $E)^-W_ (4/QC_^?!69^T=_RG#_ &1?^R26'_I)\>:_>VOBL#E.$S7&Y[6Q
MKQ=2='.:V'I<F.QM"$*,,/A9QA&%"O3@DI3EK:]G:^BM_2O$_'>?<"\-^%N
MX:IY%A,/F7A[@,VQOUGACAW,ZV(S"OF^<T*N)J8G,LLQ>(<JE/#TE)>UY6XN
M?+SRE)_A+_P["_;N_P"DI/QN_P#"A^,?_P ^"C_AV%^W=_TE)^-W_A0_&/\
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M117SQ[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/B*,_P"V\^ERU:-:,*E.7*T^6<4[-.UF@HHHKZ8_% K,UK_D#:M_V#+_ /\
M266M.LS6O^0-JW_8,O\ _P!)9:4MGZ/\C2C_ !:7_7R'_I2/PX_X(&?\FW_&
M/_LMTO\ Z@?A"OW:K\)?^"!G_)M_QC_[+=+_ .H'X0K]VJ^>X2_Y)S*O^P>7
M_IZJ?K?CY_R>#CK_ +&M'_U78(****^B/R **** "BBB@ HHHH *_DI_X*;?
M\GP?&W_NFW_JHO -?UK5_)3_ ,%-O^3X/C;_ -TV_P#51> : /UK_P""-7_)
ML/CO_LO/B?\ ]5[\+J_6NOR4_P""-7_)L/CO_LO/B?\ ]5[\+J_6N@ HHHH
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M?BAX6^+/PYU(Z?XD\+WRS>1*96TS6]+FQ'JGA[7+:*2)KS1M9M"]I>P"2.5
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MWQTDJD&V^$L_224E=M_V?HD?*_\ P0,_Y-O^,?\ V6Z7_P!0/PA7[M5^$O\
MP0,_Y-O^,?\ V6Z7_P!0/PA7[M5Q\)?\DYE7_8/+_P!/53Z'Q\_Y/!QU_P!C
M6C_ZKL$%%%%?1'Y %%%% !1110 4444 %?R4_P#!3;_D^#XV_P#=-O\ U47@
M&OZUJ_DI_P""FW_)\'QM_P"Z;?\ JHO - 'ZU_\ !&K_ )-A\=_]EY\3_P#J
MO?A=7ZUU^2G_  1J_P"38?'?_9>?$_\ ZKWX75^M= !1110 445^'O\ P7C_
M ."J_B'_ ()9_LK>$_$/PE\.>'_%G[2W[0WQ"M/A!\!=-\8*TO@S0=8EMTOO
M$OC[Q;:QZCI,^H:3X6TV6TM;+3XKZ"&X\3:]X>?5"VAPZK%( ?LMJGCWP-H?
MBWPGX UOQIX3T?QWX]L_$NH^!?!6J>(]'T_Q;XTT_P %PZ7<>,;[PGX<N[R'
M6/$=GX3M]<T6?Q+<Z/9WD.A0ZOI<NJ/:IJ%HTW65_)I\6?\ @FG\9)_V\/\
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M++LQYW">&J<SM"AB:B:WY*6):G\->K./].M%%%?R8?T<%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ0>+/&DK^"/!Z/UCO+/2%BOO%FM6^!M>TU"V\'3Y;<L^$VR?CY\3_P#@J_\
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MW,JH<N19M6DY4Z<;4\LS"=YSPUEI##8FTZV$2M&#57#J,8TJ7/Z_ACQG_;V
M649A6YLXRZDE&=25YX_!1M"%>[=YUZ%XTL3>\IITZS<I5*G)[_1117XJ?JH4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;?\ NFW_ *J+P#0!^M?_  1J_P"38?'?_9>?$_\ ZKWX75^M=?DI_P $:O\
MDV'QW_V7GQ/_ .J]^%U?K70 4444 %?SX_\ !9G]LCXL_P#!/W]J;_@F7^U=
MIOPH^.'Q0_9<\*WG[5WP_P#VP'^$GA/Q7XITKP9X!^)&B_ VW\)^,/%::+;3
M>'[74/#7B#0KOQ/X8MO$\]BVN6WA[Q/HFAWMK>7T]S#_ $'44 ?S!_&'_@KW
M_P $Q?BA^WU_P3%_:+\'_MQ?L[7'PC\#_!S_ (*#MXY\0:S\0](\*ZKX'N?&
M'@_]G#_A$=*\8^#/%$FC^-_#.N>*Y=(UBU\+Z'K/AVSU;Q'>Z-K%EHEG?W6E
MW\5O\Q_L?_ SX@_\%9/^"[W_  ^6B^&/C/X9_L(_LS?#Y/AI^ROXK^)?A"3P
M=XA_:A\0Z3X5\9^#+;QSX>\+:J+3Q$G@33]>\?\ C3QQI/C'5+*)WATOP'X9
M$/\ ;,7BO2?"/](/Q$_80^"7Q#_:N_9S_:SNO#OA?2O&7[/.A_&W2;72K+P'
MX2>#QQ=_&2Q\#VD>M^)=8DT\:K_:G@67P9+>^%[B-Y9(+KQ#J\BR0-*S2?:]
M '\BG_!?_P#X.+O '[$^O7G[#O[-7B77K_\ :(U2ZTC3/V@_BMX @TB_U7]F
MKP)K4-I>:QIG@!]?DC\/:K^T+JWAJ]$OAUM1^U>'OANU]::UKL=_X@B@T*U_
M/']F7_@[A_X)]?LB?!CPE\!_@?\ \$^_V@_#W@;PE'>SF;4/BGX#UOQ1XK\2
MZU>3:MXJ\=^._$^H12:KXN\>>--=NKW7_%GBC5IIK_5]6O9YG,4 @MX?[^:*
M /YG?^"1O_!;3XN?\%G_ -K/QU_PJ'X+:A^SK^QY^S#\,UU;XF7'B?6-"\=>
M//C%\7/B?='1_ACX4O+Z/PS:Z;X#\)^&])T+XC>++BU\+:G?>(];UG0/#+:E
MKMEX?O-2\-WOC_\ P<)_\$__ (WP_M"_L:?\%F?V0? 6L_$[XP?L+>,? 5]\
M<OA'X-LI;KQK\2_@AX"\?_\ ">6>I>&].L8WO==N] 34O&GACQAI=I;WVM7W
M@KQ?'J%F([#P;=12_P!85% 'X&?M1?\ !>/]BR[_ &-]?\7_ +%'QL\/?M._
MM6_&GX>:SX<_9A_9@^"AD\?_ +1]]\8/%6BW6G>%[;QQ\$O#RWWQ ^'5IX(U
M:X'B#QHWC?1=!\K2M!U&UT=]4U:[T>RU%/\ @W<_X)1ZW_P2R_8DDT3XMV>G
MP_M0_M!^(+3XG?'I-.U)-7M_"OV*RFT_X?\ PLAU.UD;3-2;P'HEYJ-WK=_I
MXN;27QKXJ\70:=J^M:#;:)?R?N/I'@'P)X>U_6?%>@>"O"6A^*/$8 \0^)-(
M\.:/INOZ\!(LH&LZQ96<&HZH!*B2 7US.!(BO]Y01UM '\>__!3_ /93\??\
M$ZO^"R7[/'_!>#X7>#?$OC']F?5Y;3X>?\% =%\ Z#J'B#Q!\--!U;P#>_!_
M4_C?J/AC0;:YU36/ EMX(N/#OB76I=-L)7TKQK\.+:[UFX=O&=FT/TY_P5S_
M ."H'P5_:D_8K\=_L5?\$R/B5X3_ &X/VNOVY/!L?P;\%^ ?V:?$&E?%%?A]
M\,_B3)9Z)\4_B#\;-:\-7=WHWP:\-Z5X U+6-"O'^(NH>&]3T?6]?L+W5M/L
M]#T?Q+J6C_TUD!@58!E8$,I (((P00>""."#P17*>%O 7@7P-_:G_"%>"_"?
M@_\ MR\_M'6O^$6\.:/X?_MC4/WG^G:I_9-G:?VA>?O9?])N_.G_ 'DGS_.V
M0#\]?^"07_!/'0O^"87[!OP?_9:MKO3M:\=V$%[X\^-OBO29+N73?%GQG\:+
M:77C+4=+DO([::30M%CM-*\%>&)WL--N+OPMX5T2\U"P@U6XOR_PY^SO_P %
MX)OCQ_P6>^-W_!)IOV3O%_A73?A5/\2M&T_XX3>+)]0O;O5/A1ICZMJ_B7Q7
MX"_X0^RM_#'P\\:1O;6?@37T\6ZE)=SZAX3FGBG_ .$WMK30/Z&:R(?#^@VV
MMWWB:WT32(/$>J6%CI6I^((=-LHM;U'2]+ENY]-TV^U5(5O[NPTZ>_OIK&SN
M+B2WM);R[DMXXWN)BX!^0G_!=G_@F==?\%3?V ?''P*\&R:39?'#P-KVE_&/
MX :CK,D%GITWQ)\)6&KZ>WA/4]4E,8TW2_'WA;7?$/A%[Z>>/3M*U;4]%\0Z
MFD]MH?E'Y+_X)H?\%F_V3/AA^P'\-?AA^WW\<?"/[)W[7'[''PW\/_ G]HGX
M#_'[5#X(^-UWXB^$VC0^$]'\3>#/AUK"0^,OBVWQ#\,:+HOBN!OAEHGBEY=5
MUN?3(X?.6W\_^D:N2U7P#X$U[Q#HWBW7/!7A+6?%?APY\/>)M5\.:/J/B'0B
M',@.C:U>6<VI:61(2^;&Y@.\EOO'- '\K?\ P1I_8<^,'[1__!27]KO_ (+O
M_M6?"SQ9\(W^.&N:_P"&?V(_A1\2]-O/#GQ.T+X22Z38_#C2OBCXX\*3&.?P
MUJ%U\&_"_ASP/X8LK^28:W::[XX\1PV T2Y\$Z_J_O\ _P '+7_!*[XH?\%!
MOV8?AQ\9OV8+":__ &M_V,O$VL?$;X9Z'I8BB\1?$#P;JR:/>>-?!7AJX8QF
M;QI9:CX5\+>,O UI.\PO]3\/ZEX:TVV_M3Q7!*G]*5% 'X4> ?\ @X+_ ."?
M>I?L@:)\=_'?Q@\.:%^T):>%+72/&O[#]K<$?M=P_M"66G16&O? _P ._L^W
M8B^)VI:O<^/EG\*Z!XC;P['X0G26VU;4-?L--COKFT^5O^#<[_@F7\:_V>D_
M:=_X*-?MI^$9?!G[9/\ P4 \<^(_'EYX"U(7=OXA^$WPP\:>,+WXFZEH?B?3
M)Q ^A^,?'_C?58]?\1^&-0CN-3\+Z1X8\%Z9J)T;Q(?%6@V7]*8\ ^!%\6_\
M)\O@KPD/'7V0V'_":CPYHX\6_86C,+67_"1BS_MC[(T),1MOMGDF,F,IM.*Z
MV@ HHHH **** "BBB@#\E/\ @C5_R;#X[_[+SXG_ /5>_"ZOUKK\E/\ @C5_
MR;#X[_[+SXG_ /5>_"ZOUKH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\(_:1_:%\!_LP?"3Q+\6_B!=8T_1H1;
M:+HD$T<6J>+?$UW'+_8WAC1E=7+WVI31.TL_E2PZ9IT%]J]XJV&GW4B>O^(?
M$&B>$]"UGQ/XEU2RT3P]X>TN^UK7-8U&=+:PTO2M,MI+R_O[RXD(2&VM;:&6
M:5V/RHA."<"OXOO^"@?[:6M_MA?%V;4--EO].^$/@J6\TGX8^&[C= TEH\BI
M?>+]8M=Q5?$'B8P0S21-G^R=*AT[2$:2:VO;V^_1_#7@/$<;YTJ=95*629?*
MG6S7%1O%R@W>G@:$]EB<5RR7,OX%&-2LTY1ITZGP_'?&%'A/*W.FX5,VQBG2
MR[#RLTI))3Q=:._L,/S)\O\ R^JN%)6C*<Z?S5\>_CEX\_:-^*?BCXM?$74/
MMFO^)+O,-G"T@TSP_HUN6CTGPYHEO([FUTG2+4K!;QEFFN)3/?WLEQJ%Y=W,
MWZ_?\$C?V"!X^UG3OVI?B]HN_P $^&]1\WX2>&]2MR8O%GB?3;@JWC2]@E 6
M7P_X8O83'HD11TU7Q'!)=.T=IH7DZM\2_P#!/+]B76?VP/BN@UJ&]T[X,^!;
MBSU+XD>((A+ VHAF\ZQ\$:)=!0#K?B 1L+N>-P=$T1;O4W;[8VDV>H_V:Z#H
M6C>%]$TCPWX=TRRT70- TVRT?1='TVWCM=/TO2M-MH[.PL+*VB"QP6MI:PQ0
M01(H5(T50.*_:?%WCW#\-Y=#@CAJ5/#8N>$IX?&RPMH1RG+'3C&E@J')I3Q.
M*HV3M[V'PC4DE4Q%*I3_ "OPUX/K9YCI<69ZIU\-#$SK82.(O*68X]3<JF+J
M\R_>4,/5NU]FMB5RMN%&I">K1117\GG]&!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 52U/3=/UG3=0T?5[*UU/2M5LKO3=3TV^@CNK+4-/OH)+6
M]LKRVF5X;BUN[:66"X@E1HYH9'C=65B#=HIIN+4HMQE%IQDFTTT[IIK5-/5-
M:IB:3332:::::NFGHTT]&FM&GN?Q=_\ !1?]BW4/V1/C#+_PC]K=W'P:^(,U
M]K/PWU60RW TG9(LNJ>!M2NY-SMJ/AM[B(6,T\DLNIZ#/IUZ\\]^FJQVJ?\
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M$_A6:^GU6TL-0OM'L=6U+1KS1-3O=3NK"\M-'U*.ZCU:]MKRW!2TN+?QL_\
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ME&7QC\5Y)? ^DB"1D$=U;Z5>6MQXPU6TDC9IHKO1?#&HVDD:$BX!>$2?M?\
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M-A\=_P#9>?$__JO?A=7ZUT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ."-7_)L/CO_ ++SXG_]5[\+J_6NOR4_X(U?\FP^._\ LO/B?_U7OPNK]:Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _)3_@C5_R;#X[_P"R\^)__5>_"ZOUKK\E/^"-7_)L/CO_
M ++SXG_]5[\+J_6N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHXAT<%%.4:>*KV:KYE7LGRT*5-3=*4HMTL+&I5M&5:<%^A7_  1[_84P-/\
MVN/BOHPY$P^"'A[4[<$CEH+KXF75M,O!XFL?!9F7./MOB6*+!\-ZB?Z)ZJ:?
MI]CI-A9:7I=E:Z=IFFVEMI^G:?8V\5I96%C9PI;VEE9VL"1P6UK:V\<<%O;P
MHD4,,:1QHJ*H%NOY>XPXJQ_&.>8K.<<W",W[+!812<J>!P5.4O8X:F[)-I-S
MK5%&/M:\ZE7EBI*,?Z X9X>P?#&4X?+,&E)P7M,5B'%1GB\7.,55KS6K2;BH
M4H7?LZ,*=.\N5R91117RY] %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?ME_'U[JTUSXL:CX$\,W+.1X/^% G\!Z,L4A8/:W.H:==2^+-8M'1@CVFO\
MB75;8A%80AR[-^A/_!$K]IGXZ>(?CQXD^"/B;QAXK\>?#G4OA_K_ (O-IXFU
M;4/$#>#=7T/4="MK?5-+OM4N+FZTS3=3.J-I=_IL$JV-UJ%[87?D)=))++\Y
M@N.\OQ^:8?+Z&$Q7L\345*GB:GLXOVC3Y;T8N;5-M6<W4YHI\TJ:5[?L/$GT
M7>+>%N"<UXMS3/<B>)R?"2Q^*R;"_6JJ^J4W%UE#,:M.A2EBZ<).2P\<-*E5
ME%TZ6*G*4.;^HFBBBON#^9 K\'?VV_\ @C9?_M"_&W7?C1\(?B7X=\%3^/KV
MWU+QSX8\7Z;JMQ8PZV((+;4=>\/:AI"7<TC:NL(OKS1[^TAC75'NKB#5H[:\
M2TL?WBHKSLSRG YQAUAL?1]K3C456%ISISA4BG'FC.#C)7C*49*[BT]4VDU]
MAP5QYQ/X>YM4SGA7,%@,;6PM3!8CVF'H8O#XG"U)TZKI5L/B:=2E+EJTJ56G
M-1C4IS@N2:C*<9?B/\!_^"&G[.'@'[%JOQI\3^*?C?KL/ERS:2KR^ _ @E&V
M38=*T2^N/$]]Y,HV>;<^+8;.\B'^D:0BR-"OZ]?#OX5?#3X1Z&GAKX7> ?"/
MP_T%1'NTSPCH&F:#;7$D094N+T:=;0-?W?[R1GO+UKBZE>22269WD=F[ZBE@
M,GRS*XJ.!P5##NW*ZD8<U:2[3KS<JTUY2FUN5Q5XA<:\;574XHXDS3-H<_/'
M"5:_L<NI3O?FH99AE0R^A+1>]2PT).RNW9!1117I'QH4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?R4_P#!3;_D^#XV_P#=-O\ U47@&OZUJ_DI
M_P""FW_)\'QM_P"Z;?\ JHO - 'ZU_\ !&K_ )-A\=_]EY\3_P#JO?A=7ZUU
M^2G_  1J_P"38?'?_9>?$_\ ZKWX75^M= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DI_P $:O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.12UL>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML/CO_LO/B?\ ]5[\+J_6NOR4_P""-7_)L/CO_LO/B?\ ]5[\+J_6N@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M48QPM3$RQ-3VW/&7MZDN:=.,HP4J:Y*DY24WS64(W_G?Z07B+X7<78#(\FX
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M)-2TV'5EMAJ>E:C87T;VFLZ)>R65E<R6<K6MW;7-JDNG:C8BXOTO/E#X/?\
M!$C]D+X>3PZCX^?QO\:]4BD,BV_BK6CX=\+HR/NMVCT+P>-(OI]@ \Z'5M?U
M6QNCD2V8A8PG]B:*\FOD63XK%O'8G+\-7Q345*K5ASJ?(E&+G3DW2G*,4HJ4
MX2DHQBD[))?>Y5XH^(61Y#'AG)^+LYRS)(3JSI8/ XGZM.@Z\Y5*T<-C*48X
M[#4JE6<ZLZ-#$TZ+JU*E3DYZDY2X'X>_"KX9?";1U\/_  P^'_@WX?:*%C#:
M=X/\.:3X>MIVC#;9;M=+M;8WMR2[O)=7;3W,LDDDLLKR2.S=]117J0A"G&,*
M<(PA%6C"$5&,5VC&*22\DDCXC$8G$8NM4Q.+KUL5B*TG.KB,15G6K59O>=2K
M4E*<Y/K*4FWW"BBBJ,0K\QO^"H'[&4?[47P8D\4^#M,6;XT?"BSU#6O"'V:
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M>QHXF=.6/RO%TUBLKS%4KJ"Q6%E*+C.*E*,<3A:N&Q<(.4(8B,)2B_\ .?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@O[2"\A295=%E6*XCD195221%D"A@LCJ#AF!R/\ A#?"'_0J^&__  1Z7_\
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MU^RQ?^'[C1(;91'+:ZCI]U'>7%Q<^9?WMU<7-SJDDVHS74C]#\(?^";/P_\
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M$\8?##3OC?IFE>!H'=X-)\,:MX>G\3_"6^L3&LNJ:YX%\ %;CS[6Z?5/9_\
M@Z__ &\OBMX'\&_LS_\ !,/]G+Q%J/A?XI_MW^)[>P^)/B#1M4GTS5+?X0W_
M (ET[X>:%X"$EIY5XNF?%SQMK=Y:>(+FVO+83>&? FN>%[V"^TSQ;?1P@'[.
M^(/^"[?_  25\,^-+GP1JO[:?P^,ECXGC\&7_CS2?"_Q0\0_ S3O%,H++HFI
M?M&>'_ FJ? '3KU5#/*E[\2H$A1)'F=$C<K^K>C:SI'B+2-+U_P_JNFZ[H.M
MZ?9ZMHNMZ-?6NIZ1J^E:C;QW>GZGI>I64L]G?Z??6LL5S9WMI-+;7-O+'-#(
M\;JQ^8/A7^Q)^S;\)?V/O#O["NA_#/P[J/[-^B_"?_A3VI^ ]8T^WNK#Q?X9
MO='?2_$M[XJ 1&U7Q!XPGN+_ %SQ+KDK?VEJ'B#4;S6'N1?2"=?Y;?\ @VF_
M:I\>_L^?M>_MY_\ !#;XM^*=8\4:%^RC\2OC%KO[*^L^)[J6?5;3P!X$^*,G
M@_Q?X.M)9"T(T/7+/6_"?Q5\)Z1;I;?V>VL>/[H1M;7,%MIP!_:'1110 444
M4 %%%% 'Y*?\$:O^38?'?_9>?$__ *KWX75^M=?DI_P1J_Y-A\=_]EY\3_\
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M5&$(1BE&,8Q2C&*22222L@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BFNZ1(\DCK''&K/)([!$1$!9W=F(555069F("@$D@"OA?XU_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGBA[>/PS<^ M3T&_LO&%OXBDO&2TCT*;P]/J,>KO=.ENNGM<-.RQ!B/YG?\
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M=CKGAOXL^,O G[7G@R"UEEPEY)I/@3PAK>B7EQ:?,NNZ!JUD%C,5U O]D_\
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MO$'QH3P?KT9\F1'2WG\,3W5K=1@_9WMVG-U'+#).CX__  6OGO/B7_P=?_\
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MCF?@C_X(?A?_ /0_4?\ "J?^"\'_ $<S\$?_  0_"_\ ^A^K]VJ*U_U<I_\
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M#N R&-?+J'#F6X^G2Q,<%",J[6)Q56:=2;C&T>2,6I.7UM117C'[1MIX_O\
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MV +.@AU&T79=V\<T_P#9NK6^HZ1/*UUI]P!_7OA1Q;A.-N',5P;Q#R8K&X/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %?R4_\%-O^3X/C;_W3;_U47@&OZUJ_DI_X*;?\GP?&W_NFW_JHO -
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M,<\&I:#XI\-W\L%U'IGBKPCX@LM+\3>&=2DM;J&RUO2K&>YM+RV6:TF_%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%:,5LD%%%%49A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $4\$%U!-:W4,5S;7,4D%Q;SQI-!/!,C1RPS12*T<L4L;
M,DD;JR.C,K*5)%?B#^V9_P $7?A?\7I-2\=_LUW.B_!KXA7#R75[X-N8;B'X
M4^(KAR"QM;/3;:[N_ 5VP+,6T&PO] D,<<2^'+&6>YU(_N'17GYEE6 S:A]7
MQ^'A7@KN$G[M6E)_:I58VG3EHK\KM)+EFI1NCZW@[CKBG@+,XYKPMF^(RW$/
ME6(HQ:JX+'4HMM4,?@JJEA\52UER^T@ZE%R=2A4I55&HOYR_^">__!(OXR_!
MK]H#PS\;OC[JOA+2=.^&UQ=ZIX6\+>%]:D\0:EXB\1SZ;=:?8W>I7<-I:66E
MZ+I!OGU) ES<ZA?ZC9V]I+906#S3R_T:445GE&3X+),-+"X&,U3G4E6J3JS]
MI4J5)*,>:4K16D8QBHQC&*2O;F<F^OC_ ,0N)/$G.J>><35L-/%4,'2P&%H8
M+#_5<'A<+2J5:WLZ-)SJS;G7KUJU2I6JU:LI5.7G5*%*G3****]0^'"BBB@
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M0\:?:-!\$6Z1R>7<G3KR2WFO_$]S P,<EGX7L-7EMYRB7[6,3-.G]*O[*?\
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M5 554 *    *=117UY_/N^X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_)3_ ,%-
MO^3X/C;_ -TV_P#51> :_K6K^2G_ (*;?\GP?&W_ +IM_P"JB\ T ?K7_P $
M:O\ DV'QW_V7GQ/_ .J]^%U?K77Y*?\ !&K_ )-A\=_]EY\3_P#JO?A=7ZUT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^2G_  1J_P"38?'?_9>?$_\ ZKWX75^M=?DI_P $:O\
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MX$\*_$[P7XG^'WC?2+;7?"?C#1KW0M>TJZ7,=U87T312&-Q^\MKNW8I<V-[
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M3E9J4+2JX92^RJM"ZY*%-_K71117\T'[P%%%% !1110 4444 %%%% !1110
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M9676/$VJ6VF6\L^QGCLK%)G%QJ>I7 1A::7IT-UJ-Y(!%:VLTA"'\"?VIO\
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MN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY*?\ @IM_R?!\;?\
MNFW_ *J+P#7]:U?R4_\ !3;_ )/@^-O_ '3;_P!5%X!H _6O_@C5_P FP^._
M^R\^)_\ U7OPNK]:Z_)3_@C5_P FP^._^R\^)_\ U7OPNK]:Z "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _)3_@C5_P FP^._^R\^)_\ U7OPNK]:Z_)3_@C5_P FP^._^R\^)_\
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MP[\2/^";W[%WQ:^)5S\6?'/P2TG4O&6HWC:EKD]CKWBS0-(\1ZFTGG'4]?\
M#V@:[IFB:E?S3EY[^ZEL1+K,LDC:VVI!@!\CQ;D..S[#X2C@L52H*A5J2K4:
M\JL*5935-0FW2A4;G0Y9\D90LU4D^:+2O^_> ?BGPOX6YKG^/XCR/&YE4S+
MX6CEV8990P=?'Y?/#3Q,L1AH1QF)PD88?,E6H_6*M/$*<9X.A&5*I3G*5/\
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M*6L4DHD73](T^(&;5=?UFXC21K71]%L$FO\ 4)PDDIAA\BUAN+R:WMIOZO\
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M\8R7T[1:AK-KX:N=1,K7<_A2VN5CTQFDG FEMH;@7UKI[LSK_9UO:) YMUA
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M8.#:4<@R[$1^IY;4E%IIYSF4:=*45*-6%"A.K%.#9Q8K]_5I8-?#+]]B+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7\E/_!3;_D^#XV_]TV_]5%X!K^M
M:OY*?^"FW_)\'QM_[IM_ZJ+P#0!^M?\ P1J_Y-A\=_\ 9>?$_P#ZKWX75^M=
M?DI_P1J_Y-A\=_\ 9>?$_P#ZKWX75^M= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DI_P1J_Y-A\
M=_\ 9>?$_P#ZKWX75^M=?DI_P1J_Y-A\=_\ 9>?$_P#ZKWX75^M= !1110 4
M444 %?E]_P %-?VY[;]E3X9_\(7X&OX7^.GQ*TR[@\,+&\<DO@?P[(9;*^\>
MWL'S8NHY5FL/"<$ZK#=ZU'/?NMW9Z#?V-S]<_M2?M(^!_P!E;X/>(_BOXVE6
M?[#'_9_A;PY'<)!J'B_Q9>12G1_#VGE@[*;AXI+K4;Q8IETO1[74-3DBE2T,
M4G\0WQF^+_CCX\_$SQ;\5_B)J;:IXI\7ZG)?W;+O6RTZU15@TW1-)@D>5K31
M]%T^*WTS2[4R2/%9VT7G2SSM+/)^T^$'AY_K1F/]MYM0;R#*ZT>6G4C[F:8^
M'+.&%L])86A>-7&/6-2]/#6DJM9TORSQ+XV_U?P/]E9=5MG.84G>I!KFR_!S
MO&6(=M8XBM:5/#+1PM.O>+ITU4\]_P")CK.H_P#+[JNK:K>_]-[[4=2U&^G_
M .VMS>7MY<R_]-)[B>3^.1^?[!_^"97[#EM^RG\+_P#A,/&^G0'XZ?$O3K2Y
M\5R2)'+-X+\/NT=[IW@&RG^;9-!((;_Q9+;L(KW74AL_,O;/0-+O)/S\_P""
M0/[!PU2YTO\ :V^+6C!M.L9Y)/@GX;U.V#"\U"VE:&7XE7EM,I'V?3IXY;;P
M8)5+2:A'/XEA2);'P_?7/]']?1^-?B&L95J<&Y+6_P!CPM1+/,12E[N(Q-*2
M<,MIN.CH86<5/%6;Y\3&-'W5AZBJ^'X5<%/"TX<49K2_VG$0;RFA47O4:%16
MECIIZJKB(MQP]_AP\I5?>=>'LRBBBOYS/V\**** "BBB@ HHHH **** "BBB
M@ HHHH **_/K_@H1^WAH7[#OP]\-ZI%X:3QM\1OB%>ZMIW@7PQ<WTFFZ4L6A
MV]G+K?B/7KR&*:X_LK1Y-4TB#^S[,17VK7>I06T%S90)>:A9_P P/QS_ ."I
M/[:'QV^VV.I?%.Z^'?AF\$B-X3^$L,O@?3UAE8^9;S:U:W5UXTU"VDC*P2VN
MJ>*+VUDB4J8!YL_F_*YUQ?E>25I86JJV)QD(QE+#T(JU/GBIP]K5G*,(<T&I
M6C[2:C*+<+23?[GX;?1^XW\2<!0SO!RR_)^'J]:M2I9MF=:;EBOJU65#$O 8
M'#4ZN(Q'L:T*E'GK/"X>=6E5IQQ#G3FH_P!??QJ_:S_9O_9WMY9/C%\8/!G@
MZ]CB:9/#TVHG5O%]S&$5]]GX.T*+4_%%W&0\8\Z#27A!DC#R+O4G\>?CE_P7
ML\ :.;O2OV>OA'K?C2\42Q0^+?B3=IX6\/)*H_=75GX9T>74M>UFRD)YCO\
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MU,JH4L+FF39K5=.481IUL54H5\ YU&I)U:%:6$B_:4L57K0BG^G:G<JM@KN
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M7/VE_B78^"=/?RIIO GPU^S^(?%+Q-_K+74?%VHP-X9T2[C(()TK3/&5I*K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_)3_P4V_Y/@^-O_=-O_51
M> :_K6K^2G_@IM_R?!\;?^Z;?^JB\ T ?K7_ ,$:O^38?'?_ &7GQ/\ ^J]^
M%U?K77Y*?\$:O^38?'?_ &7GQ/\ ^J]^%U?K70 4444 %%%% !1110 4444
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M(X(K_/6\9^#?%'P\\5^(/ _C71+_ ,.>*_"VJ76C:]HFI1>3>:?J%G(8YH9
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MH/(F\3R/+&1LEL;9K+PAI\K*SV.O:GJ (,4K&OTV\8S^(K;PCXIN?"%I!?\
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M S6E_;O;R/$Y5O*N(@XFMIU&^WN(XIHR'C4C\]_^%Q_\%$_^C>OAW_WXNO\
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M_'3]M0Q-3DEHO>CS<K=E=J]EL?R[XDY1_J_X<<#9$\70Q[R;C?Q6RKZ]AO\
M=\7_ &?F61X7ZS17-.U.M[+VD%SSY5)+FE:[Z2BBOQ!_:U^+7CSXF?&C6[OX
M7S:I)X9_9LMX]3?5-)F;[/8ZU9ZU8:?KGB9@K^7.T.L75MHT2Q^?OTK2;W4$
M3^SWU&1.7CSC?"<"Y31S&O@Z^9XG%8N&&PF6X6?)B,1&$)XG'5XOV=9QI8'
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M8R%D:UN(;A49@2H<PNX4D D!L$@$BKA7H5;>RK4JG,KQY*D)\RWNN5NZMK=
MFGLT_1HM4445J,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH P_$WB/2/"'AW7/%.O72V6B^'M*OM9U2Z;!\FRT^WDN
M;AD4D&24QQE(85.^:9DBC!=U!_"SP1\?_B/H/QTL/VH?%%KJT'P\^(/C/5_!
MFJDRRS:<OARTCT\OHEM$&W2_\(GIVH:;J&EMY<<>H:AI5]'%+),NJJGV7^WM
M\0=8UZ3P-^S1X$8W7BKXE:MI5UKMO"[#R]*.HK;Z#IUV\8?R;?4-7ADU6_D<
M*;2QT..>8&UNF)]S\??LP^'M9_9D3X%:'%#]J\-:%!=>%-1E2.%Y/&NF)->_
MVM.Q.RW?Q'J-QJ4&J2#<(;76KWRE^2,+^"\;0S_C;B''X3A;&5,-'PVP]'-Z
M-2D[TLTXUFZ>*PF4S7P5:6'RNG7P]=1FO98G,70Q,?9R:/)Q2K8FM.-"3C]2
M2J)K:IB7:4:;[J---.STE.TM-#ZLMYX+J"&ZMIHKBVN8HY[>XA=989X)D62*
M:*5"R212QLKQNA*NC!E)!!J6OA+]@KXO7/C7X8W/PX\222Q>,_A+<)X?N+:]
MW1WTOAO?-#HCRQ2[9!+I#VUUX>N8@F;6+3M/:=O-O #]VU^N<,9_A.*,@RO/
ML'[M',<+"K*DW>>&Q,6Z6+PE1V7[W"8J%;#U-$G.FVM&F>A0K1KT:=:.TXIM
M=8RVE%^<9)I^@4445[QL%%%% !1110 4444 %%%% !7\E/\ P4V_Y/@^-O\
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M6=7U*XEO-1U75-1N'NKV^O;F9GFN+J[N99)II79G>1R2>:_J8_X)3_\ !/\
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M@MH4J-*,:=."N[1A%)=CMC&,4HQBHQ2LHQ222[)*R2] HHHK<84444 %%%%
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MPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;7+6C.JDQ>'?#1L/#EK<)NCN7O\ 5"^+JV<C]1JX+X7_  ^T?X5_#_PK\/\
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MPU=36SP?%/P!8S>'IHM'TLVT4.GW][87LURM_J$D=U8*/IS_ (:=_P""W/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*%.<G:\G%<SMHKR5F[+35[:'YG7O_!,7X92$?V?\1?'=J-[DB]M_#]^3&?\
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ME\3ZOYL>VYL]',+?\(QI$F55U\C3[B35)X9%66WO]8O+:3/V=,?:=(JJJA5
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M@SS;3QI\)-1L;B[O;-?]+/A[^T8KNSO@0&:1O#6NF&]C3;Y<=EJ6KW,Y\N$
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MI48\M*G3I1_EIPC".FVD4EIZ"22V27IH%%%%:#"BBB@ HHHH **** "BBB@
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M'_#'7[2O_1YOQ$_\&OC[_P";NO,SK.N)L^RG,<FS#PJSRI@LSPE;!XB/]O\
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M*K<:KJ4UWJ%P%.U9;EU3"*H'X=GG$?#V;^).$RW.L^R7+,EX!IT\SJ4LTS3
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M;?\ NFW_ *J+P#0!^M?_  1J_P"38?'?_9>?$_\ ZKWX75^M=?DI_P $:O\
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M^3U?^"F?_96]2_\ 5L?%JOWMK\$O^"5'_)ZO_!3/_LK>I?\ JV/BU7S>;_\
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M:-*M'"U*O+[>G%.7+*/M&U!J[/["\!,B\/?%O@ZOX=YYGN8X+-\EXHS;C.&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC=7%M+'*WW1^QE_P4I^-'[)LUCX5O))?B7\&?M ^T_#[7;^1+OP_#*X:XN?
M>N2+<3:!*&S.^C317GAR[D>Y;^SK+4+R35HGQOX)8/,J4L[X&J4*<ZT/K']D
M*M!X#%PJ+G53*\5S.GA_:)\T*%2;P<E)>RJX:G&,)+A/Q6Q6!J1RKBV%:<:4
MO8?VFZ<EC,-*#Y'#,,/RJ=;D::G6A%8F+B_:TZ\Y2G'^S2BOGW]G7]I_X-?M
M2>#(_&?PC\50:M'"L*:]X;OO+L/%OA.]E4D6'B/0GEDN+-BRRI:W\#76CZGY
M,TNDZE?01M(/H*OYBQF"Q>78JM@L=AJ^#Q>&FZ=?#8BG.E6I36O+.G-*46TT
MU=6E%J46XM-_ON%Q6&QN'I8K!UZ6)PU>"G1KT)QJ4JD']J,XMQ>MT];IIII-
M-!1117,;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G?C
M'X2?##X@WUKJ?CCP%X4\5ZC96@L+2^UW1;+4+N"R$TMPMI'<7$3RK;+///,D
M.[RTEFF=5#2R%N1_X9F_9\_Z(U\._P#PE],_^,5[E17DXC(,BQ5:IB,5DN4X
MG$57S5:^(RW!UJU2222E4JU*,IS:22O*3=DELD9NC2DVY4J<F]VX1;?JVKL\
M-_X9F_9\_P"B-?#O_P )?3/_ (Q1_P ,S?L^?]$:^'?_ (2^F?\ QBO<J*Q_
MU8X:_P"B>R/_ ,-. _\ F<7L*'_/FE_X+A_D>&_\,S?L^?\ 1&OAW_X2^F?_
M !BC_AF;]GS_ *(U\.__  E],_\ C%>Y44?ZL<-?]$]D?_AIP'_S.'L*'_/F
ME_X+A_D</X,^&?P]^'8U >!/!GAOPE_:IMCJ9T#2;/37O_L8F%J+M[:)'G6V
M^T7!@61F6(SS% ID<MW%%%>KAL+AL'1AAL'AZ&%P]/F]G0PU*G0HT^:4IRY*
M5*,81YIRE.7+%7E*4G=MLTC&,4HQ2BELHI)+T2T04445N,**** "BBB@ HHH
MH *_DI_X*;?\GP?&W_NFW_JHO -?UK5_)3_P4V_Y/@^-O_=-O_51> : /UK_
M ."-7_)L/CO_ ++SXG_]5[\+J_6NOR4_X(U?\FP^._\ LO/B?_U7OPNK]:Z
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MF,PVOBC]AGQ]XD\-1G+$&)/!FJ0V%KN.) UN44.R*/\ 17K^'#_@N-\&;_\
MX)X_\%Q_^"=__!9S2M)GTSX"^/\ XF_##X6_M1^.HK8SZ;X,\1V.F7?PF\0:
M]KTL,;/:CQ/^S3J=S;Z#&\;+=7?POUF,W4<UQ;14 ?W'U_G:_P#!KE82:O\
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MQQT/4/ASX<M?#MF9HI]2U/0XM=U'QI=06HGDM-!\+:SJ\T$MGIMTM '\R/\
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M(/9UZE'^ULPA:7UO'0C*G3FK/FPV$]ZC1LTI0G/VU>#^&LMA  H"J JJ %4
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MH>NZ>)1IGBCPAXGT2\TSQ/X-\5Z6)[A-.\2^%]7TG6K6&YN[6.]^R7EW!/\
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ME?UZBBBOVDXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .>\7>%="\=>%/$W@GQ19#4O#7C#P_K/A;Q#IQE
MFMQ?Z'K^G7.E:K9F>VDBN(/M-C=SP^=;RQ3Q;_,AD2158?SP6J?%[_@CA\;9
MQ+!K/Q-_8L^+>OQF6[BABDU70K_RRD3R2*L%IIWQ#T+38MAAD:ST+XC:!9$Q
M?V?J-A_Q2G](%<3\1OASX*^+7@KQ#\._B)X>L/%'@_Q182:=K.C:C&7AGA<J
M\4T,J,EQ97]E<)%>:=J-G+!?:=?06][97$%U!%*GU_"O%$<C>+R[,\(LUX:S
MA4Z6<Y5)VE*,'>ECL#4;B\/F.#;]IAZL91C-I4ZCC^[JT?FN(>'WFRPV.P&(
M>7Y]ECG4RO,8J\8N2_>83%T[-5\#B4N2M3E&3BFYP3]^G4F\ >/_  ;\4O!O
MA_X@?#_Q!I_BGP?XIT^+4]#US3)3);7EM(61U9'5)[6\M9TEL]0T^\B@O]-O
MX+BPO[>WO+>:&/L*_G&AF^,__!'3XS_9KG^W_BC^Q)\4=?)CD 6>_P##-_.O
M+H/W-CI'Q#TBQA'G0YL="^)6A6.]/L&I6 /A/^@GP!X_\&_%+P;X?^('P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B?B-\.?!7Q:\%>(?AW\1/#
MUAXH\'^*+"33M9T;48R\,\+E7BFAE1DN+*_LKA(KS3M1LY8+[3KZ"WO;*X@N
MH(I4_GY6Y^-/_!''XQR0S1^(?BO^Q/\ $_7)'@$9BEU+P]J4L9($1D>VTS1O
MB+I=E %DCDDT[P_\2=$LA)NT[4;#=X3_ */*YCQCX*\(?$/PYJ7@_P >>&-!
M\8^%=8C2+5/#WB72K+6M'ODBE2X@-QI^H0SVSR6US%%=6LQC\ZUNH8;FW>*>
M*.1?K^%^*GDD<5EF9859OPSFJ4,VR:K-Q4I*RIX_ 5/^83,L,XQE2KPY?:*$
M:=1KEI5*/S7$'#RS5X?'X'$/+<^RYN679G""DXIMN>$QE/;$X&O=QJ49WY7)
MS@M:D*G\_'PO^%_QB_X*U?&*#X[?':#5? W[)'@;5;NU^'_P_M;NYMAXH%M<
MA+G2=)N4%N]W)=O;QQ^/_'\<<4TLT1\+^%S:/:._AG^A?0- T3PKHFD^&O#6
MDZ?H/A_0=/M-)T71=)M(;'3-+TRQA2WL[&QL[=(X+:UMH(TBAAB141%  I^A
MZ'HOAG1],\/>'-(TW0= T2QMM,T?1-&L;;3-)TK3K.)8+2PT[3[.*&TLK.VA
M1(H+:WBCABC541%4 5J5GQ1Q36XAJX;#X?#PRO(<K@\/DN28>3>'P5#[56I)
MZXG'8EKVF,QE2]2M4;U44D7P_P /TLEIUZU:O/,,XS":K9KFM9)5L76M90A'
M54,)17N8;"T[4Z4$M')MGS!^T7^QS^SY^U+I36?Q9\"65[K<5L;?2_'6AE-$
M\=Z*NTB+[#XBMHFENK: DO%I.MPZOH9E/F2Z7*X##^?C]I'_ ((L?&WX=B_\
M0_ 77;3XT>%X?,G'AN[%KX<^(]C;J&D*1VEQ.OA_Q,((T(:;3M0TS5;R9DBL
MO#4C,0/ZIJ*]#A7Q(XKX1<*679@\1E\7=Y7F"EBL#:]VJ47.-;"WU;>$K4.:
M6LU/8XN(>!N'>)>>ICL&J.-DK+,,$XX?%WZ.I)1E2Q%ME]9I5;+2#CN?YYGB
M7POXE\&:W?\ AKQ?X>UOPKXBTN8P:EH7B+2K[1=8L)AR8KS3=1@MKRV?'(6:
M%"00PR"#7T5\ OVT_P!I3]FJ:"/X6?$[6K'P]%+YDW@?7''B3P/<AV#3J/#>
MK_:;/39;D@">_P!#_LK5755 OU"C']GWQG_9S^"'[0FCC1/C'\-?#/CBWB@D
MM[&_U&S:V\0Z1'*79QH?B?39++Q%HNYW9W&EZG:+(_,H>OQ$_:$_X(:*?MVO
M?LS?$DKQ)/%\/OBBV0<*9&M](\<:/99!+ PV%GK7A\CYH_M_B,;9+@_T%D_C
M)P5Q3AEE?%N7T\ME62C4IYA0AF6359[)JO[*4Z#NW)2Q.&ITZ*:_VJ37,?C&
M9^%_%7#U=X_AO&SQT:3<J<\%5E@<SIQNFTZ7M%"JE9)JC7G*K9_N$GRGH_[/
MW_!</X:^(UM-&_:-\!ZA\.=68+'-XS\"Q7OBGP9*^-SW-YX>D:;Q?H4/6..V
MT]O&DKLH=YHE<K'^Q_PN^-GPC^-FC'7_ (3?$7PCX_TQ%1KI_#>M6=_=Z<96
M=8XM8TM9%U31;ARC%;75K.SN"H#B+8RL?X=/C/\ LS?'K]GS47T_XP?"[Q7X
M,3[0;:VUF\L#>^%M1F#. FE>+=+>^\-:HY"%_*L=4GF1&1I(TWKGR?PWXH\2
M^#=9L_$7A#Q%KOA7Q!I[F2PUWPWJ^H:'K-B[ JSV>IZ9<6M[;.5)4M#.A()!
M.*SSCP0X0X@H_P!H\*9H\M5=.=)X:M#-\GJWU_=?OO;TU)OXJ>,J4J::Y*%H
MJ+O*_%CB7)JOU+B++UCW2:A4]O3EEN9T^G[S]U[*;BM5&>&A.;7O5KOF7^AG
M17\B/P2_X+&_M9?"]+/3/&]UX<^-OAZWVQM'XULCIWBM+96WF.U\7Z +.>:X
M8E@;WQ'IGB6;8VSE4C"?KE\%_P#@M#^RQ\0Q:V'Q)M/%GP1UV8*LKZ]8R^+/
M"/GO@)#;>)?#%K-J07=E7N=8\+:):1#:\DZH7,?XMGW@_P <Y&YSCEG]L86%
M[8G)IO&2:6JO@W&GCT[:RY<+.$7=>T>C?ZGD_B9PEFW)!X]Y9B)67L,TBL,D
MWVQ*E/!M7T5\1&;T?(ME^OE%<#\/_BK\,OBMI8UKX9?$'P9X_P!+"(TE[X0\
M2:1X@BMC)D".\&F7=R]E<*RM');7:P7$,J/%+$DB.B]]7YG6HUL/5G1KTJE"
MM3?+4I5J<J56$EO&=.:C*+7:23/O*56E6IQJT:E.K2FKPJ4IQJ4YKO&<&XR7
MFFT%%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%>;>+?C+\'_  "95\=?%;X;
M>"C 2LP\6^.O"_APPLKO&1*-8U2S,9$D<D9#X(='4_,K :T:%?$35/#T:M>H
M]J=&G.K-]-(0C*3U\C.K6I4(N=:K3HP6\ZLXTXKUE-I+[STFOF3]JS]JSX9_
MLD?#.\^('Q O!=:C="XLO!?@NRN(H]?\;:_'$'33M.1Q)]FL+;S(IM;UN:)[
M/1K-U=UN+VXT_3[[PGXP_P#!4;]COX6>%=>U;2/BMH/Q.\4:?92OH7@SP%)>
MZS<>(=49%^R6(\06=A=>'=)M&=U>^U.^U 1VEM'<&WM[^_2#3KGX-_95_9:^
M)W[>GQ/MOVU_VT(FN/ <TD5U\'OA%/'-%H>JZ);W#W&D2/I-P[FS^'%D[?:+
M*RN-]]\0K]I=:UN6XT2=F\3??9%P:L/0J\0\:4L;DW#F!G%>PK4:F%S+/L7*
M+G2RS*J->-.I)54F\1C$E2P])3:J*49U*'QV;\4>VJT\EX6J87-,\Q<9/VM*
MK#$8#)\.I*%3'YC5HNI"/LVTJ.%=ZE:HXIP:E"%5W[*_[*_Q1_;P^*-O^VI^
MVI;R2^!99(KKX/\ P?NHIX-%U/18)VN='DDT>Y9FL_AQ9LPN;*RN0U]\0KYI
M=:UJ6XT.X9O$W[_111PQQPPQI%#$B1111(L<<4<:A4CC10%1$4!410%50
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC*S4E>,HR91117CGIA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5_)3_ ,%-O^3X/C;_ -TV_P#51> :_K6K
M^2G_ (*;?\GP?&W_ +IM_P"JB\ T ?K7_P $:O\ DV'QW_V7GQ/_ .J]^%U?
MK77Y*?\ !&K_ )-A\=_]EY\3_P#JO?A=7ZUT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^2G_  1J
M_P"38?'?_9>?$_\ ZKWX75^M=?DI_P $:O\ DV'QW_V7GQ/_ .J]^%U?K70
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU]XHO+HAR#(WFW,I#NP0J@5%Q[__ (([?L-WBQK;^"/&6E%&8L]A\1?%,C3
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M_9G^-B)*0(Y=5^'?B7P_!(&B\Y9%N-?T_3(&A>/!2<2>2[$1K(9&"GV/0/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?'?_ &7GQ/\ ^J]^%U?K77Y*?\$:O^38?'?_ &7GQ/\ ^J]^%U?K70 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:O\ DV'QW_V7GQ/_ .J]^%U?K70 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML\3W,$/B*W\I-UW=>'[H"*T\7:/ RNQO])5;RVM_)FUK2=&>XB@/X*_MF_\
M!([XJ? QM8\>_ [^U?B]\*+99[^ZTR&W2?XD>#;&/+R_VII5E%&GBK3+6/YW
MUKP]:QW<4*SS:EH%A9VCZC/^16E:MJWA_5+'6=#U+4=$UK2;N&^TS5M*O+G3
M=4TR_M9!+;WEC?6DD-W97=M*JR0W%O+'-#(H='5@"/V?.>$.!O%G+I9WDF,H
M8?-)12>9X*$8UXUW%..'SK+VZ<ZDTE;FJ>QQ/*HRHXB="T9_EN6<3<7>'&-C
ME6;8:K6R]-M8#%3<J4J2EK6RK&KGC"+;ORTW4P_,Y*K0C6;<?]#^BOYI_P!C
M;_@LYK7AF+2OA]^UE;WWBC18C!96'QAT2S%QXGTVW&(HV\;Z#:HI\2V\"%3-
MKNBQQ^(?)A9[K2?$NHW$EU7]$_@+XA>!_BEX7TWQK\.O%>A>-/"FKQF33]=\
M/:C;ZE83%<>; \L#L;:]MF/E7EA=+#>V4X:WN[>&='C7^7N*^".(>#L4Z&;X
M.2P\YN.&S+#J57+\6E=KV5?ECR5&E=X>O&EB(KWG3Y7&3_H#AWBS)>)\.JN6
M8J+KQBI5\#6<:>-P^R?M*/,^:";LJU)U*,GHI\UXKL:*^$_VY?VY? G[''@0
M2RBT\4?%WQ1:3K\/?AZLY\RYDR]N/$GB06[BYT_PII]R"KNIBO-<O(FTG265
MUU#4-*_%X_"[_@I/\%]/L_\ @I#J>N:CK/C?6;V?6?B5\,-0&HSZM9_"N5(+
MBQC\7>$H6ALX?"*VYN!<>%=+2VU7X<Z<FD:[$-.O[75)/#/H\.\ 8K.\!',<
M9FF R"ACZLL%P]_:CE!Y]F<5?ZMAO>BZ6&37LJF82C.C'$SI8>$*M2<E3XL[
MXRP^58V6!PN7XS.*N#IQQ6=?V>E-9/@&TO;U]&JF(:?M(8*,HU94(U*TI4X1
MBY_U&T5\M_LE_M:?#/\ :\^&=MX[\"7(L-:L!;67CKP+>W,4NO>"M>EB9S9W
M@18C?:1?&*>;0-?A@BM-8M(I 8[/4[/5-+T[ZDKXS,,OQN58W$Y=F.&JX3&X
M2K*CB,/6CRU*<X]&M5*,DU*$XN4*D)1J0E*$HR?U.#QF%S#"T,;@J]/$X7$T
MXU:-:E+FA.$OQ4D[QG"24X34H3C&46D4445QG2%%%% !1110 4444 %%%% !
M7\E/_!3;_D^#XV_]TV_]5%X!K^M:OY*?^"FW_)\'QM_[IM_ZJ+P#0!^M?_!&
MK_DV'QW_ -EY\3_^J]^%U?K77Y*?\$:O^38?'?\ V7GQ/_ZKWX75^M= !111
M0 4444 %%%% !117F5K\9/AI>?&36_V?;;Q7:2_&+PY\,O"WQDUOP.+34Q?6
M'PT\:^*O&'@GPOXKDOVL5T:2TU?Q3X \7Z1#:0:E+J<,VB3S75C!:SV<]R >
MFT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DI_P1
MJ_Y-A\=_]EY\3_\ JO?A=7ZUU^2G_!&K_DV'QW_V7GQ/_P"J]^%U?K70 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5^6O[9G_!++X-?M,+JGC3P(EA\(OC+<>?=R>(=)L OA3Q??/F0K
MXU\/68C3[9=3;O-\4:,D&LB2>2[U6#Q%Y4%HOZE45[&29]F_#F.IYCDN.KX'
M%4[)RI2O3K033='$49*5+$49-)RI5H3@VE*RDDUYF:Y/EN>82>!S3"4L7AYZ
MJ-1>_3G9I5*-6+52C52;2J4I1DDVK\K:?\&7[0G[+GQM_9?\4?\ ",?&#P7>
MZ$+F69=#\26F[4O"'B>&$Y:X\/>(H$%E>D1E)I]/F-KK.GQRQ#5--L99%CIG
M[/G[3OQN_9D\4KXG^#OC34- DNIH/[9\.S#^TO"GBB*([5M/$'ARY+V.H9C>
M2""]C2#5]/6:5]*U&QN'$P_JX_X*0_M2?!'X#?!K4?"/Q(\)>&OBSXO^(FGW
M5KX-^$6OVL6HV.IR(6@7Q3XACP;C2=!T2[826^H6<EKK-[JD267AZYM;N*[U
M32?B?_@F;_P3*3PG+HO[27[17AJ&'Q;,\6N?##X5:E;2-;^"XY&%SI_BKQ58
MWK3RMXEC5HYO#VA7SS2>&4$6IZMYGB<V\'A[^J<#XHX7'<!XG..-\BH0I5W+
M X+"-4ZF&XIK0B_:_4L'B54J4:%"HHK%5ZJKX6C*[I5YUH_5X_SSB_#[$83B
M^AEG"F;UI5*2CB\7B4ZE.OP_2DUR?6L50Y*=6M6@Y2P]&#I8BJK*I2A2E[>7
M>_L-?L->._'/CL_MK_MKF[\4?%_Q1=P>)/ G@3Q) /+\'QX231_$'B#1Y$%M
MI^JZ?;"!/!_@]((K/P59Q6UW=VR^(5M;7P[^V+HDB/'(BR1R*R.CJ&1T8%61
MU8%65E)#*0002""#3J*_EWB/B/,.)LP>.QKITJ=*G##8# 8:*I8'+,#27+0P
M6"H1M&E1I126BYJDKU*CE.39_0&1Y'@LAP2PF$4ZDZDY5\9C*\O:8O'XNIK6
MQ>+K/WJE6I*[U?+"-H02BDC\!_VL?V3OB=^Q)\3Y_P!MK]B6![/PU9O<7OQ>
M^$-E;S7&B6>B7$R76N3P:':O&=0^'6H&/[3K.C6WEWG@6\CA\0^'IK/2[..3
MPM^JG[)?[6GPS_:\^&=MX[\"7(L-:L!;67CKP+>W,4NO>"M>EB9S9W@18C?:
M1?&*>;0-?A@BM-8M(I 8[/4[/5-+T[ZB=$D1XY$62.161T=0R.C JR.K JRL
MI(92"""000:_ G]K']D[XG?L2?$^?]MK]B6![/PU9O<7OQ>^$-E;S7&B6>B7
M$R76N3P:':O&=0^'6H&/[3K.C6WEWG@6\CA\0^'IK/2[..3PM]KE^/P7B!@L
M-D&?8BEA.*\)2CA^'.(L1+EIYI3C94<CSRK9RE4;]S+\PFY34Y*G4<JDFL7\
MMC,'BN#<57SC)Z%3$\.XFHZ^=Y)07-/+YR:]KFV4TKI**2YL9@XV@X)S@HQB
MGA_WXHKY<_9+_:R^&O[7GPQMO'W@2<V&KZ>;73_'7@B]N(Y=;\$^()H7D^PW
MA18OMNE7PAN)_#^O0PQ6NL6<4N8K/4[/5=+T[ZCK\WS# 8S*\;B<NS##5<)C
M<)5E1Q&'K1Y:E.I'HUJG&2:E"<7*%2$HU(2E"49/[G!XS"YAA:&-P5>GB<+B
M:<:M"M2?-"I"6S75-.\9PDE.$U*$XQE%I%%%%<9TA1110 4444 %%%% !7\E
M/_!3;_D^#XV_]TV_]5%X!K^M:OY*?^"FW_)\'QM_[IM_ZJ+P#0!^M?\ P1J_
MY-A\=_\ 9>?$_P#ZKWX75^M=?DI_P1J_Y-A\=_\ 9>?$_P#ZKWX75^M= !11
M10 4444 %%%% '\R'_!<W_@HE\=? /[5?[ '_!*7]ESXI77[/GQ'_;S^('A/
M3OBU^T5HT.GW'CKX6?!CQAX_B^&EM;_"O^T4FM],\>>*;Z'QA+I_B15M-5T:
M[\-:59^';^QU+6WUC1?*=+_X(N_L;:__ ,%5/C+\#]8UW]JO4+W0_P#@FU^S
M%\6+/X[W/[8?[1<O[14OQ<\4_M*_M8>#O$?Q)U#XG/\ $%I-1U;5M%\#>%P_
MA>\T>7X:6&H:6NJZ1X%T[4;F[N9Z?_!SS_P21_:+_;%T;X%?MU_L2'7M4_:D
M_8]M;E9O OA2YGM/'WBWP/IGB*#Q]X8\1_":YMGCN)?B9\+?&$&I:[I'ANT*
MZKXKLM=NQX=GD\4:#HGA_P 3?GA_P1:_X."/!OQX_P""B>NZ_P#\%(=>\&_L
MY_'/Q+^QQ\%/V,].\8ZM;W_A7P'\1OB9\&_CK\=/'EYJWC3^TK:WTOX-^+O$
MUK\7K;2+W1M8N[;PC-XJ\.:NVGW_ (:;7="\%V0!^^__  2!T;]M;X%?M+_\
M%'OV(_VKOVGOB'^U;\/_ -FV_P#V8/%7[+'Q(^++:1K'Q)N_A'\<=$^,NHN?
M&?C6+2K3Q/XN\0VUWX%LO#>N7?B34]6A37?"^JWWA]--T[5FM3]]?\%*OVP_
M^&&/V-_BS\>='T;_ (2WXG16ND?#SX!_#^./[1>?$?\ :#^*.KVG@;X.>"[6
MQ62.>^AU#QKK.FWNN0VS?:(/#&FZ[?QC%FQ'V?:>%?"MGXEUGQO8>'/#]KXP
M\3:+X=\/>(?%UIH^G0>)?$'AWPC=^(]0\):'K.OPVZZIJNB^&+[QCXNOO#NF
M7UW<6.BW?BKQ'<Z9!;3:YJ;W7\Y?_!?W_@EW_P %)O\ @ICJ/[.5K^QO^T)\
M'/@AX&_9OU6?XOZ18^*/'OQ8^'_Q US]H6.]>T\-^--)\3?#WP#XIC\.7/PX
M\+P2+\.M<M-1LM5M?$/B[Q4UW)IENNG:G$ ?DM_Q#4_\%O/$G_%1>)?^"VGC
M?3O$>O?\3KQ!I]I\5OVGWM;'6]4_T[5;.V?3/%^GZ:]O:W\\\$+:?86-DT:*
M;2SMH#'"G]./_!(O]@GXO?\ !/K]F"\^%W[0G[3'CO\ :Q^-_BSQ_P"(?&OC
M;XJ>,_&7Q \6V<%C*MKH_A+PCX.C^(6N:UJNC>'M%T#3+>_O+9&@^U^*=;\1
M7C>;;/8B+^/#PM_P5\_X+T?\$+/C/X.^'O\ P5I^'WC/]I?]FCQ#+_8&E>)O
M$<WA/7=2U:WMTCFN-=^$G[3/AK3I$\7^,]-LE34M3\ _&#5=5UR[T[_1[^V\
M#W&I1^);7^_+]G3]H+X4_M6? SX7?M&? _Q/;>,/A3\8/"&E^-/!FO6^U))=
M.U%&6XT[5+0222:5XAT#4H;W0/$VAW3"^T#Q%IFJ:+J$<5]87$2 '\V7_!3_
M /;V^-G[6G_!43X _P#!"7]C#XN^(_@C!XL>U\9_MU?M%_##5KC2/BCX*^'>
ME^%-1^)^N?"'X<>++-99? OB/4?AQI=G<ZEXILXIKR;Q+XZ\">%S>6&F6WC7
M2=:U/^"F?_!-?1O^":G[*OC7_@H1_P $J?%?Q;_9]_:/_9,T[1/B?XZT'4?C
M9\9/BE\,?VEOA%X8OXU^*'A?XZ^!/B?X\\6:)XIGB\,:CK7CAO$$-O8Z[<:A
MHLZ17UEJ]WI'B'P]^+G_  ;F>*M;_:4_X./_ /@I-^T+XINCJ=Y+X$_:W\76
MMZT&8K0^(?VG?A3X7\+Z39!YIS966F>#;BZTK34-S<RQ:9ID5F9;@-+<#^[;
M]L?PI9^._P!D/]JGP1J-M#>Z?XR_9O\ CCX4O[.X6-K>[L_$/PQ\4:1=6TZR
MJ\30SP7CQ2K(CQE'8.K*2" >)?\ !,3]O?P)_P %+?V*O@W^UMX'T\>'KCQQ
MI5UI'Q!\$M<?:I? /Q3\*W3:+X]\)?:"3+<Z=::S;OJ/AG4+A(+K6/".J>']
M9N;2RFU%[.#[\K^&'_@Q^^*>MZQ\!OV^O@K<W7F>'?AY\6O@E\3M(M#-(YMM
M6^+_ (0\=^%]>E$##RX8[JU^">@!7C8M-);R[U7RE9_[GJ /RJ_X+)_\%,/#
M/_!*G]A[Q[^TE<Z?H_B?XG:EJ&G_  X^ O@'6IYXK#QG\6O$\-Y-I2:K'9SV
MU]+X9\*:+INM^-_%4=I=V%Q>Z+X=N-%LM2L-6U?39Q^<G["O_!'OP;^V/^QY
M\,_VH_\ @IS\0OV@?C]^VA^U'X0T+X]7_P 2+?\ :!^,OPTG_9UT_P"(=I;^
M-/AU\/O@3X1^'_B[PMX-^&<'@+0=1T*?5=+MO#-[I\WC1=7M9;>Y\,VNDZ/:
M?B1_P>W?$KQ/KWQ:_P""??[.FEW;G1XO"GQ7^)4FC0JP&J>)_%_B7PAX&\/W
M=V1))YSZ;:^&M:M=,5+:)K<:WJQ:2Z^U)':_Z!/A7P_9^$_#'ASPKIX46'AG
M0='\/V(2)8$%GHVGV^G6P6%6985\FV3;$K,L8P@8@ T ?S'?\$7/^"C'QP\-
M?MI?M8?\$3/VXOB-JGQ;^._[)VN>)+G]G/\ :"\4L&\:_'3X&Z'-IU_I5E\2
M[V29I-6^)5GX \2>#?'%AJ\AOM5U_P .7WB6/Q%J-]JGA!]>\2_1_P#P<(?\
M%;_$7_!,#]F/PAX?^ ]OI>N_MC_M1^(K_P"'/P!T>^M(=9_X1.VM8+2'Q9\5
MIO#TP:VUNX\+W.M^'-#\)Z-J*R:;J?C3Q/HMSJ-AK>A:-K^D7/\ .C_P46\4
MW_[/O_!XS^QU\0?"QATW4_BKXR_8[\+:Y<1R_9SJ5A\8]"/[,6O"[>!-\TUQ
MX2NFTR**??YR6]I"SI!Y9BR/^"Z_BK6_CM_P=#_\$V?@+?71N?"?PU\=_L)>
M$;;1Q!YMK:#QO^T!#\0O&NK2V[32+<WM]H>LZ;#>.1:Q2Z?H6F6SQ+]GDN[@
M _HH\+?\&_'PCUO]G#0Y?C%\>OVH->_X*-W?A#_A(O$7[?VF?M._'N+XH^'/
MCYJ6BRRSZ[X-T^U^(&F>%(OAIX1\0W<NF^%_ <OAV"UE\)64$5W<IXBNKC7Q
MB?\ !OA_P5<^*7[<7@;XZ_LF?M?S:>O[=7[#7C"\^'/Q;UBPM[6QM?BMX9TC
M7M7\%P?$ 6EI':6L?BK1_%/AS5?#/Q"BTS3;#2)+V7PSXBLK:R/BR71='_HX
MK_/1_8.\4W_P-_X/+?VJ/ASX<,.FZ/\ 'WQM^U7X<\46<,ODQ7]KXA^%=Q^T
M_/(8H$$5Q=7'B_P-I^JSB4*PD-U.\KW"GS0#_0NHHHH **** "BN,\3_ !&^
M'O@FXM;7QGX\\&>$;J^A>XLK;Q/XHT/0+B\MXW\N2>UAU6^M)+B%)/W;RQ*Z
M*_R,P;BN8_X7[\"?^BU?"7_PX_@[_P"7- 'YW?\ !&K_ )-A\=_]EY\3_P#J
MO?A=7ZUU^2G_  1J_P"38?'?_9>?$_\ ZK[X75^M= !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME./RG,*W$_#E)UJ]50_MW)%+EIYSAZ2LJ^&T:HYK0A?V4HJV(5X24IRE"O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+SXG_P#5>_"ZOUKK\E/^"-7_ ";#X[_[+SXG_P#5>_"ZOUKH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR\^)_P#U7OPNK]:Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY*?^"FW_ "?!
M\;?^Z;?^JB\ U_6M7\E/_!3;_D^#XV_]TV_]5%X!H _6O_@C5_R;#X[_ .R\
M^)__ %7OPNK]:Z_)3_@C5_R;#X[_ .R\^)__ %7OPNK]:Z "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH _)3_@C5_R;#X[_ .R\^)__ %7OPNK]:Z_)3_@C5_R;#X[_ .R\^)__ %7O
MPNK]:Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OY*?^"FW_)\'QM_[IM_ZJ+P#7]:U?R4_\%-O^3X/C;_W3;_U47@&
M@#]:_P#@C5_R;#X[_P"R\^)__5>_"ZOUKK\E/^"-7_)L/CO_ ++SXG_]5[\+
MJ_6N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /R4_X(U?\FP^._\ LO/B?_U7OPNK]:Z_)3_@C5_R
M;#X[_P"R\^)__5>_"ZOUKH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^2G_ (*;?\GP
M?&W_ +IM_P"JB\ U_6M7\E/_  4V_P"3X/C;_P!TV_\ 51> : /UK_X(U?\
M)L/CO_LO/B?_ -5[\+J_6NOR4_X(U?\ )L/CO_LO/B?_ -5[\+J_6N@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /R4_X(U?\ )L/CO_LO/B?_ -5[\+J_6NOR4_X(U?\ )L/CO_LO
M/B?_ -5[\+J_6N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&K_DV'QW_P!EY\3_ /JO?A=7ZUU^2G_!&K_DV'QW_P!EY\3_ /JO?A=7ZUT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?R4_P#!3;_D^#XV_P#=-O\ U47@&OZUJ_DI_P""FW_)\'QM_P"Z;?\ JHO
M- 'ZU_\ !&K_ )-A\=_]EY\3_P#JO?A=7ZUU^2G_  1J_P"38?'?_9>?$_\
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MN+J(_:HS/=64GECY;>1?WE?,'_#P_P#:>_Z1K_'G_P "/B%_\X:@ _X(U?\
M)L/CO_LO/B?_ -5[\+J_6NOYLOV _P!JGXQ? WX.^)?"7P\_9'^)?Q^T74?B
M7J_B.Z\8^"Y?%4>EZ;JEYX5\&:=/X9N!HOPS\8VIU"QM=)LM3F,FIP3F#6+;
M-C'"(;J[^XO^'A_[3W_2-?X\_P#@1\0O_G#4 ?K717Y*?\/#_P!I[_I&O\>?
M_ CXA?\ SAJ/^'A_[3W_ $C7^//_ ($?$+_YPU 'ZUT5^2G_  \/_:>_Z1K_
M !Y_\"/B%_\ .&H_X>'_ +3W_2-?X\_^!'Q"_P#G#4 ?K717Y*?\/#_VGO\
MI&O\>?\ P(^(7_SAJ/\ AX?^T]_TC7^//_@1\0O_ )PU 'ZUT5^2G_#P_P#:
M>_Z1K_'G_P "/B%_\X:C_AX?^T]_TC7^//\ X$?$+_YPU 'ZUT5^2G_#P_\
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M0!^M=%?DI_P\/_:>_P"D:_QY_P# CXA?_.&H_P"'A_[3W_2-?X\_^!'Q"_\
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MB%_\X:@#]:Z*_)3_ (>'_M/?](U_CS_X$?$+_P"<-1_P\/\ VGO^D:_QY_\
M CXA?_.&H _6NBOR4_X>'_M/?](U_CS_ .!'Q"_^<-1_P\/_ &GO^D:_QY_\
M"/B%_P#.&H _6NBOR4_X>'_M/?\ 2-?X\_\ @1\0O_G#4?\ #P_]I[_I&O\
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M3M0LO@7-:7UE=V\D<]M=6TTL$\+I+%(Z,K'1_P"'A_[3W_2-?X\_^!'Q"_\
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M=%?DI_P\/_:>_P"D:_QY_P# CXA?_.&H_P"'A_[3W_2-?X\_^!'Q"_\ G#4
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M=%?DI_P\/_:>_P"D:_QY_P# CXA?_.&H_P"'A_[3W_2-?X\_^!'Q"_\ G#4
M?K717Y*?\/#_ -I[_I&O\>?_  (^(7_SAJ/^'A_[3W_2-?X\_P#@1\0O_G#4
M ?K717Y*?\/#_P!I[_I&O\>?_ CXA?\ SAJ/^'A_[3W_ $C7^//_ ($?$+_Y
MPU 'ZUT5^2G_  \/_:>_Z1K_ !Y_\"/B%_\ .&H_X>'_ +3W_2-?X\_^!'Q"
M_P#G#4 ?K717Y*?\/#_VGO\ I&O\>?\ P(^(7_SAJ/\ AX?^T]_TC7^//_@1
M\0O_ )PU 'ZUT5^2G_#P_P#:>_Z1K_'G_P "/B%_\X:C_AX?^T]_TC7^//\
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M_CS_ .!'Q"_^<-1_P\/_ &GO^D:_QY_\"/B%_P#.&H _6NBOR4_X>'_M/?\
M2-?X\_\ @1\0O_G#4?\ #P_]I[_I&O\ 'G_P(^(7_P X:@#]:Z*_)3_AX?\
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MB%_\X:@#]:Z*_)3_ (>'_M/?](U_CS_X$?$+_P"<-1_P\/\ VGO^D:_QY_\
M CXA?_.&H _6NBOR4_X>'_M/?](U_CS_ .!'Q"_^<-1_P\/_ &GO^D:_QY_\
M"/B%_P#.&H _6NBOR4_X>'_M/?\ 2-?X\_\ @1\0O_G#4?\ #P_]I[_I&O\
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M^*]Y\/-7U.=;BYN-$\+?$?P?X+\8>!AJ9DU"+3;GP;X>OM4O[Q[G5K_]HO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-R)0!]/T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?DI\=?^4L7[(_\ V237O_3?\;J_6NOF#QG^S#H7
MC/\ :;^%W[35SXHU>RUWX7^%[WPO8>&(+.SDTG5+>]@\80/=7=Y(PO(9D'C"
MY94A!0FS@!XDDH ^GZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR3X$W/A^_P#A1)=Z9!);6&K)X,U;PKX<UK2K'5+:ZTN+6-$TO438&YT^S>$
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M?^)_#WAW6[QDGTQ=+T2]-H1IL6GU^IOPZ^'?@7X1^ _"'PO^&/A/0O GP\\
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MM>N+BV^DX88K>**""*."""-(88846.*&*-0D<44:!4CCC10B(BA44!5   H
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M+N_%/Q9T^2TU>QU"+PY?_$OQ+K?@;P#X8\5)#%?VU[=:K%HLB7L<U]IO*_\
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MC-X<TW7O$.A>"O[3%[;:2FGZ'<2^(;K0];MIM4\-:=I]YK]I_/AXG_X.D?\
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M^SO^U,TL:N1N5)&AB:100KM%&6!**1_2#_P3V_Y,%_8>_P"S0/V:?_5,>"J
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M?VIKVIBWGFTSPCX.T=YHKOQ1XT\130-8^'O#6EK+J&IW;81([>*XN(?Y7/\
M@EW^P9^T)_P4\_X*/>(_^"[G_!0[X;:[\,_A_I][HM]_P3T_9S\9L\6O:+X3
M\-S7/_"JO'WB+1Y%AGTK0/!.G2OXO\++<V>GS?$#XK>)=3^*UE8Z7X:LM!_X
M2P _JV_95^$,G[/O[+_[-_P$F:T:7X(? 3X/_"&5K!F>Q:3X:_#WP[X,=K)V
MCB9[0MHI-LS11LT)0F-"2H]ZHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_A#_P""2O\
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M80W^J-I^GZAJ3V=JTLT.FZ??:A.L=E9W,\0!^-O_  6;_P""-'[0_P#P4_\
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M3M*TG2M.MI+S4-3U/4+R2&TL-/L+2&:ZO;VZFBMK6VBDGGDCBC9A_)U\7_\
M@JQ_P3Y_X*:_'?Q!\&?BS^VU^SI\%_\ @F=\!O&UM!X_\->-OB]X9\*^._\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGW#"72[?Q7/\3_$-UH.G)&UM=^$M,\,^);._U#3?$&GM  ?U&5_"%_P;'_\
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M6_:X^*6EOIGQE_X*/?&WXG_MU^.[2X/GW&C>'/C+JT:?!+PG:WLG[]M \._
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MDW[3OP4BBC!8@%Y972*-0=SR.J*"S &G_P &PVHP:E_P0S_87F@R!;Z=\?\
M3I49D+I/IO[5'QQL9=P1FVB1K?SXE;#F"6)F52V* /WMKPC]IK]I'X1_LA_
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M\$0ZN_B!+JQL[BWNM2LUL6NM-M[BWFOX;:.>)G /X1?^"W'_  21_P""F/\
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MDJVWFV>DPOY"RRK#N\L2.%W$ _G/_P"#O+_E#;XT_P"S@/@3_P"GS5:_3_\
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M;>]DN+_3/ _AOPQH]Y=WESI\EW-\F?\ !<"YOOC7X _9-_X)K^&;NZC\0?\
M!2#]J7P1\,_'<6FSO;:M8_LL_!22'X[_ +4'B.QFA99U6S\'>#]%\,7D:&**
MYMO&3VEQ<1Q7!CG]M^&'_!9#]B+]H_\ :I^&/[(G[(GQ3\/_ +4_Q(\7:;XQ
M\:?$76_A1?W6I_#WX+?"OP7X<NKVZ\=>*_'2Z5/X;UJZUKQE=>#_ (?Z#X4\
M,ZCJ&J-J_BR#4-<GT+3;..34/!_@2'_:X_X+=_M8?'J;9J7PI_X)M_ KP?\
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MG38+.WB0:9IFJVFG/*K74MJ]U)),_LE% !1110 4444 %%%% !1110 4444
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MBB@#\MOVR?\ @B[_ ,$V?^"@?Q2L_C/^V!^S]K7QF^(FF>&[#PAI&K:A\?\
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M2?Q]\6?B#K/BGXD>,5LBTATVT\0>*+^PTCSITTFTL8I7C/US110!^87[6/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?R4_\%-O^3X/C;_W3;_U47@&OZUJ_DI_X*;?\GP?
M&W_NFW_JHO - 'ZU_P#!&K_DV'QW_P!EY\3_ /JO?A=7ZUU^2G_!&K_DV'QW
M_P!EY\3_ /JO?A=7ZUT %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7\E/_  4V_P"3X/C;_P!TV_\ 51> :_K6K^2G_@IM_P GP?&W
M_NFW_JHO - 'ZU_\$:O^38?'?_9>?$__ *KWX75^M=?DI_P1J_Y-A\=_]EY\
M3_\ JO?A=7ZUT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %?R4_\%-O^3X/C;_W3;_U47@&O
MZUJ_DI_X*;?\GP?&W_NFW_JHO - 'ZU_\$:O^38?'?\ V7GQ/_ZKWX75^M=?
MDI_P1J_Y-A\=_P#9>?$__JO?A=7ZUT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?R4_\%-O
M^3X/C;_W3;_U47@&OZUJ_DI_X*;?\GP?&W_NFW_JHO - 'ZU_P#!&K_DV'QW
M_P!EY\3_ /JO?A=7ZUU^2G_!&K_DV'QW_P!EY\3_ /JO?A=7ZUT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %?R4_P#!3;_D^#XV_P#=-O\ U47@&OZUJ_DI_P""FW_)\'QM
M_P"Z;?\ JHO - 'ZU_\ !&K_ )-A\=_]EY\3_P#JO?A=7ZUU^2G_  1J_P"3
M8?'?_9>?$_\ ZKWX75^M= !1110 4444 %%%% !1110 4444 %%%% !1110
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M_$/0/! U/Q]X1\=:'IUII_AKP58:U+XGU[7]%U;7=!N8;:UT33=7GUC5;2
M'[=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17X6_\$_\ _@M9
M!^W5_P %$_VX/V!D_97\??"4_L>WWCFW@^+&O>*1K%IXQB\!?$RP^&%W;^)_
M"9\(:&_P\UCQ1?WDOB7P7IH\1^+/[8\-:?JLTT]G/ISB?]TJ "BBB@ HHHH
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MWXF6>B:CN>/4/"O@0>#M=L+O0M8T+QO>Z%X@TK59P#^F:BBB@ HHHH ****
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M#]_/%,+[PGX%_P"$/US3=2\.:WH?C>\\/^)M&U>Z /Z8Z*** "BBB@ HHHH
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MK*_Q?US7O$US%;VU_P"(_$YU[1&NKO7;N;0/Y[_^#IK]HO\ 9-_X;>_X)_\
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MX**?\%&KOX5>);_XE^-Y+7]FGXNZ[XJT3Q+?^&?@Q9>*O&6LW>J:=<ZM(_\
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MQXB\1WD5Q#'\1M5L8H[.YM[2+3X+#3X;6&STZRBC /\ 1;KXA_:,_P""E7[
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MX;\.?$K6[*]T_P#TVQ.A_#;5O%NKSWUN\+V5M9371N+9(6N(\C_@@U^WDO\
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MZ?\ !3)YDO)IY$BO[#P)^U<WA^WMIII1)]BLYK;3(M#1&> VD&GV]NAM#&H
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M: TFS^)=G9^-O%_B$:GK.M:7H7AK7]"T*WT>[O'TYKG3[W6;JTDU[6=:U"^
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MP[XKU7Q992Z#JDGV3Q#)?Z9$^EW\GV?4C!<-L/VW\9/CO\$?V=?!LWQ%^/\
M\8/AA\$? -O=PZ?+XT^+/COPO\//"XU&YCFEM=,37/%FJ:3ILNIW<=O.UGIT
M5P][=^5(MM!*RD#Y&_X)W?LQ?LU_#;]F?]E7XF_#O]GGX&^ ?B3J_P"S!\&/
M[6^(/@OX3> O"WCC5/[>^&7A*]UW^T?%FAZ!8Z]>_P!M7BK=ZM]IOY?[1N0)
M[SSI0'K^<O\ 8"_;S^'G[<7[9_[:/[?/[0/[+O[6W[4MA\*_CCJ_[-O[$GA/
MX5_L\>+/VC/@[^S9\+O!&CZ=-X@\5:+;:8EUX2\-_'+XR'5])U[QKXDCMIO%
M-OHQM]&TO5X?"U]%:2@']/'[.7_!1/\ 82_:\U^^\)?LS?M<? 'XU^,=.MM1
MO[SP5X#^)GAC5O&T>EZ5=+9ZAK2>#1?Q^)I] MKAX4;7[?2I=&=;FTECOGAO
M+62;[,K_ #[_ /@N_P#L\_$C]I7XT_LR?MG_ /!+'_@G;^WW\&?VPOAGXPU.
M[^)/C?1/V0?'WP<D\16NGR67B#P#XXNY;+3QIVL^./#NOQZUIE[K,UN=7\0>
M']=ATCQ%<ZOI&B:1::?_ '*_LK>//B7\4?V9/V>_B/\ &CP3J7PV^,?CGX*_
M#'Q3\6OA[J^C7WA[4?!'Q.UOP;HU_P"/O"MQHFIDZAIG]@^+)]6TV*UNV>:.
M"VBWN^=[ 'O=?YT7_!\$!_PO_P#8'; W'X/?&<%L#)"^-?!Q4$]2 68@= 6.
M.IK_ $7:_P Z/_@^"_Y+]^P-_P!D?^-'_J:>#* /]%6UMK>RMK>SM(D@M;2"
M&VMH(QMCAMX(UBABC7LD<:*BCLJ@5X#X$_:T_9D^*/QA\=?L_P#PT^//PK^(
M7QG^%^AKXB^)'PZ\$^,]%\4^(_ 6E-JB:+O\86VB75]%X<ODU.6&UFT?5IK3
M6(#/!--81P3Q2OUOQL^"'PS_ &BOASKGPD^,.@7GBKX>>)OLJ^(O#5KXG\6^
M%(-<MK2X2Y33M5OO!NN^'M5OM'GEC0:AHMS?2:3JL(^SZG97=N3$?\ZO_@@]
M^P=X/^*7_!67_@K+^QO;?$3Q_P##W]EGX<ZO\8?AS\1/AUX UG4?#OBCXT_"
M#X??M.WGA'PS\&]=^*5EJ4/C;PCX"U:+3M.;XB2^#[_3O&/C71;)_"I\5Z1H
M^L:^NI@']X?@?_@IW_P3O^)?QM/[.'P__;4_9L\8_'!M2?1+3X<^'OBUX0U/
M7=7UZ)[B.?P[X?-MJ;V'B/Q):26MRE[X=T&\U'6K)X)4N["%D8#[IK_/U_X.
MG?\ @E#^Q9^PM^R'^S/^U9^Q5\%M#_9M^(_@[]ICPI\*M2U#X9ZEXATJ76-$
MU_X?_$'QMH'B*^N+S7+RX;Q=X/\ %'PQTI]&\2VQ3Q#)_;VH3:AJ5T;2S:V_
MK#\1_P#!0/3_ (!_\$@/"G_!1[XOV=QXANM,_8J^#WQZU[1[*."QG\5?$#XC
M?#?P9?:'X=C$;FVTQ?%/Q!\6Z3HCW"/)!I<6I/<JLL=L$< ^G?VEOVYOV.?V
M-[33+K]J;]IGX+? B37+:6]T#2?B/X^T#P_XE\0V4#RQ3WGAWPI<7A\3:_:0
M30R03W.CZ3>P0W"B"61)F1&_AV_X.Z/VF/V<OVKO!O\ P2O^)G[-7QJ^%GQV
M\&6OQ-_:BT2Y\4_"_P 8Z!XRLM)U0+^S'<76AZO-HMY=SZ'JOE"SNYM'U6.R
MOFMGL[MK4P2VTK?LS_P;-? &3XV_L_\ BS_@K_\ M/7B?&?]M+]N+XC_ !*U
M'_A:OC'2K:[U;X;_  J^'?CG7/ACI/PZ^&IO&O/^$/\ #$VO>#=;O39>&QHU
M@/#L'@[PO#8#3/".GRW'X1_\'AW[%OP0^!?[3G[%G[3OPE\&>'O 7BC]IJ[^
M(_A_XQ:;X7TR+1=+\4^)_A'JGPKN- \>7>FV7EZ8?$NJ:1\0[O1]?U&"TM;G
M4H]#TF[OGO;Z2ZN2 ?Z.U?$W[07_  4E_8!_93\3#P1^T9^V/^SI\(/'0DTU
M)_ GC+XK>$;#QU8Q:P(6TV^U7P9'J<_B?2-)NHKB*X36=3TJTTE;1FO)+U+6
M.29/CC_@OQ^W_P"+_P#@G%_P31^,/QO^&3_9?B_XSU+0O@?\(M:,D*?\(IXX
M^),.JQ_\)K%'.LBW.H>#/"^C^)O$^B6I@N(9]>TK2TOH6TXWA7Y1_9*\4_L?
M_L__ +*V@? /6/\ @F7^W_\ &*;Q?X5L+W]H7Q_\3/\ @GUXY^)_B3]I+XDZ
M]8VE]X^^(_Q7\4^+K+5M3^(>I>+O$!N=2AN?$-Q?0V.G?V;IFEQ6>F:;I]K;
M@'[^?"_XX_!?XV_#NS^+OP;^+7PU^*WPJU"'4+BR^)/PZ\<>&O&?@6XBTEI8
M]7*>*O#VI:AH@;2)89X=6C:]633)X)X+Y+>6&1%^4O\ A[%_P2R_Z26?L ?^
M)D?LZ_\ SQJ_D=_X(G? ']N#]A7_ (+5?%OPM\%OV1OVQ/A=_P $J/VF/%/Q
M4LD7XS_"'XC>&O#?@'0;+PKXB\=_!C7M67Q&DCZ-XC\+^)K"R^$=OK^LWEY>
MZCX9\17*ZM=:A=2V=[;_ %7_ ,'27_!$+P[\>_@QJO\ P4(_9.^'&D:1^T1\
M"M,N=<^.GA'P7X>LK23XV?"+30]_JWC&?2-.M5M]9^(_PNCCEUJ:\EM7U+Q3
MX"&N:9?7.IWOAOPCI3@']2_C#]MW]B_X>?#CP%\8_'_[7G[+_@;X1?%7SO\
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M2[DT;PGK'C;4=:F@2TNM6,_]L]?@#^W;_P I\/\ @@U_V3__ (*B?^L[^$*
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MMJ_B72/A#JVM:S<>$M7T?P[JFG6GQD_9O\73RW=U<Z[H&C0>)- \3_#?Q+K
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M1A%O*CIHFFW[B8+;A3/)'&]?]FS]N']CS]L2TU"[_9;_ &F/@I\>'T:TAO\
M7-+^&OQ"\.>)/$?AZRN&@2"Z\1^%K.^;Q+X>@EEN88$DUK2K!6N'^S ^>K1K
M^ ?_  ;)?#.?]I7]G_XG?\%8_P!J*6R^,_[9/[77QK^(\"?%7Q;:0ZQJ7PW^
M$GP\UIO">A?"WX80ZDU^/AWX.L_$]EXLNTT/PN^EV4FBGPMH\UO+9^&=+8?
MG_!T-^RM=?L ^/OV6_\ @LU^P=%I7[/7QR\)?&&U^&/QDU/X>6<7A^S\<:CK
MV@:EKG@+Q1XD\,Z9#:Z#K=I>Z?X3\7_#[XG0ZC#*OCO0/$GAK1]<M[^TLIY
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M[(?[&VEZ3J_[4_[2/P<^ UOX@2[D\.6GQ)\=:%X=USQ-'8%!?R>&/#5U=_\
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MAF'Q3XDU&&2.-K?PCHFJ7MAJ'C 2-(OV>?PM!J]O=INDM99HXY&7[^K^>_\
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M87OPV\)ZI;V7A;1]#@BU>VU35622_P#$7B"XU, _K'^*7[<_['?P0^"O@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_H@?_F4_C5_\\:C_AT[^P!_T0/_ ,RG\:O_ )XU?HI17!_KMQG_ -%=Q/\
M^'_-?_FL[/\ 53A;_HFL@_\ #/EW_P S'YU_\.G?V /^B!_^93^-7_SQJ/\
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M7MQ;_$&YD\3:=ID7_".:=X:\(^'=%\):9I3_ +5>*/\ @F?^RS\0/V(O$_[
M_P 3M"\6_%'X.>.M,OY/'OBGX@^+]2\3_&+QO\1-5UH>+-2^-WB3XDWX?5;[
MXOW/CA8_&D?B7R8]/LM5@M=*L-$M?"%G:^&H0#TS]AS]LSX,_M^?LP_"K]J/
MX&^(-.UGPE\1O#FG7FKZ/;:E;7^K_#WQLMA9R^+OAGXOC@"/I_BWP5JMS)I6
MJVT\,*W<:6FM:=]IT35=+OKM? W[67@WXJ?M8_%3]F7X82Z3XTC_ &>OAWHV
MN?M!^,M*U475E\._B?\ $#7OL_PP^$&+6">POO%UYX2\,?$3Q=X]TQM0M]3\
M#6,?P[2_L9&\;I]@_DK\,?\ !G-X]^$OQ#UJ3]GS_@KE\=?@U\'/$\]U'KWA
MWPQ\,M9T7XAZAX<EN$B/AC6O%'@GXZ>"_"WB:>[TC?9W7B&\\%Z?81W 24^#
M+NV)LU_J^_81_80_9Z_X)T_L^:!^SC^SAX?U+3O">G:EJ7B;Q-XG\3Z@FN^/
M_B7X[UTP'Q#\0/B)XD6ULO[=\5:S]FM+>2:&SL=-TS2['3=#T/3=+T32]/T^
MV /XI_V$/VNO"'_!)/\ X.5/^"F?P/\ VJ]4'PS^$O[:OQD^(.LZ9\3O'-X-
M%\.^&=8\=>/M=^.WP/\ %/B36;PFR'@SQ+HGQ#UWP9-XEFF2TTO7M<TJ_P!=
MO=+TW3_$4UE_?MXL\=^"O ?@S7OB-XV\6^'/"?@#PMH%[XJ\2>-?$.LZ?I'A
M;0_#6G6;ZA?:_JNNWUQ#IMEI%I8QO=SZA<7*6R6ZF4R;,&OQF_X+!?\ !!S]
ME;_@KSI?ASQ1XXUG7/@K^T=X%TFV\->"_P!H#P9IEOKU\?!T6IWFJ2>"/'G@
MJ_U+2=,\<>%X;O5-6U'15&JZ!XA\.ZQ>S7.E>(H=*O==T/6_R;_9(_X-&=!^
M&WB;PUI_[8W[?WQ?_:P_9R\#ZVFJZ#^RCHGA_P 6?"?X2>(Y=,N[.[T@^-[>
MY^,7C]&T2>73]/N-4\*>%-*\.W33Z;8Q#QG=6:26[@'ZE?\ !0[XY/\ M@?\
M$!_VW/CYX<\'ZEX7\,?$[]EC]H3QE\.['4Y+R34O$'P;T/6/%,GPV^)=U:W>
MDZ3=Z2OQ.^%&A:!\4XM"GM9G\/V/BB'29M2U(V+ZE/\ -7_!HMK>EZK_ ,$9
M_AW8Z?>075WX:^.OQYT36X(98Y)-.U2?Q7!XCBL[I$9F@G?1=?TC4%BE"2&V
MOK>8*8IHW?\ HU\:?"[P!\0OA=XL^"WBSPKI.I_"SQQX!U[X7>)O!*6RV.A:
MAX \2^'KOPGK/A5;2P^S)9Z3=^';VYTA;:R^SK;V<@BMO*")M_E'_9W_ .#7
MWX[_ +)'Q-^(^D?LN_\ !8_]JK]GO]DGXE>(8-;U_P"$'PI\.2>&?BA?6*31
MVXTYOB?9_$.+PKIGC&TT.)-+M?BUHWPOLM?DMTM;6;P^+:R03 'Q'_P5"\?^
M%-2_X.\?^"9$/AWQ)X=U^]\'>%?V</ 'C"STS6;"_G\*^*]7^(GQWOO^$;\0
M16=Q+)H_B)?#_C/PYKD6C:@MO?OI^N:+=FW^S:G:22_LU_P==V\TW_!$?]I6
M2*-G2T\=?L[7%RRXQ#"WQW\ VJR/SPIN+F"$8R=\JC&,D>/?M#_\&N7P#^-W
M[9G[//[0G@G]H;XF_LU?"K]G+X3?#WPMX:\(?!2U,'Q]U_XM>!_BGX]^*LOQ
MOU7]H_Q=K'B+4E\?Z]XD\91ZYKGB_4_!OB7QIJWB:TEUM_$=G<M T?[9_M!_
M\$_/@E^TS^PYX]_8'^+.N?%?QC\*/B!X4_L#5/&7C3XF>*OB)\8(];M/%=MX
M_P! \<R_$7Q_?^)-:U7Q'X9\>6&E^)-#M=6>\\-Z?#I>G^%;30K?P79VWAV$
M ^4O^""6N:+I_P#P1C_X)YWM_J^EV-E+\%/#FAQ7=YJ%I;6LNM:CXUUCP_I^
MD1W$TR1/JE_K]Q;Z'9Z>KF[NM7GATV"%[V5(&_G6_P"#P[_DZ?\ X(Q_]E ^
M-'_JQ?V6:_9K_@F#_P $!Q_P3]UGPJ/B?^W?^T)^UU\,/@UXPUCQS^S1^SQX
MJAU+X>_L_?!CQ?K2ZE&WCN;X9P_$#QWI7C+X@:.-9UN[\,:L9/#GA;P[X@\0
M^(/&6F^"(O&=[9>(-,\__P""GO\ P;\_%G_@JC\:_A]\7OC7_P %%=3\$VGP
M6'B"U^"7@OX<_LOZ)IVG^ K'7/%,7B1[^ZUF_P#C1>:KXB\7NFE^%].U/Q#*
MVFV%ZGA72KK3_#NBRR7R7(!XM_P>1_!?Q;\2O^"5G@WQ_P"%=)U35K3X"_M3
M_#GQ_P".C8)+/:Z-X$\0^"?B7\,Y]>U&"/(6&V\9^-?!&G+>NK+:)JTP8I%/
M+(GZA_\ !"O]OWX9?\% ?^"<W[/GC+PKXCTFY^*/PG^&_@CX.?'_ ,#Q:A%+
MXA\%_$KP'X?M_"\^HZKIC2/>6>A_$2UT+_A.?!MY(;FVN]&U5M-_M"YUG0]=
MM[+[F\*? 'Q7XO\ V=O%?[/_ .V?X]\'?M9V?C[PYKO@3Q]JX^$EO\(M'\<>
M O$'A^VT#4M'\1>#M(\:>+K)=7U%#JM[J6M^']3T"W^TZE&=$T70?[.M6/\
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M6*T\+^!M)U37/$WAC]AK]B?XKP:3I*2SW%SH/PDL_@=\0O'-Q+:P_/=V^E>
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M2BYN,4KV21^;?_#HG_@GC_T;Y_YECXX?_/*H_P"'1/\ P3Q_Z-\_\RQ\</\
MYY5?I)17/_862?\ 0FRK_P -V$_^4GK?\11\3/\ HXG'7_B79_\ _/ _-O\
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MWIG_  BMA=^'-'L;+Q-HEKH37-EJ$,5W!I@TJ[_EW^,G_!L5\9?CA^VU?_\
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M]*L_$GA[0-;L-.\1:!JUG#[!_P %7;?3O^"@'[=O[#'_  1\MG76OA6^I/\
MM[?M\Z3;7,ZP7?[/7P5U0:7\)_A1XB:PG$@T?XR?%R\M[#7K!GTS5]/M--\,
M>(-+OHB\32?OO\0])\;Z[X)\2Z1\-O&.E?#[QUJ&F2VWACQKK?A'_A/=*\-Z
MF[)Y6IWO@X^(/"H\010H) -/;Q#I:/(R.]P50Q2?SZ? #_@B%^U[^SS^VO\
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MDO\ \$V?VR];_P"#D#]HSQ3^R'_P5J_:0\7>"_"OA*QTWQ]\,/V(?@-I%E\
M?A'^T/J_@RYN;CQMIWQ+\:Q:IJWQ;\3ZUX*CM=.\2V'PWA\1V%U%;VFM^,=
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MKJG_  EOPR\?Z/K_ (F\3:!):QZO#8>,[NZ^Q?9_#6NS67]O]?@!_P %'O\
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MMY[?56TV5_&_V9O^"5EAX"_:CE_;V_;!^/?B+]MW]MVT\*R^ ? 'Q1\1^!-
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M/_@HO\*/&7QB_P"#3'PQX:\"PZK>ZUH'_!//]@[XG7FEZ5').^I>%?A)I'P
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M/_\ !0;XE?\ !/C4]=:YBN/AO;^!KSXE^'-&T[59H[O6/#NB:^_Q#\-WNI^
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M\16_]JMIWV2+6/&&IZA82:EJ0!_6!\2?VM/!/@K]I[]G_P#9&\/I8>-OC/\
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M#^R[JW[/+_MN>"_A_P"(_B#X/^)?P_\ C#\6_"O[*5M-JGB?PCX]M%T:RM_
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M4OBEXMU/6M#A\&0Z)X<U>PU.[UUM(\*>*?HR;X+?\%RO&7[&EW^R1XZ\>?L
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M33_&6BZ#\<+*Q^)EK!X#L]/\$^'Q'=>"K_1X-.L]9U;4O$]^+E+K\K_V>_\
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M  0)_;:^ OAZP_9[^*__  6G_:2^(?[#^@V0T&S_ &?/ACX('PC\2Z_X-+7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -EY\3_^J]^%U?K70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_)3_P4V_Y/@^-O_=-O_51
M> :_K6K^2G_@IM_R?!\;?^Z;?^JB\ T ?K7_ ,$:O^38?'?_ &7GQ/\ ^J]^
M%U?K77XD?\$G/C3\'/AS^SKXTT3XA?%GX9^ ]:NOC5XBU6UTCQGX[\+>%]4N
M=+G\#?#FTAU*#3];U6QNYK":[L;VUBO(X6MY+BSNH4D,EO,J?I]_PU1^S#_T
M<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\
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MPU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\
M#5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'
M_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-
M#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\
M-#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0
MT?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\
M\T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[
M_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A
M[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'
MO_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^
M'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_A
MW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\
MAW_A[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=
M_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?
M^'?^'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^
M W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X
M#?\ AW_A[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@
M-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX
M[X#?^'?^'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_
MZ..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\
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MBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH
M]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH
M ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@
M#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&
M@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\
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M_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\
MP[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'_#5'[,/_ $<=\!O_
M  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O
M_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\ -#1_PU1^S#_T<=\!
MO_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\
M!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'_#5'[,/_ $<=
M\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-#1_PU1^S#_T<
M=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\ -#1_PU1^S#_T
M<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\
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MPU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\
M#5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'
M_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-
M#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\
M-#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0
MT?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\
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MW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\
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MZ..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\
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MBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH
M]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH
M ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@
M#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&
M@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\
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M_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\
MP[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'_#5'[,/_ $<=\!O_
M  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O
M_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\ -#1_PU1^S#_T<=\!
MO_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\ T<=\
M!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'_#5'[,/_ $<=
M\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-#1_PU1^S#_T<
M=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\ -#1_PU1^S#_T
M<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\ #5'[,/\
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MPU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0T?\
M#5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\ \T-'
M_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^ W_AW_A[_P#-
M#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\ AW_A[_\
M-#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=_P"'O_S0
MT?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?^'?^'O\
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MW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X#?\
MAW_A[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@-_X=
M_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX[X#?
M^'?^'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_Z..^
M W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\ HX[X
M#?\ AW_A[_\ -#1_PU1^S#_T<=\!O_#O_#W_ .:&@#WFBO!O^&J/V8?^CCO@
M-_X=_P"'O_S0T?\ #5'[,/\ T<=\!O\ P[_P]_\ FAH ]YHKP;_AJC]F'_HX
M[X#?^'?^'O\ \T-'_#5'[,/_ $<=\!O_  [_ ,/?_FAH ]YHKP;_ (:H_9A_
MZ..^ W_AW_A[_P#-#1_PU1^S#_T<=\!O_#O_  ]_^:&@#WFBO!O^&J/V8?\
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?/_X2#S_L_P!L@F\GSO)A\WR]OF>5%OW>6N"B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>rckt-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-27T12:53:54.8013+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.rocketpharmaceuticals.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:rckt="http://www.rocketpharmaceuticals.com/20241231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails2" id="DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Balance Sheet Information Related to Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails2" id="DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails2">
        <link:definition>100030 - Disclosure - Leases - Maturity of Finance Lease Liability (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails2" id="DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100040 - Disclosure - Leases - Maturity of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails2" id="DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails2">
        <link:definition>100050 - Disclosure - Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100060 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>100070 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100080 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100090 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>100100 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100110 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NatureOfBusinessAndBasisOfPresentation" id="NatureOfBusinessAndBasisOfPresentation">
        <link:definition>995455 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RisksAndLiquidity" id="RisksAndLiquidity">
        <link:definition>995465 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>995485 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>995495 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
        <link:definition>995505 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>995515 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotes" id="ConvertibleNotes">
        <link:definition>995525 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995535 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards" id="StockbasedAwards">
        <link:definition>995545 - Disclosure - Stock-Based Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants" id="Warrants">
        <link:definition>995555 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>995565 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>995575 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3" id="DisclosureLeases3">
        <link:definition>995585 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995595 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AgreementsRelatedToIntellectualProperty" id="AgreementsRelatedToIntellectualProperty">
        <link:definition>995605 - Disclosure - Agreements Related to Intellectual Property</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CirmGrants" id="CirmGrants">
        <link:definition>995615 - Disclosure - CIRM Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisition" id="RenovacorAcquisition">
        <link:definition>995625 - Disclosure - Renovacor Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995635 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/KSavingsPlan" id="KSavingsPlan">
        <link:definition>995645 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995655 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995665 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995675 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <link:definition>995685 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>995695 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
        <link:definition>995705 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>995715 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables" id="StockbasedAwardsTables">
        <link:definition>995725 - Disclosure - Stock-Based Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/WarrantsTables" id="WarrantsTables">
        <link:definition>995735 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>995745 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>995755 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995765 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>995775 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisitionTables" id="RenovacorAcquisitionTables">
        <link:definition>995785 - Disclosure - Renovacor Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995795 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails" id="DisclosureRisksAndLiquidityAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Risks and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>995825 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Summary of Significant Accounting Policies - Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Summary of Significant Accounting Policies - Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - Summary of Significant Accounting Policies - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" id="DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails">
        <link:definition>995885 - Disclosure - Fair Value of Financial Instruments - Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" id="DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails">
        <link:definition>995895 - Disclosure - Fair Value of Financial Instruments - Changes in Level 3 Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails" id="DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails">
        <link:definition>995905 - Disclosure - Fair Value of Financial Instruments - Level 3 Fair Value of the Private Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
        <link:definition>995915 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails">
        <link:definition>995935 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" id="DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" id="DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails">
        <link:definition>995955 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails" id="DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails">
        <link:definition>995965 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails" id="ConvertibleNotesDetails">
        <link:definition>995975 - Disclosure - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995985 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails" id="DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails">
        <link:definition>995995 - Disclosure - Stock-Based Awards - Weighted-Average Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails" id="DisclosureStockbasedAwardsStockOptionActivityDetails">
        <link:definition>996005 - Disclosure - Stock-Based Awards - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails" id="DisclosureStockbasedAwardsAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Stock-Based Awards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails" id="DisclosureStockbasedAwardsRsuActivityDetails">
        <link:definition>996025 - Disclosure - Stock-Based Awards - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails" id="DisclosureStockbasedAwardsRsuActivityParentheticalDetails">
        <link:definition>996035 - Disclosure - Stock-Based Awards - RSU Activity (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails" id="DisclosureStockbasedAwardsPsuActivityDetails">
        <link:definition>996045 - Disclosure - Stock-Based Awards - PSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails" id="DisclosureStockbasedAwardsStockbasedCompensationDetails">
        <link:definition>996055 - Disclosure - Stock-Based Awards - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails" id="DisclosureWarrantsSummaryOfWarrantsOutstandingDetails">
        <link:definition>996065 - Disclosure - Warrants - Summary of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails" id="DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails">
        <link:definition>996075 - Disclosure - Warrants - Summary of Changes in Rocket Warrants to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>996085 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>996095 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>996105 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>996115 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails" id="DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails">
        <link:definition>996125 - Disclosure - Income Taxes - Reconciliation Between Effective Tax Rates and Statutory Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996135 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996145 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails" id="DisclosureLeasesFinanceLeaseAdditionalInformationDetails">
        <link:definition>996155 - Disclosure - Leases - Finance Lease - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails" id="DisclosureLeasesOperatingLeasesAdditionalInformationDetails">
        <link:definition>996165 - Disclosure - Leases - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails" id="DisclosureLeasesLeasesCostDetails">
        <link:definition>996175 - Disclosure - Leases - Leases Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails">
        <link:definition>996185 - Disclosure - Leases - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails" id="DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails">
        <link:definition>996195 - Disclosure - Leases - Maturity of Finance Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails" id="DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails">
        <link:definition>996205 - Disclosure - Leases - Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails" id="DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails">
        <link:definition>996215 - Disclosure - Leases - Lease Related to Cash Flow Information, Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails" id="DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails">
        <link:definition>996225 - Disclosure - Agreements Related to Intellectual Property - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails" id="DisclosureCirmGrantsAdditionalInformationDetails">
        <link:definition>996235 - Disclosure - CIRM Grants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails" id="DisclosureRenovacorAcquisitionAdditionalInformationDetails">
        <link:definition>996245 - Disclosure - Renovacor Acquisition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails" id="DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails">
        <link:definition>996255 - Disclosure - Renovacor Acquisition - Total Consideration for Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails" id="DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails">
        <link:definition>996265 - Disclosure - Renovacor Acquisition - Total Consideration for Acquisition (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>996275 - Disclosure - Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>996285 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails" id="Disclosure401kSavingsPlanAdditionalInformationDetails">
        <link:definition>996295 - Disclosure - 401(k) Savings Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>996305 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" id="DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails">
        <link:definition>996315 - Disclosure - Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets" xlink:href="rckt-20241231.xsd#ConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="rckt-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="rckt-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows" xlink:href="rckt-20241231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="rckt-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureRisksAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:href="rckt-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" xlink:href="rckt-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails" xlink:href="rckt-20241231.xsd#DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="rckt-20241231.xsd#DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails" xlink:href="rckt-20241231.xsd#ConvertibleNotesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsRsuActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsRsuActivityParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsPsuActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails" xlink:href="rckt-20241231.xsd#DisclosureStockbasedAwardsStockbasedCompensationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails" xlink:href="rckt-20241231.xsd#DisclosureWarrantsSummaryOfWarrantsOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails" xlink:href="rckt-20241231.xsd#DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesFinanceLeaseAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesOperatingLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureCirmGrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureRenovacorAcquisitionAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails" xlink:href="rckt-20241231.xsd#DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails" xlink:href="rckt-20241231.xsd#DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="rckt-20241231.xsd#DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" xlink:href="rckt-20241231.xsd#DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation" xlink:href="rckt-20241231.xsd#DocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations" xlink:href="rckt-20241231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="rckt-20241231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="rckt-20241231.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RisksAndLiquidity" xlink:href="rckt-20241231.xsd#RisksAndLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="rckt-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments" xlink:href="rckt-20241231.xsd#FairValueOfFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet" xlink:href="rckt-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill" xlink:href="rckt-20241231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:href="rckt-20241231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotes" xlink:href="rckt-20241231.xsd#ConvertibleNotes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="rckt-20241231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards" xlink:href="rckt-20241231.xsd#StockbasedAwards" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants" xlink:href="rckt-20241231.xsd#Warrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare" xlink:href="rckt-20241231.xsd#NetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes" xlink:href="rckt-20241231.xsd#IncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3" xlink:href="rckt-20241231.xsd#DisclosureLeases3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingencies" xlink:href="rckt-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AgreementsRelatedToIntellectualProperty" xlink:href="rckt-20241231.xsd#AgreementsRelatedToIntellectualProperty" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CirmGrants" xlink:href="rckt-20241231.xsd#CirmGrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisition" xlink:href="rckt-20241231.xsd#RenovacorAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RelatedPartyTransactions" xlink:href="rckt-20241231.xsd#RelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/KSavingsPlan" xlink:href="rckt-20241231.xsd#KSavingsPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:href="rckt-20241231.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rckt-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="rckt-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables" xlink:href="rckt-20241231.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:href="rckt-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables" xlink:href="rckt-20241231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:href="rckt-20241231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables" xlink:href="rckt-20241231.xsd#StockbasedAwardsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/WarrantsTables" xlink:href="rckt-20241231.xsd#WarrantsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables" xlink:href="rckt-20241231.xsd#NetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables" xlink:href="rckt-20241231.xsd#IncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:href="rckt-20241231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingenciesTables" xlink:href="rckt-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisitionTables" xlink:href="rckt-20241231.xsd#RenovacorAcquisitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="rckt-20241231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="rckt-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails" xlink:href="rckt-20241231.xsd#DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="rckt-20241231.xsd#DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:href="rckt-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="rckt-20241231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails" xlink:href="rckt-20241231.xsd#DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rckt-20241231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesLeasesCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails" xlink:href="rckt-20241231.xsd#DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#Disclosure401kSavingsPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="rckt-20241231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails2" xlink:href="rckt-20241231.xsd#DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails2" xlink:href="rckt-20241231.xsd#DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:href="rckt-20241231.xsd#DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails2" xlink:href="rckt-20241231.xsd#DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:label="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FinanceLeaseCostsAbstract" xlink:label="rckt_FinanceLeaseCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" xlink:label="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceOneMember" xlink:label="rckt_WarrantsExercisePriceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:label="rckt_AdditionalInformationOfCIRMGrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesBConvertiblePreferredSharesMember" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseBalanceSheetInformationTableTextBlock" xlink:label="rckt_LeaseBalanceSheetInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceFiveMember" xlink:label="rckt_WarrantsExercisePriceFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PropertyPlantAndEquipmentWriteDown" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightGrantDate" xlink:label="rckt_ClassOfWarrantOrRightGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementAbstract" xlink:label="rckt_LicenseAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AAVCurrentGoodManufacturingPracticecGMPMember" xlink:label="rckt_AAVCurrentGoodManufacturingPracticecGMPMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConvertibleNotes2022Member" xlink:label="rckt_ConvertibleNotes2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryLiabilityCurrent" xlink:label="us-gaap_RegulatoryLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementEffectiveDate" xlink:label="rckt_ConsultingAgreementEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorSalesTypeLeasesTextBlock" xlink:label="us-gaap_LessorSalesTypeLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InotekLexingtonMassachusettsLeaseAgreementMember" xlink:label="rckt_InotekLexingtonMassachusettsLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_August2021WarrantMember" xlink:label="rckt_August2021WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OperatingLossCarryforwardsAbstract" xlink:label="rckt_OperatingLossCarryforwardsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCosts" xlink:label="rckt_ResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" xlink:label="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementsRelatedToIntellectualPropertyTextBlock" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdenoAssociatedVirusProgramsMember" xlink:label="rckt_AdenoAssociatedVirusProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfMilestonesAchieved" xlink:label="rckt_NumberOfMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_December2021WarrantsMember" xlink:label="rckt_December2021WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PIPEInvestorsMember" xlink:label="rckt_PIPEInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementsWithCIEMATMember" xlink:label="rckt_LicenseAgreementsWithCIEMATMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForPKDWithCIEMATGroupMember" xlink:label="rckt_LicenseAgreementForPKDWithCIEMATGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" xlink:label="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" xlink:label="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementTerminationNoticePeriod" xlink:label="rckt_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementBusinessDevelopmentMember" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RisksAndLiquidityAbstract" xlink:label="rckt_RisksAndLiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NewJerseyLeaseAgreementMember" xlink:label="rckt_NewJerseyLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DerivativeLiabilitiesMember" xlink:label="rckt_DerivativeLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FollowOnPublicOfferingMember" xlink:label="rckt_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementNumberOfPatents" xlink:label="rckt_LicenseAgreementNumberOfPatents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForBAG3WithTempleUniversityMember" xlink:label="rckt_LicenseAgreementForBAG3WithTempleUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" xlink:label="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceTwoMember" xlink:label="rckt_WarrantsExercisePriceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesAConvertiblePreferredSharesMember" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CowenAndCompanyLLCMember" xlink:label="rckt_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsClassifiedAsEquityMember" xlink:label="rckt_WarrantsClassifiedAsEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForDDWithRGNXMember" xlink:label="rckt_LicenseAgreementForDDWithRGNXMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceSixMember" xlink:label="rckt_WarrantsExercisePriceSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DetailedInformationOfWarrantsAbstract" xlink:label="rckt_DetailedInformationOfWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" xlink:label="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" xlink:label="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_TreasuryStockPolicyTextBlock" xlink:label="rckt_TreasuryStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CashCashEquivalentsAndInvestments" xlink:label="rckt_CashCashEquivalentsAndInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AggregateIntrinsicValueAbstract" xlink:label="rckt_AggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfLeastUninterruptedYears" xlink:label="rckt_NumberOfLeastUninterruptedYears"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GovernmentGrantsPolicyTextBlock" xlink:label="rckt_GovernmentGrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentAndExpensesForLicenseFee" xlink:label="rckt_PaymentAndExpensesForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InvestmentPayableCurrent" xlink:label="rckt_InvestmentPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromIssuanceOfCommonStock" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RelatedPartyTransactionAbstract" xlink:label="rckt_RelatedPartyTransactionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IntangibleAssetsAbstract" xlink:label="rckt_IntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingFeeMonthlyInstalment" xlink:label="rckt_ConsultingFeeMonthlyInstalment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfAnnualIncreaseInBaseRent" xlink:label="rckt_PercentageOfAnnualIncreaseInBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementOptionsRightExpiryTerm" xlink:label="rckt_LicenseAgreementOptionsRightExpiryTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceEightMember" xlink:label="rckt_WarrantsExercisePriceEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrantAwardForClinicalDevelopmentSupport" xlink:label="rckt_GrantAwardForClinicalDevelopmentSupport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCashOperatingLeaseLiability" xlink:label="rckt_NonCashOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementsRelatedToIntellectualPropertyAbstract" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedIssuanceCosts" xlink:label="rckt_StockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_REGENXBIOIncLicenseMember" xlink:label="rckt_REGENXBIOIncLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentForLicenseFee" xlink:label="rckt_PaymentForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfOptionsToRenewLeaseAgreement" xlink:label="rckt_NumberOfOptionsToRenewLeaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SharesIssuanceCost" xlink:label="rckt_SharesIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:label="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceFourMember" xlink:label="rckt_WarrantsExercisePriceFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingAndPrivatPlacementMember" xlink:label="rckt_PublicOfferingAndPrivatPlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCommercialGeneralAndAdministrativeExpense" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_HopewellMember" xlink:label="rckt_HopewellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareholdersEquityDisclosureAbstract" xlink:label="rckt_ShareholdersEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfPreClinicalStagePrograms" xlink:label="rckt_NumberOfPreClinicalStagePrograms"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LaboratoryEquipmentMember" xlink:label="rckt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsToAcquireRightOfUseAsset" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsForRepurchaseTreasuryStock" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" xlink:label="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LADICIRMGrantMember" xlink:label="rckt_LADICIRMGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInFinanceLeaseLiabilities" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract" xlink:label="us-gaap_TreasuryStockValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" xlink:label="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessAcquisitionExchangeRatio" xlink:label="rckt_BusinessAcquisitionExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" xlink:label="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommercialGeneralAndAdministrativeExpense" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceThreeMember" xlink:label="rckt_WarrantsExercisePriceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NewYorkLeaseAgreementMember" xlink:label="rckt_NewYorkLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCostsCurrent" xlink:label="rckt_ResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceSevenMember" xlink:label="rckt_WarrantsExercisePriceSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_MemberOfTheBoardOfDirectorsTwoMember" xlink:label="rckt_MemberOfTheBoardOfDirectorsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmpireStateBuildingLeaseAgreementMember" xlink:label="rckt_EmpireStateBuildingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="rckt_LeaseSupplementalCashFlowInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" xlink:label="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AcquisitionExpensesCurrent" xlink:label="rckt_AcquisitionExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringSharesCommonStockWarrantExercised" xlink:label="rckt_StockIssuedDuringSharesCommonStockWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicWarrantsMember" xlink:label="rckt_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfClinicalStagePrograms" xlink:label="rckt_NumberOfClinicalStagePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RoyaltiesPayableOnFeesReceived" xlink:label="rckt_RoyaltiesPayableOnFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_MemberOfTheBoardOfDirectorsMember" xlink:label="rckt_MemberOfTheBoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CIRMGrantsAbstract" xlink:label="rckt_CIRMGrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentIncentives" xlink:label="rckt_ResearchAndDevelopmentIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_TaxCreditCarryforwardAbstract" xlink:label="rckt_TaxCreditCarryforwardAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCashOperatingLeaseRightOfUseAssets" xlink:label="rckt_NonCashOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ExercisePricePerShareWarrantsAbstract" xlink:label="rckt_ExercisePricePerShareWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementTerminationDate" xlink:label="rckt_ConsultingAgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SaleOfStockAggregateOfferingPrice" xlink:label="rckt_SaleOfStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DanonDiseaseLicenseAgreementWithUCSDMember" xlink:label="rckt_DanonDiseaseLicenseAgreementWithUCSDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LentiviralVectorProgramsMember" xlink:label="rckt_LentiviralVectorProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DanonDiseaseCIRMGrantMember" xlink:label="rckt_DanonDiseaseCIRMGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" xlink:label="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfStock" xlink:label="rckt_GrossProceedsFromSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuritiesInvestmentMember" xlink:label="us-gaap_SecuritiesInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:label="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:label="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfShares" xlink:label="rckt_GrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsWarrants" xlink:label="rckt_DeferredTaxAssetsWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConvertibleNotes2021Member" xlink:label="rckt_ConvertibleNotes2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="us-gaap_ValuationTechniqueAndInputDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmployeeNonemployeeAndDirectorMember" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionAbstract" xlink:label="rckt_StockOptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GoodwillAbstract" xlink:label="rckt_GoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" xlink:label="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAgreementInitialTerm" xlink:label="rckt_ResearchAgreementInitialTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:label="rckt_CommonStockVotingRightsNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdjustmentOfRightOfUseAssets" xlink:label="rckt_AdjustmentOfRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SpouseOfExecutiveOfficerMember" xlink:label="rckt_SpouseOfExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" xlink:label="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RisksAndLiquidityTextBlock" xlink:label="rckt_RisksAndLiquidityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FinanceLeasesEstimatedRentPayments" xlink:label="rckt_FinanceLeasesEstimatedRentPayments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ReportableSegmentsMember" xlink:label="rckt_ReportableSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ProceedsFromMilestonePayments" xlink:label="rckt_ProceedsFromMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementAssetIdentificationMember" xlink:label="rckt_ConsultingAgreementAssetIdentificationMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Return to provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Return To Provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation return to provision,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RenovacorIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Renovacor, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RenovacorIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name of the merging entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RenovacorIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renovacor, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RenovacorIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renovacor, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development, Contract to Perform for Others [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Outstanding and Changes in Warrants to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease assets and liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets and Liabilities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease assets and liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number diluted shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total potential shares excluded from diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition related general and administrative costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Warrant Shares Outstanding And Exercisable Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Warrant Shares Outstanding and Exercisable [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrant Shares Outstanding and Exercisable [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average exercise price per share of warrants exercised during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock units convertible for common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted stock units exercisable for common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Restricted Stock Units Exercisable for Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renovacor Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price allocation of Assets Acquired and Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FinanceLeaseCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FinanceLeaseCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FinanceLeaseCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for California institute for regenerative medicine grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Institute for Regenerative Medicine Grants [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIRM Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-Lived Intangible Assets (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements and Non-arrangement Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash financing and investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">57.11</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercise price one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of treasury stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdditionalInformationOfCIRMGrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Information of CIRM Grants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdditionalInformationOfCIRMGrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIRM Grants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdditionalInformationOfCIRMGrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Information Of C I R M Grants Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumed Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assumed Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled or forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseBalanceSheetInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of balance sheet information related to leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseBalanceSheetInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Balance Sheet Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseBalanceSheetInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Statements of Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average exercise price per share of warrants granted during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">65.23</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of loss from reductions in property plant and equipment due to subsequent measurement adjustments, including, but not limited to physical deterioration and obsolescence.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant and Equipment Write-down</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write down of property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Date the warrants or rights are issued, in YYYY-MM-DD format.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options Granted, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount by which current fair value of underlying stock exceeds exercise price of Nonvested options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AAVCurrentGoodManufacturingPracticecGMPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The lease agreement relating to the rental space in Cranbury, New Jersey dedicated to AAV Current Good Manufacturing Practice (cGMP).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AAVCurrentGoodManufacturingPracticecGMPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AAV Current Good Manufacturing Practice (cGMP) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConvertibleNotes2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConvertibleNotes2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written promise to pay a new note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConvertibleNotes2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, at cost (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share attributable to common stockholders - basic (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decease in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock related to acquisition (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government grant payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Consulting agreement effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement Effective Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Agreement Effective Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorSalesTypeLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorSalesTypeLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Sales-type Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Consideration for Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate - finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_InotekLexingtonMassachusettsLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">On January 4, 2018, in connection with the Reverse Merger, the Company assumed an operating lease for Inotek's former headquarters in Lexington, Massachusetts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_InotekLexingtonMassachusettsLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inotek Lexington Massachusetts Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_InotekLexingtonMassachusettsLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inotek Lexington Massachusetts Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_August2021WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2021 Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_August2021WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name of the class or type of warrants issued in August 2021.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_August2021WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August 2021 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OperatingLossCarryforwardsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OperatingLossCarryforwardsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The research and development costs incurred during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement For FA With CIEMAT Group And FIBHNJS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement For FA With CIEMAT Group And FIBHNJS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for FA with CIEMAT Group and FIBHNJS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred income tax asset (liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for agreements related to intellectual property.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreements Related to Intellectual Property [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements Related to Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options vested and exercisable at end of period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of lease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NOL carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdenoAssociatedVirusProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AAV Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdenoAssociatedVirusProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adeno-associated Virus Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdenoAssociatedVirusProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adeno-associated virus programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock, pursuant to sale of treasury stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of treasury stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized comprehensive gain (loss) on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized (loss) gain on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestones achieved during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Milestones Achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional milestones achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_December2021WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2021 Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_December2021WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name of the class or type of warrants issued in December 2021.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_December2021WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2021 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Statements of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PIPEInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PIPEInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investors in a public equity (PIPE).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PIPEInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PIPE Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementsWithCIEMATMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements with CIEMAT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementsWithCIEMATMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A license agreement CIEMAT, CIBER, and FIISFJD, (collectively, "CIEMAT"), granting Rocket worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to lentiviral vectors containing the human PKLR gene solely within the field of treating PKD.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementsWithCIEMATMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements with CIEMAT [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to purchase shares of common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForPKDWithCIEMATGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement For PKD With CIEMAT Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForPKDWithCIEMATGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement For PKD With CIEMAT Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForPKDWithCIEMATGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for PKD with CIEMAT Group</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The lease area under agreement for internal process development and research activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Area for Internal Process Development and Research Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for operating Loss carryforwards cumulative limitation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Cumulative Limitation Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative limitation period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of advance notice period to terminate the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement, Business Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Consulting Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting agreement with related party for business development services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement, Business Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential shares included in the calculation of EPS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RisksAndLiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks And Liquidity Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RisksAndLiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Liquidity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives and Fair Value [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value per share of common stock used in the weighted average fair value assumptions for stock option grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Value of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants exercisable for common shares (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating noncurrent lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liabilities, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NewJerseyLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The lease agreement relating to the rental space in Cranbury, New Jersey.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NewJerseyLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Jersey Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NewJerseyLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NJ Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net Segment loss and Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued related to tax (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DerivativeLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Classified as Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DerivativeLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DerivativeLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A follow-on public offering is an issuance of additional shares made by a company after an initial public offering (IPO).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow-on Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from sale of property and equipment, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of operating right-of-use assets recognized as of the acquisition date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementNumberOfPatents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of patents under the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementNumberOfPatents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License agreement number of patents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementNumberOfPatents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of patents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Treasury Stock, Common</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents and Restricted Cash [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForBAG3WithTempleUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement For BAG3 With Temple University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForBAG3WithTempleUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement For BAG3 With Temple University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForBAG3WithTempleUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for BAG3 ith Temple University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards, Cumulative Amount Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative net operating loss, subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock, pursuant to exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in Level 3 Liabilities Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">33.63</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options unvested at ending of period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options vested and exercisable at end of period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cancelled (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled or forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen and Company, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The Company entered into a sales agreement with respect to an at-the-market offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CowenAndCompanyLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cowen and Company, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsClassifiedAsEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, Classified as Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsClassifiedAsEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsClassifiedAsEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants, Classified as Equity [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForDDWithRGNXMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement For DD With RGNX [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForDDWithRGNXMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement For DD With RGNX [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForDDWithRGNXMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for DD with RGNX</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">65.23</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance or sale of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DetailedInformationOfWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Detailed Information Of Warrants Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DetailedInformationOfWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Detailed Information of Warrants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DetailedInformationOfWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of in process research and development recognized as of the acquisition date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">On March 26, 2021, the Company entered in Amendment No. 1 to the ESB Lease Agreement ("ESB Lease Amendment").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Empire State Building Lease Agreement Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESB Lease Agreement Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash proceeds from acquisition of business, net of cash paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock consideration (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of net operating loss and credit limited to utilize due to change in control as per Internal revenue code under section 382.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Limitations Under Section 382 Of The Internal Revenue Code Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual limitations under section 382 of IRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of other intangible asset recognized as of the acquisition date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Intangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Project [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New York State Life Sciences Research and Development Tax Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in Fair Value of Warrant Liabilities [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of financial instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair value of financial instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for treasury stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_TreasuryStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Instruments, Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CashCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash, cash equivalents and short-term and long-term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CashCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CashCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, short-term and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Lease Payments of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Intrinsic Value Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period expected to recognize unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average period expected to recognize unrecognized share-based compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Operating Lease Liability and Right of Use Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liability and right of use assets, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities and right of use assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fair value adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfLeastUninterruptedYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Refers to the number of least uninterrupted years following regulatory approval to develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfLeastUninterruptedYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Least Uninterrupted Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfLeastUninterruptedYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of least uninterrupted years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GovernmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants related to receivable of offset amount against research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GovernmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GovernmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Vested (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income / (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentAndExpensesForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment and expenses for license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentAndExpensesForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment And Expenses For License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentAndExpensesForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment and expenses for license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reconciliation of Income Tax Benefit Computed at Statutory Federal Income Tax Rate to Income Taxes [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Expired (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_InvestmentPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_InvestmentPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Payable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_InvestmentPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment payable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Compensation Expense by Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The gross cash inflow from the additional capital contribution to the entity including issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds, offering amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">401(k) Savings Plan [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expense in connection with warrant issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense in connection with warrant issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment of Warrants Granted for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of matching employee contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued interest or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of Finance Lease Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for concentrations of credit risk and off-balance sheet risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentrations of Credit Risk and Off-balance Sheet Risk [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Off-balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RelatedPartyTransactionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RelatedPartyTransactionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transfer pricing adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Transfer Pricing Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer pricing adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agency Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivateWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IntangibleAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IntangibleAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IntangibleAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingFeeMonthlyInstalment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Fee Monthly Instalment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingFeeMonthlyInstalment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Fee Monthly Instalment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingFeeMonthlyInstalment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting fee monthly instalment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Statements of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares withheld to pay the payroll tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other than options (or share units) converted in a business combination.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Than Options, Conversion of Acquiree Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of awards (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average fair value at conversion of acquiree entity awards date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Conversion of Acquiree Entity Awards in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of awards (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Carrying Value of Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PercentageOfAnnualIncreaseInBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of annual increase in base rent under lease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PercentageOfAnnualIncreaseInBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Annual Increase in Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PercentageOfAnnualIncreaseInBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use asset, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Assumptions for Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementOptionsRightExpiryTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of options right to expiry from the date of the license agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementOptionsRightExpiryTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Options Right Expiry Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementOptionsRightExpiryTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options right expiry term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value per warrant (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise price per share (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to purchase shares of common stock price per share (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity consideration, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">0.01</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrantAwardForClinicalDevelopmentSupport_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant award for clinical development support.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrantAwardForClinicalDevelopmentSupport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant award for clinical development support</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrantAwardForClinicalDevelopmentSupport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant award for clinical development support</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCashOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCashOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCashOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net operating loss not subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Statements of Comprehensive Loss [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of renewal of finance lease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Income Tax Benefit Computed at Statutory Federal Income Tax Rate to Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued during the period as a result of vesting of restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Vesting of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to vesting of restricted stock units (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreements Related To Intellectual Property Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreements Related to Intellectual Property [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Assumptions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assumptions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value common stock warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_REGENXBIOIncLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REGENXBIO, Inc. License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_REGENXBIOIncLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A License Agreement with REGENXBIO Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_REGENXBIOIncLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">REGENXBIO, Inc. License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible notes into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash outflow for payment of license fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentForLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for License Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfOptionsToRenewLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of options to renew lease agreement in consecutive times.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfOptionsToRenewLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Options to Renew Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfOptionsToRenewLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options to renew lease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SharesIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SharesIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SharesIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renovacor Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class of warrant outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Investments, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized comprehensive gain (loss) on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSU)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time Vesting RSU</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">22.51</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized share-based compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Matching employee contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Performance Stock Units Exercisable for Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of performance stock units exercisable for common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicOfferingAndPrivatPlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering and Privat Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicOfferingAndPrivatPlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering and privat placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicOfferingAndPrivatPlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering and Privat Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Commercial General And Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non commercial general and administrative expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-commercial general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Lease Payments of Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity of Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk-Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_HopewellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease facility located at Hopewell, New Jersey and Cambridge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_HopewellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hopewell, New Jersey and Cambridge [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of shares granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average grant date fair value of shares granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareholdersEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shareholders Equity Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareholdersEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareholdersEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfPreClinicalStagePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of pre clinical-stage programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfPreClinicalStagePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Pre Clinical-Stage Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfPreClinicalStagePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of pre clinical-stage programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net loss per share attributable to common stockholders - diluted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share - diluted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Tax Positions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash outflow for payments made to acquire right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments made to acquire right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash provided by/(used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by/(used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued and sold (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options unvested at ending (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Realized Investment Gains (Losses), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains (Losses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash outflow for reacquisition of callable treasury stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payments Available under Grant Awards Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Payments Available under Grant Awards Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payments available under grant awards program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets and Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LADICIRMGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant funding through the California Institute for Regenerative Medicine ("CIRM"). The Company was granted funds under a CLIN2 grant award to support the clinical development of gene therapy for LAD-I.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LADICIRMGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LAD-I CIRM Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LADICIRMGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LAD-I CIRM Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property and Equipment, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in present value of lessee's discounted obligation for lease payments from finance lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Finance Lease, Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value amount of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisableForCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisableForCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants into common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisableForCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercisable for Common Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of domestic federal tax rate of net operating loss applicable to pretax income (loss).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Net Operating Loss True-up Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal NOL true-up</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone potential future obligations as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development costs - Potential future obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential future obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for LAD-I with CIEMAT and UCLB</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A license agreement with CIEMAT and UCL Business PLC for granting the Company worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to lentiviral vectors containing the human LAD-I gene solely within the field of treating LAD-I.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement for LAD-I with CIEMAT and UCLB [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term - finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of reporting unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Numerator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Mutual Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding - basic (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance noncurrent lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance lease liability, non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities/class of warrants classified as Pre-fund warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessAcquisitionExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratio applied to exchange of shares in a business combination, for example but not limited to, one share exchanged to two or two shares exchanged to one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessAcquisitionExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Exchange Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessAcquisitionExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Restricted Stock Units Grants and Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options restricted stock units grants and performance stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Restricted Stock Units Grants and Performance Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of Operating Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Future Lease Payments of Operating Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The gross value of stock issued during the period pursuant to value of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Vesting of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rental income received under sublease agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds from offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest on lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial General And Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial general and administrative expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible tax credit carryforwards that are subject to expiration dates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At-the-Market Offering Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">An "at-the-market" offering is an offering of securities into an existing trading market for outstanding shares of the same class at other than a fixed price on, or through the facilities of, a national securities exchange, or to or through a market maker otherwise than on an exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">22.51</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NewYorkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">On March 31, 2016, the Company entered into a lease agreement for its office and laboratory space at the Alexandria Center for Life Sciences in New York, New York with an initial term ending on July 31, 2022 (the "NY Lease Agreement").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NewYorkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New York Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NewYorkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NY Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to expenses related to research and development cost (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">0.01</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants by exercise price of the warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_WarrantsExercisePriceSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercise Price Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-Based Awards [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_MemberOfTheBoardOfDirectorsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Member of the Board of Directors - Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_MemberOfTheBoardOfDirectorsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Member of the entity's board of directors who presides over board meetings and other board activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_MemberOfTheBoardOfDirectorsTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Member of the Board of Directors Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Penalties and Interest Accrued [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmpireStateBuildingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">On June 7, 2018, the Company entered into a three year lease agreement for office space in the Empire State Building in New York, NY (the "ESB Lease Agreement").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmpireStateBuildingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Empire State Building Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmpireStateBuildingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESB Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseSupplementalCashFlowInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of supplemental cash flow information related to leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseSupplementalCashFlowInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Supplemental Cash Flow Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LeaseSupplementalCashFlowInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Related to Cash Flow Information, Lease Term and Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of working capital includes other receivables, prepaid expenses, account payable and accrued liabilities recognized as of the acquisition date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Working Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value at-the-market offering programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, At-the-market Offering Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock related to acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock, at cost, 0 common shares at December 31, 2023 and 2,571 common shares at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AcquisitionExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of acquisition expenses, payable current as of the end of the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AcquisitionExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Expenses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AcquisitionExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringSharesCommonStockWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued during the period as a result of warrant exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringSharesCommonStockWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Shares Common Stock Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringSharesCommonStockWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to exercise of warrant (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Security that gives the holder the right to purchase one share of common stock at a specific exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfClinicalStagePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of clinical-stage programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfClinicalStagePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Clinical-Stage Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfClinicalStagePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of clinical-stage programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Loss Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants expire period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RoyaltiesPayableOnFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties percentage payable on fees received from a priority review voucher issued in connection with or otherwise related to a licensed product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RoyaltiesPayableOnFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties payable on fees received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RoyaltiesPayableOnFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties payable on fees received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in state tax apportionment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Balance Sheets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Lease [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Description [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_MemberOfTheBoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Member of the Board of Directors - One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_MemberOfTheBoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Member of the entity's board of directors who presides over board meetings and other board activities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_MemberOfTheBoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Member of the Board of Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CIRMGrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">C I R M Grants Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CIRMGrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CIRM Grants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of research and development income claimed from tax credit against the General Corporation Tax and Unincorporated Business Tax during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Incentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAndDevelopmentIncentives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development incentives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 Fair Value of the Private Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal use Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal use Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_TaxCreditCarryforwardAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Credit Carryforward Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_TaxCreditCarryforwardAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCashOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Operating Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCashOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash operating lease right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NonCashOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ExercisePricePerShareWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise Price Per Share Warrants Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ExercisePricePerShareWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Per Share, Warrants [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ExercisePricePerShareWarrantsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued purchases of property and equipment, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of finance lease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement Termination Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Agreement Termination Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting agreement termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Value, Acquired, Cost Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Description [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SaleOfStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate offering amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SaleOfStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate offering price of shares issued or sold in the stock transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SaleOfStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Aggregate Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SaleOfStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DanonDiseaseLicenseAgreementWithUCSDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for Danon Disease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DanonDiseaseLicenseAgreementWithUCSDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">A research and collaboration agreement with Lund University and Johan Richter, M.D., PhD. under which Dr. Richter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DanonDiseaseLicenseAgreementWithUCSDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Danon Disease License Agreement with UCSD [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LentiviralVectorProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LV Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LentiviralVectorProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lentiviral Vector Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LentiviralVectorProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lentiviral vector programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DanonDiseaseCIRMGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Danon Disease C I R M Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DanonDiseaseCIRMGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant funding through the California Institute for Regenerative Medicine ("CIRM"). The Company was granted funds under a CLIN2 grant award to support the clinical development of gene therapy for Danon Disease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DanonDiseaseCIRMGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DD CIRM Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Business and Basis of Presentation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average exercise price per share of warrants forfeited during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares at-the-market offering programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, At-the-market Offering Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pursuant to exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Savings Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, General [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of acquired intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Asset Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill and Intangible Asset Impairment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromSaleOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromSaleOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromSaleOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from sale of stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuritiesInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuritiesInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Investment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating and Financing Activities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Flow Operating And Financing Activities Lessee Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NOL carryforwards, expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs of Leased and Rented Property or Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement At The Market Offering Program And Public Offerings Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual term for non-vested convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but non-vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on investmentss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net unrealized gains (losses) on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds from Sale of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from sale of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock warrants issued to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Stock Warrants Issued to Purchase Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of stock warrants issued to purchase shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the components of cash , cash equivalents and restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of Renovacor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets and Goodwill [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_DeferredTaxAssetsWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConvertibleNotes2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConvertibleNotes2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConvertibleNotes2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes 2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of the Private Warrants, Assumptions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net operating loss, subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Relationship to Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting expense information used by CODM description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employees, Non-employees and Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee is an Executive of the entity that is appointed to the position by the board of directors. Nonemployee is a person not directly employed but is in a service capacity. And director is a person serving on the board of directors (who collectively have responsibility for governing the entity).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee, Nonemployee and Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Non-employees and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Option Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets (liabilities) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance current lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement For LAD I With CIEMAT Group And UCLB [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement For LAD I With CIEMAT Group And UCLB [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement for LAD-I with CIEMAT Group and UCLB</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value, 180,000,000 shares authorized; 106,453,818 and 90,282,267 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_GoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options and Restricted Stock Units Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options and Restricted Stock Units Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options and Restricted Stock Units Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses and credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The term of the agreement from the commencement date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Initial Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ResearchAgreementInitialTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 14)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-average common shares outstanding - diluted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Segment Loss Including Significant Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of votes per share of common stock owned granted to owner.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights, Number of Votes Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of voting right for each share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdjustmentOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of finance lease right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdjustmentOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amortization expense of right-of-use assets during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AdjustmentOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment of Right-of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease, liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Indefinite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProjectMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Project [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating and Finance Leases [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock purchases (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock purchases (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount and amortization of premium on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums excluding accretion income related to cash equivalents , Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SpouseOfExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Spouse of Executive officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SpouseOfExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Spouse of a person with designation of executive officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_SpouseOfExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Spouse of Executive officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock related to earnout restricted stock units settlement (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of discount and amortization of premium on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of premium on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of construction in process of finance lease right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of Construction in Process to Finance Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of construction in process from finance right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accretion of discount on convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options to purchase common shares (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RisksAndLiquidityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure related to risk and liquidity,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RisksAndLiquidityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Liquidity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_RisksAndLiquidityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FinanceLeasesEstimatedRentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rental payments due for the reporting period under finance leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FinanceLeasesEstimatedRentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Leases, Estimated Rent Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_FinanceLeasesEstimatedRentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated rent payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ReportableSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reportable Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ReportableSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reportable Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ReportableSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reportable segments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ProceedsFromMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cumulative amount of cash receipts for milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ProceedsFromMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ProceedsFromMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cash commission of gross proceeds from the sale of the shares pursuant to the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Cash Commission of Gross Proceeds from Sale of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of cash commission</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementAssetIdentificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement, Asset Identification Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementAssetIdentificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting agreement with related party for asset identification services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="rckt_ConsultingAgreementAssetIdentificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement, Asset Identification [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_RenovacorIncMember" xlink:to="rckt_RenovacorIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" xlink:to="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_FinanceLeaseCostsAbstract" xlink:to="rckt_FinanceLeaseCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" xlink:to="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceOneMember" xlink:to="rckt_WarrantsExercisePriceOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_AdditionalInformationOfCIRMGrantsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_SeriesBConvertiblePreferredSharesMember" xlink:to="rckt_SeriesBConvertiblePreferredSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LeaseBalanceSheetInformationTableTextBlock" xlink:to="rckt_LeaseBalanceSheetInformationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceFiveMember" xlink:to="rckt_WarrantsExercisePriceFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PropertyPlantAndEquipmentWriteDown" xlink:to="rckt_PropertyPlantAndEquipmentWriteDown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ClassOfWarrantOrRightGrantDate" xlink:to="rckt_ClassOfWarrantOrRightGrantDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_LicenseAgreementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AAVCurrentGoodManufacturingPracticecGMPMember" xlink:to="rckt_AAVCurrentGoodManufacturingPracticecGMPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConvertibleNotes2022Member" xlink:to="rckt_ConvertibleNotes2022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryLiabilityCurrent" xlink:to="us-gaap_RegulatoryLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConsultingAgreementEffectiveDate" xlink:to="rckt_ConsultingAgreementEffectiveDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorSalesTypeLeasesTextBlock" xlink:to="us-gaap_LessorSalesTypeLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_InotekLexingtonMassachusettsLeaseAgreementMember" xlink:to="rckt_InotekLexingtonMassachusettsLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_August2021WarrantMember" xlink:to="rckt_August2021WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_OperatingLossCarryforwardsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ResearchAndDevelopmentCosts" xlink:to="rckt_ResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" xlink:to="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AgreementsRelatedToIntellectualPropertyTextBlock" xlink:to="rckt_AgreementsRelatedToIntellectualPropertyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AdenoAssociatedVirusProgramsMember" xlink:to="rckt_AdenoAssociatedVirusProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfMilestonesAchieved" xlink:to="rckt_NumberOfMilestonesAchieved_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_December2021WarrantsMember" xlink:to="rckt_December2021WarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PIPEInvestorsMember" xlink:to="rckt_PIPEInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementsWithCIEMATMember" xlink:to="rckt_LicenseAgreementsWithCIEMATMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementForPKDWithCIEMATGroupMember" xlink:to="rckt_LicenseAgreementForPKDWithCIEMATGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" xlink:to="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" xlink:to="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AgreementTerminationNoticePeriod" xlink:to="rckt_AgreementTerminationNoticePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConsultingAgreementBusinessDevelopmentMember" xlink:to="rckt_ConsultingAgreementBusinessDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_RisksAndLiquidityAbstract" xlink:to="rckt_RisksAndLiquidityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NewJerseyLeaseAgreementMember" xlink:to="rckt_NewJerseyLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DerivativeLiabilitiesMember" xlink:to="rckt_DerivativeLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_FollowOnPublicOfferingMember" xlink:to="rckt_FollowOnPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementNumberOfPatents" xlink:to="rckt_LicenseAgreementNumberOfPatents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementForBAG3WithTempleUniversityMember" xlink:to="rckt_LicenseAgreementForBAG3WithTempleUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" xlink:to="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceTwoMember" xlink:to="rckt_WarrantsExercisePriceTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_SeriesAConvertiblePreferredSharesMember" xlink:to="rckt_SeriesAConvertiblePreferredSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CowenAndCompanyLLCMember" xlink:to="rckt_CowenAndCompanyLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsClassifiedAsEquityMember" xlink:to="rckt_WarrantsClassifiedAsEquityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementForDDWithRGNXMember" xlink:to="rckt_LicenseAgreementForDDWithRGNXMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceSixMember" xlink:to="rckt_WarrantsExercisePriceSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalBondsMember" xlink:to="us-gaap_MunicipalBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="rckt_DetailedInformationOfWarrantsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" xlink:to="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" xlink:to="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_TreasuryStockPolicyTextBlock" xlink:to="rckt_TreasuryStockPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CashCashEquivalentsAndInvestments" xlink:to="rckt_CashCashEquivalentsAndInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="rckt_AggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" xlink:to="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfLeastUninterruptedYears" xlink:to="rckt_NumberOfLeastUninterruptedYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_GovernmentGrantsPolicyTextBlock" xlink:to="rckt_GovernmentGrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PaymentAndExpensesForLicenseFee" xlink:to="rckt_PaymentAndExpensesForLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_InvestmentPayableCurrent" xlink:to="rckt_InvestmentPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_GrossProceedsFromIssuanceOfCommonStock" xlink:to="rckt_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:to="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_RelatedPartyTransactionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PrivateWarrantsMember" xlink:to="rckt_PrivateWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_IntangibleAssetsAbstract" xlink:to="rckt_IntangibleAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConsultingFeeMonthlyInstalment" xlink:to="rckt_ConsultingFeeMonthlyInstalment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PercentageOfAnnualIncreaseInBaseRent" xlink:to="rckt_PercentageOfAnnualIncreaseInBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementOptionsRightExpiryTerm" xlink:to="rckt_LicenseAgreementOptionsRightExpiryTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceEightMember" xlink:to="rckt_WarrantsExercisePriceEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_GrantAwardForClinicalDevelopmentSupport" xlink:to="rckt_GrantAwardForClinicalDevelopmentSupport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NonCashOperatingLeaseLiability" xlink:to="rckt_NonCashOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:to="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AgreementsRelatedToIntellectualPropertyAbstract" xlink:to="rckt_AgreementsRelatedToIntellectualPropertyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedIssuanceCosts" xlink:to="rckt_StockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_REGENXBIOIncLicenseMember" xlink:to="rckt_REGENXBIOIncLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PaymentForLicenseFee" xlink:to="rckt_PaymentForLicenseFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfOptionsToRenewLeaseAgreement" xlink:to="rckt_NumberOfOptionsToRenewLeaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_SharesIssuanceCost" xlink:to="rckt_SharesIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PublicOfferingMember" xlink:to="rckt_PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:to="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceFourMember" xlink:to="rckt_WarrantsExercisePriceFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" xlink:to="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PublicOfferingAndPrivatPlacementMember" xlink:to="rckt_PublicOfferingAndPrivatPlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NonCommercialGeneralAndAdministrativeExpense" xlink:to="rckt_NonCommercialGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_HopewellMember" xlink:to="rckt_HopewellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_ShareholdersEquityDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfPreClinicalStagePrograms" xlink:to="rckt_NumberOfPreClinicalStagePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LaboratoryEquipmentMember" xlink:to="rckt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PaymentsToAcquireRightOfUseAsset" xlink:to="rckt_PaymentsToAcquireRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PaymentsForRepurchaseTreasuryStock" xlink:to="rckt_PaymentsForRepurchaseTreasuryStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" xlink:to="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LADICIRMGrantMember" xlink:to="rckt_LADICIRMGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_IncreaseDecreaseInFinanceLeaseLiabilities" xlink:to="rckt_IncreaseDecreaseInFinanceLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisableForCommonSharesMember" xlink:to="rckt_WarrantsExercisableForCommonSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_TreasuryStockValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" xlink:to="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" xlink:to="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PreFundedWarrantsMember" xlink:to="rckt_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_BusinessAcquisitionExchangeRatio" xlink:to="rckt_BusinessAcquisitionExchangeRatio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" xlink:to="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:to="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CommercialGeneralAndAdministrativeExpense" xlink:to="rckt_CommercialGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AtTheMarketOfferingMember" xlink:to="rckt_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceThreeMember" xlink:to="rckt_WarrantsExercisePriceThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NewYorkLeaseAgreementMember" xlink:to="rckt_NewYorkLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ResearchAndDevelopmentCostsCurrent" xlink:to="rckt_ResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_WarrantsExercisePriceSevenMember" xlink:to="rckt_WarrantsExercisePriceSevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_MemberOfTheBoardOfDirectorsTwoMember" xlink:to="rckt_MemberOfTheBoardOfDirectorsTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_EmpireStateBuildingLeaseAgreementMember" xlink:to="rckt_EmpireStateBuildingLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="rckt_LeaseSupplementalCashFlowInformationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" xlink:to="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AcquisitionExpensesCurrent" xlink:to="rckt_AcquisitionExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedDuringSharesCommonStockWarrantExercised" xlink:to="rckt_StockIssuedDuringSharesCommonStockWarrantExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PublicWarrantsMember" xlink:to="rckt_PublicWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfClinicalStagePrograms" xlink:to="rckt_NumberOfClinicalStagePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_RoyaltiesPayableOnFeesReceived" xlink:to="rckt_RoyaltiesPayableOnFeesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_MemberOfTheBoardOfDirectorsMember" xlink:to="rckt_MemberOfTheBoardOfDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CIRMGrantsAbstract" xlink:to="rckt_CIRMGrantsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ResearchAndDevelopmentIncentives" xlink:to="rckt_ResearchAndDevelopmentIncentives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_TaxCreditCarryforwardAbstract" xlink:to="rckt_TaxCreditCarryforwardAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NonCashOperatingLeaseRightOfUseAssets" xlink:to="rckt_NonCashOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ExercisePricePerShareWarrantsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConsultingAgreementTerminationDate" xlink:to="rckt_ConsultingAgreementTerminationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_SaleOfStockAggregateOfferingPrice" xlink:to="rckt_SaleOfStockAggregateOfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DanonDiseaseLicenseAgreementWithUCSDMember" xlink:to="rckt_DanonDiseaseLicenseAgreementWithUCSDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LentiviralVectorProgramsMember" xlink:to="rckt_LentiviralVectorProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DanonDiseaseCIRMGrantMember" xlink:to="rckt_DanonDiseaseCIRMGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" xlink:to="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_GrossProceedsFromSaleOfStock" xlink:to="rckt_GrossProceedsFromSaleOfStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesInvestmentMember" xlink:to="us-gaap_SecuritiesInvestmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_GrossProceedsFromSaleOfShares" xlink:to="rckt_GrossProceedsFromSaleOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_DeferredTaxAssetsWarrants" xlink:to="rckt_DeferredTaxAssetsWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConvertibleNotes2021Member" xlink:to="rckt_ConvertibleNotes2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_ValuationTechniqueAndInputDescriptionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_EmployeeNonemployeeAndDirectorMember" xlink:to="rckt_EmployeeNonemployeeAndDirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockOptionAbstract" xlink:to="rckt_StockOptionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" xlink:to="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_GoodwillAbstract" xlink:to="rckt_GoodwillAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" xlink:to="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ResearchAgreementInitialTerm" xlink:to="rckt_ResearchAgreementInitialTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:to="rckt_CommonStockVotingRightsNumberOfVotesPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AdjustmentOfRightOfUseAssets" xlink:to="rckt_AdjustmentOfRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" xlink:to="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_SpouseOfExecutiveOfficerMember" xlink:to="rckt_SpouseOfExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" xlink:to="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_RisksAndLiquidityTextBlock" xlink:to="rckt_RisksAndLiquidityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_FinanceLeasesEstimatedRentPayments" xlink:to="rckt_FinanceLeasesEstimatedRentPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ReportableSegmentsMember" xlink:to="rckt_ReportableSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ProceedsFromMilestonePayments" xlink:to="rckt_ProceedsFromMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" xlink:to="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rckt_ConsultingAgreementAssetIdentificationMember" xlink:to="rckt_ConsultingAgreementAssetIdentificationMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesAConvertiblePreferredSharesMember" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesBConvertiblePreferredSharesMember" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesAConvertiblePreferredSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesBConvertiblePreferredSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesAConvertiblePreferredSharesMember" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesBConvertiblePreferredSharesMember" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesAConvertiblePreferredSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesBConvertiblePreferredSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentIncentives" xlink:label="rckt_ResearchAndDevelopmentIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="rckt_ResearchAndDevelopmentIncentives" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringSharesCommonStockWarrantExercised" xlink:label="rckt_StockIssuedDuringSharesCommonStockWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" xlink:label="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" xlink:label="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:label="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_21"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_22"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringSharesCommonStockWarrantExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCashOperatingLeaseLiability" xlink:label="rckt_NonCashOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdjustmentOfRightOfUseAssets" xlink:label="rckt_AdjustmentOfRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsForRepurchaseTreasuryStock" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCashOperatingLeaseRightOfUseAssets" xlink:label="rckt_NonCashOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInFinanceLeaseLiabilities" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsToAcquireRightOfUseAsset" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PropertyPlantAndEquipmentWriteDown" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" xlink:label="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rckt_NonCashOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rckt_AdjustmentOfRightOfUseAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rckt_PaymentsForRepurchaseTreasuryStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rckt_NonCashOperatingLeaseRightOfUseAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rckt_IncreaseDecreaseInFinanceLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="rckt_PaymentsToAcquireRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rckt_PropertyPlantAndEquipmentWriteDown" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RisksAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RisksAndLiquidityAbstract" xlink:label="rckt_RisksAndLiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RisksAndLiquidityTextBlock" xlink:label="rckt_RisksAndLiquidityTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RisksAndLiquidityAbstract" xlink:to="rckt_RisksAndLiquidityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_DerivativesAndFairValueTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorSalesTypeLeasesTextBlock" xlink:label="us-gaap_LessorSalesTypeLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorSalesTypeLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AgreementsRelatedToIntellectualProperty" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementsRelatedToIntellectualPropertyAbstract" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementsRelatedToIntellectualPropertyTextBlock" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AgreementsRelatedToIntellectualPropertyAbstract" xlink:to="rckt_AgreementsRelatedToIntellectualPropertyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CirmGrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CIRMGrantsAbstract" xlink:label="rckt_CIRMGrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" xlink:label="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CIRMGrantsAbstract" xlink:to="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/KSavingsPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GovernmentGrantsPolicyTextBlock" xlink:label="rckt_GovernmentGrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" xlink:label="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_TreasuryStockPolicyTextBlock" xlink:label="rckt_TreasuryStockPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rckt_GovernmentGrantsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rckt_TreasuryStockPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/WarrantsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseBalanceSheetInformationTableTextBlock" xlink:label="rckt_LeaseBalanceSheetInformationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="rckt_LeaseSupplementalCashFlowInformationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rckt_LeaseBalanceSheetInformationTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rckt_LeaseSupplementalCashFlowInformationTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdenoAssociatedVirusProgramsMember" xlink:label="rckt_AdenoAssociatedVirusProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfClinicalStagePrograms" xlink:label="rckt_NumberOfClinicalStagePrograms"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LentiviralVectorProgramsMember" xlink:label="rckt_LentiviralVectorProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfPreClinicalStagePrograms" xlink:label="rckt_NumberOfPreClinicalStagePrograms"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rckt_AdenoAssociatedVirusProgramsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rckt_NumberOfClinicalStagePrograms" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rckt_LentiviralVectorProgramsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rckt_NumberOfPreClinicalStagePrograms" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CowenAndCompanyLLCMember" xlink:label="rckt_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RisksAndLiquidityAbstract" xlink:label="rckt_RisksAndLiquidityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuritiesInvestmentMember" xlink:label="us-gaap_SecuritiesInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareholdersEquityDisclosureAbstract" xlink:label="rckt_ShareholdersEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FollowOnPublicOfferingMember" xlink:label="rckt_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SaleOfStockAggregateOfferingPrice" xlink:label="rckt_SaleOfStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfShares" xlink:label="rckt_GrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingAndPrivatPlacementMember" xlink:label="rckt_PublicOfferingAndPrivatPlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SharesIssuanceCost" xlink:label="rckt_SharesIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfStock" xlink:label="rckt_GrossProceedsFromSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromIssuanceOfCommonStock" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedIssuanceCosts" xlink:label="rckt_StockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CashCashEquivalentsAndInvestments" xlink:label="rckt_CashCashEquivalentsAndInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rckt_CowenAndCompanyLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RisksAndLiquidityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_SecuritiesInvestmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_SaleOfStockAggregateOfferingPrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Cash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_GrossProceedsFromSaleOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rckt_ShareholdersEquityDisclosureAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingAndPrivatPlacementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_SharesIssuanceCost" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_GrossProceedsFromSaleOfStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_GrossProceedsFromIssuanceOfCommonStock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_StockIssuedIssuanceCosts" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_CashCashEquivalentsAndInvestments" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IntangibleAssetsAbstract" xlink:label="rckt_IntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_IntangibleAssetsAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rckt_IntangibleAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_IntangibleAssetsAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_IntangibleAssetsAbstract" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GoodwillAbstract" xlink:label="rckt_GoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rckt_GoodwillAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_GoodwillAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_GoodwillAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_GoodwillAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_GoodwillAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_GoodwillAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MunicipalBondsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="us-gaap_ValuationTechniqueAndInputDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PrivateWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LaboratoryEquipmentMember" xlink:label="rckt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rckt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCostsCurrent" xlink:label="rckt_ResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InvestmentPayableCurrent" xlink:label="rckt_InvestmentPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AcquisitionExpensesCurrent" xlink:label="rckt_AcquisitionExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryLiabilityCurrent" xlink:label="us-gaap_RegulatoryLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rckt_ResearchAndDevelopmentCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rckt_InvestmentPayableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ConstructionPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rckt_AcquisitionExpensesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_RegulatoryLiabilityCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InvestmentPayableCurrent" xlink:label="rckt_InvestmentPayableCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rckt_InvestmentPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConvertibleNotes2021Member" xlink:label="rckt_ConvertibleNotes2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConvertibleNotes2022Member" xlink:label="rckt_ConvertibleNotes2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rckt_ConvertibleNotes2021Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rckt_ConvertibleNotes2022Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CowenAndCompanyLLCMember" xlink:label="rckt_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract" xlink:label="us-gaap_TreasuryStockValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:label="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:label="rckt_CommonStockVotingRightsNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromIssuanceOfCommonStock" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfShares" xlink:label="rckt_GrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedIssuanceCosts" xlink:label="rckt_StockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SaleOfStockAggregateOfferingPrice" xlink:label="rckt_SaleOfStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfStock" xlink:label="rckt_GrossProceedsFromSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SharesIssuanceCost" xlink:label="rckt_SharesIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rckt_CowenAndCompanyLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_TreasuryStockCommonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TreasuryStockValueAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="rckt_CommonStockVotingRightsNumberOfVotesPerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_GrossProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_GrossProceedsFromSaleOfShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_StockIssuedIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_SaleOfStockAggregateOfferingPrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_GrossProceedsFromSaleOfStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_SharesIssuanceCost" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmployeeNonemployeeAndDirectorMember" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="rckt_EmployeeNonemployeeAndDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionAbstract" xlink:label="rckt_StockOptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AggregateIntrinsicValueAbstract" xlink:label="rckt_AggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rckt_StockOptionAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_StockOptionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_StockOptionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_StockOptionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_StockOptionAbstract" xlink:to="rckt_AggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" xlink:label="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" xlink:label="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DetailedInformationOfWarrantsAbstract" xlink:label="rckt_DetailedInformationOfWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceOneMember" xlink:label="rckt_WarrantsExercisePriceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceTwoMember" xlink:label="rckt_WarrantsExercisePriceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightGrantDate" xlink:label="rckt_ClassOfWarrantOrRightGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceThreeMember" xlink:label="rckt_WarrantsExercisePriceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceFourMember" xlink:label="rckt_WarrantsExercisePriceFourMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceFiveMember" xlink:label="rckt_WarrantsExercisePriceFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceSixMember" xlink:label="rckt_WarrantsExercisePriceSixMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceSevenMember" xlink:label="rckt_WarrantsExercisePriceSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceEightMember" xlink:label="rckt_WarrantsExercisePriceEightMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_DetailedInformationOfWarrantsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightGrantDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceSevenMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceEightMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:label="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ExercisePricePerShareWarrantsAbstract" xlink:label="rckt_ExercisePricePerShareWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicWarrantsMember" xlink:label="rckt_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_ExercisePricePerShareWarrantsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PublicWarrantsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PrivateWarrantsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PreFundedWarrantsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DetailedInformationOfWarrantsAbstract" xlink:label="rckt_DetailedInformationOfWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PIPEInvestorsMember" xlink:label="rckt_PIPEInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicWarrantsMember" xlink:label="rckt_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_DetailedInformationOfWarrantsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_PIPEInvestorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PublicWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PrivateWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PreFundedWarrantsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsWarrants" xlink:label="rckt_DeferredTaxAssetsWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="rckt_DeferredTaxAssetsWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OperatingLossCarryforwardsAbstract" xlink:label="rckt_OperatingLossCarryforwardsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_TaxCreditCarryforwardAbstract" xlink:label="rckt_TaxCreditCarryforwardAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" xlink:label="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" xlink:label="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" xlink:label="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="rckt_OperatingLossCarryforwardsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_TaxCreditCarryforwardAbstract" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="rckt_TaxCreditCarryforwardAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NewJerseyLeaseAgreementMember" xlink:label="rckt_NewJerseyLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" xlink:label="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AAVCurrentGoodManufacturingPracticecGMPMember" xlink:label="rckt_AAVCurrentGoodManufacturingPracticecGMPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfOptionsToRenewLeaseAgreement" xlink:label="rckt_NumberOfOptionsToRenewLeaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FinanceLeasesEstimatedRentPayments" xlink:label="rckt_FinanceLeasesEstimatedRentPayments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfAnnualIncreaseInBaseRent" xlink:label="rckt_PercentageOfAnnualIncreaseInBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_NewJerseyLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_AAVCurrentGoodManufacturingPracticecGMPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_NumberOfOptionsToRenewLeaseAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_FinanceLeasesEstimatedRentPayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_PercentageOfAnnualIncreaseInBaseRent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NewYorkLeaseAgreementMember" xlink:label="rckt_NewYorkLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_HopewellMember" xlink:label="rckt_HopewellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmpireStateBuildingLeaseAgreementMember" xlink:label="rckt_EmpireStateBuildingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" xlink:label="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InotekLexingtonMassachusettsLeaseAgreementMember" xlink:label="rckt_InotekLexingtonMassachusettsLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeasesOperatingAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_NewYorkLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rckt_HopewellMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_EmpireStateBuildingLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_InotekLexingtonMassachusettsLeaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_SubleaseIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_SecurityDeposit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FinanceLeaseCostsAbstract" xlink:label="rckt_FinanceLeaseCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_FinanceLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_FinanceLeaseCostsAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="rckt_FinanceLeaseCostsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:label="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementAbstract" xlink:label="rckt_LicenseAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCosts" xlink:label="rckt_ResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementsRelatedToIntellectualPropertyAbstract" xlink:label="rckt_AgreementsRelatedToIntellectualPropertyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DanonDiseaseLicenseAgreementWithUCSDMember" xlink:label="rckt_DanonDiseaseLicenseAgreementWithUCSDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" xlink:label="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_REGENXBIOIncLicenseMember" xlink:label="rckt_REGENXBIOIncLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAgreementInitialTerm" xlink:label="rckt_ResearchAgreementInitialTerm"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForDDWithRGNXMember" xlink:label="rckt_LicenseAgreementForDDWithRGNXMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementTerminationNoticePeriod" xlink:label="rckt_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementsWithCIEMATMember" xlink:label="rckt_LicenseAgreementsWithCIEMATMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementNumberOfPatents" xlink:label="rckt_LicenseAgreementNumberOfPatents"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForPKDWithCIEMATGroupMember" xlink:label="rckt_LicenseAgreementForPKDWithCIEMATGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementOptionsRightExpiryTerm" xlink:label="rckt_LicenseAgreementOptionsRightExpiryTerm"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" xlink:label="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RoyaltiesPayableOnFeesReceived" xlink:label="rckt_RoyaltiesPayableOnFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentForLicenseFee" xlink:label="rckt_PaymentForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentAndExpensesForLicenseFee" xlink:label="rckt_PaymentAndExpensesForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForBAG3WithTempleUniversityMember" xlink:label="rckt_LicenseAgreementForBAG3WithTempleUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfMilestonesAchieved" xlink:label="rckt_NumberOfMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfLeastUninterruptedYears" xlink:label="rckt_NumberOfLeastUninterruptedYears"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_ResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AgreementsRelatedToIntellectualPropertyAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_DanonDiseaseLicenseAgreementWithUCSDMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rckt_LicenseAgreementAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_REGENXBIOIncLicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_ResearchAgreementInitialTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForDDWithRGNXMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_AgreementTerminationNoticePeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementsWithCIEMATMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_LicenseAgreementNumberOfPatents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForPKDWithCIEMATGroupMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_LicenseAgreementOptionsRightExpiryTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_RoyaltiesPayableOnFeesReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_PaymentForLicenseFee" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_PaymentAndExpensesForLicenseFee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForBAG3WithTempleUniversityMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_NumberOfMilestonesAchieved" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_NumberOfLeastUninterruptedYears" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:label="rckt_AdditionalInformationOfCIRMGrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrantAwardForClinicalDevelopmentSupport" xlink:label="rckt_GrantAwardForClinicalDevelopmentSupport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CIRMGrantsAbstract" xlink:label="rckt_CIRMGrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LADICIRMGrantMember" xlink:label="rckt_LADICIRMGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ProceedsFromMilestonePayments" xlink:label="rckt_ProceedsFromMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DanonDiseaseCIRMGrantMember" xlink:label="rckt_DanonDiseaseCIRMGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" xlink:label="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_GrantAwardForClinicalDevelopmentSupport" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_CIRMGrantsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="rckt_AdditionalInformationOfCIRMGrantsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="rckt_LADICIRMGrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_ProceedsFromMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="rckt_DanonDiseaseCIRMGrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsClassifiedAsEquityMember" xlink:label="rckt_WarrantsClassifiedAsEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessAcquisitionExchangeRatio" xlink:label="rckt_BusinessAcquisitionExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DerivativeLiabilitiesMember" xlink:label="rckt_DerivativeLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember" xlink:to="rckt_WarrantsClassifiedAsEquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationDescriptionAbstract" xlink:to="rckt_BusinessAcquisitionExchangeRatio" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember" xlink:to="rckt_DerivativeLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_Goodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsClassifiedAsEquityMember" xlink:label="rckt_WarrantsClassifiedAsEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DerivativeLiabilitiesMember" xlink:label="rckt_DerivativeLiabilitiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="rckt_WarrantsClassifiedAsEquityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="rckt_DerivativeLiabilitiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RelatedPartyTransactionAbstract" xlink:label="rckt_RelatedPartyTransactionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementBusinessDevelopmentMember" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_MemberOfTheBoardOfDirectorsMember" xlink:label="rckt_MemberOfTheBoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_August2021WarrantMember" xlink:label="rckt_August2021WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementAssetIdentificationMember" xlink:label="rckt_ConsultingAgreementAssetIdentificationMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SpouseOfExecutiveOfficerMember" xlink:label="rckt_SpouseOfExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementTerminationDate" xlink:label="rckt_ConsultingAgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_December2021WarrantsMember" xlink:label="rckt_December2021WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_MemberOfTheBoardOfDirectorsTwoMember" xlink:label="rckt_MemberOfTheBoardOfDirectorsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementEffectiveDate" xlink:label="rckt_ConsultingAgreementEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingFeeMonthlyInstalment" xlink:label="rckt_ConsultingFeeMonthlyInstalment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rckt_RelatedPartyTransactionAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rckt_ConsultingAgreementBusinessDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rckt_MemberOfTheBoardOfDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_August2021WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rckt_ConsultingAgreementAssetIdentificationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rckt_SpouseOfExecutiveOfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_ConsultingAgreementTerminationDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_December2021WarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rckt_MemberOfTheBoardOfDirectorsTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_ConsultingAgreementEffectiveDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_ConsultingFeeMonthlyInstalment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ReportableSegmentsMember" xlink:label="rckt_ReportableSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCommercialGeneralAndAdministrativeExpense" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommercialGeneralAndAdministrativeExpense" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentIncentives" xlink:label="rckt_ResearchAndDevelopmentIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="rckt_ReportableSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="rckt_NonCommercialGeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="rckt_CommercialGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="rckt_ResearchAndDevelopmentIncentives" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_InterestExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_InterestAndOtherIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesAConvertiblePreferredSharesMember" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesBConvertiblePreferredSharesMember" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesAConvertiblePreferredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesBConvertiblePreferredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesAConvertiblePreferredSharesMember" xlink:label="rckt_SeriesAConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SeriesBConvertiblePreferredSharesMember" xlink:label="rckt_SeriesBConvertiblePreferredSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesAConvertiblePreferredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rckt_SeriesBConvertiblePreferredSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringSharesCommonStockWarrantExercised" xlink:label="rckt_StockIssuedDuringSharesCommonStockWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" xlink:label="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" xlink:label="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" xlink:label="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringSharesCommonStockWarrantExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCashOperatingLeaseLiability" xlink:label="rckt_NonCashOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdjustmentOfRightOfUseAssets" xlink:label="rckt_AdjustmentOfRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsForRepurchaseTreasuryStock" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCashOperatingLeaseRightOfUseAssets" xlink:label="rckt_NonCashOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInFinanceLeaseLiabilities" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsToAcquireRightOfUseAsset" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PropertyPlantAndEquipmentWriteDown" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" xlink:label="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rckt_NonCashOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rckt_AdjustmentOfRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="rckt_PaymentsForRepurchaseTreasuryStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rckt_NonCashOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rckt_IncreaseDecreaseInFinanceLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="rckt_PaymentsToAcquireRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rckt_PropertyPlantAndEquipmentWriteDown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdenoAssociatedVirusProgramsMember" xlink:label="rckt_AdenoAssociatedVirusProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfClinicalStagePrograms" xlink:label="rckt_NumberOfClinicalStagePrograms"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LentiviralVectorProgramsMember" xlink:label="rckt_LentiviralVectorProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfPreClinicalStagePrograms" xlink:label="rckt_NumberOfPreClinicalStagePrograms"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rckt_AdenoAssociatedVirusProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rckt_NumberOfClinicalStagePrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rckt_LentiviralVectorProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rckt_NumberOfPreClinicalStagePrograms" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CowenAndCompanyLLCMember" xlink:label="rckt_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuritiesInvestmentMember" xlink:label="us-gaap_SecuritiesInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareholdersEquityDisclosureAbstract" xlink:label="rckt_ShareholdersEquityDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FollowOnPublicOfferingMember" xlink:label="rckt_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SaleOfStockAggregateOfferingPrice" xlink:label="rckt_SaleOfStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfShares" xlink:label="rckt_GrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingAndPrivatPlacementMember" xlink:label="rckt_PublicOfferingAndPrivatPlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SharesIssuanceCost" xlink:label="rckt_SharesIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfStock" xlink:label="rckt_GrossProceedsFromSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromIssuanceOfCommonStock" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedIssuanceCosts" xlink:label="rckt_StockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CashCashEquivalentsAndInvestments" xlink:label="rckt_CashCashEquivalentsAndInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rckt_CowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_SecuritiesInvestmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_SaleOfStockAggregateOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_GrossProceedsFromSaleOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rckt_ShareholdersEquityDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingAndPrivatPlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_SharesIssuanceCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_GrossProceedsFromSaleOfStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_StockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ShareholdersEquityDisclosureAbstract" xlink:to="rckt_CashCashEquivalentsAndInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:label="us-gaap_ValuationTechniqueAndInputDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PrivateWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueAndInputDescriptionAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LaboratoryEquipmentMember" xlink:label="rckt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rckt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConvertibleNotes2021Member" xlink:label="rckt_ConvertibleNotes2021Member"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConvertibleNotes2022Member" xlink:label="rckt_ConvertibleNotes2022Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rckt_ConvertibleNotes2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="rckt_ConvertibleNotes2022Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CowenAndCompanyLLCMember" xlink:label="rckt_CowenAndCompanyLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAbstract" xlink:label="us-gaap_TreasuryStockValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:label="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AtTheMarketOfferingMember" xlink:label="rckt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommonStockVotingRightsNumberOfVotesPerShare" xlink:label="rckt_CommonStockVotingRightsNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" xlink:label="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromIssuanceOfCommonStock" xlink:label="rckt_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfShares" xlink:label="rckt_GrossProceedsFromSaleOfShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockIssuedIssuanceCosts" xlink:label="rckt_StockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SaleOfStockAggregateOfferingPrice" xlink:label="rckt_SaleOfStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrossProceedsFromSaleOfStock" xlink:label="rckt_GrossProceedsFromSaleOfStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SharesIssuanceCost" xlink:label="rckt_SharesIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rckt_CowenAndCompanyLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TreasuryStockValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="rckt_CommonStockVotingRightsNumberOfVotesPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TreasuryStockValueAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_GrossProceedsFromSaleOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_StockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_SaleOfStockAggregateOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_GrossProceedsFromSaleOfStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="rckt_SharesIssuanceCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmployeeNonemployeeAndDirectorMember" xlink:label="rckt_EmployeeNonemployeeAndDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="rckt_EmployeeNonemployeeAndDirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionAbstract" xlink:label="rckt_StockOptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AggregateIntrinsicValueAbstract" xlink:label="rckt_AggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rckt_StockOptionAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_StockOptionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_StockOptionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_StockOptionAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_StockOptionAbstract" xlink:to="rckt_AggregateIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AggregateIntrinsicValueAbstract" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" xlink:label="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" xlink:label="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" xlink:label="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DetailedInformationOfWarrantsAbstract" xlink:label="rckt_DetailedInformationOfWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceOneMember" xlink:label="rckt_WarrantsExercisePriceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceTwoMember" xlink:label="rckt_WarrantsExercisePriceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightGrantDate" xlink:label="rckt_ClassOfWarrantOrRightGrantDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceThreeMember" xlink:label="rckt_WarrantsExercisePriceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceFourMember" xlink:label="rckt_WarrantsExercisePriceFourMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceFiveMember" xlink:label="rckt_WarrantsExercisePriceFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceSixMember" xlink:label="rckt_WarrantsExercisePriceSixMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceSevenMember" xlink:label="rckt_WarrantsExercisePriceSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisePriceEightMember" xlink:label="rckt_WarrantsExercisePriceEightMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_DetailedInformationOfWarrantsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightGrantDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceSevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_WarrantsExercisePriceEightMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:label="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ExercisePricePerShareWarrantsAbstract" xlink:label="rckt_ExercisePricePerShareWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicWarrantsMember" xlink:label="rckt_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PublicWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_ExercisePricePerShareWarrantsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PrivateWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_ExercisePricePerShareWarrantsAbstract" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PreFundedWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DetailedInformationOfWarrantsAbstract" xlink:label="rckt_DetailedInformationOfWarrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PIPEInvestorsMember" xlink:label="rckt_PIPEInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicWarrantsMember" xlink:label="rckt_PublicWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PrivateWarrantsMember" xlink:label="rckt_PrivateWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="rckt_DetailedInformationOfWarrantsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_PIPEInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PublicWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PrivateWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_DetailedInformationOfWarrantsAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:label="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OperatingLossCarryforwardsAbstract" xlink:label="rckt_OperatingLossCarryforwardsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_TaxCreditCarryforwardAbstract" xlink:label="rckt_TaxCreditCarryforwardAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" xlink:label="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" xlink:label="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" xlink:label="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="rckt_OperatingLossCarryforwardsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_TaxCreditCarryforwardAbstract" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="rckt_TaxCreditCarryforwardAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_OperatingLossCarryforwardsAbstract" xlink:to="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NewJerseyLeaseAgreementMember" xlink:label="rckt_NewJerseyLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" xlink:label="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AAVCurrentGoodManufacturingPracticecGMPMember" xlink:label="rckt_AAVCurrentGoodManufacturingPracticecGMPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfOptionsToRenewLeaseAgreement" xlink:label="rckt_NumberOfOptionsToRenewLeaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_FinanceLeasesEstimatedRentPayments" xlink:label="rckt_FinanceLeasesEstimatedRentPayments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PercentageOfAnnualIncreaseInBaseRent" xlink:label="rckt_PercentageOfAnnualIncreaseInBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_NewJerseyLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_AAVCurrentGoodManufacturingPracticecGMPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_NumberOfOptionsToRenewLeaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_FinanceLeasesEstimatedRentPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="rckt_PercentageOfAnnualIncreaseInBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NewYorkLeaseAgreementMember" xlink:label="rckt_NewYorkLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_HopewellMember" xlink:label="rckt_HopewellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmpireStateBuildingLeaseAgreementMember" xlink:label="rckt_EmpireStateBuildingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" xlink:label="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InotekLexingtonMassachusettsLeaseAgreementMember" xlink:label="rckt_InotekLexingtonMassachusettsLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeasesOperatingAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_NewYorkLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rckt_HopewellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_EmpireStateBuildingLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rckt_InotekLexingtonMassachusettsLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_SubleaseIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementAbstract" xlink:label="rckt_LicenseAgreementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCosts" xlink:label="rckt_ResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DanonDiseaseLicenseAgreementWithUCSDMember" xlink:label="rckt_DanonDiseaseLicenseAgreementWithUCSDMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" xlink:label="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_REGENXBIOIncLicenseMember" xlink:label="rckt_REGENXBIOIncLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAgreementInitialTerm" xlink:label="rckt_ResearchAgreementInitialTerm"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForDDWithRGNXMember" xlink:label="rckt_LicenseAgreementForDDWithRGNXMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AgreementTerminationNoticePeriod" xlink:label="rckt_AgreementTerminationNoticePeriod"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementsWithCIEMATMember" xlink:label="rckt_LicenseAgreementsWithCIEMATMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementNumberOfPatents" xlink:label="rckt_LicenseAgreementNumberOfPatents"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForPKDWithCIEMATGroupMember" xlink:label="rckt_LicenseAgreementForPKDWithCIEMATGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementOptionsRightExpiryTerm" xlink:label="rckt_LicenseAgreementOptionsRightExpiryTerm"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" xlink:label="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RoyaltiesPayableOnFeesReceived" xlink:label="rckt_RoyaltiesPayableOnFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentForLicenseFee" xlink:label="rckt_PaymentForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" xlink:label="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentAndExpensesForLicenseFee" xlink:label="rckt_PaymentAndExpensesForLicenseFee"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LicenseAgreementForBAG3WithTempleUniversityMember" xlink:label="rckt_LicenseAgreementForBAG3WithTempleUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfMilestonesAchieved" xlink:label="rckt_NumberOfMilestonesAchieved"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfLeastUninterruptedYears" xlink:label="rckt_NumberOfLeastUninterruptedYears"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_ResearchAndDevelopmentCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_DanonDiseaseLicenseAgreementWithUCSDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rckt_LicenseAgreementAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_REGENXBIOIncLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_ResearchAgreementInitialTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForDDWithRGNXMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementsWithCIEMATMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_LicenseAgreementNumberOfPatents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForPKDWithCIEMATGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_LicenseAgreementOptionsRightExpiryTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_RoyaltiesPayableOnFeesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_PaymentForLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_PaymentAndExpensesForLicenseFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="rckt_LicenseAgreementForBAG3WithTempleUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_NumberOfMilestonesAchieved" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_LicenseAgreementAbstract" xlink:to="rckt_NumberOfLeastUninterruptedYears" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:label="rckt_AdditionalInformationOfCIRMGrantsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_GrantAwardForClinicalDevelopmentSupport" xlink:label="rckt_GrantAwardForClinicalDevelopmentSupport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_LADICIRMGrantMember" xlink:label="rckt_LADICIRMGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ProceedsFromMilestonePayments" xlink:label="rckt_ProceedsFromMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DanonDiseaseCIRMGrantMember" xlink:label="rckt_DanonDiseaseCIRMGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" xlink:label="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_GrantAwardForClinicalDevelopmentSupport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="rckt_AdditionalInformationOfCIRMGrantsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="rckt_LADICIRMGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_ProceedsFromMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="rckt_DanonDiseaseCIRMGrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_AdditionalInformationOfCIRMGrantsAbstract" xlink:to="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsClassifiedAsEquityMember" xlink:label="rckt_WarrantsClassifiedAsEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessAcquisitionExchangeRatio" xlink:label="rckt_BusinessAcquisitionExchangeRatio"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DerivativeLiabilitiesMember" xlink:label="rckt_DerivativeLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantMember" xlink:to="rckt_WarrantsClassifiedAsEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationDescriptionAbstract" xlink:to="rckt_BusinessAcquisitionExchangeRatio" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantMember" xlink:to="rckt_DerivativeLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsClassifiedAsEquityMember" xlink:label="rckt_WarrantsClassifiedAsEquityMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DerivativeLiabilitiesMember" xlink:label="rckt_DerivativeLiabilitiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="rckt_WarrantsClassifiedAsEquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="rckt_DerivativeLiabilitiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RenovacorIncMember" xlink:label="rckt_RenovacorIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="rckt_RenovacorIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_RelatedPartyTransactionAbstract" xlink:label="rckt_RelatedPartyTransactionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementBusinessDevelopmentMember" xlink:label="rckt_ConsultingAgreementBusinessDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_MemberOfTheBoardOfDirectorsMember" xlink:label="rckt_MemberOfTheBoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_August2021WarrantMember" xlink:label="rckt_August2021WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PublicOfferingMember" xlink:label="rckt_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_WarrantsExercisableForCommonSharesMember" xlink:label="rckt_WarrantsExercisableForCommonSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementAssetIdentificationMember" xlink:label="rckt_ConsultingAgreementAssetIdentificationMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_SpouseOfExecutiveOfficerMember" xlink:label="rckt_SpouseOfExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementTerminationDate" xlink:label="rckt_ConsultingAgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_December2021WarrantsMember" xlink:label="rckt_December2021WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_MemberOfTheBoardOfDirectorsTwoMember" xlink:label="rckt_MemberOfTheBoardOfDirectorsTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingAgreementEffectiveDate" xlink:label="rckt_ConsultingAgreementEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PreFundedWarrantsMember" xlink:label="rckt_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ConsultingFeeMonthlyInstalment" xlink:label="rckt_ConsultingFeeMonthlyInstalment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NumberOfStockWarrantsIssuedToPurchaseShares" xlink:label="rckt_NumberOfStockWarrantsIssuedToPurchaseShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rckt_RelatedPartyTransactionAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rckt_ConsultingAgreementBusinessDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rckt_MemberOfTheBoardOfDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_August2021WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rckt_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rckt_WarrantsExercisableForCommonSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rckt_ConsultingAgreementAssetIdentificationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rckt_SpouseOfExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_ConsultingAgreementTerminationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_December2021WarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rckt_MemberOfTheBoardOfDirectorsTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_ConsultingAgreementEffectiveDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="rckt_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_ConsultingFeeMonthlyInstalment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rckt_RelatedPartyTransactionAbstract" xlink:to="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ReportableSegmentsMember" xlink:label="rckt_ReportableSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCommercialGeneralAndAdministrativeExpense" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommercialGeneralAndAdministrativeExpense" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentIncentives" xlink:label="rckt_ResearchAndDevelopmentIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="rckt_ReportableSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="rckt_NonCommercialGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="rckt_CommercialGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="rckt_ResearchAndDevelopmentIncentives" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_Goodwill" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="rckt_ResearchAndDevelopmentIncentives" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentIncentives" xlink:label="rckt_ResearchAndDevelopmentIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="0" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="rckt_PaymentsForRepurchaseTreasuryStock" order="3" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromSaleOfTreasuryStock" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="rckt_PaymentsToAcquireRightOfUseAsset" order="4" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rckt_AdjustmentOfRightOfUseAssets" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rckt_PropertyPlantAndEquipmentWriteDown" order="7" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="9" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" order="11" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="14" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rckt_IncreaseDecreaseInFinanceLeaseLiabilities" order="16" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="17" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsForRepurchaseTreasuryStock" xlink:label="rckt_PaymentsForRepurchaseTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfTreasuryStock" xlink:label="us-gaap_ProceedsFromSaleOfTreasuryStock"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PaymentsToAcquireRightOfUseAsset" xlink:label="rckt_PaymentsToAcquireRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AdjustmentOfRightOfUseAssets" xlink:label="rckt_AdjustmentOfRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_PropertyPlantAndEquipmentWriteDown" xlink:label="rckt_PropertyPlantAndEquipmentWriteDown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" xlink:label="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" xlink:label="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncreaseDecreaseInFinanceLeaseLiabilities" xlink:label="rckt_IncreaseDecreaseInFinanceLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="1" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="rckt_ResearchAndDevelopmentCostsCurrent" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="rckt_InvestmentPayableCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="rckt_AcquisitionExpensesCurrent" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_ConstructionPayableCurrent" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="4" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_RegulatoryLiabilityCurrent" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentCostsCurrent" xlink:label="rckt_ResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_InvestmentPayableCurrent" xlink:label="rckt_InvestmentPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_AcquisitionExpensesCurrent" xlink:label="rckt_AcquisitionExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RegulatoryLiabilityCurrent" xlink:label="us-gaap_RegulatoryLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" xlink:label="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" order="5" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="9" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" xlink:label="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" order="0" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="rckt_DeferredTaxAssetsWarrants" order="5" weight="-1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="6" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="8" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_DeferredTaxAssetsWarrants" xlink:label="rckt_DeferredTaxAssetsWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" weight="1.0" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="2" weight="1.0" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="8" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" xlink:label="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="rckt_ResearchAndDevelopmentIncentives" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="rckt_NonCommercialGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="rckt_CommercialGeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_ResearchAndDevelopmentIncentives" xlink:label="rckt_ResearchAndDevelopmentIncentives"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_NonCommercialGeneralAndAdministrativeExpense" xlink:label="rckt_NonCommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="rckt-20241231.xsd#rckt_CommercialGeneralAndAdministrativeExpense" xlink:label="rckt_CommercialGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rckt_PaymentAndExpensesForLicenseFee" name="PaymentAndExpensesForLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_ResearchAndDevelopmentCostsPotentialFutureObligation" name="ResearchAndDevelopmentCostsPotentialFutureObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_StockOptionsAndRestrictedStockUnitsGrantsMember" name="StockOptionsAndRestrictedStockUnitsGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_RenovacorIncMember" name="RenovacorIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PaymentForLicenseFee" name="PaymentForLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_TaxCreditCarryforwardAbstract" name="TaxCreditCarryforwardAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ClassOfWarrantOrRightGrantDate" name="ClassOfWarrantOrRightGrantDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_LeaseSupplementalCashFlowInformationTableTextBlock" name="LeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_BusinessAcquisitionExchangeRatio" name="BusinessAcquisitionExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_RisksAndLiquidityTextBlock" name="RisksAndLiquidityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_WarrantsExercisePriceTwoMember" name="WarrantsExercisePriceTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_TreasuryStockPolicyTextBlock" name="TreasuryStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_GrantAwardForClinicalDevelopmentSupport" name="GrantAwardForClinicalDevelopmentSupport" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_RisksAndLiquidityAbstract" name="RisksAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_CashCashEquivalentsAndInvestments" name="CashCashEquivalentsAndInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_NonCommercialGeneralAndAdministrativeExpense" name="NonCommercialGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_LicenseAgreementsWithCIEMATMember" name="LicenseAgreementsWithCIEMATMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract" name="NumberOfWarrantSharesOutstandingAndExercisableAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ProceedsFromMilestonePayments" name="ProceedsFromMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_AdenoAssociatedVirusProgramsMember" name="AdenoAssociatedVirusProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AAVCurrentGoodManufacturingPracticecGMPMember" name="AAVCurrentGoodManufacturingPracticecGMPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_GrossProceedsFromSaleOfShares" name="GrossProceedsFromSaleOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_IntangibleAssetsAbstract" name="IntangibleAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" name="EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_WarrantsExercisePriceThreeMember" name="WarrantsExercisePriceThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_AgreementsRelatedToIntellectualPropertyTextBlock" name="AgreementsRelatedToIntellectualPropertyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_GovernmentGrantsPolicyTextBlock" name="GovernmentGrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram" name="AdditionalPaymentsAvailableUnderGrantAwardsProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_WarrantsExercisePriceOneMember" name="WarrantsExercisePriceOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_GoodwillAbstract" name="GoodwillAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ConsultingAgreementAssetIdentificationMember" name="ConsultingAgreementAssetIdentificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_WarrantsExercisePriceFiveMember" name="WarrantsExercisePriceFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ExercisePricePerShareWarrantsAbstract" name="ExercisePricePerShareWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" name="IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_DanonDiseaseLicenseAgreementWithUCSDMember" name="DanonDiseaseLicenseAgreementWithUCSDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" name="ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_NonCashOperatingLeaseRightOfUseAssets" name="NonCashOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_LeaseBalanceSheetInformationTableTextBlock" name="LeaseBalanceSheetInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_WarrantsExercisePriceSevenMember" name="WarrantsExercisePriceSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_EmpireStateBuildingLeaseAgreementAmendmentMember" name="EmpireStateBuildingLeaseAgreementAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" name="PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" name="EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ConsultingAgreementBusinessDevelopmentMember" name="ConsultingAgreementBusinessDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_NonCashOperatingLeaseLiability" name="NonCashOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_December2021WarrantsMember" name="December2021WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ConsultingAgreementEffectiveDate" name="ConsultingAgreementEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ResearchAndDevelopmentCosts" name="ResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_SpouseOfExecutiveOfficerMember" name="SpouseOfExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" name="CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" name="AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" name="IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod" name="OperatingLossCarryforwardsCumulativeLimitationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_WarrantsExercisePriceFourMember" name="WarrantsExercisePriceFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_LicenseAgreementForBAG3WithTempleUniversityMember" name="LicenseAgreementForBAG3WithTempleUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_REGENXBIOIncLicenseMember" name="REGENXBIOIncLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PublicOfferingAndPrivatPlacementMember" name="PublicOfferingAndPrivatPlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_NewYorkLeaseAgreementMember" name="NewYorkLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_WarrantsClassifiedAsEquityMember" name="WarrantsClassifiedAsEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_MemberOfTheBoardOfDirectorsMember" name="MemberOfTheBoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_NumberOfLeastUninterruptedYears" name="NumberOfLeastUninterruptedYears" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" name="StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" name="LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_NumberOfOptionsToRenewLeaseAgreement" name="NumberOfOptionsToRenewLeaseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_NumberOfClinicalStagePrograms" name="NumberOfClinicalStagePrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_StockIssuedIssuanceCosts" name="StockIssuedIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_DanonDiseaseCIRMGrantMember" name="DanonDiseaseCIRMGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ConsultingAgreementTerminationDate" name="ConsultingAgreementTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_NumberOfPreClinicalStagePrograms" name="NumberOfPreClinicalStagePrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_InotekLexingtonMassachusettsLeaseAgreementMember" name="InotekLexingtonMassachusettsLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_LicenseAgreementNumberOfPatents" name="LicenseAgreementNumberOfPatents" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ResearchAndDevelopmentCostsCurrent" name="ResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" name="DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" name="LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ReportableSegmentsMember" name="ReportableSegmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PrivateWarrantsMember" name="PrivateWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" name="IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_LicenseAgreementOptionsRightExpiryTerm" name="LicenseAgreementOptionsRightExpiryTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_EmpireStateBuildingLeaseAgreementMember" name="EmpireStateBuildingLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" name="StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities" name="LeaseAreaForInternalProcessDevelopmentAndResearchActivities" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_CIRMGrantsAbstract" name="CIRMGrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_SaleOfStockAggregateOfferingPrice" name="SaleOfStockAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_DetailedInformationOfWarrantsAbstract" name="DetailedInformationOfWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_HopewellMember" name="HopewellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_PIPEInvestorsMember" name="PIPEInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ConvertibleNotes2022Member" name="ConvertibleNotes2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" name="AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_OperatingLossCarryforwardsAbstract" name="OperatingLossCarryforwardsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_WarrantsExercisePriceEightMember" name="WarrantsExercisePriceEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_LicenseAgreementForPKDWithCIEMATGroupMember" name="LicenseAgreementForPKDWithCIEMATGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" name="StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_CommonStockVotingRightsNumberOfVotesPerShare" name="CommonStockVotingRightsNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ResearchAgreementInitialTerm" name="ResearchAgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ResearchAndDevelopmentIncentives" name="ResearchAndDevelopmentIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember" name="LicenseAgreementForLADIWithCIEMATAndUCLBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" name="StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_SharesIssuanceCost" name="SharesIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_RelatedPartyTransactionAbstract" name="RelatedPartyTransactionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rckt_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_SeriesAConvertiblePreferredSharesMember" name="SeriesAConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_SeriesBConvertiblePreferredSharesMember" name="SeriesBConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" name="ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision" name="EffectiveIncomeTaxRateReconciliationReturnToProvision" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_NewJerseyLeaseAgreementMember" name="NewJerseyLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_LentiviralVectorProgramsMember" name="LentiviralVectorProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AcquisitionExpensesCurrent" name="AcquisitionExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_DerivativeLiabilitiesMember" name="DerivativeLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_MemberOfTheBoardOfDirectorsTwoMember" name="MemberOfTheBoardOfDirectorsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PaymentsToAcquireRightOfUseAsset" name="PaymentsToAcquireRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" name="OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_ConvertibleNotes2021Member" name="ConvertibleNotes2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PercentageOfAnnualIncreaseInBaseRent" name="PercentageOfAnnualIncreaseInBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" name="PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_WarrantsExercisableForCommonSharesMember" name="WarrantsExercisableForCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_DeferredTaxAssetsWarrants" name="DeferredTaxAssetsWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract" name="CashFlowOperatingAndFinancingActivitiesLesseeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_FinanceLeaseCostsAbstract" name="FinanceLeaseCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" name="DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="rckt_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AdditionalInformationOfCIRMGrantsAbstract" name="AdditionalInformationOfCIRMGrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_StockOptionAbstract" name="StockOptionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PropertyPlantAndEquipmentWriteDown" name="PropertyPlantAndEquipmentWriteDown" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_WarrantsExercisePriceSixMember" name="WarrantsExercisePriceSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_August2021WarrantMember" name="August2021WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_CommercialGeneralAndAdministrativeExpense" name="CommercialGeneralAndAdministrativeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_LADICIRMGrantMember" name="LADICIRMGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_IncreaseDecreaseInFinanceLeaseLiabilities" name="IncreaseDecreaseInFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_AdjustmentOfRightOfUseAssets" name="AdjustmentOfRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_PaymentsForRepurchaseTreasuryStock" name="PaymentsForRepurchaseTreasuryStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_FinanceLeasesEstimatedRentPayments" name="FinanceLeasesEstimatedRentPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_InvestmentPayableCurrent" name="InvestmentPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="rckt_RoyaltiesPayableOnFeesReceived" name="RoyaltiesPayableOnFeesReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_EmployeeNonemployeeAndDirectorMember" name="EmployeeNonemployeeAndDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_AgreementsRelatedToIntellectualPropertyAbstract" name="AgreementsRelatedToIntellectualPropertyAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_StockIssuedDuringSharesCommonStockWarrantExercised" name="StockIssuedDuringSharesCommonStockWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="rckt_GrossProceedsFromSaleOfStock" name="GrossProceedsFromSaleOfStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_ConsultingFeeMonthlyInstalment" name="ConsultingFeeMonthlyInstalment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="rckt_LicenseAgreementForDDWithRGNXMember" name="LicenseAgreementForDDWithRGNXMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_ShareholdersEquityDisclosureAbstract" name="ShareholdersEquityDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_PublicWarrantsMember" name="PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="rckt_NumberOfStockWarrantsIssuedToPurchaseShares" name="NumberOfStockWarrantsIssuedToPurchaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438361360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rocket Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001281895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3475813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9 Cedarbrook Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-8001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCKT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,629,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Documents Incorporated by Reference</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part III of this annual report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from the registrant&#8217;s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the </span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proxy Statement</span><span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days of the end of the period covered by this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EISNERAMPER LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p id="audit_report" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Rocket Pharmaceuticals, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).  In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated February 27, 2025 expressed an unqualified opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited Rocket Pharmaceuticals, Inc. and Subsidiaries&#8217; (the &#8220;Company&#8221;) internal control over financial reporting as of December 31, 2024, based on criteria established in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;).  In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) issued by COSO.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of Rocket Pharmaceuticals, Inc. and Subsidiaries as of December 31, 2024, and the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes and our report dated February 27, 2025 expressed an unqualified opinion.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323442059696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 163,635<span></span>
</td>
<td class="nump">$ 55,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">208,701<span></span>
</td>
<td class="nump">317,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,847<span></span>
</td>
<td class="nump">5,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">378,183<span></span>
</td>
<td class="nump">378,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">36,786<span></span>
</td>
<td class="nump">39,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">39,154<span></span>
</td>
<td class="nump">39,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">25,150<span></span>
</td>
<td class="nump">25,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">4,173<span></span>
</td>
<td class="nump">3,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset, net</a></td>
<td class="nump">42,363<span></span>
</td>
<td class="nump">44,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">527,700<span></span>
</td>
<td class="nump">566,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">37,827<span></span>
</td>
<td class="nump">45,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">40,684<span></span>
</td>
<td class="nump">48,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">3,258<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, non-current</a></td>
<td class="nump">19,383<span></span>
</td>
<td class="nump">19,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">64,466<span></span>
</td>
<td class="nump">73,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 180,000,000 shares authorized; 106,453,818 and 90,282,267 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,680,219<span></span>
</td>
<td class="nump">1,450,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,218,116)<span></span>
</td>
<td class="num">(959,370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">463,234<span></span>
</td>
<td class="nump">492,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">527,700<span></span>
</td>
<td class="nump">566,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesAConvertiblePreferredSharesMember', window );">Series A Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesAConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rckt_SeriesAConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rckt_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438200672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">180,000,000<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">106,453,818<span></span>
</td>
<td class="nump">90,282,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">106,453,818<span></span>
</td>
<td class="nump">90,282,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesAConvertiblePreferredSharesMember', window );">Series A Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesAConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rckt_SeriesAConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rckt_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rckt_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437684048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">171,244<span></span>
</td>
<td class="nump">186,342<span></span>
</td>
<td class="nump">165,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">101,961<span></span>
</td>
<td class="nump">73,317<span></span>
</td>
<td class="nump">58,773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">273,205<span></span>
</td>
<td class="nump">259,659<span></span>
</td>
<td class="nump">224,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(273,205)<span></span>
</td>
<td class="num">(259,659)<span></span>
</td>
<td class="num">(224,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentIncentives', window );">Research and development incentives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">8,267<span></span>
</td>
<td class="nump">5,288<span></span>
</td>
<td class="nump">3,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount and amortization of premium on investments, net</a></td>
<td class="nump">8,078<span></span>
</td>
<td class="nump">10,651<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (258,746)<span></span>
</td>
<td class="num">$ (245,595)<span></span>
</td>
<td class="num">$ (221,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (3.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (3.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">94,807,773<span></span>
</td>
<td class="nump">84,009,004<span></span>
</td>
<td class="nump">68,148,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">94,807,773<span></span>
</td>
<td class="nump">84,009,004<span></span>
</td>
<td class="nump">68,148,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ResearchAndDevelopmentIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development income claimed from tax credit against the General Corporation Tax and Unincorporated Business Tax during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ResearchAndDevelopmentIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433835408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (258,746)<span></span>
</td>
<td class="num">$ (245,595)<span></span>
</td>
<td class="num">$ (221,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on investments</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (258,999)<span></span>
</td>
<td class="num">$ (244,919)<span></span>
</td>
<td class="num">$ (222,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435666160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock, Common</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income / (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 454,724<span></span>
</td>
<td class="nump">$ 645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946,152<span></span>
</td>
<td class="num">$ (161)<span></span>
</td>
<td class="num">$ (491,912)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,505,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">108,138<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock pursuant to vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock related to acquisition</a></td>
<td class="nump">70,724<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock related to acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,420,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock related to earnout restricted stock units settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms', window );">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs</a></td>
<td class="nump">46,566<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms', window );">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,291,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock purchases</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax', window );">Unrealized comprehensive gain (loss) on investments</a></td>
<td class="num">(196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">31,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(221,863)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,863)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">489,686<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">1,203,074<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="num">(713,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,123,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">188,885<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,453,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock pursuant to vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock pursuant to vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringSharesCommonStockWarrantExercised', window );">Issuance of common stock pursuant to exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock related to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms', window );">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs</a></td>
<td class="nump">17,222<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms', window );">Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax', window );">Unrealized comprehensive gain (loss) on investments</a></td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Sale of treasury stock</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">39,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(245,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">492,574<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,722<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="num">(959,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,282,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">182,528<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock pursuant to vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock pursuant to vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock related to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax', window );">Unrealized comprehensive gain (loss) on investments</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">43,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(258,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(258,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 463,234<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,680,219<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="num">$ (1,218,116)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,453,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares at-the-market offering programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value at-the-market offering programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period pursuant to value of restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedDuringSharesCommonStockWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedDuringSharesCommonStockWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436819888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (258,746)<span></span>
</td>
<td class="num">$ (245,595)<span></span>
</td>
<td class="num">$ (221,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">7,221<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AdjustmentOfRightOfUseAssets', window );">Amortization of finance lease right of use asset</a></td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of acquired intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PropertyPlantAndEquipmentWriteDown', window );">Write down of property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">43,920<span></span>
</td>
<td class="nump">39,406<span></span>
</td>
<td class="nump">31,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments', window );">Accretion of discount and amortization of premium on investments, net</a></td>
<td class="num">(8,068)<span></span>
</td>
<td class="num">(10,168)<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">1,876<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(661)<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
<td class="num">(3,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,067<span></span>
</td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">9,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet', window );">Operating lease liabilities and right of use assets, net</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_IncreaseDecreaseInFinanceLeaseLiabilities', window );">Finance lease liability</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(3,671)<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(209,724)<span></span>
</td>
<td class="num">(194,916)<span></span>
</td>
<td class="num">(178,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(245,886)<span></span>
</td>
<td class="num">(390,920)<span></span>
</td>
<td class="num">(376,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">383,454<span></span>
</td>
<td class="nump">309,326<span></span>
</td>
<td class="nump">272,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash proceeds from acquisition of business, net of cash paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PaymentsToAcquireRightOfUseAsset', window );">Payments made to acquire right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,862)<span></span>
</td>
<td class="num">(16,436)<span></span>
</td>
<td class="num">(8,358)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">131,706<span></span>
</td>
<td class="num">(98,066)<span></span>
</td>
<td class="num">(69,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common stock, pursuant to exercise of stock options</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PaymentsForRepurchaseTreasuryStock', window );">Treasury stock repurchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Issuance of common stock, pursuant to sale of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Issuance of common stock, pursuant to exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">185,739<span></span>
</td>
<td class="nump">208,401<span></span>
</td>
<td class="nump">155,288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">107,721<span></span>
</td>
<td class="num">(84,581)<span></span>
</td>
<td class="num">(92,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">57,276<span></span>
</td>
<td class="nump">141,857<span></span>
</td>
<td class="nump">234,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">164,997<span></span>
</td>
<td class="nump">57,276<span></span>
</td>
<td class="nump">141,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued purchases of property and equipment, ending balance</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">2,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Receivables from sale of property and equipment, ending balance</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NonCashOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">2,929<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NonCashOperatingLeaseRightOfUseAssets', window );">Operating lease right of use assets</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) gain on investmentss</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock related to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset', window );">Reclassification of construction in process from finance right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">182,528<span></span>
</td>
<td class="nump">188,885<span></span>
</td>
<td class="nump">108,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,222<span></span>
</td>
<td class="nump">$ 46,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AdjustmentOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amortization expense of right-of-use assets during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AdjustmentOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_IncreaseDecreaseInFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_IncreaseDecreaseInFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liability and right of use assets, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NonCashOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NonCashOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NonCashOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NonCashOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_PaymentsForRepurchaseTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for reacquisition of callable treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_PaymentsForRepurchaseTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_PaymentsToAcquireRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payments made to acquire right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_PaymentsToAcquireRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_PropertyPlantAndEquipmentWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in property plant and equipment due to subsequent measurement adjustments, including, but not limited to physical deterioration and obsolescence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_PropertyPlantAndEquipmentWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of construction in process of finance lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436892288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a cybersecurity risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The program is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within the Company&#8217;s enterprise risk management framework and addresses both the corporate information technology environment and the external ecosystem</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The underlying controls of the cybersecurity risk management program are based on recognized best practices and standards for cybersecurity and information technology. The Company has a third party perform an annual assessment of the Company&#8217;s cybersecurity risk management program. The Company has a Cyber Security Operations Center monitoring our global cybersecurity environment and coordinates investigations and remediation of alerts. We are enhancing our programs for staging incident response drills to prepare support teams for a significant incident. The cybersecurity risk management program includes administrative, physical, and technical controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our VP, Head of Information Technology is the Company&#8217;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All employees are required to complete cybersecurity training at least once annually and have access to more frequent cybersecurity training through online and live events. We also require employees in certain roles to complete additional role-based, specialized cybersecurity training that is documented in our quality management system. Employees outside of our corporate information security organization also have a role in our cybersecurity defenses and they are immersed in a corporate culture supportive of security, which we believe improves our cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#8217;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team collectively has decades of experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes around the world, and relies on threat intelligence as well as information obtained from governmental, public, and private sources, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including external consultants engaged by the Company on a real time basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, in addition to the Company&#8217;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#8217;s cyber risk management program, generally on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, cybersecurity risks will be reviewed by the Board of Directors, at least annually, as part of the Company&#8217;s corporate risk mapping exercise.</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not experienced any material cybersecurity incidents to date, and, by default, we believe no cybersecurity events have occurred that have materially affected the Company or its business strategy</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, results of operations or financial condition. We continue to invest in cybersecurity and the resilience of our infrastructure and the enhancement of our internal controls and processes, which are designed to help protect our systems and data, and the information they contain. For more information regarding the risks we face from cybersecurity threats, please see &#8220;Risk Factors.&#8221;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a cybersecurity risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The program is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within the Company&#8217;s enterprise risk management framework and addresses both the corporate information technology environment and the external ecosystem</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#8217;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team collectively has decades of experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes around the world, and relies on threat intelligence as well as information obtained from governmental, public, and private sources, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including external consultants engaged by the Company on a real time basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, in addition to the Company&#8217;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#8217;s cyber risk management program, generally on a quarterly basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, cybersecurity risks will be reviewed by the Board of Directors, at least annually, as part of the Company&#8217;s corporate risk mapping exercise.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#8217;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The underlying controls of the cybersecurity risk management program are based on recognized best practices and standards for cybersecurity and information technology. The Company has a third party perform an annual assessment of the Company&#8217;s cybersecurity risk management program. The Company has a Cyber Security Operations Center monitoring our global cybersecurity environment and coordinates investigations and remediation of alerts. We are enhancing our programs for staging incident response drills to prepare support teams for a significant incident. The cybersecurity risk management program includes administrative, physical, and technical controls</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our VP, Head of Information Technology is the Company&#8217;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All employees are required to complete cybersecurity training at least once annually and have access to more frequent cybersecurity training through online and live events. We also require employees in certain roles to complete additional role-based, specialized cybersecurity training that is documented in our quality management system. Employees outside of our corporate information security organization also have a role in our cybersecurity defenses and they are immersed in a corporate culture supportive of security, which we believe improves our cybersecurity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee, in addition to the Company&#8217;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#8217;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#8217;s cyber risk management program, generally on a quarterly basis.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our VP, Head of Information Technology is the Company&#8217;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441830784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (258,746)<span></span>
</td>
<td class="num">$ (245,595)<span></span>
</td>
<td class="num">$ (221,863)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438033600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441995248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of Business and Basis of Presentation</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical stage and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-clinical stage </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> adeno-associated viral (AAV) programs in the U.S., which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The DD program is currently in an ongoing Phase 2 trial (RP-A501);</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601); and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. The Company utilizes recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to slow or halt progression of BAG3-DCM.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company announced its alignment with the FDA on its pivotal study design for RP-A501 in Danon Disease. Completion of enrollment in this study was announced in September 2024, and dosing and follow-up are ongoing. The Company has received FDA clearance of an investigational new drug (IND) application for RP-A601, and has initiated a Phase 1 study for this program. For the BAG3 program, nonclinical and IND enabling studies are ongoing. Submission of the IND is anticipated in the first half of 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical-stage ex vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lentiviral (LV) programs, which include programs for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201)</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for RP-L201 for the treatment of severe LAD-I. In June 2024, the Company announced that the FDA had issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025. With respect to RP-L201, treatments in the FA Phase 2 studies were completed in 2023 and submission of a BLA on a rolling review basis was initiated in September 2024. In April 2024, the European Medicines Agency (EMA) accepted our Marketing Authorization Applications (MAA) for RP-L102. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. With respect to RP-L301, the Company has reached agreement with the FDA on the study design of the Phase 2 pivotal trial for RP-L301, our ex vivo LV-based program targeting PKD. While the Phase 2 RP-L301 study is ready for patient enrollment, the Company is currently focusing our resources on other programs and have not initiated enrollment in the Phase 2 RP-L301 study.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has global commercialization and development rights to all of these product candidates under royalty-bearing license agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433886368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RisksAndLiquidityAbstract', window );"><strong>Risks and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks and Liquidity</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development, technological uncertainty, uncertainty regarding patents and proprietary rights, having no commercial manufacturing experience, marketing or sales capability or experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s product candidates are in the development and clinical stage. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion as of December 31, 2024. As of December 31, 2024, the Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash, cash equivalents, and investments. The Company expects such resources will be sufficient to fund the Company&#8217;s operating expenses and capital expenditure requirements into the third quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2022, the Company entered into a sales agreement (&#8220;the Sales Agreement&#8221;) with Cowen  with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million through Cowen as its sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to the Company. The Company may consider reactivating the at-the-market offering program in the future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through December 31, 2024, the Company has sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pursuant to the at-the-market offering program (see Note 8 &#8220;Stockholders&#8217; Equity&#8221;). The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares under the at-the-market offering program for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less commissions of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company completed the Offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and Private Placement of pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.49</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant. The gross proceeds from the Offering and Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(see Note 8 &#8220;Stockholder&#8217;s Equity&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the longer term, the future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Liquidity Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to risk and liquidity,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323543929520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with U.S. GAAP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All intercompany accounts have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of R&amp;D </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses, the valuation of equity transactions, and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company&#8217;s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></p></div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#8217;s operating leases (see Note </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13 &#8220;Leases&#8221; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#8217;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:65.633%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:15.183%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:15.183%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,635</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,904</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,362</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,997</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,276</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></div></div><p style="margin-left:403.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Grants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense was presented net of reimbursements from CIRM (See Note 16 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIRM Grant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for additional disclosure).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk and off-balance sheet risk</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of U.S. Treasury Securities, and Corporate Bonds. The Company&#8217;s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AA-/Aa3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rated, thereby reducing credit risk exposure.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments consist of U.S. Treasury Securities and Corporate Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to ASC 320, Investments&#8212;Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company&#8217;s Consolidated Statement of Operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses on investments for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022. For the years ended December 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 and 2022, there were net unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net unrealized gains on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and net unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets consisted of an indefinite lived intangible IPR&amp;D asset and a mice colony model. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&amp;D intangible assets which are determined to have had a decrease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in their fair value are adjusted downward and an expense is recognized in R&amp;D expenses in the Consolidated Statements of Operations. These IPR&amp;D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&amp;D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. If a triggering event occurs that would indicate a potential impairment, the Company will perform a quantitative analysis to determine whether it is more likely than not that the fair value is below carrying amount. The annual impairment assessment for the IPR&amp;D asset was performed as of December 1. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment of the IPR&amp;D asset was recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded an impairment of the</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intangible long-lived asset </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related to the mice colony model of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business combinations are accounted for under the acquisition method. The total cost of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, asset lives and market multiples, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reporting unit and as such review&#8217;s goodwill for impairment at the consolidated level. When testing goodwill, the Company has the option to first assess qualitative factors for reporting units that carry goodwill. The qualitative assessment includes assessing the totality of relevant events and circumstances that affect the fair value or carrying value of the reporting unit. These events and circumstances include macroeconomic conditions, industry and competitive environment conditions, overall financial performance, reporting unit specific events and market considerations. The Company also considers recent valuations of the reporting unit, including the magnitude of the difference between the most recent fair value estimate and the carrying value, as well as both positive and adverse events and circumstances, and the extent to which each of the events and circumstances identified may affect the comparison of a reporting unit&#8217;s fair value with its carrying value. If the qualitative assessment results in a conclusion that it is more likely than not that the fair value of a reporting unit exceeds the carrying value, then no further testing is performed for that reporting unit.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company performed the qualitative assessment of its goodwill and determined that it is more likely than not that the fair value of a reporting unit exceeds the carrying value of the reporting unit. As a result, the Company has determined there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> goodwill impairment as of and for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful lives of the asset which are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifteen years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company capitalizes purchases of laboratory equipment, machinery and equipment, furniture and fixtures and leasehold improvements in relation to the facility at Cranbury, New Jersey, since it has been determined these assets have alternative future uses to the Company. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. Costs incurred in connection with development or purchase of internal use software and cloud computing arrangements, including in-substance software licenses, are capitalized. Amortization is computed on a straight-line basis over the estimated useful life of the asset, which is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Capitalized software is included in property and equipment in the Consolidated Balance Sheets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. The Company conducted its impairment analyses of long-lived assets to be held and used in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.  The Company also recorded write downs of property and equipment in each of the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 - Valuations that require inputs that reflect the Company&#8217;s own assumptions that are both significant to the fair value measurement and unobservable.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company&#8217;s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity and/or ASC Topic 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company&#8217;s Consolidated Statements of Operations. Warrants classified as equity instruments are recorded within additional paid-in capital at the time of issuance and not subject to remeasurement</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses, which include salaries and staff costs, license costs, manufacturing and development costs, clinical trial expenses, depreciation and amortization expenses, regulatory and scientific consulting fees, as well as contract research, and stock-based compensation expense, are accounted for in accordance with ASC Topic 730, Research and Development. Accordingly, R&amp;D costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain foreign currency transactions during the years ended December 31, 2024, 2023 and 2022 were primarily denominated in Euros and British pounds. Gains and losses on foreign currency transactions were not significant for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records treasury stock at cost.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issues stock-based awards to employees and non-employees, generally in the form of stock options, RSUs, and PSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. The cost of stock options and RSUs is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The vesting condition for PSUs is performance based and the cost of a PSU is recognized when it is likely that the performance goal associated with the PSU will be achieved and the award will vest.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as expected volatility and expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations in the same manner in which the award recipient&#8217;s payroll costs and services are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet differences. In accordance with ASC 740, Income Taxes, the Company recorded a full valuation allowance to fully offset the net deferred tax asset because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2024 and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates net loss per share in accordance with ASC 260, Earnings per Share. Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Warrants that meet the definition of equity classification and that requires the holder to pay little or no consideration to receive shares upon exercise are considered outstanding in the context of basic earnings per share. Diluted net loss attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, outstanding options are considered potential dilutive common shares.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e4e33013-0944-4e5f-ae6a-24eab71a59cf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the senior leadership team. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Included in these expenses are R&amp;D expenses by program.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources and consists of net loss and changes in unrealized gains and losses on investments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company&#8217;s Consolidated Balance Sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company&#8217;s lease agreements contain renewal options&#894;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company&#8217;s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company&#8217;s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Not Adopted as of December 31, 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09: Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This update standardized categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update was effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the effect that ASU 2023-09 will have on its financial statements and disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2024-03: Expense Disaggregation Disclosures. This update requires disaggregated disclosure of income statement expenses. This update is effective for the Company for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the effect that ASU 2024-03 will have on its financial statements and disclosures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Adopted as of December 31, 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update was effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adoption of ASU 2023-07 resulted in a new footnote disclosure for Segment Reporting.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323442013392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Items measured at fair value on a recurring basis are the Company&#8217;s investments. The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.87%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements as of December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,401</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,154</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">356,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements as of December 31, 2023 Using:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">354,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404,815</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its money market mutual funds as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its U.S. Treasury Securities and Corporate Bonds as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of the Company&#8217;s warrant liability, which is recorded as part of Other Liabilities in the Consolidated Balance Sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,512</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company utilizes a Black-Scholes model to value the warrant liability (see Note 10 &#8220;Warrants&#8221;) at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in an options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the expected volatility of its common stock based on historical volatility of its common stock, considering the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the valuation date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the warrant liability has been estimated with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.572%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.864%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.57</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.50</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.24</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.83</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.70</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (years)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.31</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value per warrant</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441912720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s property and equipment consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.113%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.442999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.442999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,205</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,232</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,857</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,325</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,015</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,777</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,777</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,282</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,723</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,903</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,903</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,039</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,204</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,253</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,032</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,786</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,172</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization during the years ended December 31, 2024, 2023, and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434754112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets and Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible Assets and Goodwill</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s intangible assets consisted of an acquired IPR&amp;D asset received in the acquisition of Renovacor. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 are summarized as follows:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.872%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross carrying value</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying value of Goodwill as of December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434682048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Payable and Accrued Expenses</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s accounts payable and accrued expenses consisted of the following:</span></p><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.872%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,768</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,867</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment payable</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,137</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,944</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,930</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,077</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,305</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,006</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,625</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,772</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accounts payable and accrued expenses</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,789</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million investment payable was related to investment purchases of available-for-sale securities in 2023 that settled in 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441793744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span></div></div><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is currently authorized to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock. All issued shares of common stock are entitled to vote on a 1 share/</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> treasury stock transactions were recorded for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the year ended December 31, 2023, the Company recorded sale of treasury stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. During the year ended December 31, 2022, the Company recorded a repurchase of treasury stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for shares withheld to pay the payroll tax liability of the vesting of RSUs. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> treasury stock as of December 31, 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering Program</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 28, 2022, the Company entered into a Sales Agreement with Cowen with respect to an at-the-market offering program pursuant to which the Company could offer and sell, from time to time at its sole discretion, shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of its common stock, par value $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through Cowen as its sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to the Company. The Company may consider reactivating the at-the-market offering program in the future.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares under the at-the-market offering program for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company did not sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares under the at-the-market offering program for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, less commissions of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Offerings and Private Placements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 6, 2022, the Company completed a public offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of our common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The gross proceeds from the public offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, commissions, legal and other expenses for net proceeds from the offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 15, 2023, the Company completed a public offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant. The gross proceeds from the public offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, the Company completed the Offering of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of its common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and Private Placement of pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of common stock at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.49</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per warrant. The gross proceeds from the Offering and Private Placement were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433729776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Awards</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Awards</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Valuation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of the stock options granted to employees, non-employees and directors were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.851%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.049999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.049999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.049999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.81</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.82</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.09</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.72</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.189%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.302%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.362%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.302%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.842%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (Years)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,138,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.52</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.46</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,370,862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.76</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,318</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,863,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.07</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,602</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,767,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.94</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,412</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">317,904</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,044,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.67</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,255,024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.55</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,789,662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.72</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average grant-date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of options vested during the years ended December 31, 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.119999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">992,874</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,018,322</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.67</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">408,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.92</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,490,357</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">760,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.45</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722,471</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.02</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Common stock issued is net of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares related to taxes.</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total fair value of RSU&#8217;s vested during the years ended December 31, 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company began granting PSU awards in 2024. The following table summarizes the PSU activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,738</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.93</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,077</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.31</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,661</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.71</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU vesting and expense recognition is based on achievement of specific performance goals within certain time periods. PSU awards that are not achieved within specific time periods are forfeited. No performance goals were probable of achievement and the time periods for 3 performance goals had expired as of December 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized by award type is as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,866</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,389</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,509</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,466</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had an aggregate of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized stock-based compensation expense, which is expected to be recognized over the weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323442002768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Warrants</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s outstanding warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:21.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:35.86%;box-sizing:content-box;"></td>
         <td style="width:25.16%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant/Assumption Date</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603,386</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 21, 2020</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 21, 2030</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.63</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">301,291</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2031</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2031</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2031</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">617,050</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2022</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 23, 2025</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">760,086</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2022</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2026</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 15, 2023</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 12, 2024</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,115,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table below is the summary of changes in the Company&#8217;s warrants to purchase common stock for the years ended December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.939%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:26.919%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.041%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.082%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Warrant Shares Outstanding and Exercisable</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price per Share</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,721,267</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,093</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,051</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.42</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,715,078</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,115,078</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants Issued in Public Offerings</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued warrants to a related party during the years ended December 31, 2024 and 2023. For the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company sold pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common shares, respectively at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (see Note 8 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Stockholders Equity&#8221;). The pre-funded warrants were acquired by funds affiliated with RTW (see Note 17 &#8220;Related Party Transactions&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assumed Renovacor Warrants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the acquisition of Renovacor, Rocket assumed outstanding public warrants, which were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">converted into warrants with a right to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">760,086</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Rocket common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the acquisition of Renovacor, Rocket assumed outstanding private warrants, which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were converted into warrants with a right to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">617,050</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Rocket common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determined that the private warrants did not meet all of the criteria for equity classification. Accordingly, the Company classifies these as a derivative liability in other liabilities in the Consolidated Balance Sheets. The Company measures the fair value of these warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company&#8217;s operating results for the current period. See Note 4 &#8220;Fair Value of Financial Instruments&#8221; for discussion of fair value measurement of the warrant liability.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the acquisition of Renovacor, Rocket assumed pre-funded warrants, which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were converted into warrants with a right to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,093</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Rocket common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. These warrants were exercised in January 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441906448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,595</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,807,773</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,009,004</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,148,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.73</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.92</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023, the Company included the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential shares from the pre-funded warrants acquired by RTW in 2023 in the basic weighted-average common shares outstanding as it only requires the holder to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share upon exercise.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company included the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential shares from the pre-funded warrants acquired by RTW in 2023 and the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> potential shares from the pre-funded warrants acquired by RTW in 2024 in the basic weighted-average common shares outstanding as it only requires the holder to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share upon exercise.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,588,123</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,588,123</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,721,267</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,210</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,490,357</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">992,874</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance stock units</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,661</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,044,686</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,863,996</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,138,870</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total potential shares excluded from diluted net loss per share</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,116,680</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,942,476</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,853,011</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323442010800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for federal or state income taxes was recorded during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, as the Company incurred operating losses and maintains a full valuation allowance against its net deferred tax assets.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.26%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal tax at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state tax apportionment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Return to provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 4, 2023, the Governor of Massachusetts signed into law a bill that included the adoption of a single sales apportionment factor effective on January 1, 2025. As required under ASC 740, the Company has accounted for the deferred tax impacts of this tax law change in the period the tax law was enacted, which has the impact of reducing its state deferred tax assets. The impact of the tax law change is offset by a change in valuation allowance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property rights in different jurisdictions are reflected in the Company&#8217;s effective tax rate.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of the Company&#8217;s deferred income tax assets and liabilities after applying the enacted corporate tax rates are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.26%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,410</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses and credit carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,313</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,718</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,085</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,283</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,390</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,086</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,077</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,263</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax asset (liability)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company had federal and state net operating loss (&#8220;NOL&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The state NOL begins to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0a395aa8-c4ae-4063-a1b7-e3d080e5ffcf;"><span style="-sec-ix-hidden:F_f8ada714-1a3a-4a7f-a2c0-3691e7ff6012;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Additionally, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the federal NOL can be carried forward indefinitely. The Company has federal R&amp;D credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_476f0015-4836-4e88-9984-744d464250a3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by ASC 740, Income Taxes, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOL carryforwards and capitalized research and development costs. As a result of the fact that the Company has incurred tax losses from inception, management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state net deferred tax assets and, as a result, a full valuation allowance has been established against its net deferred tax assets as of December 31, 2024, 2023 and 2022. The Company has offset certain deferred tax liabilities with deferred tax assets that are expected to generate offsetting deductions within the same period. During the years ended December 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 and 2022 the valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Realization of deferred tax assets is dependent upon the generation of future taxable income.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Internal Revenue Code Section 382, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. The Company has completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company became a &#8220;loss corporation&#8221; as defined in Section 382. The Company experienced multiple ownership changes occurring in 2005, 2007, 2015, and 2018. The ownership change has and will continue to subject our pre-ownership change net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of our stock at the time of the ownership change multiplied by a specified tax-exempt interest rate. As a result of the merger on January 4, 2018, the Company is limited to an approximate $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million annual limitation on our ability to utilize the NOL&#8217;s and R&amp;D Credits prior to the ownership change. Due to this limitation, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pre-merger Federal NOL will expire unutilized as the cumulative limitation amount over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> carryforward period is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Additionally, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of federal R&amp;D credits will expire unutilized. As a result, the Company has reduced its deferred tax assets related to the Federal NOL and federal R&amp;D credits by an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which is offset by the corresponding decrease in the valuation allowance. In conjunction with the acquisition of Renovacor, the Company acquired Renovacor&#8217;s federal NOL&#8217;s of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company has completed a study to assess whether an ownership change has occurred as a result of the transaction. The Company experienced ownership changes occurring in 2021 and 2022. As a result of the ownership changes, the Company is limited on our ability to utilize our Renovacor NOL&#8217;s. As a result of the Company&#8217;s study, any limitation under IRC Sec. 382 would not result in NOLs expiring unused.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2024 and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023, the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any uncertain tax positions in its financial statements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the Consolidated Balance Sheets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323537983056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorSalesTypeLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance Lease</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a lease for a facility in Cranbury, New Jersey, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,720</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of space including areas for offices, process development, research and development laboratories and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet dedicated to AAV </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cGMP manufacturing facilities to support the Company&#8217;s pipeline (such lease, as amended, the &#8220;NJ Lease Agreement&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The NJ Lease Agreement has a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year term from September 1, 2019, with an option to renew for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> renewal terms.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated rent payments for the NJ Lease Agreement are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per annum, payable in monthly installments and subject to annual base rent increases of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The total commitment under the lease is estimated to be approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year term of the lease. The Company paid a cash security deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to the landlord in connection with the NJ Lease Agreement which has been reflected </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as part of deposits in the Consolidated Balance Sheets as of December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 7, 2018, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ESB Lease Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the ESB Lease Agreement, the Company established an irrevocable standby letter of credit </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On March 26, 2021, the Company entered </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">into Amendment No. 1 to the ESB Lease Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that extended the term of the lease agreement to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On March 29, 2024, the Company entered into Amendment No. 2 to the ESB Lease Agreement that extended the term of the lease agreement to July 31, 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The letter of credit serves as the Company&#8217;s security deposit on the lease in which the landlord is the beneficiary and expires </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 30, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a certificate of deposit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with a bank as collateral for the ESB LeaseAgreement letter of credit which is classified as part of restricted cash in the Consolidated Balance Sheets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 1, 2022, in connection with the acquisition of Renovacor, the Company added </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating leases for spaces at facilities in Hopewell, New Jersey and Cambridge, Massachusetts with remaining lease terms of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.25 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.3 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years, respectively. As </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of December 31, 2024, lease commencement dates had occurred for all leases and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company recognized total right-of-use assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million with corresponding total lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at lease commencement dates. The Company intends to sublease the facilities in Hopewell, New Jersey and signed the first agreement to sublease one of these facilities in January 2024. Rental income received under sublease agreements for the facilities in Hopewell, New Jersey totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rent expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total restricted cash balance for the Company's operating and finance leases as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes lease cost for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years ended December 31, 2024, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,247</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,377</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">818</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease cost:</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of right of use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,154</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,154</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,139</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,875</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,861</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,287</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,406</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,818</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturity of the Company&#8217;s lease liabilities on an undiscounted cash flow basis:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">759</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,881</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,707</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,911</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,969</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,089</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,768</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the operating and financing lease liabilities and right-of-use assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.752%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.122999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.122999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,173</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,901</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating current lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,001</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">925</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating noncurrent lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,258</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,973</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,259</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,898</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,363</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,517</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance current lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,856</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,791</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance noncurrent lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,383</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,353</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,144</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.915%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.225%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.225%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.636%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Information</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">938</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,791</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,689</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Information</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorSalesTypeLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of lessor's sales-type leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorSalesTypeLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433769360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification Arrangements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to its bylaws and as permitted under Delaware law, the Company has indemnification obligations to directors, officers, employees or agents of the Company or anyone serving in these capacities. The maximum potential amount of future payments the Company could be required to pay is unlimited. The Company has insurance that reduces its monetary exposure and would enable it to recover a portion of any future amounts paid. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Throughout the normal course of business, the Company has agreements with vendors that provide goods and services required by the Company to run its business. In some instances, vendor agreements include language that requires the Company to indemnify the vendor from certain damages caused by the Company&#8217;s use of the vendor&#8217;s goods and/or services. The Company has insurance that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323544284288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements Related to Intellectual Property<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AgreementsRelatedToIntellectualPropertyAbstract', window );"><strong>Agreements Related to Intellectual Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AgreementsRelatedToIntellectualPropertyTextBlock', window );">Agreements Related to Intellectual Property</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreements Related to Intellectual Property</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, directly and through its subsidiary Spacecraft Seven, LLC, has various license and research and collaboration arrangements. The transactions principally resulted in the acquisition of rights to intellectual property which is in the preclinical phase and has not been tested for safety or feasibility. In all cases, the Company did not acquire tangible assets, processes, protocols or operating systems. The Company expenses the acquired intellectual property rights as of the acquisition date on the basis that the cost of intangible assets purchased from others for use in research and development activities, has no alternative future uses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for PKD with CIEMAT Group</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2016, the Company entered into a license agreement with CIEMAT Group</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, granting Rocket worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human PKLR gene solely within the field of treating PKD. Under the terms of the agreement, the Company is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0f41fdbb-616b-4390-91ca-6c0083fedb69;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, Rocket is obligated to pay CIEMAT Group an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. The Company is responsible for prosecuting and maintaining the licensed patents at its expense, in cooperation with CIEMAT Group. Rocket also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group. For five years following the effective date of the license agreement, the Company has a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group at market value. Rocket is obligated to license (without charge) to CIEMAT Group for non-commercial use any improvements to the licensed intellectual property that it creates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, Rocket paid CIEMAT Group an initial upfront license fee of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) which was expensed as R&amp;D costs. The Company is obligated to make aggregate milestone payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) to CIEMAT Group upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the PKD license, Rocket is obligated to pay a low to mid-single digit percentage royalty on net sales, subject to specified adjustments, by the Company or its sublicensees or affiliates. In the event that Rocket enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket may terminate this agreement at any time by providing CIEMAT Group with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for FA with CIEMAT Group and FIBHNJS</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2016, Rocket entered into a license agreement with CIEMAT Group and FIBHNJS granting it worldwide, exclusive rights to certain patents, know-how, data and other intellectual property relating to LVs containing the FANCA gene solely within the field of human therapeutic uses of VSV-G packaged integration component LVs for FA type-A gene therapy. This license is only sublicensable with the prior consent of CIEMAT Group and FIBHNJS, not to be unreasonably withheld. Under the terms of the agreement, Rocket is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_df646047-6e29-47e2-b2b5-6f058df99877;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, the Company is obligated to pay CIEMAT Group and FIBHNJS an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, regulatory and financing milestone payments, and sublicense revenue payments. The Company is responsible for prosecuting and maintaining the licensed patents at our expense, in cooperation with CIEMAT Group and FIBHNJS. Rocket also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group and FIBHNJS. For five years following the effective date of the license agreement, the Company has a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group and FIBHNJS at market value. Rocket is obligated to license (without charge) to CIEMAT Group and FIBHNJS for non-commercial use any improvements to the licensed intellectual property that it creates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, Rocket paid CIEMAT Group and FIBHNJS an initial upfront license fee of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), which was expensed as R&amp;D costs. The Company is obligated to make aggregate milestone payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) to CIEMAT Group and FIBHNJS upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the license, Rocket is obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by Rocket or its sublicensees or affiliates. In the event that the Company enters into a sublicense agreement with a sublicensee, the Company will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket may terminate this agreement at any time by providing CIEMAT Group and FIBHNJS with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for LAD-I with CIEMAT Group and UCLB</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company entered into a license agreement in November 2017, effective September 2017, with CIEMAT Group and UCLB</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, granting the Company worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human LAD-I gene solely within the field of treating LAD-I. Under the terms of the agreement, Rocket is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_51fd1836-2c76-4d4a-89af-503fa040d252;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, the Company is obligated to pay Licensors an up-front payment, royalty payments in the mid-single digit percentages based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. Rocket is responsible for prosecuting and maintaining the licensed patents at its expense, in cooperation with Licensors. The Company also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with Licensors. For five years following the effective date of the license agreement, Rocket has a right of first refusal to license any improvements to the licensed intellectual property obtained by Licensors at market value. The Company is obligated to license (without charge) to Licensors for non-commercial use any improvements to the licensed intellectual property that it creates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As consideration for the licensed rights, Rocket paid Licensors an initial upfront license fee of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million), which was expensed as R&amp;D costs. The Company is obligated to make aggregate payments of up to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) to Licensors upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the LAD-I license, Rocket is obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by the Company or its sublicensees or affiliates. In the event that the Company enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rocket may terminate this agreement at any time by providing the Licensors with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for DD with UCSD</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2017, the Company entered into a License Agreement with The Regents of the UCSD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, under which UCSD granted us an exclusive, sublicensable, worldwide license to certain intellectual property rights for the treatment of lysosomal storage diseases, including DD. In exchange for the license, the Company became obligated to make an up-front payment, certain clinical and commercial milestone payments, royalty payments (on net sales of products covered by a valid claim within the licensed intellectual property), maintenance fees and sublicense revenue payments. The upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was expensed as research and development costs in 2020. The Company is obligated to make aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to UCSD upon the achievement of specified development and regulatory milestones for the treatment of DD. A reduced schedule of milestone payments applies to achieving the same milestones for additional indications. With respect to any commercialized products covered by the agreement, the Company is obligated to pay a low single digit percentage royalty on net sales, subject to specified adjustments. If it enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances. The Company is also subject to certain diligence milestones for development of a product using the intellectual property licensed from UCSD under this agreement. The term of the license agreement with UCSD is through the expiration of the licensed patents, some of which are still in the pending application phase.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for DD with RGNX</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 19, 2018, the Company entered into a license agreement with RGNX, pursuant to which the Company obtained an exclusive license for all U.S. patents and patent applications related to RGNX&#8217;s NAV AAV-9 vector for the treatment of DD in humans by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene therapy using AAV-9 to deliver any known LAMP2 transgene isoforms and all possible combinations of LAMP2 transgene isoforms, as well as an exclusive option to license</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> all U.S. patents and patent applications for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional NAV AAV vectors in the Field</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the license agreement, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market, promote and sell licensed products incorporating the licensed patents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Unless the license agreement is terminated earlier as provided below, the license from RGNX expires on a country-by-country, licensed product-by-licensed product basis until the later of the expiration date of the last to expire of the last valid claim of the applicable licensed patent or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the first commercial sale of a licensed product in such country. The license agreement provides that RGNX may terminate the agreement upon a material breach by the Company if the Company does not cure such breach within a specified notice period if the Company commences a challenge against RGNX or certain of its licensors to declare or render invalid or unenforceable the licensed patents or upon the Company&#8217;s bankruptcy or insolvency. The Company may terminate the agreement in its entirety or terminate one or more of the licensed vectors at any time upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; notice. The Company&#8217;s option right expired </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of the license agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the rights granted to the Company under the license agreement, the Company made an upfront payment to RGNX of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The license agreement provides for royalties payable to RGNX in the high-single digits to low-teens on net sales levels of licensed products during the royalty term. If successful, the Company will be required to make milestone payments to RGNX of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each licensed product upon the achievement of specified clinical development and regulatory milestones in the U.S. and EU. In addition, the Company shall pay RGNX </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the payment fees received from a priority review voucher issued in connection with or otherwise related to a licensed product. These royalty obligations are subject to specified reductions if additional licenses from third parties are required. The Company must also pay RGNX a portion of all non-royalty sublicense income (if any) received from sublicensees. The Company paid and expensed a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million license fee payment under the RGNX agreement upon the dosing of the first DD patient in 2019 and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million license fee payment upon initiation of a Phase 2 pivotal trial in 2023. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional milestones achieved or related payments made during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement for BAG3 with Temple University</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 1, 2022, the Company acquired Renovacor, including a license agreement for BAG3 with Temple University. The license agreement provides for royalties payable to Temple University in the low-single digits on net sales of licensed products during the royalty term. If successful, the Company will be required to make milestone payments to Temple University of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon achievement of specific clinical development and regulatory milestones.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AgreementsRelatedToIntellectualPropertyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreements Related To Intellectual Property Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AgreementsRelatedToIntellectualPropertyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AgreementsRelatedToIntellectualPropertyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for agreements related to intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AgreementsRelatedToIntellectualPropertyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433795616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CIRM Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_CIRMGrantsAbstract', window );"><strong>CIRM Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock', window );">CIRM Grants</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIRM Grants</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LAD-I CIRM Grant</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 30, 2019, CIRM awarded the Company up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy, RP-L201. Proceeds from the grant helped fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients enrolled at the U.S. clinical site, University of California, Los Angeles Mattel Children&#8217;s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edy the Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. As of December 31, 2024, the Company has received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in total RP-L201 grants from CIRM. These were recorded as reductions of R&amp;D expenses. The Company received a final milestone grant of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on January 2, 2024 and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional payments are available under the grant awards program.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">DD CIRM Grant</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 18, 2024, CIRM awarded the Company up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under a CLIN2 grant award to support the clinical development of its AAV-based gene therapy, RP-A501 for the treatment of DD. Proceeds from the grant would help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients. As of December 31, 2024, the Company has received RP-A501 grants of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from CIRM, which was recorded as a reduction of R&amp;D expenses for the RP-A501 program for the year ended December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_CIRMGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>C I R M Grants Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_CIRMGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for California institute for regenerative medicine grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433820576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party Transactions</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2023, the Company entered into a consulting agreement with the spouse of one of the Company&#8217;s executive officers for information technology advisory services. The Company incurred expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.002</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively, relating to services provided under this agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 15, 2023, in connection with the Company&#8217;s public offering, the Company sold approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pre-funded warrants to purchase shares of the Company&#8217;s common stock to funds affiliated with RTW, the Company&#8217;s largest shareholder (see Note 8 &#8220;Stockholders&#8217; Equity&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 12, 2024, in connection with the Company&#8217;s public offering, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pre-funded warrants to purchase shares of the Company&#8217;s common stock to funds affiliated with RTW, the Company&#8217;s largest shareholder (see Note 8 &#8220;Stockholders&#8217; Equity&#8221;).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, the Company enter into a consulting agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with one of the Company&#8217;s board members, effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 3, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for services related to the Company&#8217;s research and development activities. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation for services rendered, the consultant will receive $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to be paid in equal monthly installments and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of RSU&#8217;s valued as of the closing price on March 3, 2025 which will cliff vest on December 31, 2025.  The agreement will terminate on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unless terminated earlier by the Company for cause or voluntarily by consultant.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441841456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>401(k) Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">401(k) Savings Plan</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has a defined contribution savings plan (the &#8220;Plan&#8221;) under Section 401(k) of the Internal Revenue Code of 1986. This Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the Plan may be made at the discretion of the Company&#8217;s Board of Directors. The Company has elected the safe harbor</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> match of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employee contributions to the Plan, subject to certain limitations. The Company&#8217;s matching contribution for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023, and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482969/710-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323537983728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Reporting</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment related to R&amp;D and commercial readiness of its gene therapies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_451a042b-eab6-4290-938a-8e09ce736c2b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the senior leadership team. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Included in these expenses are R&amp;D expenses by program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment loss, including significant segment expenses:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.851%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.623000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.903%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.623000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-commercial general and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,878</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,805</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,211</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial general and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,083</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development incentives</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,886</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,875</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,267</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,651</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Segment loss and Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,595</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM uses net loss to evaluate past spending and to guide decisions of future spending. Net loss is used to monitor budget versus actual results. The CODM also uses net loss in analysis of programs and along with the monitoring of budgeted versus actual results in assessing performance of the segment and in establishing manager&#8217;s compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438359696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with U.S. GAAP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All intercompany accounts have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of R&amp;D </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses, the valuation of equity transactions, and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company&#8217;s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#8217;s operating leases (see Note </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13 &#8220;Leases&#8221; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#8217;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:65.633%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:15.183%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:15.183%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,635</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,904</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,362</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,997</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,276</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Grants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense was presented net of reimbursements from CIRM (See Note 16 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIRM Grant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for additional disclosure).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock', window );">Concentrations of Credit Risk and Off-balance Sheet Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of credit risk and off-balance sheet risk</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of U.S. Treasury Securities, and Corporate Bonds. The Company&#8217;s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AA-/Aa3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rated, thereby reducing credit risk exposure.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments consist of U.S. Treasury Securities and Corporate Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to ASC 320, Investments&#8212;Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company&#8217;s Consolidated Statement of Operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> realized gains or losses on investments for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022. For the years ended December 31, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 and 2022, there were net unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net unrealized gains on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and net unrealized loss on investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets consisted of an indefinite lived intangible IPR&amp;D asset and a mice colony model. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&amp;D intangible assets which are determined to have had a decrease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in their fair value are adjusted downward and an expense is recognized in R&amp;D expenses in the Consolidated Statements of Operations. These IPR&amp;D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&amp;D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. If a triggering event occurs that would indicate a potential impairment, the Company will perform a quantitative analysis to determine whether it is more likely than not that the fair value is below carrying amount. The annual impairment assessment for the IPR&amp;D asset was performed as of December 1. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment of the IPR&amp;D asset was recorded for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded an impairment of the</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> intangible long-lived asset </span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related to the mice colony model of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business combinations are accounted for under the acquisition method. The total cost of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, asset lives and market multiples, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reporting unit and as such review&#8217;s goodwill for impairment at the consolidated level. When testing goodwill, the Company has the option to first assess qualitative factors for reporting units that carry goodwill. The qualitative assessment includes assessing the totality of relevant events and circumstances that affect the fair value or carrying value of the reporting unit. These events and circumstances include macroeconomic conditions, industry and competitive environment conditions, overall financial performance, reporting unit specific events and market considerations. The Company also considers recent valuations of the reporting unit, including the magnitude of the difference between the most recent fair value estimate and the carrying value, as well as both positive and adverse events and circumstances, and the extent to which each of the events and circumstances identified may affect the comparison of a reporting unit&#8217;s fair value with its carrying value. If the qualitative assessment results in a conclusion that it is more likely than not that the fair value of a reporting unit exceeds the carrying value, then no further testing is performed for that reporting unit.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company performed the qualitative assessment of its goodwill and determined that it is more likely than not that the fair value of a reporting unit exceeds the carrying value of the reporting unit. As a result, the Company has determined there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> goodwill impairment as of and for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful lives of the asset which are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifteen years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company capitalizes purchases of laboratory equipment, machinery and equipment, furniture and fixtures and leasehold improvements in relation to the facility at Cranbury, New Jersey, since it has been determined these assets have alternative future uses to the Company. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. Costs incurred in connection with development or purchase of internal use software and cloud computing arrangements, including in-substance software licenses, are capitalized. Amortization is computed on a straight-line basis over the estimated useful life of the asset, which is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Capitalized software is included in property and equipment in the Consolidated Balance Sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. The Company conducted its impairment analyses of long-lived assets to be held and used in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.  The Company also recorded write downs of property and equipment in each of the years ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 - Valuations that require inputs that reflect the Company&#8217;s own assumptions that are both significant to the fair value measurement and unobservable.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company&#8217;s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity and/or ASC Topic 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company&#8217;s Consolidated Statements of Operations. Warrants classified as equity instruments are recorded within additional paid-in capital at the time of issuance and not subject to remeasurement</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses, which include salaries and staff costs, license costs, manufacturing and development costs, clinical trial expenses, depreciation and amortization expenses, regulatory and scientific consulting fees, as well as contract research, and stock-based compensation expense, are accounted for in accordance with ASC Topic 730, Research and Development. Accordingly, R&amp;D costs are expensed as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Transactions</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain foreign currency transactions during the years ended December 31, 2024, 2023 and 2022 were primarily denominated in Euros and British pounds. Gains and losses on foreign currency transactions were not significant for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_TreasuryStockPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treasury Stock</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records treasury stock at cost.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issues stock-based awards to employees and non-employees, generally in the form of stock options, RSUs, and PSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. The cost of stock options and RSUs is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The vesting condition for PSUs is performance based and the cost of a PSU is recognized when it is likely that the performance goal associated with the PSU will be achieved and the award will vest.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as expected volatility and expected term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations in the same manner in which the award recipient&#8217;s payroll costs and services are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet differences. In accordance with ASC 740, Income Taxes, the Company recorded a full valuation allowance to fully offset the net deferred tax asset because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2024 and 2023.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates net loss per share in accordance with ASC 260, Earnings per Share. Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Warrants that meet the definition of equity classification and that requires the holder to pay little or no consideration to receive shares upon exercise are considered outstanding in the context of basic earnings per share. Diluted net loss attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, outstanding options are considered potential dilutive common shares.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment. The Company&#8217;s CODM is its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e4e33013-0944-4e5f-ae6a-24eab71a59cf;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the senior leadership team. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Included in these expenses are R&amp;D expenses by program.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources and consists of net loss and changes in unrealized gains and losses on investments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company&#8217;s Consolidated Balance Sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company&#8217;s lease agreements contain renewal options&#894;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company&#8217;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company&#8217;s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company&#8217;s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Not Adopted as of December 31, 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-09: Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This update standardized categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update was effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the effect that ASU 2023-09 will have on its financial statements and disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2024-03: Expense Disaggregation Disclosures. This update requires disaggregated disclosure of income statement expenses. This update is effective for the Company for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the effect that ASU 2024-03 will have on its financial statements and disclosures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting Pronouncements Adopted as of December 31, 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update was effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The adoption of ASU 2023-07 resulted in a new footnote disclosure for Segment Reporting.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for concentrations of credit risk and off-balance sheet risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants related to receivable of offset amount against research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_TreasuryStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_TreasuryStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441876768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#8217;s operating leases (see Note </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13 &#8220;Leases&#8221; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#8217;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:65.633%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:15.183%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:15.183%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
           <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,635</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,904</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,362</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,372</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,997</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,276</span></p></td>
           <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash , cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441872848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Items measured at fair value on a recurring basis are the Company&#8217;s investments. The following table sets forth the Company&#8217;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.87%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.282%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements as of December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,453</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,401</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,701</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216,154</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">356,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements as of December 31, 2023 Using:</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,487</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,895</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,737</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">354,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404,815</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Changes in Level 3 Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of the Company&#8217;s warrant liability, which is recorded as part of Other Liabilities in the Consolidated Balance Sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.439999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrant Liability</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,512</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value adjustments</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,876</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Level 3 Fair Value of the Private Warrants</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the warrant liability has been estimated with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.572%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.864%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.563%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock price</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.57</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.50</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.24</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.83</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.70</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life (years)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.31</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.31</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value per warrant</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.04</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433811648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s property and equipment consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.113%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.442999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.442999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,205</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,232</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Machinery and equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,857</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,325</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,015</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,777</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,777</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,282</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,723</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal use software</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,903</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,903</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, gross</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,039</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,204</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,253</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,032</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,786</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,172</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433777936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets and Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 are summarized as follows:</span><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.872%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross carrying value</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total intangible assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,150</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323625119392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s accounts payable and accrued expenses consisted of the following:</span></p><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.872%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.063%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,768</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,867</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment payable</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,137</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,944</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,930</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,077</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,305</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,006</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,625</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,772</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accounts payable and accrued expenses</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,827</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,789</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323550069056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for Stock Options</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of the stock options granted to employees, non-employees and directors were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.851%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.049999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.049999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.049999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.81</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.82</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.09</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.72</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73.32</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise price</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.56</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes stock option activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.189%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.302%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.362%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.302%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.842%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (Years)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,138,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.52</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.46</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,370,862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.76</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,145</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,318</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,863,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.07</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,602</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,767,674</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.94</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,412</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled or forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">317,904</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,044,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.67</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,255,024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.55</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.82</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,789,662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.72</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">RSU Activity</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.28%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.6%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.119999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">992,874</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,018,322</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.67</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">408,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.61</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,720</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.92</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,490,357</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.53</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">760,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.45</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722,471</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.02</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Common stock issued is net of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares related to taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">PSU Activity</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company began granting PSU awards in 2024. The following table summarizes the PSU activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,738</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.93</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,077</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.31</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,661</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.71</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-Based Compensation Expense by Award Type</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized by award type is as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,866</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,389</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,509</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,466</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,136</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,897</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,920</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,406</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,009</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323442012656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants Outstanding and Changes in Warrants to Purchase Common Stock</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s outstanding warrants at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:21.14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:35.86%;box-sizing:content-box;"></td>
         <td style="width:25.16%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant/Assumption Date</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603,386</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 21, 2020</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 21, 2030</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.63</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">301,291</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 9, 2031</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2031</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2021</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 17, 2031</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">617,050</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2022</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 23, 2025</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">760,086</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2022</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2026</span></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 15, 2023</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 12, 2024</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">N/A</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,115,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table below is the summary of changes in the Company&#8217;s warrants to purchase common stock for the years ended December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:46.939%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:26.919%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.041%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.082%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Warrant Shares Outstanding and Exercisable</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price per Share</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,721,267</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,126,955</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,093</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.06</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,051</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.42</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,715,078</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,115,078</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434583104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,595</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,807,773</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,009,004</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,148,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.73</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.92</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, </span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,588,123</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,588,123</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,721,267</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,414,210</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,490,357</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">992,874</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Performance stock units</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,661</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,044,686</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,863,996</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,138,870</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total potential shares excluded from diluted net loss per share</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,116,680</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,942,476</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,853,011</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434751600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Benefit Computed at Statutory Federal Income Tax Rate to Income Taxes</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.26%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal tax at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state tax apportionment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Return to provision</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significant components of the Company&#8217;s deferred income tax assets and liabilities after applying the enacted corporate tax rates are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:59.26%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.66%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,410</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating losses and credit carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,313</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,718</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,085</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,041</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,283</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,390</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,086</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,077</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,263</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred income tax asset (liability)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434863744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Cost</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes lease cost for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years ended December 31, 2024, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:51.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease cost</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,247</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,377</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">818</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease cost:</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of right of use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,154</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,154</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,139</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest on lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,886</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,875</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,861</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,287</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,406</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,818</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturity of the Company&#8217;s lease liabilities on an undiscounted cash flow basis:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">759</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">539</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,881</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,707</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,259</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Finance Lease Liability</a></td>
<td class="text">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:22.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal Year Ending December 31,</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,856</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,911</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,969</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,089</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,768</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LeaseBalanceSheetInformationTableTextBlock', window );">Balance Sheet Information Related to Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the operating and financing lease liabilities and right-of-use assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.752%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.122999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.122999999999998%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,173</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,901</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating current lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,001</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">925</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating noncurrent lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,258</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,973</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,259</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,898</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance right-of-use assets</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,363</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,517</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance current lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,856</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,791</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance noncurrent lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,383</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,353</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease liability</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,144</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LeaseSupplementalCashFlowInformationTableTextBlock', window );">Lease Related to Cash Flow Information, Lease Term and Discount Rate</a></td>
<td class="text">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.915%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.225%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.225%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.636%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Information</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">938</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,791</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,689</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Information</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term - finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - operating leases</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.44</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate - finance lease</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.69</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_LeaseBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_LeaseBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_LeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_LeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323544079600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Loss Including Significant Segment Expenses</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below is a summary of the segment loss, including significant segment expenses:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:52.851%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.623000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.903%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.623000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the Years Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-commercial general and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,878</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,805</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,211</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial general and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,083</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,343</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development incentives</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,886</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,875</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,267</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of discount and amortization of premium on investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,651</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Segment loss and Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,595</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433871856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Program</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_AdenoAssociatedVirusProgramsMember', window );">AAV Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfClinicalStagePrograms', window );">Number of clinical-stage programs</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfPreClinicalStagePrograms', window );">Number of pre clinical-stage programs</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LentiviralVectorProgramsMember', window );">LV Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfClinicalStagePrograms', window );">Number of clinical-stage programs</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfClinicalStagePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of clinical-stage programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfClinicalStagePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfPreClinicalStagePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of pre clinical-stage programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfPreClinicalStagePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_AdenoAssociatedVirusProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_AdenoAssociatedVirusProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LentiviralVectorProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LentiviralVectorProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435713024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
<th class="th"><div>Oct. 06, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,218,116)<span></span>
</td>
<td class="num">$ (959,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="nump">15,180,000<span></span>
</td>
<td class="nump">9,453,418<span></span>
</td>
<td class="nump">7,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SharesIssuanceCost', window );">Shares issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance or sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromSaleOfStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds, offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedIssuanceCosts', window );">Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,222<span></span>
</td>
<td class="nump">$ 46,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds, offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedIssuanceCosts', window );">Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program | Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds, offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedIssuanceCosts', window );">Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program | Cowen and Company, LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SaleOfStockAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program | Cowen and Company, LLC | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,528<span></span>
</td>
<td class="nump">$ 188,885<span></span>
</td>
<td class="nump">$ 108,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember', window );">Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued and sold (in shares)</a></td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember', window );">Public Offering | Common Stock | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromSaleOfShares', window );">Gross proceeds from sale of shares</a></td>
<td class="nump">$ 194,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SharesIssuanceCost', window );">Shares issuance cost</a></td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="nump">$ 182,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="nump">$ 12.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingAndPrivatPlacementMember', window );">Public Offering and Privat Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareholdersEquityDisclosureAbstract', window );"><strong>Shareholders' Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SharesIssuanceCost', window );">Shares issuance cost</a></td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance or sale of stock</a></td>
<td class="nump">182,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromSaleOfStock', window );">Gross proceeds from sale of stock</a></td>
<td class="nump">$ 194,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity including issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrossProceedsFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrossProceedsFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrossProceedsFromSaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from sale of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrossProceedsFromSaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock warrants issued to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfStockWarrantsIssuedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate offering price of shares issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ShareholdersEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity Disclosure Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ShareholdersEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_SharesIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_SharesIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rckt_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rckt_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingAndPrivatPlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingAndPrivatPlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433811904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 163,635<span></span>
</td>
<td class="nump">$ 55,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 164,997<span></span>
</td>
<td class="nump">$ 57,276<span></span>
</td>
<td class="nump">$ 141,857<span></span>
</td>
<td class="nump">$ 234,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435752064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Investments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gains or losses on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized gains (losses) on investments</a></td>
<td class="num">$ (253,000)<span></span>
</td>
<td class="nump">$ 676,000<span></span>
</td>
<td class="num">$ (196,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441958704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Goodwill and Intangible Asset Impairment<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434605504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Goodwill - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment reporting expense information used by CODM description</a></td>
<td class="text">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441822960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal use Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323544182400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436915056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 147,401<span></span>
</td>
<td class="nump">$ 53,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">208,701<span></span>
</td>
<td class="nump">351,591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial instruments</a></td>
<td class="nump">356,102<span></span>
</td>
<td class="nump">404,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">139,948<span></span>
</td>
<td class="nump">50,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">208,701<span></span>
</td>
<td class="nump">312,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">139,948<span></span>
</td>
<td class="nump">50,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial instruments</a></td>
<td class="nump">139,948<span></span>
</td>
<td class="nump">50,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">139,948<span></span>
</td>
<td class="nump">50,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">208,701<span></span>
</td>
<td class="nump">351,591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial instruments</a></td>
<td class="nump">216,154<span></span>
</td>
<td class="nump">354,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money Market Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">208,701<span></span>
</td>
<td class="nump">312,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money Market Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436855664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Changes in Level 3 Liabilities Measured at Fair Value (Details) - Recurring - Level 3 - Warrant Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in Fair Value of Warrant Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 1,876<span></span>
</td>
<td class="nump">$ 1,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Fair value adjustments</a></td>
<td class="num">(1,876)<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438361008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Level 3 Fair Value of the Private Warrants (Details) - Private Warrants<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Fair Value of the Private Warrants, Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">3 months 21 days<span></span>
</td>
<td class="text">1 year 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Fair value per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Fair Value of the Private Warrants, Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">12.57<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Fair Value of the Private Warrants, Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">65.23<span></span>
</td>
<td class="nump">65.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Fair Value of the Private Warrants, Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.5224<span></span>
</td>
<td class="nump">0.6883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Risk-Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Fair Value of the Private Warrants, Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0424<span></span>
</td>
<td class="nump">0.047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Expected Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract', window );"><strong>Fair Value of the Private Warrants, Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAndInputDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAndInputDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437716544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 58,039<span></span>
</td>
<td class="nump">$ 53,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(21,253)<span></span>
</td>
<td class="num">(14,032)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">36,786<span></span>
</td>
<td class="nump">39,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rckt_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">32,205<span></span>
</td>
<td class="nump">29,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">12,857<span></span>
</td>
<td class="nump">12,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">2,777<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">7,282<span></span>
</td>
<td class="nump">6,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal use Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,903<span></span>
</td>
<td class="nump">$ 1,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rckt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rckt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441939104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434941200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross carrying value</a></td>
<td class="nump">$ 25,150<span></span>
</td>
<td class="nump">$ 25,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">$ 25,150<span></span>
</td>
<td class="nump">$ 25,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438354608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 39,154<span></span>
</td>
<td class="nump">$ 39,154<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433938880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 16,768<span></span>
</td>
<td class="nump">$ 13,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_InvestmentPayableCurrent', window );">Investment payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">11,944<span></span>
</td>
<td class="nump">9,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Property and equipment</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">7,305<span></span>
</td>
<td class="nump">6,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,625<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 37,827<span></span>
</td>
<td class="nump">$ 45,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_InvestmentPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_InvestmentPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to expenses related to research and development cost (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323543725408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_InvestmentPayableCurrent', window );">Investment payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_InvestmentPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_InvestmentPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436695584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 12, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 06, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_CommonStockVotingRightsNumberOfVotesPerShare', window );">Number of voting right for each share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Treasury Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfTreasuryStock', window );">Sale of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds, offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedIssuanceCosts', window );">Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,222<span></span>
</td>
<td class="nump">46,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program | Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds, offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedIssuanceCosts', window );">Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember', window );">At-the-Market Offering Program | Cowen and Company, LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SaleOfStockAggregateOfferingPrice', window );">Aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,528<span></span>
</td>
<td class="nump">$ 188,885<span></span>
</td>
<td class="nump">$ 108,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="nump">15,180,000<span></span>
</td>
<td class="nump">9,453,418<span></span>
</td>
<td class="nump">7,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds, offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_StockIssuedIssuanceCosts', window );">Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromSaleOfStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SharesIssuanceCost', window );">Shares issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance or sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrossProceedsFromSaleOfShares', window );">Gross proceeds from sale of shares</a></td>
<td class="nump">$ 194,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="nump">182,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_SharesIssuanceCost', window );">Shares issuance cost</a></td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares | shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At-the-Market Offering Program | Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares) | shares</a></td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract', window );"><strong>Private Placement At-the-Market Offering Program and Public Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares | shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Treasury Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay the payroll tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_CommonStockVotingRightsNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share of common stock owned granted to owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_CommonStockVotingRightsNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity including issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrossProceedsFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrossProceedsFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrossProceedsFromSaleOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from sale of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrossProceedsFromSaleOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock warrants issued to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfStockWarrantsIssuedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private Placement At The Market Offering Program And Public Offerings Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate offering price of shares issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_SharesIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_SharesIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_StockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_StockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rckt_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rckt_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323432711312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Weighted-Average Assumptions for Stock Options (Details) - Employees, Non-employees and Directors - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">5 years 9 months 25 days<span></span>
</td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">73.72%<span></span>
</td>
<td class="nump">73.32%<span></span>
</td>
<td class="nump">64.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.93<span></span>
</td>
<td class="nump">$ 20.24<span></span>
</td>
<td class="nump">$ 18.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 26.93<span></span>
</td>
<td class="nump">$ 20.24<span></span>
</td>
<td class="nump">$ 18.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value per share of common stock used in the weighted average fair value assumptions for stock option grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rckt_EmployeeNonemployeeAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rckt_EmployeeNonemployeeAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433561600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Stock Option Activity (Details) - Employee Stock Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">14,863,996<span></span>
</td>
<td class="nump">13,138,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,767,674<span></span>
</td>
<td class="nump">2,370,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(269,080)<span></span>
</td>
<td class="num">(223,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(317,904)<span></span>
</td>
<td class="num">(422,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">16,044,686<span></span>
</td>
<td class="nump">14,863,996<span></span>
</td>
<td class="nump">13,138,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable at end of period (in shares)</a></td>
<td class="nump">13,255,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options unvested at ending of period (in shares)</a></td>
<td class="nump">2,789,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 15.07<span></span>
</td>
<td class="nump">$ 14.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">26.93<span></span>
</td>
<td class="nump">20.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">11.93<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">26.98<span></span>
</td>
<td class="nump">29.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">16.19<span></span>
</td>
<td class="nump">$ 15.07<span></span>
</td>
<td class="nump">$ 14.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable at end of period (in dollars per share)</a></td>
<td class="nump">14.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Options unvested at ending (in dollars per share)</a></td>
<td class="nump">$ 23.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">4 years 8 months 1 day<span></span>
</td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">5 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">8 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable</a></td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Options unvested</a></td>
<td class="text">8 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 250,602<span></span>
</td>
<td class="nump">$ 118,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">3,412<span></span>
</td>
<td class="nump">2,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at end of period</a></td>
<td class="nump">63,295<span></span>
</td>
<td class="nump">$ 250,602<span></span>
</td>
<td class="nump">$ 118,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and exercisable</a></td>
<td class="nump">63,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Options unvested</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of Nonvested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non-vested convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but non-vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433102928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of shares granted (in dollars per share)</a></td>
<td class="nump">$ 18.13<span></span>
</td>
<td class="nump">$ 13.37<span></span>
</td>
<td class="nump">$ 9.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested</a></td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
<td class="nump">$ 34.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember', window );">Stock Options, Restricted Stock Units Grants and Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period expected to recognize unrecognized share-based compensation cost</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435110912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - RSU Activity (Details) - Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,490,357<span></span>
</td>
<td class="nump">992,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">760,423<span></span>
</td>
<td class="nump">1,018,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(722,471)<span></span>
</td>
<td class="num">(408,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(114,099)<span></span>
</td>
<td class="num">(112,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,414,210<span></span>
</td>
<td class="nump">1,490,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 18.53<span></span>
</td>
<td class="nump">$ 16.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">27.45<span></span>
</td>
<td class="nump">19.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">18.69<span></span>
</td>
<td class="nump">16.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">21.24<span></span>
</td>
<td class="nump">17.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 23.02<span></span>
</td>
<td class="nump">$ 18.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436741360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - RSU Activity (Parenthetical) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock shares issued related to tax (in shares)</a></td>
<td class="nump">120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323434663472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - PSU Activity (Details) - Performance Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">156,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(87,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">69,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">27.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">27.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437579248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 43,920<span></span>
</td>
<td class="nump">$ 39,406<span></span>
</td>
<td class="nump">$ 31,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">28,054<span></span>
</td>
<td class="nump">29,091<span></span>
</td>
<td class="nump">27,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">15,866<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">18,784<span></span>
</td>
<td class="nump">17,509<span></span>
</td>
<td class="nump">12,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 25,136<span></span>
</td>
<td class="nump">$ 21,897<span></span>
</td>
<td class="nump">$ 18,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435088544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Warrants Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">6,115,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceOneMember', window );">57.11</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 57.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">603,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Dec. 21,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Dec. 21,  2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceTwoMember', window );">33.63</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">301,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Aug.  09,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Aug.  09,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceThreeMember', window );">22.51</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">153,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Dec. 17,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Dec. 17,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceFourMember', window );">22.51</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">153,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Dec. 17,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Dec. 17,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceFiveMember', window );">65.23</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 65.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">617,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Dec.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Apr. 23,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceSixMember', window );">65.23</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 65.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">760,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Dec.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Dec.  01,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceSevenMember', window );">0.01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">3,126,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Sep. 15,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceEightMember', window );">0.01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightGrantDate', window );">Grant date</a></td>
<td class="text">Dec. 12,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ClassOfWarrantOrRightGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ClassOfWarrantOrRightGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DetailedInformationOfWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information Of Warrants Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DetailedInformationOfWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_WarrantsExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433192368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Changes in Rocket Warrants to Purchase Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rckt_WarrantsExercisableForCommonSharesMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract', window );"><strong>Number of Warrant Shares Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">5,715,078<span></span>
</td>
<td class="nump">2,721,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Potential shares included in the calculation of EPS</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(126,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">6,115,078<span></span>
</td>
<td class="nump">5,715,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ExercisePricePerShareWarrantsAbstract', window );"><strong>Exercise Price Per Share, Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited', window );">Expired (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rckt_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract', window );"><strong>Number of Warrant Shares Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Potential shares included in the calculation of EPS</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ExercisePricePerShareWarrantsAbstract', window );"><strong>Exercise Price Per Share, Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price per share of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price per share of warrants forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price per share of warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ExercisePricePerShareWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price Per Share Warrants Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ExercisePricePerShareWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrant Shares Outstanding And Exercisable Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rckt_WarrantsExercisableForCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rckt_WarrantsExercisableForCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rckt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rckt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436778800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PublicWarrantsMember', window );">Public Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember', window );">Private Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.99<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DetailedInformationOfWarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase shares of common stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DetailedInformationOfWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information Of Warrants Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DetailedInformationOfWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock warrants issued to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfStockWarrantsIssuedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323544175968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - Pre-Funded Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Potential shares included in the calculation of EPS</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted', window );">Warrants exercise price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price per share of warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rckt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rckt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436953136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (258,746)<span></span>
</td>
<td class="num">$ (245,595)<span></span>
</td>
<td class="num">$ (221,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">94,807,773<span></span>
</td>
<td class="nump">84,009,004<span></span>
</td>
<td class="nump">68,148,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">94,807,773<span></span>
</td>
<td class="nump">84,009,004<span></span>
</td>
<td class="nump">68,148,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic (in dollars per share)</a></td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (3.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted (in dollars per share)</a></td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (3.26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323441948320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants</a></td>
<td class="nump">2,588,123<span></span>
</td>
<td class="nump">2,588,123<span></span>
</td>
<td class="nump">2,721,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares', window );">Restricted stock units</a></td>
<td class="nump">1,414,210<span></span>
</td>
<td class="nump">1,490,357<span></span>
</td>
<td class="nump">992,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares', window );">Performance stock units</a></td>
<td class="nump">69,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Options</a></td>
<td class="nump">16,044,686<span></span>
</td>
<td class="nump">14,863,996<span></span>
</td>
<td class="nump">13,138,870<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Total potential shares excluded from diluted net loss per share</a></td>
<td class="nump">20,116,680<span></span>
</td>
<td class="nump">18,942,476<span></span>
</td>
<td class="nump">16,853,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of performance stock units exercisable for common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted stock units exercisable for common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433020256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Effective Tax Rates and Statutory Rates (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of Income Tax Benefit Computed at Statutory Federal Income Tax Rate to Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(12.50%)<span></span>
</td>
<td class="num">(17.30%)<span></span>
</td>
<td class="num">(16.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Change in state tax apportionment</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock compensation</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision', window );">Return to provision</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return to provision,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323438174656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred income tax assets (liabilities) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">R&amp;D credits</a></td>
<td class="nump">$ 21,410<span></span>
</td>
<td class="nump">$ 20,984<span></span>
</td>
<td class="nump">$ 20,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses and credit carryforwards</a></td>
<td class="nump">67,591<span></span>
</td>
<td class="nump">45,313<span></span>
</td>
<td class="nump">33,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">14,787<span></span>
</td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">19,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">29,041<span></span>
</td>
<td class="nump">28,499<span></span>
</td>
<td class="nump">19,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DeferredTaxAssetsWarrants', window );">Warrants</a></td>
<td class="nump">8,713<span></span>
</td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">8,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(5,697)<span></span>
</td>
<td class="num">(5,787)<span></span>
</td>
<td class="num">(5,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(7,829)<span></span>
</td>
<td class="num">(8,086)<span></span>
</td>
<td class="num">(6,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(129,077)<span></span>
</td>
<td class="num">(108,472)<span></span>
</td>
<td class="num">(91,263)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax asset (liability)</a></td>
<td class="num">$ (1,061)<span></span>
</td>
<td class="num">$ (1,061)<span></span>
</td>
<td class="num">$ (1,061)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DeferredTaxAssetsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DeferredTaxAssetsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433025648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OperatingLossCarryforwardsAbstract', window );"><strong>Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">R&amp;D credits</a></td>
<td class="nump">$ 21,410<span></span>
</td>
<td class="nump">$ 20,984<span></span>
</td>
<td class="nump">$ 20,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">20,600<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount', window );">Annual limitations under section 382 of IRC</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Uncertain Tax Positions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract', window );"><strong>Income Tax Penalties and Interest Accrued [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OperatingLossCarryforwardsAbstract', window );"><strong>Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 303,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">NOL carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">R&amp;D credits</a></td>
<td class="nump">$ 21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax credit, expiration date</a></td>
<td class="text">Dec. 31,  2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss, subject to expiration</a></td>
<td class="nump">$ 303,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod', window );">Cumulative limitation period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration', window );">Cumulative net operating loss, subject to expiration</a></td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Renovacor, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OperatingLossCarryforwardsAbstract', window );"><strong>Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">46,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_TaxCreditCarryforwardAbstract', window );"><strong>Tax Credit Carryforward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration', window );">Tax credit carryforwards, subject to expiration</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_OperatingLossCarryforwardsAbstract', window );"><strong>Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">NOL carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss, subject to expiration</a></td>
<td class="nump">$ 78,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss and credit limited to utilize due to change in control as per Internal revenue code under section 382.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible tax credit carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_OperatingLossCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_OperatingLossCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for operating Loss carryforwards cumulative limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_TaxCreditCarryforwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_TaxCreditCarryforwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rckt_RenovacorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rckt_RenovacorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437439376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Finance Lease - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Leaseagreement</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Finance Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 48,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Cash security deposit</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rckt_NewJerseyLeaseAgreementMember', window );">NJ Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Finance Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities', window );">Area of lease | ft&#178;</a></td>
<td class="nump">103,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of finance lease agreement</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfOptionsToRenewLeaseAgreement', window );">Number of options to renew lease agreement | Leaseagreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Term of renewal of finance lease agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_FinanceLeasesEstimatedRentPayments', window );">Estimated rent payments</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PercentageOfAnnualIncreaseInBaseRent', window );">Percentage of annual increase in base rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Cash security deposit</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rckt_AAVCurrentGoodManufacturingPracticecGMPMember', window );">AAV Current Good Manufacturing Practice (cGMP) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Finance Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities', window );">Area of lease | ft&#178;</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_FinanceLeasesEstimatedRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental payments due for the reporting period under finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_FinanceLeasesEstimatedRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The lease area under agreement for internal process development and research activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfOptionsToRenewLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options to renew lease agreement in consecutive times.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfOptionsToRenewLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_PercentageOfAnnualIncreaseInBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual increase in base rent under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_PercentageOfAnnualIncreaseInBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rckt_NewJerseyLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rckt_NewJerseyLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rckt_AAVCurrentGoodManufacturingPracticecGMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rckt_AAVCurrentGoodManufacturingPracticecGMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436982464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 07, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,173<span></span>
</td>
<td class="nump">$ 3,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,258<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">$ 818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Operating and Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rckt_RenovacorIncMember', window );">Renovacor, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Rental income received under sublease agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rckt_EmpireStateBuildingLeaseAgreementMember', window );">ESB Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CertificatesOfDepositAtCarryingValue', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rckt_EmpireStateBuildingLeaseAgreementAmendmentMember', window );">ESB Lease Agreement Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rckt_HopewellMember', window );">Hopewell, New Jersey and Cambridge [Member] | Renovacor, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CertificatesOfDepositAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CertificatesOfDepositAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense incurred and directly related to generating revenue by lessor from operating lease of rented property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(c))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rckt_RenovacorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rckt_RenovacorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rckt_EmpireStateBuildingLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rckt_EmpireStateBuildingLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rckt_EmpireStateBuildingLeaseAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rckt_EmpireStateBuildingLeaseAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rckt_HopewellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rckt_HopewellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436922672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Leases Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">$ 1,377<span></span>
</td>
<td class="nump">$ 818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_FinanceLeaseCostsAbstract', window );"><strong>Finance Lease Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right of use assets</a></td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 5,287<span></span>
</td>
<td class="nump">$ 5,406<span></span>
</td>
<td class="nump">$ 4,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435275808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future Lease Payments of Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(1,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 4,259<span></span>
</td>
<td class="nump">$ 3,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436891696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Finance Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">2,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">38,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">48,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(27,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liability</a></td>
<td class="nump">$ 21,239<span></span>
</td>
<td class="nump">$ 21,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436299984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease assets and liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">$ 4,173<span></span>
</td>
<td class="nump">$ 3,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating current lease liabilities</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating noncurrent lease liabilities</a></td>
<td class="nump">3,258<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">4,259<span></span>
</td>
<td class="nump">3,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance right-of-use assets</a></td>
<td class="nump">42,363<span></span>
</td>
<td class="nump">44,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance current lease liability</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance noncurrent lease liability</a></td>
<td class="nump">19,383<span></span>
</td>
<td class="nump">19,353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liability</a></td>
<td class="nump">$ 21,239<span></span>
</td>
<td class="nump">$ 21,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433150048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Related to Cash Flow Information, Lease Term and Discount Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Operating and Financing Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,157<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash flows from finance lease</a></td>
<td class="nump">$ 1,791<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
<td class="nump">$ 1,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - finance lease</a></td>
<td class="text">19 years 8 months 12 days<span></span>
</td>
<td class="text">20 years 10 months 24 days<span></span>
</td>
<td class="text">21 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">8.82%<span></span>
</td>
<td class="nump">8.34%<span></span>
</td>
<td class="nump">6.44%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="nump">8.96%<span></span>
</td>
<td class="nump">8.96%<span></span>
</td>
<td class="nump">8.69%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Operating And Financing Activities Lessee Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435852080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements Related to Intellectual Property - Additional Information (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Patent </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_DanonDiseaseLicenseAgreementWithUCSDMember', window );">License Agreement for Danon Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_REGENXBIOIncLicenseMember', window );">REGENXBIO, Inc. License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementOptionsRightExpiryTerm', window );">Options right expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForDDWithRGNXMember', window );">License Agreement for DD with RGNX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation', window );">Potential future obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAgreementInitialTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AgreementTerminationNoticePeriod', window );">Termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementNumberOfPatents', window );">Number of patents | Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RoyaltiesPayableOnFeesReceived', window );">Royalties payable on fees received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_PaymentAndExpensesForLicenseFee', window );">Payment and expenses for license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfMilestonesAchieved', window );">Number of additional milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForPKDWithCIEMATGroupMember', window );">License Agreement for PKD with CIEMAT Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation', window );">Potential future obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AgreementTerminationNoticePeriod', window );">Termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfLeastUninterruptedYears', window );">Number of least uninterrupted years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember', window );">License Agreement for FA with CIEMAT Group and FIBHNJS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation', window );">Potential future obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AgreementTerminationNoticePeriod', window );">Termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfLeastUninterruptedYears', window );">Number of least uninterrupted years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember', window );">License Agreement for LAD-I with CIEMAT and UCLB | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation', window );">Potential future obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember', window );">License Agreement for LAD-I with CIEMAT Group and UCLB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="nump">&#8364; 30<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation', window );">Potential future obligation</a></td>
<td class="nump">&#8364; 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AgreementTerminationNoticePeriod', window );">Termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfLeastUninterruptedYears', window );">Number of least uninterrupted years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForBAG3WithTempleUniversityMember', window );">License Agreement for BAG3 ith Temple University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation', window );">Potential future obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of advance notice period to terminate the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_LicenseAgreementNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of patents under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_LicenseAgreementNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_LicenseAgreementOptionsRightExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of options right to expiry from the date of the license agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_LicenseAgreementOptionsRightExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfLeastUninterruptedYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of least uninterrupted years following regulatory approval to develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfLeastUninterruptedYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones achieved during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_PaymentAndExpensesForLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment and expenses for license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_PaymentAndExpensesForLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ResearchAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the agreement from the commencement date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ResearchAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The research and development costs incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ResearchAndDevelopmentCostsPotentialFutureObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone potential future obligations as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ResearchAndDevelopmentCostsPotentialFutureObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_RoyaltiesPayableOnFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties percentage payable on fees received from a priority review voucher issued in connection with or otherwise related to a licensed product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_RoyaltiesPayableOnFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_DanonDiseaseLicenseAgreementWithUCSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_DanonDiseaseLicenseAgreementWithUCSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_REGENXBIOIncLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_REGENXBIOIncLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForDDWithRGNXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForDDWithRGNXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForPKDWithCIEMATGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForPKDWithCIEMATGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForBAG3WithTempleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rckt_LicenseAgreementForBAG3WithTempleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323435484032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CIRM Grants - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 18, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rckt_LADICIRMGrantMember', window );">LAD-I CIRM Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AdditionalInformationOfCIRMGrantsAbstract', window );"><strong>CIRM Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrantAwardForClinicalDevelopmentSupport', window );">Grant award for clinical development support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ProceedsFromMilestonePayments', window );">Milestone payments received</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram', window );">Additional payments available under grant awards program</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rckt_DanonDiseaseCIRMGrantMember', window );">DD CIRM Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_AdditionalInformationOfCIRMGrantsAbstract', window );"><strong>CIRM Grants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_GrantAwardForClinicalDevelopmentSupport', window );">Grant award for clinical development support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ProceedsFromMilestonePayments', window );">Milestone payments received</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AdditionalInformationOfCIRMGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Information Of C I R M Grants Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AdditionalInformationOfCIRMGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Payments Available under Grant Awards Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_GrantAwardForClinicalDevelopmentSupport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant award for clinical development support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_GrantAwardForClinicalDevelopmentSupport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ProceedsFromMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of cash receipts for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ProceedsFromMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rckt_LADICIRMGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rckt_LADICIRMGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rckt_DanonDiseaseCIRMGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=rckt_DanonDiseaseCIRMGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433811088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Renovacor Acquisition - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Business Combination, Consideration Transferred [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 39,154<span></span>
</td>
<td class="nump">$ 39,154<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323433826816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 39,154<span></span>
</td>
<td class="nump">$ 39,154<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437993552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ConsultingAgreementTerminationDate', window );">Consulting agreement termination date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ConsultingAgreementEffectiveDate', window );">Consulting agreement effective date</a></td>
<td class="text">Mar.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ConsultingFeeMonthlyInstalment', window );">Consulting fee monthly instalment</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ConsultingFeeMonthlyInstalment', window );">Consulting fee monthly instalment</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares', window );">Number of stock warrants issued to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,126,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ConsultingAgreementEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting Agreement Effective Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ConsultingAgreementEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ConsultingAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting Agreement Termination Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ConsultingAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ConsultingFeeMonthlyInstalment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting Fee Monthly Instalment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ConsultingFeeMonthlyInstalment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NumberOfStockWarrantsIssuedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock warrants issued to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NumberOfStockWarrantsIssuedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_RelatedPartyTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_RelatedPartyTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rckt_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rckt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437928176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>401(k) Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of matching employee contributions</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching employee contributions</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323437557792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment reporting expense information used by CODM description</a></td>
<td class="text">The CODM manages the Company&#8217;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45323436389008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">171,244<span></span>
</td>
<td class="nump">186,342<span></span>
</td>
<td class="nump">165,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_NonCommercialGeneralAndAdministrativeExpense', window );">Non-commercial general and administrative</a></td>
<td class="nump">63,878<span></span>
</td>
<td class="nump">54,805<span></span>
</td>
<td class="nump">50,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_CommercialGeneralAndAdministrativeExpense', window );">Commercial general and administrative</a></td>
<td class="nump">38,083<span></span>
</td>
<td class="nump">18,512<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">273,205<span></span>
</td>
<td class="nump">259,659<span></span>
</td>
<td class="nump">224,343<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(273,205)<span></span>
</td>
<td class="num">(259,659)<span></span>
</td>
<td class="num">(224,343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rckt_ResearchAndDevelopmentIncentives', window );">Research and development incentives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">8,267<span></span>
</td>
<td class="nump">5,288<span></span>
</td>
<td class="nump">3,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount and amortization of premium on investments, net</a></td>
<td class="nump">8,078<span></span>
</td>
<td class="nump">10,651<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (258,746)<span></span>
</td>
<td class="num">$ (245,595)<span></span>
</td>
<td class="num">$ (221,863)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_CommercialGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_CommercialGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_NonCommercialGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non commercial general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_NonCommercialGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rckt_ResearchAndDevelopmentIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development income claimed from tax credit against the General Corporation Tax and Unincorporated Business Tax during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rckt_ResearchAndDevelopmentIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rckt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIA+:;X @YV"T%DN<F+N='7 ];4[]@RNT.FTK&XGLJG_8O[E'O32BDG'4DY*
MD]>+E^NV?VS 6[>KP1[6F+1=F(6@,@N!7>NOO$--<!)2\*MZY4A?N^9<KYO#
MU)#M5OQ#46G>HF5_S/H>Z-13N$*KDUEYBF"K%Q#C.8ADZW#]DQN/['&-R=J%
MH0@J0Q%L92A&Z22F(8Q1AHWJPX[2>/.?4Q.1HQUK-+73^/'2.^I>M!]-Q%3>
M(-C*&]07,<9S# 5"=ZF$K)8H?V\DRZ7 [^=H)ZO5ZYR<^.>G:C7JL<;$+KQ
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M>'^CQ+9^IWHOE!)Y?;EA5(^T,="_KX7>?30WYC7MX;7\\G]02P,$%     @
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M6*19E>)*NDK99F-;8-F(O;M/=[-Q<77+OAF<!!JH(!>:1,DK9?GD3ZAEB,#
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M0C9(S$XB)L@.0NBGN5#_DQ&'@+:C7O%IPVO3<JH!H8D/2(_R+%QF.,. &I(
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M'@R<1S.9^E ?'/=(64KOP*PA$<?NLJM<*X!TR32!Z #:$U[(V0<&&#@W;[N
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M=:1_\*8)GQBWQGM3AY\EX=IH>0/6<P/$= ^L8/CF?/M_4$L#!!0    ( "N
M6UH![W"RS1X  *-B   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;+5=
M6W/;1I9^SZ] :6:G,E44+4OR)7;B*EEV,MY*)BXKGGG8V@<0:)(8@VBF&Q#%
M_/H]WSE]!4%9]LQ6Y2*1C>YSOS?T_4Z;3W:M5%_<;=K._G"R[OOMBT>/;+56
MF]+.]59U],U2FTW9TZ]F]<ANC2IK?FC3/CH_.WOZ:%,VW<FK[_FS]^;5]WKH
MVZ93[TUAA\VF-/O7JM6['TX>G_@//C2K=8\/'KWZ?ENNU(WJ/V[?&_KM4=BE
M;C:JLXWN"J.6/YQ</7[Q^A+K><$_&K6SR<\%,%EH_0F_O*M_.#D#0*I558\=
M2OK?K;I6;8N-"(S?W9XGX4@\F/[L=_^1<2=<%J55U[K]9U/WZQ].GI\4M5J6
M0]M_T+N_*8?/$^Q7Z=;R?XN=K'UR>5)4@^WUQCU,$&R:3OY?WCDZ) \\/SOR
MP+E[X)SAEH,8RC=E7[[ZWNA=8;":=L,/C"H_3< U'9ARTQOZMJ'G^E<WPHQ"
M+XN;9M4URZ8JN[ZXJBH]='W3K8KWNFVJ1MGO'_5T'IYZ5+F]7\O>YT?V?GQ>
M_**[?FV+MUVMZGR#1P1H@/;<0_OZ_-X=WZAJ7EP\GA7G9^>7]^QW$;"_X/TN
M_FWLB_^Y6MC>D!#][Q0AY)C+Z6.@6"_LMJS4#R>D.5:96W7RZB]_>OST[.4]
M2%P&)"[OV_W?9.']>U_,BR^@T7O3=%6S;>E'6GVM.TO?U"6KWV]K553A$U47
MRZ8K:779%K:G#TC1>TMJS@2B_?ML/7:@+?%A*0=;__NUWFS+;E^475TT]+$=
M%K:IF]( HJ;#)K!=3;\GU>K7Q<?YS;SXZ>KJ?3$OKMJ6EO3*5'X3O_FZO%7%
M0JFN4&U#>L<@RVX1I'GQT2K \=;V#5D(.A!H$@K;TF1 ?Q[S>R$UZO>A(<*0
MYG=D*C=,($V_?5*%"F># J4E\[K%T98.+ONB7"[) #(0!)8V *#<! K2>M7+
MHVU3+IJVZ1NW5=W8JM5V,(PB 0=FX^1CS\@IP-&C/8DIGCL&CKHC;V-ILWHP
M$*VX#K]ME6ET/<_D\#CZ9-YA^X5OM)%]&!NJ=JB)]0/A29AWNB\@ 'B *+[2
MNMXU)#4L;5U?=JMFT2HA2=&0$#6&-YIY634#'4"8??A+N=F^?!,PE 6W93L$
M00&3B?=D93I;LM.B53B(O$#UZ13.AS#<E::V\^)Z36>+A!\G 3#(R!!H3L)$
M?LLZTCC*XK?=NJG6^&Q/XD]JH8I/G=Z1J%]5/5#Q#Y*>M) 1$B]3+(W>T#/:
M)N)(()9V/>/_%F\)-<(U\/\#+3,-0\7?R](*/ZK14A.7\O?@86-%7!9E]XE\
M\%;;!B2O%,D)Y*(7"^2^X6TVNB.4R))](D8%-6<]BX+0= 1]/S#Q!/X<'")G
M51JR+#6DO=*V=_0JMUNC[QP7EB0$S%E2!OJ7Q(;(21_9-='^E*S-IB![ KT"
M8('@P9(MR.2H6RB!9OEC6U06V-P 2A(A44O:N3*J)@Q-8S_-V?CX39A,M3($
M-8GKFH*3=D^23-B S;1[+P+/%-@ '-%BUERC% @&UZU-0?;<>A9'_=X.IEJ3
M2 **A3K@70;-7_[T_/SQLY=65@'KT?+ D1F;$0K[Z*=-N2=<*P5=580*(;('
MBPCU6I0R/X4(99E@T#%B4E>!3_0Y63$KJF(',,N=-4_%\$"VO%C1AVT+TI=M
M\P>L4*OZ'G2%413J-Z1RM,6"_(>(I!CSSD6>3.)^@AH46L--\)XE(/S6$N'_
MKHG CR\*+#L_>_DS?\6_/'Y9D(,HRIH.I8U)%**-MG\5[0]"/P:[=(#?![<=
MMM[63L%;:4-?@_]N U*&>OX5RAO\ \&H=W3<BV\HM%.;!8'GP[MB_,G%-]='
MI,<6?RX>/[V8/;UX0C\]>3+[[NSRFS%O'\\NGI[CO\_.O_E-]T2\ZN%P8__+
MV7??/</^SV;GSYX6/^E;93IVQ3^1Q:8'Z415FDI K$F#6[WE[YW-+W8DGRZ^
MH8T[Q70PJMDL!F.= V(]NW[WX9?BVYL@#$^],,@W?%[Q69'XZQPQ6$7;2C"2
MBBP,!L.IETOR+"T90%5(&LA?_9C91#,(<!Q14(#U+Q]2>,W++1$A2:;0-.T^
M9?@QW7=NZ[9LVI)\Z2GA<VKIF\*JREFE7,V1:_;TK^5X[ZA)<5@Y$P<+>/H[
M>3"XV&F+CUUF##'M0CNT^]FT779D($XOAZX6OQ"HHI&F$?KM4=L<]$F\$9!.
M<$U)QA'@;Y1L$SOWQ4U8(V'!=5#'U[JKCUC<:.N++>+TO;.<$I^XR*O/J+MW
M#\&,X1/RG$6_W[+53[83/7&!:<F1='0K:]6R81D)"3D*(AVL'6405Z>/KLJ+
M AC43&FCZ DBVE#! J4"Y5W>O'B7')+^_ "J31/MEQA2UPK.F5(@1QTX=1)E
M-G@MQ5426\2PWF9\<_$OG)?$3Q"+LF("U7RVDG#O</L.'I;V9)G*C^)]54F?
MYUH*-SSR^.XY)7J1<H/LSH1^D0>W0RFIQ-7-=7%Q?C9+:<HR=/[RC5H(L]]*
M?'J3J&7* 0DVR4?4$A[%,&@F*CATQ!/R1O3UBM67,PCOFSGNKAG4 ND825W'
M["1W/6R&EF-V#2GAKXU:HS1$D1$]BC#U6^ST5W;R")?7ND7TX_3 Q];B(K/M
M>_$%V9;8RH?&6<Z09 J<$XT?FA7(B1$E"Z((,8ZA#'H%M.FP1+4<2JA:%7:K
M*DC#*45S71]%D-*!9F088R( CR/>2Y3('0E7D05_!'O*%K=,W9$F47)[\(5D
ME";X?Z.$+9[UE);]$?*M U-TG5+RQE,2A/Q5 B%G@R<@"@<CO/OLX5\D,4Q"
MVF*G>/MB)*.(?P4&W66T RV!Y9Y\/I$,%:Z#D.52 A=&BGXXGQ<_?L53SC8Z
M"$GW1_090T8$_7-Q-K\@1]2V1-39^"&'V>13S^)3./_AQYW[!V$50F)\);6"
M=Z-4.=AK<(A4'#O6BMPR)=KDH&Y5EEV_>^^S9\FS18LW307M;#6<EJY5.Y\X
MQ@L)F;BX"]E=^&J7T+E$218M5 +)J4 B*BVV8+.E*)H]  5=%#/7NO-"S#;=
M6ETU?&)(^)<D*4@VWBU=OD<ZET:'C?7[PE!R-K@BCR#ICB91)D%IDF>-6D&V
M-?DV=B%D8J48)*DML",/ROOJ!>(DYUU3X!QU=IS$$\ZU(EWDDDA$FP_D!3V.
M77"X0,D!Y$!J$;ISF2U% + WT"UO@XAL5BV'EKGIG&.)&*1A^\9N<I[P9%Q,
ML3ZS-BKZ9681I\/K4G*="FY>.8M#D"2Y-[O?^E\#"UFM=QTJ)R([70C)&SNR
M'>,Z331F4\;+YM:+;8E5]Z(%L,A$]^(D)10JNVX0=AOA<5E0^K%:*2Z"D:Q
MPD02F(I2?"%!Y5H'>$YI DDI MI0@XI,<@NU\7Z6BVE&KXR+.X)Z@8<NPJQB
M@<GIB\JSFE ]%$N1K$\D5'6WC7$Z@E7+@0L?)/ ;93@"%[EU^G$_VKN'H)W'
M[%RL(_Z@L$H/_(YXIR'N050I\&OW9(0@5$'$0']V&9P?DV$Q,$B?5(M8E@0'
M#HB!X?PU2ANM7:#%Q06B/2?<'%R+AQ8&I\P!Z:SE'[TG&9LY3A<%= F,B.+!
M5SR>4VZ8;N@LT-0F(2I[D,_R?N<B#RYB:-=-')O(.1GDE3<A#$)B@['TP&ZS
M),4"&E$:_N2I]R=I+1B 'X&[('A_\N79UX-M.*@F05N@>A_*H:[XXXA!Z9LR
MKE1+$:+E)+K8D 2@S@ST?7@HJ47990L;3GQTE:+'6[8L 3YBXPP/GM3KRT/,
M9Y0MZW@_!E-2@#=.<CV)$IE,ZOMI&I(5[5$M5O54AR'$;?\:ZE508+TDE8/_
MU^VM2V0&:8+8AU3E9XD%2BO5G" X.H"2WDX@IV^Z)2F6;*6'GG^9<9T#G.3\
M$3:(9<UY&Q1\Q1]2'-AS2VH&A:13M=-NM2&;<_5 \HQS&^';)+-$;%"WM(%K
MH59*Z1X)/RI'_/DTM]U#46 B?$VBS"04OAV12#[,F7@7#O83@^-]S,B00'UH
M)1NZI?&5#W%#;((Y!DZL>]48"J\I$^+B2K#&P2@*(S9HAW,XQ2 @%7I[5VY\
M<Y SW63[T9Z<%<V.=&%FR(H282MKHB>Z.PPC0&S5"ET70QMX.] RH6>LP6Y]
M&DA5/J@;.GB(JMDR6Q"84;PGS;YQJ1EU$:L2U>C29M70N<Y#:05;HVX;M0M:
M%5I)8SZ->Y\(N^%VY\4_P1-P%_O[YW-_![CPNV:]8DUJC/7NII "F+B_)2&-
MD #GYV#[* .>+)$QX)]ND+@PQS'K/O.VB(TG\FZN<Q(6;!MN0]$O9_NX7YE:
M,A/]:K!M>7,0@/OXZ^@1OKVW*2NC29$Z3=X(M);R*9NGFB)&(Z6"P'Y8YB22
M21^ ,J/Z%6N*SF?CQ-E8('PVGX+H+)5/1))0,C:W6ZN3E@[9 ( 1NH=VFARI
ML67/6Y+2],#?+9?V'1HEI*G]#NUN7@=OY\Y(F."M5>C@YBR!":8<%<U1BH7(
MS!;<B)!(JPY:=XPWL["MNNM=@UM2 *Y^.8B/<];Y6E5S!3,1(^[MF\9*V:X<
MT2CH8X(H.R.I+:<(<HC:'U>"I*>*&A-(S[-++-=?&$Y.0.IZ87:2])RB=?";
MAOV;MQ)-&D)*^%?V4UH31"TNOP=55()[F[?#TRSM_QWC8_I_97D7,.+0,&80
M<D6%&X81C2P^EWCOH4'S0:7GO4%[S]4<43K=2G;R=U+U[#OEOY,^0E_V27N9
M>Z]I/:O&A RR>'9);Y+?CN2T0[#&F%^"5S[%E(\+<J=BD2QQCX4-U2<IN?2(
MV;U00$BR)]095:3+;=-SY<B&$(AW;,L%:O"<($;*D%%>$V1F1)89A!IVRS7,
ME\T=?G:U5*3_J/6"=X:0"=,TG'4X'RBB5C7LBXBTUZ;L%H/9@QN[XK]AE^AG
M(A09PJ9G6>'9GUQ@;,CAI2/?TI>=\Z42K@Y<J]2IX"'L(;;4C<#LG"U)F;?]
MF#_JN+"?A.N&HQFSDK3",[9D!S88CJ8^;GDLLJ?82E32%*CJSYS-L[Y!XXJD
M1T0H.90":C+8KB#'\>Y&(XD+G?\P-2$UE+W3,PY&" U?*H7\I75M_HPWT4FA
MY%K;/J(SU3'/:@TFQM#<A6+2MYQZ6$I)=J43CJK5@_CM@0$CHX&@T,WD1'?8
M=*<8%.NEH^)W:"DZE^$<&?7PXDODOI+:5^GS/CE"LKARI%I<FK]7LY8J4RQ?
M]Z.G;',7=.DZ A!A'%%W.VU*IJI6KUT#Z08-)!1<LBS^9Z3M/W/:[K*B//M'
M\&H/DGOKBJ;<[^/:O3U,/9!+*%#CZ_.)9((D*Z^PLX=+64B"AF",LNV#61A4
M1)4,"&8Y$2I SB8]"#/I+E "QI1D.>76V=.ST\?TSY-91E53O&&EDA&P PK/
M\V=C$C[JFJZ,'K:?&;NCI%BQOR"E8?H[B4I+$)Q-NUP:T@X#PR,U9!'@UV(Y
M)UE)GTC*?,^HH&]L)J["P<RM!H&0,FF__=#Y[%W56:K/1X8X*UN6@.3FHA)1
M40=RD?DMYQ&=<,Q&)2RQM!RL<,]8<NO8'T<?.TYIW7N08.W#%DA;$N&$JL\4
M5K$:B<["=DOVA,1F*@T(!8"=0;<$E6WFTG%+D ;0]T4Q6:,*</^#X?Y%J"*>
M-06'R>HJ$ZBARN0),G"Y+<#^I>/9@"/"$V= LTR#=9^\XJ)E 1M%GE)O).MK
M@T[6HR)8V#<KS$#;GJ/)?0PY@/<FCE3-8+H)B,:N 4>Q;DB R OMQ0=%"*1F
M[SOL\^+7!8:\6>?<,FGV\H^,G,OY*#&18D,7NC&#M#-0*?+8B&S!O3K2[:,L
MN8W(PI>AW2/>UFKRF&)1Q^H=8I./G?XLJ&Z =+*EFPV;+O30I\SYCR#*L0;W
M@#@:&/6>R$#SG$J4M\"%T+]/W8NH4R)ID:6D<RT/0';MWL=P<3SWR^4M2FHR
M(M%Q"0_&J_3&YG"=;W"[:257A^: F\U[",JG\6!BV<HT"Q +/8D7,BOV]&7Q
M,[N'Q\4I2[^K'02"#EWHE_T^:/R/ZY62T4I]VG5KQ,.S;ZG*H-T)XQI?SYDJ
M3GG>$I7)F7*&(PLW41E==3L'_/P(X#FT@,TV&Q(#<P2RI@N(9),%#DE:'3TH
MK%=:;4RT).H.68J&G61-QK#JI9,'_R2_C?&XR/%P:L:6],&J1V9_8MJ?-N#2
M2PIQ2(""M*1TEH&+B J)F\[*,-@W482$[-R]L8)J!)I#"RY^1]/"A=7,U+B"
M%)@@*8M7J9"6)/#&[@2J";X?,>=+* ;QO!_5J]4*:D)/AZ:%ND.CT:J#<;21
M&N>]/-H&;87>C<S$$4@$'"MM?+O8\9- &0T5ROK +8G+$"\ZU"=U-R7N05#'
MY8B]D-I56.S#^7Q@^7)7$,M@4X.?:>9T=(QS-IZ:G26C^2%WW)9[E@"VZ[@>
M08M#KSWI AZVQO("D$UFZR<FZPF[C0Z#QNQI C;SXI^<%HZBF0 BVP_,D!4[
MOXX,EU-P-TB6$2<U+?1LK0S1A&$>&9VIU.$WO6VJXO(YA244>B!I'2C> )X_
M)P^S1W\;AM@>T3'QX>?(.]Z$4\7/_$W5*]J%F8#Z UI?(E6A!@V"!6?B<*60
MW2@G,1Z _6F8+:P3FCR\)Q9F&,=W>>)LC3BNH*RSPEL#_$S'1  (=4Y(=@W/
M7_9]B_P\N0]SK+/&6=YG4<I'\@@*Y4HIKG$HLV-?-.)V,"42Y"\! B)V(%LY
MD9WY2(:]*8>I3Y%#2Z4@FT%%C&HQX%F)ML'!)5/*, O1"\SSZ?4W2>WEK=?.
MPRM,+L=T317*5^36G=Q9*I=+KD.Q@G!=Q?^Z*;L!W2?IZX^GY=VBJB6[C."B
M]Y=>W*%9^8K-2%J:B>O2]AX JAHW/\F-%%>X6BKI'8?&!>ZYX9HG+ _3X_ *
M%G>%.IN=-YL8+KA7X9]=D,(?H_G(LWG",V6<GO"I=5X2_)&\(_F#XAJ_=]6^
M^"VY2E9<4W*(,MW2K:K\JO3"V7C8XJ$SBC*<&.?^*334R;7)MX/1(A>O,3IL
MT1L:>/SZI_%8K/X<A&Y0L\]\WU<6Z>.4.-O[PWD7BFG\$G$)KC _ER=.7[-$
M7*<2D6?(%N;O\ (?EW4WVU;OE5.83G>GX9-9,@+H P9,,*%SSF!H/T[QX>:C
M:YV]IY]&%R5$P6UH@XVEEF\=NC,/@"@0K7% C5:@F\E$;4/:['SMI!-TDMN+
MJ?'*8IG#T,,]*E^OV/G$J78_<9.A*W<'"<]1CR.46CE0M"B+.."]GTF/M,=K
MMG(?4)NE<O7ZY!!)7MQ(I@!YZ[ILH1_,5'GO $SZP(X4H7'JQXFP=H0+UQ*D
M=Q;;9F+6TPU76O(N/]$9+IEA1VYF86"S6N/&2CQ82,Y? _:IH-"3VO'%7_<3
M_J#P7;:5:R3$UM+KMB0!OZG6FN<[9/C 9_8RY!6$X1-\?9*XR)V\9&;]5J-S
M$[+_\#DB@J-7'CYGH-F=]P_TT%[G;+E!DM)U[/B3(J#0$6YHVZ1A/D6W1K>M
MM]1P'%Z)N*.013$/VC'(<;F/$4'<!S//')#\5MZI>^)9%[;TO"J9>@OSU+'B
MDDZ_I<:0Y1--U*7BE@WM=:RLYZVQ*^UB9;A6Q;3HR:DO!KGZQ)5#/X=@LT&$
MB2O:X_JKNS8ND?-]->J#? )005YR_P_0DWN9Z%WQTT A7'HT>UKF+F)/&MR'
M$$FT1W6E"#<M-/G=#91'MEM7C2KO7.*<AI_B[3(Y"G=!>!<KD1Z7OKE#R.%R
M(5>UB:"X"D6N+:'_4;YS5"U3%6RYXK15!!VU[0=@[J#W\Q)L=,:JY^RVY+E^
MNHAA ,&2"E$.;CU4;ET:W3+ AY#-,%??*52@2C2#^2)L+'5@M'/'QK99/FB:
M(1LZQC?NWD1A^3:/X5J2'[TY@&;Z_MX4/:6IFT1;Q&38-KY1FLMN)JQ)&C.Z
M3);R_]UTV/KLDF^'16.3SU?$3)"T'NYE@HP\U\EC[LLE[ Z>!\R'..+= R47
MB'M?,/T"TGNR._.SH%!JV7 6?^ N[10G.%]]Z%QT9F:'KI(HFR.AW.H>7I":
M? /%0DK18N**?J=/;:^VZ.YPI32;54]Z5! K&#3!U?4NXY&4'& .4'B&A3*;
MA2+>8+E[ZGMX]>$13/5FK76<[/$1AJ6GI><P;-G9NL:\NBM#+<_5W>A4QFD@
MZQ/N#RX/ 6JLOXX"EI\*RT_!\E-FN<[.G<"H80/@NT93"$6:)?0*Q+J//6Z<
M/VO]A3VDW['/*>_ D6XK2@GR+"]>\VU'J34:D>HG9_^5TIM!!-G"%2RF,[)7
MKI*)08\%/LS --9'HIG\Y5:4+;GU1<4XR<'&7-Y19&=2MTUP242,]=]?!XQW
MJ-)+LXE;%7LO82-4/JNL4(!6MB(0F([Z&8;K/1'D9HW-LX#/!Y]B[-C$D<$C
M,R:EFTG+=?Z4+-?;TJ#,*\MYXWE!R1MEXA,;C>,37%<ADO*7[F)I-@.R@ N]
M;<*@9=CR(1LY]=CQ"\1 0;2IR;-V YL?N6<:GK(8@4<WBP_S@99_,TXH+(DL
M*F=DW86V_#TSHRO-$B/%1H3P3( $Z!2 DF!R^$"'=CJ?5W4*A#31P^D,@A3T
MQF*2(A$OVO9D/^2]+F",2EEFA65OFG;P,O1@"H]8)4TNG/Q%N_1R-U2N>\AL
M@CR$"K8'-4MY\^M)$CC50("IE%RC/L#J/R>*]=<0[#\GDFGG()(C$"';1F['
M;@>#,317ETX23KZ3FIZDD[<<):+U^6-NW-#^AU"-_C5$36Z@W[H^ZI)]6VGC
MG7%G,PN\Q,.0H8-L<^=;8G K[_Y2/ UAR.MDW>DFN8C/E%(Q3G)$1\J^3,*X
MFE)"-NAXVY>928-!/CJECWCZ#E,G,VEH5<+ZM=YQ_N#%E?!VXP#RYJID4#^I
M*N21C4Q\(7!*PG,96L0=(?DJW+#  &"G$L =):?#VNM?W_S"HVQ(R1GCMW>D
M$,RM7Y=DE#!PY(H65G4-OX:HA'"NFRUE+J6O!& ?#\]DFS2"SD:./<^*WSGA
M:CY!8$7PF+U"-O&[CG#N^H5GV)%7Y!RY!=![4*4H;=HX42<7S&(+K$OZ8202
MV447E"+#B]^\%+AR5A4BX%KYEP.\2WH9$NS&<TB\#^ZZTGE\+134O<ZNS+-/
MSC_RLYZ)DHC\^KS0^1E.OH*8)&KC2LVES_5DT/3@[6>2L!P=_.>G4+?4.Y1I
M4C%/7^<4[5]^5_6^EU+D%]WGA;R**=.1Y)4AC5P/C .GK.TRH5Q(%JNV,K8=
MS8T,-,O\KWL)5,F%=/^6H(<TFK+!3O#!<%U3+T^'.+/,=)(C9JZRWCO@QJ42
M'H7D;NK!]_/01CC2/W;H^B:B-%1*GL?NU Z#D&*UZ8'O+E_"3F$R-,\E:ZVL
MRY]]2#Z%D=B$$?PR8"U'B5RAWL7S"))+CJ\I9",!R-)*JS%YMB^JB"GOZ'7^
MD*.?O[?--Q..TBN,-'+X7BLWH(C7:LK]QIP^L;G9\^!0)64.PGBAC>$7:O%3
M/%WKO:<#WK]?,ZO$"T:AQ"B5J3*^6? 8L]-WC,&>YJ<OV54M>HG$RS"3<UC'
M11XTH.3[AY_1/8[3:$#"2VI<);57]WJ6TLCD*Q^4U)X6#44)U;K3K5[MPZ4O
MO%J2"Q4IL=M8C9-47QPWVME"M_@Z&?:M>:$!EFFT3-['@^L&*P%MP=(X6C7C
M:E%H1^;1-BZN'-P\/K838:4W1WEXG\+B(B\)D)Q)^0+?;_@VG:*OU9TKNL>5
M>*?*CWD9U9F=<<$H*2WR2[.&#9\:_>'Q3DW>6VKN7-D_"=$\9M$@YT(G%Y?<
M*RTDU RG^GX2BU:F) NU:CH>& H=ET#N#2IH26GR'Z61P>L# 8CON8VOX$KF
MT 0?XD'RGDC_7=\X891WIMS!]AA_*V_T+IRL._Q!+O2E+^XUNM.#@]G>\\W?
MZ=RKFBRW.G@/0:B.7=U\Y.K8Z=EW+T9-"6EX7YX5IYB.C[=T\%*6L# =O 6C
M&F20W'WB@+\T-:/DYZ^2+H/4,GQ)WTBXB_MW9%!<VA!R6HK*RQ7)^BJ,F64U
M$KFH&,8KXG>GOGA1'X,2*ADA\;!Y8</ORP8J$KQ2E*1RB?)/?+7#$R'I?#QL
M/8H]E;_C2)*34%\$FZ\H:>EY'7T-;X:,V^+R].SBA1_Z %-2>AWET12!U?@=
MPHZ<L9?C \]\K^:!A)3NQ^?(^&R.V@_NO=>N+RFMV4W3]ZK^"AJ#0%]-X^/*
M]V#U>O9B(H$5'3M_/J5CLHH-D7_P\WPDUI2=O.Z#7UTB:2/>0+M)47+#MC%'
M\1?B0TX1#%M,?5R4$QW7O2FO.]IE,FX&*IDF0Z$XCE+[\^D,U&3=G;3/J>H7
M2=3%S ]RNS<:\N0XFK>]T;Z]*%V9LHWZ?A#3WU-?]J)*""6,=V5:V:&DE&9'
MP.N^TZ[<X#0-"!U(R'SJ3?./DC\<L%%FQ7\>@=_MW/7R-P3"IX7_"PQ7\H<'
MXG+Y\PV_E&:%]*E52WKT;/[LR8D$[?Z77F_YSQ L=-_K#?^XYHP>"^A[8.)_
MP0'A[U*\^C]02P,$%     @ *X!;6FV*?[W1!@  51(  !D   !X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULM5A;;]LV%'[7KR"\M6@ V=;5=MPD0).V6(%U
M*YIU>QCV0$NTQ44259**Z_WZG4-2LIS$1CI@#[8DDN><[]P^4KK8"GFG"L8T
M^5:5M;H<%5HWR^E4906KJ)J(AM4PLQ:RHAH>Y6:J&LEH;H2J<AH%P6Q:45Z/
MKB[,V"=Y=2%:7?*:?9)$M55%Y>Z:E6)[.0I'W<!GOBDT#DRO+AJZ8;=,?VD^
M27B:]EIR7K%:<5$3R=:7HS?A\CK!]6;![YQMU>">H"<K(>[PX4-^.0H0$"M9
MIE$#A<L]NV%EB8H QE>G<]2;1,'A?:?]O?$=?%E1Q6Y$^0?/=7$Y6HQ(SM:T
M+?5GL?V).7]2U)>)4IE_LK5KD_F(9*W2HG+"@*#BM;W2;RX. X%%<$0@<@*1
MP6T-&91OJ:97%U)LB<35H UOC*M&&L#Q&I-RJR7,<I#35^\IE^1W6K:,B#5Y
MSVM:9YR6Y$.MM&PA^EI=3#48PN73S"F]MDJC(TK#B'P4M2X4>5?G+#]4, 6$
M/<RH@WD=G=3XEF43$H<^B8(H.:$O[MV.C;[XO[M-_GRS@@<HF[^>BH#5GSRM
M'UMIJ1J:L<L1](IB\IZ-KE[^$,Z"UR?0)SWZY)3V_YJTDTJ?AIQ,R'-"]4&S
M2I&*4=5*EA.JR1JE[JT4]![T;]9*R>L-]A!7A$I&=,'(C:@:6N]>_K"(POEK
M17A]SY0V6B?D-UBP%B40!PIJNBH940SL 1GIXDGY=8^/#_#I B!M&=C\'HRK
M'2G9/<.6U 6OC;V!3,&9I#(K=DMO$*./UH"U2Q7&#(J752LF^P(F7Q1867H_
M&^TAL=?(76/RF]"T]-XH]'7IW5!5$/:UY6 6M2X]:"ZV Q:0=\#:5:M;<'?=
MUKDB/Y(P/O?/DP7<C=W/C7A?)K<04FGP[2".X"S7G"DR]Y,TMO]>)V['QB1,
MX"X(O0_[O"R/:QJ#>PM_'H3[.^^I,>,@1,<D<X@Y"F=^F"8.>9S"4Q!Y/W.Z
MXJ4QL?3^H%+26I/2#>X&KIJ?TU[NA1ZM^+Y\Q?]GOM+ G\?S 3H[<#+&?K*8
M=U?/*>@&T]B/HN39^8K#R)^=S_9WWHV0C9!4,[(2"!%F%O[B/.UO(*-Q&OKI
M.6;4W3W,:.]5G"9^,._*,0D2?Q&FST]HZ"_FL^YZ,K$'*PUS.&H@60FP^!J7
M<P!7'4T&9+_+L',$AJ$,CO6]CQ(PJ5BWOJ#W$#;&:KLT)RT6#OG:"@T/SF8C
M>898NB.)&U>&9N#<1! TRE-[;LG_;FTF)Z?<.LSQ[3['M,[)/J?7XL#3J$/^
MT!/DYUIH AL@[. &[ .\1O$CAW4A1;LI@$V!,F4^;JB$A*++& C<5<!Y<X[*
MD71=9%Q(@-:)XA4OJ70XK,M S )('1)O(@(M^A3U;Q_6D4^V!<\* E2.&B0Z
M GXB)-3Q*RB19%"*Q''\C:B5*'E.$=HU+6%#8>06CUC*_ZX-Q&:_K<4*'3?;
M%Z^;%L+[RE''&8*CRNUR@V;H8.T\!\!_1$N1J?8TC"R=61S[:E$DGB7'I6/7
M4T=D7[E&.CNNP;+TL"1;#9#_P9HCUR7-[L:W62%*ACV7@[=:.$,8Y$?9(J\4
M8^07J <2!@2S&@6O73B4>0Q?GV'4&86<2@8%K3&\#9-<Y+[I'I(5M-[83 Z2
M@]G?U( L[U*<#5.L-%RLVU 6\+XC39VYX@,:Y959-TSW^H@3D,Z<:2;AJ-ZW
M?[=-V-Q/X.0$A0?F7%>)QECKF\0&"QL0>J"MW*QDI0$!063?&GBG0> %K!J;
MYB'W N9=V?<+2KZ&Q$FN[L9KR;#Z !HX1 P78 /G_)[G#&YVG)7Y(<-TGAMJ
MV"O=6\(P(/=DH@)6A3B*[&[?VP6' < &_'I:Q#?I !BF=0YLP<8,+Y8XC*X\
M"'O'#D?<PQ-<AP6E#AGR'R;%.!-M [/&=WC;@B-OMWC/OU@CAIDH$)]&5MWU
M) 7)^&ZX!\EYN,32 63=9GK%!@<)9PUJ<&\& F=>47 3PZJS)OJD/AF'05YP
MOF/) :5"96BHQ<;D?LO+TEG$[L.XN9/Y,]JA &XSV\.^BTR?ZH.3_:#.E]YC
MFGE$7=ZMJ31;^$""T23%LT9T/DD#[]TW)C,..UDW/4LGP';N"M./RSB-)F#F
M!9DM)HN8O/ ^'ZFHQ"Y+)O, 5O6:#GL(.'&\GS-)?K5C5*HS$DSBD(3P-V1=
MH)L^<#_"DB# 8],D2,A3;XK3P:M^Q>3&?-# =FIK;=_Z^]'^F\D;^ZE@O]Q^
M</E(Y09>DN =9PVBP62>CJ"7S$<,^Z!%8SX<K(36HC*W!8/C@,0%,+\60-;N
M 0WT7Y*N_@502P,$%     @ *X!;6M:'_CM  P  2P<  !D   !X;"]W;W)K
M<VAE971S+W-H965T,34N>&ULE551C]LV#'[/KR#<H5@!([9E^YRD28"[:XL5
MZ V'MML>ACTH-A,;E257DB^7_?I1<N*F[35#7RQ2(C]^%$UJN5?ZDZD1+3RV
M0II54%O;+:+(E#6VW$Q5AY).MDJWW)*J=Y'I-/+*.[4B8G%\%;6\D<%ZZ??N
M]7JI>BL:B?<:3-^V7!]N4*C]*DB"T\;[9E=;MQ&MEQW?X0>T?W3WFK1H1*F:
M%J5IE 2-VU5PG2QN,F?O#?YL<&_.9'"9;)3ZY)2WU2J('2$46%J'P&EYP%L4
MP@$1C<]'S& ,Z1S/Y1/Z&Y\[Y;+A!F^5^*NI;+T*9@%4N.6]L._5_C<\YI,[
MO%()X[^P'VS3>0!E;ZQJC\[$H&WDL/+'XSV<.<SB'SBPHP/SO(= GN4K;OEZ
MJ=4>M+,F-"?X5+TWD6ND*\H'J^FT(3^[OM=47VT/P&4%KS_W34<W;D/X'>TR
MLA3 F47E$>QF &,_ $L8W"EI:P.O9875UP 1,1OIL1.]&W81\1664TB3$%C,
ML@MXZ9ANZO'2GT\7_K[>&*OI-_GGJ<P'W.QI7-<Z"]/Q$E<!]89!_8#!^OFS
MY"I^>8%U-K+.+J'_;)$N@^53N'0+'VN$6]5V7!Z>/YNQI'AIH#NWQY,]E(IZ
MTUBL0&W!DM]6"6KR1NX6$RH<MAO48_'@VYUT\HYOE.96Z<,9Z"^0LI#%.0EL
M'K*43>YX65,.^MOP"0MG>>&6E.43Q[FW!']F$,9)#BS+)F]Z+1O;:_00V^;1
MR0986!3%\)V\0^KM6HD*FI;R?4 '8: (V8S!55@0W[>2\"47T!L$H[9VSPDQ
M">=Q.GPG'Y6EXZ>O*X2=5L9 /@OC= YY2EEF%-:8!<VFLF][P=U=5DA_4-GP
M86@1 F^5MLV_P\:OP)*0Y2F\(#')"(K!B_^)*]%?*R4QNW+"/$P*1O6X%*?J
M-=715_6 7!M U]'?%3$;2AEZ )(8[+FA&,64T;02@J!"4K/I_*1Z2R+Q92>D
MX6XZ].-9'*9/]4MT-N!:U#L_Q@W]@+VTPZP;=\>7XGH8D%_,AV?FCNM=(PT(
MW))K/"WR /0PN@?%JLZ/RXVR-'R]6--KA]H9T/E6*7M27(#Q_5S_!U!+ P04
M    "  K@%M:8=S1S,@"  ")!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6R=54U3VS 0O>=7:$R'$\2.DP -2682:"D'9C*!MH=.#XJ]B37HPTAR
M#/SZKF3'! CI#!=;'_O>OB=KU\-2Z7N3 5CR*+@THR"S-A^$H4DR$-2T50X2
M=Y9*"VIQJE>AR370U(,$#^,H.@D%93(8#_W:3(^'JK"<29AI8@HAJ'Z: E?E
M*.@$FX4Y6V76+83C84Y7< OV9S[3. L;EI0)D(8I230L1\&D,YCV7+P/^,6@
M-%MCXIPLE+IWD^MT%$1.$'!(K&.@^%K#!7#NB%#&0\T9-"D=<'N\8?_NO:.7
M!35PH?AOEMIL%)P%)(4E+;B=J_('U'[ZCB]1W/@G*:O87AR0I#!6B1J,"@23
MU9L^UN>P!3B+/@#$-2#VNJM$7N4EM70\U*HDVD4CFQMXJQZ-XIAT'^76:MQE
MB+/C:VFI7+$%!S(Q!JPA5*;D2JFT9)P/0XLY7&28U'S3BB_^@*\3DQLE;6;(
M-YE"^IH@1'&-PGBC<!KO9;R$I$VZG2,21W%O#U^W<=SU?-U/.29_)@MC-5Z6
MO[O,5]2]W=2N@ 8FIPF, JP0 WH-P?CPH',2G>\1WFN$]_:Q?^)3[><[:9/_
MG,5=!N1"B9S*I\.#L[AS>FX(>X'0"I(H+%%C(25JB7@LM(>":9Q>S^:'5.3G
MEU4DUG "6((I<A"+U#[0,%^=")V#5&N:*/U*5YV$&A>"=P'$ G1S'[Q>''0)
MU5!W%O:,*3!^J3BV'#-HO4>]7>FVKK0R:(5J_<3DBJPI+X!\(7'_J-./FD%K
MDB2%*#AU;JE0VK)GZO4?D^/6G;*4[SB@=S3^8-_D0G?-N7]@]JAV6EF.24D=
M=_=K.\;.P+F3T=YUS\*M]B! KWP3=-^MD+;J%,UJTV<G57MY":^:] W5*R8-
MX;!$:-0^[0=$5XVOFEB5^V:S4!9;EQ]F^*\ [0)P?ZF4W4Q<@N;O,_X'4$L#
M!!0    ( "N 6UH4^ <N$0,  .T&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;*5537/3,!"]YU=HW$Y/;OR9.&F3S+2E#!P8,J7 @>&@V.M84UDR
MDIPT_YZ5G)@ )</ )996^]Z^7<7/LZU43[H",.2YYD+/O<J8YBH(=%Y!3?50
M-B#PI)2JI@:W:AWH1@$M'*CF01R&XZ"F3'B+F8LMU6(F6\.9@*4BNJUKJG:W
MP.5V[D7>(?# UI6Q@6 Q:^@:/H#YV"P5[H*>I6 U",VD( K*N7<37=VF-M\E
M?&*PU4=K8CM92?ED-V^+N1=:0< A-Y:!XF,#=\"Y)4(9W_:<7E_2 H_7!_;7
MKG?L944UW$G^F16FFGL3CQ10TI:;![E] _M^1I8OEUR[7[+M<M.I1_)6&UGO
MP:B@9J)[TN?]'(X D_ /@'@/B)WNKI!3^8H:NI@IN27*9B.;7;A6'1K%,6$O
MY8-1>,H09Q8W>2Y;8319TAU=<2!4% 2#JH6"W#_CW6O0L\!@*0L(\CWM;4<;
M_X$VBLD[*4RER;THH/B9($"-O=#X(/0V/LGX"O(A22*?Q&&<GN!+^L83QY?\
M3^/DR\U*&X5_G:\OS:"KD+Y<P;Y.5[JA.<P]?%\TJ UXBXNS:!Q>G]"?]OK3
M4^S_?G&G:;,A^;O)/%9 [F3=4+&[.)O$47:M\17;(YLC)-TCX8#,);[2VF!(
MEL0@32DY>@,3ZZL!WC+4*U#]39-?(\G@ 6=)55XY]@(V:"P-VH0AYR0:^]EX
M8A>)/QEG@[=B ]JXPX.D2WL6)=G@OFZXW &@GMHJH\XEHLB?IBF9^M,D'"P5
MFI\R.U<)OK6LJQ--1B3RPRRS"25H:U"4DQ*PN<Q/PA$9^^B)@_?8G,+,<6SS
MLRP>/$J#B7\WIG.29/XDSG"1COQL,G4CMZT-(W0"SJU<]GN#6ZK1+3FU S;R
MIXP6IT8M-PZ>;BCC%G")SGZI*2(UY*UBAF$"$V[6>#W48-P8CFQ=,!V^].\-
MCBRH!K5V1FOO&AOMW*B/]EY^TUG8C_3N0_".JC43FG H$1H.LY%'5&>NW<;(
MQAG:2AJT1[>L\'L$RB;@>2FE.6QL@?X+M_@.4$L#!!0    ( "N 6UH;7EA>
M# 8  &42   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;+58VW+;-A#]
ME1TED[[(%$E=(B>V9^Q<IGU(K8F2]J'3!XB$1(Q!@@% R^[7=Q<@*5I7NY,^
MV")!X.SNV;,+D!=KI>],QKF%AUP6YK*765N^&PQ,DO&<F4"5O, G2Z5S9O%6
MKP:FU)RE;E$N!W$83@8Y$T7OZL*-S?35A:JL% 6?:3!5GC/]>,.E6E_VHEXS
M\%6L,DL#@ZN+DJWXG-OOY4SCW:!%247."R-4 9HO+WO7T;N;$<UW$_X0?&TZ
MUT"1+)2ZHYO?TLM>2 YQR1-+" Q_[OD'+B4!H1L_:LQ>:Y(6=J\;],\N=HQE
MP0S_H.2?(K7996_:@Y0O627M5[7^E=?QC DO4=*X_[#V<X=Q#Y+*6)77B]&#
M7!3^ESW4/'063,,#"^)Z0>S\]H:<EQ^995<76JU!TVQ$HPL7JEN-SHF"DC*W
M&I\*7&>OYE8E=YF2*=?F%_CTHQ+V\6)@$9F>#Y(:Y<:CQ =0HAB^J,)F!CX5
M*4^? @S0I=:ON/'K)CZ*^)$G 0RC/L1A/#J"-VSC'#J\X0OBA+^N%\9J%,;?
M^T+V@*/]@%0L[TS)$G[9PVHP7-_SWM6;5]$D?'_$W5'K[N@8^K/3<AQE&D 7
MZ,VK:1R]?=]$_T'E.=:%FP'?,DX#)2L>01A4GM:\L/(16&4SI<4_/ 6K\)&I
M.%0E74?3L!^&[@],QI $4$MX#6$01E R#?=,XN3$FS%D)H!K*3U(VEG3G0(X
M"&A:6.E-WBO+@>H7(K]D@!=N$*M1F "^83,RE7ZL(_E=@6U&/"*FN##,=0$#
M:X[XFB=*HU !NQI8#/V1H[^<M NH/)XON&[5!P%\K+0H5J=F#OMN1D-C:\0P
MR2G,+;<:LB98UU*B<\^U$Q^PP_"RK'2289<Z8F_<V'/1UUE8"YME7#K&2_;H
M#."O5I@ORQY "K80DF1#P/CPGAM+ON+MU_EW2D-&S*Z9@6(G \RE>3L.& $K
M4L<<"L.>(>S9%Z;O<"NZ72ZYHV*FU4JS'&X+^,P7NL*- ^+I/AI0,^A "J+
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MTP1\GRME=@/:8/@%>/8_4$L#!!0    ( "N 6UJ+W_"_X@4  )L/   9
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M1DX05/]H-.5* \#5XMW]K9A/Q]%!BFX 4YFF96,(TJN TX,LTUB9PA"HY38
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MJTA/X*[+M6!_V+=JT#<S@4LJ+I[/1^)7[NBHB:D-40MRQ#04G4R)^_"T8[+
M1*:IEVQ[ +K+O>"ZY%(K AV76QQI-[H*75/4DC/IT]O<M28M$R!<Z'(97)B(
M7X2>:SC!2RYYO65^KG&U7C;4E$!6 !2+0Z:_Z'HX9K9"[HA\<UV :+-3.!+A
MY(KG.Z15D[%ZY&H4GNU&\?&P^=A8#^6TG53K;BU]T*\/RJ=5@034..%$ O7X
M!)D^#2Q52NB4K8NY_!VYDCS,;+/2?D+HA^[0/DH0E!R<DCVEAS>#NVFJ%^-K
M0OMX3I_Q=11 'R^\[$%'T!*F,,S32+V&9V#;+#\I:KP;'\"3G0.E_A  % DJ
MW8;:;8Z@],S;*WF][A@,"\(#-,*A1WB#HXL>7@Z3@TSWI-!VN"TO'*M-4T!(
MM]Q7S* @G;%74J#:RMS/+7*]KJE<>LX@CF+]+$_!H1(X7:BV+)UX*@1/>UX!
M4$%\,-H3PPOUJ(J*QD+D->P/H\- N2N0PX!H;_!C8HL7AY4?#!/2I8W OK4B
M$L.4O&^KCF)#PH]][W3>%K30PGDZ &C:[N8V=#<H^C1,EF<\_\$CBP?*/AZ.
M>[^;>,^SK?%0/)GON98A&1SR?:]98U"%]JDQ0?>L?4:5-@B%[WMZ-LN")F%!
MPSQ\GHQ?4"TYP'([Z&J:;2;7H\6>\H_;R>GHIJ_ZN3YP6,^#L)_V<SPV$VD,
M-V+X/9<A[+2U[Q>*UCE=").FAW+N4?MV^'P]F+5#D: >O#29+]>^=K;S\9D)
MG#CF4V,\Y7&3P"F6HKFUNBV =\J4#Q+R#WW J\CF[O<.C;V&O;OG[9CM>^W_
M4_F0IZGJ,#-:R4:>Y_2_I/(D[C5B X1P(N L$9Q/:[K=N;/OOL$3CQ]7L,^H
MQNSZ">4?/?UP=TNU;42%36S+)L]"B\P"82 .LSX'>.XP8.!0X5.9IYRH(?^/
M>DMM'LK\05$2H-_"7L810.6;TK#& ZL"[Z:=)!_OQ_8QDF<QP#X<9OEAV!)=
M2_]!;'A"P11,EG+[SB?XQ.C[W!=$"F4M,FJXE@WZ!(*3)K+P<ULKP;?"!X^K
M>4B19F\,_^I'-Y@0VJ%NS,@(I>:+9I5.1A@U4> M'4"/"JD-58\2TT]@9/^,
MDER+<)5YXYU#8[K9=30#WRJJD3"5 K/V7@:5IXHR*!*AN5U*J[L'7DZE&X.(
MY%3.=/N0KW6??QMASYC/4\LA$/@Y9IUQ]\XH:%U,$9/9I\;RR*&XN/>F$_(:
M0?]3DZW]E!E2<""9U9[*<,>H+<[UKT7I%CD9Q>A!EXV%X^6#U#EU)B/Q'NT@
M=15!3,!>&*9MV34,5AUBUV<Q]0Q<LO<1X/#O\T>*2NY8>3^P @%87VN>N??/
M,AE20\G+](4%:#K\24'1QO3PU0=GSX,<-KM_WY JVP%K_ZC43^)<%GQ&J/;+
MP4L69D5CCQ\K=PEV[')ZT;)W\YFG52UU3D[KJ$%]W+_XHKOG\*8-%]NAUSVG
MP&6/V7TC1PK +IDSY'K%^9R#;9LQ ZZA=W\=J:6I/Y82%/44^- 9"^^]C:(N
MM0I#I?T2+\$K$%PW_KV%-P$QVUL@^9%4>'G1/20*5O4H>G>@[&U?O_<RYU2]
MIQ?7=C3T!O6J]U*;&SQZ=4^5&CV:?[_=W>W^=\ [_U)\O]S_UX(?9<V/ 7.U
MPM;Q:'Y]Z9_VMU]<6?$K<C"^*PN^W"@)XJ<%^'U5EJ[]0@=T_V?B[7\!4$L#
M!!0    ( "N 6UKB%5&\R@@  ((8   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;*U967/;.!)^]Z] :9(YJAB*IT0YMJML3[*3U.2H>(Z:VMH'B(0D
M;DB" X"6/;]^NQLD15J2[9K9%Q$DT(VOO[Y ZFPKU5>]$<*PN[*H]/ED8TQ]
M.IWJ="-*KEU9BPIF5E*5W,"M6D]UK03/2*@LIH'GS:8ESZO)Q1D]^ZPNSF1C
MBKP2GQ7335ER=7\E"KD]G_B3[L&7?+TQ^&!Z<5;SM;@1YM?ZLX*[::\ERTM1
MZ5Q63(G5^>32/[V*<#TM^"T76ST8,[1D*>57O'F7G4\\!"0*D1K4P.%R*ZY%
M4: B@/%GJW/2;XF"PW&G_2W9#K8LN1;7LO@]S\SF?)),6"96O"G,%[G]2;3V
MQ*@OE86F7[:U:WU8G#;:R+(5!@1E7MDKOVMY& @DWA&!H!4("+?=B%#^R V_
M.%-RRQ2N!FTX(%-)&L#E%3KEQBB8S4'.7/PLP"1]-C6@"Y],TU;NRLH%1^3\
M@'V0E=EH]J;*1#96, 40/9*@0W(5/*KQ1Y&Z+/0=%GA!](B^L+<L)'WAHY:Q
M?U\NM5'@_/\<,M*JB ZKP(0XU35/Q?D$(EX+=2LF%]]^X\^\UX\ C'J T6/:
M'Z'^<3D_=%EKW-N\XE4J["W[92/8M2QK7MVS#=>,LX*>0^K">,73O,C-/<LK
M=JUXM6S4O<,^0MZ\%TH+&*<2<DV;O%HSN6*^%SKSP(,\:;@")5@AX#'Q 3K2
MHLEP)<S!5KB%7*WR5&B'U4K"54-RW$+2UY#"QF'('U?IAO$J&\ZP@B^EXD:J
M' S"R=AS/&^\+T18GG(C,F8DN[S\C:7_^O 9TJ!JP"K3* 32VH=:8)%NZEHJ
MP\R.DV^_20)__EJS.J\%DLJ^UPT (I(<AH0!(-C*(2E<'GBO/[YOV;U<*R$0
M,4WXK]D/+C&^OZ EWX_9JWNPF1FA2K92LF0WHC:B7 K%*,[]A0/I;I 3)FNJ
M4@!=B0J<@HR:K22GB+3!VL56\&-5TAI>D&KMLC?@M9+X4;A_S>\1AW6+.8P1
MN7W!?#> JE(4N'4-L'A5-:6#"OBR0#>S$K.\P*C1AA>%U8MNTLWROU!:$3%*
M 1BLCA8 A(>R$0H1$[*7EBDC00,85):Y(0P-L&T!VD#--1.]):!W*1BO(9KN
MZ!& >,&"A1OVB.5M*SZF&O;L=;JCK*AYGH%G4JXW#%E5F ^9J*7.*;A?,&^@
M'A"0'K"VD"I#-L ;5=M/R'%'R-UN<@@L#(.E$-2\L N!4?"DYHKV:K?5J-9&
M::5ED6=D_!4O*+%OL+!K% ,)J) V>+HJ27Z  12$3^ ]3JG;EH9/%7O?0(S/
M*= 29Y@)## *)= B]!Y, 7!+X)N;JSUK7/;NL.4'%C_8!V)F6>30GC*,\5PI
M<2M3"BV8J;+E/7C) !8T#T(F S=@S*(?DLX/+MKR@6I',"/#_4>LN<0<)M@?
MI<O\SHF'[#(;;IBX,Y3TM&HO?!C?K9:6T-!KR1_B6MAGS\85_)]Q06ZT03&W
M$;]'*W4OBJ1#)7$_&:IA7E9M1(_3P:I:0BF"PI_#D8[B4=S5.13[0:UK&9LS
M]T"+2H4R^8JJ^R KNF3L@Z"MDU!CJJ]H!)Q["A!14%"Z(M=3N6-RCP5K!B!/
M"ZXU[#O.2<!M5$Z92C7B[Z>F,\S-:C=OIP/G6#'AZ9]-#@10>5NQ+Z*2MSR5
M:AQ9/,/(D'W.%S;GD0GJSP#+#!LB;/83K-["X7?8\@GC-2^7*L_6T (_ "<\
MW30::-,6DQ)XLN_WL T'D8T+L^^Y04SJ?"B@6$DTM?Q:T*F[N'?9Y3&BK&)L
M"P)X);\ATQH"!&Q,(3 QB>@04Q2=J;C5D!$E4KFN\K^H<6";47@<?R57KQK,
M%JW15Q14X<.@ G81J:SH/&.E+:8BY\N.PE9VULMR<Q3Y.,XA_2&3VU/)LJ41
MYI_I'YVOJ[8,K'*ES3CU>XVR$FV%T ]5OX=S$F8GTNUB2*&%T*)EB>TZ%>"@
MK.W%O;I^D]TAXAEXB3Q0AJD;]TQU"JC!V**V%P86%Q8/>.$3; MIA:>37HE#
MM]'N%JG!;18'M]'']J'?L$O.X&&0[HXI#TO!LDW[;I?6N]_I01JBUE5[)._B
M](G.W5HZ:G<(8@7U36XI(&V[I)=FB&_=1YTV?\ODTY.WK=0?)/5F3^KDY]T.
M!);D4?;DT[CDV#7@&2>(YG0-YWA-_.3D[9 (6GAZ<EG"F3S_BW?EC9(4!X,D
M#1P_CG:_X>+D'?5134UI/S%])TEF^#N/\7?FG_PR2.$68.P$R9RND3>#:^0
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MRP:'=7)L@/>5Q3+I;SC </Q??P502P,$%     @ *X!;6N64+Q\6#P  U$(
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M-)0H;%PUOJE;K+L"WG*9!M+1XQQ-!_+#^-WNJO25Z4_Z^3F.1E*(:ZX2L+@
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MIJ)E WJ_-%0IW8(/Z ??^=]02P,$%     @ *X!;6I5(R,!< P  <P<  !D
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M\&(YMZ8#R]J$QIL0:K F<E)S41Z\I5M)=GXY3;,/CQ_A0>RDWCJX4T+/$T_
M?)T4 \BJ!\G? ,ER^&:TKQQ\T266+P$28C32R@^T5OE)Q%LL8IAD9Y"G^?0$
MWF0,<Q+P)C\>)OQ]O7;>TF_QSVL1]WC3U_&X52Y=(PI<1-0+#NT.H^7[=]EY
M>G6"[71D.SV%_J-%.0V2S6)X+>S?*X0;4S="[Z$2#@3_Q&1;0D$UM'+=AG9Q
M@TW#-A\\&;U_-\OS](I!PC:[^@@MU=O"P]!B@SNS =;_JCU:+13<XPYURUY+
MY,OL\^P\)AYR8%28'5I'<X'J(;270JD]T >P;I39(SKH*@,USRAJ 5FW-=#
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MC4>+V5#8]K[6;KRIPQUI93QN7&%9A"\-"^!\8XS?;]A ?VE>_@=02P,$%
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MP5_@RCPNFO+D"^B^YF"@\)XH+\%^I>BQ%N5,1CEK(3/&\H%0>,NJ^\!+-Q&
M"&,/NYMA43(4QGN3%AJ,%N>=QR+L\]'RZ-<?LM#(3Q@+^8EB(2/1]#\U8R](
M@T:^W8O!6!?;INPTI7KLOHN&/I?$,_IZORNI$,NB8&04H>J=LR.+1NN\[B=2
MP:SMN"H3.2'U'3%0YR3E43OC9!0XJG2^Q#V4:;T\.SF'?YY-BA2KIGA+K,Y5
MJ7L8GN;OQF!%+\>_-+K;/% )7.NM)"T&K$SX=W2>AFHHZN!B#LB#*/:H9 [D
M%.K_&'5+1L(O'%H8J5[V>?!$@3F8*3/%$-IN[:?O&A_ED%46$J$E@SV:#4M
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M #V%9>++S]$)>QM6937W3UDM81:B 0P18;Z4B3HD+O"\@BYS>P7_Q4A'L!Z
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MVE&/#<.2'C4TWH#VYYKN43?Q!.MG<OH34$L#!!0    ( "N 6UHFDA0$+P4
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M[]WVLB(:SR7[3C-3SH.S #+,2<W,G6R^8-?/Q/&EDFG_"TV;.XX#2&MM)._
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M5P)GK,M?'^2G77[8]S)F.--"H@DI2X1)68'BD%?KR0!O%\H5\/Z&R;\6;_"
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MLW5\]0N)2>E'"KX\)_L4/$@\RR+VAK*Q3S);][JT>C?N5<'25""A@B[H07K
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ME[IQ"*R'#U_<)7Y'ZS<F"$OZ)&C3../T(#3+(!QZ&$JB"3R@%.I6FH9I<U_
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M7TSS '3_3/2*59V_FM?*TD7OQ1V]K*B= >UOE+*#X@*,;_7B7U!+ P04
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MS@'M*Z7L=N(V:/\J)-\!4$L#!!0    ( "N 6UH(SFR@] P  .>C   9
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M'$H3*)J^;X#R";QC^@0>U"> TB(HC4)I#$KC4)I T71!*I_ L_L$/[Z&TEY
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M0-D#N!]+:?83>T'U93/Y'U!+ P04    "  K@%M:8X9FX90"  #Z"   &0
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MI@+D[QM*Q>.)FE?6\VG_?U!+ P04    "  K@%M:6O8[;'X"  "T!@  &0
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M*TPY(1\)%+BD#3>WLOV*O9^QX\LEU_X+;1\;$L@;;635@ZV"BHENI)L^#UN
M4?("(.H!T;Z N ?$WFBGS-N:44.S5,D6E(NV;&[B<^/1U@T3[A7G1ME39G$F
MNQ:&BA5;<(0+K=%HH** *RF+EG$.'V#>/2_()?P;>SA#0QG71S;P?CZ#PX,C
M.  FX*Z4C;9,.@V,5>GN"O)>T66G*'I!T0SS$XA'QQ"%4;(#/MT?'C^'!S8W
M0X*B(4&1YXOW3= Q?+?%=?AYD_.F8&(U).L(?ETLM%'VS_R]RW9W3[+['E>M
MY[JF.4Z(+4>-:HTD>_]N=!I^VI6$_T3V+"7QD)+X-?;L2DFM(:=*/3K_:\H;
MW&6X8SGS+*Z;K+-H/!J':;#>=O)6U#.)R2 Q>57BG324VQ]Q>#OJWVZ7RF0O
ME6]%=2J#K4)T3? ;52LF-'!<6EQX<C8FH+K&TBV,K'UM+J2QE>ZGI>W%J%R
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M+W-H965T-3@N>&ULK51=;]L@%/TKB%53*VW!'VDS9;:E--G4/$R*FG5[F/9
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MT>0:(]7U:1<86?NKOI'&-HZ?EO9I ^42[/Y62G,,7/<,CV7V&U!+ P04
M"  K@%M:F>S_#C<-  "WJ   &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6S%G5MOVS@>Q;\*X1WLS@!M;%WM=), ;<1+@>E,,&EG'A;[H-B,+526/)*<
M-(-^^)5LQ30EF;:ZIY,^-+9,_DA9Q[S\CTA=/*;9YWPA94&^+.,DOQPLBF+U
M9CC,IPNY#/.S="63\I/[-%N&1?DVFP_S52;#V2;3,A[:HY$_7(91,KBZV!R[
MR:XNTG411XF\R4B^7B[#[.F=C-/'RX$U>#[P6S1?%-6!X=7%*IS+6UE\6MUD
MY;OACC*+EC+)HS0AF;R_'+RUW@A_4F78I/@]DH_YWFM2G<I=FGZNWKR?70Y&
M58UD+*=%A0C+/P_R6L9Q12KK\6<-'>S*K#+NOWZFL\W)ER=S%^;R.HW_B&;%
MXG(P&9"9O _7<?%;^BAD?4)>Q9NF<;[YGSS6:4<#,EWG1;JL,Y<U6$;)]F_X
MI?XB]C*XAS+8=0;[U Q.G<$Y-8-;9W";&;P#&;PZ@W=J"7Z=P6]DL,\/9!C7
M&<:-#(YS(,.DSK"1RW![.3;7,@B+\.HB2Q])5J4N:=6+C2 VN<M+&"65=F^+
MK/PT*O,55[=%.OV\2..9S/)_$?KG.BJ>R&OR=C:+*FV%,7F?;'\AE=)^#&01
M1G'^$_F!#$F^"#.9DR@AGY*HR%^5!\O7'Q?I.@^367XQ+,H*5L4,IW5EZ+8R
M]H'*6#;YD";%(B<TF<F9#AB69[8[/?OY]-[91F(@IV?$LE\1>V2[Y--M0'[\
M0:O\]D]'5:_-X%NY*L'>!NST @=F\*_3XHR,_ W8[@6F)WP5CM7X*GY/"WD2
MG9U.[_=]\-/!ZOLX2!-F&I-W9\2>'/QV#9)S=K\H9U.$<Z"(ZW2Y+'\JFQ\6
M^<_;N[S(R@;ZOQUU?;<%N=V@JM=ZDZ_"J;P<E-U2+K,'.;CZYS\L?_3O+KTB
M80$21I$PAH1Q)$R 8)KHW)WH7!/]671Y);I7SS^Y<%TLTBSZ2\[(CV7#O#WZ
M$_EZ^-?SSEA*7T4B80$21K<P?P.K1G</5]9DM/UW,7S8E]O)*3FR@@($T[3D
M[;3D]=#2*LS(0QBOY49#LS2.PRPG*YEM553)Z5#SN964L;"^DD+" B2,;F&3
M/:&,SD960TVG).+(:@D03!.2OQ.2;Q32+^OE7:F3])X\I$64S$E6321(.9PD
M,IPNMIHI]5.-0;J48Z3W50X2%B!AU&\W,0W9((OC2)@ P31YC7?R&AL'6A_+
MN7J^SIY.&FJ-D5I"P@(DC")A# GC2)@ P33937:RFQA;M=LPEE6;5CS+;]-1
M=FG.R.FK.20L0,+H%C;>[]0:[5<[A><W.KVC$ &JLW;-SW?7_-QXS=\6KXN%
M?/TAS#[+@OQZ?R^SJC^[R=)Y%BZ[KKV1U_?:(V$!$D:1,(:$<21,@&":]JR1
M"M&-C!W=318]A(4D-W%9QE(F!3'KD83)C-RL[^)HNOLL/](_UE4 "19*"Z T
M"J4Q*(U#:0)%TV6[%UFVC(WF^SQ?A\ETTUE.M3EE4HJV/!@])YBF>9&?'*,P
M%]M;JDA: *71FN8;NM:.).==T0EHQ02*IBO+5LJRC<KB69KG9)6E4REG^:M2
M2W4#&"[3=5)TBL9(["T:)"V TBB4QFK:_L#,&D_:\D(6*E T75XJ@&\90[6;
M %C9-D5ITMW^0,/V4%H I5$HC=6T_:;*;PL)&I)'T70AJ:"\98[*_U+V<\^M
M%+G/TN6NI>K4%33X#J4%4!JM::8IH]41>!_;MMV42SN9ZWM^8W8I4-77=: "
MZI8YHGYDN/Z57*>/,MD,V\NV9Q4F3Z_(SS]?=XH$&DZ'T@(HC4)I#$KC4)I
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M3=7.Y6&T#VYP$S2 L[;33/[]VD!" ,<A$56E-I#/A^^<SY=CE\F&LE]\28@
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MW@J0FS1E8G^%"=]-+==Z&;B+ERNE!^S99,V6>(_J87TKJ&>7*%&<8B9CGH'
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M(>T%]TT%:-X.].$5Z/3T85<.WRF*I;G$D,3))E/Y";4<+2]*+LWUP,'XE;Y
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MW-5 \:UM6I=<Z1;87F[T5PH1QD#?7W&N7@?F <UWS_1?4$L#!!0    ( "N
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M=/<:YVXGXB,$/=3'GY#KN(,60HOKW?L==/I5R/L&;W AY&VAZ?34*7TO,A+
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MXU.LVDV1?89I2OX-52LF-.&P1,B@]PF)J::,-ATC*U>)%M)@77/- O\\H&P
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M)WA!9-NXM!,M:ON4KX3&QL .M]CK@30&^'TM,-C=Q&S0=X^+;U!+ P04
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MAF\&*@T WB^%T,\#TV1V7R'3_P%02P,$%     @ *X!;6D;:*\5G!@  UB\
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M=&AYO+G;8^X=;XY[S/VCS9VIP1EN'5BWX+G/\#ZM*5?!2Q_1>R8$6A+.OZN
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M9$!%PBCBL)HX4WPSQR,=8%I\2F K&M=(H]PS]D7?O(TGCJ='!"E$4DL0]?4
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M\U%IK*0UGEKM31N:BM6^$;7[1L6%%)XVD2Q>80FY;GWF9.=TELV>U0-LSLG
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M3X7\KJ9%W5G@-]DOB,::TC^(Q E\;_\1:MVK8R2F\5Y9C=98[H#S ;K-Y6$
M%XV5T3@(X]SR76O_B6K?J&L@6RV"^8E#B:O*6!Y.NBF,C7&9![7 ,BW[(*RF
M9:;CU,M*7GVKNU&MY3UF<Y)S"1)+G7'ART\<*[NU<B#HHFAXIE3(]JFX3&2'
M"TPMD/,QI6(S4#U4W3.'_P!02P,$%     @ *X!;6L2NOP , P  ^@D  !D
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MD6L#]7S.F-Q-] ;MOX?D)U!+ P04    "  K@%M:7;<6H54-   WV0  &0
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MRM_?I&6HUQ>J#3RFV=^KNW_Z/U!+ P04    "  K@%M:JQKJ\%<#  "D$0
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M9TIRV+):V%O5?(>NGHGCRY0P_DF:+C:D)*N-564'Q@Q*+MLW>^YT. ",QF\
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M7&TA81$D# /!.MI>-=I>G:\M7:VH>3DZJJP=:J)4$Z8>E=8*.%=:2%@$"<-
ML(ZTUXVTUZ=*NZ(4Y?I-)'M1KS1"DBP_L@=?_V?G][6 A]'!S-KLN=I!PB)(
M& :"=;3SO?85UON?J%7MH&FL]]>%9/%W]%2D4J!_T"F1E)U][A8+2@M!:1$H
M#4/1NIH?I"W\=PFH:BR4W)"T$)06@=(P%*TK=]#*'< [Z)II]]#VAL^6$)(6
M@=(P%*TK89M"\JV9B^F<T\^XU,D]](UP]< :%SUCN1*S\MN]&H*FD$!I(2@M
M J5A*%I7[#:/Y _?QSV#YI5 :2$H+0*E82A:5^XV8^7;4U:_E_F2<L162)@
M;/_Z@*="E&H92(:V)8\W1% D-H3WYQ3MC9PM/FA:JZ:-#_:2@>_IO^Y^$H$V
MBZ%H75W;K)5O39:<X+-5<<[3G7K8T3Q3'3FZ%X-FLD!I(2@M J5A*%IW ;3I
M+/_R??PX9-9G!DH+06D1* U#T;IRMQDNWYZ- O+CD'FA64T[]+S#'L<;@K8:
M@=(P%*TK:YO=\NWIK=/<>+G,TAC]L5I1KMZS>H6%3!K-0&DA*"T"I6$H6O<<
M1)L?"[QW<>(!:&H,E!:"TB)0&H:B=>5N4V.!-1<#Y,3MC9PMOG^:$^^IUQ]F
MGPC$O<!@?#T:O?DGO7MPABJG?&U.NPD4L[*0U:&CYFYSHN[.G"-[<S_R;W!U
M+J[%5,?T'@A?IX5 &5TII'=QJ8)[7IU\JPJ2;<U)K263DN7F<D-)0KFNH'Y?
M,29?"[J!YOSA]%]02P,$%     @ *X!;6GA,R">E @  U@<  !D   !X;"]W
M;W)K<VAE971S+W-H965T.#@N>&ULK55=;]HP%/TK5E9-K;21#P)=.X@$S:KU
M 0D5=7N8]F"2"['JV)EMH/WWNXY#!AV@5NI+8COW'-]S[-P[V$CUJ L 0YY*
M+O30*XRIKGU?9P645'=D!0*_+*0JJ<&I6OJZ4D#S&E1R/PJ"OE]2)KQD4*]-
M53*0*\.9@*DB>E665#V/@<O-T N][<(]6Q;&+OC)H*)+F(%YJ*8*9W[+DK,2
MA&92$ 6+H3<*K].>C:\#?C#8Z)TQL4KF4C[:R5T^] *;$'#(C&6@^%K##7!N
MB3"-/PVGUVYI@;OC+?MMK1VUS*F&&\E_LMP40^^+1W)8T!4W]W+S'1H]=8*9
MY+I^DHV+O;SR2+;21I8-&#,HF7!O^M3XL ,(^T< 40.(7@+B(X!N ^B^%A W
M@+AVQDFI?4BIH<E R0U1-AK9[* VLT:C?";LL<^,PJ\,<2:)@_#\\8+,Z)J)
MI2933@7Y3$9YSNRQ4$[NA+M;]I#.4S"4<7V!(0^SE)R?79 SP@29,,XQ0 ]\
M@SE99C]K]A^[_:,C^X<1F4AA"DV^B1SR?0(?Q;2*HJVB<722,86L0[KA)Q(%
M47P@H9O7P[L'X.GKX=$)-=WV?+HU7_<-Y_-K--=&X1_S^Y#?CB\^S&>KR+6N
M: 9##\N$!K4&+_GX(>P'7P]Y]9YDZ3N1[?D8MS[&I]B3*:@,A,%*1N0"?R"3
M%6@H@;+B\AF 9'@)%9NOS+%K[.A#QV^+Z3H).@%>L/6N7R>3>*M?[T2VYU>O
M]:MWTJ_)VQURA+T=@\+.Y0M__H\).E?[,>FAF'X;X]3X.Q6O!+6L.X?&'%?"
MN%+1KK;-:537Y!?K8VQ:KL?\HW$=;T+5D@E-."R0,NA<8D;*=1$W,;*JZ^I<
M&JS2];# Q@O*!N#WA91F.[$;M*T\^0M02P,$%     @ *X!;6KMX[ XG P
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M=#%R H<XG31-^(>*A6YR<GW1N>>FB'L&=8^-YR$S!R0.SE0+3(Z4R""E6Z9
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M-)-L\Z#XVLYV#USI2='>KO3T#\( ]/J"<W5X,!]H_T^8_@]02P,$%     @
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MI8"(60'QT>3@]I68RSMX[""$5$%G+:(,$'$;0"W[<9AKM3;6MPH,1@D@8A8
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MA(/R0E;%S K_X<\TB>+$K_%>=%5U#F6?FRLCRZ?709]>97W['U!+ P04
M"  K@%M:YN*DT* "   %-0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSS=I-;N) $(;AJR ?(*:KNJN:4<AJ-ME&N8!%FA\%L&5[E.3V@\@"/FL6
MLXG\K5#;HORN'J.F'U_*L1D/[7G8'[IA\7DZGH=UM1_'[E==#YM].37#0]N5
M\^7.MNU/S7A9]KNZ:S;OS:[4LEQ:W=_/J)X>[V<N7K^Z\C\3V^WVL"F_V\V?
M4SF/_QA<?[3]^[ O9:P6KTV_*^.ZJC^/M\M#??T(#Y?)U>+Y;5WUSV^AJN<.
M$@B2^8,4@G3^H A!<?Z@!$%I_B"#()L_R"'(YP_*$)3G#UI!T&K^H+!$&9<$
M21.L";0.R'4@\#H@V(% [(!D!P*S Z(="-0.R'8@<#L@W(% [H!T!P*[ ^(=
M"/06U%L(]!;46PCTELF/;0*]!?46 KT%]18"O07U%@*]!?46 KT%]18"O07U
M%@*]!?46 KT5]58"O17U5@*]%?56 KUULEE"H+>BWDJ@MZ+>2J"WHMY*H+>B
MWDJ@MZ+>2J"WHMY*H'=$O2.!WA'UC@1Z1]0[$N@=4>](H'><;'83Z!U1[TB@
M=T2](X'>$?6.!'I'U#L2Z!U1[TB@=T*]$X'>"?5.!'HGU#L1Z)U0[T2@=T*]
M$X'>:?)G)8'>"?5.!'HGU#L1Z)U0[T2@=T*]$X'>AGH;@=Z&>AN!WH9Z&X'>
MAGH;@=Z&>AN!WH9Z&X'>-CEL0J"WH=Y&H+>AWD:@MZ'>1J"WH]Y.H+>CWDZ@
MMZ/>3J"WH]Y.H+>CWDZ@MZ/>3J"WH]Y.H+=/#@L2Z.VHMQ/H[:BW$^B=4>],
MH'=&O3.!WAGUS@1Z9]0[$^B=4>],H'=&O3.!WAGUS@1Z9]0[$^B=)X>]"?3.
MJ'<FT'N%>J]^4N]A_#J6X=;SO<;G_R35X^6[Y?;XZ_+[(KXO5E><Z_N*X>DO
M4$L#!!0    ( "N 6UK"@ QK.@(  &@S   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W;36[;,!"&X:L8V@:6+(JDF"+.INVVS:(74"4Z%JP_D$SJW+Z4G 1H
MD1H-7*#OQH)-<KX1!WAVOOGV-%F_.O;=X+?)/H3I0Y;Y>F_[RJ?C9(>XLAM=
M7X7XU=UG4U4?JGN;B<U&9_4X!#N$=9AK)+<WG^RN>NC"ZO,Q_NS;<=@FSG8^
M67T\;9RSMDDU35U;5R&N9X]#\UO*^CDAC2>7/7[?3OXJ;DBR-Q/FE3\'/)_[
M^FB=:QN[NJM<^%+U<5=V[#(?GCKKT_,EWNAQW.W:VC9C_=#'(ZF?G*T:O[<V
M]%UZ*GIU/CG$&[:GS_SB_*7,N<"X\\Z-DX\3<_;]<2\CF4^OIUC(NM">?\77
MQ%CZXO>S\[0;V_QE=KS>'Z,[+//PV?*X_(Y_G?%K_7?V(2!]%) ^)*0/!>E#
M0_HH(7T82!_7D#[R#:41BJ@YA=2<8FI.036GJ)I36,TIKN846'.*K((BJZ#(
M*BBR"HJL@B*KH,@J*+(*BJR"(JN@R%I09"THLA8460N*K 5%UH(B:T&1M:#(
M6E!D+2BR2HJLDB*KI,@J*;)*BJR2(JNDR"HILDJ*K)(BJZ+(JBBR*HJLBB*K
MHLBJ*+(JBJR*(JNBR*HHLFJ*K)HBJZ;(JBFR:HJLFB*KILBJ*;)JBJR:(FM)
MD;6DR%I29"TILI8464N*K"5%UI(B:TF1M:3(:BBR&HJLAB*KH<AJ*+(:BJR&
M(JNAR&HHLAJ*K-?_4];OXWCXQ_'+,^VK=GC)SY8_V-S^!%!+ 0(4 Q0    (
M "N 6UH'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ *X!;6B%; /KN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *X!;6IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  K@%M:7;HJSUL+  ")0   &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *X!;6CQ7K<ZM
M!@  HA\  !@              ("!GA,  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( "N 6UK.7.'\D ,  "L1   8              "
M@8$:  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  K@%M:
M'A@"F,@$   9$P  &               @(%''@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ *X!;6LK(N"_P @  G D  !@
M     ("!12,  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M "N 6UJXO9BLNPH  *5D   8              " @6LF  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  K@%M:?CF0Z*X)  "&,@  &
M            @(%<,0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ *X!;6I$3=;ZU"@  \SH  !@              ("!0#L  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "N 6UI\2\S59@(  (L&
M   8              " @2M&  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  K@%M:+'5HOD,"  "*!@  &0              @(''2
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "N 6UJS<Z6H
MBP@  )(3   9              " @4%+  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ *X!;6KDZC JW"   ?Q8  !D
M ("! U0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  K
M@%M: >]PLLT>  "C8@  &0              @('Q7   >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "N 6UIMBG^]T08  %42   9
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M970Q."YX;6Q02P$"% ,4    "  K@%M:_B!KOK<'   .%   &0
M    @('^D@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M "N 6UJ+W_"_X@4  )L/   9              " @>R:  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ *X!;6OT[(BAC!   8@L  !D
M             ("!!:$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  K@%M:"9E$!&4,   _(0  &0              @(&?I0  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "N 6UKB%5&\R@@
M ((8   9              " @3NR  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ *X!;6@XWM$WO!   "@P  !D              ("!
M/+L  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  K@%M:
MY90O'Q8/  #40@  &0              @(%BP   >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( "N 6UI8O]P0E 0  (\*   9
M      " @:_/  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ *X!;6@X>F"Y*!   ! L  !D              ("!>M0  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  K@%M:E4C(P%P#  !S!P
M&0              @('[V   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( "N 6UH+BH%6%04  $ +   9              " @8[<  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ *X!;6K(BSCQ#
M(   ,VX  !D              ("!VN$  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  K@%M:;WDIX!T#   R!P  &0
M@(%4 @$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "N
M6UHFDA0$+P4  .(-   9              " @:@% 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ *X!;6BR+1?,2 P  N 8  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( "N 6UKQL98X%P0  .\)   9
M  " @1,? 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M*X!;6OS\$@ZF!   E0H  !D              ("!82,! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  K@%M:+O0/K3D%  "/#P  &0
M            @($^* $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( "N 6UK*9#>VE0,  +<'   9              " @:XM 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ *X!;6G"UK0.P @
M-@@  !D              ("!>C$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  K@%M:",YLH/0,  #GHP  &0              @(%A
M- $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "N 6UKV
M24; T0(  +H)   9              " @8Q! 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ *X!;6L+.C+BQ @  G0<  !D
M     ("!E$0! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N 6UH[Q'O4E0<  $]$   9              "
M@0U5 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ *X!;
M6EQ7;GC; @  A <  !D              ("!V5P! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    "  K@%M:JK?,&>\#  #3$P  &0
M        @('K7P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( "N 6UK..&W>(@0  *L6   9              " @1%D 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ *X!;6EKV.VQ^ @  M 8
M !D              ("!:F@! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    "  K@%M:\DK]<%<"  #I!0  &0              @($?:P$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "N 6UJBB861
M2P(   T&   9              " @:UM 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ *X!;6MJ*OZ<) P  *0D  !D
M ("!+W ! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  K
M@%M:3%HG"#4"   X!0  &0              @(%O<P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( "N 6UJ9[/\.-PT  +>H   9
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M970V,RYX;6Q02P$"% ,4    "  K@%M:Q6GT!GX"  "_!0  &0
M    @('5E0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M "N 6UJ56%3=.@,  +0*   9              " @8J8 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ *X!;6JF2S:'F P  HA0  !D
M             ("!^YL! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    "  K@%M:>JMSX!<%  #W'P  &0              @($8H $ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( "N 6UK[79EL$ 0
M $X1   9              " @6:E 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ *X!;6L&TB[+-!   M2,  !D              ("!
MK:D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  K@%M:
M[#O91LP"  #7!@  &0              @(&QK@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( "N 6UJ%RE=K< ,  "@,   9
M      " @;2Q 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ *X!;6F]W^P9O P  20H  !D              ("!6[4! 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  K@%M:]GGTG]<#  !9#@
M&0              @($!N0$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( "N 6UJF.1V\P ,  )$,   9              " @0^] 0!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ *X!;6D;:*\5G
M!@  UB\  !D              ("!!L$! 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    "  K@%M:38:/2QT$  !)$@  &0
M@(&DQP$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( "N
M6UH'B-M5>08   XU   9              " @?C+ 0!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ *X!;6NL3&VD) P  *PH  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( "N 6UI=MQ:A50T  #?9   9
M  " @7;C 0!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @
M*X!;6JL:ZO!7 P  I!$  !D              ("! O$! 'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6Q02P$"% ,4    "  K@%M:!)7E 5,"   /!@  &0
M            @(&0] $ >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4
M Q0    ( "N 6UH%F_.>6P(  "0&   9              " @1KW 0!X;"]W
M;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ *X!;6JJA:+0G!0
MBR@  !D              ("!K/D! 'AL+W=O<FMS:&5E=',O<VAE970X-RYX
M;6Q02P$"% ,4    "  K@%M:>$S()Z4"  #6!P  &0              @($*
M_P$ >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( "N 6UJ[
M>.P.)P,  &X'   9              " @>8! @!X;"]W;W)K<VAE971S+W-H
M965T.#DN>&UL4$L! A0#%     @ *X!;6AX&-8!@!   6Q   !D
M     ("!1 4" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4
M"  K@%M:<0)2A6<#  ",%@  #0              @ ';"0( >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( "N 6UJ7BKL<P    !,"   +              "
M 6T- @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "N 6UI 3+G QP8  $X[   /
M              "  58. @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  K
M@%M:YN*DT* "   %-0  &@              @ %*%0( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  K@%M:PH ,:SH"  !H,P  $P
M            @ $B& ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     8@!B
+ .4:  "-&@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>245</ContextCount>
  <ElementCount>419</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100100 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RisksAndLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stock-Based Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards</Role>
      <ShortName>Stock-Based Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Agreements Related to Intellectual Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AgreementsRelatedToIntellectualProperty</Role>
      <ShortName>Agreements Related to Intellectual Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - CIRM Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CirmGrants</Role>
      <ShortName>CIRM Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Stock-Based Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables</Role>
      <ShortName>Stock-Based Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Risks and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Risks and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Summary of Significant Accounting Policies - Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Summary of Significant Accounting Policies - Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Summary of Significant Accounting Policies - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Fair Value of Financial Instruments - Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Fair Value of Financial Instruments - Changes in Level 3 Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Changes in Level 3 Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Fair Value of Financial Instruments - Level 3 Fair Value of the Private Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Level 3 Fair Value of the Private Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Stock-Based Awards - Weighted-Average Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails</Role>
      <ShortName>Stock-Based Awards - Weighted-Average Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Stock-Based Awards - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Awards - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Stock-Based Awards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Awards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Stock-Based Awards - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails</Role>
      <ShortName>Stock-Based Awards - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Stock-Based Awards - RSU Activity (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails</Role>
      <ShortName>Stock-Based Awards - RSU Activity (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Stock-Based Awards - PSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails</Role>
      <ShortName>Stock-Based Awards - PSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Stock-Based Awards - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Awards - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Warrants - Summary of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>Warrants - Summary of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Warrants - Summary of Changes in Rocket Warrants to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails</Role>
      <ShortName>Warrants - Summary of Changes in Rocket Warrants to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Income Taxes - Reconciliation Between Effective Tax Rates and Statutory Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Effective Tax Rates and Statutory Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996155 - Disclosure - Leases - Finance Lease - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails</Role>
      <ShortName>Leases - Finance Lease - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996165 - Disclosure - Leases - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996175 - Disclosure - Leases - Leases Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails</Role>
      <ShortName>Leases - Leases Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996185 - Disclosure - Leases - Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996195 - Disclosure - Leases - Maturity of Finance Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails</Role>
      <ShortName>Leases - Maturity of Finance Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996205 - Disclosure - Leases - Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Leases - Lease Related to Cash Flow Information, Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Lease Related to Cash Flow Information, Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996225 - Disclosure - Agreements Related to Intellectual Property - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails</Role>
      <ShortName>Agreements Related to Intellectual Property - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996235 - Disclosure - CIRM Grants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails</Role>
      <ShortName>CIRM Grants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996245 - Disclosure - Renovacor Acquisition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Renovacor Acquisition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996275 - Disclosure - Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996285 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996295 - Disclosure - 401(k) Savings Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>401(k) Savings Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996305 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="rckt-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996315 - Disclosure - Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails</Role>
      <ShortName>Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="rckt-20241231.htm">rckt-20241231.htm</File>
    <File>rckt-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img173888082_0.jpg</File>
    <File>img173888082_1.jpg</File>
    <File>img173888082_2.jpg</File>
    <File>img173888082_3.jpg</File>
    <File>img173888082_4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="879">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rckt-20241231.htm": {
   "nsprefix": "rckt",
   "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "rckt-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "rckt-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 341,
   "keyCustom": 78,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 36,
   "memberCustom": 39,
   "hidden": {
    "total": 19,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.rocketpharmaceuticals.com/20241231": 3,
    "http://fasb.org/us-gaap/2024": 13
   },
   "contextCount": 245,
   "entityCount": 1,
   "segmentCount": 76,
   "elementCount": 847,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 879,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "100060 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
     "longName": "100070 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100080 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "100090 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
     "longName": "100100 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100110 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_4f55fe36-f663-484f-9f05-d10d67ae3a41",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4f55fe36-f663-484f-9f05-d10d67ae3a41",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NatureOfBusinessAndBasisOfPresentation",
     "longName": "995455 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RisksAndLiquidity",
     "longName": "995465 - Disclosure - Risks and Liquidity",
     "shortName": "Risks and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:RisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:RisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments",
     "longName": "995485 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet",
     "longName": "995495 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill",
     "longName": "995505 - Disclosure - Intangible Assets and Goodwill",
     "shortName": "Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses",
     "longName": "995515 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "995535 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards",
     "longName": "995545 - Disclosure - Stock-Based Awards",
     "shortName": "Stock-Based Awards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants",
     "longName": "995555 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare",
     "longName": "995565 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes",
     "longName": "995575 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3",
     "longName": "995585 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:LessorSalesTypeLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:LessorSalesTypeLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995595 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AgreementsRelatedToIntellectualProperty",
     "longName": "995605 - Disclosure - Agreements Related to Intellectual Property",
     "shortName": "Agreements Related to Intellectual Property",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:AgreementsRelatedToIntellectualPropertyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:AgreementsRelatedToIntellectualPropertyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CirmGrants",
     "longName": "995615 - Disclosure - CIRM Grants",
     "shortName": "CIRM Grants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RelatedPartyTransactions",
     "longName": "995635 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/KSavingsPlan",
     "longName": "995645 - Disclosure - 401(k) Savings Plan",
     "shortName": "401(k) Savings Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995655 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995665 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995675 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables",
     "longName": "995685 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables",
     "longName": "995695 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables",
     "longName": "995705 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpensesTables",
     "longName": "995715 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables",
     "longName": "995725 - Disclosure - Stock-Based Awards (Tables)",
     "shortName": "Stock-Based Awards (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/WarrantsTables",
     "longName": "995735 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables",
     "longName": "995745 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables",
     "longName": "995755 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995765 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995795 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_479a9661-05cc-4e37-ac7c-06504e617691",
      "name": "rckt:NumberOfClinicalStagePrograms",
      "unitRef": "U_Program",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_479a9661-05cc-4e37-ac7c-06504e617691",
      "name": "rckt:NumberOfClinicalStagePrograms",
      "unitRef": "U_Program",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Risks and Liquidity - Additional Information (Details)",
     "shortName": "Risks and Liquidity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "995825 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Summary of Significant Accounting Policies - Investments - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Summary of Significant Accounting Policies - Goodwill - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails",
     "longName": "995875 - Disclosure - Summary of Significant Accounting Policies - Segment Reporting - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
     "longName": "995885 - Disclosure - Fair Value of Financial Instruments - Measured on Recurring Basis (Details)",
     "shortName": "Fair Value of Financial Instruments - Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_8258573d-c82d-41f2-ba1a-9620f4a7976c",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8258573d-c82d-41f2-ba1a-9620f4a7976c",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
     "longName": "995895 - Disclosure - Fair Value of Financial Instruments - Changes in Level 3 Liabilities Measured at Fair Value (Details)",
     "shortName": "Fair Value of Financial Instruments - Changes in Level 3 Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1d96ec30-1174-441b-a600-2e0b2c261eb0",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
     "longName": "995905 - Disclosure - Fair Value of Financial Instruments - Level 3 Fair Value of the Private Warrants (Details)",
     "shortName": "Fair Value of Financial Instruments - Level 3 Fair Value of the Private Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
     "longName": "995915 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails",
     "longName": "995935 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)",
     "shortName": "Intangible Assets and Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "longName": "995955 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "rckt:ResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "rckt:ResearchAndDevelopmentCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails",
     "longName": "995965 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Details)",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "rckt:InvestmentPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995985 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:CommonStockVotingRightsNumberOfVotesPerShare",
      "unitRef": "U_Vote",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails",
     "longName": "995995 - Disclosure - Stock-Based Awards - Weighted-Average Assumptions for Stock Options (Details)",
     "shortName": "Stock-Based Awards - Weighted-Average Assumptions for Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_5d022c41-2abf-4b66-9515-d9ce9e263b44",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d022c41-2abf-4b66-9515-d9ce9e263b44",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
     "longName": "996005 - Disclosure - Stock-Based Awards - Stock Option Activity (Details)",
     "shortName": "Stock-Based Awards - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_e6d96dee-383b-4648-a425-7febaa2eae01",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7196725c-a392-4a09-b1a2-b1a1aec580da",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Stock-Based Awards - Additional Information (Details)",
     "shortName": "Stock-Based Awards - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_7196725c-a392-4a09-b1a2-b1a1aec580da",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7196725c-a392-4a09-b1a2-b1a1aec580da",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
     "longName": "996025 - Disclosure - Stock-Based Awards - RSU Activity (Details)",
     "shortName": "Stock-Based Awards - RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d4b68ab5-2b41-4121-b8f8-df6a4d864157",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails",
     "longName": "996035 - Disclosure - Stock-Based Awards - RSU Activity (Parenthetical) (Details)",
     "shortName": "Stock-Based Awards - RSU Activity (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
     "longName": "996045 - Disclosure - Stock-Based Awards - PSU Activity (Details)",
     "shortName": "Stock-Based Awards - PSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_ae6b3516-7a34-414f-a317-8b7d0434e4e3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ae6b3516-7a34-414f-a317-8b7d0434e4e3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails",
     "longName": "996055 - Disclosure - Stock-Based Awards - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Awards - Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails",
     "longName": "996065 - Disclosure - Warrants - Summary of Warrants Outstanding (Details)",
     "shortName": "Warrants - Summary of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails",
     "longName": "996075 - Disclosure - Warrants - Summary of Changes in Rocket Warrants to Purchase Common Stock (Details)",
     "shortName": "Warrants - Summary of Changes in Rocket Warrants to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_55db9cf5-dacb-451e-bc48-da645969b76a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_61647b0b-b5df-4485-8420-e20842c8ff39",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
     "longName": "996085 - Disclosure - Warrants - Additional Information (Details)",
     "shortName": "Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_c72cfefa-5df0-4873-ad35-93e437d2fecc",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c72cfefa-5df0-4873-ad35-93e437d2fecc",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "996095 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_845cdb5d-eeb4-4f91-b37f-77626c44f34b",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "longName": "996105 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "996115 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails",
     "longName": "996125 - Disclosure - Income Taxes - Reconciliation Between Effective Tax Rates and Statutory Rates (Details)",
     "shortName": "Income Taxes - Reconciliation Between Effective Tax Rates and Statutory Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996135 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996145 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
     "longName": "996155 - Disclosure - Leases - Finance Lease - Additional Information (Details)",
     "shortName": "Leases - Finance Lease - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2f0c010b-87c8-42b0-9da6-1c012fc63603",
      "name": "rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LessorSalesTypeLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
     "longName": "996165 - Disclosure - Leases - Operating Leases - Additional Information (Details)",
     "shortName": "Leases - Operating Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails",
     "longName": "996175 - Disclosure - Leases - Leases Cost (Details)",
     "shortName": "Leases - Leases Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails",
     "longName": "996185 - Disclosure - Leases - Maturity of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Maturity of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails",
     "longName": "996195 - Disclosure - Leases - Maturity of Finance Lease Liability (Details)",
     "shortName": "Leases - Maturity of Finance Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails",
     "longName": "996205 - Disclosure - Leases - Balance Sheet Information Related to Leases (Details)",
     "shortName": "Leases - Balance Sheet Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails",
     "longName": "996215 - Disclosure - Leases - Lease Related to Cash Flow Information, Lease Term and Discount Rate (Details)",
     "shortName": "Leases - Lease Related to Cash Flow Information, Lease Term and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rckt:LeaseSupplementalCashFlowInformationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "rckt:LeaseSupplementalCashFlowInformationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
     "longName": "996225 - Disclosure - Agreements Related to Intellectual Property - Additional Information (Details)",
     "shortName": "Agreements Related to Intellectual Property - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_3d43c909-ed76-4cd3-8437-c11a815217b6",
      "name": "rckt:ResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3d43c909-ed76-4cd3-8437-c11a815217b6",
      "name": "rckt:ResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails",
     "longName": "996235 - Disclosure - CIRM Grants - Additional Information (Details)",
     "shortName": "CIRM Grants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_a067d039-439e-4ceb-af2b-1cde0cbe0191",
      "name": "rckt:GrantAwardForClinicalDevelopmentSupport",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a067d039-439e-4ceb-af2b-1cde0cbe0191",
      "name": "rckt:GrantAwardForClinicalDevelopmentSupport",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
     "longName": "996245 - Disclosure - Renovacor Acquisition - Additional Information (Details)",
     "shortName": "Renovacor Acquisition - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails",
     "longName": "996275 - Disclosure - Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Renovacor Acquisition - Purchase Price allocation of Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_0a90aae5-1098-4d84-8da8-2fb68133b607",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "996285 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails",
     "longName": "996295 - Disclosure - 401(k) Savings Plan - Additional Information (Details)",
     "shortName": "401(k) Savings Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "996305 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails",
     "longName": "996315 - Disclosure - Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)",
     "shortName": "Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4ff701-3d41-47cd-8660-59707d56d468",
      "name": "rckt:NonCommercialGeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rckt-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "rckt_AAVCurrentGoodManufacturingPracticecGMPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AAVCurrentGoodManufacturingPracticecGMPMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The lease agreement relating to the rental space in Cranbury, New Jersey dedicated to AAV Current Good Manufacturing Practice (cGMP).",
        "label": "AAV Current Good Manufacturing Practice (cGMP) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts payable and accrued expenses",
        "label": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73",
      "r76",
      "r1117"
     ]
    },
    "rckt_AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount and amortization of premium on investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums excluding accretion income related to cash equivalents , Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of discount and amortization of premium on investments, net",
        "label": "Amortization of premium on investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r155",
      "r682"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r86",
      "r161",
      "r677",
      "r712",
      "r713"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income / (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r11",
      "r20",
      "r529",
      "r532",
      "r587",
      "r708",
      "r709",
      "r1062",
      "r1063",
      "r1064",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "rckt_AcquisitionExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AcquisitionExpensesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of acquisition expenses, payable current as of the end of the period.",
        "label": "Acquisition Expenses, Current",
        "terseLabel": "Acquisition related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "rckt_AdditionalInformationOfCIRMGrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AdditionalInformationOfCIRMGrantsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Information of CIRM Grants [Abstract]",
        "terseLabel": "CIRM Grants [Abstract]",
        "documentation": "Additional Information Of C I R M Grants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Additional Paid in Capital, Total",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r910",
      "r1187"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1124",
      "r1188"
     ]
    },
    "rckt_AdditionalPaymentsAvailableUnderGrantAwardsProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AdditionalPaymentsAvailableUnderGrantAwardsProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Payments Available under Grant Awards Program",
        "documentation": "Additional Payments Available under Grant Awards Program",
        "terseLabel": "Additional payments available under grant awards program"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_AdenoAssociatedVirusProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AdenoAssociatedVirusProgramsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AAV Member",
        "label": "Adeno-associated Virus Programs [Member]",
        "documentation": "Adeno-associated virus programs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "rckt_AdjustmentOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AdjustmentOfRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance lease right of use asset",
        "documentation": "The amortization expense of right-of-use assets during the period.",
        "label": "Adjustment of Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expense in connection with warrant issuance",
        "terseLabel": "Expense in connection with warrant issue",
        "label": "Adjustment of Warrants Granted for Services",
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r430"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_AggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value Abstract",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r976",
      "r1009"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "rckt_AgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of advance notice period to terminate the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Agreement Termination Notice Period",
        "terseLabel": "Termination notice period"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_AgreementsRelatedToIntellectualPropertyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AgreementsRelatedToIntellectualPropertyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreements Related To Intellectual Property Abstract",
        "label": "Agreements Related to Intellectual Property [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_AgreementsRelatedToIntellectualPropertyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AgreementsRelatedToIntellectualPropertyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AgreementsRelatedToIntellectualProperty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for agreements related to intellectual property.",
        "label": "Agreements Related to Intellectual Property [Text Block]",
        "terseLabel": "Agreements Related to Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1004",
      "r1013",
      "r1017",
      "r1025"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r472"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accretion of discount on convertible notes",
        "terseLabel": "Accretion of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r91",
      "r392",
      "r1135"
     ]
    },
    "rckt_AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss and credit limited to utilize due to change in control as per Internal revenue code under section 382.",
        "label": "Annual Limitations Under Section 382 Of The Internal Revenue Code Amount",
        "terseLabel": "Annual limitations under section 382 of IRC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r134",
      "r157",
      "r186",
      "r226",
      "r235",
      "r261",
      "r265",
      "r306",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r524",
      "r526",
      "r556",
      "r671",
      "r773",
      "r869",
      "r870",
      "r910",
      "r933",
      "r1112",
      "r1113",
      "r1143"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets [Abstract]",
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease assets and liabilities [Abstract]",
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "verboseLabel": "Lease assets and liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r162",
      "r186",
      "r306",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r524",
      "r526",
      "r556",
      "r910",
      "r1112",
      "r1113",
      "r1143"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of financial instruments",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Fair value of financial instruments",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r896"
     ]
    },
    "rckt_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "At-the-Market Offering Program",
        "terseLabel": "At-the-Market Offering",
        "documentation": "An \"at-the-market\" offering is an offering of securities into an existing trading market for outstanding shares of the same class at other than a fixed price on, or through the facilities of, a national securities exchange, or to or through a market maker otherwise than on an exchange.",
        "label": "At-the-Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r962"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r962"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r962"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "rckt_August2021WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "August2021WarrantMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2021 Warrant",
        "documentation": "Name of the class or type of warrants issued in August 2021.",
        "label": "August 2021 Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r349",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r518",
      "r890",
      "r891"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r518",
      "r890",
      "r891"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock consideration (in shares)",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "rckt_BusinessAcquisitionExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "BusinessAcquisitionExchangeRatio",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to exchange of shares in a business combination, for example but not limited to, one share exchanged to two or two shares exchanged to one.",
        "label": "Business Acquisition, Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition related general and administrative costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Total consideration",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r10"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity consideration, value",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3"
     ]
    },
    "us-gaap_BusinessCombinationDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDescriptionAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Abstract]",
        "label": "Business Combination, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovacor Acquisition",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r519"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liability",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "documentation": "Amount of lease obligation assumed in business combination."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of in process research and development recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed in Process Research and Development",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total",
        "negatedLabel": "Deferred tax liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating right-of-use assets recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherIntangibleAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other intangible asset recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Intangible Asset",
        "terseLabel": "Other intangible asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "label": "Property and equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "rckt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of working capital includes other receivables, prepaid expenses, account payable and accrued liabilities recognized as of the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Purchase consideration",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovacor Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r98",
      "r99"
     ]
    },
    "rckt_CIRMGrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CIRMGrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C I R M Grants Abstract",
        "label": "CIRM Grants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CirmGrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for California institute for regenerative medicine grants.",
        "label": "California Institute for Regenerative Medicine Grants [Text Block]",
        "terseLabel": "CIRM Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued purchases of property and equipment, ending balance",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r665",
      "r1152"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r674",
      "r740",
      "r768",
      "r910",
      "r933",
      "r1058"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash proceeds from acquisition of business, net of cash paid",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r152",
      "r853"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1127"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "rckt_CashCashEquivalentsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CashCashEquivalentsAndInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash, cash equivalents and short-term and long-term investments.",
        "label": "Cash, Cash Equivalents, and Investments",
        "terseLabel": "Cash, cash equivalents, short-term and long-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r95",
      "r182"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r95"
     ]
    },
    "rckt_CashFlowOperatingAndFinancingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CashFlowOperatingAndFinancingActivitiesLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating and Financing Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities [Abstract]",
        "documentation": "Cash Flow Operating And Financing Activities Lessee Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposit",
        "label": "Certificates of Deposit, at Carrying Value",
        "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r158",
      "r159",
      "r160",
      "r186",
      "r210",
      "r215",
      "r218",
      "r220",
      "r228",
      "r229",
      "r306",
      "r361",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r398",
      "r399",
      "r402",
      "r405",
      "r412",
      "r556",
      "r720",
      "r721",
      "r722",
      "r723",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r760",
      "r782",
      "r804",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r1048",
      "r1068",
      "r1076"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r228",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r410",
      "r412",
      "r720",
      "r721",
      "r722",
      "r723",
      "r885",
      "r1048",
      "r1068"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value per warrant (in dollars per share)",
        "label": "Exercise price per share (in dollars per share)",
        "terseLabel": "Warrant to purchase shares of common stock price per share (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "rckt_ClassOfWarrantOrRightGrantDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ClassOfWarrantOrRightGrantDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are issued, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Grant Date",
        "terseLabel": "Grant date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued (in shares)",
        "terseLabel": "Warrant to purchase shares of common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in shares)",
        "verboseLabel": "Class of warrant outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price per share of warrants exercised during the period.",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Exercised",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price per share of warrants forfeited during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Forfeited",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants exercise price per share",
        "documentation": "The weighted average exercise price per share of warrants granted during the period.",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights, Granted",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "rckt_CommercialGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CommercialGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial General And Administrative Expense",
        "documentation": "Commercial general and administrative expense.",
        "terseLabel": "Commercial general and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r360",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 14)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r125",
      "r673",
      "r759"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r353",
      "r354",
      "r839",
      "r1106",
      "r1111"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Consideration",
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930",
      "r1072",
      "r1073",
      "r1075",
      "r1124",
      "r1186",
      "r1188"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r760"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r760",
      "r779",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 180,000,000 shares authorized; 106,453,818 and 90,282,267 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r676",
      "r910"
     ]
    },
    "rckt_CommonStockVotingRightsNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CommonStockVotingRightsNumberOfVotesPerShare",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share of common stock owned granted to owner.",
        "label": "Common Stock, Voting Rights, Number of Votes Per Share",
        "terseLabel": "Number of voting right for each share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Savings Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/KSavingsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Savings Plan",
        "label": "Compensation Related Costs, General [Text Block]",
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets (liabilities) [Abstract]",
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r166",
      "r168",
      "r173",
      "r667",
      "r687",
      "r688"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for concentrations of credit risk and off-balance sheet risk.",
        "label": "Concentrations of Credit Risk and Off-balance Sheet Risk [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-balance Sheet Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r857"
     ]
    },
    "us-gaap_ConstructionPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment",
        "label": "Construction Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "rckt_ConsultingAgreementAssetIdentificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConsultingAgreementAssetIdentificationMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement, Asset Identification Services",
        "documentation": "Consulting agreement with related party for asset identification services.",
        "label": "Consulting Agreement, Asset Identification [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConsultingAgreementBusinessDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConsultingAgreementBusinessDevelopmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement, Business Development Services",
        "verboseLabel": "Consulting Agreement [Member]",
        "documentation": "Consulting agreement with related party for business development services.",
        "label": "Consulting Agreement, Business Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConsultingAgreementEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConsultingAgreementEffectiveDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consulting agreement effective date",
        "label": "Consulting Agreement Effective Date",
        "documentation": "Consulting Agreement Effective Date"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConsultingAgreementTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConsultingAgreementTerminationDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement Termination Date",
        "documentation": "Consulting Agreement Termination Date",
        "terseLabel": "Consulting agreement termination date"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConsultingFeeMonthlyInstalment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConsultingFeeMonthlyInstalment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Fee Monthly Instalment",
        "documentation": "Consulting Fee Monthly Instalment",
        "terseLabel": "Consulting fee monthly instalment"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConvertibleNotes2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConvertibleNotes2021Member",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Convertible Notes",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ConvertibleNotes2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ConvertibleNotes2022Member",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Convertible Notes",
        "documentation": "Written promise to pay a new note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party expenses",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r374",
      "r400",
      "r593",
      "r612",
      "r670",
      "r854",
      "r856"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_CowenAndCompanyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "CowenAndCompanyLLCMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen and Company, LLC",
        "documentation": "The Company entered into a sales agreement with respect to an at-the-market offering program.",
        "label": "Cowen and Company, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1040"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1032"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1032"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1033"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1039"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1034"
     ]
    },
    "rckt_DanonDiseaseCIRMGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DanonDiseaseCIRMGrantMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Danon Disease C I R M Grant [Member]",
        "documentation": "Grant funding through the California Institute for Regenerative Medicine (\"CIRM\"). The Company was granted funds under a CLIN2 grant award to support the clinical development of gene therapy for Danon Disease.",
        "terseLabel": "DD CIRM Grant"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_DanonDiseaseLicenseAgreementWithUCSDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DanonDiseaseLicenseAgreementWithUCSDMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement for Danon Disease",
        "documentation": "A research and collaboration agreement with Lund University and Johan Richter, M.D., PhD. under which Dr. Richter.",
        "label": "Danon Disease License Agreement with UCSD [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of convertible notes into common stock",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r184",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r359",
      "r360",
      "r370",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r386",
      "r393",
      "r394",
      "r396",
      "r566"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r123",
      "r124",
      "r191",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r908",
      "r1069",
      "r1107",
      "r1108",
      "r1109",
      "r1134",
      "r1136"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r908",
      "r1069",
      "r1134",
      "r1136"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r191",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r908",
      "r1069",
      "r1107",
      "r1108",
      "r1109",
      "r1134",
      "r1136"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r43",
      "r46",
      "r69",
      "r110",
      "r111",
      "r191",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r908",
      "r1069",
      "r1134",
      "r1136"
     ]
    },
    "rckt_December2021WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "December2021WarrantsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2021 Warrants",
        "documentation": "Name of the class or type of warrants issued in December 2021.",
        "label": "December 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses and credit carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "rckt_DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards",
        "label": "Deferred Tax Assets Operating Loss Carryforwards, Cumulative Amount Subject To Expiration",
        "terseLabel": "Cumulative net operating loss, subject to expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss, subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "rckt_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research and Development",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible tax credit carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Subject To Expiration",
        "terseLabel": "Tax credit carryforwards, subject to expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "rckt_DeferredTaxAssetsWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DeferredTaxAssetsWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warrants.",
        "label": "Deferred Tax Assets Warrants",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "negatedTotalLabel": "Net deferred income tax asset (liability)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Matching employee contributions",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Disclosure401kSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of matching employee contributions",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash security deposit",
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r226",
      "r240",
      "r265",
      "r869",
      "r870"
     ]
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "rckt_DerivativeLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DerivativeLiabilitiesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Classified as Liabilities",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative Liabilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesAndFairValueTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Derivatives and Fair Value [Text Block]",
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r60",
      "r61",
      "r62",
      "r65",
      "r190",
      "r205"
     ]
    },
    "rckt_DetailedInformationOfWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "DetailedInformationOfWarrantsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Information Of Warrants Abstract",
        "label": "Detailed Information of Warrants [Abstract]",
        "terseLabel": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Direct Costs of Leased and Rented Property or Equipment",
        "documentation": "Amount of expense incurred and directly related to generating revenue by lessor from operating lease of rented property and equipment."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Awards",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r433",
      "r464",
      "r465",
      "r467",
      "r893"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Awards [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r962"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r962",
      "r1005"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Net loss per share attributable to common stockholders - basic (in dollars per share)",
        "terseLabel": "Net loss per share - basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r207",
      "r210",
      "r218",
      "r219",
      "r220",
      "r225",
      "r516",
      "r522",
      "r537",
      "r538",
      "r668",
      "r689",
      "r860"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Net loss per share attributable to common stockholders - diluted (in dollars per share)",
        "verboseLabel": "Net loss per share - diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r210",
      "r218",
      "r219",
      "r220",
      "r225",
      "r516",
      "r522",
      "r537",
      "r538",
      "r668",
      "r689",
      "r860"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r222"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r221",
      "r223",
      "r224"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r895"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation of Income Tax Benefit Computed at Statutory Federal Income Tax Rate to Income Taxes [Abstract]",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalNetOperatingLossTrueUpIncomeTaxRate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal tax rate of net operating loss applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation at Federal Net Operating Loss True-up Income Tax Rate",
        "verboseLabel": "Federal NOL true-up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal tax at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r482",
      "r507",
      "r895"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r895",
      "r1071",
      "r1119"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r486",
      "r895",
      "r1071",
      "r1119"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r1071",
      "r1119",
      "r1120"
     ]
    },
    "rckt_EffectiveIncomeTaxRateReconciliationReturnToProvision": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return to provision",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision",
        "documentation": "Effective income tax rate reconciliation return to provision,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in state tax apportionment",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r895",
      "r1071",
      "r1119"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489",
      "r1071",
      "r1119"
     ]
    },
    "rckt_EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTransferPricingAdjustments",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesReconciliationBetweenEffectiveTaxRatesAndStatutoryRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transfer pricing adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Transfer Pricing Adjustments",
        "terseLabel": "Transfer pricing adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_EmpireStateBuildingLeaseAgreementAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "EmpireStateBuildingLeaseAgreementAmendmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On March 26, 2021, the Company entered in Amendment No. 1 to the ESB Lease Agreement (\"ESB Lease Amendment\").",
        "label": "Empire State Building Lease Agreement Amendment [Member]",
        "terseLabel": "ESB Lease Agreement Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_EmpireStateBuildingLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "EmpireStateBuildingLeaseAgreementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On June 7, 2018, the Company entered into a three year lease agreement for office space in the Empire State Building in New York, NY (the \"ESB Lease Agreement\").",
        "label": "Empire State Building Lease Agreement [Member]",
        "terseLabel": "ESB Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_EmployeeNonemployeeAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "EmployeeNonemployeeAndDirectorMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employees, Non-employees and Directors",
        "documentation": "Employee is an Executive of the entity that is appointed to the position by the board of directors. Nonemployee is a person not directly employed but is in a service capacity. And director is a person serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Employee, Nonemployee and Director [Member]",
        "terseLabel": "Employees, Non-employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Unrecognized share-based compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period expected to recognize unrecognized stock-based compensation expense",
        "label": "Weighted average period expected to recognize unrecognized share-based compensation cost",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Entities",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r147",
      "r170",
      "r171",
      "r172",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r227",
      "r307",
      "r308",
      "r340",
      "r414",
      "r505",
      "r506",
      "r513",
      "r514",
      "r515",
      "r517",
      "r521",
      "r522",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r587",
      "r685",
      "r708",
      "r709",
      "r710",
      "r729",
      "r804"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r976",
      "r1009"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "rckt_ExercisePricePerShareWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ExercisePricePerShareWarrantsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Per Share Warrants Abstract",
        "label": "Exercise Price Per Share, Warrants [Abstract]",
        "terseLabel": "Exercise Price Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r901"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r901"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r553",
      "r899"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r553",
      "r899"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r551",
      "r552",
      "r554",
      "r599",
      "r600",
      "r601",
      "r881",
      "r882",
      "r887",
      "r888",
      "r889",
      "r896",
      "r901"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r544",
      "r896",
      "r1129",
      "r1132"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r420",
      "r425",
      "r541",
      "r552",
      "r599",
      "r887",
      "r888",
      "r889",
      "r896"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r420",
      "r425",
      "r541",
      "r542",
      "r552",
      "r600",
      "r881",
      "r882",
      "r887",
      "r888",
      "r889",
      "r896"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r541",
      "r542",
      "r543",
      "r544",
      "r552",
      "r601",
      "r881",
      "r882",
      "r887",
      "r888",
      "r889",
      "r896",
      "r901"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 Fair Value of the Private Warrants",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1127"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Fair Value of Warrant Liabilities [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r544",
      "r896",
      "r1129",
      "r1132"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of Renovacor",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r553"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value adjustments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r553"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, beginning of period",
        "periodEndLabel": "Fair value, end of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r553"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r551",
      "r552",
      "r554",
      "r599",
      "r600",
      "r601",
      "r881",
      "r882",
      "r887",
      "r888",
      "r889",
      "r896",
      "r901"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsChangesInLevel3LiabilitiesMeasuredAtFairValueDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132"
     ]
    },
    "rckt_FinanceLeaseCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "FinanceLeaseCostsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease costs.",
        "terseLabel": "Finance Lease Costs [Abstract]",
        "label": "Finance Lease Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r577",
      "r909"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of Finance Lease Liability [Abstract]",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total finance lease liability",
        "terseLabel": "Finance lease, liability",
        "totalLabel": "Total finance lease liability",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance current lease liability",
        "label": "Finance lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Lease Payments of Finance Lease Liability",
        "label": "Maturity of Finance Lease Liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance noncurrent lease liability",
        "label": "Finance lease liability, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease payments",
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfFinanceLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from finance lease",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r580"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use asset, net",
        "verboseLabel": "Finance right-of-use assets",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "label": "Finance lease right-of-use asset",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right of use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r577",
      "r909"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate - finance lease",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r909"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term - finance lease",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r909"
     ]
    },
    "rckt_FinanceLeasesEstimatedRentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "FinanceLeasesEstimatedRentPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental payments due for the reporting period under finance leases.",
        "label": "Finance Leases, Estimated Rent Payments",
        "terseLabel": "Estimated rent payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r395",
      "r410",
      "r534",
      "r555",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r686",
      "r877",
      "r896",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r911",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1125",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "rckt_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-on Public Offering",
        "documentation": "A follow-on public offering is an issuance of additional shares made by a company after an initial public offering (IPO).",
        "label": "Follow-on Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r784"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and Administrative",
        "terseLabel": "General and Administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r319",
      "r666",
      "r870",
      "r878",
      "r898",
      "r910",
      "r1092",
      "r1099"
     ]
    },
    "rckt_GoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "GoodwillAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill Abstract",
        "label": "Goodwill [Abstract]",
        "terseLabel": "Goodwill [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of acquired intangible asset",
        "label": "Goodwill and Intangible Asset Impairment",
        "totalLabel": "Goodwill and Intangible Asset Impairment, Total",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets and Goodwill [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets and Goodwill",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1102"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r330",
      "r878"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r320",
      "r326",
      "r330",
      "r878",
      "r898"
     ]
    },
    "rckt_GovernmentGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "GovernmentGrantsPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants related to receivable of offset amount against research and development expenses.",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_GrantAwardForClinicalDevelopmentSupport": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "GrantAwardForClinicalDevelopmentSupport",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant award for clinical development support.",
        "label": "Grant award for clinical development support",
        "terseLabel": "Grant award for clinical development support"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the additional capital contribution to the entity including issuance costs.",
        "label": "Gross Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds, offering amount"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_GrossProceedsFromSaleOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "GrossProceedsFromSaleOfShares",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from sale of shares",
        "label": "Gross Proceeds from Sale of Shares",
        "documentation": "Gross proceeds from sale of shares."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_GrossProceedsFromSaleOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "GrossProceedsFromSaleOfStock",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from sale of stock",
        "label": "Gross Proceeds from Sale of Stock",
        "documentation": "Gross proceeds from sale of stock."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_HopewellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "HopewellMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease facility located at Hopewell, New Jersey and Cambridge.",
        "label": "Hopewell, New Jersey and Cambridge [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r962"
     ]
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r1066",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "verboseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r103",
      "r897"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r104"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349",
      "r350",
      "r546",
      "r550",
      "r553",
      "r705",
      "r707",
      "r789",
      "r851",
      "r900",
      "r1157"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r546",
      "r550",
      "r553",
      "r705",
      "r707",
      "r789",
      "r851",
      "r900",
      "r1157"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r482",
      "r483",
      "r494",
      "r502",
      "r895",
      "r1122"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r482",
      "r483",
      "r494",
      "r502",
      "r895",
      "r1122"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r477",
      "r482",
      "r490",
      "r491",
      "r492",
      "r496",
      "r501",
      "r508",
      "r510",
      "r511",
      "r512",
      "r725",
      "r895"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r145",
      "r204",
      "r205",
      "r226",
      "r243",
      "r265",
      "r481",
      "r482",
      "r509",
      "r692",
      "r895"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r479",
      "r480",
      "r496",
      "r497",
      "r500",
      "r504",
      "r719"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "rckt_IncreaseDecreaseInFinanceLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "IncreaseDecreaseInFinanceLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Increase (Decrease) in Finance Lease, Liabilities",
        "verboseLabel": "Finance lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) In Operating Lease Liability and Right of Use Assets, Net",
        "documentation": "Increase (decrease) in operating lease liability and right of use assets, net.",
        "terseLabel": "Operating lease liabilities and right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total",
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable for common shares (in shares)",
        "terseLabel": "Warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r220"
     ]
    },
    "rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Performance Stock Units Exercisable for Common Shares",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of performance stock units exercisable for common shares.",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock units convertible for common shares",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted stock units exercisable for common shares.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Restricted Stock Units Exercisable for Common Shares",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options to purchase common shares (in shares)",
        "terseLabel": "Options",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r220",
      "r432"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r338",
      "r339",
      "r879"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning Balance",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "periodEndLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance",
        "totalLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Total",
        "terseLabel": "Gross carrying value",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r338",
      "r879"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1004",
      "r1013",
      "r1017",
      "r1025"
     ]
    },
    "rckt_InotekLexingtonMassachusettsLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "InotekLexingtonMassachusettsLeaseAgreementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On January 4, 2018, in connection with the Reverse Merger, the Company assumed an operating lease for Inotek's former headquarters in Lexington, Massachusetts.",
        "label": "Inotek Lexington Massachusetts Lease Agreement [Member]",
        "terseLabel": "Inotek Lexington Massachusetts Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1029"
     ]
    },
    "rckt_IntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "IntangibleAssetsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets [Abstract]",
        "label": "Intangible Assets [Abstract]",
        "documentation": "Intangible Assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r630",
      "r631",
      "r633",
      "r858",
      "r1102"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible assets",
        "totalLabel": "Total intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and other income, net",
        "terseLabel": "Interest and other income, net",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r235",
      "r239",
      "r245",
      "r265",
      "r565",
      "r869",
      "r870"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r179",
      "r180"
     ]
    },
    "rckt_InvestmentPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "InvestmentPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment payable",
        "label": "Investment Payable Current",
        "documentation": "Investment payable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r715",
      "r716",
      "r717",
      "r718",
      "r815",
      "r816"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r744",
      "r745",
      "r747",
      "r749",
      "r812",
      "r814",
      "r818",
      "r821",
      "r822",
      "r823",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r925"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r744",
      "r745",
      "r747",
      "r749",
      "r812",
      "r814",
      "r818",
      "r821",
      "r822",
      "r823",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r925"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "verboseLabel": "Investments",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1127",
      "r1131"
     ]
    },
    "rckt_LADICIRMGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LADICIRMGrantMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant funding through the California Institute for Regenerative Medicine (\"CIRM\"). The Company was granted funds under a CLIN2 grant award to support the clinical development of gene therapy for LAD-I.",
        "label": "LAD-I CIRM Grant [Member]",
        "terseLabel": "LAD-I CIRM Grant"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment.",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LeaseAreaForInternalProcessDevelopmentAndResearchActivities": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LeaseAreaForInternalProcessDevelopmentAndResearchActivities",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The lease area under agreement for internal process development and research activities.",
        "label": "Lease Area for Internal Process Development and Research Activities",
        "terseLabel": "Area of lease"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LeaseBalanceSheetInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LeaseBalanceSheetInformationTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of balance sheet information related to leases.",
        "label": "Lease Balance Sheet Information [Table Text Block]",
        "terseLabel": "Balance Sheet Information Related to Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r909"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LeaseSupplementalCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LeaseSupplementalCashFlowInformationTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to leases.",
        "label": "Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Lease Related to Cash Flow Information, Lease Term and Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r584"
     ]
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and Finance Leases [Member]",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases [Abstract]",
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity:",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LentiviralVectorProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LentiviralVectorProgramsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LV Member",
        "label": "Lentiviral Vector Programs [Member]",
        "documentation": "Lentiviral vector programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease [Abstract]",
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of renewal of finance lease agreement",
        "label": "Lessee, Finance Lease, Renewal Term",
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of finance lease agreement",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r585"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r585"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Lease Payments of Operating Lease Liabilities",
        "label": "Maturity of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r1137"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of lease agreement",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_LessorSalesTypeLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorSalesTypeLeasesTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeases3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessor, Sales-type Leases [Text Block]",
        "documentation": "The entire disclosure of lessor's sales-type leases."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r186",
      "r306",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r525",
      "r526",
      "r527",
      "r556",
      "r758",
      "r861",
      "r933",
      "r1112",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r126",
      "r679",
      "r910",
      "r1070",
      "r1089",
      "r1133"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r151",
      "r186",
      "r306",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r525",
      "r526",
      "r527",
      "r556",
      "r910",
      "r1112",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "label": "Total liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r1126"
     ]
    },
    "rckt_LicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Abstract",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementForBAG3WithTempleUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementForBAG3WithTempleUniversityMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement For BAG3 With Temple University [Member]",
        "documentation": "License Agreement For BAG3 With Temple University [Member]",
        "terseLabel": "License Agreement for BAG3 ith Temple University"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementForDDWithRGNXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementForDDWithRGNXMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement For DD With RGNX [Member]",
        "documentation": "License Agreement For DD With RGNX [Member]",
        "terseLabel": "License Agreement for DD with RGNX"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement For FA With CIEMAT Group And FIBHNJS [Member]",
        "documentation": "License Agreement For FA With CIEMAT Group And FIBHNJS [Member]",
        "terseLabel": "License Agreement for FA with CIEMAT Group and FIBHNJS"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementForLADIWithCIEMATAndUCLBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementForLADIWithCIEMATAndUCLBMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement for LAD-I with CIEMAT and UCLB",
        "documentation": "A license agreement with CIEMAT and UCL Business PLC for granting the Company worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to lentiviral vectors containing the human LAD-I gene solely within the field of treating LAD-I.",
        "label": "License Agreement for LAD-I with CIEMAT and UCLB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement For LAD I With CIEMAT Group And UCLB [Member]",
        "documentation": "License Agreement For LAD I With CIEMAT Group And UCLB [Member]",
        "terseLabel": "License Agreement for LAD-I with CIEMAT Group and UCLB"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementForPKDWithCIEMATGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementForPKDWithCIEMATGroupMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement For PKD With CIEMAT Group [Member]",
        "documentation": "License Agreement For PKD With CIEMAT Group [Member]",
        "terseLabel": "License Agreement for PKD with CIEMAT Group"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementNumberOfPatents": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementNumberOfPatents",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of patents under the agreement.",
        "label": "License agreement number of patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementOptionsRightExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementOptionsRightExpiryTerm",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of options right to expiry from the date of the license agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "License Agreement Options Right Expiry Term",
        "terseLabel": "Options right expiry term"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_LicenseAgreementsWithCIEMATMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "LicenseAgreementsWithCIEMATMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements with CIEMAT",
        "documentation": "A license agreement CIEMAT, CIBER, and FIISFJD, (collectively, \"CIEMAT\"), granting Rocket worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to lentiviral vectors containing the human PKLR gene solely within the field of treating PKD.",
        "label": "License Agreements with CIEMAT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r123"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Investments, Total",
        "label": "Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r427",
      "r473",
      "r544",
      "r628",
      "r704",
      "r706",
      "r714",
      "r750",
      "r751",
      "r813",
      "r817",
      "r819",
      "r820",
      "r824",
      "r849",
      "r850",
      "r876",
      "r885",
      "r892",
      "r901",
      "r902",
      "r906",
      "r907",
      "r920",
      "r1114",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Dividend Yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-Free Interest Rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r901"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r901"
     ]
    },
    "rckt_MemberOfTheBoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "MemberOfTheBoardOfDirectorsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Member of the Board of Directors - One",
        "documentation": "Member of the entity's board of directors who presides over board meetings and other board activities.",
        "label": "Member of the Board of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_MemberOfTheBoardOfDirectorsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "MemberOfTheBoardOfDirectorsTwoMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Member of the Board of Directors - Two",
        "documentation": "Member of the entity's board of directors who presides over board meetings and other board activities.",
        "label": "Member of the Board of Directors Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r427",
      "r473",
      "r544",
      "r628",
      "r704",
      "r706",
      "r714",
      "r750",
      "r751",
      "r813",
      "r817",
      "r819",
      "r820",
      "r824",
      "r849",
      "r850",
      "r876",
      "r885",
      "r892",
      "r901",
      "r902",
      "r906",
      "r920",
      "r1114",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Mutual Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Municipal Bonds",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash provided by/(used in) investing activities",
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "netLabel": "Net Segment loss and Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r97",
      "r129",
      "r149",
      "r165",
      "r167",
      "r172",
      "r186",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r216",
      "r306",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r516",
      "r522",
      "r538",
      "r556",
      "r684",
      "r781",
      "r802",
      "r803",
      "r931",
      "r1112"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total",
        "terseLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r207",
      "r208",
      "r217",
      "r220",
      "r522"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NewJerseyLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NewJerseyLeaseAgreementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The lease agreement relating to the rental space in Cranbury, New Jersey.",
        "label": "New Jersey Lease Agreement [Member]",
        "terseLabel": "NJ Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NewYorkLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NewYorkLeaseAgreementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On March 31, 2016, the Company entered into a lease agreement for its office and laboratory space at the Alexandria Center for Life Sciences in New York, New York with an initial term ending on July 31, 2022 (the \"NY Lease Agreement\").",
        "label": "New York Lease Agreement [Member]",
        "terseLabel": "NY Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NonCashOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NonCashOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Non Cash Operating Lease Liability",
        "documentation": "Non cash operating lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NonCashOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NonCashOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Operating Lease Right Of Use Assets",
        "documentation": "Non cash operating lease right of use assets.",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NonCommercialGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NonCommercialGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Commercial General And Administrative Expense",
        "documentation": "Non commercial general and administrative expense.",
        "terseLabel": "Non-commercial general and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1004",
      "r1013"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NumberOfClinicalStagePrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfClinicalStagePrograms",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of clinical-stage programs.",
        "label": "Number of Clinical-Stage Programs",
        "terseLabel": "Number of clinical-stage programs"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NumberOfLeastUninterruptedYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfLeastUninterruptedYears",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of least uninterrupted years following regulatory approval to develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country.",
        "label": "Number of Least Uninterrupted Years",
        "terseLabel": "Number of least uninterrupted years"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NumberOfMilestonesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfMilestonesAchieved",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones achieved during the period.",
        "label": "Number of Milestones Achieved",
        "terseLabel": "Number of additional milestones achieved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r1079"
     ]
    },
    "rckt_NumberOfOptionsToRenewLeaseAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfOptionsToRenewLeaseAgreement",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of options to renew lease agreement in consecutive times.",
        "label": "Number of Options to Renew Lease Agreement",
        "terseLabel": "Number of options to renew lease agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NumberOfPreClinicalStagePrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfPreClinicalStagePrograms",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pre clinical-stage programs",
        "label": "Number of Pre Clinical-Stage Programs",
        "documentation": "The number of pre clinical-stage programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reporting unit",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r874",
      "r1079"
     ]
    },
    "rckt_NumberOfStockWarrantsIssuedToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfStockWarrantsIssuedToPurchaseShares",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock warrants issued to purchase shares",
        "label": "Number of Stock Warrants Issued to Purchase Shares",
        "documentation": "Number of stock warrants issued to purchase shares."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_NumberOfWarrantSharesOutstandingAndExercisableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "NumberOfWarrantSharesOutstandingAndExercisableAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrant Shares Outstanding And Exercisable Abstract",
        "label": "Number of Warrant Shares Outstanding and Exercisable [Abstract]",
        "terseLabel": "Number of Warrant Shares Outstanding and Exercisable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Investments, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Unrealized comprehensive gain (loss) on investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r862",
      "r1078",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeasesCostDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r909"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of Operating Lease Liabilities [Abstract]",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Future Lease Payments of Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current",
        "terseLabel": "Operating current lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total lease liabilities",
        "terseLabel": "Operating noncurrent lease liabilities",
        "label": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Total right-of-use asset",
        "verboseLabel": "Operating right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate - operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r909"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesLeaseRelatedToCashFlowInformationLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term - operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r909"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "rckt_OperatingLossCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "OperatingLossCarryforwardsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Abstract",
        "label": "Operating Loss Carryforwards [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_OperatingLossCarryforwardsCumulativeLimitationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "OperatingLossCarryforwardsCumulativeLimitationPeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for operating Loss carryforwards cumulative limitation.",
        "label": "Operating Loss Carryforwards, Cumulative Limitation Period",
        "terseLabel": "Cumulative limitation period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL carryforwards, expiration date",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business and Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized comprehensive gain (loss) on investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized (loss) gain on investments",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r305"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization of property and equipment",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r89"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r978",
      "r1011"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1014"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1014"
     ]
    },
    "rckt_PIPEInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PIPEInvestorsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Investors",
        "documentation": "Private investors in a public equity (PIPE).",
        "label": "PIPE Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PaymentAndExpensesForLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PaymentAndExpensesForLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment and expenses for license fee",
        "label": "Payment And Expenses For License Fee",
        "documentation": "Payment and expenses for license fee."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PaymentForLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PaymentForLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of license fee.",
        "label": "Payment for License Fee"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PaymentsForRepurchaseTreasuryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PaymentsForRepurchaseTreasuryStock",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for reacquisition of callable treasury stock.",
        "label": "Payments For Repurchase Treasury Stock",
        "negatedLabel": "Treasury stock repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "terseLabel": "Shares withheld to pay the payroll tax liability",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash consideration",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r520"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Investments, Total",
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "rckt_PaymentsToAcquireRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PaymentsToAcquireRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payments made to acquire right of use asset.",
        "label": "Payments to Acquire Right of Use Asset",
        "negatedLabel": "Payments made to acquire right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "rckt_PercentageOfAnnualIncreaseInBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PercentageOfAnnualIncreaseInBaseRent",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual increase in base rent under lease agreement.",
        "label": "Percentage of Annual Increase in Base Rent",
        "terseLabel": "Percentage of annual increase in base rent"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PercentageOfCashCommissionOfGrossProceedsFromSaleOfShares",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cash commission of gross proceeds from the sale of the shares pursuant to the sales agreement.",
        "label": "Percentage of Cash Commission of Gross Proceeds from Sale of Shares",
        "terseLabel": "Percentage of cash commission"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Stock Units",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "rckt_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities/class of warrants classified as Pre-fund warrants.",
        "label": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r398"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r760"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r398"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r760",
      "r779",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r675",
      "r910"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "rckt_PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PrivatePlacementAtTheMarketOfferingProgramAndPublicOfferingsAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement At The Market Offering Program And Public Offerings Abstract",
        "label": "Private Placement At-the-Market Offering Program and Public Offerings [Abstract]",
        "terseLabel": "Private Placement At-the-Market Offering Program and Public Offerings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Warrants",
        "documentation": "Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price.",
        "label": "Private Warrants [Member]",
        "verboseLabel": "Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "verboseLabel": "Gross proceeds from sale of common stock",
        "label": "Net proceeds from offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance or sale of stock",
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r720"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r93"
     ]
    },
    "rckt_ProceedsFromMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ProceedsFromMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of cash receipts for milestone payments.",
        "label": "Proceeds from Milestone Payments",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "terseLabel": "Receivables from sale of property and equipment, ending balance",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ProceedsFromSaleOfTreasuryStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfTreasuryStock",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, pursuant to sale of treasury stock",
        "terseLabel": "Sale of treasury stock",
        "documentation": "The cash inflow from the issuance of an equity stock that has been previously reacquired by the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, pursuant to exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, pursuant to exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r665",
      "r1152"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r140",
      "r143",
      "r144"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r154",
      "r683"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r584",
      "r669",
      "r683",
      "r910"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment [Abstract]",
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r140",
      "r143",
      "r681"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PropertyPlantAndEquipmentWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PropertyPlantAndEquipmentWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in property plant and equipment due to subsequent measurement adjustments, including, but not limited to physical deterioration and obsolescence.",
        "label": "Property Plant and Equipment Write-down",
        "terseLabel": "Write down of property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PublicOfferingAndPrivatPlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PublicOfferingAndPrivatPlacementMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering and Privat Placement [Member]",
        "documentation": "Public offering and privat placement.",
        "terseLabel": "Public Offering and Privat Placement"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public offering."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrants",
        "documentation": "Security that gives the holder the right to purchase one share of common stock at a specific exercise price.",
        "label": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "rckt_REGENXBIOIncLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "REGENXBIOIncLicenseMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REGENXBIO, Inc. License",
        "documentation": "A License Agreement with REGENXBIO Inc.",
        "label": "REGENXBIO, Inc. License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r419",
      "r427",
      "r459",
      "r460",
      "r461",
      "r473",
      "r544",
      "r602",
      "r611",
      "r628",
      "r704",
      "r706",
      "r714",
      "r750",
      "r751",
      "r813",
      "r817",
      "r819",
      "r820",
      "r824",
      "r849",
      "r850",
      "r876",
      "r885",
      "r892",
      "r901",
      "r902",
      "r906",
      "r907",
      "r920",
      "r925",
      "r1110",
      "r1114",
      "r1129",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r419",
      "r427",
      "r459",
      "r460",
      "r461",
      "r473",
      "r544",
      "r602",
      "r611",
      "r628",
      "r704",
      "r706",
      "r714",
      "r750",
      "r751",
      "r813",
      "r817",
      "r819",
      "r820",
      "r824",
      "r849",
      "r850",
      "r876",
      "r885",
      "r892",
      "r901",
      "r902",
      "r906",
      "r907",
      "r920",
      "r925",
      "r1110",
      "r1114",
      "r1129",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Realized Investment Gains (Losses), Total",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized gains or losses on investments",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "rckt_ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of construction in process of finance lease right of use asset.",
        "label": "Reclassification of Construction in Process to Finance Right of Use Asset",
        "terseLabel": "Reclassification of construction in process from finance right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncertain Tax Positions [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r973",
      "r1006"
     ]
    },
    "us-gaap_RegulatoryLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RegulatoryLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grant payable",
        "label": "Regulatory Liability, Current",
        "documentation": "The amount for the individual regulatory current liability as itemized in a table of regulatory current liabilities as of the end of the period."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r426",
      "r591",
      "r592",
      "r672",
      "r680",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r778",
      "r780",
      "r811"
     ]
    },
    "rckt_RelatedPartyTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "RelatedPartyTransactionAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction Abstract",
        "label": "Related Party Transaction [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r592",
      "r1142"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r785",
      "r786",
      "r789"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r426",
      "r591",
      "r592",
      "r672",
      "r680",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r778",
      "r780",
      "r811",
      "r1142"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r592",
      "r594",
      "r726",
      "r727",
      "r728",
      "r787",
      "r788",
      "r789",
      "r808",
      "r810"
     ]
    },
    "rckt_RenovacorIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "RenovacorIncMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Renovacor, Inc.",
        "documentation": "Name of the merging entity.",
        "label": "Renovacor, Inc. [Member]",
        "terseLabel": "Renovacor, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segments [Member]",
        "label": "Reportable Segments [Member]",
        "documentation": "Reportable segments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesFinanceLeaseAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r374",
      "r400",
      "r593",
      "r612",
      "r670",
      "r855",
      "r856"
     ]
    },
    "rckt_ResearchAgreementInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ResearchAgreementInitialTerm",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the agreement from the commencement date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Research Agreement Initial Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r1118"
     ]
    },
    "rckt_ResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The research and development costs incurred during the period.",
        "label": "Research and Development costs",
        "verboseLabel": "Research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to expenses related to research and development cost (due within one year or within the normal operating cycle if longer).",
        "label": "Research and Development Costs Current",
        "verboseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ResearchAndDevelopmentCostsPotentialFutureObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ResearchAndDevelopmentCostsPotentialFutureObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone potential future obligations as of the balance sheet date.",
        "label": "Research and development costs - Potential future obligation",
        "terseLabel": "Potential future obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and development",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r851",
      "r869",
      "r1151"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development",
        "terseLabel": "Research and Development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "rckt_ResearchAndDevelopmentIncentives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ResearchAndDevelopmentIncentives",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development income claimed from tax credit against the General Corporation Tax and Unincorporated Business Tax during the period.",
        "label": "Research and Development Incentives",
        "terseLabel": "Research and development incentives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "New York State Life Sciences Research and Development Tax Credit [Member]",
        "terseLabel": "Research and Development [Member]",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r974",
      "r1007"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r975",
      "r1008"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r972",
      "r982",
      "r1015"
     ]
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "terseLabel": "Restricted cash",
        "label": "Restricted cash",
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r837",
      "r838",
      "r1059",
      "r1067"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSU)",
        "terseLabel": "Time Vesting RSU",
        "verboseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r112",
      "r678",
      "r711",
      "r713",
      "r724",
      "r761",
      "r910"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r307",
      "r308",
      "r340",
      "r505",
      "r506",
      "r513",
      "r514",
      "r515",
      "r517",
      "r521",
      "r522",
      "r528",
      "r530",
      "r531",
      "r533",
      "r536",
      "r567",
      "r568",
      "r708",
      "r710",
      "r729",
      "r1188"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r226",
      "r236",
      "r237",
      "r259",
      "r265",
      "r269",
      "r271",
      "r273",
      "r415",
      "r416",
      "r632"
     ]
    },
    "rckt_RisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "RisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Liquidity Abstract",
        "label": "Risks and Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_RisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "RisksAndLiquidityTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RisksAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to risk and liquidity,",
        "label": "Risks and Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_RoyaltiesPayableOnFeesReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "RoyaltiesPayableOnFeesReceived",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties percentage payable on fees received from a priority review voucher issued in connection with or otherwise related to a licensed product.",
        "label": "Royalties payable on fees received",
        "terseLabel": "Royalties payable on fees received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "rckt_SaleOfStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "SaleOfStockAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate offering amount",
        "documentation": "The aggregate offering price of shares issued or sold in the stock transaction.",
        "label": "Sale Of Stock Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price (in dollars per share)",
        "terseLabel": "Share price (in dollars per share)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionPurchasePriceAllocationOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r518"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Consideration for Acquisition",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "rckt_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash , cash equivalents and restricted cash.",
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation Expense by Award Type",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in Level 3 Liabilities Measured at Fair Value",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Income Tax Benefit Computed at Statutory Federal Income Tax Rate to Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r895",
      "r1119"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1127"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Carrying Value of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r338",
      "r339",
      "r879"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r1104"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r584"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/RenovacorAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price allocation of Assets Acquired and Liabilities Assumed",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r785",
      "r786",
      "r789"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureCirmGrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r1118"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Loss Including Significant Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r431",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r113"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Assumptions for Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r108",
      "r110",
      "r111",
      "r112",
      "r158",
      "r159",
      "r160",
      "r228",
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r410",
      "r412",
      "r720",
      "r721",
      "r722",
      "r723",
      "r885",
      "r1048",
      "r1068"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding and Changes in Warrants to Purchase Common Stock",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SecuritiesInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuritiesInvestmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Securities",
        "label": "Securities Investment [Member]",
        "documentation": "This member categorizes all investments in securities to segregate them from other than security investments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r226",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r273",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r339",
      "r351",
      "r352",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r865",
      "r869",
      "r870",
      "r878",
      "r922",
      "r1154",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r743",
      "r746",
      "r748",
      "r814",
      "r818",
      "r822",
      "r825",
      "r836",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r852",
      "r886",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r921",
      "r925",
      "r1115",
      "r1154",
      "r1158",
      "r1159",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r868",
      "r875"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r226",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r248",
      "r250",
      "r251",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r273",
      "r863",
      "r866",
      "r867",
      "r869",
      "r871",
      "r873",
      "r874"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "terseLabel": "Segment reporting expense information used by CODM description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r251",
      "r265"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r251",
      "r265"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r268",
      "r271",
      "r864",
      "r865",
      "r872"
     ]
    },
    "rckt_SeriesAConvertiblePreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "SeriesAConvertiblePreferredSharesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Shares",
        "documentation": "Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Series A Convertible Preferred Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_SeriesBConvertiblePreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "SeriesBConvertiblePreferredSharesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Shares",
        "documentation": "Series B preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Series B Convertible Preferred Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation Expense [Abstract]",
        "terseLabel": "Stock-Based Compensation [Abstract]",
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionOfAcquireeEntityAwardsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at conversion of acquiree entity awards date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Conversion of Acquiree Entity Awards in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Conversion of awards (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Potential shares included in the calculation of EPS",
        "label": "Shares granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Assumptions [Abstract]",
        "label": "Fair Value Assumptions [Abstract]",
        "terseLabel": "Fair Value Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value per share of common stock used in the weighted average fair value assumptions for stock option grants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Value of Common Stock",
        "terseLabel": "Fair value of common stock (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r431",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of shares granted (in dollars per share)",
        "label": "Weighted average grant date fair value of shares granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of Nonvested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested Aggregate Intrinsic Value",
        "terseLabel": "Options unvested"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for non-vested convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but non-vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested Weighted Average Remaining Contractual Term",
        "terseLabel": "Options unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options vested and exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options vested and exercisable at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "rckt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionOfAcquireeEntity",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of other than options (or share units) converted in a business combination.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Than Options, Conversion of Acquiree Entity",
        "terseLabel": "Conversion of awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares issued related to tax (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsPsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsRsuActivityParentheticalDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockbasedCompensationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled (in dollars per share)",
        "terseLabel": "Cancelled or forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "rckt_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options Granted, Weighted Average Remaining Contractual Term",
        "terseLabel": "Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r437",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r468",
      "r469",
      "r470",
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/StockbasedAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "PSU Activity",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options unvested at ending of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options unvested at ending (in dollars per share)",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value amount of options granted",
        "terseLabel": "Total fair value of options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "rckt_ShareholdersEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "ShareholdersEquityDisclosureAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders Equity Disclosure Abstract",
        "label": "Shareholders' Equity Disclosure [Abstract]",
        "terseLabel": "Shareholders' Equity Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_SharesIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "SharesIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuance cost",
        "label": "Shares Issuance Cost",
        "documentation": "Shares issuance cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r1060"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r183"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal use Software",
        "label": "Internal use Software [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "rckt_SpouseOfExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "SpouseOfExecutiveOfficerMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spouse of Executive officer",
        "documentation": "Spouse of a person with designation of executive officer.",
        "label": "Spouse of Executive officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfSegmentLossIncludingSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r148",
      "r226",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r273",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r339",
      "r343",
      "r351",
      "r352",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r865",
      "r869",
      "r870",
      "r878",
      "r922",
      "r1154",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r158",
      "r159",
      "r160",
      "r186",
      "r210",
      "r215",
      "r218",
      "r220",
      "r228",
      "r229",
      "r306",
      "r361",
      "r363",
      "r364",
      "r365",
      "r368",
      "r369",
      "r398",
      "r399",
      "r402",
      "r405",
      "r412",
      "r556",
      "r720",
      "r721",
      "r722",
      "r723",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r760",
      "r782",
      "r804",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r1048",
      "r1068",
      "r1076"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r83",
      "r84",
      "r147",
      "r170",
      "r171",
      "r172",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r227",
      "r307",
      "r308",
      "r340",
      "r414",
      "r505",
      "r506",
      "r513",
      "r514",
      "r515",
      "r517",
      "r521",
      "r522",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r567",
      "r568",
      "r587",
      "r685",
      "r708",
      "r709",
      "r710",
      "r729",
      "r804"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r743",
      "r746",
      "r748",
      "r814",
      "r818",
      "r822",
      "r825",
      "r836",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r852",
      "r886",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r921",
      "r925",
      "r1115",
      "r1154",
      "r1158",
      "r1159",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r227",
      "r568",
      "r632",
      "r715",
      "r741",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r769",
      "r770",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r783",
      "r784",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r926"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r227",
      "r274",
      "r568",
      "r632",
      "r715",
      "r741",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r769",
      "r770",
      "r771",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r783",
      "r784",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r926"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r977",
      "r1010"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock related to acquisition (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r112"
     ]
    },
    "rckt_StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares at-the-market offering programs.",
        "label": "Stock Issued During Period, Shares, At-the-market Offering Programs",
        "terseLabel": "Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Common stock shares issued and sold (in shares)",
        "label": "Common stock shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r112",
      "r720",
      "r804",
      "r831"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "label": "Issuance of common stock related to earnout restricted stock units settlement (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r112",
      "r443"
     ]
    },
    "rckt_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of vesting of restricted stock units.",
        "label": "Stock Issued During Period, Shares, Vesting of Restricted Stock Units",
        "terseLabel": "Issuance of common stock pursuant to vesting of restricted stock units (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock related to acquisition",
        "terseLabel": "Issuance of common stock related to acquisition",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r83",
      "r84",
      "r112"
     ]
    },
    "rckt_StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value at-the-market offering programs.",
        "label": "Stock Issued During Period, Value, At-the-market Offering Programs",
        "terseLabel": "Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to exercise of warrants",
        "label": "Stock Issued During Period Value Common Stock Warrants Exercised",
        "documentation": "Stock issued during period value common stock warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r80",
      "r112",
      "r729",
      "r804",
      "r831",
      "r932"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r83",
      "r84",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of treasury stock",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r79",
      "r80",
      "r112"
     ]
    },
    "rckt_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period pursuant to value of restricted stock units",
        "label": "Stock Issued During Period, Value, Vesting of Restricted Stock Units",
        "terseLabel": "Issuance of common stock pursuant to vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_StockIssuedDuringSharesCommonStockWarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedDuringSharesCommonStockWarrantExercised",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of warrant exercised.",
        "label": "Stock Issued During Shares Common Stock Warrant Exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of warrant (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_StockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commissions",
        "documentation": "Direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs.",
        "label": "Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_StockOptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockOptionAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Abstract]",
        "documentation": "Stock Option Abstract",
        "label": "Stock Option [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_StockOptionsAndRestrictedStockUnitsGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockOptionsAndRestrictedStockUnitsGrantsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options and Restricted Stock Units Grants",
        "label": "Stock Options and Restricted Stock Units Grants [Member]",
        "documentation": "Stock Options and Restricted Stock Units Grants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Restricted Stock Units Grants and Performance Stock Units [Member]",
        "documentation": "Stock options restricted stock units grants and performance stock units.",
        "terseLabel": "Stock Options, Restricted Stock Units Grants and Performance Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "totalLabel": "Total stockholders' equity",
        "label": "Stockholders' Equity Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r100",
      "r762",
      "r779",
      "r805",
      "r806",
      "r910",
      "r933",
      "r1070",
      "r1089",
      "r1133",
      "r1188"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Shareholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r185",
      "r397",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r414",
      "r535",
      "r807",
      "r809",
      "r835"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureLeasesOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental income received under sublease agreements",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r909"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r595"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r595"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r595"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRisksAndLiquidityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "rckt_TaxCreditCarryforwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "TaxCreditCarryforwardAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward Abstract",
        "label": "Tax Credit Carryforward [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardExpirationDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit, expiration date",
        "label": "Tax Credit Carryforward, Expiration Date",
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1141"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockbasedAwardsWeightedaverageAssumptionsForStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r395",
      "r410",
      "r534",
      "r555",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r686",
      "r896",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r911",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1125",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Treasury Stock, Common",
        "terseLabel": "Treasury Stock [Member]",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, at cost (in shares)",
        "verboseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 0 common shares at December 31, 2023 and 2,571 common shares at December 31, 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r83"
     ]
    },
    "rckt_TreasuryStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "TreasuryStockPolicyTextBlock",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for treasury stock.",
        "label": "Treasury Stock [Policy Text Block]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock purchases (in shares)",
        "negatedLabel": "Treasury stock purchases (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r112"
     ]
    },
    "us-gaap_TreasuryStockValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock [Abstract]",
        "label": "Treasury Stock, Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock purchases",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r112"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureAgreementsRelatedToIntellectualPropertyAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agency Bonds",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r887",
      "r1153"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r887",
      "r889",
      "r896",
      "r1153"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfCashFlows",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized loss on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized (loss) gain on investmentss",
        "verboseLabel": "Net unrealized gains (losses) on investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "label": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r495",
      "r894"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "label": "Accrued interest or penalties",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r894"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Penalties and Interest Accrued [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r138",
      "r139",
      "r141",
      "r142"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decease in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ValuationTechniqueAndInputDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAndInputDescriptionAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of the Private Warrants, Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed Warrants",
        "label": "Assumed Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsLevel3FairValueOfThePrivateWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "verboseLabel": "Warrants expire period",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "rckt_WarrantsClassifiedAsEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsClassifiedAsEquityMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRenovacorAcquisitionTotalConsiderationForAcquisitionParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Classified as Equity",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants, Classified as Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisableForCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisableForCommonSharesMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfChangesInRocketWarrantsToPurchaseCommonStockDetails",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "documentation": "Exercise of warrants into common shares.",
        "label": "Warrants Exercisable for Common Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceEightMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Eight [Member]",
        "verboseLabel": "0.01"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceFiveMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "65.23",
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceFourMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "22.51",
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceOneMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "57.11",
        "documentation": "Warrants exercise price one.",
        "label": "Warrants Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceSevenMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "0.01",
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceSixMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "65.23",
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceThreeMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "22.51",
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rckt_WarrantsExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.rocketpharmaceuticals.com/20241231",
     "localname": "WarrantsExercisePriceTwoMember",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "33.63",
        "documentation": "Issuance of warrants by exercise price of the warrants.",
        "label": "Warrants Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number diluted shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "totalLabel": "Total potential shares excluded from diluted net loss per share",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted-average common shares outstanding - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r220"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator [Abstract]",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/ConsolidatedStatementsOfOperations",
      "http://www.rocketpharmaceuticals.com/20241231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted-average common shares outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r220"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477571/980-405-25-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482969/710-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(c))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0000950170-25-029002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-029002-xbrl.zip
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M>(SHDD5.-;G[MD8-:!/7T_!\8Q/\#=ELFMFY_9XKAD-$*UPL*WQ4R7N>@[B
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M^ZAZ5]/C/5'31B&^/7TOYR[EY&6P+$+=YCNQ),,J[34!#,,I-CB1YO\,/KY
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MX/UKNC"7:,.F#,4>")^92YJPM9P9^S=U0CY0.C6AM,'H":.H3X9,8XS[0(2
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M4 A"-VAIZ Z1$'\6[5 #*<D#Q/YS<N: )Y)(^2]:=6_:C]/"_,0?_/- REO
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M?=_7?5W/<#]RXAG0>+I"@>7GZ_&XM<=F:/ME1$$*25>M%U49//?"-NC),/5
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MR/O&P*/N+\0M]PD@*\+T)<1RGU4^B)KZ28M*1+!S'0/>Y(5I%W'4NY%P2D;
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MF4//]KX9%C7,#IN4_+31:.YUMU]C[KKK@ _['X8)'4<SU.2IK9SNT)W5YR$
MO-]RUU;XH )!6[X?/LEV02_]0%!#]HGNP'X[^4R4_/+1DYK[;MT_\@:P'X(K
MRJ^$AU].LI)J45<P(G(+IHHWW:5(5OZAZ,IHKWA$LP(+R9X%?OZVB8)4!XWG
MJ>?@>(+:=O4CI?#N1#6UD+_T)E&ZT/=/36.ZEW/V4!&KSO/:3<*GR $7DBH
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MW]IX_3>R>D*+^B\%"(%3#/!7L;IP4QM&2<09:%$3UZH.8JJ!M;P08+!C[/T
M.Q"T5EZ'+!4EBZW7E-'T'360EX+XDF%0R=+S/W),VCL350;H3HG^%ODWS0]P
M3OEVT7[SB+)D3>@<<-M&"F-*%F%]+V0H7FD>XZ<'$8H9HC[ G,B%]?00[FD
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M:/Q,#4O!3)FU&&]SSFMZD]7[$=Z<W3+$SL#P+795UZJCEA>>@>9-M+4(2IE
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M5NI^/\5MT2[3/VLYW1.]H=T?NRYNF<_R20U>U/M%R=$S2=6BWC"4O1HN7E+
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M:5&D*Q?)28M9#1GQ*6%M$K/C74POXBVZLPGSZ N8J'CYO94HRK@_G21N;L[
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MDY][*M"ES5'G&S3B,=SEC+]K#6?N![$V<8(!:']3Q\$-/^.E&O"E91X11FG
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M>)OM&[9XY$TJ*0B.5EJH3L!OI:3X>.V_'I+HQA!!T"]W\[_!Z;&P0,WSKJE
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MR TIR($E#8HNGT&#)-OC/@P+38$OKF/"8D>7Z%2OBA)IE>K^\; AK#'+___
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M-]MZ"CY.-RX.](SP2#1,SBR 385SX21QF/*V<C<BP)6W31R52G1H1(4/[%I
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M;T6I29\71]YST"TN1#XL8!1X.'P!<XYWAZ)V&I^F#+>IM/605:U*-SJQU^F
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M2,ZA*C_\\LBTG%.-HG:'[/'F@T^QTU7_6O>!W'_TK5]IM=@/FS?$8I5C!1E
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M.?P]*<YMZ CG=2_[6EB<C,G?V^<=E)P>\ZBJ_N,/;ILT1C.!#*Q*[Z%""_C
M5H@ATSB';=G\//HJ==Z57JZ%ZGL?I\%!D4N[=49&/]GI>_J!BLJRSLI@RY^9
M#5R+GISN&2T-YTK6R7:N(<Q[8T?FU79?ZM;%SF2Q,Q<P9*#/5A&F?JE:JL?'
MB=VEOK<A]X;4VB<1O9D%8]-C\[XY.93U_6U7K E8.(WOG9HH [!!V("PZV3K
M06;QZ'0;V:&ZB_.[_;&?\&U3_Y;0/+OYWW)ZYY<K]RQ.*^5=9']H;O9<P.@
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M"@XX_RK&W+KN> !E0),0QDF6_3B<NB%91NIC?6 BFF5*'&.09Q3*Z^N7XN\
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M%S!8N-^G&K),,!<)!QVA)_/5%0$%S7GB"RV%JD,0(=&:2 LNSEE_\%) %+5
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M!ILMU$$V$_.X IO2-EQ%I#.S&%\C&&]I:S(J9U*J(PMV8+= @9%.S[8G[%I
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M2-\7SHX!;$LV<_&FM,>>R1?P;A\,BYZI?YO%YH^J4%7*9Y55MJD"@J=BA8H
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M&S*E<UW_ITWQ,6Y-+!K'QIS1UVX6I%#9=-9F2'PY5Z#1ZIO:*!CY-<#KND2
MJ_WT:P-[^ZV&%_)N"25'!*?+-R@.0'.U=P11U)N8,(PAS!P^\ORN96F'MIYB
M6W_\DXN510X'QXKX+@,I7J'[O4P=XT_ZJ<+,%GC?***GLR*$JO(>"VM*DY3
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MG2<QGJ.E"*P<DK''[O]J=.H*AB:$S51TZKO,;@'5X!&U@*I:T8K]RU+QDPK
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M@$JVX\8HBS6\"**1P(E>T?([JY;MB"24XP!MIMFD\S&ASKO9: ;F[)Y^AS;
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MSP546C$GI;>]='M#4TN??<F!84X!8LDO^O*](_'\Q27*]XI+X%BNJB .853
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M0$8(O8;^VU_2>AS++Y(^-<!.8QF[VK*CA=:@W[JL(O2L]3SRC%B-PQ>Z:)?
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M]6X()_IESGG\&B6&"G"*[J<?5'0LB:6#P;@T$E,=X!EC!$Y >.9T8,PA5'4
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M*.@WY<%(U^"__3N^&QMR'>AC5L[5K,$JTRLP(FTVK/N*SK"25\&EUOAH?X"
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MK:E5'DMWN[Y+AD5)$Q&SBOIJJ2.C.:!\'R.ZD;S,;-I8.A8=^LP$=*D['=V
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MRW3ZY>CD^>5&@6@?R<@68\=L7O@=O/$J&WW"_H>\6QS^B3<OR(JEBYV%2-1
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M=RO4OA9.B.:^5:RI%&)@ALP9RB4AL1_XUK&$LTREJ#F(=?HO-:J@!3MP'9V
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M+_-16VI-X'PD:1[$UQ"R^JFRI^ IP:P+L2]"0S"8+\-%.%0 8<'\J6]? +)
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M>5;F^\Y_9TJ+-AB\;].YPLHEJ[/>O[)P/YS0<VE9?E4R]FE[@,$8[OB2'(
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MG+WASD/K0[H]6UP'8W'=:A4!?VX2X6D4#NQSQ55Z(M6/BA0TQ"83-=F)Z81
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MR!!JYOO^M[3Y]XOG30O092.8]@XH M.&AXFIV#8D"/XLES2.2U*'S"!F@D.
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M)TN@XVW(FLQZ'K+IXBT5=91OQ-F.'D,<^>4?[\*;5=]S9>_X"=,!M@VML//
MBY[9ZR*K#M0M='VLVV[+^4]H2\9,,@^;[PQG-%S\/#"HOW>%'37LS!WB9QN\
MHUU 73F5,+>Q!SQN3@(8)"Y84=4X5_YS[6O1:G0G]%.@$9R9X+(B_T-Z/ZO7
M)]/S><W-R>]3R3WREU8& _?2#<ML5S5IS[IC.FVX6][BM(*551.NJFU8MVB3
MNEBTG45N "PH*T(Y+MVHK4RBC2R9^?ZUP$&OZ(VEV/-YUSW&%T6>_S';=9TK
M?&^77[E"KP:@*!_T;I[<5)W)O"R9_>UMKP2WA5WD+VZ9J&$GUCH@IL_^W/U@
M?C=5>DL">4XNF"M:  8G@L$ 5V+$CH29XI_1[V%NPSZ7_<.J\#7-7D^JX6M^
M+E'1UMF%'VXTGPS*&_"X'UN]/9V='N:747C)]F/U&_Y]AR]6.%C]75U=CFME
M)U#G%ESQ++?'1YV-TL,^#7BN-7 HF9J-O*4H=SE8_#K0]RTM-%+'>F>*[_NJ
MVX$; LR1N44V%ZR>7S6)FG0JMR*N*CM$,"QZIMH U.$Q/F@#MAZA*H8(%;GC
M#9(*7A,_B63H$@"G-)KX95S97%O@AR0B._<B14NXY$27 ^=<#*5J)]4V&M1\
M#=TC!PUQ@SK20:!VAB6C!]7Q@/068 I*;^/C9_9'*3>KLT"&/D/NU,A<\9;3
M0=FJOH5M9/_PVK^^FO0",&<?0IC!=]@VK_G[A$^1A\'$^!I#F.A>B23)2VA[
MH(8>RU6P>Y)+B'P?Q7SM;,6L@T2.I>"3F<8:4";Y@Y8XG@/2AT %J%@&1]%9
M9"$9<3MW+M+"?)?HB6%?J+)21$;Z8F&M8[!# C^_U:'REI*Y$*56M8>3S?=V
M5CR84GV[[H.6LG /\/O,97OZ !73QS.IJZ^P9O")Y6W58:13F:CF @P\M6=O
M@B[R9>#*5OE.DC8>BI9@&U ?DF[DJJ$%Z5[P7IZ,F0)^,QUJKR$8[Y*3N!XA
MX<-,8EO>F[>[[HYBVV"M.'NRPA_3?:B*Q)DFY"EY0U9>40O6=4R1EB$\63/W
MP@"12UD*F]QU3<B63R:)'.!%MZ22^1]ZOWU3$UV95^@_'OW6;":Q0FWF$;L?
MW7!OO/=;R>@6O[=A2@+I[@6?+Y.<>CKD1N[/Q/2>03$XQ[D:!]0= \Z!_;IV
MQ.%#H)QIQ%Z*[)<%N!WJ,3P N?3G%EH(DBKT:,:#XT/SD3TR.[? I[UW(9Z8
MIL5VJ:P40G\M':?VF^0UA(8R5#B&+&C%9:[C]/"A Y,#(1X]%"(VE.N S!7V
M&(6UZMO,SP1N1N;!:2/^=$.6>^//[G=YW)\1+[?'S[NPE9+ QJ)4M^-\N19W
MBI>0.1O%+9DF+WC+8GIS?0*\I?/A;$P/5ZJM)U!GK"%,KN3/PK3KM]28#X2'
MGX53&L*M E"*4]F9-)J:5=AT8!;$]';AWWBH"X!S0'_((;QO-D"=6>0XWP"E
MP7:O\O.P7FJ%UN5IAF+; >12?FAFC])R(V1$-;IP8VV@+L2\>N]7/H^R_77C
MQSQ*7LQ]=#E4VSJ2(G Y(LTY.U_E>0_$74-Z Q]L6QP [:?WA35+R>)P^A$8
M3'/Q>C# &ACF-\8>IX5&P%9RC]&,_O!7=_,_Z$=%A<C(VF<J+\(?AI9!K;^E
M>P3?'R@9>O:0(;+N<BB).:H^^-^^-?HO'[ U1/F[AI">-E=$/3A.[H3E5PN!
M? <@JTVQ0T.PL8!'L!:M!J;:(S(,9331OQC_+5&2Z+COMTT%*7_1$%Y&RLGJ
MFY>BL-)5K'"C(_0V[JST?_EAA?\?/GYEHMI.\MEI.\=/X[2N"ZJBF'$]E7E2
M./DL,WS=?@5ST\<[K)'*ZLK<[>^KGB9\G['BR-K4[N[CP"D0VL]';.TR%3K!
M]SBOZ!6GJQB%:&2G(N@QY)XJ^#NYHT4^?>O^]K2F6;=W=>&P0;]VBZ=VGVGR
M7??:)\>Z3<8ZZ,-72XY+ D<S*Z,SLB]%%HXYQW;73L>K4QLJ,RN=*F_>5U9E
M1!UVB1@(\*>MC/!_Z[;&8_&#FWO'QHHIZ0G;^5MD[/KM-6MS#ABO/)E:=\CS
M2.,16DAU_!GK0=W1'5[IH0\[<PY$H"%-DPM87LU+#!^*OZ@=KK5N2:ZTXFY/
MBU_?1KIQVO!J8(?ISZS?00/9H=S@C%?W-YP:W6UP[4/0^I/?LH#I)?= /)65
MIE,A;W]ROTG+]VK<PL_4GNNE(8K"_N8@*=^<_M(X/[-)SW;?SQE.3_ZYR5WY
M>J_?F45_L'UT717)U@\RO=,YJ,__>9/[4;Y92L:%=\'^1-^U(]R&74XOO4U]
M?,[_=B+,Z[?15ULSD1UR>L+OOC*J21#BE@(1=?YQDE0A/A7ZN8W<^N3+J_/B
MT[<#K0]?;9">WVCP+G/3QM=%ND]/'-NXO-KX@]?Z>\G3;?^Y_5);F(LM,434
M<*8R$ >_[SB]@ 4U9#(Q<!5R#(YZ(8'N@#(#>#*^X*HD\#4@LU878KH(-5"U
MN'?+B1?\_MSE\")A7@#SRHSOF)/N\X!;O1,X<;;6$'AH,$S'=&2JA>A1)%5N
MX=8H62I:QVDB/1GAH5'R6M_A]&,P]7I-$$1],;0&=D^,W+$F;?U]'-R81T1=
M@L#M>:FEYW[Z*=4HGD *:?^O/Z$SKQZ/&Y^\7 (TA%-D,:C>1UG?"P4\'/4+
MG%O/>$TK8#B')P@*WGZAAW9.[]P9HS+GV6#::HL&2FQ^UR\#+>].[#&"+]VH
MRK0_\N?3"]ZDH;3_N#&\00*-"092L#7/- 1NEH90G]\)R/!H5#ZW3Z,7A9FX
MB^G"V"+,8AC/UV7J5 U!=Q(S:$-\)?UTJ!Q\C4H0-_ )]0E5SE07_<VNF*>T
M04WQO+D9(BN5ZF2,S.J51=5)""Q_Y4O$2:IJ2R)I86M8[O6!*Z"1%/022:PR
M5X<<0:SD@[\TTSHG73QD;>:L6*&"5-=_\5F1?VBN(1(/R"2&ZQ2YZ<3$B4B^
M!<[Y#\^538N>4>"I[H))TD**+:N<!FLU@6]:&AP!;79+CG<38,KB2@_.VN$]
MK@.,QF<O># BE[>'^S20=,(C'<NS5=YB64'VH[%^T4-Y+,T_%WR0A6T%I3DD
M:!]Y ,1TXO$0/(JTP3928EVV'I[029IKG>2F7"'/@@8S9*?3\UFV=:*-KTLP
M.\3'LQSQ+&3%'83_KIX1,U-F+03UO$79U/B9C(N<);V1A&IU;E(10[3F\OPK
M>.]QS?[=23W%5&WGKP3&A%G@'6H_H'1LIS+YB!7GKHH<YKPYIPCAR;4FSDN3
M1,:M#_;D PTIPU2NR.3#[&1]>'3_C,_U@='3;<TFSJZBPACC5]GGK:]<*@X5
M'^N\"V:-45\1$6?<TFM5/P%U[N!I#:$OI0XLX]>?H6Q!0)F@:7(IDMV(63(3
M2?H4R\'0(?,>MA:0[S]^>(QD5'-2FK,(TX[<_F/9L_(GW2/=/1XJ7UEG8;G'
M>#;U@TH:=6T:F(<:(U0I<^G:90QL,1(PMY08_?9B>4EW<33(9=O<_S![T__$
M';WSWP3V_?7XU9U-9?$WOEN\D #P::@!%=.+BU'I '5&&@)3TO=97E!VGJCP
M5!F/<U9!S1/-TG#.I^/"PQ*+2*1&[]X'[S\\BZ-3"U_P4WLQ>R1IV,*QK:&,
ML0TQDP>0Q:^/-^?Y#U9]G$'-&*JE8=1R,FIXAM-.<3E";6P;$#?IPV+?FIHG
M59:K*I!C]U+=Q'PM^U1FH*?;#\_@+3UVI^&H1K7S['MY:W&XB&RQ9GA?1<^F
MR)16&IR"Z0(X&:_">N@5?-2$V  :B[XY$VA)+>,J<(SP1!IAGCR_F5>C)ROQ
MEZ8)Y"WB1^BESLTN=H].M U3C9&4AEPK(6R30B$-(3393-*4&S#,)WX0;:Y]
MDN(.FR;ZJ+]QL94QER#F]9@YY'/-/IPJSC6 .%?R$/]ZS+(CO*/3XW7-3IG:
M6;*_W3[<L6>+567G5.W6COZF5X.$?>'2-(?E1[XCU15.+,.YY4W.@(:@7(RH
M-80'3N)':CR1C\L!S^'YQ!L^IN,%GQ;7S=Z*SVPD]S]14X/Y"^VKUD=:..U"
M4N^,=Z)^<QG$"O^16"=98+H\1XO6&YY?SJO'-L/T:Y&G:YP>%H9F\9OF#OJA
M!FU*"8+#D98=UCU7)HULCJYYC#?V$SW1V;1Q YL(AU.LT*U=H&QM#9P93[$<
MK=Z;SI3:D1MG^(876J9J*WI6U60V6"YNGWH E)'O\XYFF>>8>?K88$OFUI/\
M,0D('6L;^*S41D*DS(0U5,2FK=[6CJ(:)C<Q!$E4W8KOH8_/8%OY2@_XT5BG
M#,5V=')LD2*OUY@AHE=G(B(Z4E9DO6(:,&;3^$' W;X3C-E1 IJ)RS[,(F%+
M$M6)U"#F-XB-<JYP')OS*JOJ!>^Z5YUJ_YE<.^36,/^*57.@$Y R9 3E*WER
M8-F;<9)0<D48:_*1.7^4LZ0C?$J?7H=9]%1X4O>7=PI;-^N'20X/?@904RM9
M"+HR1'4<>V5&; *0#<2);9"/# <?7I_!2"#\.[B4HH\G6]]$"HR1$$\D]9*,
MJ#TN $[*J/UD^62#GD37(S9$EC*YS!]A[$[QZ%1,/:CQE2L#S.O%/[2#G<"!
MCHI6XL'."D_#0X_;I\(MZ]L.=-BG;GPEH77:UVZC5:5UB ]U%MM9)?0TU3?U
M+"\IGE#<2Q[J'UHO2[!/-7;_!_::M)"]0K4/U46:511T3X4JZ@K%$=T"M]4+
M3/UY#L'8"W@R04A>/!;1[\%TS>\6JDLJ\]?U\"^%1(7$!,?JUP[>&BSIVO)V
M[[POTSCL[E0_7J=^"DHS^$](S79!1ZN[72YIB1GT>,"8[*!=7#*]4Y($+OI8
M2C%C"0*[[*9&PBDZ[-#SLJ?L&(9%UL!N>XG1F[+.J8=FGAM;/K;UIV.>F4K<
M7I\8PE$:PC$-(9'Q)1NWXE/4'\G(!@T!-20?53^FGFX;(,DH?!F_3]QH:=6.
MK6.;P0(N9LVV@*OB'8#DZ.\_L?2:9B7<"Y.ZK-+/\OPT/DQ[D447*_Q>LW=#
M/&Y"3@%*Z90^[6#;R5W=O3L=R&,VPSP<TBS9QDB=E$F\;S".;4,"X/GUT6NC
MO$I*BK/ Q!J;HC.S82?>/K5ESA\:VEU^Z$7QD8P;5W3W$ !S$/K)'<T*491K
M""&&4D#M_;A7.4)OX:)FN%\L&%(_H4I_IY8#BIU2R< VF3U)JX8.VPY'<6L\
M940BN8&8P%]:*B3I?QB:_[BCU.&AD!@OV@)7QIU<T/][YYL!WZ$Q*$RQ+K[K
M<^AKW]K4UI%ITG<+C=$=G#90R%.(57AR6-='-^6L8*]0/Q!M8TTJUR"&#Y%^
M:C*?Z/(M['2D&P@AZK"LZJCE?UDNK.V<Y*P$F'[(-R,!Z<KTK@L\G99'H]&.
M=X<9M.6#$H3[U].JUPY% ]2/CI>W\Y. 92Y6$%?6W$!,L:1V*]A4*37!4@>F
M-]#,&;WE P.^9W*70=[Q@)QN$#83Y13AWS_0/UKM>#LFYKQK:X,)O$?OI7W[
MWN)Q+) .>8(60-W/<[5B!MJ4<PL1#7C/*4 P*5ZR$EO-TA :,1<D2M["2Q)M
M07P*$%M9& M&K>2N-B^&EE; (TW,*[,]P@>(N:R)*R//#\U=?2U,RCITZ9#H
MYGA6=6"S6HK+B^(8<OI(%::HH=-PV\2T2@_=_A3)A*N&[^<:((P'H1>'OL5Q
M)<D>C,\J3#P[34YV:BM&C^,PY[*Y9[;W6D7*Y#<!?N(';279S.4>4??[FUWS
MPJ(C .DU/D03+,4;< "E6> ":DA;8O5>7A[Z<^\ZG'60>,K^;1]F]C-@'_F>
MOWW*D8BCW5-Z@S[[8,LR:+S.FZ*+^#QDI7OT"&O-_?DOP',0]O"\K._"K<3Y
M7X;5>2YXLJ]UE=/%GT?9RGE%,@:EO_.?.$R*^6E4?9R*@DTZA2R)\@SO>$4[
M.^3NT(<H9Y!;*J0-^'B7=;)I=[,;>MCD8EJ!Q,*TP='L7(EQ3;KOWHT\=(50
M]1UK0,9/!)AT9%US4XR%3[UD&::'?)H<WILN=?WQN"A?Y@GLZID0+<3:AU9V
MK4V[M-GN)Z@M90JXUO/R9+ =]JM#@$^#3V*/:=31UA(-(;(;/<T^CT_=G-&Y
M@2$\9'OO"P ZRG\3(?W('Z;WQ0P[I;'G%6,=3G[4!LDU2XOG4&8"&L.XSW95
M%YX5DK718S WH<9=$#A6Z>W';XK=Q')L:5@TW.#WNZ/S'F7Z [^!T8Q5I+ZY
M'>C/M5%?-(3[+CXS7^A_%*+.14HYC@FE@.P]"#V\($%.@1.2*J >IU+Q-Z!>
M!3T,IZ^X%8FW T% _7,-X5HY9A*ES$0W34Y1G;"EDQ.\"1Z" TK8%Y(= 0B(
M1/'TJ>XS_W.*0%7+5T]%8W@4_8(SDKB'.+6\1:\R18TZL>56V/)FV>9LV LS
MZLE7[7N#>JJ !EX"2 1E)L*YXM:+Y_9!M"O+;=!-=!.6CRK$4T-(N22G*Y;7
M.*G+B_J^F#R_\!#K-29PQ'A[3.#DW&+[W;E5,E(_36J2*EOO$@ S/*%BO@D0
MTO(#[WO/7XAIU,5KGL'$N*E)O;'<5=='JY>4#*N,>CD&]+".MZ,I<]?V-E"7
MA78RS/84W(UXX*\A6%#+R*AI/?4J+C@\4V$,A:F:H@SQM.F;R.,:0I"&<.5B
ME5]M=P9(%//ZW?;!#LUB:I+S9H'27\N)NA#=< ]EE$-89MY+^7Z4&@D5RDJJ
MDLSWM[,9^>;,J6C!YWI$A9.AAYS.7"H^_3UAV#:H]UJ-W0.@SI&RGM-N0JUP
M2N6L"Z-0($I.C$SP#:NPD0Z543:Q%Z;(!@).(%]03\N"(6M(2YQSH*V.8P7]
M)#+K=C$N08H:+_;F-49?O#Y/;8+KYPGPN AKF%N%NY8YM*8B@9S$%Y[M 86T
M-+. K4-MWAU3;4D48Z@+T&>OB[E8E5F5[G:/[=Q10WU$R;[8H[4'-DUBT\(W
MIQ:.183Q(N<* 2[0^[?U-2%IY@:H9A7656/J\/#PL^'AQ6?#2R8FBA4R87FY
M,&%GC+^_/ZO'/(;!8!U;<W5(^\::A.4W@I(=?MAS[+#6)R=<TJ_XT(]QWM*?
M-*.F59@N5Q6.,A&/ L1#&:J^2Y4)0)DGNKL*P:VQ(0(9P$R9"@ :'R9?K1%H
M(8S&+# 5==40C-P3ICU2Z9B!AK"$!4R873L?.JJ\?7KOG<42Q-4?.Q(,$;&Y
M:[9#L'*!XEC@7.E2/ >,BP"EUS6$Y1K"2=(;K^'F!O!-QT C8(1MY+RDEILV
MMB5:KJE!IE6T_CXD4ZZ51EG"LFH*M.TI1>T*4,83*+ZVLESN>A2;!8AOSCCF
MFB?;9G:67$BT%Z:]Q/N$+8E67\8]HPU9#T[,@YY+FR=BH)X!>54C<1'6(R&*
M-HT-&?*;L'G08H$TQUQ&:J8O#*N.S\7I;</0,NBO7D>_7A[J3#^4[G]5&;/C
M7&%%@JPDT&I60U#-8UO#52]H;]R5&Q!3F$RK[,#IH:GZ)AZ4KDF6VA>Y[FWQ
M*>]T"8=&I"-Q;)*\EM+KW7GZ::?0@V$7Y0Y6QAUY_#3W3^7ZC/<]H3]F./VX
M9%P9H<X 0VA]IC(4T*.>IL>1B"(=UCP'O4$_NCY*A:8SN.&QC\),O08'P_R$
M?ZWO3Q ^L,\TV&/\OB0JYGSX3QFSD16_CBHS*E^KWAFC*J#N%4E(3Z/.'<J4
M-()&[#7(B("]$&D?YENRK2"BF&[((C694K21](=MEX;5AOYP6KK4+F9_]1-X
M74*!R_Q[K(R9'T30N\'</,8=O[$8P>JJK&._S9_5N0>2J-*KAIQN,QYJP%"Z
MP3:*V\/$1,P)&1]FZK' 9K^$YW!$ +^1OJS49?[<-^1>;"E-SC,:,RLH*QGO
M]2NL+YK48O146:X5,0U&L\X)@F6*7_1<W?9F]9#>.!,P*ZIT!OABW_8F&WME
MTTR:+3DM^."DQ&/L55^@[MO(MKYAJ6,5CMMU.Z@_JH-\>RB+V9N[(V/IQ]2_
M@B&#;E[=#JYN+V8M!K&\!Y)!U#5K;!:;'0L]QR1O#LZ0OY?[6F>YW^CCO:]"
M+<C_@\GD2<J!B4:IY$T;SF26L^E0[W!4(ML3AV:BTQR5(9ZKF-0?I\P'.TJF
M'T02DP.W0(?B@ 7.OV\Y_K:O+^SSV/@Z=3$TVMF7/]W*GXJ%=M9'@Y<Q790$
M.24:: MQD&%O1@"9Z[F=OCUC/:YTL<BPXT+L?KO2PPN?7B&??7\\Y+#)\?H_
M[BSZYO(6D3;GK[GNM-P?C]::&,0Y[3(U_P+9,&P+ V>&'&WV>HA4GVK38"8L
M>?RDLMNAUNE%]*(K(8_&')4_^NV*!?0;_W)\L6MET=(^>C--88ZG^^MQU17@
M^O(!I,5 A19JD(+II,(\,5C&K>?UW6=[O:;8HV&U3SIM$&ZQH(YH$<I?(EJ+
M=)"6GOC0.[09^IC+V<B@K(1,K]1\"]VM  W"3&;TY0(#I)9M5\0PH9AB,END
M3%T*2%.IT _@FRA,-QC.Q'1OX>KUZN:8L0]V:0AGGK'/%[,#U7R.+2/7M#-R
MH#9FV#2U C1C^T(3IM1ETX .0@U$(DM9JD-X[A-:Y2TQ%)%8S^M[9QDLKP-5
M716U6U^Z[)[WV1TU&L"T(_!QD1"B:@'6325A6_'1Q8)GB?WD>LI\Q*>8U=8,
MEDN2IB93'25+*&O]4YZ;=-68LQV ?E6#R(PK?C(X>'KP',=\:/3EP@K=W)65
MNU;B."T$H#!3]*Z5,EQ#*/NL3-(0NL>'_T2+U8^H)TG_W&170'1Y8)+J;-C<
M*F60('Y(&V' \QMS]=2_ B%,(]9YH:2?.AS"91O+;W.,6=L:JJ<%C6 BMB*N
M/I ,GQJ-WEL+P#;*I J('M_[0R?;G20>J/7RC/412VJI$!.<B%=]QQ'3(0\R
M#ESE50JJ-!O@DLQ<OI4S4YW;DM!EQ&3VNN$=]GIT8_9)N+)6]N%CS1ZI9T3#
MT%+1TZX:ZJ4"1E@6*3'RC,(N<B?#=;>_YRE]]X-E!,0=T\6Q?M&?;"?U?7PN
M% SE!W4\&(JGGA!-0Q@@T^$](ZGL_7(!=_*AX(J+NUS!H/46H_3A@!4UAB4L
M<[E3O22)0LD^X41Q@OGQ:%#1!\JJ8SV%(B2*G.1R4DXU#D 9*FU\&GX I8_X
MCTFHD43&10V<,#W3*!F-]PD%,K^C70$JR%?]=U7#QC6<':*N&C+T.5#84V&G
M56? &I'1$EU"I!)C%OTH+7%H$339.+F$\9D^'C5;,IEP(=5)'+4A'\4G.JX>
M#Q>>=!\D!.(W@@L :0%)-_RC=3NJ,SR98KD).3RTH9/M>L_N'^TUN^2N/O+F
M!NH5DDFIBY>\Q%%IRUP:.K0.EC39!CB=>.UP@R$W?[IY$WI,/GD$=Q( [S\>
MC*3WZ9:@-#]W!?Z1 *@+XZQ&=&?D[G7^KLYBJ=,+)M>O)[W4-[1?D# Q_1S0
M"@BSJG_L(047L'= )D5R.R^Y5GR-@XR^C,&Q@J,:+79_;K1T?-9A)^V>X*PB
M1%>AEGAP6I_2#DQ\I"P&QM;!@6 @WFBRAO IB838V*AOC[P0J+^;2F["V\>#
M9MU.!S*RD8P:JN3@Q$,9S9!%KP,,A78^=2(*LD<^:>X_YH5X[$'BI0&<@:/"
MN(:C9RJC,X2%9S ;Z&_16N@8]NQ^:%;37=D 8+A?L.L.PE,YU+@^ EQ)D"?Y
M&@F*Y$TT *?!-W/W\2^A:+/<E$[(+MBK+M<"UFKF&R+/E6PD93B6K/RYG1V3
M+TBNL95>Z^!L",,V=E<40#MZ\+ >V(=DRXYQK]NWZ-@K%@T'0#7>9L%IO\U3
M"]OW&,U#<<%U@_1/";Q$NC) -!\8\XJ@S^EZ ?AN"1VBT51.3'U@5.PM6(M/
M;S(81.QW4D[A@P]F?99J391(UU.LV3_6(GE02F.63YPUS(QS669==)_%:-1S
MK%:*5B%7Y$0]UJ&A6$K]Z+1UG%?OE+):6/$LH6$P3)\1%*G$(<]?:MI([F-@
M.N4J,ZP--&=3M:YA=FQ;Q$K&7XS@!-NDOR=%OAUUE>\;^JA4[0F/$D?-"KA"
MWZE.5F6F3Y9ET<-1PX ]WW8*S<=I&\<.$\WP_BDUA#]7@M*[@/+<T#H-H3,A
MG4X ZNZ!^$BY(#Y2%PUAS"N<7LR'O/F7Z49@&!VQ;E-DXI!N *&XJ0IA+RDO
MJ6:;E+CXQ+@?F6L%$Y/6QG@,6!A'2@SHHX&6'85=J=E^?D.,K-+;]]TB-]D<
MZ3H;[C+P0(3SU;A(X)^*TONGHHA2+847KJ@5Z(]/D#S<[+($<:OG%,6TOG6?
ME=FH[WAM)G 5 LB)1L@A>>SN^FZ'=7$'>Z<7"87/*Q.0_C&]R*"P>3-TU*A(
MV=M.E>;0'X\H]%3!XT.&3^&WI(4U=GF!H13]*E'L>E9V(V8/9R:(S!'#/;7=
M>>5=P1WV.'TW0YK%$".ZPB\6[0],Z^V%?0/VGWN\'_V-TP#, Z4B  H KO23
M%66P*:8[+*>_\9+Z- R&-/M1ZYD+L%:*6?>4Q:'P^2]$#MTNVQZ%F<P2ZX%$
MJM8TP].:E&AI 9/CBR-)B8!1S7[89/+0ZW-_BS)&ZF=FR<K"Z4D\&LQ37Y][
M06^AGCJ-LY/33#5TR D2!QHAO;)8J@>>./%WT9U^@ 1)J)T\7*]9- _^P=%Z
MK,GU%&DQ\KE>9-;+K*&Z*FX)$HOM53FZ'S_U#!S)P!.O&Y-]MLJ+N+9+0&DZ
MGV@'G +[4J3,B:BY%;' %5TU1R*@3CDQ&0V1;J^@<3,P%YA3)K<X^^%7)&[8
M9V(4IOX-+\HO0CY^]H"=XEPN!8=$R8L&[#:/'T];7Q&[??ZG=$R7JIJ'=0"/
MG5!C -,QE-'Z/3#=#7 SIFM5C.Y"/D/T!LH*&&C6=HE95 @-'^P 0LG<ZO#)
MA*G5PVUI)/./6>+CSV\[>.05CD4;/WT:OZ#2].@I&35?@+C0Q**UN']*?ST?
MYF?\I"T?<5,^1#;(R2L.A)O]W<<Z-[('29'M]+]UFZE8E-LV3#1B'?UKL%;T
MH+0J_,=-5C%=75.3+\DI<R=FF(@=SIL'(C =A>H<UDDRO$#LGQQ>E*\ZRB(U
M@Q43%&-8<AG= !4IW9 ]T(#<YL5@4%TU$'\!I_<,ZI)2EWUD^V4P'F0;.:8(
M"0)_$'9.D^;?#E\'MR6Z>"VJE1,5*F63^A;'!!O0$)YH"$UM?=1AU]]GZ$M$
M3HCY82BA+/)4!J\(B3KZ.7R:J8-(Q.+#536=G8V!!#@A^PXBJ4\/,_'I,<'6
MXAF?JR+U7?$O_7_.@_GHTL(&2P/8"5WV&=,9?,BR/=H^'6 VH R"M+B3YRIL
MJF[^239!#O0#NC@*>.:47+[.,'-*FV(:G,'6["6=26DP<?[=YZ?!M0U826LD
M@[FNV,G4$?*(_;FG\EM/^_/[+UW(J')J"P]+^[/75"\XY!+K=;WE'J'PV=.-
M:Z[ZT*7-4M.)A1J"UEX<[<R\?D!T5 N&T,7J2B"X97(IB]L0:/(:]93S$OQ\
MN.QU40_4&?XENZFZ:!B>;G&;)$1RS?ZHR/./)(B[;(970Y=&R/4\0T[41G5'
M%I5X!*CG7NL/!^JV4Z6E_2,*B6P2V4!%C3.515#!73E3&W6 >5<YIMB?)"V'
M[(')!:QMF*'KMS5.;-'JS@LEU -(\)WFD,+LVM/[:BR<> X"X_%?D AOF,@[
M"1!%*=NU9!H"NC(34HKE(^C*N93M#N+UB!77B!EV4FQ86DIC).8!4B2;3-SL
M8C,\N?@-JU/Y"1F7/6];RB(U>M]HC93Q33_TS/Z6Q4NHV15N5&7F* P/?B V
M?WGV$8L^MW'9R#0$ZLKHD#>0 CX6*-+S6-'#RA_4CZ9)>OT(49G/U$<BONN2
M0V+6/=4!9!N<YP>73+[Y&"Y:_F8@S$]#2,!<4-<NA^=J)QDW):^;'2 +W_VI
M63S[.XCGH:< *9XD0 <$ RG*PG\#ZSHR-1R\2M*Y(#'!6JGE$G0K$=U,2_0A
M&5#,D%^ !1I"_4VU %N#!L.";*F&8("4[X/!1$">"%MGGK\/U*^6M2V-!0_?
M#'#%6C=M[E;-X<W<6:TCZ&;\IY#SLKJYCF_0&B2C7Q=I.0NN Z<UA.093\X-
M-A5)7W?]9W//2_9_/^4?AK122Q3A-3N'2^Q'9^^7A;:&RCU)M/0&S!Q">Z2D
MXHPJ[ZJ>RMX>)\>9#)\,:-!WR*_5HK&DNZ2!X5#;*FS8!-.8+H=NBNT/M;>8
MV^9M?6P=C0&@5$+';:WN.&4^UBK:H+Y%E19*M H@1>$+!I]X1E+NU)0MN,[7
MHVP,DRP5F05:7.S__,)Y@K((EJ2@;B>)]9*)VF4NAB5(@?[66/<ZCDUGC8TZ
MN\#I<A#6B4;AX_N!TT.JE"CPR*VU#AN<H1BH'U*VH71U'&<QBZN,ZW"@Z_JC
M![O9GBK[4(IIW'& RU\X4;-".E!RR65>P0D)8\C,DUZ/D1'@SMMQSL8R:"9)
M*%'8T;Z'39.% R^('ZW_&X_3$-_;8+HXY5_8 />^T!!2*#;JWX&?<JCB&ZRX
M%SZF'$LD!PYJ,EM<_;8_Y+KB7+CEN!@DVINW/+4_3;'8,AA*6=W+]KD_7AF=
MEA<9$W3O0\^-,\I<JVX-P96B#=35\RL%5VH"3EZ";PZ\H*]DZ]O]$1"U.[M^
MEG;9Q=,B9?WBH>6P3=S$1(6"@FTP#B8*6(R&RO3Z7L>"H:'])9/%;"U,YXIJ
M&RL"TR6K6*SDWF'A^Y)2Y'\C[KNBFMK"=>/>6U$1$>DU6Q&1&NDMD*T(" A(
M"YUL1(00 9$6)"0* M*WTKM("3U*E1HAE"T=0A%$($$Z2"+%)23AQG/&?3OW
MW'$>[K@/\V4]K#'G7//_RESS_Z>M:L$+<#VD1TX8:E!NOSFODVXAN 8/\)J6
MD'S;)%*DUTS=D4!FN%[IJ&\=;7#*$]#U-H,XCC?$RI>"VW_M< *2QZ"MJ%+6
MOV !O2N,4X"=)ZV("F,/'P1$4O5>XBC5GO!P&&*4<<G/@X FWJ$'X5^HZ=[:
M#*4%QU0W)@9G!+<TY#?)VZ'TWJ2X(AV3%\SS]3,LN-+N/<).M=M;V?J?S[V_
MI#V2D6W;O 073&\LKC974)L$2PNO?/H7WC?:':9MLZQA'I?[RA^_XZ"?1DXK
M*EG9T7+1 7M@QV$TNX(9\$$HP$];7=+>G,5WAQV#$EVY<4*8/P$?2MC]6CKN
MQ5ZC:8Z7&H+7H$K4;='BG-/FU'<O[9JFRAL!&(B/6F:;RFN@YH?^1-4EE@<,
MN0- I+<KZ>,^^L: >\4ZL<[NF6_;FK4Q$#BV@=7,)V\?@U!U(AG=V^X69KZ?
M[S;&Z:"0! :OV^+]]MO?+H99U,Z;(1%_8C\0WQKU$(%K&CTZQ!@6Q^1VF_3B
MSN_(EN!R.C?5L-VM?&-6.D)5W,XN75079D[>&E3RGI>?OL+Z,@%5HF@U(+@_
M;\88T4].S YGH=S*$"1F,&N0#53ZQ$^>!YAP7E<Z^+F:17(';)PZ[GN?#NX9
MZ)Z :IQO]OA=W'#'"/ KZ7.C_#%.V%G85G^"B-_&^(47=_JX^TDT!_B+;[,*
M4]>^"I_+1779,[Q]_9^_KM#V3VF_LG2U[$;9]R:9 %O?W00;YWO.L@]F:JU*
MI)Z3' R&E1]9OS*V\4=JUSI/&U]]W<%QE>SY"M?9YGJ5'L,V)?<L7CR)2<#H
M4Q$7G3N/S #JP.T.NGIU!8J75-1'&UC<HI+-FR=]%>\GFYDYKL)S_FWT]VY)
M["VZVAF@,*"QPV]-KM^&&9&W5!,O=PV8CM>WRKGHW"&K;MK+!S)U+-X]4ZBJ
MDI>O+HJ;'>X?GKW&AD4?:A(G6O+VFT1) \O''?JBL?9M+AB3TG+92;%)U9_-
MO+4-$_?R9SMLU\(%1.))E'7+@(.D7#[GV285EX>?F]()?[V)DTN=N_8F#O2K
MR3&F<,B1GYH[R; #>SU)W(93I=VA]7]9(Z:WS8,M^%S-V/YR_QBT+W8,,H1Y
M0A@9KI>/03/2&;@-*D?TF $_ \#5G##@NWO"P&OM4(] %4>8THY!,7OM1L[3
M#4.&?49CJF82O:O6D_N)".OFN &S\;UV]7Z9'34NH[MM^:*FHJ*W'S2W-F=?
M^S/.^/XMO0*ZZ,$3X(@6=N?M5(<"XSS026LRFO1+RBCU7N#I$$&3.T4>E)3'
MA_H.Y[GAJ#Z"=QK:.@3>FCWV45A^M>A$DI]'9(B^G>*3&\XS&2V"!Y8[S4Y&
M:?7GZ6QO7TU)@)"S*O<T42NAOH*"40-TK20.[N0^F3:!LQT0;E/!A+O O""7
M53'J'I_\3V:J],!47S)[@"_G^.!)R44;K$N3>T1N &<Z$304YCSQ,#"<]];8
MEF^0+L)^<E\GLZK^"\24_/!-_N[=B2#.CY3Z=^_JHU$YK5EO(DX7I]_27S\&
M\1 ]"<E$COH!+A1UX<-. I@S,!P.K#]Y4$T7I> 3H3REWHZ93>E;ZU."K*MC
M@0-. Q34']-7Q^<=%$^V*0\M__1OY7*[V;8^47U6S=,DK;W:WCJWG-PQ/X[4
M[&)J91/UHSL\TRG^:&<B;^;B(X#Q.*?S[THJ;>\=NH<[D?)H4M:P\=+-D8*9
MFYCVAV@FGUTE(+>HT0>)U1.>:D/1-A?[>G!@M 8IP-4)B._I. L$48]!_&C/
MO]Z3ZX$@GYM<*-?1^C"FG&EVGTEST\3.Y8[69]N!/REM>5:S-B_3M&U1IJ\2
MM=,\/15-'J49/^YQM5J.\QUS;$))54)$DS\LUV/K,I<>99Z#U>---X7FS,04
MP"BX"5_YD>,NWF+6)L<2?]X7^;&L1Z-PF<_2X$%0%/\FXKS>"4PPT(<LWP"?
M[CC+< 3*W=XX=WI6+6 T ?\EL)@C4B/$$GHPU9(W$JWJ8R7*F?/"/?1UQ#HU
MW>OEUT0'OI?+T^DA3X*6IPK*'.<^+7R:&_$,<P_]H[$I/22XMEY0O0E.KC#S
M"_!3AJIT*E]Y9Y(H%E=3S"5E6"]#KM2VO61"T*@MEWV<J)U;,WX0@#3$$(P?
M-WD6O>LS4AJ@:U:YLM=/)U7I/;?G_I:XF.W9]U7@QF1=<#5E?=CV+6M*8A_F
M<SKL]M%8RT2U ?\VZS=F%@X)CFOY#:BCX+:.Z$2J453^]U4+BXL )\4H&>KV
M6I>9WAEZKV4DII[+R!PUH"]_;^63<];K7=ZA6_/-@5[P;HL9]JIN-]5Z;(G7
MKEN&FWWO-(&;%7^IJFE-R7P0ZFM]XUZ=,^GW=#>7V^/VN23!F,[1H ?%%#-X
M]P3>;"([(==M:$A*6#4OK^UFW&'PTH$4L\[G4E@\84;T(*\Q0K?C_@_P"3U9
MTED_#X.%*_E\-B[#_?'-T0YIAL:_=3R:5&VWN#6Q+R[H2";4)[K?[F@=W_>1
MMJE__W9BK]V\BVIJRM2Q?-N:)%<IMRE75M+86M\<)Q>/>E$<[35^RT/0Z4P<
MZ5J;H2C/#9,-Q0:1U-3LR;+F7HW:R=D58=_PEZN*58\35F6'/ RD'3R:D[C%
MUF4PBA5=4Q7KY8&/:\//JEHB3-DQ],YO.['2WGZCQ6XKY\ATXXDKWM.G#-F2
M7D"3I*9M1Q>ZA9UUGEFPGW="PYW"6G5:0]WS9U?.7(E&WS>^%V($EXT6Y8U]
M;/]0%Z,?8>X=)9OF;!UL;I+KT9]C)C>[[07WR+L_HXJTT!BJ':S@7]8<3?=(
M[EIT=[QK&9 H<Z]BW%;JI&9SF99FN4&K"V(E3FZ!87TDS9J8/S6NR+BQY#>#
M7V)[XWIQO?$#UC'(B6[127S1(3$N7Q7X&0D)$OW<;@JG+9?D-91$Y5I]F9\;
M4M9'^?"E#-.[$Y8^R,!)TZ2/1CPW&\ZH!8E,K)J8A9CXQZ.&Y 0S'LS _4QL
MO^>.0(:NW71.J<YPO_YI]FX^H[8\NAS.DY;RP\G"+"+N6I7%7]?>M()_PV@#
MD733[NMLFY3Q#.-!%^T)49^V2V<)T:2CU8B"Z.@P4R'&YN>R0 3WIPV1U,8I
M?^S!1F"C5_72S^7[KMZ%9R9RD>3G%3:YJ6ZG#?H#4H(M$^[EI.:,7<GQ<Q<S
ME.:.+'3BCR<8<4:3R&F.0(*!_=W"FZF\J1M3U7!+O'GNY=P2K7ZE.+/&EWV6
MKC%T7HI@#^ZY2&+Z2[HG):8;%G786/+P1W9P!IVWT_4*S;P(AQ25-0[R\*"Z
MJ-QI;FDT"C3*/UT<ZS#I\.QO[GSK<O,2F?X\>_.\VZTF_)+7S!6GZXNN%.=E
M!R.]/G:Y7\]DJ,D_X."/Z:7(]0Q'RYUQ39?F<CQKKFA3.9:Z;A.7ZB%XS;CF
M_N2W3$N7Y&=ZXI@;0 E5""-)&_C0H0PD4EMS4)4#N'-H7I+(0GR;OFY) C9H
M>T(;$K,5Q&7BA-(DA@5I.ZG"Z8SOM1"U;P@:B=A(8 H?@[:-CD$OCD%T]V-0
MENQL$J?PBYAZ$D7)EC*X-&+$#:_22B-(>-TTS0J0J_SB$F*4D^D/.>^A-B6H
M-O+=N8YOO;>"]$"XAN.DRWANB9"MC;_:^D3@\K5^I>QD^1+A*Y_-%Q0M$4:;
M!>]&MH,HB;SV=$@LS@,W"R/-B]$.,LI0V2QB#88;R"E>RY:(+9XUPU5LBO16
MXBCQ8>(JIF1YG]7V"37.F<7ZVOH(5$Y64;1&T,^N-XVB/-'^29>CO"^^:K/U
MMB[^VMICKN036GT^H4FK7R73MC+U0;,ORCQA4GM2>2Y84/RL=6IHT=FZKLE*
MD8#4\&5AU;D@D]DH_C#3\7U=/[:*<1$T[V!SNNLAV70\,$]QG,T5UI-J.D<O
MMN55M[6[QK5\"7X$WY*XV?'Q61E?15^I)"'W4'$;YHER5A^B82JVV!EU.++U
M[L@(*<*?US+OLOFD@*VT8QM%#*J+MF:"_,M=@'MRF@J?!\WJ!I2[/Y//A9QK
ML7<V0P_;7-_?-,QOD#)),WD9T;"C<;I!7.U']J@]8T>JOV*T,&OEIZN+$]]V
M5%%R'^5ZD#\D^WK#671<_:K#;O_U!C7($\ND;<E5D6MOWNI>?].R\SM#C[[3
M_07+?1:C3C.*9_T)E&X(URBTJ2WBN%!Z\M/?%+8/?NYV%GFIVQTFC':V0]?=
M&^_'/]GQF%,^!HDSV*%&:^I601M1_=BA1EOM"9Z::LJ0$*(OL$/M-!#-:;K&
MV)0KKT=<L%\_3(5/O\0>3(4TVM=(_J1ZNJ(LW)UFPG >UI\"CF ^'R$>VPI8
M"Z2O>1AJ (M"H<1PLUJX:6*=7GLD:QP=$N> F_(*#Z78I$I(;^0>@^P/6W+N
M!K47U%EY0Z>#-3>NO:G3^2WN"ZTOBF&VY(,SIA5$8G1J@*8>[?VO3[ Q%,(Y
MI$AT.V%3X_O7'O?BM5G;]OFBLGD3_H3@J6#RG2/S"4VU/0W&]9WM7[=SXXXL
MCT%4&,/^&+1BTG)MD8[.;':CO<^FQR^GEHU6PI72D]/>&QKKJ&[M3X9 ,7TO
M'I_+K]86[@A-60ZJ(!_4EZUHY7/^#B]1].1&FN=?;9<9+H!ZG$?C)>XOA94F
M9UPC>-'[MA:.;F&4QVOV%V)A)["J&-TQU6-0'9-H3^_K6A!#6YC4'KD,E>01
M9O>YPFZ^K6\\,OO"C*HFYBF'3FLT_F/4XI1IRW!]4RTR(;VU.59I&&SUM=(\
M<+7_L_'W(8.9^O'@!O)6T***?*M:X7Y5'3AB\.W<MX*IZT(50OUB&THY,8VD
MB7*+/,-'*<EJ$YX"D\4Y;'W\[_9_?V2]E!82P7"G\W9G>T9BP8!%][P6'=OX
M@V=MGI\6'%F!SNG.;DM/#Q&)FGOR(.;-[/Q&Q@[*#1D2_JBQL;9>/;A)4/ED
MM+!X^ ^64,@!VPP7P9AE;!0!L^1QNU(NJH_L!^\XTX [9F@9S>:Q0GB5S2NS
MGOX+KZQ,+'TTPHQUO)-%E:AZ$A\W];ER/)O5[5Z4&\/Q^DI#US5ER44RP[FH
MF^GLF>Y/*3=_9"LIR*%I+K-K4/)]F7^3I</,9^EA%&ISK($<&HP=JJ1J]9EJ
MJZ6[] 62A0C:L/_+3D%_K7$-X\:;==JMZ5?8;Y/W7YJ1&"\Y?.7^E9.M1]TM
MJ".8E C/,M+<9 /JV@ODQX.#GWPNTGFDE83(&K6O:A*/'+Q>8R['^ZQ[K&?T
ML65"KNU#Z(;U8\O4^^-I$QZ"*+7'<7ML;@1S8/_$X("BQ85((J>J!ETP&1I2
MH9[V>AVE"A\3B!A?M9H@[-2LR'&E9Q0A!;2CZRH73#"M"HI=W]=)\E(6):P)
M7"UW'^'3:N\3HP@]'> &5*L,G7P+<0% V9#57&#=$F+T\YE-W)[HV0<-)1:Z
M[SK&"44H%Z?;;4=7"?C8AY#5=RYR#F-J7*9>B_YUG1.#EYYWF_YN6.5EVVN8
M:.Q6#G\5GRB;ENJB:5;>-9::\F.Q*==O%4[%BI'HYWF?TX6_6>O'[IX[Z3S]
M.VG?'_ .[551*-1.W71_U(S9D+?%J&F-U93 T[0,9/F7L8[\SGH>O]S7CYO_
MOY.C_A\WSO^V6J0_*M0SR)<^XA/D _4?\O,_%RNO_,98M++B+:L7]K^36T0&
M;C'S8%Y#CZ?-@9W_S&T16?C(59+1*RIW^VVZW7_FMDR-&K6$!9T1C*,:=;PS
MF(1_&T<L!?^W.3PE/=7+>9.M?;H-D_7T/K7V;N4K;_MCK_C65)#6-=UC=\\+
M#DK&=QE/%%KV"LWQ?9T4L^4[""N#1_B,UJ2D::EGYVE-X&&]&%^:T7/&(XIV
MUBF<F9O*G<O5B%\Y/$(6U_^M.].IB';II#YFF$9I/G!XN'$S73'UDJ9YM'(T
MKV#,,>CNAAQ-FG5&Y1ATTJ.66;A5;S$S<A _M1UX#$H6":\*UCM#KV:\='3
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MV>I&BY0\G$(+;)L[!&%$B\SYMF6C<-Z_ZJCMQ(JL=EH EP5>TL.Z!+)OL62
M(%K100%])?9\'5)WZF5(#=J=BN\5-S(3Z6E(F\\+"?4:_^2D'R"F<5#WT4<H
M6B>SL0A"MT3,A&R%4IBXG@+:7P/'H'-H._U)ABF5K9)/,JL#PSE(\V"R7U!>
M@-/D/G<L3J0ZD FY/1ZXINBWKV!XN&*_O;7UL'JEN3G_5K10OI&MKIY@?['*
MP^^!SFE>CQH]M<W/[MJZQP[,B5TTVY61&KC_941RO5W_9-PBC/-M<ZK7B&(W
ML-ZIB>G*OVRB^213I!DFH,]_[E;Q$O]-&^=).YEK92Z-KUH8S:.X10KAL^(
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M%N;&0[_>,-%FO20*N;@NHI"],!).J323-I]JX%4V<ZNN2C<N\7:!, 1Q!\*
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M63#)%E((8GI^![/.\OS'F<?_Q=Y[!S6U_O^#N=<"BA"17G,M@-1(KY*K7$!
MB/1.+BHB1(P(2)28*$@7<@4!I>4J)2(EE%#$0(105 247@22H'0D$8E'4OB%
MS^YO?[.__<[.SOZQ.SNSF3F33";GY#S/>=ZOU^M]GN>\7P3<=6CB[*$1(]1D
M,3@!1\[,9N_AVG=C#8?S.J?6\U)X>Z=DJ:C(LAF TT/KG-4>0VFP]\UF5/HO
M*RXF7M?Y0=)VC3L=4][2HI@Y296X?#O$*D81XVTC5Q#RO<CB5RS'RQ3LXKDT
MXE$G??(2T?Q3I87[@B,KON+M9[^Q61P(36.&*C);0O6[ <G\RP'[NLDO+AG4
MG J(I=UNTDOR?A(<DO$^ZOQX(NO'J5])(F*9- M#@KJ&E+OH:J?Q<>WNP>]Z
M:?R__]<ZSZ>%.N8Z-'U[C,@^XNS62_?N]!@RABO7Y.OI?..AJL.]CS0EL[[W
M^J72[ZK/N37744<PKB^7ZQVJPK;5JFXI1@[%0 \O%_\Q1/40G,)U7,&%0B>&
MN_-);\ 3O9R++&PS YR\G3.8A+%E.IM\&V=0$XT#43;'!EA79:?LDXUU+W53
M0T8*W!I',*%,A?7%<>.34&-+V7$=XY-69^X6^W;^T ZY,=! 86;:YE[4=DG:
M']4YULMDCVI:^]4_2WAF$16M^<[,I:&HQ&@XHS!$K\:0337H ^:D&*0DK.I"
MD&9DN6L>H\%%G79A\.8WF;?HT ,9#\+I5Q<*;?.#V6CT OK]D:3CXGG#-$?/
MJQX/G_F.9-R)QCU^K\T58QWE/]HU6H6!VH]UW&:1G %QKA//1-#=0.B^XU50
MCFQ79\7-08[LEKQP:V!7UZ0S;@N.88S&Q4DI$;PS=-U HV5R.OME.IK<YB00
MQI3*'.X85H?5U$9'20-Y'4%:PX1S;/L$WIDJP+\K_WR#?X!#V>HL9.1Z=-$E
MERSF>V2!^6S?!7)+T^UJ/8VFG.?0O4-=;]?["#?6ZN_X'+JEI&)O_-[0,4;C
MWH<7[D7R(SD'3GJ7^(-=WY<KMFD:E;E$K/9+\\NT/A*_ =[,+:BD/L639CYX
M:,'J0"]//+V#T5*9T'#^BIQ^Y8.RIQ?0A<T&?5'7E#7IFP])2G8&.3I7% N/
MI)=X7=AN,OTMI?MO5UN9S="U^_]]D?+_A[=]E4JK,WJ<0;=AE!YYW=ZEM;E]
M>$M,*;5ZUW1*W2G=O\^R,C8S#ED9-I^)C$LYX?#LZ9%S,X&>R1Q]H:9\*HR:
M^DGL1XZ?QMHBUPYYJQ77FV$]9@G9"XP)SE7KM)^:]+-]4-_VSZ\;_AB[IOC3
MPV^>'6,'G/LYIM7Z<F;*B7=]]/_N_P^QJ-*7 ,2I3*CHS/G3]O*7;KAE>]1Y
MN+<5XR?'$J=+ FW?%Q8XNQ2NN!/FK4W1QSNQ9C>*SB? RFMOUXA[D6@8A[,/
M-9Y<]GU S[/2H[-];VEV%AKJ-,4<=9)S/%RH8:-@<R"=AGL1(P/(_8^&?I(5
M-G29:[MZJS6VM\A"V-!]Z+'M<Q$Z[?J^?C8/ZBE1N_Y:JE.B/^'7GQUE7S[Y
M<TQ4V-#)/NXR8O257LR]P>_;YIF!GAXEKC<')-[7J-8[C-#&$^?4_&+_A^^4
M5!Y@RO1.HO@R[&4O ;"'I\ B3^AS_WO?J5=>ZA?BN_^.=/PO?:?P]__/'MZ%
M*>/HU!T0&=\S-ZDD. #A^@H^SC40\(W@)(@"%H+K%&:W#RQ[+;P(SU::MR$\
M-0)YL(.P%YW\MI:MGE=]M6$'% 9X=[4NX*'3T=,$+96S#M6\@A9Z2_H:#M!
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MP#-Y;X*T1XW[[:Y>W\ X@5/^N.N&Y![8"A5HDG2^_5CMJX9=:'Q51ZU[53S
MZ?E^( *E\VT]Y*I>Q/5JHD?^[,+L971H_&6'BSF*YC*!YU2]4X!KIZ_1])CG
M#^+<F 'MF?I!L]_T'F@.D9S+2D,5W6AQGM3F&%+UX*MMY47S]L!.3#!]46H
MMJJ1$."/9_SJCM+P/_JA3K[JNGOZ@Y=Q6S>VZAYOQL2_(.W+M8%>P&2>%'P0
M[-F=PU+>74N.X)D590< > 8I:9O4^<6W1I6S9:W)D^#N;V!U?]MX)N+JOP.2
M7/9#W8-N%22G.2U7\QQ>V$:JDO9]R'@A$&9L'10"",;0 9;9[IS4L>@Y4P?
MGB%JI<!0JEP'#S1;FP,/-S.<W#XV<A.^3*W,JK"",EXN;7<7$Z2;YR9QDKK6
MDS'!(>C<*9IPY,_.37E25-B53(VUCNKWA(DY>;(=FQJ?[]\R'P=7!7[O7(A
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M8Z2#3WH_@]TI).@4AD0MKFL(Q)R$I+$)2!%7M_%KE5S)E5EQ=F[%OY\G=+]
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MEJ?SUZ)=[M%9%X.*?8D/9!PTY)*++!V&"O#?J?=_!?GV!!G</;&Y Q*O<.U
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M-=,S80:9#][T++X$8(F<&AL:Q?SQ0G24E5?8DRN .?PWLV#V$V65.X]90-J
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M'0%\+.0Q_M6E[]\F:[+_#LP[-*QW0JUR,UT@_J6AL97?U'YT,/)W)[TBK@'
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M#"(T-H8YN!<]WBG;%+5B\3.QL3IP Z7S[1J9'^>.=V6;E(54^%G'-]V\*I0
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M(R,X;\J5.\C^2<7+DO<H8!Q8YCP:!A^8ZN&D\ ="_/[8B_H,.<$&SU@?Y1J
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MA1_Z0=QIUFWAGJOI9S]=C58/6V1Y(/*^-JI-_,:^ZK]]R^@T\])&L P.=8-
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M(3UD/7JG8WM'.F^(P18X,E2>P"XQ8S2B=J>RV$&#B?_^Z#Y<DQ^J'&]IK)N
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M*:/6NSRD!_4QK)$>I;EM[QD[EVV4!G,*&?*8H:ZR^8?2H4(@])_X="+JTXG
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M]K)5^'U\R3. L>4_V8[.O^SJH+Q@B0:C?LBP1WX7@H=0Y]6E3%;_!B<4TW=
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M4J^D,LVS/IOR1XC_.F)7^W]3=#\?P?ZFP?P6#(Q.:S#R_&ZMF49T/?Q1W>V
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M8;-8%84F;[YL>;-^H;6HFM'/V 4R4RY,Q80UYVT#N:WL-//UX!C_X5B;1<6
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M6RFACK@W"L$X9JMPI0;3Z(R804X2OBRQ"&A"U6,9\X4YD0=^R!5;Q\O8X'?
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M:*K3SU/Q+N72CS__@4<](;#F1*M62C@=""6"WCAH&W6Z$QVI-\AOHYHA'8Y
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M[KVHRZSIA0+BW_;4ZT:%AO\PJ'@-7<;=).R%+'^R!;"<WQR=([Q[C+_[Q33
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M*NKSPUE)OMGM+XBI!#-U-6,/--84R3."<=!*3EE-5&S9=V=$?<P6_NH  5D
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M@A&D4J(J<>T7I D'!K"NY"U_HCK>=8.^_@']$-^1\=AYIP27#GR%7S\ 6Q3
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M4)#.KX:IF2PRKN>'2&2=_;=NXZ^@*;2)V":4>[N'-WT18LROC#;TJ8V[<C'
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M ^CG3S$=/'RV7$-Z P^FZ(1)E/58[==\#Y#T1(-TY4)X#DV("%IYV+TZ6*0
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M".'DC<)WTE<\ 3H(KH_M=ODF5$_P 3O,9:!.0P_\ZM4N/A*PX[?8VF":M%4
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M;^;VTGIFYE9SWZ(G5XT_K-A"[ 7GDKL/X =Z0L %R:4@^%Z Z.T(%2+/2V<
M!U%)OT+=W4)4 L6-A=S=6N*3-WK/ =4DEUJ WL2Q!I!MCV. 8=Y2E0O1F3 Z
M5I6*=V84%^*F3!%322E>#S:4IXZC(,]IAG"-6BK!]"F8\WCL++-Z(Y0>9UN.
MC>>A9A": DG#L'_^GB/$QM)(YYU:'P986B"%U.0V (HO@-?(_($WOD=X>/P
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M0'?*#9.1B\\_!+8$OU@=H'S"6Y2;_6M??U"8R<BGT46WX#(078 ]3$,3&48
M !XR8[_:+LVUZ.XOD"2!F1,=[!==4IH[7Z-.8:5V3!9(UUI75DPUVU^6X1)@
MG.2673TAH-#4Y!+^>DS4P]]%W>,/8S<)1Z-+D]5&](F#&M*NO0"S7GWDV!#.
M?PX]C&1*F67TR=V,::7Z[#4(642/;YE^-90^@;T*"8]G:[=_,O<+6?@FF^4K
M*CI^-2- %C#UDGN [Y2+K_S>A/CL4NWD5,-Y.OV/D.%6*:-_/^+Z0CB'K7/P
M ?5,: ZYJB7HXY,XV:3Z@?RK3>SU]_?3#^>@X?N]5^]J6#[Y[JT>SVBDH#B-
M AV*]7@ B^K'Y#9\ >)Y3Q<#NPE0@7J:H7!W( .JNL 'N#_(N8)M__@\)Y3S
MFH'\1$<7>?2Y=CRG)U+RXOM\D5819*!X?C$ZG=5;623DXJM0@<CSQ+X+@9PI
M39PUK'+9XNSVZ#V_GGE1Q(]=8>.],?@KM?_:WQOO2*I#!B1YA9AAX;"=^@IM
M+:<6SN>^H,;L8)$[&/V^LARO*AZE^(^VM6BR[+G G'796PZ?84<\\"G/1%NK
M. N1@9CV!@<OV<V@?<_J,+U,U&]+A&5!@<G\ZFUUP;]Q@!?$92-B/-'RI!!Y
M4 ./TD#H,$"NZ<I@@:C1?:L#0H= :J6&%,^(^!9.G,2=)%:?@8+A1'@B;HO7
M2R8\H"W!W-0W;-<6P#&EBY_*A142@.<B:@3YC()N\E-AB]W)X@ ICXQ6B:#I
MK"C7!L.M\JJK,K>EQWT\DZB/ HMR"@9:2N<B>(SLK8X7(DC,=UM0T393ON;B
M719<P9DCGYQZ^$$7;6Y-6.JZ_'[?GQH5T9MGWX3VU-EZT[[(RG?6,_N_+A<\
M^+JXH.CTOD6A1T-P$VXYI%R2I@VD*-P BBF0J/(YL\X+#=BZT->C"''/?OF2
M?VF%:DCWX+*G$/+36X9LH<0((.@O</SOZ+7H3>9;%6^IU3PS!3T^Z)CVC;U+
MYT!3;!@)1; H*-CQ5H)/\&))V<J <-/3WIMD[[Q&;S^[W+<;\"8&7F8BR>>]
M@%HD6]0I;$,I?)[WN+/<#]VH@GHYND*YW\EB0Z10^MRR(HZNAS+;JV,PYPRV
ML<F3''F(3+\R#I"-\M9/].W%39>4(F7+X.8:OSK\.<6(,RN-9^"@RQ);K*@A
M6PB_3>\FXLA)RF>@^](F5PNP144ZA&[F37"OTK\O-R>8F7/T-V9.SL!R@?67
M@N*\HM/KD[SN>YUIF9T4E!IQ59;6QKHI2YGEGGEMS:&PP[^296DEH,#]#)<9
M.6R5VX,T_>66:@)F4RC?FWU?0PK^&&!//LOY$?60G@T7^GDQ%Y>W\T[3%@!(
MGAR:L^#-!@G"[>9,R*OAU'CVJNSZMP_:]=:@MY :A#:?-?-R#=FD"Y2=GS<E
MXR;AY0SE$A\@K"AO;(>TPCY^H[0T#=/4-X1'N:>*)'URU6YL38RL$!1OTWO:
M*$UAC*EN,L8LE+8U#-8+O-!K9JP6)- H:)(H;7F]Y6/AR5GGK^<VYWR^_[%[
MY$T(_],GS[==E(FT*6QK=0H^G6V/3D5<1;^S3*54$:S;G::'Z,0&%U@'[>=N
M1-JXII=]#[54)]A:^U78%[>;7.O=W60;3/=H.)J5,NA>6O0\93\OBA#:!Y))
MT=EI//E>_SEJ2';P+15;+CE-I$"V 8$'1V*:ZG&HR[@I3 V7"XH!M+7X#1]!
MS56_8M/DG7V?5%O0::TROS)&PK46:\&Y8L/P'%9R^<6@E:R0BB+JV5!+[_"R
MEJ9X-CW[0+>/)?(UZ4%SFW]+X\T(_2\WM0Q'HVK%S:EC\YFSIR$4,)\=:UJK
ME%?&.'V\Y;W@%-LP",Q7<<R_EL6M*&HZ&]84'5YEWW2FF'[O8T^II=RDX$&;
M3Y!]8V:$[9?,=:M'HPP<29@;^IL]MA%9JT3S0+'YMQ*2'F&O!2SB9#L76Z:@
MX/3T<&_QG\+?J*BE2Q^DXOBG'(U7,?"WL'[I&OA@*]U7JB$9]#XQ;;&LH.@'
MC+C9)$?ZQ>&6*+0#&:B ?^CVN/S7T8'0$IU*3PXO C;.5K_-+WRR-Z0,#'N<
MC!DP\*F'58:L%'$U 95>"$]$<Z@KB)'I3ZS&ES.-L4/H2:FC7]_#_7H >M#.
M#D8"<*:\LADY#RQV4F/#SIDLP>OOV&]^'!B9](D33TG@3=-AG+&80F$8=T$8
MSP5;+HS7.2F?6+9N#N 24WWB7@P!]J74'GL$W#L 76>B]IG#M^0^-U6+B#+@
M5!![8LTO:)S*'2[;QK%"Z=+X.$PK8)*I9PO(1+PDMEUND'UVW-MWV7Y9K)"]
M<KL*7T3RHF5[MJR2Z\0KM^=7W/1I5&TO04);JBZJ (A.NJ,^290DD^K4<?@4
M_%7+YFRFC&S @GZZS$#YLONS/WD.;I5[5 Z8%/5"TX=*M&SC3GVI+M?Q3O%>
M+QIVHM?=='#D!UQF=,M[#7MVT15KLJ7DY@7[4<)^+:8>B+"O\SX[&N'%W4:@
M.,[:'D]J^?J!LQ9FR)Z_4CXV69 !W%4\OQ_ #LAD><J8AJSS^XLA?M#QEI\?
MLV*\+O;/*O :/$9\2>#C4G,+'2YF?/$5!;GJ?X!,G*1(]PMB+,2;0>;G]X%*
M37LJ2K_-)JL?EAIZL7]%&9DLR1:4FX4>A4U05=F,[K8U-:'<Z?YF>X5^,O+I
MMF5(>$+.U^!\AC$KZ6?6@L:]KWO$>XM.?VT).]2L,,66\^)A!<0B'A/?)!-Y
M!B2CR\@ '[-LTQ/SL47VH#ZTK+'Z#M,L\6EXFH,A$B(5E@_$,O1M])BZ[+6H
M1SN7^ 5+@]8-''V V;;S)G:ML9B)W#X9%'+W0%N/G4G+FKCL#P$U=#@B/&KY
MWC>+WO\UF'])R#S@ARV'XWD*&OHO >X  ;C((!XO!LS4'11CW\(F.H0,%ZBY
M0C]J:V9[;J'*@?,>TD]'<Q"XPKXP?NB3AV@7*[F*0[[DS1"U9-E7Q<%!,GH\
M/A_A)]F\ZA.T;_:]'?0D*")PQ#[Z&\"E\+UYD3HOQ*<H>O 182QE6ND$]@SD
MAH4VZ@K<OLCO%*8EG1WLZMGH6\.VRZS\^T/SFD<R-]?]\FF"M=K91>]MWWKM
M>C\T^^[BX@9F;NZ7:WY=Q.OQV8[$?:;.F)7$K\T)@) T")%'' I<,](NP98J
MZ/CV]!7/-21&/2-"!A=(^OQ4J_$V:+) 0_(;:'DC/<J3ATM79 JZ:$M312.
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M(!X+38:E5.)Q@O[QT!TZ)IS9V'I'MG9[WA#RY#0\7,5%]TH E^S:B##P&2U
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M+2:,3T%N('GJ*5I^J3F8AII"WD,<8"SGN7^:G]1(]QRQ=!T73F>M+7_[J3,
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M9;-HE=I=PW1N7O-PJQ9A_U EC]++],/D7&XZVUC&A $8JA??G(\5?)0MZ"^
MG9OERL<)GH.HCGZF%OM::FQ@&;ZYZV=(EZ-3P=&V.M.8U7NZ8<@R#2<@4B&
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M25G*@_LK<<S4"8?-\3@N84M/)[=[6/0;6)4IA76:W8LA@(K89K^@7P=I@55
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MM,IB3.5"SAL8\LG#[1/4)5J1B6CEHPHSZX4RL'?A^1<LV%=&VE6FGK%%@16
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M9=U^W^_]R]^)I!BMJP6=2>^O/O(U#G_W#F:[T&5/'*Z@+$N&$BF (F1M:W\
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MUL#RL?B*A?)Y;]FP9<FV9'1(J7.?ZH_&4,E(M'"!U.72*5.AM52D%^@8 LS
M= >F$4T9IHG!;8BEV?- >+D:"D.!PIC[ 3GEJLSLN;R<1W'W438$/ KB;]MU
MJN5HO:.FPLJ_>;_D6"[<DT75CK?HGE3N:_G1>M\P5!?+_]% ?YEQ:P'Q#KTL
M80TG5:X*V51HQ'YBG,X4&UG><K$(]Y%&:8W8 6;N:F'T2=#91XIO.CU\NVU2
M[GI4V=H2OV/<$P/,T^OWY#AH77T3-8O,*^4E^SJQX"E9!4 _TZ-A;5NOPZ%
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M09!DR)\^0[W'2GC.;W[3"NK<=C5@#)V$4CTE>#Q42L5$NT8V9K,,V](ZQ)T
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M3'UN$/%W3!.EXFWS$#PH0M&R;3)8$T5<LYS(,QY'[LI'C@7>]](H(O)1XY/
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M^&PJ1Q(AE%>HG9K3)V9A>FTD_^E3$_JPQV)$)+E_?G5HD#(Q$@OR0%URW."
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M\8FRL>+H*\7'-_]$0)_^_SP QK,&Y.J^Q[A+ER5MA#M2P\@6;YD"=#_QC^>
M%IU <@00IV[3+&H9%B:M!NNPJ71MSIC!78Y.F'6=G9V=<7+Z<B%>.8T9#\+_
M?5'I0>3\.8 7VQ*TQT(OZ@']PM"HW+0Q]?"DC.'4\?3T,0.@1'8&*(EAQ[P]
MP8:7T0^HA&G?T!/LZ,+R72'*JSQN9?8E'LQ\P5X'P5 S-OTYVCG1.A+4#EHR
M->M;HY,W4[X=P@/?A-FG:GSOEJ 2VM164M)NIC/,5F$G<_GR@96]E_(2Z7;^
M=9][@C-=G",58G@SK5]9AN^;5F>N;HS%^CW?E#WT'+$=V< ,1N$F4!K%J\Y5
MW?D-J3HK&UXJ)[5G#:#%1@3%E(//BXAZJV-%:3FF];OHZ5J8C=T!W5!U)\G*
M=AS&S-@6&5%C>TN*8;DWHIP,Y1D6BUWL)ZNF0R)ZYX#'G7"QIHEGS,?=>O!3
MDE%O:APX)[Z;+?S&&-83>]FE4KV((V@/"&\B/WIMLQPO>5%;,_J&10[?>3S-
M0B*W:Y&_M:=O3W_Q_8,&]BLX19SJ7H!<&[89DTS$V9U][A:C Q=?)(H134-(
M70!4'P>PUA52%.KQLMUL-V_11?V%Y'U^-2%%?GBNIJ>&O6_YG!.1V%<=N1(Y
M@J \LICB6GPXM;"YP.;'U*97$S3#%VZ&^XW?H;KFB6_=:VO=9USVA)8R],*,
M)1V68D2<<."^9=Y[$J6YR8.MXQ7C]]>7]N72%32=#64%K D!T8[?L^:1Q,/Z
MW*[0SP+#,-^YGS)N*LZC5?9E^FRL<UIC25(;:),3Q29I0\4Z8OCQ!88M;>1F
MQ6[+4J]LGEIT-Z(O-!CT'"#J_49M>*ZL#]V-*N^CC"VN)BM\+C=3A8J<)8'[
MTZHWK%V(S2T;5=#<Z,3'"K5USQ*/5QL/73@>40A9'I_A@4;X0S8N\[@O%>LG
M"D70,JC=S9S0)^K@B*1[8'#O\[1EI2\WO%SF_IGM+3"AS[Z6VOK0:2B;,5U]
M)#RNU=9FTVC\]>OND+T'2G_C7K,>,K9$/Z\ _RXQ"_D: W69=MFH^V+ ;?_;
MC_\G4Q@)]', TRB5[QPP-5A[#MCH(6/KJID&X1<,5FS@@C%M/R<@#DD!D$)Z
M-',EY^)?MI S900XXA9VN8P\<LI) AWI"B=S6T$RB^;>0FP9;&?U>E*1(]W7
MJ1SO=%A*Z'><()R;Q^T3W]%U&V_F=KL\PT)*IZ"<9^_"%#DWVKT-W$3>N4P;
MA93-^W85DG8%5^?P\Z"LNW5)"HI<[VIV*.B*AXU)GZIM7J<G391F-*$)*<1"
M\Y"_EAE&;[,="SWHX2.*66"UM:@^@^]1FS]RJPP#WT%-TZ'&AO:)L*<]"7?K
M @EZG\^*$#!$ K#I=1%95^H+KRL7015[:][16\-.5'X,#:/+H;87LZ?K#E='
MC^:N>)5U8N"_=?(ISSW:\/!R2V$Q!KNFDA [:*H-B3UK:4?V2Z$(/=@;>S,<
M0N80].;+ 6O$O>@</=*-),Y/$==%+1*0._*'P[>=:MMU6TJ@U68W&DUI0WGK
M'Y]!4M91AMG^'W]$7P\*0%?AKE</L)=(G'X@,&7>0UNKCNQ'O6I3_QJ@<%Q9
MS3IX8NZ&FWXMTQ)B<\E>HP!LW>)N(X\9]TR(\N2WS09FO=(RL@_1>S'W]6YQ
MY]+62"7"<X&X0([=GJN@IQI3#'*BCOZ]=)@-3IZ(30S: 3-994\U)5I@75K-
M$2$/<J7]Y>>O^E_^AK'2=@3SN[_%V^6L(3AA-O",7L&]N#IY.1\%M1U/&T)%
MP]B=;#;UK[[6M+ -7U6Z9^$FW,=W_G4,7KK.3R+EUV3Q0D\V,7<K%S6E#]53
M;_C!Z#4;CIC (&GC>=6NDLZ?JNW6$8H>H^*IP&NXGPJ7U+X=?.-UBL&]F/[V
MDCJL-/X'R4FXOO[I!<-R:%K.KWKPJM^Y&MPRXXM9![+JB=,322RI# TJL.=9
MW]$Y@'5N)-B=MX+GVTEPS]S4W$9.=LZ/Z;DI%U-HB%M8,.SE7ZY.CT=-OG@X
MKW9AEXYWDJGVM&3*;BH)(@2=OX$/<A$"I_;>=(+;F!+DP&M/8_K/ 6;OP@:#
M4V_"ZK8NEU>$"0?\[3NFTJ3YB@]XU\K6%)A<$HU\5Q9?8W'-U=RVTM"NPMKL
M@8;$7.4#W6 KXW6W))*?R#>53A;.I5=)O%(Z7S=DM"(][7+49:\9FS0O7;?I
M2D^B\JRQ]K6:U*[PYN==X'L;1[CLY@)'Y!2"NU.%PKM%"QE3Q5Y&] B$E, S
M'D2 EXPG5JC6T&[9"35=>_N$^Z/D7T=[TTUK%IR^R*Y;B/,V5EK[B:6L1%H7
MM]^;ZC2_92L1@]161AK"WS26;Z\9EB06J)\#LLV5_ AOY"W$-/]Y%<[,9D\)
MSG%KDG&,=(L=?AE$M0R, =[K,:Q]26\UW @#6R'ME%8[G;V--9M[NM/.BD#>
M_O&()I_N"Z(9);B RT7F)+C7,T?QX8[0FDW!Y_;@0 N:K^%7$2GG'RN8;B7G
M85_5\E"Q5HQ2Z>A]IQD=D(:5*5M\[Q];^IS1-=H\&POII2)EHEZM7V=J- ?+
M<Z'EPRI)>3+D&QV<F9X.PGH>V>0)M;@OY,\CAJB&FNN'^>G0^0+OH,V'QA4"
M7U0/M8N$Z'5[ Y%*5*/D8#:0*?Z(@W>+6!%W),3&>W\J*"_"R+$SSQ++>W.3
MCY@URXMW&5%M^")_2.:4RN)\;*TYMFZ1BFT!]BD257!@OFB=@#*Z[!/\H<AS
MV(\B5JAV5_+$:FDVG[:/]<*%Z'[O9"-L=XS)N].4\ET]G91K=3OE<N**C PI
MI:^'O_TE2G-L0+/3^0X^.=+1)&#-."AS&6_G>N!T7WB"#ONM[]DKG1=2LCV3
M?2_'O0?NH.R4JVSD;"M'/]MOXC/SS(/J#W^3MBB$M$>AOK6]NZA(-K/_DCT]
ME/\,%SD(\I\,&AQ_"/EE/?*:H/2/%^/-!5+@Q-YC.WO!#._V)HO08/+]+O'9
MK4D;EP)7K^;'24,1KWVS"8Z\CYF6Q0GKO<^HFECWHX2QZOI#M]CBTHDJJPJ*
MS3MC"?X%-*WCM5%:YK*6GL%%]FPG83G^#"UW@ZA]\W@H;R'P@=P6V9#8:VZ=
MN6E;3<[/RT*]3G^5]?5D[.\+CF31N_<+@V=<[Q?PNMZE21W6R@U7F5&1HS/%
M7N4MNQ//)"'+'#LTNAL?;E7J9-2X]A3;T?AQ^WEK2VNK@D>:>[S83X4$N(^K
M%(O6> ^A0&"\3$9-XDK7B4U 8(7XF+ER0"(4Z?->^Q]EOSLX$J5M'A+[S<M-
MJ5E%6%[GT7,"$!AC*Q;;-YKI(6"#,E'S-N1*RC!YY:3N5(_MQN_5'NDJ[^^9
MCS=O=82=@2SK6W._G_2<?'_>VMS9U(&!KZ$[T(6::YC6=X]RKZ5)Q$],.$1L
M+)X#Z-*@'3&2RQTV*4O$)3AIIR2%'^W/#T=81D &H[B3I=HHA"Y2I:+X=,/S
MCBYT:U>K5^^DAHJSL0Z>\1\#Z/MO =/A97*\"MT"PQ)J)GY*!2UK,?49X.G6
MEKKMB>F!7IW?<,+VYLD*8O\TSI(U7\^+.LRJ::/K&<-:U?R),H?N5OUZ>.Y-
M0QXM]QTQ!5M_9+<"<P;1S-%OIGWZ@-!IYDDJ8O5^_6+ AH)])R?T:"R87UPE
M\<,>JLXO6)%S;L;UR[WFKK&*R>?X.N2SQROU+])7UGY*)LCJV*GP)%?M-, 3
MIG*S&PN\T_.2_",=YM!7YUI*N(OS_(@%H5(<R^$:[QTC'V2N_-3CR"M\JLR0
MEU.5>;IB%0S3#DBJ(00D)-7896X.BI>II^ON+1;M*%+#%G\]+B&MQ:6S 6WR
MY[R[^0ARY(E.K4I75OOFE*/M<FG=Y'VIZ>F]YL0N[=UMAZD9;RZ7J1GDYY-
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M.:!82N*"@]MB?P8LA%O2DU'A3M3C^$@Q>*&(PHP+U6S;'D,[D:]M 3NS72Y
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M?$\^F65-9&[0B7-*&BP>-2MCEX*-DIALXP\]%A@IQ+7>+=QG6%? DCD\3FW
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MCO/$U@7L^-D-2,4B5.<\Z1-]3A?*^YKRJ$TV\8&9<@:!B::P\Y1[1)Q&P]A
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M%KO?_#8\LHR2OF'3B!/U.^IF@LHS>3'#VU,>\W444?OKU:&D@K&^?_\E]UY
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M.&S*S?9D::>[A>9;0O9@8<!EDE:"Y'7%,SD&][,'+E*N$</@5\K[GI,?V 3
M#C7=/EP!J:"^(G#V"H_Q00]J#W7R9'#]M>+,@3H^2!+(<;2"-O!!4MA]?B%H
M9NJ-A:Q[1G ;5FA\]$H&$L&\Y.&MJ5WL<2 1,:![3(G=MN%;)J8O@(0H>>!N
MK%7?D^006Q 5)GG+^8Z_\K$F%\I[F-YQ2Y_G^=^"7&<?*MW>?OL%#/:BU4IM
M W7!UJ=*N4.^.V80K>- 2H<[XL<R":_Z!;O#-CX(@! Y<IVU/\WP01(M4;4'
M9ZD2*S;B,^N*A,B=,ZX#D1Q5>E)/L6[L">X%A//0=":XQXW<7!#J:\19[8G^
MB9(P^G%X84B-%$UT+=E?/-N?GN&:<.O9D'FK#3'[B5.V^6V(C<4SM9YP#=^)
M@FTY>_)'$J8#AW'$<L&>?<7YSP8:C3T.Q#'9+?3%NW,D[.VQMA-M\!^#/?H7
MNF>;Y!5K^HA]M9&71=D#^LO(@Z]LMKU@68F^>&.Z_XUAD?K6871C[5[.<2 D
ME+GZ+HA2NY7I.3$Q=1\&#0@*"J"'[F+,S,R,F[Q."TE/CR[V<)G*=+I]-<T)
MI?PX=23U:8+P0@UD2B&#P-&&1."_V<)$^*#PP%\%D<Y../T:YR@?E!T]AN1H
MEH%YSK9\T,XJ.H$K2?V!#Z(?>(Y?JHT''&BB?-#7#$"6#Q)6W"H@^+<?:Y'Q
M*1Q(PX<_4B!B)E @9?-=@;M 0?T?*<#7EP""*.OTXCLJ</8KA$-ZKK?$P5+'
M>$H7_TB!*_R[@NQ@@8*=WR^_3);ZG8(<GG10 WQ=%;==$.69_<P'381N(:6,
M3_!!0LQE\!]JZ/JNP512H,'I&H3SZ@\T0)A%M7)\4-<))I0G82C$!VE^%<-2
M(5  'OGT#^1EX@7R:IG?Y:N^RX?_@;Q@[MV9';QHVJ]XYN-.^!KR9_0$L(:O
MX\ :_DB^#/==_K1 7GI((*^E]CMY,X[&HF!9K3F"90U[*%C6UO6M2&A+&P],
MG_QC^1R!?(RJ0+Y$('_Q#^3A="?L]U4-$JSJ07\PSZE3?@UGC&3BP8?^0/P/
M6/47XEV_9]7=@3;6$A]T'[@=N4G+35INTG*3EINT_"?1<EP+=P!K9!/EH5:#
M5PH^?'T!)C=VPEEGN$E>?J@CP*L$:Y:V,*1P'[L_.<295)Q7$:Z8>^]$FU.2
MPXU]T$'![/_%RI8<::%W- P X8Q852;DOOQ'6EWFULI[7=70+'*QK%/:5&/P
MC86+%'T5M8+*F.96S=3',N;CI61SE^31W8(@Y7?SN\4O@-+*$\PGZ%]C.C>M
M?-/*-VFY2<M-6F[2<I.6?YN6;EZ-^"@:&%.K!"RUMK5DBE975S.]8K1]M+6Q
MMEF?W=W=W:X%==;Y^&#$EMM@RZW34H<:XPZ^.9*M>104 O\]-5::L6: WY].
M6N*AUZN%_M=)2_9,]\) _?K_.FD)U975']C]*??[24M"@Z[U&]/]13F::C^!
M0_XWV3?/2S;9ONF$-VFY2<M-6F[2<I.6?X663G*760KT&>PIENDLL%P7Z^4[
MUK%EJ"YP5*VSOS^DR,B/ 1L([/RL0)<J'6H*]=3^H#9_4'S4M?IED:\PKN/W
MQ/!-AN_"*5$;H5(N\+N</?V!/%&F8J],'#U4C/A+9?6 \8&&(#^QBM>'38UZ
M'?5MW3Y$O;%1S'AI\:&<&;9UM =CQ"GGX+>6_HO.YJ:1;QKY)BTW:;E)RTU:
M;M+R/Y^6A"@XTW>BIJ4% AR S"<R*6.YDMA?@'1&/.!% ,[@%+':T;R?@A<;
MD9\(9.0[FC@:_LE#G)DVP_NICP]Z X/G>E<N%' )!9]#[YOUZ(E9S[:^>5.1
M":5\[YIA?)"Y>)<ZEHYGVA!^ &:175C9<<QV7B/D3608Y_+8HHQWN?%>EE,8
MQX'><7=T2Q?'A$Z0# YQSNQPZL2>S/)F!Z5YE.9X)P=6/DQY,?3Y$PUQTF_;
M:^@P'[2YLIL.9]/A;-)RDY:;M-RDY28M_QY:^B;#Q6N5"AJA4A[4>-B>\B E
M4:9BL:P/(T[,QZNR=,#X0'N0CUA=K;BE4;%3O]WG^H?=)Q4GBEI?4G:GS FF
M__?G/LPI^BSG%,LT$0#7Q7EAQCJVC)R\-BK;.=0O4M3NQX 9!!T:3I>4LA\Q
MO>PI_>&WV(.LP:'<XC;,#NL_./<!550.3^ %LWGW7V$R-VU\T\8W:;E)RTU:
M;M)RDY:;M-RDY;\$+5/S\H)I=7=6&-/KD%@.M)A6AM'X-.W*2WPQJFL+NO+8
MIWAA\FG+GI^JPH;NWFO<ZFYZ:]WI'DSV^:A.5A9@4K^NM][,TF8G/4<9!C":
MU'XXVS_YL5LN[!9HZ_/0$I#H#NG>\_#SV3%JH+]S;)VR&9)D6W$)5&\K87^;
M.+S8-[AT!]I'N3R.X1_WC: 0[.N2F_3CKPRN-C%@6,2STC=$_Q%&I3- ,RJ;
M-]!-WG.AGA9)*S/C[#X%575ER<XUL#R09<(>B]8 BN6X[3!,61X=*V; 4(G=
M67VK93^Y/!9%#+8^G:I<'NO"LJJ@5/3=P.>VJFT%-( Z/FC;&O<U3\@\1/4A
M[@> X:/4.O4;1A(PKL/>IJ?$6":12VL2G9C8M ^N/N596H^4L]'HO-'; _KL
M(/WDU:701U@4<OJDARS+B7V9FXD[=HS &*B+C_2 45T<K_0'+(J@_(![!LX^
MVJ]EH[+O*0:JY9:_>E6>N6=E6P1CM/FC\'B"IK/$(?!R3S:U'"G%!]4IP7^!
M2@B%8.X/$<)UK@S7SM;3Q'$_#2=2YNB!GV9X!_O]G_KN%5.X+>_OX35T0R4E
MM,T4YN%T6_ ]CG*C;]RXDJE >+".M2GUR2#$^Q>41U[WCILHSZ)KSI9.'DE%
MME>F2)S8P3XMH0OBG7A!FD/8\$'W%'B-@7ZZ%# KUO%,=([,>F1\\8'PO96'
M4A&6S-KTFY[GB?*1&?3! \GAS\ZP-F0$UKDM6B"&NV:,QM='\X8RK6:G9OF@
MW;6JWL9N-E\(&B=LQ_?XKWQB+EK&OTYO6KX:/Z\BM'17B 5&8GGM>*85<JB%
MG=SGG]^%DY_-W,)47OU4LH!3QIIWKT!V!GOZA]27Z&G_H&@Q2KO R@0,:HIQ
M>TI[M:\\-5.<YV5LBYB!SXW3:7,=&S"L\L96CAZPCTFJ<TJ[:I5)?!ZLT)#L
M^NW&J,?T!.L'U!2BHL)75&/5R35L0.=5/5'=.4=D_MN6I9:YV(W]'"WN0YR,
M"\<0\/-BMULOSPWP3K!&N&6'@V-;:O?'R,21C:QR4+B6?)>UTCHZ;5<=K-Q0
M[,&;_>:W"T>]UVL+5XS^QO7F:XM8M_L,&D?Z*&^G#X,/ E^3)7C7 -$LY'FF
M4T2 PK$ (Z\&*MA8+%B)YR-B/3 T_"$J/^YY\ E+8]4!I<_7V+R?!%98B)>N
MB<AC'!##.]*^=T:/IKU2K4/N1*W;1!E+#G,PK%M-"K.9,* T**1X9&8@T_W=
M(Y=@UX^3;75#NU)$1CZK$#P]L]^_(+[\%(=&#) 5C<7LJ!DV@$%;HQ*(29HG
MCQ-V"Y);: 16]7(^KGWT>"C8B>4458S5*\BG!K' =/UGVO3*7E*QUL*B5^>B
M7IUB&/'X-1G&PC%8FVXF>*Z-)P]E8P5>=IZ)X8-VX>_AUVXC+S<>*[ZJ1-Y+
M%=+HO?D):W0P:5?P\2H7/XN,] >7LI] T2-E(VEKU9D1\F3#MQ\L\AQK7/L4
M9]ZV);D;'3 ZGNZS[,I^8Z69,X$7%QB$&GPLPT/C=>@)>VYB[9ZAX?=2KW4S
M]\9Z, , EP>FK=Z9XOW?C*S53T;#"K.KS)__Z!!QMK%'&)[< 6A2.1)X<V[$
M?B:A&7YO_2.5 ?Y527>@IZXR(I41FRZR*(Z%L9Y5.C07Y;E8O43$JJ]PMS;)
MW+&)TO&?7<[Y>4CL8R(WL1CI[N9=J3M &*1Q=)%S:P*O/#Q&X^W]TUO'2TM4
M+>I8&56:]R,PRQ.N8O%!9SMKE;&JK/CH>1).W-M8OD>7L <P:33\)A\&E^<I
M(9#(KXZ.=^(FLZ3G/!2K![07%LJ 9/^N&V3G_$?.'8'$AL2K<DE[<3*21=&%
M9\C>_MX]Q3,7(K5=7OCIA"P=.Z[N9]JT49[HZV-<W29\KS",I%8?IF&79_@J
M0V^'!3,V17."<B3!K;ID%E&DF[8:#QS@@^8EB;QN_"M,O8T40+&KZ8=AQF[K
M=83QH'VD\,B,0F2PTK>3ST=3M0BAC3V TD8]YH6[MSX[+6FT.$ D_4FURZ6^
M $A/&@^/'QM>RT]A*P#/$MJTHGTV+@ S"OX)9P+NR0 VS#/T['#GQU)6OK#E
MIYT:J?G)=@:_S=$ZI6]7D-5L/[!ZQYY<W&MJMH<H=8$ UT <K"A..5T<.+&B
M[+0]_%GZ+?]?TD,HTJW#"R,EG$^VIM)3BK_^N64!M'YQ306_BP^:,V7&\W+6
M0X,<.$O!7CP1%!^THR42!J>3@*L8"K[>*!OE"AG&T_U"T^<)@_HR;(CWA@%'
M(S:^E)LSQ\,\GNJ8P"QQIO47,=F_';.',_!$/NCBF''-"N3B"HE=+*,P&.HU
M' )9_6 -(1!F5O"1'6WO%Y>6S=*72)+8Z\R6.MJ<&0,NB2^*C:*6]0L<YX[/
M)].YOA/PP45!1/18QCXM%#G#!PTY0U=)%^=#*0M&!:7$.3XHJU)S[7N7@,BO
M^+X2_*0/'\0R,^/ 37A$/S[HJ,!J8@S7H4#X7CP?= K,:?U"Y;#@&GQ0]-#Z
M87Q7.Q_4?K01P@L'?_TAAB?X"'T=LH(FK*7C.;:"B K<R0<5N?%!'X;Y(,;#
M^'^K!0QDD')DN7MIG![824&$<9YW5XTTQ0?Q(%E\D&,%'Y1*X8.:%"%,+GB=
MW,%II_+4OM\4;MO"!WW[2:"SQ)(/ZMB]B603R2:2322;2/Y[(OGL ^=9>,52
MYTR!(#ZH4*A)?J%HC2'0=6_XMI)*'\>4#Q)MHVXXG6(NQ++A@-L&-GY.S*1)
MEH;:,.-H1"SC!@29-33IRYKX&N02;;*=G?'H!A_4\ T^,P!?UN>#@)P<WCXS
M"!_4>9\/.E(!Y8-@)CQ5]-<F/LC,@ _2[=B-7Y>"/]_Y-S=1.$/*EP_B[H O
M:R;P0<N-<$9@[0/D-S_\\CF6(#W.,ED'95,)@G^(B^2Z3O&NTO@@*7_\)I!-
M()M -H'\?P(D8&5J+I(/VFX"^&Y8!W?C(XU5F)$<]45YCSF,D(NWDDYLD[Q3
M[.!Y\L<,5+%!)%:;K7W'*-_2706M'I$#"GQ3E3 AW^D[J:3 *G&ZWWAUS^>'
M>3 5F5W$.T]>IP9J7)C.KWAI>.R<YYV%W39IN3G6M@7;-1)]PSR5%YG4[HZO
MJ\TN/)>&O48,?4G)#*\]4?0CGW6.[F-4)S_4E-8=T=+U71LU2?'L)'F8VS78
M%L46V$M'9<#TE?1\I5$]A!EE*5OD+KSIO[D!\R95"O\EE7/Z^ZV)3;3U^!GI
M$2<1EAG/G-!HLR&.=>>#7O"R_D&77?Y7NGD3\@3"=(,.+8]#YQ3YH&U5W *J
M]^+@^FK#>E 3+1S)S*/2):I9UO>%HLO4\/3CW*Q:2:S!0.U(MEN;J&RM5P3L
M(M$47>NPH3<^/%(R17& .^/J"++5GALG>0W(U_$MU*B>Z57X[EH#7BNDE-2T
MJ/AY6E]\VM6AY4&M,O8G)OX!Q]8X-?]TATQ&01MQUJG;Q?G,HF)&J=F-!VU[
M5)<:-AOE_6L-R"27A*\[BL=T@-%I'W\-V#B(]:-6=*[XF)F]K>W$06:'>)$A
MQJFW]9Y0[NA7Y;JZ3QN.)OH=%-//*)I."7(-S+O*''5QL_+1M=.WX9Q(8;/Y
MH!PC;C:>V0M0^:"D .X:K@=97C#7OJ$T+8\KVCB)M>^&@?4I*'P0O0-,S"22
M %)C88$Y&N/'C::3P,[>=\@?S -"4&AE3G__ND-QXEK* +N\TZU#J(.V%3]6
M G\%F=_.B 5O"]8<)T?$C8NYKLSYAPHQP)'55F,R??D(>S^)Z75:M&X15*1=
MK\N<>/W;<DE^44"(Q%##+]TCGT2H;PL:4VLLC$?E[ I-5>]TYD7[<VG1RT5-
MREY!@3E]TZ2V-I6V'/M!2R6Z+=G[5J&I#4*WPM5ZWB=OI,=\A7> 2O],I5"X
M<HOSDGQ01(' N7.*<GB*;1LA^*Y,7A<<\,8B^:#62C[H[$95%4($D3X[F_Z]
M8?KMDD6HSN3_;)BNG\:8G&1<_5/#]._7^9UEQ,F-)%UXO(;8L,'77:5>) RF
M(4;$>?OAS:2]KGFM!F'&0AFJS45>H=NB;VB1J;**K@UUKJ>[W*JC"UWX(,PH
M.LW;U2/:WP5Z@/*FTAFG^H%ESP[&5F:@5B[TH5R"$JV[$+,J"=V+5N[7$[><
M@JV\3E)OJ1[1"RVS3)Y?S+;B#JT%<7;?'X,VVPS.LHU8'>'&!EA#%K0!(@G$
MLL-97G&Z\6"@_#=497M+1  X@B:LBS"R\]'[@J[:1KC Y+V^5CX4YDAYR3YR
M8EC+1C0!US?P#L*TA@R_A !J!N\Z)+!>L?0PJC"A 2E%ID4X*<DE-EN.YU6D
MFS(I]SAVE8V&0P"B?ONE2@KKF4S^^V\W^Y>=6QF3_JGZ O>!U$ZUJ&8!A8S"
MYH?['1!%%MH6AY)2*G/S=/N(+Q-MLA;&<BR.N8IG&=C%Y-<\^Y)V*VZ4J">3
MN7ZLX(N4K>G-C)/_^T@1^6XO;=:3#RJ)%VRB\CP^2!/8FLZ]3ET1I%C?#B [
M>3]@FG"ID*ETP@1F7A> 2?%!LE&TE!_$NTREN1+XI'W_[%;N_]%A/S3B[CR"
M0#I__NPR.OC9),#K-EHW>=61XKBDU;^J/[#[C>7V1HEL2]$NP_=2,24/BI]'
MJ67E]EBII)7:7.@9T>L[W&SW($?M?;.MM^T3A-V#Q,HGKJ56NFFH$2-;[G%\
MW7'\6(X,56[>GW /HD!&A\!C P.GO>@VTJ.P0#95@N@S7N\R4C$HI:1_[^"'
MQW&/@1@]=)&#_+W/B+8-1>0[H[R1OO ^\DI<>U/2?%*C06!0<J*Y3P JP&=_
M.\;/QU?D8*?;R2,'7[5+YCX^&_.UM74'+QT^]HS&M(VUB9-)<ZJ#Q%62:U*:
MAC7]2YFD&)+2"30R.C"YBZZM\VPN JQP4D)2Z\ 5W+XXL;[LN),WM'-YUU@&
M#:IW@Q_NIW\^$2PS@3C2=JUY<=O(!,Q#0MQU;/0-\8PF-\7UR4!?18X@F/*H
M%?PXMX.E=:MC9[7#A][@!(UDH;"W%$4'-9:HW07FFDI U(MNEQD+W3><^EQB
MAHZ;O@IRB/<Q'[TA9RKE--:R[OKG#I_U'%L^*,&+)<EK1,KB9^ OG )^UPH!
M%'3AWVD0^I\YI/]H\_N#!L'_&#1>,Y76227.-GGH.U<)Q:@4#Z<A_WG'UN'S
MKRJ65!Y.0HP_+APG3B[=V!<37/W;<%N:VL0Y0TT1F>3D9)GR?AF9?K:COB-S
MR&5PR$213,S+*T.+U9#)U1J/ZC#;U!Z;B)Y]W"2OL?_EBZU+.3R1\ T/K"?W
M/G4L!5^V.N^^ ?< \-;_@[TW#6IR[=:$XXB(B,@D8[8B(+,( <0(6Q$0$)!Y
M)B(BA!@0 0D2R-XH\[0% 66*#"%,(3*$,$<(@TPBL\PD"#*3,(0((7SL]_3I
MZCY]OJ[NZGK/Z1]=E56I2J52]W-GW>NZKO6LM1YF/:V$S4]D7;'-EOWVB*X>
MSL.2T:G2:/&)V-N=J#+^X!JVVT/KB ,5X@*[2$\;@H,)DXQE[ K/=U7J;AS)
M4^<[C*'"W*6+A&C_I JU'P+&=!D!S,:Y^BSIEMOR1C7TM%;\&PD>.CI&9E#M
MRP?J8-6O@$:O/6/Y,U-SE=6>:_T?W$[^$0+YCWCL\O](69V'_QUJ^Y\?MOX3
MC./7 /))(_-(29VZ== $1AT"SG:8#B-15%1TJ Y=,9$,EX:[V/OCN9"*M(,#
M)HUJ5KR<)DV^0^N+9"F??)5=XA_189)L7DNJJ_ADO.8@*MPHRJ@X!(1IA7Y'
MEV^T>+)!3/8$I2.N@<.=8<9\@->^Q,3:C"HW'7%XSZDEAY?OV8J#+#U*(F>O
M(H%=4J*'P1P"PGEBU%9NU0=E6-5_JLHPK6O:]F%>QG:0_D17IJT%S*&C@$"D
M'Z4O,EL(S4#249'^/+R(5*XBW&A;75HK,#S-9L2&Q\,-Y0LOG$*@3.D2T@F:
M1#L#E/?6R:S<M#V9@\I#P"P&2#-#QT J@&MW:!MW#W+9PDQR:]-UY@FZWSU:
M8D1ZGT-]F@T]:^9/T##MF: *Q//*,.@)_?<!F?ZR?(1#AW7$5X;PV@(Q 7%$
M=]K=*L^=O\49UCP[#^:^YKKTU9P\C%9S]S24>[OKNDIY6F^TCNQ'8MM=/]6
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M\WR5KVTR'_Y#4TKL>'_ON?ZJ0/7 U $3CQ /-:%JRTD')UTU],O0+A+-!))
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MP5P 5Y:CGKJ7*6*:<VJ8$0W:YOU*^[Y2S>F7MVPTLONP%SOC[#@Y[NS8K=A
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M85+S:*-4;,QVK*-:A"!MF(U1KY]=F;A_V=AS31DIA0,Q7LL9/ T;&%BX=2E
M_,9QT^1@UQOY1:M_)]Q6G0O8W]/0%Q7PVBI0TMDR\ DXQ;$$%DPZ=X>:T<>K
M2[V)O,,]-%*=Q"2U^,#AN=JQGFE$7L*><$#&I1^";7.J[-<31W&%9U5IL@.V
M;^?@]*78J<.'YBV<^9L<IJN#'O+^VM.'=G''NU23Y&>^,BO_>/%AE+*Z7'TQ
MB7PW4]Y]^(;32QE.TZQ7#_%GVM5N+'\W$+;$<8),3?0M?-,4AG))*K2M9F#^
MC"AE<X.?I?WY)V)L@1EG_8Q'T+7A#J4'"VZE5O3 D41>"\R#[I@*%D/ \S'-
MNK#H<=%=Z\NF(%FM]Z_>%9O1(^<BVY7YD:',(NI&[+1:5;\"TF3N5I;VBF4E
M;1ZWEAKM/?XT'NMI\Q;*J$O(*X'H7?R^]+*>/5@XU;45E"3\G&([#(;L>X9^
MTU9F@F;Q?_C,G:;-D)5/(5X!SZ$>,^_>BC^.$H2^9(P*7I]@CIJ';1KWOOIF
M-]E8.JZ2.DH>S79NG&(D^A5..$YW-(?VSYQ:)WF@X[-UF*"@L@XJM(&G:,R^
M@"28=9!41RC#Y$'KUN(I@]HSQ2%AA@H!QBBMP7W]W2_OP2C/9._E7<AW_"S/
MZA)]9(MZ5:>*HZ-7=?9-J' UK:&)W\2X-9N;5D/77=Y<Z<15:;!5WRI*:XDL
MC=\/OJ4&^Z!3;?'T2<QDY X]0/-%A%[JPL[UAVWS-Y\"3\1TA20<+[OA?\T&
M8\ =5O*F)5AVU%1-?M \M-<JSW0++7,5 PS_0FN2?^HB28><<%5EZ1NVLR ?
MZ!+&[7W UAJ%2.X/<[1+#=[PUDL*6UJI-R(<+;*<.I3:C/*UB0KJKC$/R=_V
M.D:@@T7S.A61K7U1I'--VDCY(6VQE5?SX6P<G>_SN#XF!_J*L)#E-G=;>ZNU
M+B2_26@4M[80,V,^&&"W7E"!\+EH]<>4:(8?=X]O#_H( &F.$RAN8HM/F(:M
MY5()E1EZ!5:])UZ%NS B19OJBT@W$^A[''%'%5J]A\&^=AMVT,R^6E?7_Z;B
M7M_9[C54!7!5=5\">9T.9"ELO$%=\,>/\[7O.=<[,6'60ZR@V9F+GB["J;=B
M,V2&_6,A)Y>(%QR\N&63.@E91K>]';DR'JJ]&51B#VRR]8_<WQR4.)[6BA+:
M#M&=.P20OR,Y*+>5S6H'FX0<F%Y[<ZWLTS"N)?9P,8@8'Y\5)S(:JY3]]3OL
MF]/2-'"(4O%I0-J'&[J'K-;0F$DW[WVQKD*7N=KN'OU(\B_7<HNVD8Y@\&FW
M#T,X_7Q9RB>F7(5=W="B+,C"#RMT5K55.K<QMN@@*'&V29XFM)A(5=)M/X\T
M=FR=_"F%37J$"* BTL(U=3G_[+F.B+/QS? 5/)NY^8 D\'XHC^--CJZ ^6.5
MJANUEBG0AA<MH:[FSC[AK!-S>+&0>O8%_"DFL>T0,(9R9P\>T0T(.;TC2J>R
M:8*16'Y0OR_]=6,5#=N7FAD+[9\_R%LE2M@< J1-&CU8UW02T-MZ30J' $HM
M/?(0(%O"*'X_*2Y;%^"+\+*6]/:TPAOQQ0\D-;B#I!!5PR-%!54>OS;"OZA.
MPL\\?FZO!(\E6R\P$'%*SG&M#XLZ;UJBI1RL/$R1*9)R+^:3C[!2""J=@&:8
M' *2L0?I.JNSVMRHY3;:?"@1U?SB$/!#91^$^JY![6"G(,'XSL0QEY&%;L:G
M@\QG>/C/JH:J@QSV!8>I<6<]J<9>7"^I%<VC=[NQ]6*Q\3E:5Z)8^?W8JR_D
M)8LK_M(Y4B"SM:C-2P?II%51NMLAP*A)PG9A;,ZL3?LTM"#;.EMMI @;UCZ&
M'5;=6R$CNG3N;N2_>7($Y3=H"S?BDBWBTGAIRU!L,71Q</BV,#-VEB=J^A;3
MENJH? EYD^[=.-MW\;N:/K<C>2^^'>U[]?K4^$Q(Q*\KOJ>QF+X =YCB0G)A
M6T !)$HR@3% O?SI$& "J3!K-^,^\C=#'?=$(.L*<_&3E_;M;SC%AIMS*[VJ
M1L0!C_3;ULH>-)G6M6-ZI>,"B5%S#0/>ZS+$3T21$'14E>Q"VN_EM/7R@B6_
M0X ":/_6$6X;T07SX/N_LZQIF?H\JUD^L_,=47C=>R9]C,1P%IRBJ&&L8E)S
M9E9P6GF8W2_8KGH?[G0CZ*0V^]H/YC,#;NI6G1I%]^:7^8B>&ZSV=ZYF H84
MNEKM4MVR]H!5X[MB4_[:=S97^+T47?%IV^IS/1-R=-A5VI9X#.[#<XZH[2UO
M(6HH?_O7:F6I=O*-+E^T36MI74#JQ6SEE7?/F:^8)#>YBF[8W*>O]%(,3^<&
M$*E)-R"CH[45F-9E8P=Y;=,7Z"]+9NLGX'+R$^\)XH[&PU(#J<X"'I553:3R
M8?=X)7_[^#@^+T%;F^0.[Z97&)2I]$S+4>@P1GTWV#>=,/JV$:H(^;Y4K3%Z
MXV1-;+N.*-@2%NC'W3B_REG@_'<CG!6TV-#50W1I5,/E JV5*JL8D&6TO@?I
M\AD/-BH?.O(0'#1OZHZG_X'MW.[J+_=@[B]VJYC7%N5,-_'%^L\=R9HU'\HF
MP^S 91/ODT*G_[XY"!.Z@-1F<E!VB$TP9[-V%]41Z;J$8:!)Q-S=?K58>5AP
M_0"R.WCE/4LO4!KM]=K]AV!ZYL"%$16/GYK)PK8Q]&GA'PB2WS$TI?#G6+5$
MAF^$U,#G@78#;NGTT#:IZ-C$5W^E$XR>PW8@G"_ 0F$-&MM-=%%)(^)%A'N&
M&U)M-FY0P%2@7/B>+\LP]HO<PE".IBF7Q.1F^K>2B@11WLA";$2;+5:G^1 0
M Q$-540^&_4!&] MJ1S12%C1]"1FH@P72C8BI$IE73:1^;W2T9GC7C71L013
M7=%?-<%URS7@Q6]A*KY'.O@Y\]1^8.B@3B5N_B]:8*NB;JN+8&4E<7"4\K-5
M-,NXK>FT2$A*5ELVV@.[E":24IU'>?\,N5@0R[ZPYDA.F@3%Q^-8:>G/@(]0
MB9[X415A=?/8SX> I]07/:>>->HF:=ZD>!ZX9%H8:7<EA87+G$R[6G3-*"/.
MG4.(?Y2V8-LQZ9M$YZ-.EL0RDT^T;I71097+-[\^JG0R@9I:RQD+QZ<$V;2W
M5V%T2BW:OA(4'GA9A2.LP@W;(3DSM <XHUV[ Q+[O-?>NQGH4(#C1JQ(RD%'
M&K]VR-INBUD4T=8RZ*$!/V]09;?DK^=M8H;USWQS3YD?7%J<$?Z8S.A@YNRK
MP5Y"U=%XI @-VW;[./Q]C''4AC(8.'=;^F!Z]8/CPT''EET'JY<C]R4CC>DG
M7*9JT\PB='Z>8'/Z' )D)FBJ[&4?=M%,%(C!P>(7I:[GT8#LL_8T+'4A2W$2
M10M'&%"F<TKT7.%N@<&%")<-2[I+RARWR(CX?5P.VIF&81/R#"1[80K<H3+5
MC>5U,:)?=(3G2B/ =SHLNJ#M<E4L[2+;8[ VRW:*GQ/\V978^$Q)N7=S1J:R
MFX.9.&&D\O[^XA35VHRK*7X(,<%G4[K)TAF(Y'Y-O3?IU<?WEP>8CSP6BEC6
M)\RY8!2DY<K4W\D9:0\*1>9..9CM?F+U'."T.:?9?>@JF=:-" MHTE*=] >J
MLZXY37]C3?91/4VPTD\]CR*\YD.P&_AIL:_^5DW$)N^E5&,\J/>6=<5^R&IU
MTJ1.GWHU48.HSK"QV9J:=NX3P&$PI19.3E-.D_?+[_CXG#3:[ 4/U!GPF^<9
M7HTKC.GY#%S48'/ITO3[[&FC9.5Q#W(G:*C:Q)TVTW9QS,'%V;&/TF@?@.)E
MZCC5UQHG0POLE_;RT\N2O#&#PP1Y/+\GPW+Y+*/./9.4C:8]0/UICO0^*&9=
M5BHZ6<&$4*QTJ07U^TF,HS @,E0U3VM* Y=V X2R9>H'U@LJ4SRT(E*P7I]"
MLF:%5._L@G7:U53 G.>EVTVZ"B!I(PEN0@$WW6@7_(LM ^L9[^MB,I<*IMB5
M)H98?U(&RXPF>J-+.^D]^LP-$5YL.#7AVN<ABE'50>:G;28L&E;Z5(@/^#0'
M6/+DO='[4FW90CV#??F+2^W/'[X[!#Q^K[O/%=H^4XEN=@]*;$7''@)XV1((
M2WO_J'O], DP_64&U2R&YU4\J"H)6B<3\:.!B7+W%>$JRD>3=S724:E[,6U;
M'BPA73;<C[WBP][4HB=.8.>J4(*DV5S(&99P[O( A&D\>\1M(K-/5X=IN&&5
MX]WI7Q.#Z,<WIS5NC>R)Z]^^U>)0\B[Z*KJY7\'PJ@IFN*_R"*'\=19&==:/
M6-J&)+Z'Z:?8^HA)(D]V  /3Z6*($IV>)]0Y*<OKW;Z@:Q;S+Y_'@S4J0KLZ
M+8NTWAJ-DU9Y!&KJ%?J0G'L6S]'G:CI>@V5*9HD18'FCK/M#6 7E<[[>EN$]
MY=D#YQ^V6K4][1,&EOD-92MS1;989QG>DF(= OX>V"*(>N?ZSYP:8/-L0VE[
MI=Y9UZRNIKRIO"9BO8OQ=^_MFM+:O^V]#?C7WMO"_ %H0;*)VJ"MR6V1(U[@
MF/./]ENCAYE/,,)Z-5TW8AO<A>5!5X^^E>ZU8KF'_)>F\&:]-6T-^R74*6W0
M<C5#YY("/&F0+"'S7SIP'0W"PR@)7Q[1JWBEEV:=WS+#0+!Z/:$5/Q^952G4
M,4%;8GK ?%D.=LK);N;[I&Z0>["'6NKHR[27 __#$!BQ?PR!25PY!+ Y^^G8
M.8\.GK%=8[I,._Z<T_>9[T[2*12\N/.EM0+FAYP)W7*DGO8[:YFP!4[+55N1
MBMSO*YLED'&Y3S7*K$8J,9+Y(+KI2I>4+L\?;8\EC052NYX7T)CIHTG9QR]"
MAW+,BXP07M!N;@\M7X2W)X4T!LDQ&WBM19=0H>$3H$]O8OE^C+D_<#%K\Z?M
MT'U[-I%GL:;^FAF\IGQV3MUGL4;90(TV(WZ_ #E_%6M![Z6AWE!FF1 UD96L
M$X5F7&'6'P+,#^[6%U-"KQT".E69T7]/.XDE[0"'Y.E\!Q=O%5_+_>/L/]O^
M%RM;_O@/68WJ?TQG[;%?YH> 4RT'>.T;[.89FC%I/)A1=G"$A3I8I#/3^A!P
MUI'-*]_'OW@=D7$WDLV''A>E:)!#@M?&I7H^-0<O(-S:189LZN<AE2ZW&\?7
M@P,L=R)7A>G![9 JX"IH_Q(KF!FOC?:C<\VA5G/VM5@N]*FOR:X2*1@G1#?5
MMH6'@]G7QK>4_N0!'3J.K)LFA$BEO/&FCTVHO5SL*0_[71O_SZI-_&_LQ/]2
M1=IZX3]['?\WVHFOVC)(":8YO80\P#2C[I)]3K >T":+;J#<F#_)(CK1I1^A
MK-Q=0?/ED30#LT;[WXCI7/N"Q,;JVNKJ6F*V?*RG5")=EY%^"'@=3'I"BGGI
M4(VG<=G1=5:7YH)^)*VW?QU?W^T@G?.H2;U?4$MLHA&C"">H)EJW4A/L2I_0
M=N.J#C3N:%1T"T4&&-]R5+RBM/L917/4B3@$".G N348ALP[-"!5J#5$PXKY
MI_(?.&WYQ71&G$)^K%$C#,+/I".OC5@8'GGQ%GDD-9T8]63T*IW?(?YG1!6E
ML"#ZU-30*R_VY&@A-OW'%L8KY5-2T2D'_H-\=^&[9H:FB6J4$I,70V$I@R:>
M7SG.G783;C*R"Q?6>H&6M+ PMA:ICJLR@7&"JK$TF?V[J&8>D@_Z3Q-4X2+I
M_*KV+:9%__KT[<#9@CR9Z("GA!B=*L<@-F ([H^2Z$;Y>E^U5U0#\C##QD47
MI2H2S>NVJL9V>+)03V<FR(RO!W_L<'LT \^![8L1?,;:EVM'D1!:8D?3^?*F
M?B66+@H#5>>;7I$ T@4_G&_,74X3>9J<(^^RN#LN@54L0+MS33;&=I\\!"RN
M01(A--N^>#1'Z#$6B!E,12?HE)]^O>_  M.U\25,F#U='>?W$6J!5!A>N_*I
M@8:I6TG+YJ<+1:G5(EW2IJ\EF@WY.S:*W+JI!EO37J#/CZ[AL+LT)ST(\-HC
MWP\AYP*KD45Z@_D_!E[4A[]<K!W3=C1-:W0'ONK\I9F9G2U@+!#1-MRR#WKY
M POB'W<P2K+F]QX%S9D[K+LLPU]UL"[B&;-TTAI]7^,(P82:+B,T6IJXZ ;A
M37(KD'/*JRQA];+QTZ7CRF&L8]344;C"3G>CL?F WA!;-;O?OY8 =YH@N_%'
M6M0$9<HLP4.]4<VR^0?).\IC0G?I'JN!LXH>E#0R2I39W98M1=<( QN4K;A<
M'6W0H5^]'?&:>EO5?"2@U\VI9NBWP>TUGCN?OOE<;AH+H00[GV=O3L_8U0_-
M ?,#MH3#,&+><FJ>?3RF(.RE;X4X+:>RKS>,+(\8 59JK"KXO8%&^,=EJWAH
MG>^[X@Z[K\O+AC5M8P7$F)#AEIAK9:KY_[7L];\;7C<S_]\./]D#?C9AX@<E
M65M^+-Q! 9HC#$VEBV[.WM6ZEDO*-=O,E]_687/^2=,:G3-;<Z;([M1S--&P
M+?7&B3$BDZ;)BJ6[;&!MY>L60<NO2082CFVCX]I%TFB-[/2RC'RO5#^'[B>C
MB3P_PT-WC[B)(OLR\OA!)LIC)DY'2/LRTH+I@4'LMN[NCJK__624OLA']*G1
M-VR))2%+SSUX6OA/DA9SB*6'7];^S?&6J+AT$,&.[UZM6;5W=<S$'/CWCKGK
M8O(?#@$>%JTV/2K?(NQ?1XAD+MM8^VY:R6CNJ\US6I#KAB];FCJ\C2B'&X8>
M7;PK)3,V&@FE<+1I3E8>:V%I1.';A=F2&JT4VG>AUY0ZL^MDRDJ(ESDF"AO7
M>SF-(D^!:!#(-GB$59P[9XC[OB?R[A'-@B,. 50![!\H+Y\HAT]T?(MU?7GL
MW8%2;171V^<A@M\7':9F87TG$5[[=QL;&LLC=37@W#L](XG/TD-&Q];7E!1S
M?Z$I[,9#P$EW)F3.AXNE2S-H)0DN-LG_?^R]=UB36[<OFK6L"(@@35%B!ZE*
M$40@RP((")'>B8B4$ %1D""!+%% NH* U"A5I(06ND0(14! .H02DD@GD #&
M0-J-:Y>S]_>M<^]^SK[[N_O<L_Z8/#QY\N8=<XXQ?N,WQCO?.:B/,:YEBT]B
M+V&KHS;0"FXB^WU<=$4VUM68GUD]BF#3>CN%[SI:I!7PQPB8<5H.LI4+B)K1
M&=4]S]*C];=EA62N2&O1G#^2BAGXQ_4.=IB/1N3;XH>,NH [YU#'EES=CNH)
MW,8[M A<N"X %7DPLKGM$7$;YR;IV% HYA<AG=[2D2V_*ZR7.EPY9]UTK*)Z
MT24;8GX1-X(VK_KV^L-E?=_L@#-S,CL)$B$7_(YT'O?0MHJ@.GQ"C(EN=I$V
M?$Z3#N[MK9BRTI9V<%:#!TN\F2^.OC BY_[F5B-?:@M)=J"U(]E(V/:)Y),'
MA4:HK79>['_"<'N+L&&G:_,Q]>#Z/\ C) ;RO6=Z7',C-%@AY6@_#AP-FD@1
M_Y$.K8V&A5PMT[[Z:+9Q6@N:C1<=7/MNEU,'=8O&DS>J_M,&N@1>-60:LH",
M%J80O) >Q'ZKJ\381YPOS?-T/L?0<0/%(GR)P/U>3R)__^XKI*![>,S?$S-0
M8-\%BLC!9ES]/;^YFM9%S! TL$X)PH"J4#H\,[D#7YE57NVE2I'![< HH"A'
M'(HZA)EVL#@_6\,()QHVN041D1$[;L3!:K;\]4BK^N$U-,*0),4%'(J[I"C=
M^EV]Q_(KNM1M^&YB[XEM 7%5+6(S/VE-+!YXW$&E1_6RVV5%(TN8(>E"T+3A
MAX#RP3AUI(>IYI1-=2'K_.@[/CES*':*$7F*R@6TH_(DGH:J#??"'^UJ14!:
MU33);0)*&L#?\P70(.J*8&2*_"\9 \51R2GRARTB-\ ?[EK IW1W72@U@G?+
M^26,(&LBVY09Y\82."?MX?OH!8SP8J&CK+,.C9+5BG(XLG#5USF:=WQXZ<S>
M)JI!!+I:?K)G4M)?]?%7@F.O)[VK<#HD>VV0A%=.XP!7"%1]2#CG$A7;!MJ-
M,*;YQ)"P^V#66FN1[W$PYDV4W$:'V8F(^<-$9:5-<%/"E\KAK97DQ'Z+H3*E
M:N:X>W5]N@Q+F9%%GG8EH=H@QUB&8Q-]%62TV,J,'#:N$):,R7 8+E/_Q65W
MR2LN( =*ZTNY9)9WNUTPO^D0;O>%CE<R@A!("MQ-X))9>,\'/QM)EZ628U!2
MN:8"0=!8R0K6TB-E&G%D[OOI8SKVW^5U#8UR7[MO+YB;FB,C_ *']@EG^HT^
M:K?UW=.TK]</K)VM?(ZD>V+V_N3Q=HN6.0S9(+(B*-ZK+E?0O #ZO*<\#2%]
M*NZ8 M3RG5CDN\C" _Y%7, M7E1$1]CO:T=.Y'Y"5=L\]_5G.RM'[D1$O9]<
MJ4FM['(I8:DQ<MEI+KY!!1GP@MKAH^0V"5W^CT,%:91W)DKK5NGR$2FVI66@
M-#PG'G07C ?/<@$=0N/![:"J?LHOM,!/("%U[]/7:!HM*^=9KF3D?L9UBV'M
M?<7P(!=J=F.N7EF<RJ@A2UV,A1?8H_B],!XL,.ZE55W56\3.Y (NCUEOV#M.
MV1M]U:ZIZO$]C9]V<)Y4>_EYH-%A9L+8SR-PETJ2V$C>IH.COK7MV409 V]M
ME<+X[O+ZA0-DHD-&9)77UQ:;HB,=V:>5.KH#WIL^SY?LR EP<:[>!M95J!%E
MKTX8)RP]C2+VJ?4AKM!R(_R.!!>24+MG*XY=3R'*WRZ*Z:Y#1RX1RX\D"W3$
M:8UX$0N/G45@E=]6"$-L4ZRB2O6;SPEVH[96F"+3>,XXA&JR+L(2H@DLZ=82
M>Z7:D7N1U>HARJ:-M14-0Z6*/%RM=<:41WB>:JBE_BP;VBK(9%5/ZYM8M#XR
M'>/W?P63.&;#$B%\HB.K$E8K:)WTEXRH D?/L2?AZ]&^RJ48_N!B1=/)5LA>
MQ8 8^2SUTK)9"7'[:HZ*](5!'_]%;^EY6.\5T]HT'^53T7U#FRL</CWFC47D
M+B[ 4\<&-W.9YHPB@B*18MHR07DK1[,_OE_$*X=O$43A3AYCK/.EL)W1B@!7
MZ2P!:Q@)>=!6Q;'ZT;*S/"8LV(8@-I(P#:):@O']Q!N0*GH6U686V(;Z!9Z#
MC J5;\#2/K"T:)?B2!E.H-;'^+BQZ( 8!UX6*S0#F81*A)ZC9<VD/:3J3!UV
M7GH)>PQQ335M0GFT> 1)^QI'J?KPM1"+FQ)B-K^@=8JB\DWS'C!N =41^MXF
MW:+3FB8DV:M#,>FQ+L_>B4DR[^6R+Q()+YKX8ZFI8:$OZSFP%+0P@H^Z$-ND
MT3HG.>4N7@#-7NA+L4MYH*^D!B.=CFZ['>^0=O===.E1D6)M_> W5LE&/;^<
MM^*$-$%(69!.:06:01SBJLK4RLP%FG@M*<N'N.LYRH:V-_]1L9>%;*+A/7Y%
MRE1?CN&]!Y)[7TTJ!.%ET8OOKXD2#_B3WIEFNNZ_)C?P_,1K5\G\'+-H0Z4H
MX)SI:6&(A'.S_&'K )IF^LA%R>CO]Q;,,4^&DHTP7B;3W0%R1A:9&4UYDT_*
M_WSO%2\%W15ZGM,-E,#> 0$0!QEQS*L(;>K^$1Y<9^^A.6<5(6Y2E9^QO'.<
M%S6,H?X#2Z$*#8G& 8F;Q@XQ\C&E<K 0@UO94L7FKO71;JSB]ILCX;K"'=>%
MHMK,/OGI\TM$[Y1)EYWR7QPP+[[\T#PV/_#HPSG[1X8/"Q\CO4+XO>X4D[5]
M/\/FZ_7M$DB0O8S(,UU<0(VJ]CF;R'9WR9WJ!_[G%?152N6@<N/I2L6FIEF7
MM1(=*^YS'.5W@G\>&@GO;'?6X0701[/HHVC6&5TAJF_<&DN9^*A$08/.!8QK
MS3QU+8+I'DR<\0^H'U3;7L]KBN=OST*@1$P*BY$>D_;X2=8<%R"PA\=&VF)^
M)(5.75(616H7"76B?M_K$:?K81NVJ%J1_%I8TM;=^]O=\P</_4!)< &^D DD
MW8"A'$P]3)?U1%PE&:I1G'7DVYZ<^8$GA#<=*86':2J5(>S>,S+:YAGPH;8[
M7H(A!1-0+F#27BSY^W/[2V4[ 2EOLH&^4K&;[_UF[*Y'PH//]EVTBSA]/+ST
MF(^&0MN=!VE.6JH?;UDY6L';!U_GRN@];-^TR++,IQR7"PC]L<@%?)),R(5(
MSNN>9Q1VLOB2'G38X>PZ(!8G/FOBY$G:/V(K+L>)'5,R?M95V8T)K3?-\KK0
MV655!/2(QMU9UE0XXU?W18*<\"QT'QYAPB[S#OV58>@+Q.'[.THA+?3-<2_Q
M1.=QQF%#FN[;AHX*V/MEZ0#,%[S&,[7IZS:&^?&T=<'4-6_?PO0K4&P^<O)P
M.[8<&XXX/-L_T4]/HCW/WD?-@>Z(-Q*1 +BI\HN7%.I"^*DFZGJD2W,-PSMO
MV=R!X=YWLR#RYA &+6/:..PONU9R,GL=Q_%&D0-9(KK@9\UBC!$R,@8HSCF+
M4*4>A@-;:)XS_!A&. G"S[A+X@*<:9CV7@RGGMA#$/'"!Z=5@X0\\34Q17$J
M,T&A/63)G/K&JC _W_>L"J8_ N&+UZ"G,B+)C5=>+%"S4T-X+F#PNW84L:$&
MN8=A"LLX?L6BMCZ^H\/N%$UOTROTXH9/RKRW+EC8,#^?,I(?5UV(O=)5D6G3
MP1#X4*"LWN*6>?ZU1;M5[P4+^"V36V2)U:S++A5B4)N\Y0:Y<!O-UMR\(M*)
MY6MY9.0;ZF9"I=!N3GR38<>;^TEA=9&QVE[D3&N39[,S)]\=6SF/>R"N][WN
M[M+\MO.^XRGDDV'Q+MHX/@&=^_I')3NCNROX^2#\^KF07,(XD'H=NW.\"<P%
M_(ZJ3N "5-1WSC.-&4@BBM+"%&1463$L2@W)/$P>5 <?1:B.'9VTKACQT?:@
M]C"=NXWM%!'@PJ6=]N;"$CUH&>.NS4C)_6]--6-'.>='!S<F;_M^,\(^PLZ^
M1&*0SW6/C;-N,2[28"0@3ZE$NS-5M!]/U8%2L!U(1'5&B+6K= )94%K1U[&^
MNES$ZZ)RI+KB%0.FH\+9*MH>=FGUAA.A![COZ /G*^<_N6@F*?1KHK2_,(*!
M$1U?<>X,QOQYESG[UW[R@J;Q!^)L^\SCI0,H&GS$(BN+Y^F1RD-L8/-+1_4.
MEDD6P[!#^AA#A]B_'UZ(L^L\.&]7N^O!2*AXD4*?I(#3K1R[9F4@BDP-N#!<
M9/5ET8TU#B?)>DA."1I)1E\(& &'86>SN !QA>:#G#$D'T*O9-D[GP%S' X
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MD16\>&0^ W:S_&NU,:0":G_O5WS'6']=_<8):W>^A>E>G2]U[JX-T+S0!PZ
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MI_6<^KY08JM416[*MG?\J*EA@_O ?\NWER-77_'R1G,RI]T$P@48JWU@%G:
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M;C(9*G!Z\V=*BDBE<> F47']85O;=_-2FQ:NC]VHAL>HA')WA,B?FCANMLS
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MM9]K?@_:4DY[=:_Z]UF]=1Q4+SX 3P68 4YDZ)MI<'NP:0D6&)J5YI?(14P
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M@^]6?Y)E<+_T;&JEMX->(@,I^;%8Z='LF._8UBGW5S^5$KT/ZSU\3I9!]+Z
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MW$K%H#IE25'A6?65W/)(<3&O\!,R(C]J3*4?E7F7'V_/ADK#<W(4F8H -PQ
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MHW0=IA (O'[)=F56I%*ZW#H\I <H76BR)9G/.@#= 1']AELS94B@ZCQTOS:
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MC4?_"*[<D7D!_?V!UA!^)@<IA?>QX21?$7H3Q'&67BNNH5PA5G7']WZ^(])
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M@V?U>Y[G7,]UG7/^><YSG>O\P07_L%CK\[GO]_UZ?Q;K<Q^2YZW  ME)R/T
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M[U!O@<_I\D-NQ:9OBR\=/EK04CR^KJ]$)>+"#Y?GHZ'684K9[G@GV3%Y%IM
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M^:Y/A\CG0>(X(MDK[[T/J1[*8D_6G]WTR,7-,\>+RO([ZUURAO#>CU)C*M0
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MP$B1KM@YOF203H&1QML4.F)1(*^222".SRJU2Y::S&R2PO?0[*TZ75"QIY4
M2&;7/5F!O?6@C-6B)%J#[,5GS'"\P)5L(C6GM$**<U%CJ$A$[81G4.HU7E=J
M) JT*(%R-QQ^7"^E6D84VW#QP -?5Y$#D9M=G9DQ3M4GY7,4ZB_NMQMM[[=6
MZB%KE)"()T,DMTK?S?AX/@SQ7_*'453@@"O[UP4]A0H>DL)WXQ&*QRNP@&!I
MM$)CE3S9JHNGI5#N+5+T%\(_U="0>V.YR(-U@_P5V"E&'T-U1!"'TEET56U%
M:=&]%T94_PWYPN@AGV"K*;9])L6MP##]U+98.!"0RAL*\O%M$3F<1 DPR2C
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M&F2T"9!YA1:C8RH^#P=*&BK+";Q*1\..1I':B='IJ*]S4CG^=$M+#C89IC"
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M;1=XQR[WA)#/Z>;;:X0&.53EY#;^C1G'KV>/);.!DY0[*&7%GV1M$"O5EZ&
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M)-LW7R:@_:)Z+9F- X+:)9G^.V&UR:D3(61G,4VH%_>>6)Z&[9K5D9<K]OJ
M([ZW/&W1]#= )=>G77\+O;&EJ1?96H*^;GWH*H)Q&)4JU4CT_3]H>N^P)M+O
M?9A=NP@H+0)"5A%1JDL1I22KK" B(")=R"(BA!:1%B$DJPBA"+@66$&(2I,2
M(I(02DB$!%AD%:F14%)80)I,!,((27CCY_M[_YE<N:ZY9I[GF7/.?=_/G#G'
MD@920@"'J8M1A@)C-LL?E>;QI1!?I#M'MR2PJO@:<37<Q:;X$V41=O&% [.;
MUO+??62K?"-][E^D_H\&8KLN@DQ[T'_SA)1)>!N8OO(A7&HV1 NZ41%Q(J<$
M#^CR.PG, +6U\X5.E+]GAW5!XFV+GD?V(>BXXEN!3G;#Q55Y:XK6C_X%4YFT
M+(6KE=E]LR6>[N&72Z"ZS-J+,PW33ZW?$#WU$PJSWSY^:Y;^5Y5)__26W+MB
MQC;P*>E+GE0A[9-E0+!T;Q@GMS@F<0<A#1Z:E[4A;5-KBE68>1I;A=;O ,:X
M3YONRY]GVSJ5!KQ\9$/>C"?^K3X_;4)D%+^7RD0C[R&\(3]31GFQLB>?C$'+
MCG>QGP.UAV@'A)#N0+54U@K:T#-CCGZZGZX]EULO-@6#)$6)56TEQ5/+V;"3
M0XO'\AR'B7%1SK_31FCFI6#WILZRPXCQ*GU+3J7AHH^):G>(,'#LU[Z!GMLT
MU3,A"$AFUT?5FU4>V)4<@]C;3P:F'TQ?)%B$>A4/6][1'X"MI#P:DMYB\.BP
MPP,T&5SNB):\B3?6G#,U6J*0TG1T"GU&-3P\@8)W;FE853;1R>&63O>U_GBM
M$ZH/%_1:C;)R-2 ;*K))-*E+'C%X7.AHJ"BT#1TE=IZ2Z(L"P2"!O_9)SL2H
M"Q'$,9V%#=T%?P6<LWB:H@G7 @_#^EYG:_6.5:%6^QK]G2VG9XA1XI<8<]Q!
M+%?F9Y<)^&4A3%^HE 6/@')('7E"1>U?%DXU7N:(W<%G?V#\U?.C_ANQ3-G6
M,7GHTYK=V<@'9I/0O6"P<T;WX<:!X8(-"QFG)]--+=FYC. MN3_S"QKG"R'W
MI;KB0/;J=!3,N;FHL[ KA]>W>_+?9X\]&ZB-.ON$9/5:=;;;4%E+ZW;N^-PO
M2(9-X1_Z^U8Z7)4?/YATPTL'NIQL.IT/]YY<?1.O\C;*[< YLL>MW#H%_\GI
M,@FG8;F20%O;DDN?Q\INWK[O&&CU4O9[$;M3? X4"NWYC X4'K?7"),LW#G+
MPJG9!O%-MZ$#%UCJ.OM&+."[D9D")8V(0IUG.VN@6982PVMO[HVN*3A,;2J'
M4.LOI'555F+N;-[!!*,X\J(A237,K((*S2#W03%WP.(:$.%%;4G?&$!MZQ:T
MN;D!"I2T5?5&=RZR!76OEJQ@[M*V:606\-EW;/Q2!?)H\+<0M8T;9DDQ??4:
MXAK7^(40'TQ%\:Z#!G''W3N].X>>'&W[[G; BYQ2ODK1C CTC%S^^GJU%9?D
MO"IV^X(0D+H9]W'R,H&#&AT3A8)WA/K\'5MR7=R\+3DR*H.6LOF;^!10F871
MKA/;]]/T7X+4[J1N/"5/)VQ29:ANS47)LXT"A+Y[2FX1OA];<'[5'L7_;.1G
MIW\S<YTAWK\IZI;DV/Y(5.>"E3RE,6]!:,=K+=$-2>E7>-AR*D'1]LX4:A\2
M=GH8VC&I!9!8T+WM /4=Y^E'0BUZT+<1?/H"_7;6A3QP1+AC8K)5D%KIC+Q9
MZ;JR)9>G:3@;J[C]W<P95[AA34[GX!W\?K; ^F_.7E6A1;VG4+&T\IS?MW,E
MZI\U8Z,]U52+4/P3+A7%C\E7HP9ZI8KTRH7N=@;GJG2<"_@04G%DTI*WT*J#
M*R\^(3#E(#J@RFMMP0+%UI>CZ&W\/B8NC?,>/=@!W1O"7DMF[/B2E(@W7C7=
M.P=7D 51C ABY=V2C6[P)K-M'5^'[Y^GXV3^]U#R0JR_Z2HS&R<X<CF+H41#
M0'.Q.LZ"XFWM,FVDEOO"TN[G+3E[,)Y'4@ UDQE[ SI<<KK3UEP2SX[$M^EL
M.AM71IR<SR'Y]R5+7J^S$7^O>C?C^8LZD%,=-]$)7P;?W<!]/FVTX_2YTY&G
M- 1A GWKZ,G!$G=FT.NRZ5[-.+*KQV.5Q\BZ;S.H&MRP=&7SA20C^I7,P^-P
M[4T(5498D7_OEAR>H8X]!3H*\EC&*HB[3S&.H<)M@L9&[&[,]A%;N*W*Y*6%
MB!>^:/GNPDON1Q,VSDV&MW2NI3$*B-=ZQ:;L]1_"8LZ9\2<<.._V.524!,S4
MV&HF+^ :$IEM<5V?/FS)[=%/QQ[$R DMQYBO+Q6Z/##7(D#"I*K"0^NW_.<@
M$,WTXD.O_CUK-T%#,#]@4&ESP;>>.[%B,<-@:N:*P7PRY5['D.B@]1[*AYYS
M:U,N9YP<E)U\5P*KX>GP7K5U2N(&](N,RFT_*'EN.98''L%EKW+Q.F8%[Q R
MQAD1L27'"?;KQZ2\]N5$ ""DT^K6/+2A#T]9@CM1LIV:\YE,$O"^EW4 :9W[
M$F=1R&HI%DS(*YSC7B2#;N^@ #)RI$1OD$0WP8YFOT9K?L3! P=@6AAHTQLA
MMJ:R&W5[Q>_+CVW\)9S;@.F_O9&'FXHZZ,>4M%RS*V@=>H\Y#%Z#4@VV!P&<
M-1TU%04P&@=)&$?!@MMH*F\YQ\28%'VCH8$!0/[4 TNG%!"_2P??O!FN(QX3
M<O\D;\H?_+KZP23,@GB-,N\[?EZ'$ .NRZC/'':4H0I3E$XRY'&AK<LZ8!;B
M+D.':!O "W![5TC(,*D TG,$:X"H52 [&_W8_A/*I3,MG9$L:#,P570^E6_1
M*Q,YZ@C+<7;?H5./I"E_EG>"SPFYZ#&\^89OBM'-F.=3\(9)__N=7IW3WT-M
M*J_DAOA>K;I(-+(A.BHYG+Y:;ATX8'G8H*?;\?WSP\>I-_*_LA/F*@.VY(SS
M7C-X,AH$>,)'B]JY#=J58N4&Z1Y*V7R@)NC$JVG&R N]NZV/:LZFT:PQ=OPV
MKZ]3+*B"[?$-ZB@M8,J_3P/DN#A[@ W";8&;=@79D]J>P:U@FLP>?=BU<#M9
MB%J^3X6JX7C5N(:U_JR1 "V^JTP,"-@9Z@(?Y7@J,'N70M1BOOUL'XN\HS8\
M!+,5ZM_7R_^E<8596;ZV5CY!F2Y35OI-AB5_T7>&,7;B>)4P,S99;]..T+V<
M]J,A^9D)GQ,/VD.(X1YH/)^:H3G^RXKW9O U,.0U^M'B-=HC;6=_.OI!0E3$
M=O@+!H!,[#A.@68S*,O=1<6PN6- (C,/S]A-=O%R9*2_%YAFPHX-VX8(<F C
MO^X2!;Z,O_FCVM'A6,S2;=-5-(D\G;L-5>?TRT;A4S-:7L>^;O/W(X=QD=/*
M+$']P?=<W^[KL;9K5]X)(J[7*UH\#5]=N'[(KBQH-R?K>1 V]/CPL-/8!-(P
M[%%NHS/E+U,Q!"_=([..'7LD9 :J+50 :8>/%G1CX: G+R\-IRB%@/!.$2?O
MGD6QC4_VI6P?83Z=$T*G3AD:^_G;0-7!699F<, D,NER,^UM:[)6<IO5HA^]
M<DU)K"S3$W>C?F1[ -Q.4_ X5:P:W!VH OH*H/(8NV%;FU=H@S'_ ;%+!<82
MF&' ,C;HQ+J%$AWK,I@A6"\H/L=1^@DT;<<IU:V-^?XRM!Q9&RT.$I@>1%KC
M[C,@/^1N!Q3PJ!?V39T&'3>OC'W![77LS,LHY>=F(@&4*$JH5I$'K$M5%(*E
M^]L,V"S-O YB[&5VU.J6G"STW.38UR(B_#IG*@\9)L=7AZM\7(_%^F 'MN0:
MV4O!F]?#_6Z6;SJ+T<(MN<[R_J./4I3.LRFG:VF'7TQ\S%'[($WEI>P<NP!$
M9U8%GNN87/<86-5RWAP+(R[5?;UY;V3R=,V.#DQ\'O]?:EK#OD3%Z4-VA]0A
M"@]*/ YU'R@6W+J5=N8JT]7G_54@SD 0I9=9XW31(+; R.#*3+EG\^"5VQ>O
M//U*NE%04C@G&U!)Y6OI!(*,RF7P2@F-!5W+')4.^FYAU\M=.9:&OIC#O"(;
MK3[5B!(5,)2O8.X()*9%+4=BX*CDJ,HW@XODA8D[<6N/+[FI+"3=O[<AG?E.
MD>?^S>"?%<=MR;TR%H;*EJ/O ?R["P(CPQL;&3N5.2+96ZP"9\)5;'\%M/C=
MB^N"#+IA!!W*IKD3Q9Z 8_9:GLJ=$HW!-06XX\!2?-\.S.^ PG\<M4?S+<43
M)8]KBP/'7(8L[?Q6G#0Q+5VU*+I4J"_6_E5F9?N$^OCX+3E%:@=W5,4A '=^
M.,YKQ (AAPG!^PZD5P7;90Z1GZ&DL/E3OX8G',%1?)R2*[E^>D/NEA^*AP[S
M<*0:[ZRW50/OO^E WB_<:-I[^IK.3KHN#)U$4G)(,X@H4EK3?(M_VU#QN.9*
MO*J:HV'?TW/_);UW76J4C*TMX^:E?E*9?&L_0E>V%\IT;L"F!KAW9M*YU0)D
MOT"O7";G_IX1@"3L)J*DQO,)@PV<R5T-!#?@_+_>0*U[3\R-=75A(/+;^P(1
MMQ8.Q,,[:_+4I./0W3!E_][P#:L.T]%-YZ'I\UE*5'O!<F:@B="DE-AM]Z]5
M;*LO-4ULPSL328PFUM9%?3TZ%/VS&S(%^2,+I[T6L>>8$+_$%9H*B!U;<JP:
MWNP[XY2@>*M79P6$#.Q18!E/OA^L"@^*" 4F"#E^%Y9-'L7&:)?E)WB?,ZPA
MVGS;E,HK"1/84WBQZI3HHW BV[;Q%$/#$HY73U0X1K!(;&3L(!-U></TEZ&P
M?)?BKF>OF;RC](%HSQ+![*4F<HG(R?1&4X*0(#X!DEOZ^26JT9O?@E>NN=0V
M3L>?M*0Z-5:15Q]-)U_9DE-E;,_?DC-?"<PR7%N0[O'^40T<E/'T'4?!'"3.
M3C;:@]A_=;1:5[!',+&T3[/JA<\:BTL+WN'V%KFGVYEWTF'T1Z=2+Q?N,5F%
MXSG)Q8F=UR-Z\_:A/;J@N,*94:S3GZR;OA4&)4H[TE.+_8:AB ;7Y\JQ-7ZE
MZTCW2HVK5:=*=[]W91W];_$I=TUR[4=SX0NX=C-:LFP$AR2E%MK*"Q='R*11
M)E]**5^ 0[%'QMX!'#\0NS/J+ P:IID][F>(YG;WA,<96RZ6T9J!1D)*XI3_
M!_/+#?W>EX88/C+C_X\!'N<RES/]\*EP7@FNH>OERPF,'0@1^%CV/=@@W,?\
MC;&$LI3DYZP"-0!\AZEB8YXQ_6$<(=TOH91H]2#N==0RN=<-TL.7[%4;L.S#
M%U)*UQC %2708/T=X7,>[X)LT"&X]F/ZJ4QUV,'4JP"A4\8TE#JH>G6K18WZ
M;L+ 8A[\X&^'6X7>G7EJ <Q;=$NP,[ICD*E^S\Z&/SS4,MZHV<TD_>= WW6L
MMT'1I.\6)J0DJ'KZ^TU?S=XTLXO":59Y@)[M@EDJ:E3PZ_[+Z$@K<<N#XT-M
M<^?JCOTW=)T/29!:#;H\^A: XXWB(G! 1"*S3QYC)GG&B,*-F2,:FTN2W0[D
MX?/B;#/A#31C(/F=^I:<&L8SJL(>-3,/1XX0N@L/%19PC,OOH1:UU>(^#'97
M=7&[N*R^C$ ]D"K4%>SJ1&D&Z*T_P!X#N9VX_33?9.7W]9/H@JXDF2S*M!Q[
M/7*G+O1JT["E897[S::2RW7;'U_\GB =P_&*7GUD2A4*)=4F%J=YS4,H[![I
MI"/K0*<1^Y'CG1B^FR8R4?E:^Z&OD:%4@)P4SV&I[[XR:KQVXL5?)GKY.'YT
MP79X74QHQO=R_Y8%FXYIU>^4.& T8.^3/UZL/S#8?/SDBE/3^<:)S[-E)\K%
M=0@KU#]2@NR1#T/Q5DE;<DO=PDJ!1Y>6(QB_>6K!^LQ??DM'LUDE=N!=W@7R
MK<F FE$GU+$T/@&2>:291FTVSW:J7:J;NO?-'][#!0W[6$OF,MHD5NT5]0M+
M<F8;BWZT&CX :H[<639>'EG%&*1W\R-;GCZ=J!T<^U 6_AA]RL7Q]U_?MULD
MUQP<=>\O1<R;2W?W\%W,I7MB?H F*-G$B".I>1>&8;\B&[?DU&WA+[ECR 1V
M(?>^K5U% #J6IX2_WI+US7#IW(+ +=O6XS4BS&N])>?)?J34?/!F(WFP9,IC
MR)2!AZNBBP*$I$S:^2E3U7F/!=@Q871K#5C$2NK\)S,Z/B Q<,C$,@!QI<E'
M-TNM9/-R:U/+$WM5]SUZ08?"_G8_9*KW')W:]4P"Q>TH^/0.^*AR0,/*E1*^
M]^"#KOW(V\Z?KR//GBI:#_=XXN\1=2+YS?VDUAY2@)H4D=!-P?[#W?U*-I&K
MV(_0[=%QFT0W5Y D[.:C_HQO=;9BI"- 1XS[5 #$2:@]5.!W#6*UD5)">'EM
MWCK]9;7_6=TY+W6J]5\_&?OBU^2WY'8A,8$1)&UL]Y;<3\:F4<,6IGO$CF ;
M:>X]!U,0:Y5MF:/57G*@[9GYL9I05*2MQE28L8]Q':'**3YA#Z-YX+=!G!F<
M-YYWWTPLBV3W*L3'V#[Y@]@]H):@H',I<-P?<='D%16HE8%3W!]LKRL=%OQ0
M05^&5'L8-IC4%QPWLLVQ\ 3B:M:I]S(:F$$_Z2@,ENXM$I)<R<_'YQ"[:%;
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MW+00O:_/%XW(6JT*WM][)&VVO\,C4: 1M-O&IB:S5J:4,A&-:I7O)N"7LZ3
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MUJPJKGWU@XH?92#R/\ICMS>Y4 &;1V@G91#(5IT$.8P*Z,+OE;%SL3WX5!
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MD,S5MF2FGZ3B[IU7[2(7N/.0Q8=0KT;:$$7KPX'0+*:P0"KO IAW< %74]#
MZZG ;?1<EU+:K_;!0*6H$@PM0W*P?U6AD_G=+'F<^ORZ.S4- Z\="^=88#7K
MA7U_3@O5G_&-O5V:@:_YU$?HV\SSV1WJA8%/(:$RD?(9^P&F!_;)C/B@#%3!
M(X5*/TM[Z:I"JSRQY^MBV.2WC\LLF!G S8!I@RH=?3&6X\85W'FKI*\40:_-
M/XMKQY+=?@[/1RH\9U^>3PA4D5WGJZ3,"(Z$@B>HW1%M>^??;W80=A1=D)1@
MSB0CHZK'>F-,F3MHJ=U'-C>O7"GP\,-X#F-P0:$I91R?+VR.9<73^.N%&?D!
MR=[/:_1[;_>IQCR+/IM>F?:>L,>A<O\?QU=LMW5Y=;X_Z./)["O,(MD:S5U]
M8/S^RU7B\;)Y]FP4U>E,^/<V]L@(.V#=;1:EN]$AL]PLZ1!."<Y+A0-<!L0R
MY6>NZ&^A(QY.H1T4T7=](I)#<%J8F!^OA?AI3##(4J5T7MV*OKUE0!QRQ]R.
MTH&$Q+8BJ9K%!:/+\(=*G&6I_)G-!.D88U<T?;LX3MB72H(=FM<Y\DGL7#V'
M505VWN5'M'FM,!]=NS9WBKJ1\P 5>ZP(]=IY9\7(7^3 $"DAR/"?X+NO"C;V
M;\FEIBDP_E>HNU9R#W>]^,B\H7_:$%8;G>B>Q4.CPULFTS9MQ8>S[=EUT5&+
MV;H!D^C>3JP:VW(B^#?\/U%7:Q,U[_DOG.-Z2.VVY$*Y.Y (9:R=^  87Y?#
MT<^CFV(L :\WS<U:9)(:NN_\)\I/13:M\O5%SM_3HU"U7QU]3):FQ\R"^'7V
MS+7;M-ZLZFD-3+E_1L/SWN/$0]H0VYT!:<1%@/S&.^=+U_TO7G&E&OJ0T'B]
M6U4G LXM\[.2YR>*N?QQ*0E^'3?:^Z.WT#TKF0/"XA"@ 63I#E!S :S:],0X
M69]ZN6F%@8]LST\BI88(NY[M) $+3,T 0L8LP>$3!GFG<@Z"V(]!"=65Y*^!
M;/YZ:FX-?WD?9X+K/\\)S0)P-W"@,4ZLGBBJE9315&$:TH_6$%9>:HDIB"_M
MK$7[,W$[;1VAJ;8G@/GESH=(SG@#!OGX,KD!6.4X/$-6(^O!OB[-Q18CZ]7;
ME,F\> /F*]("6ZP>+-T[)=25[@DA8C_254!_P/D=S': ?@*,[687J("DRVQR
M%/Q\]CLJ5G$P;@+ZVUM@GN/O>$B=L]+&L1VHO0PK4FNCE(4%+GP?!ANVY'8Y
M_F@$88L*K4'B%#&ZFW9BM<:VU)Z!-:X2J,O2,1/6Y>B.,E6ISKBI+3GU!>D>
M1HG-<%/K6W\&/IUSL#QKX!O7_:1=9_>__S4G[H_)58(0!*#C\8]"#<DU_W<S
MW[^B)U6,WG50+ED>4E<Z\1)?@Y!WVW.EV"GYHF=0(/G)[(D3+H%%#S3SS*\U
MMCR(1SDF+(?B0"5[#H.WX);.^)FFM^F _2 ]#9S'IZWFY1)4I%!PV1WD(E\M
M4MB6# 4PP@/(306RN^@&@R^>!I6L7/U5_#M042QP6H)X#,=MR6US?#6!F/1%
M^SM3!G%7&;PLW,]8)=!4NCMJ2MM>E-OR^!UW)R/,B6XK=@:Y-1/AG-G[=?J@
MZPVX_%K9D&6V_U]$GR]T/0#"S&]\ *(VK:<\ &GS[!>#>)>@>'\N7T6P)=>%
MD^EIJ!A'PEP!!X7;.N$JL%_0^5^3VQ"=.B;#=?$!YQ"P&<%29"3K@RA*WZ$A
M?SYN@*QP1%Y;Q8$24C\0MVEX_!75;;%7YJ#5"XSZ//'^*=%)R1.,<?5$F&9W
M+E&Z1VP.9JHU3N@L^ -;<FDP]?F24^"S?8TMV#<W4S=1@C@=S:;AVI4ZY.W1
MP'F_Z/)$(VI"@54@^\!_I\>5%-')[Y0L:CRT'_2=,&A.L[(\'?1V+:/+"YUH
MTV,O5W\:S5<=F$[7O!>31M1X0#)X:E1;2BWZ_YA[\Z@DU^AMF',:3,THQ]*4
MTZ"6$Y6:.<$ICYF:DIKS0!TK0T,J)U*$RGGDE*DG2RG-R!1)Q=D@Q>&8J3FG
MIDR5.>5#*3XIX$>_O[]A?>M]U_H^UKK_8#VLAYM][WWMZWK8][VKT?&U/RE[
M""ZR6'\LU258@C4EH*&,5E,0VT!KD2F()CW'A[7J;!H3ZU9<)1H+T;<9#K4U
M12>> TNI%2V6P#3'O:JN :> B44F+G':NN-4"U;%NLKMH[LV(*<X,CDG+_,Z
M&\3O,L8")7&?L>J0[%X+OD8V8BL8TP[;+MU%L*4X#9AKD3(H.VW<]N,3WC2Y
MTDNG9R.HJ;7(WRNS!,:H-F_$H:9F@'Q[L<6!W[]'27FI?2TF^=NU#<@=-*A'
M;?,G9Z/K-R +<4#?(=J5VM$-R%58\D31:Z5/K^Q5F;L 4FJ%&",X([#PRA=5
M3ULD$FQI68C1N<&XL,D?V!"K6QZ-L$86$)6R*/<"K!$] U76CW^8SN%1$ECR
M,V!2^>3)V+]N@DO\OL8HC)%F'D4S\=8R3@Z$L;UC74:&JWLW(XQ&@AEW^PR;
M'T;MK:E4?'M82-_V:8^JX>> GT&X]'YA@XWGU6#A^*42%+0GK?+3C%7#VU?M
MO+FQID=K'S_1%LJ>#5,.?C:."BBCJ7Q?'D+!31>@H&[_KZ)\4:.DEL5]"E,B
MA2!E3&0'0AZ#5D0<);5U)7?VO%F#I4<NJ8 'I#M9R4%'P8320/_YM9FL6O_X
MN#[T-D7X3IKH$71"RHDB%?MCKDR/V>?\JJO]WUS@_ ']OUJY+5Z7U(D]J-(Q
M"N!+S^BF/\4IB4])&,NXNYE?YKT;+(KD@?SL9=B=)A?1;.E@5)Q;&1[%/N[=
M0[6_044],_YO<*'2V+U/WN-#=W5+N:[0]$2R<T)R8-YGFSTGKYP@P"UJRK/H
M6=EZ#V;D':=+6D\=S_U8:D 8S#=WK#=N]/"."8^U&-#%]8\M54GDB&^0OR-#
M6.#^,;%*%)+[',WHOVMDX[+N1O #BA[& Y-MB#]&L OF85'"SZ]'7P-4GMP=
MZJ-3(U\ 4H;-9=ZCW3;!0G@@5L5;*)<4&6<;/3C7[@,ZRP@UM+_70KKCN:3E
M I@EEQJ%2]R U(0_!;CS=35HPHD:@)/-Z#W98I0O(\/7!I?[M1T%KT]_[VJO
MUPSPZ)!+HS-L0\[4CH;[>Y"V!LY6V?,^KUM+=PP+7:G/OJ)?Y;=-Z9U\CC?!
M,*W YTNGJK,GE([%H]A>)'F"-<_Q "-]7.D)\"V'#A;T=5IC[G^8G*_I'.5\
M%2VP.B_G)DE+32=G1[UC5G=-A&I\/WD9:SX\\ 'CI6'UO"Q6^.=]JPE,T^7"
MZ9(7 =6IUQ:,P\._Z5CC=>]%<)F:;T]T':9WB#T22A]=V6N7UG7^;D=?Q>SE
MA]%:&FCYY#=</G4WC^=X[O&(']:3(8A-=W)I?'N.<"_:S3F<]FPR9 '7T2P)
MD2KF_-K^D")5A;,SD F["/AF@$BY65^W<VY,1QE8NFLC_]Q!J,@/:3?L_>W:
MHLW)LC<%B'H2]H25\]Q[J +H[MP^<ME_G?P1-1DA5=@%D*7;:B0/981E1I;M
MT01YX&]"J*9WLCDT ZUJ'K>G);C<7@!3?A1HQVX*+P\1]6Q 5 DNX--*3"RM
M\WE=D?YP,3!S.Q*W"^__)T!,*\/4(S\@-'Z2I4J6(.F)#,,8K$4'H<G:X+2@
M789@<!Y.X:MIK^K][N PH5RG"XGVT>]H@_KHJC+\-F/^].-QYUAL>#B61K^V
M&!ZEA7489EWE@%8:H@(0):0(6&VH[<1WE,W_B,U BM".UY]2BU*3?<=.<\5G
M""5A4".O4&\#TAY[A?(2Q',"X"+LZ\ZJX."(IY+G)V_@L(B'KP\F]/9]#8[8
M85#2YGOE5,VT#G>!8N+>?=1R3'1%O<YTE]/C5_B6>+_W[:ACI8EL@^O4Y+(]
MQ)61,LN&X3+7,O4' 8]IAQW7/]83,==R8M;K_ (DOZJ,;:1#+. <<K*_%:UM
M\VL;L+JD8/E?Z:9YA-+0,ET>7]\)VQ8NU<9P5 1"HXG.0OZ2' >TZ%#6EN%Z
MX@H4^K$MQ?^]V!+W%-.%:ADTSY!XGQO=E]T#VH)TH*9U6E=2@S@H5I$\-C?6
M\@?CZ=*AHJ.@+Z#A0_:3P;"(SEWTYE>6\.!)$_?QZ7-8UV\_3K,&]-]7YOLU
M- R;A!M=UAARB3&LZ5[=@"Q>E,UN43;E+.DH4W58"IMG*;=8 +@WFLMZG':$
M*KB)UT/_73OZ8T#KS;Q\YE$9=*F)'1-0$K;?-"8V)"M2 O=[U=CT:FRAUM^1
M4/J# NZW:#O$-)6E+'=6\-*.J=E5[PE<$N) OS!:>E5'NLVLF[@=CPL 2YZ$
M:JS&$E1J:^EBW2)50/+ ,7K_JU\=E+35O^%+AG^@[=CCZM8)7X4D%<&+RP_M
M]YX.$$;BX_3*_2K1";Y!RK6.7F56 R6N^*9OQ\.@KJKW'RQ,EO6X.#D1_G%Y
M?>W3<FQMW;?I^I EE%C;3=![X U+ 7F1-8YBN_:48FKP[*Y\=>35ZI0%30>V
M3#Z#,;RNVT7Q5H-MJE=:ZH30S(OU#;56V%RJZ/+PS@\!&0^L0O@68N5-4H4X
M+AG4D\N66A)."?47UC<@BN7M:&6F]BQ"!2BB4<%R%$!LYMTRB[\2'[[.IOJ]
M!OK3].H 2C8N.2&"CUEX4L ?_='*W-L<J.5W-=@9^0S)_4+.U)?=795U'M!E
MOEB-C7E#2J H$74*$8>7-#O9 <(ME4^%WEX/+Q3LOI9,C0H1;K*O&PZOT%SJ
M37 9JH##MXSFK1$+Q2O>Z,W -'0/C^GQX HCQ%_IT44$*^LNS2]Q7A*WQ^AM
M3JZ?2JF71>(+_>X396TVU5\R2]]1]5X>9]14CT^\G9(1P -?21-#HG2AQ2)V
MW4D<)GE&" S6N5=!N #>J<2_-MM-K6G):%O3?L<?:V/N(KM5#YH=JDT5'^"%
MN6BQ'2M=GHV':L[-VOF,!&-=1=]\$?CB= D,FE*2R'[?QBOKS(8IG<[323K$
MR<O5/))E=5X0S3&29;7 ^DN5XT4S*UTRJ5I T+&B=_9/L 53HWE?8)L)1P'O
MMBPM[R+%UDV!8D>A;7_Z2H^M5<0QS%#@A)_XR #:X_?IF7.OZD;,/OMG* ;Z
M^=0BG27-2&X=; >+6[@!V=42OWY,YHM'I3IB^)CXW*_^V/$"RD2.@--N:^HG
M?#!]'!3PZ:K3\\3C_K:GN]H1L!9A?MJUVIY"Y[-"N73QR9B7>))C[2X0_F;"
M./G>$\QJ'C-+!H[7\F3< BF+FQW$<4IM7>Z)(9L(_B?)DY8X+C8T+"PN*L$-
M@-_!$O<03&^_,_?'K"A:P],UK]1$]M5;884Y[LVOAHPN-Z=/SWA(=6L5UR5>
MTM7S(_#P%6.4>W,C:SA*^]27L)[U]?7N(OXWD>@;[U-#4W-3PWW';^$A]QVI
M!0YYWB%7@L%1?_8'DZ,"IFFO:="U(,_<X.N6MMOK/ K:_K[Q[_;]21C^K%XN
MGF?H5/%U,"=24KG?XP%Z/[//=>==O^./Z6-!T^41$ET;C7*QHNR',&5FVH=0
M)A E+!M;'GT37M>5)LSG$Y_R,IH+K9V!&FD?3(T0S.O?,Q^D,[I$6T&IXAU.
M@7=XZ-] LHMPN^;68H)_*>C0V3238@97=2[3K:R'<_7;ET#+$KXW&YJ6A_A=
MDLP*H=\F05G!].1\X5<$!("GVLA78'3^$"(3%RI5%O/=6WE(M:M$'4"-63U_
MZ\75V--IO-EPAL.P'VEG$#X;Z-Z,CB"U^MMX5$@[6,"?2^-:(L]7#75#XHM"
M7!L'0E3#?S:C.>VN\\7'M;H1?$!ZS+,I7U_?GA>S,5+D^^6LWQ=2L3"/]RVH
MF^89Y3514;BR#<@A-.#*2LPA1$F:69?(25>;:39NPE5>>=B_%D_'VB:@:=<(
MSOR9I(I]!9]-@@$FN;P;^\?.D]IM[:LQ3?'%_?&X3]>]%3_Y+)2GF7Z<W"%\
M;)O<=R*YSB['B^YU*USNMU,NHQUNU'>-56J'![+5U4I[#:ZS+=F<\L,[;L9D
M>C *R&9YB\S\Z2GL\*]&<]R%I1093^4/DH)1&?*ELU;(#MJ5#0B?>A=769)A
M5R?43VM1+/7!FP;4UXS.U*<'^ON_ G:\?GFFP#+#C>( 2/K)YK7;?N"SIT-_
M6DN5.+*5#1,? ?N1[?#)'M$S0*R9WTJZK5F5P7M.YI]YV +CP[3P_F=SVJ5'
MA=2TY>Z%2^B=>!ROKF#-;"*JV/G&LSF$;A.3[%;?A-"DH!I^G:!<R80[\U$3
M'%$,J+\-3B4<!E7B!9B0=1?1L%"C@Z,9ZF65>_M5T:&%X.-K&FRH/$?;J<UQ
M0AR:$1P]JT?>Z[BF6&Y"73<FM;Z4DFY_RC4GIZ(W+:N/11G9?H@W%;T A:48
MYHGL-7_\<LYVAS<<97.D@D_.WNYK N>:YAQ?^Z)OJT8F^J9O\+ZM#TVT-+R5
MLOGOII-1*&6JKK=\_I>'>2;EN7NHO:I 7Y8N3>"\RWR']^Z&[+Z*R9'3-J/?
M^/>K /+B/IF8=R8.",4WA7+B8R@V*=$*O;#R!*5.YKXVY<\D$.PK0$I'G1^F
M2$-HTD*P$) 4+%*>C-8[F%!X-).KGP<BOQHM?JO5>O3E=?#ZP,7UFW@4?U6\
MBR-*EMD[!X_FKE!;6:DP%58(+GTT=NJQ:SW5#TS@^HIC '+;VN.F;W>;7,OH
M7Z.95DU-&:A1W,6!%H>M.<VHIL:Z#.>:UV3Q9X2FV$(XU@F#@4A>"!N^?8YH
M"B8(9-1FMD@=D E\_*"+G=]85-P#1E5-8N_!XZ-?!__3^2(2Q6&1J%K'I5K%
M<G_#6]\.2+DD+@.A5B=)1'(3*;]O0((OCP[YCD9EA7$=6@-CS@T-8JY%2="M
M[SGB8"$GU7B+6.2=A]C;).RZXS7CG.X?-]E\J-9%XVS>N\.4<]6S A,H[VR]
M]IN?.]QNER2]J]G[8XN#BE54:,OI [IM#?W:'EI;$ %_4;W,#-IH5Y_/N94O
M%+B5_7?J9NA-+".'>#_.OR[_@S28Q<V R9$[.:"!W,(=WJW(^A&S?B6Q*YG/
MK/H7KE==Q0"M2T(I*M>6S"T8!5,7&/&XMC57BOSK1^N()7?6JR&3Q24!2]K7
M(FTF<:LH@ <G"0:<I:3>#Z7(2??@[?@ABY/"_C=^084W^!QU%^RMBT ,3RXI
M)Z 6N#OWRK=7AZ7[G,I?1+=;C:40H)?U[H7P#1O%WG0PI_V&/Z9(<R *V4$!
MS1VX8J*AI)IY0GRIY79_")# =7QO]AU[\;XU2D5\7G@E'W<Q%J[#=<:> /H3
M")<O[MTYWB-JB%+,OR_JQ=K7E8 =,FIE"\[S81-PD412@= -:YKJ:[RT =%B
M_@$ZM[JC(E>/S,IBW4:>CT6U(2!#1OGK=N<9=7>ABK.:U\:.8O*QSU%E'^<T
M1*%E^(B%+XW'M3)M7,L3NBP]W^)Q*:\RM!*RG/Y)AJN1VU$:#E#T^%N3\[IR
M*72OO=WG\7[7"Q[H'G3*2;(UNYE3,W??$?G]YRKB$4A?QQ('T8 ??*)+I =Z
M"W_(Z ^4,(E.T]$ G4MF.8IB<W[OUKY51[!$L*1X4B C\NF*]#UAJQDW=.Y1
M_9U?AFIJSZ1<B^R%_A76;]+-;1P.6S\B<_I&XBBEVF%!7J.M?R*!'W+7C)*^
M :G%)=KH"I:V$#LW(-MK?:?C3=E^Y+1/P#Q^GJ]4E_?D ^C4.:$-:XOU3B7@
M-F_J4+DJ>H4W;%WUBPV;WI>[ ?D'"5K$<,4D=22WC+7%7*M!J2\7B&.3=C&/
MA%Z/S]/Z=\(%VE9/U  ^?>\V;D?^K:YC*B0G1^VN++Z[AF.,MU[+ S+RAJ]Y
M2'=H_EJ'3#1P'IK%U&H>_18%W2K>40V@VBB_SV(COX]_'1C'&[+7-B!9B5X#
M<QJC.Z>G":?&;%S#OQD'5S<6](TYUXX8_\T<^O373!\>!^\[L90">BAJW/X/
MC$FY\?.YH?R=Q\! KLW87F %V%5XO-1U-V?*QB\AHSRQ+*C@<<"2^K-A7?V*
MTH,Y8=4N2.O(A072*0[P%QTTMEC\U<="5?("H4?8)'E"4 2B;,RQ0,RO(HS(
M> ]>5W*+"^_GLMR 33"7LMV%-[^.C>@@PNM'Q-;Q.$%DLCSN4\KYND;&'9,H
M6X_%7DW280[@A4QB*@-0L>JDJ [$ "EVXT]A61;&3_ A?RJ'%J%3;4(NEN!3
M?-^;^5N?-"OI$4:_?HF9B$[":!U_5*>M/+%Y??\I%A,)8%AM<7'8$%&OY)GY
MXO$^MNM[&TM@GH=,$5]\X1"FZC8Y%Q.T3SC33CMN[.7_WZ1KS= %8(;MXN&?
MS1_VFS(>O7<3?L#JDI EX"SH\[61_[/_8YKP!Y@C2*77NECSQQ;O\%%9](O\
MN_5CIVSUO87P#K+BU=C'QRV\1"ZXYW4I)5<%9^MBWALOT X,>;@VO^=+>QY^
M^I?0G-+ (0MO(91WGRU) <,VK;2HJS7PY@2ER=)!]T3+4C5WLR,K94ZCU\L,
M\IT\<KN#W)X_&G6/QM4.2E!36$,VNJ9>K)6TOEML"-8+D(E!.\!?!P@< M<Q
M,=0/T^CI7F7P\E_HB2#]P0IS[5,_W'\]."-J?2TZ\ I@I:^@(+.:Q$9A<$=]
M@7%>HWG>'?.LI01C&7DR1')?<@ ?^L2,Z!EXXRGA3U I6( ;IW3$EO0+M;KR
M8)M76"E2=9#$,UR$N@\O+^+^! MM5Z@IEQJROID5VIU]OQ)&40U#'!G$:K)/
MW:'C_+U39DF@(56LX2V BU4>B<J&D"%+OXFW@E&"WAT_>/!$XK[Z-!L,#7S9
MX];$%.HT\A>/\;4,X_?0C(;.,E!0.]P>XRC3Z=)UV_^V&&-96_[G@,[>#0C@
MCDI;"Z(5XW>+E4$Y3+QY>W1L/QN=,C;1GWEMN3'\TE7:P5'B(7Q^UYKAW-:.
MO+<SOH-BX^*/."BIU*XD\"<4]\/2&RK44+LT\F,O3N'2>-[E]@?S?VNHACS\
M5&YD E.>,SIX4URCE%R.-BF]76KVPJW$U[G@</_'<R6NCTOD?1U+M4S.=,73
M8Z+B5CDDRBY9,H81S$$UH$>JX,\/@]_UTM$8B(*J$PP!)%EJ@2>U-1LO,LA9
M1*.1EL"XBMZ7LT><1F,M4FT\N9& '-D\%6M<<;HJ@M\/.M$O-(P0[%Z$>LM\
M;>4]6-,Q;2A<2ETA[<;/M$OW"2D9A)/18VNKZ01?6FC0?J%./>'KO=IO=-J\
MAD5!46ET]]ZK8Q;Y'F?_2RW][YR<+?KUISW8 (KNV^\OP3)!^84C/@3CLY[.
M/[P*#4)-'!W?NMVM-S[TUOT!IG/7@V=#.'GK;@8M>HK\=4:JM"*;0!!>4?0?
M>$^ F@@6W1LP-F>-UXABA['&1F+3BJ#9>W@T']Z1$></WU6HWRG*.;NJ0?P-
ML$@Q,6IQY&?MEQHC3PMMIVMXKPW=6D;$IM!,@G7\<OYBB,Q:]H3H>K"&CO<6
MZ8(10 R;!&F!Q=S@]<N!C[JD*D)7%I\.\[DZ-B8Z3C2J&_3V TY3N#C%,*NS
ML>?7H'?#":;(5(;/Q5OF61%]3*NM*2+]A7O8YX3#,F[G0S3!L]F:@5G)54(D
MSV'1)8(___KX!.=LRY@Y4HT0)*2^*2_T\&O.WL/Q8J:\F3!)*Y8\_ZS.#X0Z
M#$7^53"M:!B6RDI1$$\>>@O81+1_]'TH5-KR+_?[]HEZI4_C5_9U<U]1W!V#
MJUSO4G0#3IO0#[XN/</TH6HYGDXO*0_?=3<[V_DALW(]UK]'O+2>+PO+7[GE
M?2@,<-^ C.=P4]J64F$0&V-@ R) LEEI!93,ELM"C38_QBI"8S0RU<;PUM-9
MS9 $!C:4<TZ(3EY8Z>$HA]83]P/2<GXO<1+UJ"U(:]@XBG83&_NEIXU$)]7(
M0D)V:X%TF\;Z9K&MI Z)P25803MPX"%H9]SL$"\FN5:^I=>#U]&5+K:V_9;+
MI1FZC1A_H[7LL#'DOOB&0YC@9]C3VB3E+%)' 86M91OF!WSN(]^Z)69(92 .
M75[:0YSD5(VQ23KX6,5^*'Y=5"!YU&+-AT+QCQPT_*+K>3 =@C-P]MC)LJMK
M=QW4RY[B,]BQ@V?W/73)JRJ9V]5DDY>/.; !N8$&?*&@<7XG%-1+Z>(D4[8R
M8=)^Z78PH00_QI50VB<I>_&< *%]4L5:X6J6S46>K_APR<35O+J\NR3H!-ZK
MQWLD_-((_9L>N:/@/(HZZS9I%U%Q2QQX)^]WUH[K,,7+[K2\*RKO:BKZ#4H>
M]1O[B+4/E_5 :C2_TPQ.6(T8C!3&JI;H6UTO=;U/5;,LWB$>RAGQ.SPAPM&:
M:H=FXBA%2  % XU08O5@4:,LGT%;-19^EA"<)44V6($$>1),>8%WX%)295'-
M:24J6IR:[$3HU8)=I++ V2:3$IZ2U9C[2,4OYZ?YUBZ&CR+E?3$3V;7ELU8W
MP'KICE0P&#CP!EVOP>;L%)N2SPPP#Q'.@DB-#*8EB#XUY%+XN*D)+/<?%.L+
M-WD5*5YZE=_!M!BBF;L@ ^K3OW)>4Q*6 ^/.5R63=NF5T;Z3-$C<F7[P,+3=
M%A;T7@R]"$"YUV)SV[(,VYF_@;?*YZ7F[QE?:^&UNK_*/U3$@0*6?!!G:I:+
MT2QZ)I6[;8,R%V6$/)G3F_XR!J"Z$%9@H7"2?[I&0('AR1T45>)AL?U8<>/(
MRF+HW :DG6@H]&*]L%$_?DX.QP@*"CCA[P)W',(>^+Y(*ZX>9/3X8"_4U9''
M>$4[WAUY[.*<^O*SI84\]U4C\<#FZLQ':AX:'CKSB,L>IA4O+KZZG[1YF&=P
M7L*8=\M\R3SSQKW@QN?F'*QUM]_HHL0_:$843.W@0S^L2Y7\ATU<LLE8 2P;
ML;G(5V-A+5%4SX1)J-+CK:5V\7'FA=,/KT>103?$'_4%?7QO+&+,NV[H&MS8
MG'9LVB<*QC_&8O2#EGZ"-DK-V(+*!F3S#TE:BV5('!93/%\07?JDHZ[OFQ9L
MAU264N06$>J=!<SBM<<%^:+*)QL0#6/=VOO6+J<YOG':T=_7/>N;JNM<4#_M
M)=G,+:$D!F?18QTAWC2X+"Q#=B S=!2!RK)-/3<VJTLUFD9I(<+LLACCPM["
MY6A-_<3%%5K(.2SBB_$97Y\ 4LC1U]_5ZH&)U^;LQE55_N4>9^O^'^*UJ,MJ
M.\ZJ&527[)X_WGC82/?6Z<5#/YPL,!''2C^6Z QD$J-EZ/9>^EJFL*L+KH.R
M>-HJ(;:SMMFXUM2G/ZN7D)DZ/6JOWGE)]0#.&TE<._- P:5A%<?AXD%C3ML:
M[8'R\7^CMH6',QZ%K1_:OFHZ*>/M(Y($4NL8&L9P$%HLE*T?P%_U/;D!V89*
M(=@)2SH*XE,+#+''8#O_8VX"L<]/8JZ^GSWN$D(%<5W>RN/.FU=%:\2GQ<ZA
M34&4:%(=DEPP"Q0G7;V>M!>+MXHR?=QCVOOQ8,7P#9^R4X^<?X9ZE"B\6MK3
ML:*&SJKLAC=N475#/WN8I.KVYY;_GPX-1B_*?2#*&.D[4*LXI>\]B,-&&<//
M#X53JX8CITYWXK]5T!?@V$OI7_I$?5\.51J'TSYGQ]T2./X=>4\M994G\S9;
M&?3S,*S:Y$>\I7%G$4VHE)>S[C)[W TS#0'OO.C9DETH_.%:E;!K/.@_0GD8
M,D,]>D"CF7%RKXYYLJ6Y\7&S4?>U3AQW*QT3^[RT.-2/6%,2JM'D2G\V/3$7
MZU7^/! 5_&*V*2M3..6+_A TT:W66[A8^,XMP&_*OV>OZ$?G_?:O7RL0#ID-
MUD8"HVJ?O9&>1IYJEI]_)OY1BMX2Y!A:&S0$]<X[VG[QXX/0#KW'!FVY?E'R
M#=:TILHL$B5D:/#K!N2*@>'/[%^]H&59YGHD9Z+K++"Z0%WWPB?W.$J>+S\Z
MM+P$ =?=[BMJ6PNF"X.W'JAIB?CL[ROVKJG+B/]<O(TK?':TNPQ3]?Q5_:@I
MR=5<[-9N8_L0Z Q!&_1>M?))1Q44GID^?_3\P0EJ&OL\QN!!Z,&%A5+YP^[E
MNST3>3H?NAWUZD@CE'_=[-7XVWF1&Y"?AXM,-B!5&CR.]!E,-:RI4@.U ;G_
MD+^TOHNHO0&9.RD\W?P2<J@X_?]T&+XEJA&V@3! ;ZS#"[T9H40X#%J$".AJ
M:'"^<Y2BP-0&[7B?Z9D$[,NN[5;43((GCJ<-<\AH1Q@,%]?5RQ1ANU534.CJ
MO5:%@* S57^@O8IO*QSZOQD_8!FLS<SMQ/>([0W@#>$\#\:&9G&@</B"N3_K
M-W$@ $U"' 2/S7L,EIK.QF9U)8E#GLW[[5U=N[9PY55+7D>ET6<]YUL';KK$
M1JG^MH5&HV71:K.R:E\7YA:V'*^+CG[5A0L+"\-ILG%8+$[AV3G_5N6#Y]C*
M1C=.OTQ]^1)2E'X(4OS_8M"18"E X85TP7X/8RD2S<5F($F8P,M/1]8@>7I@
ME-"YE;D7O,-%[2+]':9)2F7@%CG;P!J7$3&R? -R"9]P9K!VRG3=#M6POK7J
M.6:MD)X;=QEK$W3'7G:1Q%Z#)BYKJ[0QU0;,R-O!8+;5Z4>R.-F!CV"O8?.R
MGH"DDP,5O"%&O,I? \M?L0R)X9E!QGI8G)*%RZOZ^NJJFOKDT='=3])V17W]
M?S#[_Y=C P)? DV\Q<_*!3!)#GE<QG=]45P:Z842*7]5K&$H=?<4DJ7=70LR
MYE9!!;Q880!,ZKR=+>U^%R*MJ$Y06'<8D3I\DF$C>I1Z5'*!U,HB 1[P#PDB
M$\ECUE5H$JP6W:FXE%2P1"8:DMH\G_PD[6#J@8.3[H!D[$XD3*D/""+8 NC,
M^V_7%'L12T="\T1O@[^79O;M?O*-Q%.2I1$GY-=R< ,B8Z><>EGX6/M)3[Z@
M]PN).ESAGKJ0QQ?Q&1G'"*XXKZR *!N*&?L"L**?\JS,O059,S=\/_'68T^G
M6LM I\>TPV:81>W[-S+<)F998_])?AUM5B8##< I4#\0-$%R\X,,A,BTY;1E
MBA8ELY<^*;Y27U<]7-("_ <<FY5]KK'%@K?H-M-02U)]M %9N-S\RH<W)/ZA
MU-K.,B*^H=3NE44Z;I&\CB0.A5$_AD[@VCC:K;?XO0:=XW#S0&?>:IK9E$,K
M2=G(3.O62KS"@-@QA@O;!=[GL!W.C=#,7JS,FLU&>1POR/?Z+KYC'W]:2[?$
M63?/(;U#\..:;<!Q0_G4]B\-26E=_!?!VI>]3F3^A1GP""W$N"6<%_0X'<FN
MM.F#TX\Y7EM@^)$"5Y%-:-"@2ZP1+%(#4];EQ3&@VSI,',0$4X0EHJ3J*C#B
MY>SH!F0[T1A_W%:Q3<>PBC$@/8@GM_O1R008=U'SFSQ1^VH]";JXP+#U]QSF
M^ C5TV(D.23>NO'-;Y.@7W'ZCP94XLU*I3=>/=\;^?-VN]+P+T>$(QBO]K[P
M7*LC"86:N_$&Y\L&TZE;'&_6'Y^\>2WBT:/FNM'JR16%M1310:$^&[9%^@%=
M \U&F($UTIVD))W-X#S0U56$$%H"WZKX551\6"O"9+#%XT4G <E;U_;V'48R
MB@=)U5746;]G(@YV/41TY4G>8@BR9]A[X.]7PHZ+5;M]74M/\*]ZL=^6ZJMY
M/0[SR+6P"K]>ML7=P/5<!/5$F6ZOO"'U\#AU_*/T#HG+@X.'T&\V()-=HCO@
M;N05BLZ$V!$TEZ&*>G$&_^*OKL9!BL-R[?2](-L]I]/O[$1,N[$^V[M>$TM.
MMM$'YOAMW_O97B_&\M?:34,G7K*QN&<_H>*='*F"0^FO0B)2:/,X\U#830RR
M!MVEK<YI0VM^"QZ,"@Q'*06"45&!*-Y,>YB+(;LIJ(QOZ_JCK:FRI.*JMU_X
MP[!;,V!(Y[1NHXM, "TPT#5$(S>TM7/"]]@ 0RGUQ!CM@<3]N4I!Q:R-]Y)!
M_\XJQ*#91?N_R_B75PJBU+9L&TT\.,LHB.K[^7-M6AI(F\5:(-U9W"KB<4D&
MPD Z*;4 V>N*X"!ICQ@.LIYBD#O%T8+6Z2, XMY3<>BHN7'T6)=(<RM90-\.
M>K>[^\R74[\R$<-T_5=%O6(/ 7+GQ&R^(W7"'R."E7'VLKBEL"ID,I)[%[8=
M>0$YOLX/28TBD8OV 2BVD@H?GL! ;B.X#F!;M.BAI)TTQ'$QCH(64K/-XN&G
M1LRPWAT9?-0.E\M<\B[\W<ESE/9_?&8+ EEWF!_,-B"?B]+3Q;!\_G6"^=UV
M@>E9>QWUS@M5H+[WKE.>1_&9S!U%RKX9/IY[3Y6JC\PZ0"V# H9"(]PM"VYB
M=-\5Q'TM$HV)Q7=9%1N0B1]2A;1U->D &CA%3D%73W$ZK24QHC:9H(>.YY_2
M^:T)C!,Z+&(%2%F2 U I-MXO0XN08P18#+>\\1MATW.0XM\X4M%RW:0V;KXC
M^;@C+IQA)_[7+;!Q;,>%B(^NCND=PQWNM'^^/(@(4'U54[HC=C@ 7=4>YZ?V
M&!BY]??+MIP2=Z?#IRM..G;.^D][Q8@E;NN_^B: Q#%8%6O!;=U!' ;VK/L2
MW$:(NP/FT%L$8 3 %R&WX(<ZUW:4;$#DH5D$:SY\M^Y*RFT;%0%TYX?YO '0
M@AWVE-,X%'GG^118-+@\-36%:>.L^ OH9!)W##KAP%\B,RW%:'!1L*1"< 1S
MZ2@^7&W>49;))G'.=^?6SEQDW-5RL3@+^H==_/4*PU QHNA7#FJUN:4M=C=.
M+8J]W8)TPMZ<L.FW;A=NL=F I'U_3#14LI/W_#2>K26'F@/QK:<?W'JE5G[3
MZ;IGB+S7@\M>WQT-#PY/!+148:S7?S7^D^PC3OG)B;5*GDEE;]7@R+_1FOCU
M#C0#3&A[+S8:O(2LU<O!B,;%8;S_6NSC23%"?][G^KLZ;%<@#I\LFNMR+U!\
M[7J"5,,(>VWMTU0UO-#8#QYT$*NFB+:"6]8M"=Z2C T(CC4N6N?KL^$RYJ-!
MX=_'_R28EA < $E2^[0"P$G"1G)V@5:S#(X*_B9)GI5LLH)2PG/>U",."@]P
MP$[1J#&,+<3H^PRSBA0,RX"@'97.Z(-=,WL="CQHF=1LZK]7]C!>7OG7:=D3
M=N'5OR]5KYXNM#(M7<0,Y1ID3 R76498[+ K+(O052NMR,NZ54[Y\)Q\0[;
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M%,2TD;.1BH1XVM1XJ7AP ])FS2-I?FVJ3UV\5#LX4\<:-EI14IAT&UI1,IG
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M_0\/9 7>3R[UR35]_J"G3&'E.#DSG#-2_3WPP^@*Z_4:P@(YQ(7VK<AVI7
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MK3&MMF< H0ZHJ ?_M?EB*?NQV*+PUR%N%OJ8<%$G"*IUIG5<LO#^1)M8E"Q
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M1N7-J+LT$.\]W]Y S49M12M-$WA*(NW;MEMM%W^0'?9&*@8#O^9N:;'XYTE
MN@V5I^6M1$*SFM]I?;3=\EP\LIA>.;10]V@D+B@$VYWG>]!=EG0:NR$3G#O
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M"L1(4/+*"<F/D*?41C$ -/,7*.$XP8(S![65O)EXM:"7?16:\'PVMA0"KW1
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MJA>$/31P/\6/6RVJ]Y*%^OZN8OLU!U+=AOZI(7Y]]N>+'[B1(D4$M%]I3ML
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M1#T,E"/J>*4-M$H@)*F>HDLW28G=P002,)%LTTLY,EP,7F6)B.DASE"EJ,^
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MQ0U-]@5;!FQD_H?[+\5ETG]Z]L=AL&KHX>F@ICC-$&6/HQ!V\R3] V%-'5O
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M:P7]V;OG4T?[\^K8ZNPM+9^)G\L._N&GB"E*8NTRQ\7D/0ZNEY5/Y@JZAUF
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MG$#5/SVIM;C890>Q76.VYWW*NLX[/\S*H4"@1!CZ>OZW,*QRXB9%PE$ BK!
M 12KK7AU("+0U,;2AR@"C (G(F9TJ;<;2F:1&R",QX #^@D%#R7[#1/',1(T
MIDF26%<]K5O$?1 ?'^W NND$NP'_?V%]3Z/^]Z%"A!.,_!F(%CO([BC@\A)W
M4)PHRZ>$(F_B1*_V+/1IFK;U)2$VR[?1TZS'[D1:QL@2R%N%65OP6GZ_#0QA
M<%49?QMKC8A.?' TG!@3\%]3;O+KZ;>PPA688E&'"EU>T]>XUTQ 29C?R7I0
MK!">BE++#1XJ930-$9L ;E), MPY(5BNK+P-231Y8=MT:C3 R6' F+&WF.X$
M(W&[<D9[Q'&R)];N\,WR?L1OJ,W2.& B+\KBRVK7ZRR$LE0-=#\^6/L%[U<X
MS7$#NZBU'_P_NHG/8,S%8K!G5T! ?=U!4'-*KD/>K9ADG[86/PX]&:O"7 OD
M"L6WC(,T7I=L9AH(^6M(MB[^']\<F K>!M06E8<5D@J/7;P7<+;=Z)K_CX_<
MA-6)Y,!'?PI,VPQ\NGE?VRBK\ZB&IVQE'I-;0F7/R/L@O* /-EVB3CZ[I)LU
M"95T\Z@IUD$F\UVH'?&M(7XM"?@.GW"[W'/A+9E?/O4D7!M87M0\I?27=)^L
M!/4;66W8(:&6K WM *A"K28PL ,IFD^WZ^; 5U>':C5HVID3536!3I,F5)%\
MG 8BI2$B[5<C-O&5(TRG@V75-ETU5>\B3S9Q+9"/2)7M+&VPCTHLV4#B<N*4
M,AV,14=0DZX@/$7J4S8UL1WX_JI\O#1[QF,DQB-@8O[DL+7D[S?N&?8SN+DO
MQ\Z<^! 5.'1*J8>RF7V^[T.E@)Y1RZ0 !#%*EB]7AWXL"\;YI#%A@:*</GB=
M:,E\9:L^_J"&KDX*; \X4Q]U-;*R^%.OS<P_D2;Y$1,7L[M!NESUDJR6&0W$
MB_7[*2&$/W5]5V"9E/ ^: \UHY9]"7UK!09?L-=[P%?#)\*XM"N,^2Q>?H'>
M?ZP+W+.T.^3;H*!KA:EE(4<>LK44*$*\VW-L.%*1F-]$Z3#I:L=-)TJ;+1/^
M7R/!VR@]>4^Q3FL3J)39V\GMH&3+[1J:F<5](J5NC#:NQ8:>13Y:;ORYHG"$
MM6W@&>.(TNN)C8UVS@7QBAJ!ON5@B[Z]_15X<OD[K4I>Z.4$V_H3H5##'QZ(
MK62E-B_)[N!/L8OL;_DA4G;TA5"N'"G]'?(%D8%_3UV_AEL^7^ +5J;8U$RI
M%ITW;SQH_!5]L3[?'4^QU+Z(]O3ZCZ$Q$"H.DSVDA%K8?761%:]V;TO"KEG(
MX.Q@#L@W2_< INTRN]G>?2___O@!VG7T_5SE@8]KHG;DF_+WJ3=>U*L9"WO\
MIT/J3S$9VE@EO3A ":,Y"JCM>O,\Y:/ 0K':>[G=!-D&N,3M\M!KCW:J/FJ;
M:EV2-OB-/AEASQEH>S:SY<WCT9F_INA:-=7.(YW(VGQL\.-TF%P3_7^QU/&5
M)<SPGR-G]XCH:=P5F)X#1K)5_B;1".I].KT" _X*+]&VF1_M%HCK0'MO+NM=
M(WLL5GYDR$$O2E33BYVMRN?S_'09!>Q0)^J['T.[%_%]BLPQ*0-S766/&^"*
MS"&PPRR4. ,D%T=HY@; ;2O ZE@3-O9JE?\^L6T@T13SF)W%F(>[KZ]_YFB2
M$5KK6,$,J"W7"]1DM?@GQ"E*2A9&?%56;,/.0AG(GA!+_N2OMZ'P3-MU'>0&
M0$EW*T88>W->;@UA.4MVUU^5??P6; "5$TO=)XLT7)H'R%ZB",L$*P]NQ+/R
M0:93[:CKVL#PY5M^AGV*"9_$;F2'(D=G! ;\++I\'7D#9 4$2$3!C&(C*"L>
M>""D)*'TQZ$56(>7.\4Z3@%"M61$Z;=!4DU =H3?Z3P;#^+\_-T@-[G30YO/
M;;FC88_@>R VL$M F=LHO S8=O.3L9L2#Y&,OZ9.21$@1<B_A3*&_+_3:B/H
M$=\#.7+K_D6:<672C[?OONMDE=XU>^".Z\\_NS-&Y* C,5PU\U%%Z9%Z!%P.
M?S14? U M,-O\Q)&<D%E(289M8%L!; Y!(,IO_[@MO@*4L]K'B+5G+Q?E(7Z
MH>)R*G6Z)W!@GE:[D]V:'59D6:F>H.<$BT*HHG2DMM!A0=%:864[DCJQ ?(#
M)MOS!T>A0 7*<G(VA:&4 $SJL^_T2*+9@Z"U[<7;G@\L6.CR)KU:F>QB%;MV
MWAY"Y/?()\[%-RXFHH6$6:'$@:P**G5@M<B:D H0(E 0:M8^O)9\)]0@(J2P
ME9GPU;['"$WR45P\/?Q,RWQ'4&A[G-:=*FCL;.,0V4>4<(SO ]J\JXQ7F;^]
M.%/UU7\QX9A[3NCC/P_#$604H-V)70]1A=Q.^.\D1Y$+9UX;-_!-;@X@<Y@V
M921.&\MTX/+%&PRV@H=V' S(3J/A!IA1C$:[O*Q>1N;M/K6]3_R@**!/R&[K
M^_T;0@6EIHCITLZF&FHV%O>U\^%R?9+/40"=1+8))<9'5Y_C?3/4!#I3"TK#
M1KBZ67.?I0!N1*O?/3XVFKC3^F?/+O'"J358:VF$+(,=0N>%! \X^$I<Y&_X
M]2YS:T0):T^LP&Y1CH&(+OY-M'*B&9YGDBP>*W*1:)P8<8@5!L6?&HS)F5/N
M4:#9[)C][2NL,47<3[]^OIU?:-!< W"I_^W%X8'9@(\CI#&-5W=>9*E,I,A#
M5Q",,]P.S,\6 /#C(PLU#6><6@:)05:OM;ABVS4&[S'X*,W2H'L'MR6+%VDT
M6A:M(2NKH;4HKXAYL/'Z]>?=!#P>3]#E$"(B")N>G IL4S<ZQ5$WCW)^>OOI
M4UAQ.NR?_WV6D@J]O%&N2MZI8&U9ML*2UWTI%%749K)M?ZV-'@TA7&JGK%5H
M!FZ2]0/:!?GDZ>':&/XFDJ-[_X*>7I:/3TO+$%&'=F7G7;'\B^C'Y_+F0E>]
M_F^/?F,%0)T2E40%^V&@TPJZV REV7B)!3D:O!O8?;G80O%'E-0$>B"ZQ$A5
MCC]+\PL&Z;>(K;X1HL9Z1E/VFNL[3UA$B'S5VM3I0PIV>4OJ*<M?@5W&9I7
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ML*)@U8O/@'UM;$-Y/[O!@\TQFT]EZ0Y'D%7 8YA,NF@%ICGZS1#1V/K>AK1
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M=]WR+XQ%?+L;T+C@[C4P@144?,D1GF$G*HH5KR\I6 =BK]H7 TNW'3PV+^$
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M[>%Y%GXN&/_^"\O&W$5GK,!26?!A^4%I"*#T9Z2""W'EEN23 #WY*^C\@AO
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M>#].HBX65< ZXBL2$K220E:7.,%4\,8DH1U(1>YPT( T!(M_DER%CLIN@PQ
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M5UCJ<M*2])('UA"@/\!UX;,D.CR1W />Q1+Q E:KBHN(!#<]D3CD=,@.<*P
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MVIG*<-5 JZD]H(X!;WBVJ]P0+<F7( %HM<;P4W&J"\L:H9.X=+3">D>_=KO
M\7NQM_<;_/8:<KG3\)J&6OCF&A[^3&("HT(ABA";ND&6757DY@YY)NW^("C^
M-GAFP!HS+%=VAWZ1*35!>-FF5K$YN;=Y9?X52!&HI<<L(B5.N"1_)TI')6';
M+%,!)-QEZ/ S,H]<F9=8\UE:,/+<$%U1V#30(#WXU7/[J'^X36.LT:3[R%Y&
M6M7OF"<19O SL$:B.293G8::DB2VDYC-\G S8@6/N[')%A^B 0TX[K2=2VJ5
MNRRE)ERT6IUS^PH=.38R>*K>UD?GYO?"@#FW@&[ \EUS4W(TD2.RERF:B5WE
M7W&%[$"<FU1)D6BYB [ 2+$%K,QF:H#C4VU%!(%_WT:JD*7#F]-Y,7?;IT*+
MM[ +:G:]LM\*3ZP>.!Z=N777RUSM2.>;Q<H7?Q+G. $' = ;"9NG+"#%6O+O
MOLSB%V- #T(*<K-L$YS/YRU<6$-L[I9;'%3'A.T (S86LI7/(4DL]B!.\=&E
M:XA-%M1_X.^_@XWWY9^_9 O<(F]WBX$VM*F87![CR%A#A-)](:G-J9^<R%I
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MCN- Q$W*?USF:_[/RH8)Q?^M&"'B[6"%\& CUGP@%"IP_])"(UX<[/0/39(
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M.AO\VCW9UX8;9;.+=\*AL;>,4B!E >Z.G"/6$$A<.%94YW1+$(\/@##M%-V
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MNC=EN^D>7NF#UW'G2_TF#;*3YN-HX=;7B+MBH#+. >OF1C0-4@7W+-KMOVA
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M5[Z=;7QI=S6^.I6:B%;J=<HXNE[BPVT/8D1ECT3SIBUN^@:ZSDX1(WLSW.!
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MKZ63N5V,4=UC@\8AB+?;[1V9-DM$[MEPD(-/D'01^#W$A! W!FLUS R)[N@
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M3LW:,>O+VM&"VA3XG<WM3=,_B5&L'!2P#0=&U0KS.MAH$04I1KM$_CCF4SI
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M1R"[/LL8Z.!&M&^Q.+!U3"&+\"C%2V3(*8H/=U28\OQ<'*I5GWFL;H!VL>Y
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MCW-0P\Q9A!5/2?-6'\]2[3SJ%6+(N!KE5Q(5/B/C.<9:/'H=FXQ,/K:K49%
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M&LPOJAV%OQP+N7A1+^1LQN>O7S^?*ILKX]X)?'RL^SX*D&*!GF?]!6=6#AG
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M&6C):^7>N%=1N=E<5;(JJ:MQ5_^5[I G 2&<^DY_3XC")LL'JVL\MU<^^7)
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MYURK/W:-^/.;H1"!#&)ONZ$EWF[S-&?6\1>5(*)[(;IHS//4C"66][E2K3=
M?6-/*#["*O0;P_=)L$KG<M,U@S3.-56?P7.]QM:]/^>$"4U(_6C0DS[2SL_N
M#Y\)QJ9D9;ZB)RQG=^*+B/L@_3!LG%7N'=]5^HN .G,SO U*X?-[]FT;S +D
MA@F <UA4'9!@9&_H]+*'/-DNW#K/.^S<"'$$QD(E;]NI*V1IXJ[!1AW'_#P;
MQ7M9F60B[@G!8=#YQ>W35D"X#+4ENL/+*,ODKDT*]WM9CK)GG0?6'V!GL<!C
M\\.]? ?(BHU5%!Z" CF49&Q5;1+Q0![A;KNE"72#(W"4LV?CY8*B+D2X6\I
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M-,NW^S?%_"YWQ$W.M[$6CEB$BU$W/!W%*+6'F)DE[%>X\?@_P+A(&(&3$I%
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M9E<0(TB%+\7L;Y^9OCA$.@:^RQ/@7^HJM\-GTU2'!^TO8&-"+(,^7&R.]#W
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M_5),C*I8#CGTPD!,%#N+G27F4\2!*OH^ZFL.>%$3WB'%3#T5FR"M.)#% >\
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M0VZGGS_[W.Y!.5QJ9^;</651X[Y63K1!P(!7H1T/$!@T91M#R2-23#].>$)
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MC>PYO@/WX5#0K-M+!FQ,H=4:AP85F;.!G8$^/=1M4"JK#4-?CU].@$]7M-\
MV8&YID5%LV9C*U/B?ET-AA]%%B( !/"K+5((!,7&+FO]3[&W_:-D4@MM*N8G
MX1;3S-*YVPN3\%BCX8_&(R0_\:+Y]='NK *2GVE5N>Z17PZY0YT]8^YO2G&:
M2X77X]'J:-8[3"T F_CP42)"7S;H68:P L0BXZ4 T:DJ_$=D',"RW*C@2ZG"
M)R.Y _ A!D@6ANE)_M"?N>"G?P$ZZ?S7?"$4)#=R79[P7B V@LCWT8$,2%UU
M\3!O.T[X8F3G\F3?[%<22.S%*'YNLHN?5!F_;ZJ&:PV<"ZS"FBKES@L0ER&
M"4A_G]D[/.XZML(S'VGU?0X!=H\5^I*JO8:M1U7K>#]H<61('=6Q9,T7\Q8@
M1';#.S8R"%)7/%SQZL+9QN%TZ%&]2TZ<.^Z*SM\LA[K'4\*)R50U,#Z-2_*-
M-?%Q:2!UHL5A3?'5MBFHA=>]_N3*2LB.F;?W4--5H>B]_$,X"Q:23DQ"R1@#
M%9,0T [L,I9DTY(*],?)?HT-M8/&AYE5.X6ZC*H\^N-'\-=&2B-E.#SH!)?+
MCLY+TF*GR#["%J9?&6\@_P/<7)ZP;A<@&F47.S@ ]Q*4PQ9.$'\KB.RA(=UP
M[MW4(Y !NP*S#3:C#&JM+AWV;!M>B2$($.<Y,O_D DF'AP"6$L<VL\+?L">=
M;2<:T+*<L)INN'QQM)IU"_E+F-AB38 .%$%)B QT+Y,_I;! QUE:T  *QH&[
M'\PB)P,='[3? ;;A(YA3,5?@4/:S<KP5]( 5$^D*/00S>QM<3*6A4!92#J\,
M,NYKZ2IH2='+/#PGK<OFW+R>%%VQX3T0(/9<%IK7I'VG$H0'A(24R _#CW?C
MIZ&OHC_:,1-A28"+ 746\WBFEK-BC,2"[6T<TRJE-HZ8\Q"%H8@C>7 BDR*0
M$H&&WU(B/,7.@ W)$<\M0PDM,2^'6D\777&;,R3D^4K_H]^O2;OQ0>2W,(5U
MM(Q',>"]W_AB^;PHX9^'8&Q5X+BI)$04NJ(YJ7,JG3 T-.7,\6H$SYK8L7,Z
M:#(S'UN=DTOZ9QD30/?,<4[!RW5$M/74/^$[NAM*2MRPZ]4Y_-@L:(-W!NB0
M1%\G34KR=QX&7?@[(\NAQED:/632G=E0 7YS3C:5Q=$[W/SNF2K;@&]A:KI(
M5]66;IHX[%<YXQY E3O<KG1("<DQ>* Z@M]7CMW6G5TC'QC(V_(7JKT1EA?.
MEIJ-<!FZ!(B/=D)%-);"&05B]'YK\1! AU"M^MH)X;27,9G*38,DV*1T_@%.
MXY)WA4< X=00_RBN\<]U_'B\JO1XNK'Y;'D]&>$*!;*6'U"B34Y3  F3)D!F
MH>#$J*SMT,IK%T=9U<NM0HAV\]\"7?H/*KJ&&"".N'B_ D?FVD+"XV]#0C[5
MN >=@ QP#95B>"2O'$JDYW:/W0>\P04V(QD^7?*=H#Y,"=+NI_0AY6 T-%X*
MZP%;Y^7O4%A0>%^('-1[*9O]RS617C/%G_VS!V?L7X0^VB8!@EF,4:(QGQ?L
MYNCT1"\3&?4&<:L,4:BQ4^D0QR6.3$#Z'\<] A(;Y=_7L5#(.?[FH59L8*4G
MFEXA;<]&)BD='JP:]N0@&@?9-SY,G>6MS99UH!-H]3D=Y!04@G <"D;*XK4@
M.C-DKQ"M&8EEN='.(W@#=OZ)6:N1;=G/_$'&G#RET@45-!@Q?8(][O(A(CI0
MT>=":]U(95#P-01_&YJ9+PQI(><5D00Z[IJ*\2=0>UH/LE$[\ K"3Q'#[Z=M
M;;V#1X?J/]'/]^$4M>?(WZ 48X][82=->IX<Y^@LJ0E! +,'UHF(W)Y9'0B(
MF\I-5KWCHT;"^^QV8X%F&ACI C\K8LMNY(3<8ZP__C0^UPOO7>:+JOUIG=FA
M3)"%_X*\>2>F83O.(=B>DUZ6!H?-DM*\E,&U9'Q8M0?6S74(;U+8-A!GC&*B
M=DU^5U)HS'',N4"I!=O:EB<I_6ZS]B-ZVPLV!2V@0'L=2'6MPPY2*UOL9J,G
M+&9_-'-0=#02MF1C=N!J/:-9ILVL923$L!F%92N[*^>(I?-*&B IP]B$&UUJ
M6;]Q7MR:+I_RQCOR5I!X_KH;9@IQUP*6P/#MA6EKZV<AXS:&I 6(YTH/,6^)
M_X%CWP+JR.W$3?P^QB;";OY[C%C1Z"P4":)9M#AA%!V#'MCSQ\=+P;78%6L3
M,=N6L=7CVXHC)]L^RP1&EGNX3WR<M(S6[7G?V3/\IC[QUR\NXD_/:/Y;$FB+
M)-(HLDMRX.%NM )\9C9DDN[<- *'EL"7."$/* +$3LA6@RR/2^UUQ'HA:L!Q
M.D,D@!L5%L _%'V+KS5N[/M".[]D[N_J4FW;\KOE]PCU@^8XS)(1[PR$% J6
M E-=_A!-LK0IM1VSA:\ D=EVR3ZU=B<OT6K!GLRPY[U%<Z'><2W4YDAI:GIQ
M5[MR2]9&Y>T3AT\^%QE U7Z#I26Y$AOU5%W\]8T"V@T,,1<0SDH:"J$\.LRF
M/5B"13G6G;WT\J=0-69KP)JS_%HZC&21=D&O[&HYY\RL,QU +PI;RZ2_.^NS
MRPGL>GSZ="\C L8 '24"Q$M&U]()G<EH_LY7G,B+ D2<>LA4H M'/PN,9BVX
M!;STZ 9__F*;+&? +K/E?B/RGSP@H&M&*]5VL'77\O5Q@UR#>!V\F>+47,&A
MX5Q@:?O_O+)K4(#8WB2$BYUH;Q*OF;1Q$SVYD^: #J9]I+/0L)0JUQ&JXRG!
MMT;@D"*\#M0=Q#IJ;%F!/S6ZDB[2,QE.W<%9BR<H0X1??XT*22D2JC!O:&X4
M8F(]5M7&CMY"R1]]]&G2)J#/= 7M;?=?;$I."6W:"&TBA38K81W(*(C]T=B@
M F\AM!G=,YE&->"LI5"5H=A?F-%P)!)R,6]N;N(8I$4\.6!SDMYBDU^5Z>YF
M%E"Q?0VQ/DE[/\N=T!'"F8^0POT30F/^RP OH3,(>I"=\!#2'*D6D8Z!V%R7
MI""JDBNNK^LX7N5#JPMS2=6R;;R*5M>;03!:(!RQ\<3[:C^L@'J[J-M>U4.A
MX+?+0Q@G,*.Q&"@T(9@*8_8"C1DOE%=V=I#Z>;+O+#!YDC6>W&K$R;PX>!4<
M3>S%/"A0,]T.Y1H;^6N[#5B,=G/SV':;<52&7?9GRQ(/B-'.5QFI=V6Y*RJM
MTZV;1S1#_D+G8R"M 7AO(E_\J]#?(_ETE-SR"BJQ0 1RYWD'\+>0+FSDU=N8
M<;,VBEL#.69=:(D&UWYL90=8"J3.J S_T$U:$NNOPF5V>>UHA,(*/P5$>5++
M(TLM*[YGCZ,+:6#0<B\Q'EV'A!7Z0+I0B/;J2 .=$B"194OA6>+J>F>T^'2.
M:C+P$H_VXWSK&?00)O6KD)G%.&SSXNYMN[T;.>:#%(5QQC]+3YR25D(FQOGB
MEG]ZX1,&Y)'=)@9\"7(:3<'8G&/&ZNTBQ@\*B=TL.1V/8I.D\/H?3%4A0V!;
M8%0C7?%DIP A#DL+>?T93@.Q; 83H+2'\[Z*2=R#J^A<[U]9:[E1OA\;%!2R
MGOKG#NP)](V0C\M<.0RD2DP,@C$<(C>T:9BJZD\],$0P]H+<N]V^I=:C4J.^
MOJJ&Z&8<E8$X_$&FR<X%VUR,1(",_J$^>DO,:%52@U:$W@HZ^!8R!XT=@%0Q
ML$0F7TP4' *(7L+3VXKW&@XV/OD<\Y$_AMY$4/D^@^+HQQ?/G81*9WZYC!".
MPB9CP^9C5<8Z+XBRBF864'X(FR@^9\A]4B$>>4:^(/'$%<(VH.,Y(-EJS\1,
MN?-WAO!VPD>A<2&OFY3E[H$47RQ,]BXNS[HS) *4U,$C1.]B.)2#2336J(0<
MOFJ=H'=&:3_CD#MSQYX)W[(7Z%0)+,)%]T0QXI9AZZ<3\^MXFPID4ZO0K[??
M!#J46VUFM["#9+LQ#:KT-JF!H&/07>9R&F%S&QC5N_4K-LA\N0OY@'":(T \
MC):3:=2<.65@N3FAKKF^>?HVHXWQ\ALLV<<](UR^VWBM)LB2=PBO-$C=AP-<
MFFM'6GVJ\OKMN@A&4'RUJWO_5GE&AI @:O1;=Q$.-C<:N,7E>N7IK7@I@D/S
M4?$Y<2LV(M;-@8A-<#30 ;3Z/(5%A;&7 S")M'K9;O>/QHJ@WSDA"Z1AJV&S
ML>I%W>5=WR_AW+F-T%3HK(W[E9'E'TM!]4L*'?+H#&,CMH[4O.P)"YG\9YZ4
MS]>^7LC=LM&/BV:O=0*RN+K+("K>5!4VXJ SPDT.377)CS\P-IG%B =Z:0ZN
M*$R,C0VXCQH;E<Y'&O:0BCT_M;A/!;C<N35A9Z1I?_'G,4=P#99*Y8N>X<D#
M'9>IBE!T.T#!Q.H%5CEV2"[( KNIZK@MS@U@63>0F&/X(_\(Z85. FQGFE,Y
MX3%G4,55M%WKI*H.XLV92]97!L.U[)S U=7W#Z\/XBS@O0O\'7:\O4"'BO$5
MCAA;9)'Q' [F$+N0R5X2->"1MEF=="_C#[#E<W><PW 7DNV>KF$U9"S!I"5Z
M[6WDCXRP/DRNKR_3<R8?W\(%6B5>;!V.9R3E>2(V\O[<__GSC$+^ FU@XR";
M1GL+/Q(@$H__V28"7"5">!2LS%"@L<J$B9E %R!VD&"5&0DA653EDJ%+)+"?
M,84&4X%.FC!E#/"L^=*D=8,L 4(,R3O,"^0?84QX^?VH6&VXAXY'3O;Q7<YM
MI*$7G^ L!(@K"[-90,3J[\!9$J2,7JSA(/D[ \$I_DX*V\2/_8L_"(@92XL\
M,#9@&:%EH*AQYB<!XCK8FPH?]&4'N=,?=!!G-<A[)OT))T>"9JV!)!F"0K:[
MEO[7!7JCI$74.*/\\B9^:&Y9?#@9TB+#^]-YE_B] .B(2D?MP6\#=;BX<;0_
M>AOA'7J3+EF:#K+I/9EX!2BQ!.?87B -IA=472OU!-A$>I5%-T9I=5ERSC!F
M+=W8G;4AO;@2<]=8SN=9/FJ2QF1AH".)\!Y)OBB')XYW?PG)"H&G';V3%E(5
M=@ER+\.+@#9E2W(\"]@*2E>PXQBURP]T*9HY0H%LNU2^T8<5--(2O(R;.<>Q
MZ +$Y_@*)[WFLMUV5PCU1D$5RRB0-B>,]>/"J(2!#@,:LW1&=X2OA0\!D>D$
M%/[.V-**M5;T++F=+#.%TV#+)E7"1KZ%W]?/F:K6<60>S(8D4H\VU8)?'Y1!
MSL.N'-G[>C91O?1;'25SZU7%;H3'D\ [S'8T<X0,*3,Z@'A@'U71'><WB^H*
MV0M?!;5?,;=P:.R<=&,%X<G2=NF2]TS,Z\M.DCO5PAD)DT@ZL /WU&U^^PQ:
MP@-O,*8G6]]H8_C#NNK$FFOM2+LVT''(=)<709CSP9N-G0,3LW:M0<+D-CNP
MZ,)SQ.^KH;G$ZM>T0D55^%#0A,)^<UN\5J]^DGU1B;E/JG3N3-HQ<N\ =/(5
M=QK2 "U8I*4_^^-\AWCL:3$F9FF3#\\R@"%K?)#)2,WA,I!ZRPH!\N/W\2B0
MSI:E+\GW=;NXW?PI)+Z^Y;!"70L'=5];2[/529J8I!VR&+[A,$RG:@*[A"Z%
MJ;%;)((,[IZ-'(($X0UF!X6F !%9O1TQDDX?\%I5>(N1>D5,SS@WBI:\.B#]
MZ0UYWFL?./Y@1:/B\4@$[_75&"-ZU&5K7^GZVV::<UKO&$\PX"4&9&# %\T7
M$H6#4'HTA\0FW8=C0&#6N>D 9A_>:>-?V*D0$NM2,@[$.EM',^2_*ZF".42"
MXD(+E-:/#9L5Q4NBTE:M1:_6C,)FS]W]U[>Z71 90=?[P=(,[L&-?+XNX3VC
M+IPDO8)*0]6K+FEPUEBT=CM1>#^DPD;NQ)_A-#X(A@%VE2K= "-AJH&=O$%%
MT@<2"R0\[2.T7"Z-[XH:(XM7K1!D/JQV#^'/A!8*$,< \.XXG,6 #J,W'@.3
MB0*$ _#Q/2T&S2Q @R%VL*0/7Y3,V8U* [:W;IFU2T;)U??Y!\$Z'/?9;\GA
M)"4<N?U=>,4TRID*FE<GLP 1G!W=L#?I)D7L-24]Q Y\%]7>V-PT'/YJZ:1%
M<_-PZ5H(='0-WBO+=1&FB2*HCNO.B5Q2JQ0FRFKALM#DH+P>T\W#A'VX1CI?
M=@B^1#TQ0E6<)ZB" \2$.B9#:MYE1FFT&/)F_:-DMW/>:P]'*ZMYY/P3MI':
MCZ'H6\@OO#_/1"C!?RKGY C3!3+"GRR@XS3^N%99.TH6RM52X Y!6JP/N9@'
MNMT<1AJLHYJ\@M[3UM7R>X@OPQ^<.12]3[-Z95DT7Y4I0/38&'2N4^,.TL;@
M+45SI(^T12-> %Y,:#26\$Y(.(  NXE?70WKWV)-#_B/909$:38Z.^"*6+WI
MAVKJFC@N0E*"FN.ZR![_/G,*=%IESTWV/^HW25^T\64CD8P ONQ8O4F@PYH
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MZ^G) X^ +0/*N05/%+Z3 6^127!9(GKWQ>VF0-/0*?PY!ABE[N0N0.1X'C2
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ML3YT"!!U8U2(OT.YW^4==3HFE0=O1/N?P:!F)P=HM OZPG =ZU>YLW+#=$D
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M=5",=8%V&R4L%M]S*M$=,23N#@DMAN+[NA7Y$WKG1_^K&QZ:+8*/D!Z%28)
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M.&0\1[7O/S/ -<>E&$=&Z[Y71^T%A8T\N!(6<=>CKNP;N^U956A,KC*,^'@
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MX$H'&8XO=O+^HX'L#D3+*G+]>.7YA^]FISZ9_"L6R'@HG8EE9F*4B0>)/1C
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M$0WLO$S&61Y'B>$Z_MFT(7^A2^,<96"8.DQ=IM*7LSZT?LWYRC#SB,FMLXW
M1F,C-#[@(L,CY"W7I7')RP\J];=ZWGU[7[U-;"1;BF997LLSKR*A@^7STZ#-
M> =G8]LNL;&$>H2!KL+G<1=[C5(F%8#&>#&6!&ZTK\\560.T+D6<O3/<6D#:
M##7S$<!(>; @8\*&U?D &Q-PX-/507K?25K*%$Z\NT]T&^H5IDC2V@RD;RD[
MQ<X5^.(N2BTYDV"  Z9$/JT(\RS*&^<,#6)C-)>SY;0Q0 H)NZT- \GQ8E)0
MV1>_6;,YWN*V.=D(W+,:LGB+</SMCW_ YP^DBRN@=5V:)2&W*4@Y=VEBE3X^
M8])*%N5ZIR&5:NF QHJ,^ZE]QB//2XJ,9>^@#>36"K+"EYE[)O 22\>2,'-<
M<KUB@/3K,OPWWY"PZQ^:Y[(LA0,?P.EY6;3)F9+:S= WT.,J,O"HE7$5"V%6
M1H\4U0JB"H!%OEFF%($GG8;<! 6R> @Q)Z>5-@S6A*-^EZ&6\M+MX7I''??6
MP5*0THF1]TVXK-M099H38_4(\0?RT[#:+PPH+Y7?)MI+T%TW(IU<O]DF/?@%
M/\[C="T8<9/+P368MTRC>TFUH6#AC4^6FY]#OAY@&<TH5:HSAU0.-Z$I^8<6
M[?E$#[>1KO@!URB\@DMUT05=YP?/[!<WK'<]D8LGM>\E; ;W,C87.X@<Q>X#
M>\&=W\PPZJ@]!.0G^/\^$)N(0.FZ"/I3)S=!]RJ@VP,UWR?*!A@;*\,:_YY!
M_ SU<2K6ZLEDOY1;/H'YD-<CHQM', LF $NJM'V]E#TR1]QKVS0A_<A1$R.?
M00E= 2>&&2? WTA9II[-E([^5.G)(@-$EP=)9=Y2$1>6WYBPU(=W%?$^%A^>
M87'._;2+-&B=H"WTSN>(,-*/E$:S=J0B<0#Y:KIK LFG=-!4^N/*Q^=\KIO)
M*'4QMMFM5[N61U*#<#YTEO@LSUEEQM&$T9BOS2S[C-'4_&#F24^?MAFNIYY9
M@=HD3>)P;G\R!\ WSE?*D"*US1#H_8L@QUU,,)=+9?@+<!ISJYY)#!T>!CZ#
MJ<OK]6UU\P?UTDS&6Q0USP[4CWO]U\0<6K88]]6WP$]BTP19WG_)K5"M2?I,
M93078$+[/>^A#ON)3PXLR*B?<SI*NW[D>GV:U)A@ 5GS/""/P**%<*/EC!!Q
M)'A65FA5C9;"57<;TFX8K\&28SS-A'_7M^VI&_7Q#9F69J"OD=D8+GGA'F#[
M!EGO.3\GD"#YGAW.:3Z6=WN3"8[%_\Z>]HR-<[ >J1]/S'"129,T,;JB.[(8
M7]!I_H%>1.=)PC[^M!^^OD S*$W[PXJ=OM[X*SZ9U![#Y#Y! A?Z=Y\%ZH1I
M4%W-'%*CA%7O?VN:V]OA+!=&1(&3,H89=R.(1:>H?"G)=XZW/'"@(5[KC*)\
ME_38H*5O1<CJ_;R:4)3VD#%6%"L4KT#;UMUMUKN3M)D1SGR2(>I;D3VQ_VR7
M3T_&LQGI26@%X+PQ=^X<CUV(O$AVC ^/Z2(I2@T)3B3Y;\(3CFH]=+[1SL^A
MVMH#]<)LUZ%HAUA]W[<+;]"5AP_+^U;YSOEBYS0+UO?W\#>J%PVNW>>/S([P
M3?(GI]A\=7QY8Y&>W>5\O9"O63D#C[U4('>N,W2R5[JMBD^6%14ZIINI";7P
MD6_("M*W2,172%,@;Y09H %\(*>U[2=88W&[)D+OFK4[P_'R/5(T$_R//8N'
M=_5T#+H/1/M:Q%DMHW>$-AMFOIIU@1&_NV#Z<.UHR&):NDT7S.!_S (:/9S9
M;MRX^\QJWV]W8[K)611%\<;GA ,.<PMAO3:LJ9'H_LT$/W QE6!0/!'7(O(0
M= 4<!FK2> MRUG5M3!!5^2QUD[/$FCWAP_$9QWA]&9_T#O#MC Z^@S6.46_T
M:%2N'EDQ'=U1UVW% ,T=% 8L;(]<K\E\]^;O;7/ ]/_GNZ\156*IK-XQA0V-
M'""*+%:.[UEE3_YX]X,CW3:,O1,<K?"_!XD$7."9G[[X^HV_IZD*?W8MJGYZ
ME[6GMDZG2G_''^CS! O9*&6$])!)*\YQD(Y.7(,U&B4>,:K9A @X "(Z,/$K
MY@>RE#T"[U3Z0@["#- V3;?1]=GV&6WD\(T5\QSZ02W6"E.(D(5P@;23 [C"
MMW(@FO ,M,+#I<7<55 ?A'K?F!T+0^V$JKB!$8H%.!#3B5$;^R8UK!W<_'5:
MZ%B>:6#<MP;;B&VF%Q4'\VBJ6%OG9KPT#1R='Q:=$E\$)E82B+KB#= A4*5]
M]?G"D/B0@)9$W SBDI?5MG]3%YT97=(ZZ]#B__#\/Z_I?X<_&-UU34Z\WA*.
MVTQZZ4X6[S@A;)4\8'(K2< %B;X[=%:6DUWHG<M&BE ?CUI#K9EM^PW@=,GX
M2M9=T1OAB3FY2\VO(!RXR)M@DJ,D#F_R[M(GVN()5OP#P"5SF]1FPVS>3?@2
M]GG;:=RX+2\3^=*"U'XN>("!B02N(<<V2=DG\*3SM2Q#0EP$T(-.0 *,JP/U
M'TYX#-<;: BZ?T"7-/7UM1S\!NK?1I>E3_[T8"WX./Q+VB^.D2W%:5FR'I5J
M$7LX&YG723O]Q3=\<6S-BV!K8R=EK-<9P-W#K<%"TZ+Z4R@[UJU)I'H@)M52
M7Z[K)S#=V;8CPQM8'I[*H<V2U/;5@YN?9)5_0[-1!P<)=KP/"AM7#S]GZD@5
M2>VAS*OP^TS <0V6@00N&?TV@]E-?H.,'T&9YO46*8]8(I[*&.NN(W3*AK%O
M*\V-2=7&F\'2_OAE@[#OZ!TA:67^XX0_4+MS_:TW3Z=>=V5+%E RD1Y/(DZ@
MY9C<$O2KQLY%]B+7B0QN[*0H$?=QH-$++ (:=+#Y5(_4FD%,;@(;F-QP#\48
M)X"9)@[F=8G\5U*^#D>]C2*ISNWH*Y[5B VP"WRQ!@L)]8 A@UTP.13@$@8Z
M(C??*"-Z?P.+[3@5(JM("_K MT(+RC,L915F>S<0V5&D!CI./IQ4K1TT423Y
M@<;$PR#GWA7ZP/7?1Z.ZQTN<J7,QKA_[@IY_J3YA22HO^AW<DL"SDO,%/=/I
MK3J=J%W QP>5^(0NH@ZXI32H. 2%_!2%/477"O0=6<ZRP8:C[0>-J2@V?PWF
M.D3[;C!??7UAJKDY_^"^F(N*=_5_^4,3LB64*9G]4KCXW(AX(V_"3%@*28*>
M^?E[.X,(+KD3GC**5EI<G*=K2LQGQ\\-20\1+D/>-*S'[/6'PG$?%L,L@O?!
MS8GYLF70I&#Y873C5^D>4KN "5P@IR-WB.4 UA\00A3C/<?<(9LWTL:0QKN]
MG49CJQP[^C##M\;KFT9X3Z55W@*Z(N!T^>D[%6<-ED9R$8W'QH_0-I>^?_'W
M:[GEG/^GOQIB/C:*]QB(%/"1 M*\!"?R^.93GLPX!IX5X@>^/QT)&C5::MU!
M. L%1M]>J<.[*KJY,VKC,<J0[Z6F(<NS7,FA8&SAGV%$O0'C.2M;O^$H7Y=9
M#N#F#!EP.N"?\Z=](320WNL L43V[ X \XV#?="F)39J)>4@^-I595\Z[U3,
M?<J>HFSXAC!=S=]G#B5X RT.?\I(<1J9C1.V29XSK\,U'04T]D9^2IKE'4(>
MPC7DKL'703;>H<,CSQ NC$D4ZY7;!O,6?OM\[N]NR_S;!9LGGW^BCE1&QMX=
M]$-/^P5UC1G?_(>1?VD-5A]ALH]W<C _Z8BN5TO'+5H?FN.2[RJ\)# (/!P=
MY&A*$2(&6.W.RB^F?\%3_^XVW/$6B"Y.ZW3OO5R.T:)P]4]W*B<7YXCL%8.:
MDM4CGX.?FX<,-!Z!^.U>C\\4GB>PW,;]^H,M8TSK[#9W'=$X=.5*=?5)/:OV
MW1ZNVYL?5F]_J*#JR0\_D!]J/+QN>CA34TF9L0PZ:'\B\4F0>NENZ]?OCF<T
M/_*I<S3.#RW+;[9"]?/CQ"Y);:SP[U\V:U]7L2HPW2)O_L_WO^N0__S"[KSZ
M=T4Q#+7"C_LOU:/W0OS8N[^#7A=^3W]X[-%Y 7U#WL/2QT-/=B8&.><.^%'&
M(-0-W&7-2:%K/EFZ\</;'U\;'RPY9.#37(5H=O0=@QO!#DJSXU)FLZ$,@%H7
M3C'Z5I,K*\+JXHHO-N=.G2YL^7?;KL!<K^<7:\^59.9DJ:K\W.%L<B;]INV?
M\R_>UU:$[K9Q5WWU])K.WM,QES;]+7^\XK][_A'IZ2ZR/P\[_?UY5W/3[NA,
MSPY7^MRJ\BF9'2I@S+H_*3_U=BS K>!6]EW]ALE_<;_68"A*RL\/JBX7XJ<H
M@1&5')_//C6BC*:'NWI/;B8;?MXT;ZWP_8_]^VIA K4E84$9>T;==#7Z'TGW
MJ^M*MWQB]C\VW*_K9G3BX?1_?VS8KGSF+TLF[_ZCS!7V4.7K[@+Y?;?_?G4^
M?>760E!@TV4\/^M1I794XC']].797U]&=TR[7\Q8.>3=]['8<PWV]LJ@?\%#
M]&6N9=')ZPIU]B]EH-7S\TQ&;.>V;;[6 R-5"+/)'27#]"9K5<^'<="Z^=3Z
M;HDI\T8QLF60.B12B<2+I4IP0< =?W0F37VE*_])ZJT'%QHJOZ'Z-$X?L/CS
M_4-36[E3>_:,'L-<3LQ(UD@,R')-"/U>8%<OT:P5+U!&[^N9?] _Z^6@&7 L
M=,+>>&JFQT[X,/[AC^ Y,_$.3L!K6;T3JR&$F**=EE0;$=\CX<YN70_?N$CN
M&HR\]+ESQ[;WGHWJ>0?E%(\H5^TH&5TU\?S536K?L71GF0D=1L[7!BN$[QN?
MP^R@WWD'[$OX [(5+-S\=^&-^T_C;P+-5,[^M)W)=]2<5\U'O[=I_"1=N;(H
M>V"81R-M^"AAY,?X=*2X9?7:"X>N&F3$JQ>0SH8%@Y;X?GS*F%G-BC!](>"M
M@:O'P>?I$@7IN?_A:OU//W3RIS =$@$:H\(_ZJ&]8#&?W XQL&LPQ0UKL&V!
MXN-@?YJE8C1M#=9AIO=F+,IH09^C,&L>]-\:;,RQ.JRCWVSC.[(;,_&:?DMB
M]DJL\"@8G"J^(](FOM,^!=ZOC>4C$?A^81BDQN]7G5M]%+_NS(E,;4/@?;U&
M33)^G:G(77$;6I1I@9+MSZ:+;+9O>"/%H;DSSK]J2:(FIF3EG?@3)(N"S?.2
M%J*2^"@4 9 [E FJ*!7(FVLD)SX%- T3M6<]FY\!B_&65N7XX'/F.?\1CS0X
MM/PLF\GE7&]VB(UZ_?JGKM<5)672*6K7+D)!>AV3-M3U+LG^Y%:7<D?SEXDC
M*HJG3)S<,B\30RVZP\;;OJ_!AC_#Y>N<T(!O)W,9*Y\]^/[E9ZENU[5=#+]G
M";2 Q#K&*-S^>!>KT[W*OW/,+3W)-H15OEEKKRKSDW:ZC #P=8R@@S'B'^N[
MI\G],K2;^DB&4ONDV[768)9MOZW!>'7#Z%]U-%L)\5_2K)ELIF6RK,\Y3P:U
M5T']7Z]E3$6)SOR5LEKW@[F28TW:A7R%$"-&A>,0372)^)&Y';5W!KEY&;-)
M[ X-  )>2NI"/6GS+%NI2JD0A'??Q210W%AT:] *BE^QSO8A>S6F.]@]9>2V
M7Z_YK3U"AR8D!0A="KEUS>Y5?Q8&^*BIF:?3T<&ZAVP?&S\JR<=^7'&:">%,
M^47SIG= =[+></%)?[;67$XJ,E(\HG2(']H<-=M\(O-+I<L3O=W[V3>_1CR,
MR ZSUU5U"6@"_J_S/QC!AM@U&#*/M/P3+<VZNP8+7OT?3E#M8*.X#_U=]KK1
M\%FC8DQO#XG'6^RWT'>Q5@."EX]Z+@7_'[PZ2*=R_D\F3@%E=FLPG>M,:4<E
M:<:V"Y^]!MN/4"=]SM9<@Y5]U),J8=9@CRH@D?2M7CM-8IU%W."YN"C>PUR#
M'7(!5R0/G1,PJQD:XM\J/Z+_P_ZS!OM\36<-YG1^M)/Y:^])6^E;L2P)7 Y1
M9  $R%@D^PXZJ!\Z1'[C[WMI:-__HNX[HYI(PW#C6A 0HB"@H&0MB-*BTA0Q
M60LB($9 B=0L*D) C 4D0LBH2 >SBL *0A9I(B4B32F)$,HJ(AT$A!360I.)
M0AC-9'*'>\^Y?^[]>?_<'SF',X<S\\WWO>]39N9]O[X&/4GZMT5IN.1=I6W/
MT1%:JT>5#*_<L+BN-C68ZB<A.4-1)4'6Y)XW?K3"R:$'WHT/GO;/ ,>(PBGV
M, ,^*"_E:C+[(W9D^G4#@>RXN&;$K*&V@F**[&#HZS)9TC'2J6B56MUV?G;
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M:S\R"W?M)YKQQ.OPF@I,S\] (G1/-TZ!(8S(5=#3FZ >>AG#18$Y1YI%SU7
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M35YE1/Z(4IS%WPI,(FUD2,1, 8](G\D+F:K0=0#>)E@-!.*3!:KS^+TWOUU
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M)E3EKNVBPC2)\>N1((CLU6,9<EA&JJWJA?$2PV9W)D["X9,2AERH7!V)^^V
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M=V]((, 3C!J/*Z-?#CZ@.K;\5!\M5&8<?Y FY#1Q8@65O&82*N2XZA -6:O
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MSRQ88PY1*9;9 $V>B"I]>B)C1B0"DO754,'7E6@M4%Z0JTY08N%M(IZ6U:L
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MLOJ#-B#B&1V0$DM4$HV#R(<#%S")5!2HEL%:W0:)T1&O$6D$'&=5"C,U3T0
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M@ M!LBS*0TQ]S])]GA<_ /(#F.Q_1VH(6. KU81P"1AXV*I?'4B6^E6U52O
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M.HTY=\>4TI7E'W;XCLF9OPW^)W& X12?Y!QR\LHOSA-;O9F%9-R/*L*WT_1
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M/Q!FO1]T52EK,W? Y/HWO*S>$69(BDOL&BQU@!@C&P[U@E]?E3[6G.H_L#'
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MJ7SEZ@E\2L<&7RGT(4&S>'KZ>Q0WVV+L:=6$1G'YC)?ERZ!U$V-WC5TY8YQ
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M#4QRG\%%UV-J8F(VHYW7M5NL3GA:G4AV<-4>R4PS<ZGH%EUDB=1RN587A7^
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M!"Y&]%@2_Q"99;V4 ?0(9?4[\C/DL3ZG\SMH0![A+/AM:\=J_+#-ZS$CS/)
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MMT-2*7FDIC'N:?Q@)B1)"188SV#DK@/7D*"S2G"K!Q"G4+\EG-TFU*<E>>F
MTL]_>"%2V%,Q>;QTOD8Q^^"R" /$"]493G6Q_9T?7R<,,4)A3L'8#; JR=PS
M<2A0]?M<$6N,>6F*=:5S?JUI LD<=&(%D5F^EJHMW')MC\XM!"4.)G&LV2U+
M*^7MV.;/'N?.$8WKRSW-9*0=="<F*7X.(WG[.G8)*/P0D$Z!!ACEJ+>+B549
M5QG<K_:B0I2/?A2@0*WT-VR^18LE2E.$.- GA]"J;.C$"TK'%YRL@1V-O_!D
M5566:@\UX,?QW"LJ%"S>EW-@'+%B$@L=!UAC,LQ%_F,P1' -1OKXSY(]<M5
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M>#!:D8-Q?$$FYROA7N.P0Q7O-&;-HN5O0J,>R[W8%4R,YIL>8UV3L2-O5&3
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MU*\'VSDR:]O-I,=\DCBH<)]^1*K5O0<.^DWG'GUT?JCI09!2'3F.7"'0/C+
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MK0$.18[X\?A+;FXLIS5@)L<MH4Z5^[7ACD/_&XX8L1-,L>:F1WXSEY7"X';
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M(38[0H9+I;J,%A7>%X".P^\:T84<W+8(60PK8#,M^5K-H,K?R+<$T_R(J;I
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M[ZN!2A7Q<ED.FP^E".YCBB@AIW8@;2-++FIK-.0M8*$R@MBB2;Y5OK+U!A(
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MA#B-'P!??5B>(ZJ. (B2S V?\2]$':3!@!BX!0N1 X/#J4^A40+V![('MA6
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MVA/\=^C]J$GFEZZ)%J>=<(5H1@B.K($^B.=W?003Z+HD&=D[.AH1,>]DH@$
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MU>CR 3HP:<-'<IP$(T9S(($T>SK$T;WY.S>* !EK#&%G3/HX:90<XRL*S0B
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M-.KY)MYRF]<PG".7\[ZY=8,,SU0>F,MZSFR/( ]<K'X^!73MRD/>H&T/6T^
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M!.E-P8<,:\2,J[ZC.<58)#R:A,;X7&0>TI0.3+M"N2W@%X)04@J?A)1!&6W
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MS2$O[Q-(_P > QD-!I! 'L)9))S#6:!8*%UY$TC"=MA=_85MBN[NP8$T\MA
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MM&]87]<$6RNOJ?,Q;62M4%[2:IV%NPA?#_VRC_YIN-Q:#H@$:=@JR/SRG$7
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M[G.)_&TL1B5R%DZ4K:V[38(X@\BP&S1V]T%HH"UR0DY9-S0<OD!*G;'95AI
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M5$FT?0)9 .(?HGXBO]TO[6OP+O=CZKD^[SU7V5V5.]"W'9I.+KNT(#NX B2
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M3:*'W KQ.Y*=@SW%F<8U@E,XLJPH1LJ"'L,_GG,"J.B_9BCB+<>$QHZQS G
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MG$MC57LC<^*><7U!GN83F.MW$\L#"I4F==I)>C93E?[W&CH*?!$>DI+WTF[
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M4D[\=N?ID2,S3A=>JAJ*P)]8GU:/0E$W'[,TZ>PH^$1#7H'+7*\'Z:\.!-5
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MJE65:?,O XFLSE;E8>1_&$A4 /B.G)JW4_]I(!$4'NAEFS;;+?T?!A(-C:A
MM;FZA"*E_1I_EB2=#+SJ0[R,_?QJF#$1+96Z[XAZ:I'C>L!P2@T1\5(Z:$-<
MOCC!O+Q#1EB%#/T=I4A><U2ZT9"4BHK1F@]2(D_MU+S5OU.0^;5!>:.HN/36
M:1DYG9>G#YRX]58OKO!YD:K9 ?YB<L.HX::RV**/6L45V2(1;5CF%]W<N6ZT
M#J=(FEYHBSMV1('Q.QL)M*.=97S;TTSI-S8+!"GVKZSDJD[$W#SC_O..83 +
MSCC$/F9%7Z)40OD#B1:?PXJA;1O?#5=MP0^QX3'SK/+BU<S)6U-(9%?Q-Z0,
M 4H\0%>SDPY+8X:A;K8R]_DY&?1N&43Z2;A5=MS'>)-^.I,[J*P@7!V86P%/
MJ66C_R]\=\I;^'FM6IE]=7E1/TX@Y(O&,$U&_8P#XT=ZJ6VI<X%8'D+7UZ^M
MX7;.-'=GGB!V85;N*]*\85Y/\%$#^9!S^Q=P)[V<*6=J)9M/NVW7\WTW_/Q?
M#VK]T^)<E:ZH%^G##R7B9:Q8U7CM#=S &%O2E_640]"*0EAR7K+Y1/XP6I>3
MR_:J]F3$O9Z;\=FDI*&=X?M7!JZ55ZWNIL;0'ORR$U;;B0V7=:9M9\6/R@HZ
MIULW(L4!\K4LBV'L#S_D)&3]2/$RB>& !<Z:/6/Z3(XCT4X,_",$G5+X4.)1
MJ=5]THE6T66#UG2F9OLLI%^M]O FOIKYJ)89%$M;UUX<E==8E9,;N?EVI%8-
M9KT/(!(B8I6''D1=DR(/D6_=/9'3<,=;V=_"IL8CX_[B=)'R,ZQJD9+.@HW3
M0OQ99SK5XG/U!:SLG%[5@T78TX;(5+U(=;JPV.>0'Z^5:-_+MCB%[Q_>)=N_
MCBLP_\VMF6"6*A>K9P[&OEKIKE-WR1GB@?[@@8#S.VN:#_;0Z%,,W_95:,)]
MJN " ]>1"X7HU(;3]-%(6?;]_!-,\WB;S#H15!(Y\,[&[!FK=_>#EAP13D^F
MTB]DPCX'/\8Q_J1.E+-LF'79_-B&YQ1O8610&-I';.<N)K;6 VP)6-,.;X.%
MIVL7Z@CTU76KSEG%$4/[UWX_3 /0.<+Y^7)Q/QSJZM^/X,>T_ AA1E;]F#DZ
M[J<6+H;$"GFHRRV')X2SPYP?D5WO>R=_>E.RI-EV4]F1<(2V?*/D2V5CI:Z,
M>W%96U]!HHVLM/D&[*JZ,>/'$Z(;P5F'@3U$F;;/6IA0UQ3"+;I[Y-+>"@<(
ME]UXG4!+=#&8\%'./]ZM+EYFJ9<;ZI"8D<-IXH?[SE]N#&BCO1LH AEYL/7H
MS*P'^BC@6+7B-D)]JJXV7Q]/AW><3=RY4LM4SSX:AVA@0VDSPJL.[QDM':2)
M,;=2IDY+9,GR>E"3_.4%S '87!(/5!?1A8TU/@B0:2=:Q?U:)8#XUV0Z7'@*
ME=X5ZA9@_6;6ZL)0<'"@5LLAEYI:[F!-JIKEY-3Z=X\VOXC];LD2!H]G7*:B
MKXWU1XMS*DG^I-^!2$L&]C',CS );IL5ZZ]L[?IU")ETDBL/1)(GC?#99ZG>
M@S4>\AV9#X-P@8L]JJVF134:#]*N[D5<$MTN5^^X<>$$6L+*'AS/NA@42AG,
M\[6UL/@"3[O.^;JBK7BN(FTA,=G._/NZC?''AK&4ZEDH,P+:%[KL4W-:1ETR
M3E-&Q_;H 3=-\F![?_&[YQI^-RXT2-F_MGSN4_:E(E]>Q*[E888*K)FKSN])
M,1[HSN9CDB [DAE,V61DSK>3A-'0<H#<87O;6&=$6Q:Y)VE2D[9GE];9B11T
M,P_5DGAFI9^R<0.IKNOS[,IB"Y4K-,,G'", C@\!C?-(#@*RO_Q[9 >N=G/=
M>U[VD!.#P.]@?_"D/,7SQ-B:[^ V51B5/H_LJ R]/%K34Z@QXS=9ART%<E;A
MPQ5!7@J*-<3ZG-F_%/Y*>4XGN6#^S58#(GOTY!,]C(YK"EK[86I2V$)<D8%M
M,E2P5*G;NB=G8Z5[$A)(RX<^TLC7!VX:[_L$Q"A^,-$MD F7._69T9A_I@Z:
M)3;O%'M-71HLY> H>;C!VM+&[Y-6'O89;.XM]7L:>-*72X: 2=O7V3!"KQ1'
M_=_M;"!I!8Q_XBLM^PP>:+SY )_J#&.[#>WY/8&CPSA9+Y$\4*7PK2C?/3'T
M=4Z>\3$TNI_HMV>//M4"C#'2IDR8VK%\8:<%:*W;?>]R&]8JO36@#:"U*U=V
M#\6S[5E6_TRB<YP:*Y99F1K^6'J >>-HF)!ZY^JN%B>;-%<$8YAA!5',<,CO
M[/W!$^4=0])JQEU=7&7@Y%R/KBDI;_UK?353D4P]AKXR:FCD4U20[M+0Z"%M
MG0:N[HT("9'-UB%UR[V>@\DL&XOV&SXH S0I.;Z/B,ZA&%\:YN2*G.RH*E&1
M;M6BO+C8YU#;;V@:ZBN'K7!?KK\?<;^>X3>6=7%B>G*Z[>Z[GOUEQ*)0'WUU
M49U[>>YF%R7Q:V??CC>V9S4JZ?::_AB\9Q>D:1=75^W>O31X%YPLXTB+4M61
M5/V(LA>70E'7<[0UN2?(MT+/,5^@8=49,J/@(]ED(0.MTK'V+ZE*]\I2'<HL
MDPL.<.SX,Y7?HS?[DGD@"/HHK@Y##IZ\N#2_^0LYC1J9J3C&C@,&C%C./P&$
MAQXU8/$I1*P!/B90J^\0D-JY<R6N!\DTW$W-]J)[F/_)&-8]0L>)=7G32$>_
M\4"'^0__#?:5K4Y:BT?S%? 0*29@!\<]DE((I,_!V<=[R,XX.35<6Y-Q# V6
M+&<<".NHPTUD28')@0@W)CRILDH[*?+G1X>12BB4;1%4+S*1.:1=?MZGUM7D
MD^Z/WWB@_6E J1<CG2MP:,]P5:JS+,<LGDXXMD(5TK8H?!\POE$,I-!F$.WY
M)]^E=S_V6TM;ZIS$QNU;L:TEZ@C$S=LU8,VM_X1]GO._I7%2][BWLL/J4#<M
M@4Q3&2R2\F_1EC&Y_K5 _(C-EOTB5JM(N?5'9GK6EKG4PD\Y"SIUX$?'3]O.
MKP /),)T%8ZDZ.MXOZ"'O/_$'%'Y*ZPH"54Q6,-\?A?=6%&J[+A@F2)P$N%P
MGI:E(X6MXW?*?<S"*>Y%/L4/9?"%I2T-F1K..<Z_WP';S[9_PXX$K/;^,,$3
M9W]GCI$C@^-V# J/E$RK9\]3]Z]&GQG]Z_W(TM[ORP9V ;,2S'/9NK'KJ:7J
MKRLM:#@IF\QC4]_>N\.!^#U#]F'FTKH:,^D#[@!7UB\K)_XI.J!JW._]#,*E
M+RJ UBMA56*/8 ;5O!7[K@45\NLSKBR;ME"U5%O_K-'8D'.8NGQ1QEKR'^_M
MF:N=&3)B\DY!5IE@L*1->?IR]_*GYK5FW-^H&?+/]TQRRG=_%U53=(\.O7O[
M_;2"@5WXNR2C2OC)+'.P4!1^]'1R@520^F!ZQ()?$8<O?-J<SEGS^>UOM,!+
M=JYW"!LU\ F\9=P@?3;LI;]..:UY-<FB0&.C+E,Z4.?G5\DSQ[!!_:)+Q! 2
M,P8YZLR6T67Z6C"RVF 3.RS__OP /[8I?8)[BNHVY3%SJZ<=*1PF2!"X;1!4
M^%<3-=*WPK]5/?-[KWK:5NUFC/7T8%MH\)T=V*?*NW<#]<T5P_]ZZ:1R,K'C
MLM%/F0(+&%O@>4N$FU84=K!'-IY )]YKTK[IA-9N1^O_0\<?G(ZNMHE%=UOT
M_/FUU"?L>466"E%!7.\3='F(*\17;WQ9N![) ]W /(;L(IAV)$%2$)0?7Z?V
M<;]@?[E'C;RC3_YR-XD)Y,<VV)XG/[A!YN*YF6P'0ON_.6&?R5^4"D$8_@,;
MP!QS<E87Y'NRW!',A!4?I'>;OL"S^(IVE_SSZ?_$]H>CPGE'FHMOPJ_?W+-&
M7^.\.L,I4C4\XLN4XH'(SN;DB^AS#4RUT12Y>!I8&.7D*/6&;=9_:]@S]+71
MUHT)%^6DV#H?SD0#IA<.Z$;PWXV.X>0LI6"V[Z"/$_Y=,(\CF)Q\2I]VOZ"W
MD#7B:JUD6=T^2/EA[WA;$3XQ\MQ+^E.G^W)=HWZ@GPZI^OVUU2?W8&\V!>D-
M/8^ILMZUAO#/)3>_ES#/>9$A3IT]:KUE)G+,">^CI@^[3SQT2=9LMQ$I@E5&
M^FH;'(/O"@*VM.!Q$^[A;$86A:LXQE4#)^*D#0.+W_BG>(>^@<BAEL.D/P96
M&BK-07]S]=_)S#_*:"G&1T.W U*"W8;5/9D;5>%847^=7:?X@F58-[23,&E.
MAW=2)S4IU)K%YE*,#]J4J9A::1A2[.Y'/Y?4_O[VQ?&NN3QY"[\;'2Q/P8&M
M*$&309_6Q,CR7".YT4!+J^9&=9_<#^<)&+5/KQ^5)U#H&N*:1Z/5[CE3G)[<
M?&@Y6F#SW+W )JM9NDT'=_:X;;*7.!#_U%.-WWQ5&O?$Q_='P?L8SH(.F2H*
MM(H"\:>4>S[:8IQB/^SGU<Y,><@+1<2QY5N^EADNAC;GBBR<.IPK/3'CP6PQ
ME:L\4/P33)N"L0QWB"LZ%+B)]ITSVG<9F"]U]9.4Z)5-O)T3_9H&P^8<(.X(
MGTFW8N1]CCX]%C20/V6;8;COJ*TY:W#2>FP>RQ8!SQWZEVIMCU89":/^AVHM
M0[N,R/TP^4_5&O\'@+FIP.[X+]6*D?XF:C#]2[62LJSK4JTL:JVA6WS&L@OL
MX5$\$ W9V3<^UMF/\+\_*YO* ]$E8]<V-I[E.C .I1KWT7!/C64"#L\_=JEI
MD>P077Z80+38*&IJ!&(C@S7'N[QOU'O.[$FPC_#;Y\C]!*EW[H)#)EQ^Y6:+
M453ZG\;"S:/:V5IC3.QC8U'WE5EAX+37@Y!(GR:GC$BF=%=.*T']Q:YG1GA(
MZ01 (-]"08,'A_X8,K[B4I9M(VKT\30F6-5!R=NV:3'OZ*A[F4C@U([#5)"5
MHU.!L[4G;,0E6KJ'?9V./< .H5A8G2<S1J&:3*BH\CV6GN$JV5*@NH/NUWF$
MM"[3KK6LK!G]I0KQ&*_76>C+Q\$ KN #)@_$E82O?Z+W"?BY94VA%1BB5P:Y
MHLM^OE48?[_C0.9P+X']!RFU_9AJ3=3],8I4;]=C;<"V*O@K9I^+::E[ET*A
M@6?6WDX!MS]:B9,)FTO "+<:H,ZTDZ\S,3$87_B33$\I:WNAF]X5P!22@?_[
MCG;S"ZF3\ZUPX3[ZD[$QJVP)JE.ZM;4./0"E_K4A"4@?T;:&(X:W90/<AH-K
MH[R<6YM'M ,1#LT-I.%M:QLNW:J98VY+:DY#E$^M3I5Z-S8W-V8BDG(3_LKQ
MDS/W@8UAU@5Y(&7F;0C+A.0#Y;A3CY0/?&&(70"")'O<O>R>:+H+2Q6Z^6M[
MJ5RI3FOA@1XNZ%LHLO*PCQD1J9K)>T^CTXQ/V1&<?WMYBZTS+W>Z9V7HI:^S
M:J7YY*U[96$^M![H6E/8W9KS-M?1 ^3+O1;UF*]PEU%MS+&57<)3P\ME_@:+
M+57^NI.=]96KDF,&^80*_]V\S_5-F:5E*\[O^QZ4^!O$?OWA045Z]&KWSGP>
M[#-\;R7?R$W#S$UM_CP/JS7G))#X#=C:F1?@^@7L7N+'RWN&MJ\FT+<Y!43I
M\)*SQF>9DF3X82#&=$A*.FUL%_Z$;1WI11=\L9$I^A<6/PW4DU<"SS4F?E^\
MM*RNNKZAMJ9],M H6BD)#7O1J3&9)_'<:2#U3%)0C_>)8NJ?Z4&?(!E14N6=
MQOH,V3NFWI+VD%PSQP 'B^'*IS3V;)Y>8^_>2,!8J<!=Z\:1<KL+6*VOZ6Q?
M3@/IZS;F#GC/ #:Y[U<(3PI@:7*%NGF@M.T]$\S$F7[2]L5J0@\84-(E8\30
M4$XSS-]#DN)4'AQ*AR3/7@*>%?0*> I:;0JRKS/YI!E+U T/U%XHRF[X:Q!M
M$NA5:M1D[1M<Z;IR7V(GPL^/E0#S(\W-X!XC1;7RG.>=NV:09-T<>/NF.("P
M9D@^,30MP;XG)(6OJW3X\$ >? )XU9!C<K7?&L>ZCZ]4+L[FU*KF:*?T;A04
M!;!VS<\]<,K:Q>M'7KTWTG:CP*)185U!\8IMLO9.(?UE1=5/+\6 <V-#@'[&
M(I*I.7X--AQB4^=,8;LB+N*EQ!54A60,-1/%RV_]O#4BH+7J6&0Z4C)O/5)N
MF9.>YQ:2-=_'%G/V'/E7H8V3G$(TG+:W'-822<;)0L/71>W_-AM:GFS%AN)7
MI *WSCBDR:L5K1-U11*\TBXR2\*\NW'??A4F\Z/U3?5PC]C.82=S/XB81Y4
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M\K+Z/$F;FC)WD;]GQJ:G@MGV6$!E/0T"0CN+X&U7[';_X"%@BHJ50@<RZ/N
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M"6F82YA1^&%PM_))=E_L:JA>3 _\#Z"CU^7QDK*.<4UZZE;YKAA#2B04MI3
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M=\5<ACJM"6X(R(D)[=7&*Q.9YF/(^J##!JLM2ZY\V73AP5/L*6[;&/$H7U>
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M2$BCLZM(C%!L3^ZN6)S/KICLB% :";A"V1F[8CU4@,KF,0SY:7!V(K#. _/
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M(W;5CF?1',-N8>*I]&1E70[]&?8N-%K$-)C3_.!&H(,%$O?WULND$*4!R^(
M%V]#(*H4FMB8JBFI1Z;!XQIG)'IFCT[PL>'L#X,V0CQI;A047:@"7!71<@!@
M5 D46W*DXLK12"";$\+RRGG)O&JPF?^",8"DV*,N]N0UYR,>O?!^SUB70?F]
MB[!+Z816>/4DU2S"MIJ;2J^./RM'&+; D^GL *6"XE][>$+GWKJN!S[<'I_
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MFXHPS1GX/;9\OL4 P"+YF!;@0R*O#.A^_OFM>5)P6/#SS_XZVRKBNJ0HQ^Q
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M&_GQ2\^PS D=_MXQ3\#\ZL8]-&-$::6$%ZXSNT7[EXH18CD!>I0S0Q#I4Z]
MT2&"G-$SJ<&C['A614&#%!5K:U+3;4I7\FS(G^3H;!?DW&&47 N3-_]EUR?W
M=FJ?\*JR-O-J[A96 ?<.X05KQE&T#ZHAH&$V4,:=*0-UVU(F%NJU<UJYO[#\
MV'=9:ZV]+*)_:,5;E=@?2&_.7@TF1A>_S>,.$0?".^;^6'CZ;HK?^($X$F)T
M[B)J,3MN^Z/E_QTN%GL!7H,01OU7 AGX+7<&(?C%// QZ^.:_^"3>LXM*>K/
MJS&(%P:1)0Z-Z#:64])/,W=%27J_*UPA=J;=Z#RDNM@/G_W_KHCV_]?KO[ X
MN(E14<&XK9<]/C4>HALU/+QAV#W_1J*IG^])2=R2)P$C*6<(%4-IL:+#M,X,
M[=)< <>9D8A\8BO+2C2HQ=Q5<[UZR6IZ@KU4'O3\0V\+,0IB&L@Q4E.JGG&"
M7="@0PZDUY$^\]/W,:TSI_)*-.D9-:C'R(<%XB/(HW%S[;Q5J9_=$Q<73<;M
MK@O4QF579Y\?/\1S\RHN?L X7%L3OS#.PO"SMU.B3QJU!W@JT->>V:;H(=EZ
M^%ZZ^.7D"1(TT(JMJ2V"?Y-HV2;<?Y-W2R#3O'%-6O!6O'H3TRK^Z<-K_I4%
M.-..[1VFWRYE%-YIZ/ T.,N8;A,Y)FN$'%)Q_?)E89?KTIZP;X\)@B4Q+ 4I
MZL<F*,^K]]<:0/P[6QWX% \B4'E",<YTV9#+(174/_E:QD=7 C-#H*/P%;1[
M%-/_17@/5,@18$<XS6@(!_!V@^9%ST@9IZ->(?0@)^X[5@L*8[/ X<+'T\[
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MT6<XS[1X^O9<R=7%:L*MI0,5@\7KYYL)X)'Y?E*KI6(+66-RV%B2"_ACUU.
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MS!T^?(0/4^(;!^9CZ]4I)]N4*?INM^E_4@)_S.[1/MBT-:V$G!^@Z?1^SV>
M]MU91I @1:U7!1K\L).>\X.*2VG# %V*RCW!"EXZ[@>HQLWZBH+%.Z"<4=8
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M'C[=F!^8U1 =W\6TSQ^<<O0S^_!P("TK@"/\1?YPYZ47M96O,A=U'M]: Q7
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MU*$_E;]/ERPK-#?"<B@^7/PA?G+F@Z,WTQ&G!Z^U_FD*$?P% EC8_MRA;SQ
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MLT:MBHJ:9H.7OO%;NN[XIS^6364H4.S@C<HZ?LY95_-?ZTL^/-KR/I%<"^0
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M4[TY?5P:@'WLX;KV!(_N7T"^&GQ1\XIM/EI5Q[]=.&T8I"SB6 [*"E$+X;D
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MV(D;1++ S130(K18LO!,#^YQGCRPP*8QB,P=D8Q,1,M-9!0,"J0Q1%J0ZT:
M7[\/*,I5M\ W\6"LKYUI-"5E+]M:-'"B7O5*@6^M84RV[Z'I@RX^@XX]WQ5]
M1):M088**RE44+A7!*VI1@,#RU5.U IOVJQUATF-UVM*'>7U)]5HQO#4V!6,
M=W66 J8@^@+F:^*0LHOS74&($$)!T* @P&@RH4Z 1EVZ7F&"XZ'GP4^G^NC
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MRJYCJV6]'MO(<S>RDZ\<9*U*=AN;8?^%O%1>/<PF3L%YG: TT-)M-DY-+-0
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M=3@%8*%MC:/6%1<"R]W+"F)_F^G8EA#)1(-);*R<:(9XD*#A@?X .PJH\?"
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MQ9%>Z,S8V?-+\H$\-'U_J2<TQF:!H^OZ]LQGAR/NN9^6VC^F*2=_V?1W[#N
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M"4RDA'R@HRHK7P:=T@V@O\E#/-.<%/Y!\\^@0UB0500WHPNM1MT#-@_T64@
M:0]?-5!;CNBNGMGZH^9_I%D$4'^E64PM_=_2+&;9V&\722L5(IE\80Y1#%V2
M8G$X;,9(IF 3:(U%/3+'@_6/LK);?+2&! ;H \AMB9)%,><SLK< V-L2L?ZV
MW-FW=9AV[^!#K8#?HM'3&ZW#=?15B_/)C>^/<;^]-V4E](S.I6!ONET>#3P^
M<XTJ52H<XSA6:ND0/VKN ;*C+T'+NE)DD@9OXQ'DZBR(4:-=L+-2];7,V%,'
M\VP[I&SA'?G^<4X]UYZH(\1P9ZG@-B^Y\>;_N9WK_UPKS7O\?RFIIK!CYO],
M:]G_3<.6_Z6FFM'_D<GL "0%"E&\62Y)()_".PT.\/W R3>B/\!'K*(8(I<$
M)PN461AKAY&(&7^1$J07NQ.OT\B7+:[17>1M2TS1$](QT& 2^>3WFRLA?Z3(
MOU719/#/X+$CM$#25 L/+RP-UY>[RNU+XE\0R($(@&;-G:@+P]RM!J-L01+3
M?&=_+B&A:F;J?F!$9:!QKL!8N<7X.1(1ACWV<H?\"5+__XM<DX^2C!__?P.>
M_V]^%/^WZ1G$VC3BX\C5HFT)[;O\J\0IXJ^6655?V]"!G<1U'(,OF2#*AQ>(
M'D&^:;$8?-4;M(T#$"-'2\6MPX+"_XXJ;!)SDUJTLN!DO6AH6X(BN3)^9[0B
MJ?T\X-#/%F1''O3HQM3BG-EN#\AR$C/-F==;5=M'%^XE=)][ ?R>B>ST]X$D
MX<_R=*M"2*2##/ IZ3G13XY.Y)BL1 %Y730-T>^X:H0T;KUK!"&W_APIE.[)
ME=FJ]9R,;4>^>/<66X_S]VJQ3-[J<TUFT]FZ^OY6'2/M%\H"53L2GN4Q-7W_
MJ8N+S=*QRPPOT_U6G?6E3%'7N_+=!YG2S]=>9V+<^08[V+A;"0J^/\?O.9-B
M*E9??EJZEN7M<?WTM3*KVJJ3K_I<3KR^V'[XY 67\(['^0J?.:_Y-PCO( K$
M&R2Z/%MNA0^@+X_=W,#N65;N[[8XTCHJFU>.M^8JM*9MT&*IQ\#KKNN.+7G=
M(OW1E<$OCA>JT(CBI="E0J6)PLF>7%E*Q92/: #29-(+H7_G%/U#V"G0^@CU
M]N\A&$V&#YA;.[X<P4*1<KMPJ&BGKFX4L)YL\:_$J$"791<\-P:-XC];+:8?
M;DSVB8[R_YTQCDV ,^?@GY8Y&=W^7/3J6_[^X-GC!V?H]16L#-D HC3!'&\\
M.=)E#G=JGBCJ+E+>D-NQ+?&W-RFQ[O>)5L4NW-/ 1Y\"M_()VNW4WKJJ&F+G
MO^B7VQ)OB FM+?'PZ[1/82@N9J/'QOC9\Z!9.="2>Y2U8M:SZ9811JP)8.R)
MH!T:K+(,:)'!/YSNK_ .FG1SRVY$+^Y(+S');U('''F&Q_/Z;G^+\D5EC'NM
MY#1WK)1$#JZ\SK6;F9]E>(+6W?X9=V/QE[KU8NAV\L+";^^)O'?/JTVW)?PK
M*8,G^?#/M?Z-3K<W)U36A+HBV2"P@648AVY@K$SSC^+\G1_(!/=:6 SCK5K5
MB5.9,YU<$G,RAH*011(#/:8_'5D\%80Z 9C$%5WN(-MK&,YQJ6W7R_M#?0-K
MD9ZBW>(-O(,VIU_4&"F<) K],E(I/S?XCH0QFNJVQ$UL:N$Q<!%8[]W4U ?Z
M$_$UYP[LG\(1NZCJ#9F1PP(-YLR!8YG3W2+%8<O!SL;1NH'!B.C(RN76P=D:
MMKF/QP04$O+?-*.QV9W"9-I_TXS(0STS\KVS1[@FW1X61]*BK+E:A6F5N,8E
M0Q6!%C#?S=<>T6N_4(_#6K_*''4&O)^LCD6V?BTL[YM=Z-7]O*?XL:V*[Q6E
M"\EO2(P;0:S3Z?B\:SUN948ETE-M* 6.=D@(RJ\DRD!O(/5E_B4VP;XG#+'C
M,?/[!TB:7"TV[EWCYQ!5ISKO"X,7**J?JK-8[ZNBK.UM2Q)@VQ+68M[S%?'3
M1J-"F$?K6A>:@]^H9N+9:Q/?.6U+^##X$+SEMD0UIX^"%NW]SK^%/_VK(AIA
M4A^89RG'M]]E87=U<KL[";]37H(9/BSAV5YEY5G-5Y,DBO1T&KQ;K/[\'@<'
M'MMB3*U,F-_Y%GB#PK^R?/.[,!ORNW@@/&&8>D#X2&QSVC]%9/^,<.P!,*:3
M)MV.O%N+2[G,C37S'4JJ)P]:=]^;3_AJIM_<5+70ZC*^T3 ^L::+7$5?:7G]
M35622OG^^]MFB!S*]/=;C15:B:+! L._5P=7M2XZ7IW]_,%>_T=4OD<Y)L<5
ML+T[KN=]<@Z]3)#7V/CT/4HYMNSIQQK8Q?:[!>=&8RLBU%[5E/Z 7R<R%Q$_
M+RMW;DOPSY(2MB6V6K<E LR$><*L<,9^PC2:&Y)%D\;O"!:^!G3@4]_9D5W>
MAET\DXE'J%G<$$L[F3+.=8LGC(=63+E?(K([U+I%!PKI:H_4#U0DKNIC-SY]
M4?:D$T\1N1ZD:0X+(E!PXY5PK?MH#T2'P#066@KGQH3'414_?Q)<'1&<+0&3
MEY'#L&C@?.]D#M<#Y]Q;>'94V38*H1[(:QZQJ95^;8 QW-?\T/*+4948G*O%
M9FT07!8__<'N/N.7X!6\"Z@+6$3+<OKAL@90?IKL^I6)\$"MEF: ]  JI1]A
M#K\"'!HQ6".OHD:BC3QQS1^F_VP:)^DC+PYC?S#,RCU2:A[YDA>='?N9VI?D
M'=*L2@;-'+S&2C]GIHUE48+6]IJD3:.]8SFPA%UL?^4;#;@J%U;AB6X_%:NC
MD+C4)1VCTUD+43",66B9&>6HU/ 3I1('AU,DLVI%#:@4P0']"1T8.9GK5^$?
M61'D&3'3&U]<P9@>](^^'NU_=GIF:M;3ZU@8?88^I/[0"SFD:O_[OX!M\M([
M^,=+(AF1\!G!2#18Q$5D)$D#39WW,KJ%2/9F3X:RP(E;$1\!EK\$_M3<UPZ&
M,H?V!>8F))+//[W1SA5.5-UEU5E]&[@RYFK^YZ*3.\-K&JF_<H)H\:L\YJZ/
M8MO!@E!_O 872W_58:=D'"*,-&_>P@W8 _!4JA1A<!;2V@%F5)!XV3EU040E
M/;PS!Z%TH<HS^"/=!L,I B]2L <^W56B]];G8VOU]1).\D\3.]\W$Z?AY/(Z
MOC_N*-NUN +<O/HQAZD<0]V%([YI'8H7J>"<&#: 9E$-&(S,ZYTU!(FU06:I
MDY&J!DW1'.F:H8-!FEICV C<C5$\A"64ZT9I>H4%^OTLWS4<[P*#^9@Y5U>/
MQRZ-Y?LK%"?$:GR^\67>[''CK13;$=?H=FF[^^>T$SD9O:'URM Z5+R)S/UL
M::G$D@==5ZL2:DQOG/7<8([IC%_C)!3'=[=FIMVK=CG&',WX;LH_3'P[11C8
MEN"%0G;!-WQQ?K3*(?"\KNBFO&BM9%LBNH_VN.@!ZGP#B 2*6)">&8=WZ\ZC
M! T\@BN7OB%CW%ELMWJQO\M"=P1_(=+7;W/?0ZV9SZKXATCRVL/:D<-/GNP\
MP#<1&[U#;/0RP4[Q\\D _TS&_<)]((UUCK"W'\@"LQ$IJI 8(].(DX2C+5T-
MI>5Q<C&"*$YIX7D%KM(+>FK.]\7W=5%_-P][R9FS-T*?!FV<?5\DO]?IR5X%
MH)IB&>(94B;5M]=S)LRFE#R^=99]6YVCUXW#]#^SQ/OJ>&3[IK"6GNY3?]U1
MKW/(:T &>4#'-27E6M5H_OS=XYG?W03(IA&1/EZO!8P&?!"CU"."<Q3@ZB04
M$4<\N+(*LV-)$P\:QF^<+]H'YCB"T9P31T=+)G;'U&K-)VP,T&2#W';:C4W,
MV] RI8OU7XF>B>-M"IKK09SV[T.3&9V03WR.26*I\(4%1'!Y; ,MXP'F]%4;
MB QQQN;P[GN,Q#XQV9*6^(QD@*,.H[3&>A(%X+#8V -#94DO1BC+CKZ^%6^_
MMPCDIT72+EPL$['2P")]\N>]%V8:0>CR/!RWOHZM*U1S&JW%Z[(+G-3@!W#3
MSF"<5D4BX1#>YA_0NC>W.8=-.[!,+XQCG\<J@1<QQV?U5?O,C8.7/: \OG_W
MM@37&PUJ*:]T8NO!?MZ)7U7%@ZEJ((585IZ"K0ZB2H*&W,!UHQJA59>WS^4Q
MB\.X\SUP)1C2OSCQ!U_??2';$\93_5I7_@DY6YX[W%M+_^:7(9\2KRWE=B3[
M.&:\(K:GKT[2QLJ^&CIC<VZL^]W)*@=EMR";MU8.L_.[K8__VV!J=?<^8%#H
M')]ZZUP^7[LFYOTB>\XU*_#:^]L+K(#1FOCW"V-9VG9R28X8JZM9@;84PZCO
M-)&L*:C!;6%6"!0NS^ -/^KAS]!4"-(X:PX\XT>!EMYJ>!'HH;J91M7".?>H
M4K*?^6"QLL_@27IXQ1+<8V]7#P,H6GYI:SYQK3R3@WR8P5@'3Y+N0PU_-3W9
M/\WR[X7'FFGTIT:0I,#S3.SJX7(PTBY^#AJGJ<*-GH^S.#[EOO@QR/E26#5X
MMEND!_2TIC_6GR4W6;.$MM-6JLT489H>K6=RU8[OB/];V$"%@C0.HQ]QD-AU
MB9.A]/G(,:50&Q_6T%Z0\.^_N9 8O$9)^^912RXI835_>G'"BKVVM>3?-A$Q
M8^T.:-;4!IME+&'_V]LR$) 723%*O?#* "-&C;V^,ED-QK@#EX?U2/-D,(6[
M+8$>7]6[WI;WQBR[K)+8!9M5&:N_N;NX%M1U;" W%R$[.@#9)_4!DYOT'ZC#
M[NU-&NJRSDXIZ4<A6>\*K"6-2U ZIUT"K6XWW;MX.B7'T$B>4CJB:=,'@R*3
M<,LR&15NNJQ"T[*D;NL#>_>ZG*'7EXF9]9-38RZ7RP91E'N/RJMU7,IV_ZSJ
MNPV7#I[^=7UQ6T*#L L7R4I()IP6Z /8;F\UCDG"!EQ18$0\%,CXU)J1)#A?
M&G3)MFV<_7'MBWW8%7+F7?UZ\OP$>15**5"[.M)^J52?%U.SF/N$L>%2\ZL3
M%9R91E";H,BE$O?1F+GWXABK.W<NH8X,MU^H$>P4/A7L-)]/(Z7-EAC75.*O
MB$V2C ]D1VL[C6VD/-M=QK%#[%G6/'(*Y3T+K5N)JS6 [X SQ4C =2I*@8L?
MR2(U8+-'3AKT86W&64 66C,2J&H".'? KDI&TF'"D#T6D;<:V>O&12X1M('=
M==#Z ID9.CV@]9A2KLN#0 OU40/?\;4-M)UTZOO3T,6JN<9.ULCC.N<#G@<K
MY][]/&Q58!*Y_NKUM:*V=Z693@W?/";E;I4CLME!5SE[3448IW"?G+^^Y<L>
M*512* @P U/[E9.\'E%VN1IQQ]2J:UJ=L^;L"@R7)/]WR3OY1=Q@ZUZ,7#><
M0NPGQ;;FO\54":Z!IZ_7XS!?4G2C*P5& .SL;.#^#P8N)6UY?P(A%36E^CY&
MSIX!;HW0U:QL[G00*A@@BJ1E^&:_WN \.!-0Q'68,?S5DBD/DM8,D;&0 F67
M>S:W#.\G= V1!?I@"1.KLN091WV-Y?P4(/54"]-84C<:XA$[D6\U*Z(U:M>:
M7QH7:S/A74/)Z/U4*;PE-[*7%*>I.XZ7 Y3?J*X6)0JTV 6JE[/Y-N,WO;*(
MQ[_JIJCQ=2L]@S7<+H^M8L/3@NU>MX] 4]16#7AK(UA#R2>3==G^AW2XX5HI
M[T]'!+RN4_<LUH&:3S".5B&0P7^O-%L,P#E>+3OZ4!! "8E2*=B7$7<&IGD=
M(4O/#^KR>*)'.&"6+'7C>GSOK [BD<-5ITRO"2%<_&<7"$.:^J"4&*X.@_S*
M94VE:#DQ1U1KOTB XL]/U$WT+%KHCN(#L=B[[)F+$_86:N$)SHW@ YA+1?"$
M65H'M;'E8YKG,O]BM^<(9=6?L_X)SO,"$E93^*X"%5"%A=T37&@@QDE.QCZ4
MP!YSR.9W"R7PD@];_S#A*-B-'(]M'@ZXYY#"FLZ+LYLR>/ZZ8\+@1]K.2\CU
M@\MF!L^BA<=P:B+9_PBSJ:8"W48P2CQ-!6%2?T]PVW7YI9(WLXI@)(!F;292
MSH<SL&QIPP3:H0V:W !S8&%.YQ&RGTU2_.QI)\=[4M@D;:]9]+<P6"1[7)@H
M5F.(^-;->!JS$/XR&+>SAS[WH3A4@:#/Q79M2\1H[B2/KQOYQ3-Z9X\-$V27
M9W4GVJ/" JL^+61'$C2B@[M,S)KO![SLY*0=M%-3NWZMX>ZXNOHINQ.50/A"
MO]P^VQZGK::Y!Q6J:_C)CCH3Z?(OA0V$%1^51[C(]*$:0/W5NM2^#.7TJESV
MF:2YIY/YEA/U /3;OXX\AX,I^647"P]W.::J=I@-I]28#X%F) XM 7E9F"W>
M\FEF'(<.P'9)I ].L5\=7$RO8 VJJNWB6M_O:4ZN4Z$ ON/;$NE?/'PS38N)
M>_KG^H^YI2X*\A<CMR4T?WF, @[=FZL_W[O^3Z'1)%ZK&)SN)&B-K,'\N2V]
MJOWW\6X*GJ3X=F]6M-_P#WWD56Y.TA_-,8X?-X3'OV(@[LFSN@/2;5E)QUS
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M#%=8@9TOW 4G $A*.".Y*6"+D,$9U&1TM=S;G95-,'E\A2^;P!:J.<9X-(_
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M:>4)%-L7R4AVPY.,]^><KC&:N9'GNAN-6IOT=TPA5EK@I9)4X@6_]^6I8'H
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MND*@Z67_P5@1Y31L,A;N5-.[Z(.PJ7D]L!3BYS8P?[FFG]&,<JA)BNZV<AI
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M9#)D&Q?F4(S&V>ZC+K6-_4P#\WD!^WS_@O!+;<O+EMK'POFY!0/#[<>%H<*
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M;U0'\L=^JC)FSAJ,E.6OQ,$B+_Q7I,+\#S9^^:^1ALP7>U/>RKDA*Q0U,BN
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M_IF!>@ZB/J5P5V'URQQ>XLJ-N,G<+3UM<G=BJ0Q\P6X9(:6CXF0;ZK000,:
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M/K,*<\'! ^M:U#\88Y0^O@TSR+R=/YUM\*2>L#O+F3OM=O[BZ-L_@(YUJ.O
MFY2C'>N,&'%)UNI_)JVI_A^E>+A_QGX6VW\[3AE BG R.2V9B:H<7OEK^(<9
M941..2/IS(U2.>Y*9JWDX9FB)PC9<LHJ["6).LW^P9N6:_1>7SFUJ2[4EY,
MY>_6.YQPSY%O^?\5-/G_]?A?=^K^_W^G[G_=K?OOW:W[V2E&2UK?)#?(=0+I
M/<H1V4B+"8!)0.\C!4SP)/H]0LQZR,NIGY$;Z;$*BZ.!7G+85-["+@Y^MQ+#
M$MUX-IGCX#DKW$(>M=!(V-O^[8Q-O>QONL9B%1<O"I'2,4&:"E8#ED;/*1^H
M:V4J$D*OQ*3,>]0WN$6KKT4?@O\&?J$_FXF\\;NG3["Z0R%+,4[87:S:_VGT
M[2'8Z7?Z($>F)&?F#W=0/O&6K_%6/E)KA?+X+I<U5_[4@]HJC^ES;S!^5&D
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MQI.S%ZX_*VWJYY#6M*$(W OYP"EX68LD0_T+VC^0_:\!B_U_A>R_@/V?N.8
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M7?FV_%LS=SF?6A!]4(WX63\!K/CNX8\!;Q%O38&\54JKN/LM'5TV#_@#!\E
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MA,E/T]FO>X8A$P0=@T<-*HW%=:;:])KR$:HN7> (?XC&J\VG[+O1GE?2XFC
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M%+F%M.G^=_PT5O[A5.[)86U13<N^E):T0#OI\_<)SWJJX+B0P*TRCGS])UB
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MOHG.U1'[AMYY$$P==]T=2*M$7EK:%=HK(=_.P$.:$M;?1;(=T4>0)T!/]M_
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M-[TV)*E?P]??L534K?MF8[EOU<<W2L_7HI-3,H# PZ>_+YR-0AC,0X_N\[E
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M]U3>?U7B!WZM0'AN+@-4J72-T$)$-!9E0D11U;U0IXP>/^.[^;?[] ;"@DJ
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M\ZJU))QU:Z]@BX=@_.0;[_1[R,*&&1LXR31<#_D@5Q>=4Y?FRYS5F7,<VS1
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MYS=O+7S9W==3N,'\H'V^J^"C/]<=>,QQM'.F-NUC6?\"E=]FEM<4OS43$(=
M5/$4YSHAHD,S.-^),JO-'6J7SU)ANU S/[H08\JX@FI$5,X^'T?J%ROBR_:
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M=$!]SAA:P*IV>1O1X?+?E4Y_5^('EB!AD&.A"*-NA7]^DACG %.CXO0>/U2
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M)A,.T.M)F@W.@ SG]04EF"'%I==:TK/%V]4D8TSW^4):W06Z^BBF(SVL#&&
M>EC$OHR]'O(8=\!<GX-,GM7H+\0CA3CAC!1YM2Y=Y"I"#I@MKES)%C]PVKJ_
M<U2KI@8B9G7_4^AJ%.0CA".:PKH-3&P4LFTY(7NOR+=R39%)'X#%8.6>UBE8
M<C"Y^=Z@)-8!+*X!4QQ;)EK8:K&HW1[\4Q$\R2+B3/S#0[O8*3RQQ,[P[;1[
M2A2Y C*U]%ZNKR=C$LU*!(-?7=I!_,6LZ\(E*2D!VR4W0MXRCQ31S%RUCG_Y
MI[QGO#)8:WH1HHDGOX2 1DNL. !.$4DME.T4!.=\&H#Q(F;9%<!LXK'*>&U-
M\YJ9;4_G03)3JQBTGT6WGX( 3]#9YOK9#-L&X^B=+S\T:=]P*ODM@ZI2T7*D
MD"[WVX.9'L[9YB5J$ZUCE0&B92H7[6QG\K)"*JST".=(H\%!F>0O&/Z]XD>[
M>@]5P@L$(U;"%F2!6K%.'<TEC\_B<:M^NC\_+> KK/>*1:RB_.@F+95#SR%G
MI"+:VX'F&1BQ, 77 %^O8%(HK )Y, 70H"T6!Y;.>/B@I*?,'Z%H\!.WFE"+
M(HUIRM0"*3N(S\C&)2\O2EC9]*I &=+KHB1QFSC0C#H!QK+&]TIQ\\4/X'U.
M@!!+>>]E-<?-WY\FS$_M&.S5D49E?J!-M(^7='XCHDPV$[<'^;'0X=I[S, %
M>'#EZNZ/,NS:W>#F-9=_36.*.!9@,?"+II,0P(RD[O,I@%[OE60?WPI&>C'O
MM);=\HR>]3[?CY:/VA:8]ZIBEU'OOSG?&;$P&F=]Z-P%(20O';^!<"1@K XF
M8:,?Q3[ I>[$\(/1])1@.!S@%C%U>N7N9U3/K"K]92Z:T5?P5[8*4_M9W;*)
M#IYD^&JO]O// [Q68Q)<1PVF1XH)F4MV#81O].3? 5YQ.WK&U:W2&;W^H$UU
MK$A<U+BYT^['[ALK'4^"<LO' JW>N4DJ77V^\GE;P?]WR*-VI%Q804RVZNG_
MVD820*\$X[I$W<V>U&E8&8TL.-1-RF+RB](KYM=^T1EQ99IO9-.]_HWWS.IL
MB.NYN6SLBQHCTG/^?_]3^+H(1V*:50*FL$]Q/SX@]^+BQKE2G4Q_<BI6]I4G
MKMNM=!9M<K9^8I.8_C,,5;;:<3GS\XTX+1(>H#ZV"I=(JZ_[^><>BU#0EXW@
M&# A74=QZ,$I90I.B61;N]QI-@K5+9#[<ON>*9S?W;)J633H>EPC,!$?,W2D
M7<.]_\B&]ME@Y+7VYA8E[VN;[%S>DX@!(>"9X&RZC;D:J&X#S;RO9+-J\P/N
M"<Z0+WP^.P_]NVNT9Y$9I7U0)*G?/W>4,CH A%/GF9(!573=Q@K[NX[Q%X9;
M;.Y:NQ9?L-?8-4K!F@";^O2ZU]:BON=$1"I'F,K)3=Z%J>48W*,! 'N ZGP7
M<>H#8!#DWVX?:2V06F0S0F7H?EUP$K"\&=1^MN-KD+.&,VA]B5?C&G@@;T-&
M^0/^@^MU@%APB#5PY!GMJ+DAF@<&;I68;@JUP&#4\L5$-<.*-'82&']\NBUB
M^%ZPC@.AQPDUWAISNH/<-#)K*ZRZD0&J0SB23GU_OD5('3P6,P!I@L<;P*0Y
MZ G->UK65)/:AK)93(Z.B"V]8K$%:(V]IR.(BKP?Z5F6;MAC$E-;>"<SVC18
MQWGH9NMP2W3-K<YGFV3 TD?';@0WGSMW0'MKS_SCQS7DJ+GVZM2W@9IF77C5
MZA-. ),;+U54WB^G,8OH>[W<8?6<8"1\NJ)L)5LJF2[D[@"3C%$+FD+B8?/S
M55J!=.R;\1PX1[L.;XN.KCQ]_XV>.1%(Z)Z"4Z9[LY>A I*EO$SS/T3V%7K;
MFU_4[ '96]<0&N;]8."9WL'$L!:]/)^T_W2W]5Q<#&U5*0S=[:I1S-D-^[M$
M==T:A\Z@]*RK'Z]7:/_S4^%9=X$.LY5Z1[:()G+\1EOT,IL2H[GX%9IR$.IR
M#9?83CX>*(MPPV>(C9//ZXO %6UUJ0MMQE;.H<^9X.T.9S3M;$?X3U[ ,-H(
M9$=C"*R887+@X'3N_+48P=&(33DPA [Y-^;4]"T_"KK2FE:C[]$T;B"_;-#_
MS:][JH7>0X\62O(;_G'/QXFR(3>]NNOR8;0H>Y 5POH'?$L/^9<,6/"PC',#
M""Y->DC/.("59_:VO)["9/8^M+U4\(LK%9E\>RS"5"BZ7Z!.ZW*D_<"=UM#J
MU,I&J=0.(]5]/O[#F*KN-X4-.X])RN5HD\L(G0ES0XR?.\!Z9-C3/K[9_$Z<
M4J ;ZSUV^W9[AUQ,WE1I(1H74YX]9%<^.?5!)S?RF./= A%>%#C!^I;*Y+V)
M?)]YX98K]J)3 H7>6*!%3PXYWQ/@4I\GDE1A(9M\;_9\6MFE&O6(RN%4EZO/
MRQX\K3"VNB->FA.D#K\V8O ?N,_W/N1_S*?S"BFQ=TG[?"MFF?--]HK_K3!0
MP**_7-MMRH'TG@50,]ASN&N^X6O$M@EX52:Y#4,/!2M&\@)=B28X+YX*U,BW
M,^1B1I&-A51XZIS<!E<1A')@8!,#?@P.>[QE0U*A!1MU*RD _/]"41&5JZZM
M#]Y4/O7V&J0_#(IF?V][/#-Y\0[BVS]XU!+G!YDGK6KN+,^DX3TA<J 05Z '
MT+CX%@B)W<AQ8UHGK=_+)8O9^6I]&ZC-IRNB/9BM25 ]8+-;HTX(Y?\%JEKN
MM6KRJ1]5#IN.4 Z.#"X+@P%V7UO>9H"G$C@2_Q,1D3U"/$-F6W(:E*&-*PS6
M?=!YZI/H*>R&5F]J*V!5D:US*O[0/(37K-AP0[)0:W?(%(PROB.%9MPR/X6!
M>XX%DZC2/T'/7Q2GK\OBORT/97IT5;F#V7JG;-0M##]XB!TI.-,VP9^S^+L9
M U&.>J-_X-BT6H]?TS&*D$GH)SU'2F]K4Y&%J&.^Y57;R0MVO<?MS[G960T2
M$C'B%"Y?S58^TX3 %[HI23?FSSBG)$73%ON\[*>GH/KTR\!2]EZXX:?&O#,:
M0IH1:B3L+5K%./62Q-IP9FJ1^N?0L;WGN/F:?;YF>,(^7Y"B$<MFC\R5738_
MR$0F;N_I=#\(3-[Z=CY$" $&4G>_GX4:A=!]#",4T1<GL*;TZ?Y\DQ%;IE'"
MCRVVO/2HUN;WA_ K.5XU1C.\[%.! QSAJ9#ZS=Z,R9UN[M%ADFPY*-3[P*XO
M*>9D;0N-O1=(?;;B&9F\?F_/:H+21*'["/8.KS3[8C2Y8_(5Y!RC')KOWQ6_
MTWA^GIK9WP<#G,F\!Q4*+^$W^\8[I4!IFA:2K:YC\F.PSY/0@Y0,>B!<\UWW
M<N- Y?2RR29>Q_:E"FY]K>;\G-[>B]<__GQ_YW)A&JPI';=, .OV^1S;JE+D
M"P-?QECTRK@OMN6YW%'ZW,@YSV^8FS!>Z4"]>;/2MVKTL4.5R=7CDO\P/GWS
MZ&HY?-1B&0SL+A0"W_8@BSNCO?[]>?N9#C.<8J_U&2Q^%/J%JIDB_'+!0W-6
MQ/@CX)Z3I7XC%%RYZ:I\T#[?VDKCL(6XS*"XII6JZ%MF(5>PG]<PBQ&2X6ON
M\*S27J$!)&ZN2>I=#25DOK].#"/NP#3,?E>&V"!8FVLR519KRH)^3J_I%=?F
MTH5%K@&(E"I9RS<981%W4Z %SRIQ78A]OCNPJ2I*]AM(/6&]JUS1JVM69"0"
MEX90?T899/*MF*MV-+=';64<GK*-#"ZQ+KW"(H0O/T&?GQI,YESVC48K'O]V
M;W)Q#&:#FV]DC8_O\P'7]OFF3HW/SLX*H<]RA2T#0PZ)6AXNN<ZY#WJ%2+@.
M624_L98XU"5WN;Q"0*_\Z/V)=%X?'Z3A(5^A_<=T>[0F>G&)=V?Z%1Q*"&+6
M_K1$,9MOS@:?GUA*G/TIY9]LS' 4E;0NAD).4%*4*8[T]2EW;(R-PK1D\G5*
MGZA@/=6-\C'[?U^^OQ_.]PRK"-+K*/DF]7WC.OA1P9(FI?K>I--@>!<6*JPP
M'<>Y5D/C6F;"Q7/'/^I=B%$]^_%7D#%7'2XNQW'(H,PS(W1)O]/L/1A^"EC)
MLQ?F%_Y\5X\7DQ\78"WW6C;-53@0L/TUQM8:[)L/$83(8<*IYI"1%GEA:6JG
M4H9C,\ JG]K!?^_,JHZ '$=/D1-B1G<#JH*/M 36O+A1/[0T7-(V:EP(GMGA
M2(RP'H,TMB?6<2\+%O0.]MY3-64+K2/EA4',=><<7GRD14CCRJU2[)D9<<B-
M![W%9XH5=OT[F^J\/D #%@^\"N+?^-\L1JL(#.0>W5:XSQL!E[FI;!G1F\D0
M >X7IJ7<6>?TL]P+&%DQ@^NZE<E%S@?^Y3N8',L53*#MN;'D>4W*Y\CM-9!.
M^AN2\=R_5@L@8 9.,D?F5.<$1]60$,?5P01I$:TYSK,BI)&0%EEL3]0/4F!Y
M?D5K-$!KXK RCG_WOICX*<QP^3O' JG]N:6QUS\+W2>B8*6NYDGT-@TKNPJ?
M#:\2^/ 1]=]N]68W3JB)1QN. $&5IE"HW@<FT*2<>A'RT7DCM$[#]PM935=?
MNMIZADSYZGI0?=UD,XA"CNF0@XF4+V46PL;7,Y8#.1*;7$$WYC0+M??:7#AF
M8*Y).V4>(HIA]$Z=(>#H0B'2RP]JR093$^E0!QZ/#OY+,BLMS:U;1OE%0#LB
M]L96;5GMM7^--4<IL]75V&X^/$$I\'JA')/!NL:TYB%[(.YQ ?\7KCIWI$!K
MF&,:5DXQ+&TM!Y'=.YTJ[>F4R\/5'(UB!(4.$06+>Z3E%[] C7/&\MZ<=\LQ
MW%Y;93B\J>_@?-E+I>):_VP,PNEN&\JG[Z)AQ[@2:W)+5)WCWV:Z3M\/1YF+
MX$=H@UV2)P:.A?B5S\@TDQ4M I@]ZM^6/9]]W#0(-R#-]9@Y]E%@0&A 824'
MWM;:.@+O+<0+^$57Z#[^J+,1$J<D.6*N>.W,2Z73MG;V:Y0GU4NW];Y--V2B
MPQ4RJ4P%FWS7;K]?4&T_-Y'8P3:R &72]91W$Y&P\+S84[(!=/]@$E:1'.8]
M'+EP;_7SN=31@,!GF NT4A\J5+7+8XG_1E/,7T#5\DXAIKWOI8L14B2#_N-\
MWUB_G@=.*##BEKUQY5?O3,GORS3:?V5PV4=%GEFW#:]^#9_D*O,D;4&>;\ U
M"F'0=.L-6T#Z?1DM),FPWS3<_WP&[;_U2][3S;R9FFY-QR7$Z#"%)V(CJOJ]
MT.U;0PQ3GTN_[]QL"Q@Q/!KLWXC\%G*$.XT[S/%B*UFS@\R)VL^ SKGW!*[.
M1'7MZ<?!@9?'ME!G1@QQ!Z\\*DK>I YA2OF!-R\%95Z/;ZMM_;XMY+GJFDGN
MAP%>=M'='4B.>!-#JI!NFGMV&RZ&+A3:*CSLY1UU\\<.E6==8AR-V@&E;$\U
M6>U@DEXQF,Y:&>G7(4X'2<T&[;W2X&G(^@JSA<"1'V&:,/1K,ZHX08WC?FFT
MI]<*!%,8TI2]4Q=O>\"B^)B]!,-/F53L*[$%CTX;RP<1^IH3\;^JUS3QJ+1!
MW6:,K315PC70!)-G+RZ+SW*WDM1PC#\#_&(%A9?URU\BFCOG>:]B[<5CC<7[
M(,)08T801X2"D%YJS\B8@=',;X*J(BD?S]UF)X17NLN-A1E[OY5/ZNL*:$/6
M?$Q3\*QR&:7>:$ANL;$JN>5KANLN!!Q#0 W8QM,J<+"WL*'U/>38)%85B&D<
M)P<$*U.FJ WES>DK!HINO>90)G_";:@3W; 98RBTI]_E&8PO]I<J]EWTL#Z\
M$->*<\;Z[O&0Z4[A<5S7A6I<T-$840R29MT+.8)%MH%AS%P>3P+(Y&MRN 2_
MS#7*=4S_W\#BVXK)N5L!2+DY,/IJ9K];&_-PY8#!H/#W-_/=LR]YG@IA2L=M
MP[[J6 UA81$W9O\"!JGDQ/,%%YI:]6JVY,:)E=95*#>3."\Q)Q99R&?9P=/'
M*%=BR*.EV8G0F".$&\Y(1DB 86Q'CA3X#G@*M:%MBF-">DT@J>;28,)U@%M1
MBGD$-:0[!*JD4=VTRGS@BH0DDG+E!_^*\[GW@#G4;AJQ=<HWB14[G>G?W@L[
MF1[05F50]V+)0RNHOMCD*X9VRZ_*2K+<EE_&*:Z>[%S^#G_*X#M#13UY--/!
M/(1:H ^LQ7'<:KHDH4?GL:UQ4$,F1.O]37T3V1BTD]F ,?( X@TR9YAN N8A
M3N$?_%I7F$5EN?8ZI'F*$_&9V><=*UP1*FR^F G1F'%<(RPVQA2L#!:Q89H]
M1YS\TJE^D5B2[:F=0,?QSUPUM'V.I__8M14RL[@8K-KC,-T?J=?<..Z;VBE^
MD%DXO\21-.(*7F [K9*;!^;6)X RFEO*%@SO^;"@=3[M$$8?V<$T8N&2S-66
M<U3CFZ<K_)FSN>C*-;MY2Z9]5?DF?N ,MWLT1*OF)*:H!<G#C,E?K&9FPCH*
MX,5^(;8RIHX'Q:E85.D,!D;Q#!5_L05+? *FP^)A4EJO\V_"_#O> HI[K*+#
MZT][.D(.35H<^P(/$X!](7!.%,_+@K9L.4NFLG,]6S5IG^^6B.2JDF&V1['H
MK,CA96$C/%0R\*RZD.?'8,-]/O&53QX[4V"%_S&IOU/H"Q=8@3TOTA4^ZOY.
M-SK@)O0\0!+,[)1R*$MR3W:,NB^?_U$L#DVZ?#(E]+GG E7-6-N9L*+PD.9V
M$.1_#O;0CZ.[.$8]F&._,D!K32!08_#LH&SFX-E/:L,,A07:RA#5H8XW*Y[3
MPV0/Z3FOJ:F_O+92.>Q"5-OGNX $X+ADW!LR)20=(AG!ZP\16D N4Y6.KZ/Y
M. [VY1S>YTL(G'@UM"6+11(1<PA+?Y'$+>F66R0+X?@G675W'I?T*HM+B]5M
MN[!=N',=A'47-@1[!FQ@/NOJB/FSP&@)$&+O#8+.K)S'RRPUIOUFUQL3<L:G
MGZ<[!L;JXJ"BU?UA1UZS[JZ>([6::*?FI(8' 4%A7-ZK=1VI^ZM^KQV'>JCT
MT[]E3)N'M0.O&E_(+#U?*90B*1&6D]\?U*KRIOZ3<LJ'^.UZB6/C PA'X1&Z
M5C&2=95,^(0[+JS*T,HO& N7['P38BYO5Q&5SD]0(&1K$*/4[Y/Z_4+='KR?
MAI)BQ=-I^WPBX=X[AS-ZG&NKG+N_=(_=J[P!& :^'*' I>V?E>'N,+SRV=;&
M5[%YH[_EK;]A&C*!UA2(;>U!X&V2L=.IK@6X3M=2>VGTHW0C :J"P^-N *%C
M7$0!/]W3"XMK_!CQ<R&V%'A"H5?08AK6&QSJ#GWN<]IK@<VW%,B">FBV[UKA
M4?-CK>^G:^3AS#RNU#Y?W(.Q.UO[?/^;S8U.@4OXW+J.87"E%$L3RCU\+")8
M%1'HM]-:6KTMT;Z!I1H^A>-UD]-<06E@@E&W[D$G3XL%R_VB3.$H.L?!63:=
M\&A#QW>L14<$?$;CQD$MJC#1MN0<L_.*=MOYVHRK9.#[KYZ;=VY,&"R'B(TO
MW''4^50CSSK(@X4,3@"H172G\-CAU!#)&GA&3Z#8RE]IOCP48?KNH#O G\+1
MEU C:GA,_=9'M3X0!IM=6[+<_@N]\?2**R28VXT$[$79FMQ/9$588$:JDNFP
MN0H8R<!7T,\SU9?/NTT=>>E+*Q3%G.GKRLDO$0]R&@B7*@M#A4 W*GJ?/,S*
M?M]][,UKU]V\1V'^T.[SZ1%.6M0%PWQ/SL6D_C#=LAQU+'C;7G*^:K0*+N3J
M&E<>/91Z9OKN0AR/$9,WWRL@CXYG79V5H[6-J#!FWL@<:^J&$E)_7@4[CQ1H
MR]S>/#.(8BKYQ'7=;"(=/NS:HCG685CI5F2?YR+M)OK_L/:>44UO6_<P=A$P
M(!TI*KU&$*08R!$.<  ATCL(2(UTD  AN4=Z5ZHB!!%#+])!@4@)*%5Z+TFD
M@R0B^!-"^,=[G@_'^WY]/\(8#++7GFNN.=?>61O&]I- #CGX];W2#M3<+#JY
M'4SKHT.$QNB!9H9<)[90P=X$@P/RI];Q8-L(N6&+B%/[Z*M;!TVS1<7N6'B.
M[ &V7!B ZF#@+Q^.30HT3<K3]E%]&&5@A')U&=2UQ$T;$0)5TKBH[N.5#5N^
M@H@;HXP[%=\K#?ZD6+Q_-;,P8SN_:=/]>081J3NFN,LV^V>PO?:5.8MXY];F
M*)%D:C_5_3@&[;,$B,KED1Q3<;7%.XR!%=0KH[Z/@J&<L[:P\_GE-I[5)7.>
M.>93J>V\B"<LL ^TFP:2P7<BI(]"=)5G*_R'0U$YX-CO/W([CGX-DEDZKMI/
MG8,=.))W\;OLZUD:0I3*F+9*@+OG(.?/$+9U2Y0(>=/*3J.Z !\B\H/K$%6-
MW7SG\&K2Q,X>[;8$"R_"+HP_CO>7]7NL+ !3*LUR!ZJN%>>WGK/9)X?2]1*R
MF!-4T2'C8RG%JI]>5"AEE"%6TCR$;5DS,N*)$%;QC9%O98PDH1F_01G]'3BT
M$A2HU;)$C<O]=4GEJ;40TT_POF(6_T'F86Y5%U236GW-UM4X.B@]=!KX1<ID
ME)A=58@:/UX7_-\1G_)_A[CAC*!Q\24E_TQT2][9.@217S'^[\]=;)]'=_\[
M]]?R__XXK+EW(/00'<U@T-:&ODOC^&<JL.[OCXCH\Z^E]Z+.0?_[\(]4LRO$
M_>=8R>D'?8CAO6+S,$0@!B8 <)R2Y?C\W]_</V.0Q"\8[N=U0^_+J*GU?PX/
M.!@V/?TC(X=]6'2LEK]0EK":0X'?,!KYI#_8__E_R/TC<RJ+XRS\( PH)8L
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M>L>*=]YRJ>$NM:G?)-;PMT_6;UKDZ;7H:4K-SY=JBV0U'0DJDKY*4YBN9I*
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M$>DJ_5FA3:ZX!&ZUE)X1BW?*0?QP-H3+0<-D/30J9V]>JV1#^$,Z--D'J7X
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M'Z'9N84_E,-,3;X3RR_L#_&M0(#Q:L833L\]*?.VGN]ZHD8]1QNW(NR[+;9
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M+UZ)+5SLU9CGZL(C=\AU.GC:WY.KJ1Q/3A@.#J!\LKM!6Y7A/1C16$(V]5K
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MG=Z^^.ZMI3]9KZ[)A&/?ZK'7G(S07S*I>Y=J]'YTPCGE&W2KBUY#NT 7J &
M*PD6A6:5K08C>4D[ETE=M&N-8[M50?T;,CY\JHSUN*8;MO X;(*D\]/S]A^Y
M_OH2C[F]!YUQ/[ $[AX)(-4G:+Q(SMHINF-G@F/DQY'!)=I$EH MQ[;T;CY,
M,N'X].;#UI:_9J5=B@!WO90[#^_RZ7'4?MMK@=Y*69:1NZ72%TK^C+F;_;!!
M8?TS!LR[_\X\,W2B2S_9P=U:)RWM?OZD:91EG7'0:.+Q^VA:IO4)PV6$?V\Y
M*(=(7I2AH.,11O+E.4Z(\&NI()?:S1<63*=>C@SXL17"Y#+MPKLFLFX\^;3&
MKVU=\6BKXA'6 <I%YQMU]'(:74#@G(4X-M&<R+ND\M3$$P:>ZOK^-FX]"A.
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M%U(MV_MPOY;Z8L6XQQES1=7BZ@58/IM%I8=YN?(MPNZ,[<$YP.5(E#;4?@L
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M:PBFFN<[4MQPQ)8DFSM>.6.SVNYRK0=LW.-5@JMWS-\'-WD.UD/__.T25E1
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M?UHHHO0Q**)@U*"1WN#,X[#8R+_JQC4V-DP&_4\W/77HR)1^L&<(]NT>P:F
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M )QU.3:JS\Z [5'8KG<\\V7[>)NXVUINM1'I(@.32#ZLVP.J9HR,]2.3%H0
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M6KQ9BM3<41HD-^4D=_KO!N/?+!['"^"LQJDB"=S3H!D+N1PUJ$H6-%LZ")
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M^[NU__4.X/(X'K+JFMW%F.>;KM8U+K"W:YLL:;62>P&#>>G/0LIW-;G#"V=
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M5BQ(S_VTZPJ8L5K_\SWD"^3.*/)S-Q6(HD&;I3BG#L#^%/ED0J$BB-C5P4%
MEZ6"\-X6NU&XP;*(+/AJ9Y<IG/42FSV&"UOWE)M40@"/T+)'B<&J-V>:$ )"
M?@L_9M[-O=[T9D5G>SQ\_:T]0NM#LU&W"*RBU);Q#2F^[=J:'G+^S:GR"[;E
M2*'DZC\77E><*[:Q>4?(_PS7Z7?W&"@\[2<ZY.>NTXLSR [CD_#R10K(S^K2
M#N;Q?*M\59)VHI5H6A%2]+EW_<49AQQE;ZVIP-'.C^O>E;3"3L(M$PCG%FC/
M"D=V3W-/<:Z#!);QM8DM*>34-B*I6Q?8RM#=,]IC6"76=W<!"Y65;JZ>>ITI
M1O/N5O(C B5%_)H^I%KNNP,Q #M6%<Y$94!/<(R#B[!YW),U=Y<]P R&D**0
MW!#*O[ECGR?!RB%[G\>MA63#,OB 4?M.J,/(*CAM_':<C'LZ7*A(&-[G>8"7
M!OAH8Z *8E/+_\# "]* % TCB!_N$;%G%CY8^B0V3^-*MX!9!*;N3!.ZN'3U
M\*Q9PU0/0R 3_8([["/N+H.IE1=X394)X?1P3]!V53CGP44&)A5*G3T(0[X
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M@"FOL&O$!:_U-Z="WU=;NT:NV!BF3B3*%M*%C)[]4?GS1RE!WCB/ 2II5 Z
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M=9?EW-OG@6,GZ'_O/4,$],P)T'N:R1NK19PP4&;7ZL!)9>,]0:H91RZ#:<%
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M%2:V?:GM1K[<NN9[.<RY<+3:2QG]3:PQO9L?3&'LPB1Q"!:!" ]G!/_]5O<
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M3"]ALKIF$A]K[=7EZ*F=8?4P\KKG@ W^IHLIDMG-$[)7S)6#^P6_7)VD"?1
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M(M3AU@=O+]!YD6)@=7^$5,,83OJ:RHVQ:"#O"EB21IO8#:.1XME</"XC9*3
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M>-$/J9^#E%O4U^9N+O2*,/T:Y*OJ*-L,\2#%8F[8>P&TCV\52K>L6T$V9WO
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M)X*RM;J$;HF]UFRHALCE1S O(BP<_+?=PG3AG&+V:G3=OUN@W_+,B0P?Z?'
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M:<H+C[]ZH_^QQO$@<,S' ?@5K.9C3G/EXQIOY*R.<,,K;+!A.Q@C0-T$F2*
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MR&KA U3&R!O-W_LT\$'QRK!PPR9CG1.C$KI:Y][$19<K6HR=$<LY[9X5/BU
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MB30_DX?;OD!G Q"3>'+"YJYJ<6LZNH='%K#-)TE+)DFX?6(R^(00C9L^2B?
M<N1\G4^>CH+F:_6'L2C]<<(]ZQPH+N(8!9GS5ES9:FP!?<F0#$9["%)P$_0
MPFP!9WA%G(OA+(RA38,9J=ATJV)(+S5C1Z*!*A[I'2NM:<"FS1/;7OI2)7!
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M$)7"5++? 6&[Y+^X(IP.X8("!^VMT"R^BDBIO7_Z<*@NK3Z4L3]7)WKCU]?
MQ^(@\4-$-[&6*E4_*6[)%F>LEAH)%[F+559[BZUK E"=6,AX!:: WF#D+X16
M[AJ&N?0 ^(723DW++]D6.(W0Q%^ND.X=L#4"#%G]&QJM#?)N7;[,EYU B6X=
M>:586Z!'N/4*;+%2 ;M'N,#))<6U5\J[F>L5)R1_4A<7*CY?)+:1(4N U,JP
MZ+5UD00063<)'U%;;%MR!VV#A)G*3/YQO+W!3M!S!18Q>X^6G'"+ G5[D%Q_
M,)OF]VH][,$@%K(=-&#G'131R75<L4AU5F!8ON+RB\&R1!XI61NANEJHEUS?
M)=6T$:!% Q*]3Y^D#I#1W=C*Z?SY=/Q!3/!A7,UL!X?-<CW2?0GHYD+EN,C.
M>^+' ^&$3;U1*[!MT^_#;3 CW).X$/G&+Y*S>"/HY&J;>\ J2:X[BN-V,.M]
M1+$5J]MJSB$UNX38Y)N70B>04*5J<HK<""+[O 654J,JF:E-]]RJ(XWC#0M:
M<^7F@XNJ9BS=2#_.Y^D7'QWE3>7/X/QH%"^;"'A3X?)VY@XF+WD9,4<"UOK)
M\NQ-" .*T$E?7;F((8(][I=A^#K\7K* F438X_\9ERPF- T40_4";-IP(V.[
M[I69Y8BDAV48,:<8Y]:O)S)V;P)MR6/4/_#&6![B%\CL76->GG4FY8'4B,]6
MYLQH5QM.H/VA2,?Z/CZ]Y6[9ZYQO-XKK?2<Q-XP?EL8@+:I<FOP=8)I0C.0\
M04'#= F'5A/M5F!7T)P @K8_CBH^!\5*=A(&F.OE1W#-2^WRC4WU S126K-5
M6D.F65L38?,@W@DC++PSUNZ=WWXG>V+*0&<HJN!,S=,PG^&P1X]E[0I8R"!!
M>XG2+2LP<:^L@&%$^+R$:-!_J@"S",!8'"8K68%=14)&1D5OA=@D:Y&X&! *
M*6GV^W!='F# HU!KZA->7(A?Q W6R4&LW+ I:?$+>L<L9U\6NY5CF:#EA]!B
M7H5#IMQ$%(\[/RJ4*_L S/\D?JK$")+;4??EYD!(%U5CU5OE/?(U*["D6^"&
M=%  3['7J)6S0'AJ#=X.),K5[=3\4PD#/&Y*KG>@ON1(C_.,__M'?Q.O+IQ3
M^G%8R%Y%RN@5&+]'O@,Z)CE&:-5"U3>)WO/U2$G,NHF\8E>)MV*%;Z.EN_]A
MOP6R+,7XK<!$JQ7==4E:.&,^,Q%_N1(J.&L/[Y6JE,].[ &-$TK>Y'7<*?:^
MN!\ILC.3;_0'FL35LL>VFHBYYZ"A7'D74;)%NF^ ;E8M/0UB138"[!B3IRWR
M!)6$2UV2<<\V#J$R#E1A<56D5B6X#%QRIV[PQ_JJ#L'V&L<D6_-2R*.KS3HN
M0VO)VJ]+IG;^M_7$8RLP#28OCZL8#8QBS.!2C<E.A+8]PKY0LE/^B0FXHC?(
MNPE:$ 6>AE>^&X-LQR$ME%JL8Q)VC<Q+L25AC,TMK]#;IJTG6O@JKFL6S0V&
MJI'4/0=/(A<N*[! C5FGP.6M_O)-QU\06_<S>91EM.@8+Q0?*R'(>YD;Y%KR
M]XCZKH1O#$/ICL%H%>QHBSAJ0(HHP1_KC>+J8^2FC5 LO]"LO?;3DV_7:?.:
M&$[G,\;&OFBJ;DB'=K_+K06T5+-8O%J"J%J*EZ6CKB _V8CC5G?QK,#:!H 5
MF$)9K"=TK, T\9$@6ZXK$6,!1S&Q _U KL( YC/E2L2V.K"161RH0)202PXA
MQM+];Q&=NDW)!^1C]6<&:!<:<R-EQ+[?$-U8J0::AY!J*HEY %NJ7B!^!"I)
MU2=;&4?[&,HXH= X%17N#AE2VU%C>OS"I0?VQC--UH6,1 #5H9CWCMDX^RZ>
M=L<9^D'*5 ^X8<P1S,TIGY9KOQ[)8YDKR*9C):YM^&V!?"-1HDP80M<;=Y+&
MZH7<3OCHCW>(5\A6)">F ZVV2(U7"#YW9")3Y[K](9P-3\SD,^%OD[,8NU31
MK3^,VT1Z'B"=XMH8[KX6LWQ=O>-WSL5>NA6?N1EWNG-V>?^+/S;)(^4FQ%8D
MPT3>CP N(" 3=H;] ;Q]G(WXN*R6R,MGJ,IRI>:@&T(#VO;]&SH%" R%WXF:
MWWB2RH6X9X;PVV-^9QCU1[^-:=/*7SOC9U?IAPX\<R4)/=66!I/K$X-7][,T
M237B5^]7^A);W1>8G,AWO="26"9[3E"5FLL>H4)(RN-X1^A8^8P6MSYF;IH"
MH<Y D<^F&=8#4J\(8(EE[9,:5'OX\VCXA.D +?,X?NN+V4 +=AJR)%=8)JMC
M7J5"^T,ZD6F(6G0K5X&4K1;&LE<H7B&YMND==K3.!3W:_9N,1KR&&IW\#1)*
M'''N/-+].;I[#3YZV-970-(-GT "32S$#B<!>SV&H?0*:,SF8[?Z32MYTT86
M U30@P5H^>B^9W#%ZDE% R[C+O)-#^%S;R1H^= (JI$BW58I?@.9\+ I3+4&
M1,(*K)8B2@2R9L]!:/XXMH,SD;\G6>C^@+%U5MQ<RLVTU0LOF0B ;T#C"!^[
M?QM6;]/MR?G2^232#$  6,HJ;5%,ZH-8G(^X>9 92M4A](*X9 %)=!@\I*",
MUE >.-**TF0@9M$J58O^-EPE>:]+,4YW]F)MO]P*[Y?U[3LJS<!PV#(<OC7\
M5:BUAC4E86%O?;H(U1>G ?/Y[@A:R3>.2QP)O?_I39YHNUW(3IILRV/2N*(U
MP*SX@2P1[X7(DN]@1PKA.Z1Z??CC OB&L#]=RG#%%^A0G!95@)NSU7S)))G3
M#<L=G^.*O8J0];]EHSDK,/_'YY1 5*PB2&(5)B3-HH SJHXL\E;&CB[04;[)
M7W*.V'K*7ILPPJ1Y57>U(Q\,WQMB)/+FMP=@AH_$R(^AM::(FRU5W)6A(VVH
MK;Y0>.O$KK<#"V-L[1F.>^+<GH,]8465"A>^*$M9S;TD-FV@2'[#JZ[**V-"
MF_4JC4^S1_5',/2(K?Y2&U#"UWY@B^:QDSGPU(54@@$NN]-^^Q#=*%CB-8X;
M6^W4%!5PN%5^H*F/[DZ%KKA I>Z;(9]VAD9M;=^-%=BK9@4)\X,2)1N(K6[$
M*T@.5VPBHQ.#N<E%!HJ?? @IT+Y+JE[92GR%$OD"8QTH1(/['RNP+?:&LX0M
M.99?H([G^',0O6D"T3) 0VBVEJ*YU)0-%,%80I\^]GJTG6-[=KC<0+:J*7XE
MM)/UF<'P)%3#9 >9TW06B$E2@+""IQ>(JZ!"B8_4%T#\02O'*Z1H8E>7U:VF
M9(:N'U0TZDI..4 _ICR(M50]Z?J&T9_XK=ZRC%P>]BNG\/0/\94TF-E/0ZA
M,24W9,7,4,3ZU23<HLW@)"N2[\+ES(O_@*(EQPEM#%-2%U$MY V8G$50G6+L
M!)7B+<\8#=B>?QF(MT_W 6WO&&P:0G?E3FP=-.REGW_)UAY]YD05$:L_*-0*
M>56M6*WVEH@F0WLV%//9*5RU(&AU\XZYK'QUJYD*,YS+>3DL%&BWAMN%<4\
M,1DU#;-Z-BNP'=3T*%22;B(E0:IW&9%2);7DS6^9F%Z.F$Q?C#!N$V_3^4IS
M]_K/=NMV(G .-1;O*7MFO^$3L56=>5F?*'#L0""FCW!5F;QJN3XD ]);#9!
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MDQ*FD R>^?V"@Q4SS,M]U=N5QFAZY_<H-$T1AHEQ3R'J25?3/LC@:K=Y#DM
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M:+YQBFWT2\R=H'.#"]P-4YR<Q<9B0=Q)MU>[E^7L4XV,-_7UN[\*CO)WS1:
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M>7&E-8F\]PR=<-U3N<JZ<?GFUP1RSK&KL4E-R^PNA([< H^ :(ISQ *H.5!
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MI<4K]Q*7EJP>K[A_Z2 Q]@(#Y:YA&FHC^"D)HUK4\?TTB(=XF VV$SOJ1^I
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M41%FD]'2HW[6_=B[MYRK>&KES\6ZC%;TQXZRZ=X3C"'QRK078%X 3^)EI&
M]4^>_"\;72C<MFK#[WWBKIA&$N?Q$]SMV5>KR1-?\\4^ :6T&U7D-G[C'HZO
M6';\!6A=T>XY)B@TMEEH@<!/YU:BF@#A),A!!-0(V"2)$]RH[&1<.U1\# @T
M2N@,/E=+'@XG/?!1X@(ZW&" ?M6$TJWA4E]KY6Y13]-& \%2#^?H:_.U65-[
M$__Z2GFS'-#)FFN>_1@PB*X30U1JQR8$"Y*Q;4?<#C5\<^S7@)&D^B0')U4J
M8MK56'I4+UD(YDJ_G1^Q<1MI7+AX>@Q>H?7!7E+M<=F$*B&%/HD\C?Z4R.B>
M(MN.@L\9YNC-O*!@J6\BV[$D/>4='!\7PL^\!C#@Q=\Q_'J.$N!*1MA<1E8.
MFW[N?]YHS1,PZL#.&4W=OB3;6-B7RI>.B<B4&4RF(%Y^B]U=,BD1L_%S[QR=
MS,T\@SGIX;P;^9)NGT4>+[<[>4,^C3.NYX*7(ABQP@1QQ'3<NT"L=3G7YJ+R
M\17^7H5\?G&9U8X1S[N7B"F7$#R>-S:57W#%0@S6UQ.WG5KH[%((KTFMC\\J
M((Q-P??"X]I4GUD.6S[):R^9S1IJZ#K<4_+EM*Y*4]MIC2LW%R4]?O_<,81T
M9H(.K52/L!YW/V'49*RMK_=D"7\+Y& H;U_ME<[\ZA3N!>/?%:/>""J?'S"[
MY25RYMC;6R\DM&E7&^G:4EI<#B&)Z3DV)5(J[],QUV_HR37(V-":=ES&?UQ/
MKLA,./]5.C+UM'^I:=I#T]:N.@,.^6<GXV6M_/4Z3IJ\7ZIWK]6NX1M_L*6-
MF.^$$ Y.[ZR,3JNO1T&$-?QR$)RMS^[<BUXW3=3SK KZM5V2\H@AUE<\4S=$
MOU$\KGVB7"MO@6J9%G?"U$Y9S_W0INZ*+_T9JL53PY D'@VIZ0UAL"'&.JGB
M','\".BG8#XF*,S/GO(X8)S!_FV.@N2OKXG2</-W)I9(6 VOB>UM# _@_:Y8
M+::G?!(3KXY6CI;,3(">^SR3X3@346AB5M":<D<;?L/;W*?P*4;(N!)K8F1L
M,)&2\B/G?#)L/EL92'A)QH7(>9T\^(O6Y9XR_]2#$EUDX/.'"'N1SDN^]K*[
M*7X6(7DA^/YW#B4ZR\29ZQU9@J2+WPIEMY@@=X;P'_NBWH-$@:]6D34@W+ZX
MPW:NJE.C>Y91X', "Q-;LT\T9T6_=$"=MM/S<B'2]#;&/.E6&A!GMILUWF,5
MK>7!OR%HI$@\+CS[Z%"P%/T6A15IQ:=%^3HT=8TI#^L*QVP>]=F,/^:+XQBX
M;MM5=315P*?;X*R77^%X[^%2].&>-C(K-+:A5IUIY^E'R9R?4*-C[8Q3^^^#
M#Z!/BS^O_]K@[_+NT12O0I5G J&JIATJ-MI"@G+T^D_+!:FQO1TH66V48H)X
MW7LC2@GK>-.B7]U[\B9&WB#A^^_!EY'F^ZRTS3/$08TBALFA*Y,GRRCB^F44
ML1K-V8ZX4@(0V%9O$4ELTK6D\3;-Y?@[DG/P]3U3D<IC;@B/\^5]O4EN]Y6[
M'_<'W0%T#\9DG\Z'O6PWP?=R6W)&1\AR$CJ4'1V,\DZZFF7.0N[-='6#K0U5
MNU?F#].'PO>,*9@3]P&TTDQQ0L2FQB8[ONYA$!X1+]R.IZF5/)ZLAMY,/:A&
MO9[J**(B<N4K?"159J0UT-7J^D#N4K$'NR!DB5.'A8+$GVMO51+X;1$P!I]X
M;&61>D-&X&T-EV*Z&D4J(>Q6C4*9V!SJG/VS5L+UXU+M<^_>VA!LY?;?^\]4
MQ@>^Q%DV0GXFOS5:_8V&1'MO78IJQ/:8<!#T%H4S<EM=P4UKV&>LMJVZ/B*E
M"%XQ_MWUJNJERUV>?G OE<:^WRB_?[Z!)<EUXLIJ5BCYP9WBQ^G&&,80JB($
MR(9&,T'"9]-(OM6AE-1KS><(BV!^P-LW#WF]S 5PK4]60X>O*RJN$>S]#/NW
M4F!\!)72PJ<AE,=,T#W<]"0T*EB9HKLR0_$C#C>I;.^$@P60MP=RR2H3XSW*
M:D&XN,J,+$L8^6MZ\8^Q[]]=][P1425#?)=0I+'%H3>E(M)'O']SWKJ\]";"
MUI0OE9]KY1)/V6_)=@,ELL?S9/3C^'M63S\-,:ETVDVY?J-EOR9L\IK7L&]G
M[<G#E(._M&[+>HG=WFQ,N$2T,Y3M9C.Y;GYBJ?3@I1Q=E9X'!?*\-K^]BTE>
MH.EOY:S(.BX\D'!(V.+7YK'L$!\Y>FD&(@1H$4<B5-!"P$[;'G\H4H*XK(H;
MT3 @V9OTZO3Y--R2S7>;N,FP4GC'*2%I+*?7[/\C_IB%7NXMSR3&SY(C.K@'
MD%A6' #\R//4*#*X84;3P"1)M]]'_?4V$W2RN\05SI9IO6#I(-U7Z<;QU/H;
M;P6CJZ')8/%%33E\[6@*+!)%?L*9H&%*$H^#5%BNK!8BOHK_@I0:0JHU:PSY
M3CP;L_0\<H-4 FL7Z@VS; .?$Q,9J.H]Y7H14+KUT?]'J.&W;;D>M>XV2^_O
MUK#QJ=>.](_[&)QS;ZCXB>8CC-YL=;(E*Y*%J&&CMZ&AA-*F8GBS<,), K6F
MH\1"*1YW6D/%DS1U1/PT\LJ CZBB*#=^F \L,JB@H>4W'?A&D<[[H=<3XZKD
MBUD*&"',(B^%MM][XDM!%)NK[<9B1.2?;(GJ*R>;.U@_D.I2=*LW_'RI4*]=
MSUN%5Z83H+6A<CUYGXP(4"P,\2*J>,1XVO-'1%F*J!WM6OS!JSVB\%FT5<ZK
M;_&70_$TJ3<#&)TFI-C]$X;ZYKP"1HUD0)8)FC+G)8_0N2U)"?'-EQEX6 6V
M32G*9&("T6M.]EU+^[ 4$!;BMOJ,DPU .Y C$DARBSM7QF&(R%O?*E<?[BT]
MAOKZ!VFVU<$-:L:K-@323^,?R!'S9V2(R^;O5/D1=2:9A5WMVS%>[N "Q@<B
M?9ZSS?JD7IN OF_A?>_Q'(6O%P?+N'Y@#3C?3"_,/!HHX?!W;<U"=.2:P@V5
M,XY?>%^FZ9U11DD+4]$,-"%79Y"P'$MBTGTS5UP9(F4CRMU-@?HOE66=!RMC
M @M5V 7P=K:%@1F(9&5R[)S9A)8QD$#>U$VP2K.@S(<JUS9J!L'SW39<P1>^
MK3BRIA28=!.%6 5F+*3=:6Z*OBY56=ETT<ZN(Y[<L52L.Q=BM30I"/30?D4^
M(X]?AA8@SP -+JK16S1O&;0#X$S25'2#"5@?"_4WA>9T.KMAK?RC8P[:3'[I
MD7C)A<#%[.6_*8*+5\Y5.-?8]&TKQ:,.^:H;NP@Y*!9A[!=41^Z65,H_LV=?
MAO-H<9^J\/\0][SC.<2V\<I,PF%@6*Z0+DQB@MB!:G9!B6BJYXGE/:,FWLSR
M(F7C";T\^XF\QD39"IW$9!?S!V^?WUZ2V]R<C@Q9]TT@J)H )=.]H0P)@)_<
M,?*)@Y@QP=Z6+5A!5IB/:M12&??V)P,W6Q^&3$Y>&&9SH$H&PB4'<E[ETIS'
M7Z+?^OQ1]+5G 7R9'!F-&5)HO,32-A _?ZN6+V"H.;04GMZVISVFT1=C;Z(
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M.G[(CR)EJ9H/\)M4Q,_-*GBF#MK;YK4MGR@H_UU8RPKP)N^T@:7)L#A?)N@
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MIR7@]:>TWE]A@%C$ U[^5VDA2QW= R%ZDO&D6+_CX' ]X"J4C)X8%F01?!*
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M1)4H^=WF23NQ+]5F;_9TZ$G4$9Z'N$0:LY[LH0_,_+4^#LKB/_ A ,QP8A8
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M0VI!#$B?I*AE-HT7I8IV'NQNFM<D%XN6/QOUUU+D-;BY8#+-XT# 2ESR/&B
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MV3ABH\^NQ8P6I1CB/$"H7T_Q5"7M7M$H^A3RFD\-[=F1\57(^WSEM-J[(-7
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M#/JFT=X'"!O)/<K3*!NP3ILLX[ K_1_LO6=44UT;+9K7#HB@T@0%I7<$Z55
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M+IHM*IG<8_J7AX<7DU55,S6FT$Z380VGZLDB84@\=E\#[)5F.$7]+=JD4*G
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ML);-^+H>:CC9 ]K/A%8OPP-("Y?4GZX R;_)C5< Q]BUE0O+3L!.M6"984/
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MF4NR5F? FG^.OJMM-F1^WL^3GR-&_UR_6\LHOW2,Q=0;:EU87IY"^-V-^UG
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M'7-58"K_$/#;:.O/E*$S%:;J\' ;R*-^VA(C4"P-HW9AB3?]"&B[4, 3B)2
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M8_U0K$,GF;RP;7HRF\/93%2N?S4).])$V=5-R"M='W8J4Z;?&ZGLW[4-N@(
MR2<0O!X5^6-OBU)D'&F9Z>RUXG-"?UG(DXC&D@7Q.@MEOW_M(O!C^C4=5P!S
M-^Z<F3NHC^*>PX*>ZIT\+J;$+6N.CEK"4>W"N<3]>;U5\-'4E[:DX_BQ0E?K
M1T3ZG#+*I067C)N[* ?2, 2VZRW'!\!D++_^.!R6/]&N)L,7D)2B0.X;I= :
MK/+5+2J@4-&FU*4X_"W!8H+UU#D<%#B;\ CH)[7&)D,JL%J@O5:>MSLP*M?:
MXCQO.^*UM3[9D 1YBW*(@9IW(1:2#+\W-/'WC2:]JF^ MX@47)WUDX;.QYEG
M9Y&R$5\:JZ$WQ@?>R<6A@G>,"'JQ^5-7 /1=*6NVE@C8S1%< .28I=WL\GX\
M^V]5*WXAKAR>CIP!W<ECJHK(%G4M?%- JV;@ OQ[]DE/*1H*&PAFG'Z#Q"^=
MRQ3"R5H>,&C0S^)4][2ZG60;9:\WS-^18A #58?210C1<KXV#+MDTZHL_<>I
M2XF&@[B>O5XINQEU7'T[4"_7@-B>&)W0D*1'GUH=@VI3Q3F+Q\L9Q*ST*])U
MY QK3C+\>4LS5S(NDH-=$IH!GT7[KU%ZNQJ=KGG9:KN?]N:%1W+:,LH,I:KI
MZ!=7 &E4=+.X\PS;_=\5\76/5PALI#PSF@=!^P[[39@]WZ']\M>_+]IQ-R]:
MID"TM-26#<!L]0?1&)N'(5WV1\EXA0!U(ELL6HG,V7O*%B>A<XL/>K0EKTRS
M%PXKU7D &@LJ'?E;H6530Y? PWZB"6O?L:9B,4H^%00:TIM)QTFE50PK!W")
M=5)UNBID-3VC?;36#OHDRS.6>&9&#IX"AI#8[0).ZC#U%J\3?FL\4+X1?_;I
M]L$ZW!R9PUZO+6I8QN?9I:PBK)?>3YG;E,> #8ULR4]%OW"9,7,;%&A=FN?R
M#9!K7SKNP%F/K"J\V,T KV@V91H$#>?D8Q\,TI*6-RQ>]*\[DU>9#Z&R0SKJ
MIS/]PJP;]HF^)W19@\]("<]'@U)FQPD]3]I$E2G#8I@F>']X&<>KL"?FOQ>X
M]@73.;QY$>S$1J2Y?'7Q7T4-K[KJ7,'_*FK0X-G.HT\'+GJN $=;#C:*_]7,
MV%D-62JY MC87":_GMK^[ZG_LUG?_5][WL&SPT?7"QKV+D/:P00O)=7SC!JA
MUI#< ]/S)S0_K@#<5;+9BB%?'NK\N C)-WU\H3$5(H$:;&&K/M+NR2T]3=Q
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MU>"(^8BF]NTTF=)%TY\K#^5_MBQ6)FJ5Z%XM4DOQ9#Q)*5K\)"'<E'K=D>-
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MDO>?.,',G9BK]&13GBI6&]_($4NV%S7NZB-E&$2G:!N ZK8W1?*;XJO_=7.
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ML;IN1BXZ])5 G#70,!Q')V#L'VF7Z6+.ECNIHG\&IM??UU+5HV,M/DB(:RS
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M<+;[8PGU8I.\-<-$O>R?^CI<JK $9UL@:^M%&&1AJP,<C6!69_=42HJ@\\&
M[7!V=5%7GVL-#37$R8A=0?9S;L_L9EXG$50XW#.AE4;/'.^JMRU+(+]=FK7,
M:^6G]X-!8)S@!!CG2!^>YVD6Y3)8!$7,\U4? 7A_8C5?#4PV7P_(G[>ES'>
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M'D^N9*IHF9I+/!&IN, 8X!5>"_#9(4OW@1<^0LZWWH"M[+3YANH3]S?"B$>
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M9$YR;,"OVXJRR&__Y)&35:Z&2O\>;;2M&4>.$XK'P@<+,S='J 0,OAF[ RX
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MBX(;#;H\PF=C1B3<C7_2MX2MRO62PPU#ZV/[JR29IE_<MGBDN==](0IPL_;
M6:*/ \XMDF)B7.6N)+)TV"]M/560BN0]J-5W#0HJFZNCV+:6E&WMM)3Z82-;
MY@J>SK63[34$U?ICY7(O7]H[!J5&56Z_2G4KOS1]#BD2!W,4M>>7'-?EO+-\
M9UFQKY@TK<"O:Q[JQ1*D6GK[BR_WY]3;3U@R.?*U3+Z4@G9T%9\Q6?W08U4[
M#K ,%GFJEI2Q-#-U\OA421C*>KT2B7S-Y>EG=0\DDOK-!W4]J_^^+S__Q-+Q
MQT)V'M]'[E,_1.@93\UJ)GMP)-PL_R4A.B31M%U+%UE*BY/TLZOO:H&65 4%
MZFIY)(=;0J2G7=SG;T1-$"Z[;93_#.;=R?+S%6YVRP1K;"HY[^0E,)W^'J#)
M+?GV%$]\Z>K$-IN&>_GR&VG;;P']KVNO*HZ+5M2^[?56+0I*NW!5VO<;RV4K
M8_WDCQF$N=\S4[&YUO@QQU85DEZ%5+OL!H_)[#!/=R^:QXGUXEJYOG,N^*UD
M\K;TS[(MY^K,2YH3*X(^WE#Y:I#[64VWY9GMXC89N>,1':*:@(Y,GQ84?Y^4
M__M=8P^#[9+/O>TCQHG(/FR$GD7H %( Q3OQ!HN)FK28G=7P7*OQ&BJ6]_J4
MU#D_53DM^V%$_ B@U\QWWG _B&58KT+'PRC-?U\^N?O/3?5AP:<)5[/'J3=I
M,7,3-T0;4HPR3*YYRT0NB@SKWWP#^UX<V&D-?6@7[#NS+/;SB9%2[2/+N%F3
M&[2QQ,7S'\[PU^T 9J9?]+[>/!<?.5WGQI8JY.R-*H_')PG"UO"KFW+>3\M>
M/P_EH"6YYA5TCTQPOWN1_K#)!="(#PY%)O(7?35&L[L4F:=C1'*%,E&2Q34Y
M]W7+88:9IOXY9FO4R>77W,*\2",CEYD"?!D_S2A#G+\@/RBD5WM3.7$C=1H[
M--;<'X.*\^]DKYCL-]<4X>/ Y;VK0LA/?<.=Z_'_)B]QJF05\31QLQST).ZR
MN%C[,+,"\K.&F25?UL]2W]DO:8]9KIXT*-G1(-L$VF3;U&9Q[\?[.(N.8#_R
MJ3WYH'^K@"\+QV*E ,INRY"O^)[L%*FM5'&I*[^+U=J(G"\B-7)]>45PIN!3
MA[QN\AE!6T&K=[V H?;,[&"GD<KD)E2Q%Q:[2?8X%+ P>+OE*1M0Y8-I3HO;
MG-#77P_;W/TRD:8K:G:]J<(N(\7M[ &V(J8_..-DAE]UM_(+NVL\-BNGMJ<-
M7RM>DS'^TE#AGYB\6A!8_T;T.NZLSYF>[(*7*_7FYX+X-'*6TM/P*_H97DA]
MY,L<36L1O;@\'B.9#?E3[_:]0=(5(GD2MF\U1:JH>FJJ"#FW^<OY[8O28L?+
M66I'Y &2[Q)R>0BNO&C_N4R(SF_LN,U$8&.S5W>-YT'@&CK/4K^VUF .NUYA
M@;M3E\O[85H]5HI9^'KL>T4O 3?NMZR:ALMG2T_&%91(=JF>?"-M7JE2J30^
M=CZUP5US9O:NRY>T!FOCX[W"F[I>9Q^)B3X#G#W>_:-+'1^4Z)2)O6E^S.PQ
M,+-D1?F4IOJK)U5.G FW3RI+/J+*O[WRC#2M6%ML_/+ZMVC_MR^;]B7>*,=D
M>3"=*7F7,#*MC;6 ^A;DBV6'W[+/?3/8BQ+)'$X^E"&/#.EW%6RUH+UOJ0)E
MZ5C.&>#/?7(UVX4$X!1J<54NTBD1?P2(M,1_>/$AI]5LTT>J^X3R]TWH%!.F
MPG?H"' VF"I>^K8[8;X*]-64GS,CJ'.>55W,,>W>X\01J?; \_<\(XU?)L]/
M^^I4'"8= 3S/U]+]^3!5\!ZM;,V^1.Z=4$F2GHY"Q,4'0: LZ6.\W_*V7ZE5
M<KF20;D<5""]K[8L@*?KX/ #V+7( 0O2F.[_DHY3>9T\8Z=;,UY[8!JQUN9P
M3VN*_^!-0-&.MEROM+0BN5*W+*=ETUS.4RT4Y+2;T. ,M:W)2:5Z4*TA4"6,
MWPH;A,XB21QJ@]>Q=R;]G,<'O2QK9L,-L+:%7Y@DM&JLSUW5(<)C0IV+*;=H
M89X+\/-8>YA'AQXQM\@'ER/8+3 971Y@Q+=VUPYRRN.9]2K1*":]4P/(P#)K
M==E%= 2D6KS'T_NED$I-.FZK>_X,C94"60A!<T^["XE2!H\ G)N*PL04F[&\
M274UW*$@+C4IIB=^E^!+7GR8WAD+S;?7"A"K*;N7QKL3TMU /0Z3QM?U' &P
MU!Y(->(U_2)-GP(BD7O($#@+1=7 M<N8DJ)) GU-%.Q2;HSZ5&*W6BMTB?Y-
M8<Y3>16E$AVJ6U1;E]^*+E@G3J_633X/__1+0_@PFN99 KM+9SF6UY87/CBG
M4'M8&*Y$,<6#VH\ S#0CHQ@_F-3H/>(1X#6-X^.= DKMKS:5(P![L_%"$I=&
M"2YCB9B+69"%6S40R]I&E?K=:BY\5+V]6*9ZW=?4/[OLU-A[E J+(7U+RM=#
M<L!F4TK..'7QYNV)S!)16'&<[(!8&?^<A:[B;"J!+\!E*67N>LJ?%++Q8<$F
M70F6OJC2 8Z%G\%36$F8A:@ZG#XH-O=T=/?SH$XHT&J8?OEWI:?#,9)#-.F$
M(4._J!3[475CU-0:[[;MT$?W2:QR4>&<E9WMNTI=C8ZFP]V*:L_J+M8V_\WS
M0V1WKD-.I0^)Q#LG,P(2T ,9?,SUKMLA9.[#F-"[1#7#PT]T4=@K"-$E<C$)
MRVY"7$9VQQ)=NQ$<C#:1(MTQST:H"5/0JJVDH$B7[Y+$N^=NC.^I'7H_)$$2
M:2;H(-E98F5UYLJHX9M@C-ZN@<WV'/%W9D9@JUNIDFOSSH7J#,<F64_1J+>5
M_;*$SMI)WN'>9W)7H[#LU=ZVL<O/\L3?O';=\- V-D5>Z*[.RY':3A<)RQ;>
MDC)%<2]OU?!_MI'_I5MV)2HKNAJCF']3<GC<K#"?O'0X%^XJ9]G74+Z)SS,=
M8UN.*CF)98_>T\_8W/V)YZ^KCQN&CH:O>W[R6YG*P+NQ*N8&O'TSASL+#?:K
MY$OI$6##)"I>P:W/ZG>J<CJ<%.B N3Y,>3!V<I)WS>+KO&UG,CIMTUR Y^'.
M([V2.JEU(+?MNI!@F&W'?HH'QUIOV1WHQ>&L6^F\DW46>/'*EK1^DV:,;3QS
MZ0;ALJ?/K8:TX./3_6?QI9D:)473,#6K*A(OQ@TKX]=?Y*9\?.*66A<TB,NZ
M5+7L>V ='Z]RFB6;*%8TH6++*4YR*?7X#(C'S=RO\W&)U-X5FVPWLT\JAHDR
M,LXQ_FNXI8+?XUF)JBF)P=K(P]2;#U%\-ND58?XH_F*ECZNFJ1<:VDN#?YF4
MCFL\#^!YCQ/R>!M1D"T[=&,B.]\P=+46>SI2\<+ED0C(G4.T4FW&MI%?9)CR
M%=F6U!GR,V1[338S4TI_D/RW'V=*L4%G%$:MII01SLYL8\,#\./\5QMY\Z;*
M+XFE$DRDK:S;66W]+E[G\;V8WR]]6M1C,-[1W=&YT'V$U5/?OTI75B;"7N:+
M._F+3N.-UBF9?:-+#6XT:GS:CBU84:URP-8D<Q5:6!^[Z6@U,^ L&]$M5WY5
MF^O,1G_)/9=,2.J]IKLR25?:^,L;S58?1ABWF^:;Z.=T:2>!5=37%%$;JX/9
M8>57?9<;33\?+*7+7+DH999J;3MM6*"J9XC,U#MOE)YI_#Y;4H00<L<-VY1L
M/U!BKQ4H'OLK;F2L#-G!FI55(OS856EY)'BBBT-H6S^@PT[O0\X(_U3"MZ07
M%OSBE9./OZ39YC.5OQ/L^%P0:/ENS:^@<LWR6NN,KKNT_(M+2V*2-LK,4OF!
M?SJ)TS]7$SU2W/=59SN?K?FVH'.6K@ZR$1(B3&0GW&UTXOI,WQLWX,X=+\IG
M[7T:YY0I_F;"_7)U0H&Q^K7.+;*;IM;%9_I^*KT<]]/WH5'R VDL"^,7M;2\
MX(%2!<7Z&:B;DMV2[?YKOE1)"<6QU!OZNDAN'&BN,'/4(I]?VEY+6W8-*;C3
MU;0C*@F*K'-WFOM=*[9EU'IMOAEKEYDZI:_KE3;L,O9XZF;FA3GS--TS;H1/
MNK37@7T=-9;]2#^N:5N^S('D%6+?!#:DU[61_M/ Z0C@K0"X?]YV1E_R]?NW
M_!J^*U:IS]_7)N.4;JG<GY 1&2<D#YG;"@Y@W*M&G5VH3A#7M/N/ZZ@^;^[+
M;#D=OW$_H[:IIQI7^_+C-R]AKC7#1*BZKTR*B.K-M 4=GM;L1_>"'6M&]2K>
MX)G-5_3KW(6TKW_81<>@^;L4BRWLWN9?O)=9\+G/,. 6I;?/H'9-?Y;BV8=6
M1/8S2SU#2=YRYI=NH"H]SU[5NH,423:Z7^90?0#EGIG@!I5B(2UO$*4>S\T3
MRU,?WXI".@>SW"+@DE>W9#9WCP"7IZO=SSZ\7\?R*5>%=^'\FXYZXJ_X4/\_
MW069WU4-MJ(>#_M7(=>D6=VQ95LQ<F@OIEWY F_1HB^U551%GXT(/A7!?GWQ
M#Y]N$!3T&HB_(G?[60<\YCLS4[-) P'EGIQ:*XK8R-G.)]@3+G%D,BDXHGL0
M>R-#5O8R!X>PI/C''(%I WGW=PJ'<0HKJSL/2+?%&/U\V+36=5VYA(AK"6^,
M\]X]L-67=+3N-L\>V_R-9)U\+;,Z&%KKQ8EF[NV"8,=2E;1]TJ\^3+RIEU74
MG960C]3OU<Y&\J+.S"D'ODJ2=O?M,AB4DX/6W2@"#<$IDN%EI6N3F"\/D_5O
ME!+ "TA(Y6Q+2S5'GX7^BO?%=P%^T@TNYN;7N[A=EQ(+7* CGR$C]GK+&UNR
ML@;5OO9*K^LX'1 :@JRVPNH<,PI#B*JMX+@/!.N![[V"J@?&2W4K\S3NF$TX
M19STYL9B+'P!.5_97NU$W\NN2_RFH)MLZ .2T*1UOKUO%_Z!7U8V/TXQTXJ0
M4&E=:HML9/<I4ODFYGXR_9CP^];>H.*[@KA,Q8O/ZVWO:+CK07M;;.UF>E%"
M4 +WQ]0;R MAJ).9H29!S[6T1'F<4LL; FIG!F8;U&J<6Q/H@:V\#+;QJ%61
MDKXPGX0B378@6/6I#X;@^)7#U-8+,-,[8]5' +;P'ZW Z,XY*>(E1-PRIID4
MA88CW>',ZG>).SV-Z&Y!]X!YEG<XJ+1A4]01X'[5!'1+>CU'F)QR6-$*"A\$
M5['WH%\[G#K,VMWBABTNY"))\8NN79 $+#K&'_.2T;0KKM\Z+JLYKS?<S%%(
MH<_CQ5 !BS>O8*Y37NZ5)+*WV3B\"A+#%#GT?K8MJQL!5OW:T%D ,>X#*$)>
MA5\>4U=:1/!03AM1?A525!8#*XCK]X?WALYB0\-)H+AF_?(V7%KS1.B=$K>T
M=VUX3P/63@YK2EX[B$LG?[IE_AUWK[?[SNE.;XKH9!=(D,Z@597S&[,X!!8_
MU*%Q[# G]);[)UC__8DC@&L;'G$N%#9&4_-S!T4-)36K ;O!9^.33L*>KTSH
M?VN]Y(%%QX5*HN=G=(+P$GL?"%#HXJQ9<<O*#+ R5:+1.%*Z&VIHM\FAY^63
MDJ@C&6*HJRW;Z&/V;1F[G]*88C!O-F+1%*A;\ON]5WFZ@J]Z/GZ?QB.,UXD^
M CC"(\&7PB^$*G]I.2P(A1.CULE1).\.#,\L)?HAQ918A;/(*,/"5*S^SJE6
MNV34X2#61!QZ$_#2LX#&-<QG'F'@:4%BZFZ>Q$:EX\(<EH\ _F5[B2:$ZG[%
M"$E9KUT(@=E[*9DYORJ[I;+L?:#ARMH=B5P7OJO><C^[BX05*HMH+RFC##^%
M4X*H=T(52#<IZ,5O 498=(_JJ5A<F!_Y/;$P97$H.IPO_AX127L&TYMCGT*W
MS_.7:0C,3O\68JZN)'JLIF>^3AO]5@E+M&&[@YVA%\ <<2LO&=0+EQM)Q'PU
M^/S;!O1*_3J2XMJQ(U;R>;VQ.\>YX Z4[;VK"4D.5>)ID_:1/"P=AK89JQ$L
M*?01)<QV)FSN&-KM1!1)Z,E=CU8_:'#7VD9)FU8CJE9,EMV+E+RL"U-DY8:T
M0MP#Q[,L0VX&-=:%E*E-F^D*K4AJS%V)@LV)-KM55.2;QMA<+M2']=62KK_K
MK^@]8WQ29=M.MJF+N>KXDBY[EJ^*ULET-:9F(Y:D><77C8U;MZTBM$=\'MTG
MS]F/SV!<(P;Y8^OKZV,MEI$).C=;$A_>2V8^+E_<6[-YL3)!XKLA.5T@X25"
MY=T=*M7JTKO'4;^!LLOZON?5XWD?!9OU"DTX?7WR0&^U]GTPDF\+*6?[>3:D
M3[<0?4%-]\;-4!6#6U<WQ[><MES&QPG#A>4CSUML]AJ=:NLX;KO&K:WA0]PN
M_XR,ZU"<^#XHH!]B]<HE^#[?<6ZFCW<$F !I)6H.;'>U$Y>BC/U=:S&QXR.G
MK,IX]Y;K(FZ@=E!U];72)^;L;.^<E1\L,/#]P52C(?O![F,R*2]C[@ZYX6Q:
M[69<NB:KV^5D?83L(Z!K]79_OUIC0453=MY55MBROE)-@TOZQK=XSN\I\^4N
MF5?$WP_;Z:6H?:]D2I<B-3_]*I,1XN:WK;PL>EJ\( =]^LQVK[2:G[V#4::-
MC8F!7H.HLRRGUW27\G1"SE99]>2]TBW_# O+VL;6G*NI<GNRIT2IT+=6F3)K
MUR\L1-EFY+W]E'MFPN^,1%^4RI.^A0LV],%3=<UI?%SVTVT*O=Y>^SY\\CI0
MSFJ2UM58LT'>:PG(*_+W._JT'U^TX O4T;[O5<-Z!*CJ4"HO"O(+@,KNS1BP
M9UWJVHCWBE@A/H@_"79] Y04:9/F7.AP_LRO.!U/>"PGRRCD"9/DBJCZ7)$H
M]ZNZN)HJ%9;+#9 ,3@G:P7&%9KT^IJ=+: E-T^2(A,O8H-0MZ<_;VB:6S3/!
M=JF+S!I.*WE8K5Y0\)RN5^Z[JBIWJ'.8T)\2A]RB<_E! 7 1Y1W7N\DWD['T
MS1 #<8N0?OX)_(RNESTJJN]4R$OA#AG6SY5M MV.(7'8QC%%I[IDSQ1!+-:^
M+$4QS=2@=OO>[7==G--J=K24F(3:=1F/@:N*6?DI3X</HM1BO<K/1-Q6+Z/$
MF@!*J6]":^-APD/!2P?& +7@XS>OC'8C_,A)53E@OYF9\TW06I$HW/*[=[7W
M>?+E!Y=272SDS]T7L5-<0GT['/1X:])<L&@HOQ*_O)+R,+2VRC?+\EG"PX.L
MRJS&Q VT4W[@>,YLZKRKI_6<02S/&#3LLZU,&7G=UC\S[);X&U?>C+<V#LA:
MP@_!/)$()==8Y^13T*;*%=:2C"4.V6I&.?6*;.ZNM;VN-/1NI8MI[,OTD%)3
MXSTGEDF]]FNL'Z;(I;X."OJL]G8&W&S>"E."O%5QNEMRT(*']IMYB1>:ZW\]
M,Q[KY9N*?X _7^DH\E-5 Q&&:AB3([#U?VQV6ZIOKAOK9[_*9OE8WZULR5%>
M==KH6DVBS/#MIS6F[H;7O7(FI>T&5^F;)*.-=36M(L7\ 3F7]S:BA(%^:<_U
MD"[ELA9T0.MP[2HFLE76MA1.-#L"4$1Y?C35UU-MPF=^.39F65D IX8,S94#
MUZZS##0W?W?03JU(/ZYD?CCA(I'PDUILE;#W5?S"S9X'0NP.JI8X2%>(H#Z0
M(@6F<7I(V\+*\M^ I\N9HHY;\.='DX-&^^Z]<WWJ*:@K=L;<93;MHFSXFFJ:
MSD-MZPO:?FW"%ZDA+VX]\W 66<&&#D]IF/.Y?=92SL/:B/IGM1*:9E:*RZ2A
M>3NT$=H[RATBFLY:1T3TP*O !%92?A?P5+/6 B(>?*I9WP\W?XP^&$B7;"2I
MQ&'<F"9"M4HH0%QA%;')UOOX;S[5E7?X+2#,M8O.2^+I?HD#<V)>%!*#8N70
M^>,#"8&30O2_<TC9XW+%#K/!SD:)F#-PQUG/GL9]@C2QQXQ2A\927N%G41W>
M+^:/JTM_^CUAD[,!X0:[0X-PR_O1&TJS'EO&-2.A;'F]"TW20SQ#I] !4HR+
MS%(&OM/[&:+UAD[1Y \1K7P_0YV)0>T8_O )(-,N&%O7,7^V59828D&*'(S'
MY8#(L:3YSB, AZUU+%H1?4X#?2DW?K&^[%>* S&P!!P9H#;$J;^PKSWFA=[3
M< #_?$7^213?@%.OT >%F,?ACNB$< &*/?%1J.@A$N,*Q!IU_)G 4#5"K<?^
M%W/O%=74%WV-YF='1)H408A2I:LT*1(;74!Z!Q&0$B$B($%"HB @S4A7$"*]
M$X&$4!/I @+2)0B!(" ] 82C).'B][\/WRV/]^$^G+''.>.,[).]]EISKC'6
MGDO>;Z?_3IOH#=I@8J4.#SR&JE!4/6MVSIOF[-.H4SSGR''2 =^LOJ>6:4/*
M7[9=UMES*<_;=J1453$)U3KK.QM[9,KS/RY3*SO:!R"; U#$*ES+YML_":&F
M6=.T<"HI%GQB!Y:(5/VF V&-@$^B/)V/?OX+?LTPK (LVT6Y:9@.<)R.5Q3K
M,N,NO2YW#L8%U3GZ[7$QC9A$Y3S66@QOW.YXKI#V^ZN0U\9@S&_[X/ZC=\>7
MAK%!AK\3P29CCX94V;.%]NX/2X[*SS6E&!.;:1OE5?#G&]MF/HF%_0-1E:M"
MJAVTYL9'I27VV@)/#T!J0X?<3X#DXQJ#Y!A::^:>YYR$S&\F:H?N2_A":M!=
MSHZ[!;1!].8Z4<3'$JCM0EZB#<9"O+(=^HSI2[&B?9\SP0F5S9S%@&UGQG,A
M>*0A@)IML5AR^E:5MW\VF_D?:Y#$-@]PTZ1G!UL%$;?"J%]87 QYFD"[+EVO
M\ B9 G\-![>17:,'&D)\:W]4%I QNSXMR=^=G>)=M7K4E?\@ Y.(FU!8<3J!
MXC>]OL<V5;RZL#S.Y%X=FX6<(TKT^ =CCP"AQ;CQ)5P$&^*6R-H3CJN*:1Z-
MX9 ^X]@<%OEXNH"/;LW4O;FQ ME.=SJZZP!T]EWQ-X12>*E:>5BI6KP/=NK[
MVO!\/4'^;T*C'W-$WP\Q7MU!RWH7,J6O7'I-#03[;VQ#5<.#6#_B+T:+FDY8
M+H7$!IO(MG<)%>41MAT/0+X_*A.&M<>?(_,O!+9*O.V@E;S'/EZ,OCOIV/4A
MR]0)1VU9DB6.Z:>I;CI\D#3O7,&>8R[TC8YSC37HF?S*Y_/XD5U)5\&6[3V>
M,FGRQ@X2,<7 <\.-5YF5G1NE)]^?^*! =O11.Y8 %1#PCE48W5.S&'P\_,7F
M46-]%I3]OD<%EF?0+3!OA2.\P- =Y1X:RE%!FQYT?\8"-R;/V'GP[UH(IXVK
M=*5/5ET<^9GL_(; 519Z*3/<M5.S)<O'ENS1Z%(*1UA+/(_\E;';)2+=IN/>
MILIAKOH%-Q4OHCGSO65A$>/I%Z;"ZQB>+%.<(+\YZFMK$\+=%7S1 Q>W:C&&
MUS(1NWHCU3:]4J5N1K:N <WC>"NX^&[<2'BA0N&;V<_FD=B,I?%"S=0&\1Y%
MK\NMG5UE\0EN,M+7>WWJ.[=O]Q>'RH;@4L.OF]Q^\N%/RI[GX3M&_5N=>FKQ
MAOC>'RDA"T^?E].0Q^A[D6(C&](CP>R3.*BZGQK7MJ] HS\V0*5M:].N.7W-
MR8QC<^I,DHMO1@CTFJ/AI?2^ ,FP,)&'/0S=0JA0X:@K+=F;/T.!8T> OM)X
M/]*.8&**X@#:S>,F'_^^ >X@*XQG^ D5W%*9K'*KAS1DOUS .ZNJ,L6=ARH*
M\,Y@EX9(AV^*CW.;/TGUSJUM5.:1FBV%3>1<9;*QE7EU=DES<7;3PX8+^+G=
MQNBK"C.%19U!2;[C?\>B4ZXTOCNOT(Q93]2SZZ@@I%34;<N:G>X!I9_2SXD,
M$"N[G5QHO=W'N>;5?_RTU7+7M0@+7$JY.IM)EV7<_<++(RS5T;REM069T6)X
MF*N/J'V#5:E<UU]<*D^F27U38RS^N<]U4GZSJAP@978.2#%@=8TPE,JF.JG.
M6L:CVIZETXTK 9,N%/C$K5&]PH R>Q_(=^7/$]^<O2TXU$2DG!3?"RUOA5+N
MMI94,O/,BIMY#&\4V-Z7ZUF\N:KB1A6#U]3<[HA2UJT'W?$[/^7Z08TH-X;X
M;ZXIA'=Y;^37\X$,@=?B8])^8KTVS9P*Q,J29A>G9]=^.-0Z(&+6)H:,+S77
MI5^A31 1&L#[TO;P0D!SP_E&\,E/X;!6 2'<<V1B"1S3'O*I>?PO7TY6D3W9
M)V_^)M$0IU72YJB><193ZC@8P/<S27>%LII<6DD/\KE=\&?>!F*7*Z@GVVSM
MW?4TWD@9 Y%?US#MY4IU^SF:MWRYW_'[0. KAP5$BBDCY6=JQ6^HOF2>TX3O
M <@^/^;^K=MZU@P"CZP11KX:YL*N>]%[ZI+=M;>]%:=C;),05\?\+HUL5+BA
M#7%#V.9;E2Z KS/$LGE,8A2%VYBR&"\>DVJ(N+[V6PDPK,+'^U0^;&B.\K!+
MUTJ20/O!5CO<&0<@-"0[H/=:H?IY:?[L3-_QL4"Y&YF^_3<L'5:\BO6#A_:<
M13.A/Y'FWQ-0K<]<64/RW=O,:MZ_$ZLK6EW+$H^MYSV#W,:<3WFZ;9PZ%A;'
MB*P^ *6N$9AYAZQC]:$DLL7*.(3I:$*\$\;(_R/^BT.6J7I#9_SWDS-#Z*OZ
MM'NO"DJGHI+LSKQ,:_VEZVW[#A"PY.X+*.RER'_\,;7T,0ED_S:DKXO[\R_M
MXAMF.N];PE%W6'Q2U2'&&Z@)ZE,=G0-0DMDA7!$XF1KV$Z_L=QAF6ZH;,S<>
M(*3+7J"6N@\_YF-:-MSD?X2<78@GF634[]\'H&657LUX'4PL2Z_Q?X:&L/_]
M+ML5O\4$_5IO0F$V;1@BG-\.0%(5[/Z4I?TQTLD[.Y">\C?%9IA?QT:"(*Z_
MTF(@YK_!_="G_C&K3)Y/2RLZ^7\J+_LS(58G%/ZGB+?O?TI\G77_K[=!C:A8
MY(NG>\["OU#)$S!:WR:4M'>&9?N[XW]J@)U)[4HM50>@'\I_7,?_-[GG<G/=
M  @/XQ;U '0:H46?B&6!@1.K5.P;!F0.S+6J<P;P]*3>.-FZY\J%L"Q:MK5]
M?C+R 1T6YU5'HT2#.S(+;!KU&1)"/WL*?U'75@1R9PGPJ8ZC=7DD6=1L,J4.
MO<Z^#V7(, L8=_;O 7)SX!<ZD@PV9BU1D_5U!!XXVTR4)]'2JC)HV<W*Q\3"
MP[HT*W<+J=F/Y)BNYK7-=-VJC%FFLG/T^/#?D=8<D6V/F@OZC'/ZNW1FQ0'(
M8Y,,W>4!8+3!6=>V*<KDTFX2LP1Y@C5X .+1N8[0I^ON5E*ULFVIBZ7S[WZ;
MG4!<!GSF% +OC.+\ EMG+M \1,7&B!*(F\1&6D<*4'[K&P(R2SIG!J/>N',3
MQ$S,:U;??0OLS6$G(V<'$Y":P$@;B1OA/(N-&5H6PB0JZ/##C6 B\-I;M,3Q
MAJ)EI 1]!&[1NS%E.]9\E;:M3VRBD]X(W(RTH7-@(E4X0LR'@CA"[N,BC9JV
M29,QNZ. S+['+;IQ![BVL/LU2XQQ#?"A"BNQ^1R A%76I<B<D10!;0.R4V;,
MZZ!_F@S*]:-).A<GX:*T6W,4?B!]H&NDS69&NCY<P& "7YZM[,3J!?TEQS'N
M,E^C9@LPN*5.;-R_CIB;IUC?,4>1YQ%L!&:4"O:5Z+4AH@A"C2Y53.?L(JM'
ML2XA1.GJG=.N[10>';&J:O4(;=B\G[31<-"J_092!/"Z2:O#E/67+CL@\^?9
MA:%*O*Z("9HRZS1EWPS>;<5,#4:C_W:OO:>9S78SSMW9U6/F0WQ0$22>RF9E
MZKHB^/LOAD!<7R?-AX33CV6)(0)K:.BN_M/@*/)N4@D4J?X-1YI<,L;1TW(*
M85(O#T"GEC)";H*'P_D8V4 [Z_3F_DT7Y!<*S<Q,""$-M,Z#15WAD9VH_Q11
MOA2RZ]QAD)5>9YL#7X *[:V#:1.S_\2,'E6:=4".L;B!IMF,UL$X%S&:;3S#
M;'Z3;]GVN>V+YE#>911'\R5:_,TFND"GEM>A/Q8JD=WG-U]!/+&34_->ZS+S
M?28.AXP0<_30QE-4[&O<-,_THXE@$[E6%U'BQ-)P4%983 1XW>2^/8=.]WJM
MHX-N<* PQ<G146)$[[\-J\,DIWT0N"S=O<_N.GD H@JL&^[;H%IE#D"/6ASG
M%Q-GE>*?@3])O\&3^(&PW=1_LF26HU,L[G@1]OE_;1J]XVT!--W+@-9!>2R$
MBCD N35QL@'[U$<Q90RQ;[]AG)/.TITBRF.0V1P2WFN]93^4<1T(WO>Q<V1]
M!7-"/ 83=*[3 X&CL_SELZ@X]0,03AMR%*?@94_32:%S=KCB=++I3[?GFEVY
M\&@N;X&9:V91SS"U#X:HM/[Q[#FYP3@A9#T,8>C[W_Y_NBAU# _$EY/,VT'\
M=\IPC?4=Q<92@D^U8SA(;JZ3[1VN-:2UD5Q'Z+55R!DQ9A[K+.+:!$N9$00T
M!-#:79UMYX@M\Z33B)MTZ2@=X?:JU9SSXXI@/1I^,V;C_<ZD(FY^#5-3S."O
M/31=(LFC1T<2Z-8%INEAKH  K6G7A ;K0L4CC] X7PA_I@B2'J/1+%X@[#&I
M%M5:6M'L.N>G[ 1\UPZ;K^0TI%<E''HP.HK"H0KC7MX5O4S/B/;C'O]V= \9
M!Z3L7F<25-!3HON[+X=QFY/[NQ$ 6P6RWU5 "CA/%S $]F T(_(6+/:9J,@0
MP[;R%U$8<H*ECO#$C54$N7("66V9'XCBF2O=[<_'L+$[#0C)<GCLI;$IXWW_
M%_^KG_O_UY=<%AT=SU"?/;1\1K?.U;%U%<[3\#MWQK0-J3=\F8RF&TJZ0Q6+
MHZIRJ]&@ZC<SXVP>E^.V#*ST>;03RE!IJ%@(S5&)? ":M^T8Y(*C=O5IX&C$
MU5DFIPD='*LR96)Y$T</>8,W8P/$34</08P;GN*,L6V)N?.)H"/Z"6/;/!14
MJ6C<+S5.=H2K9IMZ0-_?>(R5['XT4-[6]<'GON$XUJ6X)M]TSU?Q6<I3'W7O
MSJW"4'M5U%>$'CTPLOE*M/U9L4ITQR.-,<.1WAJGC./RW>I=9:;<Y3;IYZWR
M3<_E:J8NEXYCC:>L,+4?RP;XSD$J>N7^M#)3(+/-C?Q-LX,B=LBQ&:%A!&0>
M=0*N;$<WBT+HSZ8UXX9U9%8T8<GIR&.NG#\2S1GJ\R(6AGG0&^;!,@QUE."H
M9,Y$>Z09(=(*&'0YW*_C2 I+LYE.Z 1'YP@ 87/H5Y2SV)WWVK<^=LX):AN[
MYRWG*(QAC&C9A'C&K3)?KE7"A"TA?;,X\4Y[>WO=]G3/):B<;O*D^(X/[4VP
MYEBI:9K0Z?A7X7C?7A79WG*C#]X#LO[Y60%Q1G+I%@G2?6IYB+-:RV9SH@*R
MO8'W%#TSE_B4?>W*5F5ZKY6]^S"OD/LBH1A=F>4F9]U^Y[CQ2=-LAS%IV6WK
M3SN^5!K&KJUU'/*I3&X[D,7V3R3D-&UOG4);=6D85=$"'V.X &%J6=## ''2
MSGDPN&#:P;=ZD)GR#[?[0K/:/_J.3+J2^XNF3<)*X,]8HY.N,S-3T\N:1:5_
M]5U.*+&]_DR5G0NPFI;=\>R[KI9=E9HW8E*J9^YKGNIH$6^BI;R[(4A]G)+P
M5+XI%AXB8G:U9]OA+)&3[]3 62-5:;U*65Q9%Y\W]<KOY='<U[DVW*5Z>(V1
M#U9Y@S'_JD[%;6-):P_&43OS@4[,(%&%0R)5WD'9O0*%_ UHJ$(V#,(OY\6!
M_EW,_R61QQA$S<ZB_QB3UF$'H""!0VZ*GFU!/H1WST/BM:&SJ B7(R3"T,ZT
M\JQT#,)DCG3<UT'>(2VG(1A*Q;Q&B@,98:%5+B9ETU/]I?:K+&EBI$G]\.,=
M[_6=J3#!P@CJK@QV V)Z /I_S@%E=9-P9FMT@9=(?E^7R\P\/X@G"HVJ1:\M
M[QLPV $H%74>SDO%QB%4$'?H6?9 [3P:A'AR",V8"!<04$@EG6+<HZ$.O\$%
M '="*P#C]CW-DU'=,4@QA#:=B*>V\#&$H7].R&:69RVF3L/GYK4?*1A9/DGP
MXDNT"&@Q'(D:=AF7M8Q++2V9UI B?7L<(R#/":+I*9[W?#Q0>%;D2Z%I]JF'
MLJ.Y%DX::W..DW-/OC??S;6PM#.J*8PIE[6B6U3-J1JVN7Z@X-"=9F0YZD)W
M&XH'.70 $L#,ZS5QMO7)P8X"^;9 ^2PFGJ7QB<:Q%X]PI HK'*6"8[4UJ!!>
MH/L>70>#A2(OI6G+T)&L*:IT](Y6)?B>G](]6H&+8&W\)V8R\2CC%#!Q &)_
M251GC1R.!R OM]G-J!R9"<;1DQWLV%A^7J"IVZ:.4^?%IYY94@2%KU(5Q>FS
M9QZ*%*-590<4,XPGTO_V*L60P:^E(ZWX;]BN[]'1;1!!UD6$=-.PCKP3<@BI
M38-\QIR <\Z;K2L'SMT(:^.DSU--WU? \ZU=N?4Y$W:8 E3I^(LT_0A5[ G&
M10*008>TSP@#L71^<(P/%<;]2S.T&<<3@OFDU TF;PTZCNIP(83^UP%SWF;>
M(GB8$]T#?!3RP)4,H8:TB<#NCOJK)IZFW*<OYA;!;>?4NRNE6=QSDE2?QCFS
MF.<>>XU=U;DFD+A*A_^*?7]\2Y1^LU"J\?!24$/A^8<B^E_2"DJL+3(4R_>L
M93NO%YZWBB$RG^.O)LU%V;+%%*;:W@\6$>*[O'"E;>1O1[',_=#T$T&E8=YD
MI_HU49Z"? >+2C.VURV"7HA  *=]?%\1<8.9A1#9?PPF$PQ&\0<@/F<XX7.Z
MP\D.$B_B)* ZA^&<AGM9 ,[JG[^3?,U>@L\THV@Q5%-\A2_EG !5%$M#MAM4
M3R 40@J]GZ<W!7J5K?Y5I?S",H0O'8"DE^@P5K] -^EO _*_B3X2S;)2B5I!
M8CL >5*$$!Y9K-/GYY2$@ P78*[H!^*?"DX<<C@3VT5YK<-;3?N).6O3WD4Y
MVZQ$Y8S '&?<FD/_!U\4L?+9!K#6W]:G.EVD:='XCY,^#]M;^5F7Z.!15]KC
M& 8&TTG:5W$5/0"M+  G7=+_,])@'>'Q*PN^,E246<XGY/_*2[#$)MOHK<OO
M'TY$:6EO2AK"EF\@#<8&%/.:<B?>LQ%0*8_++'V)E?U>LFB1:U- UW@FP/:J
M0^57V?URHSC31,V I?*^=4GF88;6^N\HL8+K81H03=1B]69ROMF!13\G="JH
MMQWIZV)='-X(SA:XG=**X6)(TO\K& W:-^YCCU6 N=/*EVO,1'JSN$-W%Z.7
M_1(K* -FGP] "0<@+H@75I@UHZ,<R3I=>P ZYDGO7G^_;X)09F:R>!!:$Y>
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M?]6PI[&.(8=X20R%P2, V-*,UWO+]\FJPFR?7U@G2YRN'LT2S;89/P!9U;3
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MQ[94H$J7^-L-:N+LQ&_J?#VS+M$=ZK>8?$I1$E]3,^:9*)8I%AM\+*!;?)-
M2+:*'XB>O8!+*K#X%+R-Z'K-5UJV[%<21? SG3>+=LS6633T\WIG?*S1JMJ8
MKPISSD?,T8'R,'@L.R/HU] :_+8.,UO(1$_[4[:NW#9!L"VEL$+C@IMEYH6>
M-GJ6B?%L JS_@Z^9LY>@JM>YK*<6"Q:+)EW]7<--MB//?E]5=10VW&%*^;G,
M;#!Q3'-M:Y^2[^VJN-T),L(A;6!J"GH46C<CHJ-?8^?OEB[7<%YW[1%5)9
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MRT]&?NJO6YR9NL_Q>$].2&\\(;Y)MM<Z@WUNU4U^R%XM-[=/]?O$]>81>>K
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MRU]'>@1%+LN>'3C,,R&K._+P39:NB2WK!VIGP<M%Q&N$#ODR40_\OSS$OCP
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M<0^P+(</M@GM:,)B$1H![G/0&^(=.L+J!Z!SK&DPS1X;0SJN;4S#SJ'7.JN
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M+E8"R7<0@#X")*F>S-=F:^L'( [^"2+8]=0!J-T:'(NB%:)J!AH>:ML?@-C
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M2MV0S$2.".^UL0S/FL$:8_EES8Q9^-E?RMT>%,Y\+A^?46=_Q3I1F]4:DU3
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M7LN\+<;!S'A*QGG*)[!$_J_R46'N-Q_B_&C6'2FNRT][A8?@.>/OW*^"= 8
M+M<=]$2Z+G?IUXFX[5SU2REZ1L^IE^^\J)ADD7-0BW2)P3XC951H)_/>#I*:
M1ID6H<ME;3/Y/4R=6C-^87,#TM<0_?WB_>(V)=Y_R-PY#Z>1$@/LY>-132].
M,N]^-HLFE$CX]]Z)]V_Q6S/\%<S JI^DU#JHVO!]\+&+F\W%B;)[YG0;*=FA
M5_."OUSQ-S140D9,1LP<95CM=P;)(.>]U+G,-B;8;3KJ;NV]59?YYTEM'^B>
M_+N?S-T^,4UX!A^W<1_A4%G%P=G)GXV1,S==,<%AR\-M%8J7:_0#-TP>U2S6
M?=Q#>%@&2X?ZH,,/GCR+TD-H5BR &K)84AH<N#_%K64^U][;]?F8U&\7E=E]
MYY+5G8H+1/^R3RH\$N(2RE/%[?_.Q8CD8I3C3;P'C!=:[DZ)_"B>-#*4,7NE
MG#[NT.)Y$#+G\"L4E8CZ;6?P9UJ)D0^I<6R:\K1^;/MYH^74GS:CQ470+Z3B
M8.7Y(([V3]"#618\?G'X7+Q[2":K@C#3L-"L07WM&/^&85G]6G4^SB>O?.XD
MSS:9+)2V@?1-6[S)SG6]6'%?,R-9K0GEGJ^8+M^/QA7F!/DQM6BUKZ]<F/D>
MTMBMX-M#<+#3AWY8NBCN(^@KKYW16Z&I5EYMZ[2@Q6^)R^S],-.<F3DT:<O]
M,VOOLON2<K:T46(Q(Z4+*Q&7M2Q9<BDIAB^2W:NK7G_<!,[_>,W4--Y01<YU
M]9[!G%$MNCS J=#D<SZ_,Y<^:_A$N8I1@=PKH]S$H&RM(->F#%Y]>Z1_N=A0
M?FZ1Y/!$( 2<>$.T/;;$D6^EPGJ^;2BW%&/E_VXECYBN)Y8MO)/&D7Q/]!J1
M+D;KX5HB'S.SEP8_+[*W[/VH;&6E5KDW:S:$=5$*(E/U0G"MV%>#,F?7 V9C
MS+K3Z!$Z^[SXVA]"#O;3GNGCK &U=S]R' T@MS(,%=2]GZ2BO:/?#_)FX;89
M)*=02BDX=^TBH]"/\8_6+'%>KF\&ZK'*UE^2!NS*_D96_/4<;L*(ET\<_/D4
M7]2 L BH]C2R6LLH'Y@NQOFG*-UM'$ H)*1GWLHS?.+1SV#B.&*2EN#G9VR]
M9-V(\+(USM'&B2 "<X-&DGQ%*H,$$J\[8%]BR""NM'YFG*.U:[Q5HKA[:Z&4
M=A9CF O[2UR?2*%C-S3SRY1LD*%\9^Z]8MWU-!/$DRK>;Z6-]79)M0VS=OX\
M;Z0[6N5?7 A]#O^#7/AABE\<NE4[53VSB>W/$4O7JH\?P-WU74ZU>>PSRM..
M20W6SI:NK,_F"<P.>5]>4XL^MI_AA;(Q5C8]2"9.0]^*K@UYNN?N&!8;O/Y<
M;)G!+HGL-,X-<I_*%QN]$I*><6L*Z66T><?^BWGQC_FU?G;XX/9:D)2XEF)9
M6H">38](YJJ Z\+:R/SSXHP\+YS^*5W^OYO/E"6YGKQQ>TK"4-41!_:IK=@&
MI5.ZU+FXX%%SX.UGYI?G21>E?O_YF7Q/Q.M3^LCK;U]TA"-GM:64FSW0@])F
MNN/:*QS! U=?,)S/I;:?TD6^<^HLWSBE^V+Z3<CK^5G[8\0@IUE]8ZZ=>]JB
MG,!)FU"N>5(IRZ ?^]V[SVO>=%JBIF[$OA)Y]DY8 YHHP$E0>MYU]U9#7P[_
MD^AX*>=$R-..5\TKD(WFQ"+Y%,E9K4J3B0DPIMBOH<%=SO*W+7PP>*<A*Q=Y
MS]1R\7!B<Y1G9S<Q*VUN'C]X4BM(ZQJ@C1?O%4=V\<7]/J6K[YY+M@)VL,XS
M"(AZ\#WQ0O>PWYU<3O9XK57:+[I> O95&D9G'648<%;,1.Z-KZJ8*$UF0]87
M0"'LJ:%?%+6*[XMDI:HGJ'67F;M[_G2[I9O0:[+PD$:%&-94-HRFW^!4LAQ&
M%2ZZM\?P67%Q^5U>S3!FB)-= /MP+-X]2$@(X!\]G_([U#B-,7I^]EV4Y,-C
MI!=WB_X=@\5UO8<(GI[>ZV:M C@?P_W&_LF,3U*W"LOG$&%S4DURH7J.1LI>
M!R&VAJ)80)U0;[!]I9K]"@\X[YM7L:AK8+ VN$8N(_F\_S&;'P]^B*L9ZH\/
M+W-KR&^H%FHPKP>/,]R\,C*K&_3/XYK+_%TM[(9[T4IEX_B\P#UK79>XUG)1
M=SE9X3MEZU_ONNRE)ZZ\8\S/'2TXN]20]%1+L@V-D1=_B?3AD^_TW'2!J93U
M!7H.7-(Q:WV6LE>6F6Z:WNR;8Z,\:>E]Z#>N7#4SC+H__;N^V09OA]C?;0HU
M:9URJ%U_F20SEB9$T/UQ2\W*-#'X0\Y8+;T,:Z;\1<EU>'2S:&]Y*#C0<8(6
M\-)&4(\91YS<SG8TKVVMJ"G!O\OB3A5ZW2<9+9I3$9AF.64YA_[F<FS8^K3
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M<ZE1X-?1[)V^-U^6[X$V<DZYM7QB@MZ4.-2FXJ<GGB$X*6(3M0\Z[HY9QDC
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MY(HDO2T/G0C40^="D=(5+M(Y)5OLW2GP_>KE'N-Q*7GJF)@[3]N/*0D>_W7
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MC,?:.()!]V;XSQ@E2%0YW&<+PJ3)0&^Z3%@HQU( UP.@S)_(&]PU_@&'IK'
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M M6%J!1)H N4T(>Q7 HVFIU8#GD!4;QVDG_Y1EKE_+I?SWOA@MS%2!>,S$7
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M+$)0DEC*YT"6";$CV6DM20:*:HZI62^+F\S>35RGTP?+I?!I>]S8V/COO>0
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MD'T.V&1E,; PCGV0579_-%:ORFQ9I4;D8V+R3Z$?1Z#16?K5$PQ-:Z-&9HY
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MB G$8I2\P41=^$D>UG/6S; Z6'MT:CTBE U4%S?;QJ$/2<^[>2FA\WQXF=4
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M"0;^3 KV-FF@"#/"NO;DZDMKOUZ&/4[1T+7W/H5II_I:=S"S-A\S6_7]$2>
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MG"'"] &E(]"9OZB!"*/+ 0^!T$]4(X95' 9(UETJ!]TP/AN@U_3SN!J48K-
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MWK,?;=8M=OH\V\V50&'V5=R9AZD9G9M;Y]@4(Z8D\INYHXZC%M_9JHT0--3
MK !/%XR-_G^X>\^OIM;H712W!9&-*$4$1)0.4I0J1;#1I?>$(B)"$D.DA"(E
M>TN5(M*"A"9"" @A @FA!) N7;J$FB"])2@A4L)EC_,[9XQSQ_T+[H<UUGC7
M^K+>^<[R/&.L9TZ%0\41/4^E\Z*"S(4G1SFZ(F%"XR>?]W!$QPSD 3FXMZ9[
M>_A0J2@XNUT(LEH)CI#(;W.].W9H3&T0GKFT-D%NW%P'"Q#S&QUV-&M1P@?
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M +_0RJ745S^M2/?ZM08O3S/->UL9]8-))'V%]'V%K;02"RSSM8+=V&X#G$!
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M O&>C;H\Z<R!N\43"EA[7BB?@ # %;6/[4@:S2*$7AE1G ]^@7PV%)XWZ?A
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M;I7.FRK9X@=611H?=LIZIG<0T2D$V<=A:E6H['[;U:@6>Q,ISD !;4M$6J4
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MP0(BZTZFKS^-.3DT\96"YXA^F_\@KK(G&LS9,G;S<%4TU[SMQW5_^QE?A%J
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M(MY<FAX(ML&DL0RY9PW\*7D1:]RXV:*VH!_/GJM25>4"Y&DS,&_)]97=J4A
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M%4GT=;;S/8_*6_TJ/FD(%EP#)3\F3:VCWCIC\(N6-*Q@*&C//.!ETT[ YM0
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M4'2V^"_]L[]_6(XO1%0\,4]IY_&$P<AKF3\K?D\T84Z'K1Y0B%NJQ97:^6E
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M;XC<,8*J=+E"V19'O8QN)17R[+-R=ER[+1FE)C4J>MDT-J[ (9O%0%E;/HJ
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M%LL)FR FM?P7WY+MQF]?O+H90M"?8B)H0?H:;GTNK/X#\;=OA5;J=9^H8!_
M!/=#J?:%0>_DWEA?O.=8KN/R9^5%I?9DD4&.V-CCQY7VF#&"0[W]F;RS[1'5
MT0>J=)Y6Y/=9U2V*>?N.61^W?%JC'?QE?.N\J$!V!9J(ET9U:D<'1M6B:^W:
M7X\36F),=)7UOTP8J[H'G+,O.%8L<RZ/8ZZT9UGP6U:AZ&KF)]F]?K<>5._:
M+42WEAGDK6S;"6.3IUZ>ERL'PS4$'\^57:4=R7CK7KSYM=.M\O1>YE7[G;Q%
MIJ2H0!S'-%2<1;<+20=2W%H);HRL56V#(*4>IM= .;1P4A'M^L21*61)MV6Z
MNT(WY1^*W-/6%%&X9MX5.)[E]-;-*DI8WS6O"ZZA\\V&U:1H'1Q<K'W7^U0]
M9.B^#;37Q:/K"5J&XB].II<YAWZ-<2SOBBN].%[!=BSW.?DBV-JNMWSOA$W)
MUZRGA\[>R*]>OY&U&%II845> 1 #-87.CJ$O:YV"V8[Q"\[C(?M'X6V6VI0;
MV3F+)OS203495M)$IVA9?_6>T8U?97E6[:RN]7*UIW^*29Z>UA$%9OZ/HU]G
M">:'HWWU:>YZ=TC_S$4=O:*RDY%#2N#!HYEF0T=093YT20_KPU&!Q *'),]9
M'Y]9S_;.^U3B8N6_^66C,@K#^:FY;I7))*#Z[ZEB@D>J+5).(!:!+(%S5J(D
M/#VP,^1FZR(SQ(@>:)7VJO'O_:(OJ1\[=/'FZ^PP[(^ST@=FN@W_KOD*J/$^
M3.#)[5H:#9I6&@FF<*C\PG7"[H9*7X[N"M1\UI-F6G1IZ)N7VZR"^%&9?[UI
M058*EVF=YC77<VS"X39GHBS3S[5,'*YQ*'"R#V?.4L/BSV[.V3C>B] LZ&?4
M< ^XO B^=*I62^=5H76OO5UO29?ID*.U!=C=_F"7NK_"ST.\2*%)/?=S\Z@[
M@A2=*[!-\_(94NTJS.EOI_T[9OE/:=2)MP>0Y=-1D9*#]-\LCV65Z,]0>39L
M&;[S4F[#GZRY/'C\U]S+OW?1O/9ZKM:BY$N,;T:V]W4KPXO_XLYJ2X?D,9I
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M9$PU/+?)-D;T#8BDM!K#M>"A 0)[8P D80YCVDGUGMM:]9]')4BR7L,P.LV
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MF / 4M6VB-\*Y"!/DHD70P?V%FD#)YF&AVS#$/M4H/TQ4,9Z0;G&O_P=\U+
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MSYSNQU_1AV[!DE7V)X<A:F87T)$"<2>N"KK4EKW>5<F[SCZ&9] 3R>*\*/;
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MM6K!]G-F65;/XV>LK #ONF!0X];::=;"0D4]-QCPN\XV3 VO^@D[")@NB%)
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M"J'W0[D57 :\*!Z<".5 8;BK*GN,4108&G'9GBM'E\/8QH:!B\UDSU4Z:IT
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M5%)T*L\2HK>)8DK&R8NC:$907 6\HZ\2A]@87IHKD>MW )_I>IJ->Z1D\X!
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MZ<-L_D^[Q,;/F)5?[!/)!Q!6=/QD;I<DL64 $P+>;NB""BVB+.K@N2!2"><
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M^?35^Q+MSH+'FQ[7_._M"@,TALLU+OCQ?#IPD#ZD4F:K;^+,J&1(#@P>@6Z
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M5_!(<)8>_AD3_3DHH0O<[BE(.&O54*A3_Z4L-7X%G92C6_@;?CR;B%"0/$!
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MR^<(<^MGWP_II&2L;43GH=LR\S/YO3D>^+17=Q(V/K;FKMU59$["G:(E!B*
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M"4-\W]3TI,LCJP'5_67OADIG9)UARRA7IJD42[(R]W9^I^G?^3!#ICJD5;G
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M;N35X(7--^=\ZW1[MT&*9?^[S^:BQO]]O)0_P+?XL3/C?_7F)//!&R0$[Z'
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MW3J_7#\]H7H]=@5ZU!N[FR,5LTQQ*D#V-K["NCV9&VGY'&861! BO BW)H_
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MHX+W)+C/0'=ZR50C8/1N]+]*S77H/\_R<T$75790T@]0%F&]/K+#S&C/K]P
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M8^37BG>J'4>^D@Y]2IP=()[;%#+-GK]Q'3_Y0LE7=9VS*BA#_!4(]/$L^9:
M",>_C5Z>U"B.D0=*V4F.G*@X"G(&?/P+YC*P-$6-=Q9OG8\E!0Z7JAD<<IM&
MC Y,W1IY%C AOSAO'_%V6!LBTQ7N:?1JORVR'TF^L,BH%-+F_2@^'M]*Y6DA
MY+=!B[. B,M/#Q,':%/WYZ.:T04O%MH>/(UWZY)W_'PNDV@#>^72H3->_DE@
MF\"N:!**GXN!42W3MQ]EKF7O][AO=.K0/M)#Z^);@\411;9@(^_4%[G+=XO:
M#L>[6Z4D549Q\SGE,TJTGM&E:=T6< )#4KMONCP*NA]SK@A-;J7W$NL'%8G]
M 7]3.B0'8!\BF3SK08U9KQ(BR^BSJ&_YZHIZJ?H,\MX?.!'%;=#36(P$BKFU
M8_C[_^36W;L^  ^9^!W>T",&AC,^C&?V-Y<V&30721\8BQ'CK/O4N/QT=C%?
MMW<Y4,Z(9\\I>#43UJ#2SAK^,/ZRM94R@*W%,G"5$P16/N]WS,.M3 W*+?!C
M!A,1P3HQ8. 2Z#7"E8>,\"\PQ2%MKL<' RT4:JO"2D_*!=/J@KE$97^)QLP1
MN)C.(6H68@_F+C#$D>6F )X<">X'(6V]Q#4I!&R#HK=!%3W-T"37W5NO^(KL
M*"8K#GV5B6CSB\7O\\7*?5FD2I.ZK8G9LJ;L% ;]FTQB?8$7U/U5N5;56Z3K
MCCZ-LN.$)1.VV98+Y@C0S69PHP#8E&8"8R_&3"0.*XNQ8+/P,?Q3Y4V[APAC
M 6/=W_HF'!E7_82):"]E?7N!7I:!\Q,>>0=EA(8O'YR 6\@(S@O)XN2!\O>X
M)HU?:W%[G?[.]$TNI0MZ,S^3RRZ^R(+[[</V4B4"=3_8E!__W?6*RZQ$77'[
M(?O3FEJ0/@B@I+M<I;2,X$EA1+=>KQI8YP,C3FQHY+KLK_U:"9>_PZ("\9+H
MF9;,D20#:__I@APQIUGV>.A&C!^+*!93LGROKO_WJKKTYF:SS,_@>.I4C!YJ
M)5=8K1NWTIZ%4KAZSB:<14-;*S+I\>Q0ZTC[:MQ!>"ZCT]GBHKJ8Q:G676HC
M\4O'*_-,;:R6JRD/:NH"Z4\#<FT>!![)/W;+;G;9^TR;Q%RV'B65(-W:GV;:
M>NMAP>S%>6M7R?HJI+[OT+J+>F  X]I$:A#LV\0INWZ^&?N'C[-5,;+P6]WP
M8X-AO>SA+(48?^37I\@BAM?-G\%/QG]VJ-!-9(CC$2?5:A=9;<4$)'=XS4>G
M>J3:P?X>RFPV_&3_SZED"1;VFM1.G]NOG'6J]ECH4M:8 8&'G@X"5),J=EOI
M5NKNA+2HJ%,?:@6?G[29CMU$EA$+[Q,:ZT6U@O?,^<3<A;M=3-S+3'1(V#BK
M/"N)E:VM[4=-D1ZZ^7CLHGYQ=J7Z;]4BD<57??=DH4KS--6DN'6HV1*]A+^(
MU$3.:FZ(S'JFS?P/>F"AN[)*7T85S;YH/=:[Q&LH)<*B\,JC@I3 M\>,M=_N
MY1G=RTJ >EK">KRM4RPO662DK567^\*)>1-#8[/!C^ ^02.YWE)%9=[%I]\6
M?%F8N=H8RU0N44HN65'TLG<Z-8PJHX=YUE;4QHI;]:HXCSMV5I-56BZ9?!I"
M479R=HRT3$HUIJUW95LX#L@L71DJYQ<%9GOK^X1?-:^L'%0OJ/"K5D^+#X[9
M.5&3HHI3]C6-AP]C,PK@2(O"Q9%-WU>>14"$QCKDT.UO;%>S72,[X*K!@]I_
M^XKRC*N*$F(3D+L'C2>[EE>U? X>=NT/M!0Q'5;7+BZ>T(35])%<E*Y27[RG
MCW6??)-AU9N;81T+T?-3M7XR=RR@-EC\#XO[E9*Q7F#5@J))M$/LK0>]24.*
M5VX==HRUS;<>+;I5U*&RV/="Q39[WCQ/SLCKQ<1R0=%:3U:V!;S-O$-_K<P7
M[G*1E$>>]1@+83;D;%RK^1#CI[9B_*KX2[WC[=O.8V9[,YN=%*MJ0E!T;N?#
MAYZRZ6BV98M77I7-('%,3G)N&P0?^MV?L# I45=!(44.ZU=H)-Q?6[S!0NTF
M;D:,+;#I6LF7C^3<3G@8T.VGT.AD></'&LAH/>QMW!W0-H3IUCY)CE!ZE7?>
MQ"#XD6P,(2C1<882N=I)1J@P+QZ5^_.\G->=1GG+@HIB^D)R-[=(C6*3ZOSI
M_I33Z2>BLQ$LUM2+O(3[&?VW:2BWG9,JJG^_GUU+\S1K,[_YM<C\-4'&]G76
MBX6!(FL;WPNI+[3CXMWL2VSBW5GO+T_DAQ5D#P0]B@_55RTNW1C*6Q^UN"&J
MK5D] 7?^XM@=[!-8,,:H)B0?>"7^8C1]J/3>[PW=+<GGK;@5[U6<DT]92=M(
M=7#P_!,C=;?F(TBB1%XWU)6=S0_%1[@/.7>NA,O>..>X-&+]*:-Z8]Z*'(N6
ML$%KG,R<Z&R^&^(;._*PB-Y-&(/IO))K;/#]WNYW9--E4.IFUWP6^J6T^_GP
M'-/["E+6;1_SDL>BA64]M 2]I2>Z7.JKZ<M7)GSQB;3TXUTN]54OGX])N9LX
M:5J.J;F7MEZCKNZ1.2FJ/D.J)4?J4_5,A\TI!@MDJP;=,^]M8I\0HI^IF+^/
M?>T-R_0N5;3R%K=*N]AYWKK@M??@D*6%HYFRLM*G6=&+A0M21U=J.HCTV1?9
M*[.>NPDF4UM^/(E./;DU^L)-+RFR@X[IJ9I(%YT!*\> CH#ZAS&9CAIW*])N
MG0I:.YH2+':RHGW0MV3F0[_OA*]'1;5[(7UB?*QJ<H+Q.>6R4=GJP9IS%D4E
M:W](*@7RU*B>#LF8;BY%L5 V[!X12)),XW;X!=1";-EUBZ#5ZK KU>7JXP@O
M&;L1KXW0K!B[_/<EB 6Q8YXK6,6KXMS4?)_&HRFR?P>JGUP>%=-/JS9+E]-S
ML;#,['=ZD](_?)KXQ,L]W0OSTNY*?WNETM$.O>>YKZZ\+NP(OX,I/]H-<;.V
M(2B?7BJDVSXH<I;O]V8_LWF G-0S7LE>+;'QEIEDM0F6?.EY_<XNJ_[ME$N[
M-O>2XYPL-6 '&1,3BZ$Y16\7R,@WX46S#O5>&F787JV6E!.>4L\W)#F+Y^E=
M>M=8TF/WY)2<H\P:^PP,??R\V9=+VJ?GAS1S^ HI%NJ3.2/[;IIR]_I^M4N\
MJE ]S&6>37WW1E]&*&D6L<=KA;[/*NEV P<<5>(W]P%>Z'=R8.Q&K+K5Y,2-
M T_@A64*U75AT7?.NAR;/6>B=K''<+K!2/8@?;]]YK)DW?72+E>3(@NC?/>B
M#J9L%"7S0MEMR;J&5*M@2H);S%1LORK^Q+NU=]6'-A,K"SD2-@WF@6[*;7DG
MOVD?/=-6HOQ^H?!*R6Q4Q"7; 'KJ"V_CP[-.\(QD^,1#Y$5JB Z3CFH/RM!'
M%;D@)0?N?4$9]YBRMRC]Q(W'ZNY#I),:IN0P+YEP9V;8RYETV0<KJ=KU74<;
MDIWND!)0R;F'IEI6Y4A#C6^+O9LM3>R&&-?3)^$FV<N:[BFFED75B=QC)QZ[
M2R ';G]49^J>-0GH#CR?^X-<,?9M$_/]E&N(WKW7ZB<KJYZH?N-'\VMV,>ZF
M.UI^>:S8W?)HPD0,6?1@[6S;(G'3)0M&<'%SE[G3Y>.G^*)M^)-)B*\Z7=KM
M6;3'@%-N1"DKGW'$MI3X7CKWRJ,$Q\OF-K'>CU[7YNXMNI2W:*SZZF*;^B!!
M]$QM6)G+_='.B9+E_MC91Z/ZI\><&T[2@YU'4?Y?8?3-.0'T"X%;7M6@ER8T
M'[0+V#X/OW5QC<EF]!U89(Y:XO#GS4EX<5:%%M?#J M3?!*A6-N8#@]1)!MS
MH*.53.X,5V/KI<8LF_7.:YA:U?[1%$K4BOB^[A-RWT@2?5YTW6)IJ3XO\;-)
MS9JGY:6 G[F#OYNIGZPEAX6%W-LH'WLXA_@RSR6=O^U<AKM7GM3]M2W:F2F+
MCQ"<3/SRB76JLPJ.>M%Z_AW\4Z6::?1B/#9H*_U'PX%M$/?"5IJVR\FUI>NU
MT!U8L8:M=4K=GXDHAZM ^'2QM))DYB<+]]W=I*VZ'I_B5H5$LO/=YP;W'!RD
MF^T47UYRL+9;<E-1>?XTX:+=L_===%M+WD5CE+/=[#&2B*]C:RW\VOLS&A;?
MC1_,9MED*.1V3FL&L?(] R8;N!<G_*=$HOB7>0[C&"\@59[,7-T/QWZ6V?@(
M/8*!C@CDOFT820 9;X"9MCI8'$E4G6^3HTDA9[("EK1[-3&JP5-:_2LH?*"@
MT,TGRR=>\S"VE;&?$L[9R8WB7!\N+OZV#=I']=(<G?G(J$HC-'<97C#MPW\T
MDF('R"O"H<O;H"..BZ7Y$Y,+W+IQR4W=J/L8;0^?Z;]_=,F-;+Y 7^,]6,@Y
M0VSL+UL^/+M:7JHA:]=0GSZY<2/BOHW+)0UW&6(0/:)$9ORW\=;[;6A!GY]Z
M2X;UW+*O',1J>%^6?OB5-AY-CY)NW]M0@AA5YH9)/8O3UX_^G4(E4:+A+HL9
M05+/*1O#U649E7DW("D%.T7M'WIGT?J_$I0?U9&HH6^7509?AY<P&_*].F]W
M'<B*<-"6-G(L2[-YZ$RRO[UJ/'.TD_[B3L/?]-X,%?-<UU6-.-OO(U/0Y;B9
M\J=0Z3*!!M\3V$!QR&W80\") OXAMF3Y>_Y%=@]M0HG&.##-T<ZIERNKS5MP
MGFO0C>.[!_KG?D.5H842WGV!;BF4*BY[718AWN5]<'+ONI=E*N-;$?/,NSZ%
MP0#>&2F[0U=#0O9G!B01:I[:6QI]&X4=R H_^657M)E!U-W#QBKH][+!]95>
M)804>]Z-"A7Z&&'LI*BWQ^4''\(+/J/[+U+]YYI]CWY4/VG\U;TIO"BN*\%\
MKK-?7YH0N5=A8*/[O7K=%1E9U(WKON+YW;F&W75CKSQWF:A_NC*18^I@8.B-
M-NUH/FQU](0*:BC5^_:/A3#3NL5W123'FC7?W(N"E?B^1WF+:\5YK^_F>^5-
M)MZNG*T:>C1:JY7&9"G_'M=2ET@XGCF<Q<Q6F7.QES,>NY+3R5VR(3;"[</@
M%LR[O/WD\S1O#])@Z7W<PSVLZN]J%MUFS*&"6E*5B_%D)\.Z]C7B=SAA<."/
M)WU,G](]CN9;&7;D00+9KG909E$_(!*FH2LE*N/WD3SB$$*V"%'36-GE31:3
M,?$Z)7^7?,C@G-;R7;*JF,++QZ_<:=>^AT2=7MP&65-2=--]M&+%C<(LH;;5
MHL&%)N^=0_J]GT\@[1\8)>]H]Y+P$9LYU;G6_+O9\TB[V2/S]O'*5[(OZ1%O
M79=)?0;'[1]7[LSSLGGP*)9R9%:%;4UD64(?2: ZD;9XC9BQ]!&SCNN?D7D_
M,E3L)@8<OD1:VNNWU QK[H>,VB*N[NHZB>S >>X/^K 0+//BWAEFS>#I)-:%
M3]57U UGS^O16PRBW\X'9/M<&_*]>=WOT9VA=;&>"C6N5 Z&# Z<O1SX*#6_
MY<,?57^9T.^.HYQE:W/C<XEGT5E6@Q2G0*,X'_ 7EL&92?EAZ<@L=X/)4Z]*
M?'T)%?U[BLY4#G2/AZ%\-0U^U).0G1>O;8/,)$E@$>3G!::85I;#@!IQ/;._
MR7?N;,Q\ FM%<M)"V7GS2Y'MT5Z2KF7CSN-7SE=1LMY[4PJ[UWA#U!"K?=XJ
M-H73%]O$5<PL=<]0D4>M[%[#"V8_>09:7;#L@-ZKQ4K=S96V34W!L!93;Y<V
MADW:5Y;L*<]?T-$+R+S6&$AZ"M_[>X/>JSC;S)M%NT*S_X;'%>9%4T9L(TRS
MY.WB8SM]GO?2!W@.ME5#.6+%AA*LS+L9P7IQ"'2L5WD <*,NL2SBG8_^O9J_
M:$?(KIBD_><_28NIZCY\H$$:>CFN=U6[Q+DQPB##9@(I]1#N?(0"^[U#Z;GS
M58E# 4RS^>LQ:OEB"H7G*&>YY+I/=1'-R.4.[:_JA8X+W,K.7J_DEW#S$8VI
MPPJZS]L#WBG6)VODW$H6."D]U]7W+[*N#_OLVO_P:Y'6VUMA8;=>S]KTTZX<
M==$9]^B^V.UJM/8M[F;!<&S?[%.;V-04;WQ-2AS)?J:[3U%A:"(>?, @U+=<
M*BK@Y0J"MIHK33&H>*Y5GWUE-E]7IYJ>/9XJE<B<U ][25^[X'??95*UUKWN
MX-7%T)6,W;/Y)44ENI$D]+T^14J#V?UXKH/.=\<&0?;^M;;[=\E#.G&J<0&'
MK@:-7&9QJ:.=WQV6,'3Z=9_I^KB_*=$IXBYX6&3G)8GS5G/('8@..6JV[ZQZ
M*5WY:T)N,/*YZM+XDI%$AG&X25NEDQ,0?/5)LXN-'+9_<G%QPS[).AZ)"I'H
M"#S\IF%M\G._!?BLJYAJC>^[-6/]LXMY[_NYB58-SB]4;0J'9-;OU;YV$SFF
M:E=ZT5@C[]S9N5)KDLLDIEAFQ:#LIIGQP1<J5S2L8U'&:P[!UC94U8+^6->Y
MV,5%;R.%P1+^GW5M<0^GZ\O!VA-)HP;1VM\"LW4L5>X]M66_L:].9Y6A)D4%
M[467N2]))N%ZCHIQ 45=WW361KTFCU<AW1,72N[$(V!>F=C*X4\=ZC]TJQ\^
M^3!Q;.6)"_W*',V\/L5KZLP[71^Z9HR6GY2<B&-?F2^I5,EI:)83GX3>&-8K
M2](N.0\7UUFZT1 94D*HJGGH$?A.*YU#_WG^=LFGTEG+TI()PT\5)>3,\.KL
M.:?3V>A^D]T3P[DA!ID!P[HMG6XUY,;:E)[E=\.FGE0WKI+-E(4&D.BDW$LX
M-OUUT?+SBY#<BT.TCMZT8\UYBPY5J<7* \5.L)2S5H>>'8DO\K_<9KO%G(U2
MR[1\]/ELAGZE=9V94Z$A/!A_ ?:]G#M7 U9:/GI_ +%H ML&/4D5? I2LJ?6
M))27Y1&IG$]2DC:YK7)=EN['@V+]-.S] TXG3A->S3X?65K>C#]WV7WV8Y&_
MG]N1.]_44K+\9P\9^ 6KDKI_>MWS.RT='W'Y>I*77?L,@7_D?+B2<1SWT&#I
M#]GT$:UM$'#&87DC1&W-B7'*V].RAN-1RJJHK;\V..=3^R/;8*Q]!P7AN;?7
M3'-%,?6'& W%R;@U\"/<OS7#2**OY&OR2W1X+W)LOO&VLT9%89/B;'I< 1R:
M?(1ZKV90VX)\JN>5F IXIY8-X>4=Y?YG\\[%;[9B\S5]+G4/V91*61V(?::0
MF>J??RG,]+W6W=H7>F?[; D]EYJS]?X'6V\>E=0:M@][3K/F4*:FEE9.Y=C@
M4&9ZRN,<FIH3IIPR!R D4Q,5Y9QR'DM3<\X1)R05<)84A]+4%,7$$<C* 852
M)$'\Z/N]?_R^]7Y_L%A[+YZ]]_/L^[ZOZV*MY[HAWOS*#.\U!338-.PC!FK1
M8X(M"AIK1I[8+>(KLDQ7&?:MK#T1(/O [)[(J2XC*%&QPQE,9]H."D:&^KTU
MR2&%RL!QOI9_20!5/SOB )X0"Y;-!5>-UD+ ^E.WOKFW-%_L@Z6SVCG.W"A6
M)LTJ+?K/92HQH;Y#CJW52SS!MZ@Q2X3CVH54AE2-]&3?V!-)[+@)JX0 #9^7
M@@TEH36K3C,(A#=XV\$? EO;\*?HIG[,,;.T0<]]O]4S8L?#W-H9<9DPR%\]
M;&L1\+*ZM6C@=M+LD"H!?"SC G(S8X?Q(7Y[("Q[2N=,X=\__RZE:3C@/ZA]
M:$X\KI8YD@ X\3K7==]2A^WR-_D_F\X'O)HZ\:":IYGH$J_*T"(_25FVRS/0
MKQ6/PHQG.HY+: (6+"J7^Z[:LB$FE.W,Q@B[@*X?;AE/DPCHKV;IJ,4LXA%^
M^*+D-)E6A&:3.7&LXO]0#Z-T>T9I.L6D3CCMT\32I'Y[J)W9*>[ZC!<70+^A
MUT>4VKQVG,8WP 3L2*04G;0;HGQBZFR)?4!CVZ-ED$9$KL^BY#[DC28NFGV(
MKH*($")MYAWV1K_GW*&^+B/VP9RPN@6HG+%?$R9 0>_YHPP?);123GD^2.(6
M3#_5^+IGTXT)6+!9]:P#+.#9BI&[G&;SCYJX#)NE1'[+_10IRO/4=T<SCF3X
M[R]_L$ODWPZ5#VE/+%FH-(>KDMML(']/&2Y'^>TSZ+!!/1Z#0UMA%2U2;>%A
MXJ?*AHQL!N8+ BR=*TN.V$ZA%8+0HG>"*^GCV[_@AGFAP*^4L*#S+?@-O'PM
M!J:AH[JV0=39M.?G0PJK'4Y%&.8]G*KTH%)/!H?[5KXE'QVWT6[H((SKO_6L
M4ZR3/0#VJLRU>ROV]JYL,"BJTLN2X9S#.Z"WMKYV %- F2(T2_4]TF4:M.9Y
M/+A\;TXLU]4NMMDSI$C+()6?^F-J<@LN"=Y^,0=1^&$.+G.(@M<:K)? *@.V
M@^<_6UQ*6X>NZ6/@E>L=%Q1_@3L_RWZV7M'(_@%3>Z2?&A1B!'L@?NL&U%(V
M>#CLE&YSJF_X46[Z&G47]W8:=#/HQ-"Y\K"+ATWZLNH##=3LQ^R\(2OBMTZL
M3SC;ZN\.]1OA[M$N7*U29;Q_CSY,V @''[H1V#FE!H-#:]LM;8T<<J\7@>EX
M\F:^3EA_6WJB?JKNR/B42X.<,:8Z[KI8L<SP_0K/F=R'&6#/[6H%TH$71LUY
M:YR>*T?ES97_[3A0O?QV]B8]DH=F^Y7(,%]%T%?VW<%U-#9EZ:PQ W'M=\ET
M.3G6+Z.#6N[U:FF+L_T_WHM:S]6WA.3G>]IA/!9; PRBKGH8EE5^B S8>;43
M YJ^OSGD&7ZFN25MTRH(=K$Y57LI(/#TF(O_O72NG9P+6^R[Z2G")+J]L:V+
M4.R,Q_])LB->UG8;FX,J!<YX :F*L9)@T5S8N<M-L'SM<QCK2&-1Y'BM'=4I
MY11-4[?095C"_<D@FI"R\N"TC7TY[?S(Q;L3]W4CTW'18Y:#TE\**NF,JSPM
M]0)<>A/8N='1GMT.:\E7\)TC9,EFED&>SC]%<X:X@3Z)!^@SP^C:7+RXO;O(
M<]NFC,-E*?[;PV&:RRO>]YZ/=<;(PM2;5 WW1. 3&L??U>^OV/_OP,G]UE*>
M6>9''_KIZ?]Y[H'X8WC]-.*Z._D1-M3A',.SLS7)1N,A@3@5"C"^NJ1P+TQ.
M1%4!@,<M7VC"Y8G-5#_KK409TO+1DTA+BO1G"# U9ENNZTQ'X[-Y\M\X,J;^
MKJ=YZ(W2?+5S-E@%Z[JUCZ@.0]>?:IMQ5\^UO#IOETN8.W#^@JUC]!<P0"W
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MSCH6'E))[*1L13*]#[X=PZ6;'GGP;/1.(5W6K4__FE_&]-F\>;JB^U)>A[]
M]*6_JAENE"_=;O]ILU-I^TXC>4\$BO$65^=0Z S2]A$8Z]N[GY@ZZ9J/@7B=
M'8NUQ]8S71^BV^XU9];=K+"77/R6KBN86=11<6>51VNPLSC$$H]E;XVT,>WR
MM %[UFC"EH[#KD$O4Z(DH#'_.N#68'^X7T=K\X^E2W]_7Y#O.TXBCRS)66),
M#!!CJ<99<Z)9%,UR-6V3,OF>+"]?X\9:X^#'9:<L).ML/CBY8RO>@R>*/%T?
M5U6XID(:7YU94GA2-F0U<Z%]4!QX">>O.$S.K)!MG=/3YEYA*2C_!SJJPKW)
M4/W$=V04BX-1<GZLXM[D4<EI![K#8?#"<8.-8][<LINLC/RYP#T14KJ)DGIX
MAU.>'SK (.'1@TC&A8P^[0YB+Z@!E<*/8KEQP%Q)VFC:,&UC'_(L2V8$3Y\[
MCY0O[IN7Y@JEQ8W_6%_+Z'/73#41;G9MX[C5VI."Z45QE%<'6='QN-?*X]6Q
M7\:AS2OXK^VT:SHXIEVO(145V^%,M^E8?=C1:<@"37L.+#53X3I]RV/97K)C
M3 -H^VMZ<T: 3VK/O(DU<D^D=UY\DJ].W1-)P<QM==Z:(0$[\1LQFX6&/]9[
M?@ N_V3.B\JVR18B?J#\ QH6%J@KAJP9?'DV-0:(^VG[W21=W4 C)F75UH4M
M5:"F/GN171N7HSHWK^ >ZNB2ZJ]Q;4%2GEAGJ5]0<F&(<#=@*JAL;?E30?@_
M&=5>/8W):)F3E%BPY=W9$S[[YUSS*H:=-"&7^(G<?)X$0I+N\!_2I8IORWU9
MHC$ EZ-Z<%41"S;C?!?6SUL=F3W;@\CKNLDL[%_LK_DLSHJB\@%S6,E)@_SO
MFPUJ?2.5\GAYUYL[N:RA_IVP?TUNT.#/*-2"H&7!P:<L(FEC+0KDQC8LCA36
M-MD=B5Q8'?<9+,)SV-9#I0CJ1\'74F+TTZ:HY<U^EC^&KX7> 'FQOB4@/1<!
MA]Y%2[3A)_'?0SRT'YG8!$7605S_U5DOEFC6H@[<5YTW%Y?]:@-;PZBTZ(7K
M9;]P*UVAUF=6? ?V4E$Q.*\K VX$A7_&=1?'G1VZBL2][^O4XQ_I?/&Z;M&1
M IR+;R _PO@UOR"=;K/R^QO_E70LB73+FRQGWY9JC(BW/8XQ.D^_R*YK#0DJ
M<1-W^TQ& %^^H7G9/BM?MJU3CNRA0>Q-7KO9/\FL8"I4R,D[U2U'KC,IJ9#
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M[>E0XE UU&3)VG1[.PO\WG.P0'OTC%(F.^?.6Q:<-*V:[D(VN58_'TXU2$^
MZQC<L!P?\NAJCN>Y1FH]F ^='/[X-#48!M.206"\[5Z<M?'8$S$C/L0F*^F.
M1:MR\;H;*FP;]J%T$[-RI"69,:FK#U!Y9YR3@-TZ'#*T>U9&&L .!KN=N5EU
MVOA@NLWXN63'"?P9W;/_K0G( J,<ND,"WQEB<JOHL%-Z"<(!8!S[Q7B)DWNZ
MO-E0[N>RPXW^')^ZS]R$N<^SWGA<L^6(P]M;[0\MX;:5AB%OQPG'2PL:CE4X
MB,<[EXB.]Y)#'QL\KKD3:_.IWWR:?G'9BFHOTSD@/W@A'+I_Q<<I"]$6A&:N
M/- T< KB/$FY)(4%CURJCL_/4L@[KP:PZ2;E%EW8$]G?ZV4(XFJYI>$];4(^
MA)I)H;I-.^RPB$: G&N.T[@O.[J$9XLT@SW]Z=#4FG1]5-R\QD$!,DJ#-JGF
MZ6__M#@:-\S,,JNJ$7@0%[/:Q#G)OS>8L&4HU15=.=7<>,&1&3K,W_%GH%#+
MV_]0ID9VFRH7>^8%Y&(^YM5^M]R -86?]7HL:WXN?<7O[;N6H4-QKU2<+F4I
M/%FJR:@J*"UX]<K);CYP<,JQ,:<C=RA7XU2TIDZ_O4&%8G>S;%EI$VSA[\PP
M_ 942Z6,Q5S(>LRIB[;[K_7&_JHC?*/*FUN:S]J!/ZJ^(,IM[M 8H:&F*>7'
MN ^?7$_3(F/0=E7GBLS:-0_N^[3I:[KRKGK[8%N:BG1?\0^]A3V1&:P@>\8M
M]_\8!RUW:>^)O(S>$Q',H38)U([!430=]1(+VB=@FNWL[(ELYOT3*AME)LU/
M_9^O)YS_^\B8"%W:^6-LYO_V%G*7G2..;M=&2\1_1V6ZG;8O-OMTI/)[-'%,
M2R*Z;,4LC_)E3G)J1^W^Z$24U4_@G;F=Z*JCGO6IFV8?H/_C(]26_/\]7 [9
M$SF^^\<R-UIW0.]_&0O]^7^LB!989O.3*.; +R]*"W8;V/5V3V1\\5 4Z"1"
M4>"DS'/<$YE^'=V-VNDP6RS;XD0A[R_"?UFCF%9[(G[W>0?V1%98>R+/TJ=>
M2L8U[T:"=IZ^[$L2F'KNB=S'FVUYI9MJ[):;+19$N#'%>#<1R8SF=+-_BJ?]
MZ?XI>R($''=3,J'KMZM-@F"J6'QKU_\6Z]%+=X3BW2E3):XD!SB!/$8;_B>
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M7^/M;JQP;4^:_,'R80#03$G6U%][(O')@LE&X6(;L>,&>HV_)3&1H-U:HS6
M.KXN'+@GDK!5NR?"M=K:M7-AM>\VK34&I/O"P;!#+_A.P@?U RLK1*LBOM&_
M]1*YZJBU2W2]!-!QE1>((5"Z0%22YQK@<[<]S].FWJ V2H54W&#_LB2@2Z,M
M;U!>S\3MS7*>?R)<R8[2.EEAG/8FD!CR_8WDB)XHTGBW"GF,[4DWZ]\3$1,,
M[(DT2N2RS>GSR8O%DLB;;#.^T3>F7.2>R)&#Z:R5_@T "U;,T2WC'?;B1MH*
M!AJ[VN*9"NJ9E7,0)7ANS6B4IM6Y\/@THJ]#DC KUU$!R43%:!*J40(?Q',#
M$R4VT],;4:0^,PC&2" ]=YUFT49%_+G@E\D[[JX12WRK,^;S$RG;=:KX;O\N
MQ,OB@\].#GU4#N'\SEN1@O1E%$MS([N+I%A+,51T M*%/@P%L#;B-D]?GMT7
M5+5J_+4AV+]B^:G4GT>G<J;N>/8>UCOW'-CVM R]LA.5ABE?\%C)<ZWVAU4M
MYQ45!A]8+ZY:WGZK-ERXE;K4- 0+\P^#:8?)3AG^L-G/LL[HW5"LE9(<%DZ"
MK[Y;WG&??641VZ]\3#"@W"A1QE;DA.'8ONG="\=0I'<HL*(#UYR)#*9][]"B
MOR8V:J/NVWF)]2I3\XX><X>S[7,Q'WR;F<!@JG?3/>4"'=1BX<7/_$C";N4:
M:C$/]!:6TQ^I=Z*/D>QPW$,PC\)U5B;"&"?U#J(ED\YPP^$\"2O6O$Z$CHN;
M>[J+P^'D/LI="/U^]1\A9F[%C(&>UX+KYCQ]LZ0&-H%!>T14N"_4^<J)0OT2
M]YA;8B*OEXBBJ2A<8V4PV5KU^;LIU!^KS&*"[JM'?[0I$=:JZM8>5U6\7BS0
M?&;S;G^!"$*D^.9?RB^5\7IKS]F2G D'T72J/^?@;K*I^CV$!N\F4J_:B'_B
M$">?%=U<WEUS4O%.8[HW2W+M&@T&80#:,JA'%NPZB*WDV(]V3[)K@W(E-'I!
MGX-[03)=![C2' @;RY=&<V3:N2JL(5?C[7\[Q$L$\\JX^.=G6",-9R:&OY:A
M5Z/%=F/Y-^APW,KXJG$%I6-;86*!]6+!>QA5+WYK&]8C*$ >Y3)9M9Q77-\W
M2!^N%KV8"S!5Y)8RO/"?.JQVX^EF$E%MJ*/<YW=9A&9ECE6R?JJ8-X$GVUX&
M<;V.U6\/:>4943$*]!%H9&+4DW_-CN!&N>JZR:5\8#RC*%W("\9W$_2Q2;)=
MAJSM7JCRL64BRU&92NE?N,W&QF[MFO7NF+:7<P-G.+K)/6VW/]0O9^=08PGY
MI<#/4'^FZ\Y<?1FX"B+E%7EJH=&L=S7Y=# @GR.W^\)[J+<8UZ%,D,5+\DU
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M<?C(!2U/5E?1LWZH%B4(6O49\.0/>O$Q,S_E9)!L]%7DA=TRP;GH'E"#?Z)
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MZ?E8?9CA+YR#Z'*;/@50C2CK+;/\I+_KX#)F8A9>U8U=;3/-1?[Q8ZI?641
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MFQ'B%BTV8;?R!\Z/+5&C1MZJQKV'G2,TX2V+7?'_[I9R>EQ?>\H?TXBCTDK
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M:0"^8V4&;NH488,>!](R^A[I#@_/S>T,!6;,+KNY.A_IJ H\<_E#^/X[P&G
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MD;D!+H,0L?R-2?_]GJ'-4,D07=]64Z42W\'[0!VL_/+6$I[@B1<?TEB_&-V
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MB@4(S'6F,ZK1);-K6-?/3&^2KD%GNLZ^39'V\7%\X&X01%L4<"=(:>CN"YD
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M8MK2^RB),6W'@ZT:(O;Z_.-I XL+5=W2X2["8QQ!G3;I5MR8GBQ;C#;>BUU
M&H!&*U1\J<;&.!ICL.H:<Y1EQ53MRCG!^3M <YZ7VG.DW2ZTM> .TK?9(-I@
MS_YDWW:\_KD6)?H%"K8]FFU1?,02YW^+\YX)_7K(Q<>VI4?L_9LM1WQ,B\A:
M&!%!2)_B2/R4.C_J&R\#8J9EF6_8H;?^CN'B('ZKD-P75^-"99@6CN,<8/ _
MX6SK0ZZ33&?.=[&ZU/R 6J?O+9J'7-Q';]BV/AT5@Y$2(Z"P:KHJ?1]$"V(&
M>\1"XNMJ'\/M" ,,[J?WTS(/DM6K2 H+.;US3-G$!+8AZQ&'*"U*/>1"Z;_-
M$?&#QATE'@<8L*]_(5B=4$#3_S=$O)<C@(KD"#EK$/3/PU^"PX>*&>U16\!=
M*#\S8GTXZ,# YI=?O(OVR-KPT0V;MW&S[Q[DM^D'_WU4L?^P]5L.L/HPB[_6
MT3C['HOIR$YI83UYIC8%TZC0/<+/=.]LVDX$^F:8)?(SLZ%\A1.%^;!T-;#^
M.WR6RZ!M,\T)R;,=*3RP/C!6/-#.?\CE83%]?GC]%P-,1,-Y2=J]4D<-.<LY
M=!I]#E<E,,.9FCM_R/44&B=UD[;:J00-P\R=G^O5Q[OWM$HYG^J=%#O.T:2;
M%Y:Q;]7WUE=.S<9N( #:#[[[9F"E6:BJUV@$FJG@WL5+VN@CGV:6E[,?'12V
MG6";TJ3#=U''86T:!QEMRHD132OY"SSNEHGV1^5?);<=V6()D\\F%2!>K9KC
MB,!M60>9L4H4=A/'1')IJS 5BM^P@V@;#&WFY2/M%:,ONHLBG:)(]D5(=^M=
M9Q:7!8,:F5U2C94!:9:M$]O*.(NH-&\G$,6"AQE29126ZQQ2R9#[0LR+(>^L
MS%[YT/;]EVX[E(,/T-^<8FFQU0]2VG@"C.?=.R'.SXZ(DM?9#H)(Y-_0=+E,
MEZHN1^P?Y654L$'5QO[0#T>5W1 ?YW%U'O/=A0A"KR@P=+#HQP_8=_!4QU;*
M7PJ?J/N'7+LE_S.\L2&7R4I0:/L!7&<$-7G(A;4<_4<@,'NNZI +G*@ZO7M$
M4C:^#X]G_P^4YW]C'*#WQR6/X"*"_8390V<QN@\^HV$@HT,N1FH#4VX!]=:;
M;5K'#**MS%%<L#2:Q^+"1$'ZL\0*.,DNXTQ" -!YM8EN'%V<OFJ/&RO* -6F
MSX$B!BZBH>WS*3DX=(\T297QC)FS,!=+>LTLI52]XZA,MDE,!W3XW8RG2W?]
M^LGG K/;:Y.?XAI35[F)&+K%S.W63$M7[XTN7<]^63;9E,K)H1Z1Q/$(YBG6
M/VP;^JD>JD(OFH]S/B"C[ZX?,]F=MK]AFGB'7@Y54W!H;R"J5#S5$"MJJP[,
MOA3@GF,RX<>EGG$@'.(28K5GS2IFO#C(U!/F#,QQXZK>M9]1B_X]=QZV9_\J
M:Y>1_Z*>M!>U.VLPR/D^R;Y3$O59A)1%N(-\7O'^#L+],<RMV $"_N$X#>G9
M_5.)2*'4I#L\5U>R-^/9+ T!"W(*-S]C9 YR$8YV_F"-533,&N-E<M2=,-T6
MTF)T;E,2W+N=##^Q'F3G4TY]>@;=.*ETW>E1[3GK\B2Y)!O/[(<[,9XW]_)!
MCW4SO]R21H97:<728AFJ!Y%]72HD_P7>A#XV7Q='-);#W\XW2T9W_CGDBDS/
MB=>G8=E#W':X__Z9'.Y\R'4&><C%EI>&L2P8Q@S_'ZL[:%SHW)>01.\#Z!',
M33+;6;KLVP?1>E>8KI1"<OAC.H)2_U8',C_W^N9<@)(#_7R]/S:DO=.>#"3\
MUK^PEBTQCF6+2FZEG<\D%>S752UL\("U@Q O&YJ3IJXD,M)C_AS;__+'G7&7
MR:)U,1(//G*DV"9,<4H*/2T<O2 8UEG7-)8N':.C*\V6Y? 1<[_[#9XBMH#R
M/5Y-#&F#:]-'*_._L-1)O>[$2N"C@"+4O[SA]NW5.H=<-".+J7*S@T8.D#FR
M<#Y1H6\[5E,C5+:&UEM//\\.#O[>=B/8:7+KJ#^59-].7)CK07,S)\T1]_U,
M=GG/!S^B2=46SL*VCUDP 'Z_!W^VEX'__&*$'*2S3[#42,%6A#8)N-XU-&^P
M-;-]425>,U1L<I?GYB&7(<T_NN45P]Y%GJ##(X2)+W*!N0BUC"/E)W()?F:S
MG@C044<!)G&T37)K7Q^C379)TVQ'WA[EIK[KK#$E)YJCP!8]J*&VB08C"*$\
MH=_T-&B:FW.+.5,LSA$ "L.AYW8E[Q+MF.4+TGP!&H,/:-P_P<=)/R?]YEZ'
MBK<G;'?6$WZV2=$:Q_S$L?*\%VEZN4=C#])5-GFP4.8D \><#"QRX4PUH:BG
M6(:A8]":[<Z1F+GS&0OM5#,*5L:1;AQ9Y6LF+1!\<8)M.3\2J2$P-<7TZ6B:
MBV1+^@6*1">\"0I$?X:#A[Z]0-NE/#SU"\"Z078^ OT8-HK>SDA@+K(<-]I.
M,_E9EL$&K0>OVW0V#+I46 _9CVB\"<$2>A>9D,Y]X7 ZJB/TYFBHW+KT13=Z
M=N/\]MGV^)8;95 7*&*G,M5_@5OWI.#HA07_6,Z-T'\/N<1U^.<!UIV'7*?2
M*.@8'6Z6-/-4%_H<VTTE+MB5+FW'5%],C'F5V'4:_2QG*KFO?S%>N)-,9+C2
MAE-Y>U3BVY2KF7YTJ3Z*?K?%A8TV%;J@U%G:0,!=@/X^/.^UOAS:342:MHMB
M7O,:/5)A3W+.A?;J3W-,T%\210^Y.FOHP.W=L*.*UA+YT3;%T)^E\H74'B@@
M0^O_-R:V^3(OL-0"1!CH2;W; ?E=8NVQ+284%.D"9:66GD@YV;X(.9"V_$^?
MX'7U+0B^VSP>! _2^3<\.6$ZBH6P+S"R"*%R84QE$U#0(/*J+5>YU_*W[O\_
M"/[?0%Z^U#X=R_!,9N ./K7)! M^&=O$J?!OU.V[5,T?N%M=R-+HZPD5'7^^
M.R2IKH&/H5 D56R#;OOJ6NV0"?LK7>;CP"KJ<Y0G-K<N;>.L$EAH_7'Y:+=E
M&@ L]!B<69%5;&[JA=05:[*W,*K,CONEVI*C0I'(4?OJ ]9W&%3-;!=-7?RI
M:)I1'M;W>/UQ-5_\?74M']\RLZ0""7?SX-IW*7GI'*E#+O@LE#'.=,L-5C_(
M:G^N+QAL.=IRN=@).H1V5>G!T'<GNZ'<!I1XC9T1>V?^%M?2-:VR ">("6J^
M?-9_4_AA/WS_E04RL&AFV@"U8-^-)@&A)/'%JB[4CR3I.+)H+ 4[UZV4I3^/
M/9(8H1+,X@ZMNGRYPM[\$DDM?<$U,>>16#UI$\GA#ZYEN"XHE!>F*=+44YDF
MJ E#[H<= 5W$P2?.;0OZ2 <4;]&5&(XYY))@BR)H$\2%[6BV(GHAHTJJ;T'2
MS&S"CS4(,MKH%!;H*0-]7G_)D6499N<6&_@C\S?LQ+"]>$ ,7,NA>0'MROL.
M*H:&H9E7\SF35L%\8YQ3[(NTQ 3.M0"*I(\=S6_D]>[V19-%?:9I_O??60]F
MG<U48EMLO<F7HUL@96M&BW?K:G%C5/?L,WAN;L3(..Q9 &RING<@&SJXJ^P,
M'R/&72^_SDA9O_N.EI!??@T/[[W&F_-)-DO;.LF"/?R-K4U1EHY-7I#0TTZ0
ML].!=DZ9VWX<RX?R=]L&2#ZJ#E!V\0NG1#T2MC<&#+ZX%3-^0PUS9N&@]D4?
MZP%2U 9ZCVG!.?-G,2<"33,_Y(J5/A^J$CKL%3J3(QJJ&6Q!V^Z1CIH[]N3@
M\S(3Z#?-9-]9^+.YT,Q<D.-\BK?OU'_20B]J]$Z/^\Y,A.18CB)1?I#;@"I@
MJS'GC"M+-?&UGA*SO827*<_+UF9Q!"QX ^Q&. +23*0%$][.=-2?VL=4Z3,T
M&18,1NU1.^3/ECGD@K'\&0E?]?%'[#34RND+/_B8UP[HH90M>JE7V\XX@W_Y
MI%U;?CMZM9=_$L,78QG3C+,"M8[\S@AGHI07SDL/-"#DPSW<&O4$;CFI=MOZ
MT=61BC;E4=T3<+W)"S%55I4R_)9&_%FO\'(7[P(,T5?;:8ZH>#'S<KI[#_0D
M6YMN;#_.OL.;T'8*0:IG7_"W/X@/-K*@AE4Q$7;?M_.8\06A1,YQXB+=KO8S
MF6FK''Q#*+X]"NGY04\"'BI9]T[M(7AHO_PHS3 M]!-S;('VQ0,2#)P0YN.W
ML/UN4@\PZIOQ"8B7%._Z=40P@2IQO@W 3=<(T@I VPS!,F-%4V+OIX$B=B _
M"#T%EON#+E[TL 7[L+;;;"5F.,V'(I1"BGP;*L\T<*;91V.111!$5P$SS"+'
MHC&]<RWO$U)=R?"C\UK],]'0_I 3K7VIEV-AJ[J+M%.<L[-5H8,<(?ID9.B5
MF5#"7)W_YAS+D<09'&6Z,IRD:YWKHRN"+] I 'OGL=W64PM+K[;?MO"4*43+
MHR^2 KSU!0.>L2@J;WW?%*^W\;6^49%-4K0?^L]Y)@<WTC5W/+0_YXM&+,L)
MNL81/FC8S;)FJ#$;Z0_6H3QX#'V0>>S?T)L@=\H)1CU%Y5S U34M#\+NT5E0
M*V;@R7Q8"+)J!F[I019-LK-4^)U/J_]7(^=LFQCSU (FIXJ9W*.%[IH[Q?3O
M>(6.:G'U+X8RJ\!$MFH!Z>>$5F14%2Y>R8"(\LN(A=R"/FRN):C]]/1\D RH
M,!R8#/Q'.E(:+Q(9>HY#:)-EJM+M&1!Z7[P.E)[!Z"#J\3)S_B4+X!J(OU'O
M]"[1+#9_43)&HJ3^/BC4TV*B>D-/6L3J2="D_XT/@CH;31O05*+UQ.#M@L'.
M94S7A:):9&E7Y9S3&EF7I<B^?Y"K/F31V_YE^]_V&#3/D0 E;2TRWM-%8D.!
M4\& 9 J:*DX+HVAVYB1F\]*.&$/D*-&I,A3>1#ST3#"(KDF-SH4BLJ]^1^.#
M16@I >@'8YMS'2^8:5UZHH1LE9]Y,5QL,E.&=1O=\4^;6#"(MIV@IX/NL'C"
MI--RNN@;_BXJ3'O]37>:_H*LE!P^K6L?6_@N.?@NK;+=OY+I#3AEWT!D&\O6
M/=0B%[TGN4V9:4]'BRPDOK4_Y,*=HNH6'7)U_-,^7ZC/]5O<0B38X3^7E7P&
MY*C5"X;YIT]\*%ICM)]L$V7&+-YOI6,R BE'A\[_K!-@_J(H:Z4EQ&R0\!4O
MX&1)I.Z2EN^HH<_!<<M_I+]"-V$T[=Y5Q@ SG"7+^9Y3W;/][]Q? ;6<,ST(
MVC;C=6OC07&H)'.RNPD5H4#OBPEV+N<00B_3^\*I5\*Z7:XR\^E:9H-(BWMU
MV9"1LTZS/"B;I-7.E]S%O(BQ]KHV202'ZZ"B(MBG8) F33E%!93#I;E#;X5.
M8<#^42V7L0&31DR5BI]-]M1J.K13^BR>=ZIO83<^H3F/K42;ZU"94C&#5!T?
M>5S$K'W(["J#,-/ZLK5I*UGN!_=&_Y$.(ZLPRRE5\4<!FF/SI2V>BF)?/H(H
MZ1[]Z%"Q@]P6!*7J](^Z J/8A6T^SHB673X%\M+9_#0P]WMA<XY9\Y>ZB7RM
M^"H2 )D$B66Z9UN0H?_#[O;#Z9&;H_/.4,9GVC;5M1S. 8ZU70K07Y"JI?ET
MZDDTMX]._ZLG-AIL3%%"\S%CNYO,D]+/O5IR49T8RBJ*+X'7,I,H';^5 C9S
M"9=3^GT/N0R^_W_+A47IZ:%?1^W^#'KH?ZU=MH!:,*_Z;S:%Z)9OEC'[&#N'
M7$G2\RB6SC93@9?3HLEPQEX]4J-I!\&1G)0$Y4&.X8]#+M;?/>BUF$B2R_][
M%J%/I/]?4H:#E*9!PW*82E#J$_3FNZ/3U-CB57WP@_],15CH 7 [0IJ5J[\_
MI']R@TYN%QY"+\$^H7^$JAYR65V3_OG?0NS^"QU'/:C9BT,N3MF+-X:"]G_M
M7H:.^K/%CUZ1PBH=Q1D2Z6O?;PS]:_)7_O]Y/_8#^NNBRB'7ERC. Z:T8/O2
MG!?T(.8H1L4PZ1^1U""628 UX^Y!9NA5SBA9Z[]/7D'SV^'[NA%5% MNMC;!
M=Q;5X]]DE%^Y!CY!G2W*J8"G S&DT$3A"K^LT)5#+FL<_LMWM0/S?7NWNAOM
MOV"Y_U68_GQ:-K"-J*?,1'!.*[+N!&0O.J=+"__D:']OG\^!'L-GZ,)7&!94
M;K0@C-2;4^ZT1LH:FNV*-^5Y>13J;&J:90*U\N4(=,(%GP]SN3*ZB^+=J!-.
MKXRN7$O;UZ@NG.N0'$HH+(2_K)F""XM@B$H]7K! F,[$'I\I5N++5WI33?6I
MCG8W_2GT0O&F%\V@<ZYVM>,/V^:HF(-%_"GB.3PD9I>+GLRX[]=@LZIU/;DV
MXN.Q](FA]EK KJ[=+HYE?88E*Q E-&7IQ>+GO$KB#+1+X;9)[O/&;SBJ:_K<
M;0IL$2+;IHF*K^^"QF4+A77H\['5I2-:C,L#G)],L%61(24=10:A:H_+?@Y*
M3E?L2S*R?(4O:Z;D9.O3#.+0797H9RI[;>KN]>P9E9Z8@Y2JWG;FY5Y>ML J
MP_6X.X!>7G60J=D3T^!YH&]SCW'4YW[:V^Y> ^#->@C**EM(]4,N7@^QM!C/
MW-JDB9-C:I'<'DT@:O?/9Q$39J_3/WL4)<P-?ZE/8"BE-,;<H( ]RT]S1F@'
MU=G;]K4 =?;>1!H=3/;PF1KR0?C!RN6:')PWKG,KKC3@[[UY5'>M-MP[KRVE
MC6:(7VE=#/%<OU7YB&[_#@<Z@;T<%+5-<CZ]_NN<$^K,<4U0D+O$BW\%=>IZ
M(7D+X_:K(IK5:QK[MF.D\()LJ7&!_J):;KU<6?\]3'U\(?SZQ6*'E;HQ\)[)
M.'!>SZGN)>5IDH 3[_>;ICB%\'VLJ&EHS\*R_,SC?NL+=ZVP@ M9#M8]YC8R
M)E=-ZL]^*%L4,9>P%6QLK&M"C!OVR 6QL#V*&M-0P><9S1^OCU(F\1=_LT!6
M/*!'K4& \Q<I$^K:TU6U:TEGVHA!L/SU.UA*_=,<JAW!Q+,&@O-6>UR49C:*
M:PYY -O7#^_6<JN*I-2"[!RGELUL,0M(W"W 4WO,2N\Q1E_0F]N@VU8$T8>&
M/IZ=E5GNA3\,U5Z2LK:CKA!6FIN<KRA-A]BA?Z]^"$\&&PF;13T'4E?%9#6M
M>AG SM.2CZ/O>J[%!M3[+R^(A:8)5D/6ZCZ]6[GXY&X]V/L?&=8U\H.7,PY.
M2O69A9_(HG=YS0LR7:V3?)C(0--"=:6@6U;F*>XB6BEK4ST0##'=.]TNL# 4
M4H G])M.-ZI1\Y*)(<]QH#7YVI(-C.:-]7U@SLE2KB]F(0:FB%+E;:D#Y,3
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MXR2AE8#D;JI0($IP8!$E!8<0E$2'F89+J<%4%H9Y=X!I9\CTZ,0DY@D#[D7
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M7TW_-"I/,S&/GJ1PR]T"PKG*D?79 Q)41Z"$J;74/2\.@-E/@GE[J6 Q%NP
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M56/<LNT;:H/GA8[>J&N>=S)Z^G98)J+7RH]HVNR('1!2'OQFX2#SR2BRAST
M+^DY>DQE S4Q81?7_6>D\M.[;G I1I](ZY_.&Q4)V.^?($C4U+SB ,]ESJ$&
M?SH5 %QLBT.<1&OMRS6;FC$?U>=1+=O&BYEJ)DCE(IE^?7&CH]"$[7[\%>T^
M2<\>-@K=]US3Y"B5< !:[ZMX<C6/9<_5W;_\RB36>T#G^/Q@F$M-R.1IXQ#E
MFY8%IQ/NF?J;"-Q;_?5SS">,%7C+74/>Y)V997SBYE&*)8)J8<E*\LF5(["@
M4&61]='$+"/L9(A*(L$M=<_LVU](F;:QO'.XJ$P6TF>LY]@^&C6=8 4G#PM;
MWK]2URCT9<"3U!;L%IDZ\(3W^ZO0^]_)]*<I5Y/Z(75>61%OO41'U<P>- =^
M0P;QS6[K5L1>3E\X:W ^T: CC__B?ETU=YI:<\7>N<N7[80>O %_N3"A2AMI
MU]O7BMNCK6-3;5),[I0 K5Y6\X0OH;WOO%/,RTTN$@+>?*XU"LB?&69=&=]1
M5K4SI[2P0N)FG#2)<$35H0;T+44\CU6HT)?"%WFA90GC 4W"G[:=.\HH/;KU
M<3H ^8>B'B4;>[ZWRLG&0(P1>K/=WC@M,-NR;.E4OT7N 2CHG*R\5Z'T;QPR
MQ(<0MFF=/>*9ZDMH)M:-<\"GM5O6KGU&^:GJ:.G%>GBX8@T\!)REMH80[VWY
M+TNCUMON?322G)G[W-#/&AI2]*P)55-)S]GVK")F5*E_QC;5AW3-U=1GTB=Y
MX4^K)Z6,%9Q3D2!B\"AUR/_"G:G?J6'AA6@*M39;H#PXGM7&R4"6UH\%HNH\
M61@IM/"\ON2K53])A5^!YW0<6-F5L>I+LN^\D46>E%\+[JC:V&^K/B0D=:IS
M_5HFB\CYM\1\]N_"I:7ASO([)GK*\5>"<5%7%%+^[C%*^@O\W?THW 5W#/)T
M[;&'67_.G'Q'IU-MG26A?"(U,KO\',7/V,O2+^V=J5%/NT,EQ>2=ADRH'C'-
M>V;7L1GP3KG/PND_R&,_;&[_U]P5YV7J7F$8Y%%E\&S/@)6J@S9H>/OBK\;K
MK[^?]&BHB>J_#QE1M;3)O:(WN##C?+NG@=(Q1D XOS 7 LQ-R(&_<=XNO!*5
M Q>1*B4-)M%/,TR[ FA?TW-UQA6%W_;FG_2"- 2MNX;H%7@<5@CWBQ6<^,+*
MH0\IUJ<:=5*Y=;TJ]4MS*UHQ<3]^BG(L94C4CIAQ/.^6B8C UU&,3_ZT?@=&
M$*=CZLHV0P_K*8P0^/F<//=:X]EF^^=&JW2N2]N==8'._:0<;;_,]JE3WOFL
M(^;BJON]N3$@_5%Z8>*3INO_.MQ-4DF\8*IS.T\R%"J<QDDML,WEF>@V]>O?
M@6\9V"2NCAAG=5OG6!DS4E)+*7[UN26RSRDM"5;-+4ABJ/SM1NGAEL#-(\&N
M^J/U[,UCI:EP[-4*)6S<9_<<ZJQS_XB7W_S:M>RU[):R;T3;.R$_E(0<<0E^
MCG__C$T+**A:H;B)B4[L[MF\J;_F??^;]EN3B69^:;;Y#'+^JJ-&U#=UOC.,
MGR/7?+_MR=(C#QOC 6@4^4M7<Y)%XKPY$?F+F&W1_'4#XYD<L56X)C:Y6>XR
M?$%+ZL86O:JD,<]!K^][99]?Y8TW5=;.X_]U&8V ?]>K#D#>J&D=0V1 YD-]
M?KH XY]Z/^G%18B<X9*,^WUW:\^W:.M3PGS__$'3U[)(@S>/UP@F7>K/4VB)
M*Q?W3ZJKA/<;MWK<*B=:!OU CJ'2#=V-*/L5BNFR(G7HU=J1T :H@TI\*+4+
MX\.GTJ?/289X/^:+6Q$U8NMPO]I:P">N%T//-;8#_HLS]4VC.VQ+IF-59N:-
M>SXGTOY1? V>GI %7^%V96@/H+]0ZU*5210E:4"+D;0QP?JQ85]49Z\G$1S>
M .M "F=68@ETPERAR;,:1T[V^N;IS9/$>YLD;_R,&NMO)FD]F_W TT6$4TKR
MX/@[,<76Z4RB(6,Y>H>4D']FX]<< CK&O0 4/2"KYT+NU#&5FA-_5%; =''M
MJ5A]I,RO=7+'44V<^HI0</3Z9_9#].<LN_54!KA3ZN(A5SRU#V%Z4^OR.TG\
M0&-^PCRHEGD\%A?L3\-$[CQV#W^D,?U+]XH]T5&&V$I6"4CU]R@W",'..W((
M/C04@M^<+[ZG:\T&IQW\PL^/]<&H<<(BS>.D"<5T"WM+SJC?,@%>G#.V)#51
MP@-Q%X'/:_>:X@/]&@EN6<\C*41%E'4.;$:;^\^D]GB$;3,+7TQ(G[4;F><)
M"'_@E?6WGSDDIEY.R2=GWNAQ_'V\J@]43-/HL@M\B"BH$U]9XO6U#WZ\Z.CW
MMT_BC5]II?R8N.4:Y_CV&*XTT_="RF"0A^ E5]^;68X7_Y4#Q:*?8BA4EE72
MC-D;[GA^79RI1YG#2E"04)@- *\R#WSOY#@[Y57NA?PU(-%R"S6"=$MA.(;'
M\<0;!C[YN77#;15&2%['EDEJNG%*2!ZYMVU& [/O)=* 84:SY[K;F "=:EO7
M9"Y$R,.RE*]E\PZ47Q:3?69U02"LAOE$-CJA#=N />,@8ZKJKM#O5'TM4]?K
M;<ZE6QWCSXQ&XG(YDYZ28[/%39+?2XHW9<PFX^%E=[;U[,[Y:PV'[ANOL_4[
MT9),GT0:!^8PNI.MZS,:?D\BT?IGD-_LO-.:>'>J>5 U_TG#0-V-7.]NQW>+
MA)3[%/C):^<$0Z<NDU60B\TUK58LQ^RHYI30^XN:$QDW_DYU<OG=->3H)D;D
M<<TP$K41NT&_%_NOZ.\_R:QZ3L;1O>&8?%8[<*41;NKU=25?M%WL9[M,O/TH
MFJPNMJ=1E:="( =*Z!KW/Z^9]@W>UBLX5A^O;EL]DO>Z"TPP7T<]UIW+R2?P
MK[.#7"N[B96^U?M!@$=@2/',YZ-HLYR4N> L1T^/V"4A<W<PA3O\?$LI2*BP
MMPL%-T:MB?BJEYRT+BWO,)KK?YA6X2][RV^B2W/T^5Y]6LFG)3E**6KN1X1=
M6__O$D*1E,$YZM\T"T7BQGAK8'Q">OLK<JL!7V1[5/1?2;=4"(X#BI&C$^-V
M1BEKMNWW;6T)K4V$/$?YQYI[,5$;(1,6RCL-C'=A::EVM0UZEQJ2S<94U@-_
M+X;K6\6J7&5K%G=(F!*3-CK<XSX9>DMG! NT-KDUWGE^);VU#ZSL!6N87 \2
MGM@5/0"!VWF<>$V?ZVJ;F$(6@[K4W)$:2W-"BW:$%J941B;3Z$+&)#0)6V(4
MXHL,SU!4Z[FFW8RE/V9?_<1Z49)/=V!K&_KK)4LF3%P/<P$,+C3L/CMO/Z^Q
MM5;ZLW@^],CC$'^-G >\,S-7WH5U-EQ]'745I_TU E'^N2(PQR9@S3+04]6#
M+HZXUU1>=OO6W=H<UUMGXZV*3BKV*QO.QZ5B58S\3+<;*Z&?*4[]J\PZ>.A=
M(Y'!TDQ$2?"P97N[":!A'UCI#+F;H>MA+%97U7QL/*OGJ7+KOT^33E8O(G3A
MQ0E.GQ*21DQF9_5U$*@+XB7SV2'N.G8-;SH?)"R$X1'E^I>_>-2_DQ&JX<&=
MZO[;4O_J4["< WH24QN5ZX^V8[WGY%_H5%_K""")M@L5KF;A9C-&YJDAHNTR
MB6Y9IC%[91C9:[$\<-%S-./F:+H[6WZ6DW43<JB+VCGM4Z?S*6#Q_6.N1RIF
MLSO\Z/RQL\43J7_C/-Y=3.S\.\F^?USU_*G QW*A&J;CF77QV)<V\-%6!3Q<
MVSA7N]HN 37 4Q%$K&LGKH\M+"[#Y60UL0Z=_HATBEH+%J$KD?Y]5[6<P&N$
M]]EP)X\LG1G@002\93G-OI;IF7UV,^5+KQ:N_]/;%F/NDP>U1+[/%,<5J$J=
M5+84+KB9P"KP#2R'IT(UQL<R=S5?+J9,6CZO;ZAOD!=R;@:M"==*:]IFK(KP
MQYJSG=%?Q/.BPTN2*5T+FJ]K%T<=D59_ ;\9D\:31_3#,M$/[ 37)N\ZWOM[
MR^.+DDQ4:(PSCWNW+:Q!;#U1</8.A'Z,?4NYPD27<C=??!^T-0L[:;NEN!T\
M+ZNR*R:F&'7,NNCBO5>W36.>Y%WA^SRH9&G57:Z0MFR<'>$Z:)Z!,QJJ2"DK
M&=1V2MGU>)%(-NHMS<AZ;JQL2;R2:![";KXK?Z?< 'NN?PVA.& 2;N)>!IMR
M?$"T@)K[GQ9[LKC14WP'^?3E<DW2N.R;\ ;?<&D+Y[L^E]YD9#P[?SD8D0H\
MAUFEC+@@6I"BM]=VXJC=#0WB@;MQQ4V16$=%I.#&4.^>I/;,D-&,%=GB\IQW
M1K7/G= LIJD_JY:3$GB5+ 6A1+.>QXU1Z@B9^RH'H*B-E%EUN(X%E:?U;]-6
MT=%HHT?_WO5Y$&E1-/V*#9XYPOH+)43AD%CIG'QEH;_B+5O(JD5 #Z/.NIY$
M;"37S^FI)X7\LLN\VVA4VI)>GZO '=\L)K#=.P>/7W;)4?8*]+"PP4<G/!NK
M,..GW%/_MM+K=3T@G_*]4CP@]SS[IO2JG^E=/VRZ;9&9U- -/]S-\DI_,YTA
MK93,[(02#8T@QIR6!.>QWV2F^"#Y)X50!2_Y7,[WHI_%H_JH=EQ\:!ZA?&/B
M "0P"\_(4/D<J+W(#1DD@[Z6QUJ];7ZUV2,EQ1A8S4)%!\)$[7&YO[ZXR-2,
M(]6=9?!2H\K/E^\VC>\4^/D4$KJF[%=%%QT_M#MUSFMDN/V>P,SXLZQ:6B?<
M6CGO#T >;,\ 5[B_!P[?BX\6CYP@:<\4.N,:8E&+(NE%2:/7L8I#=2[&=!Z"
M-3'V>](O$AW'5EJSFQ 88#_D#D'/I"E]3]DV:0.:%GCC9[+/GUVA29.B'5*-
M:L>6QDY;&<"/T;]_R7)+Q&C/R%1>7RMR.>-??O)QVA6S'#*+&3^:5OI3-OIA
MSNS*V#/<"5EH&O:4QNK=L]_L^Q44Y!N*B\FM*-QB$UU+T:''S[-(.J=(HMUC
MX0!$I ]X@<^2'I'XH*L9*'_9?6%7EO56P,K(_ ^/YK%61V'M>N*W6ON9DQO?
MZAIKT_JOOA5<G>Q/XDU#3:+. I;L!P[>OW050IUKD*]6AWACWF?!D4^$=$N+
M7*7-_PSQ;!AU48L5&3M7^-$2<Y;D<P"B6+$\F"I%;)&>A63*D05\++D3S'@(
MF<[N0\MG=I%$6GFK*8!K9Y9UGD9VMY[LQ/?17R'S75TO))PH)E5 %-=\O4T9
M_R3NQ\;4I[=@,EV1M<?)#NAM=H!XXZ?C5C_3I8S$EY>HG2LE#4WW,^ZW'[8R
M>>J+"_LIG4^\&WF_I_" (?'E8DFIKPMSY!\FN*W*;=_L7?7-D0GX+N+!.V1:
M7V2YJCDJ]JV-JIB*O#U'3===8CGO&CEXSVWN*./H<^,1OI[BWK4STGQ>1%L+
M7GC&QGEN\)^S2IF9IVG+C>'W-&;%=8Y_U[SC3\,=[M6DQ60%WPIQ#1&>$!-K
MEA9/G*B1F)LQ/9EO3*P1I#JZ0(T7MQ09IZ\/GPMY755-V+8&$_'K)-P*"9G)
M&N7D5YU>^T&9F0MS!6"(D-/](J^<X7V]%O^F9[Z@&R$G5>X\)@[<^,Q&<3^1
MY[O4803\^E2-P07E/^?WPP&8=*R.H,D5U,S2'^(]<I[/_QPQNA##=CMU;XKU
M%FM[HU7>NN!J6YJ7%];,J#2-IN#$RHI+SS+.R8Y<+U9L;*QVN%?:NNDL#M7:
M^+R:_0(2-XE %>'5%74A77MZ^;2:,B>O+-&:4E=GYHNU(.+N\H.&I-#RZI3S
M.ZQQ;&M]&X\MAN YB'87R_ ?=/]6JCM!\G]\K(HHZ+"BC6R;?"OAU)L!1H;&
MY#CRANM1CF5)0DTF%1H\[WB.X&4>VG?F:W@=@!I0Z\V3#78L4H/6>HN[NX=.
MZFI9OB1:?%6\FSF(DC8(> E?9)Y+J_N0'Y!\I;/'/L,[:@U&P*R'5"A'XO+I
MK]G:\$+>?S7NM==S"KC\'7Y;?:G2=H+#B^7S0K[".%2@R+LDC\@?45HV:B<F
M<CZLEB@0$/ZCE6)#N1[RM)F<)17[K:U>O]J*K)*;<L8WTJZN%U*UI N;0LAF
M&Z?(NT]&_9J1BHW31B;O;M_<X+ZZAJ-_[Q9RFJUGMNX%]K&*Q49T>!+>&H4<
M^_8V=IF8]J"2;S MQ5#)][9T<L;Q#2)2LFCFYPO-<G?U%\C^^XF(XR7%TZO7
MO 3^_96H^XB\7-N>N/$HSR#.B +;F:*URL7UWMG6Z*.7L^4.0 @H7):%YV0K
MVQ01QL!0\R38J5^2:NLC<[5>XM)WJ;T"NJ58Y4*EB<S,((A'['?3<E\ETW/U
M^0V&ZPZ(JG>.K 9.7O&KDUGP:C=@@/%UYC.H%O[]FB$6:/^Q&AJ1=?/BVZ/N
MU0X_DH8D2NV[ED_:^!67+XHIN(Q;1%U6)K]*$-/Y+5U88:S<EP)NK2_&\DYG
MN619!E[,2](*(%NECZ?X*&^5$D?E]Y570]O+*_7RSS)V+.#-[>E![YTI<X"K
M@\!G.':E.<S/R6&(.!04$F630O'T:9VN=LNX7!VEJ3P,+'=)76*P7M+HA@O.
M/\II#AH%15U!5PLSQ1M' _Z(;T(B Z:_O7T\D=;4H%]6-2#^6AA? P(+HK^"
M&Z+7F5J1^9: $?L^>BA/-AQU?SQCK3,+VS,<20E(\1H^*O^44C;6:G3L5UMD
M69,8O$1?LA7:MNY#M%MCW:*IA4ERJO3^ .P^ZO$QI K83OL\+_>UR\OGPN[D
MLQ(!UP/024C<YKZ^TAXV9CU0XGRKZ;(GU#8Y1!WJ\A:AE"EV$@NM>L[L.],E
M>Y2I8K/VM?*>/S[2K\>Z;RQ70Z[?'\OS^(KX5H3O&:N$5;/<6\:^K_&RQL7A
M/UF=.3;B-V/L2L0#LPH9+QH_W[WAC]?@W?*;/VMF88R:YC(UKOR"&29!SL)=
MI.)[,GK9C@V.R.=@>KQ6?>L[;XI]4;;%!^);;\H=Z0@).-312#+#U9OGW-8!
M*!;S1RG3+BX +Q'LT9LU_/H7[HI#[1B!]YS-9H $76^&K8M?5ZT?"?SS_F3#
MA!7E74GPZ#F547G<MX:&AU1%3])_/_ZZ"M;T+K8ELWX :A5.7JR,(>8:M1[3
MU<)1Z3_GG/#PYV>I)E8H8MEA6J4_*J<[)L]KW1V7?QH]=0"J9<6>P<(/0'SN
M;"5SN&9O3>(!R#,YZL'DUV&O'QO#-EF[O0*F%TJF>I\:VD\;]PY)VC8$IRL(
M,W[]'+)NNKQ\PC'/=AE[TR8R)^3I[&,+O\_&@B:[B2[[(Z4KX[E>Y^(L\EJ3
MW\H19.#DE(R<<J,^^W9W7!&9SG\V^.FR-?/D^./1!]N.\$%P).%V W&L*B"^
MS7S]+?7B=FMQ?=0\KX5,&:$&OE&:832Z*O(DVF]UH*N!HEFW$+]VOMK.*6IB
M768XF_,N^+.O\.3IP.,M45LCZ73].<?IWLH;7/K1N-&RWS S3MT!R$U7RT@
M0H]G7UO%2Z4KZ!?.<D<P)W#T;Z3&_"^:2S;)W643#:SGW?93:M"*GM->6P.^
M:N\J.]OEN7,PD'(]5<0! +.PG&S57Y4</02*W]F42::ESV>6/MA]/J%M4'<_
M3RZ]IQG7Y00; &TMO3J/;<VZ:1MB]^!OSTZ-'"^%,:S\>$K"SYY^X8)3M<:Y
MQK';&F?L.RW\<LWGR'YISK6%RU#K][/RQJ<$(DJ&BLX;&U\/6UVYI[Q]2U&N
M]-OOD.IP$:;'XL;+!54Q0&O!_+6ZL@HL!JWR]1=._^.H\K:D;"?Q0X_NCIC4
MQ00"JS3+6Z"/M7G9$1[!ZE'VMG&XEO_0LWFKXSU\>U6K8;"RI^B31U-[0^-H
MU88&3F]> FFV/C7 7C/5#3P9MI-(?6'H*WS?O7=O'_>5Y F;#NH24PLSF#P
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MVAE-M_O%YQ\\"%IRL(=O,:<[&(U$;%F!)<L]FSR15Q[[WU;HYS_\\^4LW*]
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M/E^F&AC?/)A#E5!LH5O-WQV=_R6E^UIM+67F,WED34S>R>&%\:=S'?[4N8X
M@=ZF6DG*L/_\+J+]"JPGR3VZS.Y4Y%:2J;U@\_)^NYMO_I#4(#($5%P+KO["
M8/7TT@<UW5M)1+WHGY'LI^Y-EZ_=^@#G[B(=OV#"7V4D5[ YK8.,';IQVVZ]
M0?R+6%/N/M,_\\/;C'++RXJ3MTG?6Y+.O/\-MO[1VQ48#)5V\PR96H#:$+&(
M&!5LZ=K^WN4FHI7#%\@E1\UOU ZNP$Q@C:\I5+\[BH@5V$* \)51W)>?EQ9&
MN\,GJ416Z);QPI\C$ JZH/#8DOX'R=[ E#O]K_7@\PVC6\-;MKH#C[W"22D)
M;^YH-JXUTJ^_I8A:>M1>8&=[34/K:>7>-5\ S_NC(8HG.U'X<(GUG.!&X)WT
M<[>H[5]3%,O1MS>$5O??>[-\; Q9(V]G']M4634L,KHV3<]U'E+:?_XZ-C_D
MV"$N!6V.@DHPK"J]$%I+[U_;]'MJ"-5SGI&H<U2B5<"Q:?*V!U1N82&22F$;
MF\>0Y]X-.I!\5V"T%@6:.A;:K&@*8U4AO.-(4*T+\X/2GDP7*E8KLPA/L$V:
MBPJG;Z5T7)Y?7)2?50MX^JB%3^>ODB\NE%PZ@U/X.43F&78-E0\)_IQ.>7[9
M<LB30OL3)?<UDJ8H+2>JEP1IJORU\?&65R$KL&*4Q$%Z:/HK%2Q<L"3-+2RW
M+BE8?[R?G[#$3Y*N(9GG2. [EVD3*P5IB@/LA2N.^:RK,"I>)BTM@)3F;,<&
M*5I=?K$03Q'3X^3JXBB7&#:\FZT]IJ/"@ZM#N/.]+.\P.L$NB=2( OK/]L:F
M@<9>]1P^RZ903_,<0$IL+B#R<M_F#]C=-3%Z<F4/#RVTH+'?C0TNS[^:F2I7
M&0N0IF<K[UF*AC8I[WEKKLS161DT96;R]0^4-LSC<V$30J@ISDD6M^%$,Y12
M: >_*3WGIQZ#^DJ2*IXXZ@UPXD)G'S('+5^S4]ZA*5U0BS>_N?BZ'BWF<TN#
MKU7C%\/<X"W@FKR;+5*.TS!)B$ +%/LA6]%'_4,0!E0Y)5C?CYX@_M1AC7KV
MIR-^PR(OGH9Q;96=@MJ;PRW/9MR5II>&&S4^!.9?+-">@=X^WBTF'Y?]DJ>G
MC<#;TWI#[Z5S+Q%Y'*%7N#+G]9&&+R#DMRG_XVJB<VK;I_5N7<G'5P^^6WP3
M3C0'_,C@D">H'9/SA<0<4R<<%?BU-^#$-I9Z5YT<3U2#&U*N=(?D=^^(81SU
MI<]?9U:>?Q#@!*5)7#0)QE /#<(U<S:P/(KQ9J>Z3>4&H)DRCI#+<01-4A@B
M)L/G-?]%EP$H2-S6'4:'^Q@+AQSA":;[")-M-C-5KP=5VTP]%H(\F%7I J$-
MO4=./3D??.176<N_K[KK<GXAJ7TY0_'#\158B_$<\PU5CV O1FP.U-'%+PX/
M)?)=P4UDLAC@/ S-/L5OSC$ E@6Q.WIO0(P7IX<T"'8_4.]/SWQ^LHOAJ^)3
MH949]A$GV1QV-]JT_:5 [@V^(.GZC UJ=2,WCV=N'=+T%N7D9"K3AK5'>5 O
M#[G9J.D8P2DJHA OX_:&LWW&D8\0L<_X4\1.5=LB9CS-UX]'*3V/,3\?,FVR
M49^&CNIO)7'/(<6*+CYG5-&Z OO^F=+C_T["8(;FE#%T!7;O+X3+1U,EHTE=
MHXU[(HH)!SL6U.RYZ T+1UGPXDM!7_!,\0A-3/.:/0NJ41N9J<V65_C/.MCO
M\C6<X"V"<RZW2\N2+=NVL^O?@AF\V:1:XF]A(C$E)@<.+*S DJP]"OJ#P@?7
M"QA;K(V?R5%0PW.\[L4>:R=2-+B&>[9GG[F3QI?%\SV9PE:NT_/^XY;""=R^
M1Q.9M_&11W!"IS[?/ON%H/=+GDMRRWM+OO^V]+O_O:@TP.,ARPW4,8L;W!9A
M;2]R48=6N4,5N9"E\4D^8YQAE^H*'1+-;C1EB()OL7RC7XSK;TD]EQQB(M]?
MJU46@JH*4SN)_\/EETTLOJ0PT8QE \+]<&3]_=Y4W0]C2",+I!9 ;U8*';ZE
MZ6V1$3?XMK@;RAI>0]=_/JS$F&)+Y\R.KH5YL#JQ<+*VJ;9;1R^_)>9S)7BJ
M-/PGH+L[HCZ/UM;:)1-."#BY3-^[KXG/_J<FH*JJ9I5A\]4*[$T1"OI,#,.K
M\G1*Y>I02S%>Q9T_TLO:61#$K$6EF"#WX_E2*I!26N(%.:NY?NIBN4I.RX]9
M9Z;=2WS;0S OZ/.&HDYWAYB8)GET?9S0\7&#[,6H)KAF/8_\@.4)M/MR!&S#
M/OQ=%,(^#U^'!GQ[GVB_,5$1;Q66QXB.LO?XY!=374]U-6?DXKF.73LU?(,6
M#WR<O!UT<"*@ISB*PTH=$;X[,E"*#:@=R&.]6=[P']#%!+6GMX!1C?IZ +M0
MO)N]=2=^E)NS'K1)9_B_Z!\7PN^;L&S]Q76E]:BF<(2ZXJC\"###-/BT]$-R
M.J7(04)=53L0=+Z?FSO)=)?V+LIT6J9W2HR/="C:24")2<BH:)3KLN62_+"V
M>\X.D,ZK=VNV;*XO"!K4AWQ+\%'B:[6;\3LZG]5T+>@=@<?51K*+-89\=8UO
M=)?#2SL5$?1++7/U],]1S!=U'7 ^_'^D)_M_IU]ZFS$\)6>/@'7HSMVE12Y%
MQU%OM,'IU)(+&0W\'O@2O\H#)/',-N!);E"$Q*H4$:>3GALE]E9UK"G8[],J
MNLCVM3I7 =K?W]6%,^R:":B#*L D@I6+QL3@;LA79)5LV[@"6\/>92=>R](N
M;WN!=VL<M  C,<A=72Q[7!GA9]52[_',7U*^3#8!:.B*FXO.TST%XTQ#OM<K
M)-WQZ\C\[4[;ZR2KT*ZVA?JR-\N&W^X*Y"8QXRVC1<M##ZID<'WY=D",)[\A
M&H/7V1Q)E'%_O05OJ86,:*P89^L"P<F%%/G1Z5OB-,%,R.&Y-:5B[P\[F/>"
M0P<"W\U8CZ*7GX6A->268$AJ<%$@4A]*#AA&I412XUD'\B>8[L1#$.G6\*3D
M^K"DI"&XQ*D$"EF2.><8]YG2:5=371\YY[[@X0+9E_1U$H*C''R-I[6C^K$6
M \0C]7\@"E#?4(\TA37$%??35[>77H+:&Y$6E<!0O-SW!TZ20LL'2N7J_P@2
MM#B59!Y:RU%46C/O$D?<UOV)!4CK"SXXEBAI]LC]0#/MT_65BJ;>LDW34J(1
MX3)8Q;;A0%@1=2M^3;MK8A-:5<!=(B:'A U@G=(7FQ7?O>Q.%:O-DA5F1@E5
MLI_"O)MZ""@:X1"0GDP;CTS/>N%)L*WMGKV6XC\Q7S9D7=6)T0O)&I0.>'K6
MU5>MFA_ZMIB@Q"[3ZJ"N2)HFDEF]9JGHUQG20<29'H)+48.(J@8I[0-@$4>;
M#T8Y\*] :>"LZ'>D'D= "Q&<>W(%I#2IN3DFO)\()-B4>CXQ+5M4Z! N@$9-
M+DE^6ZI8(/KA^8%01$*NIQ)MQ6:Z3418?2?+5E1O=KH*2@N')X;1S+QZPE0O
MT<WF=1M$0^OLMB*$E.>%<8?'/W6+D/0S<M8<IZXVP6^A=O"]P,OX*^:NRACE
MVPYEU/0>Z"&^N21(%/.U&W[#HQOTS1\/>57U3,D#RJ%$ORH0,?T=J"D2],W3
M[LJ:E3:FFA_:KF9;U!\?6A_ND"*^DSMNJ?_@A;>GM]<2KAF[ OMI7+$#:'L?
M0RH5>D$J)P3$/5 F_RRK)G;(L[/*R8TK].TEEUSR;M_<(^DF6!3AWXV>?563
M(!XPKS_DS#ZIG>[>M7.)86PQ;9!?:U]:G1V*F0THZ V$5Y+^G7X1_P8[SD'6
M=K"N)8-]" H?5MM@\Q,JJ>H#<?L LTG/^[2.HO(YM'@.A"=KM7/O6M)Y:JN:
MI>[$#4!1[/LF?+B(WA2M@WVMRQ4<Q)NV_ES/H51"X>!0,^FG!;I:8#52O]/$
M)8%E,UQ_YTQWNL"SEO&XWZFVGBQQ+[REW6\2D_,H-^A(!_Y0XX:0&5-=GG8O
M,_,W3E? O>MHC]S"68-29B/S%:G$JQ]M6(YXAO[&L#Q1[ "[.,WHQ QISLX.
M1K2MJ#Q+CQDK5]>>_DY"W0#="Z,A&MUU$G2IOPI_J@0$B:$F 3Q]HU==80AU
M_(,+<85]\KC@&S*UBM>3UL>5[C<'WL6P<MD,U8F,8L/6*G;YX2W[6Y:H9)8=
M_'Z92>@LS!/?*W/&_?A6\H%AI@[E,XY]!HBI =<E)AK1(=.F#"LG/=/#7-'R
MR26&">Z\UY%J=W[=W3/2:"]?KU7SFM\>DQ"!Q"AIG]S*7YP<U:1<:;_G$OI/
M8TA=LCN8DB76Y:R!@H*-1?F%B0QOO9T-M_"E#MWFI(W8G.T<%E"0)9HD:8T+
MV;E1(8+38=[)AB;?3P:\06]F[X5^PZ-\>X()&PA6Y4$6D='-E )\>%.U8E>/
M"0VI]19<(_/J*B^W]B;II^FG%F6AU5QR!P(M>]H6Y+,:$SIW=IG=5M <709=
MT#/EX[ZTZ9)P!N-5\$=X!^=;HO*^G4S=&AQV1XR.]SL*90/#> LN<4V':9K<
M(OK."^B0DX!P)SR::(V(%JOA>%XY:1*SS?AK^!MJFK([SHR.:S7UO6:A5<#[
M>"*S]LX-!S"JQ4^=W,A6MVQ_&"P/N#+<3L[9WLU2409'NCK!%<HOP_>.1''4
MQXGKF13>DMK@@RNB2\_J8Q>;PBTMDD/;C((_9>9D/1_+T7J==0[MD7]M.:]L
M%D?.K:X=CPZ.1AN?F?T9Y<#YUK"POP>434*IXX>XZ4SBFEI@37VIS_B02NA(
M][2F>[>U$3R%0**C;<7+V\U"IZ]>B=:^K^RD04]/6LPRKZ>ZB!Y0/-C?NE5:
MO; -:@!ME>8MF=0T*AJLR/L J8K1"2;!533M)N3&)RC1#Z!?MBA9NRF271HN
MGMW24 AA>2\F9B\\YH6^+0!FTOQO15G$F>,,HT))[KFY%PWY'IR]KWH'Z7YO
ME]\0'W[;@!'4@*P6A2GT"-PXSD2: 91$ZV.BH];';^?L@J*>0P\:!_7 D_0\
MZ.BE=_L6S+;@WZMA[55XD?<Z%ZR"_21.W3<Z\WIN,INE%/@!5$O[YHESD.Q<
MA[4=\'Y";167M''65&Z2/Y99SA2W/UP<_#%'X@S4MS?1G.%ZW.MWBO#EBHY\
MSOTAKA^\9W4&<]79'D8=8OVD9?+PR^Y,3E6Z5&AC$EY/"P_6G7T5K#*N\FT6
M'IE-G))?!YAV$+I@"#_:5)L]Q,VV=$E :[(<]$LE&*7]RO>"6AJ6].MQ99Z3
M?H9@2OZM*W=$V5'-ELG4V)'ND/FX!;U-IH?5+.P2WC6K[<UA@E8M?FL3Q1R>
MGB?N8=<*K+$"8">+ZJ,N,EX" =P:EOV1TM)U88EH#8C[AJU.=N>S3&B0VSG0
MIY:9P#(VI8FS&I2+Z7FET.&YT_JE>@/62%EJI)T0'!EG,U.R7J(<OPDQSGY&
M>XJ?>7?HP"IN+3V1O17OX2F0HX839:UH.&VF4-R^:6SHIP69S !TN6=*4%KY
M\UV$/;F0"U=+6MM,$QO;X,04<HAYW=MY-0N>U@C?J3>L_/Z<Q"AN?K-)U0=K
M!V"6J[\;1ZX-:(I@K9)XRH^+S73D/X.(Y,L"\SZ"!;"DYR*^08G*'<O\L??6
M!]VLHZPK!9Y9Q?/]:D9<(8F<FP LU2.^?C6ILR<.T.?JQK)[N//AW^:TRF:.
M%B$:8*N=&'7DRVUHT*%&KW*Z2#5:]R*UR8)]4/ )$'!=((<%G(8/M )K0AZI
M8?!#H[6;2C*/5$2+O=4NMF6UDTKQ#\XX.IC-F!]NWX*O;%F!K0ZE:$!45X#>
MQW("'=\@$8GNP,W,74LW"D6.0_'$38#B.29*.Q:YD^ #?&8M9?.#!O78Y#,0
M67STVLN<0Z%"Y\);X;GC[1/=Y8*J[*Z0WC/2ZK;Y\,ZZB'Y'\M *[%N*XX5(
M>MPO)I%I"RBMCX/R<]V$,'#5&1!]WQR13#3H8) V8);".(FFUH>P!<1V>($O
MY(@&=/&.9[O,C4FZM@CR0B(TPI=?U&>6N!0-MIFLY6#@">Z6BXT#1CYD43=.
M,JTJ&DW@U36(2&NYI1_P2^#5U\!L[ (B#E5E$1M6-^#=F Z>-C5'J^&U6UJ\
MZ]G\J2$N4B^;)NHNG)BO[4Z7=AIUF?DR%AEGI)C2C_!NEV\1=>L3%(8:'TE.
M(=B)U+1=@!^2N_U,R8V6Q#3Q%L)NX6+,H$1\X]ZPE1,6#2AB0(DKE$CO0U^:
M2)W$X** .M'3(P7!>U>5^O8--!0-C$'M8@&%8$'#WYZ]!"4"=0VU!1G/Y+]T
M,M99.Q9BJP?7@H/UP\H>NKAT5*W X- 9=)S0:3HC(:SU^$',%;F#>-KVK*<Y
M%JMFX>4X(CNP$.F.RXGT#MM4YU@ZQPG)8/]*S%R!?3MA^HRA&19->E<E8JR+
MB+,>H^VG#MA36':XX63L.>!Z8:+\4 ET(E#$GV:Y%(R3=.3'016WBI[J5I-/
M&1P5A;YI>H:[VJ:1?)P-K6<%E@MIBC.:ZKTEU;E ;A-Q!^1J4WX/&X4LQ!8&
M]B+U0.>2BK%(F^6GM88Q100\B$B9[IEA8(QJJ&Z0%ULW&N$413O$RZ1(DY.J
M>O43&24N[FE?KS+[E1K:I8B\M[@"^P\<9\2C"C7%[A3)"@PAMP$> 13R3)6>
MD8^3@;6M]KUR:\?;-PG?623N (G)^4&DK?-F6R:KKRXJ#*2USE3 ^Q+?T-NX
M50J:?[K+%(8Q"PAG(&XQ9"12N6>-*\#/B7HK(L2),N-=8#3[P3/$]]"#=KZY
M]U?=,TBSY6?L+?AP6]-]ZWX=DKOUE)<;5->\>MDU6VZ NH*DV]48G"=.S^9=
MG.K"^!8L3JD,?'-D5LF-P"FV,40"'[0@4:#>4$SH9>M#M*#(ASIE'<>'L\TN
M0"I 75/F!T#>%E9F2L%ABX)JRW.#]:FW(M^2PLQ[6(L9E5G%<L/V9O:J[OGI
MGP?DD8)]\E5W\B"!!^0N1+7XWKDHH,DO%9YR,FN,;$\ZW*[A@QTT ?..=''%
MOJHB<H+U1?&>3V1>Y=@</LHM\6>&[SY\D(/1M#ZS\TMA[BO<*Q)1:.,%[YW]
M9E"FD/6M$R\*Y %WAA&Z/G);*"8/^G[9V@G@7(!R"_TF,H=XWE%U>\Q>=+#4
MQ(B?^C[@58X#%UL_0G>79D\Q@4(R \,X/3VC>[ZN\WEW?R?QNZ#!_;74)B]$
M8CG+M@#=!]4UC1MF@(:SC4)J$N'X[</TM4':&<BMI+5R!_!4ZO,Q2S5%893)
M"HP\5696E8Q$J >Z6YJ,9&"O&-3S+P4Y#['2F3VWJ^H,I>RE<"^_\9>RQ&^S
M<Y9/-^&8R@.6;A%>UK)(A ,S')F=_.)+D!S'%VLQ =J9<1?P/M>^8P&N%>BW
M#:A?KB_(-B-;6^5[>;)I&\-1?99A5<6__"OAP_Y)(0R][H/\',00FVV0;_J#
M<#)5M)C"0,7[[87"S5*TN#Z=SP"R5,!SLK@(E!?26G"B<<97.4)*5T?)]Z'A
M>?JF-3AMIX+"N *T>Z%\UMMKQB;"KSZ#E;;08UY?CBCX)L*H'.42B4LIFS$Z
MX7&L&]+.(<)AR+WW"/)8PH2:-\^15$[ :Z6."\\*F^/U,R1#ZOAP+ALA8/3G
MY@=9I'X(S.A=S-QX:O-,:#1."VIL/07)5F!KWZ>!!X6+O$AJHXN^8X'\( L,
M2=[JGF-405HS!'GU\AN/L.T^U9878Y;K2_I])JHSJQEW"JM+;AKIZ/U1R<"J
M.?$<A0Y!:?7]$],?X76H;TH_DJ@"%3:&(TTJ7@$"GHU;\UWD#L P1;$+K8&?
M/0^Z,J R_<7S-9W[K@H85E3(CN"-) >+;1R;$&KSQB8;U.#.'2(63G7\2._'
MB&QJD\MW$SJS\2PK,5RX01DOR=5H;?/3+#OQ)"YIW;./PKRA'UG'HD7U%N=
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M480H8#TB4I\7OZE*^6(WG^#YNAB)B)Q/[9UNE8,WCP)A3HGH]0DT>V%;K(:
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MIG% ?BO-5K7Z<Q?'1CW/S9F.RX)^@XX_G.#^6^?>UI[#3H-/BFX!.]6K(*"
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M=H0T%@QS17>/_R(HE44(;XTYN'E6/_6<_5K+<TAW_#<8/G1XS<L"^1JO%/9
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M7,,%9%)X)LIR!\<%*,Q?<%Y'/TT#2U/[K>RGOLF3MR"F9JJX O_XM?XQY59
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MCUNONOTF#>K7Q>](*CI=]>/N%+N;Z@]PW0'1%Y_Z$.0+HAQ+#]U'PT.I4U=
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MZJSQ[%3L4*I;:@7)D.:COQM'W0GF38G8R&Q="*Z-I#.XQ4N+$(HA^.&);8*
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MXQ9(#A[NZ9@KL0%8;>C54/I7< NZ(I20+&L&S\VUS7F5.,--5= O\[EO6=%
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M ]*O^@.88Q"KNMN4WW2]A'>J&M=SP>?C_RIK#Y0"4\H+U:IL?KS.J??L(W!
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MVB36%!9D)Y!70D&BA^,_$'%; %RS9H3>ENPRE;REHRK%H:;X[OBN60<3S>]
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M"Z<FZ1;:B,KQIK VM 7]:\3O3<;9_,#H:# HM Y0,[_C(Y<,5AF5F4OOZ=;
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M<FR PJ2;V.85&4%"+1F$8E?] ?S)'TH0Q28V)=145;Q@,OU<CN=(Q*.+3->
MR\,G^U&;77F*88PC\DH=POYD ]1<$QMYO)9ZXKEN:VSRD08I"A5+7X68YIFT
M?#93%J<0ING6-668L>_4]B2=2?:@_R#1K9F*M+U,W:44PB!A8!TK&/1J)X7@
M^F9A*S&TIF<7P3"Q74 VN2[7\ZVD/?+H\]EBY+'G;]8X?O:H7HH@;R*VHAE7
MWUH>-/BRF'ABL03INT<YQ;+4KI><'4!'IYKX]]>UI."@@+*@5.*IZDG<9^E?
MU4&A!4,IT/5THLR^'_$=_BM)?(O;"6%^QYQ(6LBY_BIQMGV*OEY@-7E!MP6
M9:'/J.UBY]69[MTI8A0*PM!'V6E#W6.9OC"E;2WH]$ 5=5KG:CWVHT>N58?W
MKZSX^;!,:K 2O0XJPO5YI.ELF@6]'L;U,Z24T8 KVA/*'J:=H!%T;LO6LTB!
MQ7/^CK*)9*3(X4"/&&?9".!J.5,R8^FWH T7=!';(;.0[L5!N.9' ].W =QU
M J>EIA 1LN^@:]]"?H'F'%2-9/IBP$^IYX#N!C$R"V7-4JBOJ*=1%I.K%*&
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M6<D;B"L/_N'<;%"XY0=4:]DK;N9&R\WHH3[0%OTP0!SE+VJZ<O$.E?A\2\/
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M/\.V(J8?[@T[G+]D\-6)?!?3>&S J;$1$S[+= INR$%M( J^ )8,WDR1;[[
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M#O1 U0-_VNTG0:RCLU3SCPL'B4,D_&BVV1[I2<%"8S)F/4\$/Z%Z38V*I\B
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M%M$^2!I3VC](B5[,8G,)9*51E&UWF;T.25^KOA=WM09M#0VJD7I]CGXBO5<
MKZ%-K&1SMM@ST@M*E.3:*8I9_K!5$H,5 K,LRE5;&.H/F[?$=R0O+MQEV!8-
MCMD!+$FV$N8$,X+RQ=Z=99-SEO[G[_0W=[>5$FT*0U\$*!44W..6ZB95GFT
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M0[Q"(CD+[?KF]=(/'!EC/>B#!<L?J]N7/<6+"^)ZY3?A_X0-'>H4QF#N%HB
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M/XB1C!O 4)7(1'D@NN)@IA+!-\./ZG+KB-HERO!  ZS_#$QE;$C;129<,7&
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MEUYFFZ;.P(24(94B\))Y:4K_7GU^0S=C>3)7^23A>(1B?"Q)/LBAW#!LJ(R
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M'U/_H[&Q;H2HQ6@?E;H]_L?[,:+6NOK741)>OU,4]P79W+)FL/L((\O1VVO
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MZ#'=J98:>FH?TO"V]5YH[F7,<4.L','5IS29*-VN63A3_F->@QV0P!5DX$^
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M@:]OSN?2I*$@1J#W'*Q6;SD:Y><ZUD.9GBP3ZG]O+#^B6W:FY<IHOJ><WF;
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MPM^<Q5]XAQUWZ"3&OWY3-<89RR;7MJO]G@00?6(S!;QC#;MJO&&X%/Y!IO@
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M]_2GJO8,Z&3.Z>G]D\S/"TD,6W<*5A02-5;VBH<*]U"CU%V3.(UUD:(53U?
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MFP@F7434>/D'&0U7W9MC8GO-X-62;#.NL"J 9*CJ$6?C&%U]]P[Y;',H"NH
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M70?,#^22ZEOCG6\9;;R7>%Y3^6\"Y0%\<+KZ6-WEZ9%,;$\7MOYVHXT:VO*
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M>2Z>PKY(?*<%:&AT$))Y$=Z9A2[#TJF)I&-+BZFP1NK;1;%/"",/L?<Q2QE
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MWB@=D*7A<"AV9D;X L5WO,351BR7\:!RYH9EXY>^RLEUB]N;8U7V>V?/Y[\
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M4U<EF',W)+3$4F1+.]Q?XRK_2+AJVZU4>35'M0OVX:\G4E5N71R\:&WSJA'
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MX7PIRYYRZP5^JZ[I@@C2=K(CI['&<=S16SJ:5&GY34$>5;^4$3L+%??])#V
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MQ])*:+Z=;J7;%09-_[:A&@QIWZX-TB3J?K8>9]MT=]>W<28!/9Z$U ]2NL4
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M@OJ-"+&Z,6=9,D/T9G)?(O:<&J>?*>N<*$[8>U%PFB#6KS=$Z%S&G?.-^8:
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MT<UM8N/J1+ R.>TTH"^*B+!E*>AO6&L^A0^JY9KG_I(^=S'+ZWO52)0JQ$[
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M^5M)_\O^Y:L=O[>)%* 9VV83>;WWY!5?UBD/3#.>.B5AFJ#,<Q,,U\-&IG$
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M3U4T.MY"GTGJ6;1CF./"0_W.%RK]:5#>9G(K.[ Z)?QYMEU/V$>M(+[4;@_
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MM'1LUFR"UZ];O_?I,A$Q)D0H4M5'NMZ'D8T$ )DLI!X%'=J3+PR/T9H1ZG4
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M'SIC3^;!A+/NU'Y/M8%,$UQIR'T.]JENRIJT2,O#EY1BM85V?QF\Y- RKQC
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M:D-5%\Q?R9$7Q9S"=*%1<A3N (8L *6X*'(.5HMV8868<D$4[ZV787_4UL]
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M4\[X J5QW-]K'UL]0&,/'S$')W^42YV7[(6?1T.00HRPPS\; U)<10%N*F?
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MXI>'&0[5B8*P[PU=ET_F4D,_WE=OD;K5,PT,FARQQ3521IE\:D[IK@=V /;
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M'_IW,^DM=8N9Z0OB3&G&*/5X1Q=1QO3N!]4!'?8,:QL&J#<VS) UUD9'%U$
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M:+WH<PR53VN?#+5*JN>9ZN1\%7^;*=D_WBF9*;KT*X__B28>5F]#.%@#4L*
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MM3(VO.)C<6+"/WM!?5N??P**WT80A[%2*&TOJ+U[KL'P(>V$8#B7LK8.H)W
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M;):]L[Z;C1$\RJ%29JY76HW':\,M)4%91/7Y-(<_'N'0YP#*VA.@>XFW!;4
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MBE",KQ'34+U0ZH\FEX$# S3$X(12_CL1JBF$AQ&AU"\CH7Y_C_TZC+W"@$P
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MC>9'H'3](Q>:4NRS4I)O3 .GH ?I!489)^],'7\<X>@:=,+5U56WN*R2S\1
M2@**J2(BY!N_#T0O.-0+GU]W7SLFCB+?:C^UO<4L,HQUG?(77X7P<,A;E+G
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MOI@D 1\+-)%U9O;+B:WVXB^VGCV!6OF3>0OJP8:+5(%"C:,(11D>FBZXSPV
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M0=7>GF#5,Y96FR7*\M)*W3K;E;L-I]-Z[BE2SJI5=US3-$SQO=7JA9^TH[/
ME#S-;:?W>$XVZMNKK(JG]]HILL]RV";2BXY"-_\[/F?R7<]F1V5\^H7KNO4L
MSH!8=<T8\1&_+R$LGW'OI2UNY!D%][W]BR]5%VDQ"$.I2!_<FW%T[!)S+G1.
MF' 9:69)>R1@EN$JUJDZ1% ;7J^TMI>$6-,D.]Y$$W +5Z;5'!#UTBEV5V\Y
M6@GN9"K1V!>/LXM4/QF>M8C@6&ULXZCMDC833]Y:<EQQ2?H$8K70BX),+AJ6
M="V"Q, (9+PO7.,H[KJI0W!]W0&PEJ-T'%F;4:_4=X(]3PGG>Z +SZ:-MZ>:
M!T0[18(_.4["6ID[^J3F$MY5ZIYQ,[G@O>^H>$Z2^\N//H_*X]*CU"TWLR]=
M-O-KJ5#94.!X\F!IHI)=6FW2U;-6CYNQ#WCH75V',C2/&B9M+-GV*=TX,<3R
M(/4X>EU_Q_>,?OP::[L7W>,49^T4<:FS1]O/1GG;9MAML\T KM!8Q;I$&= +
M"=:U%U$$DH11V:Q@&^&T\'?C-6#7MY&357J8S130_!GA!.\ZZ?JVHU<]4UOZ
M]4JU9?F-DH(.@4/4AM6'1:@#ADC^/U$1FH9"NJ7"V+KU\"!9&?!1DN;7"FL@
M*193D6!8"6Y_2M#N,Y8@[*@ RPG5)HT)6$X8F'2JM\:+L[Z\R),C)<^?:QB(
MO9C67$R5ZJW6O.45P"E@Q-2M^$=;) (1BA\F+(+7@05LE]@B8A^F(E18E,N#
MR)M@I-->IQ-5G'HA^RM-TIT[ /W,![B_#U^NWI-*\;Z1I2H/WS3N\);0BMXA
ML29"B4N#)3U8&D>0E52J)$+-*@A6$PX)\[#>Z(\=C4ZXVX 7>DC!":2/DL3:
MV)U:C1^<J;>*#<.YHQ;O@SOE.&X4]I%T-:5C+4L._>H6=?E7AD;BE6]S% IJ
MW0/,*HZH-KL+BTS,'VQS,9)7K54\G6\3I6YGY6V*M,/"TL;#)Q_VNNKLZ7FH
M8$UJO?1)I^6'\J\OS^WU@$MP!N_F%>D"+4S2AU9.R;E/2>*+A(N^XS)U+UYN
M9N3$YB?0J^\W=]WSKCK39#V>ZSQ%&A2'U^WFAC0M8V>/D<L&XFF7R;',35@O
MTI#_/&LCA?N&KUD#8L7O0?IL!34E/>L2<)(CE.,LUN463KNA>9[I!2<*+]=M
MXYZ\#XQ>ZB[T,C FC4K9+6KLI'<##<I83](@CC4'R:9SM.H!67*<"+6UG!3=
M3]2@"=,6T0J0<BJ[GRS?P$JP:1JJR^6]8:>V8M;A<1RO.Y ?FRDQ)7\-;[#T
M*[<K91<ON'!(B/BHQ@- KDL;5V]FY=>9:P*Y,=&$H[Q#+4!YY<Q9+IU/ >^/
MDA.J2:VSZ-& VU HE=C.+%.Y8^A5R(R@G>&RP&%N);V:FK"(K*,4FV=^;&I,
M2$A*FEMB@D;"6%?YT^&O898QXM$T5BE.>F7'JJH= ]HZW(P5K]G),;*?:K7A
MEH!Z%'R2+9?_V)>E0%IMRETR_W %"M1\7(ST28TG+N1HE,_.Q05 1YX[^X0Q
MAHMW<L?3+P1[YWF76$D_^)#B['3OPOHSK3:9EU2#I^S.^8=ES!=^VJJ8C;FT
MMR6CY&!0 B=_UV1'SO8'8/RCLZ,;:!AGF=CLQU='5!-77P\,=4/_-!\2TZ!Z
M^,I/O]S-C[<ML$W4S?2IJM8_L=?ZQ60_?M)RVPOL8Q&JC 3MG0/=L%NP['0:
MVQ=H? B/B%!Q"K < .W <,OJ&'P%["P9-!.AV(C8Q9DCUOI.DL!#<$B ^0(W
MP>\$#LO 4$&3[R#V,D81T@!3>3$ML 'BPP+K4 1MGG*.7P2;>L>$@[EKK(9>
MVU)]*;DNYTJ=,<\N,9.#WJ294W <*-H>K'9NY$/YGIY9$>K]K%\?P;_N6H%E
MD8/<VDS3LLG\D^F6EET97MNZ]ON>RS]Y\.RKAS;5V//U)P/K63G6V]*"=]ZA
MM^0:7C+3";R:<;G!;-N+JK#REXL'-C_PJ363>?$ATVZ?3?[APVW?C540%2??
MHLWX \+?:NQ<@Z_]Z8@KCGV!-HW(TX+0(WT5_ /IG3\VQL O#M93OP;P0T6H
MY  @@"HPPMS!+#MSY6E99L)(83R6E8=;N?QPP,=1I"S.V B.P<TX;C]6TG@_
MY-)CK.[[.^**3?"5+*O[(=F3(^C;)[HAQD]X26?>5MKYOAJ,=V%$!:,Y[**#
M6P@_8B1=I^Q:>G'AJR+YX$")\G,?$J[(:J'EDQ(<C^FH65^-.9AC663I7.MR
M04TS)J'EG#KQT*H4<\WZ_G>^YP^38N:='ITVNJ(DOWCUM;_7<;E86Z]'[B_/
M.=A94S1/V35UVR3GO*,&+^I!FQUL X;,^7Z(C/X.-!PLE_8#\A%3C\XG^(+;
M<Z=0Y:\@+]!1J72XP5.L0 ,N"I>[.3?(Z6B]Q#Z2_WA/G/Z.,%S9'DJ00!:1
MRRVTB^1!/W>R!8C M685F%D$]]-D9B^FG?I6QHS*VE[#_4;F=IB]*;MO?;FH
MQL&7@A=K2O%I/#Q:\[[FN)C)SK==QI;<5FBK"3\$7"\X#W>2RW$S=@+$Z=$U
MAR#INOXQ\!9WD.:C%4O>?@'LS .CAUP5;'N\> %-V T=P:Q+28U+RRTDZ<FA
M/94^FM2B1=]XR?PRT.\+CPSNP\PN<:S O:FSVDQ,<,#J84B3.Y+ 8HA#1F (
MM[BUZ2R81Z_/0G,SI#]E[AG&Q=#=-L>?D2?%ZEAM\NU4!0,L9&,+3N2V*E8,
M^=601GB/?,Z)FSHD7/';:UMOG;G7WG8BLLF6<C?SA&IOOL5AH.S":Y5M;2T%
M@?%QUL;NBM@,CZKBE(-Y#LY:[)H;:N+-YR#C0]*IYG+'[WXOW*.RC\Z:.MO!
M^SAU*'''_O;29!S:J6B-S:HVIT+?WNND&1HL<8B'@R6VLS%#9M,GA1E("25S
M+9@?Y]GW<&AHE1&I 3ODP7%H0&\@V/;H^":LQS@,4!>H2D0&>3/AJ/)]CF2&
MV^4>"X[W;%[YFED_C9W"SX3=2/'L!^,%9U0@Z1A88N5Z[=% 1<Q,,Q?-O]N/
M93UUJLBFPGTT>8()=XE.*X5I+WR6 VY^X17GY_D2?P:].50Q(8FSJWO$@L4H
MP:_M&OEF=(PAV,,\Z1![ >H6Y@ L*HYKA1T:Y9RF;:-=9H([J9 Z*7; #<-%
M3A508X.X%W&0R1*ARKV-MY>X'CE5"=.Y6G0K*3P17>J\.NN*@?NGSLP!![DM
M4HL\[,H-=+/=5N$^=O"?"..(LL1W-&X!K B%"RG:P)!80Q"BI1/]-0B1)6+H
M0UN-92MZZK:'NNW@.O#G2-!=0^T2Y 7>!7CJR;JDV73*A[SP:P/*R03FAI+@
MD@.M9N5ZYO+/;:)W'K*Y-]5=+K.MC]Y#B0IQ>6&[YX>"T_.6B>8QQ37I0,%'
MQ71I^M:7AYOCV)3'[B7;K=:8HYVBQ97,\$M.%6)Z+>[S;X\I]HV9Z]!M\(\:
MS1_8O0C72T(6@SE($UA!9X39VIEJ_%QA,1:Q/\/8YKI5W#VD9_@0SL0,(Q\R
M&H!E6MFS/N-+32;T%.6?$6).L_/2\Z>6W7* $.&KRJ&M2_UZ-I)'(]37;U$9
MS]WJT.90I+KXPCX](]?:TJ(WWZ!TYN$+B]>=SQ[49,[<%W0YWLQ-'@-/U]W9
MOS#)OMSR(%%Z_?%5T>,.0<GJRO('LF,23%];=.?*K&NW_-SXISVD*[+XO^XY
M>H'YAE3!UN,BU+5''.R7P&1$%/=XBU"YER9<_^.C#< $R_UMF+:6V 0@@WF3
M0#6O9J&$!NXD:)./5^-?1<R8B\67SR %:7H8FRYCN66:"UNEGW7[N&T!0T+]
M#G\O^K:FZWX^F.MQR>_@I,(H &J09SJ>P%WDRA"2#B/FC+->_=R0E<G[E<$C
MT_(R7A:3 #8VKK_U7/_Y;NN1P^?+>\J8\N@MSMZZDHK7G,#0,KWK@X$*;;-8
M-, JP)44DP6;(2EA#*R'R-6!8N(1O#2KB_H<SW%UI?EA[^+6DULP,L$3_<]X
MXJ1%5SUV:F.$/&^L"K?)Q\D__IFOV\\\];"UD>K:SP.*1]JT+G['@7L1O6IE
M5<ZV<LWYWJ ^=XFO_5J8/L _]Y*,&#VIFJ,JL]*%D$\:-LI!7I><AXY)NXVG
ML($8P[//A[TKY=$QQ0M*. =>7H%NDE1*SL4*!S&'\'A<-M5AE7K>ME/NS\VN
M>[^GFFW.C;<;NY=!67S;=:VQY4'>9.^=G_OLTQN[PX)TB58IYZN>DI4&& >V
MRWJ9H!^Y'U(O57(KQN[(<C7_F?Z!+D(5++[LW3NA4S(G;247U>3NVWANFQEV
M&/]6,-*R7J@G0*QN>R6M<D"816I$"S5 *9<82(')\Z+S<>64)JO!G1Q%;F4C
M8YC*"B'5B8'1C8LAD]_!'(&875^-2K"AYZG;G\S/$QS8'3]M?& :SCFW,^ZW
M^_=CXN!F,M=&*Q(HK9P)Y '\?<)LP)T*^F*BR-N(FMYD69VW #NGQIFK\O;-
M^X4Y\8:GDT2O2,,U16 <[J7/"+JLWWC8BU-[4(UZ1& \9Y$VI&\Q<)/@*"Q$
M"JPO+A&+@O7@)J"D31A?CHTD[NFN\0Y_AAY"^N39U75Z/(<8@L4S?#Q]Z&%U
M99.1UND:;E]=5MK%(;^NS-Q6HPI* *">BM,^E: F$T,Q+-B^P6*[^9J8[&-U
M,O0M!1:JB[4U'EH%0M<66U_MX>+BUP\L!HTH]\<?51L&_^Y^[4J$JN*)=(]Y
M]5+#:)4]*:OOB%"OKE5=ZGMAXTCEEQLLE*I7'[IC[["WQ>SAF/7^:QE85^/-
M>+UF@'M:"]Q-F3T1-'K$5#N 1*MHG;U#+B'&KK92/^@('037<*PV@>$<\MV9
M[/M;3+4%PAM,CD.D_Z6[>Y9Z:_1O7+H^N%V(:&=D(K&C6FNV7'"%V+@TF9=]
MF_^;\+FV*V;T2B.KP=\8#=YFC=\2G)Y,&WD3I+:NL.SQ(C6*^ O75NLG_Y9I
M1S6=OJ3/SJ> ^U:@*@:2R6EB<JV!./)/!*0_%9^MD\"C643R"_-LPH$2WB>B
MWNTSO)@X@HUXK&' J )ILPD+)_;#(6NOA1:]_Z!3VY,1G8PTV^78VC=5??[O
M(_Q&M<##SJW5C"9$W0".R6V:UP_"!F:%RLPT*R#2B9B,:;E0V,E-:G83XU;&
MU^S+A:Q+^DB-"1HU-M?[C0_VYB*>TO\(1B(TZ.A%!F?[4+^<E5FB5W*WW57_
M0LJM/*[MUY%D-Y_W=*&'G#U%J[1&Z?25[+6Y'9JF*H4>:@1/CX:,@,2BU$ E
M0REUO:WNWCQ-E0/F"K>3U=<0/G\)72LI/FNOEE)S-4,OIIGCSOUV';%3>^=/
M%OFX]2S080DE7I 9^ /1:L3B1FXA^+Q?34)#9Q'7[S$*H ^VJAM[Q=0<Y74A
MOO=8VJF\!XX[LB+V^.H7[_16N/C]5$'YKV>A3T"#7<!X-XWU'%N1F'\EY9J+
M-ZULKDD2W-E[O?.(4\^7-$;3*Y??4I=U2_S"G_GT7^&]^.R=EILYD@FL"G>>
M]I[-35%9H&X"&LYB*XF[5A2*^ O0F"#0@HZ0ZFF2D(SPO@@E>8B!Q-2&E#EF
MD\&-6B%%F(T\AC&@ WD8.RA"71)@/M8$"3,G$)/J6_<=2AWJKM,EMN/*359^
MK:0RBQ580#NYT0F%!#.N2@)Q%\P(LR_E+34/A<37*4/!O*R"YX-X#'UD+9=T
MNXPIY4JXD3)ZKD]=R]#J^?3RQDS6W$]@.#W$8.+N#*>REU/VFMWJ_G5<HFS?
MP!V?_A:;9GU+G0MKY$.O>UA;NG5^'RK<;:DW[7W$IF:@E]MO\NAJ>KU]TQ@^
M[9$Z+:9$7_TRN^!\X.%8NY; 8*='9F?S>%?ML!\#MP;J[,H-\*28J9Y[]O)[
M*BRQ:L5-"LDT'U(D68(H ^T"-9E2BZ3;QT]Q[=,Y!7-1N+4+OXQ2HS]XJW$R
M+;^W6G)S7%H%AE/WH<O]\,_3YMPEUI<'>*VFNLV\DZ1+'%<W9]JZ<\-NL-&'
M$WC\O1,N=@[V!?'I]SR^-9]4W>]28J9VXN*##ZZ0=4UZP$)&SMZ&+X\.L_9O
MSE<T]+$K$@P]*#K;2]6S+ARS#LG(F-(WW3,4Z9.I([&?8KGFF@$92B1N%:%>
M6B&-ZP(6[>#ZQWV4O1=$J%BM91[R?*]/TP3VVT-@QO<^,#6O:3"U]^E+(YMI
MW$<K/FX >X4V-,JRFF$^?3:-;B(I3=X@[NO5J&=FX\5,M8JAHSS4GE,.[SX0
M%/)\'?@?MF?[%KSU*\S^W2IH$[9;'))5. ,B+<V:=<(XPP >D^_/_99\*1]H
MT$0*IU$0']=?I+U^1Y:4"?_2&X'X'4AA](A^LILO4J_:.!$J1],;"]:\JZAP
ML@'K%EI>]+REW:5QS0%PK]9-Q(-ET&3@'=!YGLH,,U!P#)_>C+QKKFX[WK<#
M;-!J/,KRV]GD\-(%3[=^65<*!HQV6D>$.Y?V+,SNH-MWSQ'TP[,G.XN.;UCR
M*_1_)8AGDY!0^1*@$K>5'P-:<1W@]0I!W*5&9CF:/DV.P<@]P58RFP&EO-H<
M73+UXV3(RT&")7A\U.*(93^$58D-]A4JG.LITM"1=!YLRF-#58W"C3B'51O6
MN!A=L9.XUA)^*2[![-QKN\C<G[C&;=UT6XJFR[%DI]0"S+6S3FW:-!5.C=Q6
M=WS!JK2Q05FO>[ETAD:*A;,4Z>US5HF60FP@)RJ!DM#U$E^E^MH\-[+!>8W3
MQQ=VJF[:E.T=\S;P^D 1:I^2,(8V\]58"I@*>.:P$,-=^H]^*DN$NGT38#UV
MBJV@]=8=\1&AY(@ZT(;N1933(/$0I-YO;XY7KP^^1.NCNG.5!(:.^!FDE![:
M]<%DEQ7T%.Y@*J3R?87/B.O@]Z;L&[P'!'DPES47NX\M/B >,]QDSM:XT>/H
MNKGFF';$96\-HL:)_-Z6J.?Q[N.!%$NYMH!BPCYD]E5XV%LT%F4H!MI*;B1O
M%*%*M<IQ"<9J8,YS:$> @N'[SV! ZV:?L(!8:!4V,:FQ G9G?C5HAC/E[BHT
M1/D5IS&MX8;DHO[!DHZ2WOV]^VP*5+P]AIN.GK0$#3XZL@O,IC0U<G5[-;]\
M23H[%<(+D/(,[;J4V,QZ;I*6NL$&;F\R*UJWE[?1.>M,U[4AS8,%\F6C!E5.
M9KDAVS[83APV>^'7+*0+3DXEK1B%W[0&C_-=+FNJ&^\&&GXUWH6_S:\ *SWG
M.V1&R%P*74X9\Q+T?N;J5/WL_3"^@F'!1=^=:?C>K?99LFG3JU/?M6\O]7=P
MEF( W[E; \H*PIOE5H,X?HF01*5=]*7%C.Q!--U\>IEZ&^ME1<))&=IX2.46
MTC89;N<DF-0;'^'I#,1KF__X5J3AR=NJO)7[6W5S+BW></OHYP"7FAZ=UR+4
M[UK@7AJT5:4%5RE"S9H'"$S:6&#=)N\Z62XUTE"&2V77I7.V$1R\N1/TNO6.
MP9+.1S2"#0^QU2),BVL<GOO6[=P"-!ZB['[>R^Y.V5=T_>LNH#O>"M2BW&;S
M9BFS#L$KNV1!DPADVJ3+0#=C)=JL/T(:*-B;77N,1] 2H=;]SO,O$!A_O*Q;
MM[VV[\N'R(\6UP@XV5?:R19K&;A7[]D5/:R%_:]3-F;ME+;@V!GNNLR^^O#B
MUWY^\GX0WZ6C8M$BXY[K="W3^T(@/O3"M &M)E/%3.^'^MSM(,C3YJ&[_6E>
MJ)!P(R1K7-O^0FK'^LC.>1_0K,I%5U.FY+!\<8J89 Q];*&T)D:;DC96TJ 7
MF9U 27S!GB?/% A^@ENY1#IL+*S!!LS%DLOT(HD8:NL-83IQ&T%/F%F#94TS
M[PY@-Q657>]?M+!I?@4=[_ZF?:)'^\V!%QW!V>WPUFH!-KK\D.P;36K^Y>4-
M\#!B1K:< P%SL$VPUCMKRP"%9Q5U?0[<,S<C]&"3I3]['[HLY[:3*Z3<-=[A
M_'5HL2LJ,##$.-Z8FM?J]]SB&2,X2#=]-]VQ+?!08[=>!V+0*B$9K:.@A4 7
MLA4^ 'RL!JT:R!4!]=2[N*W.HXD)[,_A')6[\,9I-S18?KA4X$\3CR5L?CJE
M-Y"V>Z8ZHJ8'B85$#ZK^-.T4-!WPU%?/Z<RRSSR?)WR(9>60*T(:D>ZA CO3
MQF6P*3,_N%B^>B\L[0M+D/FQ/'(D0>=""'< WF*U]:NR!NB9M>%]C<9H0HAS
MVKP3J0%>+20OQ).W^!C$?3ZJP8R=F]5^,]SA?]EJE8W6<J9$59@.[T!#HUMW
MUAX=F<L.Z44VFQV/Y6+<G[)5_:6J3!X?;F&D#Q=$<^YA9*RPG?L=BR^DC!UB
M3+\_=]K>PD%2?:V*5H--Q\O7]JO/W=-UGQ>W3]F1LL_=8]U X62[C.\^^B!@
MM& S=C'TXN6<[SG>2CGQH4GM)]VMC6:C(^*.S5U(:;':\QAG0*P$ ;>C?]RB
M75QL4@]\WWL9NS@.+!#*/V"6S)C\S5$B5 ^^M+T(J7OOWL#-C@PX]XN)=T"
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MEGS=-SY;V<5G&'&Z$KW&J4EP'P]K 09Y955LGLZDSTC\3+\DUN9B)ED3<5R
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MZ@8;^MO,280:0A0DTU.L.OZ< L")5K;6?N.FS^-W-XY_^.GB).9\& J-B<5
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M;O@XQ+\RF/UUL36IR]$ H?C7S[X3DT&V'02[VZ);7[9RL\2HNZ\75L3XXL=
M>HLCQTV0+#XN'EL01K]=@Q>3Q<^/;TK!OY,N0(AK<P?L-OX262'P:8T]52&5
MYL-W-J7>_D_ZM[]+IEE^<O#[O>$S+ CN4-L^'A_CPP^TN9)?NM3<P(RRR:/<
M @M[;S1[JZEYUPW$W4RZ&6?JS6]N!AUM>[XY[#A$SZG$&P-K0JU?@M"5OH$N
M=90Z0T(/\OCA E)R?S8/&4I2D7R^E<\[MX$H(/!+:PO9/_/3FLSDWD<7[O@H
MG[FF,8OVOEM/0"][ZQO=P'=)UDB<,!Y89Y.$ZG"Q; @HSZ$7Q+=TDV2P;FSR
M7408H8HG?C/\P_8$_]Y$1-MDT^&E_<_);%%53?"A[+>S4V<[-?ZELH9F);^]
M)P$+8TBRN+;>@"8YF'_),#M]M!I*16RXO"FEC%<3C]M<H7+:Y5E?[['@N]#1
M-TNB,\&U[HEU_RLD_2)VJ\_?&$6T9NI0QO ^3?M[_S%G72ZU(!]$^#IYQ2&"
MT"$KW/ 55BW3IWNPZVKJN0/AR\T58U?<8S]3W^5:CK6V-K;\)*;]XEM+=]*1
M></O#[_7[C9M2(\C/OXR%7G1\&*=1N!&Z=;;&1497;T>%->JGE!5(V=50\^2
MU2#+L@4A!QKH%.M#29PU%2RLK\ULC8@(8=%VKMBI@#[$GP=\?RHH]P3#Q\PM
M:R(<V_^..-,Z^E/+.=./WGH@ZXVRQJ</5? ;(@DVA"'O$IJ9O-W &C\4\JJ&
MCG2+;:%'8CT7>1\HN7REP"?%#):*VT>#)L_;2'* B#C!&0S?<C27/;"2A*Q;
M5/_B<BK EZK&'[+Z"*?#@;-N:9M22G@EG+&$FAJ@-59^*N(0Z"R60PM.H(LU
M '+GXH]%.A(L]!LV,T>$<EQT.8PLL;)??PSGEDR_>-_]&,WH3&UG1[==VC>^
MNP#B3&UZLYUQ:]WDII1OQXXIB-I+;B()=_9S&;R;+-X)]H)0)9/C318$3 DO
M#TM 4F%8K ,Q>W^7)]@")$YO2_>:!LX#<"6IWL<F]%1<O.[=T-(VW+B[]PN#
MT[XW<L,=>_.ZMO+KSDOW:#_]<XU=3C7YNQ<9N)0;[WJW[W:10<87QXN_GGTN
MKT3]\>6+VR>),+F+LZ_)1ZQM3>D*B4!)W^YW[^92LK- Y7?E0-$5@Y+L-/M%
MU[C708;VF>_T2/D"9[YY2L5<JU 7V]VM+I8%$S)PNRL'(V(KL0X]B<PT*Z,?
MO_3SNI)$TAYM(S3]NKPO<R.<@.-7S XDH0V:FA^S+Z%CV->&:<=1$Y@>S(Q!
M'[/93;CK@5B.6X:["FQ*=6L[.(GN$2(9*1,2X'4M9*/2\## JZ5S%J8DC")V
M)]:04L. +X]#$WD)SWHK H)7;'KGJCA!?H@SG.U-@QC/EC&U[78_H" +7AAP
MPP+2;>DD00:T3@7=/@+@1LMA;L.KKA":.MI+A7L!9H^%'%;@!];PG@H3Q_ V
MT)HO(/@(G3C_@7XBH3S:1H,^*33=H-W]S "BT&WS9:EHUI3^;E/C]^;%^L_*
MWV<;UU[M:IW\4I-5D7SANE=2TC'/4B/7EJ:V,HXH']&JUB2T[V'5CNMFO $\
M&_;8A6:]\LG1M<U1-[WZ"N#+WRWU/_[P6XM%#>?JHV7/6@A683B@*@=B>XF4
MG^D$F?$? O%KLL9_HO^-\C^]; )^DE^MT++S&%*-A8^;ICZ#K@W<-[A#55 ]
M6$VW16\="%@L<"U\AK">R:$EE#F;\>:?^ <5E\)FS4TWI:CP*6XO2A$9!ON]
M$:E/YZ#H_E.@K(*%N5.@F%\E5,\0N(SBO%CMRC[ [Q[#ILZ4; NW,?4+([B3
M[+4M4&<077^2<*5NK!J'?!;H:/;NR.Y@9#JS)4*H8L!_)@%4 @(%9@AZ\?I0
M/I>I@A^U.PQ9@TP4D-!)D_[4'2,PFQ'N'3< LXH-1Q%&+-@J9BOVBJV_B]UZ
M$)0>'?H?:G&](.7H!RS)N:ZUJ4ZQ^ (QV_@^[6Z5S8!\-DT.FZA49 D\2@_Y
MU5Y%4S_V]ORU"]E6V)>MYIYE=4]N%H[UAZ##6NVE8?GT];3ZCZY'K-ZMA(#7
MTI(>AL01[8_)W0R+#*D<*<WP-/:JR"KG>LL=I!CX#<"$-X?/J'Y?6"XYHW)^
MB^1/1I=%_B4=O"DU]0F4WI3R&-KEP[/HA$&ZM%YD%KG!HHLPTXT2/4?^0Y@>
M91/Z,C>E-);PTD1^,;3.L4@)WCOV$RZ-I08 >:VA>Q(8.^+=8,&?2K^FQA$4
MFK,YMM[Q(U=,G]-T&_/09B5"__^[9>@&LTTB2HUQVA*(T?A=X]T$GZ'RK>#-
M=L1JH:N(NBK48W,%IW'VHN+^.S^C49EV2/+Y"=<J8,5YW%QXUNJ$0T;/4MN3
M6/_I7TAT:H'C;H>FU&YV%>?[\8M/O!"V-C]'GZR<*B!/1EX(7(,Y-5T)]A]Q
M//6$?"3SAF/3KV9,0?@O#.RJ"R+7.\_$LF?^9OS9D/(P*,L36",V[+A.(:9%
M9PT QM3&3O>'I:C=9XR=GB;G.FQW!MSX,Z(T_#'QJTTIU>M#J2BM_,Z99W/Z
M0$XN=^T/[!K[]X-KV690 @CK]!_X&# -/>CR_SRA:4^Q2F]O:*^_KQ!Q9KA)
M+^DZ/4!]A/:C_=2FU.<:72?&9'S,D=,C_PF\*ZJ7C_I[%T9_Z9:9P?S4>E2]
MROK^]5+:'-R&$\G]'E%@&/JIPT])^J#X/C(,/H/LWY0"O)B0B<%JIDPJ7D7\
MGK 5#\>_)^^P0!P!D"QF#VP']@$7+J';M#DIR(=]*\)[],N#[@),IIWR"GR7
M,);*= R)8S?93*8VWCJ\<.:#54"VL2_=%C=#7H4+528Y0SVDK?C7A#H8SUEA
MLL^7@&82D<!Y%Y-78B5H6N"$'V3(B96$(2U R]U&0J:-04:UI1O1)D$B.1HD
M(Z#UW)AHOH?U<05O/-9OY]B><!@6^E2X5$7M7/(7K.V@**13,_M"0-609(JW
M4^YBY?T*5W(M__WA7*<CKG;,=>/K[@497@:N,:4+X]R/7(/>SWML"\.PI@X[
MOQPS/MSW(G0AE9K:%XILG-CB67IZZR/VO!.-GR"XOABZ8(J@NF.=--Y:CA+>
M$$F;4JQ"IHH8)KPD*L'_(41#@X*#.$TH5W!,N&>TXR#VP5DH%XRGVV*XTU:H
MK8O!Q^L@+R!-(%9Z68X@@/@5%W!KD>12E[.?%Q&J3B<HDCGR+RW3-@A#-IM2
MI]9FR'WD1N^7 HD@ZD31]4";H=[_X;8!UL)=!"X"U7!FKH%E@E*$POE#/2AY
ML<8R4VTH61@-(UH.D._&SD*+#FHOS>;:.:'L6VZ:IK!G]LQ_$'"ALMS:*^8V
M!NL)N=:J?U4RS='\>JC&HC\HNM]%\%< _C5CQZ;4I;4]$NT )UVV$IT:#0(L
M> D<VHR=F82V7XFWD5Q:Z$ +,;Y(O1>_I:%^^)_"LVU@T[-UL5:TN/()\A2V
MX@(EN-3X*K9YWD:Q-+R<L\3^C^+H[?2T_6_1L\#C%:4>TQ4N'L'FRKWG^F'W
M/KRK^W5%63NSIW]O"IK]W?"?;XN>[P[OL(]-K_+1\MAR/"3B36J%>DK5CE.4
MS(>UF6I+Y_.,":]B$A,Z,<EB&]%_=F:X$Y >T._2-"[>*W0'KV2R:-O1+6VY
M.:2(^.?1+?>F_?3F*BI<,&&A432#Q[&QB/\.G)U7<SQJORDU-KF*!@VZ)3G%
MN,-@<=;2R0WD[AJ35XD^W0H)[!LUP!"[I2=;2_*F8,+NHY7A'*!!#)H2&"E6
M!F$DO%KT5:$MJ'Q.K!2DW--A ;2_7$Q4[>V@U 0$8%YL5)T65>(ML5P.3*C5
M)/!8\5\@<J&? H]@7#AD 6Y*<70>LY#2Z UJ#YEH!L+8STEQ;)'K' Q&B%B*
M#72XM%[KPAYP40M2VY2Z,%X*S$;6+JNK\=XXZ%,,1W(# ]<,=H]1W6#4.O&H
MW^4GQN\;42>>4-R-/4,CFXN>N.>_? 2E/[I0E4.Y\[IV[OW#*#;P@AX<K8?D
MP7Y:B&)+]]AO2T/YPWU2MR+T_$;>&1AYI>BY.*F&&2-[U_O64O"&T%:0Q,F7
MH)%68.1Z\"'H#'=32@UW#'09(C[_2FLT$IYD?;JR_M?X_/ :YO+U@9?M5FO5
M!D<3K&UN/1S]R]W1+"3\$.U?[/^W ;,H5X+)G["C_ R0*E1)XJ<09LR'>O,2
M=#1 :A9""_#%-KSR[O@CB3R]\!>4SHT4J\UA$T^@%+%7L2^[&J:'*K35^Q/D
M:X*P]ZT*_.BG*[6N@F*K_^L:W^M42NQ]EP\N?"Y-3]'E[2^Q\WU;'SCL?M_-
M[4L"TWGZ5K!'-NU1=VH=5$KTS0IW3.^9W"CU0<%XT1X#!L@PKY&G\^I&UA&N
MB!Q@O?4F.0A%[=CUN[8=/RH^)OK7:@@RG$QK(J3ZYW?6_#':LU&S?OL_4":S
M%'H]!P=069.=P2;@ 9W=Q%?UD%>CRQ^+@=&)I3W%QS*2D(I^'Y>/!)A6:3]C
M//(2%>-?H;3I)D 2_W>5Q1E(EW-11&5-\GS !/ZDZ+Z=.?J;BD!O,E5\')OO
M#4SDZ@&/\[:OUB#"-J6VOVO+'6M52SPY1O7":3 O4V6)O>,]IY6-[)6ZCY^*
M"JPL\G^49:=3Y+BXMMU&.$+R;#GV8@TQ6+]GFU?Z&[934^)T5YI^JE/PA.^3
M;>K&@W&!P6IWOI#T#93<S/F6QB8OQ@KJ$Y!DS/206/:,P%D\BJR7Z1N:C>Z<
MF>P:DL?I0-JA7)&#=STH;N&:P?OPU@U0!#L J0HU<]D3N12L?(_-T=:8T*VB
MYHR6-NK=ZUK*'-VC^69C^A/+D80C)H*G8P%=J(:U%.05)*0?T6V&II]D,::<
MQ=OGP<K)ON #WRCU$LFS C:OG(1(H'J/C^;E;9&7NWT_05>G_6WY);&EMSH$
M#@7+#O4WPWXRII\B,]5TMHKNH%BJ+:L?R,#?ZZ(L-EW4=@4G\>URAQ>Z?1B[
MF*_$1IM2J0SU7A)T-JR0X]6?Q1,Z*R;KE"H^WCWB$7C+>ZB_]&F:<Q+!W4]!
M,R?5.#[J5+71-<X3M"A$%.*3+3<R[V5DC+ULY:#G7_^P=9^JG5^<+Y01;!BN
MX?O%]V.PO'QZY\5#9-_7;-2N;W>KBV]>:D!L50_V/7<)])N(3>6K7OO8YEE.
MM]]/KYV;(=5_(;Q234KHA4_W<ZT[2=)"->@>:-+) +(A"SX1R"GA,I)GAH0'
M[%0GD&P+H"RWO/\9<YDQ/;.MM7)Y#O[-2C:T10#+,+WNXA0T=_GHM;]V)&\(
M)4FTORC.2_3$[O@B? O=@B*T_=WN:.8!1UQU2^ 0:?W[CG2F.<X,F#SWP72T
M&[6#$4-+@3<J1XJMQCKDHSK47S:UCV#$\E G(O9ZV$2-.0:G'K&MHAK[8,$"
M,AGJ0\T>X28(=_7S'4!Q)HCI9&@0PN4%"I@N>)-%#@Z. 7R<ANG.8,,KAMH!
M8+U;J]WB;*;;*.(F=38P('(R7\T&T_W2M_'1C]F0),Y*V)WH@($.U&I4[,!R
MJ%Z D@W9.S?Q?"F1U-!NTQARH=6ULL([*]3KN#?5U9+52AVT=ADEMTB<(VQW
M0 8@1#J8OZV=BESPK*=?T=4N'-^8R3'90NIA4S0M#_]B'[R9ZC^E65N2SXEM
MJM-X;&QI6ZP=NB^C!*((M'\7?>(-\%.;4G]V[,=_://AR0H.X(?(<F(-K, 9
MPG PRN(QLAKB-$!QUCDPT5ASPFN$VSA1TP&'*-UWY'^,\:IKE,]/_! (:AQN
M-;5G40;NN_T%1@B5XOAM0$0. 4T@^G>T /X$%?$@H>$GE7=&KRR;BU1:N2J\
M NV+$Y770Y,LEXE"5N9=NB,F)/;91W^4'[8'DA.?>!RS2PL]L6R 3)(,TAI!
M$-@*+?_?BI IL9&HO&/+''Z$L*U$U"B6FX(*V6EDT*07*8?YJG5^F*X:@^9H
MP54@.^=;%P.&%,[R*F<CMZV[U()_?BA[3*A8XH^V?T3YX_R@[\\E"@X(H$VU
M</@5-*Q/L"B-@<9,3[*)G:AI'MVL)&C1[L]1"?MC,OQ=^E,:"5++S?GY!=D-
M40R)QJ]:$NN! 83(C_29P#:=TH2(DOZ*DVR10:(?/AAX8=SDV5HI"IA]JQHQ
MZ'JL\L43FQKW77=2(KL\EUZ\+7(<F#&0NY<5H8@YH=U+]W&SY9BJR4\C[*0%
M8?.-H(8ILK[/Z\W5W3H1I@R9=$IZGGY9R%U*9F]7DVFX6JI>VI-#&C;CRR%U
M2J7" :P#_SA4R&%.2W-:>(UM:_\*D0"![=:S)BN$Y_7W^)<QHKENVM"F5.^-
M"7\2WZ";9^$&]%&?+DLL_IDQL_BU77:M' O%3!=]^X+.^.-/\S[9N=(6'XCE
MW5AN"N(NI@PR' /I6_S[TSE@"F?&A661FR)Z PIW%X2-6Y'3@ZU!6&J'_,GR
MMQ=;;EK!%7!&PY]'(_S8#I'/+R_(J7X@+URA7\;K''-:V<'(M,\]QD%9'\:F
M.\QX9MVHIPYINA"LCMM1%Q%FA3Y#UV8>]\Q@$?@3ZAZ&&=35S_4%7G95*54>
MW@NF 24>VKN=AJ8O5G3G&<ON(=TE?+9E(04:31:BTW2WWXT#__]]LK,Q;#9A
MI8?QTV!GPOS_V1$;B48<ER2\(U1Q"TAF$?HP=^'-:T)E#)_P@1'I1O0WZ(41
M=;1%)00T4DEH#.91V$77^M[^DD=K,KN(#2]?CMJ71$=7:<MX3C0*3KSQWE)^
M3L>:D$RX++%W+[F856VP;(&%Z8]&*FQ*==G/:0_30]EK2EB+0)T# "H; :>)
M*FTM>L1JXY\;1S%7+ <R!Y'NHS.V/HXC\888RY5[1XO_9]6X#A^C]F+NH@"7
M=C@K0:BDSI8(A!-\5#M4Q4:E(^MAR3_:3;BEU+ZA#)TM+9!N2&P99.&*CF=L
MP4H' J6T3+K5K9I/Z/R. Y,TA.,V*CM;;8*_[C+2U)RUU&*>_VK.$)P4[HD%
M*&P&C\MBI+E#%NR%KF@>DG\"*+Y=(BIDNV4)M[+6Y"&*+W1PXRB9\[+FGVC-
M1IL&[$N/CMI)JYLUC<STQ*U]]\J"!DH7-TP34 XHPRXGRXH/L=D2NGT)&]+,
MC;)Q[_V0[4@/LGG(WFX?^''JYH6*"Y[HT2N'W9V_G6L@-6Q8@8_H([G^4SN.
M7NA]S!A?_@<XYLLMO^27!3S"7CI6;6ZMC%+VOE]J^.7A]SWF:F6:JD:<$-?K
M$:YQ8K-%VE<!?[(#,A'\;;#J(,,C"6SPTYH(#T+G::$LL.X$30H2(&>^/G2<
M$,>*;G<XWP2N=9[Y():&:%UXVPF\7)1CV>R*IEOZ5[%JE-WN"6K&T/F7$.56
MV*VR&F;W;[>'49<@CP\NALV #*V[F!GD>K<ND0__3T@/U'PM/ !E@M;LECMX
MM=, G#V13K/+!E[V$.K7LO/[4(H6B(1JB&$?H^P$_JEI2^N3?_WU9QI@.(P[
MCJE^PW;..6=_MMR>/K&_R<O%8;H2:YSCTJ;\?&Z_<14V,>H@VBNSQ][I&ZXN
MZ]>MCU4]%>'Q]>\0]=6,K1ZJQN2 8I/T@XV+IPZ]JYV^M._A1)Z<R=$^IS+]
MPQ5W:O8\;SJN=\J\)JHQQ./7OJ>,X06V$PX.Q0@0^#<$Z0X5_#MF$[F?,.W&
ML5@-+8,8?7/*D!FPPM=K%>7@#?MK(,=GX,+=#J0P&!(\QUF!S;?!6/.OQ+O4
M9DQ&\-;FB>=FU>'UH_&S[28]WD?)R>1Z),^*BYF&B;>C!>>$:%&!_HBEFTHD
M&?"0+L4=!*U)]'TLQET;YAW+012[OSLZ";9SJ0W/".-8R/1S,V.V:#G;C$PM
M3]P E_U?C';7O+,V\JHW/'^5_ZC_+3 .JH;M,'E &E^Z4&4X_*5FNT\6Q<]P
MJ+BP;;U$X^UA+ OA2GL\VHN P[IG3Q]_^^V)JJE]G-R%RH; *];2]LVVHP-5
MG,,SC5$LJO$4II+#8AMH'BMH*I\HA2UL2O'M10\Z+/"S2&VZ@0"!@S5\N$*_
MQ5FT*EQ!TR\\/\U>@RTE.A ;7Q9%!TY8Q9SAM+6I%=PH0ENNQ90N;9357#O5
M'5+VZ5V7S:^W_ EGK8&71GZ: 2<>\\(B!S1FG&\&JT<.&!\Z]=HI[\S%%WJ>
MGV$_]D.A8&'_#4E6^3&GVKBG\_\"..)I)N!,DL*YBR@\!)(-WS%-ZR'O6;2!
M]S*4(S4__?Q<X-57%Y+P;)D0D3$79.!>_^+EJ&FC2->C8%/*I;ZYF03%B.H1
M$8*_<2=%96)SJ)M/:P"#B+RM-=BT";>[><7' &U:MX5*=SRZ9,D??\<*(^V'
M3>BZ,2//2#6S-#(+S>S>N-I>EQ3C<I^]YO\5C^LWH]SI]G@8-5X5L/(H0_G!
MLQ+'+I6KX^C9]0>Q9+-+O_QQ7[U41RB[O7YBW;*.Z.B^C_4T8=4>V_,'>Y5J
MU3V<9E.F"]_A:J)5\ ]XX3[61F6%S?61ML%/'"Y;["M6HZ0Z?K$R^L?N&(@4
MI@@EV!@:)T%C/4[E2M6]__]7@U5"4VM1(EE,KKZ5)BWZ?F)3JBX5)O(,(RX1
M5A,DZ-T.%0E"A;N@=,&I)52CP>H]@1W.! KA\BS8C'2ZF\ =YPO"NK)-L0_\
M1QIY/LXYH_[-$(%#4MQN,>K17-_H<CI@=.UKDS9_@G^89.YHDTF&=&D\=!E^
M#*5&N#1(<(<<V&MWD;*,".8N_.@#Z+Z$/SOVMD-)7$9*\9[FAA<V0]V\I+^
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M(KI@LB;,J;$IYEZ05K!NOK&.<];%Z:,GV\OO/[JZ\*':PR:69YL_=X>^/^Q
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M3:K0/-F_#\PBILBGQ+6P=AE@RWD^H;M#9G:^%PK%J1<Q?,9F#(?LO&>I!DY
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M(W:=U+/?//KX"=OBJD<L5H\XHW07>.#<_& 6+#+W$\4>6@.&*E)[.(N#@F'
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MRB.&]ECT^%A,^]M.O]DI/@Y. )0^0CWI'_ILF;MDF/PRGBDE:8.^%7V@6I#
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M(*GN*UOQI%^-@Y%R3E*UE>Y-W*'L;T5?R]3^&QR9?/W=XM'[?-<\7HSS\'S
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MV1-;4PIA&*:B\C*L'GF"J5:9]LYC*MTN<'CG+V%'GXA2(]'OLF>T4V@S%2C
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MGO7* TFB@GZX=N+V;[X4P[;AW;D#$[J$%-*A."06M:L5K02ML@@J>'\NYX#
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M' :KVBB3S ;?=]"U&X.AW[AKAH)]] T]J)+_ZQ+I(#Z2%ZJ"OS-(D"RS*6\
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M?Z++N-)QN"8I+"T"B]YWG\FM'7*SYQYQ<L^\I/69HX TDHS- D\&K2BX!;6
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MD"$$BV')8E@K.0%OS?_7*[XA'HW9(3 % Q):5Y,Y!^OK(\U>>-L#C6V\6/0
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M\[25+/2W<K'<.C\@Y]1S4HBN4<G1A*611-.13X:]JJ1,C+)AG(YAG^I .N;
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MM@,[#W.S.3[L'PE>S$!2\_(>8C<*1=@R)>].O7N]D#'><,^J#^US#XCJA<[
M%+A1N*:FO$=SU5DSI)JTS^@ /KRY!V_3TB@LH5G@;0^[DS#PW1'FD6O=HI8O
M)A5WJ5DH4X6EK:ULE]6,]TOE6W[+=$,F5QQ0:K,=LS<]J;->1 NY&6,O$6J8
M=C+GR?2KD9B"2KF !8S$-$;EK<_'Q)<OZ>5R9.'MSAHMEK'>B:6),[J*A],2
MJE>1L)J.Y]80MXX3KOS;@)<<Y'"G *(Q3);TF":L<V!&*1-)[:0WF-#CTF$0
M"(#<Z>/=$OC+PRW1A>8E'Z#*QB..YW+FG8C/LM#AGRIZ4AD8X>B)XR>/SW83
M#Q _8,'S?F-DUF5N&&\?<4A! ;[';Y\G];F_&6V;H^WB3; -<>ARA73ZR5O6
MK_L,#^$8YK0*CBG3+Z(RUK+%#;(<K# G+7;O^2#H6+*7][RO0V8<T,5^SVQ6
M#D?;!HHC"\">&RW?C&U5+B29>8NT8J2RB].\ZS\\SR"7S?6&3/'DFF;6C84R
M_"/R(CLF%7+DV@6?63<S"BXK?7SJADIR>#N[L[G$.33'9.3%M-A$VI.;0"^9
M(V)N#8F#6%87MX2/@+/3PV\<FW[T%;^1;I8/E#--VCV/E?]"V(YC:CH,<P+I
MX]@MG./0'<8ZYX A4=CH*',V*A"U;PQ_&2ET]F3QXL;U]+P:R92'>GQ$QM+_
M4>(G[YU4T)-]^M*LY;&"RZI&%SN3[;1$PK5C[C@<=+=,4O&/G;GNH.%W+^G>
M.E%TRX-WY7)O'2OWV%V[+:K\YO1@L<E87]/,L<("JV+G<5.&SU"KN__3U,IU
MI=Q"FYQ%2N"2RK]$_AK_COS=^A/Y.X[]:H1_PFO=/-EF;I:Q_:]&_JR[77I-
MX@S/*0\=*Q6%;)H>OPB_4"%<_]A'P1 G[-)5F:&3>CAP6YE::3)"?S8K5J6Q
M6Y)=FTJ?]KN)71$/"ZY3<$/+/\37)XR\4ZW"V=5=5O:BE-X*#%K^7-*WB@LT
M^5>>/'#A_5TK;/ZQ%;/+*8L^#$%D'!8T[H:49A?C<SIV;9XVVHZ"X^HZ:O?G
M3[XI&?M!Q? 9,"^D47URU+DES#D1- E?,5 =7TU*/4(PS:U04M!S*X;2>+MC
MP:V.T.; \"V(Y$-'QFA]1H$8OQ#*#B,4P;.\!MS<P/@BTZ@2G*L(&_K2*.7<
MSMSAK.YC7BM#H(W:X,D70+L/,UELUZ2XV5%H^W?!>$[MNL:QSV?$#DE;YQ@G
MYM*5[YVGEUJW7B#4%R8U6U]()F<(._L \03=WP;;/"X^MW0W*S:\K7NDW3IS
MCX4*UBX_[6,-X8GVPY>%YN-GA<VB6VSJE6O%%VQQ[PVCT",DCNC6-CYB+S"5
M"8C NJZ<MC,0B]2-:-Q&'.&I#3;JS6%W^1+NT)'AI"J)WQ>FEZ7Q=4U!J-WU
M:$;'=9Z0S]W<R*#@3'*4!L>":6X*TAX2+#,D@L],M^COJ M@WN4CEIJ8W_Z-
MDGA7<T2^4>_2J-TR> P#M4@"95E#M1# 1H_CQ^FSK<N1*"'#8";F5 ]!$51L
M1<L1K'*AAYK;QZHCKGO"U)911]GNZE/E)!EQJ3[DC8S&:SI7T0*'CJ!];\"A
MI,8#>GK)[M!#/[&,IU5/9L*'W>-B[!3/DB:*95OO 1ZOTP+&K?S7-SYL31Q^
M/WF<<&Y[@IE@VOX\O=,#)=!-%RWK(B9I['H(:_3:M$Q9G*.<.2N +F?[ZWP;
M>8$<2KE."W4RX8A,H"\'8TY!L;>8=RB^72A6<@U3O?$Q/04*5@Q1(^CFSDG>
M]6-59*B'M'BV)DR.6:C9H\%(C;@>?8.%QW]S$N-N@9[ ")_"?6KHSKX(-)TG
M&N RMD&K H^ :Z@1C666"X3+PT)8^J+;@1[>CY@I5U7JKB+\_'L:(W;H62[^
M!':D2]M;9D<I(]C+L>(F$BD=[9SW3?2[OM6QAZJ5)V5\Y':>C%7LYZHEXXS]
MZ09UW@/^.M<WJB581N&BS1^4HPK=*EW.S+8,M@_E=S[MCW'YIN9A$]?R]<62
MV,+'$<EMC3M5'CO9WN8](HIO)I)?R"B@Z1C:DSQBPNH%UY9&?8LX0E#^-!\1
MY<- CP*F7!*]7V>O3:O,;-S'?K5Q!ZB8,=Y96+<S "5=0ZE6V-=W_<#@4O_B
M1FSK\Y\GKFX^-TU$$3LF-_?3J"9L9P8MAN83>XSDN<F-B#E=4@70JBE-'%Q#
M[5;C^$XUH*8F0XKQ>:T;:Q&:1K(?G"'][C=?O7^#''XNK[,/MAZLC$Y+^[CO
MS*%H4/"?/P<7I[MO]E'Z-3F58"MZXE69HWGV 6"!2KJ>G9G;P@4S3/*26Y=N
MH X^2"5.UBCS?C=3"K/TV8,WEN02+.<F@(Q\_V$FNK6WR2P@I3)F_GV 37''
M+G,[I6K)E? E<V8L'^'E-^8P/=ON$?5I$AU-DS+:3_BYO*(^>,U>WS/:T*[
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MIM =6BB0BF<4FN[.T8:"F5L7T:\DJ?:PCS\:;\J08SJ,C!![41*).F36ES2
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M[G'%MDRAP X^HJR;*^OP!LG1!O[#)F@6'&G9WA!\[S _^C ?H9VTO')!X#Y
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M=^,YT!/VO#[>)%"1_%BSB10J@K-'EVDNFK\<Q<7#GH?,&_.6R6O#0DKB57F
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MMX8]Z:;GQDQ-7;WZ?&R)[PA_.172& \]YB/VN\$ZZ,8RU^#B\/M_G_< K*>
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MF>@VS0C:KD9-@ASD_Q)H)H$>F85CT,/QJ9(0/Z: 521Q/]3??%R8XS0T6S7
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MP)GR*%E*F&$]R5SL]/NILQJR&.EIQ3O6-BA1)-@4V3)B@#AWDZ4-]8(<7^B
MT-/^FM]4YN22M>5>05=[> %&N^2@\^JV&8[+[4<[??QICDZW33<E:N1=\BC4
M\3^1C7E2_L.WYG[;Z8\"RX:K;<X6>N?]#HH>506.<"R,D3KN-WNMXJMPYJ/G
M1N?&6HY_>\TBS\<<_,_QFEGO.[B<ON-#1S^RUQ&_2QHAN-1-T8W45.Q3]'TC
M70,Q"T?+23Y(0Y86%A +#=+BV$FMQOJ WB*U DH#TGRA&"%;"U(Q8JR*(_1P
M)T@[7V#T'9W!OXCEJ/6S/R63)HW@P9OCWS-!%(\_3N4)5JMTCSV!$;)YFDK8
M*E7N_PVE@3QG*$CJ. $9"O6? ZVB@"1*J*6/I)?W3782W,L0&IT1_9C<"M51
MA'3#B/'+98! 5,C)P70LXV7;$_:%VRO*JK]<(A8.8D[CUZJ\@%W6)["0AQT+
MDI0,_7YR<)9$?YB&8$?2,^V5L/E3\<*2-:]ZAH-Q T+V#4<,T"NI5PE@CJ,:
M<.#P<$4B7@TRZ"S5&-K1-D0_ V*SWY;5?YB;W-KZ367&9"OE-;*5 %[2*\]&
M&\K@;)"=JOH/2E@Z94L\/87=;,/.)>N$XS7)",A.4C^$(I H!MU\K:B0O7T*
MU%$1/"5 L1-LJ:A6?41+H2]S'9#%J**PRS1ZS8L'D8C45F0JJ];18/CVCJ<9
M?I5/CM6%C)V_>*((913RT+X>H;)%80^%7G&[?3Q=C7PUG8<^/ISSNH^)\17R
M%_XCG#;^HRZW4PFK(Y(NA[[L'#Q(L.NMXK:5FF<TWB-K%"M>=[FG(G7OA-[5
M,XLC%NOEA2Y9*6$!77R]]*YCU2+:!$J<V@J:=K/U'77%Q7)#(8^CJ@I*V!,D
MAZVF>'MLAJ*UY&0N1JDH/>J#:<=R=:8L0N7D(T,V/(,*D1EQQ93,A(LRIQ?0
M%=#@,' <5]@I=V;(5W;;YA&+/K F(5,I%D**,*KOC\#1>=@T6[L0ISCLF$!"
M9H)A'"D\PW@;1)@* W>FMH&O.%WG09++B#4]$R<I%D5[< H;/1]!S@I]R*%S
M<E=_=%P]-A",PMX#8R7NP.5Z(3U)8:RJ:-0_V%Q+30YK,[2.W9Q%#.L<QNN3
MU4FK!F0'ZF99-A08<7+J,*AV>(CD*4P8(1M!/LA542OPFD2J""O;%6#[?1:'
M;M1:_(_]S_D$, DK?\#$"I'JLIW-+5"@&#[A(#DAKV6:@U^.#+.,3A"CA&$<
MU-BTD'"#:10+^'SO;*_.V ;=BA#M/@=%) A1*W%$9,=5^HUR@,*=_;I("A:^
M/!_ON69OO/Q63MENU)F;]_>].7+I1&3LQW+@]OW*":]ZW)UM0?K%44;^VBR$
M55R52\6W"B5LO2JZGKYZ=I4R)G-*YWSL5TVBWUD(MP@O'/S/$]]:OY>UXIC1
M^UY(H]+.MKVFO%./SMVS,=O?Z=\+QF,B9NC[GD+5#R=)9T84JGSK<A(Y1(<=
MAJX(^1F6HD!:US<HR*??T4T$7P]=TK)]8\'T3!!]<3K]2LHIS#NI1>FZNI=*
MB=[>FL;(N9"H=4'@]F/YUY6N8Q&>@:]TBH8<>F)\LOI>#'A-U!=Y6I/-\5I!
M6F8Q=&U7_Y0MGIBK&SY7I%<CFL.([FZQ1]R>M52K$=]:Y<4X;_3V^9L4"U8K
MO 22W4K8\W^4L*&PJH#1(9#_/W5(09L)\AO'5>_)=5RV6%0XW]^FA)W]:JZ$
MX29WJQ#P&;5$8S=]#3@R+P:D(E3.8R9%=32R*P-+'YRLFV]R.M@,UP4GX'GG
M_KW4BR.VJ5(AG8/)4NA L;7,?JM@'T^/KM9+407":)N604OO;<%['GEY^I?\
MY?*VO]K=)O1-57[VHSXW)\+>R\.E7U@E)P[^'>;OL8][&AATNO\^\F\@+F8H
MV._"7^XYY\G!:P<*F$M^5]SU_2M\%@L_LC7)?<AF1:L2MGIG"Z0CIJX(QVNP
MP]I460S/,;8%C--L7PCY!J1_07?H$%S$[X*O#9+Y@GZ3*82:"-8J8.CS/=$+
M%T&'\9I^IF_-E]C9PO94-FBL=>!D>Q]SCW =%MH=4@4V">$WEN!(TG;Y8W8X
M?)WL&,00T_Z0;927D-5FC WEM[XJ##_(SD%93JVI,LNHQ!I("9/X0C? S4S3
M:B=6/0CG$6J(DJ^@M98A]]@LHB!+31+G;_Q%A$QFKR>PI\HH&HI#.(CR!@H2
MLL?@8M<N>50W<KQ]^[4L7H@%U ;@N0KD.U41WC&8SPU CB.0R<S#U^35$978
MBG'5H<J+?AYK83Y_VMI6"Z8)U;CP#&0+?SY%?(]DMY/?B;U>JBU_X!CSB'A]
M+D1?:H%'.)ZJ)+H*%SD+Z.@-*LE5;.C-L"09/"9Y#5HR/$W<[8/OO/ZGNR;2
MBN_$8)8NF8T>%'U;GNS] W'\V\MA[KN+%?YW(B%"O5^N<3FWO=\/O%1QY#;-
MKN53?>0%JYB,Y=R55L+E0XL:G\U7=PWN.^BUCDY]N[_][DFVT0W>YT 'OM7@
MI<<G#Z3=\\\-I0UWA#Y###G1)7E5=W<+=[HGU_13>_#-U3WL<?I4MF([<%=>
MMLA636\H9M0 *Z^6>8J.3L&3_5L$#'J/(79+),MXF+1'K*7I"UV[6+H%NJR$
M <F[\F,K9;J#BBU$OA<38I11(??AKUKJ%]!LH'4!/R5/$#,:"L6H;#9<Y1Q"
M1*\P*KV%LS9"$]UL.--!Q,Y1PHRKVH#)"E!'AHP2J6\'\9G1+/C[.1R\J]@0
MLU)@8<#6L:%EX# 9S8E?^-I$]\_( /E#LLXL1H=I645,<E,1+%U$[6&OBKP<
M#3ATTS8P#:8(&WN!@.[2;</-YH=8%C,!I?M2"-9]@&S\!.G/P1\"]3E[0H;C
M,4?#,^6SN@WU>XN=6C^[+NA)-4A^3X<5>T@.T"'@[7?1[Q;?<-08?HHP+R@C
M^;2#A.O"(=8?$%W([L$:$K_PD'IH4X[*Z.K.&F\#CY-M:*)-4..5!MG!=^2M
MQ GN[_,_YC5\D:6FY_,A"Z9;8@LB\!PZ1>4[ZF_2(Y_<<5ZW<_45_KHZO^<?
MJ6V;CW.]<TY4AZ5W_3UTR*?LP,#+NHL!&T.?K=L5L866%FNZY0*B9?_&_5M:
MU$4QAQQCUQ$<Q4>REAF(N\R1O54YU9M?W?_^[[2M)^Q'+5J>RU^7,YM.0&75
M$$%$Y5"3[8H,,@@,;'KI)I"7;LW6P[%3)C@MYL!/A4[5T&-&;X3,,UJ\=C%>
M#W3*;K\FR1<:!7%N_947^,7^,[4F9*;E*KUVY(W[AIM)>4]KC8D.U6_T#@VP
MJ%CRAIR2DH%WLM,M",;:4W-^:196<2$F6GO#7_J5;7$FF=?</OL^&J\54IP]
M>*[$]OV5DT&[RS.38/1<DHX2MF?E[U.D;RFG"/)@"N!M+T7\'[O[9.MZ%1V_
MX9<'NZ:O@O;M;U%*V-,$E?[7$S1I9[R=];BD&6_GBS0=A1&1(J*E-)"0HNBC
MO*LA^0GQ80F6 @XU$Z]+UH:J=C;>/_EGP>1!R%FTN!(:?C7T\5AK@3]YZTV^
M=U)\2QDA_OP;G9K=AYR]?+(-3_8G'_^T21"PZ=" 3T1D^?2JR5R/6)Q&<IU/
M[JXJW(D$'S,&;N.I]'JO_*C2N)KC]-24R%LY[R/X.D<.1#@/W23UB@7C>%%"
M=[V'Y+Z\"'-V,16S?I&L/JN$;7(T JM%U%SR7F+B$< TG;SU<#G)6&6R]=_R
M.MA:\ZS=4$*/ %[/H.G,L>Q;V:!^+9T([\D?(_JZ#.JZ]?_X,E%&CZ#LB<*W
MXGO8*\EOD8QS.<;/A2A#69R\F!U%6$'FC=MU"W3"<?XE0CEN0M2:R=(+)\.A
M3M"P*\1HT-IHA8!KK-M'-BT$>TK*X&K$ SB0DK*XU_J::5>[=B4)4RE'2H^0
MWRZO21%2DL@&@(HS^>"$I )@)S-C1#1=N#XQ5L('%52IOVSSR!(2?C(H0F$"
M$<!8<1J/!B-.>P."]&&/10TB[Z\!=H1@M5OEK%T[R1^]'BS-CZ\=GYD, [(D
M1X?0^HI7 L9Y''6^<0II#!5+2D%6'7@ )[\53\VP#V94\5.F ?9-ID&US $D
M]#AY_!M$YXLP.0FE6X"JZ5S2&?$'7[^A'VP=$A'4;XJQZVZ+&QL1M2UG6SRM
M$>YKJ#>SN6)^J@(1KQ_LWK(]ZL#]1X-T[].?TBN\B 9F!ZJR),2#EWQK%XI*
M#K$G+N'>PSU,_C.=W?D)XM>)OT7&/7E6<S$7ON\->$S\;\^3%P[L[[90M$07
M"ANWV)@]6^>"IUWS37O2JY72S4S,-=5,+PVC4L(7<_%/U;HQ&9353%?P:)#\
MT6(#Y=3O*QB,A"ZYAPB5K$ 0PT1::5SXC:Y^WG% NRP:P'12UI$.-4 K54J,
M.U<A?&8ITYBT[8NW=.C6+RPU!XU2OA8:I,60]15#%$.T\4LQ.[74 GHH:*9F
M,1:O"Y[RN/AD,@:TS0+XG!: %":OBD9OC8B%-(_E"TV39:N%+\DZ1/^)#BVP
M+-Z#IC4)C7#8&B+P;7T#5-A=<)6<.BSGSS^7[G*B+APV6#!-! Q%J(YKFAU(
M-4<W(*JS*&QA-=@ 'S>4I(-#/W,8_-51X\//17BD*Y@OR0[6% ;<:*:OG8#"
MA/@;%1"_-BLZJ!NI&W_/44^X-M[0@:U+[UX<1?3R0E;*'[&,2890,% MB06^
MU@%A(@('._:3PU('!"E,+56U$-%[4&G^RP%</'728@!M&.2L55#]>+9"Q>ZK
MFG-\O?L,>2'&0&H:N#]>T0=,<XEQ275U^=\?VYP0TNT/!IZ.B<S5MI(( F_^
M-$FILX\;W"VUP96N:<KYZSC7BWG'71O5<D( )S=NJ3!T-;WC_NNR:]!!_K;"
MBTL(S7V!+U0&O,G[/^!=IK'VQOTJ+^UZH.OB,/HX>)=T+BK]=>0U@H7$!OT-
M6@W:":>[4:E7M>N +^*1&RK#Y."THI_71=X!-4YA-I(PH!=-A-D4ONQ_/[[W
MA0\E=1U+JS]^XF=;V@GVN^9$I_T#7L%>'Z+C)CSV6/J\*&<[8<Y@4@2Z/^B9
M2&.6K>Q/Z&B-@N^/V< TE!XBV;]#P^>6%SE8G<B" 1(<<&%7?@FQ+E+"A-A,
M6:SP[H_ZD.GNBT2/KI:?Z#UM(Q,<\IJ!Q?@<$\["E>@JSK(!_A"URCW7K'+W
M8 [N<I7-;O?;XLU^51IW]NQY)^?*<]Q>9=W94?NR"\SV_83_)\9+<V7A]-W7
MML%9%3E=W_X&->HUH'6>9G[@W2VV!PQNIIJ:MP2E!U[>^X*TDGXC>Q\C9//;
M'+-CD?=_@RN?AO;Y_](5^YD]P5'\.T'R6C7</O)RS-(QJ(MU&YB698W#Y3>:
MV?)M-Y^;JE1>AI&GGL'\Z%FU;*:$?7,+Q4N\PY2PY<?"IG.9YM_R>4I8*[:;
MK2$[I(3=I$-L++#(N<= C?HH)"/"+0;MKAF5C>#&RX*FZ9LL\PJ22R;<(.A]
MY%>2L\CABREZ<QMPLT3?W./O.E)^Y(''NS18]I=25AOLMM_SW<T9KY-1EEP=
M];,^_2$M_+M'6>E1SA7:!G_Z48N4S8,<9KN-7N2K3*SUVTOS6>KG!EY\7S>@
MCJ"]='M;UYZ$7;J0^3T'Q:LUZ HV%Q'2'R]M#E#H28K%T1<X7<:;0;LL&]?]
MT%6MJ&,,0)!,LCHEPAI$_0PM/='\0O/H0/R+Q&/Y+YL:&>P7>0<_06<D%WZO
MQ":SA.Y)S65;(#D8X^@ZA=$C!0W%8[3#V5I,#! F9CT7"?2@TKX&1H0U+4D
MGV>N?DSZ"QJJG"'K13G(*3RD2EU$J@QU*GV1D% SJS.SS,C]9W;*ZD[M4)U+
MBON[JI!2!/G5AEI4E+]>]::>?9Z]'\J\7U:%2UNA6R?0^OSO6W;9&19^(K[N
M2EUYH.OLDJ(JK3ZS=DD6O8ZG>^2.V?%M]G<"&E\UQM;N=G[DYB.YSQJGV<W&
MZWVFJ)/WR0Y"TU,SI"L FQLEPFBS:A^'VZ6*W4<<#S7,&.\ %F3C^'22N6AQ
M+53W[S['X"F^_@SB]H;1+ZR-X+FT<BC+M1UOZCU@67+;+IGX79($TE*4L.C%
ML6E)Y, /_CK/*7P6?A4937('C>NOA#YZ*9JP3!">:P5:/0'YPPS*&@:A8B+"
M[A^BP._:.4VYF@_S68$ &V4N/[2]+??K'J'Y8)U_FDD*SKI1+W+@4<FA(P=Q
MOO6![OO=:GLV?OK:7)SWZ?WGKH^!I>9&N;WD>D=;A[V=GT?G+Q@8;A::"V?/
M/MOB=8I:[7\GO*?*T=D"O>'I<=--;X;<B[T)V"=?/J'^AS"OI]]F$^"_K 03
M!Q1O/"3I*AMX5*SQ6$TJT51T 8+EJVMD*B>X$Z--&96J<F H=<NR+X?V#16.
MD:SI5\)^I&J,/2;\O_+I7%OH\R7*/=&PPA*__ LCWY.RT?NOUQ\=$T'-#HR&
MS+2.^%-$R77<!H@[QE>,HY^+L<90H3- 2?YQG,UB],_C_4&#=$+< M(KZ(.7
MA._5'-7['^?NI0_UE3N_[MV>H["0WU/"IBHI3<@%2S$E@Z(MPX!)4\[5V8[F
M8&$W>QUY"Q3F OU4,4*W8B<T(*2M(\8Z@QOQ&V0ZP@G#'(S?H+63O_G"N=UE
M[_X&;9)UH"C?-D_R[.GVS-X?&DQ?H6D'6Y.DUPZ]I$S)L?@73&@,3.Q&&CJZ
MDSQBJO$3$2P4Z)\C7-#_QCN:YC%@[?8W\.$%.S7N5_1YPE<;HV.>EL)"W)V=
M-RR?AWO GHS6B'8/EYJY(_UJ->8V3OT2O^%C1_E%?9^CVVQV,S8]NA3R;MFQ
MH77=T5UO9S^/KN/IE RF(J5PO=37%:E=PNF%V40"(>7*9=/Q;_U^H=Z#]%Y<
M<0Y"IVLXL]OCVX3$1E[#P.<F*#2@#-!5\DI>Y6B> &+$IEQ_Z!K0Q@Z#PR!S
MB0]HFH+E\C<%D79!;D+V.+('WWC?GW40M&V<TCK@VL(<<-PF]9Q#HX<=G=>\
M>!AAP GL9Q@F8N/E50U*6!04#Q\O%MU6PIK=%3T"&'H%R3;)!T(]CF#I0YKB
M"4P6RZ0)2 ZQ! E4EI4':'X$+&@L)^JZ@.KX-(3I=9EE#6DW>*%Y>+R%2?)M
M4<(XK^]A-LH,I8'D(?)J*%2*(85 IC$ CQNB!PF!,Z*P;L*X01?+%(I4POYP
M="Z7Z4#U93+76^2UX5:DDV#"PLHUS\6W@<F<4^41-%WT)F(DAQ.=2/=X3,R;
MGUG^$[3; W[A8)I-NY6P\:235''8? JHA(E1\U0@3PGK:F6O1NN3+,'J^:MH
M0](YD'&G\FI/!8@7]^2#9R3%T!D1?_T$A.7Z3)R0V4)!CXFQ"AU+>]5N@]#W
MX-:AI=Z271-'EW<\R>^1$BFAQZ@[K_AQCI?Z952[)UL=3'#^^^'LJ8MW&@_>
MV?,NV2INSK_LB$V,7JB^T(S2X')(VR0]])[*RWL_?666&A&T.5_4N$7]_JDG
MAT(,#KZ*_ 0(QP<Z/[9IA]X_]V-.]+1]$TD)T\SB?1H+WG(A*K?DT/$R7_CR
M3JDUR0T,Z,&.34SAN^E;(+QB/6VS[-^0*_"=1S8'_FEE-E,YK&U@0(IU/2&@
MOW[!9G/U8'VT)6HQ++=_Q*?(TWUR\*CV@Q[0E'Z!OF$$;8-*J4>KNXDHJ>SU
MUD98<4"V-7T%3_CE.3O5[BJ/0UL_-VDP(O,I4#C88[@Y6/?!TXU)G*+4DIHW
M0.MQJ,#RJV1.XRET;L('7)W6,M(KVBZO?&3F7>75//?V]C8;G_4WZW9_<XE@
MA7<V..]:W'&;X>.I,"WJS^L>[N:I>:Q,YHEB&,")\^A=FYA.&CH]_E5+5VV$
M/A5U'EJ[[3?.O9QD'#S2?++,Y\ MYXW^:G?U:%)+)>R5%]-*"3N'!$>4,)RF
M)+1>@R\O4,(^F89L4HD;'/JB<F*KI?M'QJ$K*O&Z$*18EZ!X<!H[BRP/D-%*
MM96P)[]O0AC&'\2<0___7-/GT1/,UX'_^QG3C=/>80,@YC\C_^L7ZO_Y:J!.
MPL(_,#)J)7R7SPF2RI:1'X=N1$_(E+"KK5,SY+1?-C&#L]_EL*(+:5_D&YY,
MSZ$K?M5?\'PGIY3[;Y&[#E)LJK0$U7/7N_][^9ZVQ/]N/Z_YWU\V%&)!U#OM
MD"\5U^#?<#^HR6=307UUY+>U"MR=*_^KC7U&"5NK^)G._JHC8YB-Z"EF X:1
MRR=AOSBN.W[W3#J&Y6%E?\,Y(6Q)S.\%>/39Z#C*+_>P;)7+ZB C*%^<22?H
M[R)!F,HN_X\_LB45%IS75<+6@:!)OA)F^KL_??6I124L\-_RQB^+3)KOKR((
MKE!O5,)V?0=-%'PE3*&A8FCZ?VUNA\E4$WFSFVC 0^JRIPIIK0:J;:F3VB">
MBS$FMDZI9<<1-""3#H7QD"Q0M*@;9> ]D15MSE$8OCN_I!46.-B@\>0FS^MI
M6_OMVF^B\P@Q>ZH2J4G>.G<5-6\E=88,.]#FT#W,/%9Z EHIYG-1::S5[^)5
M*N0^C-X@D!V 4H T4?3B[X?&1A3JS$W:@)0D:[RJ& +%.,CP:.,0,TA4A]7"
MSX3 ^QCTC1]F<?IURTW.,(HJ%EO4YH? 8H7&9I4 M\GI"G69-M1TZB') MHF
MU9'9RXN9&) M;.7"QP94A-ALEX,Y1QT?4D$#/*LH+)6L)XMMA,Z(%[7#1UJ&
M%7K0F2F!/@D+"&[\P.M ,U$Q,_P$8:*ZHY_=)-EXB(&92%-H8*0[R'UH3<A.
M>I2$@:RDAF0^K3F>G^X8)OV7; 74*]T?>9760QB/5>C1DG[ 4TMU "P/NY:H
MUA-RZ!E0>--14^P9RPO9 RRF+F%2QZV76U/BY)B>\;>M-6[5LX*FYF-JGU'9
MS-7B7CIDD="!RI!,:H+Q/$ZPH4*]3^I)1 9 :6II-O>8\"KB %Y>3CD73#@"
MI%:)1N<G_FP$71@5X8BO],H9 UPRKJ'B87@[0UY2.5P4__&)HN3C,NUUO_>?
MFOESE ._[VAPR%#"4N*E+I<H'Y4P"N'"M"*W6!1\[==_;6-_+"'WT204]N].
M=CMN.TPJ-1U4G,O^'4WNNU<6@F];14@MR+Q;L0V@)2VATEE[WI&LZ%%H0XA2
M&;F\YL8C2!PR8/V\[@.R"W'AN>B%JRO RJ*(/(\87C,>\%<AVL-P7-S/6Y.1
M(Y*"]7Q'RC\" !N,D90FB90P*MJ&/(IIQ"S8"%'C69+,%$OR5ED8Z)I+.8U:
M3UH!K0:>=S9&+O-4AC%IZD,A!SF!$@5TCT"APIPC2IA/ 47?M,N!L)X4"-6*
M<F)%>*ZE0Y=]Z-?",J*))%65,G;R^WLI47P$>0S!7["3_DWI1&,B2TQZ1@R6
M6SNI8_V:\-\7A^PRR3"R*FZ:)*T-@3R5B<OX09DX1\A0[(.JP#MQ.9K=["W,
MZ'*2T0MPUYT',Y-;H,,JV]'>D"*\YHJ#;BSQ>ZBZLE"H&%A4'=)-U@%*I]4/
M_O@!H0V=-TLV<@4N_!3QYOM 8U6!')E7PBJ)L2X@/ID='FP@G.9I"E;($$%<
MZ$F!O8V@DY9%V<#4$6&T9D,0;"BG,FI9P@@3TM=$"<I^J")&3:9*72R7GLQ"
MR:N8?J:=.;$29WF18KNJC*^KD-]7PD[7A_70X*3#R(Z!*24,'G49N9'I6TXT
MF:)EH[>3_H!,RDG!H$O5&?H$"04=^'T:$[H:5+_KIPB>7OPOL#67=%0H/["T
M\G<(Y&7"3OZ.@OW7L)\C?G>ZJSCE$D58PYXJ(-%^.0BRK_'E)FS)*)U]2?6.
MJ"GDN$#AE:505_FUL$20JH0%"Z3G P3-L#9T]7?KL_\=E,AMBE'TCA; *PE(
MX+6/S#_&1&(T(%UQ83+)6Y011]7 <*GI@J:AE(=4490'9MQ!B.FJ-^W K"==
M U$\XU5#],?6!,A%L6&V1;#Q 3"=*3O<0/1C8.:+%^"^D(EPI(N0JU( _(*>
M2F<VR2O0*XETD=U\(2"5W)/?1?\A6P59@@8B:@<\';T:NBXP9&WI!O-&5!S3
M;*-28C&8.C+%YDYXT/Z841P$"F^03&I(1_M)>Q+%6,BE_$5?PR))JXQX^:>_
MO*G\.J:4/U8M^5/>2 FC0'L$\XM5D>C=T+8&!1^O_GL9HLE]T#'67BA0NHET
M424Z^>4<L*ES1()?%\1#6\F?D@]&#+.W,#Y$3L(S$+1LYN''$/48B$Q[[.A?
M*-!>M,F)46P-%[Q[B*V5O=FY\7\?QA),:ZVIB"#3==U!@_C/6=6*QT<EG^@Q
M4!Y-YRR4*$Z&#L=,U6$SWP@QZ^&I(Y@-YY<^'!7.H^T5K]J5L&0_64RH,&OA
M +<0K8L0C*:EF[PC+,0G51E6/'RUE_LG1%A0E?>=#@KU"M5D_DQ0PAYODUX:
M&5R" C*^?>(#&YI#>^\<*[0HM YN?#8285J1Q2B::Z!FBES/QZN=74A-:@KP
M&JH+'_'[@,PKXMW 1% F-,7T>8QH,9/=Q%9-4&B]N<0.*J/++D+Y*AO/0ZZ0
M>53(@L#),L"#)UC;O+A6IIDVM=A#R"*;YG=0&X@_3X#&;?6RLRK#T54?ST2>
M*8L8+C5N&UEZ<V&@:Y)=(5L'E:A NM-;%B-UAWJ[\L9EVZ%KTDT0<BJA@ZWK
M\0BR_S;A![9261;$.A[->%=K7[V-.=UP9J0 AT]6P",PA&'K#^8N0Y8Y@[CC
M1<D%/_..+F]V)NUH0C3L75]UY#:ZSE?-:^-0D'<5[CG7+^Z33[W;]\';CXYX
MQ=Z_=L>MRRKD"S45W!#Y:E_VM=NU+E8^S2:'VO-B+MVG61?G7?!L"+3.ZQ\-
MV=W'3R<=$%G"#J9_*=*G5V1XG-<I\< ^>ZI]TOG0GZG7NI,/1/>0:JV>*+1D
M9O(2=A1;4]&- ;R0&GSI/NAIKX@OT[43T;L2!1MEVT DEWI]/W7<MXNL#:'
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M_-13)3T(71CQAOBG8LJ(:5YI;FW V:N"=.>?*7%O$CR9R[&2%2 ]*51>P[Y
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MBW,*^>QTE _NJMI[KVSTI+-!^M?F1PIK><V2EII8+5VA"6E*+D+?P5ZNL2;
MO\'T%E]+$!942!W"%?K '3K7@[]Q@AB%'?S*.J!XAUR[5"P/":*LC1RO^E2=
M9FUYR<')UA,=> '=1UG=""IAX]\YRUJ%"^HJY9"#1J49E3AB6HB\P876$#4\
M'GT?\;;IU -%+X6Q,OPRKJ%VXYYK->/A;^KFWE1.A&"M[6,CBS*:_O)<>%GX
MD3Y^63R%O('>IA@WMNAGV<FN0J>DL5$(_SMT!5^@L<0?/W 22HP PT1JJ8IU
M,U<)G8;\,:DD$4H0UYNXR2M9QE]*;0>V 05E0FQFB!ITWP:>@0C@$C0CC1$M
M[Y;,>RU#5).RUV2NWK?>O^K\RF)?WWKXX\?=IYPJRXX\-*ZRL#1#V#YZP[EU
M/-)-JC=TZ^);MWN/4[T[/V]Z[W^F*Y_[=M-=4=,ZA[>GN@6C.MR1LH+3W^Z'
MP$TZ0V\5-M^W&JI.E:SO'LPA>LQI_ERUX<\=>CM6'!>;_35SN>!D;EJ43FER
M;D24(2<OR@=*/%S(O15T6+39.GJOYU7#?<Z5]@.C'>.5_@^8R4&NI+"__L@[
M^FEU;^.OW#<DJ7]TL(-M \/K@^\<[>BW0%Y>;(IXKYN[XSO2.U)]70\^<N](
MUMQC?B[96@E[.:'H1OZ\A%Q^_./1[UMC()4Y,B5(-U(^_(<RU]1?-Q\YWTU9
M::F$/3&C+3?R:(=5X/R?IF3,?$DWY4M0]Q\G>3G,""$AS5@;#.#"#;_XD[<
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M2)3B%FKE@T3,;EZLDZH1%M%#X,!\^@FX5^2-7XF^K&'%TRG^(J'6"*"*FFA
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M3K?TC2T#,>/I*\K)HUW<$TS%0=(&=JX-UK+5LLM*W*\A1"5NWZ\E+S!4FJW
M=^2F0+'Q(BF9BUP]Y*&X=DB)0PNWG7Q[/]DT]3\][[LYH&:J.-_+GL:>@RJP
MT7]<:X5F7QP_S4:NS>8[\QME89U='OXON=6.E];^4].*;W^\,=Z-!J1XPY7
MR >L4WF:SK:&&_YQ&LP>1=RWT:A+I!B0;U#BTH4S;=1RHR!WZF@=ACK6(%=Q
M$V@.59P@OKW*Z>4)OIF>$8)^W*FYRX!]BF7<#P@8I;@<1D;+OM7+S2$=].?W
M?BBF/68B2]E913,,XV^Z,\82(I)4TZS@82T8\:/N.#2)4"8L%6X7E;BS+$4,
M,..X6<&T3ODCZTO-WWX\C?['LRQJY80"-S3V#&"-NR/Z^#;,TXO4_K$Z:7H^
MA37T8V<$F3IT/8'L/$5H#3[SC[E>UIU2D _.-_\;0+?\#;Y];/_K:40-D,2X
M\!_52>\C:X\62U;ZL4:SN8[VM<-_1^[9)+;1?/*TZC]!M_3^52%XD*NKH<3M
MG0?.)LLQEM0Q8CT^93^R\0)$.5P=NPOX!(_F %25*YXCRH-H77<:@B6=4+]4
M!3$,:%3+65I$4$\+&+7SUG76O=+)Z##;5S-1".6CJMM%^#YC,0O18:(+@\6A
M?86R.);L)MS'+3,>?5$,5TOTN?%'0'+LED%HIR(_L;A6!>RMU^Z-NC&@!9\3
MW:S<?)_&:+,G1B;$RQO/SZ;'3O X#N'0QP_9+>R^?E3W*ZK)0K2(J+80V0P@
MFP3()@J?"?N/PQYDL)PK!A1L5-,CE2L^@;%,N1(7>P<U[WV+<;75$UA/,-9Y
M3BX8I6Y&EQ$GQRHE0O 4@-RCR#!P*:-*V IO8,G07%E-,NK!60/4'^&*\@'-
M*7*_7#H]JB>W1)M10T6\$B>ZS=5@&"%$N-YX;(44GZ*K,K84DKK#:CGYB20K
M7T23A*^IAJ-%SRCXP*7OA($;D3WE7:?8DW?2=-$.?8HOIPX\E3EEA\TG4=GM
MRLQ&/&Q$:$S1GRM&XY2X'V<P"/DKLA+.* SF6$%9\=4!$%4TW32^B&Y9 V>*
M*?.'&::5T&W:G(BQTUY">'7,)F"!S[O#M,P]W>PBNIO!G0_\"P3N%@\H <2C
MZOL510QK]'<E3K/R#OZ2<&X%L3^%3Z[J'2V6VZ O66J59!S=C2D6)G&6H6_.
MGH:KQ3KIG)^&7D",4,T@K[1FGG A_4!OJ.7L-N].GJ_!N6+$[$7.KD698;Z,
M/*#^5<M9+KB'V.\?^J'Z]K<(PL7@<Y8/EGE[.9PEGQ!>OB1Q" XLL?A477VN
MNF*#0V3X&N?K:5_6^F_:H#(>IX5@;*I^-U=T@UN6B2S#7.>I>!Q>KX)H1#E
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M]Z*G16<W6EV^$W(TV+3RIM_54&%WWT:/F-4W7A!VW84"M.PLQ-OMDIY<VE3
M@V]UA;T.UQQV#//0<'6]XWGMHY'3W9]R32L7[+;ZF.SP;Q$!R;\X&I/UO[G
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M3Y6=AO?(@X,X\\$%BINH(=W]2?<IA"ANT5\6LEF2G0]UVH.AZ?1S?N'@U^>
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M-XK](0I([2JDW8K%I-2++DG'U&1:0Y,-UX3.K<GQ&[((:G4$=2@L)FI3=V4
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MUN2ZK1\!^:T/YYV ]N73D@ZD&>$,#K[P.GR(R]?LW8_<2$!""34X3>#%E<+
MVT+X#M^Y=GVMD08_4Q3[ !^NVEW!N:&7T]!(S!?OA]8!<)[U[2^,'6(ER!"@
M\#@LW/PBVJ,32@#*^,PDHAZD_\U]K)[7,A:K0U. 3CH,?M?)7/0;&AL;=W_^
M )V0*4H(V]5QQX>?[?T .BDR)+Z"-W]*$2PIBG^3%/X2Q(GZVM"MQBH*P0X@
M\[@L6FJ'9O:=Z3??T+<1 >7X(ZQ",ZK /@D]$JNXP]NWO5/%EQOHO],GLLI1
M3OP0@"=%_ K31.Z!-*, 2I>?81?ZUZV0Z2")A=DF57T+1?5,ZP,MS#8:>^DV
M<=^S!_R&4J"])UY7XSIF"_,B+$6*&#0 S;+K3;-LV_OG1<>.61S3D8$%+,*A
M51 U;3HS0&0*,4I0M%0A6T:I;X&XM!AS#<A1JK H4H;\>XF:8Q;<;5 H6ZHK
MR66L_TS<!7QA/IH^6?UY]5-*/;9D7>M(2W:PTXAI_=+W*33Z67MG(SU1I]97
M4+(G5I1Z"TY?A8V+<3PT9)CT-["TG#F[)F>X(HJ/7Y'4(/?"_40"QF^R'<*3
M7MA)'LF,@52F]U&2<%2ZQ[J5Y6^?41BP[,9W. T:WO]0.;1?_R@@@_6-T'.!
M.25VT;J'(0]HIEHN:4&OV*OT/JXSL)1"/U0QA2/N'+<\ /3I*!D[/WG.>/Z7
M\?9$A1W&V]:)S20IJ,N4"=;RLH1F&37YY=TR57+?G$"Z 3#[X1N8?Z[)36QP
ME)0RM'!P;0M.8MQDY=_@!@&ZCYF%4J:C!/5Q?8&Z4 7(/ O 4RQ=*.1%?N@8
M0UZL#UBE! G>[4#<;"#\/M@2Q8W?O^'G\5'&=BD7LPZ%HT%[$\4AD+5H)[Y6
M&-H+>U>V7 ZQ0#5!>S(3MY3542CVAS*%Z E-8225QGJ,M5U:V,5_QTTMV0B=
M!:Z/<;JYO]&/1-2)SW5D_@[=X&'(MI^:@O1+Z\2N3R2.DB<,$^)+#)RN!:/$
MT-YE\N$+5'"#5.&G*/)SQS%*'X>B?>TS55ZL*7+!!W=Y>S&,(6MP@ZP"U.A!
M@($;5"-K1%V"!M0J4-(0P&54I8Y 7?TT_]=\H";X=$1L6H-]O;ID+T?<1^H^
MN(#<(SXCJ45%<M\9LC$:4KB8"$6#22Q4,[P;0T;I$K>)=X]+MQ+4H8H;(J1A
MWWUZ: -!&5A)EQJ)+X\A/ 'F*3I$+<=?,$\'Q.= 9BHA3C@%[V]';AV73XV9
M5S)TDK1-WY2?EUJ\W+].]!^4SOY/@9Y^= LI+ZDO6I-CG2%UFZ+A7^.8.SI)
ML_KP-B:S]>;*?U49?/*=U"U)JH!;DPM- &5K">"++GMS8^0D__DK#O\IJ,I?
M5V&0NG]'ZDI?,S6_DR:2^-Q%4]!;P.FI/W)>4D_4Y@ E4<F!>\&"6Y88/<+E
M(?$1X3O.;^)C8PQ#O-KQ3M"1E6WGWQX@$[>G0#29'@Q0>\_@68[ Z_8DZ9[/
MT_N?#M7%HN\0=:"5Y2Q(2>1 ZG9$A5(F:EG<[6MRX5'KQ.LE]QGKQ&<A-1X\
MBZN/< +A[&5F*XHM0F4.S\DT[MY?O1"VI(_3MZ*RB/L'Z); >'_[*H:-3I\4
MHY076B?V 3_&;I="U#\&C)<5!?(LIFRQ&@0= 8R,4D<H\9;223""_X48CKJ,
MJ65;B]'"6[,GL87&257XI!ZI0=-(B^LE]OOCOWT:/MOTK/W(R>V,0&@PU;HG
M*@DE+UV/-WO%9W8Q4^!*1$6"W7#D#T6)71=&@:[()Y&1BL-+K;@JQFC49;HI
M3V+N,+ 8^<-NXB)]Q.S/IAS<NQI]P<</>1/_R']+$L%\Q,Z0NVQ!6,B1C]$C
MOI#I\O%DAB&T)K>\#GHE($TJ"JB]]:1EVXY1<0+HTL=LP=Q"N MIE,!=[;)^
M\1-C_-'D)[A"MSR9+T$J#42VKLGM@ Q8H!@)I.;R2H&9GO9 PT%F=>=_'O#Y
M)$BQ:P@OX IB2A2!(JIJ/<(TEH?#I*'YK_7$5R-X#Z;\Q@,[@5AFIO:_\P#D
MMW3^2?-8)/V8_L,.U[YZ+*[Z5=A*/GBZ.$0.]1_8&?Q/86'OGI&?(2WR/HC/
MR+ J+ ?U04I#_4A&16+BO],F#W-8?I0%"<AT ZM83#WQ>>!Z*5 @T"-G$M7%
M9B*,V(26)M7J!$KJ94  []J !@V36C5 2H9%3>1WC%)EL8"C-&=>.SUI1JV?
M;4]5?$KG_(H?O%,F@V.9?6M>I<L,[3;),]R\D?@(>T*$W/FJDO8EY-Z-V0/'
M14\7<$-7P\_&8_>W[N]T[T :I\/-4,JBH(??(XX9>R74>S\>C4$51Z5:H9IB
M^Q=E/O@W<8%40>>1> ,P71$L1*F[BJ(FI!PEWEO$V8?$-R3@H3A"CYE"BGA*
M5[E9C?M&.$7*DN_*9ZBU0"O[JL #2&-LH-'SX27AR )Q)Q=N)6F(H4"&IR"L
M".=#Y*S)R2/4@3+I%BX)U!1:SG318-"4^)",P39N ^&+AH^AOUOA&PGG)44-
M/\QU9&"83/J-'ET_90_*=\LLM5)LL3%_#UPI4AQL1>/3E#]O$Q\?6&16&1E_
MV%7\4GW6ZT.OR]N^PI6F;[%7E4OV5>YUU/%^NS?CD:2V8J'"[7"V3:_#HY5G
M]+RL\*M44^]_'K4VO']\;23/Q:M@]W(CX3V]X4!U^=UV9@9!AJ+P7OC$-YF^
M5T*:0J$]J&V70'+/<XXR?IZE_2DI2(#9A'_@UPD,)GFV/ .D554!;\,+[=^T
M,EP2[++-/"YN6VQ1KMDA#2:%WA89XH.E"KZRG14.T.V" '<G:%T(6+"< '#$
MZ@)8RF1<4LQKE/-(#"<):39LJ6>]/-L"$*SB^XKYLPQ;/_&>1DC&B8KY0\9:
MXMU^',$[6*KW]-Z,F=6I1\\:?<NZAVKLAXOX"$_=<Q[S'8>2:X;8YPA-R[&J
MU7GXD5+O>/7JH6JAI[V]O:Y+A<*)(>QHBD<9\H^B8)O.HR%+?N%G"MX6&1@[
MCZ$T92JB^#IUTR,)C7091WWK+]VVF<2C:J)D3C'4R6*'=./)2L.%9PDB+RWD
M/G_Q^4X)]2(0 P=J/A;"4O,Q\@M2"U3/@]L/97;HFL53NI,N==LN,"B)3U,3
M[Y"D(C6)(QC XZ.L/;)GJ5O^!+W[2!E>I!VD8#P3JUBL&F'82]0!0Q<D/+1B
M^"1GP;\<*OPB^!(UJ<$5>"?E]L!50B"5<*JN_9<DP,SXK2!GB7^'(SDQZ'_R
M:-$AFXPY=:&N@Z9B:FY5YI5>_RW DVSO# ^,I3-E:V=MS+F[H7LO#OU]MO?I
M2(U%99YSS"S#C]Z*NC[;:NC^]]2+X97.UQZ%WU#Y-!6Q!KT5)(M5#80TL?IC
M8SM*RBIZ05'(222U4M.DMN&%ETD;ZE!A>M?-DY!V )R,NOR JCY]DG?,Q0G4
MK^%'7/ _!/KIT'[C$@>E*L#ABM$E2@-A6R3*#<7+6XUZ:X*ZK(74+%Z/>ELH
M6JX>C4(%9:(V683RBU";0Z @8$*<$ NX&5M*>]HA@VK"M:AT;^0&2O<7A,*Q
M<?&>>/+M/S$*F+ 5:VIMR[G>T".]02'D//6-^Y\Z'*J6UCJCSM=FN9>F?&@U
MFAW!DRX_;OT1&4XHR/WKL6#*+U)9HP.[UWSJN.U0/=Z]_;G%QX6?/ZE?EO3]
MGZ<058FON?-,+$>$Q+QS^74'2G^KJ!V33&V.6UV:C)9R"I:'9/B2#B[>&%R3
MN]*[)C<NADMS,U!YC/PUN:_AC:1EOXO,U<<"M0E$ JC8A=HB-JS%KPA(.8A=
M@+!K<OTD\KD0K0\5V .DY.\>3$;KT +&"]1,BXI9A+OY3[DM<]Q:<*_^L>_]
M,55?OO>+V>[LG_YP"FG]#U1*-"%FF&@AWC>"W/QNDHM!@SG] NND+U+U[I#*
M\-RPPKP/W&T/QRX"=Z]W$)NCD'_?O++:P<(^/FZ9O*3W/DKU)W?1Q7QAA4]5
MA'2$\HN*E>=Q&JC?&'L@4C]*T4*T@^Y9/Q]'U?IA'(#N(FYH!.)DHF?+>\M^
M-BG-KY.3^>4[:CW^0H F6W,#VZ^BLJ;<9W)N3*.C@O+Q4BT@8^Y!HC'QM70G
M':BZC=3$<Y<[).U$<^) *+\JQ_)!<7 7]S>9)9:^U.:F,K2/"X]MZ+;M>R#?
MRTGW6C5,7F(<Q'.ZI3M 4DI+,4D06SSVH%)\<LCD>P@H_/[GM06D&?F8<U[8
M"]NAZ <56SR]].^"ZE>^JWVJ.<""N8[6I.,F!N_.GLU3<*O7\I1J\W-47C:_
M;Y[WJ8NT-JMW\\T.3>]UD2>_ N</=%V(/D_TS'=P:S-JV)WJF9)OIUGD;*Y8
M,,K^\^O<1$@X])[18+U\C2ND=>LP4VC@RV$AO.<Y+?'JV_/A3PA![5 *7XNA
MT5\Q,:>*M8[/%1^G>$<I[$UIJ-W>$=(K#!=,*YTX:O+Q[\BS97K6MQ$D'BH#
MN7V($ =P^J95H$S>3:)=>HRY%EZ-76B=23]0;X^-NUHUY5(.9;)6.E+_KG&,
M(&%C0ZXLQ^6:6%\?UQA2+]12(:D%?@IC8F$I3 7Z5?[2YG>X28Q8?8/+B$SR
MP+3$=H/T8-Y2,E=+:H A=D\;0R^ I-Y)# NN);:''DDWC=7%*D:1VTH,@(^T
M#,3QJG B"C"EL-_^V&'Y^K)CV4VF:)>CY('(D=1]*D9)=;,I'18L<L-O\!N.
MJ--E/)#/0?B+#HI5QZ7[=GCNLEJ>3"UMF/*=+UQLL<Y9K)M;*5CQLHJ+^W9^
MSC+CY>>!TG/E1AYW\[5+D \*#)OS-1J,\E6+[<K+YYW&<G8?"7^0IQC-_SR2
MFW*L>5KAU==_VS4S60*PU=AQ7P_HM<4S'S[7>@UQ/>[V/\!3[Q<[QDJLZL#O
MS<XV-74&-?D)J/H0+:)9ZVFDI@S^M8B#\&:9N*7J01A^%-L\AR1/4 "M^V:<
M]16A:*%Y.F,+P,P1!\8N^D7(G]37!%+;Z]]"21C;-\\CKCZ:/>DT_$4FK6+#
M]@W7B>?_*5'_\?Q!+6[_G@[ZT\2AR6W:_IGWRQ(WWVT\,^1JO"=,\7"U29?&
MSMC=S ,D'&R]^!B87R4Z3GS!;>:RGD>I$@>I;9>*^::8Y0+PX\+D]#,^+9&I
M_&DP0@J'$@1K<NP G.^(N8F%:_0?0'\R[4\)5:J"]XNP]@#-LV,>4+?/=N@7
ME/I \WWY-PO$VT4]VGTU(A-(QV&080"]ZW;'DEIH"[&A^]KYKZ+6A_LQ:F>D
M@U1%,2HTNL::0E 3!AQKB,EVD'+ZK%3]WOK=K&)W:!1L>FI)V<*AX4/]TCY^
M-QIY.>O0ZJS6[YEB2_7).E^J4&>;L\^B)MK-XK%GC5_QYC=NGD$.EDN;1S]6
MO2;S36AZ&;RBC;HLK?P+>*K.284,Z6B9<^S^('#[UZ=#;_;SKIC5Q]ML];+6
MO,<_/.F3D5M/886,-#LB++?&L_@DE\^T?E0659<95G^D9TVNW;&/*2\=<,?C
M7"6W6Q5),(C$WUZB!CG5X4.%3H!\-TTFQ+40(772 >WI,D"*UIOMH+('A2Y,
MQ3 -TD:Q/9#D"F0S[H?6'Y=/:S /;6R7G &];LL$P$E^6SN_F88?[C(6<C<'
M8*_AR=U^3+$!$@74!>X>FE2@T:UIF;AGA&."FU;&5;;$IHAUG4.6FX6,)KRY
M*:\0>=EA/3Z,/^=9[]1#O^M?M1AB9#K($FC7: U7_3NJZWE .CN221C\U($X
M/9X":EGJTM2R^_\,3?WW<<_=F62?EZT'56\0SQ:^M"GTR=JGXE%T33R_,1#E
M7I-><=3V;N>3&D6$N0Y7?!3*!:H$(7GC[)M'7 '=0A2%KB/DZ.(QO9,;RXDP
M\@EM&IFQVW\*JO1B#M'-:_%."ZWUUFQWS$_KDNV,)H8F=6(RM803Y=+%U4:%
M+D;Q+9BJ4CTQ!G(2P!+UMP[1>,^AO_F8M&G5<88V/MH1B+W34"\I$Q;;R=38
M-!7+KU6\,DE?F6S!51Y7*3AS1WWKCY]3(C7Q06A#J$@#JN7-L(45/@3=9DF+
M#$XHOWTNM,Z6[II?O5GY[/$LJBTN*X*A!9WT AU:!?C8)6TN1.Z]KJ\G8[Y&
MA'W]? %<A?;%^_?Q!;%SQ]3'E#6Y'/$YH)^-TH"&EZ60O5#)GV?>Q<F1M5I)
MND@O$#NF/<Y6BO:24%M1R7Z<G!_FB6/KO_6/Z\.@FT)S3>( 2:4<Z,^FPU I
M'Z";_ 276APG<5H>X*31SR[K!0>T?B_-/U-\V4MM?D<*6C'[HV?HEBO)U:_4
MDWM>5CW)FO/(\W2NJ_6Z,E.5ZH$=CBSK=3@CLD5HYHW]&_W^]J>)"H29(SOP
M98FU"KE[D#7Z:B[TOKXC1OV'D2=HT_'V[9_@TZQ^/81=??++ Q^ARR8EARMC
MW1HT?\SS48L* $PXXO=^36X#TH:P$QJ43RUORF1'$PRA AXSK0E/##@;23V=
MZ9_;O3K66.A1F.$;V)F!N:>]&&%6^/Z4Z<<#I:".,*Z;E-0,!8X+9GI_37 H
MFA&B'ENE\YZ3TJ910%6B(4ALH>!T9O4U,]F3;??W,1^;%(SM']-VGIJJG?:K
M2;-D[Q);\VB]Z*R#A!@H760ECAPAZD'"7GU5R!.8$3ID@L9\%(NRG; 7*.Y/
ME>Z$:@6&B9K=MK3;A #07^A5%B4P5?2 <#?J6 (7--R2G&;!W%99A#!]>!X?
M&.#"?K^T> 3XPNH_2+B6Q".G2#>)'275='= PSQIVGR >)#@ 2K?KX+0/%K.
M</]B66 X<=.@V [<IF2( 2W\IEZ&&;*8L 6B&8H<&5,?+7#-"E0>KAK">ZDF
M]CT^LOPWZ^7VQR>NU+NY3(QG6[M5G+8/]\$/54H>/8@]"-XAM)S?_O$-(^BB
M[T6;.S9;77H'7QJ?Z1(T0ADVXKT^$N_#9<GYFCH9KZ]"NH]R8+^-F>U('^D-
M\<"Y$SGF)?KJ<Y)+U/>Q(*<7]O,8=T)3^L_2XHTUN0J9&0RY#F^BIM,-A+ )
M\^4($':KU5PS7*K,@ R!:7-8>" J\0VWWSK^>C$_X,CI',R.DU68\/@+^ >Q
M#RK;)06/PPO]PXVOK$965/NT:.9>79/[W\9&;>+=<JS5'+P_59RT*/_Y2&@\
MW'V!MZ3Q+K-CS+2MI&" <Z ;;29 S)C7<!8/:GGK\JH6L<XI;@3SK3,C>Q?W
M.[WT"'WM^FWH;H71-;I.Q'F1]C.J%GZ\FZE,,*^#N +-3,(1'GHC=&W@5^M)
M#X^WT!0AS/%&54>%SK%82>27?J>AQ=^&>E6>,9XGJNQIZF=&5Q^S)$9)WQ?
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M(]_KK]?1T19G^KXP_\9H(8\2!_U^G:B+I&0389*'E<#8 ]&&< TI'%B3ZSF
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M)O$O *Z9C-(@G!M8C=&;F]4A& HHL*AVO2:("B"=H 0N1N=ME Y-UCB1H5Z
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MX\-%:213AZ<*_S5&;X=\_HPF&4JO87H]Z+&8+P570]9A%2_@)1;8^TVR3O8
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MNJAGE7 &>YZ=B]U2H\-\#[Y-TAHW:BC!/U>+U13*$CPT+DNT?Z,5VC=R^''
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M7I<>SK+\]+K8)5\GY$#BZ?1OGZ#\]P<2ZX%G/\/Y:+_ D/S&5X+PP@GE75I
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MI)I6YT!/R^6-V/3D/04H[9>:AUQN8S:DEY0Z>NA</)ZXUTVGA%/ZW%S31JP
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M3XH9:'EHA;T$:4^GC'-Z>W#KA$Y-N?P=T(>1AU#@5/LHPT$OK+<7&&M6UBC
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MZ?S4R+Y"#A+2DEH8OT_PX+$Z0N&A#4WWLK9:.17B+3G[,%)  &E<CEN6V*;
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MZ]+.Z\_(R^V%@1EM++HOUISWP73 64.:VCY1/>8L1A&:?V(1F$D(X&GR \'
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MX+J!K02GU]0S*0ZH+2N4]=X$FR%C9QN[P8;^K7Z3\WE&2J-6YH+3Q'X_;<B
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M0=N+! ,QJ\K3T6@K^$;,EZ1G..#T]_O!MA#263LHV11#2838GJ0&ME-!W?F
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M-;L.2H(U:@V&*?.E9#76A*V<OW"M'HP\\I%HMC+Y("3XXBJW+G(@%=V$>."
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M4,=\KI%3>)\_1BURJC7W9']0Y!]M"I.VKBA#P9 !4<<ILJ?< "H(NWRY@>3
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MY6]BO:!]S<*A/W!MV#S6YB6<)LL:JN]/),O5F"*MEYZW,;22(MY['"3TPWI
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M<@$4PQ&@XVCKH6SQU1[8D.2%VR3+J<=(O6O(NA15?GD.Z,O&Z7<8SS*70QI
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M3,V!FN);HIII%3"3#S0P$H3-&$6J.MCZ"QC%9L;4KP2UP$)>8IV],#2\&6?
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M#.NTYLM19YP%1F\)P\TS2)6J&%*3:WCCZ)-HD_E&G&IOG;=Q%^=@]V>J0[1
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M?/15&_7B$/RZ'T5G,\OZH4$V#M4+6T[P5*I(^\C#43'U6P\,[0*C+I^AJ5&
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MU915VQP$8QO]E62%9_#!;_4$]DU^WHU[+O9>G:)ZE!.S6%-"S2D96CPW1"^
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MA342IQ%'99<"(DVL^[*X92[O"?WO34BTDW%5!^'XOD6* O[!4!*R,=*C@XD
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M*UVPI6D"#9OJC:5G(41CEZ_KPI/:( --J:H07O4(3T:G6\!;("<P6V"1P@K
M:DCQ,H003K3U3UC[D8YTUBGQ\9H43O-%N^?W /)@RB1>E3)) *TGHGSNURX<
M>=!6 C$XN!VBS-D3_'5HJ;H.9QG0$2-=/$TE$2HC%$0*EGS+DSA10WOK+:E(
M?L7<AEO]-6390$BH41-O%2M0CM(9QVV$Z (@MN867H$5[!<N*&H@:/@1<1A9
M5AVA*&2@.D\4Y _*I+?@#:+S-P+XTU9?'47&W>770C4*S,8XWQQJD<RX@ ^L
M0EZ_A,FA ,.(Z]1RE:JCX+<:N5NLM"<(523I:80:ZF%L0N>E<,E>H/',P$^]
M"3&=UA1O6!WX_5;_"VVK)]^$DI'\R_CKA#Z\.%"6MW@7W?*?H8U"@A9U/<0"
M1U]J .!9O9>$R[6<9JP6U5S$2: J\O%I5E%)TA4+;6SG\.:%^RD!^>/X=3;F
MY- +)22<0FU7J-2[<( X'V7A<TIET'%<RH4&A7Z]\:SA(4P*YM$!^,^+G*1(
MU_Y!<4WE,Y$<-3T^_,&;'Y2*/T77F-1F<-YN.<(U9R&6?J-TGT Y&H>EAG3/
MTM<& VOF, J4=0:C[?6J#>$"L@JE_#7WT',P%6&P4S]MBEFR[-?8/S?-+8M:
MP=(MPP]?9H'V@YB!%>@!6IMX(Q1.$L7TMG $QF53N@90">:R<5V N*9+U2MV
M.!^"J*KQF[H($CNN$YT_,2:^F'P0()U0_E"G:K?D*U(C(I1SE;8= 3U=C@ID
MT3-9R^J( G3,T"ID KPF8<U$H7,O.S3<"_+C8U-4J?ZBASW^&^D"LUIC3MPL
MYNIU*,CWV:U>![_3W"9F7LC75\K/N'.*JY\#()GYLBV9L$2Z! '>J!W>3M45
MS3=D TAET7 ,3W+=2#7OD$:!DB;"&K[(HO%#")?_H2:.&C@<C6_2MDO/ZKT<
M&1PQ>=MFKV#C#SJ,-;SF !N?P(\EI!^+9I5M4<"6@9KII:)+L.(<\OI.I*\%
M5)K(0JI:!*\*D!R2;I$5X+3A/VD:4*B0U3<CMA7A6\BKAD((:W!KH)-8-7-.
MLKDRJ8&V_FG-DRZ3CQWOQZS>/0L+?4@<R&44#_:U!3?4XJ^P'LU/WY&<IER"
ME4HE)Z@_0W@!OG^I "-55QK&W0&7BH] VT0>1V-=H5(^L)QJL7@B2Z*VPE7:
MKF-C3PZ2AIU825;Q;8G3GVWP%VQJ1^/S4YJN3?PVX>,XKLV\BBC=A/Y2R .D
M-S('!L5/(:1>6T9!!D)$VE.\(O&D_8E!L!K.)5027I*3 %TYBD1._NN>M&&@
M7]) TX645]S/W2?2?$E.W5,S\!0J$]!3:^MZ:+M?<*F[=AA7874&QR?#P@3.
MF[>+7*X-XZM&IQY+ BAZXCNR(MH&^,_%HXB8D#[^"LY(>D96N1EZ5BC=(HJZ
MC$.DKV$_,)R"I+-=A>#H621];.R%^#3\*JH%G]??QL$95E@QKGXVKGKNJ@95
M\%EWBBCG 4W(0, U8R%QDW=$;8G4$WE)T.+O-09\$0L3DTNQ$'>] /%2=5(+
M4@)0+TC4B4C-7M#+&DX=,F+803/@5\%,?)7,WH<% 4)?Q3J\0.:.N9QK18(B
MK0>A,K-)VZ["=!F_=XZ,;BV8X+5K2E5\Q?[=P"DTI(=^B8VUXK'IR8P5<T<+
M1,RT&=Q:ZFFHC>]*9ZW%:3N(5#G:<E2J-UM[I@E81MT";>1?&N1JE.E6%(]E
M$=@Y^I2@H]USQBN^2/RZ=IA4E<YT.^HO_7H05D1*YZVJ@B@90D)2=:2T\$?J
M">\/<V"45+7P):0HLD2\A-Y?IT3YR5&]!7!?[MS\>=$8X"KZ0Z'CT- ^]#AL
M1M9-G)6CM%'1:F^%[3!#:/<_>DY=7(: Q//U"Y*?Y:A^"5) +'3AUY%FG/_Z
M?X1E0,.^X^A$5J4KX1L>&&1Q6=/[19L6VA5XGAX6](,+0)H.)T^&;[F,L=U-
MF<4701UU%S%<:?"2V?_48YR2["'KXRAK.!,01^&U\'-#K.J<Z!G"#W"/"YY?
M! QGYE!DY;2=%X'.?:Q0T\D9PJ69?W:(_\%SJ53VE/6Q%/CK4"HF,!?'.FLH
MT:ZWD#W5PB3S0.=-NQ&XIR_)40^W2<*\^]4AUV3\EWT-0-]].GP_P#5)0)@?
MP(N5T+)]1_69JZ PB1O\AJ=5%R[$)&!6LH*95PAJ\#:J=:@M;A/5!@H3A;_4
MM12U76'\TJ.06'5*1(^KVRU0]B" K<2+W[1U\VM[&"?/5,68M5Y3'_]BB%6%
MN_$5"C&T'6,8E#108B]=#F9R".K5O^=J0,8"(!6#CL"DX+8!:YW,M'\(QJR)
M)*CX4-C'0L]=NL#OU'3I*'<IW*%J?TJ/\AX["G@WA=?2&FML3DQO0P?B(EU>
M^W=P;DUL*,.=?W:&^X*^M+_K.7WKMXP+62,WNT)II\MHOF8S5?2+^<E&ZWY(
M-OK4ELJH#IH")%84NBL8-:T@\8+?,GZ@^I4&MT-T1["FQ34=4(*U*'0/<*YY
M6IQ-9A(7,&EU'GD34;5F"^EW2HX>?.#K\RK ^#,C.N1&I3A3A5-H=83D=#W-
MZF;0Z6\&C4>V!3X?23[;6EH=;[<K>R0NT.!\\CG@G#/#H>/H@OU5)#W1Z'':
MCO;(#QA?L+RFH)^28BO:<ZVD/\0?TRW%EQRS+2$.?,Y\V.^Z)P<HX(USD3HZ
MY'SFKGZ_8T[J7:JOEB5M3FF$]<&V-*G%'Y36!MJ/[74$/EH]>"'J*A4K8"I-
M+-!8?-:Z8.WF>]X+=L_^(&4Y-P]E/@Q>*(P#_<<'<G,BPP*CB6;>>[BMJZ].
MK]GE4*.103 *M3:P'L!6=(S-=8A/5O3:%U1P@\KI%1WC'R4Z56"B5'4>=IB?
M5I*C@GB2"&#2A6K'?#[)1RAD1GIC9D 3;F.)QQ"_<Q=*\\L WH>QYN85Y*CG
M*Z[!R@11I_0!)JK#5KWIU.+19_8['OLV[_C:NF'G09U6L\Y:CIJ;7>''6\<V
M/+#?$%SXX7W\D>6W+RLRDRL!R "A"WJ3SZ>;?#H:H<6?\"?]HIIJ/Y<%_#&6
MJXM03 CKBE7NLX>DK)R//K3L J*/<R9=C]5E'GH IIPY$S'I=(%I,K,]>6!H
M_?9K:Q=L&%5![)7U.]%7WO*!@5^@]LFPX*6^=+&9C/D)PHO'R];-Z>$K=Q"6
M8H97=BPS*<$FN38U\/\T8?<Y/^  &VZU@IDI$7WX,PS(L#H'_-KD$/I0B@PR
M)E"*!_$M&YW8FII$XW26A"2]&.N=R=_S["%1Q34LE,981E,D^LPG42UDI<J%
M0S<%<E2R]MEG :O+BOJ'](KB&AK]^X7$DT3WHKA<XR,IGF7./CG;\[Q294^:
M3H:TYRD>B!!J>MQYU6P=X5ZHV39=X&Z:IG?$P1P3]4OSE]?H',^[>2LK!3<R
M=X=NF67X0/,@E@UHV!B!FDT$;9SJ&'Z#-++@/26E ;-\CGEU"-T)[Z!PV.(P
MDL>'R5QU*#+ZX7XA>NV8^!&%W.1Q/.2B'?U"X#*?-55;*QX0HUK6#/4V#ZF]
M$-D]'KZ$584NSK3D;NRHQ*I L8T:M3W988(T)?:0P?/>,S:[F23M9=[84F*6
MQ55F'59 ,E;R?%$9P_%^#GY^3BYJ"]MSK7@;:SAJN@ T$EK$UF-IW4,V739+
M!8HXM/0H-"U92>O!@-T+A&0:YC@22BBIBD2K>5CFQ,$KZ4$72BC-]7M)/-4Z
MATB0?:P2VEM W00=$;JB(6X3"S/<$?F6W-CI"R4?6W"]@J]!T^O5J,>@*YK-
MV/XOKZ:H),2&K(,4)&Y4,D,@JV*FUBE(G. .^ ?P]&,P=G@TAJ;"O(RUV2W$
MQV$J9F)LR*#><&9R'1 H8K OEI<)!F?4H'DV0[G.BSR7%G1\XH)5:4(\=6.P
M8/N8Q]UQPSY:H)=;X^O\GK":BMP?CWHGNE"*?-1.E]12;NN3YEQ"0B+NW9?=
M]4W.P+[IUC,><+K9=1,?%.6=:THM-U=G72K.3P;3-RV>7LB,PR'UP>L#+*06
MDFS&U&#@NW+4J0%)??U:""GS#5;]M3,\CO8>6 B7W2!5+)5>D*/Z= /DJ =2
MMS),.F%N@@7?+H[FV:IYK__=S7;SNS7M2K].+[NY3'CYZ(I-JEWQ)Q4L]^DO
M(?W/X,%OOJ54,I(/=YH16;<'BR[G0Z82LZV:F$><=*HWIJ$0>19#!5QCK3+V
M,# VZO?TFI5=OB&%BF035%14V Z^8Q0R&Z=M71,BC5W<1+IO[&57BB\QD_%!
M],&4EY@JPO0E28!T%Y3XWUA[\Z FTJYO.(J*B!"451 RBLHF1!1$(22C#C+
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MQX$/(2W5LA]'SN--9I]QU>.8J1A-G&\II9J$#&GF5,].&%/L7^Z:1)REP<@
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MEFK[9/+5_!8A=CQ1H<9](-.O&[0GF ".?7:,45?^MZG,>)IA--X9R3.[!?B
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MX)J98B/H]?7R<=1Y>VMRR/#YQPTMENVH0X6?OLVJ4ZZO_>=8-!:<XG/3,/J
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M'3D%@U[$[0M7GE&9>TM?S4 LLLOU9@-I#6 L+V 382F/NE^>1 N?O(E'(7]
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MT=:2O$=!.Y[=EME+=]#:"(N$L&[3]A UB+AP1^I'600QR36RG\I ?3X)K>B
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MT]!_,?&D*_[/L6!9?92MY^ESV/ 7MD=B:5OSE?;]>;YP!AH]I#/B'OQ^_['
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MMY4G"3TN?3[X,3D$Z3*$LKQ[:NHM(:F;:?@&958=N;J64@#1Q390O!"9@=E
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M>]Z^G*::3#4CE\RXMR>3(J7V2OQ+E!Z#C@D0$W(,A=6"RT@8R,8]:L%I236
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MUS;^7*FJ]<#F;WR$5$?[%$C)1.\@+ D1N=(H 2(;T_RQ$4P6X#+D&E+<$R"
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M ET6+.Z8\DX-*#A9&O3,[;6[8<S&_LN?,-I,XU/2\#>=<4"R$)/VM3&&3^'
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MT>C=3*"FN"E%R(/-!U[*NQ,5NI.*98ZM),]KV'1+$0K8&B%@UDV>C!<G0(U
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MGBO5-;_D7^?7E?]\(J:NVY6V"C6B=*2=/T,$(M$0Z,60:XJ5F(*5=)C2/JE
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MKZN->8UPHATV03EZNX"T3![;13U41.N[-9]8(#M-&S T2N6C)G'U(M#X _5
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M&L^:"RW0'GZ 1[XF-">Y#;&1.+^&@,8K']2&L&C'F>R6>_30!42[!0U,:J/
M]',4%3/\A(3Y->=T$",],MKRLE8"^)ZPA#!Z<"'\!3+ (P0DT9;PC_*(D5IK
M7CJ,XNUS')BT_^_1=+Y=!6W^1C(',FD#YE?A=_^SV74J,>K=H =RC?Y7B!Y
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MO+/D^>D;Y .OKAD==;^F<;-H\KIK[6>?BY$R"V+Y*+.=_%:)D7;V<\)17!S
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MV= 8\K095!U_ F,;LK4O.KPNTI_YS#&7D:C.+]*DF8J'=O804>0CV18B1)T
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MJ<<&B^QQ)#"K)(WEJN,!$1+K70K>!E+"?<8 P0/.$O8F6B< $A=*89,;.>I
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MMD/:4T*GR6*P5;H?)D%E/$"-ZB(.* ^1^L&**)GO>- &N+9<K@[9M+0GT9:
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M-/HR7Z.^PN,QH@!9>+C:+]A\JI<L@M:%QZ-1]0;M]WF;)M+:MY1PJ0X4(M&
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MJ:YJIT1^VOA^8^VFD-!PB"YLG[20_4@A2 \J4MG:!_E5B5D0$U'A01N$PR]
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MILA)XJF,H$V!-L=ZHQ7F055@2!-_Y7O80 2D5:L'H.P?;\@&6?VI=GZQX/.
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M4LY&\$%CA#@_^!!$>C VWWSK[E@GVEG^AHBRZ<U[0O4'IJ["2I6P#<0"<**
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MAH&/'CX?3+]?;?S@3NZ9&)M^%HI@VJ5>$[J*:#'N.%9X(-;&_F"0.R?"],'
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MO+F 3CX5&5IQB= =8)82=3HA*@P\?M+65.V:[.Q!E\,V^\]5!%6<3N&Y4)V
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MNX;:4($W5TJ3>?=+/(.-FNY(;" OT*^#LU/V4&Y'#0-@[%H0OX@#.2,BVVM
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M.<OHW&<H.S#R#ZJ1B)L5B@/<.GNO8*V 9RW"V#AV>%Q-""6IUW/@$8M?4!0
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MUQ9<I?Z6)1S);1AGIGY#_8.^!2KUVA^_BH#<EJQEOF,GY"VRHO!!.$5*^&E
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MN.&F<<0E;%C!L6I0V\3$Y]7S1%,A]2@0+RO&5AV^=/;$2G:8_;S+QQ>9$8R
M4T\V\_H@(XDTBX_>0C_-REU%(#EHRBX^QZZEC^H&7*'Z D.,CH:1E:G-,.J&
M@+89M./?AXS)H%7'B&+B&%+=ZJ'@6)$G0X4O]!.E!+N"M8VW2NZ9%W;6I/SR
M&O-)8@#@)$8"^ABYBZL>;\D(1#_MS8/M >]>GL.G1;>[\&^/(4&=XE]:"_/-
M,8FQ#TC<!GDA2>I'8JHN$]6(%!4#%62.7FF%4,V(3RC=GR7T.#';A-J5OXK
M[WT4]F=WZ2_/?M&2=;]^X?YF]D6/DN_Y JTM!6+,]@#E"0?K><(#67E1,77!
M3L>_XUQ=6$?#OHN\C]HF_E6AE,+=,]DUO'=%*R;"\L.;:Z^47Q&.F9JR>I5_
MVW<[,SJSB-^CK;><\^_7*W*Z_MWJQNU(\-,JXK=+#'D-Z(94747\U:NM^-F2
MCB( &98PPPD]S$8[A6#)9AK$6V8U&_&F<E!*4$JT$)VMA^Y$:D71-3A;YA6
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M:P(9NT>7UI"?/CE:'CQBL?KS#3M#,$5-\-I[A4.QC:PUPE,E*#I4FDQ?>/_
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MBI);^*]?1>;0/D&6EL!P[(#!=;!5E HRFHG1L_3&>"DF0&VOH)D#K"4'B;S
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M.SGK,EXH]H)72*ZB8X=?-S?GS:*0.4R4A1=LCO0NQ,F2+XD;U3=V5M(4_6N
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MD)>(9E6# PJX@U1V.W?P)S#9_R*MQ+A?T."OZ?H?SOH7*29^>PO*%H)!0*B
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MG)%=Z<5GK^@9X8I RY 'O4,F^L\_E9L7O,]7NWUL8%^,I]^3EG"[==P<BV'
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MI[.YHS)W8LO%XOQ^QG"6(C0!BD6/)354%4J0)!:6$WN2 9%/@*P(C!78Q1;
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M+X(G*$@"PA*-^*(T*9W0&[0+C!*U!@FQJN%ZAQ*+C/O C?+]5.[OT]9R]5:
M.ZR704VSQ.^\,*TWDA@=:.W9)SU#G\XK+;@3JO1,5OEGMSO/AWW^>CFE<*M.
MU4E$N5O5S!7-(^_.']&)5:?K/:_4[7VX2_F&N]=DD>X[3^H7>.;Q)O5MKVS?
M/C<( *"J2G7.PQMO:; 7>/4,;O!QABZWIL8K/^1"R$'S;=%7(P\Z^/C#DYX$
M60$[O]O9F7IPA6:73$FW+I#>ZHGI$GWI%M!DW@GHXO'U6;@%&-&T5VYDJ"W7
MPG+_^@<D/1,RM+Y8&VE!,1(7'&*;G1?^,?$J%"ZHOC;2OKP*TUN"I^30U.6(
MUUKQ(II!8WX5IR+"M4IZ6^).>HVR !A4.U=!%SEI%;:#=%CJ,$(.I27D^<S%
M@*+34(R0JN,G/2&KQ<M/0IR.M4[#O(\QO"#5_GT#Y"L+.P@<KM$>0(E[\D9G
M\\3+2:0JEJ#!62[< +QKN%U""$)O?D_^>=@G9RRCH/1)R/["=RMC*EU.0X'>
M.%S9 X*QRNZBL@<FCEMG:M9Q]I]8WUA7-6UDT+>$W0[%>PW4GU0ZO782A?<?
M6HBL_VCBV&_9%8Z/7NMVCM^;U,_!U-;=QU6.=Y4_;6IL2G4J_6./P\4<?53'
MN:I_GKPK":KV[4V?Z2@P/5^]M:\HB7[[SM8CY;H#!7JXY46SX2)W9IB;P07'
M5+M3.9^MS.*PXQV-H9F=GF^F+QUY>/C/ ^_?LI."79!O#C/[6WY[RRP\5+A'
M-:5-<!$Q?[#NZ-NC<^?'*T\S$0\'47L(6'NP,QZEB[-N?A1D";Y+$9[$<9Z=
M$> U,8]GO"?47/=#&<9@=$T:.KX^SFWCT-S7JGK54.S TL>@KOFFV&,%97[3
M?L7#<?/$.(7^SI0])-GBS,$8MGQO"^4"=!M@>8#&.2S0I6T5IDE2Z:(3=<'B
MO&MU%<2S0 <5I'.,UE/\H<B:IH3%X9<00U!MX0D,]H4KTZU3-YH:%T4CE%=A
M5Y&C(I';']6S$RK@NR?TZ2 $$$GG%IR>$H;>1>V5[KA-TL7Z?PCT([KWS9,L
M"?9MVJ3=$-9.J^D@;8?=R<WEDQF B_I(PM_!1M$!6ON4QY4R$LHZU'D2/XW4
M$K_BJ;FA;,MIAYL?K;8,+I>@8O1Y/.3OG=<G\)2$/(%\-^=\5_DY.LWNVH54
M.F83E2>,@BLK&R<EU-Z,.NZ8D+&5T%'IS3WPK?B3\_DGB-(PQB.4BGR8MDX!
M::I!D4H"6BKQU(UJN,I[PNPO_=)PH%/(8*?QM0@JGB\EFKE<.*67Z -@[F.%
MF+O[7MWQOP5VWE5*L3/=UIR3F34#&N*<M%F.(U815K7?;U;V5SH\=6J.+G_S
MJ#]B^H6K@Y-51?-0!'4/(O>*KO<^7[N>#>E=SZZGA]@=0JM@E5(2KKQ\8GJ.
M>[K MR-JV)QG:N[5Z].)VK(*>WA//D 3AZ)KF^0U+&A_05S&?\[L&DB4;PY9
MA?UZ?A6V%'SWY-7_D,$U*=]/= .TV\F4PB,0 W3DCI'C%4)AP[\&[3#"!8V(
M2X)YRP)]UX3N&^C1N<?-@\BOQ;O,ZV7(7^I;AZ)Q/ZKK/QYZ\_W<J\:&W ?;
M"YPZMJ?33[PYG+!+V_3=;^$.1U)=WWA$[N?M&P\WOL%^<IIYH-7@F%Y&@(.)
MNG?!-I11XHEA1E!K>,7-LKX25^<2OX8(Y\-T-_6'4PJY>,(R\UL+1LAB,PRE
M/[?T?6W9)7&11D*JF__"1>/OT(G[>\FAAI=ZN$<_N.S\(V@6#JZ='767G8J^
M]$>+5OEC[)=;^)W?\L==7G,M[.>\M8>;"S(*2X*1M) R/W^^G^OSL])9_Q<>
M=VX37SXX$?Q]]Q^(R\^*4PIJ4MO*?@RT(QJ6YWZ VD(?Z0&\,C3NV0+&O65:
M-/6:#)(01&=@ZIXT)@;X++O9@_"5'H+H0JS2-$)%?C#":%NKA;T0!T\J/ (&
M?DUM]'LTEK#]5$F$QU@D)6GW]\K3"162+2^]\*H&KC;N]8P#M>5N)<=Y^U]_
M/Y^1:Q9>X\]P,>-\GBDU,<SYE'VDZV")1\TQS]?35Z!?-!&A/H6--DEFRNGM
M_?2M-V==O7@>SKG/"WS?'"W^A.BFI9#A+<BG\CY:/;-$$K66=J# :3@\(@_-
MD;#>\WE!>M &A0(>VS?"01GVD_3#;="9Q).3ZP!J^PHS17*$>&,8M7^Z*6CO
ML'Q7CU*[+]$IJ@RR]^]KP466$DR5$DU - \_CIZDSK$D1J0>HP,-D*!4>A6B
M3/I7DJD*5%Z%):$V$B_):J.I=YG:P-+S'WXAKR&+26I*XX2-[&E#Y4E'!Z F
M5TC=D>'8GC4;:Y)&VC6;&[0[.=S;;_D+C<,:MQ!?AZI%E1A*X29P7EY9@]-&
MF3\',AEW (DPE((R(CJU H8?ADE'GT-G0!QW0JV/J2F]U H,YC3518AI*L00
MH23?1=7::_"?-(FU\^"U^;BOD@Z2Q@#1ZS&DMPKC^IUDI$L]2]>J%A#-S67-
MLV,=:0)*OQ#4>A9<LF"=-6VS=^5S6F1%A(OV^ZH:A1_OO]T_Y5Z7BH\HO1CT
MJ'8QZJ_+XT5;O;RVOKF>[JVM[*GBW&B4&*%!=\B/\'T48.S6NLU[WX-LWP.'
ML[57CIFE6=B9_U*$%!IMX[[^!%W5L@KY*T'AJ;=G.OX1_%N $7K_FZ@?U_8H
MYTQ^R Z817.&V%=.!$4_^G67C_YIG6TG?VF5G@+0D]IS*2+&:.'X)/T>25\:
MT<?4)B [<N2F=_C)3&59.2L4F;',TJR7>8QW6J.UK[9$B>:5!/#.2$>A6B4C
M$%5"!FW9>GD!$=HQ-K2DR*60 5%+[RX()T3,-5RD0QO$<5":D'87=11$SJW"
MRN1])(,A^1'2NQSF!I#.6]#Z@GC>22'"P6OCD[<HH+9@=UCA42@;O!. R9!;
M]K'"\&-*#H.+6"-(OBQD4>W.5$ =4[P<++RJ85Y_N:)E5DCCD=<1M8'$SDS4
M[EEK/=0]M:*B+XVO2[\$[0;QR='=9*Y-!O./QP0\NU 5(&4Q%!X>M7\DVK;R
MCJ$^![6SMZ'@SOF765W/!N@')+>!T<9#FI_+6@+)52-38J\C5F;>V<[/'AUP
M?O1D"Z-Z\)' HW"?95S5@?[B_@<>Z=+T_,SO4A0N)0E[<-E2_K[;.-G7P V?
M_M9"[WU5G!Y$] HP_P5EE(&>GW.-73SB&R#,]%^:0UEOBK\I\,YC.+#^1C_7
M>E8F[UZ%/=-FIS&HUZ$N=F/S+7K9]-@Q:AF$Z209@S[W[#8IME5:[!"]K4>)
MP/A7_T$[+R%9C<S6GT2K$S388]#PKG@7*"Z2[A(IM*U6<N[].M&UJ-:BSS8Z
M"AE+? F;S4/_54C6A1P=P$\M?J44H2J\@[EQI.4$"!>04^8:PJ1HQ0 4YN$!
MHHD(HSHKUP6-_BJ)&#&"@U,4RQ^/]F65!X9KZ\5-T.RDE^3CV#H7Z3ER0A3A
MNV\^]YG4 :U4"FJR.(@T;832)/3"$BRS9G?1QM8C-C@!N_G"TQ:',N6;:4([
MTGZ,9@MI6YPY,7!W6$9/<DDR;X1WWM?.9UC&-%-/+]EJ<9W#OI'>?_U<M.EO
M3D->QMYO)KK-K/9)T\>5\D-_E,:DTW\/=3DI'WQ7=VU7^\5OTI^!']X(]:!L
M@JG@"24'N6DI8NE(+>]\QXN!<RL5J0FB"STS;\P^5_+'EL5Q W+S4X#']X[F
M1ZAC+\ X&J>$B88SC5F<L\R],WH[H!R.()O?\;?4:!6V^2!I'S_L^:F84.#S
M<J=8;M5\YY7*<4M39+2*6;@\N^; 0S/W\Q\CK,(/U'J9VCR<VN3QB*GW\,.#
MJ?CI_1/((E2,;L[G$[$<%\3=CLG@# Y'.S['0@6[[1G!F<;A72R(N.X%+*%X
M$0&+4^++/?\I(_2_YWS^8(@!A?PUE-6AYP998539>=1A1HG=B578;G&\PO=&
M(E=A9W^MGE)\EZ)E2<'HQ8Z-2[A5V&OC;/+H&=HJ;*8NJ3M/.@WFSO]8A6W)
MO:?PW$5&%JNP1(SLR2ILVX;;,>&R?(5"XH^B!5=EN9.L1!+R!^WJ*BSAV)1\
M^\E5&)!%9I^LFV-:C(N1\Y'=8MI<%[DO0GY3?I3\6FT5%I].GCM2L0J;U2::
MU4BSE"@=WI7;SJ##=;J0[@%+NT*PQ]HN5LRZN>/S$F-KAYA!U\+&HM)S!PCX
MWT-.R-&'B_(OHIJ<$Z +'M0F;N^G"[F&0*-K1L#[B,$09&3.9]\/UBW\.O'$
M6&X=U[/$F[80W<3%JHT3C]1!U4(9Q@%P3/1I$Y/L0*UJH?FU3K=>HMG3UT]X
M-3,^>3W)T1:EX<-Y5ZAAWUJ_5A.OFN]NNN]22:W[6<>DBU:W+-VI(;X*"23(
M,$3#M4K04X!F]U!B$R5?F/N:P5P>?YW_-$U-ZF+U(\T9P&>V8&Y4A#<C*"TX
M<LG'L-BJ0IU!DR;6O>@NG>I$68LX=YGV"W'_1BD"BH#MI25-J,'6/7 "F(]@
ML-^<[& V(]\K);N(IZ&+DV3%*VLW0^V38D%LHB4_'@MC[I /K,*44#]!+*[-
MYX>%2K)\%LXUV!<X6*C7)[>*L+9.*2$:@!^7[SIF$)%%&-%R'S(23W12NZ=3
MSP)1-,.O?VY[!4]_DMEJ\ZV:PO,\+TM?,/7P_:5G.P"6"FP'N>?9'D5;GT]=
M?_A4X%;DEGWMG9; @([N.E[0H_S7^<Y/%S[OT#D1LO2C8JB-\Y/HZO!MUVT'
M@:4BNR!<VM_7=4D(;?>1RM.-N]._7(SR]&P/7H45+R@I5#!?W>[(4VA<(:[3
M[*Q$C,V$!]W1"#7H5?O8UUPA?AMN[,ZKCMR50ZRG@=APOY+\UP;)3=[6-]K>
M93[I,ELG,#HL*R(+U@+JMY*Z^$"2C"77AK/)Z>2=:('"MA,H<RP@<Q7&+AEB
M&DV3WY.!]%78Q0^K,(5EXQ6W8Q3V'JZXGBHEAY!#;F-'5W+'6[K0>:S)@MSM
M! IW%=:H<,C4=:/=>(FMU$U6L830)&X:K-XT&*0*5E.D9EA8.$M#OE=Z(I7P
MI*X5P%)1!T<)++]Z$'7_.83OL*F,D._M6XC6P?\S>.@QQ%J%F5Z6I9+G% MU
M%2]S7H6%OGFCL]42A%K,SQSXO2A7%*6>/I[H'/TDYSQO@.[E^:#AJCG.LUKE
M6W,]7=<^!SB^_SH3FRA\M&S,._!GLXZ:IO#@<+;-MT*$9GRG ++6+KQX_<5[
M004G]_#K9_(>Y3_/1;KG6&\*RH@PZGYW7W;\/^:.KS0R/?Y#^GK\.KGL_BJL
MML5:7GCON\'_B91RGS^E@1!G$G&/I)+?J1#1T8;!;L _?B-)+=9;@*EX8CBH
MPO6C)Q.#&=-R;: C\3'!3,"GM'B),.HS*\.M%>_#&_UNW1/(G+\Z7=N8L;7=
MX'F'0'GH4?A 0L7Y1P]W;3GS[L:C@B*=#M,W'EGA^XO'K[T.:#FFKY'!/=<^
M"2R!A!8OOYN'WP=8'<@&=5*7+C]QSMBZL\BF(6+PT4/3 ;JNVV\11](B]Y [
M67#B!M"3'=MTEVD"(=@(=:DJH_HICJD"+B358W4(&#\7E=E #YX57@U*ZG+O
M6])\/CA7M:1_IJ7N3P5I]_O(WB&<,-40,D8KY<HLB27I[80E5  BV&O;<P.6
MP%?8E8YBX]H+<I,7:?>,8(!/,G,;1.8R]?M:T#B@JYUD,C"W%.COTFO)K1W>
MZU*]KL4V>&_0OJ&?J)S?E0_EK<)&E]#C2I-!\< P7]B4LL T(=AR_"@9BSU)
M8YO31-31!7$"X,A#Z!(6_'!1Q02L8GNU([2DYGU,"ZG]4/3QJ9S/'? -D!)W
M_4SG+R,,0<QSX#,KJG3%L7T5ED%6E=M"E[[S6-N66NW/#]QDJ.-0ZB.+_.T$
M3]XJ#"X-%F T(5)TO _0DX%"$$_W$LU%/9L(]_M"&EKUT*E2ZZ(9;3V')R6X
M6XW?OZPT_A47PU>^\N*70[L?>1]+4JN7Y1@?]Z*?]M+,IY\X7M91Y.X<Y6;Q
MT.<@PQ!>]L0_\[=M65;L?HKZIP#TGY>T-EC'<X*!EY%7 PQ/N"@E5]J<*W'1
M/#Y W[H8[%$0.[A'S^KA%PGE$[KC1(NCQ!&BB^-&6C9(#DE=("4)F> OPK*#
M083P9]I6TNYI(T,(#]QH8QYA#LH/$>POR)Y["CKCF;I2 G1"R-IXK*[X"TN-
MN$>$U_"#>@+ G'LQ)O?F&/6!ORUP@K)P0K@Z:>U<AS+_6HC<+C6$!* &AU;?
M2)_$9M V+:'ODS<QC:7!C2 BO>4$D'8*P@H9B:3]+1"YF/"@4T!?"ZMJ00AD
MCF>&Y28!$+Q-KR9+6/HJGM=G0FEQ;D9.+R>VA K0!A<B]'+C6\X4032W_I93
M#(+/N4%+6TF<<\<(MU!K\*LE9L<7ZNV(;_X%+O\:KEJPC+PTM#?<<M[OS?(O
MK]2#1C^T:[L&'NV.U$XJ5*^R?EZ@W)L=6SB\U?<1RMR3[E<<ZE&PU>OZH,@A
MX^Q0MHUG38&3=\4L\A)#7V+C\3KJQ#9!ELQ1/4?XO'DTYXBH;*#R4<B%N<,$
MNTYMAT8SI9S)J-%C.W(V(+G]'8.<R<HKYPH/-:(1=F\0&TD=S)V-LG3T9?Q[
MR:02KRCF*21>A3GV$=?="'T:)C<&"RGA8#!7G+=,;3DED-GS4+K]5AE*_QIX
M,H3 #JQ5IR2DN??;'2G#^ON%^P55W[A3'GZLB79GI&/B)UDI^3)-0QH*-'$*
MR#SMV*9,N2'12R%X8X*RVOB:_T#V@I[,V-Q$*]6CR'4?B6&-0"VTGJ6=_R_0
M6)Q1"JE< -\RC]4/+97TU7_< =<(\A]#S?R?8J"99O ,GG?A/M^#^";N@?=S
M+BNMV"M#$0-ELQZI\0^O2Y]GS+AY!'2/>3NQK&W?0%EVG<(;>2VV7(]NB[#/
M!JZ/>B0F.K7/DR[^>2D*?Z2-??SV$#W[SH'!<=ZE X.E,V_"O?XY]]O*\]3]
MC(/0XQKDI)*TF,5&B"^MP@S)2V12M^:8CS:P0>Z!%< E1\B9K!46ZTJJ! M'
M_U/=16Y7.+[!;4ZR/8L*1Y/UO9TO5E4 STK7E-+L2.HJ[)]UY%78-5;)_+/_
M625AH,7K73SI9#5K\?E$R[ON+8B_9&J./V:EK(I:]%>%RV(P5F%.I>1G4ZZA
M R#Z[Q'W_[H@_^OB?V7SV^5VN:/4=$B"1?:JSE[C3TF&6$KVB^C7E>O'FW[(
ME_#MO3+XMPA1^<#4RKJ(4]^L!] #/WS04?\NF_ %^Y7V_8.W\=\&JS :!K1\
MO+3D+;T[]?_4SJX)FBV*@W_SF[EV;Q=% ($!K6._?R2(J'AR@/ROFN9 -$]^
M.F(5%DN^\?+-QT?7-AK1RCN5OE6OPC;6>@_=H/V(DFWZ>"EH76$A!?S[<Z/4
MD#,3K[,*H^XFT>>Q K]+^2L-7OV]9'3X.IH-M&TMP_%G4(!8_%7!;%=A2T^8
M9C[3KJ0(@I+<@R+JD1RF)I%7>OF:E8LU+>?6LD#_TP=MSIHLO*;4UI.ZA_8#
MO58)8$3>JB%F+S->-E'M5\@91+.U>G^KL ?ZH,M_%6!H4+QC^[4"#'ZP7,(B
MF@[UM<0B!J01!_:O#Q3URFDB!_ +&0.6E3U6COGW(_0[G\C0'4^?WC6>. F?
MEENMU4;]U ;%2>R7UI9<UBRSE0_PU7NJXS[^NR8MBO4/C?3OA'!LDX^\?F$M
M(9S_OS.2)=Z(HIBZ7FKJ?Y_I!@%BK+53:CDBU5!B(!I8O 7,BF//_..3N(63
M_WXR=B-I:!7V[086^ 4AL<6O9<8RQD\SO_TOC_3?9PJ_SXIT4 5OR)5+-Y/_
MD2ZL*-QDREK1U7DB6A).?AWX/ZNQ8O^K&JOF\J;_B]58L3!RNVN#JH6;[,%2
MTZ"6<'AF5LB?$] )P3P$\,<T<T<?TX@@.B=[S-3S(V@+0]/M3E5!_AUC9VCW
M[=8)1V^2=Q(:QST 9GEX=5A>Y,3]^=+&LKP.VK+L,FYE<[RP5<4/8*7>=-W#
M92J4>'996- NX"NK='361JOUR<QPEF]$\[&&XHC#'Z972K/+WW_ A)2%CPQ_
M'PL:<[5J>'N4LZ?HQN1LIVH:YY*)DH?ED9TXYZT!-<X%9[MY+D6WGH?^&.>,
M%AS,1;V^$3MHDE*4_?DEZ:(/W*VRR*/5SNA SNZ;%[WV3;\I#G]A.EK\<2QB
M2E28)8S<(&B:UY5$0+GB,80:Z82"@ZO)=\H[8Y>H*2@#J45S/-NGME.$3K56
MZ&>4%N0OO@WNJP;]N7Z8^6TL[6Y^LIWAS568=DM<)=1U#J1P9EG*TWRXVE^&
M)0MCV#IK#CPU!K%=?I T2#.Z&8=N1VN0++],* %X"FE'N$U!SDL$&QY/5KMF
MYUE!0+*99J!1SK=IE"GTI )'.@'Z),M_BF@V5IAF8GW^_.E.-FK'8$/U'@Z'
M.[%K284\BA1[UT$X,G!I0!PJHU63X!'-_Y!,AE [_:6ZT TE3J +MU:6]094
M787=NP2,04'? ]+FM%!!U5$E3B3:I?KQZZANM3=R5=G_H.U=PZ%JP[#A::L2
M4]EF-Y5*B&ECD]W,4Y(0$T*(><HCAC0)&1HS18R]IQ1%S"-ILFNRCR;#C,U3
MDCTA9E?99ZW*6)F-=WK>XSN.[SV^]\?WXWWG%];,[5[W.J_S.L^UYKZNO]%_
M,2F>J#W]4@2IBUE#OQW9H_8L0RTM<G&C6 D*Y:4AE.UYW6XV$>P^*'7@)-"=
MT5R?IUBG[-.1GO<XVK!D]F[G\_/)QGV7=0KU#K&]2CP/1\V<*]>RV5Q'>3K3
M!:>4)"0(SPE2$@_N+?=@6]OY1)8.8NXE;HG"]7OX8>H^'&O8]_[EL97S,9<)
MUI>MX/<#/68KRC<<-+I2;-#ZEWI,YX:$XL<7@9@-9]C:V8P!S:167OC=>T4Y
M7PAGKL(W;(WHD/J+_QJR1A>)]\C"Z7OPY+'&@>RVV/Q9\WJSO'2<S7 )CYF,
MKC)GX=>+U1JJJX/';@J'B3=+0IO5@9'1RLOF_GIUC?T5-*I;39XF/DHV1J(8
M3=Y!:L-N,J$F1TL/UPQ;VX T(0*CY \%\=6RK-?=U"F- 04\Q!V&4U39G,Y&
M\.I=\O5=&L,E$1?#GX=JW.IEV.O<Y4]H?!]ICU5,H)\G)1#H7$HK7AL:;_U=
M\2\<H/#(Z<VZ8AO"%P#>!E>!UK$*=X,-MS^G+BZ #MQ5F,KLBO/7U[S<3)'$
MS+P//__(6!:URBG-L;.,0"Y]H_@4T%S#S4KVWP'T9(K5^%:V%_F(382NX_T,
M5UY<;,M;K8XN[U[3UTX+>N=JC]HI/QM;Z2><N6N_O_O?IZ;Y)TRKQZH2SS/V
MZ\*3*P:?E,2J7U%5824XWZQ.VN&!-,;R.W*-2F4NA*K#>WY92SN+S0,'R_ZR
M>.&>=UE1!>>>G^.=?>VKG37*^YC+D;-M%[]O>5CJ4O.$GE%R*_+3(;AFAO@<
M).(S=_@0L-(M%N"?Q!CH+9>>2J[:7\SS4Q->!Y+N@N[\RPE<"=R^7ZI M 1[
MV#A&.- &W;4^+++CB*.A;#I$9>75OP83'*","/[#712VCG+VZ:&?^6DI3%P4
M5L47"FIIRLT0>VSNKR2B>58]*H1,V-SN@;"?!3K.V/-WK([HYA];^+;-RK)<
M_;OW\;W7QG+GIT0V<ZA]$%E@@^7:MU9Z=2 VURX8GH:\^-U./'(\DN$$]#CT
M8M_W_F125A:&*<:EW&ZK4]E3_14,BZAGX[B>'][M\A'^M(K@,?ODV@QWMG17
M?^U$]/$1D[D)79\^TS1-/\SI89,"QS%?&WNG(9/QC[2:09,YD<6SNC?5KY-"
M0\MQ@?&$IZFG;+O3.\ZVL3=O&GC^0/5-<4A>KMY+5M\#RPNO.]S90VV3SCXO
M#)[@>L:\Z()PN>V!,1UJNUG]K$O%6YM"YZ(,[!5<GOSS?3X+69K0:FGLW%>>
M\JYJ=.!!M)H6*3HMO<AK6U5,(>Z71*1.5.Y#[2)U>C5-=?CM%!_GP\?SG8>E
M5D1R==,@<OZ%*4%J-9U3,TI8&^=D3W4:O-C+@ ,O,%N(!@,+%5>YZ<&%&ELR
M6=^_?,V7;L[F2=:QR#7,#*(1SP]^&NA)(EJ(SI-&8Q$4AA5/8M9UJK?62,U)
M0D,=\,;EG<IXBNOUQ:WXY]*\V0HE2=0 _(:2@EK7X_BMX:>2T7]$+EAA^GZ*
M%/0<7M;T_ZPT_C#B,F#2;3DLKXUV&9C_TRG44%[>\*_4L0\?^L<.5"Z$A?$S
MY0FZIY^<S%"QETFQ+5)U!UX&IO4(\1B@7+AU>&F.HSR'VDZ6@V(8A\L)5#=P
M-YA3S+?!' \[-N.U(M,=:6]!CV_T*)QQ413_1-3;;WN'-C>5^![.V:/^SD/[
M='^[()A?O*DKKV!3OP>O:XN+:]JU$K<" ]RQ$I?[%[O5GX]>UO)S-V&'Z\CO
M "-?/EK>_J5Q2,O&H'!@<TY?JWOWH7<96[7*^I],V:]+9_T)5"44;^*]-'GY
MZ>?,B3Q*"Z=V?S9B80,?D[X*JZ+-_^!2%:"0$;Y)WA'I!+E6H3#AR4QL=!+1
M1H!0P(U%+=^NG:DT\ESF8Q<."ZB)]1JGLFE=I7;1SXAZ4-QS KZ]T&AHF$^F
M3&X#S6?\J0%A)1_/S^2<OE0S4+%0$:9K_%U]H7*W$V';6UV33+<#?4ZOCU9I
M/DK;$?JU1X/41JW*:J/*ENH8E"+:(WV/0H'TY&\YRVVH0R"M!9V(T@==7A->
MVEUIB.U)-NW9S D9*^D?/[ZAZ1/6K^= O/H31=T,Y3BCH" <;<SGXWF?\?,?
MSX\?#PH,#%KO.9QS(Z?OH-EP?7UOF2T^#+]E[]GC._:ZGDS3"GG^SU:0D&H:
M?#&X]X&_S^&OI1JU_'RZY;F+GK1ZC]EW3W*K,RS/"B-WGTHT<#W[P,&C%'5&
M9-X%-EYVR/U2%_XN<VU:>5IQ)JL_P_'1"UVY7![X<>2A_9$.CXX3M,%@WK7S
M^++ CT2F42MWYD3B%;\S-XZJ7&*4MW*^W\T:14J[1;^+%0YTSK_V+_?WX"[^
M.MTY+],[ER6BR^09@="O))?,P$A;?B D7I>R^IHS9#(P]AA2?.'X*JRBGD#Z
M,$*1]C$WD%1(O6@YL1<P(,#$FV!3$'"\FC.H6LJE*MG;3"4N+=BW^I10T\06
M\)1(NT(C=-N*$2WYIQ_2[34PDKQKD&%18?K8LVGXP?/1G4;43P86EU+Y^G\6
M'O@:'SRI7_1 ]71)JIW^7K<.WKW3GT\=F.:6ZQNTQ-O9&627N*G@WITML.BX
M]GBOX-@[(],#[XR.O36-''"V<4<//7S;X7K?U\7(9 #WK&# .82:A\Y#;L00
MJ8!+#[1+]3:WP-T14&M_0^[DU'QX  3P1]*^U.?S,&RDFJWH(-'_]: [7R]^
M<EB3FGH#L8VH$,:G)TZJ0>[_$+IXB%1K;[Y,V02'\:AITK5#)J^05]&V9.ZC
M2GZ"  D=N(/8L<BPX2^F-^$7ZDIG$"HH S%:S<>+14T>>U$ :'+OD%3PE,*U
MS=*A0:E**Y<,8R8RUO 7*;%3;>AT'VFV@*X(9;D-H0P(=^:VX5:0',NI%L1M
ME!YDCVB![Q K0PY\Q"T0IV%.X4-Z+V21?J,2R+218^?>,)?J].E">'+Q!8*I
M2<9&T9D!?&28:>3%P)*)&:&YZJ%6TY+7'810KEP+>2,!W4*&$Q$ AH=(M%X'
MT+%I[>2MUG >/4FJT,M  (+V;<YEGUKYF#50J%-?921V4RCP*;3I,QBJHU,]
M4*?^=3C*V^TSJI@P<//\X^%,77A*R7S9"8\YK]RC9^\7;WDU&N N9/25OLL_
M5W('.R]>;B^]B8]:&FQC/36POTNSZ)[L"]/WC,K^VO2@/J%$;$4/>2.!=[SV
M@-)$9M!1/G7!#T +NZ 4L-N:_+N$'7DK@2H,'6K>+-X/!0 UWJ!<^RIL3,!"
MUV S49JA9B1#R#U"Y$9FM4!V/*,3SNA6?_,^J1E$9J'VDRFHS6"9&#U"T@FQ
M?);+YQ0SN34ZL%YBG&@/P8W3YD/)J)U VTOHZ$N:I71K%? H'\T2I=WT"Q56
M0;8\;<<IMV&2)D1G>?TXCBN!4K_/.5!=WSRP/LHGU"(UH+B?])T$/#M6^& Y
M5?J>7'-)'$P>.TX.8MZ>$YUT@M5E"_K%>L VJ&_?RUXEUI,)J;[".JD2Y1;!
M_YC8;'=89(?)I@%[><GC\JLV\IU,N'@#Z-ZZ\GN+5ZK.)B"K+0M&*/MWIO
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M+MHN$YX[0M!U%/9.1B"?GHR%2S=(!_(ZV>A$U$&P(=54EF7+D IH&3 2)\U
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M\IS7%YD#"$*.TG@22JHI9L=OOJG&36YL;NP71]PL(HUBZ_72%AC;GX]!7F?
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M4Z3A>"%^WK0#=U.RI_!_ED_"@D>,6%U3Z9QB%=^E'9ZJU^9EU#Z SL"<,N)
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M/$M#- Y<KS!S*._"G^%C/5<-;9N>H?'?,8EE5IK#B'^@.<M9_SLYI^.ZY8=
MM'!6<M2CRBO&?-Q,SKA[#<X$0?I]XU+/I(F5(%J?Q?)C>,&^X/PA'5-8/SX+
M6&D?XV%"/C,)FH[H2O@?8)!27)!167$M,=WU_61&[=N18UC'UF]XZ='G];/[
M[+NODEJ:F6'::3GI"R+QR$:&&VL>X6<ID3G:*%\X&[/AQ92*G(X)?W<2-!J7
M=8BRC+"-^Q,T_E&TBF/'G],L&= (<H@UQI0P5>G"I_!43/ZG?;*AKI"@B'\[
MTW;8XW)+V3#?"ZS$7W&]WQU9;T>)8B!PKN3_PJCF%I#SDC4"T?B8")D5UI(7
MR/$B%F.24UPX(!-;;30E93?9O4Q:ZV*Y4_^H;M3-K^E:;%-Y\XV(+.<$B0(]
MZ!5JC!L3H,G2/.Y-\BG'!3Y1.2BF'R$F4YG@M0E&>M*;8U?B?=G8":,,^P%+
M@N=8+G_!:(KUQLT1^FBFTWZ>QZ,CJ=>*$D/V&*H_ACEWX-=7>$IR!AT/5AS/
M"#LM#^'W>L]]DI*6PN5T4G2N-052KJ'<&*<].\[I41J8!50PV=ZM'VMF]$"D
MXW2Y72+#/=!*RZV//\7RZ867/$L;F]N7S/?!@G/Y@?"'9A=) <WFV2J^PDJ;
MPY_'_R68,X.R.124NM7T?(XG[(L'&Q$5<V9;Y8I3-WO :L2!%_#ALQ#O(+;#
MC:NEBSKX3CR[QI:NUD\ZEE<WXYTWKB\;6KGOUTO?5,%T2X%\-6 :&"?Y2XB/
M<#?%L)7FL@7OW0+,> KA=YMWSZ#]!-]>8?Z _P2QEQV+U^<'B6?T'$A:?0&:
MQ5J94"MW.A^9Q1AET%-MZN_7/4FSBX$4]](Y-8B*7K0VOHE[*G9>!Q4_0@F7
M6GQ650-X:D1ZCIF.BDQ%H$?O?WA8WTQ>H<R< ^5XIZ1Q3FFKC_P ^Y<3&[ZV
M#V[Q^!ZRJ_%G*__1LV]?#$^@6'WIPA5#!-0_C)ZE?"F]26L+1*8J\- H+@CF
M3\8$+6(:C]W"J?)&,437?_+."KDK3ZF'SH0P72680AO6#N_ 7?L-!\35 E6$
M]Y_1^Y%$1D&L?4DH]K**LCS%'J^J*$6Q77%GT@!2XS;BB[.-P>J+(8A.Y$*$
MM,L]> 60K:1(YF,(J- D:7XC_>\QIJ()+S8\O,;+W'GW63SN-O(@^0HXUFBJ
M5W5HT**0]1*E-$NHY"X<_(-"<!-3%G&5:A*)S!_K,^K92JTGV2Z>)E\$(M6E
MR[!?-DXKP]>I+_6KI7F0$^PMGOU&[$PLP1M$^2$KT)E$[+NA,66).E&^B34#
MJZVJ!)Q-(,4@GJ)1ZD<YC2&1>#<Y8Q,F5"*>4C@3AXQ')#BG"76@++JP9>U6
M_L,^>W9/M%Z4NP K%1LX9_CK@0V>P3SC,87A+E^XQ5C(WHY-52LNQQLA4=I#
M8A4YC^L"K\$JZ_2'C W<GSKY/M0</@KBY)*K<8Z"D:>M812$0)A9SQYU-" Y
ME]!F<8](P;"1^Q$9]37=+&]>NJ(8=85M[O";A4;F%&HM"-9"H+Y#+,+HE.GK
M094L?W#%30E1//U,[D'$/DE+.:84.V]8^>YDA*;Y\"X)+UAOA+=@@L9D*0/V
MZI EIF,;DOCS01;NO!5,-K)G$4> #[ZXE0,<,[%RTRR+4#85R^U;[ZN_@*8S
M"#_D),NQ.Y#CQA/NO.1_+%K4[&&2VK1KL1W:Y^G&L-%T/,!T'*<K'S%-66N9
M38^.J)OO M00PIHB,,1GP^%E/*VBSS^!\+P).DP?6:[#FUQ%AE;([GEBL)N5
M-DWN2SXD(>S&K60Z92'2\&7-@>(9/,08,=GT[3LV9PG-BUX,1=6I4<<721Q7
MV8XRH%;TN5M*D021 T]ML,D^KX8<*F0L[5S9"9Q-3H_3T067HA9=?UN8FN__
M.\8AG ,4:L6Y_<,X^22JPXNC]IXQ('<B#E 7OTILQ;4M#$%I$,YNEN;DWX23
ML'C!M>Y4SFG6DNXTT1F6)VKYP2:7V*R=#&_".:3M"2S>=*2+](XB?$MVE1I5
ME^K4C-ZV3^Y]W:H@5XE:[O%XR=T> U.T=4S"Z;PIQW)==M"8 BE7D;_R%X&5
MO@4AR7<(#^QM<S3;-HFU%&RZ"6?M(SCF#;R7[:U&WY%L,P=>@7;U@ZH;T<G\
MN>W5'!K8I2ZFXJ #*N$E&]\VY3OO$#5K/R(2+&>@!(97Q-'*@4C.)#CT-AL+
M:Q+3@Q@SX6W/WC0<4L@7=8Z+3FI=62Z@+KPKMP83J.OM^[*E0]"L'PJ4D7B\
MLHV1T"HI:8AO8=C"*0<3CV+]JKXL\S[BLW=;^8&]4%'L7+!% N\0;@8!QO5.
M/?(E(%-_\D$7N9" P#!NI^Q['RNMP?)A'[,7V;-6G/<&[5$W3>R]C\6K:_N<
M+1?D*V.W'#)(P38BDJ*\&!;#(R$D.!M.,W]*1((RLV<T<>P9FG#^YCZ@UDF%
M;:=DSF8_8I/0Q,.A,X%F9O[[H,3(;$'/BIV0S[2G.+/XKL31IV]^KDZA1X$T
M*3K2?^VWZ"!)?B"SYQ[='MQ01[>?#+'2&B'L8[&(-0LK;FJS&Q+3H4/0[$<Z
M89MP\-T)5D-]"SO&8Y)-GW3*E\&1@(NO"P4]YJ !U!8YB&13]%##$**V#*5\
MZ5WL!7J&[TRVNEXB)2?B*ILHEK!'FB_%M=T&G'=/O3:">%,'V&3>%,,K:<P8
MRX7=I:QR5MTU8B-ERQ@, GK2:TAO1MR&(#K,""Z =*7('%8 .$\-HS 5]=3\
MQGNKD,^TW(4.H_9 ^ G.**SVBM[0^<43GE#55V?>"R=;[A%KS,>(%5ADXS!#
MLTCNV#LP$45LZ@ALRXDPT$]KY.(*@+3D,PK&K32G_:0"=1H-\N>$XS'=.:D5
MAW]Y:WH#EAK$]!=40BSGM[&68>\ER9EXY&/.K+2QWGZEN.I-VTER&?RYI88X
MF&)HFS:PMK2&,B+(W6XE/8_CGL;.0V=!AZ.S=D#QO:)<[70K[?.(<*4'O5$X
M5B#&SB?RW\=E5IK]..H-!S_K^!B3%" )D&WA9QT[:VF6]RVWH,-0 5I3(VKD
MS$@6.U6R)@$J<EU"5=J"='0ZD[ UCKFWXMO5RKUR#RPX.X3III:>] X!!XWT
MG*Y6PUC>A#JOQDIS)P*>RK:EH?;$ZF<AZ_4-R_X<WE6/O3V;@-P-5B=3HA?'
MDVTQMDWG4?<;92I9M)_P[:@A(G,G+BDB[#"E*1=C"F63#(7\9(Z@?D7Q4=Q9
MQ;&13;H>8>S-S,Q:]U&V(8<L.UC6%\O[HEE:E&U\*33O"&ZDR)6CX$PB?>##
M@%&NX;D=: #G[A#+P4'L00OIK]4A/=+FM>HS(?85^^$D .%"I7Q.73=_R2 Y
MIUTZDS_['KY:DL8@%F@V2R1#'C=37T.YG#E(BE>ZL:LNSI .\)00TA%_\3:?
M=!K25J5(!>AA*TT@GU$-=I0E<VSE\XFE $_#ZKOW@E/X@V;4Z<:])[(XK,A*
M,T:J/"NFV2>W['733I>YN)VZ0Q$ [:B5YHGJ+HEGD4PXS'+KS1;"QQS0(&Y!
MJ5Q8O3J?B[<>Z S9=0L^ NH.XNGZG3P_???(&-ZJ>$TL>_"D6GN2L@\A4?61
M9^%%=P911W+!%I?NDX3;B2N4+Y2C4-Z;PO#)!E_"J:29M>0)R039C6O=&IG9
MD*M\!6^709 =%,-I<MYT/$4^AU>B&VOBSN"%F;X2-E/$1[\SV ';W\/3E?Z'
M(I[!2V\3B[OX7L\'/)[B=<12U#E9<Z%&-]C0;TKI0G57Y2[8MGIZOAW9P?<I
M"0-;# WI:G$-2Z(7]XA5I'L]CC95V$7CW;DL+UZ\CC$BDO \#7-9CN"<PZV#
M7%W;G+J3<*A^D/NJ&G&%/WL6NR[H*7%>)\V'OD +-&HE-+F7? K5>9_3MXYY
M/^\C/@.W<,BTD/+:X<URY^X[+#JO.P:GR&/J$,,1B;>G*_I\P+IXW',3MNF&
M"'?GOS>T--TF/PBR!\&FR^!!^=!5;LY)+^[(N_=UO^,VC9 S[(-+6IAVL%]#
M)\L><(S'+V/:S1UP.#9L""IN&D4,TOP0^Z4/P!*Q/?09]#Q>+U)&N)H5EX+/
MC@1E,B=3H"V2'$HWBMVBO#BJVMA@/*BC"1>0MELPL]%7A1:(G4,2L0>F#!S-
MD_L2&\"CV\/UJ*C:'6;?I+RG@VP/YJGDT\$>'>)\XZ[.$M6]\XG,!G^@B&6
MJD.ZX5.9>O8,7OG'=X%8S[L.1 QQK*.!HPDU_8%7?JNW1+'SK+2Y_+G 4S>
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M-8%O)4/A>R!Q;HE(O8PQHED$YZDX2QA,6+^Q<#X<\(!1HB@LUYHS/<%3U^6
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M%Z,E,,)?34NE''/$OT-8S@R$!F9P"DJC.X4&NRBI8T0"(^$@U'UA<J/0 &T
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M+>RNH$L1 !-A+$+$.,;NY>$7F7JV#.^&?+VQ<NTF!E\DT,.T)J>"N"1RNLF
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ME!ZG[VZE2BL :WV, SV6W^"7(FN@M8]F>\7'K.6=K9$DNW6B9DPSB'C1.;J
MUB1P>L?T(P'XNI5@\YZL[> F='%FBRAT(3>(NY?KKZ5>J0N:?E"^N=OA!IKD
MV5IQR?;R4(W-S5M7?^GTBF04E]7':2>09%PKV"TFLFW6U[VK"*%(!(8T<SAE
M5V7W*&(D< +//5(VE/1'/HL21 T)K"'#2L.[B\T=>7_5I&4E/(XT"9[!%?=&
MN1RA6C>/8VI?RK]L8Y,G/E)-W@:.=6(JA;1#(<0S5#X57167ZT&F8&U'1;)C
MWV%H<6):T7'KM(LEWKQ@[R<C!AM[(X?H#_NV>#V*G#IB_ X^J75L  =W@0/7
M2'[TT@\1-IM!3A;MH(V5CVNT!BQI#-FH" ITS([2[ WZ:N\\&5?G8C&_;6-)
MV^ZZ+VG3H>PFPEQGNE%TX:;"07%B +(*2^06$3[=8SNW\6!_U#G7*5&S6L\G
M5G^$HTP?Y<?5GY,VW#!_UT=AKZAIY9?<.J ]5V+R@.M9D5OE-3+8[EO*1UP.
M.!^'B\![GZF+/.@01?%AG#$.("L@#Q7=H-GN"E);%&:'K$K/+W))KZM]=UJF
M71$:4S.__]FZ'B\>LA.<P;&1^+NPGA_[H(]W:*NSSQG9H;TQP1X5(5NMFA].
M]&GS!-[OX]V/2+VZU1,/[[9_M3]5"7XM.^,P=BJGRTIHTPF<2!H1IKL4;GD*
M7SK>-BDTZ8-3FLA+!-3,&_DG>]_#LB"H.+4^MP2CKQR"(;+-N</"\L/0&G4V
MDZ@J/4_DC4TNJ.B+3JAO4[L3E0FOO%BVP3"D@##W5-EB-L0R;JNP9TE]M2&#
M*0JPKG?\M?WO6Z+.>IPG\_"9S-TG8U=H9WF[^]RE5YS?<5MSK;KQ1DUTFZRT
M/9GXZ9R%$R=S!F<8O\[)J1Y*2$.<^=&%BY]"TPR7)L$:<."6RL"ML;O+]@#:
MT>GDU'7F9/7S<O9?WF,[ESG$O5A3_<(O>5532TB)IH6=JAP:I+T3:T?T1*5A
M.EZ81@+-_J)6KGUWHV_,YFR7'KMULOW!7)<B3\^.OP@_^_\(+J2<>/$)TFL:
M^587&'G^+JS>"5GGL!]$';$A==!)UKP1=,E3\'10?V5QBS@-CHR+X^![6XH"
M?8J9F\#N3.ZN&]8;5!*37367:_AGP79-4I8"D\?.%/,0^ %@_&'XK,,CYR?Y
M^RU/&*CZ@WV>MC/IJN:TG&FHS)EB$CQTQ#SQI."]4&'1>LNOU=Z!_X28&[/[
M8$#7ANZ!Z;[Z6@$W'?\,?G0\@<^X]^=@H\"VE;E287UP!K>KB[QAI(8O>D-4
M3$=-1_44]U^).:MJ5:UXG9R8?[#_&.PZT%"YKB1E[+C9VNNG1I3<QB2"X1<!
ML1[+OL\MC:&KZUP3V$R_>!5@$ PGT#K,RHR?Q(6<B?%SZC\(A;:-&51F_S4^
MO_+%P9MIVP71"GY/S,289Y.+8&4'V6*X#>9(CPPX=L;KYLB'P&H.XA%#5PT)
M5A#9I&B5'836,?T>['XH+@H,E-1LO1X9<[RH0?_H,5NI=;4=9"5G-UU-5NCF
M-%!C'P8SRIJ51U*@.>(BD8VAJ^_U>TQ_:)*;B03:YPZ40U0OB)(6[U9 7MMV
M)-GVE6S)O8[3HTY_8!PR=0X</D",='B&)/;'G+DAT"5$SAJ[S@R$(TN&VD?(
M*R%N&M/V'F=)/TSQZ6*&*-WGB*9IZ<ZEZZX%'@=UDVCI<LM_G-/N.N!I5?RA
M)8PQ%!6C\OK8VU:7!*I#.NE.]GCIP,*N^#>4_:[]:'8QH]2C(S[8>MG)HU8!
M=>T\YX5E8Q7BFS=, :?U46M.7FFNN\ 4-@'EX>F35F[1%#S3LYU)F@HU@V\I
MJ,;#">39/K$!+\OA F4<=*H\7I'TDA1PW"*MK$28:66_?]A<L([CUW:G*J?5
M*7M/K^Q0YINI47'T6466S# (9OM6:@-2T+5PLEU>XZ/S4=-2,=YT2&#;59GM
M24T^MZ;#29SB5?&.L#WXEE=XJ^7G-NNHUZLO!U,BB9]HP(-;T[J!G^*F \0R
M=N'*-B3L^YF(;!^(EE9G?'=M_6,&MW&Z+)L/)W[%ET>[!!QQ/<)[$)6WM3KQ
M1H%AUN8.^_XQ575T[5)DZKQ=<,PR="WBTEYI[[:]&XF5S^#TX?*#[_0RBL#P
M#%*@HIXH?AKQNJ0_*B^A_,NO46-Q,7$C]I2#A>CT^V.1&B@R__(,[G12M->#
MT(-J>7C.)&4A7"(*XC=Q#$-\(%NQ[6'X^L,&\#/ZFHAL67M1H3;H9_@W;#5"
M=FU4K$5?OS-_*PWJ^LJ,75-?WWZKGW*HSK.>.T?"+2>FDT[,X(R<'K%6?#E'
MQD/<=#7S++U8*K=ZS?3"7UD#\KBI$R(ES8S(B9%#=I<KXBK2/N/Q0P(;\,$S
MY_J<W"(O96=;#-&^<DOOOKX0Y(DZH7+B^?-Z6< IO:?1H4Z@7=IH6271F-'7
M:#F_X*23^51-6J4RA.#]O*)PQ#?FYU[]TM*1+RNJ\U5>1SI7Y 0:?V[/Y1<=
MJ9KOM[-92149[&MNRK]1 -F^<IE.2(E1U4+)NKPK3/?_P=Z[_R6510__SG2Q
M,M.RM#2AZ6;EA:F\3(HP969&1F5I8L(T710)F49-4I0I4[QD3..DDXY2><L4
MR01-1$CQ,HUC*B@DI@A4BHB>4U[.*.+CO)[/]_G^^/T#OL]/>Y_+Z[777OOL
MM=;[G'WVBKVJPOBS/S1DC+3DGHX\>_A): =IK7Q_YW-_DMU Z\Z_V[[K9WB4
MT=;(<&IE".AW;ZK+DOJ$=I5--9*/##2E%VNMC0X"*,%&S/XZS,(WOR6^L>WA
M)578KJLYS5X%X>?[HJ[D>MAVO]J #V#>FG</H!3A+E OMRA@N8E/M'33F"YS
M3!75A; ^0E8!,"_VTOS7YGUBFF:ZVG5>U_$_E;FS#_;K^.:#.46DLK#\#BWY
MBH<I-_>SEE.EB)TLZW@['(?: J4/,^TBRTLA1(NGWSWG?!_/+R2C3=]45H*X
M>L#M\[O#D8K2W&>#Q^3RL[>DA]>>>0/OUX?_%O+T\IJ 3BI3T][$,H=([4E[
M\M7!MZ=#$:E_70932E/4BR9KQW Y6>6"V: @SQ4++TGK2_.KQA0%!6^S2XD*
M[ES"^[$SF$B\^YV;F7ZJD=<#HA4#5.TT=LM[*#L,_.#QZQAJ.^,8#U@PF">P
MJ>T726E%-0)^G<VW8=2V,:^X=&=-AIW9SO4_?FO3H4]:#DT>HYA0$TX+I88+
M.6>HILV,%MAZH/3AL,4*R$'%$<,M1XT(LL,Y8*(:A+>B=LN0_IH&_>Z.X_-)
M*?;&=!+ELHDG.N429EYD"9.$-1@:B$ESC4GZ[OA-C-9)"SPU5]5U=\*53#_5
M)]Q-C:1;1>B=A#9],9WN.U\T]#EQ!T-#@*X,-[U+Z$+X2:E;OAXV(IZ-GTE)
MH!01X/H_!L<W3+LRL^CKW)P]VHS?]+IU(%93?5X7[F4T!QO=P<+RQU!T,Z[J
MB??]APF;AM(KAG2'KTK*R-?^?MLV?R;S9!A.?33?+\#GU*N7(GXU:#IL19V]
MV"OXGG;Y600NZZ/\SH[J!ND45-S8/85=\@#M ?)*U_QZSC+<&'Y?#XVN;G32
M/?#;RC\PI'@_T#_8>:U9DP&RQJMO<"(4IU@JD1TGU85+AT&9;>Y/O=#V1+ZK
M.TZ8.F0EB<%@Z*GP34D;H<(.XWKF*I\RB'*R4-E&*L&6M3]KO:727A+QDC%X
M2;PV 3] >HDO")7^K7L69]P.U0,=XN"Y:\P$#7;M11)?@'->8#'&!?XJK5L;
M,%-W,Z<;:ISJGR:1'@)9Q<?(1Q9-6M:P+UNS2-&N!R[ZVS;K&R#V<.(A<LQ@
M8&@WEP,C0#<1Z]_1''MI1&!.KC:?LMG_9L;1RQN%W;QH\N-[+#UVB[1R>C/O
M$S N+[;0M]:%N 1VN1'Z0\_TNL06[.MJ]]R= LR?EB&F\Q%K(I06QM;G UWE
M!G=LBA07"=O#;/LJUASM#[S^K4-L&1*!<U*$5;23R]_KVM[^G9#4+UQ-?4JP
MHJ82!235"."01J.K6&EU,#CSM>(>;#_Y<G.7RD;*G5=N;=5\E$R;K[. CCHY
MZ]FAKW_%-_V8D_/SF,<9Q:&&)$G\:(,S^]/\))3XJZ<-E U(S-C1IQJAE.%0
M\^!FA6];@[IQ^Y<VE%UF(%#%O.K1SYE&KU=4/9\LTLXERLB(6#.Q?4KCWUQL
M=,.6:W6:R77OH'T=[9[FQD?J!7AH+]*C&(K\(IYC5Q65D.1&)]"Z0)5H,Q[?
M]F>LF=^+[/.]>J/\6:CS^YNU#P8O_O'1\@!\#]@^7H#(C"FPE4C;]Q9'QKN4
MJ-'K?9^Y/%"38GN1@6I.&LZ/R0L@G*T'&"W8Y5#M=VJ6[PNN1-U-N_1X[*:5
M(F30/)*T9V?/A/>.8"CDN1:^!GE0A5[++OA4I_*FOT;M_CW$3$>E^953H]OF
M'#*1@0?\U9-6$./\$B58-5;5_(R@!6C,HP,3 T_;Q,O3W#"E]<)7WL4\P5GI
M,9X\P)E.^&,CEY!QFIK<@BW5HI:!"UTI5J$R@:=HHV]NJOSU2Q(,YC$S)\ L
MHSZC?O9VEP9)INU747_3-%E"N)% 7F=I':H@^NJSBUJ%X2+DG4@O)MXD6*.V
M#$4F;>N-<DTT/<4#1U(F$-.->,GQ[7S)5.;QV/!7O3P[8A2[Z%5US7W2'U?J
M;^],QT6(?WI@_$<.4KO$MO6@PQT*TG%8M('*:4%M2 Z$+M;1-]*\33/U A^7
M$E780?6?>%<NKPZX%Z],JW(9EMJ\ID=E^]=(N0D+03.?WI&<NS#SVX=:GQE0
M+"R47.</L)*--I /OIMR>2E +"$!!@0_9^2D2#K%9"R:;$7!H*BW"?51NUCC
MQH/ ;$M"J-TK_96Z+'W0Y[\7$ORU$^SIAJE&]I?:R<;7,QA1!GK-=3>+]40/
MI971OC^RT#+5BVFMK4MR P9KGZBHNW*&-I>!F_Y4/+T8\6N'VV#EF3?E[=>9
MSIV"R-9/]SR\GM-N0MY%8=3CD71+PY;P)U2-GXS'7$N5C;0.V=0!QZKXL+)B
M8K MF9'NXO:J<G*:5%$0%I!5R)JI1N)N/L=?N%+S^<.7[^B7&YZH93**<%M5
M]6,%U$\C/M5Z_@/?.%W@<_(W0GJ>1PO;[Z0E";TU%I[R(I0P2 PHM6-:&+X!
M/OYSXKK;U]*P_B'S8"YH,ZY38QJ/)6*;"ST!63JJB PF'.\+)D!Q<>HTY?=0
MD]K;KL6SM38G!^\-O'P7*;,H\J&L+(EW2T1-?TS('USYO?4:[^+I63*/AWTN
M.B]9-)'=\[9%I*'7[>X3^#X6@Z:O/^N$EC6)?JU\)[Q3=W&? %'6MIV($/B6
M[7Y,<<6XA@R'\WM5M;>/]EC_M#.@/]ZB59D\M%?NO/2D,S/1:P5^:@R$5[>+
M%19,)*)"EYL#AGI_R%80/9/8-^@WUMY\\";FLSAJ-.>O+S6K'OY!C<J<M^Y\
MVD\5BS5JM[=L559T,]P2N4OUE^'[I'VZN9'48=#P26U,2'-CWK<1F7$>;.EW
M476CK*B>FK,7V%=^,PY]I(3WN@G@P*3Z9O;\"2BS91:_3D!8KAS4X0EIL=ZA
M;WN<*Z-HWD7] TH(_[=84S"4OU)4'A;!#TM]8M\^WJ\BA\3T/&^B@PX7W7OP
MU.*9&K[@;'#PH#81S\2X+!C^@-6K)S,)JVFFL>7:H?W0PV'*NK$Y=\8-=9C?
MX5X#MKA)_9VKW85=KW+/$=8E5O,Z,@G[MIS$DLK^B;)?&Z1S*CG=WRMT,#CV
M"!#%5,T%Z-$2ZQX'"&FP/5R$]9CP #!3H&)?"U$71BQA:\?@"?,#1N)V'O_!
M=EY]SC$,*=4L[:KCA\(#"]F3AA -:S,UVVB]\05$;SL0J4AI9_!60N4)+LRJ
M,>'7E*_-,7XO)49WB*XB[2IYWAJ]04=?-5UPZGCAY[\3KV'=_]8%3-'A- <H
M4T/_BDH0GS%@>=U(3#$^]"*4C._FLM(*M_0( C;:)BX\J WP>(W>8EBO2;1%
MH#Y)C-]M@PKB?IRUOIZ7<K^(XK0?AR8Z)_9]$":&S7%<6-O<7%GP4=2V6K!S
MZ#:E7/<"LIZ0O+W9\Y3;9YJ^LY>V226RUTH@_TK."#.HMM>5OE'[4TC7P7?M
M;N"?>ZW--AF&PM%ZTS(QY5F+R SEN!3TB-M#66U)YKP7@*MB)-F5_;7\A$@@
MBTWT,5I- TELXHU+;&U<_%5F,BU079!P+C0SS2F&R'%E_SB U1GM#&OE0FO(
MJG5H,]!U?QBU35XYM6J*L#$2M85UFO%]K\ ;:&BBKW.:=F1;ZUHW=*K7=@Y/
M@<M"!W4WV3N4]&N#%P<3"S'S;Q$G%PJ,>[4W4S&$S*25-?)I9SL\(,IP&T0/
M&U_]1F4<!5>\MRV15>^+9&UQRSIBD18TU\+OFRY+#^^;-+@^T.U^2__JO4_9
MA3^DY5[.3M/"KJJ</A(EM^*=%].<=K['X%?U?O0S-:XU:6LUQ8( -8B']H#.
MI<RK*J4--?1$P\N7O=-Z&,8[X73?5(7C(3?O Y?@6:[T-03"NS'+2,_S)0L9
M81=#E8!-BW*UP2<]_T3."(:?>T;&=F4[MA!^E$PWTK$]VWNJRD 8LVC1).)B
MY,&(P'?4S,,B_RCV^+399K<LE#/IE(03'GKX#71Y)AZTYQ8Z]P@2-91U5,WK
MH=V CNJN#'@!T#.1FS1DAZ9:WQ^ V93'X*<'X(]CF[F-+JU5N:?S_8"JE.<Z
M18ET3)[W^ZGTZYY8!F'U-"5%N*>O$NF5\#S2N!H\/Y*&#.:,X;\%F5D&@MH<
M'?HM-? $\)91/ B)VE [!8767!YH;VRLN%A\X.+#[O'NXS^$IS__C<^7<I(*
MN).?E:07'ZN,;@]?W9&+EV)IP2U-1Z8>JPXH2:E+CD*:V[^1)EE3&1@@-]TM
MLQ>4WS.8K?%#ITU;UTB<N/E945].<V\C^G9@4E+=(]%PI&?.3Y$H:R"NQ2+-
MDX9:_Q*4IT?1'$I&3V.&.>9C%N6[*H4[I4B"FK*&=$#GR_5.=$%^HVKT:$'M
M?YE_5, 3=CM7C4BW]=I@(1\0__<G\1F@ZQYRK\HY5.PYTL;VE&E:DY8W@A]3
M&U6$="%2BHPN&>H/C8!;(5??*!ZS];PPH UT+W,>44Q<:OQ=^^L KUCZ5EFC
MS#"@U\[%B2GIM86;)8+#*GMT<Y([93UU@[S5<Z)\5^98DX&@:@P\#MK<X2K-
MH6:C=\+YA#>\@&6M0IO05DG92Z"D@)?U\7[YOFB]<-XQHO*A83*!74L<,R6I
MF&E""S"JG@W%G>C;9EO*3#1G-S;V]=T] *4JL*NI!]M^UL'L>*%:"L_9MN,$
M.,GX1B0@8:+#Z3=?=&X0NSUL'?)(%SI#EYOQ._L,;A7:0B=_+L4T4GB0=8XA
MKJ,4$T*)-DGPERR_[M(':@%H7>=J=.AY6I?I4]WK*HV-WIV/*E_))D=?LL$,
MHU,\6!8\SH: (EUMX!*]Y3U,+=J='OMTL);]8PS6A(8"UC'()/4*<%4=U5E/
MLTF@/^.]O>TZ=X_?^J<EIC0+=HM7Y:@.?ZVT,QP%'\@8+8BUHX5;,IL4(RE.
M,3%0[+/(I%TO<T,:@:%&Z]K"/7PH'9;N-O%0S5HUBBO($AA7)AR3%C5*JIZ^
M>E6?'/2R["R-OZN3[H@S5I05?5Y&;T9;L@4!1'5M+VV7!K%"AU]#%:F^ 5AI
M,0N.0>!6Z[IX',DV=H9E*M9'M]O>;%A7=NT:QB[1-+"7MQ?!CN+V.VWOW6[=
MV=PQ__THYW$(*<]//)DN_"8OE+ E,EZ87*)-LF%<!(0IPUC+(>@R0<8;G>9L
MUMI&9,6&KM9(N0'PP#Y#R/.VESPFXUJ"]S$OM _ %+/2YJS+U,SUI"0T4-BH
MQF[2JH?F$M",O+;,)^^&(F9R9I(LR(Y^N>IK-0DK'Y2FQW9T;2#6Y7U<6#1)
M=S/'[8T9C&[.R:.^;/C,MIGY&6(_[1],S-? D[?)W"($<<6DO(>Y3?JSJUR0
M;IJNC4/4OS\Y'W@[J9YY$OO?3_1S$]5J"\@OMB,K\%S/=BGO.SV/N8KDD8-Y
M]D]C<24W,6I!WA?Z/#AR5B*7#6SS=(543P.>02T#$+I-CC<#[#,(4*[ZJB#)
M,K<YJ+IC. "NWKH>1S33P*$03W9KVVV.=O] :RGUZ_& \C!VWO[U'0=(K:#-
MA=PC$IZ7,A7O N1P.%3.T25KH6+9C>'-N7UNW_'0+K.G99<I*ZBL]NX0Q2A_
MN:>L.O92.2^GBOYB0G_M!3=D.Y_S'5@W?N,I-'+^=_Q[&E+BN@L8,>S(F:NZ
M#;"=4-^.N>^GVE*6X_[SZFS$O8G'8#C#6G$C^I:J'VE5JABSO*#UO/*%S?N=
M&5<-L&;B>I-@5!FI_C'@6YB\XN%,/>4J(']=2S<SF!1^*W.Z+G"V'\H:WHP\
MKQYH<":=!-IRG^\6<?"1*;$JM<Z+=+IZE$V)C'X[3_S\62:+ZHC)%\Y2CM[.
M(7#K?G&#+WM'G9 >!Y/?*2&?]J%OR;  K^-U\G%GH7U5[NZ:XC'K7%M#T$^1
MLP#),W;HCM7IW!.]XRZ/>^F\'U[4<^M?36'0\.-. H\;:L+74'N3Q]!><&61
M2N]U%%QN7"7J+<K& L)ZM;0\K'-8:0MQCF4&\*4&]+-0Q;\X[ER:T-(OM@PW
M@)DI^4P.G/&J:[A]22KXB?\3'S*O,-C)]5>!2@\^OH&MC(#!@+[<%DS^>@XN
M /:$_)2:)/?OY28G?B?C5H19MP7@_XFX^;GK'>0W[) QM1)(>A3'H<$D-+OA
M3K^+\IC)-88]T#?EM/UW A)"@)$T@:L\2F+ @:FYYJQ^6@#]5B)IY=W<O/M%
M]HU-?>0BJ\,'SN\CG*L-8R>ZS,]*Y@A5PY?[C1*\22,4.XQ.7UT"U9I9I.%=
MI#2;(NI-W2F)"CQ?R"Z/_%FK3L2]UI4V*T]R:]-(N3:U?/98YY.NJ[?*=AER
M93>_S/VRA)LM8[ ]$M,6IDE!\.N98%QN5DR3!FYA[]-L&YNCK%VZ^-(V5T%#
M7R4VHOIB*WR)*X337ZX$B%'^I4EO_,O\B!8&A]DZ:SX]56A#=+>-'OUV]Z-P
M#F1W!CBWY,4O6FO.DQXD:-@[5/)D5T(U3]>DZI-R.#]DG\N_T'AOO&G>$WKY
M#O].0<.\D+IF[1.K8^CKKO30;)X1\?N 3VS0<^;3HLGIOB7JI"+C.]0]9=A;
M/Y&SC_08EI6_/_Y#KXM;=J5"7,[>]]M+?L-+X8 VJ<$;/_GTRS*_$$@SG$^P
M\-%8K-XUTDI?V3*73&6T*M=,(U9!'+%P?;7$_$'?$N'Y&#=4K&@@;>:HZ[./
M ,W4S-::T)U?^J'XCSO>= NA!E4F=CU4(797!&=,5W2M&@T/ZG7AFJ\,PTD^
MSWEU>OZM$WOB<._=B^*JB)WLB)I(J3O+@A&3YN:L*!01=^=R_(K_3<V>_]80
MU#V.:KH$LIKK9A3,>\4@)\-5N9F&@HHTG8XM\2FE62KR#O%-N4>2RT+Q-&6K
M6^HOQBT!9V(6_-IM:W,3GUUL_DT+:!6QM84)[Q9-KG50UD&IBR9M< M:8$4$
M;(< 4*;'I.D%P6IXAM*29D.IH-81N')>XU7:IN>T$"D7(KLXA)TXSG7VU 7P
MDL_T;N\+&N[Z\<';QN+YFWSI"!E?R/9VC;_MS@8S Z3(]2ITVD]4AW:%/,6
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MO,EGM'FO(=S[[- :1A++YD(RFW'LP2[&1V"BI'Q,42*(]J6[Y_F=C0_Q4GA
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M[OX*55S@@NX/K;-5KWBCYGDX[).=P9A$GV%E4T&H:F4UO82(PXH[L!;4'.?
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MCP*GSU]MO5P);6BFFU--3]6!E-NHK=0Q#1:T:$.,8[<.#BQ%BZVH;X#!MGQ
MU\09=N1"C#C5<21Z=TW509UQTWT[NU>8?U>Q]P?K_M&+PAH'T0C1F]N?C";
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ML; _W\1=O]K6:_2F(22TX KJ[I'SH'U[VI3_2'4O.8;)8&V(U>V93D.ZTGY
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M?+P_53PFSGW\Q+)(J:2=D@[BJ8YM1CC ZD^"#]G#6V\FV8/'RE5L=#-^^RN
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M0[TTXX5P" 1:RNY-SYNMMCG&:BG<%.!U'O!(%?AI6)8T_T80+::OH];*0^J
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M)=H<5E65EW4_BUZ1U,GZ&HE^#D6^I5>WV@L?J>F9\FZSG8\,1/K51/*S2-1
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MSZ4'O-I7#7EJ_A I$!>W8FQ![C5!'- 4"<BJ1]FK(487>A-OQ63-Q,25M'2
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MO(#=CQ>U6GN1[50I<P/$:'V;N !JH&S"]?6H$1[1K$8/O%K\^+1Q$JHAUFQ
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M617DS&0F%-F&T-=-XTB#$O&"D7MPU%'-6++Z8JKSX-;=6BW4T@'1\G&4&9E
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M&?_5>,&B'9NQV^"VWR_*%JQR9U^^I2+#OU\=6K#'^)#V3.<_ 5!+ P04
M"  K@%M:MQ_JL[AU! #=.@4 $@   &EM9S$W,S@X.# X,E\S+FIP9^RZ!U13
M6]LN&@NB%)'>R5:47J07D7P60$"(]$Y$I M(DR"1[(WT^HD4J1$1(B4@'2$2
M@02V5.D0:H+22R)M 2&<[']__[EC_^,_>]SSGS/NO6/<LQASS##7&G.M=[[O
M^SS/.]<ZF3B9!UTRTC?4!YTZ?0KTD/$'.ID"W0&=^E\\_ICD?W6.4R=?0)SG
M3W]C ITY=05TFO/4&<Y3)W@0& 0ZQ?3G!:!_':=.GSG+=([Y_ 465L8%]9=
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MR9/^^0UM[4TI-C<-3(BR=$C/S#HJ %&FDK%F?=79_*>^6ZG0QA6[ [06%2]
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MD0!W5-.R^K!@FN=A7W%EU=0LBCOPM9E) ?6O[S;_^;]G:VL<]N\.L,B9WZ[
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M0U89'8CO[2+H>%3]QQ-0>1! &#C^W7[KB0TJ%_E[N<H)J#I"XP1D5H9R(IV
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M3G;>,AO=E=ZHFQ$V',;5!W^HK+2K"N%_;=9('QA28TK9P. R40D%K)3]+S!
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MF7\AB(6B8<XSDW#[+N<6J@A_FK>&=D-\Q314F>Z,;,-=5=QH7%!&+D_3@N;
MV[HTN:JU1/)K1CU1 R1N(WOCR5N,\KP4^6"_ZKL#_3PHX.@)_/<E,#6E57,K
M]0"ERS>^B+V3]E"Y4FN>.*%MGHP84.L-@!.W2\TQ]KO%-NQ2#+(K[C%-*Y4R
M0U^TM8B)=_Z))$9P 8F$O*"=AX=Z;M@[J<4PN?E6)I("F%31R!K9-G_=SAUF
MP)0[6+Z^3)(:L@J K[A(/U)A<[\\BG]4S9IC\2!9^RF]C_:OVJ*H3VQN_]L)
MB*5WCCY.OWD"&B]"'L& _1.0,^[Q7@0REL9-6X2\%.7'P]@8Y -(+\7MGH"F
MK#R:@:"P(T/$?5@BWV'>(890G%3M$R'U\=O.L0FFP_M.NS9SW#O*<4JAFU^B
M*"XJ^&#]<HRP9N95.H;FQ7#%"$/K!=$'9YF&JA 02A I,[_0VSJS,4(8^(W"
MM61,>3U-[/QGF^B/F-KY$D;:A>,?3-_Q>Y3CY-SC$./UN*E%<^1Q>/6V!XV'
MFWY^:QY"[,$?XCJA473I&L""6FZ;HJ5CP%?J%1!.843;_M@8E3BU*C2BSBI1
M2DI^=N]*I.P&TJ!^U'=KH=&N"J$55 8-*>NA[=@"Z+U5QH,9(?SJ*;LSFU7S
MY?%78YVSVOFUZUJO C>H#O_@Y_ >GW.MQ3I)6C5^NE=<YZL_LJ*K1-G^_5M=
ML]@[H6LT]@?E7X"\'@X\32NVOT9D0*G4R>-5QR#!*J%R**&BK-/ZF>,:ASD\
MK+.ERH+#NCF=$9?6:ZX4I&$OZJ6*_UF::Q]6C6H<"8>P9D([9#Z5N*;]V%W*
MO-5??[]EU3:!Y;W6TF[8XH2]5JM8JPU4OL.]2:[!LDP?\HD!I(ZH*8=[0"AE
M 0^ISL-Q[)K86 -3E+GV".5&ZL[SC?J"#-*R*BXA/KB!R[.OQ-'1NU$%?,KI
M:I58T:.&GE)[XP;?E.0#289S)AEK\'X9_-&FHRK.F6E,]Z(/F.L]M2L9@[ 3
M*RX!^GLZ#$L(_H63GAN/]QJ=1<>$5O5]+)Y*.,3Q,'.^^<F*FD8"4L@4+/O1
M762;!,+CZ+;7+/_PHT_4K Y(5*LLA4;$9.9^@,>V(RFO$/>!,(GR=PYKNG>@
M9\=LN)V];'[:&I_5\&7#H[,DB <>]/.GYJ%GX.7ST"[A+1Y H[W@ZN<:X'/)
M';>P*B#<8$P!<UGLXI#[3XR?FO"-^+=)]SMA"I)ZVQ<0?E?'_?RC^P-:Q=W2
M>H*(JMZN@5JNREC7GN6Q&'Z%G$Y(N;;*\*55-?MW5>:C7%6\;K^G':2 ^G2T
M20.%<T(N0%>'7)=R&V4I?J3FHA9IF>KGDD56F57L@,:L]&BBW[A8E+X>;F\O
M<8HJS7PX3:DML+-&Z\S*O$<M=_T1E"QFZ(CV"&Y C0P!+!C)Q./7JHQL-U!
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MV!\DQ_:%[&KJ)QE#7XY\N%.,]C[;%B6)]KZ4I6I3=B?>'XNRX$%9V/^1^VS
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M@G+ME&97+4)^0U4'';&H&[%*KJP*U,[WH7Z/>JU[N?UH_]>D]4J7;NQY;W:
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M)L&"&.N69@PB2R,-HS #2B_:CVZNV =4("!^7 @+W>AY-]DK6I<\+L$<EA-
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M&7WG(^F//E]OCDSG[I5IA_**1\&0&?I2UD/]YM#ET_[T<BM(0G%24=Y8D:/
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MJH\Z5)9B$_*SPNE$^(K5WT^Q%'\ *!!<,^OT"D>PF[+HP>0(N/<J0@@ZMT\
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M9B/\DWEIT?!>];EO^X)V15+9[^T?OTF.?B\TQ$6%9&N$9/]]?#5,QA[^B?R
M9(2U"_5B@[[")F-6_G.75BAIK3N'*1RF5+1SU"<;:**E6(O<FCE-*)5XH77W
M(48<^>-[-5N!9Z=5?NB=<L2O/ U03H<:C>&5;'BM<8]NI9@/DLGU\51.I&I2
M/K=MQW:^:OI?K)FHKHCAY7,!DK0$'GD%"XGE9\62-09(KV)D4'J=$S"MA'[1
M%[4M;7,HPVDYA<A"D*8T+;V!0[*_15.I!E=43X@-Z_N\KY-5<($+ %X?S436
MP2/);'W8I"Q"V,3V("X5&KUF7KYVYMY;XSX',\0!/R!8%99,5ZC;GX;4"!:>
M*;,_I'M28V.G(UQW-S#4DHKHJZ54J^H0"^T'-V=4[[U:W9/:0XGB+@#\4#W<
M[ >8E8_+K/4U1'?(M0H%/M_.A9]-J5WF@?Z>+&N625W8BA53_,;7L871 ,FH
M<GG@S)0]/SZ_ ZT4MXKOBW8@/!W29^B+O3O>,'?R%^LR<2_.TT%RUBCS7MS]
M-9?E]?0^;@$>HT>(;E6M:)C=%[O?_.)C\A#6WTJ_!3O&01HEECO63[?%KYM^
MF_2__\9C__D#>G87V^N #RGV'B"9"&4X:YK$<O6,>8C)PT%?X(OS*N[R0@TF
M@X*[8G7^O[":!I66NAG; PJ"UW;_.A(5*-D9.Z3&-&BB^I7.BL_V[%B0-(["
M;)406IR[*ICC9-4DS9%A!A7A;4KW4=[VPT-YG_*^3;J9Z"%LJW>ZTE1(1I.]
M+@!AU;"0\_8.=G=TO=?NGS,U.ZB%)2$ZTC^P0W(G!5H YJI$O)?? 3:0OE@-
M^V)7F%P[V,?V[^C<F4(]KK*U-9"48M6:P.F_/!W9:@=3&,;_[09[R/V@ASN/
M,3W2O0!T[0M=^9?VT@?!O-?.7T>/9;!,E\D@4K!KH,,J\!))[CM1-2)>X3PK
M B172'*;.#73X!X,]/H\;Z7A>[?HMD4V7QC+I_?:E?I7'E/E]VY;>!>%>PRD
MQ'",VR;R7=&>;(!62SW9Y> PVAJS$>[&JAM)%/ZB.]SO8UMYOYJW 'J<[L/O
MT_UV6*8U!.3(W=!1J,?P>+R:VM^%A@S<<A&NRGK,YHU!J4@1>P.9]6AIN;^A
M]T^?>O-YT9+^=!XPH>X6?R<K]7SL  X]^#AZDLN3M^$])#OT1VK$5\+<!R)3
M:-^ASIFC8DXG->C=0/ KS)R(M*ZJ$C S=:4PP#OA% "\2Q\_B?7:$_T\EZT@
M':V*0C"B/'WH@[]XT9#:WK7CAT]VH]4DCJ79-7Q+;-X/6!_U =A\PH&;3&3F
M42I=G6E0?K:!>YAX[99)<8.KT9'1R0H/#<U>^<WF[&>46))XL!T(G[<#MDM;
MR<(=S4@UV8&=U0WGC'E;G5,J3%[K/__TAL(;.K!@V)7(^_-I.2R8H.N2]<>H
M1R"*Z3I4\OB !1HG\.Y3W[7EPK)^K*>*YWS&@7QYNZ.%G_>0V"B9^<JJ,-6Y
M+P#S =:D9)P=^Q]- J0/S-[1RJN:G][V[A.(%JM=,@ZZ4[^PI,6V@ G\:@LM
MMY_<3#'F61*WG3R0-*K<3-I86_>ECZ;+)M4_*0#FF-:T>+#[YG5J3A4F=)FX
MWRB^_5=HN_2%L-3KJG+ST*/TR7-T)$AOA"3W6R#;8MA1,PFL-MP2CQEEDC$H
M@YZ2P05K=X[F3?**]DHU:,1L]0W22TU3(VJX8-Q?OF(7SLZ()Z0_:\GSS40=
M4A\!25T<I%N! MX^&UM?N+@]$T"5+"^1&)@7%G'3?GOVG6+]4^$A:_;<JF7W
M4)L?F<4-)TK(W9=!I L A9;Y[ WL[7DM[!(AZ,\:S%IXOPC_IX>?:_(8S.82
M=#L4&&W91&#,+EV"N%J\RTR#.^L$%_87+_QLF,F<J?!L'#1MT1+G33RM#?(X
MX=&K!#]O:$+7M#?G3! 'B/>K*J7VW@BZ()O:FO)T&'I0!#DM>=FB/B&/']L#
MVBKV/&,HZ=4E&3_(#:C78WQ50FJ_=XYAU'$^6&.2)3 LULF&09;.QBSS>8S0
MO__P==UW4M,$/Z].WS"#1E_+,1EQ&Q_ D\1:8)K/2INUV&)RJP=CT\_+XM)#
M*N]5&Q@G3Q=Q]FM6[)&-,@C(ZZOD>S@#FEXH_/V0\J(2[AF[9P8TWH350"5*
M)\-A+5-L7H%>K4NWHM3L-%-54HO+(-$LS[S4.JTT#-/Z!^+VYQQ^)D:^<EX#
M7RT#-B3OZI\Y4%?N.^4!"5P"I>;,H"E/$,]7LESJOJ1&IVK[='Y?&.JA2*P4
M3&6M1<(_4=HZ:;:7!9JT:%PS=?SPR?;R_KC':L>D) M8Z4_X'GHSX )@7T/6
MHM)^+[=^;SANA<DE5'3L , 1I!1S_(W!2Z<-\.#RFL'4:EM]'F (D,G^W8F/
MME+N9[7LD'=ZZ;I5CVT6CP8KO3[HV7T-5H.R2-6&91[FZ%+AFPUBP4^5N'R%
MC?-5#O4R1[.Z*!*K%.91PL<.M55ZCIB?*MF_2 D(CE1<O82F85RG08?<I7AD
MGB-7"4O^,P,ZN:Z*V_CC;6,_1PNZA![L>3N;U3#\'KA9B<R&MCUO46>U"1T!
MTZM?<^O@:"8@8D *_M5Z_I7-B2BC:MO?LS-M35E8--WO-L7(EV/:%(&FANS&
M:ZFG9T9-C7K:#8O QI^73A?_,YWN/)KLC \@WB:5XG=PD7GJO*3(LV>N'0^^
M31_K/^$R/NJD  F&[XOP 5$-3*PV&4=%T[MK6<8S)\& CM"<A?GQ_1?)1C7?
M3$[]L=*1*[3D2WZSRU=)#OB#3HNJNO)EJ%YG 3=^?5)B(%:VL3>Y9%YW4$R+
M6Y<NY6YOW-^;GX* _Y4S81LFG99M@>VV9S'UB+V* 4O1]6,VD#"(G8<AJI1+
M\W."J-YR7I%QA8E126JEN;&9B/#]T/8^A+9'-.MW3B =Z"[^'.K3.05-8^AI
MS:O-)DK'RL%65+M,"VWH5%L2/#AJ"G6;6*^9^V38FFZC&!DS1!V\CYTUT?B]
M,V#H%)KU/\\T 1N\NMW!/&3QUEFIC8E]=2!9DQ10[O86JF<6Y<ZGNV@RH; $
MM$G3G+GNJ?MP)J_/L&4"]O2S6Z4$![/D"*)L8?:\ ^V"7I CCJDSGA>K"\&4
MT["CG?<;&0RQ!YWML@\G71/]/#]/DXTDHUKASB5N!;)M!3;BCC,@#2^DM8OB
MD?7\;Z(B<38SBX F(G$K41< .E2(KV?@&CJ*<HE0N5[0Z>J/6[D!#>X.4/Q\
M=T/ 4[T6N:Q'D_GZ7V3Z3LV/=6^K^L9RJ'L7-R7;^;-[!QM^N;'(==F0&)I2
M[M+F5%QB&9+#ZNE%5*,;=*WT#!U]\^S67V:1#%H9K4;&A;]]V%"W0Y3!DY:Z
MLOZ'#01."9;!K9)RW;)2CH2RLK*,4A/7T;DN[V*0AMF4Z "HFL@9(J_,#?),
M(Q5)7\;+$D3723!DK'*FK4E":FF6T?=1&C-ORF6HRHL:SI^FCO1@8I(@DPV/
MAFCBLQ)H@J/8\@)B(R &[LYTF]*+QC^KGMM<DXX.Y66*;<H$WH0[,3&2^C1"
MGAQIJ3I'-'I%J 9VS%B8-=9-93UKB3>IF_ K=R_?4]_OD6IT,8;R%<A TH#X
MYT"2F,4N\NQUZ*C2\K5QM#."JX=0M;_S2)V'@$YHJ+[:BV R'[2MF_)W!:GA
M*GGLIV&&Y5+E)9V!G_6*=+ZX!'E.N%6'O!N5C& _N@"8OY[/E4/FZKUZX=G1
M[?',B$?.Z>4A0V%37ZIG KCU4#'0WF*?Z(%#]>F01/%JCV8LNJTY.A&1W-(Q
M+*M+)=^^D!_BH_(KBL=;].K?MN47I#!L_^3Y.O%K2(2%)T*G.3".,T3*MVN>
MZ!!%&>ER)EESV7DT14'BNE[6Q2DCN8R+=]U>UC3:68ZPB75-) B+[+H]-<B;
M6DB'<^!W>KWH6DQ4+P"V<M3R\$6-)A[NRPZU--\;K5-_."1[?SI*CK>>_IY>
MWFIA6'E4M\,#A:FMJ>HGZ? &[VED5*^#\V/=?$@_F"2<M=M)T,.LX VDDR@W
M"4U9I5!WB_,O#J3"@%4T_<YCOYU<.Z8>.%W#P667TZ63RM$LWR\_H5'$B>#(
M)(IR=H.>'8?QS3LH37 ,I,9PKQC'1+HWVS,:;T1:P;)7XH*K;[G4D*2[*4QM
M,W L/8$F&J:!K72LVG/,L1GFL*2OB6T45RL7:8P8).8&_ZC278RI K<P-5T
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MAMW<\#0B0\#SL>/R):?!W?T)F_,TD]:F5.+BCY1L[*&SH>A\MF+MO18PCL<
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M-3J2MUT8]1\X@]A_Q#]U(FZIKG=IG0=C.8(E4+U/9G[BQ(7D?B$P?H+;5E>
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M$@6:QY2_UM@_'YU8<#6,6RE"NG457R_,65"XF;>E]^F 4ZC*9:V8F\IRTUD
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M3P=7@(%;CW4S0O9=\/O0=BG?O)LLU%MP::]5]_W<(RUW4YY*1N!$X3O8V]K
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MK7&1,5P=8:)9_?- C7Y8_FAQ5J!!SC=.@L%[^ LIF*TY%K6@OG&*K<1YA)?
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MB&F5I65)M=)(VXA145$0THK*$B%M(Q(AI%2$L AIM846&Z(@H"(@2T!9$B%
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MDJ*MUOG4=C^HN#H&.S37UUX+]PFC1_VVQ5_6R'"K.P5^,/A>2"?UMP7J4@0
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MPOA?6$C1R QAO.3[2^(WV#6##X^Z1J;GK/M*HGVD;\-@S>BWHW_E *3_**#
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MS'=,1S[C@%X*0,9*=.1&S:-@&+CJ.-2I)K#>]Q/ .85&'R,5S0DXO>#TZ%T
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M5DI%&/EH5U/8_T2[UO\=R)_I2=;_0[@&JF7-M<VC?,A;JE_E  RHP\:DG[A
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M_%DE?--&6'LF=&%RT,!NH"DM\;EH0]BMVN4U7OW9&/Y7MJ*\G@ZM2QZM5D=
M V_3-FHRJV9F,\)4L2"+E\-J))I":MDORJ=QI5=T:E=_HTPO.K[$NKU>6BQ&
M;1"6NFG7"^KUX(^9N0R:XEYA!#U,8>O.MPOQ'5_"/FJDH)3@1P< BNHEY%L
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M_0M]P[GZCK<%EHS8@2VX957K0RK&;P:/GP0^^VQ3Z]WO$KZX_HU E0GG,?<
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M6FPE&?_F&Q):6GK<1E9>'M^1_?\4;/GA@:#<()?V%HW+'.]4A:KUF;M =N0
MY*6< PH;R+-ANZ)V; ,VQG]6NZS\@0,4%I'G$^3#RKTFW[=2V!5*B2IW8DEC
M/8\4)"\;.4%M"22NA*^T,KW4P=.E!?79*,CN&9$[UM)[E;*TC)=0M(H!98*-
MLJA4'H/L"4Z.?@63G/6PBNA:?.],52AHR,'>8EX!QGWCFA6V>146F3JUS0MH
MQHM)JKME_2O;)KJ0ZI$:UF+D V4F:Q:D5#K6D>X(_FB'L0JZ9&:=Q.NN8/V6
M^&LO=SV'./5F+H\Z'SJ-$DW#APC;TH?#:I&I2;^JEI#J+>Q%P^7)9@5EDY,_
M(IYA_I(6D4=39704:RY0= 064(8860_X)RC(1D&L6>50(G^'(I\L%]]ANK&#
MLWU@&R"J2!*1Q<.*4*1S"XK>U5Y*R_<ZO,\RQ;?IR*@F-1C)^,^?U45"*GL!
M' 0FOR7%$XTU3ZO",IB;(&4! ^_Y"CJG%"ZBNN51B<O W878(K\^'X+7VGDI
M#BGO>X^%ZWG;KZ_,=BAK=:AO_\@)_VY_2 <\0/">KN\*:3%J!^85S8-2S9Y&
MU2-("A '=G<2:, J16E#*J!4?=,\%:R"#'S:"6Y MU*("HC8E'"QG"QQE-_O
M&K-UR"X=.H);.N+C7TR756\:'S7['J\@Z;-WLE\%C*9F#2[V9GWJMP1<$P0S
MX !-%J+/,#BJR1*>)Y<,;6'/70V-97WN&9;P&]82ER4X?:W:"&Y"D"YJ79)/
M6IIJ2T7]@.H;:@GGA7XL9*(Z%.)-4X(2S\'IL:G5X6\]%\,AD!NZ/"+6?"CZ
M3/C+P:DF8725QZE07E#%PM<5+A./N/'V@3)AAV5;2+-A+\W89]GW=#8[8]>9
M\/ K!,'D_ZYKQ5[+V@!-5[P]JDD57J3'4F8CJY!6]D(F.DMZ,] 1T4C%=-&X
MQ+FF;$B]@M5N,;LJM(AR2Z #"B*7\6-8,^! 0!5]Q?BFR4V'\%2*B$CH*M7U
M30@_6H7*\3\[B"O8GH_DI!*OT5; 5?4*"@X#DI7C-WZ-XZ"5RF-MI8,V%PM"
ME^$]6DLUBY5C3O[5<J%^8'(*/8;@F"\Q<"@:3K'@G0I?P[V634UTMTO-IOA\
MQK 6L&OLM9B3_!C!]E;8*IO5P9U)W(#\PUY".H65K#K.0;5DM%QH/FC R*C'
M%9?'E"YSK6]C?;18"9;FI_&P]2CKIQE5=CF0%[Q3Z+PJ:T=?C-P?9&$%;6<H
M2ZA%6HQ;J5Z5OJ1F=LF*.UL \:P=7QX$Z-?&F^FD!#R@'E^7T.:VZI\!F^\?
MW$S_-P;\'D*I3<!(1N;/ V8J<;5\"5MN-8932*-PA0/1]L[T>?!NBSE06 :\
MJYV%98@\.L]2(&_24J*9M->/ A^!W!767]N9I)<T,\NQM$K@XT:[7'G3N@A&
MCS?4_(T3B2OFC"U3>R)=TL55#FH*Z[T6LQ ^IK9%/G.+M9@HPB[EN&27Z@PX
M:F$-&;R$3T&D%U(MIO:QYB5+?^1Z7AOT1$Z_&\J9.YR$S*;H]8G""AAQJG#*
MXOZ:EXRMC*@:=DZ?[[ZVB3'\D9:))D=R5XD[C5S5%IJ \RPNZPBI]G7K"'Y1
MW&'?YT:NND=STQ"1-FH^W>9[>I)D6.*]/,TQMH><",_0I"'ZK$:IGKWTMG0F
M<TV:#G0Y(ZC?LBN$O6#7RY'KU5G)H8HF]F'0CJ\7V5"=/9Q<)F&KLG@A%T(&
MO[LDI5XX75(<M63ET6<+N7+2C2S(%VA\2]+[3J J\3'M#)-:'Y/(LZ"T;OM^
MZ7&P.=YW=[NL78LIK_+*]?&F D$^WY\O-S%+&.ZI[79<^..]A><U7$O@\QO3
MMGD^W(\N3S;#2M4*EH_FYO)&'91]7C5"0WBSPL^\'EF!QM%EVG-X%\21+9N-
MMRMMG@$[@0EC91DTU$4.FZPB=]A\2=S_VFF*^H!QJF!E6>?WO E<FYGU3*BY
M"BJ?;NBKR:JR5:]CM;(60A$R;N^/9M45J)W(R6>(:RPLV@3&2!NR#"A/*&D
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MQ!-V*&+QH23#(+,7US\^8DPE?+Y^/O;%[K)XVA>RFM9H-9J;B?S#4=LC'\>
M23>P4UA_%MQ8J7E!DA,KH3S!DG;8-!O>62E YR16B[ES=+AB(,I^HBUTV1^]
MM<:"F3?M[.@A]+E#3MR>\6#$U:X&;-IZB)^B"#I6UZ&P(3H:1+T]?>E(3=M[
MJZ36S)BWO-A(LWOW<$N&]S^U?F^0OW5_5;M'PF9O)Z=L2_IYQ=.';YZ^*4E*
M]J*Q8JEO!K48"]+Y\9[*/S4Q@L73=SAUK2"EC&/(_!,:5[+O3)G<$FQA1->8
M:3&P'2ZZ?P[PD1OZ$KX*S(Z^ ^O(&CES CW]-Z3"5GS(1WD"RN$-^FAZ@%&<
M?FANDW&$JR?\F5]."M)B>FF'- 5G6@H(OFKGZ>*("YD[Y'XZM0(]@!O#,CB!
MM%00B(L@MJQW7HG&7#YPFX6#1*H;H+AFNEHW85[*U AY^@GGE</*X^%-@5*[
MG%Q:F$]R7>@$<[O;ILSDTA3-Z:UO%(7'JI/65"\]^JHCJ.O1_B5!C)?'@JK<
MG0R_F@55!QS,WY?S[I"H+23;XWU&?/(;VE_U?FL*VO95VN?U=KT?::HLUJP0
MRF[A?L3R>UR1$1Y2PFMPTMSBBZ70\FCX.4UU6(NI&-)B\M>"]X0G<^'ORN;?
M=EN;D?>"E2A2"#9,S<>]S=!B_'.TF"%]U($+#G4@X5J,#&6^G^@,3)X@3?[+
MZZ>4TA(-F["18 HR$HW\F(^$CTR-U&HQOU<4D=3H5X>5&T@#XT/HE]:2%&&:
M'O;4... 9H'FKO LJO)+RD7C=U.28YDN"HUN0[]%!Q,O)T>.I/<-%D)7?S80
M\2U5M/#GOHRRQD,MI7I[5+63/L"WQYG6;:'!QH%1&:NJQB(#GX#FJMUH;@H_
M=8N$9J'NO@V7F1<JNN#Y_6N ZOIO=].P+57;P:60]#!0G3O$!3B\F#/@+,$2
MH#^^H(\@4?NZ&E<OMHW]O1\> Q)5B5 DX%4K&8]D&NE$*V_[@^,B7$S;L"0R
M*V=+\2D^;-UE5RK4$_/(U+SC/6M2P\+";*YW5O=%?NF^FGZZ]$WA&E>6&'4>
M8XD@17DQ&?3:!Q9P9>-6BLDZ]CSX +A@RI];T/MYZ#K_%KS9ZD[),A-1_C6%
M,W0!WC;G[I!A63D0E'(W<=?2W)=9Y[S#:2=?/_?N\RDIO'^/;".>$<MSZW4Y
M=@^')>NZ&D5]#9&JB6N/U7<_W?;[T05;"]]U/\J;OGYVD27@]5X=7TK''LM5
M&-GI*^XF&R4PYK?5>#85GS@?^O?9QXW\I4>/-&W:)OMK:3G6[U!(T+DWJI.Y
MK)_KGO/:F6&0'K!>'GU3>*YY&<-98<(AT.7<>!5K^Q,QR\IL3BHOFOX'5'P0
M^)9.$FDQ<X=SGP=M\<S\VO&LF&P\TM87M*>__4C*=B.[U6V* 3:J46\+%PB6
M0;JJZV#W31T.P>$E\QQ B2&<*F!NA.[S UEK0:O(DB<D_:9,R*WN7S2)"9HJ
MXC#Y^+*ARVXO!TE!0/Z+HEZ?=V'T:]>"+Z6YA4HE-54[Y/S; OU*#5?P!R\:
MF4,S\>'?_-4=K23F!*JFRF,,ZBTL6YBN5 7V[E03+Z8$;SAR.+.AE)KCVWCI
MU9SV7T^:UI.3:-Y;R1R*!9T4B#/L8RCK<%B"KIR\)"BYW7^D?SF0Q -]?@R<
M\"PO*REL'RB"(D%G<0J1DS&85%;H/>A#C@R18C]1/76-GP3_,526M"6I>LE\
MT\^TKZWUC69#+77G.S<>&U9L\$A:&7EAC^W73TR7^48KW/I$7:*#^4'VF>L<
M@!  NGY)U,7W]'<U/,\RZVS<6I'EXA:EO-NTB?5'[=D>?]VUB@.$34^[9SRZ
M](LA<GA_A= ^+Z:!->G8>.7N%BS^P^6'@]^V>2U2_#S1;N+K^/;<WT[^>I3/
M Z/WM9@UF>I-[)YJ&(7U3KK\);)D1/U4\X#TI4-XGJQV%-[28J;R80=*ZO2^
MC)55'$0$DJ8X!E,_551415Q6!&@>/'9%\K]$S$/EZ\]TI":2K<<%KN!A+KN6
MKK;GS)C.:FB"\CGU?WZ?+I^$'X8(1PV,M)@7N^&90[;H)4W?FSOSE*O%D(^2
M4E]JF)HTH2R-LH#HK,74$%A6K-8R_S70?;IZ#R.\#F>"O<&T/!,F'^%&$]>@
MYH6B"Y/ @7C[^.H%D#?LB:RM!BX*%8V:=3^:ZUN.QZ<N;C-IX]F GY$=W5)<
M<31L2%-VCY;*I;?[S:!SF4Q"..F6T P^!3:+ROV7MQ'(UR(*&-%B"C99SHNI
M<E"4MQ/.9$BDT*8!T:F[UUE/J!DC&X,6.W2K?J[<-8M2_.TA.+'AEQ93_-+Z
M]-KN2*\FA[D=D=8?60U_74[^/G+TZ%!'4?#.([0SD-OM0H)#U(="THBG!>-N
MN4&R5TU]6\:ZB5>EX#$ U7;8N1V9S(.ZNC:>J_2:'$R]> <74P^.#$I[G9%Y
MXP!)=0IR4:\9*83W@_^+O?> :FI;_T6S;:B B#2IL2"(-!L""D1%1$1 0'J)
MB$@38P$)$+)4!*3O#0);4"(B78C4*""1O@41Z1"4D*#TDE#"(F7E+MSGW+?W
MV6?<<^X;[_W?_;]Q'&/A8#+77+-^W^\WYS>_KR]IE/JH5H= (\RJ%F%+RCO$
ML"(T8DPY>A/W$!.F$?4*,HS(L'(^8J?S("A@R1PF9OE4^7TJI.NCK:L8O>U%
M#V^YG"N 4!PW?#NUM'^FC5D]8IM,(XOA;H._,+3IZ)D&!GGT2W^7]H,:;2:R
MB9V;4#Z_X^N ]_&C21/:P9H-^B*-UM[!I]4_%69R+?OTMGCF#7]IS\6=JBZ)
M,:MA4J/YB,J6)I%X!3$&\ !2P6+>*ZAVZJDRJ73R[,805@Q:>@ -=C01I)=G
M3Z"9S>'T(F,3YKMP"F@^%JI[?0G44U>.T#/*M7=Q?F6@J.WK'>@[DY;*%2]L
M3$MHFA^<'W6"6JFE/B")=8V!CL0K<(^^KNZ"5^IVT!EK6">C/Y?,F+_0OX24
MA#H5=H==J@9#M)9@D<T])9?BJJ2P)[K-IJ_BV34S@R9U[I3XD8*##9S@Y!+K
MV"/[7 \23R<?+RW45I//52SH]M8XI[/8_/!J>NS+=(-4Y*\WE;1%G_ ,A1^T
M'NPMO)G55D _S&V16MOZO)AEK&^5:6Y=?V6W;M6OT:\+)B^U]#Y,+#)_.KJ^
M X7I&.R@)<Q\8&+J%#:#GOG8N7U,[??4<)28GA]CGAZ?F3F-%(4$L?,MM4AH
MJ*]6 MMOSUB)J)'*14\'"]>DX9_/#&]CM"^_RRCQ] O-?M69GIX0,3T('>>Z
MA8VFQLWC .4&U$:<;O]R_K*\:5,2%M5(EL79:<?I&1?ZV#GFY-([Q'Q1\@::
M.'>F/O61YGAU0'5&A^OKDC>;R]HNKY0ZNW2,2LR,9#IFB(D(G2DPK_%NLGGF
M:AYD=H.J.&5$_([ONGVK[&FVP35(RJ#H?J.G;ARN%%8SJ;U-ES)VQ$L-A>RT
MO/OMHLV$6X%11=$YGFNX3L^=N*V7)@INH:?6<Q"PU'B$;T*RO)%E )3?L<FN
M;WG!> 8F%$J[.>+ X$M\.RQQ<O6DT4[]BTHH'D>6CW##$GCZ1V!*25Y5OBW"
MV?$=S0X[N?]%]#?]YVL'7D_^F<7A\OP_-T_\LX^LRED(>.=T\$>$DI*B:H P
M;_M1W@(&@L<*"(T0.G'][3^:'Y;2_FB9& \(KN*]MES[DT<L'[,5H"/OU=OC
M!)A'G79\=(.'NK3)H\5P&?71=F,'L,BC4-],X'-7H]^_G8> :I=#('FV=_6,
MT(F_.L.ZU0_<!-X#/Q>WT/@(%_1D+J#:2B%Q8";6(,+30 3KBUNZ>FUN#+^2
M=0=QSOG^F_OO/XQ<92:]GT:GHH2!Z\1X=L*L!(;1UE(E-;-"U]PX#%K3D3%Z
MQGX,9#.%W"@BP]T2]IZU>(%BW*SOY?J!=JO8),\(&>'88MKMW_.VK[ASUM.&
M=.P.1/C:HM='.N3X)31^S"DHBU2]8#4Z4U9S_?67H!VB<M"9<(^%J[L5ATH>
MV2J15;A2G&U<WYY:%-:.GMJD.C](K*O2#O.K"?',GX*%8L(#F->B%+@8M.RD
M=IH9S(.:WN2:NFQ2Y;SU=+G+]>Z>/C8;$EA@?S9!KJ\J/&\=5Y]'XB.\0GA.
M(RT)^#TX== ]E[N%]W(9(S%!V%).WC*-WTL&R2_0DVFNA?E82]SE?DU4^'(J
MTW<2Y59>SN ]2^[9X2-JXI]"LOV0/76"NA6X090!LTQZ=_4>%=G(/<7L?Z1W
M@D&QB,"+@>Z>KR8^&1P V=2F0,?Q.DT9%U\%1>9UV^#^>A=40PP=&95QX&U2
M@WHFUINH)=BQT?[\T=^TSE,WH=PU*6(->&5P"ZT#EG4[\)(^U UDCSBT2[^!
MQ*F14)'&NX3M-;YYKJ?R)MERY.U#]J=>>$6]<)BRJCI%2V\_I=%K]FSU7<:Y
MY1C@$IC+4<>NT&=3X[GH47G3NBIR8Y%%8ZU,&4,['%-A=@6(P"N NC0+62_7
MO3UX:;,\5#CUHAC.K>QS&\Z6*=P2MMQ4%5*-W&;\TE=!FO']L=1[I!_HK6>"
MC"P_PXS[%!E$;^IZ91RE@=/R '+ 8#_,#$R:O0VBW M\9(JS?;-ER=HSA]!3
MVH&^-_9JBQW-OC=$7,=+PTM,DS=!$A10L_&(5U0H'['%.%[/:%,XS;?]-,P&
M#82Z:JSIL^[H3JX(3?:9A5FGQDO&?+C_$,=/V0(UX"@N\%MRD7^HP=<LDD7H
M\W71K56?RTTGT\96C+N(&G+[@^;*.:91O^X)/]G5+EB]\:+$J2L2)]<C; #0
M:"V.S.FYM3V+.!0?\<O$^KL_3-W1#:@EC0DTN+\;Y@X*"?\-\VG3)?.!3%"@
M1:8O%348H(^L5]C7>W2:<$ :Z@!R)TBDNTFKVJ+M&.VD6T*W@ZR;U [[#:K=
M"'^\O/R-+($[0BL'T<S=W0WL/<>Q@LU"\54V#TI+P1#+ ZWU7R0\=FT_M6'[
M9MWB%4@4$.(C/E=G B-9%GS$MV#$UQ>OR30I1@=/L$H*VGJ4CX",L_Z3ZS^Y
M_I/KOUFN0LDJR2CWPU\&O=@VS^HW;=$O)GAC#D=:%4O:NQE?;#W_6FB]RJYO
M,HC>/\1S0Q 7I8A+$VL_F[BN?$1:"#1%Y7Q$=8H\-^9^!3@EP ISZ_X79"E4
MY^_9OP*@=@MDH4W'\-*E8OF(91^N)+$^FM?_3P]\V7BXVHFYBGS$ZP%@4@PE
MS38$/CQF(J$/%"K[ETA4B0Q<=H$%4USUGQ_"AH:BUZQ*3Z.^U:UY"^(<15+L
M^(A++7&^!"EH$M:LKX.I[!O&Q 8^8L'@ VH&DP*_YR?&+?-Z$0T!J-Z?_VX!
MQ0;A^EF3Q[CDN7Y@A>[+!HG?D)"P.1^1OL!'5+OP$=0HXC2=?(V&6E5F(%>T
M^(C\-TG<:>809$Z4 +Z*\!$.'Y_" ).]=^'(X@JT-15&IWN9W=!D E2,BJS@
MXOI9PGS$1E,^(DD4G.0C_&&P9X=LH$ &7O]77T])09MA"JM4! -#C@Y2 IAZ
M"UJCVWJ!BV3&&5@O:&&0<.^]7XOT:]-1GX;@A?UX;6P1VA8!%[P>-.0C/,-&
M1'A6U')AX%P =QBH^TQ=N QL!F88.)@_%SBQ[A,_ZZG"F:/JT:QCV7Q$SM13
MD+P23*;Q++GRED824"S2X.]>'8"7VMSMAI"EUII?MZ_^?$3?8[ %_=IF+8;+
MANU\Q&,S?"MJQ06UG&UPJ']& DAS#N(C]K5(PY6T:T2S2<U(8T-0')CN1?'V
M[(;)?JL,H0/XQ]T\N)P'\WQ$.]RHKS?YB.%3Z(Y0P 6+YB,4CQGS$0$HGO,U
M 2Z/IPU\5^;" U*M"6/;^2WAXI9H'* 2_L,.\ ZAU)B;ECKS 9X<*PSX51MR
M1"'H3IR[PSH'M]6*]P0U,PP)PH-/8O3B]XUZ<J,74!R11CA!SV*)]%^W,0%/
MYR#4I\M_GW:\D\!EY.HAD8$LJ'TO"\-'].J.M+*':\_Q[@'?&E%7$N#2!\GP
MC!X/4YT.AASA24-V!V8TQ?B(W!R ^$4;[J2Y4WS$%6>X]RYZ;12W=(XL_Q%C
MUN 0#!KN6/(1)!1/LX*X^P=M<7TWBER5TD)R[O 171S'!=D?]ZHFW("'?,3T
M-_)2VF5_R3^X_+75^L&+!L/RV82Q7FN0T+9P\H;AYU @JR^;;+F$_*W/65^@
MGZWOX[2,/,6-N]5! S3;?U+[X^6J(I/:^=5EB51E:WB!39A:_H@=^_&/?,9I
M15X$9D^'[*7T^8B.%=\<E!2OBKS_?N3?[E5-<]<-F1<UWX9%V&=7N]U_3\5M
M[+=AP\/6NE!9!,VC&/ *-[VGD# 6@B?S?/0Z,+"\*;+L=/7:$91!)?(1C@E'
MAF#J,'W)_^*&#$_2-#R5LSZR> "[5U[\)^4GLVQ84N4MZI/14(6Q$<+D'XHY
M^?]6*0);F%<LP KRCC=\Q)/US;"8F7+I>5=(_KV,H/&FA-5]Y!WDF9/,5"BK
M*CEPZ?_#NOZGE/_24A!#,9$14BDG'(J_(E0Q-UC31U^^WK#7Q<+OQN8-)8N>
ML7[6#YRVW@8JX6(F[/I1#.4&-/>S;9/X3PF\"@"F#K5O^8C[!C)\Q-@#\L=A
M<C?\$T^68H9 WO.<0F#^(!]QQN ^<C& CYAK@K5;(ZR[N,YPX@^GV>3;?,0(
ME9-?A+J>$'7;T"TPKQK_<?BPX<;T@98#*F NPR/V%69>S>U0_L6':D4:XU8E
MC[=] +W1500&)I>;X=G8P3F&^MT@2Q-M44=8N/2-P)(5X>WQ'$6=PZP>SM@+
MJX@33GR$U<'QY<F_5#AA%A9G;(GE#NX6!MQC1R5*C(!+!+K*7YNVYI?EP7V?
M_E)\':'R"X;6?FU#$LN(]_*7W)31AEGQ WS$IIIK16H/Y&][Q]YZX-)H::IR
M\<RM:IH%Q69!BBLN"UW8RQKF(\I.\[*!Y0M@UULF,/<KD2-0!"O&;\%<F'GM
MG4F"FE<Q4$XGJLTJ>C]Q?)'G\'>;451Q JAUET7O@&1)OW7-5V@>@:0C P=>
M=KLOW 4:#/T6@?( 0:'5]/@.Y?:6%.C:QQQXL+,X:V%VPD-A&;P.!^.(]HV
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M?K7/#5<M^N$LH?S%JW?%>Y(+0O2&MZJFKY2N>.Y$?54?;_/6'.8:+/3C/TP
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MT!H A@V5K87F?D*7!?(1!EM1?TV"*@W$@#I#2!-GV[D\'PYL&P'5F6VL<*9
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MKRK J^?9@==^1[\<.-5\R^]8>HQY>]&O:68.+_L]"U"[ 5\TJ&P\J\4YA0L
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M(%A17=+Q#,N<:XN\'8Q]U24/D,#[UNU'=K87[5-3DL$*K:M]C76H&_RJ$:S
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MY9!O*'&(]- ]LF$_J?^U\SD66\W$S5>)8W]IL]G=BE'4^EH)4EW'^G9:T/(
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M7&GQ56$C_?H89R;[AR:FF"!"J-#)W$ ..$*/Q52 47SJ5G"8WU1.$1Z2P?S
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M=+;/)V U;;<3C.1",WZ^F@K:5W>;BMT ^Z2I?@LO59?JJHK!R8$P.56=YIR
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MO:0)DI_0' S>TTP*@R</&Q5!0]A-T&8)=@@Z+-%%;#*?B_Q@E!+5UKRK7JA
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M\12M5?&M?!UTA_ M'Z[D&7BO2[GXV5N+F@>B(G)A^_/I=-S-K*M6Y9D&4ZY
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MS&*WD;8/F#=A3]0T">T3&3KK"F]FBFJ'=1%U0O4:MLU?C TS6, 7/O(./ZH
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M*TYI?C: 13;L?A@%C;)89/WR5*:3:UPCMW&#R;K,0]UH$Z>:GI&-VT_K22-
M&I>:0,;ZWB"_P&OJ@$*^42NT65PH<N2ERH/MW&_7JP)<R(J^!26^5\7C<3E
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M,LF!/U@*XR8U$_X7!G_/L^<T/.X&*=*P%/"0!/&TB2&N';<1YPE*=WSQI:^
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M39">7YZ]0O6=X!S+(N,O$L1YFYTOM5'I/=!* Z&V7UB3;%?3+^17V1OY_34
M&U+< 70/,RDK&]2YX?;+Z,EJ9_G[B:I"0P-G=Z""6)7[##;NEE"5E1$F>)<5
M*T$,C[K<6/%3M"CJR7_3[O3W#3Y\;<%K?G%J;" 906'L(:N)E**?]X_J5X%^
MQ4062PO594*)31R[>\Y^S11%OBUA/>CES4UL)+K;7BS.,F5]4\G><&\P-!!W
MW"I-AB0+R50(T1#L=?&32GL%(IN+K>)T2I-V]S0$^Q1.>>P!XLO+H@BK?3.:
MDM=05H7:VMN%._>&R@7.?.@U*5TZ\MC48YU:5E5_CF%Z8:+M@9_5Y1$._KO-
M\^\VS[_;//]#\NF_VSS_(]3CO]L\_V[S_+O-\S^AS>,W\3-3H/'/I:P;B^/U
M'0N$LL[V6<H4:N@2&_KT'0W+21'["[#E__O?9_FF5/(>D0;_?),,E853PJPK
MP367\1R!#Y-#"[&O/?;"!VX_,@H;&+,SY#:#%\SU), >LK"\.3_1NL[90>5U
MDM3(_]@HIU[)G7*]7)%W\L?KT&F%CZ>JG>K2TI_XU1S%^PVE944L"W-R%JA6
ME]L$7O&^$JCOK%+C].6E5+.BE?%.3%!14']0IF?>Q%!HW(W'?@(SIULY+JZ3
M=1[IN4,67GE^=:%)"D.#)T^ZN#YVZK_L=+G+DA 00%ASP8VA<8&E=O#ZP\]?
M)W!X?DELN&% L$NPJZ"QJFJA2M!4_7[QL,? H*, ZAP.WQU.\.Z8:2S=)LCN
MI+$%I&\?/GVK#>PH?NF;7_/GFU[JG;^+*:WW'A@HJ_QQOD=7YE&EX-MEE<?=
M_AA)'G]+IH_]JCC0P5Z-\R(,2O,ZKR_@M$C'Q7=PY^82R'OZTUZ:I*X3_0JJ
M ZQ6#[V^6[9EU=WS'WM%ECR<[)1KR^([O^K+&:$W1SP.&YP/#"Q>KS#,6!,P
M?^Y?KR;]VR2JHG1&^#MI1Q]69@*_I$EN@K8\M+4A,("K=0-H8Y@16)J>53+<
M.GJ@XW.GJQI8Y5ZUQ4^CHSQ@9-)(_1XGSJ_FI>+.>8H<5HFD!Z*Y#SCT:+H<
M%@7GH$OLD:E'</AAU+F=2XB^_NF\#1$%<K+,Q: [.8E"QK(EGP%7\4..Q>H,
M*X7<T;D_#.IJ6$0.B'R7=I*00#!7E:7IU4K>  8"I=PVU@B%AX4K.!GIYKW!
MSR%IH"UF(54KX%/X]*,28J?CVY!Z6?8:_T_3QWL_4RJK7LZ5DL0'%PFXU_7/
M_#: P8 C9X QP->GK8 423M!%]UD$X<2L 72 &6932LH*@&GWV_O)QT>7===
MV3H0>G0@[("_VH.Z^N6?.-\',VQ';_QIUU^O.'T872>FD9<0]5CD/4!8-'F%
M: .0'H/5[2@\13H,E,:1U4"C?0"[V3R9_,K6R)W69J9UY^&07[9!IFN/=[I]
M7\[ ;*AT;U'.S6Y^;N2041\)"T]QCHN.A>O4):1M #(*6@>B#H6_#*$M%V&!
M:BJG<^7D37_36U-F,1D4:L,>K]Q)%?N(_%/OV1Y[J^[;AEZYN/?UQ_$TJR#Z
M/[R87 _Z &-'^8);?"<8N!)$%)J\Q5=->3QV'IV@2E[S-H@4\1#T.9IADRA!
MR$]BMV<P1!9YOLX#BNU[/]WPR6?EO>_0O]D1]'FF#<6C,=#1*(WY<"22=!ZT
M!%AC\I$Y_JBA(0\JW_XY=@T8_6BR+C_*S:'@'3S1[M!PO;T6,Q4=@8)AHG;M
ME\UI**/V&[V+3O\:?%)[M0]UDW Y?G4JT3F30YL3'IUT];N*37[LXN97YW0G
M]^0^S>*4K-S)_HL6?EZ>WH%KG 1IEY^V$ *7762M\E/;EI2Z#M1F4!0:3 M
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M]]]F(A8;OAO5O@FPC!;EV@&PM\..*X>U!U4 +B>:7VAY!.SEW ;J:J=H4#M
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M%=#]9! _J,VLHMSBK1@'^E\8+[HVZ2>96S_%P,F-JRE8AY+Q6<$.H"7M.8:
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M<B'OW1![=XSZ ^$M$AN11/#GB-YNJTH.^?Z=#P6=FF/Q5@*YZ1OS^]^,C*S
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MQU- ) %K_ER%"NP> 22U4%4 J1P%YB3-$"\-N<\0$@+(8DZY %(L&[JY_%^
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MH[I2M9RBF&WM"YM7A1"@![PC@C_Y/2,)\#5OK@YQY@[Y%0Q4.;V%<QR]*"F
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M-KX1*TA;.!'\8;C8,3[L(A<.M@"T>\&Q!''^(8P*\^  5W?:+=,"O,=ROBB
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MK6BL:10'CO$;#@^97E84][.LSZ:YQW"OB _,)05S;<++VNA1HC8M@TY&ZEY
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M,'L]%TE5'>)N6]URO_VJ#@FLTA\23:4:V[="%W]HQ%72SRNAHIY;68A$-63
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M:5ZNL7$XD>ID:U-X#_[M21[?*=$>DP57 P+[XLA2Y #\N!_;D/>$:_$"I'3
M(5B9B7'^ *P.VFEF0>,WO, 8@*5T @[A4X Y"?KM:$;=S!5K&OPU/](#,'2E
M,2;U@Q6=N0_U)P;_9'QV<86.X]GFS+YNW7'YY78!1-Q<"EW:-H#RL,IG6;,?
M@N/CY$XEL;;(KTW$V)NMR@&M$-":5IISLWM:F&,W(M%;NKZ5:=TA@"0K*_</
M=!/$^7OK\U\:QI>;VC 04+M7?%(_TCJ.ODC97KWV #^DDO$-)*G)AVFY%%C5
MJ\,2<K5D\)W]^8O%=#]CVR<!M%<9\A)MOLSGFI_;.9K/FAPQ7\9_VAB&1_AW
MJAV8'!]?^K&L[1P!/TJ>SFK5Y9487 HG[\8$?,8 !>"V=K*(^6Y5><,.V/UQ
M]S?9T#BJXI',KDB@@QQ-WA$4!N"0>\JX?DR?-UE'TF@[38WI&F5<X'IB:-".
M')9U![/G*'XM^C^F^C"S)^."GM)/K#*-+C<9\ @<G?W["L_NC]4X&^I8Z/#$
M>/[CR5(GV^>7"PV/AMJ_OUUDG:JIX^"VH!X!4H.=_AW">HX1?F69]"OI00*$
M*R,D6M./ -K36V<$D-2! ?Z< 59T9-F/*\WA!R7R%Q#\E4"N)'&!*"8$R;BW
M LB/0@&D-.F- $(@OUKFOA1 XJGK0KNVT$([GI>@M8S_=OQ?EF2!P-\58\T]
M/M*VUYH[*,3T-7<N@'S;"5Q&,L\C-D[T/8"M.Y'7@M%\\F%6/M_FAB@/SR1O
M5O0B5L780GGUCDDG<@R,9_EUW#U1G'\;!;^FJ$/,?^UC7G 0_ Y8]>PO*-\)
MY^H3*!(L&%^JFZM*9L8*()TH%K1- !FE,I\"[7 !9)<,]Z&W-I/,QK/QW,/C
M,MQ8["0;42F _,7+7'(G^&_F)8S''6Z5+M.BE0Y31G"&:H%2ZE9EQGDT'=LG
MWWX%AGBB=ITH9]3\JK_SJ>_K.\'1Y9DSC7ND_>YWW(.7_1&Z1WO/S;WDZM+=
MJRWU"I(.Y?*M[^LTPXM_ME].#VA_&61D27R/!V^+<O<O\).3 -H\[P6PL>0H
M@.S]3=@&7D!_%9YKAJS5%4#,2GCNQ"< "C^A/BV$;2239PJPKL(4%DY,OGJA
M\YB&Q'E+-K."$];N!<E>LJD(E*#,!HSO3<S_?BM0.G2^:3W1] SM_V#O/:":
M[-HUX;QV0$20CA*57J-4122O!1 0D!JI$9'>1$""A$3I'96F($0IAAZE" (2
M(101$6E!.@D"4B())432_O!^Y?A^<\Y\WYDU_\R<6;,6F[5VGIW]/-GENJ][
M/W<A<7^=&+-C [STBB-<W$*6K_72TH3L\X%\.0N:Y3:/8W2LUP_ZHL^>]WU<
M66WT5MM-%*V@D>XSJR[)16Y2:+T9I-P7U2"R^W[K8$C@F0ISWEO6W_M?YJ0L
MG+T1FE$L>E%Q[=F<Z$6U9X4B:_6,L[M97!P9:] ))F\BOF 9U)V7:,>1K:K8
M[U^[6)*8,<X:RQ^.D*)?9(VU[&7FZP+)G,G1GN;!>O(EY:2U5PIPJI) LMS[
MM)AZI("NCP_!5,2L/P3$3RML%_[B?2\@;H.7#_<(EG8QSJ9Y"*[/I2V>88+N
M0AX427<(4^EC"$E00W()4!PT65+HBYXB;;T->9@E2J//GE]Q%OFBJQ!0 3]+
M<R)CVL4A,7K2,&P7WEF9TA5[XC#,L'VL65P&GS)3CA6'Y=HUQY(82@4^U(=)
MV4OH1.+8T.(P.JU/SJS2R!*M^>3F3S=+[J)BB<9%.6_-L+"*EXM#U^[<?NQL
MIB1'ANY-Z+A!<3S[7C 0IJNI["['IRK>G>=]W7NPK4TH3"K;V"I-Z]R^^>?%
MBA8=+@LV%X5*/SH:_JLC-_R<$4$&)^F=6D+M9<@$8&@H9W)?I ;F*&RAW5X_
MI9"F36#HR6JETY3:6*K#59L2)LM@"=K(E?SE]AR^F!6-/&,6'Z]7C0_B!*NM
M>HAQ3K:>5-=EI4,4-U-\&?#LHF6TMX':I\!$QW1(]#,GG^(S8Q:-CE\"<YK=
MA)G-X-]H7DDI1@287*1/6Z9W0]A0,4[LZ&+9ADRW<T[.^S4S:V\%R_(/WTKQ
M,<;JWI4Z#],T9T![8!!"VH-F,?+X^^T;_;I"Y*TVQ#$R.&H#6N\MGDTUC&'(
M%8Y^UP,.L &U(>'O+MD.@6LV\O0&!DF-Q<P?A2%S85OUH=IJ)NJ;3R4+UX7V
M"LT:6SXK/MO]T=+?,B,WHUCAW%NCIC?C?IR_IIH?"I9H@SP=#:^V3/%K,8K6
MI1<U%@?09HJGT&;\QJ>B3V:X'"@6[9!^;'3R%QQ4$/Z39+TV<H#5T_@-V2/)
M!FQ0A.[8_I%TNP2/_286Q ;X(C<*%.=(.]XXD!<QK"-L .8Q&S#@]>#+G]X=
M7<?_\2WW0^@E9*Z-.1$)ZO[M[:^)MNUN_YJ#NPL<P\!J[*F)F%Y?4E(U0U/8
M@"]9=;)_\MZYK(U E>U6^S6.><!$,-B*T7'#<8MSZ\FJ)PPH=8E1L._87R*8
M*Z[&;4\R5; 9P\:K/_AH?&M"H3BF/RMK^J/W6#V]>2?)'U,5$!QLH1^V\QH-
M\!\5Q$76"+(F.Q7Q&XRZ0)UFI@^H*+7;'PS-J>]$Q9TRZ'X.P^'NJXS$:TZO
ME-O6F\3+QHJ!FJ%H TJO]$-TLD9"!>,">L+1.12QEX-M;U@?)66_^&OR"4[#
MN@CS-2[%7R<G/>_UQ8)"7I1XJU?U3&KC<M)BP75$K,.Y1W6JFT]T=515BF.7
M/\2)!-HC'L(P.!UP"AQ$--]'BYVLVN 3_B[>%1O2<SES)KP2Z#Q8%5QI-ND>
M7_&JE@JQ:I=)R9Q5/G;@!B_B)JL/138&1D_OTY.;9%RD>"1B";>]\+(;-/76
M*06R^]. (L^TN_XG$K?:E?3**[_2FBP'5]PO#_Z0N-*OHA(BS1J-,S?Y4*'7
MNBV[6YOP;%RFU"19+B7?(\,R1AG%_\!,=.4NG^%1+']BYE$#20O<9]U:;^)B
M1S]N*,/+^EE!*>H#'/)>4O,V,$'T:FC_ A_NNC_W+,-?"DB4M.E01\<3\D6(
M$FL08G.Y](LG;F)UBJ.=DF7EJ:VW1'.&UH^.[#6N O/&H&VO%^Y;9G%;4"X1
M2>UCYBLQ=$7X[[1D^]"ZI,X6S3>Y9N2ZH@_.QT?PV](#7K<=>N0//?;./_?%
M[?J7HC>4CRLJ,^ :%$,028TZ"4V%UOH_(LNU93_>AVH%<EF@KD=.QONDZ,TO
MX+1UKH8*KY\XI>0M":;H>H<VOTDW*#C+!CB1*BLK*F=J:^HC!P;&I"/'QL;D
M9^KK8V6XCIZZ)% 4J"\.*#WJ79*XJP3PF]5(-JN6<%OGUM%SF6[5]EUB*5%]
MZO+=?F<@GTZ2,]Q&MD3%[X:?=V*-LX[?#6N?8@,26:J4$7'+_,R&H%C*8?)@
ME/? O1Y>J#+!N+9FI2TQ<X U2(1#=?WZA(<<D5*Z.V8>*.;39FTRIDND?@S5
M/LT/&^B[, PW J;6\0DYX,KU2Q>U(.+E70$O'1:E?@\_9AP>Q+OD/>:,*>6Q
M*Z9KE>\=-6G?-M_)0FD6\)6.0P@-ZJH$DN.,*$:#*V,#2 %8P?S:<H=]TX=5
MZ?JQ_/*7)D5=U&YQ@[&QB)>H -\')ZOKWR2>F866(A20W6H[*85ORB5A-X%#
M2DU5X@R'=EHNW9>N&5HJGC^O5B=AK&B1&/<ZX^P)(84[ W$J9]X:6T2F^S$-
M(#-\D6%J+ZO9 )XSDI)]O%8'6FIPHPB7/N,Z8QLELWIJS%$(_K1-\<7(RA0,
MZ73="X-,Q2<)5FA14.0FE"9KN&)2EG"=(>JD$R:L*2(.265)VXE&^Z*W;).(
M"X.7KI2Y/LKO'LT<?2! >@1?M>9LORN(KNT'#\>\4(=K3ZTIE0PP @-/)5Q\
MZ))&]\9=E]4"JXM=3=\'4"Y[:[4=J*_CZ-)A[=?=;C><]3$L5;',P3/3OL;(
MJZZR):?Z]+0A=E<-3[-Y%$L"#4J$.1_Z\$I3>CS]3N;50SR\VK+?5N54/8K'
MYU*P,GT,_O49O3PI4X)Y$A (5Y?./DG4KZ<81A?%A_GV^K]BIK?J^+75E9\^
MW!L8%"+O7.%8F\RA[)$W8=-7#L"/T0-87_3$@Q\[Q-QJ&9[C@7U(X/W("^K,
MX3+B=[7)C!)SU]>W<SF@OCVBSQ&?&+@MAX7F?L8R8UQNBY8O^B%J8LHCSE&=
M'G'84WL5C%<$#HJC^59.+7Y[NB!X2U5U"1)'U0J[_PW^D46JF*BD&'.8;Q15
MF%D;?!A%3F8#6B\C3GIWBM[R-$P,Q@@:2Q*MY&%HG;AVH'#8PSUNG@L99I2S
MXT*UB*O^$UC.(O (H"G:QLU,"Z+CD#XJ/)W]H#A-">LOI&"ZDU1'XW S_I/J
M2NUY]ZW6QR;%RVM=\X9%2_VP-%-LXL)'3TT_'4.!+KJ<OHV>=N_P%>MV%[6#
M/M&SYVXVA,IN/;M5[*$HJJ.>,H;8D!%3JA<N=G_5$2'6#(8Y&HC(]<%M"!SE
MS#XRRXBX&E]J8>-EG*WA.>^H_X2P=$=.N)2H8%L(]A"U05MF:\@PAEA=C1P<
MD*"Z)G6T*+UFYNDI,WZGA99\>C-U@LR75!E"XK'5F8!Z-)H+P%SUATC^\.LC
ME3?3O4;NO7Q$J'2X,B1P?6;(EKAE/HCHV3X[PT=3[%M9K_0&DE,9MOV,<+)4
MQT.="R5>4]IDTB8KVP=&MW9 >G[/VM*IX#Z:&9[B@\N1YO]M_FI_IUCVQA)'
M#G5Q^#A+E&$SV)E-D7LO>9C2^]B T@I,V.!5O_[XDU%>'WIBRJ$G!&WZV,Y?
MV;T^3V+!2.AMU4I78K7>B4Z;#H]F37&A\COHU ^4X=M/&CH/)Y]<^M)QZ4AD
MAZE\T<M%EWEBH8CVQZ?KCL=F( E3_&3J;BDRMO/>:!8T6W%8"J<G=[N31^^#
M#P3C7'SOR_MYNV/P] 0U94VCH:!@A=D:1UTEG4R7N.1R8SR<EP(B++1/JH1@
MXA!GR.B4C>J2OG""'_(JGGB_Y??45;K>?&A-@ZVMD4H57B*^V##Q^N/+(<Y3
M6%4&ASGL*:(="2]E ]K,R:X=*'Z.JMJX/RR8=*EUZB1VN+9<H0BG4>I1[@R*
M+SBI#TE54>_8=FHV=M:(/AY]H1W9QF%_>RV8^5':T<VA,^ Q3"M5#FYOGA1]
MM^7TXV$]NV_Y"[9-Y!_U*J/180_;\G4I2D^M^.TFC$D!03AFU"-W\6_-IK'%
MEO85?(>_9%DY:]<]?UT[E]BC^'G;^7JR3D16]G8 +1&A<!OUE@B.?(M7YS*?
M*&V?XI\//D-7+I?&Z.J;B7=8?FCHVQMGT72[,--]/>6Q5<FX!3.\ "M;:TY3
M=$?-]!KS\2*&4#6K'0$/=-8;HNB7Z+*K]E_\[4[)M%P),0$?6E:Z.:MVB?G(
MA^CF2=4(M2KD\EGEB\'63K_G2S'9Q5"CU<ST"4(=#632+B;9F&IW[-+U@+<(
MXB%F%&EN'>%<$_V#W O'$]>#)$7[JAO"?=WM$E+%JCQGY>6)9+6T=4.)Z$RX
MDJDW-CP<:GJLI2<:[DO&I)Z&CDZ<[WQ[_NJ2NO72[7DOG0EP^T99DYPQAG=A
MZ,[$#_7DG.3*!X'S@;4Y&0Y;]O(%S4<V3_WU[/ OQZ#S/-0:6M!L $T*0WK@
M1@]']"& 0YJ@K_39^G@5W;-T*\:)+S>A*UBNI;&I8N75\D5AL=0^H[IWV*:W
M(RU IZS:5U^:G<?0][^U##!.SZIH&Z&V(ZJ4B& <9B_<D2R2U"+*," SXQ*;
M>6<K]UN01Q)UP:4&SH-6 YHFH?5OHZO53/T"15W.9VY6/)Q:''GM,/UUPF'*
MX8(N N'Z8)LDVAA$/=.LRWS#)Y!5Z]/AU>OG9ES G/3V7PH>;_0SF+9K.VK*
MJG)=5G8&T@U/]);H-L7?23#F4(HW1>G9,F/6K[]RT"O[9L&L%5\B6LP@,'I)
M09N :4?N@4/)?-$M<@QMBE!<DB[/;-ZAKG:$".70TQ/AIB;&0R<%<,<AUCEC
M1-EIOPC7$$'MQH@-;6%M/'4K:QT'#(!^XEMY03G2B24;@L:Y9ZE<-"91@N1
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M?%%3IZ=*I7P$*OQ['E;U7Q%\V*F]VXLN_C_GK/\C&Q#E++#)!A :6%V!/OO
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MH!8;+2GZ:A"N[^$62&TZ9WJWLY]8-TRJ5,4.^#T?.MF0R),V?3E!KM=Y6A\
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MP+DX% '<S@+C=<&%L#?KEI'+[8CCY):\&::<\0@)4YNG-=;;# XM6\Z)'HO
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M:U55\[RW2<\[*]LO&TS?)83<*_*AI!>L+].U=U\04Z1,LYSLZ5;(/3#CSVQ
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M 1OI6#KS(_Y@6L:CR)OTD!'F;W4@.KV0#5C#UY8\/SA=[X3\(F')!F ;P6R
MBN?_L2WX-&BH\#L(<<:E_5>&K(&[8;7"7L%Y98<>E.SJ\B_I?3!$LO4-WD-Q
MZANOPG[G+45.3P+9@*RZ'H8%&_#8@W*$U0X502Z!2R A''#U;V0#GFL5LP'(
M8"3+OI^ZC-G>[0W=VN+PM;E*+XO_U^*_2(N1]1UK!S/RH7><#;W(+$*(LP&M
MUEB/ Y6ZI[63X0$>Y$%J),TJ+,RK^#M2<%7W$MK;?K+WT[7%&J@!M%,'%!,B
M2[F4:R7[E-@K@FL!5]<,:6;CJT2V0S%Y8&_4J"N!CY1&#H#2@)1RHY8A79E*
M1WOON_=2DT(/Y1&AW+0D,[L18XIY3-VY7-.+8SBG0<NE'Z*WF@8W>7AR37HF
MSUD-KFZ,CS>=94R,[U6^>^AVP>Q!)SEQFF)O0^.9G("<9T,#_MIX@7ZTF*;T
MH%[7 UAJ&B]E'_#($X-B>)($]], _ALG#N!C71[/2JU08/<RY.0-"A/G,,:#
MT03[##FSVSE7&9$T#J_?+X'H<)8B<\/BB*$Q+$6X.F4(4I\U@N33J.35.UZ1
M15'J\2A9E%2MDSPZ$* 2<'+M.:S.Q&_?]L@U+Q>M].L&.45?3#F]'&)P4ZS7
M1N&'F)E8'[ZDD=?&?L,JNC*$%#VN'[N+7$YPI%UH>XO.T,6S#:]'J2EJ/,^F
M3KXK.QUOOBU!ET*V<KCB+>C7P;90O:.T4#)KNK-QF%41DF)"-.SHU6YS5J>E
MA"O?*<J)R%G.8@GW*P>_ UTY_6*PELES9: 2[Z:]91)2:J2R@D(XC+=Z[1%^
M\^J2GX_?P;M4/)Y2=,JAE5OY=NN>TV5=@J<-RH\&=I8]*B@KBP% A(&\[>J%
MYLMV^0(QSC:?2V:D[$-9FT8C*:H^ =T7+FY9V$*0ACD>DD=<:@ZZ=L- YS^1
M_6OSQ>VR!6W>NPR?5RXEW!Z-@'L7Y0UKQG]:<&H;*-6[2P NO$>V0L S'.CA
MU\*T]M&D@9TJJE/NNWKL:7EEM''SP=6;2)7"!IMA/3&XWJM$80.E%M!A9X>L
M'A[,9+=H"DL-V=J.Y,_6 :_4TT_!A0;GY_%;D)'F<R5+'^^WK_@3FFGCLT9"
M/>,]_DF@F(VMPU,"+G>O!+BP8CTKD=6O;<!3ZLT? ^KV1K<9_BB.G8<JR,V'
ML0'++88Q@TKDZ:@2F=J:LQZC<S8+\+MW2K2V2UTFM(VY[$ +MUB?D.3;^]MO
M&J8A_:%1*-[@MQ N%_("KD7<SW*$N\U<;=:8ID]P*!@T]_)0Y">.SSR<<@Y#
MNAV@BL@C9U*1;_:GCH1V\=$4L20[8I,=[2UY(>[0NY>>E ?SA6'[K6CK)5Y7
M/9(=:I-;!.L4>Y0#J \MW5@)W]',F,ALRI(K):!%[G1G+W+F=.4!S6^S_CT^
M0,H1VN/4I\XB,6N:X_($R:.XGCG;*H?XJKSAG\,V6IMW[J'Z$!SU=-\JHFM@
M4J^2<J1KN@[9/GDG1"DHO I^@1;DM@>K?B9$.%\HPB,L3/KN^N9RAO(H?[F(
M!V.1EL39\]NT&,Y_&]H<.93ZDQ867L;JQ^YA 6&K[>(>[;PBUN2ZN%BX$WFU
M=4IO(,1\U_B[CA]IL[SW<-#&1O)JPJ:?['3GG47.<JQ@W-20#^'CZW*KZN+%
M4DT=MY+@<@2,) S:[LQ%R4I P[+;G%7Z0T"':-FXL7>UH3G.=2^6A1]_];[G
MQJRX7T2M?Q/4LZ<_OV1AK\,>EWA"\YO;R:\R3D1U6F3XN 1:_WQ6"D'+?WZV
MI&#466M-D/0<MMIR?'OVUL\T$T5*5+(GT=NBK^:J&?*ANZ#W#?7F=*$5*4.Q
M3*+G$.YFB8NW53'7W&8>]_ QQ0:C_G?7!VV&[8T&X>9MX.0I+MHB>:05*Z(G
M/-%+Q )H6Y?K1AB:578FQ8J.HXZQ=L??UF=;F^2!K0:K"AL&ZR(4J?(!&WF6
M ^NFV$B>'CN"N?Z?!2WV*2K:68YBSN 7H6*1H^-$?TS9TC39'#@6U)Y]KZ\5
M&W^ON<;Q CF@,[3:P<'<!>,M\")V2D6W!55((SA?GVGY(H%C P3\[/'S@QTZ
MRM.#%98=NA:]!Q_U'NPO>FURI.*1B6"BY%FI1UR&*5]B#2UM,F(M+^QK6EL)
MZK1ZIG3!HI/@L1+X)'QZ=+ANB!#A=K'6SS)YTS*J;J)0:JZA*?;%PYODK\E8
M?N6N./4ROE.$B?&L:8?6LVM]? E&\@.?UI;JV]RONQ?JV!#ZNL5M2IWC_D0&
M:B,:EUGWQ[*9S'XVX*>/O36D /XH]\]"!OAG 8//Y&A8_PM:N/O8XQ\1WDG8
M4D3B-<_Q'KGP);B'Z>. #S$I\0WNE;HR0')K&:H[;T"=FZVO>?6J.M*GO*?T
M6ZI$.*PH!V)M<"/72&O,2.G-AI'*>(3 45<%X]/)CL6RA:(=V@I&3?(=2F_&
MO:0SQ_N!.JQA5%T #O.5/H-,UM.!0V)9?;^3AU_5#]0^^5%[:QCN0FSZ/B\)
M)-]]P$?-&'#TWI[\I/KB,5?!8"U-D]>;H5^\&#IRF*7($;-GL:[0PZQ1R;,4
M#$,0P^+>39XVHF57P?UB1F8@K=,2GCK[XYMW$X"QEHA5_9'Q-DG5,))[C?C-
M#O1.1#G?6]8#O%MI_N,V(W ;M(\X,H<&,:?L9XAH4\>SNZ:.UPY78&>> :LA
M\2\'FY5>3.F'N/A0T)T?_!:0]9<4VP<=865G*C:AA_6E;ZZVH7A34P@H*6/*
M_F3,IAVVI-S!P4?")UQ)"::B3#H>BQ\8P(N22!QF/WO]>7U]I,R5YY$''IV,
M%7WDFJIIK6]S;7_?E\3/%!,Q2T4[9X&BK%W/,@G)[0;D?)U [X%"\RETC-D6
M?#@87L*$GBX''5(SNB6JDYHMX?'56_-,KIB!OQ M7*&LE'BJ63NN?!_:!)CL
MW".2]UD@"FWJ0@8V&Q?AW0I3] ;P;3A<MJVMEBUYS,[.GO?0V,# P)AF[!0>
M/W7,]$1]?7V,@+Q+@L"90OU439MK>[_ZH[-^3WLY-:ZPYZE[NIGGR.[C_ %(
MW;>N[\?YQ<"G=TL[%;3$^:5]E/@CS-*;3;]WXQ$.W/(%#_[=/-]_*_"G=#BR
M.Y$UAJ1ZH6H#6*6K8A!\"$>!J9W&F8;.&JZ,TR_"CY'KIM)=B %)P-TL9;@&
MF43%GI^KBG&KHJV^MV<#8FJ3WGDOF[T:#N'QDQV_-NPW/X1^/;"I],%WP$O%
M%R1G79]^\*J;KM9)?M./UHJ="OYSBG>,0%ICANC'^.*XSW=R-M'BP9[N,.YA
M;Y,K@\7F0L8A<G*,U]&.J,?@'N=$5BR2*)XV7LY*Q*X\Y=QMI!/("A1$MFL"
MZR%,(>2H.AO @TD&,XA*%.1FZ#DVX(6_'!OP6QH;(+/PD^JQS>$A_ &X@&UE
MM32&&(0-R 3V:0HQ#[(!_VT/\FQ O#?8'[/-6<_5'BP1J"CR9[L%JVH!N:'2
MS@;,<+KZULP&Z'T"$U5H?FR ?BQ'F8CB-%XK_#E?@'V!HL464CD:;0&&+HLD
MA%#BV(!G^D *KR%IF-,82KW*45*79_G8@#.)X.&)559, XJQ#\S(1BV,QC'T
ML;S8[Z\^@LEN4)9U!(?&[6M"]JXA)VO8@-7W(YM/H?% L@&*)HOJ@M+DD R-
M4(8J1A@N0S%DJ+ !-&L@.0795C4"=ZF,B&,)L0$,%2 )19JFF>CNGT'51*!9
M1_R4Z.HKP#%$Z.@F7UU$TL<W="B)B4#CGMRC7<W>&]<^F"D^Q'K=9W;7,DU/
MM7DV7+M91@PDF\99#*+J\/KS'"2J<2P4,P1FW\16ZV&2GH\70[[>LG,7KY=Z
MG(3X_$Z\MCCXW7>3ER_T!2$-",__C(6,D/DU.O(K"%O=TL4LI9Y#K4R3^,ZM
M  /6H"M(?[KVMN%75O\<$[W"!K2LA?Z$-H]#Y%_FY=PUZSUWWJK>H!$]]+0K
M7R!.H[!7S#"'+RMPWC3(P'[,>"NIIL8(]0PIS BCS!*V6I<K/:A/:0_(Z3.K
M\6FIP39D4"?T 78_W(M2CL/R#BN#3'^\($[SPK;QU'7S=Q3>IFG:)1/\1I.[
MB?M(UN24=J/?=+ZX>7P6CFHVB-F,$+$E_X@!DE[JVJ%9^&UHM*[+_JQ.ZV$K
MZH-< FZL6W/B7F4A)EJY6<]RO*U:<T++XFO5NY>:=5T;$/V(ETX=M:<$A;33
M!X.R7"Y)6!!\".1@Z]OD9R>,8\[,;98SWQKU=Q(I/UTSRDSG_$/*/Z+7/428
MP'5)^4]3:GK'9T_$%K:%9?.ZG,B;>XOF=Q=2G-]))26ZTB,$2;HMYI!)SO#"
MG2(T)\4TX 6]7$HNI<S&O7>KO8V,9P, 1#(X7H^/84][2IP6@/T@(O<SPBE\
MR7I 1#_B )F$C89[T"_ :HC V'ERQAO)8[1PBH@!!10[#L$3\!+OL_2 4;C7
MGJ_R+GYVTCL&M*['UT&6X")5-#K5A99$Z#OH_+WE-TEU/%R=? 0G;AC5_#OK
M^ C#*9S,V7!3FDUD;[@D[1PQA"*;YR.$;7TGV0D69QB,J##DB.,!PC",W= F
MR19TZ/OL11/HUVWYR@Y*NTUGN&/]&.'T8\>O]@T-/8\S-?4'"KEP^XV?*32^
M;A^N-$OAMG;5M<;6E,RU?-8."^A?>FD32>AZ,"L3V==P-_E=:FCD!\5!V#.$
M+&PN]1-%% XY[!IX)MGW=E#W;=&#SF"UKGDA\D]I$1'7AJ[E3!NU1'E,(KCX
MGUDU'V1"6+H<H'D#W=;1P?WE/#,'PX"9LP&^V(W@D+C_ZXY [UOH"P+^2?FM
M[;\]7W$$=0!_RB+YP2OZE%!6X79,J/4_Z^9?+;^MFY."Z$KPT\QJUEY8UXQY
MA\G),7 \";]ZD;*WXK!))4VJ@\K_"0Z>!1WJUMIC_S(M4*GBX<]'N'(OB$Y6
M3(G(H*;#5S<&1U9$.B.&P4>0'-A-;!QA"*"I_2U:2&&$<.$XXC/R<(C$4P<C
M6CD9/Z50I6%^:/%>\4^CD-T^!;\','8K9>5#^>R])7F&C@]L<E#[91Z2N1LR
MAV((2;&X&&#?U9@<\V0]42<.]@/IMO!#SVC8&?.T8/I@P1)$//5ID/ K.&]$
MI;YFS:B]CPCU[A;B*%ZF(:99COC!-P3F7UF[G(*8MJ"L'U7QM([UN)^FI<UW
MR+C6JKK+!=2KJX%=7'%:<D&7IYB'3*G?9>Z.#JIH:3ERI!5NZC!ZFQK@K$FV
M2\[6I;F>G[-^];-#>BQ@K[UN@^_"H6<VOA(V+^3QN-:>3;5$!H8S !Q)WOJ[
M [6;YE(!$R'6H1DGINO2WI?V1>N=I?%8UK#:AT$!P>79_7'_'WMO&M94MJZ+
MILH&$1&13NE2)=(W$0$1!%+* @0$I.]!0(2 B A(Q$!*:4*?DK:D%4((/0*A
M#T1( B6(**$15"")TB.)8IR2AIM:^^Q]U[Y[/>?4.O=Y[KWG/N='_F22$>88
MW_=^[SLRO_&BM?2MG82UM3ML.9XW$8Y8BT@Q[JD!G9PO5PIGJ%<&F)N]J/64
M^!-77.5O*1:JBNF$N0:-RS78:,/4[*$W;N?>+O5KS0VO_-RS;/O[[4_A6<_;
M;<Q&Y!XV;*Z?_K[FDER%LQ)'U?;/O[EI=_+2@"(^81X?=BG<ZEI5AN:3S_]N
M3_8CL10"J,>-+*8CNZ!;PACDH"KQNK8G)G6=+6K%[@-PN'M=QM DKEZUW]Q$
M/=R,_7GF<A$'2KIA:]MR<LXB6K+X6\8G@A%S3F>KN83<&S$R!V:Z0=_N@5QX
M>7SY5;"0F="(83HQ?'%>UH59-"C@!ZN=)/<9@D%$XX).,M\TX6?I&\5[((XE
M+2;RAS<^0Z_#_32#;FMW*!B2>K>P\6+<X]_8/U*1 2T/CT,R55!D(MZ?\C@"
MX<]BC$3[E+E]WB!+I#=O<14"&E]\?N>_FBA9S/_N?347ILP22XN,G1!_L2:-
M"0[" >=W\UZT0M1(HXZ5!TXNOTD[5ZHVYG&M[KFI9F 1"\SM(WTQ]9GTK[T]
M+"<V^-W"S&R\=K+IL7N=%^K'CQYIZB,2Z"=3FBP5C7Q\H6^>'38ITV'C'J[=
M-K=<T569;;6YP8%RS_&*$D4!N:7(H01YF.(1IDZ>8D7H=7$S;./ZV7:?#;/3
ML\U5&5(#LUSSNK'H^O790#7&_;ZBG'FY\/--6Y7L4;666\=2U"Z5G1^67!L^
MDWRJZ<20NJ5NAM?I7&N=='!)8.OYK%NJXEF4F;IT2F"#*SDP2JIFQ:T_GAJK
M,5UG9*AN7_U1W<;N?><;1PNI&W_M.!^I[RVL+_S#T!J$2"_O"7[<G^W%:U9J
M!V26H)+P5C-(N+_0K#6O# &K#9UW31E^5 U$TS' XYFOL>/>KJV3/U5PI/>M
MD.I2G&:NV:8J29B+B,'\$E_*-H><M(;)J":Z;(76?-K$O]OYW%AQ]B5+3+@P
MH%SS6/[IM6&LQIT.FZG52PLSU9*E]=.X R>B[7K\"Y]W[#I:(&4JVORWE#EF
M;Q$)O$9"5#U_5G:2>XF'@2Y5#)C,)BISXP05\%>^^OP$#3T/<9DB6# J%-YP
MS5[=XIH^V7 S=A@""WF&SD<^''@>5?5F0WI!YFD2*9[2W)%P -L2Q)'BC_-U
M,NF*34S'&&U_MBI0Q!%PV4%C@PT(R'=U4<I@(I,OQ:OA>M>/1=9O5,@38/>$
MT+%E#K0;[; G[_3>P'^D7O;<6?T*E5J/3^R F3YY97+QRTXW^BU'+" I)3+<
MJ<E( _Z'P]RHWM7*D_:2P982S1]%-*9#!T=]\C4"54.)TU$#XEJM-_SGC=A*
M/S)/7#FJ4T*YS4.<I3@UH-C?"\)<HHQ2Y!-\SGE4>D[5/7C&8!W#VFX8E<NH
M5>K ]T"!+NY?U#'CM7!57U;+YFP]7%JN8FYQ&(GO'T>C!P[R1[IZW9J6!%3-
M@CDQ)"KF- ,-FDA5U ,$2=9.3*(QK\LB25!I;@"OP>#$3LN!CH6&QC>(8]1/
M"$<Z\AC ]N*C$D405YGNP\1DXM$!+:Z1(9+YD'N1F9-.1XM8(6O,,A,B,.MW
M'>W"@^]5=^^!TA/>/\P+C@J7L(V0?&4\[Q 5\6%"M>G!"Z6L@LL< YN83Z4^
M[TJQT@56^]<&NR_:%[9]K,4Z4;$'GFM4")$1FNX_85/)6E=:NQ'.F=FAKU+4
M''%>N74IV7%'W'ZVDO!S:7WN7+-."W8XM![ ZGYL8J&EBA/$]VJ%RO_=9IO_
MT2MDG<BB07EM>Z#7KV<4_M[!]FX:R1A"<H+W0!A,XX7_!4Z-*++:B-Y)^F[M
MZ,L3(.\/_$O8U[OO>#_QG?[!6/'6_^M=;?_=CK<5#O]P-D<=80?(L*PN"8IK
M72*E4&6,H3J4G+/"3F8J5D2>+@ZA(%,["UGSX;)\+-8SI<BQ>.(7% <RXL;:
M U7[ H$S)$K\]?F0-(0\I ,R$SDGPFX$@CDAB$-,Y(A_2E<E?CQQ<3-1B;E%
M9HTU G+#;KH7]T#"8DF(B[+[==>-+<A_O/(Y497D,:D3,W[?X3BL&)L_F:![
M.FI,CJ)QNM4F6_[1'_6LYW)U[E:6!WP5K-W<#GA:[S\6_CT3&*<Y2"$'CR/#
M/_"P Y*KO34-?QZ?PJM!6(57<2.!B,JWSTV)@K61>3]N2FG&/H&QVKSGS(.U
MA[$-\/T_98PRK//(2%&=(OM89F$C_^ IB"K%0<$.NKGI:\'#V&A>T;[GI?M"
MG8(<ZUD[<CVPA3F++[V1B,M_J?C3=?SY(*GSS9 _GE+1AQ@:SU7+@O/SZZ=H
M5^P\H=\:C=D%0"+6DH8,+^QQRK8YPB];;8X>4H0P1]!<3=JB/%S3EXIPH(&E
M5^?CTA &= 7%CQ#]_G"+Z::@?FJ'G-SOSSTC/C75Y'B\3?VAL[>A06UU8\'.
M6MT")YUGIT^U\]6?R3:H#[=$C^&$J:5K4\EU4SCU2U@CRM#M4KFLRO//U2T=
M<\,<88(_57F8H59SV?W%'JAC<<N1.<LV ,08#CE[((E/SR8)AC"V[SX2^YNX
M>2-\<5B&-3J@P+SU,/?@V3 ORE3$BOVI0@55FZZICK=?[0QM^PNA3Q 76P0D
MX%5LBR2\Q(VZ(W84'FT]%?L>Z3/=3'LZB8^0L<8+D-!EVD#S+2IGX27)H:VK
M?/W3<MSE)P_5E1\52#[B#@-"UK-[H*4>:&=IA;2)+RZ,#67:.\R9DR5@?ON9
MS74'*-E=PVAYR-RG#Q%N,Y?*;P[\E&,*=6?=U*F)/ J(\,7W0$)I6AUHJ?5Y
MTKU[Y>=J%/69;SSJ'Z?J]L)M(CV&GM^_8A>Q92XF,V$JE_<1)_D.S_$3I;W0
MB? ^6;)2H!%PWAFU1AT.Z>Z-=R-'CQ4)YUV3BW)^T1XVMKYS/-<%=O^FRWRV
M)/;3(M/&8<Z?[CX2F<Y7%B1&4^(;=NH>B+Y-8??T\BI,%&HO:L#V0*(#\@O>
M9F4U0(4--5)DO&;D'NV;&1A 1JIN/V$BB@8T^KJG8Z$G2;6>R$NQHOT$Z=\N
MAH?O/S?3^6HD,B(B4M;\ .%8U<B18^:RC5'FDF&M(_)A=;(:];57#]AY+YUQ
M89Z OTHNL^ZQ:8K_PE=1$G?VZEB_T/G1Z&;S]T#,_BW)>Z7.9'BSVGC]LNL:
M=8A&LRD4T1R[O1MPMK1!!!SR8.SV;]:6^K=W&JL9)SAADPU^4<X-/PD(*O[[
MJW\\F+*JF/*P]9=&FK7%#;7&-Q?,S[MK5"])'_IH>=E-20@Z/@-=&;$3U/ F
MP;JIU^ZSR1C_$HO^SJ(BF>&Q>Z#1,)/W07Q$S")7]CWR<_&O^K6-BX8> O&G
M8/CG 7C^W!K,_X(CF 21_=MEGB%EN+^P9BEB4@BC28(U Y)>(<P Y!ACXW>_
M>4W'("6XZIE.O=.S@[OHY)98(^Y/$7)7^WO*O8$8M=CT&?]3$9:VUW,D6<2Y
M#;XP24"-1HO91#KQ5_]]^$40O('<J[R"B@5+6@BD;EJY$DN[,[-6TG#&^"!1
M\(;,QFY7BO1:5<I*T=!LL2D9?: /3]E:"N6/_7?^[9X%"6&-1PU:YQ1= ]1'
MI7QE;U4K.RY48PP50T<C/?'4O!F[<KP>EUTH/7"P/+;$>3 0=K4R?9"D.VPN
MDE:9DI$JFXTP"=<P@ 4LY:LYUPE?RG+*-I!L1'QIX(\0VX<[F%W/*@ZN,+7Y
M94N1J5Y9O1._HE(1"2REP05=YG!7'*SQS?K\<AGKPE BY'6B2G8T^:[@MHXH
MZLS@6(AY7):$WPR1IM8W_;(!$?)-;#]<<X@H2E"@1:(6#K[:)!@L31P(E75(
MX6K3>$;7O;7!%U]M5E+Q_6;OQD^W_U$HJ$ 6*SYV!B\VFPQ>4!U.YY[K*FE$
M3N24_&G*U,)W=ES> ']AU B@969C#Y0_?1MC6=I3]QHK?,>R0E]]Z.R'#)LS
M!"?$(\>,K,CKN=:G'XWYZ[[0=>'E:"IDD5^SOT;YC0YH](<A/9O47W8JS4V5
M8K;61Z,+O&;8!<I&/<][SNW\CX*JP3EKLJH=\8\+@O[/'W@BJJ%I^'^)Q/^\
MG*#_/<+_'N'_>R-@TD:#G(VMY*L5UB2;],/NW)9VSS@8E77\BO7#RX/[5&S^
MWGHY\5\)?$_]'FA$0.'98WL@*RN/NW^G\*^&!/1O#S3['+FF_VQ5^T__"[<7
M"@X"JGVN,?P?CJZHQ[&@11]^??>?]A<;N_]Q[Y%1,<3W+_[1\S]1>:^\A,6)
MG5/M/M=+.?SJ8TB'X2HYHL/T#P7_V2I=)$>/'U]@,/$._>4[\D'S[Q?&^.^[
MWE__=\L+]5WUY[V*Y5:?"W,_!/_"!O\1Q(7%^"DRXT] V4WACHMBSL\MD!\O
M)_YZZ[6%U,I?V@3\?W;/\>\O]W*$)^"\!,Z!BG*#F45T%.HFP7T)HK@:EPAF
MZ: 0N+'>UKZK;N'W7C6RC0M21B_6PHRQI;\MKGEAFVJP 28RA4^OE*,LKF!.
M#E\M=:D\WSUZUGKX3W*9&Z]/A>$P]B\FL\.ZXZ=:)36F,'XIE]TP7OD?[9LT
M\-4X^R8C2IV E0Z?3:9/84X7PZJ1^HNM1$JDHB#.5*%A. &KNL.GFBD1IO=
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M?+#$'!A<\HZ6?APE];%@"(ZVIOYM?3[X_<#C^D;FPMNN@U9F%^B'<SV.3)C
MO?RH&_?*KMB'?G[Q(^Y2LXK32)":)>',V)R +!4OY[5E^8ZW^OSMZ2._F52+
M"<W[QIJH[LBWT\NEUPHT[HQ5K6Q;JT;(N"7^"\+#D!7'/VS%.880!O+-CB%<
M>)4FZC1T&BPN. !9:86%]Y'/K,H4;=W2WB*X-P/^I.)9% *L9MMWOP3+LF^J
M3G@X>A&9P Y7OI_"1N?XX[\]@\RU/RM$'N>?XUYE+CXPD:FW.S"0V>!K^JD%
MFG9+)R)[\PP\Q)*Y5=[:#!2ZMQW<&7FR5IR)_<TP]T#G0:]E^ #4X0<9]TS)
M=E=$,X3C:O)<67KA!P-$('YI&\7.F,R<M_G&(X(7.*47^!-8)'"11GS7'R-@
M?,*+?7-<1)_92-E?OW=E,:XDD7VB9' /)(9 0$.1(N9+>Z ,XZ[,':A0>%&\
M8=9F!&Z:<" HJ [H'2.+^P$W%C8&SZ[VWL5A%UXL&'8Q-^.D=\M+M//>-5?>
MN+$>&_EVA6W^*G$?/(3]>#;1(+17==!?UB_,"YELXMX8ZJ=+A7"=$ZK#C L+
M:N?A]P?=%^231HHIE(Z%1[5YTA6T3%3ARS?K5]/UYP+Z\JQ=6-)'2T/XW4.N
MK9 #%C;E43+N)[!^8L)VYW'.QW$IY,%7V>MU 0V4H9TPM5&Z1N1C+"G"4G'&
M[CI"_SNLXV"]+5\"G^2J/A 7.G\[#H^Y!Z4]3M1 OO[&GP$#UHFD1=[!&.1_
MG:D-)$W !SDZB!N !=T!#18STP?,70&[I;G()RQ45JRG ?B0-]P^PC3H'H-E
M5L+0%!/;B-]G*__*[II!Q%DJQTVDQ!,_T6D1O>\Y8P\D"EVJ77P:-PR6@-L.
M(D7YT+4!559<#L%7[ %!FU9K(L:Z1/*9XIJ;=KT]94DUB-SOX;NVJYL4%2D5
M%N4)]S(**ERP"];YN?"T8Q/]-+^W"AAPT"ZM6]8X,_[QZ^%'20UJ01$R7SV'
M2X.='%LV/U3*G,MWO@9D%+/=?<[UM]EG?S:3]9L^5U4& >QY]#MAZD-KG86;
M.^"_2I-?_/D<YH&CO$S^/JY3&P!AA3"^)1-^9JFP\%,EI"]S\!*7)/,$GTN[
M=^!$LJQT2CT\9% [*B(J(E%F6/9E:N#DIX@.S^3X"+*A0SC[S]_K?DT<(;8U
M]]? O1G$8=Z^P425Z<V :6V3"S ,G#A<O!D?/%'"MK-RG#0Y0%N4#),U3=G.
M,WP#,;A_7RY\6\.AS?;<\*!-5UKLQZ04&<I7W.^ORU4A*6HWOBKGD*B.L9I+
MC$-=&9@#YXVFG^ .U5%&;1_[CJ7!*"[Y14<M''-30K0R4W.QAO<O8>[%5JJ&
MA(Z.S\V%>OX+Y:7&!,P0$T%<9':AN)%+V4A;ED,RPA7KN5&NP)).CY/B%S3"
MC),UHT(2@N-$].^0].W%KK*>AGYT*5"0^0#- #.=_-_$+4U01":2D,>)H6@A
M()RN4B*9&[:KZ0''N;6^JDE=6%ZWNT!65'U%@-;#'7Z9F93SU'L2;OPQIVMY
M//B6_AX('V:,<#=Y<V4L1^_PUZ?=1T(D&*T><)<Z?]'DNL?T\%<IZG>FR\+T
M?=:=4]0-9'-+ RNU3U-U:NYO5LH6P&[SU.RPPE-_G+]S+"^7X!*LU:%NI.UD
MU]EI_)=W(9B+\TC^X2*.$7\"V>Z01 QM$G'*HU]'RL1LO#=?LDK*1F4CQ*)9
MCOH1(=94DTMK]6'\?5,AS.#R])!Z9+CU??KX88J!"#PPR2:'?9^CJSI=T2ZT
MI2P0 BW !5I+5L41 Z$I?85@L\$Z"-L_(X83 :&X27>BR/.B*;.9)GHTS>UC
M7J'&6/+\99948?;1@KH)V 6OMN=2E'ZBGTI+VGFM-J-AB#BYVZ<-OFGIU1K+
M.C]_U6-3,ZH%51KB9  ;+;L\A1D_;WF\Q5P"E8SU%DW#V9Z/.J+A#H^/ 1)C
MI]7<8F@DKJGJ)BY$N*9MN!@V[&;7(3P4H?;RJ _DKQ=81%"C0&#Z(2[0?+W)
M"_HLU.8:R_ 77BY^0A[8ICF@D&'P6%LQ\=#Y%3(1U#%=ME#4@#!FSA35 [BA
M!2G6P:X0'13-_\1$=)U%@__8D3NP<[E>&ZVA%1>!/O88T/6$_P=1= \4JJW$
MMF7M@=(2U;CVS.<L*>)@MIY?VAKTZ";88MKD2NQ$!E+"8%R$9(Q,YAH&T\9$
M[K_M:[+ZI9U8X3XER+KPH!6Y;,NWG9TRY)MZ@XV64#V,_%V5<C%1)]RQ (:-
M1QVUP2U&PY7_*F;5=6@HOSS GE WH9U?9Z[XE-IRR4 /+3%9@?^ R7T^F51W
M?B2ES5WG;_1\!G@S!S:,R66??9C;!#.V#Y.(VB'^U>AB+;YI86-Y&"@,^>8!
M$:8=1$/^V@')6%#O87$%.9DH#WA?G3*1H#5%.[R*[2.* C<6O681GBWPF@33
MY@Y?/<<2MYDNDF3OS:@)7&BXIKG"[(MSR"[4U@C3F_T6$.=H)$X3CT!O-,79
M\BI/92!%PZ'MA96LLQ'>0X5=1;O#Y47Q7X#/[!O3,N8EME\Z/B:1O+238($;
MKM38]/&REQ4'\4]+X[QERH)W@(S&UCF)%])Z0OQ6@[0Z7H%];+1P &RTMP >
M4#=TR_G;SXY#MS$:><F,DT42M522*URKSHFBH5/F\-7[U ?TS&F,A4L1V[=J
M^4.N5T?,AUP8\9787YTD6N)/R$&'/5  .*5KX P5<8]S,;3W8-T25'%=,$<$
MNVIB<J+2NG$'+COF!_'9F#Y1B#4SEE_9,A_:8DHP;NZG<2*<2?.QX^,=V(4&
MT7&RN'6'$%<RB:U( !J6T ][X[9.+D7XTPW)UYEKS,2\*BNZ:/3EJ1561*\/
M$&[?S2I\5+4 J%K,Q-;6=$@;*_;1M?4\"\-YY]YNGEIQIM)[OFS3S6L:U*(J
M6@MDN].FV483[06'CZ5X34]]-_*5U5]WKG.K0N33SMO?<<SWGN4%8<;']D G
M9@WU \9XZ223=Y]OZ683VUO&U54P<K[X2;N:F'\V"_^UG,>N0S@6W)-HQ@MH
M^TE6HRAK%+D/2LYG:GD9IBT7F)PH0@?&WD<?L\ 04R).&QZZ!#/TVC2>^@T?
MY[@V'J[O#.V8S?.&TE\8MNX.1U1<W:4<"@R]?]//N*B+Y+K,]L@P^8+&5SH7
M^A0$C-LCVC[FM1LKE4Y7&*K(G2HZ7:H\1GIGJN,Y/)O<5&CFJ=E F6MHP'R
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M^;'./@HQM3Y9R*RSM[8Y[FW01(5Q?* 5-^0-2@*B$9VW79F?\\,<&\"PU.&
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M4GW ,<GI_YG/5A#\^IYB=)K8Z/9V U*8M &9KX]['/&B:PW&(9R404=JFL=
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MXRP<M^T)Z"LK3QG5&E_^9Q_^'3+XHT=)K#/<:2GN%9N+2EIR//DAO W(<H@
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MTC,_2_L_,-7!,&%B9A&]"(D+[SI%0R,S"?O@6R2#UV@"KL9SL@=DB4!6'P%
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M^H)Z'[=Y:V9(4K[%B>?<F8F7KH=(<>2<"X60A:V335%/XX^<2,+L<IU5LV*
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M5K=2/_+9/IJ=+7;8I5#MQ!O#W;/VMO8==M,>S"5 #]9*2,[; 9#+V_D3PAQ
M%S6>=E>N"B>*L43>4HN]E?%E.3F,KU>^CQ3?YO<)'0,]^:M)Z(5/37V+8>5*
M[C+0V?1+J#DWZMW)#0/>/5^U'>5X3\1Y2!XS L##< <@!BFRQP\R=LE 2(SZ
M)2S##B@4+'&UFLHKZ>/=D1UYNKV89@@V\!R?TFFT:^PCSHV:;-L7W*C*EX'L
M!8,-):D*'K1!(PV[!/?^,,^72KK<U04B%_)!0?B9;WX7OQ<_Z$UL >]UX'.X
MC/E4?N $)BY8["@Z"P2VK-76H(IQK@]DH%=2U?YP7P0S3RF-Z=KE?_G7#B5=
M^-VW0>H7XVJZ2Q%!"!M\'V,+]"AN!] I3YI/4$:_$36D)F(5289XG6E"T@WI
M>JQ!\[Z@][AS_>+]7+F81/XTJ_Y+=E[JY8(63,6,MUE)L[; MK1@AG,YQRM3
M493<#9T=$%[^R4GEE;_^K_[P=0]:>*&7T%'8+75YZF5M=ONXYYYF:L6==YON
M;WM/N?_6.$AMKZW2E<_QGO/0(SEY!TY$!>>%'S\Q2RV\6$\M:XT[_*8L_\07
M*S^HB:[IIM?]C_?;@2VJRL9)\\6.[+U?X*MVW,"TJT ^?[65N/T@WSQ-JDY/
M6J:R[.XTZTV[C\FK&/?/S]G7>=4"1 +:U/J:@:H;MM"!U$]TSIL<U+A_I<D!
MU9XWN$U:&&^;J28OL[6W#SRPHS]I[?_Y77[V'N\QKP6V9Z+>_KNW\PV+VH\F
MTMCGQ.K4? M:@%-VH=-%W2-A;I^=76+3;Y:4V=<YGC:P<7)\XSX9O$"\N'O@
M2K$A\G#1YP"M:YG5G[WUFVY0/:J<;92?M"8=_N.'[T?S0<GOC$^9 $?ZCBF4
M#_K@W];'E_T_7!]O8[/;8VGJC;)1/#H LM(C ]GN+XM@!F_:HYLV%?LM;8BB
MC)\/IO\>]5@&ZDV^.)X&BB'D=Q(N03K9#54+T7J(0/-O=E_6>P]<_20A/(7E
MDY][Y)W\)#VI RZYY7BU=9N"I@Q42+A/;KAI"^LIE1:4Q$ )?Z@?U_P8L2&-
MHBN&^:V4;N^ C?9,GJKXD+5!"LN7P\F/6K @G99F]$")L/>;S_9\LOLB]2PS
M-C1>T15HPF=1/Z?LM-YVI.*/KYTXZ=ZO%^A^Y5_7'W!Q<A.^%O\$_E+Q=&C/
M2HOXY13EO51M$172OV'J@84,I"TY+D&97?\&?0:9!B]+4/F8&93AXAS\[;8(
MGE7*\@0,/E0+TVQ><?]Q"T(KL;/$'(Q@\GNB!I\:/_RP-7;AFU &&HZ9.^F*
M@MV86.YAO)2&%]N)2E&%SLBH-Y;BWV)V.U_Z>;>S#>B?#YRRR(_08BG=*F7[
MZ?")B5(]+),GC T?7]@Y=;IO>6D=EO1S?]A)]"+E\X!.4WV?E0,7K.)=4M%W
M_KW#\YDNTD??X4XD&C\4\L%3$9-D]?T! !7)D\]\:1WD'OXP#ELM<)VQN L$
M?VW#[P=BRK#X$5^4O6T&M(Z$)"HNI]J*[)-$?\:<'F2Z]5-TJ3L[T;<QQCKE
MHJ<V6+4Q%:ZXM>F&N_$1ID>;A]0 J5>6'K1E\U?;H&Y;O4,5K/2/$GA"XPV!
M1]RMCPS=/T^,G.BJ?D8YO\WWG.=M[N&6H;P#;I(,;^7=,^_(]F]NYCR^2CI,
M>S-/. ZK21!O)[6O$>^+S\M -'@*C*O)S[BWTQM[;61\-=&DB[)];BV+[7J-
M'/(<F]9JT4PLN6Y_[5%&-?&<13NKO<URR.D!^U2H\%VLO+/&DL=6)\DS%M*G
M F-A5NR%7IJ&M=,[3[D\TH1>?5G]\@'/((L-;R7#W*@'"[<$F\R)]*=/&:$B
M,2?L784125_YN,VM@,6%DNHWV,333D'-1US*?>F& ;=U-[$M#A=O>'1N%4U?
M_B8#]05VR!F[!D+5\'A[@$EY;YQ"YJ?'U\=O39\VR=#[<N$9BC5%7G(C6V3,
MGG-]]OB2WG/7!.Z2>#?80=+<Z"OREKZ%_@0HB3836B<!M$@7*W(%LHJ $:EZ
M]#B#R0"\(_-^ L+-X\,16V6@5O,)/0/:DER(M1XG$'Z2@6Y\9 ,/#%#S3VNK
M:/%<PUU,PG7XL)UT"SB:QQ@A<75;P;]!MEE=Y%.D6T[%\#EM%CT=E)WB(+XT
M 3+/NBG=]%ZL)]#]11!Y!_\V3Q>(M7Z<'</GCQ6/'S8RN!([;U'\UF)@R-Q[
M(U&B[HSPPV\AF"*49:#+:2,-\AZ80>9I(AA.#4 +C,81"TTE.,W>"4E!HYW
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M<! Q_SWU_;A1$'C7ZK* V$G4;#2]/0[9-@J@[/J:]P ]3'5X@BZM<:"$=7#
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MP+D/6[N,VDA'H<8*]V-)WG$7]]@Z*>_[B#A:>+ >.8MWD&,@AW#-:$VKV8K
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M]-*!SQ=UJCZ>N7WXT!]$\?Z8QVR_"M%/24#/O[M![[]!P5R.=/^0*N%]-01
M9,E 7YT)_T7/_SOT##_VZ"#\NX;_+J3%9RH-9:#\JS ^0SY$DW^L-7O(0#:'
MG.7)YZ/<C>^TY]_\#Y)!X;^.Y848A+X,5)!^6-[S8+DKIW8( _XG@.R5NV(N
MF3'M!18;=<E WYY#*1GR>]L_)G#-M\N___[_"&G3<E>$MW.6CR9(53_+1W\
M\E^D_1=I_T7:?Y'V_V>D(79*_[PDUA<4;G.'LVN$\]EF4M4DS$BD,"YSSX7E
MZY\3^\Z.WJ)HE)<>>95#8B)J,XN4XFFBL^(?^I;+\S]Q@B#;Y)A84IO6,J/2
M\3HY3.^>-$*0#)34#.ZGN5W*\:%L%UL*(G)V/T&EJ@@4,F-R7D$W\J>8<(7K
M6C_R<RL&L\$)1VTR'HV.?@Q2C_N8=I3NL59)*1VSHM<WUY&#S%6CFALJ.-UF
M^14HU2%VKOBKGV^WOO0.=W5SX$D5_]3.:X^1W'S7#?S'I67+J'>W<J.4GRV=
M+CYKN]WM-EI/S_ZUEY>9X"UJ_'" <M4)7*?2$_?V:R>V(LQV/H#F6IA4G;C1
ME\)"^O,]]YQDY5UV['/S][K55S'[)MV-Y=2<=)@R",_4?G+-3*N8L+S?X8>=
M/\^#I]96>[@-[(QZR'.I_XR'P<0BGB001T_)0%K"RGKP1Y2HYW,1X<TK[[BH
M]>\A/7M6UV0@CA_KQ0_+/>LY:;=@OY=M+X'S"*Z/K&-^1!:D@. G9[X]@F7H
M6=+1N0PX:UWPOM!.G.B64XCWX9>@-!(T=NT9(6_ELJ:E8"W=PPX4\^/E0]^:
M3/U\\'^<G7L0 Y^[\/+/-4A?Q4N=D![8Q(6!97%3F 3T]FEHGC5!^[U431YJ
M9<;[]%.^/HBI#Q03P%$?'FMAIT.!T#5"'BOGP'9[&0C:.3,W\VVP*G-T: 9-
M&%^7?#10#JK9M;6)M.=K5]UO"'X_=?'$U(D]G4XO9SB:ZUH.U*O^; =Q?3 V
M,2*6'+97V7QB30)S@F7U'Z#VMK=P?()HL]0JM80'C3'8DJQ3K,<QGN Y;Z7M
MNAO6S8ST,^ #T9]8)PU:9AY86X:M^2^+K[L=6$VG/_(=FI&$_6#T$VR))%EF
M3)R]=C\\\_A*N RD?K_53DWKF01:^ T\=T$CIBT>%!6QO#+S#=R1S6P="B7<
M6F3T2!5NTJ=:9"#K AF(D2@U(5ZGRT!Y?+GK!^3A5I98N[Y?:TI\5GH1,NPZ
MM *9L&/-R$!6S4MP!&PF2!WQ+U<_%]DPQ*L)4JE<1"I[H8,*\WLFB)\(9//Y
M,<Z4=*ULK8*0*^GJDH*Y(Q<&__E:.[:!/-P;8:LK,*!,8 "9T&7FAK;'MKA[
M9S9LK#.D\)1^:'4,?#5FQ5]*H#5%MM8@F#PE#:;?<8%"_'+/)FRA6_^VC+)N
MTX2$\%&760='?;?FNWHWJ',C]ZU_FD1IG+SQ:V,CE9;C6F]F<</<_%B+87Y4
M+=V\.]!_;W7AZ*A!1L9G+OTW^V,T:MU+O4\M^G]4O8\J2R57DINS";Y#;RT@
M5!\9J =+6)HE"-QB"CC2:*8,1'"5AVH%L2::0!3-IOW]1&1IB[^(LE8X:][Q
M]'_N$[07(W<Q5^[B4AFHW4-S(ZWPTAR;'G^YD4.>CKKVL&(V$Q%8CZB>J5]>
M:VK."!5F):)U16YLE;(\QZ:V_A:A[]#QT^DC)@.-QWE$,/"&Z<C"G0R)(12C
MM#3?BR\6SV(*YC+5PZ6)/)WZK'/9;)%+__S"U28L60LUNM=!4E/$-$UAT^)2
MO#.?K3K,OI>!B&F4X$S&Z!"-)68V_^503"R3_>T&%U=$FH9+"QY^JJRA4T-7
MOACFB[95K#EE51J4B.X7/)BR\*LI&;TMQ(3<@/9_VA/79KZ]O1K]:D,>:$/Z
M_$E8^^G6E@4SR<YO4D;?@*GT7QSA+$PF?%L"2R1PZ9&7!MKMZAN;BH! WUY2
M\P U3?4;.I_#OE[_J:IK-SMFDJ3\KC!9B:V4/N+Y-CF&8OCT&J:HID\L RU8
MV\&I]:--F5V.-0T#X1H-OC!X56W>ES6ID*?O8ZEO>3T;E5/>4/KI@2(*A77^
MG'<[]T"2#E(G_**.HJ("=639H6OM&^5)&.2OL7PIO))6Z#=73XPG8WYA#Z85
M3[/?%5ZK^AA'[[<Z94;&%/D:C/Q2ZYK\FFIP\1?WH5V.FVB<T+UZUC6.="$&
M\U4&BKE0545 -S]X'4Q'$)=I2IB_1!1%][WT( !N>X%TO9X]@2BA\9I"6RPB
MLXKF0JS&=/B?,RFE04*7]A!2NT$N51V?\-QO9':U%%,89,:X3'0<,)Q@43.;
MEHW^CL>XN%@V>LWG;_U#_<MM"A=4Y!5Q#"):(XHOAN /#X4A-@+1'@+X_<KB
MZEX3RY-&*_I/CH8KN? LL56;:OM-<E +KA?J'@Y?H;_HKZBD!$]AQVGT;.1.
ML^36YOW]5OY%);0B;^#!N^ZIO-'+ H_81M]Q7T_[X):K@>^M, 5 M.^#C3JW
M55V0Y>A;=2AD\<4KX+)6X50D;:%X86R4+LW,_RCY2_MN98\5EV!#SS4.TG*(
M+V9J-SWRO73;7/7H77O_NZ8.T6>GZO+LKV6>*(C?%)!IK^F\X\D=;\8UH0P$
M6V5!+J9]9=01Y RH^/E_\, 5IQ?>+:;=S(H+/NTZ7\\-C^QUUK;72;WK-&!S
M[<2&\9OZN30!/,'(IS411="A3,3\A/9GZ@F5[+5DH//T*MI 2>/3JS3;?NT'
M?6O=SX):V]M6+W@MB*Z6!L/+6C#FJT8'O\U\11Q;PO\E^JOQW0M2PE(9].\G
M@EO:UZY%Q!!!GF,Y_R''PO[1S8#KV9E/>09F2OZV=:)KN;=6G4<^?C-7F3M>
MTY#7$7%VL?"NJUI=[=,K.5U?*K4OOJ3?1G].\D#\S3>W$6MRTV;_.C ;11<%
M@0E4Q$YL9*MYS2R8!][=^?P2TDP].):G=-T@+Q/M+G(9-#)!FTF9S*CSN_R&
MV:F(MDAO]Z>F"ZRF%-5;?HY[E;K *82MX+LX9X&J=.?]SECQGM*@>MC]%?<^
MVD FTZUW\0JUX46R/=H$Y9W:]O6CM](!:R.G)@NQ!SNF(TY2C'GNY7!RY;K!
M+,RZ7H<SOO0I^UL"[:^'\_+(IL6%\?J$MU^"+R?QC,SVD#]_F;1Y:-45'9?$
MVVQ6Q=DJL#-Q?)QI$AZ@MA/(.I/LBU':'*Z8>N6DR?-%]'R8=:3SW5<H]_K1
MR1PHZ;DG<M4B."LP!)Q ,T4MV"X.OAO[Y.DU"E>:K"ELP<>X0]ZM?/&6@>1_
M#A<6_]J/=4\KR7\,5(21DB^@R*<'I8N;+_>%^Z2:G:!.U3C<:Q[\E9IEUV]8
MA *4XC*+8Y"WRP[XO2[Q&>TD!2FA\O^11IQ7/&4@2U%6UHI\S/ZZA'ZA[!3;
M\#'WC,)SX-MG"<-SW"6EF;'#@Y7GX2&:&0_H%9>FH7MK'@RR2"Q3 U3;6E-\
M(0D;:M,7)I*<\62\B+%XM]E4@VS1)UR-M0KD]F@-(_R V[27'4]C)#G//V"S
M6O%'^="&RQ%H-*70H6<;=L26OWK?H.!E30.]KJ8^Y[R#SX>K7PUTGUY\0W2/
M6UC0%"'QN5 9:,8RH?"OH_RJ)&=$GLXY;C'_.$M+(5-9'QF5,I"\<#3_=>&0
MK/?L%<-_72M)B!3.J:T8H,[>%B>7WPB":@T:436O<-XT)HWY"ZU]')NH7^]=
M4TS3[:%E1B,/9#M2_IXELUA7I".$@W*2K\!?^$]9XG]9>-'%ON)*4VU_0",U
MS;F1WM!([?]4%V<43#ZJ0TU:FV6SBG?U8 (,)"F1H>T:-NB#"P7G_QPZE@ M
MATP1;LF59NQJ)3OAS#]U(>V?RL'%/[')'GU6NEQ):#MT7X-H8QRW6]MY*+Q\
MZ<#LW'R4>WJ@J30_7.ASN!)C".U!;JC^II+Y]6-73=?=/3H!MI-6@0+M%@2X
MWR&K/>I!OO_&BFI'9596O!A>.3PC/&:/5'Y7P[,<77^698#3Y<[9-5-].#N
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M_PH$4GP!(Z<^\?DL]:PV-<RBE7Z)?3&J-JKXH_H-B\8AUR!O]&(.)H;[9RM
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MLVR0JZ.:FKLCCOW!4TA=]^/W6:-!6/V.9A4@CN07A%=M;,JS-G8EVK+F36/
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M;&Y2N/R[U@T#)N-%_^$=J#$Y^-DBJD_#UIXV^8'4:XRP!W2K$U#:_8'3AHC
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MDT5$&+GO J\R-H=/XEA.R;.<@U1#3TJL:GO.>Q%A=BEH'[%E#T\<T,0X-/_
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MZ>%CB:'UF7D/.DB7N,V7N#_V]PUX=YOCYOQ834M5 E0Z9SW3F5[4(M5^:T8
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M)XN5).,F<(<J6SP1@<D^4]WCNMME# &V,&^YV.6>J%T6,:DNAAX$2=GM1-G
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MJ#U406GB=*P7G>3U\@V4V6F8Z^1X,B'?(=@&?A0\_T!0<?WZ51*11+]<?OW
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M5J'>2<?\P6&6:L)#Y<OMX?NI5DJUODHT1'/":@*^(ZH3$UKSJ&X6J/4T)/4
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MKZ"0!5=*FU*8-LTVX[6@C3=$,?MUNP7@X5&!#71'M4H::VSZ"67,"8K-M ^
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M7Q<5LFGF Q'\OQ9F/J40?+IP@;G'GZ.#N(L_C^"DT>MR$996.2RR42,G-R[
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M(2JXD<8MSZ\M+9JD/<JB-+]=\*NC;SK*CK) '"!8VH0RU; L^?IT8$G/#_@
ML^!T;ORDJ'7*K^@ ^@2K@O%, RX[W7&(4%M*B>K$+9_5M$/_-U>_;V=;U:>E
M'*)W6[S7+>Q-"JY)L!E %B%9B1$1TP%)2WIXBO:B*FW:@[0*C2_!4:,%D.^3
ML1C">.<SC87"T-,/W-/9=D?#?OS#SS52_93!-G1/\OAK\M-1-^0.OY\JDXZ3
M@D"<N />-.C6Q8>S#IF7W"G7HJ!L]2):+%%L*NR^(K 917Y;\[+NWDGT=P4
MKD4=_G+A2-POKZ-B"TDVC[XH*K"_T0BC@OV+3[7!P%PKS0J,9H&5>/?.9-HV
MC<[\)2!L@EM2\EM"'4%B:Y)RP6N'<DE/[ .BQO' <6-C"'Z:Z!.8U]YB!?O-
M<S-Q:\'DFSE57_)LRE^Z]H4S6H^7H%O^D,%>EU(9/U)H[,HTA,Z*W)?TQD=
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M0,&-*O0N(MJ6!QRK!\)5MTO*J8?YO=1]*RK*BW"/K(Y0;$;2;,8^4NJ_[?M
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M1&QG_<,0GZ/ 3WW&7=//@!4D,)"26I_;LQ)H=6G1</S2R$#VBH!ASPZ?H(J
MOSD/X6Y7Z;VZ]$M4[H^;?'.MEE$O[?GM16OF$$9S;VD).A^B"!)1=7-YB_+A
M;%19OD*6RS!#CKY@MH??;G$Z_%64C%]-PPY>M]7+$%0=D!QE#2%!D$W=S*$]
M54Q N!JLSHT.+U:V8%K<@]C)-)QM85!,F<6T9K1\>%VPL-R'3R^ 3JCR(%C
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M!;Y&%$XIQ$@+CH]>?ZNT(ZOP'A772C<H\.DUO5PBSV^3Y_=2#E\NS>D+Q?&
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M?Q5XV]<,%%&5H<MU\.4(4%K*\#\"=,61@4< ?4X0<0;:%,Z4EB6'L_A!PD>
M0XK=ETF!3;9M-0OZZH:D;.8<(B>@V=_= Q*. /&K)![FB<!IUN\,T2/ L.K6
MWL!R-)ZRHSK?RGJ93FT] G "DY$,F@)NG<&G>K!;7]_2"J)8(U.^<CEZ?^'D
MX87?MR2=+K1\FM;SE;_6Z?BSY'4.-((ZY8$[ OSNY\CJS#X"_#15ENV:O67^
MJ7<#O^&=$]+$-#A$0B 5-#+IQ!NK)"S!SR00S+J2RCUY7>K@0TLED]V'-#:'
M,0 F _E9JHCA(\"% (0"XQ85V?T$3%@6PFH47':@]N(K8"5.#6-?]"X3GQCO
M?ZO>UA+*K>[)#V^R4Y_O#(W0""N+L)PQX'L(?!M*,ST"G#A[!$@/H/4= =Q;
MH,P_&)>@K39P9<M0&%*QP'BX=#4./IZ?_WG7MM@N(\^_7ZIFWUCYQ1"Y4(@[
MBNJ90IG1NW%61B3+%SQ+I$Q4?"H"HXY'5^B;6)>(!*Y57#=WJK/+1\M6/F2+
MW\_C7P/_197_MS29N#=?<C!%"=@)H/1_3WKJCF584.\*A2&YX=Q*'\^5("]4
M!=.>.=F+J_C!%8LTZLS*3=+._BSH;QJM\HB*;%9]^.1LI6+?>D2LD.+@E6\]
M;G69-B+\WM5.!0N8ZZ"P H5 RPK;JKD8A:!,XP&U)-\DM8]7(FRY>%^Y;1-X
MHKO&0Q5M"ON5^=T$]LQ+/T_(CR<&5UA:1/-EO+RN.G\$.-BGH';"5ZPPWC*$
M;I1HFS-F@><X[.:J\5]CEX*4WU$Q2:ZI!H4\/#,+BM4IS]6<:-D634^N#=Q1
M]OON9V7*TM$+)J<),DRHX?%Z$>3VQVPK>DF%:H[6K\;ZYN87.P[29RE<UR;O
M%$4)O]3UU=7U(M;7U<<N#0R?5E8FQJ@R3&F99&2RQ'4JL#LMOH6YGM#F1JJ^
M^5W<TZ[=G4<);2NG7/TZP7*IS[RV,5546<NL/E%46:=K:6EX^+0?,563^2O\
MUIF]R6DZDOCGA'8OT?_8. $[MF3ZQ(Z81MB]/VL"^P(;R?$EC5R8&2Y%G9K_
M4#=2O&G'NTM],) ][057$[M"2Z<+2??3?#L+!;$Y:YG>TT.*7;R]]XOXJ==C
ME3$Z#K8.9^9,><[(3!Y&3,@F]VC?XDWA6=,;5Q^!6Y X[<]V9&RL[GO*N]9^
M"YCYJ[:_?.*CVM<8TO: LO+U9J>26,*W 7.;QU":C"R#3PP6#PL_>,$L"0'
M]0QJFBBMQ-0ZOQ?89V_)YE1,\D-/EQ ^>BOV' VQ"B)%T*OMK-/H0CM9N2/[
M&8!?K[]^>P\( 80=>PYXK?#WF]<G[P$ O_T-$ -P ,X!T-A5<U428SKYFT].
MH:=5%N\:YFGG+3-BK;"G8F^*<&NPN:TEUL78&FL1;)JE4*"-_#-PFMM]036+
MH/K^UE=X?0]I76"7^BJZ6@$':2^NF10Q?F?Q;#7E\_KU# L#>,7^I?_;E4RE
M63/XM[)_@QX"8[(1'%1+@U(:QL2QVHBXGEK4Z/!=]30LROZYT'MYZ2_/WAP*
M'G1(CD*LT^XUI,JO1/K9$DPGE#H:BEL?[?2)9I!KF[.<XRNB>U>V>CN O,9S
M(5M&_4OJT>F!%>8^UEOC&143R47R!E_)@?9.?6?BWY.];O-%]UAE*NS[*/8&
M9J/SW04SBK1Q.L')GF<,@Y*@ZT< :O;*7AKK&,.0*MNUG/!8:@Z8R%"'3?W@
MO;:IA!.]?O4GHJG$A?_/"0UGR+S[6L$3D:=*JF^M8]?D=TE,MM:( K-%[E8:
MH1ILS'S%TO0MA1UWZG $QQ0J3_H'\3S]/GCH&!"-<ZR8/T^S<FI_CGS@U*KD
M(C'E+Z$8ZRQJZ;T/G<+2Y.QV-%^S9I#<B/&B'LPF4%2/US,41-B[,'QAZ8;M
M,<C:^OLER1:NY@9EB-\(9F' GA;I\-SG&JVA9:I:4Y4,[2X4G6X#DKA]NPKE
MQU3W@1=@X5;MH[@A(>NF2.?;II,:ATMS![U?E_Z0D-]=3R&'7KYXT7+@-G '
MGJ;U >Y./&OND&N%N:U1=-I(_%9!>^-QD1+IV*&WK+#5'073G%[E#L>I3KM0
M^<'"IF^G_++6)82HFF<1T.N3@]LFX#.0\ /[CY<SW*$JO5_10-^3 WG&+A-U
MUM8RS6P+JZA:@.;.5C?%O\I@\R2*F&?2U1G>TP(=4AN"DM/$[,3ONL_683\(
M/T.;78G5YB0K^A% B(88$+QF9\X*CV_05M?IJ$,ON?@"FW&,G!XQS9S PJ"$
M_GH3.*Z\X[$F"57;Z^JQ7-=#_,Q2L+&&^)+0EIIR$Q:5YD'0408(]9=VFA)A
M+0>^9_YFM=+$+-))15)>YYW/II]EGB\TME2:L]8_GRQC82#PK:_A/\]IZ%_X
M[\.^XQ)5-4[O<LD2+*XGEY5$3#ENGCQ4[EMX:?)AB+-$%^^4XQ#8LG!N8$IM
MR7C=0*(AS\+<TD?-N''>6*K)K_V"LZ-*P?7)?'G+Z"WK"KFN IV@X/QUF0S7
MTP;732S]Y'KE&^>,G1A*S!+\JC;RK2KSI2D/4XKV#=J.8ZS0YLEV7?A4% 62
M-AO9O7RZS:^$1B>T\$3AB3P3N,7?:CS'..)#AH#D:R61[F[E0P'<9=5GKT%Z
M"ZYN0>XVS3DM>WU=:<^R][R#+]DZK!&K,*]V^;W")+#2/.+@4A?ZNF'@RY\U
M//8#RKVF0]?2YO1<N^Y3+B*C7]T-$^5]UO.)TJH0 U=12;FK+YE\!&C\MOEH
ML@1RI<+<J5K?H4=78]<CBFTLE8'X.3].X3]S5R)GKAX!V%S;O5KGO[F 5D:5
M,%+DC@""V4QX'"LCC9!&^]V3D8?L!=&5QXX 6QQ$3N8<M@OZCZX6$E4/9:]B
MZ1S9K,(WB";R.J/PG,X1H*X:R+3[ZU</BD&__ZO(UW]%6SW9Z%?*F=]H?J2
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M8LV3"** E^>:#K)0!ZW,5UCD@QO!!X7,G Y-VCIQ/5I/E?KBU MJ"9N7$%+
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MW _\U(,^_: YLFQ5S\Q=\S%LP4#F,+.9,B&]\[#2IMH<-"PA2<VZ'%]');H
M@['/[./O8974'V7YIMA<B.%TPDL(IE@W.Q\J3J7A6C'F&:L[T-KU'6\RS[PH
MJ4%"Y*U0KA8!>;;?LP)N3JVR4!D2,LPRNN(MXI1N)-W&DJ-RO+A1D^2S>?7]
MBR6?'_=,W<J<C&0/,BGT]Q+G:78K6&ZX'N5<G"=QY#3,U*1I=%]9HH>3X.OM
M?\[%0:QA.KPI6*,I-[4H5&JZ)879,\3<^;:X8*9^V/>KW@)<GYG-XH=%$HT(
MK<JYB$S@'*[:?TTNVYX:$/_%+=FG0WIJ-1EX[2?+?O)^M/K-LDW*[*:MI*ZH
M*&Q\29$:<('Q1S>UPW?PYD31\]5O^8\^2F&%;+8O>@B7NXSPN>A8/6LAW//)
MN'%H5V'W7?_$RH"8;+;+VQ@G\L73IL $VY=E#1F!]A&0K9B+OM<5=;Y;5:B&
M:13=+4Y4_'9[[W_4$?;LHJ?A&-R@U"?W5'O9K*^(3!-FR5NG-[W"T2 "L_78
MHRA &OT]YGOI%F5ASGG>5$GHO$F*6-V=C2V;>"S9D\6I2C^WA7\KU,.SR\,]
MO[0%/ %'1D2$KW#[0*\2&[@Z6]9^O(<LSON[5GCSUF4;MC0CU9T_O5"9,O[.
MQ>VO"]HAM063U]\O'T>,XCGA=I1TDD#:7(@JG\/5FY&<AJ&J/-NVQ-)1AG'Q
MH&1MTV2#[U#VM9U@[N[[D5PSZ^-[*KME3!Y"JFXWQ3!49#Q4X?/,IE5)GNOE
M\,<FMK%7HP,"JEVOH^64;^"T+*/SGY1Z@DGOR-&!#(=,DPQK^;57!CK-_C(0
M2(GQ"+>M(Q-ZH;A$]?"'A5551K.8+ .!>(]JM&VE2S#<<%-?2CLF$/RT7E-E
M(5)VK-]LJ;JWJ6(2B-_;%AWM1U+ENM'](\LT1B<ENJ4P?MR1VRQ &=DP<@Z6
M=(N*C-L'"\#<;-Y.ZUTGW5 @.'["%>BXOZN=U"@PG],=Y*(;9R<H?ZDN2_6:
M?X9[_Y?P>= SZ)SHBFHJT@.;Y")/,Z(>&Q^<TKL1(D&PBI7GNTO5BOLRV)%"
M\KOX>22O;&NJ<DWAB_=#?W+KV-X)2$S, B^BB:U=+B']1VA_:-*!LYZDFK=6
MG1**$RB6@'YS.9B>Q@EKM<KO5XV6S;7M%A%*"I".:,B_VH>AE84G#7HQ;M_H
M2?LBH1IX333A[1MX "&Q4%;(E /,FV1OC1:;5SCP":%F'"(3$KHL&K+RO]<F
MC+<62L1<1Y@1L4)V'X(Y\V4+KQ,IDVI6);&PN$&E5K7UP$(1C'J#W'T?F:;/
MZ 0?)/?C^K3];0-^NZ^N3+%__K'>_Q<!O<*:1N&TV'39;2]J#M\+O+@YW;*1
M9%E'68]AJ&+ X@7KB7"'2H.(H+*-T2V^VT&G<@(.;NA:3N#$#1TC2SS+O*?K
MYV>AB]7M,</:B?N!#0JD(('+)O^6Z>%E>]%IQ?Y6F<6L?IGYM\:-+S;<'6Q=
M"SWLQ5#R79-]'@Y9"JD\QZ-+!G<52;Y#MPJTFP>N1#T*SS1)C]$)LJRP#(QV
ME][_7\A[[Z FMW9].&X+(B+2$9 H75HL%"F2;0$$Q$@O ;(!!4(H(BW4* BA
MLZ4J56I$FE(5D- "6]B($(H$*0D"TB2AA$=2^,5WOOEFOCGO-W/.^;WGG*_\
ML3*99R;/>M:3>]WW=:VU[OO:12\3YGX)NW<Z*3/<%D0)X&,1^DV>#N$HS&F4
MS><U\4Q/615U/[X;Q#72MW>)CM=+5UJ(+=ED-SD)\$=H/P90@6VDT>*=D85G
M:)HYU)O=>T<7S+3(D=7-SN?#'P6(DI@!E4,8RFT_M^][SA+OJ'];'("$<U.5
MMQCP20V\P&I.ZW+\;HHM8F+W3$I?<34J+':VZC7BT^^6UWX41ZKOA5@*WSN9
M,23S)TCUL?)V=7^OMZJ^YP.TSO,77ED1EG1UOU'S<BFO)IGF]"SN*/SD5_#.
MM>%+48."?5]OQG[\WF82ZFY\]/G2*;7)<MNS3A:=+EXUD:M"#2;A7C]^8E[A
MT\!49\A39W&&>P9#GZE!X^O=,-,B<"7I(94!F:[O++?VAE$1Y4T1E T@X4R\
MUTP-_.DSJ"_H793V:SU@ONH U*+0.^039 7T!%%_='-/A(-Y(RZ/KD= 2J;J
M_TJ/GZ7<&HNX677CCF?=*7SMZN=&EX6MWH"[Z1%=5#C=@56,\4P::P TJ!E]
MSEJQ%2);:\$.R#?4@LS9/](&Q]K=JO4+R$Z7?^\MXC!%NY8_JQ^UEJI<SF05
M +P<*"=$RW[MW80A02F?\LBF\I<&_>?QL51># (-/[I1IX>H=9C^[G!MW4YI
M;FJ?+TEE[EP_^F' =M*9OG93#HX3/:E7F,8;<>R4$@NU;1ED%;*8Y4 <>41H
M [\9QD:ES/*,9 9X?KN:3RK0Q)U<[$]$QU6_]\X=&%>Q>BCP^L,PZB9DD/IC
MR[)2;+MAUX_-'<"P!+;I]:P77,EL><(1MC85D:I1A-79C%=5*2%NM#N0[J:0
M9Z+Z>^4')A2K52%+1*8IRJT*_J4L>/B5'0QSM";E U/S853*9$;$:> \=9H>
M#/B\C+@ 6+Y4P+:?)W\K>/D$E[UW;TR#9\JLK[1Z32>E"U5@:C-6:U_1VOHB
MNB2^1E6ZZ4U38V/,!(I^LCE5F>]Q][V^";MD)R4A<GQU7M1HF1M2'REW8=I#
M6TXI>SG=(L/HYUJ?=IQQGK\-YL7#6<>M?*Q$KBM-V\9)L3NO>W[5^E$Y[,MH
MYHH+<0+%:QA0&FMI%V:9I>.?H5B2^$/?\]?V%.W7P<^&M$YHBD-A7DV$ Z!+
M7:.HO2VSZ\BI\)I5HQ:FU7@%.[A]O39%+,:W-Z6O>%NLVO]P;;R<A_95\ZV(
M4T]?)9=M0X _ZKZTL%-"YM/8$IM\!Z"MLY$^!H_&.N=??[)6FJ<V*1G/6E9B
M2[4_DB8SR[GDU]/'/PBGA? 0),V>](QV__$NZ5H7V1,G?M5;S>^Y"W6GY-O2
M @<7W+I O&OV\15!07YZO#DBXP!T4IC!(8HCM4S^ U!/)(=^L6^6LL64Z:H'
MH%(G0.8 %,?H.0 QL0BXN3DK+P?S^1C/ 8C;$[/54,H*6.#;YY"] Q#?>]P!
M2",4\NZGPC_[K1'SHNTZ_ !DV$8U.@#Q[F$/0#]/=327I*U_;6,_OH@ 3&\>
M@+*P^\M]X!UK&H0-#H"QO;80_IT<0F-))<[O8;]1<=UUAP 8>3EN:<Q7(W0'
MP?7=(3@&]W6UQ1_>%5 Y U_Y_'N.[3:<Y "_MMC_XJ&/CZIJ^[ TZ?C"YO>2
M5O)QRZ<N=_EQQZL,3R<F2V</7$HTEIN233O,G]#KICQ.<%V;(+BBAL9JXGNM
M"\)V7YN&CE?9<'RA7S5.06$\5LC<RO6_?S'1=MO\ ,2ES^D)H@_!=!EA7(N.
M ECZH]%:/5O:)MV&UOR6IMP#YO/^9C7>(0/(]#I(AL%ZP3QH,XE!08 B6(YV
MZYV5?*-U2;^Q\.P84Q=W,Z0.I:/.M6];\A@Z;,GFCN3PDP-0&OU/5@M^/H\-
MXCQ[LI>.5N<!*&FNWB,&@YI[$G416*;]QF(JDS<39N6!!O+<4WTQJCKBM$H3
M7%D=0-+4SL+(J54EZ*4UQ/MZ:C..POURS& 8"VG2HF[4[2T&4-<Z6XMZ$;Q,
MEZ(>NBB4/P(R[R?&U.%01@'3)Y$/YA'Q89N/F>:4.;Z7<63OVG6-@A R[LDN
M[/(/TA)EP(<?TZ"F0AD+LML\ &7B 8@'D[]MWH@I9$2GL!+88+0%A)<]/"?)
MUF?*LIJ:A@68#ZG],3N,)+P$D#'OAV4?6L6<W& KKS2GX4PI&VJ]0!UB9'G"
M9HE/U&XE++85OIK3+*Z1C87T@:F_STUOTK^Q8C'S+W/ U.L80+$L%YO@]J9E
M<@<RM4W0Z:AFGV^GBA23ZX[,11A2^V+)^#,S8C_TK*D0BE;/D-+6)OF;3GRD
M;1?I/8=S/5U?#X3KIICV=)P%L1?4-[%LGE$]?TI=@H-?W$X;#(R>NTY-BVVW
MI7R9/P ES+XGXP\Y A5[7;G"NPL-NDA]\0\T?#(D,.\X'>XP"^3!VVZS1RJ=
MC.5M"0<@<4""W-+MEPCFUU=P)-DS-:G@GF%Q]""%=QQ(_C(-*/1(28XUU0F;
MH>OK#2=&O@?;#NG\M9HB]L =E.&<A'@";5D\ "7BYU\C1'<1@!RL4S7 8O0
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ME,V:4S]U=P^0SKWM0B%1)^]=%U"T2A'^G8)'TD+2'C*U<FY&7_6RHGYY3[Y
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M+$YG1N1ORW<M_W2&*/7?S(U3RDO,-1XKMM'?E320IU<9EEBF&=MW([LMD@Y
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M7__4>$W0W F@P?#-Y ZO\U 2?&XEK* ]Q*;AU1_UMY:T?QORNVSD[Z/ST2]
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M^3V+DU:+L/R9&8M2Z'SSAPX8$5*YMYM3R&2\3)E<>K'*4P<Y?&7UKF]W(9F
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M*FA8.9P*ZE@&4^R9#O3:J* 35:XZBCAO!Q7TV6-CJ(\*:C*UV!\_%P=[XC<
M?OH@:!Y[]5>YH\68JC3QJ/L-+.QEWEB%AOP/(C:V5<CO^8QE,Z;VL1RI=!Z.
M<ZIO::C%O'W\9^R-FX]S#=?,F_:072OUM);33T]J5DUN&+Q4*RG+456_77[-
MNB147FY._=FQ &+&QHZ,CE 5,'Q77\K3D>1CN)W&^4+*)";GDRIKU;J#R_-I
M SKYO.7@%&'.-=T,F:BDSR1Y=_R0W[[WH\^M?F<EYS-?/!.E;^$/LC\)VZEB
M>_)+G;FZ,EJ/N%T^8F7K%]ZI,I\/_[RF\F=+@O@[)S?U?-2EM.03W+Q.X?K3
M!9BF4X!0%4Z?'$D^%\O@$LHTF'_AZ>A/(%JZ???*?,VWUAN 02*@*UVE]Y$R
M@"*X5$BI.A67U?[4#*#IB>!XTB@I:B<U+_J$;F6UV23UV;U0WH?E,#;C;$P8
M?XC9&&\^YV"Y3GW[C:1<P?(AB&^KGA7V"['I*T6*9)",##(S^2/EF9\J;*Q2
MN=7)O%"@LSM9[, 34+W#GVD-E/PJFLPQ1E)!%AUHQ-5FW4P"MCP[+KL6LC5T
MJMCF1071!1".0LB*I6W7DE4%$'XX*BAVY_6C9V\U%\\NJ.EUWNCQ?MC#<# 7
M6I%6L>'<$J8V(DVHZ\$"TB_U#K?!AZ[ PSWP@H;'4G:T3\2/&XVWO)P680RP
MZL9$R@=GGV*_QCM?(V N;S^Y31[79?GO%*9M;,#=W=V=$@*B(W_Z%V;Y9^:E
MP/,_I.DXI6@Y)V@_?_WJ^7,)'70%Y6)0&PJ#.C_"_:&P[*NJ6A2N9I'>I7C6
MSBPFHE'=<]R1>=I1!'<WG[N2SF47547^:N0_,=;R0?Y12]!; R6J"F9A?NZH
ML"SFI$J_.HX"C-/E!,J9BEP&ZB.EOC<H-HO9DY%1N8??66;0CD[EX[G\\VG?
M^N9H+OXI0)5-]8FPL7ZA*V=S#P]MH^93]PW3UKM!<V!,=H_:TPW(=75E8,>2
MW2)E\@%QHEPZF"SMP!DOZ4:^CX=L!4KIW-2T_-S24M<T]NFBW%&UGN"(SMEM
M5!L[Q 45O< ;1(/\<UA='/&F)T:[G0KB6+<&AR(1!+KT6 WK,;ER1^V XV:U
MHDT.?:$)M&*X4&V<GX=T0?T8<X]=357:*TQ-U6/**^#:[X( Q-;,0TG'PP0
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MJ\.W9*[KAHRF;\D\7:S6BDADE&@%5 G[JM2.S/?1B]V!9+;OTKM8>%6/SKB
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M92QFZ1\2(<JIA:7<-A+CT)!R?BS\6?WA$-:4E_=MW/-;,NZ,?*Y\.?M;.MN
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MS=@/*5]G1].SP5?U^@<3>G<2 N[);S2R=?]TI[I" 35[VI8D)J?9%P 1KNY
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M[,^;NFLR;/.=\I=0UD]0P!FO*/S#4@"9PXO^.<#"/S!BH<OBL FLP)[VU;]
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M,7SCG1^=+ \NV/$XOFIQXV?CV:OU,V:B3_HJ$,%SR;:62;@XBC+<7V+2G/V
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MXZ=U4>69N]Y?"&'<?Y[SWO6 ]'N%5T@@#0S@)_6+"&UA4V@0JI]$YO/_W>(
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M(,6;V: K'/"3V#R.3X"#!T&D /*)AVR^<)Y?+:1<Q3V2./J2/-]? )%,41!
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MJG(8F&OB1"O"THV.7)U*:LU=./OE[3!1'Q;-0SJ%,+*^FNO;B\;GHE(O/Q!
M'M FO?F[2!PG["C!OPH,ZDAI$R;UZ@_.C9VKT*X;S\'8'_WO]$V3K_+[-6H8
MW]"=";.^4KV^T!5M=CPOR$G_J\2R"/L<[W&+*D<-(PF,MV?O#)5O^N)U83.9
M2 3SSR?K>J]*H_&>_R!>+4E[3K?<]SAQRCMD,_#N]<_&>0_\RZ<^^X7*1_J$
MRKNW@V3-'L82T_#X:)ZWV]VGEJW'G.]6'C\YA+8/W?LP(05NQ&A]E-\Y[Y);
M975_4C[AJ>[]P!;S]G\PVPT,VZY<*$[UO *3SNH\W\>T:>JF6G5=(/KE='YL
MIMKG[OZYN:Z]9"\3D54:^*M0YCSR.?3=R?]P\^M_\85\C^#*3/,1B<QPWG X
M[X+?7\0E+\I#/*C=R,6+=-,X+VB;+UNVGH 2<( -\;<)5%D(IVZPX/Q*6M+H
MYCCR(?Y?W?Z_3A)CM86YW9LR5T@C-:[@6%O96KQ2BI"43WFW4>HH*P<YXN@^
M!B6=*PKM)(J!B6Z ::<Z2"A%*UF/84P9K7%4PU#%HG3ZDWZE]D:R$LL@CRS*
MNH#5 #;22>;.4RX3W>$""$KKF<3\5L9JCP2H]V?![11EKF",(HN[2)MT^\9.
M^(25XL_<1-PFP;;R)[W(^<!IAI$0<=R%!_7A5, >C\8QLBB*LI>L])VV9XIZ
M9E2?JW. ];&.B29M#/Y:";#.L7TS9H!=_;.%%M>NCKD%Y+-)8*, LMV41[;2
M!4W9=X4?)7*#A^:!_BJ\>+WYC.X<;)D&""#+L07JC;>Q(NT,!U&H7.B:-;W0
MI(=JB-[H-(N]4^T+QI"439AVMQR0K)14C"<G)N99L/L4.8<X^[W)\6OKL],5
MT]^]9L8*@R(KOS=L#GGU5)TL770YM5$0;58?:V)7T15DI(W-BZV,KB6TG#1^
MN;6(%3B0MLPU)?@*IP_82&U!;K\[A(X[S0JZMP[;@0Z_,#(B43>YY*<SR%5E
MSKB<?)U;JS%2A5%B.*3NV!WBKK8"?6?:O0JJ?N/*N3 H7#D$?94K.WSVK7!X
M*-#[ HA\!9J,=P@@6Z]1@F%3X3YU34(VA%%_":JZ?C*F0'LX^Q<,'1E0R>\W
M!9#4&8QC$%W)6U]* /G[]0,+TXKV,KL=9;S,\R?V(ZC-PB],X>]&5]+2K60!
M1$)+O.F4D!APC8'5GLW5+HF="QS8-=77_%X6Y1Y6$7-P+ 9?O]"'BHEC4U(V
MY2>(5]Z\3N&<$@U>UZ5\Y?!WVW(.X-K;Y)"-O?QQ(6P^1YS6[/ :;]?WIJJ(
M#ZKS[O./@.35LV XW;Q5]$S=D 7B,E9E25&N7*BB+C/;#&+];ZYG'',I+(H*
ME?U%<.^\F958.NL5HFB0^1*Z,"L$J;N&*)?AH*[FROH<$QCG[RYAQ;$O@R(<
MXZ4&$S9-&AZ$!#6_0&66N?$LIB/*0]H5@'9E9U&D6DX3_-"J]*S6&/:;%D<Z
M[&Y$0S,#L:=? -DY\ZW3/-YS]8>! !+3HDE'B($2';-*@&W"+V7-#K($$)M8
MBD9V%.W[=#7L5ZL$E;S_DY[^+X+TZ<%?TV<9I.%?K;J.I(8_;SNSCND3+J;M
M>W!>9D^"4-2S0FV]P+5KDE:GF(R>Y7G.=?Y[L@50WK8*:L4MXX@+3<0.'!0]
M[C023E;@N@ QR>4Q%9\QRN# GL3M/:DE0-E(01$ES)\8'+LQONGWF$'9MR =
MXI6A<B!A]30+,=7(=A7^0ID0?UKM6X#6!JTXSE$F.>SMO$<DA!S:VYGW(B8[
M00"!&@M]W)V)7/ES0&;;DI?[/3VN--"K?WINO(.VFWL 0-PSYIG07"FC&%<<
M4T)V E'V/0)1&CIEX<6^QT!\3TN#_)1(H.P@*V$'H+NL]F-$07-Z/&P[1A]T
MG%L1;<-N TB)GQUW9-,I>R9.EX>,K?G..D3B7LZV_,TK<1XEZ3YI=7$?N=(T
MLN[0UWKJQ]>OR/;PR6:V@E#V-E">+QK'6F43P':.7V,Z;JY(13>;(4;>#9K]
MZ4<>615B:B7+DLTK@7;@4KS@[=X3[AU6.\:MI$+S[R\J4C((&-+HV+0+_MR;
M$8.6<*+M"YRMS-\B'VDD_'(=$,4>XQ62=?A]PCFPL)A5 SU9PB"&CNLT:1CJ
M056&Q!T9V%'V#"RGQJVUQZ@\9A!W@@E]#BS3Y!AM_6O%M6._*A5^A,'T\U!V
M%'D!Y#+^#@[P@H*:\#9?&%L)= 5^LN&\&KX"QESE #"^W,=QP3B# @B3=F>J
MAYJ=XO)YE@;:G@ W  =;T) E>H$U0MY;]&NA()!"A:6:77*D5^J;6N>XUJ/E
MG5,VM9_?AA_"S>7B 'N\Q)\335>M3+B>8"9+"CDEP9[D$;CA+[GG>!4"2/"3
M_@/!)D7JK#T5U4M^:MD=5A"@K0#=HCFG+^W*VE%^_?6901HZW?F?4+.[7MC<
M<M"]@RRS@02U\[G2)7]*.$JPS[/REYM9Q!6O,UZ9H\0TLA+WS)!^6#77#BAG
MQ-X+CY=(L8@L]IXQBD#J'0Y5S+K'4)8*6;G$DD@R+HRR]EXQ^,J>=GO-^TLH
M,IX&08?S19?FX)-46UX&@0OER(1B+0#*[3"^W)_BHG8O,;? .X>\01?'NG2J
M(K13W('MEC/G^[&UBALYU *3,:LKHW6^P:HL%IDV9 D@SJA"]1_U'%HC;BX/
M#YS#)U  >V$N*^B;T^QHM;W (J:U6!/LF .9E'U<!\GT+J0\7VO1Q"36BWAO
ME> X^\Q(7\B^COU9GT4[3?'9M%/#JB'AQN+AG07XU!8[ O_AX/]07@/ZKQ/F
M_VL>_?<7=BNN_9( $O:37JC!9)\# RH?L412]0C59$.4G-0=C0?TOHF'2TZ
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M9**($4 ]C''4FV0KPD]]!Y'>2(8IIZD?"P$6^[[V\A,1E9[RE4CLL8\CU:O
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M?;LS&0N,=&DCNJZK]8TD_&=(Z(O1RT1E1I;ZAKHK7B>_UPJ81RZ4D%+)+N<
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MN>_I"W/Q9_[@CFD"V9,E1U&ON7+XX8TD[+Z!0TL):YAN>=DL1[4EWY4X5/*
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M9-D1&5>EEZ9Z110OAF<I-VP2HC'I5_$L%,Y1O*]AJVB^ONL@7M3#V,?X^AS
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MOO/"&06<!JZ6?P&,(BAL\(?.OT2FU2!O8G("_^B87>EE_E4?2QL@<^?90 Y
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M;*K+UJ=S .D;5(_%ZJ@"25U -U&+5#ZC6:1]IUF/I(X9KX,?'M*86,NFPGT
MPQP0'[?63)J63#:+'5 SL)%O,!R5MD(3E'[+\V40EV-;SMP)&]K'5=#A_K&#
M9/_S3HREAVN!Y(%4K8^O)0TB8\\5[F6D@GMJEPC]>]6/G0Q*#^2:-[315/RX
MP?*B<5 [S2V^SRSU)<LF;; #;9N]J[1T4(&M[XNJW=(U$7%/3V;_W=X-!=G
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M1$"D2U>D2)?> GD4 2$"TD('D1J0WH*4*+TC7;J4T /2.Q%"4:IT"35!>DM
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MY3U]DBY4A_#AUX&K_O?E^WD;;_ S!6^W7QK5\DA L];,JY(H<V46=P/Y2S0
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MS.@$^VOS3@^)2TO%F;O_W:HVCJ!NTZL,R?8K/-UL[OAVY#(PTN;9P4.8$TE
MQSRMF1K]__3BL68L<7[H\A[C"LUO-U5<E4)^>,TE]_D+/'+>-5!^)9;ZG1B-
M64E\B0:50D1[#33"0M;T<K"6F9D6#1E7*=J6_0#'+@Q0B9O-62[.!X?.KG*=
M,R9>4AS@R0D-S3B=/F"HQ%9;9*];))H)CNE4[_Z .&Y*#;3"M,<2IAO^_&H,
MF(W4JI_YFZNV80"TG1&M^GNA/:O/ZR/$EJLL)PWD4J[,_#58:^@9$SS)Q4AC
MQWAW.BNVG!%L4*XA-U7.ZJH7QP/W;8A;<P3]!=[# 9@S/6;40_$W&;[EB)F6
M/+9QTJ'7)X](LPNOPAEX?$%+EAJ1AR)B#<IG>WO@8@[,![.H2:\:+9@]C"CB
MMKN!C[A<1ED]E*I$SNWTGNBI4Z<7U.Q<J^Q(O\.N:4JQ.,3?3FZK^X/#/&GS
MO5DRN86F/8Q6O7JC/3(7B9/''$"CVOIIJ<H=)9W74R(%'=^FO$E?Q-Z[(40?
M@&Y/YR[6#[EYN0#>UZG\ES;WA%S-[M'LZ33Q"'.0T,4,S7^#<^AUNTN,[>84
MFLBWN_R$#>([4I]:T1NM'16I>1>^7M_R>\PAB#S;(> ^?T.>HXFM6R',OF8^
MA9!ZD>I6"+RG_,BB)OSREZM8%P?T*P@K%HE.43Q-R<!=]/5J%2]8*$_ZE!/M
MCU[,.!@:+^N)AT0>#9?VLH,YK<!CSPX10_P4[QPGX]FU9'*S$!'!HZGH@,,
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M-CL[.O-QR-+=I#]9$ N;!&D'WWL4-=%(:V#\I13Q)VZGEQ9Z>$"R,L?9M[K
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M41TS2&)A*Q)@W)LR8I<SBQ H+L>MJVCQ>Q>DVN$U3LQ;?!P*9ST-[U$Z267
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M41H3,NIS. >IW(CN?2>NK=<[,>ANK E]'4NNI^]J5/HIIG=*+W@<W#<5;B2
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MTF")DI(T'8=-:\E[<C\U'\1AY 9R^R$F_5LR.69SC0%S._#CYCI=2U[\ZNI
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MG@-FIU=0NWS8,*P 7(!1D9%W\XFP*O0TG-&K\I?/TY:7+?CCZ JANFE?GF(
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MG40;BNT<\(-?\QP0T;@O>QKVA](PLJ5^Y>)!#5P4Y394Z1PP<@[8&ADX!]C
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M"%\>AY(?J0W]-4^_TDK&  W/W *T^YKO=L,O:XU2A*$R65V_W8+R(O.;:G\
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MGUW5K#:N_)?[F2^1 0_Z"JM%=B[37?!]'V26+&. V\C+=)/H>9-I='"\3GE
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M;X2R\]\EKP66--6A^G5I_TB:NKOYYJLF%EF=W@?G+M<A2:SC1[;D+,IRH5W
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MN]3GR/'=30J;B ZWZB=5\RHQ0)<P@GGN)M?O+MA-G54LNNT&=XV!XFBO %U
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M$YPHC(L%VQ*71X02E0=E337F &!M#1Y=^M5ANGO)3V!R1H_0?K&?:TRO'W+
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MH(>7^!OG3@HH)];X726V&DIXT3M;35]KJ]AKM-;[86WB[ZU(+X<;,VUK95Q
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MD3VMRP1^-__GIU OZ;)0C2%8>%"H/SM&N@Q=5[?6-'.QEI[D7EO$@?_Z?4C
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M(S>F,_6SWL?>T+>SRW_)TTKYI'&B6AZC%^!!-=%+A5FR[3KY%88XD#D+BIP
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M39V)I1W-7<T=^CX_X;YW@I/"0]=#*A,Q*HS9"5J5>),DB$[O-"SV)%UQA-G
MQE&Z'.5/6]N%NC6S%9TQ-S/CZ?1L0\SPYJZ^17JO/SB^0X1Y*"1-)_<Y7)FG
MG_[&2AW\XY"I\;V!8=>))5EJT:HY4_MT$IG,";$@)N+=AKC<TB/90U"V>*MD
MA=QEC]KM-EU./F'QYTVHUJ",,4NT=%3"82#<&'-HU),LZX 9YQ2'ED]^7R33
M\JZ9)/(O. +.88)H34[BR@,_%U<"%QJB=9-D^/)K0YG7NXX,D\N[S#EZ^9N;
M7B4T7_:"@J3+L-N1XS ^Z,F7"]J6)UH-Z5D0*(!]F&)\E+HQV77YL,\'A/V
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M%5VQLC,J)_7\^MBC?V&I=\ZS*8#M:NC&.P(W!?">2PO;"76%GHJ#_SZ#Z%(
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MAO Z25U'[,468.8*]YUZR#D/?Y^:;'ZKH3P:IQEB@.O! BJ;I+=U@"J8+;_
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M9H"O>&B@?_Q']?$/;S223O_\I+N2F.46^^%-TCZ!L^CQ?0+N]R)4!*(*I%8
M\MVDSGN.19?YU?04[D5A%$/SG.EO8M>/K_V!3:5D72D17RN3M8JJ4FY;@]+=
MH7\L%_IP+'ZV)B^^JJ.T,\ S25P!"98H=XC0B%R;I8 EV:XC^IMB,VQ->M4J
M5YKN^K 65;MJ.1TA=,[ !V,OPJ,>RL4KKC*!#:%5\U^^K$RUQTYXOEUQ<Q,.
M"PZ4T@+'8:8)S7U5+#>T'".R6S;MP#+W$)V0%# 2U#9Y8G(C@H,A(X^@TJP9
M6H_.:\PLRT3F&'S+W&]T>^#?->;8AZ?#A]^>@GZ7ZB,(&Q#X4.35[KWG(FHN
MV=_*]1A'!.7>]Y4%QFPD6QJ>V(8R7UR*.:8E]NE&N]7UA.\65C=^09.B%&"]
M[B_HV;H%?D99?C]LK]-1;--3Y==7[5QNCM7(:5EW=,V_=,K1+%J7O1:\QNVA
MBRG2MTE=1^JH\U$%W\YJ+BC3DF>3J0\&BPXKHWU=GGS0O9H_'6<B_Y#D=S_K
ML*W1[T21M"G'\& /QV^YNZ!_ZN(6I+C'T+X MH0'>:&+ME(DB/#O/(]-S0[[
M()-9#R775(8OJ9Q4WA\4532__+-?R3@[OVK6?44FG#$@]+NYH_R]Z0()V[RP
MML@#XS,&.HGS<A,J__S32B?Z ,US?Q2NY1!=R275R*<7H[9%*A64;BBY4<#=
M.@^Q>/MWV,^*2L##8B"S1P$,Y#!ZH%*^* V'N)_]SJ-;^O2"K&+@'HMD[/Q:
MHT8<%>\^ME%[)*O"J]=E:UAPWJ<2ZC-S7BH79 7::W4<=-!*Y0%(+L/^/!32
MSS4)8FNE%6924)%\-C(_UQ1TNU0,=K[\^(3Z$/)ZIU0TQ=O \O*91J>*A&>=
M=?@B5=^D+/MO$-';?R(/,>J.WIX_GU:6OQ3EZN<F%#,48!QAWF2E^O8<M4W5
MM2(^,UNR^9XI'NY6Y%BB?KMT48+E1^,!;4[/D+XM^+&I\")$_(OE&\M39:>R
MJ/<-J7%WGV^XWH^\=F4V&4^^=$?;?B/U'%V-Y\:@HGF>K07@>(6#:<0J52-/
M[U9/-GEBY.N2UN^)KIB^>6]_T0'J8/%^\)>7#(91K/E>-HQ!R)B7 J"+"#OR
M(C*S'/LO= :F0]C K:=<T+#5.B^W 2?MP5R_\ OJ"*AP^0<8X[UB7I"D$+86
M1<OLA=#";,0EQL&&PU<Q_HBR'^#@<>W \\,YYITWXE_EU6"B+Z::HFDK$V69
M(T/+HV&/*TQ;%8F4GTNGQM/P_8NG/[VLZ-0Y;&?H7"+89M'_@A";JF'8J[^L
MGMW>%*O:)S4>]<&P]5E)8.L(,U^*R_^(M8\[XG;/?IT/3O_5NQ.2SQ#80XO>
MW+N,.3T9#N87<ORYB*G;GQN2J>09]T+IWC.CEE;7 O!T..>$$OQ1F6>W\$RR
M+Y1UA_NIBQ\X4<C6C:=,$X6% $%J]9E50\]^MJ*G1'/B,"U*8: ZI,.MDL0_
MT9S'JC$\=WP,V;S*8F79^%R6C;HN:MW$);'/T;73Z(/OYJ7ID@\"[VOT[-AV
MO4 8#%P,N\O8R%CA_NBKD"(W"PZ$Z(1<LI)3A"?L=RCVNQ;1ZMK2.C7N,3_K
M->_IW3?RQ7/NHCP)SSA+).F+5I$T0\[>B CPZ][OMM6'?>?\IBQF]88[H>+K
MGT]!,8-ES[^=PX@^6^[7(PX+)O66V.F^7J&LT'Y\TDX.'K=[^8PV,0:Q&'Y#
M2 :*5(E?_^R")()FL@6%+\0:NYL&PE)(_RZWRZ7R2":\W47.^Z3TQ,L A\MG
MMCF3R"4I"SJ70+-I\*/.";M-U\V&S&I)V79.:L^&]M#(??S?3)Z<N/VRX*#M
M?3 5_/DM,X,1GZ-,(-Z_>!Z?*5O+]HGTH^*4%.)L39S:DKS,?BJ.+6FD/=>^
MC'UM9F(]KA_M%U2\/"7C\^KN4\_EJ;M,U^XO2U_.(^0<^,(&3WLW?,T(YF"<
MGG&.Z5J;-GX"<G3[FX/4/4*DA++'"3^-GR<$NJ@HI#HX!R@W/C*7*;"TPDIV
M6OVY<*:T4T?G)IF%*^0%7O1-+G]6;?Y%^TZ@9'%.1E[W&*U@%W2!?DMJ>]N-
MKE%EEL/\5G$P(S?L0YM5R(FQW\(ZWT1"E(.@TS[F/</6]8UC6ZNH=7V.X1BY
MIV],Q%7#R^2LX_S4_'$KQ;/_IIS\Q^J$\^'<5@O,7(\I'U%.V%+,)KYQ.ZY
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M72!]XMK"$SS"<B>2J"-UDZ;F0,7H5?'WW=XI%3Q+:C9V6;8S'_JW*=*1$>*
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M^"L*R=8S6ONS"[H$IRYP17>"=D'21?^3OMW:'"QW&HC0+?L;6 #V#OOK;+0
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MO^V8,GC!*(8+89]D3+_3$<*,DXU2]:6[#@)E5+L7C-I!FD))N1>,*X\'X!6
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MT]@2.&;.B+D$=]C\R.@M\V/H4QDWT2ZLB\%=X'U.>9;M;S(TDF::#]I$[X(
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M3TV)71F#X!?.3VL>?!6>?WJ>GTM$+-U/L@!A#0O^GGG>AX)>X91A;Y@,/U[
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MS E"D;DGAI,&2K<ROR35^_EYU?+PZ 8$R!9E.P<$>$ ]"4NX]:, @G<5R8
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M&OJ\4RG^H&JIE/F8WJ:+8JH"-S]GC>+L;1AICY9AH7\6RR?=)>,V-D134SO
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MHV+U+YLC!^/T<06'>]+EEJDW6J;+]>*8]\L?3L0<?D+K[#X2Z+0_*P>YC$;
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M"[)['!U-O26>V"[Q=O<0YM+5SP%&WVL:B,&.+*K4&S '?5;/'O)?DAE1#0K
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MVQ+UCJ"5,BZ4HF$][O..J8R,OTIG'M[)OF1>?S:EM<Z?W^6![1^YFGK#*2)
M.& 3J=]9(":;7Y!%_ZI]M;^/#'BO@;\\>  1BKWTMCG^S4MP7M3=F[@*6?05
M&),&&W[^[[^Z_K_=*>E?NN$__$&_\)\/A@L*2X-B.SB+W2XLH;OQJ+'K":W,
M5/K179SVAK"'FIJ\U)DX3 %O*3FD=*DT.5Y7A>>>4PG>_JQY )W=ICRXK^&$
MT*J@&7O?NN?5-9B#Z9M*\LO]#5[A?:$9Y59$ _-I._O,&PK!!US*I5IJBKM[
M5,D3$_7'?)Z,S9S9^X?.+E^U9TV9*LU.5X/="EWVE1PK<\62=]KOM2-'[2,
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M4+QN6*C=ASRV/G2,Q,T5>VP:6 +L(:=K"C:+!L!FH& XD-I WUYG)]+&[.N
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MXYZ?G'P>LEZP]KRRKRI,H VF&]F'IQ\CNZ3<=XEACTO??1!RV"6F4&]Q/SQ
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MQ4>T\@_RE!^]"&J(N8SR//W[35A/MD!1;(]+X##?"]_B; ,1BRF%]X,F4[1
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M>3V_A0:V?PT*'1@8]'3<C*[&6M1!6,!:@6".\\8VM&=H'9Q<$/$#OBF+X=Q
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M=KM&>(<%05=4[R&%+>!Y9*MUL8K:@Z4_WXZ/':I$B)A:[F'!H 1X*J(LF_Y
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M_JXZ*[ZP?;I[5U3T%9<!R>Z?[T]5528J?GP_;'0^K)IW@_9(JK]+YUZM);
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M?,\(7=$U+3"!61W^@A>@IJ*FE":I-SU>-6._XC]7TRM+!LOV\V,^=V20;E/
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M,-?_(GI0,"Q2$M7[WMH+DOEV:%>N%7@@BYO"O>1KZWZTB:##7XU%W<SK]2O
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M04#+H&^3Y,+K\E'OH'U<&Q"]&54D21XO3RQ7Z,8)72[GR=^Z><%'31#SPVJ
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MK+B_#A=>,(N)"C[RUK&"$C(<LY?LV>L80IH/&(K)"U*-'NNKS;,]5G?OL]_
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M\+/J.W@)QI8U6%*K36X#K"+(YHX<.(AKKIU=JY]_OP#9K^$Z[G7N5WO(R6V
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MOX*AN:^0)*+6()!92_AFLF,Y3_0<\2H!(FF\N,)(@-[[Q?) Q]0__K[:FA=
M^LLUEPZ^YDDM[P9@<F41)S9A^<<IHJ&68=4[3>-FN!K=.<!^ZT0P\H%T -I9
M^4-^D[?#S..!F/5\KY>B^H:7]8WW(ARL,[!L\.G1*D:+E8D6NO(L6J[9#Z<2
MKS2MZ+YXL5) 51#-D .0(UC8F#S$HBF4T6T8&YG(PK\7<U*<E/Y^5_0MWM=>
M[BB#LQ44V#D;75X&6;2C-M BC@.$?:!WD%R@XJ9G<&&[T!8B*$^J+TPN+.)2
M$*_*T.Y2NOE0S;-0]&W?!\EDT --VWQL=NQ:00W%MK'*6G1U^R/\*P*<V(DN
M/[Z(.[1[$9>[6XWEY;G]@1]R])"U/2IW.%:]DJ7M"7Z590B&IZ(XM)ML6DO9
M\(EDUR<TAZ?:ZE&GK!YYL!U[;Q;!"J$(X RY19G(:.( 9=583P7&/.'@>]&[
MG,A3(T'OO&@+VSQQ/Z'+P? DX0:8V$+ L]87C7YBXT%"XAQ^&=/_8&U(70,Y
M24!\(HZX9II]4=3**)FXZESW,R]"=ISJ@HZ2G_=,:Z>?&L(6@-H-XQR\5QLE
M*3L(?2!7DOHD9X;==U<RZ1U!)L)"6@&SOI6T&52BN<\F7,?R:&63=9OZXNQX
M<]W^_KU?XNV]#@\PRB^17A3<(&.B\98(O"C2-O*/$=8_@J^J5?5#)"MFMM\+
M(636$N*EXL.-,FX2:6-F1$58B$L;R1P^78:X,M9,/.<7O/YK:E[\VW#^Q:R%
MHG;-O68Z?H;<0DS@KB#A$#>PIX5RB[R*M1XLE'$2+F9R99ROF$M:Q>&)R*Z"
M4??J,^\M]MIXU_/YP;E3KTM$ [PG&;,QOH<^3AT?N.3 JZQTV#J7LWT)H<W5
M,CMUSC"Z->B7A?:Z/+DEP?_M[ QKK]P2:''5-&55G-^;.+! 2$-VE'X2[@ [
MJHS-UGH7,Y-;@][<YWVJ+UM65!AYU3R#SQ^@<A9Q:T5220^\C=A!3H^"/LOK
M7Q'3J*M1%TN?@T-;8#Z6?D8IJD_#[,U!D>QUSB6M9CE .F\11]O#[W9F&%Y/
M^IUYY5WHJ*'^1:71D>"#=8G^JA_2<%*2.<L)G&T!5HS";BUB#N=+R.:ACQ]G
M;'M2 1-T!RL"\O>YXO='MI4KW*X@6,+B?T:.$$?**Q&/O7F_.MAOO.&]D;%9
M\POY7$^BJ&JX==:418*#+\N;0HD$Y"Q< 2DZ43MHC!=>"?=W2(S9WS#KYMM1
M1\@EY4L4^4BOW<S,^09,F=5"JQY&J7P-O/LNGJ.G1N5/ B7;'WTE=-64 ]^+
M1LI4$G"F4-HCIAZ$*Q2<K^A!#GDR[6*!;N"\<I?:%[&&H^37B=Z#,U]&UPD"
MP2GI> <>Q]S2[G(\LAZ(S/:'5B641L92O^_=V"C('VT5&[O&OJOUT_O(F]8.
M[*=IL&CZO?* ?%YU"*9#%.F#/+0Q2AY%;1%NT(Z+TI4^,DD*7^U&GE9?#VRG
MKF11($4('"MOK'V^9J0&OM^R\"AKR"!B6V#:T(<?U.K.T/4B*#L!\92%$#LP
MSH@!>!.QYN=%&<@*EK-P)]A_YNFA <3-)AUQP9Z98>LS3ZNY^A>#[BYEGI?>
MA*=]N!1VB]GPQ_8EGP-], OW8[]VY;2+\"PFK S'$GH+_%(JI;Y"K3'(L8:3
M%>') AVFTKAF4H07KI[L/@ON?G7MSWEGU7!Z&=-+EIGQ]'3H:'M,\9E3W4V2
MN6?_6\OZ_]K6WX3O@Z.M$A,!D7S;_?A36.W3=^E2!6-K(QP%!<LYS5QCN[H[
MRK7[%9P$=!=(S(B*.O-2?3*C/F53=9-?>ASCQZI'U#\H.*!9!(!'*(G4=4:J
M!)@.XN7<FT+7XIH*9B*Z$Q/5@YJ&*YS40%=)JG $RYK.)8#"ARP^05P=Z<*V
M#O'RX[3=HTK>Y[$M#Z"&9T);XWZZA_[9NV_#S$/9=9?#8#Y7VAC,7>-3.)%O
M60LV\3^68+?:E,ZVR_:M[@_K._MRP#V^?"H6=1U$#JJJ[.K9Q$&65[R\2W/X
M=065'NO:5BTAR_(KM%.P%G'-^!A-H/]PC.1=C=\0OXGNUS3(SP@+T)2*+G9[
MG1SDAQSZZ-/MX3_PQ:!';$YOU!Q 9VB5/,:EXJR/DQ]/V^1[;[O[*SI_?!_A
M!OG_ #V\1J=9>!MO&HA1ZX8"S4[NAC*\$6*EN<>0W_ICO)EL**!75HI(F'@W
M^AZNDENNG>HD[<GMM+(;L'.GRV\WUD-7%O)+X\LBKRVK*/WT<^35@.@#]HNX
M@T\?K5!E9669U@V9F@ZI IP#0/'I$;&');^BJ*B6;MC$YPN^_KF9L73[78^5
MA^^VFW^]^=G3)7)@=!C5'U1; \U'T#43(EW,_(%D?WBJ16@%F3-;6\RS./*]
M\2U6MF!XVOUC37WD.L1-CL=33Y_I^$S+2?R0-_.@M+CD4>1QP3>1KIX?VC.Y
M3KSW6*[_K*W70@U+,(N.0(SZB"Q"!! )6+&( SS>[!=B@I6+IHSD,()8#18U
MY<2%)8?"U\'Q(/CZ8SCK3;?#I:BLGK:?)U7B!Q6# Z2-G--FNQ^2HU$"RQW$
MMS!T80:&S+.Z3']93ZM$C_;S)Z$12+Z)D(N8@2VAYGU17;6NEQ)ERK5#74?Z
MIN_^=6\_XSQ]Y:'36W\IO>=U83H"2_/M*);F+\ORPENN#0ZGVM4V7>TN9UP2
M;-*F^;V0X^K&PNQ> 4UJ&=T:N@M42L_Y-7"2ORB)?@>)YF?*?SI<\>\:'F;0
M9/ (V1BA,<0>;50<^O44M=:(R?6%GB&7!H HSFCUN%Q LN_-X*F(J?8LP$9I
MQSI.*_^4'A9FF@[02ULO/VD..\\HV5MKF@5UJET\<9?9>J U!YQM%L?>1%Q*
MX;[Q(WUA _<Z_:'.-L(&) !*B:)@QFB=>QP:;P=6PY*.:TC6?.QGAQQWS\I)
MB);#"@BROQVP8)UWMB08EDS?5-L@MII4$@YV4_T$.Z,VC6!@PBP25@%<8BH"
M$]I"OX6\4A! L1?H1!T@\AV6)Z.$YE-)7QA.%?@\"SDCL3#X_KD3_[==7E&T
MI;2Y=F,=J:@6R^U@F*H9)BKP(U.J!'",KR#<MB(G=0QWL(UZ21L1+S@"W?+\
MN:A^H*"/3UR#V$&,6X) A_3+L32=@;F3PT;>0U%O1R)5L4.4;8TH)L/;',C@
M <["+BXRPAW%+^(*5HB IQCUI%-AIRET^6E:-"/6;)JXI(ON[K)FV[!RDSJ$
M&NSX\^'J@O>G0Y'K+VH:;S[<ES,THZ^LW&)O#+XV:G"9_>7_=ZWX=]K,4*_4
MPS)#D>8!2F)=SE4]ZI]!G=EOJ+7"HD<EB>Z!T+CJ*#RLX([,RXEM^!6>C"@Z
M0S:;,AQJ,+#I+1(=3C/,S+-\,)OJN-<CJ#K]2%^4,N94U)7&Y?::7$Q8)I O
MX-_%>D*)G&F-U"##IDUDY,2#O87VK)-022KB"]DJM#U^C?X=KB>#/[/\X"I%
M=V H)+K#*&P8X-NFNUWW.15E>R3[N CM[*^=$[SP)K46W%BQ_7_[D'[2#OJ=
M)R>(^)S;E2Q=J()M&VFU<N#*7J#5=3R);<7N)=027S59M).LH(,!60NJ5(4M
M\2;56&C1KO E'J^M"=:W$P0TM N"HL8JBD<[#9/JRX,EK)/JG4#S:I$TEU#%
M2(O!KT?_ /1(.Q"]87YA(6>--R:7VC1\QRC;]A\_F7671@RQ=X%2S>,B</R.
MHY(TXY.4<!0BW2^CH2=G'D>J>NA/)?LO+[1[XIBS2AW03 8H/4!&YR(.1W**
M$ ^GH,:LX[U>24B<[,.2SM"],.,I'270IWRFFE91S)!O('*"@![V9+*CVQ'C
M!]H"-:4\BN7UZ'UDJ/EPP0!K;]EDP_E9!0$YH,">_O9%7.'Z15SW0\WS1=S"
MQK+YA30<HH-1^AE FDB8"R/_6T.N(V"1UH1=S/I.DRY<P:)"]=/I"KR1>$IU
M+7;ZN"*^)T6DR[:,,$],>@B.D<UXK1HO67VB$V $Q\SEEF6<H":AA$'^>B'!
MFEOZ:>)Q9/:)D#<-MP^XG5OX(PUG^P\578&%\J7:WBX T'Q<0)%14@A\EU;
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M<A/I"&2::N]5,NQ_I#BT+X277DLPS*46?Q[OVX,+#,;CD3W52H*WGMR/!MV
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MO>GZR;./ TH*%^0ZH(KL,$JR>@E1D [V*[0"T$N(D9-E T#C&?0O]=)V/P.
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MCK MGF5,O&Y7?(>N?H#??.N*7E8 LL^3Y_++70S8E]^?:P2M?G'NCYI;PT^
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M.Z1QK_3<X[VG[[_:<_0Z=J#;LQ@Y=R:?_9&5,KN$2+Z^A'C5OH2P4K[6V I
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MX@WM4CP+BBR=4,7^:CFT@^=#/WSR1("!FE]RP@>%$HP$/9C!2#'[#LM&T0>
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MUF'X5\VY,Y!I,NF08$C%$W)/E1W))WIQ]-4?\S)K1>A-837Z1G<+0OLFZY1
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M2U\'_I0W@_CDAI62[DW?,C-]@I+M58'Z)OV+=Y_1?4#2+2O?(RZS?-U_D9V
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M<?*<GH<(/=T;RS%S*)A7+94"@\MEW%8<VN!J9!^L#W*GETL(6"?I(N9V[F^
M:C*\7TK0AR*=!%:NQ#6.5-D<,"6\%V)3Q\@O]@ZY.^Z_Y76\=U6:?"2CW<XU
MZ3.EE0O]X86H4X$41$V@L(*/0 9 94>T:?(B)AQWQV%]'UU#S%T.!;3J5M)8
MXL2',L.U$^\G9<[I7L1<7^YJUR<A4:P34%1AJ+I*L92MW9GOYS/0)<G68+J_
MA%&]$A^ :-.(8@*LEXZH+P/LWGB:N@+XIFS\D+O$.6Y60(VB7YU1@^V4%?9H
M$-:>R1[^%<1KL,YR2 \*#^=>S/HN[OCZR=7D_7=&+MK8!X8:K ]PIPX CM*Q
M1(?U]#V J UEU"&&MJ A$+0[".@E7&4F,2P$(C&I?7"THW744C!;PEP?UD^Q
MOEOP7_]066&4NFOA>(\V/O#2>0R2QA0_9M9T3S'!$K'J5!/ DE"F(Q36=!](
M4,#XC[]J#,2CB8VAQT#G9-VW;2^,;H(B)'9XG:XRFED+SZR/[AVX._ZYBYRH
M^999='C!#V8']=[1TWBIK 7OR_A-N$%A4R7="5K$@/$25A,.,SS2PNF4$5,<
M[ !^2[=ZZI&O^PNK!5IGP8O%!>,5$U$1P^_[HZ]Z86.BOOQ5\^'HNS]_&2!J
M(XH]C"ZF!O\B<]!+2FGA#XZ)*3<8)A,HSZLVI4]3DAS4(3<Q7ITF.XV,0H$2
MLY$HA7-;EM'- *X_ZJ'\=XU,B$+XF8HCG]5F[,?_C$:N+&+^Q@]W2\:FVQ1!
MR!"AMGMZN6(WTB^JMF U\]-L^5/#BO4THH0T!4J[A_:)9Z8&E^2X0XY-DKU'
MWG!(,E6"UX"O0/]28TW]06ZR<4UVF_7"GMJ/58W^.'624\@.U5E0L9_9='@1
M<PX_])/$ S*GNA1GZ<L@H<S0=O@DOP'PNH%LIP5X@E71_@^OUD0G5N5JZ(%0
M5NQO0Q+)$>'T;/'5(-]LEP >C6)Q(7OJW2+&81$#H8)MZB=H+'\("11[&2B>
M ZXXR)0R/0\$R9NA()G&\1DI,766.*C:(5(U 77*V-LRD^R7RU)>7ZH".6$.
M?P#?^4;51?Z3^WQS2*U&..&Y'GNGR))Q_>UW0SB+F"O\BMITAVWP2>4C0A _
M:1&C;Z]53+>&.F3L./X:NCL8)OG.S2?18DX"SJW3E*8ZJT4,JM@B\D(O3.@'
MR;$IIGU5 Z7A@U_3U(-KZ\=B,#$CS!P]&+="%<8O8@8,7]K@XD4;FRZM^8=G
M!42<()Y:=G'SU95IMEF+&*>A18PM 7)01USGIS06,1>8,F>D*'?-$^RL1W5-
M;45-;655\N;JJCB#L&!C@X#$T57].\ZGQIA$Y.6EO7OB=0/2DE<I'SGL@,^!
MPJ5R3X&LNYF?1-J(Z'T+D^*3<6L;M&0']-H<C '=!T-YP?7P.7*>'\E)TOFY
M]TMB/QGGF24X<Z-[A>",\PKPJ)+2WAV'6[.(">:R;,>:B7=L5X[=YAG1LJ=*
MI'@-U RW\;3CS]94O7)](*CVG5&9Y!GU4:JN?TE5>9KW2>12,/$RO7+BFM>U
MSZW,]UQDU0&%*HT@S81U,I'5G0J#8?IA5!JWB :#).^Y($O2W4ID^6/ZJ;BU
M4+Z,V(Q%86YZ[!9]'T#Q@PH#BQUEE%60NF?*<4&VU(2'Y0L: F1^NF_A772O
M@N"%=E[=_U3G66(FM%,$:_&EI':!X@\Z05F-:M8-\&6RRZPKD>5@!%5+-(A^
M?7/?<J7[83O)3W)Q(RL)=@G95OK.'XHZV-!++3&-.UW_,N'N#441OUN(K,U!
MY>\)I(W]LG:*A>)X'[O<JXF,E9.A=/',4$ S>W6UA:,DMU!JN,LOX+ 0P<$'
MP9J;4K/)E*XK/R0-?N)%C#9]3P_["&A1CH*#LO&9V[-0KR,]7:7\%X1U*!/^
M.;N(N<$$_L*N9C8Y\_"#GVB)D\>4MWE8>K2P*F:'N)S=1M)T,$9]7*"<)1EH
M#2=7M8'$5ISNN*WQ)^.W*IFZ!?.[*CHNK7OCD*,LY(=3!L;D-E6"W?Q0RE"0
MN/9-LE5G".6JAJF4D%Z%Q4*9K=8G[,N)UR6BU6?]<5IA\G_<UOQ#C,P?MWGI
M>#E/[8++HW5\%@6RRY?_3_F8'SJC@G;1#-G.Z"+I\W3IUX! ;JMH*.7P:Y"(
MXN&&;T9[*WJH?_(K#=OZ625=>:-^W4\G>"<JZ[.=^P(J>&%!E?5A[BMJ>FJG
MNF$#*T"%F+HT999"$',7,55S4GJ0LHH?CD<?L/75.,B'MZ>GM&R.DH@R&L\0
M&CL+!13 ME H11_U (N8-6Y<FHUOH[6_@;[5#6#*:"W08+W\&)#&MEB2>$:&
M"EU8$])3'&>TL:MFFDDJM)@W_CN4166(,<24Z69+8O=:Z+F"Q&1DW01[]7=+
MK)'?>(V____HKL]#<)K?9V.9)^-Z^L=.I3OVA,_DRA=<2^XM0]+Z0)OIE?^G
M<F\P PE:V!6,C^P:PM0X$-]QR,W*%#"]PS.C'6GI\-P3]INN@%)-4G$N[I;&
M&KO4W9::W>JG'M@E</$]$O86?ZI__W9BVM)D;2TZ *BC>$P"W'!W" ;(1L(@
M P]UG_K 4X6W]M_YAP-OS?T#NK^V! =O+W>V_;?6EA5OC\^'LEL7MA7'23?.
M39NYNG[S/6Z3P#BIO-?@KL AW8N8BIJ; '9IT6P@(D(#4P0R$R[AF<$D''P,
M?3.6-B9E)A-"\,FV<ZF%\^D\8]@+)*:\J"83I4:%TAE-@YRC!FS-3R3'  [S
MXGC66<_HB]F<H>$;#(2.AV0 249IJ2>D\%40"[H55 J4G&"=>%4!W0<F.XST
M0?;-\*T]/F?FKN3N N2%SX)O5B6?RS7TL6[TMGPKSE7_7)NQ<1T#%:BL<F:3
M.7]\&_NE*K+=>6IR$=.MS[\K@K9&O<$-Q\N7=D[IH_L"M4V400-Y*^2'>L-G
MRB)[=_#46ST9H1F7-*H/B&Y<-<"OAE(ZF"I6T][T(_<<4J4$=2BKN5-BR.._
M&/7WGW#8".J\FQ#Z)/361-4L8CS0#.XA 8?Q:^$8:,]S]*]#A LS+/TC=Q6'
MZ:L%NZG=:;GK !+K1:D)- BDN&&9);3V6./CU;ZQ05)"\S=9ID_6#U^OW@9W
M\9:RD$RA;<Y,(FQ<^(?J'%Z&'8Z2XZ'K@.P-:0/,5/@S.A$5R GT>K^(22"!
M[NTX'$,;"I)TM*97MOY$H[1*+\V*J^M-"V@W.KSNK:4(2 _-2L]<;Y]>K9,T
MA:Q">OB5F=/[\B8=3)39" '64CZAVTFZ3AW MMJB_<;=YJV$N'G??'IK[I+:
M"L)L.3?FIJ,[7/M,RK,,!F85X^+Z&)?SK\\<VVO,_KQ/S)Y.0<5C4Q>AHF.J
M3;%R@+9=]@99!_1Q;RP5WC9Y(SL&H/.B8Q_L<1RZ*>C*:<'?8F-V?S?/:CD.
MCDU;20FKG&4I?L[.O^%NL;%5(LU@18.+B7[B_0AE$MT ,@,RY=&H"&+>(BQ'
M#"%725 +8>5X1IUS8H.>N%1?</BC9:>=*XU\,J&Q(%B8^;-CQ950_6HXTZ>L
MA/K5?R*J-NJ^F]V-Z-C_VQ 4_HX,,M?;QTKY:21-NIW4C^@1[PAPDW97$;!0
M2-GN+3UDR^SM*5/ZMZ*C'LFO[Z8^TQ6=R5@X?/V[0]\J;]TA@S/G?FWG_Z]R
MIB#78.?[2'.N>K,.V%LQ%6ZZ?.[%D:L5"P^?GPL[GN"M/!GX1\?1M5<_BSE^
MO1&5CW>^ _P-STY83AQ_?/G[T?4/KA=Z'*S5%<Q[[!_TLXL1ULBC<?UM.O!]
M81^I0K4U'4=SE+%:<K M^F4EVU.EZ=KC_CA0-;'_JY2\=?Y(7WBK_L//0^$_
MPRN_R06?)C7]"T*LJC(J]OPSW$G5%MQ5;OM]L(R2\>55F28W+O]_ ;\/F-YN
M&8OHZ,VW]P@^P;%*R'"/EY??^?I8ACY2N^AW'Y>JG'J??ZI@B_F^VX_SC8+[
MQD+>%K#QE:EST9,,833N(U7;ZV>](A#^"YR_C>RG'P1FDJD'/#6PS;S-=1]@
M@J3HU2N62U7/I2S\R]!UXZ-!@Y]?]S_QC3WO.[YN[)7B])8+OL'D<ZRY[O7T
M@RTTZOUSE4<'R?3^,AO]EW]<LM@UJ>;6*[<*>T\%K^0GG3ZWX53H+LM=O8^S
M3K+,@_Z(WO#IPN6KLI--O5<RS<]GW6[,CGJ8\_!^==XPPRML82NW<Q$S?+]M
M:+X5=8/T \H'".[H_3!;I#"@E/;R5UI-_XS)E:Z\H5#*:A?S:[:>69FCYOW&
M/XK.!6<Y?=KSUGP+5G: P4-SU)JGKLQH\8=$I4/GR:[3#CH \3'[6K-:)K+^
MP$7#X0?*(OF&*M\0P85R=8U0E?^\SB(6":#S7O#^.N<;+S?9V:>H97EPO C_
MC8_A#4]E8B6[CM0$''JLZQ$GW]<^E*:B,^+2D:WY[-V#?.]W1I<B?OY7\/*?
MO/$C^<=?]!V_]JQM- 0?9+!_?,5W8>/%:H& ^3<Q>2BG.Q$^">BU,\B<5(?U
MH3;]\@RO5"0#O<=\B\(OR2LJ_QK5%Q[K/^4PL]O.PO6OFAO7+]\C.);\J)2_
MZ+'"#XKDMZ 8!1'R' W\8.]8[/N-KVD^U;OJ>UE^K>Y03L.S:\,LT"8A_]%4
M;4D2M6NMG\^A\"Q=;N\!4P_!W(B96_]LRBON;.GYYN[3 OP3\@?_,Z3A#FH0
M55U3[7;,]8"':IB'$?]@=186,8D#GSS7)H:\>5WJ[=%%,],B+F=Q3[V[GK[V
M_-:)SQOC!EU>Z"_DT)I<3A8GW@EUZ<T^L$:[4,==_>1HD>Y1M<:Q(SX?V<CR
M[U4U$2X37:O-?HTH*Q 3FJ*-N8FW&8IJK<LM46%)2)I^P0P<(#A[UK%@*,3:
M36_ :M7LS+ZI'V<G3UCPRBUFDWY^BGVN66%19?VRY8<;@\2.-0$&CT<^"J3Y
M:W+3"C,#(O[ E9[?5YC96^JN[G-U5_=$RLYVVQ.1'-.5MM_S4Q]+CGO%24IR
MCN2X"-(,WQXZE6[Y_)FU=(@QP;$SXU"BY:/=C@L#>?Q[T0LE\C^AN[*95?3+
M4.13*,"C[\+'AI/2'+,69#,P].F36X'_MZ'2@?A3#=ENH^3^6*.AF)SSZKVI
MVVON]1_9:W ]/"_K"J&@R,"JZ\>G6IUF'>!TY)J+!BO ,_3O?RP\"+I=NEK[
MZ\N*=Y<9_7L>"QX'^._[0KRW[^&3=]Z]H:=O;4N,<'\0T*7?,+W?\OX7>02/
MZT<9FG%<V)UWVVR!/O\;/SD=LG67KP*=86U5^2>4Y0(8W2*5\T!N,BB0HFYP
M6"IKR?K*#0@*P=_YSEA)TWM#TFLP!&0^X,8PEU)+I>\)5NN"7N(,U?6U)45M
MTLBZEUK\Q-6U]$RWLE(HQDX/+V)V FBS&LQ! OJ2QYRT@P[=(&SABP>QD 4^
MI6R.NK0W'&-TOJ[[%C,8'R^,YK<L8@9EK<QU3OW94K=PW'+7ZYQ)4B4S7>5Y
M^8@WW1&ZEA4X4GOC0N\F%RXMTNT5<)9_4=A@\\1)VCT]RK^3#NWO0%:QRN P
MP<6EN6RD5=^Z]"G2QU])OMJM#0<#'2T?(PLACC0]H4%E,_\CPX*VRPT[M? _
M2  4B=QJ7H68FR!#8- MRY(_9A]U)#?@GH;D;E6($(U1M+F18!)PFG\C2$)J
M]PMPZ>&313?]<0()Q"[<4=DCD&'C2X<T\,<AD<1MEY:V0^"7EJ$0D99E[*Y1
M,YP&K>Y'O[RG^R@Z'K?A_1Q?S#4^$%Z3$U $KUQ:#=%V+DSGQ15F$VD10SDT
MOEZ\OP;$Q\U"ZA?N'?/T],QXY_+O[55"*)+TP8^QM+E4 _O'(:;X"5N>.3,\
MLXAQQZT6SGB^+OV&Z'^D,M=!+/?RCU>QV/'HQ-JR,-N<_SQ]PN_GCWO>)TU$
MYSZ];F>BFV&M>X)(C8K<5W#"M\VD8F_>'@RNLP/>9%= /X]V)P[J$%/@=;[R
MO_NG9[N3"'H,(_BHLH(?K''J[YYQGA'D NQSZ3\'&4K2M8_4]B<;L4"6_';\
M80".JE##'132]TM&R.+752Y/LF4X:)^K7-1+)P)VLJ5J89;4KV^4+>L>S&^S
M9;41$Q!<?W^,V_EA"2>-^LMR)IFGF^+V2MWJ'MT>JMTZL5!E\WO3Y:STMNKX
M,&6&1ZUR:4ID!ZVDF5"%3R60B9 9IXVD#?D>!"G3(C!QOAE7.9H@3=?\-N3/
M%Y,&./)H7B-$!6+<V'_Q>[?6 =]+9%WN?_4W^$GK36H2A_TR.EMX.VZ[_J]Z
M1R#W*U,^([R*A[82X$W%@$ NA")*Q[48_Q&J<<E>4E;KAH9MSWU#HYUJ;S'V
MB+K%[*',ELR/XU=<5XZ62-BZG_S@RQ]FK<Z4DK]3B;\U;4HB>TO14+G4(5JH
MJIZ>2<LDK"&0L9#Q-+^=I#'IOTN9!FN >R=EG%;^;VV;:AF&4$FDF'U;I'Y?
MBD^<J?+MRL4)J:4&DBMO\\=/BAX5EI=#.2^&; 8O52ON7U<*!OT')ZRO926R
MH\C,<TSRRNG4N0>@G_?HX,CA^\-^0V??_'",($>H%WP@JC>X'QXW"?_W#;N[
M&]K)A+4<Y1'H*!8A[VW3I^84A\:'4N]6]#(E.Z! <!_JGB[$=Y!6TZDK"^2>
MHR; 2->4GFYFAE=&[?KQW.W >XYVG7.R9;+/QHQNS\J/U-+-RR?8-TA5JDW$
M(9:$<,O!!NE&%=-.D"1Q3IW]-H== W4T#=WQ2<RD;EA=JZMW<IGAU]32<??P
M\G[8[H7/^,+WF\6.$863^M2TI9TNF!G,]7QQ+K(1X,*Z+7)4G,<EP+N@J.V/
M8F2HY:]B-1.'**U&FSY05.XRN=XTW^9:MBI,EDZ6K,H^]E)HY;H*/BGN;*2X
M^X;E1%AR5X4P0^IRWXWN0@P==B.M;. L";*.EUYL!"OE5\#Y9#I9L<?M>>GW
M6M!9DI@9*R/<&-W]<;I <:" 4!759.BK.$$_T'_\,3" 6Q^FVQ58\"D4SX$=
MH%IJ<<DG1V4HLVD=0?P9'T\ /#3"L8-C4E&\)8I?/^5MU1\H5B78U6<F?H02
MUCCL'0BNZ8S@DN@[>^="$NN+H!37&M_2 '<HA,LK?3X(71N2>7^DGY0.'\"W
M7OF&P?%1%QI;W3@S!8)?WT^8Y/;/B#O:#,+^9V*0GS7*7#YYUTTK;2FB+77W
MS*#;BYAX_47,9X^ERLE%S$"38CMSO%Y^ASO]4YZPB+FW'.Q _EW$M'8K#\W5
M(9O19&SG_])AB@N9\M\9;]D+X<K\'<L59>#8#7MUU#WK+VTWFIR[!N"V$I9!
M7&*F"TB(@RD2I5F;@PZX]I'#FB%&M409WJ,XVCOU>=>+_OF:RL-^'O+O'L9P
M']IX(5O%81<*42])@ ?W%K^:.+4OMF2 T8FKLJKA2OV,)6M+2\-LC-;WS3+7
M3F11.>W$07Z;H#.*&EGV3=_2R.2#/1$0M=:]J1?:F_-,/WRIS787TC=>?S'!
M'R\EM3G#1J)S^2X*+:0CZS'HR];T1GKK&A,?[=ME\&R6["RQ20FW&GAZOK"M
MH;:.Q/+_XO%0_R^R>HGVG2>J<G6 (-.[20BFQ#/5'>S@W_N\?*$H,$6RB+G%
M,X'P[BJXO6,MN7L_3%5/[_#K6"%<-QRJZ2-RIA1[7^]Q"7CF&!FT1^O@9GV"
M+F,'S4S,:A8EXS;R3";7T9B2F6;*;[1*J7,:=?!&\&RZ&LWT(!\T3:+J'NK\
M:N!FZE;_:(LG=E]>*]ON&?=?)F2S6N';RQ0G\U]:=239*'D$EK]M>:TH1S20
M16IG)V=1$B/88@>#JIX&WJC_I[\C_)=*I49!(8S?R _HADS8B?9>89)4$K)Z
M'9C5/B^_(7S/#2EP$5,&:L46?>FM[-2AJH4"H2=_()J3NMNR5*O9?VW,V^E+
ML$>D:A)LH?WC[,AU\V7P048/[P]E]2(F@#],E&LNK?U&=GB'_HF,$+0;PA3'
MOOFO2;1+^@Z; IU_@5='UPMXRR>B6S,K6W:GR[B#!KY 8&W<#">W.2Q]%13W
MO6US"+PGEB::: $FI:JW',SI!,"F#<]:Z.,FVZN"IDV(/C@3U^!T_LS@)$\+
M9*0&2K%K)W4+^TA3"QEWGWF/'C+T:(W<0?5<@6W&0WCF5#S@+.];VED8]H9,
M :$?%*B7MH@)8FN$$#;R+RJ7'P%-65%GPD0KKQH,>+W)W?2RFA?B#?L"2X5B
M]A^NOGKGRPP+L]WT(\Y\J]D/+*ROI;C.;'%96J]3G3X8T*XO'&:8,MJ,=J0W
M9UV(BO*_EE],7P,E6)=("8E1@X\R0O*!]Y5D&0730:%LRE@@L!KV2U:9//)!
M5IU>OD"'1"#KS2*F4M3$O2TR<M@>BB^ [:%]P.12^2;YF9-^5R19POP-BCD!
M[JZ17^LR(87QR02W7#MUD[N!C8TTBRW_56XF--7"FLQC(!/6BT)6-RK<F$W'
MF>1I!U''Z!IEQB4Z7O4-)3YW,VF:F\C6@(D@U@O<1S<#9EA7-8[OK(H9P:.
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M=OD?OW#6?M6A=__YIMJ@H3+_*WW]-:<D>BXW1K4&I,H\:ZJ6_R59SF\6XNB
MR$V<6EB517$*%3%M&AK\@>9]2VF;W:)R8S1IB8/)V]^OHI'5Y[5O@ CQH&GW
MX3IM]BR&PD[DV.#VS16VG.S262)[YA+3?.1C]BFW5M="N.3RB;QF@4WBB0NG
M;JWOJRY;0&5IMA"N5U-A_5G,PO>,[1SU0RU'9P<T!L]BHC>=%VS7#1!Y_:W"
M5-"NA6PN\2J/)AOK3!D>?7E-URV:I"DFH_Y,@C7L)FY6ASO4^6.;)HH&?)]R
MC*)^AK9'RO,=6>\XX!77\8HX#0;6J$-1X_[ ;.RDD*OZV_ &C%,\. *Z'P!?
MB[1@C2.7GH])%A:]I!NUV*P'/SXR?HDJRO 1G1D$H)2L8W3+GP+W#@]?>07N
M)%]875GPRSQM-/.SE,\=;T>M\ >\7$%F<ZJ_-<=8- IP7=5#@61#^-BH6Q0T
MT4(V'>D#*#4@7H0U&AJ6A,/<EI 'E:%['%4[/D6II_5#H VZ3+G&3QO8#X;J
M%LT5TN=K.4 4)PG'([62)!KU2VVN;C[C/#S7W'@!!GZBD"Y 3.$*C3?B"N9D
M3.)2^H5&A'ET5WE0,L,.Y52K8,XOD,W;QQ3+2-9I\.K=LI$9ZP9.*J_!(C"W
MK\MQCU_[?N: ]JD'!<3^KQ1\_BXX64-%A2<@PIK262T<T!^0Z"N$B>LA8:*'
MO3(L5C:=%4>Z2; 30&'L6PQO[DAN0='C,!AHL[$V[Z"ZN?3E)\014R;S#P08
M#Q75#NJ\@<;'P%SG$XBF,\A33N 8Q[4%S(6(/]27J:$@![NKV9:,W7/?3*^$
MJPYT3W*2A?/B/)W:_"%<ZJ2Q7_#KJNXX^[$A+U(-KS[=R'VLO:SN2I9"<6*5
MGF8=U,;VP()M32$3;,$&>GL3!\LPDM]85TK/:RW8"9G?E1,-Z/&'3D3<EHX)
MUO5/.&MQ^RO-_)?M&SM<S[_IYW#ID:M;$I331((WHWHL5BEN?LY<@JS2OA6>
ME:8*S2;BG#NK20OH$4K71/P4USRZ<D^.P2E9U+Z7=V'UER>QJ]F-]\9*3(:6
MU.3LP7T3*?FJ3)E8,J@S*H$ F6L;\9:T.E)EI]D$-#H3K.GG: N98J*>P 3.
M4W)O>\1JCM,_,%S*AADT6 Y^V^OJ9L,O0;9V\\(B&CG&,?5!9Z]1G]!+#J(F
M@SO;XV)\8)BV$K5:'6,U^+]!8Z>[IX"!')U!LN;:=US-MR:I!=WU*'P$,L1_
M8K5)%]-X. . 2JDE9R X!6 ^TG=D%A/UO3:>=8R>U*265'[V?SQ6@*MBBW+<
M0J)KJRU_TU</DIUT7;.8&NDX2V-%N7Z(JPG0=1'U"7JA\"VGO\$O)<T<ZZAP
MZWX/?^M;NP&[% ^7N/A9C(%%FFE+43(MU*MKHJ_SZZT+BV.<=\]BU@,1W,$;
MZA)M-B!+C)^K-%QF(8]L=K10/] ^T!DS#G37'Y>A #>SCROCK$1\!'!<^6BX
M)6Q_34%QF=1UW9A(M3PV/*\;\5'TA;;GDX/?]O'^3OEV.'^<S0$:WPKG8UO9
M VNE.L,TS9%V&E2G[M"^0<*@[2VZM7"94D48)/<+;!B;0'$S>1E"!'T:.2FQ
MT?[/[6[I5DB\Y7Y2\P$Z640>R-[H0:(6#N_V+&$Y1YV_2;P$1!)1+SNAY7IX
MEM++U.':)P03QHV.25^5*D[#319X@!,9W\"A+Y_WW?##FU%J_:=:2^1U@\^7
MB6,B7PZ,3&]O6OQZ+X3T(E> QG'SO@GY!&R[7+DW,TZ_A<.NZ?CH,[&.7_<:
MMG+\Z\#0/8I#A<WNH<<HUS!.&"M#@^1B(D68+ 7)[$5 HY\P8A:32EX@,&"B
MRCE').&V<5(D&\2I]78*ZZ,?&!:1<GRZS;QN@36=VE0A$YM2.&93GF8'H,8>
M%Z()Q3R7ENEB-6'^F?+/F,"FBQ,$XW78R!.#C4+PX!?>O9TO0Q7];0_YV5%_
MO?;9U258G'HF>P-=$MRUIQPJOYMS^)C;_3<8()Q3+57U:E8Q6W=(C-M4 1H_
MQBIXJ5TZAY;B+$PM<.V<))G *1O^""4E/*6?_;$>,B\M"OZ\/".@S^'*V\F*
M3<-;2\-#_DVK^ZQ;R3@,QT E[PJLX"=@4MOP$O2/M'4'3E*P;$[R^CRC\YL(
M:[N1D9B"L7W0PN3XA*+1I=YQ"UJ*&FO>_C8X'/HYY-"Z-XG!]_^):,6!NSF?
M])3L%,'J41Q/*-),2+AH;!4]&9(P K0O!'94RR8DN+9_PJ&(GQ0 A\64C":)
M</,]W.46V>X BZ '7WLVHK,&:U@EE.O['A>LIT]Y>@4BJ.1.VE(?KS1>)P+
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M]_& #40P@/8O 9LIG/873AVA+[Q)#)GKM4/^YSP!==O*GPI &R0T*IMZ*=Q
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M6#)=RVYB9Q'T,TB5\"U0&MKSF,\^[J?WO#'A;#GLWDP[>]HC0)9_TJ]D]/5
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MH^*OZR,V+-E$JLTRU''XJ@19J%7=A^TR8@LYO6!9/^]FU5"4P!(:KI4N8FY
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M=ORC(-).E$2-\CP5*>/V;>H"_]<6L1S6D3%A<Q0#&58MW9BZ^>PKP: /Q[M
MRL":XHV@*X']=&+)B#OU(:W-Q$1;B]'#6FMG\O)X837DRU1:$],:-]."/-HR
M[+Y+.R^)2 G'%S&W7,CK@"-H=#@"P#^+VMGPEK;B4EJ<N$NIE]5*<(;59%BC
M,;-=,!/4;>=5.20]!N6OG@AMDEAEXZ/KH(U8@Y!!@AF->P:<NF6L/]KP*%VU
M>]K:TVR"#':EG.^VI4T1J<0P8*A+#$R=!9,%BYAEO#!V4J,Q7 7FM%]U#Y&2
M5\&/!]S+*^M33WQN/_:\GI,[>+)[;L3RV]YH+>U6?U-Y?N77V-OK(HR]BD+C
MUG@_4"N$S=L:U\/WQ%WJ=%?0,,669P";M#<:==>'B$5Z7W/<XXIH62V-5CU3
MT6SM":'G?]<R)SS[9_.&/10FMWY<J'F9>8#O8R5@IXFT&2OIOT"+F#9RNMFV
M7KPNV"M)OL41;:3)!+&MHUZL0AJ%GTM?*"@%=AWK>0L-!]0.^PV[V7V:Z^6'
MA/PT'[..;_5M"%+(+9<*F8!F(X8Z+1W5\IMVRHM]0$37T)66$I\!D5Q?55R/
MI4"A4K7F"K/P2W/Y/HL8.0VZE/&$YB(HL =G#0T-J]S!IR8=SG^L7S_OTLO8
M!.?Y]EMB[Z+;XLD:Q@6@H.5/8EB7'O(: 'W80A?!J";(OE4>)<+2?U&E,%:$
M&Y Q#!VD>X&7L//2)7QD"=T#*O=_7 %16Q<&;Q9Q>NL]SH*C6)T/@:[4\ JX
M??^ [;5ZBR?\_28B,)(ZR82<Y$OM*QXQ>@$P@)U.T.ROMP$S"-OI#"BFV6!0
MG.\M #80]E&"MO?.69/6>&RRSQU,8F@JG2"'%/RNI^.7DY_70!<J)'G.QI^_
MG  _U^<2%];Y:J/R+.&C:R=K*[$H\_%-0#$RRH#;ES)1QQKU0?)-I?7CX3$S
M+"A*KDZ/XO3.-N!(G%^3-&D_'\A*RK[F[Y&>:O$RVX_\\H%V^]+TPZY)'?92
M$A[J17*)9@0,K#'@)$I?L(VU0A7K9O8?G1O5G]+=X? 8RPJ*Y-[=WS9E3K0A
M&U@"LY]Z*W=:<JI?]"D]0^/CKNCGE_^'8(#F?#*7E3R%K%,&HU\GT\_U%8.D
M=EP"3Y<>#!E*W&XJ+[@E1X\$-R] 7*8TAJ_"'>S/J"Q%(0J5C\-^75C$I-9[
M/G"GF+&UDF]/3S<*Y( 6I<H/H,[!RU!K-5L:3<L+%@T/2ANX4P?$)$.ZF^HV
M<-%#RTM[G4!Q$.ER.!9N6+ )"BK8%*DK:+0'GW869[@)8BT$]3'V!;O F)3Z
M%3+*T$$@DL8ZZ>%I=W$_$9CXS!;&R>^#W,E^"6YMX)DQAP(\7 *Y";*Q:U!\
M:]"-BZR@GX6RI 4<O=ZQQ@WO'[UTE_78FF))-3PHM)6Z<5385:AT@*\5PEEM
M"]\:DFX/S!/_Y&D2Q2P1&,A+-CYOIE:+2N,K;-U6H-/[OKR:O0%6(.HRL+>-
MI6L3-1'#S>Z?QE&1K:<[*R,<+(>F*F?JR5) G^RRJC1^5Y^=>D54,V5AEP+'
M:!K5@S5ED6XRMH"8#N@3*3QA75 W*2F:)'21J;J2II6N$I;FQ[<X#FD971=T
MN&6+U5+B86UP\&1_^G@NZU:C*2W.ZR6T\LV0N\PF1N ]YA\B>*#V+6L1H_:*
MT84X0 [-71^"Y?=[;-.'N]24VR%F&S81JT.UL<R5\_?W->X<XZU5'A![W"]L
MO=#SYML724YZ]:NYDJJ;)ND3&2N\ZK--RBJV#U G3>1FJB*ZG2*0T2ZJ(D_9
M2&P.1-M8R7#-O.5PSS7\IY<%[:V&0M-RPLYNZJ<3;Z*I6K07H@!0_NS&WZY/
MQV+N7(J\[_QERE#A1#=6E3,TE =5!4 8=OD85@?141[K?M2-)TN<0[:L&QG^
MT3WZ(<+ ,'M&"\E@?_6OJ,A\)>E:%^YKG]N>/#=%) U$Y75X'GPCE!*;14-$
M9'6#XAK0[%"A# 1+$/7_A0"WGFKLD*^ 83Y =WF@-%25$D.<G60UI6#ZL<'S
M!X RV%R F,*OP*9Q_]NO&:+HXD5,".S=8IQ=%:DJ?@+_(3O>'QUXZ#?MUT08
M-].LY2)_BVII*FI0]\A5OGSK74_A-^T2;@M3E^[5%U4Q/VBF#5,+E70X%5K1
MZI]=FWW@44][DE);PM*![_;C0C@.Q&%__RUW@/"A#H<A%AC+53[L$&-5K$5,
M2Y<JE"Q\ROL=.(O:KJ4V7S1D)64)>,(B*:Y59(3TD[E64VJ1X6<AEKP<+GK\
M-=:2>TTRO+4Z;(JP46D#6B6;FYG";F!N<SWQ(8$EKC#[XENG,V9L5U B=?;G
M[P=5E?>^Q2CU)Y#5[1 9T9@)E?"26>M0_)"*K&-T!:V$.GFMP$KESV#,I.0A
MI?8V8U="\S?XB,V5-NPZ.W*:W!?96M<;.<<RRE_N3'0!&Y+R@V6:"A.%Z;G/
M[SI.WEXQ6X>H3RUB+#45VL#0 T8G<>$Q7I_\6ENIZX'X+I6M90,?;D#SBQ@2
M@)E8>*"Z!YSG"0?EYU3WJF>&GB]B(HFKE<?["29*9Y@,HD(18/61#I_<JR5B
M$NHZ29/7*I!-M)A?X1%J.'1NXC@8\CA5DH$[YDEJJLW,VGDW6A4Q(Q ^+J1U
M_L"!UH@6"HZ)H5W#LG86> *W-)[RV%QD@/PON.@);7I&:C&83CR/58M@J$.1
MR:W[?GLYB'>^)J%HWZYU[ZTV\9NT#;=UHFJ/^SN/WK4UM=2,$[W@7U[Y6JT*
M/4[?(N9; DOX!6G3'JI;Q/A3)*9Q7Y0F#;;>Z!\->+^I)9W^[ J[51P,LO+3
M\Z!"N/9C))WS6]0W%>S[^;[ZR,;G]9?TW_\5M!1 T"_\@N"7DDT(&B2%'2U9
M/E(%6X,FK0;(\D8X08);S>AT=$C%N\K8^K#YB6I((\*P<=< 8A/@^8AV02;P
MOY0E-<%JACL>-?2/'KA/1=&2YZ7N^L@Q[/\&W0ZV86'+]B:>%N.M8_M4I/:4
M"6@E^9PGM28E+AAP0.P1^+*,O*I+2C;PE YW4)@;PQ8Q.DH/;"K>*?))1(%Y
M)-&]3[FWMJ(\]T,&_;#0Z][C,!#E<0 845,6J:W4^XYHQC]TVE3?1[#T?-J4
M=+HU([((Z08V1NX<.FO5>6=]X-77^">/]_K)W#6JH57(]:56D;P-,*D9 %UG
MAMMF!-_'W@LG>)K55+6P;&'BVV-VBYATO!^THL78*FE3K^R:>5S#H6'?NIK^
MWVJNNV]E>N6.R2AQX4- %@!O(DV^@@)D.4K]%8C&$.0FIZM*ZCT4.Y1785.H
MC,P%V].RFF*)@IE$-%"06P$F=H,W&A2U";OIV'Z.:%6'C+TF0M;,,.F;]8LB
M8V'K0)"=.AN_IS4VJ/+2Q;NKD+)&:W1C+)$]C%'";MC["?K&FQ?!6\7H)JYH
MU*'E,S:%L9ZW3TZ YOZJ L+2N!'[_)\6J,G*4]"5,Q"IC95!U&VT] ^/#9PN
M_40[":>WU&J0GIX17M,-=S#^Q$K93[RC+<0BZM\A)E\$AB5/<F7N];LJ2E+P
M%HKC;HI(>)"/G.FX4J34@ZL,6UE)!$-HH_"<>ZU<4[06YDI(F9W?AO^USY#D
MQQRO?15 T8ST^8R;=$&T/O_/-Q\!FK'$<_%7#O093!R'22#KD.J?^N"2^@Z;
MSPE2\O4!B.Z43&H\9?.??:$D$,LWL^HMM/J]N_[ H]<'C>QQ$^Q4Q(RFV]:X
M;+!1'^8VCQI#AGRR'LW[&(A+H:\L^SI@V*@S0#<J"S_Q-38G,5IK>9C)T9?=
M.-OPXIXO/04?AAK2.=R[FUN87US$1.4Z0)ZRU"&33H;S9$380DVIIXOH.32A
MFRUL=?R2S@O1%KJ)R4K;4+ZUJ<_HMKL=)\"9M(N(A9( 1=\2'MVMA?5ZF?$;
MY#E]0S\Q.9T>*BUZ=/H7C'(I#^]?NN%3)1UR4*[/D0?!P44E:8B3,@#F07F'
M0(?D'1L^3FS&Z0(M]\&,$N&.R**";\.'!^Q&#KYSM]OV<\!I*3A:LNN"I^/4
M ^0!P6J<7$7FDS60UR+0BR7$M0AQK2AV0?H86NB90JEKOR(.[VTC*4V$7?6P
M.1B+-1C]VKBC-WKHDW>TU%2S)8<[:JS3'/-[XZ;>J6!N@>A4I+TOQ!O*0]3]
MSHIQPDSR\+"\&9Z7XH9CY"/58'GC,E!-@-6!=??#WB!7C+M>['EA5,8G5\TW
M8[7'"[8\!_6$'&:*73I)!\XY#0'I2O>R#&__7-'QGKS6 @O/<RRE?A:B3L(I
M]=6.JG(+>Q<QX:R-C([&+:J_D6T4[(9Z71D[.4BO!E)+?PAUA-4,!*WOMVWP
MD@D()@2SK);:D7N/:T,Y'G4CO[;47.7&[JB+UL<@@3QQI0B\.-(UZ2+AH9"L
M^3 @OBO:T+B9;ERG*HB*!V0.:<@:IA&<--B*K%B"U95V77HP6^PF*/. ZP/6
M$'2[=\QPXE"B2!M0G.[CV!@/^D8ZM'$==HTANGW $Q+\L]54 ^2-:.B@_].F
M8A%1KY,A#^,91"^3D9;1)EH-A/&-.8_A&3\X7&8:W,P#"\;D]K\/GQXFID[.
MUGET7AWVY'!ZIO ^^ .AQ4+_L0%Y#?0[H <L03)OHM!:7,!36#&Z>: WD!C;
MU:1M!E^@+J>3H?D6Z@<&,8G(P0F8R8X#+(-T&>FG0%J[MZH(?PT,;:JB\5PB
MW4@#]$ )ZV:.X?KVIQ''A^ X4G5=T@!_5ELR/UE6PNC$OB#?X(40/[!.@[S)
M^8?*[>"[5 DY*7<P%;\2)\C'N;ZH'D"IK>=36G)+AW01DSQOM@-RR+CP"EI5
MPJ8,FFWMG:Y4!DA-9O3)ED6_]PX%8@ L&:1V*<N7FM()_Y=I%09,T(2^?40P
M]ML^U'(N(IU_K#R7KO@==C9JN9LV QK*KY_WN?C;GI3_MC_Z=',?)O%BO(U"
M'VBN9YD2SY*$\U+6U',P#]&X4DYCRG#M>Y6 81L GQ:]H"9Q%C%KE(>(NOC0
M$$A;$!/;F/683NE^_*S?$JIDA4MMG$YTST3]6X[;?/>M>C5ERN-(@VII*F A
MBJL(6D#S22#$-$[N#W>641KUJZFZ7X%U]<MDZ#$?&?I_X7>EFAE5]\]VF@A\
M8@/_NQ,N_*CUD);>RC#MGXT\($T_UJT\4"J@Q#R. '[KO[C?F2JW[I\]H#!@
M"+H_1BS0S5%SJW)H\B3N1YG"/_8]$UP2Z.$RT%F9N/V,FYU*W#W;X.UWLC?(
MXZ]>V^$I3_MA/Q*>W$I5&D.*LS0/1%VD.,\0 J [3\CS39>0TNK)4,U7^O9!
MQJ8@7'(YAW2[8%D?#L%2"I;WX>R,?N[-"H!9DM=TFTJZ4\-(^%EI^.R^Z@K'
M^9-]]22)B0EOK -11Z'83Y?[ '&!#V-#(\Q71-"OJ5[B \&Z%N,</OGZ<>7Q
M'!]PL(4Y))*\*]NR[4F8:#5C?1#MB]2"G:QT>1IN'QN:R%8&7)'&*>IPJ\*O
MCFJ!&<Q;2MR5LG!'5A<1/(V%[7OE2_T8GL+36*8CD3G'&@+D>:]J>F=YALJ3
MX."M0A0'\%)C=S*++;,*VV5=R;X%6\$HWX*?NRMLHJ:('M"%9&FDYHFL7SG&
MA#J#AI6/;RVL4YO^TLYCDM6)%["WS)QA".IM6[#B\Q)96E&:73HTML!Q[N/5
M@9J:[-*4'1<?7M =KYU^?K4[G&#6;?MU.CH>"*A__GXVW:/AD%PXZL%;H8R6
MDM.PJQAZ*$_.N4$E&,)LJ2&?M8HF:B5J<6P.< *]FQRY:?7.)1/<@K7],\->
M/8WORVF7*)][["YXK-[L>:1G?"O]PQVKK!]9JAN >!"[>FD6M2[!A'Y25<.[
MN#3JFQNK-!R891HHS6 +:0!V/4P2DV[B@R7#O7&2$> DV)5"L*"[OH3N=U_B
M1AC[9!:U!)E0\NY/V:DT6V,IGI'1*O*Q9>0O;BC9:0;^9:AN\":92M2S]/4V
MWT-2"OY?9X/5 $N><!A()X.GM-.#].&&_R6#16^;(RVG.>.UQ4P-)4&5A7>6
M$'^"?7^-^\$)])P=V2F397)*/T;DRLN<1!3'2G9%1 QWE;7):HN:GJC./:0J
M#/)T G9! ]EEXB<" )Z946S%5C.1&D85N9_:HCW4)9^#0\$+$Q)6"H^**J/R
M))24(Q&IT^*:  ,E66$Z9A^TN<?PP,LTT^"34&6JI"M3Z)4L&_$^TRWQ))C\
MO1F\TSOGO# "#@:Y7V1]LY)O1<]U#2$PF@$.2< >UEZZ<[6(\1E =BIIR6V0
M\CPIE?C"+0E/DI!3?,V(T'D&?C#:-/AP+V+_U?!J[$/:NPWU+B6BKXZ5=RY3
MKLC3#<*K*2J/H_68;P",GT>.'P!Y2!<@P2(H[Q>NKR/"6WDM3*.E,98)1^F[
M).SE_*>C$_YJ2MTN^5HX_UKQV/%_G<91<;H_HF/@>[++<3]M_=9Q]A'LU++P
M)>7S!TR:IX%)*BEKS5/1^?\E@662-_#$%;5K[X%E4NP4&O,TF'(:R&ZUQJ46
MZ,+>8MX0VVT@.A$BL"24&<T/03!?NK84BAWX+M JYK-IE9&6-L3]8,-M'3CM
M-'LRVBF?T()@ZXB_,5&VM8B9S%#@:61Y"&KJ;F-8#I'/3N*MQ>N".9+(MC*0
M>!0.E=I@F\RT>^R(:W?>D*77$;'PL#N<\%.C$6$#.,W:D6N5?,G&MFOMD>C[
M= ^@(C"H:1F,+G)5!J./L0+N1'<P%R0UQ>/.W"2C<@Y=*E R:2>8Y$N8ISC=
MC>9T%X@JF%D.9UN?O_<IAR_DL&[/D=:.+=Q*7:L*:%Y0,;-=;Y(N_UBB]-R/
M+N%+&L&I?77G++<&&IPB7L:S_[SCHL'HO.MAODY=(Z6\\[K7,FEC%\15&@O*
ME#JJ)QQ R$34B6B@607?6\JBZ)L;>)4FDS3P;K )%O"50[T<OZ*Z ;S30\H,
MI,V/J65=/]_ >5%?#6JWFFJW^SP;<=W(&BY;F72?$L[[7R%[I:^(BV=5#30H
M7(!F-X:3TA=^+LYP:_NFC(,ED';SPE6.%)=BMF% #.8H-Y/7(FK*?;W*4X_H
MNU4%='U)H)L[=.%9S=5<MTQ<M"FEK3:SI#*(TM+E6?4",T,4@]HW&3B8BZXT
M@ZI'\S@Z$!W6B$%Z6!J-N^%:D5N:]&L _ M,D1);&DBG^BX^&#W?:YOA)DUB
M/A$%_<"I[E&H=LIOP^'=X[K:W0#\<[M2CRU!B4N<?#WL(*6NH;%_)6XDZ-,)
M8 R?*;22I/9O!@QH#NT,@_<2\+_&+;4]5O?G<+!+X^9%3/"_4MZJ"=Y8MJ%]
MSJ#_&N$_H^;@?,K%2<9[V$BAI]P%[U$X1*#1>R:E/@1BHT0S3LI>0X:=VAV3
MI_P@<JO(1.DI(Z\9+S"L 2\4251'@'6>:Q,*:7]\YU\M+>F0 #_1@)8"X]T=
M\4\7,>=-*=Y]<]9=GXC2>:51B2300?:X$/*5;T0CQ0WE4=7=>EPIY6Y@>)#V
M2SB^DC8AP*ZMCI.8"C[G28AI#"S< 0ZWUKYCG8U;YXD]"NGSY&7AHO/IIZ&D
MDB>GW4LC]F,'U%I9PMYF@H:J9&FBUY )?^RLC'I[$6/T$&)GT#TE@4X!ASG$
M6Z+E='6)%G"LGV!+:WDSP#]9T+6_G[#934Q-#-*M[LLY3-:#\]KNVN<\<>8E
MV7VG2+#@\47,,$X 5+$2ZE>"+O+H;EL@E<CUG8JLC"!J N<7,8FU9>I1E/@+
M3MAJ>%#&;/WPT'UZ!T&#K@9^[(%%TE4/(A\%>E;,,M4#JAT(/P<,[]1%U)?P
M9!J\5/?* ZF95F#H;?P5B"=/A7D&J#%HELA9<'.</1?2;$_F0Q]+DJL#K-WG
M-+\J<>(*K<I'=WOY-;G%\L(GAVMZX*Q6_UGAA8R=]Z6LY8 X:ZDJGH^%M[:A
MW'[E1O@^^M.D 9Z0S1C2-!&]^32"&9PC#P!K$B5:./'SP2CF>AR?>8MKP-*?
M<YJY5>.ST)9.?=+^Y&MIJ6?I.(JGV-)AJEY$;6-AW%ZU;UR()":V$V';>40#
MJR R^A!MR#<=<4):6)Q5-R2+F"16];V>K[6';D4#&]J#5RYB!(%:]%T/FDMH
M ?NAM7?*!4_I$:K\29DQ15N;G8(8$$ICBK\V[H96<9$D%'4Q+&F:,M1+K4 Y
M3X TWZIM$;.6L 7V=8&X-Y2!A6<T*\Q;@PPA2]:JLJ*(@3UG3_.O!5]9TWBF
M5+]U;9#FWV=?9A[.^@X@&I^6^J% *)/PD%][H?K;0E4XR5BAW-D(&>1)6:8;
M"*N_\O3Q?E*;8+YC0=Y3F$!:2TOWAWB)/,ERIL=+;I]TP++G(BZ:M.[T>*A'
MI+=GCU?9V8IK5.5Z*J)^"OJ"J(=(-$DWKY*YHA1B&'6(Z54+&905*@VAP2;G
M%?S!4:V!^E][@D8ZQ>24;.)ZNPH*7VCZ[M6.W.EBB4>^P^GN2W;6%2?F/3GO
MHYU#??JH&")EZ\,T#(1+)58QFTGIM<6-7$BMR9_QJCR@J:;C*1^H^.I_>P#*
M>.X2=TTR0G)_V6=^@Q%PGG?W4^1?]ZX?*C_PG0J?I0Z1D50J$K2(T>']0$/S
M$W9>V^_4U1<VY+Y\"VB HTY&*3G.]* ]YF^@O;F]+\[,409:WE6X^UET[OMW
MR")^34@2_YV7-__]/P65)XJ]3E#K+MGP\@CNZ*8:J%#G^C5[$?-I!C)9Q.2.
MSY*2L55DE/'>JN7#"4UFF-Y9S\OB["&[@ RWP$'V5&$^_E5/RY=6_\H*RWST
MQ6BTN:* %G0X)#3-[=#\]FUG]^Y) #?D[GVKK?'[@*9A<FZIB_ZMUR_J[2T3
M7:N_#A8E)OI?";10/^11I/?[AS#W(WMC=?X*["LZDGLWOO>X)]%67TI>#X1B
M;[(,HSWBJ5+MZ]6J*Z>Y-R)S3J%:%-#-,:J0F9Q+DG_GUQ9D77[BMEQ9\R]@
M\69XFS4FXW3"5+4O^^^0^Y<BD[*U[3K ?05K3]S^=.OM+W_M>AGNM1;\Y\FY
M\/Y'G]3*SXL_!I46^;7HFW><T/DG,.^VM-A@X%V/9WBO"X25WX>-P$SL;4 +
M0/W-#3/-=%>HH"Z:>D7:>8:"[!@\=#^T%'<_--*YDLN.\ %='W\%1;0BW[ '
M 44E&7N;?_&S2B,/$5?!I$.@52+>62S2#E#EN8(#=T**QJ"-1FL,CI4'T:>7
M_^#Z>IE]GO[#X6.@I^T[C]>M2#RM76X(9Y0K3T-, 5D3Z39FWN( NA.U[TI1
M)C*6VYGYJGA,6/[NW'O?TSUTCY(NB^*,U&2/VX<VI04XG3[^P-7,OP[9,"%'
M=[2H$TY=>CZ#!;['D&^!C2M27I((TK>#VI)3I_"R77(C^A\78S1"7FXT<[UQ
MO/AFH9O6FD@S?[AT6_"NN5-[XV+?9?U%/33QIM#X0^S+M#M-Q%&O;OD5?HM.
ML=:FOTYFOQCPONI[=3*^ BJ1)-V'TB4YZ01L1-#)T(!>EF*GW'5$E5,IU(EY
M.+[_R>Z5G+ZS-RI]-K,OGQ^T+Z[Q$BN3%<OI7GW3= <I\WKCGN^1^' PZW@C
MM_I%/76V2C(S912)VW'8(O<0.%![X<6=^6N7AR+\7:M7=-RZDX[ZD6C%D47,
M^\_*I5QD-I/WHZY"E(!]'IJ!&"G/]R [X019X&#ZC!CI1SYZ9)B?B/1M+2T-
M]S6.N?.48ES >]*!#]^1S;TTKW/F=5#;QT/G[FPNP'IQO&S;H79-R-+P^A7\
M_?<91YDI%.F5 BS;S9#_0?CL2?&)#1=;3A7[;A.(L,D9>X]$ ]>.=.7NVE9_
M%#IIW:Y^(I]]I.K>$9LCMW-CG[R;+\'%^U&>$@K@+,5>I1Y<]S1@ EA'7UDR
MD2NHU[Q86^ZP,)KXI).Z85C/@5M@VC>;EW%PK^&G&H\?.WV&W$__%-&*M?^_
M&>:",$WE8-1<__/?YR)DNY36?-KDA<UGYB#:6Z9UJY3B]>^5?G: IB/'XGR.
M[1>K\_=FG3[]_\?J]8Z[QF][Z?M=H8CQ7(<BAP6@>=6YW6T6U.1%#'C2YGG.
M\9]%"D?X5,YJ+]FKW_)S5MQ+.K';G,[X$=$=X>OH4T(M(@^/^3>TL>)6W7L:
M^,'4I]>SK[CFKI.)(M^&:ONYKV)R.M<ZM=SPV'.'.VT#TF\?_OU2\GT.:D=6
M#RN"Z7$J#B^4-=PA(((GV[L9NQD=/OZ5]T&R"PA,ADMLG"3LI&J>?OA"4H9,
MH<E:,\XSF6MP\R.E""W+GH0UXFK[E >NE'H6=VH]3H][^)CUV&23]E<?WKM%
M#**YE(;0#*,4\J=453E^J3_2(_3RSKM=%A.3!U@Z-G1WB-S<:-";/XN]2=2A
MN_TQX'CO4WORI/^&G<30KHR28XV@**U^S]8$5W"T@7T&/C<:X+Q"@.CW5&-G
MODM\4J$]_,95/;9,U#36X9T@EW9Y3X1G!6VPA:?]"0XL'']/*AT]$WYY"+8$
MC&B(IT7UU/8 &_O/AR"?(E51=+C]H_6"2X*,FJY,I:9X)A71@*A\9@K#^'U]
MJ)AH1KOB!R;?KK>06F^P<]9L;=P K65=+J;$FCTO^5C6?*TD(C:Z7Y _4O_4
MYW!(]-XMZY8I49S0_)2LCV,X_J]M3!@S0YA]A_(@@KAAJ6L3C^,F\%"M:OL<
MT&&S?EZJS^,S#4;"#6*NM.O-^]1>7*C/OCJ_QW5CE4##8TO8Y!M")BJJ[THR
ME%FB(-*MT#=12JU!LH?J$4]<2M2?Y0U=:;GR@>5T'(QI&@KJ]5,]85@'?MCQ
M)T>4A#<'RZ:"L-#&RQ\/_%$39*\(O']MQR/U.9)2UQ!1YXAG8(LO34 Z"OU:
ML"9D.%GR)0U=+0GUF48,=*DM+B7NA H0A5L,PGO\SR5AHRL'ID4G[Y(V=(A_
MU-MM49<:6?94<E3[*HP71H>/*4ZU\O)Y.D1QLH@SWXJ"2IDD5*D7@_X&^I!U
MN%,KP"-OOA^$3ST^C;PNT.+"OF*V6L0"*24*IT.S/@)NY!E=VI1U$/*Z(Q6M
M]Z-E?EO$'*N'O![;>5^Q2AGX[O5^.DJL75:-@QTZD-5#A6&Y]BG$WX";M2_?
MSU80CQC7U(6S(QQ'G]@J#D<2JZ/S#W!>YBYB3C5\8_0^"=H@<_#]HW/?K[AJ
MQ@Z@N04+[F=^8+6P0$]<.F"ZB#G'',II(O[4^ O2Z>M/;<M Z;OJ<5GD91GQ
M5JU&8+A(3TDLLY@NNQ:V@TZ49)P 4BDQ<H#3BJR@:(8'IY^L]2,^6\0L'VO<
M]5Z)E8SLD6JG1;%,8&&[!Y<+.:1'X31X-VV!=1&O'YT9CXVY%0)II_T'SE7P
MSQ;U8EMS.P)N5(LZ_V'>Y5%Y0PDRWZE$T+"-5?6E123T;Y='@&P!<SD\+V$+
M*F)Q"09$ Q36::^B?3]<TXV;%:F3QPN(8&3RS4MYO[):8T\ACQ="4V9V1G+^
MR_.(5SO14\'^A%'6HC'P+$ ]KZKAB7/(:^A[I/'1T:3;P(NCV:(JH/5TY:43
MGO[?^8WZO3;%L).T[N_[H]\" D,E96-F9CE^]>&6 TI?<9?A1_P+3ST%HQ.6
M*&*X32S8&C<9K3"EB03"2XD@3\Y1Y3*<NL0JI^/5[VW,ZU4/Z<MDY.2%DH3?
M4'^:.=[C[#7"F4GN@'3W]T:1IT*>#]1[$I-M)YP=OYQI>+Z>X87:C!-J'D+>
M;1'HT97N*!+PAHB(1HYT:I5"L+#1S!B^(>89(&]&#2%?/B_%WS1C.,+X5$E:
MO0.QC>+N__U7WK7**&?@U[YJ\OJO$W%EI\<6.AMS*B=J''.^8I5Z/&1U(AB,
M:+ @D9@L8#')&Q@XFIH'O )DMS$V@">QRSF!V";$L0K.EQ(WT-Q:<QU:X\@;
M*+78VQ47(Y4V5,F$I.1K]H+Q2 TGKB0B-.!P%/=%(T;UO)93TUCS\D4#]^;T
MNVGUBDM3.PLSI<)QH=0^+2XNQ<(WC6:5.KJM\)[Q/O,+;CX^FQ8Q>5BE 191
MA\!Y^2_HUMQ"KSI?!VF.M6/S;0 4=Y4JG)5!')@L[J,$&DJZ6IL5KL2D:/8Z
M&N5 KTU1<@L+#?_.1G;##:OTXE<<RO*$QH6NC^$C3IZ&1Y"J6?8',J*Y#^0?
M3FC"JB]-6VK4ATJN[_B9@M.&\^0YJA2\(>0@R[SQ>+=-M8&PJ]5&34I.M%W$
MI/IGYQO'U^)T8"Z_>WPA?_*%2[E[S,4[SZ:(9WFP.>D&[P)3Z"0@<T.GK*$9
MJ>'4L *@=7C4@JJN*0O(^\![I?Y#FB$_)I8>Z]R6"(:*YY.I'*J6<D_5R_?'
M9]VRM8+/-#SKGN9X:O.YCFLSV/!=OA]&Y:QZ>#X3.Z20E;]X?<?5L+DKM<=C
MQ^W2C9=+;D;77-MR]>?C.@<N7/CYU($MU]794A-D#641<\<7T?!%";[:)$K^
M'L\(=_,JNX:9\E#5XT5,!#6Y<3?L#E+EC3V\$-$R^F'X<H42#PD&\A6$<)X^
M87.76JKOL=[Z X"$9#0!Z-;O*H:/C3.,&ATU$D%&V=.QS$MV%8:!O=&ASU_V
M NK$<T38GBW_"W6[?P3!GQ5+.W:S7>D#[UC*%7U&RIRRX9W'WBS8UX/W0@S3
MSR3P>R/\#5M%!G#OKW$99KCUE/2S5PQ8>J#ID1@_AY0A#+$\)RK#V-WHN([?
MR,C-AYMOOGW[=O^I8^H7MF"6;1'[_JA![> :ZH5Y!D#S-4!<(JHJ4>J2$?79
MW^#G8N;U',2RFT-*]=>[&X%=.T/XF<8[UAV)[*0?ZZL_4%SQJ9RWFJ$%4_D+
M.S,+<*XTCF>D\BQ5XCKX<+!^Z\+,G ODAJSN59"0?K,-3(EH:JD78YZJIA%'
MM^8]>]6K# 7GQ2R^:(@G/]Q#OQ:"5PP?@HXN8C0()F<Z*VGGID7VN8T);,L7
MM;>.TLLZ3._L !Z(GK&5NB0Y*HZ;5)K!]R;>"X=FG+9R'_(QZ0W1"!9^#NA:
MK_2$E#5FP<.>,A)VHI=,2_?E<E\63$_S73*G>_G&.^9S@ _&9O>T^"W[G3OD
M9^%E8NJ0E?P2;*6P5Q+O'A>3KXLT\5AP\-<^.^QVDY$C[<U"_<<YEZ6F9_],
M,3PU6!E9&3T2<=):,\)A_FYEWV]JWPL5&Y%_B56^2H,)>:'J)5%<#'"X+60M
M1C>VZA^4/EX$SA-AJ_ED.E55'",)(ZQ&WL7XM[%DBYC;#).T-XB 6D[XA7YZ
M(%KEZYH[O95JZ_8"(OP]MCW0W%6!:M[*U:HL=(N 86OQ=!WH(/XRE1&OV P[
MM*.^"9N ;)L@Z,-['BD/P3>D+&TX;?7%G;-L+;C.!_J2N(B1+./4]ISOCVKP
MF3C<,SVG>&FG'[_G3/=_-5>BQ4MYBFS8LJM=&[8DMA U&9TL4*C#Z"97Q=Q(
MOCV-UQ?CUB-=QL0;]<&2 #1*PYGS@L'N,4"GFIIFW-LE^0^RKY+:1,Y&!K<L
M5,@")ZZXA%>,+41S.&D8=-G)*U#=,@'&S$08(GB\<A'S;8&7(;H%A?- JJ]R
MXZ<XL,8(7=]:%8HXPB<F<)ICEP-'\,9K,T!M>7;_;_7@RH\YQO?>2D5NL"'4
M?C"YA5NPI>\":RG+TJV)897KP3'NE[DC?]DI'P#-;H!XB)>"!4\"3']@2DWA
MA7XT9RZM6-%42^*3-<((*U1_16EKT4A\LS7O.?%QY)K>*(4F,V.A0M79/\"5
M1E)/]7&<2=X-];6O&G]IDR]$/F:=O;!,988,8*L&$P$*<2A')IKLD/F>QN^!
MAB6XS$;#<<<;W(!746X0D,R>S2"V7OW=J8U=2J-XOZP:G*UJ6!.;F4?97/MB
M%;9E7FG\+Z36Q@,]9^"M\U-E*#+-495/8B6#K:)4TJ-QL^55 YTC!??8]*/P
M9OJ)00-$XV5]TGN[?'/IEY8N/4]H18O9IM.N.:GX/>+ W?&[@W>6A%-C5(6,
M%EX5,+5-8:/<T8OHTN-5SZG$BX&X%@(6[$IBF,$\ 7%5%#.)I5.=;\Z7#U[5
M4LN@>Q?1)@0HZ*W-\PHTZ!&=Z8^J<&I]NQ R6BAUOB)P?,RVF^)E LVN//$=
MW@M J9<K:D:VPD4A4E$2MMJAY?Y%*J+!Z"?^-/=<S,ID:49[FGA' @>-0U.#
M:UYQ!Z-L<*T_C<MK#7BAL;FGI@1(L<1#M(8RSZYXH#9N >Q!52[:=RI=TC6D
M0-039.2AB2.-D2ZRDBD.FQ8C9K4LE27@+$2I'.S: !J+/[H99K&'P[*?=\0_
M&=M%N_I&U/2'36VJ22M9!V]'-3[SX\5^T5TBZ,V#MV&5&T-1N9*S>UO,G <)
MZHR^14Q5?D^&B80]U5"&O)L_/I[;Q<(.55=H2T=*$NK)1;!;$TNO_-[)YN#*
M,8<:LUVTD'[;BBN"%ZZ5KB7(GT"SQB(FE#?DAF@8+=V) \#3HHQ%C#&R&?E(
MYF;4NDMPNN,\8V92-56=\5JTOM[Q;F,1ZM 6,4U=*X?]8>MFXZMW#*H++$!<
M"MO7KY'76^\2#*G]R@6!-+M._X'N%1,DV!Z50H6T"[84*77+^ 6F<%V1YP-&
M-U!MF+:3X:@\!\Y)[_71M>RYC\+]<3<08U'",T$IS:-9Z,6*D7H8IK@7TV2M
M!)N>[+BZ .N '-7"PS0,$LH33[TR)\&;9P2":SK&U-L )CC1[YZ_GUJKM='1
MRS</Q.BX[B@^::#3;GZ'LX'Y (W:0\"/ UV3YB@V7<2TB53A[ Q;H/DD4?PG
MK]I!J>_;[(M=R4!Y5//^0MA7X32L/(Q=-TM-%&GS0O(-(H.D\;N=%,#JL=&]
M$%(!%7BZ"=(EE$@O2.QX*4MB@_/N^\3TZ:O>=VE69:YP:N:%4.'-VDH];?E6
M^)1D:=A=%4EIB),9\F=NC6HE^W/!DALX="6\H2ZI6:+D*]VE\B.<=YIY.%UZ
MM4*VK]QG/JB!UV_R.G^-@W_FPX'/^GTXG]^U>]FP-<JE-&$/1#U>01MG8:=M
M]S*,20H<_;?W;!O.<)G'KP-X$IOF<.H]@@USW,*]G4(_6TE#OO/]0V_Z&!BR
MP.R/7[LN_/O'G<.L]D'E!I68F?:>UB&7PW=,'Q=20,(\G[A*J1,#[,;'^G"A
M (]^>B [?" W*F-S>_036D"+8V.)??6? NL/ 33^ <K]38%'WE\B1A&<@.8Z
MQ^0I'IMV;A[10"]LI:N*"U"PZO )J;.O)QQ<Y*<TAC7!#Q.3WQH^/QY5![$W
M</6XL$$/O/SXR%BL/4L:I[7]0/$0[:'):>E)59_J[T5,2-=UX#F[F:G.Z&)5
MN?$]U21N+:2?^+_G8A.C<#4?#>L:[U=&.X<&#$13*ER"(%P*)^XQ)9_<&O1S
MWYPSY40>)8A\Q#SCV JX&46$TD7,?_>6\# P^8#Q7K202=_$'O-%--F@6ANY
M>D:YGBC_ CN#\YY]T3RC<6#U9J@D>=;YYT?&E0WQ8');D '<K$IXS-=4IU+G
M7N+5['/"BP6UGOYQ+V=;,WWJ='BM+-"'"6]BMHI@ZZX,I789&@=Y.^F:H$RR
MM@1:)1//\[67,][F_L(%!<Q6+;?#!3^4QZ6H5[ FPZ+69^$$$W T13B9[6_P
MS]F>XMI>ND,1J2RB94;^71X,4U%G[-:B<F@F5AM.K2AA](SN>N^:Q#H+.0Y+
M;)C-*K+W>]LI;?=><\*.[EF>,:W#?8#N'5_J%^$_4"$UW0I?(=7EG P(H&I]
M*/XS][\5/U 6EV!/#"=I*#U0C$&!)^31Z2>.RV:&\F0E:5OZH_99^N82E]&#
MC\O(:K2;&^8O979Y0Z[<UGCSCN%;=>!<ZUO16)@:2M":18[SR;-=L/GGNH<1
M+X3 )5J[/ ,V?0#O?.?W'L>F'Z  ;%K:N,WV04O*1#7X+IE=_>?^VV-AEZPV
M[:#/%VQ#UQ%/9:Q@?$ VJUX!8A0!< :*%<OH;M!2"G1,LZ>;Q/(>E">/@*8J
MN31<M,J N(R8CM=V2,0[/1DWH1^@/G1U2"G'[V$?V"C2+@3Q2QW\SZM<BY;2
MUO!7H!F9J 4G]$ TXA3_I[TO#6LB[=J,C1M"B *"@A!W5(2XL-@8$VU%6FF,
M*R@1THH( 3%C Q(EI! $!,1T2PLMO!)M-I4E*H0TB\00(*VV'18!(4(6;&65
M*I50DDIE*C_FU[QS77-]\^/[9H8?YT^E4KGK><YSSGVGGCKGL(\N#,[4QG?S
M,KDX9#;H*1GW5!'&RD"IS-(W*H8<]Y!#QK*N3$/+I&QD#^ZOJZKVLG@Z*+#'
M')&I;5M3W;BX]MG-1'*("AAK'P1ZZ2C^-D0:FQJLH'R4:9Q2L0"3"U17EFKD
MA""?U8$WKF@FTI7ST/6(;S=Y18*Y+.8R/Q6+YG)UV9#TTK[XDK\>\9?OC=0P
MX*W;_3NJ#3AXM:AUNW[WD<ZQ<S$T!6-P\4!5_*7XJ"AF42"=8ZTO$'QTC=U^
MN^C[<R[C8T#GV;QAS0UGVI?TI:>^CD[_"?&3$4_(3((Z@X3K,??=Y?/9@]+
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MPO;^8'?MCK^.1'QB:JDO>&/&1I6)@6RSDYWDK;I#QA+-C6X8._TM)NCBCN^
MWLQG!4NA, EO-OM3AT1=WSF.T']2VB&7(HN.!S%VG8^-<I;:F=O](12:[(,J
M[\2[!>10VT7C_;I%R$%C;0"8>D;>VZGEU^K3N'81%,M\M2CS/1P*INV&SM?>
MYVS@[>U$J"7(-C#H+>H"7F?@.3LLTB.C[XT0U$-K7[-B[']M+W?]$KFMTA\V
M 9/1!;-TJ]ARU.)P)]=MA&%*/E$"FVC]]#R,B:=SYV#Y>FW-K:*3/KJ3W%Z;
M@&ZOL&:Q/=!TXE*I,L*#^"0WA='4@2SI<&?,W_\S6]$JROO0?'R2L/ -V\H'
M_'0>D#PVX,!CC*6<4R U$U#E\&N.UHE2J%&T-T]V!$BXCH^AUZF=+5PJ?$*%
MWP/3#X*M):[%3!9W%0<OKN$U#:Q(?/RTFVQKP,V?N+8"[:EM1YAE"@-N%]58
M49[>HGQ,&BL&!=I B-JBWSIX-A^D[^PDFZD(2S#77Q##O^IYD$,&45[Q,->Q
M/59OL@?RS'#31S=?O!G(Z!\9V&+K83NP.O\@_4YP:U3P=CWC&&)I+!PTMX/C
M#PMTW!$&>+B>!J_O2:<L1E_G4CPPNN$FMN0XZ7\EKU!'$79UDYW4":LDE\_Y
MUYDKE[AOC_*7'0);LRRR-0J&)45HFQ7%$I8!UFL?,,N5BA]FZ8/;@R^ /*G2
MDK,>_- TX  _A8@_P/40<?^3 D6S 6?I!LSJ0[8\@D*?B^MSY =YSVHHRR'O
MG"ODRV=R/.(>]48&>.3&=8N\LH2-^7/>70[E%[;-\K8^^&^-\9R&6"M06O(@
M2]_)TA\-GB48#13?Y,/K10A_7JM25Z*<OM]@LI-8 8![!5\]B!@GZ;T$4=$R
M94K7= _C)O_?'=XYQ_K0C/WO&M<5?<L'=_'?V&O[X9102,LR9]=KP_5E,7ZG
ME2V!\\9WZUQ&VSC.<$'!EL[S0'4U:S$[SRS*2]=4L+FG/)9=/D%LGFY-Y%QL
M.R$]%3+HL&7VM1:=MS>.LUE'P9:I 0<?BE/+YW&BX"F0J*T$'3+W1=[G''X*
M!VB(O1.#5<S?K>G;[\1Y@UPQ9*]VRA*.7DK65W[>W<9=.#Q]2_PK]<G8^9S(
M>E[MT.^)"];]&X.4-X+=8)&*9N);P;&"-X@=&RY.7_7WY\[A:WQ24>LW9LR-
M0K.T+B%M"3OGY3%15:>J3ECU*,=ENW>WT#_[2*H&OR4R,K)VA7;#.A/8*(#7
M Y)M@*J""OK)%9[:*OU=KB?W%=64?$G%4CAJIORA C[8J;T._FIGP"4BASR;
M_:)E_G8W?BF!4UOE?I!CYKG&C9!-;G1(] -FX$V?-5G_W'F7A>_F)^CSV[UQ
MUH?^\^TGU!WT2::LAFD,D-B,R8$P6<$\*#C_0B&[4-*XI:U:; 73FR][MYE%
M%X\V$KLK6#$5=-H?.-/RB7$G4;8))\R$F-J(Q\;*C+-9?Y.R/=* J\Y%+'NT
MR7"Z;@[[0^O!?-(UJFEH6P4UG-3KJ7']C53<M;*SX0CHVVKL64$^<J9&].FY
M_I<XE3ASP*H.+,YJ^<A7B<#^QGL<5X!S_R[!%G955N^YO+<X5+?'&PP>#:[.
MZXWA67)L^3(;.Y]K+F_Z,VN%I#ELC>+P4S"F;?[8F9H:H;'#SN&A@2"I2_]O
MG:?XQ[09Z^Y^\Q\TPC]5Z (L2L_>HJ^D+$?[ WG(8CIJ&J8+D>FVH;U>HE1D
MQUWX)4;?+>_^T0 G#&YK\%2[V#_[!0B#K\30[(:[O0X4JB;,V7&TU^@R=J=:
M<+W!OF*T+DITC7@4?->>=8OC\ !+O?V?Y"S5JVBI$MSO>_Q,O)\7*Y/KG*LQ
M+SN7]],K\VG=</ <R.3YBAZN;UDFFVLOREU^9>.7.Q9;+\Q'2\/O$E[RWHBT
M<^ R4*SQ^S#.T%U .P*4-3[CI0_AO5// HE9*\&+/'!0)1[3@Q/'GU9WN<O3
M^%6RIJ>.I"?L>-327H'W(#EP?NA>PY<!BUS<7"Q=#@[;_+>!X1[Q5;&#6'5;
M"?XTT4Q0Z :Q)&-CK+)2SK5&GU.7<!(&[0TXL\CIN.8)&^4)9!V\N2)R.ID=
M(N%:P;:QZJ7+00.N6;X /OQ>[LOS!V\([K4\'/%W+@OB'!&*_XB_3WUBM\[D
M']Z;,NTN^)!N/OJ*:$X-G4C>''&3[:ENS&5GP\G- >L!C7(9NXK11>)X#]*(
M;-F1XQJT _*YWG#H843>QS*OHHO=\CC'_!()L^C-FQ-T/<W;&G?H/V@!GXY@
ME!G38=DJ&$OB,9@=LTV,G.X6O"M%%T09<$X22(0.B]"')%S;O%$&LJ@,]4N3
M =I@#@V3B5/J6*ZPYUWIOSO\O\Z",S9C_R<VPZ)F[/\F ]90P2.LKQ1"EGC*
M3SQYB#U77!&![@=4)<I/'*(]\#$?&/D=Q..X0BS9V(G?O>'$&7"A'S#Q,2W@
MV@:,!G%7 Q(GBANR#([6><&=>^ 4*$S-3YPL$V0%K^R*BN$MA2>:!FR[7&-J
M$3SXOL-A/YY*[SIW_OVCO(^MVF[G/]61EUPW?KRWSSSG\P8N'Y >Y?Y%_7)!
M.4L,3B [#+CWJ8D[WF> +#B"UYN&WMBN\D2QM9$F1MK:#3C\(=TF ZY=QIEK
MP$G%X)0!EV>'F\ISEHC5#ZEGB=/;)A*5<!SJ:,!]WNV#N/N,20TX'P<0RY06
MV!>4:'BXR4"X /MRZGW];\#08*,)H%;"\0;<*SP1[")6$?3+XIZQD.T&' 'X
M>N\NX=+O#?:H7:'VE %7> /&*%<:H)XPX-S<9F#/P)Z!/0-[!O8,[!G8,[!G
M8,_ GH$] WL&]@SL&=@SL&=@S\">@3T#>P;V#.P9V#.P9V#__PP[\NMZ RXI
M'W@.<J(,N#K,'F8^<]>[8B?\3U#$O]'@=4!& VF0I;#2&'#IR%*-W[R6 ;O7
M!IR:8<"=A=.D=JU\P=#EM#>-MFPG6H/.HJ+X9-";(/U-M&.D]<.??V3_V5#S
M1TWNF;8_,V9]=FH>I=.)Z8R%8^>B*L;&RI%HS4OZ]NW'0T1"H5#4,SD_:KRB
M0GTTPXR]<D_&DM/>-]:U'UI\;.<R]_\"#]=G[/]-8P2@?SDN [5B \Y4IM6F
M%$8::VI?C1P3]TT'W2C6LJBH)8$Z9L"=2V(Y_?WIU&?.T\:P6S;Z@4#5[XE4
M0^]_!U!+ P04    "  K@%M:)P^A;2QD! "G\S( $0   ')C:W0M,C R-#$R
M,S$N:'1M[+UI=QLYDB[\_?Z*O.[;TU7G+<C8%[FZ[I%ENUK=WL:R>V;>+SY8
MK9RBF)I,TI;ZU]] DI*HS=I($9399\9%D;D B.V)0$3@U_][N#^HOL:VJYOA
M7_]"-O!?JCCT3:B'7_[ZEZW=[9V=O_S?W_[7K_\;H>K%JYVWU=OXK=KRH_IK
M?%%W?M!TXS96/^V^^;G:&0[J8:S^\_F'U]6+QH_WXW!4H6IO-#K8?/KTV[=O
M&R'5PZX9C$?PKF[#-_M/*X2F#]]NH\W?5R_L*%:;%%.!,$54?21T4S#XOPW,
MB?K_,-[$>.:VYN"HK;_LC:J?_,]5O@O>/1S&P2 >5:_JH1WZV@ZJW>.W_@+#
M]!O5UF!0?<BW==6'V,7V:PP;DX?NC6 ]8$V&W5^?S S]&]MHVB]/B3'FZ6&^
MYLGDHLU#UPY"?7)M_K._DF(LGTY^/'/IZ-)+Q>32T>RE]9D!S%[-GL(ZCF!J
M\?AZ6/D_OG-Y_MG9[N3RPPO7GYE?_O7XTOKPJN>2/(Q,\DSQX\N'S? M4+ZM
M_>6WA5'[='1T$)_"A6@XN?)D5%U]V9A@!N3I?[YYO>OWXKY%YZ<^[M 7:P].
M[DRV<_U]TQ_@?LJ/+X;7H_SZ[IK1P3T48888.;[3'X6SE.NBW_C2?'T*/YQY
M17TX0O#;F1<<7WNZ7D]'K1UVJ6GW>Z[/RPG\KF=>&'U W=A=_M+ICV=>W+6C
MBXL 7YZY:#QJK^03\Q1^/5FI6%_^:OCA['R[AE.BOL>LDRMF)G;EI,X\.0)_
MT,O$A>*G\7 4AUWM!A'%GHWZ9>P0W<#'M[?^C]&94;6-_R..#O8L++J/H ^\
M'4S44'XKH:=K#S2\?#[?(V#F&(J(?/+;_ZI^W8LVP'^K7T?U:!!_(QC]X]>G
MD\_YV_TXLKUF1/%_QO77OS[9;H8PH1'Z"-SWI/*3O_[Z9 3S?-JKFZ?YJ4^G
MC_W5->&HZD9'@_C7)P<V9&V]J0\.G^W;]DL]W+3C4?._Z_V#I@51&3U[TK\S
MU%^/;PEU=S"P1UE:(_SZ:WVXF9\<V\G'.H0X[#^>BG-5 ]5>?<9$4B.]1(Y0
MB;A6#&DF'1*:6$E"L)*G)]70[N>WQ'KSV!"\ F-A!^_A24UX!=]UTTD>CC[$
M!-/_+ )/26&"6. $<04,KJ7$2!B%51 R<*F?_/;JOWY]>F98EX_2\9 B(P8Y
M%S3BTG!XF #I<E0XF920*LZ.<@N&&/IA#NR7NXTL 2_%&PV.F:"##P%YZ2GB
MWA-DF(C(>FU!J0;OK9@=W,LA\,W1-HRNM8.=88B'_XA'=QLD!E5*-=%&7#'2
M5ZWUO16>#%6RA*VA"5DI+ Q5<^0H\#EC01(>G.">'0]UJFXWMYO]_7J4%[/;
M&H;,U\"< "GJ>('F\&QL;12(8 -D"O!X':Q&-#FI"6-.8M :XV$]N>'3YT^[
M+T!$NWIS6 ] .-IQ!.9]>G;H5TQ%2:<H2QY6723$!8G(*.V0QM):#RQM@[G'
M5&#UI><F(<VQ@O4W'IX<./(,JYB"$)+2>4TE>,QX,!@1(3GBCH ,8N]1<I0Y
MGHBCD9Z?ROLVIMBV,>R.0 O^TP[&\?P4)(Q1<!80,P98"- 6LBD9L$I:<N:]
MCQ+/:PK)<QJ%=<AX[1%/%-Y%:$3.4,F!23T)_ Y32-(0[X)"U+H(#$45O""
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MKK-FCE,9NLV>A5R!UK6,('4(22%Y2VR$OF[:E$ZRSO?L'(4_2Q#V@A3\C:5
MK2K5R2/>IW3!F&-&E40KRVI%?S(WM'(SB8;'9JY<0!/[&@)"UEF%2%,)45I9
MXXW/<1B$:4ORX<D-64(0E1<G1T$(@A#<C1!@ W;*F5V._N%0MQ.R7GQYF-)W
MQ:PG"OJ1G 2ZIT6@Z [E!*X&_VL!!Q'_H.\[:\N[=]R2[\9=-&E[DPL5HQYY
MU/TTEES"X,09\:#7)2R(51"KN[.PX$28)J-]7>--]A\_Y>U[E4F(I).>U"0:
M*HAK:S]Y!I/<AOYA-W@>MT4RQSV6%>KTI8R#)L*FF,.^#_O^;O;]]=RPGD8H
M#$J<]J5!HBU.5BYN9XTEZP@TTN6P"W>IP46'!WD@XGYXI\$672\1M]1$*?+.
M)$7DHE<(SM'G,\0!U4X;/)9DR(8Z>N>0>QX,N(J'I;&>!5MX4['PMHTF2&"0
MP'OAV]L I>UPPV(62Z.%35)$]AF94Z:H2D3OR?J#]&;8\D7+37%HRR_)Z=%H
M%WZ,.]9MDI",35O$X!-FU(!+-73V1YLL3-KW^4JD'%^*M;A)%O$3#AJOCWO$
M)B%=IRY8ONH%,^@T-=,J7N"'>$X385L$&0TR>A]DE$ZY>$(;;1Y=&DA/GL>3
M4A@0Y%B\,D5:XER4<$,]SY9=5&Z#$+.,?SP $00@","]$  ]I'@[UW&N.Q@P
M+7%\DG@IOT;FD[:]<)WA](EBVQ#!!1^R*D7])/\6\0M.0[O;!;,M2,1?0")L
MS"Q-&0@$XZ<M.%A 7])5O&]Y#^=Q@30^>3@FKI!01RC \U3(_2JK)NSLL+/O
MQ\YV?DBWM2=*O /KG%$PFO9'6\(\S^"JL-I/:!(;$_U6DN:'302SIM[D4=#O
M&$V$0-K$%(8&!)TO@!,\7^!U<$?\^_=O'"0F2,R]D)B>;VU-)>QZ\K,7IDH4
M.@?#IC')7+ J@M.[!I)M%6$39HDI:@NPP_%1VV]5(L-^#_O][G*0@^ J1$"P
M^[1%BQ:@Q;9:<P6L"WQT](N$>>-%4-MA&]\/M2VH3C'2LR4O-R?W&+KHFS]9
M 3J?#B#-N$%&(#89$(CLU^(VZ)D+FP:]<3M5'S!48<_?ESW?,U7*)3H\<ZM%
M!ZOZC;1X#0 Q[W;ZAH9*1CE9(EW@'FA]Z<ZHD<NT="Z"GS;G- -;[R(BR".0
M($%DMJ"WV&H"<CX(3!"8>R$P'C;*H"$#DG)<K<JQRZ543V\)5FY,I@V<A:F1
MG]!.NH*O/$-Y3Q.U>):IC2DD8#I&P!1^PA1&%N]XB$(6S*D@*7<E*;W\+1T-
MJ:CO9$X386B3\O&!W6_/!L$;SHU&^OO'BQY&83N'[7QWBM^6A=4P4-!X$@@_
M0*%B(?'T;96GV,YAMX;=>I_,%"\=E:%=K\6>5G%6&[>-XSHJ#*P0,(/2U4A=
MJ0*6@MA*2F=-I[K+)<I.VX+C.KN;MOW?NZ[[5\QNR]AWU-IRF( ])#+C9B66
M 6J P[FH.-3R7J0W;/GQ#46+BS@UF^N >T2+?^\5."INK&K>7$9=&5((:L#;
MXJ"KS%ROU\RIJVNNI&2[8JEK'7A'Q8WN3&*$'!F[O1 ]6XI_6937A9;BR]]<
MG#_J5^9[*-ML@2$"(8OH:EEI\ E;J*NU1]R5#R:&[HYZ3P>0+IFC#'MA'9:)
M\6OQI3H?[\Q5^4A0Z.M\TOVVU>\W'RG"W8U>;'ZA_LO<P!]@ETK*M6,;K-#2
MWGA1XMS66GLIA1'& <B@P0*D]-4[.@2BTU%T2L.*]H]VHW-:#S<T]OCRVES3
M7;8)7_0RNV(/#>\[(%B %I"::19X.D(2_"9M,;D:%2F+3YBKYQ_ 4 >=[6#7
M-,=Y?#V"V<SD#:ABIB,@MUP%-''M$BYHQ*"T*^C^CSU(\9V(Q\1U68QXIX,)
MHB!9S K>!'SSB4E*R&A\%6<Y!W-ZP: ^]6N@*@I417](JS\*5$5?GZKH;VDO
M;&#BB?.Z[#AVG#.(,BYFSW!X7SV@/:U(5R7R5#Z6:3))TJO5J!< &:U%0*!T
M]=A ?9@1MA:O\@RU,ITOBDOML-*H9D*>J9YM>LON&2 QI255,X0F\RK.^9\H
MLM%G+D 60A, Q)I ;D =T[V6D G5$7S(%.>5-RDP;9.X;OKS,[(X3@=X0U%
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MAUP>;M1CX^N@>9+**QF6%*S#()=W))?O*O5RD$U$>XLJ6P@H;LEUE';S:@5
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M4E'ZM;L-G2!5V<Z OZ!C88*J1<XW=]N>O9YEW,ROX[#SP\Z_HYW_BNR49I[
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M9ZNQ)<<) EHFF]XY?7/R %!L<@!CQQ&HQX;K5<\/(/^TD9T;JTVXKV\B[)R
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M_<U@G_3VK"E^7V'NN?!PM41N@(O3THH;DN/5V%A:+9:T#UP.U6[$J#?_W+X
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MTN$6_RJKRW6,A3:I8PO(%8:2M>];0[;TDBF7.L-(@J_C=BDFTM->=:GE-1
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MKJ!X+8;#>U-RN[&->4=#=:M?.E3L[P>W3$MN_\4OO%*/C_M=6Z4FQXHL2(?
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M&YK"\92CP)XFVHT9(^S'QX?'Q:9R^TY?+&B&16>-ASJ+M #H7CYR,MRH^3D
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MP]V<G+?0W$$S?!2P//E->A<$M')/&Y1V7IBCL73UBAZ*F),J3EL(+>.-&3/
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M\'^C;5JGF78F8@_%K<C'A+ W:=I.";"^C'G&Q-S&>GH&M]U!_49GM3^P6$+
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MB%EHQP[<4B4\MYQ*F YJ]2+2'5W$GJ5'1$JZ;*&!8=(@" ]6-2XV(_TZ)<F
M,I <A?L1QMD6OS%?54$O/5\X*U4*-&/'M[<HM4T+;6VT]6)R/QFB'3^FDS9B
M9L2 693.K''7U%WV_[/?2'JI?O2MW*"BMQVKUQ/;K&W; GK3CD"BJ73V[<+W
M=M?M5B0I*PT?28@4@DVZ9IXM/_G=_)D&JRK4;4T#B)6#27JX^[M)JKQYVJ^R
M68D"$9#TM57=&@%6J(A@!-XO;'VNOCXOMC\Q01OYVNC$)-*IT/89_,/JR-="
M;\FSPPKI6CRKD+\\WHV>&?21QL*=94U#IS_9 /4EDRJ?G1U["N?PAX.'4#E[
M!_N/]\87IR0;?TCC")?DVA:_W<Z[7[QWF['%]V\3?W5REM<QS'*T>]35W9QG
M_)\U,[<%:V@Z[JBSG"%# &:S^A9(;O02]2)!;_8H.\'"=+"W_YU$%'"^"']
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M.IC/N_#_5#A8BK<C"UO=A3/W\FV16,DB:6XUJK(*KDC)AN=[,HZEF8X<3 X
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M.'7UR?/Y7(HOH%O+76?U%[;E'I(6"U;DA4FJ4+$!NX'AI: 8'HXT>.7!1#
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ML,!J=C1RJ;J>EF5]'>0]_(]UW_$_@LJI^&\;,M9VW,XJ."A8A*>N\QP O<%
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M+G-=7EVS:S!".\9H!O#<9Y\_=.6+^CT-?8R^_>1A#,*R2QMNXJ(FPB,&\SS
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M=Z64AWDXOP7]CJDY=;9EQ@-2L0A5*1R!TCR,M4,K@$1]#_F1US4Q10$EBOK
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M=) J<=2BU+BN9F^MWG"JA9GGX64-!6-X6#9X?<931W\WWR*=+B5Z]?36?4M
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M&+_61D3L"TZM(8C(^)$1-V'JM,="G70#DA.)OQ?^^UXTI+IQ9L,_<Y'[-\:
M?%.M/DD66[@OR?ZLAL-C8A.48MJH]K/*]WORISMAH32_)7O-XBJL?!5)*O'>
M^Z;NCVW@P-1/KBYJN@:Z>TN_'[O5I__)A2<SLT'O1AIK9>NVF(SX!*"YQ'/Z
ME_KT(94)*!='"%3(U;><=J8?49Z>&!G#;\UWA9PQ5Q)?.FR$[HE9A0;N&!I!
MHCL6:_?;V.TSLQ!;78F&$%(85&@0M+&<-L1U&R$<7N8$#H#$^)(9'^W@A(:
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M.<ND I-'$EKYAK<JS7#0N9>L.Q+G5)L1?=6+HAV\=5^)?@HE^W$74(C(<,I
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M5$1@B(:&^B//Q9_Z_GUK/Y[O' FO] ?(3I+Z<8O#G?_AAV83B+!&3]WB#GH
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MTGUMQG7*R^317/FQI@;(PH>$KEJ=_%YLL=3"P'JS5;I?^*Q$MB_/^$%/12O
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M? X4)"6'U<"6C,^F@W\";GS<N@-2WGGGPJH&NJEH,7+^_;JB94J)T^K@_*"
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M5TOG3:(;DO(R[,C0Z?:B;F]K P-7;;!G9@C:#_X89[>M%:R*T;8_&D9N&MQ
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M?8J N:0'=:J^J>=I8'O02B,]NH_2!F2I?VY+]IQ:D UKCS_$69T[<C0HZI/
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M5W\NSK317S 2;LIZPB4Y[3$>"B:9]=^OR1A/^)E_;J7KEW6.[%C@%=$]Z%C
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MQ(FE2F6<F3E,%5J&^"_LSL!T3W^!MM=GZ'0UZ#)"J,*DPBZ':XE!W?2BKEF
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M;+DZ->A?9I@9:]GC-GOP;=95%L5\V^#OUO,Y)XH7L-!NMY+A2!$P4@1\($7
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MPQL!XY&2HQMF(F.2;&2MPP;Y><,TV[L>MUXT=7>]P/YB!,O@8TIB,4.\K,0
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M)85//&I3**FJ]M(( /XJ1!KHG3]KVP[^Z@K\]045?<"5YQ?3?KVOHQ)^/WE
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MH79L1IQ@B%Y4-W5YHXF%GIFEHH807@Z'7<#49TUXO5:;FSW$%A879ZW,;L?
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M8)<BGJ(' ZB O1H]O1[#M[FH8E/JZ#P-D74H_ #O\,'CHE"#N 6'AX2).?[
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M(N<'Z6=M,N_VQWJ-(*X1ST.)I_=X\7Q^U#$4V>-)%V->&'YL%'[=ZRS@<S5
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MP%MI,6EA(YH;3@N1HX!52969;5TG110(\)[@<!$X0-M/"HP! 3/+>9(U(</
MI"VDO4Y?@F('7:T, ,'B .DBJ)9/PS2P /I3<'=QR#"C?D5L?!&OO0I)6H72
M\FF:%)=3R=L1<2N^)U\8U*E0)[9.B\LBRRUWJ%CF[/SK[Q:[9BF25[?TBSG%
M2WO:MJZP/)EU]O'\DV==4M"-;L4KLV*.EI8,\TLC05=ZL"(H^:>G_],:4Q0/
MU1A>#O,%*_[KE]9ISW%+$<T!P')UX[MW;>M+FOA@.4O!PDO$" 1K3GDT%^RX
M=M\59.D:; ?\;V7WH_"AY:.T);[ZRQ3#G.X;#]V*4$C%1GG3Z850".8S#]%,
M4).A$:J=66UC"F> E*_MN\#="2T#/$G?;X&[5[:V%974BV *\*[9-A'MKI&(
M4B+.A:J+P#,% @'RS(2[."D(JJ[*B'*8E2Y@CDH8+U*_ ?.7%IG ?PWYT6E"
MU2%4J_"14A8"CZUZ.H2H9 CP):1K6^<31/>5.Y'C,PJ.@]U-\$N@I[QC\L'Q
M4;1=.$TB$&!INU;JRPK"J! *]Q086<X]X..\<D@%4"MFM2@>"Y($[YW-T9$O
MYH@/66U28##'Q/YD1F.T/PW]?&EFNB,:A3,@@XP[K-"8K "XAL=$1^U-.%0,
M RQ@)E<A+%% ]L\<5!=)<T+6UFR6Q((.-HS\!R^#%YH&%'YD?,F$':RN  O_
M$@WPRF0C P-'@6:5T#@YR'HF+*I,4'*)A/5!RX4BVI0KBQ2545SB1DD[]!,P
MKC-A5TF*+@;2HR R+"]NVT+;<L)@25->,9OB,":FB(X%Q2$ 'WR!GV295(8,
MK"OS2U:OS%,8G9B"V(ZJE@>HG16"ULI,M"BK@5]NM/V/&F >N)G[I1C##=;G
MR81CX$FLQY<4;#* CR\1#(DXT6"T9K64*LSUUJG>,H9 WRK*DM>#?OM-B"E)
M8"2ZO2H[RLK ;Q5^!%HE.CQ8*'' S[1.B7H:V)J^R*UPO7;/P5B4>,;Z!92;
MLRUIN,H]RDQ*BL E;8M2&\Z:H>BO[H[HU?*!8GOV,@6G"&V )0.I),7Z(9+5
M42?13^ZHJ_M4Z'')%WNZ0U&2A<PK6YB&UZAQX#NU8RU] )@/:"<!]B(-I=HY
MKADT^+)[3X)&-_2.+\WL,5LG#\2>,_B4,A$_^PSL?2F4K<&:)7LP3M(9Z;KE
MP(==&3]D$/F2H!JG2T-"1#\%C3GJ:KB:K XP4Y3K2^\2YA8F:T[PK3*EZI*E
M9!*1L52ME-@PP1^$080Y)3F[D=YV1"D:! R7TK]&?,+091A0TH7UYS\-/<]Y
M^RF!08%,RZ0BZSL^@WYSW]*C:M=UVM9'2EU35^#FQ581++4CK;_[''ZTAFWK
M0WG#M^H&?/<W\"0C^ANC3^]8SMKRQ891M=V^("&;4(:4*%$&'.N(O(=LRGE>
MYX32D%3YN6@]8CX-6*-C0/XH_($* )9VS(DGRNOD:J^S >D161$)'U?S5TS&
MC<FXV1VW+U5[,ADW)N/&9-P\H=F(0:T/N*EA%'!981=-MR0"HI U1D&9K)CA
M=L0?Z,>A>;1^+PAS843(23DU58BH"A7:PCY,BHQ1. O](]HIDPDY&+Q+ G3Z
M>(98'9S<T^UY4HF]:]$?(;%TDE'2?P,$2S3#X>'S839X>0NT=E+DNBIP':?M
M_*RN!]:*V#SC)YDXH<'7H/*KE7I15V$6BJC8B7K ND)0XH4]MSWJ_;Q)"0C=
ML^X^]R'W=-N..W"J?P]ZB!GLP0:[ZRKJ:X5VBYIE+[C.%I 5?_KKJ^&K1U-G
MS4SV2:W'6?0K5L=6Y/P@=R/_2>D6[U>V(^]]O/^XB+L_9C10T!PH\!X/!?<J
M7OI<P0+W=?8'"-O4+6T$D0W;'AW;WK^2EV%;P[8'9]O[5U<R;&N*21\B>+=U
M,6D*N17B@/G:#+SGWF3^6,K:/<N2=<[('CS AGTA+/:X@IW/F#!&]AXO>^ZH
M:X_<OF$Q(WM&]IY:]@9#V^T^;:W6(V*Q.ZJPFI:X3^P>E.F0X\6;U])7^$7?
MD7\QSL+NPC,&*[=LV-5Q[8'S[,V4)V4L0P\C:*M&R6AH._UG+VC&'S 2UQ2)
MZX_LCF<D;M]>@-DDV+47L#;_MBE-5>6T#82:AK_H/PQ[]J S:@IS'GW'7R/0
M1J /*M">,[2[CML4YC0";03:"/2C-'2O9WO#85.8\^@%VNR3',!#*MM]O%:=
MP7ZA<EB;JTBJZEY83PI^;T[?QL.A\[%L2;_0#J.N,[ 'WB$MKP9U&#TBV\O(
MMY'OK>+1PZ[=&QKY/J)](B/H1M ?LM7KV>Y2A2 CZ+O=GC*MPJD2:7F@Y'3M
M/M'+KHCS3C12NJOZN+V^,G8ANXB/M':5LG&!["10]SIMK?B_*$&'#Q1U=HJT
M[!2QVB=":RB)%Y4-=?TID%DVEN@.JB:A>H'J>O==6<9^8P_>;J?J/$$=I%+N
MA[)T=*V/IW[32*L)2_,NF[+<WO0R++MHCF[OHKF^MVB]?ZCL.^Q634#/:!A4
MM++>[D'K*Z(/99LZ])*PU*5LN?VI*!\[9PLJ[$.EIF'<Q7*;X;Z^3BI6475=
M729.1R]M2P^MOUCTZ^%S%@;U/A;B<7*NHKOHX/9ZLP8";FNI>PL$8 'BT>XA
M0&\-LPT$= 95P>.'0T!GI/?AUB%@M9NO?E\=?V; D*DJ=DR=LE/10A=D,B3Y
MH"KT5-@]#;%Y7G(MNP/+'EE4UA[N*SMQ  /O"B=<IZ+47H"BLP.@@$&Z2Z)?
MQXNM)=\SDO]@R?=NE_R!IG)V)_FU!E"B,54NU>KV;+JB;-:)S&U@TE\')MMA
MB-MV:N/?'D;Z5<^9O4BF1R6@PPS#_@A-#Y7.T5*/\J4';2>8G8K&QU("?O\N
MRWEYK,6X+(]P6>)U:8/KC@Q1M_N?7)!9S=+<"%9ELP/BWV&G:F)0M3^8L5QV
M\J%>%97RM37D42TEEJ\I;9]17?G5KK_%2M!N-,KN_F9NO%R28C/+C(8U[;(=
MQX"WW-D'QW1&SD,YQNU7%J]AF?O;1_=@F;ZV^K;2Q*%H?%/C$V_@Z3TP[^03
MU4F[>D)7LWJK!Y KDH5EDSH>)U?,3]+M^6S0UZ>P+8\-EV(DM?LHX(P?BHS7
M/?:.,0]6"G26F>_&/-@HM \P#=:=*)"FP;"GFP::U%:8K\LO5><7_>)1Y%8Z
M8:WTJ5KIAR3ZX':T_DVE /,;;%TMG 71;RJ9K_;O,$QP.Q-T[LT$GC/4XT+W
M98)O?)Y++NC)",EZ+ACJ6AS\ZV4>P*:1HMOD4MLQU4Z76C#F+7AI"X;U@YJ!
ME?W01,=1T67YX=QENL.8[C"/[ [CKO"3Z0YCNL,\07>8EZP0[^'*;&D9]7H;
M_)FME.)G/T_P_7T9F5RK$1T]PHR::Q<:D!RD_O%%'Q_326B[OD'H76(G]E,1
M"4:B?4E@54(9PWT/ZXMMYHS/4>68%-A7.V:B;1_V/70';S/:@"NHB:H,D+-H
M >)!7?=NZ<^\MCD?-C,7>PZRN_.=?1Q5FWKJ-3CF7(;DQ2XDWHZM*[$/]'68
M3ZV_M[^UK=].3[^(YK3B4J:B!"!)V(_ZSM:1*:=]SDSOG<D5OP@B@.S.A$4I
MNQN"9/HYH0&\,TGQV6PF]B!P>V+]/@?^C;<@B:,DP[;9! ;$KQARV'2?>!-.
M035E6D\[ +=K'E'O[=K0RNT,ZFR.Q PJ:!57$<R(3D^BL;=& 1AG;16G@)9)
M2O*F]7:GK9+8N@+\3+!C..V:3 ![DS0KFX^/>11R;".9\JHE)!=-?6DT?ICZ
MQ0PF!8_,;#G DK4$<R /T"\PJE!L'\&BX0S^5027,K T3@I!-I^EZ0)_+#-:
M-I"YU@ =!A>@'F!SY#Y8&['G1Y/*@ @PNC:&,K#!K1K@C/K"(VB7KDFFLY*8
MI;A"+G?)5DE:"10\^1^J[Q92F8*S5R'(>%)?&/B??#DQ4K7MMD3%2=DXMEHO
M(3*<&)EH6W;AQ'=E0GSC)39(.?@(=/9&]91=)U"@KK(Y>B=7V.>S]-)T_JV2
MC=0+3""@BI4!,V#20.:GX5RA&2Y]!B,-)\ 2R#R5IIM+36?C^J <);6NNIVV
M]8WZQ9%5\TU[QAIMJ1KOEHD0H6I4C#RP=3M>$!NPV/#!/,KX]13[?].3PDP"
M#O$XF5Y*]&=)!F:<TN1KYB=:QF*ONHSK1AD.Z53N]G[],YO-W[ZSWDO(LZUO
MM/7]*P)8ZTS;^K:MWY(DN XCT27\O$IR.25\> G&U0.#N8IP1F0517Z5;;O1
MM!^#0 A01\B4?(R" F)=*3I]2V/&@:<#@<AYDI-QE>4RT4&_$*0'U$'BZ^X(
M/3(B#1<BT4&X2:>B4R0TG5VI;[@AI$[*$I]+^ VTK$_2+!*H];>CO+?!_P(]
M 710]D,]6U3I5I4[MF++H,[C065TK3%!E187)L4$2(S[.4ETQ85=4\A(GX9D
M&^TU/0E&U[=D/THZ("5%<W3A18:QZ*5)KR]R^L.N,M.P02,96[CQ%(57\J72
M:9OA)NH\HBO R;N4-@,PX@PMABW)(Y2MC^&/0-I_8;I^L:0BO_%Y5JZ:VJ="
MAQ9=SBO)=.M76]Y4,8R6^I=IP\BL2RGX[0H[X0H@A^)O+8.0Q7%!MHM@IIK;
MCA9; E.<(!O Q7 5Z @P!J[$CEVZT9B!+] FRKDPUXA%:2%FM!L'ZD$,@8,X
MO;\!71")"68%&([:XY>>2<H.Y*2H+, H!$>#Q Q6LJYZ Z!GIALQ$;\4;<['
M)0Y$1&B;)%A>G_++ I16DBXH)"&ZFA>@/4'CA7-:%LK-RDG<Q+JBQL*>ZU.D
M8LRMC&NB$>O6>Q&'N>1^,5MA,U:+MK) TC[6E7D$)(+5_0<N1BYW@]7]PAK7
M!X1_BT@[B5"89H*#8/[_AK4'O4(8HYR "35QU\<KC6XRT37FPHGK#Q#/I$'+
MI<KD=PJ$"#71+\1]60ZS(%"X*O>8Z^N][,/I$):N<1CJ;A(.G,:(QOVF5\AQ
M BKX:0(2%">ST-=,?,2EH,CR5&P[E^N.D!Q?A6D2TW3U&U"*&2YC:7"!+8^^
M$+[17N8$1#9D6'V($J*4U<6DLZ'S&8NRI+R A!^'@920.FTM.724%1O^("TY
MSE]>KIP>'UW _!H=^]+DD^_0%D'!5.DQUY>DYNB"93"U1!#Y2B;^27';M#9V
M^5BP)?#-P+O"L=3;'F]>6:ED>4 .G\9&N(A@]&;"8&=+-"K5FS91TD(H!O4)
MMJUS,8@-0J <3DQ]Q,4"TE/ AO@:UAXPF> U"G^@!P9?QP1I)60NZ>QEWD%E
M@H'/=:3/$1IB5)@I*3:%$O!.R8Y2%=#+EJ3&&(QZ5V\E<Q7=;EES3&K)-3 7
M^;G"%*,[][WTFX#PM(I"K&J(V@C1"<0 /'!/.0U='XG861S4$H*SS0D1M!^-
MUV,8WKAKMZ3F+KFV1@S7D$::OK4\\_,O*IZ@Q0P9V)H^HGV4 )?/D@ MIM4'
M:0&*ZC'S-/D7!=S0RE1J5ER$IBM0'[0[3A[]BL#" $A4ZI:(*Z.1C6$@TD10
MCEJ6)9BJK\5 ^ 0$*<](F]"1'83N "V\1*2XA9EZ+E>!]TL>DY4!EI3O%R!]
MH7:O;L#.<:\-;!"*F)-9P7!V0>'3<Y,Q;4@']O+@)'6NDR(*<,X!YS,11:JF
M32^D"TC;P%7RX 'N[&WARH*#."DBY9M)\)LG(=F/%ER%&K9<D^7C39DD!2Z1
MCE^)V)68,CK2DR9S&1L+4QU4R></,+4"P^S)=7S-TD"=-5!')M"G @OI#Q%?
M*]>K"M-+(-4L\V]5< U6_/.\9K[!(V^;#XY).FE B(BS3'//@)UH<9F5I^'E
MI=AQ).M'L8"PT6D]2N\+%CM!&4(S5,/P<G7DA6CV5Z8A[6-*-[44K')SUM:=
M/BDH2$.-8<L @ZT=6:7K-=;4[6?2)M*U3V8S3!." 0N&E8)Q^[2OMYEV7>^1
M7I,Z'6X ?0[7*X6NMM. FTK>0OK+(,&]]#?NK@%IKBM%+?:@A$4O%KBN8$MK
M0FG8)8 C]5R9(TN>N]NV/B5+AP0W/:2,&FRERY46[XBAK^ K/5(Y]N7Q0PP,
M)9.)OIEU6_*<208SR6"[3 ;S3#*8208[1#)8\\SR S@UFS;\C&]34BBCL\/E
MG@"FLV7RQ LFRE"NVI9).2IC0VX+@/52QN@H;VUI,90EB^H\S,I7E[LX(C1-
M X +*04F+7,4RLT+DG<T"\%R*V(TP/ .BIG1*7KX,8EC3CZ(C,HMK(RG5V$9
MY-7RB$JK1F:QC/F41<*YD7-11@0%P6G30#Q+MXADY%!S:'"K3LNL4?9..0XR
MKJ^Y& J:<@L\K\3EIA9<$J )3KM$UYC##I>(Z&*Y T=))O0::1ZQ?R6I#'93
M6H :ILA^3#/U9,QHPA@A#(S)^'LYK').-A($?3?>TKR=S)_RH(AXZ1ZH-<*Q
M &,"R8#WA&LQX_E;:YI< ]E2V\J26<DI&(O%J&F )[.)EVC;?RG%2DYCY<"V
M,#\I*#MF$25/9E,.U*-,DG#+E++*)ZG28.H1W1\Q5K$ )BHJ;U$XB?H.4N5>
M;N+V,N@_X4A@/$B>)R<Z(&D:&S<$P=W-\A:/:*"$!/,-6MMI=SJCWK!3_4-U
M63/SEA%LK4%']L=;PJH6;4F>('70 EE!M0I6X.5=QQM4_X;UQD*W@)[7<2?>
M?D&OVQ[T/'<P['='7F?0'7B]G_6*S#\XG\,XHY)8TN BFMU"(]3#0\_KEXI8
M,VK$BUW'^7GIJ4V!_K.OGS.9,!D+ST# IA1Z!#K%O"4@U&"Q,C\JN_:IN-<Q
MK/N"65>>0KX4\1)P!WA6ZL>:AEMA;A^F0:EC.:8Q9H:%#0L?AH6OP)E/UO,H
M%>U1?*I'-JLPZ%NT4 SO&MX]*.]JNU=J5P<>5* )3=%6N\Z]N!D=8F.&<:$2
MEDLVSXKY/ +&;J]CZI?MHO]#G*P0>?W*B]!(OZ32E(U6<YUJSB;FTI1;:'+_
M3SP90^+@6>,A-,IXJ7QN B:5MFB1Z2AW?&):=Y$YA%F:=?C*\B)0QUHV#%08
MD\)KK7PS=#+5T+%TQF7*5=HXN(Q9,?Z73,J,^24XPS);^PH3V.DP@1JZ/@TY
M2E7&!K&WB'$[1WF>%J5QTE#0984K:<.URM>2NW[*485+ JZRRY54T-:.2)%8
M&RG(JA.(U:$HD:9#,9>%OFU2TDRN?-OZHMXMTH3)D]8/,LD%"SBNI_)H<5R4
M[R<3\N S!EMP Y3':1)%ZIUS(&29T[2\ISQ96D+-Q\?-;>'S4B4Y&6Q 'Y<"
M0V4@B/+P0!3DR161=2J(6@5#D(!CKD<?U@_2MN*"=F\HT9<2>U%#"O\[#BK*
M"R:7&^@EI^/!$HP;B*&4^50R?@&CE <U*3!69='5EE(&<I;?A ><X->R!J":
MOXB2T<ZO?!=03&2%JK)RF N>8C@\6K2MTRB?TL'/:RRC29$A'#ZP<EW$Q<S4
MZ9QHH1T@HC&H<V=B;M&B#$79]"!B)>3R0)LR1D<*R0@E+59#0Y8*PZM<<TF_
M;6]'*2.Q72.<F99(5$)?>00K3Q)K&N*IV)0^XRXGBA%F2V$]1+^(6*I6UV3^
M;-(OVMD72S_[8H+DF@;&D]F\5B&38<X&21X'A$P67&HY5'_E-[:6*Z-.P^&.
M_W(-$MOZ^NWO,F'A"WPR29 Z\6><T4%8I8_6%295)%]9@S5V#P+_C4S,QW@W
MIM]3!@X^Y]\%1LU1Z:?%4FQX-362\$[<*GZ^I#+HXA#,=QJN.*-36VT:(RZX
M.CHATWS*(Q@4&4>-IN\ND+K47IF)F#R,DR%FM-!#D*==R5J#F4UXB&DMM9<(
M"T"F;HE!JI)NU6EMI,H7.4!=]4G6+VT#>0 )KUV:"^T'B%R5*DTE7]&EEPD>
MXZLV2FCD>!$^41D"H*3Q0+"VLT(DIY]Q[$9::BG#=195/"<95!VP%8R*R7TL
M0D4I4N+4[M:O$0.@^^9/$]K8$,<W\)P07B"R;4JI^,$7M5-3RLX4A@I<<Y6@
M@4 G+]3Q8OH>3?QRZ9I /,OPD8:Z%$:BW=*[ZD++7;:M4A&5&LS8# W6.,:4
M-N575;*-):7GH7[@#QPC] 'D5BHR4@GLE"<K1AN*G=*MGEABJ_*HZL\Q)N-&
M[O@J3N/H1\/3)(;/OECR(Z'<DR2@K*>0]0E<N=, D'4UA5(E/!HT*LD(Q@!F
M9[:<T8EU'OL8\_C.;N!IWY-YZ%N#KF.UK/,9!E8D?3&COKS0>E=64U'I)L6<
M-"$YO0 /,&!4A3F_3%*]W+RH?4'>+3P&3_62D1/[H,]DS*D\I1R$&;N\3/EE
M65TF%"/(::CBV)DPL##GMORMI8)YP:91BF39*J]FK ],#56E%N/?$WB2./N'
MQ5K@>EAE.HQ-*8):MJZHV-BMG^^#%W-YFD_: UP=8 ,33EL,88)1T@JF<P/9
MUQ=ZB.MS,XQ=6AR2F-V6TSE!+EUB(,G"I3(M,]BLU^_.O[W_I<XFZSBQQE8:
M3Y;+LYR')9^%/+ -BXF4[;L8;-"VWK,4SWD'TI@4CL4,$[2#!W ?$FP'W&<R
MO$V&]R,SO#LFP]MD>)L,[T/;T\:6OK<M/3BQOLE*(5_+;19A4'O#=0:UN(H*
M!ZD;-QK6I2T"Y@6+Q68GG36C.J>(X.%,5\LB\5@KH***F*SN^XAC?&A-E!NI
M<NL)XX03K9=4 #X_%3W 9.)4OEK6+,-(H]H!+(L@JD@S;56)]\,[@( 85, F
M7G<82?<RBCJV+/HJ37I&*1 8J<AKQ?'@5Q95QCRP1\;C.^KKR>-]RMJ"^6CK
M+K?8Q!.8%0,739(DQ_)MNK&($UIAD*>/BEAA()*9!NQ"/R=YH15!:&K-V7,8
MMC4X;5O_73_@&> 7-/C'Q#_W/GP<K";ALF#F[^(H]]<P^V%.TN@14P0G@*LD
M$X@DC[RG0*=:ODYU()EPD&>R7!B5R5BGO,J3K[8X(R):$-HKC0@EP"UWM?&T
MMDS4'Z'K#*J&'+9V/!Y3#C17K(R4UKKQI%PK@0V3H *[WU-"S@4 AJ_:^."[
MSI(4@ .Q\M<D5F5CQ>T+02O:V*L3*\SJE $LCJEV3Y@O5 T"K')'T"L*>6M$
MI6TXL>M:Y670(.ODMK4L@0@S?7Q6R#2KY?G"4[,IX%\+MRQ@-&J*8CKLBH41
M:L46(&8K@[70+EE.5ZI/C*9+1Y6I]A;"?!BKD]L3193ZN,MFA)2QLOZ2:RZH
M6O4MG,UX@%MLD=B$*4#/)ND,Y[VP7,>1&X=4_R"CVFM8. Q4#GI;F-5%O]@B
MFX2H2L=@UA1<457BI-,NMYWPFZ5]*:*S&'5++3"7\R$;0R.B.&%/KGY==TT7
M<\SZSF6NK$^;H*+!TO!P%=!+E36\*)7S1:6<+RC;D3Z#&#1:=PW;UH?2O*CV
M=!JMM8C!O^DDMMZQG!E55=LDOJ7*.2$JE>$5/" QL"KV2U^[/9&. )>="M->
M&(D'%+?1A=0#%Q0!52FC%[*^*IA@6:.E;53KBXML_$Z?A\B..*TFTVPQ!.C7
M_'6<304EE55IQ%(1[!/\>$CA81>4/IQ$(#!Q<$$'L@.T^YLM,^!=G=&X&RT-
MD;"'OY1$/9(]\@-D%[PO*XF2-U0%),XD>VY#R1>)(/5V+7:532<\':P?K'4*
M #<LQN_P< &8VF5HHOY;92C(AND*T)/))/2I]H+<KL-L\JHH.)T^*)/G,7G1
MQ_Q&S;BH60UV?;L]EE4H<"Q:2,K7.: "J+;U:Y6CR?)R_[":Z]W/V!0YMC?2
M2A) /F>57NIW47PU4 4X[S4<2J:C6",%%\I@(U.-9<KV*)B"EU).I:S/3(7B
MT5^5?1[N?J>M&CM04<X)U7C TG,%)@'>@JY/< ROSN=NA[7<WNO)+S0!MQ>(
MOQJ52UA5\7^O<HU/?6#S&6=Q5E^!\MRR6GO*J?7E?G@9]PXXQL=E99589D1C
M15=J>"38?2E+1*ZY$+KJD3)*(L+>65D7=A)&XDA+5HQG87G$:'D.M<+SMBK<
M@A\S:B$BTHSI:),,J\M8^]+AGTS5GZY"V=_>GY5!IY383I9ZG9FL$:WGW=WH
M45:K1])CT)8JU<N,I4TW/9;!BFR9LZXY,57%4YM8"L-YOE_,9":R+'<N*_I4
M'5QTY5:5C-P&H-66T_:*C909E3"%>^CL&NW#)-?$PWC&2NXNH=]\R>C,5D6>
M"FW;UN_EJ*L,>;6?!=*X"8VQ!C)0';>.IO!6*F9>+A'A!FUTH>#Y+%:;8: $
MJ1?4&L6 L$*I]#*Q)DRMA *397^*.HVMF*-DBTBOV)W**,^F;+Z!&VCU7!U,
MSVV-07_CIIG8OP<*3<,Y'=Q+LHQJCF[2X\8HWB3SOZ^V0*G93VC[G"./8VZA
M-)2MSWB@I'*ZRTT\ Z7K+69QAB6;8\UE9%/< >491J-#8&$9Q)BQD#)KZ.\
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M9YD0]M_M*3/,][TA9P.OY;L=I]5UG4Z+.2._U?&#[FC4"3J\LY)OU0NZD\G
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MY7\&PJY/A4$OW!=D9/@!#/4PQ^C#E$43=&/P0>20R NHHVZ!'@T]#X!MFJ1
M@<.ZIW>MSEVL\0B\:5I5TWO5*NW>74)T]:;. ^[I#A]5JY289X=[=EMOH31*
M=^YD4PF8 G_ZZROOU=&19K>Y=Y_/_O;^N_7E/T^__GYZ]O[OW\_/3C]^LZWS
M3V?W2& Q3+FOG4Y##D,.HQ3V@7S+785ZSX<3=TJG7Q<G>Z+,Y@K+QTZS-]D;
MZS=6I.S*^C9E4]OZ_9T1;*-)##D.+YI&+ T?&G(\:6@0+S\)<WB2?Y\4QVG(
M)QL.T*HRV8^)Z#YP6 \\ 680XR6*B"''4XKFZUO.W=^C9:P1U9?(FX8<)IC5
M2# TP2P3S#IX,$MO%6RDVJ@10X[#RZ612<.$AAQ-=TI%&&NESIL16,.AAAQ-
M%-C7MU1G-%$DPYN&'$T@QRTU*0X^M_V?[GA)<S7'[LRQN\?QU,@QQ^[,L;NG
M ZMJQOIR.FW7N^WDUJ/KF-%1O%UUS-K[>;<OG__Q_FNC3^19GS]8I]^_?_[Z
MZ?T_K=-/[RPZ1&C.Z=6(])[Y4VO.TRR)K>MIDF&A#Y"!,,!B&56[-#:?<Y;B
MD;HHN:;R4.,%UL  3987N:PP A<E(9[O6\K1HQ__*YG&UN]XI(M'46+3=QQ?
M+@X#SFQ1N&121)$U5YW<LF(LWJ"*E:1\Y2OM#JQ0XN?TH*3(Z=1?@D?]J&X(
M'A9,4AR[E:<%IWLC=@VW6TK68/6!HO $FLTE%\<7\8LPUN^/V8S;6/?)%X_)
M<LX"^@27<TI=X*KE'%Y+/\%PY8%$F!BOR&YK%,>SB+$HZH87^ P/V^4+>($H
MR(+4M]6+L-P+E2JAT0(1J#**.&%)IR[OJ'JB/X::X]&L:!7P:;)F4"8.2^9R
MR8B>5J *6N)0@0UBV;D@5X7#[/N4H;%%B2C@58O.9&8L#,HUR587)5O'/1H;
MT(7B2"?0#@]Y)O0=T!L+I(@;Z0G@>"TL]6P@6'QI6UCI94+E=V2EO4F8SNA/
M>$$^9?G=XZ,R-+ P<G"RNDV8$O_ JI0\3 5KJK^PWMA",B4634JHUI@HST3G
M6P,093S/>A6F><$%N9/)^D.K+Q+.=G3LN#I77%8QDR>'!0#*(\63!*#L&GE#
MB')6%W*\Y&MU?%E*-GXK!5O)A) <JE>4$1I@\3ES%OD8SR)WG ><*W;W<Q9Y
M-R_R[I[1;?L>P_MM>ZRRY>XJR6Y.\;A'C=EA(ZH7KQC/VQ5' @V_OT*]&\EK
M_7_VWK6YC2-)%_XK'=KU'CL"1=?](N^<"%F29W5>CZ60Y)G83XZZBCT& 0X:
MT&5^_5O5#9"@ $DD<6N Z;!-$NA+55;FDT]F567-ZU5CUA]!][SH\8-7U;?U
M= BZ"KIZ#+KZ+#.)@TPL'F,9]9XK,XCI_F+JQ?D/QR@XT*^')Z9]KA7;H3?O
MA<T?I/9#'WGHD=K"B;ND[9X<<X=MU8#+H(L/WJ'U=RSV7A<%(  @8,MJ=_<]
M^Z"$H(0'V3W=^VQ<+P;F&#4:#!_T"_3KX&(Z<?WJ:X #&;O;%+B =!T@R,'2
M=;?;/@X.#-3O(3JP_H[%?NN]@/V#_>\N/7?+8@B@A*"$D)[K[< <HT:#X8-^
M@7X=7$PGKE]]C6X@/=?\^-GN;TC0 8;T13O__FHP#XWBH'H31_5X4CW-WT[&
MPV&<5/]E+RY_JMYFO&AF$\C;@5:"9SN"L=@J0NS+=P$"@-:MS=P]\7X\Z^JC
M0.H.M!!2=\<Y,,>HT6#XH%^@7P<7TXGK5U\#'$C=-3]6SX=U8UV<GE<___._
M_H-R^=/D3TC@ 9+T$DG 4X%^/41/U=^QV*H_VJ\O AP W5NJ\@7%%4#?(/5V
ME -SC!H-A@_Z!?IU<#&=N'[U-:"!U%OS8_743IK\9_7S.#8-Y-P 0GH)(>"B
M0+\>HHOJ[UAL=P?[?IP0   H'23;0-\@V7;L W.,&@V&#_H%^G5P,9VX?O4U
MDH%D6_-C];?Z3QN'U;/QL(0[D&T##.DEAH"/ OUZB#ZJOV.Q54^T+R\$" !:
M!^DVT#=(MQW[P!RC1H/A@WZ!?AU<3">N7WT-92#=UOQ8O8IA,J[^.K$C&VJH
M"0<HTE<4 2\%^O40O51_QV*KOFA_?@@P /0.4FZ@;Y!R._:!.4:-!L,'_0+]
M.KB83ER_^AK,0,JM^;'ZZWAZ;B^JO]D_\RV#ZF_/(.<&,-)+& $W!?KU$-U4
M?\=BJ\YHCXX(0  4#Y)NH&^0=#OV@3E&C0;#!_T"_3JXF$Y<O_H:S4#2K?FQ
M^L6&3SG2&=9P: +@1S_Q _P3Z-=#]$_]'8OM!J%[\$!@_:!QD&8#?8,TV[$/
MS#%J-!@^Z!?HU\'%=.+ZU=<P!M)L93MI/;'3^K)ZE7_,+IK9!PLEW !(^@DD
MX*A OQZBH^KO6&QW1^D^71'  *@>)-Y WR#Q=NP#<XP:#88/^@7Z=7 QG;A^
M]36>@<1;\V/US+ZO0_7JK'HSGDW//\3A$/)N@".]Q!'P4Z!?#]%/]7<LMIO\
MV*,G A0 S8.T&^@;I-V.?6".4:/!\$&_0+\.+J83UZ^^AC.0=FM^S.W(,JC]
MG]4_QJ-W4,L-8*2W, )N"O3K(;JI_H[%5IW1'AT1@  H'B3=0-\@Z7;L W.,
M&@V&#_H%^G5P,9VX?O4UFH&D6TFZG57_7ZRGYSG6&8<&,FZ (;W$$/!1H%\/
MT4?U=RRVFW';DQ<"! "M@W0;Z-M1I-OR+]8-8Y^TY?K=7WO=1HH5ZO>E]_^=
M?U9^:)LF=[O^&$-W?WNOK4=Q\FC1VGGG2D<>V]ET?*5-[2<YTLBZU+U;M;\O
M2:V]W(T_EGZ5MLX;E@7U<7%9IY(WGKO04M'9<FGHO"G_1O4HQ(^/$?LI#>-'
M%%J J<=9N\;#V<7HIU WET/[Z7'Y=L40SFAI77[GG'?@,YD_^.>LF=;ITT)H
M[:THCG*0.F[J]MF3.+33^GU<[LE5N/7QEG9#Z#<&=6>FLVV=,F1%GZZUZGSR
MF=K4HV'6)M1,[60^S#>_R)+N/NY>I=M1O[3O8D<&D4VYZX_M\(/]U/STZ,?=
MJNYN5/6&RK7=6]&L7KFL/8'0=8^7APF?$?K=Y^U8D@$MF8W#&-*';@S=>!AV
M(ZC78_]GG%:OSNWD(K]^UGKV9E"]&/FS9?&M%1RC9X2QKXDN^_V[RNZ&YC-R
M9C3Y[H@$^J*88#4=5T_'HS899J<Q5+_4(SORM1U6;Z;Y@XM\;5.N*#<U:^7<
M$Y/\E@O9P"1;/M32H2]BY]SEE>:5Y^?>E,M1=K?CV709PPG.FO;=XOJL#$-[
MV<3'3;RTDRSO-7#Z:"4U\+YN:E</Z^FGQXL'K(O[NQ<:_MV7H+OS&.MN(O>X
M1WSSGF_F.9SU?[Z;C&>C@.9FXE/"R6\S 7+KN&!/;L=6YY.8_O+H/^PLU-,_
M)O%R/)E^&3-26M_M]LDA^G&IE96]9Y9AG!02,9]5N /0MBUHJG&J"D1<9A*2
MOZA>QW=UD_$L8\2KF1O6OGKB?1ZJ:7Y@1HW)Q97!V!U&,9UM?O_JZ9.7/U<O
MGN5@AO]PM]"P;^-_X$AY51Q=8]=)Y 2#8K20ULY>00^>\NV;QE\AGE\B'G\X
M.\S$(_[1G,<X;0X)@#?XT,]=LZHW;;,JV^+BL^CCA8N3BI$VE\(K.PKEE[U@
M( /  \#K+^#=81T?<+]U2-A<!5Y_C-,?X\O8(5I_,'$I,LQ@^/*J@54:3ZKI
M>:S^-]I)4SW/;PNK6-G^GRT0\P9D J !H/4/T"0PN'O@EA]?7/XQ'#=]A:VG
MN7V3>!Y'3?T^5K_FA@)\ 7R=('PIX&/;Q+7XKUD]_=174#NWHW>YU_4H?S'V
M?YZ/A_DMS7_]AZ9$_50];]L.. <X=X(XIX&FW8>FV>;\CS0<?^@M3\L-K'XI
M#03< MPZ0=PRP,_N#&BC\30V?TS'?]Q MK18NY Q[N*@<ZB_E?;=:FT%X!/@
M4[_QB6!8*0PKA;^V4EB<P$IARDBB^UPIO)GE;KLUL&P9EBUO==GRGGJ\X6I:
MLKWER<]?O7S]MGKY2_7BMV?/7SW/__OM;?7Z^5]?O'G[_/7S9]6KWW_^]<73
MZLG3IR]__^WMB]_^6OWRXO7?#KFB]E!84T&G'TBGWX[;?,W/8SL)[;JI^9['
MIDW/+&>H\[</44!WWM1PXO)XD%9RH]-+=.,.+\L]J3^6M_PVNRC5(ZLZ_.71
M+W]8K 0GBB"#N4+<:(.L-@'1&)2@W%/L]:.J;<G'Z>N267GZAP@\)84)8H$3
MQ)4/2$N)D3 *JR!DX#+?,[(7N84AUH^?E&7KX\G+RWJ4Z<_;_*"?AUFK'U6Q
M\?8R7S2=S&+WDGHTB^')]+8M^X/LA4*ULKK=XON=;=AI7_6XGN9V^3MHSESH
M5?ZWX.S7\DM'TJ/U -".6=WN0WA,^?4FMZV'B'V"A7_$ZMR^CU6KFC&T(VQ]
M659C1Y_*IHOEW&<U7SY==<NGB[/]FF_I_._,-76H[:3.+?R^/+[,$^<@^&GW
MCO8O\M,/WUKTS ;M;^4!;?"36W.C:<V-^9SK]8R#RM]8@U,6"^7/KJ>PFS53
MV-WT>_?&,G=5I:NIH6C]>7E#:<BG=HJH[NQB>CZ)$96/JOSR>ARJ^*6YH\\[
MTB::J^_+-JN2(GD?AY_R=RE.RCZ8Z;B(9DEP5PGHI3XOI'A69<E7X]DD2Z"U
MVD%[Y[I;JBR4INRY2;:>#'-G<S_L<%A=Y LFY=+\]65N3M,]XH:PKY^WB$@7
M(IF/ZAU&\\:#\SMGPVX(\W?U9&D@%S?D#W<P)/F.W)#\M(NR=N%#*=1BKW<>
M74[JW-W+81ZE=W&46S3,(Y2_CY>ET?.W_3ZJKR86VQX\:;VD7<^Q'BK:9'08
MWX"<3O&RK">AQ996]D6>655'(7/ZA38L=H0M5&QI9]C+]]EXBQN91P'?WQB+
M'ZKOYZ;3[NA:V,I@66'GEE]4)ZO_*&MV:?5D/*S&^=E+"M]Y[_+2+ZCX(*-D
MD]^=;<)/ZM:6,DLIV>LZPV:K+7O*R=W3.[Y82.#I7 *H*A^]FW332Y-,RCZ,
M)W_V*;'X?;\E2C%A?1+7#U7=-+/BSS\M;"##WC3&HM!O+@L@3UJSFKRSH_K?
M<_R=6^';2;3A@_W4W=4T!?P7]O7TY9N7U^95 +NXHLYDJOGTY.<58JKXL7BB
M8C)9,K/1OV99NJDN%M2YL!OX^>.-".0."<%#0>@!Z.W/MJD[SSBG[B='S[._
M_'JAA5-QF&_/,T=;3]_L),Y)9%,L=KY7_S,>=N76\FOMN_;.3!%?MD9YX[:Z
M74@P-\5BB..;4=_GSUO;I"O'5ZR^=>]-?EMQ^KFMMKKL_/<2KTKUY"*WY&K/
M]Y7O[[9>%P IMTX*'Y]S81>K>FG#>'O'G*F6KY<YZ!=XQ>]G;\ZJ%$.A<543
M_2Q[Z1*<#.V'*Y)9V<O+W-:V&L-D5GA?^2*W=#:\B89OKN\O5SS_V$46R^"X
M>&3;IV^3P0>CV_]HN7^8^>(6KC7F]G2PE6=5O3T?-\M?S[4E7V.S?L3J,L>L
M[2#D&* 0_&Y\R[N*PHQ=F?K+-]EF/&K'VV;?.&G?;=UXEA]Q'O,=DR\'4D5%
MTZ3SGE?14QG]Q26#JV>$66SM;#+)Z)S_39/<D+E%7G7?#V<E2IDWMXL_QCZ&
MV:1;[I,;6(RT-?ZZ^;/YXGL7DEK7ZF^T:; LL<^;4 3;X4?H;*X,0-N4W)4W
MLQR-+5U]U9_X,6M,48M!@0A;968^+9!1Y[;$]W56?E],_5T>Q/+"=I0N"E)T
MIA7JQN?@??[,+_;KIC#;:..Z!>_M<&:G5T]?&^#-.B82JAQ0C#(1\38+,C>U
MOFCCN@L;8N%-UX Z*)% .;BZ_/SL%25X*$'U/-:VRZ'R%UJ?S<+%81W?SS5X
MR3*R5(N<LNR6U-5=>?NEL/^N>?T'Q(Z>%KCV6>IM3KGZF\W$=P*HO,0XVKBU
M%5&'DA>MB$H>[6(VRI^WF< X''\HK,$NOK89 %J?/AEW$)L=XZ2 T#SUTCWK
M*[H_!^QL1#?>-)Y\[O]O?#WW^=W3_54@TSE=.WU<?4]^F"?:6NSL;+XICUU&
ME/;=!<BO@'3^X/6(GY_^/<UAU.C]>/A^[KY:$E*WJ:%, H;#.'K7@ETS<__L
MTGJ#\M:2CAS&C]4_9^'=W.9;F5]U:@X1ZP<AC'-C1^/<UF'YL_C*S'1*.+9D
M_0O2MA[WI_;/."I89;,+& ]C!_4?.I:6'STH\+;4G#F4K6]/JP>#.3*52Q<U
MIA9M:1:-67]_@:W1,AJOCLPX-[/V+0GX-!_)8X&WK5=3R\0V4^9B51T):']M
M23GYJ7HQ0JW?;0H':J*=9*&UGC/[DN'XLEP+.+<0Y9,FRZ7)2NFZG%RWF+K;
MTB&_9OR#+R?^EH./<]OF,XI8\U-*KX;U^_95F:B^J^=$,[:(^)]4G-',W(;#
M8KR=MM?-U?3 M%"8;P[M51+FQ:O7_V4O+G]Z=CVUXN?XV6+SZS@:O[>98,]G
M:7+GK_I2-K.<99^XX#;Y;>_K^*$CFU</;ME&?:V+&2^6F**MVA3.M%V@MJRG
MN:=+-V7)%'@93S( ODA?OFM^W0*CUP6CUPW+4NM>4?+*[2,SOUOSS&;1X!C:
MMY>G?O'BI0;$=K:D*B0O+GQ9-XSYD<..E9=1SS#F[632SJ"U%P]N7OIA4MS4
M*,/YAU$[OOF&ZR>?54]NJMB5AEVSSNL.M#??4>3="$Z717<5O"]=U3'G.?U_
MUZ8&\A._J(&V>+DV&+XQPY;O+0XPWKPX/Z@51S.?9KN^?AYFCR>?JCAZ7T_&
MH^[I^:HTFV:GT'JG.&D-,\/-G[$XT26E;3GZ,GTO(=W%91>XWXPPAO6?F6R?
MC\<=Y\]8-6];1A\_K$>=QRKM6_S13&?A4Y7#@=ANVNCR HL)R:9T)_?7V>MT
MS%)W[&5QE'8X6.K!/+_:2:&Q)029"ZPT]PS6@\-Z\%-=#TYA/3BL!]_F>O '
MR61+]#C/7W73UDT=;A3+*I%AB%G[\Q.Z\+)E4NN3>YTF%>_84>!Z;<@QISXW
MB)?]0HC7K5[)7KN$]LM>>1$!WTRG%0;0YD&77CRRPT]-W4;*=9?]FTU&F6]U
MJV.J\VP2N8?OYCE8VRT6O'K^4@A>7'+KYU,J4Y*%G*R50GO-=2JOZ\]2DO):
M1GWA"67=3\&2Z=6BGWFC%SV=9RK*-[,F=A1GG&([1V&'39=HGZ<PLH;F=_Q9
M#[L^_3D:?\C"?A?GV>>Z^5QTTW:>ZLL"7&K/0HA=XGT1E'S^ )@GN8Y40RC,
M>R'&N55=#>A]%+A;[33J=*<;^<4SVC32/&M]BW326<E77PUE.X%?%M*5R9@V
M^35OPUSQ<L2=I=LVKBY9L(NKG'B;KXO-XL+YLJ_<GJR_7?)L-(\^YNMR;B+5
M-7RL"PK705C;\)NMNTZJ+]ZUYK'+H<0\4E^,Q WH+;<OS1PU\>:=<=*M?"LS
MGXMIS._K']:&MXMYT]%H/,NC=YV"3!D[1N\RDGQ?YUM+[-*NV^E"HD[*HY I
M<D:48*>V@XY\;;EXQ0RS3HS;UMHBAZO@MBC.6?7J[E#1=K&=3+D!&N6A"\6\
MG@M9%7VK+G73Y@2KR3UR?J>W:O^A=+H<VOJ\;C+_?G*1<:#Z]==7#U$,#W+L
M'V2G%XOPFS@I?F2^W/MS-["@M9D)9-RFF$B Q'UW^@X]^M)N*2DY5C*@%%Q
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M_KLTRV4SORC,-YO,OTHA[_+)HN]+2;="Z.MYQXLJ+PZ2NCXSH#V5K[[)[:_
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M>R&TURHBG61V"EA$Y+32R";JL+!),+52@O@^%'5N.+LDJ'3 Y($9ZBG7'@8
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M62X<PIH;1:512:S,9MUO]KS3\R>C\.Q:RY]W5'I;1_8I,J#\P"7=3MV60!Z
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M9\B(C&M26QUY"%+%%:9_+Q@LQ7;.,T^)D^;YOV;U]-.6UB\K0P (^VN_ (0
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MU6N'I**^9%FQL^%S*!;:*$XY0PKK#,56$V2%$4AQ0R5VBN%RS[ZA6!$V4$H
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M0I(:\8 YTM9*%)VRD6%FQ6JDM-5Y_STP#36@!([? 13KLYB ;0#; #OMOYC
M3L%.P4[[+R:("C:)"@)WV!!%$18I,WRJ(G(11T2EY33)Y*1S.YW[WT]40"$J
M..S\/VSFWX$G_GV493C,30YE^C\_X#R.FOI]K-[9>E05&Q^5LO@7$?;OGZ@W
M M8("@AB CL%.STV!00Q@9V"G?9? 4%,8*=@I_U70!!3'^WTQ+*E,ADAL"=(
MTL01%]$@QU1 5";)$O7*,K^2+16,ZY0(TE12Q(VCR*ADD*%:"\VE9O'F&HJ7
M3U^\N,[;7.=X_F<\+ /Q5UN/?ATWS<\QC2?Q2?CGK+OR2<K#\-9^W%8)!05%
M% #*^BPFH!Q .<!.^R\FH!P;E6L24A!!*8I>!,29TLC2))"Q&#OGE<LL8N,)
M6J <IVBCL$N[%[.T;[(IE-W5TRS*9C;Y5+5[M$&Q3]'Y $D$!00Q@9V"G1Z;
M H*8^FBG)Q;,:16ID)R@1&P.YKQ-R!EOD(N,FY)!)GYEMS^7B1$J,!)28<1C
MJ<XE24!2"4$-\518L@CF9@UZ9^WE5Q?<OIW3T/::U[%NK]I2!,>AS!; 5Y_%
M]/^S]^[-;1Q)ONC?]UL@?'=.V!$H3;T?]IZ-H"5KCNYZ+(7DV8WSUT0]Q5Z#
M -T-2.)\^IM5#8 @04I\@$2#K-E8FP8:_<C._.4[L\+7_6)1@01-,?)<ER4E
M%N58$A)!&$^Q(IQOK5>Z30OQON'+5/2JZ#5@,E4GJ3I)54Z'3Z8JIU5.JYP.
MGTS5&[B/-T"<9UQ:CJ10+H\-Q\@F&Y$@V%M&I..4W2<SO6]O0-1L]'ZST;5G
M^"&RT5E2P&WOEDW#<=K9S-N5M9^BRJFF867 2J8JIU5.#XT!*YFJG%8Y'3X#
M5C(-44Z?6*C%\Q"L=0Q)ZCSBQ&MDC>)(J<0CY8SQ[0UM=TF\GI?V=[_/CH#^
M^1[LY)UMPIOI2WO:S.VD;+TI_N/+#??Q??QST73PZ!]B^ZGQL8_1O(]^]G%:
MSE+"-3N*S# SYKA&9RKB#9E,U3*IEDF5T^&3J<IIE=,JI\,G4_4@[C7G69*D
MA78H"ND0#XXB9T4 FUHH:XDC)M!=)&NK!_%<1;EV&P\BO_M;G(\FL^[1YST[
M>&FQ77_R0IS.1]ULTH31ZL$&0NWAZZT[DK):H _)Q'TQ"F;/E8TK'E0\J'A0
M\:#B0<6#B@<5#RH>5#RH>%#QH.)!Q8.*!Q4/*AX\5SQXV$S930%A_9YO_CZ^
M7[V*_6;FN)>8$H^DLQQQ1C4R4E(4N?9&):J"T)<S<U@P3823R :O\E!@C)SA
M%"6E+/>$)^W4Y<S<;W'^9NIG)S%/\KUY&JV#-P-_?2.?1KD8"R/VGE [( "^
MR%HWYZ(?!D33BL05B9\.$N/D'%%:(DP8H*IV'%GK+%*1."*% )#>JK*^2XU$
M1>*GC,2US_VAZR ^]\1TLTFXQ=OZV4[LU,>1G8]>11]/7&Q'C(Q'%%,V(.&H
M*O49J=1'5W&64IV,8\ACDQ /"=05-3SO)N,V>JF8WAI BZ,UPG"',(L2U***
MR$IBD2?6YW,9BL76S)9<XM>]7<R[N9UFZE]0<UWY=E._X6]-9L1CJNF8ROT/
MF#T@Q59C/ =*R J##SR'FV"JB7=(.D41%]X@'1C\IW#4><&"<UM+E>X$@WG8
MSC'8*;'M?OEST<S/=C6I%K,*A,.5WPJ$3Q4(:_*KXD'%@XH'3]0PBCAZ[KQ"
M!-PME%-)R"IE$55:<V%D,'[+,"))4V6M0]H+C3CX:,AZIY"2/@D6=7#"/9IA
M1,9<X+&BM)I'PY7B"H<5#@\"#@FVE)IDD.0.(\X Y!S%!CS&Q!07+$FYM?#$
M&^]\4@R<21P1=S8B)Y1 A#LGP>E4R3\>'#*R_YTF%0@K$%8@K*GXVP"O,M))
M'"S8E"F/*R :N:05PB0)SXRR2F[E*3SS4CNED,$Q("Z)1%: %:N"8$XD+**+
MNP3>F^7CC3!CIG!%X5H95>'XB<+QH\.C#\'%0"C2.%NC3$=DH[/(6QL3MB12
MK;;VB*8D/3<):8X5XLIX^'7@R#.L8@I"2$H?S2[EAHZ%XA45ZY"6)U:<=*,W
ME+?9E&*D6<I+.$YF^3(@:N/1-,[SA\WJ #_KYH\^RV4@)!^^UJHZZ5PG.2Z(
MB#2'CH5$'/N$C*(,,8<CCEIKP]QEG:2X8Y)'@3SQ'''A./R&$$2C"E(*(SG=
MZF.X9AU47W$$]"I?=?>L-R)B3#0> ['VKJ*>J3!6,E7,>H0P@]!"XX@,RQ7_
M5E-D8O#("6XC#<YJMU7QOT/,*A,-KX:L>V3 Q/YS7T].&($7\U?_^SMPD9ZX
MH7M/01L4K#U3ZCU[<:VZ\^%UIR$R2*8D$A8T)C>1(NM43G:FB"4UH JW)@HS
M'&/DWB+)3$"<.H:,)AA9BXEDU'+CKHY!/9;NU'0,CU3U9]6?AZT!*O4J'U8^
M/'3J/7NU4>VXA[?C$E54>,50,$P@;DU"EE&.2'14N&!B<GYKMUS@*2E,$ N<
M(*Y\0%I*C(116 4A Y=ZWW:<H+K:<7M-'=:Y!H^8.AR=+MK\S7PTGXWBE]CZ
MIBL']=_.3K, U$QBU4C#UTC*:NNT%2CB'%D0+B*7"$.,"*^%UC1M-Z'L/)-8
MOGS;2\TO2W$*]\PJ4FG&6->48DTI#IE,%;SN U[<,TF4L AL4(RXT0GI&#12
M06-O-0%C^2'!JYC3W\:N>W245/2JZ#5@,M5UKD.9!_!,&;"2:8AR^L2L#"%H
MKEU2R%DP%KCT&BP&*1!-4C+PG;BA6U;&KI.O#VIEC"FNX;N*8$,F4[4TJJ51
MY73X9*IR6N6TRNGPR50]@OMX!(QS'JQ1R-.@$4^:(,T(14PX:K'!U-H'3^,_
ML$= 2/4(:B_P ,C_^ G]3[&;PYGR,2W\V39^'L/RN"Q>-;%?==3P=90F,1DK
M/,+*@8Z"%X*L% &QJ!BW3%,7^'UR8ZW_8_[UK/Y_]7+T-KU?2U$Y_A]9ANZ9
MW5>4CKFJ.JI:V4,F4T6P>\7=%6,Z3S4 Y$F(<P B2W5$TG*GN;&2XWLU#'\-
MP8J)?7, N[NIO?\=*\]4-BN9A@AA-:!7&;"2:?AR6D>NWJ\/2'"CM<8(&V,0
M5TD@D[A%U!@G W76X*T]U+<I*7@LT^9F8UFKC7,E7]^<B1Y]V.I Z/7$0;0:
M.Y4!*YFJG%8Y/30&K&2J<EKE]&!RZ;4Y_@%X^!]3H.$$;CE/^CF!$QS':==\
MBJ/)K.M&V=6=YDSZ"1Q=,^85;RO>/@,&K&2J<EKE=/@,6,E4Y;3*Z? 9L)*I
MRFF5T^$S8"73$.6T%BG<KX)<6RVBMRB20!$/*B'#$T&<2DFH=59)>[E(P2D1
M*(D$.4D$XEQ$!"<AR!BJF&*8**\O%"F\??GFS7F<Z#RF]']FD_SB_V:;Z:^S
MKOLYIED;C\+_+/HCCQ*\]M_MEUV7*E!19R[58H4*IM7HJ0Q8R72(<EJ-GON-
ME R!4*<9HI1CQ+7R>=B31%(H%XR5./&MRLS;M'97HV?0X+!;HZ=V?0\B4UTJ
MFY&SW3)5':>=S4S^3'G\B2O :JA6!JQDJG):Y?30&+"2J<IIE=/A,V ETQ#E
M](E-_P!/.!!/!#*..\2IL4@3P5#P3"AFL0C1[&+J]GEXI?M]=@3TS_=@)^]L
M$]Y,7]K39FXG99Y1\1]?;KB/[^.?BZ:#1_\0VT^-CWU[[?OH9Q^GY2RETW9'
M<T(X&QM:MQE5Q!LRF:IE4BV3*J?#)U.5TRJG54Z'3Z;J0=S'@W F8.]U1#IY
MC;@4&&EM+?*"&A]=%"3(74SIKA[$<Q7EVHD\B/SN;W%>FHX?FY4=O+38KC]Y
M(4[GHVXV:<)H]6 #H?;P]=8=25DMT(=DXAZL,'NN;%SQH.)!Q8.*!Q4/*AY4
M/*AX4/&@XD'%@XH'%0\J'E0\J'A0\>"YXD%MLKS?^HN('4E8(9<<1IQA@IQ(
M F'MHR0<_@Y;F[THQR0H8Q#A4B/N:4 Z.(6(Y!031BVQ[G)F[K<X?S/ULY.8
MNREWWS6IQXK+O2?4#@B #V:D1$7BBL3/ HFU$8+)8 #62$ <4!EI1RE26!(B
M(\?";R'Q76HD*A(_922N?>X/70?QN2>FFTW"+=[6SW92MIW;^>A5]/'$Q7;$
MR'A$,>7[%0[Z@F;I"+.%F\2J5.^G5&]!S&&HU4=7<\8#,92/2"7J$4_*H_P!
MHH9'9BPET8C+:HY+@CG1"4F3$C@IFH'#P1UR*AE&$XO*V\MJKE]\_G8Q[^9V
MFJE_SS7G!,LQ%VRLB1Z8=KO$<T/3;X<5ZADT&M[55/BW"HM#AT5/=$@D)D1H
M $L^I(",LH!X@4E.'+>*QIW 8A[ <PRV2VR[7_Y<-/.S'=4TDS&6HB)C1<:*
MC'M&QIHAJ_"P=V)6>!@J/#PQPTD:CP7F AD2*>+>$F0M9\AY*PS31BBUY4]Z
M;$W"VB/-@@ ?-$1DG&<H22,%CUA$X1_1<)(:CRDQU7BJZ%C1L:+C3I-*0@L#
ML 9N)6 BC\&!6ZD"LC)(S@55%&\MC@C26>NE0RI/[>'.PN$L&O@K4,^XS?4!
MCX:.<FBYI J+%18K+-;<_JU@V&(F?&1@80;,P> D%ADK"/)>>2ZI22K@RS"<
MI!9"6($HU6#86J60=0##.B4:8L04T[!+&+Y9@I^ I:K'A%18?@[E5A6?*S[O
MI2K5L\BP$$B*8!$G+@'V:8L(]MH+)9)C[#)>@D^/K8T"#C(:\: YTL%J1).3
MFC#F)%:/9K9RR<:4\0J2^QL$ W]8>,R'%9>K'N,;]@NA*P/FFLO=APP/^:SG
M '1GVZW<RS>?O9SYQSRKJ?&WH,;OQW%D?=XJ8J=G</1H.IO#R6T+'P.PP&$?
M6SL9G=IV/IJET?PX=C%C2*D+M/,81JF9VJEOX*!N#A^4.5(O+G!9:#YEYOIW
M^/?(3VP'6)":+S'T-U1NQC;3V'ZW(L^2GIE/?K2+^6PM:^43_$)D 2\/H\K?
M&R^J'.YF7S+I\L,OGQ3>S9?58;W 7CCO2H9%+\+Y1I>W\B_43$/\\B-B/Z5)
M_()"T\:"2G#FR>)D^E-HNM.)/?LQ?[L%)B]HOCNXYK*8L+]"'K?5I+/56R@_
M17$:?CJ==65LUH]MG-AY\REN/LD:E;[<4)U]4V;NRK:4D41WQ+8W8M+7Z"J'
MY &$Z$9WH[>8^YS%C]M+/-Q,)\#:()T@0#W/7?P"7GO_<7\E71CDU'Z,?5DI
MLGEGUH]V\MF>=3]]]]>'E:.'D9LM_M]F\P>VS^ZB<';'+U?HW<(T>U,[WY3?
MK6K=79/D/5B0<3YZ=VS!'/1Q4>RR;CQZ,_4O'ELS%^MY4Z/]\UR/_7.6_NEM
M=_S/-)E][H9*S9>;ZO@#W/Q7T'+_=]M3-AL3+X&RH]>9LH.PQO9/FN^;*5A8
MLT5GIZ'[8;]$V2,^%D>D^"'7*K*E,91O+Y\?GB<?CL 0FRWFFPJ58/#,_K(Z
M'M[TQ)YV\<<N@D4+\G*%;OMNJQ/D4],UKIF H_OCZ@17]7CT%Q3J!57D+]?I
MTEZ%7_7#._T&G%-.'^MB]09O=;&O=145\;GE>-4K)?)FO48/T5;TH-;93L-E
MH^L#2'"=_-7__DY_]V#DN^)1AQMQN%NCUNM9FT,#H_\;;=N-?@'+/USHV+I+
M!.\)$/V>?'O'R<T56P:&+?06V-(_Q,,THC]5]+EK.^@N2/_U=, @B/]P*%39
M_)'9G%4VKVR^=TH_.)O3RN:'85-^=0S&[FS*Z]_EH=F4=Q.)MZ>QM?.<G<T5
M$9^:>1.['W<,5<.WVQ\8X"NE'E05'N3.KP-EN6=!O,J%E0OW2KQ=Q^!N9AJ5
MY\VU%=/YCV"YWJC&]A[VTV;F+5]N\_+X<CYPW];5 +:M'9JI.H *\%N2;!BP
MLE.6O++?YA$JQG&,B1HL$"9.(QYU1#:W+T9-F,4L\&"WYN<\\^F93U>^'ZAK
MYND2K +BDP-$DG 2CFED(\LKEYU$!C 2!:4UB<9R8[8ZOPV3Q!F7$"4\ B#2
M@ RW%!&5O%7>69K2XP(B%V-A'FNLV-.5[PJ(%1"?.R FSWCBQJ.$F0! I!0Y
M&0ARUFFFDS-"A,N J)WC8" :1)-EB&.?1V%XB:SSQ@;JN+'F<0&1DK&6K +B
M@P#B@-)&EV,C-0QR_<L\"KD-K:_%G\]&;82O?#.)H^DR/I(_S7_G_H?1HHMA
MU$Q'LT?(1!TDV@\E1EN)5[FP<N$0B5>YL'+A,\]7E:L\8L*J7._P3;57$7[D
M&UO\,CL-(WLR W+]J_]@ED:G;;;+YF?ER_CGHCG-=MUS=6\> VEJU.+N,07'
MG6=8820HU8@[K)&AR:+$>#0:<X;]UIRBNV2=WLZ/8[LI.T?3<+0A.3N:6J3&
ME)(:6]B3\%4Z59!Z") 227/J T86ZP" X\  2EH@QK#F*0C'\=9BR;MD@AX)
MI/C8\,<:K%:%K]*I@M2C6%*$4J%,1$$KBKBQ'JPBK9' TLD8A!)R*UU]E^S,
M(X$4&QM&*TCM4OAVG9RI/O]CI6<NN?C]E,4XFD3;Q5&A1/YX ?]ANRY69[^J
MJ$&J*$Z5T#Z!?LEUIMSF(>X2E)715'@5"?%\:XC[;9S]UO\Q__$\E_DVO<\/
M^C;]HXM'62YN44SP]1J",1'5@*X&]+#I5-'I=NA$.><8BX0D-F ,>PK 9&A"
M,3HL3?!$;N]!NXV77]'I.4A=I5-%IP>)03IE(\X[Q:+RB$LF$6!21%9A8;1G
M),JM]IS;N/>/AT[LT;8Z/!.IJ[G\ _7KWYR<VJ;-XI;==^O_7#1M*:V<V^G'
M)H^\K>Y\54F#54G6BV@LRQU1*B#.142:\_P/RL#TE9PZOXO<_=]FL_"YF4R.
MIN'-6C2*4CH7H+MIIWYCPK]B.RNKU*M2JB;S@.E4\>F6&;$40PB,(">U03P8
MC( >"D5+N(Q>*9;WF=T_;?]P^+1E/0M5;><*4\.F4X6IV\&4I 3.;<!NRKL7
M>?[+48:15"QIK[210>\B<5_-J .4NYJS/U#?_K];^/DHS#Y_I2A_G'LJJWA4
MM31$M:229J"1##+28K">X2_'A$ B><F- A=?\'LGZ]\MY>+=Q$[GH)A^68E&
M$9]7(#U5(QVNR%4Z56AZD%R8\$$Z,):QUP S(EJDG<YU1,Y)9;T/:BOP>.M,
M_4-!TW:E*ZD=0Q6AADVGBE"W'*9)&?/*1D0$IX@S0<&[QQ9E T@S&["S6VV-
MM\[6/QI"458G:N[;JZ\9^R%X]1_F,_\'<C9/0/*SD],X[4I5?I6&JH>&J(>B
MIE)3L)0=%>#$2W#B-7<<"6V28C;RY,TN4O0?CFT;?\YB\7)#*G;5K\K&AN*J
M@:J-/&@Z56RZ9?F0%H:I"'YX&2>:P%K6R?G<9$^B4,%[YW:1GG]0;&)FS'&U
MCBLV#9M.%9MN.>HX"@XH%%#.<@#.&(M<I P9AJG33BILMR9^W"4G_[#81,88
MFXI--1]?/??_./*^C:L&^M!T'E[1_)H!>O&D69R,,AA,/\7E7.2:JZ_J:@#J
M:F^S_P,Q.+F %&82<;!YD=-"(.P8E@039<V]YO3U[6<K&=T<>/$VO5I*:W<T
M#>]ZX>Q^^>(GB_S&U[_I5P:\CQ,[C^'WV4O;'>> ^"=0G/#3-^>2O"/MJL=8
MZJI<KV3!FW/;L]VK4B'UN4,J9TP$[0B*R1G$/>9(!V4155%':3%8C5L=O;>?
M-W!(D$KPF%1,K9A:,?70,?6:DE)F?-(&C$AOLA%I ?&DTSDY%3&UW%N;[C_#
M8&"(=[.U5*0.1=A[H*:66 PA4//RV$X_QKQ?*MFF'8'H+6(.RWRV;6NG\]&D
ML:Z9E&5354"JGANBGM,T.:550$13!58ZITA'HQ'#EENK$^;L7JT3J^S!:Q"0
M_\KRL3FWY[][.=F933[6JN8W:WYSV'2J"#6TZ(;'Q'J7.)*>!\0I#LA$'A'6
M-E(3E&>&[J*Z8T<8>#,KG<EJI3]@=.)F6_&>K-SO;55>I>C>ZP!VM.BX7/JY
MNI>?>_*[V23<VM_L+BTT+B,O2WG AK]9EQOO$Z4J\>I:V<J%!T"\RH65"P_-
M.-MU[%\\<NQ?#-TXN]$[?=?&4]N$4?R2:Z%C;X#-\L*QI47V7)WMZ@4^]WB:
M$B8HK1+"1.1N*6*0]@(C904E@1M!TM:4P+OD%-Y,?9O7BKV*_;_?3)="^2JF
MV+8Q_-++YM$TE$V .UT.(&4=A5*K?RI&'CA&7C,316/L+7&(V[S]C2>&7!(6
M*8R9M5@ZIK>RHG?)"#PT@MTL54#'TM1D0<V;#IM.%<.&9N<1'+QQ>:*=%Q1Q
MH372*4@PW)+E-L3DR5;>]"Z=IWNU\]A8&%;!\4$LO0%TJ-;@QQT[5$N!\NC4
MGMFR_"DWIWK?+N)Y1.2YRDA5C$-1C->$)T %<1]!^R@":DM[@@RF$7F6E%%!
MBZ#MPX0G5F+SKI<:T%='O<S\>IZXW55X8HREJFJKVO2#IE.%KEO.R$N.1><H
M4MPFQ*40R*1HP/8. 4<IE0M;,_)V$Y=X1.C*K96\8E?%KF'3J6+7+6?HX108
M#019FV?H*2&13DH@RVFB(?CD3'B8:,$C8I<9R[KV[LEU1]8@P5U@X.VZ1'62
MY7"S.K7$"PHM<KODHEMNCZZ3JZH"&ZX"XPQ;Z8E"$AN">-0.:68\4D&JX)VP
MRMYK0'49";"MO=9B]&O^[Y7*.@,M]CX3XFWZ1]>O1NQ^B[O:W:KK*,9J?@^;
M3A6];MGH;2VE7BFD<<*(,P:FM'<121^$ 42SR=]KA/6 T(NP&CVH\#5L.E7X
M&EHU [5!6"$\2HZ!J4:U0<X:B3 5SK @DA!; 'GKB4^/!I W'.54=Y74TH8:
MM=A\G:^;J9WZ>"EF<?9<I:+JQ:'HQ6NT5N0Z:0$FNN ><9$"TMH%E**3#C27
M\$0]0%!B*247=-8.H^BB:J5JOP^:3A6G;EFY@$T0P1N4".&()Z60<=HCX:@7
M2FG!F'B \,/#XA1A-4Y:@6K8=*I =<LL#Y<D)$H0$4[GP<\4N: #DCI&J50@
MD3Q$&."!@4K1"E2U**&Z]_]1&H3V.9C9P>N.[?J3%T#643>;-&&T>L(G)2@/
MJJGN2,LGJ,OV%32W45FLJ$$F2(>X=Q19J2("M:<CB\(:MY/QT5?$S;,@GP?/
M[Z(R;SA(=2S5_D<]?(75>\6"V6" XV#&050LKEC\:/47,25#@D,"+H&X%8"9
MQ,$_P%/@,B0BPTY6B#\(4GX5(!7>?[CVD.!QZ)&2BHH5%9^.A>HE"R( :*H\
MUY]CQI#5'*/@K$J,&9;8 [6=/)J%*O9?[G9(^/L4"CT>./!SB)&=W^)\Y&UW
MG-M)PJ41Z2 4GVJTI^K2JDOO-Q;/!^\MR6I4),1-#$@[(9$CS(D8C0'UNHMH
M#XAR7F?YKIU]:D(,/Y_] T1ZHU3R:"W/.Q^%A\U8T?UW<#Y??5K!N()Q!>,;
M@#&3)&FA',)46<0=@+&-22.F+*%6B2@MV45 :7]@3 P?&[+_C8X5C"L85S"N
M8/RU4:A1D"")1YP[BG@('%GG )&M3R*)0(B6NX@R[1&,E1X3OO\RHN<+QKNN
M.;K''K\G&VFZVUZ^-]-/L;L4::H+^':-O$4$;@\V3X&.=0O:81"R$J]RX?X)
M68DWC$7)MR_J?N2:[J=1TOUNT?ICFU?PS=*H*:;8"7Q3Y\\/-EXQ8'1Y$M$(
MP2,)+GJ49$[6!6N1ULJ ,Z^IYLQ;F^(N\G3O[%F1M-]G1_[/1=/&-^?2MZ/B
M0LK%6.O]QX"'(MP'$]\="L$J&CYW--1"!4T!#2/A"G&/#=)<*82M$DQ&[!/=
M6E-UET39(Z A,WALZLRFBH85#2L:WK%L@#KE@L8Y/R7R'%"-G!<2!>V,8I8R
M;+8&!MTE4_48:*CDF-']%S\/1;B'G6ZJT9#'B8:T,Q]CZ$:IG9V,0'@6;3]R
MOP9'J@(<D@*\;L.5L4IIB@18V&!X,X6T-P3)@!V5F&ON]4Y"%TLQ>0U2\O>U
MD)2]LKW>.IJ&EW8RZ=ZF#\>S=@XD/WD #:;9F(O]EQL_5^FL=*HH]A H%CB/
M5!J-C/ .<9O#!P!CR&$9C1=.<+F3VMR!H!@V8(?7&&U%L6'3J:+8[5 L42DP
M30Y)9D,>60$>OV8,GH#08,'GMV$G1:W#0#&JZ%B;:HOM5#IK2<5!!A%RC?GH
M]$(DP>8H7M<4>)BED5MTS31V_<:^_$%IO3ZU3:CR4K79$+49D9)%"T:X8)$C
M3B-&5FJ' &PH<2*!WMK29G>)+&3968:\0]9H1^>"<S=-E9HO,:!_Q7;VW7^@
MJIZJD3UH.E58NF5U G-<D$#RJ&F)>#0*&2,9,HKE< #VWFUM%;U+J*#"TI,4
MMTJG"DL/ 4M.QFB)X8@0!=BD<\& 4!$E[BC 4_"8IUWX_CN'I2V_GM.QJL')
MO;OUM39@_V[]JB9G=&)#',UGO5/?QE&A0?;B%UT<V;QMLHI'U4M#U$M1,$V<
MY4CK"#H&_';PR+%"6%AC@J5@/]]_W]U6[=JE5:S58#Y<@:MTJL!TF)6[TF-
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M%A)'W"N!M.,<.>>D%R%PX^Y5./.-#27K%0EWV5#R=9^#D;'"U>D8LCA78*S
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M[6&N]RR+J$;@$Y#:NHY\(,&-J]:1C](5"ZD&)!)5C54UMN/R8RV%]6"76^7
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MK(A&#]8[C5L@>-=H][Y!4*@Q5==O:1B*'#\1#+QDT,-_YA+:KS6I7353:TV
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M"_,QVD6O!,H\J&[A_F<U$&HUA>'B5(J\HP*>$^Y@L\GNNCD0RT$_J\7J")
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M=3Y!:]QK[,44WLD$>"",/A9M7\9%KL8ZE2&+H=QJV2()+[[?X6&]7YPL)F5
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MM<*8B+"-@ $<&^0"H8B:E"2)'$NZA6UW&IZ_)E:6_2SZ;Z<;UN+-=XUUX'7
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M2L&FF4U+M^?931=[V*3 /H#?MIS:&\1P5>ILLG%H.V-N>%S71K\=H=06B^5
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MS176V%N4DC.(DT"1X=P@(HWC7 ;FTE%Z=GT/EC3LRV\RQ:_ 5 "YNVSJUI>
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M"+C)ZN,<=*9XG3NDE1KE+#^[ELG]1F\9:+*(:UYZVP!P>\OSR?=Y'%O#O/G
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MB.6(ACSB#6 1.4T"<E@#3#)KF1Q,<J[X^/+QL3;&&)FCN&F,,=MNO>??"K6
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M]CF^*P00A_YF%[_'U>2GE&*1W:#3O%_8R_&9C,_%3#]=3;Z/;K&VL &H/J3
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M3/R<2?8@?]60D>C8@V*=)3&F1:TN%O/U^TZN@$I6\+U('OL>#BFFRC;JDHJ
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M_W_VWK6YC2-)&_V^OZ)#N[/O3 024_>+M&<CY+$]X3?.L1VV=B?VTT9=)>Q
M!!< )7%^_<EJ@!3(!L0;0'2#Y0A3)(!&=U=G/GFIS"=SA\3BP3*S 4U7TM*.
MK=R3E+#Q0%S4@BQG"#D#PQ4J8R8<XUV5&<H($PF\=P*4SS02FUG@'5[6QUBP
M9T,5/A!4&??JHC9]\#B)K>]>4EI-ZXP]T,C&>^U%BGMOE/=II488IPW%.Z4A
MFL!+KJ+DMX0G&KW32$'G0 6QS,G0V8:R4E.?T*-UCF40)F3PE&D@>$"R@D@=
MQ;&]4S+>W6O8!QEY>=XID9EF'C,D+FU)O#KPC$;P2CLN"7'2=/J4'B)IS^^=
M4CT0.[+=.W7G*$%?\%:6:7HY! D23!'&+ ?C421$B )]51= *A6C==Q&U1E
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M8K3 <]0(B)J"83&"D5ES;;+Q=DN'2'2,6@U<2@/"RP3>.04Z6<FD950Z>6*
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M9M3LC @6O7&3%#I.P8-CUD&V7">EDHB>__?:+.*A&+LO[WT8.SQ\/"4\76T
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M-9;56!X)?FZ.RR4E%=<L9M-)O/=4YU,%J!7[P\'!Z1L/X-O3BGOQ"*K GX[
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M]HUU*L,)K\5S@^KQFO'M#[>^L4>K<%/5_N;F<W>V,47Z*]7J?CDLO<5E8<$
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MAZ?XC_70_U0-2#4@U8#T,L!3"-6&:P*%9A>$SQYL&<$A'>62,>6,[\S\.T:
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M0I!2/ZD:XNC-0D/!_"'C>>T,ZF5GD.B/ :9',<#K[_\_?\&#_7SR?T8+=[:
M!:)$[K^%_N;4^AK9/7'E7I"!=\E0I8 (8T#X0-' BP3$:J8%)RH&>=O E_PN
M]=F!"Y&!L(R!#0&= AFYC31%29\QMMMO^Y :T7ZV#]V2TQKH53O3GPZC4U_7
MNI;[#P3PCS)'^M^O@!;AN\1G^'><?+H7J%&&?Q_!]^[,U_UZ==^ZFOLOXU5T
MVZRZA9K)6?,KPOXD-+_DC(MT]GZQN<;72[6YH<1$R0M^8U?I6*NW[\5Z]R$U
MQ:=P9Y?-9+5>GZ_6;SEK7#-/4X?N07/NYLO+)EZ4]6O0B6@NDYLOFH3K%;O!
M43OOO/ GC)L?9_/KS^_Z^%,(O?:](M>7/FHO^VIQ%BBO33ESOFCO87.5SB_F
MX0.Z7LVV^WC 13X'AYFQW%#J0!FA03"IP(B ?RI/>-#6TF[#NY/&XKMXZ]Z&
MPI[JP/!,(1MG(M$ITNQNI*16ON0O^??E+/S]2AU7VOAN]NMZL7Y?>Y<';;#I
MBT#UZGKZ+Z7<&$L8RZ!$BB!R"&!L2F ES28(QX55MZ64:<E2(@$TE2BE*)3@
M2PV-YEG@QYFQQAY)2N^>F-4+N5C=6$EVA=G'C_@P5B^,T 8LSA->\*<TO6S<
M$JW">3OE'C_Y+_T7IL T-R@!P#'"!F$L X\O0/26:NTLY;$3I,LR_R<J!H&%
M#((Z#L8H!]1R$05C> B_':1O3<3?D7FGS]&KLGU9&#5,1!?!Y4! B$)C8K('
MP@P74BLF4F=?F@5!/&4&F*"HEV5KPP67(:<H3):&,M%AL^SMLNQHX>FSAIZC
MS]0J9?/'14K-S[-E:LQ6/#_6)?[K/QO&R)L64S^@RY301UPEH=IWZ)L_C9OB
M<V[SI#XGO#$7\--S?-E?-N4#B\;E/)E.6B?T\V3YH?GMW=\V;I_J9GW.W]:>
MZJ^MI_H.OW.Q>H:+ZU-O]?O[Y^0?/$1ZBU;N(R[5;^EL]LD%]-"O-+!&1M=<
M$V<%_/[GXFP%FJWHE8"@%=#%I'T1#>#U$H[P#.'O":WC>G%G%\O%$GV_$C"=
MKP+0*U$?-7@?X<-*XONDOJ&D@^?+-FK&P.:K:I:[QV"PR.7 (AYK#!4AD=(<
M@S8+K3<88M'.)8L&D <:6&<3/F@T^PGC'!DSVD:C.;C()5B>!->1Y13"O>S<
MM8^9 D;.RTE:_,5-IRE^=WG;Y-WA8O[T\X]W<3$K#(7,[HD.?1"O5F%66G+#
MQ6R=RK,FK;V"0;F7/DJJB-3 C%8@7"1@T1>"I(0S@:BL4H<5?&_RU0<_2LDQ
MVSTJJA=B=^TWW?  MJ=.VY__U#3_AO\VH2PZ2EQ;SM)^=?NU;G)6]LJV5*:[
MB^7L.EW=OD+&LB2[V\O2[>\;QK+]N)]]*;=<;F-]S6@<OUQ]K,7<F]^[>FGU
MQ2B6Y4+7E_*/UDQ_>0W\39ZF+Q#1E6J?!W[S].+CV9LX69Q/W>7K\FXGK3YF
MY>KPG.O2DM49_N=BL9SDRZOU; ^%=!;?G,]69O!UFR/$Z'#S3J[WW[[<<Y/M
M*7[#UUWF+>+&.,WL.<7M1^B3\#-V0^9OROB'^2TAGIQ-4;8!'9?Y6NANOH'/
M??7RZE2FE9!S]SZMBHPPF,0'\=I-/[O+Q9M7?SZL(AU&<3H*T)7S7E7"[C^$
MZVQ#M4*SL5H/.._*;)9OGYQ=N V[F7R6U!1O+(@R<I%JL I_(U$%I[TK&>G_
MIJ]J&++/,&0^^836_W8<TB>X6L5$)QB':.*35UI"#HZ!"(&""SF@T*=@E";.
MQTYG9[+1LBP=&"HI'N,\^HDJ M56TQR#5([T+0Y!11X1V?,MF1.,0Q3&%,2X
M#(IICW&N*:(E"#A#C<Y4.VL[.WM[DZ\:ASPP#NE5UF>S"" F=.#P@PB]RP^H
M#LLV67O3;#1Q$INSV;+YF(JAF4Z+BI0/!L06?)JN/*@FM6G?E><WR?B(R_,8
M-V\#6JEBC::7-W?8KSZ(-X$O+]K":X?7TYX<O:YF.G%^,BW?.4&;5PH9KU\J
M!^&+JZ\[:]NYVESP50WW[Q_P2A>KU//5^3XFM[B8K\[69#>9-Y_<]"*M[V6Q
M<;OK94#?M[R97/C0S-/Y;+YL;6K;$M=6#6"L-7M_A@]GT:!5.GO_]:(VOC[/
M9Q^O5A57:7WX]<6WUU82UE2_630S?-NUI\$+O9CBM>1U.07B^!R?WOKX<?/[
M54)<7.7#?RSG_,^K6_IQ<H8K,7'39J,:=)T8;[\4(\-P@0]@Y4]L7/!ZG<H!
M5\]YO3)?G\CVS'IUV![CL&W9&KG*%_<)-$[53RLI.\F( 28E^FE4!/".)[!:
M)*N("E%T9@5[IH,B/ /Z>"4':#1X;01PZ90+@7@,9I[73WOJA/<^2-@I>FG1
M,4^DD*"C=B TYV MRDQ.W$L9A8^6'DRZ^N"E?7/J="^D;L-)>W?3#V@A[TKL
M6IO]?]W9A9M?KDH=;^>6-Y,>&TF4*\E8YYW7@F$TR=9[5>;#<1#98WC(LH,4
MB',LI!QM9YL*Y25G32CP*-!]UR&"48J M)KH*%44RMP6C!]<NP:+7].\?8KO
M\.N^FZ*6O6H2/L_S8K;G%VF='5NG[7#M/\)TLEA"FK:.0+O^YQNINQMYY=M6
M?6L&N4TQOFGM-Y3O7[SV:"!*DK%CZ;\^*C+F@C#]]3]SLY^X9[ONZ/-P_8?-
M)LR_IW2.USJ]3L2O\ZKMNGUCG1"QZ;6 ;63B5N>AA/SAUC?V:!5NZM?/".?_
M[VRQ:% "FU8$K_7F:VYZ1[+Q+A?QU7;=8HP3+X0#)6) W>*H6QDQ6)D0)&I6
MEGXONO5[^)#BQ12A];:6?><6D_#V+'X_F5X@JKXKM?N[-*]9XT:*;Y?WO?J:
M*/WW=HG;,"RN%KDY0TF;%DG[6C;EELOYQ%^TO1/%+[WR*S;+E3YCW(F&+5RL
MRHE<B;FFT]GGQ>L'E@\]:_[_KJ?XA/S_=<_):MEV;=:L=_S*)99SX!V5CP-"
MTNQBN;EIA&@U1KQ:?SX4E^)\D5XOTKG#8#=MV;]YM;4!_A.&4ZOP\_75E^SJ
M;%^=6)JQ$7_8M6VTVJW:=2Q]['%TK-ESG[->ZQ[.>0@6O:U:?!\VAC&AZ.G<
MNSON]H9G>W2O=BWWW[5IMG=M[F/EMMSE(5?RF^4,#_?@[E>TL,XK_E?;UO5#
MIT_KX2V>)[/PPQL]5V'FV<=//G#E[B9([*\^'!:('L>ML[_EO^:&Z.\#J.)^
M4N+^B"'S5=RKN ]5W%D5]^&YF]^D$WQI[N9>]PG;5+5;XA<^*T3U92V/Q/!;
M5ZO*696S*F=#7+FZ6CV?@[-:SJ?QV_7E">W7U[G:D;W'/NQC=>#0M,#]?##W
M?P:/8/S?ASP_>FE/D$SXCT^I=WL2^9MBVB0+1H9"/4P$V*0DQ&"L=]2:P/(^
MZF!0S7\Z0Y5.I<[G[2<WF;;U+K._M%J^R0W3%FW<+#O\_?OKPD*^65@(^-<"
MGP_^=D>)(9-FI,7N*L/>(,JWDQ$#PI0_]6YI*UA7L!XV6%-G54@I0V#)@Z!,
M@W<B(@XSGGBV++L.!Z+EBGKK,S J$H(UBV"%8T!U#DX'[UC.?0-K(4?2[F9&
M[ VB5+"N8%W!NH+U]N9K97G2*H/S.B#P4@I>:@U416=HM@Z1^398&^\%.M86
M$,DY"(*>M>-!X5<$ZR+S H_J&U@S.C)J=]=8;Q#E!8!UW<CK67+K^W0VP_?J
M5EY-??=DM:J<53FK<M;GE:NK5;?RANGM7$T8!K<:,7R+HF&3=0X:?[LWLW<!
M0\]2$,^%,C7S<&!R:,8B)8Z "QYC?$D%>.42:**D"29&03ID,H_9<;LU[_N:
M1J95QE^^ZF(W*_!PZI@=Q"9)J.#P,JG1$J\Z!3 R&?":1&VRMU$=\D[7C?6=
M&W[BO5HQ,D2/M-Z6\ZA)D &@6K42U4KTW4H$;1'\2$+<R0P$X^BL>JI!446Y
M8=R;U*&&?<Q6W_&M!.%6!ZHM$!'12B3%\4Y5@$!Y"$)ZP7)G%M<>[_1 5L*(
M$2$6_Q?52@P3U:J5J%:B[U9"29VRLQ9TEAA+I.3!L9B \L@RRR1'TQDT\Y@]
MQN-;"1N=EQ1QWJ/] V'Q)CUW&8@DGLKHM20=OJX]WNF!K(0R(RK,R+)MQ2[5
M2AP+U0ZQCUHSB_MH$G@8;5O-,M9"IY?C(ARKT(FDY*3F":1 JRQ8C&5RG8,@
MC;/<2!9"I]!I'S2U6\J9'LU/?+]:IQU5N<I0X20ILS4,B(#W[ZDMM)S2*)JY
MH^H@-+UKG^195X"-:]JSG[5?U7Y5^U7MUV/L5XI:&L\HV.PMB)@-N.P%(*Q;
M'@U%,&;[2$#VU7XQ'_ &B 1#BOWV5*$M2NVP"V.(#C(H<HC[/X[]LJS:KVJ_
MJOVJ]NM4[!<:+)Z=DQ"SM:6%.Y9IXPFLCZ$ >+2A,S_F,:G1OMHO'C*Q1#C(
M5);)Z65BH?4*_R0\"9UD8N$0]W\,^\7';%L3>[5?1[=?-W+&^$?)2_[[CGGR
MQYW*L6OZ\KV'BCP&W_8^4'W-37Z9W+Q,8;Q%37X]5&[+T*7'@_3>Y[ 3QF\.
MO)R<A>E%; =M#F$P'H9(E$0EP#F%(N.H ,-X@FR#83$I;D4G]96\<=R5>;14
M9!2S=MXQR<!U$M0$FM!J=:;HK.U-BF6ATMFB?99ORPRN]^WPJ>\NOW[D5W=9
M7GK[V<WC#^W T8WQEK^4&:'O/KBS7\[+5RS^VH[Q^NGLUW9FYI,G'?-1F:)G
MY>[F]3[(77,^*[^5R9_KVNR-":2=29.K,95S?,5?-K^]^UL9<E8D]VI Z6J/
MY?/]B[_=HIDLF]G9]+*9I_:K5P-75]LV[6Q(=SF$R7W:>^DIC4 <1\^+H2C[
MY# >%I$338U#]^,IXC\/?U]N']MW:YOZCBE^K9#OS5.Y:Y8?[;GL7V\A7IS/
MOHZ,K.-J[VU;"QW_H,U6=%:K:#)X;R-&3!@LF)@).$%M=.BB"M\IFZEFZ^AR
MN2>S5:H!AB&G@G*AG6# M$3[DAD&J%1RX%9'EZB7FG>*@(V0(7H9(24O\!A+
MP7.=06O%5!#HUHO.9-C!R*D@9(2K??I2*JISQ301ABD#25-;MA@0I)WZ_]E[
M]^9&CB-?]/_]%!W:E:\<P>+6^S%SCB/&,])>[94MA33>$^<O1SV'L$" 1@,S
M0W_ZFU7=  $"G.$#(!MD*6P."?2C*BOSEX_*RG0([*H0I-86J^V,OSLP?S6N
MGLBXVFL?UVBHAC5/H,#S&;/(,#(X,,!)YCSH:\:V3P\\K(_K&Y#MDDPV^ABO
M>K)__[FS@'X 6<\@NI@7#-UN^WK;%J^WF5AM\?JG]VM6:/R\9H5V#5HS(F[A
M\31M9 N>9%QN\R9$R' +/^$;>SY=9'C>@-9Y$ZT_RTP.RBQ;QB=7V.ZO%CV_
MX($-9U-O@G>O DB'$?C2>]9%;Q=M[$WN/"RX[KSY-%V,0W,&^@%^!+!QX'_S
M$5HR:A-3BGY>V]4>>[M:?*KE8[=59:?Z:%K \E-^1&,U+Z=;[5WJESR[4B6W
MZDI[%PH-HBO5L76?/3H"'U_]G H/!ZN8=1<*?;W9X"#X>XA=8_=$YE7&PR (
M7=GW*-GW'EU@*_M6]AT*^]ZCJVMEWZ,YK/S@W.$G3_M[:+G#?B/@7ES^D%3+
M8SY:?SAV>H89Y3=D+VB%>4@*!9D+"%KMD34&H\")CE9R(P7?QY;'CQ,_*[N_
M=MSW$BCA\S=KX>OWT[=V/.[W>M],PE(D'E@6@YX(K4\(W4=7@2IKE285?_:)
M/SHJ(P26". '(XZM1%;AA*PP@3)%"-M/%ZJ*/R]$UBI-*O[< 7\,9P),&8\8
MX6#_)&^04PELF<2]B1$;S\T^SGL])?XH2DZH5!5_AK;!43WC6ZS+K[$%&?$Y
M7:5DM11IJ'YRU1./VRW54>P3MH@("G8JL[ED9$KY-PIJP+. M_3$7?SDDD!Z
M*R7QKL_"^KXD8?V<KN2CM.?+V:)MGV6:;_AA.EM_U@.5"3GAA)]0<G/6=!7(
M:LQ6D'HB8S9APHQ,8,Q2A\ E!IN44X,,96"S,B.T=0]QIH\'I P^ ;N^@E0%
MJ0I2 P,II2D5Q'KD8S[[* Q84H91E**V6F-K/7Y0A94C 2ECZ(E6NQHZ5'&L
MV]5#=\I_B;/"W1,?JU=>=<F3>>5*@L;@ @70!&"\<HJ,5 81S131B7AIMZI-
M/HY7OB8@CZ!,I#F1\N;3G%4<J[E;(>II(,IB[*3R$3$:P"?/!\@M81XE85PP
M1GL9'M1[;: 0E4:?8T#_BK/I-W]"%9@J,%5@&A@PN4"2=4D@RDUI@J61<93#
MG\PP)8CP#ZOT6H'IN0MAW1)_(N^[SQ%Y=&;]^EF48V;GP_';G<[P/&^M8YF@
M@2J)F"/@?5N/D0&7'6&J@HI.2$[V4F+G5HIGNP[9596R!V]"R1/,^8G4NTIL
M#T=N5X>;7H+D5KRK>/?86_(BD1# XG389%?>$*2#-RBPH"P-B2:_M=MUL/SV
M@^(=/]&2G0"85[P;BN16O*MX]]A1!<Z- ?1"6NN >. &664U\L8KZ8W!7CU>
M/OU!\8Z=$*9/M!I *N1SQ[NZS?]$@8;W4Y"O[9J7J]J8I6#ES=4I#R0(YZ,0
MQO&^'<2.61 >RJD/H]R+46(T<J$#Z*^ B4)<)%!(.C"DO0F:4J; L]]'D.):
M;>B_+G(YNKX36*?/?KZJ&/LF_&/1SK/J>NB!,'Q"B#R1^M$TUSW9[EGHK@IU
M%>H&#'6$69XP<8@&9<%>%P!UG 6$/1C?U >MS(/2$YX6ZH@^,9R></5H08D*
M=17J*M0-$NI,"L8R!U9=H-E"DP0,.BI1<(1RP@-1;NMTU'U"$T\$=?)$"W:"
MR:.E@;YDJ+M+@];=GY8?NWNGWKI;QXY^I)LM8=>;$DAU2O6W7^CB\21AB&XD
M^^L9TZPOV9+&6XU>L)3:.^F1<M8@SIU"QAB+I",R.<M2HONJ>C8]C^_MYW>C
MUH^G[>+V+5MN,\3"!+D#CL^=AP 8YO$<C4?M',5Q"7(60E_$V:H,:1BU%V-[
M^2J-X^>M#BX9B4;I<DG.<A$"H)K-7Y>%1OGY[:O<UF0\FL0MEKA:%'S*.*;J
MZC^]NPKZ?3AFJX+HP[O \%/!U+?K@<+?8[R L8Y?+PDVFN0IHT*W+] )<)BN
M^A.M]29:=?KX]MH3!T2%34GJ6+<!WHU7B48=G@V@[?0->N-+3WZ,8HI$$&]<
MS,=1P#&BFB&' T:.&2^]49'2K>06'J(+!FP1:[U"7'N.3.0"):HT]E)CF>B-
ML/+]Y]Q@+_XY3B*,;[-KV&_O5GW!V+HA@=B&)8':Z+,UD9F_C9,;Z[11*64B
M$=!/41BF$4@K!3K)*DNC26! ;76G35$2EJ)'VAH.]R@%]\#4@$8B.<5#R V=
MGWQJCEJFB-/(Z0@K$ @ .Z$Z=^0D@G$B!-ER@8FS42M86I@#S^AL<_(LZ&GB
M/0])6^T>=VI_G>XP^[[^02?7]U?<^^SV-IOF#D:P++E?58I@0=IQ,\U[/79>
M6E1E/)IG/&H^V;:919_-S-"$Q6S4=:XJ36;;OLOLD":WH^/MJGMHKFU]DCLM
M7NN!NYCE1HY3T-Y@V\'\\M8*O#[?<FY'DSG\'_YJTF(\;C[:<6]!VMRHK!S+
MM!_R%?-F-&_+UDR(*99' @GA=6V<MQN=]&XP7O-/,'37S8PNA;K,L\P1WK-F
M8JS;G*5;U=)!*)_@4Y&=BT(C57Y?TPY]WZR=O8CZR]:Z8"V?VWW4/?B;#:W[
MKZ*7/K]"['71T6$$3)/)E!MD+<XGKS?,H>N.S"G-HX-W]KN,W1MV*G_@N-<7
MTW94GCV+8YO3V==GLO*(/M_2[7F(HOQBA7;*2**/V@ :#4D2K[5!V.3QL]DU
M)NZMOF+;=4RW^06L^WHG-UTXY *<_LZ,1#;!0KRRXT_VLNV[:1U.D XC.%L"
ML,WG3^#(/Q[#[ @$?,U_OZ7K=B^/CWZSYYZG/#$2L*-@ND@--BM)R&03ST1C
M<=28:_&@PF;;/4^[8S[ ."N#Z%=0\+^".I_XT7A4*/F^)/#<X"H/Q?EX*@Q[
M4VR?*V+E%J%7YE'C.KNR;R(*"M_.BVV1[2@0_]GERKA:NREWFLS]0S?,K&)E
M@8(KQ1?['M)I- 'SHB2#9+NLI%(UHW)MUR6UK7U!C[TOJ#FE]^X+>HKU8[>^
M) \8[F/?AT_ET8R5G"K^/'J*;H/&U_= 3C&Y2P.AZT95N7NW9:2/N$%0)=?^
M>[4>CG1'W?1K_SU;CY;0@VSZ56&XPO QD>MK71GO2+JO'_H9#GX,L3?N_LB]
MRB@9#L$K.Q\U.]^C5VYEY\K.0V7G>_3.K>Q\=*<5.X+>)F$8+A^*OW/P(XQ_
M._WM=!7P+EO?\[5(> ZDWE<X'G8T="C$?E(_Y2&'GH="P*>@U9[8[<6D_FL9
MDL@'.A.) G'C*;+&.J2DP<Q)097?2OV_SR;G;;8VW\Q_Z-#HMR4*;5R\D0YV
ML9C%53X8HNL)8>QKISS)Z3[.=SX?.=UDL]MSU+<OF6@5W(8/;LSPH"2G2$26
M,S@40P[@#@6M0P8W[C3=QQ'."F[#E=,*;A7<GB6XJ8"MD 2C5,KG.X&12SHA
MIJV7F HAV-:Y@_L<VJS@-EPYW3^X/57EZAJBN6&C'\@^Z7(0PP@D<=;5FQH0
MX-;(S/$1L.KW(>GW[QYR#.0!%H3PC%*J(TI,<L193,CXP)'UW!(C$Q@7CQ;[
MZ9%NXXIW:X!W!Q.BA>? QU^K"D%/1;4E]F%+_/$E4ZTB:472'_XN$\74X814
M9("D/I=%M$:C&%SR(1#C;7JL0-/C(ZDZ915)*Y)6)*U(^O"H%DDI$4-1@-_
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MG[!DVR&5/:+WXTW_V! ^@T.>_14,@>UWA4*V'&C/GE87J^A.[?;(M.;S7FX
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MG4EP=7INVR@X@A#4_ R0[FAB4-__]N?K"#VD\2V/L6XIEAWCOB88ZTT-P$H
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M>6=I2D-AE>-HP]+M\1T!NTBEA!-$($]R?V;PUI"S0B":K'-:*Z79=A*2<QR
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M$*\ G+9*ZMXG'K!_(.-X<)',"F05R"J0/=&!P, 2MXH@4CJE,D&1)5$B;XG
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M73J<K"JU>D7(I7L50<82@P*/.,7  S'B,=5.]CC??YKN4=OL(Y.WRF3U=HY
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M.X2B2]Y[9JQ#+B2!.#$.65!W"&.FO54*_A7[;J@X4#5'3(U]O$#AKK2J0 A
MZ!0S'! ,&9.!,$2%K+86,8(%,9I0KLV^>S .% @I/C45"%^<<%=:52#,0,@M
M]H8J)&2*B/L4D#9$(TDPCY@#3C*UC]#',0 AJ1;A<Q'NFODQ],A'&+4^=\]H
M<H/8FO)1==P^=-Q!6'=WP0%-A!,,$R23SIV6@T36$XDXYRE$Z;QC6[NG>\\C
M>=<+T:\@0[_$6:;X1@V"B\4LKHH0(+I>A8!_K93JJ::U!L$>RH%\^Y*)5I%L
M^$B6.&%&LH"H)P1Q(0&53# H$(6CML:82 Z>!W)0)&.U*G1%LHIDSQ[)L)7)
MNF114IXB'KE$6H2(HL)!>,I"C%LU[/>>QW% )).GO"+989&LIDP<6^"@YDI4
M#74T&LH%)5($YU\S$D#;,(,,C1Y1I9F,6#B<]G+ZY OA]H-:VK7<:K6T*XX]
M?QQ+CB7M>4"$@6KF6EMDHG0(@S&MB>4DBJUMPSWG3U0<JS@V:*)5'!L^C@7.
M4XR!(*:8 'M,"J2E%TBDY+&)1"FWE0>VY_2'@^*8K'6D'S%> ']8-XX[TD?"
MZ&/W:7[F:+*P_5*4S\N/:]_U_!EM$D8SC))2>9<1G ;C!49*$A=M/JT>^-_)
M-S<_>S@%+[MWPZN_]+:'8";,]X;)?NF-W^S.B\(,>T$X0Q([(+RV$=E<(-Z#
M9:-ET"2D+0/G/MU[WD[/ST?S4CW^S22\+2OX(4[\*+89&,;3%L3_/;SCS^.I
M__V;)@(07,#]\]DB?M/-V8]M"V  =#]'XU$[1W$<\P,+[2_B;%7E)XS:B[&]
M?)7&\?,Z Q *-/K'HIV/TN62PN4BU,[M;/ZZK#;*SV]?.0"P\2BORS6^N%HG
M?,HXINKJ/[V[VLQ]H'ZK$,_M%OE+;,5/!5/?KH?N?H_Q L8Z?KTDV&B2IXP*
MW;Y IV_^1/CIDB/7N+%[#\'XVVM/'! 5KG5@N^+*QDY"L\&7*YGK0.VV,%.X
M[ FBC \A5GG5J]$<1N'O0+Z?1O/1AZTZBRL:K5>NI3Q7;/I"^=JG(MN^6>J'
MW,EO#K<W\VGY]Z29GT7@K',8W&5S;B\;%YMVX?X1_3Q?\]'.1M-%VXSC!SMN
M+F93#X8:O*;C2 "]T7D+C[#S!BYL8S.:E >"&(.M-;L$;%[,X.-I:D; Q6[1
M@L"U<#-801]A?6)[VKP9S\^FBP]GY<99;!?C>:D:.UZMW_J[O)U,IO,\2J!4
M&'DPX9I/H_E9X\$,LJ/)_')S2F$*I.KN&(_B1QCAO!FUS05 Q66>8+YF6@IS
MEA? R-=?7.:RF/OI>9D#+)0_.VE&"<R_?$@0)A,:&\ " SPNCUM[]4GS:;H8
M!R )".<H+ #++O/C>Q+9#Q]F0-1YS',!Q&NG$S!;+IOX^2*66<'3SBP,V,*R
MP,M&0/_^54U,*:]/-E#6J'K:_ H/G('UUQ8"K@W^9'U20,+^R9/5$T<PY.Z)
MZ\1ST=M%MWPAICAI8UF*-L[GG7:#]6WG[4D#,X3'Y(?#I<"28%&7KV$Y@0%\
M[-BEHW."%TUG[>E.J1R>"#X!<OT(J'0^&26PZLN"O9G-[*2C:%NQ;$FE7P!9
M%G928*J(P>78?NH8S8* 9_&<9SE: %UFS;L(W]I9;."?380X@ZM'UR@^=>->
M6MK\^#":Q<*T)\#?<%',O\7SB_'T,L+H0:B!X2?SE=0M'YV_F%S")$!D9A]S
M6FTG_"!'8$!:WR/@>[CEW'X>G2_.FXMIGEX1]O.RP0:/3(LYV)^ 65V#HXU7
M^((Q!4+^N8!A%MR *S/(+<"^ 2+$T+UB<\)@TI8=NP+><-\B2VFFXSF,=YZQ
M&Y"H&+Z%I!V6Q8Q1!4/A+4"3*8@] -3%=#;OA3^_H!]O-X&,M2,8P1M8FA[>
M3ZZ!3 'F7HWD;R(8=QGS F#%: 8Z:+R(/6F+BME<*[]F)L&D@5VRW[T;7EZD
MH+P_FV7]"JJ@4'>2@Q7C-<V\U!_;8F%!176PT^G8CW$20 JZE0)C -1:;#Y,
MIZ'M]0(P>6:C%2^ZRXUG9J997%=:/P*!LGX%EIQGCH1Q=.]9?_UHXL>+D*5W
M\F&1-Z![MBWO::^_9,DBW=O[IY4NQKV5T 1[#D_)Y@3HM^OC_,._:TK4:Q"@
M=LEW_4-6WZPF_9_PY.6\ORIFG1"!(3#]=$<9*K=WLMX96F4V.P6B?5I9VQUU
M6497MEQ\FPRW46MDHU2(6VJ0X<:A*+PSB5FP.[:JOMS%Q9_YW^>OWJP8Z5=0
M S#9]],?X8'C,: ZV&6_S/*YA_GE31Y^T\=T8G@SO^V82SRH!@:&%1@0SR,P
M<,7.3<_/&4K6.;I9LO07PP0O5!NN>6B=80=>5U9?\TY/%O4$+G ["J-L!OV6
M!^5G-LV;WP [)R?-3S^]/2GPOO*. ?V7SA' ;K0S?]8YK=/QV+KIK'=CU^SX
M3E?,X8.VVQ( .VG9R1+&TX%W#"MOT8.F:T=+#5%"^&VGZM96_:)?]<Y1S0C=
MWPXD]<#2>9N@N3BS_5#S%#K7.,)EH FR%LCZS*8X+]9K K]TY$;@/%X610UC
M Y79QFNV0AB%\J R2M!:H,<_C+*A"- 7LW]8 @=MN0]^G4]S]?/\_*OS9NUE
MFQ%L4X5F7QCHVEZ18%9(LFO*/4GLR@A?)UG(?G;OW )&CM848/9@2WQB<FW4
MS05XKIE6H5.VQ7MM"X$67:1C8ZD#\,9X>E'<WJOPQDE/9* <^/ 3F"OXW;UN
MAZ>TMU"=Y>>_-<VZ-DFCSS%T[%U8&TR:-4VRWJ3)+N;3U<Y/^02?BKR15$1#
ME=_7I+Q<[J:?L]AE4>KE!J1ZI9.Z[:.-YRYWE$2WH;0&KO\J^/+Y%6*O"Q1W
M @=+ D\>+\XGKS>TWO5-JU.:1P?O[/,^NS?LQ'@PSUZ#NU*6^]4LHR)0>GTF
MJQ+MGV^YY_40P/MBH7O*2**/&O5##SDZO>_14+7!\YL\?C:[QL2]<B\JO&.Z
MS2]@W;N/NU?IPB$78-MWU@("V(ZS5W;\R5ZVK[_YS\,*TF$$9TL MOG\"79Q
M'X]A=B1F?&W']I86^KT,>WIX^#BR>.5/O?FSLDN+DOSE_WO710W>_OC]7]Z\
M;_X+K*N+&I6Y"O(V?RG& \5$;II317ETA@X8#E?6Y8J\-Y)U"!,[:3Z 55N,
MNE_!EXXY[#$;![@TGH!%Y\>+-AM!5R;L,B9S8?,3P&3Z?3+]A,ZFG]8V#6ZP
M^0K^P8O@*3_]3]OT"%X^ 7J>+6#DP(<__=I\B#D(.QWG;9I,O=XN3J,X#L5@
M!&51G@1<>]K\K82,\P5YE^?*HEPNP.9R@379QXL[1RQ;ASE0$F=^U!OS_>Y.
MV;F9SKII?V?_N#0:NXFZ0H59_+" 64W!\[ 7.<8&$\[BE*/(\,_Y-$>"9].P
M\/-B0J],ZZ9$DJZ"63W;W& OG^2/RV/R?A^PX>YG%A;LS.3EA!H0L+RJG<L$
MGL.Y_3W'M^+Y^C:6_6A'XS+E_@$7"Z"1/VF^<U?3AE==/1?8L &;/)\@F9?9
M]B-:&]#=IIA-](T'E@POH&LFY^J+7:)SM\R5]3MSF1PT^HS.1@'@[-4/?\>)
MDQ2<0Y)(AS@S&!GB+9(>8\U2#$Z:H4#2_--TA<\;_PQA<#D;+^/B;'&1Y:Q4
MZ8&5S+'4++<[Q.:DL.AW_H]%(F_)+WE+-/X3C(D,5H 3V6/.CQG'#Z,N4IKW
M-\%(+/XPP-E9=ND+2ZV]X60)?=>Q(>_,K -W?N'B H&#";#>;_"<-+/I)?B+
MEU<[/JZXH6#>3."9K1W'@DDWB>S'Z;AL-I4MJ'0K,%CS7OL)KQ$45BZV\R*2
M_8 ZTK9%I(MNFN7(R.+J@DT_?I2W!-J+Z:0M_G7JQ@NBLIAWXPQ-KCZUCMVK
M ?=:(0ML#LST(8$,7R#/??P "+.E$D^72V#'[;1XX1W@S]KYU6!*9".O2\Q=
M.7WL/?D4.VS;,8H/-N]3P-O3;-3'<I;; , *0%GX\#:#^R%'5[(>O,[()2A?
M]O?SMUW@8F,-;U)#9<.F4ZMET["?:5H O^0I7@6I+O-V/XA('T/L ?HKPM&I
MIPY[-SEXOM0(9?/@]";67[[_NTR-O!D%])I]B'_,WVT\,+,'0 %:4SF+^X^[
M!'I&\+:LX>,-:0<OT@)]4PRF%NRRGDVO@5CH;;05F.6-W"WT I$MV]6+BP[$
MELN<8F'</_R[9I*_?J"6?80D=**UT=(:Q+W7.:$\)_EBAHSVG >BN-HN)21I
M-,:YA 1A"?%D#'(X6N2\YTD;ZG6@&QM1O_81PS>3\.X*<=_F))J-=//O__;K
M*MM<KB>;HZ]EF^-3S&[,-A\"UV5M,LYD_Z[HZ<]%IX+!^!_#9Y$0M4F46D1\
MQ+#<."!G8/69BU)1KQ)PS:.QR-]^>_?<6>2/_3[&)[O2^R6WY]<_V/.+U^^Z
MY+,M2V-#Z13?Y"K5;MN2R1@%0 :7'@U22::$2%(@CB-!G). +"$649PB)H10
MMUTME*7DM<FI\R+"C<IQ9)+Z_]O[TN8VCJ3-[^^O0'AW-NP(%-UU=I4\.Q&T
M9'DTKW6$9,_L?GJC3A%K$."@ 1WOK]_,Z@;0( ">(-606N&0*0)]56<^E<>3
MF8$4&N12,V>T$3<5PS=+BM+SG,=XO>)*W1#"Y#7R24_V]]?HDG@>(8*QH@BJ
M-(*4-1I)0;0"(:(TJ)B\42)N(=CCB\Y^:+M>=.11B,ZVT;NXF"XSO6=(T<F.
M!6!3=0'/ED;Q4H)QCX,&:/@O]#70P6D8W#5)L!5D"6N_\5(X!2.V-W%@[0 )
M3(BNHP!+-'D_QH8@X!\CZQ)37WFH2N/#MIW689M:OGXR&S"EUSB6ERAC2)BN
M\_'-G35\RY3 =\L&/?KAV6GZ@"N3S?WFWG,<M5J&45O>ZJ5(:OLS=-[PU^,Q
MDBIW//HEGM:F!3V+/H+;UF2,<UQMX\[!+UP_MA_-_.*\(;WU?LE*29JWA\4(
M-<D>=^[YV:C%1T2G,W/]L)0!)*;F(J+[O*%4^>W>/\"WB[<6*.<!O'2B:51$
MR,+7-8&,%J((E.J@MMP%;AB7VEOBD_1$\."("8P2I:CD1LF@A-_-6_N]60>0
ML5?3.8C3&[B5:=C9H3O8SQUYD>8AICD>'))AO2JL@\@TS4E>W=JF7*)%3:-I
M:BYR['@ R[QVF2- ]C)&4X>81W O(:8<+LF9A@W9S:>H $,Q]%6U$CQU["9^
M&E5KQB?655P*16V'Q1%6$&N: /<0/X.?1N,:&"=AB5:8=L;[!G]]5=$SKPD9
M]06KLR6??!7ON1056"9N<$GL^II].<<MTZ//3[?#@GE??_[BY[^_^L>[?C]H
M94K_L0#[NDZ4MO?V6^5(VXN[3E&.[IZ>'&)TUMXW2?G\]-73TVOSDW4J$Z]B
M+^(","JSQ_"3?[[[)_D5;L[_"597'01]/UNQM<&JQ,7 ZS9"-_]\$4ESP?I\
MGQ'N1E4;[Z83N(^5Y9+3>'D]:R[A*.?MX*NUB;IOD8>9$PA/#6BRF+1R@WBJ
M,WBPFR1:]YBA?8YU?X[U6TNQAJ2$*D1)5&0&'-3(B&-.$I4*J4,R1I=E5["L
M3[$>+L5Z%0=C1YYU#?X=R;FVUQ/NKFZAB>?H2KYUNIC=/-_:7N%.YUXW;_0K
MRL.V)?S0.=GVR?O\[!'E9S=0[VO)U7IKO5"YTV%P1!@1B-:"$9$LDY2545!Q
M.?B2RJAI,'",-HH(&P1QE@D2B@*+";WDNCAPKO:Z:'5Q0H\B6GV$B0ZA;6FP
M)K3T2L/;]I08%B+1K R\4$&GD!Y-0NZ>SS@6"?EAV*=J=^;;;&)<<D&T8R5.
M=;%$"PEH55K/?$&-V@8J$YRD(5E2,,>)*#@G.BE.;"R4+@P'@+NQ&#YTJE:>
M%$<AGT>(8,J*)!Q/1#*)3<J5(DYX^$NYQ(6'7Z3XY47G[M FCS95VS:JNI"V
MO5G*]H%RM<TU[Y2FW:IYN7VNMGV*+YRTW=?\LZ_?[>MWOZKZ7=W7[_;UNQVH
MWV5WJ]_EWWWK@:7#$6S:IM #DFTB2U8%'XCUV/!)PU_H/\%9P&7G@5)!MYI$
M!3";F2IP#%T$60A.$5V4#(XI6)3:6*F*^Y-ML"]1%2<=>;&FR&R6(V#=-(W4
M>MY-S[MY9-[-;Z?/R(L]6:$_GO[V<Y]_V-$IZWJZ#8CE*\S\N#A#HDXY;"7/
MWL6+>?N3ZQ>_"X_?ZF.PX65^T68&M?3>N)M!_GI/L^E;&1R"9R-I"E1S19@O
M%5A4PA(PHQ*1!0>C2A1@<;&N8%?/LWD\GDV]SV)?X)L1:QJTNB(@>90-#]80
M^BB]#E:KOIE5ZPKCIG5[AZ'8-,O[B.R:EEQ?IM-<E<>\BE.S/F5/HNDRB68#
MTKX6UDR,PA<:AY<9+#^R*A(78R".&AMDT,HFN<6)D+I@,@A2EDD0X1PG5D1'
MRA1YD$E&E\J^P\%7DW1VJ2@-4YHXKR,1,2$%1A7$:2D\-X:75CV:B-RKP\%Q
ME) _ &_FB-DROG1E-(Z2DKJ"".8+8ATM";56<TX#3<46:4L)'8W0DK 0!89Y
M$W&EBT0EZ9"R%22&AKO!END;&SR8Z!0F%$;R1%2@L+<9"L"%W% MHU N!DK]
M=O>>1Q>=;Z2QP=IZZ@(]I@Z9?5&2S+T;&AR *=-W-3CBI&N6XY56/6"F51NG
M'(N66$,U$3HA;UH8XI/591%"='JK04PIN%$\EB2RQ(F@4L$Q<'012S FC2K*
M<("V!GVF]8[(W*=8^Q3KXZ98GS6-W_]X^NY9OP&TVA@\CVZVP)E"=1[TBI[O
MVPN;5Q1U]VW<F#797N0N/.:P&;A9^[5X=W4>%2=QYG#:*FLZW.PP,%RG5E<*
MV4JH7CGU9ZG(.?&Y-#+'GZMI-<59AV!%SM"$"R,PX/,4HGJ>(&ZMSY[=(OV!
M W'/XR[_>U?F8WGKJ]%+]4BH=?9Q1YIA*UOR_=XD2,O.M1B8'C5#DMLIX:OC
MQC\,ZUQ$G.0=(L5F4.^UA<9[0J%'X"C&0C%3)DD21RJ9*00QPDM2)J48+0T8
M.%LQ!AX$]Z8P) 9,?/K B1:\))Y2JZF$PYQZ_ C7<3B$6Y&MO4.S<J@+]UY6
ML.)@I6)'()+4,0TGE(2"<&+[X41L 3)FA&*V]'!=3R^+I/>&1N$C5C4*$&,>
MB9-:@H3RF"0K6>2^CUW<4E1!7/)^=:"HQ>Y="?>;TV;@,B"M/X.?QAD]=XBQ
MO;@8H\6--D&^EZ4S6.$V=.E2+0L89\ZOIL'>(W9RPXDGZZ:0APV>P,Z<,'!Q
M5"&/R\B5,_*M)UV-(![!+47<=R^]Q[9PX<VMW"(<F5R__MW&T&JSSS==BW+#
M_&I[:<WH2?"]]Z;;U_;[(,]*K =C9H_KT\6H6:/+3(L5Y2V/<X9/:Q,0AZY7
M<WP/RV&4X+5E*@0*=S-8. ^E[(BC=6U]3^<<K;>_OOH_5R!J%Q]HT#N&RZ5X
MW:+.4C-$YU#?92 82L$0IY96"SO)4%,KX$;T>1GZ:#MB:S,>=Q%0U#].WIVL
M24"3I6JW-;:J^:HUH.*55Z/17YW^<W!Z^D]B!A\ H)#[LWL;1#C(I-8*=YM'
M,@CN**UPJQ]&'Z:/=9<WNJ=V![]F:ZB7'5Y(B.-1'BL/KQP)R$@<?OF&U?.&
M\X&C:HI&6_UZ\9U?3*N:L0:F@6N"LMF.WG?D$*WYC[ -Y4A?6YRF%_/&G&H$
MJTO+=G,!1[GMOO?@DP7/U6BBK+?@"6![]N -^+=.2>Z]#<EL>0^E+D52E#"6
MNZ,D0;36EC#I%!4:G.)++=V;[6>U^[Q:(%J]3F_J)=QP%.K?M3V$%Z^>;X?T
MP4U8A?0S6[?+'D++M&[@K0&W%9OU.7+ONW3/?6UZ7YO^[=6FF[XVO:]-OU4=
MZM[:]#LGU>]:S]X7IN^I4[NFX>8=B]::,,MP,Q8V;)C^0PRKG$_G=9%$A6;N
MY30U[OU^.KN8SNRJ2O!R,*1+X(AU@&/,J>\.^6"@9TE,"8-H9^-1S-G\FH:"
M04%8KX_#C<-SI G=OSHPA!FJ"7BH3>:<.-Q)F\3]Y>7##[<R_\Y6<!_K!#^Z
MF+.E'+1B3QO%(EC[AE4M^0XV?MO.BBV+'FL3'X7ATLL:W-_>W\.J*< &YX4#
MH]P+'!RG.-KHCE"N0HR!*\K\O6WT581_^49?U'4+2+(Y D8-_*\N$#H*3@WN
M_*T2JU92%T/;==AV2[@O<5DVJ3AK16STK>')9.6ZS!IK?SUG*^P N;HSO &T
M3> BEVB'H[3QSS"%\V-[?K^8-56SS7%-\MBVXMLU<PC#^:-IN'RF_.@8^$:U
M7]:$K2K'\MUCM5@3])ZFS'X<K[AL&8A!06>Y)'@6\PXPFM2*F[D^3;%:78"[
MJTH-O[7,V#1WM0I&.3OY$\LL?4V\A&N./\#=?MZ,TE^UO$@]P%H\@*19G.?3
MK+_:KF2^' Y?.HAM4E^^SP?"&!:5I[8@RAA+<&(I<89%$H25FD;*@K@_QGP%
MS+UJ] G>UV1^=@Q LVR3TN;N71;Q)MJV9-CA'A@>:NB5\,I)D0CC#N0E!!P?
M"/N8\$$I6Z2"&G=9QF3!2N5<03CW%/8^G8@N=23&!RU- :>S]LI8T^O\?-5;
M?+Y?\/$^'\F.EK!__M%L:=F20P"[L@ZW)W2O5NS%9$]E:<-)6[+>F@K>Y5ZS
M6/DXU[@UY^ 5UKRR#5K9,M]R)'PK$8667$8<DBR)8"X1DX(EQFJO"\[@XP.:
MO@_6B+L\DD;'U]J4**0U&0-Y)2!3R\8F6:::8/892/!&'4RVT\#Y(_,8)]5F
M7X8QKGCVU;<=9,#DI6>\9("@\91Y'6!T(L,[+<:[V[C.XK\7>2];$KYV\&-:
MNG \="\K%"@$):77)1&E5\0X2HG51J3",V7%5JF:+XR$+VFB'>B!T*$@IK2*
MV)@\2P*0@MZ8@?C@="]^)+JRKG#8\M2N9X"M.+TWHX(UBI7SCOBM7_[(K.-E
M7FE3 ZJSG) %IR0+=_=%FOMH0'0=@#S:>%))8G3 V:@\E#0Z)MA6F_O;@_P2
MM=[4H/5Z\CS&ZFU#U-H0W@N0ZY7T$M867W:-]+)NR^Y?EI;9TAK(G.U-MIJM
M1_2-<D^Q#R.XRH<I./CH5U?5HJ[;@3-.FN*8S!W!KES()?@XRISO%;-C.XJ1
M=YBJQ>A;X4=54[UV<?HRW;'^SBAME.K49Z^6YN=HAG[]+&].>+;E)G#)7U]4
MS6RIE9)L\OE ?;"YRO(>6XQ!#-F"(_[]*+/^?M@B^JTY?IN7S&U!4'/77.9C
MV&P$J&8T3I(2VW6!9L)FHR,GOI2*4V=-++?,+UYHIPKGB0T)^<A%@&-2250(
M.ME$M9!N0S/?U+((>\TO]>)4SZ>SQHT#'3T8C;C;JKG:5MI%$4LU75O]M;1N
M1N^RVS7-%)Y&O>NPXK-G&.0:-6$H!NYU3=<Y!LEC FP6;2VZ_/"7-9Q8I@.1
MW)DD6.%UW(H5W'I/>!S)8T<M>2A@=0NC%3P.WB#==L &%Z,/4^Q_-L^1X[KV
M@F?@ ^S]B']U7]"H#-93KDC!"["GG<:.1KPD 0QJZ4JF!=^VIV\K:$O"T\N5
M27=:6X:;AL?JXUO1G_;TXM%.1&H2$85.V)["$&V8([$0-,4RND)M]^+!#R,W
M@-46##$.+H(1U! N' N"ESXE_:6?BVMF=0J,Q(1CMD*TQ"D52%DX9A65*:6M
M9MY22\VB API603_)SKBC.8DBLBY3=:Y0!_ON2:[V&K7_Z)#@-&RP%I.2N/L
MA#H34]N *U<[AZ-:_GS=S _S-;NCS5_JV9Z!09>IU)PBE9J)_#?/&R?\P/HB
M@UL6&?Q\^BMOJH_C^<48G-@)<HLK\"_Z8'"+P[\2O%KNV*9/;WT3S7H;)],/
MUD]G[2+D79S^:];^[I&^K5,MHQ,8X-N,^EVN/?XB$;[M^SVF<)^ADG+C%9':
MP];%>""VT)H8BG6="0=2;G54D8:66E)%DO)HTO""6 RJA,*9(&E@-#Q:9ZKK
M*I&I.6%'4M]9,R5V1O3\+0-Z)YUZP(UBJGU<[_M0&K<RP3R!>Y>P2U]R#(PX
MG&EIP9(K;= J66NL9UM2'03.4:6$!RR]+ST<@R-:I2F+,D@5A-HT3I\"SH/L
M34;VQ:2:C^:+>03W+O>_R#FW#_%E#",_FL1?,==6_0[7^GD\]7]^-X@@RQ>X
M&<T6L2&_-JQ<>"GG9#RJYB2.LQ3D%W/18N9NT,8O[U4[">*90?Q3WI4(GK]Z
M@OVKD4.\M7^MWV%QPD7!RO4?/9ITH17,'I&#G9R7?_D)C>":_OSDSQ@OX%['
M*YY]0YO.ZW;%.@%FJ)7^M*2RO@[ XE\NG;%#J["I>$]?O'TYJ&5OI8%KSGG?
M*VC3NLQ]^-9+UAN/+>/Q]&(V&@]XD:L_S;!>)OO1SM"]VJ /'(O=HTM31%XF
M8DL*:$^-Q1TB@.$@8:/@*G&]U6W:%JH,!3=$< .VD@<WWR;F"/4A%MY%6)I-
M-S\+TBDN$VP,3YL=O&4!O5M<8%K@8"2 8S%T<K39#I[^]N(5JXDHM3#EK$R]
M)G5/MUU&3\/1_.V?I)["T"XT'0[>OB&_@8R>#-Y@A[88JC5SJ+[061Q?8#YE
M,6EE2>L 8]WBI54V"L^W2+"2"_0"PFSQ?I6!1>^ECE+2']DR"H[QAMET/,;L
MRWR=4%U=!9R#.+SD**R-B.'@MVDU.)V\C^C-O+3S>1P/GIZ-QF$6)RLZW=^G
MU05BVW PKOM@@&9._.@BQT<_@/F'YC/6WF/T) S^<WHV&0Y>GCP[&>($HU-<
ME@1.SS2SUE^._&SJ1B /[V'I7IR?+R;YYVQ8OIR.HP?3<C;X%59X/O+5</ &
M#!H+B^6KP?=_CR"*^>L_OI[X_,,/P]91^1QH ,&MP5*!X/KUR<]K7[1))_PR
M'M5IYU"S@G^>36T8/,V59/B=MDTU6!I5^8AW8,[ %^%UO5TU[IGG)ST9G&:?
M<$? I0U89[:5GSP"W*):"X N2UPHT4J-DECOX)_&,J&U-)%OX99R<(B/C&!"
MC8A86F*<BD0)RV@2)7?%)CUCJ3O/0756,<@FF7$HRI(\,<>!5AA]R%F(!EIJ
M'&EP!3?"9<HY)R1 EJ9Y5\QRM4HKHQ W/=.;#.VE!.Y*!NT@C38"GPUN'0>?
MSFEN95$JXJ1,(&K4P4\I$J\+HX/6'KRLK6TU".FXP);8GH/'9F%;Y<J3P*5+
MIE!2E.S@XOGU=#"#__X!^U3NVU@C7$;&[LL*8P7W!1A>3%!X[UYZXC1+1%(C
MN)<L4'2X[PEEIZM4PE) 3I?STG(YW]I$JT"L0-7.]PH0OW\6ID/BT\JQK/MY
M 8"MQ\FM20$M$RW7V^$R=211T457\MFSWH_<XT<NWB,W"AL(U:;8\3N2I7:,
M!RM(Z;D"SU!J8I4IB=:Q,#$(EMA6J%%$G7#P QR3##)0-'$<]DM-9>+4!.^]
M_(*.I#S1W<:N@SJ2V)5HCR=Y*L'<V]LF<9^'^3$W\D8_\V&\S+MX-LN':6S7
MXS F;2R484:2I%D@0N5M/TG"RA*L UVRHMBB8I24H\:5Q)8%& @T(,6$:U!,
M+J6T2& /C^[KL),C&0FV\FG:@Y_:+HU=.S6[?)J5LBSEK3$65K]'6D;#RM@2
MWZV60!NU:,LDT>Z$#[Q83@5G8 @F))(:1@R.S3'!VE1J:FBYG<:\1<)G49'W
MUEX\>5OS3M[8V?SS[]ASK'Z;U;-1Y<?3"E1X7Y9GT"2]8CB=W_2._XOVR:'.
M)8?*KR,YU$CR((ORH"W+5^:*ODG+]06XV NP#9"I=67K2ZRX7(SK2;J;W2]S
M5^2+*39_ =S,A?D;C0I6 =[X*<_BQ3Z%*8U\;(:QCB;U#I,[%T9_M@S4A@^C
M"G/_59Q]&&WW]YWXQ0SO;P70R*\]MNEIP28?K 1L+!/LY*6BQ%KA">SS5$?J
MHY!;@8*[@'LFI+3(VFVPOZ$EP*\/*Q7L.&P!#"(=@7 DL"5$$0UQPH&1R%D!
MPA$H85I%[8R7.FWM_(8KZHQ+A%$1D;0;P$BTC- R>5MZ9UE*#R <-X@Y'HEL
MM,VY:I\]M^2T F0V[=T!U<:?AS5Y-]/RIBO<6K=QVMD3O(^BM*(H[^+%O.%R
MRF&SPCN*YG;M+A>Y@@RWEHC$R$N%G6!L7-H=NJ__M)!E*8PG&BSFNJ; TA1Q
MBK3Q190%\W&KOD++9*(MB9?@4PK&.-%!*1)*&9V-GBI:[N3KOYN#8?\O.\M>
M](M<KOC[],UBYM%)?W=F0<XWL*!J?G4GKY&?T.-  [P,1CI >3\V:Y/G&#3K
M,JA789_!@QV:IO@PL+1X&)ZI6@^<#$WW\-__-=QY^!BGUU?S^B)G(,&@%M]7
M,0Y>87<\C>.%&2M^RF^N_KA:MJWYY=^+T3R?B=&??KB!^]GWH^W[T7Y-_6AY
MT?>C[?O1WD)@'JL?[4UC8]^\*;BNZF'+',#!+,$CL/V8E*X,C)2Z*,".BQH'
MCDFBDHN<1^/*[<:E%/0]2@5F7XEI 5&6Q"6/M2PV>$J%%U9]>=NO.!&][?>%
M;+]O&U0VY\ RN2/>>66TLTM26O>.V1]K=5/,%==<U&K8#)K&T.O#]*?TUJAD
ML',)6)T 5^" .NP'4#HCM;0TN!TE\TS0I#@E4<E A'>P%:H4"(N<:J&BX47:
MK$I:O915G>POR^=Z!CJU"3S839'D?J-X"A+L9X(Q'=*9+I4O,Z>7Y\U-'D&C
MRF&.C:VB6JU>1;L$<.^T483\#R,LC3WIE$:=9LS&".BZJ63K83%T%\.P&<B>
M!3$S(K"BMN$B'$-,N8A"1F,$ 25+8"AH0XSE@<BR!+/4<N.++4[//13U>8PO
M407'G[&0T(Y1 @Z6;Z#'4OX**N)BW<@*)]S_&V='GM?+@IVQ85W&#4OQ.!(3
MC!JML2E(C-@4Q*=$'(V.!*.#=$RY8+8"DR!:A654$JU*V"%$BD3KD(A21E,7
M@]?*]4)T%1DZ#=Z^^V.%KQ_L>%$35QH+ $D::*]<S+!E/!RPL;\L22\(5WX\
M2FF %37XM<O)#7DRR(G6=I87#FJW7G\@(T*R8)Q@B5CM(HH(%H!(3KA- ER8
MY$JQ50!2*!.%,9IP@=B4 *4,!LJQ\R&ERC!7TNN,B%9+]2,T([;>WQ&8$J"\
M]3R4[;$GEZ8GX"[L;>86S 8?IN/%9&YG<''\WGH;OM'(M8.6X;,4RL =>MCP
MEZ!6$A=E0;SUPE!3!E]L&;QW2]RO39(F+YO3M;_FJK%Q7WA_+-PJ_75PJT1!
MO__SA\$[BP/1J\&;L9WTI*K+B_3[):ZR!9,DY>&_^)W9R"VR,54UBPCO?3+X
M'E&OB>K@JB[C-PUIX%T3]&S6O]GS7V#, NM<WH*#-5G@54,."8"!II O-:I?
M43U=OL(NJS@L?5Y/Y\)FK=CA9_H96]E^/)L.SF.<@\$Q&9TOS@<X/;X>P96=
MH&73H+6E"L=//U9UUUBLTYTLQWNE3%UOM86%>QUAV>QDD5GB+2\K3]#!MS&W
MG^H95">M 3?KQ:J6?F9^'!P; Q9UW:B_YL&#_OA9;(]'O^R1_IQ#(L@NS^G!
MZ>P2HPS?5,31[DV]1F53A%_.W'36J;T33!.PY. YNN\HJ) 2,RI@$R6#;"1)
M3-")T"BH5Z5RUM-#[)+/:O5ZVA(8E)-?:N&>O<05@T?8^#S._&4_XA[=J[L=
MT\[-JY>JOE^OANT>TLO!4>/1^6A>MYG>/0;GO%G=37#;Q:/JTI+LZ58X7+4K
MS 4"7;KC^P8&[J7AFP^]M\-H$* 1GA'MN47VD2$Z@AM7,ETZ*;Q-Y;V:4]U0
MWY^M]@([^]S^TNDY#H [6%OLLM-*OXP<#(\AI*1561H!CGM0T1&A:"*N$((8
MF3SEE)=>;Q&A[\)U[83D%$?2(&)X+ %)(0*-P4L"9H;$3M266$$9F!VF!$\]
M.<6WRNFT<P)@QQ"6+">B -RQW"MBG3<V,">,-1V5'G4DTM/F1M^L!.YP 1J7
M@A$E((AFN:.5U\19Y4@*/@8GHK"'"="\B^_1(WH;L[LS>7]]N5P?F^E:;,9\
M';&91A0'*UGL(S/716:ZO[590Z5VI2-<1(/#","X%MB.P08:)#,\E>D0.+;D
M@M7"@UU2&G':I'XUO[Q5OQAXZ&YO6+/5,P^J1H=:[(9E)3C:0JUQTP Z ="@
MJI;=%EH]%D:M/L4][VI7T.#IZV<O<? ]+MS]LXGM(U'\R.@3.1L%6.8G8!Q*
M:@N!\SNL [UAIB"&@X6(74Q\++GRS'5EJ9Z>C6(:_+(JE'U=%\JN9&GC?UVX
MX:P5.5H:)Z/I;# &K8BSZFQT,9A'>[Z;XG, ZXXGST/@V&8&#'[/&7&Q*(EG
M4;N@;+3%UNB90UAW38GDBW7)\A]5##^#L1_.GX&5-QOEF<D=D::L>*AH<)A]
M'ZN=8?'I13-&-P\=L-@5<![?SS+ZY8#\*I1WL9A=3.LJ;PS]^[K2$8S\Z6*6
MZ[/_=18G@XC,A*8(<L?EL 7@) ,H7#>OXL3'AHF)MUHW?9^-ER/TJJ9%X:K,
MNS4*KL(L< 5PAWWD<X<< .5J-=0 MZAJ]6 Y[U /00BQ234<0ZK\19Y540\/
MG.=NC.NEF,7M/B6Y<>IF'[-./$=[/]SMZ5VWW>W! F,2N.I8[5@6E@@3P2-P
MH.$TJB@+Y;Q.V[/1[X(%_BR&Q3B^3I=1H04'/W]N/MSO_?7&0&UJN3B>?D0;
MP ZJQ?DYLK*;S-W2" ,_NFH/:VFK^O([2[E_<LNF?8]:IG3=N[OY\FV5*?W'
MH/[SU\9^W5-3UA0FXBWB->")\.L$O-KI8MZN;0.']P1<WN;[("5C>U'%)U6\
ML+@G["@S^VYU#W 3J\JZ#P"];C0>S3\_69ZD_4WX:MCTM"4[T9+^95]Y6UU5
MM^_@.Q_'3Q3CQ?K/H]_ W6_<%/QX;O8Q5_FO/\YG.V6RJ6_,4."L__/];+J8
M!-) 8<I_VB&ENK@3?[$;(/?(\[+N,L/,24%'DY\^1.1(V'&#(36N;%4BYZ+2
MS9K-?/3NPDOS10#MKL64\W!IL6#5\>/__9W^[L$6;L=3/N36<&5!]NWC@S<K
MNVZ,\_^;\^R_;/4KN?HE?-4+_[!"W*/,4:$,.PC*K/H[-*TCP&;'BN)1&"SU
MN[OJ\+ XA!2:!\>:*Y:_UJN"=_@%].+^58D[[\6]%_?.K/:#BSOKQ?WXK$T/
MBY;\'FOSYH;ESF=["&OS0:-T!\W6-Q47=U6*]M4GTZ]A/>] 9+[/HAU(#'>J
M]4,N9+[Z@TKFOHD#3)22&2*D#?!7 $"0!;8 "(JR0N@B'H2:W>@%SAS(#$BX
MB7^-YF=/%Q4L19S]\JD)YI]6583_PN_VT\W&$EVNY:Z;JOUWG$V_^QO9RR_Y
M%O7RL#;6U[U6/88=$89Y)Q-5GA,JA ,,2YI8F0(QP5#G2B.Y/TA#[![#OKA>
M]AC68]A7B6%&22JXTD0[AJ4J26")G";24QL%CZS46QAVEU*5'L.^N%X^O/-_
M_.FE+T3+Z6H$\AM:N7ZU>CGKY:QKJ]7+62]G1YC*^-8LFX,Z*J_K"I#)^]UD
MZAXD>I#H-Z/C6KE^M7HYZ^6L0ZOU$&SAF]LW[4HS+#-[8#Y'N_H(+]>^?'%%
MC5MW3:2W>Z89].'-QTW1]-F&6[(^"J4"UY*4VEDB(DT$?A#$A9"28M$;?Y Z
M^:5^G$["L[5V--7R=\LK;/?;*^F0B?V--GL=[-.D75NK'J]N.?9.2<]""(09
MF8A@P1'C*6*/+9/Q1=!^J]O1W1@>CX!76@VYV#_VO-?!'J^ZME8]7MW2OE)*
M!$4%"<D;(I*2Q+H"["M/*2\"8TQOC:RY&YOC$?!*R:$LBQZO'I7"\2CU&[W_
M?T_M?S6=D%;OO_?U])UZ"D; @1G5?):'9/?*TF]87=ZP1!EUJ9F!W8:!<T_!
M6-:,2Q)9\B'B=')YKX! /5=Z.GFZ4I9F4A7L7*<;FG+8S4OQ(3Q7OW?UMO;1
MK%4/7;>#+J>M<HD56+>&S&E%B4M!D%2"@\^C466YU>?O-K&!+P5=4@QUL7\(
M::^./71U;:UZZ+KMU&WP["/WI&!E080N2V(D=:0L"U,8H;51]RKZ^&+050P9
MI3UT=2ABT#,&NA$Q>-K5:,$=F]P<LRH]Z,YV_Z9!7_?>5UIF?'0%20K;<Y<I
MPCY6.E+8E'0J8]#*WSOB\-@;']?#0O-.;'QW[IKTC6ATCX\]/G89'U4*RODB
M$>-4)"("/AI+.;$AE=JETFFUE4*\=5CCL?&1ZJ&DW: ^]/C8XV./C\>+CU$(
M8PJEB75.$J&,(H9[!E@C-"M+HXJP%?:]=>SDL?$1X%'U\'ALL96^F^9#J?[O
M><;7=*L0M6,:T6]P_09W^ U.62Z5ML1G!R#Y1%RPF@AMHO6Z3"YL.0!WJ=%8
ME7DW6UEUH+V,E7S(.I+ _"9WLQX+>RS\2K!0,1^ED9QX(P !@P4L9)81Z;C4
M!4]))7&(^H\'PT)IADJ:'@N/0'M[+.RQL,M8J'WD1BI/O/*6"$4]T9Y;4C#M
M"VN3X>P@G4(?# N9&'+1)\F.+<IQ( 9)'^78>E^_3:MJD&;3\];0]9XKU?5]
MZEO9A;Z_S[CX^Y2DQ%+)$!DQ3AHB?$&)U8D1+Z(N-%=<Z_*@\8\7$S\]CZB,
M-]_I</0X_'1$H9"N*/E=N]/_\"TO6H^,/3(^_Z\24*RDSI/$4R#"*$:<*0W1
MH2RU+(+F]+#1D =$Q@X%1KJBY#TR]LC8(^/=:@%I22TO*3&E9$1PGX@5NB2,
M*16<M,&HK3Y!]XJ-/" R=BA,TA4E/SPR]HR/CL5"]G74'(PF"(ZC#U^&_-&5
MM>ZWN2YM<WL"%YQ1*\ H#[J$32C(2 QWE##IM"H%38;>O[)E=^>G%RLEZ8=V
M';_B]6O5@]2#S1OTTJ=0)B*E3@!2O""N$)Q$%F.)8Z =NU='S1ZDOA'%Z]>J
M!ZD':_M+4^E]J0D521!!P8B"]5!$:Q:5L,8XM=65[-8U'@\#4CMZ8O0M-'LZ
M0T=?QD%U^05"4JSFRVJ-7LK[7:8;N\R7"DO[F!R/-G>"5D28PA&;%"/21B=H
M07VD_!!4AJ7F';AH>ZBUZO>N/D/70V$/A??.T 7/DO&:>&G /*<))WD4FFAN
M>!*L3%(=A+OP8%!8]C2N'@I[*.RA\-Y0*+EW,5"P!7W$2 4@FM6,$3 5@RF2
M2HD?I)#CP:"P(ZTJNJ+5/3NA^V_E4*$-9"=,YV=QAKR$Z7D<#B:QG_K9;VD=
MV=+VM)O6UJ@4*0DE+8CPVH+9[2DQ5#KE0[)E80X9ACB=A->H(S5)[F MDI@J
M^WVGS_H=S5KU,'5+:H*)UH1"D,)'2X3F LL;&(G>1,>XH4)L9?WN$R)X$)B2
M0Z;[N4-?6O7ZM>IAZL&JL)@(19DTCAP*1,3"$L.,)C0F;J.31HI[-:!\%)CB
M0ZW[ZJN>E]#1EW%0-3[U?A:S D_3((PJ#\M>>_+V? H+\]]V^2&<_'RT.!^@
MKD\^@.XA(ZCZ8CY^WV'HL-+==QBZ=F=3+A6<%#QAAZ$B$L>4PCA!@<DZ&20]
M1)Q@I9"G+?U[G9XUJEG!CO>FUL3JQ5H-#Q9'*#HR&/2;;$+4PV4/EU\)7'HX
MF\!NE)H6A@@F$C&%!(/.*QJ4"H6^7RE%)^"2%D,ENS'2K\?+'B][O#P&O/Q2
MS I6J.AIXL2* ,:H288XGA(I*=7>:NH8U8<(S3PT(M^L4X3H1CKLF&"YIVI\
M]=&>5W$^>!??Y]X18VRPB8$>_"7^X\OK!SMAJ"!ANG#CV+F-]J[Z\3^[L./>
M8FG[/?=PXTJ8E85BD2CE8,^5*7.Z)1$ZV.@LC;0\2+M.4.&';$>GAZ7H1K'+
ME4+]#>RH/13W4-Q#\9W<GU+84@5-DL?>'HHYHJ5CA.E(4R' ,7('J;%Y6"@6
M<BA--XIM>BCNH;B'XAZ*[Y!*M9K1I"28M-P2 -22F  6;J$BYYJ57A9;J=2[
M1*(>%HH9%OMTHQ7IMP[%&W$F^(>%!__;\LV\6IS'V<C#O\/H0^MI\UV.)@%.
M_H0)C,S]M'\!*%M^_+A1G?7-7'7QFZ_A[V=Q\'1Z#G?R^7_]#]#"\J=J\/3U
MLY>#105GG#21H,%\.H@?['AAYW%P8:OYH+J($Q2>'#""3]\O1B%FO:EP, OR
M@])BOIC%U3=/5G&EP:C"T^?CSJ>@A-/9P"W">_@8)+Q:5 -0G84=#V:Q6HSG
MU<D@WR7>%>CD]-*MC29P#W;\N1I5-2MI^GYFS^M(EAU/X18_CN9G@SF<HKD8
MWC9\L[XDW,;.B^;S5G"E"K]^$6=9^2<^XJ%XLJH)F^%UX+NQ0BD;56?X=?BB
M?1]GJQ4%S,&JPASY/KD/R![Z]0\V5.AJ_7@D-'B\A]^1_L(G!MSX*_Q_X,?P
M_N&Q<R.]?'P^UHXF<?;=\FZ;A\,'>6(7\^D*5/-OBA.)2)ZO7>:?6ZN6O^ZF
MG_"Y\%Z;&X.%^K3\6HW,&^==@K6LL1IOM+F5_\[@]>D)X3^E<?Q$PF@6\Q8$
M9QXOSB<_A5%U,;:?G^"G6[O&"<.[@VLVH?CZ"O]O4<U'Z?-RT?*A!/3YIXMI
M-<KGGL5Q'O'>?I+5]O/IAMO)?=!T;7SM4"C&:6*/J5#/29?4F],MZ5[+^-GL
MDA"/)F.0;0) -FN$;O,#>._UK^M+Z2PA%P!T=5*&V 0OXHD=?[2?JY^^^Q$N
M\M<?W31\_MM__/7'L_GY^&__'U!+ P04    "  K@%M:ML7Q=?SI 0#WT!T
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MZE1Y'J_H;@/J3&!.+^IN0^M)QN#[KN.AT5C+P%NO6[>K2YM[]W7K=6,E,V_
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MW'-9IT]H_$*I?[Y:48PNQR*8A1*/;/2=3.(@W+(OAL0MZFG2],2=T14-0^K
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M6BRK84["2'R7Y4@\"7RGV9I:6=3@Q19N K068F^R0-.6F.FF.C.*F<^LHSH
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M@\45^@OXF^.C0#>XG:[1\W@G0H8-EC5'>\'%Z_ZEF$9L5RHSN/C@ML@A0&?
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MW5A^%F_\M@=%==EI4T&M+<^3WLVU5LI\J=E8))2+KDWSU:FJ^=.7V?:!@Q$
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M5J%&/TJA62^G41>E7NOGZXT7;"D%">S9%>BKY9LC#=A4XTCYQ< <[@?YNRM
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MTZ\I)VJ:!TO2-?UD^@QRT_T+]6#M C]^VMF+J_M#<>GO_: +[\4?QA[/#1S
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M.9%ZM!'V((RACX_A]CP6\?YI].PF#!Y#:SUV%G4]$^(U+>ETKGY0:+E2]O*
M](LL9@T3YRE7!L.A"_QC!8Y#S=$<392=D8&J"(3&0<'!C!#3(W"/S"F 7:7*
M/D.&640\2%D?[,Q1 7>&T]^K8964X\(7DRG#'UD:-51G/P6>C!)@@29XI&R@
MCT\8>B+5XM("BW <MAV$#K,-L9,(*W(P$6$,<A6TWR1*6.!%LD', "$?(3@
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M,X9=JR3Y6]USGQ#P6!H'-D;(=CV3PV<>+0CJ]%*'04%^I<K\-VS#;;Q"@>B
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MZU$WM8M;>+ ZJD=PK]YJ/0SPE-C2TG0![JDPAP#-10KK]+9[AL ]&2$6OE6
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MB_0DF,=B T!/SV/=&73+J6Z64WT>)SL.7IRG%*5T9L<=WUR<;*2S&!F$2LB
MA4.(69WP!(LSN&&TZ[?AJ);(ZZ'5\H\V)DE_J\I]HN=C:;"S3Q0!ARE$'<_
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ME2E.F="4@:HC_1?A>P5 >1\C3B+B7'&R%,09_-=%LI2]__J5?8"V_G#]JZS
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MV,'H%5\"AFE<B.X"J- ,J\G*;,06<G!5A[%/A F1<X*RXJS@^8LL3X,$X.>
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M)@#R>/\<I!L\JXB:".E%YT&<[T2$MXI'9:"F) _<4.-\@QU-@V=V5B'4^]=
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MTO,34Y1XG96\^/KYZY?N)AU(899HAK(/1)%ZQ:<X/4J>0H+X#$IB(1DD6+(
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M19&'T']]'J;HLR!9(UDOXUP#VX"YA=*XR?2AH)CW> 8^LW]V<37;(D"Y'%J
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MN.2S$:3A%HPGY%4A=#0S(HIH3N+DO#Z+@1 ]#A<)W9]0SMQB4<OR.A\=U!2
M?XX"#'%*0&5LQLMGYY&&02[+I/Y6?["[]Q%!>50/<895'P&G5B;_6,N%9B:G
M?L)\K1 :C7R"H]<O,M>\U&/;4ZGRRE6&&-H^Z'8T3KI/ *<^J>.%.EU,<!@-
M&=L+'!^B ]%>K@S5"V9U UDE9$>8W1.%=J7ZL@)[);N#J\MMN=<\$YOF9*I1
M*2?3J3A'>L *),FPI=B(ERC\@#2JUZMII30J)B+^1+R(GU)M#/&ZQHY9W'I5
M.=DX?]Y<!6B6$_C0*68*$ TGF>FUTD0DW$:ZSO,LG_*X%#?)3H5J5'Y(K3-J
MGE'[YJ*P4JTH:;\E;:?5$T^>!^\CI@Y&T22ZLNN)E99U !9HMBAMAD-Z9H$E
MGF)'+*4MZ/%2^09#K2>FG4'?J?P.B[)']Z^W+&X+$V&\8&H[Z7LBKA!EO@C)
M*I>!W_M,QFUJ*40=SY9ZZ_0JF?;A8C.G'FR30N:ZK-'K4,F%TC1$)[4ADBW#
MAJ/":[=J<'16UGL:&WMO><L:PEI<M8K\I2"J'48</$WD[#0FO?/::[$^&>K=
MJYB86]<:5GFC_%Y8Y='X. :'$, #\;3 I6G!^QTOS2.RU 5M$XD+8:43UU*N
MA66:AW'!;\#W]=:Q(R_<71GDI0K.5Y$<'_E3G")&/9Q)^#1:)A' %.96-8G[
MBL<AC^!9&C6/'T^C?XW<^CL6-'V$;3.[?Q7L2RA M)Z3G50W#=G/4;4(8*5F
M0/6687>=6X]5HU%F-8'A*(W&;B'09@M:_#.T$K92'PE;O2O:?E& 9"ZEZ\&I
MU6+HZPPUG, /4KCS3:$_0/O]0-4C637>'!)934?!4(NW\3Y;W=8LR-V=L=4H
MJ *$=BKN5 4'\'AS]S\*U40^' J/F')X.3@!\[X#DAP*82C%,7[<6Z(R72;"
M>X*="X56PTN'J\MJR4KL6RU$)X4 3Q8&R5\7>5Q$,=Y_^X I!%I&?P[P7A5)
M;!TPY@1RF2W8FVI-!/(:V[(3IV(;%[R%G.DXHYS<0''Q.]'G_&,11W&YW#F?
MOR&;!&*).4>#4&;W6X[V' I68'H3U?3H0#15?CX0*(.B4J27ZH6>M:EXYE95
M\HYHJ*ELQXH"O%MVV"^KG.*'I-,6Z(Q&P[%K#7'MV566Q5E1QC,8[ELH@I,0
M,)V##& O:U0;%BTX5K%!@I3A()4NFT4:\;P::'",EMB__NI,J%3:C)B6S6ZQ
MI,\QRH\CY2K<C%HCI!ESC5LD(QVP8N"F)8M(>RBS,#(5MI0GY..^E$G>B1XK
M.X?6IY!RG>T%*S8B\JT7E_R%)S_W0. %<MC/!]3[!LN6A(Z85,:;W5Z%**LY
MQ6\YV-7J2P!U_=)EHE:0*',E7X:]$67XJ$Y>X)FQH/\QT.ZV&EC;BEM?MT5/
M.,7_W52E+VFJ"^0IF<5ER3'CB)B?$^X,XDHW+ E(9-/,:MLQY!5NNQC5YU%Q
MGF>SJSCA19FEO">K#6Y\X@-,?7]!A)T%X<U@PG7.0Q[/2X(CF*FFM07@UF+K
M56TYWTHFI2AHJ7ZLM%X5LC>SJY69H9E[<9\BO7,4%,H.RN4%)I!@ER?BHI#?
M/P>I]']?9YB@Q:/:)HA\#0#ZI0_!VRQ)S@G8OB\@-&R$02MV(:&_.(P5_>FY
MDK52/[W/2M9^54QLK[ 'AB%ZH;GX0FRE3WPRA209/"** D.;W_*L*.PW_BY
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M52WR\G_OXU(R[<8O<;0(5AQ"K0\-8I:D&QB&6_G=R1,GWBUT XC- _-ZMLP
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MW/\RK+.G%-O4*Q"URMWB\>_B>+_/3$2GP471I_A!S'G%)-_6.;GQ1X-0S63
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M)H$ K3B"3*<1GU,^",36Z]*?. ;N,';SREV$4:OK#OS9((#E>VV%E5<5IH$
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M;%6IP]"]36I_GP>!;NI/RZIMDS)196<B6QGGCP<!4"KB7<LK]3WFN%0Y0T&
MT36:K60SY'FF:$,$S-D2RR/^J2]#!-6UV(9Y);M]*=IIU:&MNWD4HD\E4\R?
MG>*3!C]9_XGLF*02G]R0'8#0?BGS:-C$;P>4^DHD346Y(T&0J.0:\9]&2A/-
MGQ.SRQ8MRZ73EJLTP3Q(3^CS'T'X>[4;.0<:P5@0Y'=_/.$G-MG4=O<0^/L'
M3$%.R@S^CCSG+@B_L0T-2A/-GY4@QHJ1]:XXQ3Q8S$ORBG?KZ]RJT@00Q'AY
MDU*C9*&-92HX/8*&,B9TSG9;T?PYIX>SW6$)=A40I7-WXX98%@=A]/89<,Y:
M91*(\^9D\Q=AZ\_(M[RL>EINS,R,+Z)#[V%9$.@IL5C2Z.T41);78+8**FV;
M=<R3_NT1*YN(EM6]2ES:85M)XBK. W'"EP@\7M,=0J,D H/S<SE.6B'.KZ^O
M@$ >-5-G$CFE8;ZRS!MKGLPI;4JJ#O+[)K1< L3YY1GO%_;TP&E:SAYI_NSZ
MK//V&WXE$%N1=7+Q"7+C@/K_E'DTBF(]&(]W;H7+ENN N S"O9<ZZC#YN^)<
MHX R6R:_!%ZE1[)ZLV7N3!"G64E<3<,KN"EAO+$@ ,F<GX2FB'[HBMMA\D>#
M $:6[U ..LSJP"FT+.J^*@CD%*\C-1>R8#@(<)K%MH55G[FCS4O'2N1OZI+D
M6:[X0T&<2;V[3<46I=X4AS$-!'A%!QC^0ZPRPCQI-12'-/JT% ^8F0USE#L-
MDM-? L99I4E^:=9?+J_."K84I8D@0.1W66I5? <6<#WFT8L"6+"6Z>WXA9['
MWX5YGI&V49;EWS &@:";YS!S>2O'YHMG@ #JTB#4^6>2IJ)M=SGRF6%!H@G&
MPP O-1[3),$R!*S?S=^)/)E1KQ$'O"X</"&G6,)281H(\.HA/J*7 6\L"$#R
M*XOE-*VG7Q8H)-*,!9!LCOG;]!*<4_=<%G&]]>\0"<.T$?%6-=WUPN$@SHD5
M9Y7_6_90JR@0OI/[+-D:!G%;,[W= WP'! )5:J'1QQ6Q=P<VB7?-QK&C_+NL
M!P(AQ4MRNRMB?)^#K*&OT- AGP<"0&8D(B_,F3L8!"@*65L0,[6*S.-+X0VF
M9[4Y#,3V4TT]M4S05U0NP;D/.=9@.*"T>69>]'SB^$O?G(3$2,;TKX&'ER$%
M'NK5)T?\+ CTIM54RXF3-RBR0_<D8Z9*$\WK4X)P,/T ,@!O^<L;\/6 /$]8
M'*D\ @2Q97%F^+FWP]1#^S,0=574@4DXPSQY%07^F:Y!SA @!(05ASQVPJ;<
M361QX R&059IU(?(-UL9 6+3UYX5187A:1O2]RB_NYI@.!!RRNYD80 AVG;2
MZ",O&@OB7#2+K;'.2G,)\UR,'?2/82 7_H/1,4,V <1)%II8*0@L<Z<Z6Q)
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M_L<//OU79$6!C[D&N2&<0B2<P2!.)[,+I#XP^USN'(6Y&OVK1RE7I7%9Z\5
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MXVXH;[W#WU0Q8MR-;4^N3XNA\RF/-Y*QT;(SJ1?7WLDBNL]_V ?7*VCL4OJ
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MJ,TU!QJI(;S=466Q6NRU#D=S8-M-D\I/_Y&S$[J;M/4#"DGMZFM2SRV,2;7
MYYP_IFILM894MC^MJ<;0W"S<);D!@@GF;K!^5;/ZO=98 <)9X0U2@B?]QK#T
M36L1JI^<>+HQ +5!@@C$Y8+33L4"#LP::1#WF?I0::O(TS'20>8W6V;^Y>KT
MO'TWQIL'8;O+.H587EZD5DKU"E/- 78(PIB4%V8TTJD#PAHZB/"^:B^\Y5.-
MH9K3\ETLZB23H 'S%/AV&WA*\\SIL*6.]2)-O#[,H.P*,#;C\S-^+M,JHEBF
MGLBU+#6%:P@QP1230OADN<[M#U+1F:ASM#ASY?7&%\K2F<; 8K8B%\,CG (+
M$.E5E\TR!DZEWVAZG447GCO<& #U/CBU#1<_PS#2J!AG0#S3Q/N%]+:D7*ZT
M(;G8Y4\P1R2.XZ8F[&?,PN_]:^ODQA:/J'FCC6U?IU%5#1:EJ1!NA/PJ&#4C
M)<>$MCBFU$T"&4)TP'J ^X'2#L@/0131!J=OU@^^*4EK%6/@7IJWUFS TKNO
M,M.HTNVF;TEBW@Y\\C9 ^)',)3[1#(.G$UNNCYQ;*R1->Z(26=V@G6N[_,.1
M3C0&U TZ$3M%E#$I&9UQAP.R4"I;)@VRW\#?JQED6",A2 VFO;JEF1N*A8/3
M8%EHW:C/ ?%^4P-$-,/PJT+XG# <[-&P^3[4PP J_7EJ?O<LX&.>@6+,9Y^H
M$;&BMWP12..[UXL62,IN[T4@3.XH;]DH:QC\00A44Y7(BLW#&VA?!-WIH8OI
M?%X(GEC^ZT;/:[;3>.XW4,?9S$19AM2YXXD=M]C4L);*BE1T4'5NGR'MIUDC
M35D[9<=-+ )'RLJH0AC'(A"FIXS*PD2&0!DDKMY%_U2(2ID[^O00UHQY6<2-
MU% _2])S[J0CUZ?$$4>+(!UE#4$IJ"E#V9=9HTQ/_HFCIH9 &*0[V$7Z2<.T
MYHX\::!Y1?0QU-@<0?-+0VVG'O CY7HEI5]2//EH3_S>D%B77"1>0GWF?KN4
M)1];QOW<JXP+8LN#1"AZ,D[@5U@,FO0?=X*@QR&0!^GNZ6&*&UDY"(U!4S?E
M/%LM=',1R.K)VW?IW35K]J5Y#74C5 ?!(32*DU]/I5#71>"JR^T41M;F[4IF
MC3T]?*F$\"X";?(+R@\,'@)!D/2P+A=2P;GZUUD35E=T#80F:$J&_/XQ0\2'
MP,U<KIX\.#VO!KMPRI($O0^")6AL2HXE83Q]7K9OX3C*@_4S=/PR_,4"6\+P
MF:+S@.@2!:[6>H9K8:JUHI[IHCS5$&Q\4[<A)66'^KF>44BWR4&]XF3S5:O6
M*F&+KA*VP&);U:N9[FF3Q >L@?P;.4KWN3$)%#"T 9<.(-D$4$!4.@HH0U*>
M!:%:F*;44)D) 2S%2R.: 0<,X77AC8:S??E%$4Z!5&HKW1T'"OYX&.]>M:0:
M!4OOO'./UGSE$?-&^>)G(:A;4TG75-(UIVTZ#*NI6"X$96O2D0 K:\S^<'<M
M?_TL(MVH.[I8C0[G'0;:.FM4JGS..T"O-=ZX,G#>L64=\57C8VNXE*+]9QF!
M&YUSVW+3U'@A')!B%@I-#&M861P0_G5:\0II5'T!B<3IQAMML(SP!_(3=(?)
MF@1LD\W\YL:'ZR2*\4;#(DF%!-?@_W/X=:W;K&2^U&J6+"_K1<D?;[(\-\*<
MBE2LO,&H]P):%B';'_>,1'/,=9= /D:O1ZH@.D?7=PEJ8_<#B8&1S3)/7)>,
M&QE9E4::WW9.XZIWH>\H 3:58A3A_\7G6]^7VAR371L0%F&2FUD?97R[>?F0
ME#(ENZX--MFA(414_SL&8>S^FRH-V]V-&Z7E5O$^\>O[Z";'2%[LO.5BQH!_
M0K&4X53'&-MJGO&4O]VOK,BU.5MFCP6S]1O72V*NGY\WVMCV?T,D>APYFP_,
MQ/?H*2$>A.VN\8 3G8C>&M! S8Y -<I!=Q48#U/)JZ2:A=CB!3!W[YST?5#+
M'A9IXG/'E0:M"="Z"(><%EE)7T5S=]2U(:RR!C2([PE:AIT623&>>(M D@(E
M*;X\%^&;T[AXC==MKTXXN&7:6J"H_J*>>^4"#12U?;<OPBNG@<>:"6 1*>8:
MZ.&8'1:1/]T!386)8XC,:ORL?@\FBRI-<TJNL:]OP1;FF1QYP[YWH/K'*Z7<
MRA;>:;C)2V'A*8W0"F&-ZG3J.:M*JZRV>,7.[I)"@5@2N(&#_YU$L* ;E/Y7
MYC/OOC XI'SS\08]$C[W]\"CQ3LMUR< ;?U79"=A6O G="/\TPW^J[]/(93T
M!!_L<R;S">O 2' @F@%#N+7D87(%O5=U *!"U1^+:51G'N2.+BN+K3TU]W&N
MB[#[]X!K(4,=SX@+5CT^6/X>1?<^OP_\Q!3EATG7O^)NNC'0?.V<="/D@@4^
MH2:5$D#,.>:"4JJ[$5;O8H^%4'B"6?R'/\X\X61Y@7J%WU3FF@=M$O6[%$-X
M8%<G$5(]?[Q97I^F196U9YJ+]X0^Z2]\]JDRUUSX*+N+B?"$Q'.@G5)Z%5H>
M4WVRR3!?69L+\9DISX=V?O2FT-^V5*V/;G^@T'8C;@"J_CH&$UJJ[1"$1\@9
M#.V\TBO3PX&)%NJ[2*. 9'Y%$0D?VNXN'5/H\&^^VXBC[[C8.%"E>.T++)75
M1CRMDL[\FQ6&%GZG\,BOVUI#PY3BM;D%/6CDJT!C'Q3S&QL_#M("2FWTJLIT
M: !F10E:0\B8#Q/$&BO8?%IA:G"^"\(=<N.$7Z&P^[HCLIQ-_'9 CU;X.]G#
M#M%?PV ?6@T[5J>EQA0._8 D7PO&H_3",T+D7 =1_(CB0\#35I2F]GQ8V^O[
M4A @U]MSA79!B#;./Y-TY&87H[#I?NQE21A'5V*&(5>_%,V QCHI054V_()<
M45E=_74,VAIR*HK> HX1@1[/NQ4AZBS"SU/JM'A!J;1#KRC\<&V4POB"[&#O
MTU6RAMD<<\7 GUU#;@9UEWS_\M,$#:[?OWR!YHE]T"NG/$Q0P"E5#6(KC$&Z
MJT6>L4K$,-O_-/?,1Z';C5,J:V%%IC4\94NN!JQ1J95])Q>#(#'?YD>-+X!M
M*[,C@1=R"'0!C$A<*R-W5([D#N!%5/Y5OG(2U_(BD-6)O!J>ZT5D8JO3E[I+
M?!&(Z\[*.$[;11295B8[GL]^$5CJ@9^)B6SNE;E%Z.L:BK"(T@#M4:@4]["0
M&MZ=R% <8[&(T@)M,*@0T3%('_=IX4X_/&3V%09Z$+ILC*VO^J[1*SDF>WW%
M3@>3W6)C<N0M^5G6,18G1^'ZZE"-Z<DQUL]# VZU-@6RZQQ5E..RUQ<'9-.Y
M.OW5 Y-R5"WY8=$A]"E'WY)?%>.%4>787M\AO/(E7^9>OZ1MT! )UBJ0-( '
M^M:?D)05!H<56.KU[<#'$M@R%E9TN/."SZE6=VN</."B%9B9$73C]\.'BY%W
M=?Z&)<2]7]3(WMBQ^Y$6"Q+G]+=8R!S0@6_CO::J+MF;[V1MVOT]/0\9K,KS
MS5642*4^K4CMI+8)++02PC6NDO@IB/^!8J(?<"!4GFXN#-?R4!90]V0=\1_?
M0@LK-39A#L+2'PH3>\[5>$[>/=?.G^K,C%[^.(,]L*K5JDIW.:,.>9M'U04
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M2E-AJ&3TJ29BCJJSILD<A^!UYE!Q"=6\]/F1/Y9DLP ]C.D[Y\**6[R&^2O
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M6Y\3?5C8"W3.KG]YBW>&V#^08VI]173S(!2([/6!,7%$\KT;.;;69X6Z4Z1
MVOJ:T'6Z%*A;WQ(M/#H%]M8'A)KOJ# .KT^&#@ZI HLC>">F$>7^1ON$K#'N
MND!P(F=>[0-R$H]4=K:B0\WA0TK*(OQ=UR;94O@WBGQA9$VG]:9TI7O WG(2
M6"1M8Z=XIV?3//9"P\7^BDZ!I79*F8W0V?HOR$["$%\/_#QT(R%+&.8; %!U
ML?V5MK^)+R6T];"BN9SY^&650U.-9=9:"X:(T&T\W/,=6T103WL<ZU[.(0*
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M+C?]B;Q%R]+&=VCEHNWNN7S*CN.F\)=0>(-BR_4FQA4JT;&^\X1ANOQ+N8'
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M^YH<CU9XQIS+W?ON#L_TXXUM!PGMY/H<>"[IY<K&W@O&'69U,7+(;Y.L?,L
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MMB%)-0O1 ?D1'I_^XRWA A&AR%L_.:*0,@LI2H;X)@"OCHQW5:1^)TZQ"/5
M38V28'ZNYJE.!"=@9F/J4M-"VR",<I2$RZGIK#F? Z.KSD(=XM6KS9$M4+0;
M8XSI+7DT__9$KY"_?T5[D6V%/]Y@ERNZ@Q=T"D*RH]L?)\P94(G$,5-QKL[7
M@7,D.58Z*E8_:T\"-3<HLD/WU!,RRJL9)^YTQR0?0Y&Z&1., 9'SBK+@C'@
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ML]MS]X:/\.I,GP-B3[G& O" _!H&D?:II9/@ 9-AFQ\/H#(3'EC2&!J5F<;
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M*!DNLXCY#;BH6K/?#>8%S]D]O[ 4C34Z'<A!0(X^8\N?A;4^FFA8T&Q#^]8
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M[P;=)<3FI[(?]E  KL=N%L:U?; 1;\#:,[M54'-;6I\[&B<4X P);<HVPH(
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M96P7[>N,E"L ^6,7'A#ZCR#\72,<E#L<5*N.M6?8DN-L_X[YU"?R/#Z2:R-
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MV7KR5LFWB??Q6"[;<\[F4XHF(8LY%*GP8H_.KW\!D)1("E>2(!H4JW9S9D8
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M1*>!:>-2<A8;P0<\Y5;=MVP$(:ZH?#J>:".( J,(#7-C&\$-&"5@H$/<"'+
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M<EOT$2#NR$K74E!]ABYIC>3OL I3$FC#JE.G9'+H7#QG*3P&IL[0F-'GVE$
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M2 ;;/WV*Y(R^O5^$$(AF6"V.3XI'M0,0CEL]Z0$\[J@\WQJ(-X@&/(8?B*7
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M.!OZ-Z80Q [Y&RY#0(Y"Z.$K'4NH:L4"FI!&(.-=IH=I2R1'Q4Q9*@"-'J7
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MX#@@9HFBU7?;U;-EP7L7QH3[TP[M-/MPO<$")AW?=&D AT^-YS1J2K99+'P
M^[!8 FY87E,\A]B6L#Z!8K_)<IV"7&B"IQ1<#SX\)K'?N:7P095R8"PF8$6W
MKE586Y$[TYP!5XTA<P[8/7#Y//@AB=]Y[^I/X.%28T:O*3Z^(CW0T24C;O/@
M!J"__P(1SCXLF#7*F8.5<5[">QIC&"P7/HQ2EGOM9<393?Y##O##B^A[FE][
M:7K 7(E+Q$ !5F.Z3:F0RW+A \MGN1T#<O:(\J.C[<S*\$?P@*IQHU40A.6F
MG[ 4<1]?>_LP]UR"4\*2F&3+X$OP >53[JF\>X<G,>#\#X?AO$'[) LQJRWO
MYSEP_PD>.,5;Z?O%KJ U%.B32@J1I&A+G" ?Z.32QQQJO:&^?V?@YQ\N6V7Y
M+_ 0J9WH,ZGC$*/@UDMC_)YDC1.^09O0#UT"F7^(3VF"=;/\0"IHDI F@A :
M#OC8L!W]R6$ VZHGSSKV9UT()TKG:X'53<\K?[0>K2*)2+%9K(%WT<\J-)P-
MM+9IIA>)N6O62&O;5E6L.S!(IT$ 2+YW$-OLJ(+\W=8#+;,U\7[;8^SQ$*:_
MC,U%6$-M9H*K^\#8)Z"Q@C4PA:XO)EBB&=; ./=J,?=^-LSJAKE^*>[>>3/L
ME]/@FQN8P,CGV10@Y/XEGD AG0GMI,0022;9>[59SB+VL\T8:6W;?/\/<^_<
MX?:(2.#N8!,0?X(]UJOFS6 S8:6Y(%YSQ2LNG&*SB)"":X()D-)4>V(ES_W
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M(NT((^<V1M+H[N$:J.+3[%63U!$4<$E9L<!UOQ<8)E%+2YZ[!JPBDSKAY!Q
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M /9*,<_!F2*]PZY41])';WDM[5>2OON84+QFE (KUS$Q;30B;!S" =A+5L;
MLB\9_+*LPRX9E?1N$!;T_+#<=!PT+QX3$0ZA@7FVC(<,BXH(!1FY7?=95I"8
M:*J&UU5>W"<(U2>]@8DJKAJ/I!5)#L>:,5X48:F8UEG*G2VUWH]BJ+VVEGON
MDO09[:L@QU:5#99##:KT,[(,R$V^G0%.>K"3%X]T3&,3!_R2POUHHW5)CH3!
MJ_GY'\Z2@^21I6A8!?\L2N:XWG0P<.*6\,L/CW<A?O'2U"->1Y3Z83-LY#_=
M%#$4)2VUAJN,2L;S047)%GC/PR]8U$ WR>=)YH1?[GC$9X(\#&L*6U9?C<!]
M3"A>CCM\ 6C)JR:WK!C%B4'\>9:WHI[]LO52=(4%R8!8WE&<M16PO\R4!,I'
M4MV]>XKAJ.>4AM=C%9&.Y8"EG'SY,FN1HVLF:<QJ9Y<1BTM')&GF#'UQ5.E7
MO'#G:*H*;]Y4];R9!3A/V'%7C>F-()52Q"<$.:O>]+MDK%SZ%C[@]Z<8FU[H
MO3DQ'Q92M$6;Z8I[3F^M9E0)G7 3-B,Q-,GN/$Q#=8$EW*3W>0BL/FKGP5K
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ME@MA1E%&<1"O"@EOW&R:M6O)OW*$OL'+@!4*B2_"R[:RQ/^3XT)AL#NV"0H
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M$ED6< K&E#*I]XF7=8*$#QE)OEYS]JY,AD&Q)&M:Y\AM>EDP%E0R1XV$[2!
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M@K.$;"=,FA)\/YJ\:$X=A^&JB?SL"!],?2D#8X@"B7>OD,\C"&IP9A&<R@=
MW43M,#RQ2,MX_*,J\!)NTMAKM[F-O09M/7,YSO&]U*N)NJR(N^3V*B2RU]8D
ME%?8:2"[,EC;41;D"S4ZW=EB9J=M7M5J/.^LQJ]@->Y(44=@<_TJD?M2;5J7
MRY^)&^[1L<85/#6.+B)I85;$E3OH5B,P8%(5]2;-I%[@F&)Q)?F0%F.YI/XB
M> <U-<_=\H&D3RUE@;%":[>#%YNT6P*,W3\:2]][RC:B$$$(R1-8O **#<L8
M9M&)5XX+W:KY78@D*+?F,D1R1/0B@W=,U3S2,:B=,"A24(M"F<>8VR.&*Y]
M9Y ]3$K=<!EEI;/V^VY<=LRF:EV-ZA-5%!A' J:0U*R%L',YG19KG_7(.N-^
MTG8T879SE5%_*O"EUD9)+*$C*?55*P$Y'VT9),8<9[K,"'D<N$O58H'E@\N5
M@-^0IGKAC9B:FV0(?U"S 6#:LSG:37PPZ29> E_N'H[)+Y=OCFZKG%8-SJYT
M8=>4^8Z4+C#4_^1DLQ3XARKF*KP(1@%QGP#FHVR]A00YMWWM8N8QZ6*,!84@
M3'PE93W8C"T],N] ]9R0@HN<;K?UG$RA/)4I 9^"-Z]43KI7$U)?AVF5JNTT
MMY!FYD^FR^!Z*9"Y*,V"\-1J&UF\<RPC&.@(16\ ^&=+PGWB]E*.JH+C.*S@
MZ+#9'3:[PV:O%YL][+#9'3:[PV9O-S;[^&)X?ES]>1( [<7MJ#V">"ZM&X@(
M"A43:!0<M!G#42NCX [8Q_YVQAJ<U;-)9FT0:: \@O*U]#'YSYGG]/(V&U%E
MP(=0,X0^6%1-5LY&DDB"K'D:F)^.HH.;U6:)\^6M=]^"KG$!>':6";5 H7?'
M!D!/6K6#R0 F<_F^="C"_F84R \B"/!?[W<\%6V[(R+K/K.GPQ,_$D_<08F?
M$+(XW48H\5M;@ QJZ;]*E:!H>30_Y'EEX;0>M+,G6T KML!Y^.=BHTV!$.+F
M0A3&-D'/L2<"*0N54>YTGF.(A M2IMI(A]6C6 ?:%,;H6 F7\:WE/JB>W,9#
M,;"*<529SRA[/Y=(@T=!FUJARR/ ,%3EXK@NGWBOKZ-)I:"HS/WX5V4[Q#LL
M*UI!_>AM# 8,_CWEQ'$>,FBTL^34445!-%I4VWIBM_5ZVL-VZ,!7#PV?[@K2
M_9K.[K5($4>S26;T/ZVUBR"+IJC!(&H30-PJ$_;\E4U!X9BJ"!Y$>:3],(^%
MQ]PY1/P, JP8-H%'^M8'=?<$QW1)1"82OCF2\<$A M&S?&4VJ^[@?X6#OR.P
MX+_)9(([_7.@9C=+ GRN@37T5(W0.Y[:<:,A@R6NA?J7Y2Q:*:JEGXPQ9T2'
M$US;N574F LO*,LSEW"3S7@3DW#"3)45^EB[Q!/F76PU0Y5UMT\*Q MEB_;X
M_G3))HW[V_X=#P^?W7-=X41$P!'N>4' ,66^,.E.(F,*K5BSR++R^<3[_?DL
M)/U!$BFJQ^>56CBRX55&4"\&<>&KA!J+2H+<S85*HAN1^TKE!5;[!,T1W!HM
MQ-PU2,@MFDXZN,NXS!+#7)"4^\?R(X>OMDS,8=VU#7BX@NIQB?7,3B_D'JW0
M%/U.ZKOMY @-?*5V)Z]W3E[O""#O$R%Z0:" P$;RO5_F%2L7LQ:\JP! 5>IW
MDP1Z/VHWZIJ>WMQ-M>"I>JA3.RK742#,2Q0V6/AAA<L]N*@>T<1FE?QAS[,*
MH^M\(C*8?V*%:R<8=DXP[ BXY[H0W-/M%TR";MB!]X.C#*T)VAJ4U"\4><6)
MHB1"=RD:Y4J.75$!6CU4D? 6B="#QW"^Q$:E!+*/?Y&Y3X<$ZM_B=X@2L^*Q
M9#,IE>+&)E7P.5@@Y[ [V&W:%40$W,=U9&%S3"%FT)=K6+8D.T)/R$F0IR87
MYQUE&R@NP9@K4ZPUB,HL%8MQF3;#5YUXVCGQM&G\2<\43W^G[TJ!U1+]#:I"
M3=&7V#11U7#AT!R(>%=BV3ECD5'VX-BIGI0\F8+2Z2S#4BTREZ(U.DV\9*%(
M,OI6&(NN"P5;T3462*2OB72W>F]L74%[2RHICX\%3!H\R%0;]'KL$Q(Y%B@E
M;/H8QX)BRCY)Y[5[*&3%C:40:&Y8-B'AK)4K6._V> G5LP@#HV?@0ZH\+F<H
M'F,TM!X67CU'8(6M(!#3:6PD/4<I[Q"3+,MU]54.:'6H*<:-3N'S(&\6H].)
MM\+6>]!]4_@:: LJKMHB+@'FQ0]:4,-'PC2\9[]H#,)4+8BT3>PG:#M:3"HN
M5N!74HD9=1?C[ $\%3]) -@7>8ZWLQL>EN%1(F4<NJ7X>7+9EH"@M[9MR9YE
M(\.?.M1 @\2/:#E:-4<' NU H!T(]/FK<MJ!0#L0Z*: 0(^H-N@%Y_IT0$R'
M-=I"K-'9-F*-/FG8.9\KQN%:_FN-J*/!4Q7:5D.0/P>F*OY49:4UI!V?F\/2
MU *]+?8L6>Y<*HM&-1OJ]G-Y.C$\]I4=;61^HZSA?@>CF*CXQ);[:!$S2L=<
MAL1?C_5W7!@G;XS&CL.6SL(4L8[7C]U4E6N$.\#0]AUKX+JJB:+V7NZ[%Z.+
MY=KRY99X.-7HAU2]4CN\;8>W[?A[7TH1GF^C(OQ'!E;Z5.>4XWK'S4/+O!5X
MVU'R;F\<^7SC@(J/C!HK<E5=3 Q^,U;(?%\UW+ZC3ZDTAB^CF"PA? KJ--YS
M*G899H<]1X=EU*=8Y$)R8-%58B\YU=2HF>)TMLUH%7!_0<B=<#RH\9%AIH6/
ME)1W8:H!S G70B0R668KX"L6F<#4H#!?M1RN_F>>*TDAT+H9A&B?"@>=^(..
M2UA[#&7 F_R]9*_(6^3K:#0C98(<3+K!N2'"16Q+8!%*MD/N1'@V'?AJ]J]=
MJFKG1,RF02(?#2^T"5[<H&"CVU/1"BJN'YS6CMYP%BSK6]XL#$CEQ/97YHXA
M$:YZ/*V((&)+3^=2)>BN($TROB-58J1(ZK$?56.A8EF&@@1F+SB;T"AC4-35
M7,T034@M3-"Q0# DYJ,,5TH@.P^E$U;$E,T54.?NGCW8+(8RD2X-0FZ<)^;+
M-*JL"N(.RPS'/D*8(@@7?4<EQTA.13IF1$ QS74YF4:!A8(8RAN5E"(U79>2
MSLOI(GTOZ>!<;*.#PST<N&,#BCK%0G23*@NW*<3WSY!%=2:I-IU1]B#-06LI
MU(E.K=BU9EA$,N4<>+TG%A-W8YZ=\N.N/M&5V^7$;.WL7RJE1WN3Z_ADO;E6
MJ*[07BW$%TD*6\UA0Z))+&S#Y"HB"+^>*6.<FX!9_2YJUNF33I^\A#X9'&ZC
M0G$BYBU1OFY:E?J6Z9*\A>.NT@W*5W>6Q4R;PGLO,19?PL4HM"EODR6V@#T,
M>(RKW!%^,&J3P,42UKVIWF2C,)8UQ_EQMN1LA7N\RN'8E@TM-=Z,_+J#(31Z
MIVWZA[PY!)VE,,HRLY0M7 5OTTMZD7EH'/F.-5;69@$[)Z]@A2U3^VV/:=()
M%X( M-*&P:@1C\@1+"=O$%86.S+$6-8;L'8PL X&UL' GK\J9Z\* WOS_4@G
MRQ_^].;[:3%+?_A_4$L#!!0    ( "N 6UKQMRS1*00  !<^   /    <F-K
M="UE>#(Q7S$N:'1M[9M-<]LV$(;O^16L,N[)D"A_R ZEZ- T39TX22=J.IW>
M0&(IH@8!#@!]T+^^ $AZ5$5.35E*5 ]TL&AR=P&\ ![ND-I1IG,V?A:,,L#$
M? <C336#\>L_T4F_VQ_UJG^-0:^V&,6"E('2)8.7G0(30ODTNBR6PQS+*>41
MGFGQ \T+(37F>MAQ00F=!PG#2KWLI'0)!"THT1E*!->8<I"=)F 5!#%(M8LT
MK%NHSH3=<\J'SC>Z<,>Q6")%;VT?;##@&IE3=5^0I--L+4YUJ@K4&;N.U4W?
M(LH)+"-T.LR-;P8KEH505%/!(PD,:SH'Z]LSSN-1T?BGIGW;%XCZ8:&;+FA1
M1.'074MQ3ED9_4YS4,$'6 2?1(YY8Q@+K45N;#4L-<*,3GED!VU;LNY-,XN,
M:D"JP E$A02TD+@8KK7]M>;<M1N0W&K&!0<WVDK3E&I4RVB:_?%Y?Q .1SWK
M849;['>L;F+6!YL()F3T/'2?X?U#7U23%0M&]J/%ZV5&8ZJ#:E-\&T4.;/;-
M/C9TP#&#>S=K+"0!Z;IGXYO16'/$<"EFM4F]>2^[X5%C;B:9X4)!I*# $FO8
ML'T=1FS[LFE\3I69$49U&34!&BMC1NX$<^V==,\'9T?WT<+N94WN\SWK=\.3
MP9;.IV?=0?]\2V>SV"Y>/,S9',DO)*H1YA;%PFB-8@GX)G)_D3VQ>4=M4+&A
MIUO/W;!OD#@'J6F"6;U8S94[QC:+V8)S#;O.M7-(^V9+%&Z<MO^]3%OS]D$J
M3F:QHH1B67HE'Z?DVYFDBM#$YB2!2(,KG@AI4BYL3WAQ'R?N)Y'<@ X^+DQB
MJC):;-3S/X$;X^1F*L6,$U1W-TG3,$T.BL0K.B=F\"#W/9N/RO(>-'O]KE__
MK02KE_MO&9:Y"3%S.JCCX%H3+V4[*5_ATG0AN%(,<Z*\>.TV;A@>;8=:3]2]
M3LR)Q\!61/W%WOQ=1G9L$S2O8CL5?P:&%UB"E^T;8=1GK-^'KZ>>#.T$FUC'
M1.)4!Q.8@\'K]?4KKZ&GZR'3U4-TKQ-SYB':3K"_(#8$I2H+WH.<@@PFLSBX
MNO(L]2P]>);Z3/7[0/;<0W87SU977M< \8JV4O3#6R^8SUB? DP''J:[>5'U
M4_</+V5+BH+.0/JW5#YI??J<O?!PV UGW^3QKU[*=D^J%U3?5J#UROFT]2G@
M]-+C="?/ #Z_\S^QVD+-S]RXD^"=,20B]^+YY/5)T_:%Y\-.:#LI,.7'P:1[
M[05M_6,+ZDL*=LU9<V!+XPZI$&K_Y:.N8':OY< KJM4%B?LH#TX9+!&A$ES]
MC2T_G.5\2*@J&"XC>_7+"N*_9TK3M&ST<58(./E::?&=7IE<$X1R9G1"2F-9
M#^#?%TS@U7++RZJ(&4^ANE4CG)J[8X39 I?*W9='/5O6/7XVZKF"\'\ 4$L#
M!!0    ( "N 6UK%^/)"0@0  $T5   /    <F-K="UE>#(S7S$N:'1MY5AM
M3^,X$/Z^O\('$KLK-7U)2BE)%ZD'8=4[MJ 6=/?532:-C\2.;)>V^^MO[#30
M+;=WO!2QW%:B./;,,_/,C&-W>JG.LZ-WI)<"C?$_Z6FF,S@*_W1<K][J-<I'
M%&BL)'H3$2^)TLL,/NT4-(X9G_K=8A'D5$X9]^E,BU]87@BI*=?!C@6-V0V)
M,JK4IYV$+2!VYBS6J1,)KBGC('<JP!+$R2#1%BE862AG6HP'5M/OU/=Q/!$+
M1[&OQ@,#!5P[.+7RQ)%LFFZ@E%,&9N?(.O4M#T>+PF]:Z*\.XS$L?,<+<L1*
MX5:S$(II)K@O(:.:W<"Z&Q,A8Y#6"[105/@)>F=$P&\U"UTY:*T%=BVA.<N6
M_B7+09$AS,E(Y)17@A.AM<A15L-".S1C4^Z;@!@;1KTR,T^9!D<5- *_D.#,
M)2V".]M=-+UNK2\9S<J9:Y#<^,\%!TNX#'/"M+.*+-K:VVUUFD&O832.>HT"
M_S"&6Z?9KA^@\AI5F[5-KI'(A/1WF_83?)_YO,S<1&1QL.'?O[GT\*B$BY1-
MF";E?KF+S4LF_Z^9TBQ9/C+_K=;6"^ 52#XS\9LQ>'KBC\^'XW!X2<Y/R6!X
M$EZ$^(6/H_#S8'P9CL(3<G'UZ]G@F/2/C\^OAI>#X6=R.AA]><'XW=LZ3RR4
M[>V.%R^9AU)^:-EL.P!_ ,$'A0]$"Z)3((Q'0N+Y2,TI0B9+(B$!"3PR2U9B
M!%.F]$I@K*F&'/45$0F:CZY!DXN4RAR=GVD6T4S5R(!'=8+2IT+F9+RGTF7@
M]<<C\F$HZL3S/,?M8B(Z'PGE\;I0UTBHE8C7.6QW:N6XV=YOME;CENLUN]6X
MTSUT5V,<-KL6T3ZZ7KO;_6B\%#.)K,P=0)$8W4>3,)$S*I?$/:@1M^GNUXRW
M1H[.8E9R,]03QBF/\+6$>;OE3>WR"4203T 2KV4AVM8R#CP[2(0D0*.T0EH"
ME:J*J$XE@&.F2 &2B9@ 'N_Q?<P:L6!&!Y($(G/ <U#_&?N]W87;;!T&QJ+&
MND "I@:DR(BX0?P[7F5<L&Z^1ZM&L#J11RE(F(&,LIEQU[+!B3[G,X0:E1)5
MVEM-Y_=ZM=5^A-HG/_AY^(9><]L\&1]!WB+[3*/=Z!'A:*@&"9G"FWT_Q_U&
MSLXN_G^Q>1-;X+5XAX/Q,!SUOUR$HY\X^P,%&>,UJ_L;2 7+GS00]X[_?XS#
M^J__CE<9?R-7Q/=CF H@5X/W-46Y<A3>,Y*GOBGL#^L7[)RL1=(*;ZV3LM8W
M23)8.#&3YA(E..)FLYP',5-%1I>^6;U%JRJX[AX8Y]8:+G77N+M*6!4MJ^S@
M#>X5FS%6]WG]F/WZ_F8-'2/81+(GEM"+WT*ZS^:\V8/:YI6K[$;=;IU4;NP-
MQO%EC+YI*E?5_.T"%E0Y79KKVIU2T"DX$PGTVJ$)WNQ]FLWI4MG&9J]AFJ%'
M[WH-VT;]&U!+ P04    "  K@%M:]YG(O9<(  "+.0  #P   ')C:W0M97@S
M,5\Q+FAT;>U;WW/;-A)^SU^!<R8=9T:T)2M.&LGU3.[B=C(W[77:/MPK1"XM
MG$&"!4#]Z%]_WP*D1<NRK21VQVJ5!T<$%XO%\ONPNR!X-O6%/G\ASJ8D,_PO
MSKSRFLXO_IL,!T>#L^-X"8'C1N)L8K*E<'ZIZ;N#2F:9*B]'WU:+<2'MI2I'
MLO;F'ZJHC/6R]..#H#13,Y%JZ=QW![E:4);,5>:G26I*+U5)]J!5&)4DFG(?
M-(V;$6)+_^A4E>/0=_0N_)Z81>+4'VP#*Z/2)VAJ;$FLNIRNZ8E-4='!>3"L
M&?J/1)49+4;)<%R@[Y0ZDI5QRBM3CBQIZ=6,N.\Q.I^?56W_'..S+30:]"O?
MFN!-->J/P[U<%DHO1[^I@ISXB>;B%U/(LA6<&.]- 5E/"Y](K2XQ&IO 0W'_
M=IS4:&-'+_OAWW@^59X25\F41I6E9&YE%8>;QPE,C,[&:[;=9TZX=T6V9)^6
MIJ3@C>CS7/FD<3.LNEA,U41Y$8'"_>"3JN.1[L/L'[T];4?>Z*3!R0.&W>.G
M% :1?;:.^A=9KW*52H:0$S5@9L6OE/*E&/9/-CKO:3S%S^)+_?38;OG4$S_(
MVLJ9^'4JISWQX\>>2(.KEL)/I1]U_=)906!?D6CE?$*:"J8\VUAU5I%,N4K+
MY2C7M+CEN?_5CH=H#0E"B?/2^G'P4<+ZW6@B'6G%YJ]Y<S6=_M$)+P[;N?=D
M.,A/GM:]PZ/A</AJ/#<V2R:6Y-7HBJB":7K<>D25/*<D..8>1QR<#XY:[W>6
MR#C,H-]_M:;PV4!*3.6,A*69HCEE@)%R0I9E+34:.28)4.Y[8PLQZ"?_%B;'
M$.D5>?'S5-H"!M8>/-6N)SZ5Z='X&H%AJ8]_]TC\<Y%XLI-(_"<>6L9@*Y;B
MJC1S3=DE]2(@&R1F!KI+XT63!@&H2P0';VN"]=('1#%$I2AP915 G,L435:8
M H'7FRAW2Z"DE)R3=LDBA;PBC-O1Z="6P1@,J3GT\1@LD"J;U@7$2G1OPA0\
MEDZ%J_G/JO^<+#5*> *%<AK9(9PBYLI/,4%7(;SQZ*P7A% FPS1GZ):)R;+K
MACW'G@''AG\MCI'(50D4,R%6J.V!8!#';=NYK\H<X2"D9OB=ZCJ#3C"C ]$>
M6*6L7@I,QS$GF:M:KTC7X-VM#0U+LU V]%BBUA  TPRPVV2";$\JW53DVLQ=
M2T-+EX"[1?4D)#=&NV%EK\,FUQISR]H]H9X!H=[L)*%^NX&^;UXN3OJ#]V/7
M<*;)S7F5-SG*&;*'[G7 YB<A+046 -5JHHG1*@C.F !H4^[!8@6"' <ZOH8#
M4FU<C7X\OC4ZTJ&R)J4,S4X< OT9@4X1XA>+="K+2Q(?$%E^J34D!D.9#$X/
M*5HQ.,WB5;Q47!.6D8:L7W#XZ; SLH5MV7J@_,9 .0;B>:YS%A*<A8Z^FH<W
MZ^= EK\M-=^\>?=^\'[PYG30?SM\_^Z1:"IWDJ8?R>&1 *PA+7N823W.&%-9
MN^V[<.HV(;"B&2DF@Z:V4 "(SI0+80U25 8]7+"O F(WJ,8M,]"LR0975.DU
M 9=O*@1'V.*,5IGTP=")4YF25O$$5,Q90Y@O65/M.(\,"Y,+26<(@L81#/((
MNMRIPD-6::TEQVY,*QBQRD?1(V:WW:0<OR;$@GB$Z$_9UX?3/8V?FL:3OP"-
MMPY7M]B\?:#;FM18"&8J8ZY*9TK)$1U@KRU7ADQ@:;.63*"WDA.EE5]R KMI
M6%Y: N\"I>*J<$.T4UF&Q&'13*BJ;05*NY!PIRF@$@P(->8EE<BC-9B-.U3Q
MDL$BJ)\C>[&TJ JQ>\_?Y\_?="?Y>S&3N@ZQBL%-><X[^C/ TFTHY5;)]!;!
M-UYN+N\"7]$1@=/%(G)B:G^W"=ND!_):FKA"SA_>M1&3MO8.2Q!%5\">,2O?
M4^[94R[;2<I]C&"^30K>.FVJMG!G,_4^(U)R.FO2M+:,_4[NN$EM89S'#7X+
M"64NA:;?:[@9N@_OZI.#QHAB:^*-[2EP&C9^RYLO+UY'NZ;27:?:'/\"[2D+
MB4%P21.TET*K*]+-+O":?._KO?0X7/_;$OOQ=IM.=Y+,G[O;U&PUA3=\6;L0
M]%:1B -CEXJKH,1<^HS\^E:ANK)-HEKUQKKKG#8T0&=1*.^)[@O\$X.TF04R
M!0N#ED,P%EQP',?Q/Q?-[4)#O]<*$PAK2EV&LP+N]7Y/Z?E'UMW<4_J@48;A
MH81S*C"']T-31>!&DX]>[^W,X1Y.,&-9%E+,4%"&UY+MNXW/8ERS#1/WD#?$
M+IFAHZ/KT'4W.YLZ%'W ,#S,7DQS'7)<5Q? )KP69M.D#1M? ^U3V-T@VF[N
M^GQ III;A(T>8$\AU($XX2UZP[!>S/)4.3-Z1ISJE?*R.0Q@F^A(1:7-DG!W
M/C4Q),H;_ 7?'B<5/MK$A*<\]+@)K \]GH=.Q&W_>+YY.7C;'W=.GKT0?"@V
M;('==49U C23#>:Q?LR&Q1-@#Y5Y%+F&Y1& V<@#@5I6CD8N;HO1AF.KX?@L
M&V#;T7F7+BYSHU9!*P6Q["8/3M^]NNN(+!]@]=E='=\,M^J(7_:6A<W)V0"(
MC0^NP_[P-^&&39-H#^T&/&%)FW%.B'JI00J:K\_UMDB*QWK_;'QNNYAL5^0"
M"B/Q/4ULS4=X3M[UQ$G_Y+1[&G+CD_LR;S5@;%N.3BO,BM_"[+P?C]WQ^@'3
MC3[<@_BA1?;+5L['1.FN8W&/PST.G_IX/HN/E(>F]',^3I@JRL7%@M*:7QV(
M_W0V6SXV&Q5[N.[A^DS@>OAS?+.+$N469E_?CU/\X+S\.2'DL8O+#6#B>NU)
M/\'K>*VIAI[BD[Q0^<>-4_X.#RBKB_4=E?6O]C;N'E"9W?<YW[6_IG;-(<V^
M1-A]B!.X>0.*N[7>M_'#053N<;E+9(Z*>R3U7"Y=6/#.COE3RO,79\?A(\S_
M U!+ P04    "  K@%M:6JC&7+H(  "+/   #P   ')C:W0M97@S,5\R+FAT
M;>U;WW/;-A)^SU^!<R:=9$:T)2N.:\GU3.Z:S&1NYMKI]>%>(7)IX0P2+ !*
M5O_Z?@N0%BW+MOPKM1+GP1'!Q6*Q_#[L+@@>3WVA3UZ)XRG)#/^+8Z^\II-/
M_TN&@]W]X[UX"8&]1N)X8K*%<'ZAZ:>=2F:9*D]'/U;GXT+:4U6.9.W-/U11
M&>MEZ<<[06FF9B+5TKF?=G)U3EDR5YF?)JDIO50EV9U68522:,I]T#1N1H@M
M_=T#58Y#W]%A^#TQYXE3?[(-K(Q*GZ"IL26QZG2ZHB<V144[)\&P9N@_$U5F
M=#Y*AN,"?:?4D:R,4UZ9<F1)2Z]FQ'WWT/GDN&K[YQB?;:'1H%_YU@1OJE%_
M'.[ELE!Z,?I=%>3$?V@N?C.%+%O!B?'>%)#U=.X3J=4I1F,3>"CNWXZ3&FWL
MZ'4__!O/I\I3XBJ9TJBRE,RMK.)P\SB!B='9>,6VF\P)]\[(ENS3TI04O!%]
MGBN?-&Z&59_.IVJBO(A X7[P2=7Q2/=A]G<_'+0CKW728/\6PV[P4PJ#R#Y;
M1_V+K%>Y2B5#R(D:,+/BOY3RI1CVUSOO:3S%S^*^?GILMWSIB7;F]S;GZ-&L
M^2@MGL8O969I\6"S'M%+/9$&^"R$GTH_ZF*ELZK"FB+1ROF$-!6\#+)%56=E
MS92KM%R,<DWG5]#T_]KQ$.VP02AQ7EH_#KA)6+\;3:0CK=C8%80MC>_O[O."
MN1GD]H>#?/]IG3G<'0Z';\9S8[-D8DF>C<Z(*IBFQZU'5,ES2H)C;G#$SLE@
MM_5^)VS$80;]_IL5A<^&9F(J9R0LS13-*0.,E!.R+&NIT<AQ6@#XGXTMQ*"?
M_%N8'$.D9^3%KU-I"QA8>ZQ=VO7$ES+='5\@,(2_^/<%B5\7B?M;B<1_XJ%E
M#+9B(<Y*,]>4G5(O K)!8F:@NS1>-*DA@+I P/2V)E@O?4 40U2* E=6 <2Y
M3-%DA2F0C'@3Y:X(E)22<](N6*209X1Q.SH=VC(8@R$UIP,\!@NDRJ9U ;$2
MW9O0#8^E4^%J_K/L/R=+C1*>0*&<1L8,IXBY\E-,T%4(^3PZZP4AE,DPS1FZ
M96*RZ+KAA6//@&/#;XMC)')5 L5,B"5J>R 8Q'';=NZK,D<X".DJ?J>ZSJ 3
MS.A M =6*:L7 M-QS$GFJM9+TC5X=RM#P](LE%(]EJ@U!, T ^PVV3';DTHW
M%;DV<]?2T-(IX&Y140K)C=%N6-GKL,FUQERQ]H50SX!0[[>24+]?0M\/K\_W
M^X.CL6LXT^3FO,J;'"4>FAB87X2T%"@ 2*N))H:J('AB I1-69S%"D0XCG)\
MC=FGVK@:_7AP:W3D0F5-2AF:G7@+Z&<$+D5\?SI/I[(\)?$18>6W6D-B,)3)
MX. MO0M=!P=9O(J7BHOD,G*0]0N./1UJ1JJP+1L/E%\:*,= /,]5PD*"4]#1
M@TEX>4,A,.6[Y>7[]X='@Z/!^X-!_\/PZ/"1."JWDJ,_D\,C 5A#3G8[DWJ<
M+J:R=IMWX;QM0F!%,U+,!$UMH0 0G2D78AJDJ QZN%I?1L-N1(U[B*!9DPHN
MJ=)KHBW?5(B,L,49K3+I@Z$3IS(EK>()J)BPAAA?LJ;:<1(95B47,LX0 8TC
M&.01<;E3A8>LTEI+#MR85C!BF8RB1TQMNQDY?DV(!?$(T9^RA\?2%QH_-8TG
MWP"--PY75]B\>:#;F-18"&8J8ZY*9TK)$1U@KRV7A4Q@:;.63*"WDA.EE5]P
M]KIN6%Y: N\"I>*J<$FT4U:&Q.&\F5!5VPJ4=B';3E- )1@0"LQ3*I%$:S ;
M=ZCB)8-%4#Q']F)I415B]PM_GS]_TZWD[Z>9U'6(50QNRG-^Q3$#+-V:.FZ9
M26\0?./E^MHN\!4=$3A=K" GIO;7F[!)>B OI(G+X_SV+1LQ:0OOL 11= 7L
M&;/R%\H]>\IE6TFYGR.8KY*"]TV;JBW<64^].T1*3F=-FM:6L=_)'=>I+8SS
MN,&O9:',I=#T1PTW0_?;Z_KDH#&BV(IX8WL*G(9=W_+RFXMWT:ZI=!>I-L>_
M0'O*0F(07-($[870ZHQTLP6\(M][N)<>A^M_&[$;W=_&;M/!5O+YGKM-X0U?
MUJX%O64PXMC89>,R+C&=[I!B7ZE5E[9)%*S>6'>1UH8&Z"P*Y3W13;%_8I Y
MLT"F8&'0\A:D!1T<AW+\SW5SN];0'[7"!,*R4I?A_(1[][*M]/R#ZW9N*WW4
MJ,3P4,+9'9C#6Z*I(G"C24DOMG?F< _GF+$R"UEFJ"G#:\GVW<:=&-?LQ,1M
MY#7A2V;HZ.@B>EW/SJ8411\P# ^S%S-=AS37U06P":^%V329P]K70"]9['80
M;3LW?CXB6<TMPD8/L*<0ZD"<\!:]85@O)GJJG!D](\[V2GG:' :P372DHM)F
M0;@[GYH8$N4E_H)OCY,-[ZYCPE,>!%T'UML>SVVG!#=_/#^\'GSHCSLGSUX)
M/B@<=L&N.[<[ 9K)!O-8/V;#X@FPA^(\BES <A? ;.2!0"TK1R,7=\9HS5'>
M<*28#;#MZ+Q1%Y>Y4:N@E8)8=ID'!X=OKCLVS(=Z?79=Q_?#C3KBE[UB87.:
M. !B[8/KL#_\3;AAW23:@\P!3UC29IP3HF1JD(+FB[/.+9+B4>>OC<]-%Y/-
MZEQ 820^T\36?(1G_[ G]OO[!]W3D&N?W/V\U8"Q;=D]J# K?A&S]7[<<WN/
M>.CVZQ^LO=O08BT^;B+HT??#SP<BZ4I0>$P"KG?'T;:P[+$@_P+R%Y#_+5]Z
ML/A(>6A*[_*=RU11+CY?Y,N_Q#VJ.^/S>\J2M@^@VY/LO'U0NG$_#OP:W[,#
M_=?RX#X[#AN-_>YFIN$'UV#/">./O9&PA@Y<FS_I)Z@=KS65[U-\DAIV>>(F
M.7^'"MS4Q>KNV>I7JVMWBJC,;OJ<]<)?4[OBD&8/*NPTQ0E<O@'%W;K^Q_CA
MK#REN& G,O=D1U+/Y<*%)?MXCS\E/GEUO!<^0OX+4$L#!!0    ( "N 6UH>
M@SKP^@8  %(W   /    <F-K="UE>#,R7S$N:'1M[5M14^,X$GZ?7]''U&Q!
M51R<A S@L%2Q$.ZHNQNF2*9J[U&QV[$.6_)*,DGVUU]+MD,(@6$89BZP25'!
MMEKJ[L]?2W*G?928+#U^!T<)LHC^PY'A)L7C_N]>I]UL'>V6IR2P6TD<C60T
M VUF*?ZZE;,HXF(<'.337L;4F(N %4;^C6>Y5(8)T]MR@T;\!L*4:?WK5LRG
M&'D3'IG$"Z4PC M46_6 Y2!>BK%Q(_4J#>45O]GEHN?Z!OON>"2GGN9_6AOL
M8"B,1Y<J6SS%Q\G2..6E<J"M8V=8I?I/CXL(IX'7Z674-\$%R5QJ;K@4@<*4
M&7Z#MN\N=3X^RNO^,>FWMF#0\G-3FV!D'O@]UQ:SC*>S8,@SU/ ))W E,R9J
MP9$T1F8D:W!J/);R,6FS)EA5MG^M)Y2I5,%[WWUZDX0;]'3.0@QRA=Y$L;Q4
M-RD=&,DTZBW9]I@YKNT:E;"8"BG0H5%B'G/C53"35?UIPD?<0$D4VX\PR9^$
M2*O]%2L> 24D[:C6%I73_M7PXOSB]&1X<?D)/G^Y&GPY^32$X>4&HAJBU@%\
M:0Z:ITT8]$\=3*U.UV]\(T#/CJHU1^=D "=GEY^'_;,->U;A4W/FT/\(E^<P
M_$<?!B=7OYU\Z@^\R]__U?\/G)P.;4O;]]LK87.^VLE>F*"]U^S6IKTXDG;1
M>BZ.+PW;A0 Z$1C:=0PFW"1@$@0F1,%24&@7;*"6<ZDR:/G>/T'&I"2\1@.?
M$Z8R,K$P/&2I;L"%")NP;?O_\G[:]EMA[U1F.1.S\C3J[4 LE5.0H^(R B2X
M(SC#$+,1*NBT&G1_VGL-8!IBGE+;W*0O@C")8&"8(5\'&!:*%E\Z9"*"_C1,
MF!@CD,*,:VV=H3_;+R)Y2% A&7['MBOGW-RT!B +$^N>%2K(,*7I;I%*&<<\
MI#,WRF@&=&QX/&M 7BA=T'8&C+0&.0@M_ZHQ!DR-F$#M74Y3G,%):&R+Y5\#
M%B:[JJ.;[*@?<\,E7,.UD!."8(S!(E\7-DT$2.:E7!L/4\SL+L<2)7]@X^0W
M.YW#[D'G]F/W,!'7><IF09SB]![!_UMHZVG-%R?D:<.4Z3DJ>]8"'8R8QI1;
MEBV1_I9UI'S/;^_??@Y(]]K$Q%YSO]MN[1]\W#ML=_;W]MO=#[V)5)$W4LBN
M@VO$G.Q,YV!Q8=WU'&:/8$1K6K.^=0M;RE)GR_<_+ VX+I.")6\9'4!*0QM_
M1$=M(\^R#%@8NKBVT1<7:4HA0>>I/9V'J\(_"JZ<O+:TOZ7Y-ML!F@5:W>UH
M9QXJM^$\#^4J7EJ'G7(^8)F;+7HVX.<!X3;;Y?=/"@Q_$Q7?&Q7M5QL57- "
MEC''Y/HQ-:*KL! R,>.*0H*,T9;\#=M,, %UHT7/K:HZIVC0#=<KYH*)T%ZG
M 2/W/.F6-)(JTC)V)#'7Z=1UO%3K:G-5'/S(3?(J0G[M#GQMI_3T._#+^]9'
MO[>P&+X#FYI@HQ0?S!2,B+"HG'EV?/+&BGM$+UE4(G/F-8E[E3R1+&6YQD!C
MS@A\7)$\<$D,:X"JM=]P3<^^*3>SH!Z@EB*QZ"[5NZT/#R4J;!K!1 ]U?&Z_
MSD_6M[?WI(YTI.XA6>59''$7YASW[=D+JP-_!=AUBL?QGJ;7&[M[H_UJQ6BZ
M/,\"U8PODT _.XZ>.J\]*53.B+(!G.-(%4S-H+WO-M;=Q8WDRCOW:M#Z3GSN
M326O'(X7)<]OL_D3QP_3 6\'^]="Q:7FUJ,)CF]#J%HUZW/:..8$CTQY]%.)
MNZMWX>^L4.P&!@E+&O#OLY6X;I:<U\7<#1P;.#9PK!<<+SIQ/S)IKZM?3CS@
MAD8*O^6'P(1C#/TIAH7]Q1@NR^2R>^0_XPI#(]4;=G_[L^(BY#E+[V.P\_A:
M30?VT7V= O^E4TR;!,<FP?%V=YN;!,=FN[$>Y-DD.-XD%?\:"8[O8:Y#XK#&
MY6F%1TQ) 9<B4CC;)%/>0)1LX-C L8'CF^$X?"V;FX<F[#7UZ;OR*.?SXHDJ
MA_#72)W<<WN3.KD_(ZPN[/6;K<<K>_\_E'@Z&L]DS]"6&DF%8TFB50DK385E
M51%3"$(:B! SC)8K;Y]0:VO+>O-"Y5+CW6J_@V=4^,'VHL1.PVFM33021K8.
M*Y2DS>:M(AC-0&&,"D5H6TB"B9EUPGKZM7)E5^B[;.&M89U%PQI052\OVM>
M28)T44'&(B3C+,I6D,6F&GFA!+E!IHZ9BE+4#BAKZ1@%*HKE6Z<L="DI*-C8
M>@2Z")/*H>:=2+<%7S_T3:J%P*BRC3_BS2I7'1BY[+=]G8JBILB6*S"77[Y:
M66%(M^FQM[+F>"5J"9"J=M%5*)8.W&V@@1=SJ0?E^U]T>\H'&\_=[("E$S;3
M[BGF:->^$7?\[FC7O4OW/U!+ 0(4 Q0    ( "N 6UHK[[:KD)X+ +^P#@ 2
M              "  0    !I;6<Q-S,X.#@P.#)?,"YJ<&=02P$"% ,4
M"  K@%M:< -]I,@3" "EL@@ $@              @ ' G@L :6UG,3<S.#@X
M,#@R7S$N:G!G4$L! A0#%     @ *X!;6A\PM.%[, < ?AL( !(
M     ( !N+(3 &EM9S$W,S@X.# X,E\R+FIP9U!+ 0(4 Q0    ( "N 6UJW
M'^JSN'4$ -TZ!0 2              "  6/C&@!I;6<Q-S,X.#@P.#)?,RYJ
M<&=02P$"% ,4    "  K@%M:ST6$#E7R! "B#08 $@              @ %+
M61\ :6UG,3<S.#@X,#@R7S0N:G!G4$L! A0#%     @ *X!;6B</H6TL9 0
MI_,R !$              ( !T$LD ')C:W0M,C R-#$R,S$N:'1M4$L! A0#
M%     @ *X!;6K;%\77\Z0$ ]] = !$              ( !*[ H ')C:W0M
M,C R-#$R,S$N>'-D4$L! A0#%     @ *X!;6BF3@6$>$@  N\$  !
M         ( !5IHJ ')C:W0M97@Q,%\R-"YH=&U02P$"% ,4    "  K@%M:
MPTPFP5\F   C4@$ #0              @ &BK"H <F-K="UE>#$Y+FAT;5!+
M 0(4 Q0    ( "N 6UKQMRS1*00  !<^   /              "  2S3*@!R
M8VMT+65X,C%?,2YH=&U02P$"% ,4    "  K@%M:Q?CR0D($  !-%0  #P
M            @ &"URH <F-K="UE>#(S7S$N:'1M4$L! A0#%     @ *X!;
M6O>9R+V7"   BSD   \              ( !\=LJ ')C:W0M97@S,5\Q+FAT
M;5!+ 0(4 Q0    ( "N 6UI:J,9<N@@  (L\   /              "  ;7D
M*@!R8VMT+65X,S%?,BYH=&U02P$"% ,4    "  K@%M:'H,Z\/H&  !2-P
M#P              @ &<[2H <F-K="UE>#,R7S$N:'1M4$L%!@     .  X
*: ,  ,/T*@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>rckt-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rckt="http://www.rocketpharmaceuticals.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rckt-20241231.xsd" xlink:type="simple"/>
    <context id="C_81130365-ff4b-4a54-b76d-5c0eadb8eb25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8248820b-9b6e-4904-9222-9f0abb8fa0d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8258573d-c82d-41f2-ba1a-9620f4a7976c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_842fddb4-2c73-4db6-a334-14dfdfb8754b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_845cdb5d-eeb4-4f91-b37f-77626c44f34b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_84c34b9d-6390-46b6-8bd7-a209b92ac32e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_88bd68f9-d4e7-4d24-ad5b-0cfd4a8572fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_88e568be-e56e-4e25-9251-014e7a901a92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b46be80-cf70-47f1-91fb-b0731982128f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rckt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8cae4c49-ba69-493e-87c2-811bf32aab54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8cfc4f1d-1cde-40f3-8c46-dd26d0bccc8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8e233e0a-2ea3-41c0-89a4-fc2fd285a9ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8fde949d-0acd-44a3-9e91-5d4c632ff5be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_906a09af-a884-4b84-bbef-d07f25a1fe78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_92d0c82e-65b5-4c8a-8b1c-a545c812be74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9361b9bf-214e-472d-94a2-17fca7cba2ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_942d6d11-281e-4b8a-9341-9398c05c7ec3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_943dc870-40c2-4855-8570-af751ebf236a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95348ff1-8262-49b2-97f9-9288584683e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_956a0bae-50e5-4afb-9e3f-ce6ad3fb91df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9571be56-aa2f-48cf-b127-0409e94057d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_991c71a4-2d8b-4a30-b81d-b081fa3aa360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_995a47c0-d6eb-4aac-a735-b345f6e0d985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9b1dc6b9-f15b-42c3-88cc-60968fdcd0ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9b231eaf-1cc1-439b-be3b-21ff07a55616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-15</instant>
        </period>
    </context>
    <context id="C_9ca4967a-2d36-4cf3-813a-a556cf2894e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:NewJerseyLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9db51dfa-02b3-4033-8f63-ae0680935120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="C_a067d039-439e-4ceb-af2b-1cde0cbe0191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:LADICIRMGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_a0c2517b-dc96-4c54-8ca8-8365a9a71c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a111d06c-dc8e-4e3a-8e0d-78a1e5369023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rckt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a1502da7-9920-4457-8a72-b7448a4ac6aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_a20e6031-eb30-4c47-8d1b-adc6495a52e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a24c8827-54a1-427b-bed0-b964f5520e1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a2ac1bfa-acd2-4922-9ccd-25d39d1ed512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a390a215-8672-44fe-88df-66981bedc86b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="C_a3a9b56e-e418-462d-87f6-73709057c6a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a589b03e-fb9c-4bfa-83f1-f8a8d07ed1fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a62b5264-3059-4dbe-b8df-0bb7b813db23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a6f9948b-434e-4c07-bdf1-b761c191b422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7d9a7dd-fff1-4380-9e5f-b878d0a03f2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab8144ca-12d4-48b2-a36b-ecea9a99ea61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_abe62c65-86b2-4c28-a166-de2d40714fe1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ad2fb098-5ecf-47f9-9732-d89dedec0a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ad45b344-bcc3-4fab-a36c-d35bf9065472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:LADICIRMGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="C_ad72efaf-99b2-46be-9995-845d7bf8494c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ae6b3516-7a34-414f-a317-8b7d0434e4e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af781e94-ac4a-4e0a-b76d-1f546fae593e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-15</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <context id="C_b27c603f-0be6-4a87-b784-35a6acc0b66b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b579542c-2ebf-4d4c-99f6-66f0c8bde726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b57bb250-c7e3-4d28-a381-947cb29c01f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7504ddd-7215-4a12-a2a7-05b47998068b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-12</instant>
        </period>
    </context>
    <context id="C_b75d21e1-b615-445e-a851-9927373017c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bf12f724-78e9-4689-a9d8-6cfcdb16921d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf567e9b-5f3d-4efa-a215-8c9b02dd65f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-15</instant>
        </period>
    </context>
    <context id="C_bfe02d27-19e3-433a-95db-5d94f0827b20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c05bc945-3f19-4133-993a-f7a7c46cf63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c0959b18-8b8a-48d0-97a6-aefc2f4ade16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c0a9f08c-83d5-4fde-9bc3-f69654e05e5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c0e3b9f1-cd58-4ddc-8dac-3bce6794b077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c12614f0-c656-4035-8e89-9961453df24f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c182ea63-0464-4304-ac90-99a8af5eefc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c3286afb-2e4a-4c4c-99a2-97e9d815732a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c3c68b77-90ed-4616-a582-7d53b5f05ebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c72bc269-579c-4d57-ac72-5d5633259ea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c72cfefa-5df0-4873-ad35-93e437d2fecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c7874f61-2268-4af4-888a-25b614890494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c85f9ea7-c5e2-4223-8d66-d75ebaec1617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-15</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <context id="C_c8dbc4c6-e882-4412-ac54-add80894cf82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c9cbcf73-650e-4bae-b575-14bb681c7fcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cc91e4ce-92d4-493e-b585-ed3ef5272e3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATAndUCLBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="C_d25d260a-f7e7-4db6-8072-fa02e589a560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d2c1c330-8750-4b70-8dba-88ed15df03d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d48d3908-3513-4784-ae1b-75c7c67ca6e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d4b68ab5-2b41-4121-b8f8-df6a4d864157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d6baac6b-72b3-4bad-a3e9-4bd2c34ab5f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d7655a81-c814-49e4-8f59-bed89f97e80c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d7da2197-3558-4b5e-baa6-7e95259215a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_da15f6ac-8878-4d40-8036-e1c273a0e120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dab486eb-7044-4902-b0e7-0bf059248bfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc209532-0fd3-44e9-9598-91da8bb7ea6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_df02e688-dcfc-497e-8173-c2fefd94643a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_df19c97a-a904-4e39-bf6b-380f08b81962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0a89db5-ae0b-4a17-b75d-9c2a60a086ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="C_e1b43b69-998d-4796-b42a-aea9aafdd667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e1c16979-17a8-4d46-9822-2b46b4a8cb39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e289c72e-5a2f-4c23-8a80-507c89a70c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e6d96dee-383b-4648-a425-7febaa2eae01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e74a48a3-05d2-4751-8cd8-1f14b04dcc09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_e769f56b-a3fa-4858-826e-d12445d19397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e9d92f5a-8151-4cab-ad6d-17971fdc56a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ebdeda00-9ced-49ab-96a0-78c4cdd5ca46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ec293a7f-d32b-4a44-a134-201656a16ec8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ec6889e5-cd60-493d-a8e3-c53b58b5fa3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f241f631-e65d-4cb2-96fd-2e31846e930f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="C_f4e43627-1bfb-49a1-9d5a-28545ff3ce67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f58025d4-77f4-4bb3-a4eb-7fe3d5f5ebf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-30</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_f6793c34-d860-442e-be6e-737f243f3d98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f68555a5-2282-4a77-abe9-8ff2dee0202d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6f45e22-281d-462c-89e9-34ded8f15e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f7122f45-e86b-4832-8a3c-08b89787f233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f7e81d9b-0896-4ad4-ba24-d00ff70c5380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForFAWithCIEMATGroupAndFIBHNJSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-31</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="C_f8197a09-186b-424a-b44f-83d44b69c54d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f889aac3-200d-4251-9867-6d16afb64a27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f89a9364-484a-44e7-a942-5ef3c5798d0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f9abc263-c852-40e4-bb93-fffa5f59bb9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:AAVCurrentGoodManufacturingPracticecGMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fadd17aa-74ce-41d1-ba1c-01a9d30e8d5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fe041e39-6da1-43a6-9419-34b2d437cff8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fe613fec-8a94-4877-8745-1c95fb74dd4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0037c99e-c1ca-4b23-b24c-81e17fdc512c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_053815b6-adc7-4370-b942-f77a4c14f8b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_05d3269a-9c6d-44e5-9b7c-99c1bf950fb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-07</instant>
        </period>
    </context>
    <context id="C_069e4998-345d-4f31-93a6-b24211692b71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="C_07a7dd6a-45bf-41e3-812c-421cdda9cc6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_07c3747f-e2f3-42a9-89ac-9acfd5f74970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_08780583-41ea-448f-ad3c-a32d151f99de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0a90aae5-1098-4d84-8da8-2fb68133b607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0b068067-3bc4-428c-8a9a-66ff44763c0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0cfac2e7-eea8-42c7-88ef-e2f0746599fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0ea9594b-03e6-487e-a61a-c1acf9b39205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_15399861-ccb4-4e70-8bbd-0ddf51277dc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_192b6914-1bac-4600-8f9d-77f09fef2c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1a9df4ee-5889-42bf-97e5-3fe2409b390d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1adde562-4738-4477-bfc6-f6adc114c4a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="C_1bae87d0-dd44-44ba-9b20-91cc4df8a8be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1d96ec30-1174-441b-a600-2e0b2c261eb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1e1369d9-110a-42d0-b7c0-84ac9ece8089">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1f827aab-8c58-4267-acb7-76cf53e8db5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_20f6fd52-2ba1-4fa6-be1d-d13c170008e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_23045695-c17e-4d48-ab1f-bb772f60c66e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_231c38bb-1d40-4602-a048-1a166b10048d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2323ae46-2e58-4ceb-9952-42b0e8c29897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-06</endDate>
        </period>
    </context>
    <context id="C_2401d799-1468-4c2d-8db7-16420132a1ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_25bb15f2-0efc-482c-a2c6-da231c955822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2752ee0c-715c-4d1f-bee7-73f449628989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2765a887-d17f-45bb-83df-c1b045d9460d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rckt:HopewellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rckt:RenovacorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2b8daae2-1c08-437a-af18-31fd63828d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingAndPrivatPlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="C_2c3ff4eb-7ecb-4647-a320-5c43c59dd844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2c40b128-241d-4c5e-acaf-fed48f581245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2c62f640-e90d-405f-b768-464bdc8fe131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-15</startDate>
            <endDate>2023-09-15</endDate>
        </period>
    </context>
    <context id="C_2c739877-da67-4ce9-9177-ac7aba511326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2f0b3d23-92ac-4213-bd74-31dcf6bf23dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f0c010b-87c8-42b0-9da6-1c012fc63603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:NewJerseyLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_308b60bc-adf6-4c0d-98f7-6dd8faf1845b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_30eee4ca-639d-42b3-9810-aa01632a49b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3215859f-0d66-4427-9688-3a638bd9b0c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3300233d-86ba-4c8f-9f81-9fb876b5012f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_34f5602a-7c3f-4806-8c95-b68c3340e325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_37654162-418a-45b1-acc3-24642763a46c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_392358ca-cf5c-43db-9d21-66153965d64c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForPKDWithCIEMATGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_39d4c570-76ba-4c52-80e3-dde4aa7b4c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_3a2dd3b1-3fb8-410c-ab6a-47d3ffbd35f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3abe252d-55ed-4732-a04d-1b253a82ba3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-12</instant>
        </period>
    </context>
    <context id="C_3c6df573-5d38-4acd-8c24-1b20574901cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3d43c909-ed76-4cd3-8437-c11a815217b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:DanonDiseaseLicenseAgreementWithUCSDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3f829c1c-8313-4171-8476-384337e26d5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3ffc89cd-c5e5-47b4-9f7d-0851382b9894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForPKDWithCIEMATGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41fabef3-0abe-4db6-b3ec-ae0243277332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_427ef717-f6ba-4ddc-87e2-99ea816b4e39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4610418f-69ff-4383-8d4b-b7f932f3e7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_46f31250-5670-4e2c-961d-6755291c25a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_479a9661-05cc-4e37-ac7c-06504e617691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:AdenoAssociatedVirusProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4aa60fef-eb52-492b-9a6b-0ce93d49fb48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4debd961-aac7-48c4-9e45-f2780c6806f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4e8fe46b-7cf9-4f88-b35f-815f319dccc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:DanonDiseaseCIRMGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-18</instant>
        </period>
    </context>
    <context id="C_4ec9d6be-c702-40fd-a041-258f0191e5ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4f55fe36-f663-484f-9f05-d10d67ae3a41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4ff6c49f-8407-479c-80d4-c307efd55622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_501a8552-7901-4cd9-bf47-33b094f5f3d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_50276bb0-33c1-4f8f-878e-9cd8590b54aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:REGENXBIOIncLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_51821ea0-ebf2-416d-b94b-558384084f5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_522afc24-fadc-4b87-92bc-1830764fccf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_546e10b4-ff00-4699-b1d3-6c11db3121d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5579d6c9-7175-4d28-8d03-b3467227e674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_55db9cf5-dacb-451e-bc48-da645969b76a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_56deae45-2475-4724-92a9-1a0f1898168d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5788384e-0e15-4c14-b7f3-ea8098caef5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_58582e6a-472e-48eb-b983-e4e33afabbd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForDDWithRGNXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_58974243-708a-4a81-a595-749260b730ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59178516-f6c7-4b30-a565-d0b9d51d21d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForBAG3WithTempleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="C_594c6d62-c2cf-41a3-886a-1934d4223d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5bed0892-88b1-4193-a2a6-7964d153c972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5d022c41-2abf-4b66-9515-d9ce9e263b44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5d1d40da-cfd2-4824-a96b-b4971b74b346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LentiviralVectorProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5d4ff701-3d41-47cd-8660-59707d56d468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5de73c69-3b3e-412b-a788-62510c450a86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5f849fe8-09d4-4c36-86ef-cef05c3dbc49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rckt:EmployeeNonemployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5f9d43f8-45ec-4f28-93a5-f42279655025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_600a0f88-6bde-40ff-97bd-99954442846a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_614d6896-e6d5-492d-9c77-ffb84b0406db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_61647b0b-b5df-4485-8420-e20842c8ff39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:WarrantsExercisableForCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61ed228c-04b4-492d-9653-316c1c51bb39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_62e99bbf-513f-4f99-b0ea-bcc4f892c8d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForPKDWithCIEMATGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-31</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="C_63ad2220-d8b8-479c-b35d-56ecb8208ca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63ca01b0-e7b0-45e5-aa8a-17201501dd48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_648e9485-2de4-4dbf-b7be-6f5b0c53d513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_65579abf-153c-44b1-82d0-fd8168b17b2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6562543d-3991-4041-aff9-088643ccce60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rckt:SeriesAConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69408d2a-0545-4d3a-a4f7-3c54eb9825f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-12</startDate>
            <endDate>2024-12-12</endDate>
        </period>
    </context>
    <context id="C_6949dc0c-ac58-42f1-b238-512744e2f55a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69c35b9b-2ef7-4ee6-b016-6923857d4819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b479ce2-ba9e-4e7a-9b6e-64a21f473b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:LADICIRMGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6bfdea93-6072-4e09-919a-4629747224e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6d0adb09-8317-454a-af5e-3df33b3384e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6e010d18-1522-44a9-b62f-331c4708e6ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rckt:WarrantsExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6f626844-ba06-4567-931e-02c5cb0a1650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rckt:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rckt:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7132f227-a70e-41d6-9438-433555a0c26d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">rckt:DanonDiseaseCIRMGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7192b875-69fe-4a97-bfab-df69481b623d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7196725c-a392-4a09-b1a2-b1a1aec580da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_71fbe897-d128-4353-aa54-ac82b0209669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_743963e7-e2f3-4156-9218-0e77929607dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rckt:LicenseAgreementForLADIWithCIEMATGroupAndUCLBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_74b364e5-c1c4-45b4-9711-2e7d66596427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_74f8d0f8-a7bf-4f11-928f-7f1a09f755c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_76dc7d6c-2561-4ef0-81f4-82f6593b6052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rckt:EmpireStateBuildingLeaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="C_775eb4a6-0d31-417a-ac1c-4d459d9a1b5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rckt:StockOptionsRestrictedStockUnitsGrantsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_77b45e56-1ad3-417d-8a7f-066853f32825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <instant>2025-02-21</instant>
        </period>
    </context>
    <context id="C_78dca576-a930-4462-aa00-b27c81826e49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_79626284-c57a-465a-9017-f3638fa6a020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7d36cd7b-896c-4b98-9546-ea32bed606cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7e23f455-be7b-426a-9098-daac61a450fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="U_Milestone">
        <measure>rckt:Milestone</measure>
    </unit>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Vote">
        <measure>rckt:Vote</measure>
    </unit>
    <unit id="U_Program">
        <measure>rckt:Program</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Patent">
        <measure>rckt:Patent</measure>
    </unit>
    <unit id="U_Segment">
        <measure>rckt:Segment</measure>
    </unit>
    <unit id="U_Leaseagreement">
        <measure>rckt:Leaseagreement</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_016296c6-b126-4873-836b-581a61dda64f">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_b4dfe319-bbd8-4694-8658-3b25b6f7567e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_39d8dcdd-c6c2-4cc1-935e-ac8a013dcca5">0001281895</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      id="F_63f0a92f-a65a-4c84-b222-33d614db54c3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      id="F_76b723fc-c65f-451e-978b-806aac96cad9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_6562543d-3991-4041-aff9-088643ccce60"
      id="F_dc034d90-1564-4b13-80cc-fb23b4f1b2e2"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3"
      id="F_fc42e5ab-9c8c-4f21-a12e-b9264001c1d4"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3"
      id="F_ccfdc9a8-1b03-4d0f-b432-45e689b2bcfb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be"
      id="F_4bf39ad5-2046-4fcd-9234-2456d6001b5f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      id="F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef">http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3215859f-0d66-4427-9688-3a638bd9b0c3"
      id="F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e4e33013-0944-4e5f-ae6a-24eab71a59cf">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2"
      id="F_0a395aa8-c4ae-4063-a1b7-e3d080e5ffcf">2026-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_6bfdea93-6072-4e09-919a-4629747224e6"
      id="F_f8ada714-1a3a-4a7f-a2c0-3691e7ff6012">2026-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2"
      id="F_476f0015-4836-4e88-9984-744d464250a3">2038-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <rckt:NumberOfLeastUninterruptedYears
      contextRef="C_392358ca-cf5c-43db-9d21-66153965d64c"
      id="F_0f41fdbb-616b-4390-91ca-6c0083fedb69">P2Y</rckt:NumberOfLeastUninterruptedYears>
    <rckt:NumberOfLeastUninterruptedYears
      contextRef="C_d25d260a-f7e7-4db6-8072-fa02e589a560"
      id="F_df646047-6e29-47e2-b2b5-6f058df99877">P2Y</rckt:NumberOfLeastUninterruptedYears>
    <rckt:NumberOfLeastUninterruptedYears
      contextRef="C_743963e7-e2f3-4156-9218-0e77929607dc"
      id="F_51fd1836-2c76-4d4a-89af-503fa040d252">P2Y</rckt:NumberOfLeastUninterruptedYears>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_451a042b-eab6-4290-938a-8e09ce736c2b">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_04370629-a4cf-4773-9e67-ce50419f1143">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ed934fa8-e561-415c-8fe4-e455ce81b16b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_340d7d87-240a-486a-b291-feb69d55bae4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_cd0e85d1-0a9b-4f15-b9ed-6c3ce52dd963">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_d9daf1b6-886e-4aec-a50a-51e127c42674">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_5d7fa59a-cb84-45be-ab8f-947df36dfd2f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_c5593215-765c-40a5-ab1d-b7847e274481">001-36829</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_204f5f95-7ac5-41a1-a999-d62b4363a8dd">Rocket Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_5be7cfeb-95c3-48bb-a247-b9f6b8e1e2aa">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a4a6a4bc-b948-4cd7-8f7c-20823ac3d479">04-3475813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4b4bac96-59e4-4c49-adff-2dea82a2a5fa">9 Cedarbrook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_9befe8cc-8e6b-4472-b276-851251bed538">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4332390e-fcae-46c3-b2dc-549a7e155991">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_b5454e71-a8e4-4d5a-a184-033cd2cff3fe">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_0950bc44-940f-4d91-a2ea-ea89e5807178">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_57a1d8a5-f951-4bec-b052-f8e9ca447bbf">659-8001</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_0820c7b3-cc96-45f8-b165-e2afe79c2c9f">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a2730a36-be88-4bda-98dd-b0fcfb7f7389">RCKT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_f3fb417a-954e-4531-b79a-b56a7a046883">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_28c2057e-cba5-4fb4-b843-a72e10961664">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_6947117d-2ece-4e12-98f5-7540ebcfed88">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_2e3969b2-59ac-47db-b864-645307c91a2d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_3187cb93-ab9f-4d17-893d-71847f7c82f9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_18cbb91f-29cf-46ed-81f0-111f739d3e17">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e70e6369-3c3d-4c87-9aec-7c47d8b07d72">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ddbfc64a-1d6e-498a-bb7b-7265cec251e4">false</dei:EntitySmallBusiness>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_6a5c7474-bd00-4987-a3c4-b1bcdd30c924">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ef839645-ba8a-4f22-88a8-aec6f6e0a8d1">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a0fd0de5-32f3-404e-84d9-0ac9fd51dec2">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_f4e43627-1bfb-49a1-9d5a-28545ff3ce67"
      decimals="-8"
      id="F_f4c034a5-aafe-45b3-ad32-61ca939162e6"
      unitRef="U_USD">1400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_77b45e56-1ad3-417d-8a7f-066853f32825"
      decimals="INF"
      id="F_fcf41708-654d-4f87-9535-66075bb25250"
      unitRef="U_shares">106629701</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ab6f6e70-7268-4688-8c4e-bd0950aa4177">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Documents Incorporated by Reference&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Part III of this annual report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from the registrant&#x2019;s definitive proxy statement for its 2025 Annual Meeting of Stockholders (the &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Proxy Statement&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The Proxy Statement will be filed with the United States Securities and Exchange Commission within 120 days of the end of the period covered by this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4464e2de-fa6b-4e6f-9a73-822d4dd8f09a">&lt;p id="item1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains a cybersecurity risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The program is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; within the Company&#x2019;s enterprise risk management framework and addresses both the corporate information technology environment and the external ecosystem&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The underlying controls of the cybersecurity risk management program are based on recognized best practices and standards for cybersecurity and information technology. The Company has a third party perform an annual assessment of the Company&#x2019;s cybersecurity risk management program. The Company has a Cyber Security Operations Center monitoring our global cybersecurity environment and coordinates investigations and remediation of alerts. We are enhancing our programs for staging incident response drills to prepare support teams for a significant incident. The cybersecurity risk management program includes administrative, physical, and technical controls&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our VP, Head of Information Technology is the Company&#x2019;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; All employees are required to complete cybersecurity training at least once annually and have access to more frequent cybersecurity training through online and live events. We also require employees in certain roles to complete additional role-based, specialized cybersecurity training that is documented in our quality management system. Employees outside of our corporate information security organization also have a role in our cybersecurity defenses and they are immersed in a corporate culture supportive of security, which we believe improves our cybersecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#x2019;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The cybersecurity team collectively has decades of experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes around the world, and relies on threat intelligence as well as information obtained from governmental, public, and private sources, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;including external consultants engaged by the Company on a real time basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, in addition to the Company&#x2019;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#x2019;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#x2019;s cyber risk management program, generally on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, cybersecurity risks will be reviewed by the Board of Directors, at least annually, as part of the Company&#x2019;s corporate risk mapping exercise.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not experienced any material cybersecurity incidents to date, and, by default, we believe no cybersecurity events have occurred that have materially affected the Company or its business strategy&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, results of operations or financial condition. We continue to invest in cybersecurity and the resilience of our infrastructure and the enhancement of our internal controls and processes, which are designed to help protect our systems and data, and the information they contain. For more information regarding the risks we face from cybersecurity threats, please see &#x201c;Risk Factors.&#x201d;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_90f96cca-1eef-4515-ba45-5398b1cd3526">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains a cybersecurity risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. The program is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; within the Company&#x2019;s enterprise risk management framework and addresses both the corporate information technology environment and the external ecosystem&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_96f17f83-bc7c-48e5-bdb5-c305062fe1fe">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_fe206939-d834-4e99-9c81-8ffd590b169b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The underlying controls of the cybersecurity risk management program are based on recognized best practices and standards for cybersecurity and information technology. The Company has a third party perform an annual assessment of the Company&#x2019;s cybersecurity risk management program. The Company has a Cyber Security Operations Center monitoring our global cybersecurity environment and coordinates investigations and remediation of alerts. We are enhancing our programs for staging incident response drills to prepare support teams for a significant incident. The cybersecurity risk management program includes administrative, physical, and technical controls&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our VP, Head of Information Technology is the Company&#x2019;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; All employees are required to complete cybersecurity training at least once annually and have access to more frequent cybersecurity training through online and live events. We also require employees in certain roles to complete additional role-based, specialized cybersecurity training that is documented in our quality management system. Employees outside of our corporate information security organization also have a role in our cybersecurity defenses and they are immersed in a corporate culture supportive of security, which we believe improves our cybersecurity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_28884b5f-7f9e-48f5-bec6-f58f8514093a">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our VP, Head of Information Technology is the Company&#x2019;s designated Chief Information Security Officer (CISO) and is responsible for developing and implementing the cybersecurity risk management program, including and reporting on cybersecurity matters to the Board.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company views cybersecurity as a shared responsibility across our management team and plans to periodically perform simulations and tabletop exercises at a management level and incorporate external resources and advisors as needed.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_61ab65b2-e352-429d-b6e5-74b15d16f8cd">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_7e5c027e-70fa-49b6-b102-97d80c35f9d4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The VP, Head of Information Technology has over twenty years of experience leading cybersecurity oversight. Additionally, members of the IT security team have cybersecurity experience and/or certifications, such as the Certified Information Systems Security Professional and Certified Information Systems Audit credential.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e57ef899-817c-4e68-9fc0-842c8a3905fd">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#x2019;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The cybersecurity team collectively has decades of experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes around the world, and relies on threat intelligence as well as information obtained from governmental, public, and private sources, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;including external consultants engaged by the Company on a real time basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, in addition to the Company&#x2019;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#x2019;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#x2019;s cyber risk management program, generally on a quarterly basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, cybersecurity risks will be reviewed by the Board of Directors, at least annually, as part of the Company&#x2019;s corporate risk mapping exercise.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a6ba43e8-76f2-437a-bb99-b9885517b27c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Information Security Officer is responsible for continuously monitoring and assessing the Company&#x2019;s cybersecurity risk management program, informing senior management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents, and supervising such efforts.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_edc7717d-758f-43f3-861f-3bfe14e5abdc">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ea456853-8a29-4bd2-8d4a-43afb69a9ff3">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is continuously enhancing its processes for oversight of third-party vendors, including appropriate due diligence for new providers and continuous monitoring, including ongoing direct contact with vendor personnel.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Third-party vendors are re-evaluated at regular intervals as part of our supplier qualification process&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4d6b0d55-58ba-4b73-8fe3-c034474c55f8">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_76afe941-c355-402c-be5f-cae9a47a2a88">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee, in addition to the Company&#x2019;s Chief Financial Officer, General Counsel and Chief Compliance Officer, oversees the Company&#x2019;s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The cybersecurity team briefs the Audit Committee, Chief Financial Officer, General Counsel and Chief Compliance Officer on the effectiveness of the Company&#x2019;s cyber risk management program, generally on a quarterly basis.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_af962807-7246-4849-a685-0d57a71cb671">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a935c1b5-e5a6-40b7-b0a3-43ede6228591">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41"
      id="F_4ce55352-d99e-45a7-b868-1094dfde8ed4">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41"
      id="F_ad284b4c-a8db-4684-a6d6-d59c950d8b0d">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41"
      id="F_4de3d90c-6d83-47bf-b044-804dc4fd12b9">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_4f55fe36-f663-484f-9f05-d10d67ae3a41"
      id="F_fcc7b562-cbdf-40ab-8872-488afe1fef7c">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_cc28ea72-c130-4103-a09c-3cd4993d3e3c">274</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a0754171-9047-4989-a89d-2ed7524c20c8">&lt;p id="audit_report" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Rocket Pharmaceuticals, Inc. and Subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, changes in stockholders&#x2019; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;).  In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;), the Company&#x2019;s internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2013&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201c;COSO&#x201d;), and our report dated February 27, 2025 expressed an unqualified opinion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinion on Internal Control over Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited Rocket Pharmaceuticals, Inc. and Subsidiaries&#x2019; (the &#x201c;Company&#x201d;) internal control over financial reporting as of December 31, 2024, based on criteria established in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201c;COSO&#x201d;).  In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2013&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) issued by COSO.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;), the consolidated balance sheets of Rocket Pharmaceuticals, Inc. and Subsidiaries as of December 31, 2024, and the related consolidated statements of operations, comprehensive loss, changes in stockholders&#x2019; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes and our report dated February 27, 2025 expressed an unqualified opinion.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a664076d-fdbd-4a7b-a623-2d448e2151da">EISNERAMPER LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_c3695472-7ee4-4369-aea7-b82ed7b5de6e">Iselin, New Jersey</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_f82508f6-6726-41ee-ad21-2a0e54a43f22">EISNERAMPER LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_c9700c82-ec89-47b8-9bfe-ec86438ac898">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_c7372f7a-9076-4541-836b-c27c9dd17f7f"
      unitRef="U_USD">163635000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_7a4ab1c4-8a2a-401c-8325-96925abae580"
      unitRef="U_USD">55904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_e473563f-2f2f-4de9-86e7-b42c30da9cab"
      unitRef="U_USD">208701000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_865b19dd-3571-4e29-85a3-c5384f9eecca"
      unitRef="U_USD">317271000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_b2fe9d36-657d-401c-bdbd-24f5c6fcd9ea"
      unitRef="U_USD">5847000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_ddd799d3-b3fc-4723-a897-f408c4eb2234"
      unitRef="U_USD">5047000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_e91cfbda-b972-48f6-baf8-3ed34339844b"
      unitRef="U_USD">378183000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_1cf8937f-a796-4ca3-849d-2368baae93d1"
      unitRef="U_USD">378222000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_8bf3b110-042d-47ea-89eb-3d58da384493"
      unitRef="U_USD">36786000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_d99e3dec-a198-4802-a6e4-dba824c195c1"
      unitRef="U_USD">39172000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_e454198c-e051-404e-af1b-576d30077070"
      unitRef="U_USD">39154000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_ca33475f-5dd5-44ae-8d9e-3c4187e5c6ed"
      unitRef="U_USD">39154000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_1d9f0af1-bf9a-4f41-adcc-543ddde92f32"
      unitRef="U_USD">25150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_6e5b97e3-1b1c-4329-84d2-c6eb2d4cacd1"
      unitRef="U_USD">25150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_12c96d3b-ff99-4d78-9d2c-efbb9f1a450f"
      unitRef="U_USD">1362000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_d7de6332-35dc-469f-94db-345d77dace62"
      unitRef="U_USD">1372000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_d7cda09e-c0c2-497a-b29c-285b5f0cbbe3"
      unitRef="U_USD">529000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_8ca70b7c-680f-4b7d-b103-988d0059bb07"
      unitRef="U_USD">533000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_3b18c04b-14f5-44e0-a1ea-bef016c871af"
      unitRef="U_USD">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_fa479b1f-d290-4fb5-b164-174d6b06142f"
      unitRef="U_USD">34320000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_0beb781d-4c74-45d2-992f-81419fb3f0b8"
      unitRef="U_USD">4173000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_f0235947-0f7d-4684-a8cc-a1a02313c138"
      unitRef="U_USD">3901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_6558c87e-8f67-405e-b878-af2b05af5374"
      unitRef="U_USD">42363000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_c469ab6c-d895-40d0-ac28-3c2319de237a"
      unitRef="U_USD">44517000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_60787076-7602-4bda-8aac-6be768e83443"
      unitRef="U_USD">527700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_e73990a6-6b82-49e6-879b-9ba6dcb4d295"
      unitRef="U_USD">566341000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_f545ccb7-577f-4802-bc6a-9b9647c54e17"
      unitRef="U_USD">37827000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_071695c1-6c30-4464-a274-49a3d393ed37"
      unitRef="U_USD">45789000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_af8764e7-e0eb-4855-915e-64ef7957c7db"
      unitRef="U_USD">1001000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_1f86e41f-2a0c-4f57-8be1-fb7f1f2d78a5"
      unitRef="U_USD">925000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_e7ba4acb-c7c4-4716-a2ed-c04dd105cf65"
      unitRef="U_USD">1856000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_d12652a4-ecf9-49b8-84be-d20d56f43aeb"
      unitRef="U_USD">1791000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_a947204c-a606-4c31-9645-f47d632a48b6"
      unitRef="U_USD">40684000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_92b04728-859b-4670-a12e-6c47e73aa2cf"
      unitRef="U_USD">48505000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_c63abb43-2ac0-4c94-8178-4c2ff98727c8"
      unitRef="U_USD">3258000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_155e0d25-0e70-4505-b2da-65f3ea43d460"
      unitRef="U_USD">2973000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_0e6a2a87-8ce3-422a-af6a-926887c461b8"
      unitRef="U_USD">19383000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_d5005a81-5f01-4beb-9c3e-860a6ac0177f"
      unitRef="U_USD">19353000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_d9b4c68a-0279-4acd-85af-c9d728a8d084"
      unitRef="U_USD">1141000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_1b0d8a24-7ef9-4047-a6d4-9c9b3e02f0c4"
      unitRef="U_USD">2936000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_19b5c2b3-5262-4063-a515-9abfbc952efc"
      unitRef="U_USD">64466000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_70f1030d-83d8-4f52-8e75-0a287ecbf7a2"
      unitRef="U_USD">73767000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="2"
      id="F_d1dc9ecf-8546-4b5e-9915-fb958122f7f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="2"
      id="F_2edf3808-01f2-44b1-96a7-2bf165465f59"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="0"
      id="F_d0dcb5fa-d778-4055-82dc-ed8f6c455573"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="0"
      id="F_14954af7-97a9-4a10-9e0f-f55960458dbe"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6562543d-3991-4041-aff9-088643ccce60"
      decimals="0"
      id="F_b1e74c20-35d1-463a-994e-63b8ed85923a"
      unitRef="U_shares">300000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3"
      decimals="0"
      id="F_8d42fb03-fa26-4ade-ba72-ca26f4714201"
      unitRef="U_shares">300000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6562543d-3991-4041-aff9-088643ccce60"
      decimals="0"
      id="F_c3726097-48e8-443f-8e44-4ffd797039e5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3"
      decimals="0"
      id="F_dc090e66-695f-4a8f-b147-cfb4f4e55ede"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6562543d-3991-4041-aff9-088643ccce60"
      decimals="0"
      id="F_32d8a654-13d9-4e38-b3a4-9b814c28407b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f691cbd7-2abe-4d27-9cde-ed7166d285f3"
      decimals="0"
      id="F_01ed6932-b4a5-43f7-9305-45996bfd0334"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3"
      decimals="0"
      id="F_abf3af6d-1986-45c7-9b12-04f3a9dbe1fc"
      unitRef="U_shares">300000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be"
      decimals="0"
      id="F_41198bd1-f12c-493b-8d3c-4252d14c5fd5"
      unitRef="U_shares">300000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3"
      decimals="0"
      id="F_3f3c4307-b7ce-4905-8d7f-1dae5ceea5f3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be"
      decimals="0"
      id="F_43473417-cfe0-41e8-80b5-be2fac0ec8d3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_942d6d11-281e-4b8a-9341-9398c05c7ec3"
      decimals="0"
      id="F_052a55bf-d6f6-4562-a7ee-e567a9aadcae"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2fba9d85-f25a-4c6e-9046-3376ab42d1be"
      decimals="0"
      id="F_41f4c2bf-6cce-403e-8e5a-3597a62e06f0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="2"
      id="F_9f81b38d-c7b6-40e6-bc89-602a2535253a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="2"
      id="F_28337d0f-3632-4b47-b4a2-715d98348b11"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="0"
      id="F_503974f1-3248-42b3-9d95-8e3d70e07435"
      unitRef="U_shares">180000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="0"
      id="F_1cd5b126-84d3-4d79-98ae-2dd75ac66cc9"
      unitRef="U_shares">180000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="0"
      id="F_d1339b06-6303-4553-9409-1e98d793373e"
      unitRef="U_shares">106453818</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="0"
      id="F_4d9a1779-9550-4b74-892f-3fba446a005e"
      unitRef="U_shares">106453818</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="0"
      id="F_178078bd-bde9-4a9c-919b-f6b446ce86a4"
      unitRef="U_shares">90282267</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="0"
      id="F_dbca314e-569a-45a3-b8b3-aefd8a358262"
      unitRef="U_shares">90282267</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_a3d142dd-b2b9-4b8e-81c3-9cfc55db3d42"
      unitRef="U_USD">1065000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_fd6acbf4-eaeb-446e-955c-597afaa4ab84"
      unitRef="U_USD">903000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_b7662410-e195-489c-8808-1874a28fed89"
      unitRef="U_USD">1680219000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_72bb9757-1d40-480e-bfc8-4722db17c75c"
      unitRef="U_USD">1450722000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_4cf90265-9f35-4c76-8d32-2b113ac2f0d0"
      unitRef="U_USD">66000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_c6f012eb-9743-4bfe-b260-1fa3f8103005"
      unitRef="U_USD">319000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_199c984d-d28a-4fbe-9677-9f00d2c0f1c6"
      unitRef="U_USD">-1218116000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_eee087d4-d316-4b8c-a05d-521b09f4bc94"
      unitRef="U_USD">-959370000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_10ba6980-cdc1-44ea-bef9-623057870b16"
      unitRef="U_USD">463234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_3fbcc647-162e-42ea-be62-cced41deed2c"
      unitRef="U_USD">492574000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_ae57d85d-4bf6-49a5-a927-e83c82fa4319"
      unitRef="U_USD">527700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_f5434f35-d172-4eb7-98ce-5b9a718bb20f"
      unitRef="U_USD">566341000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_52907c47-3a52-4c89-8925-f7fcfcbab2e1"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_2bbde882-726b-4248-a9d1-4e2fb2b92d32"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_93f62f68-3922-4892-abcc-211779f06219"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_a0052a38-9cc0-4f96-a45b-084972697f52"
      unitRef="U_USD">171244000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_6b13bfdd-d611-4a12-bab6-53f0bfd7ece9"
      unitRef="U_USD">186342000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_92190900-dcb2-42ce-821a-a342bebae210"
      unitRef="U_USD">165570000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_81ae962d-0f4b-42a2-ac6a-cfd8ce3e308a"
      unitRef="U_USD">101961000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_c1f0d40b-458a-435b-93b9-5fc37f3fe881"
      unitRef="U_USD">73317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_0c0e97ae-6648-4fe9-98af-be971230606d"
      unitRef="U_USD">58773000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_fa6784c4-0253-4fbf-a7e9-db8bd93a2a69"
      unitRef="U_USD">273205000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_910d9a9b-1d19-4929-acc7-ca5c909358b1"
      unitRef="U_USD">259659000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_e723e27c-e0b7-49e2-85ea-c009c1856a7c"
      unitRef="U_USD">224343000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_8d5fe501-bad1-498e-adb7-3f7731743c01"
      unitRef="U_USD">-273205000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_de6d98b0-e305-4231-bdb4-bd9301291a87"
      unitRef="U_USD">-259659000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_d6825238-66cd-4432-b2e1-8d3c238c9f07"
      unitRef="U_USD">-224343000</us-gaap:OperatingIncomeLoss>
    <rckt:ResearchAndDevelopmentIncentives
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_96f4d280-6207-4622-93a4-7a6b63b69495"
      unitRef="U_USD">0</rckt:ResearchAndDevelopmentIncentives>
    <rckt:ResearchAndDevelopmentIncentives
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_ef2677cc-5d7a-4fbc-b4d2-1dc36fac7171"
      unitRef="U_USD">0</rckt:ResearchAndDevelopmentIncentives>
    <rckt:ResearchAndDevelopmentIncentives
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_b5689f36-aa13-4123-a300-395662f52580"
      unitRef="U_USD">500000</rckt:ResearchAndDevelopmentIncentives>
    <us-gaap:InterestExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7504b384-b0fc-452f-b73d-0896d62f816e"
      unitRef="U_USD">1886000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_06d69791-ca9a-46c5-8f2e-9be493d9b87b"
      unitRef="U_USD">1875000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_8b235095-4c02-4038-b085-b2d93646df85"
      unitRef="U_USD">1862000</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_96fc89f7-b6b8-4ff8-bc0e-5956fec5a0b2"
      unitRef="U_USD">8267000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_54164b7c-c023-440a-b4c4-7f279fdff8db"
      unitRef="U_USD">5288000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_81cfd0f2-47eb-4c1b-8466-82a909561288"
      unitRef="U_USD">3889000</us-gaap:InterestAndOtherIncome>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_acb2ae89-539b-443c-8759-6a905cf3d18d"
      unitRef="U_USD">8078000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d4c35526-5894-4f8b-8520-8b0820883067"
      unitRef="U_USD">10651000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_92496749-359c-4762-8ca3-4ca6c6062f41"
      unitRef="U_USD">-47000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_b010e0d6-fa86-46d1-b8ba-e8724a4d95f9"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_f836b2c6-7aef-4290-8e58-3a6b374cfec6"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_73ab652a-681f-4e9f-aa8f-e6ac92cef05f"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="2"
      id="F_d8d0222f-8766-448b-90d4-7582c0367466"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="2"
      id="F_2b12eb4f-3c45-4ed5-a46e-e47720dff843"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="2"
      id="F_68ab32c6-6264-4845-87a9-46604324603b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="2"
      id="F_2bc10fca-321e-4a4d-b67a-e44693792848"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="2"
      id="F_56f784da-92d5-4c9f-8ad9-8ec71a3c0252"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="2"
      id="F_0728dc6c-d1fd-4b72-850a-92f05e6e09c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_5ede6654-d5cc-4228-bfce-798867586906"
      unitRef="U_shares">94807773</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_831e4dbe-308a-4b03-b048-9d555d214295"
      unitRef="U_shares">94807773</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_4d576af7-ca2e-43e4-bae2-f592448eaf72"
      unitRef="U_shares">84009004</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_90b1b612-570b-4c77-bbee-1f45810339da"
      unitRef="U_shares">84009004</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_f3bc7c78-cfbf-440c-8770-6a75d578af46"
      unitRef="U_shares">68148925</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_d3fad02d-9c7e-494f-9661-5766e75a213a"
      unitRef="U_shares">68148925</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_d23fe1d6-1b5e-41d6-b3aa-f551feaf2633"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_fedbe1cd-1819-4382-babf-1139836652ed"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_3b3f2423-f3c5-4bee-ad22-3ceb15bab8ee"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_47ba9e1c-0c92-485a-8bfb-1f0cb33864a4"
      unitRef="U_USD">-253000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_2d970939-f4b8-43d3-a72b-ba226d09de84"
      unitRef="U_USD">676000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_3172a91e-d2a7-47a8-87ab-5035f21b5b30"
      unitRef="U_USD">-196000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_97dce9ad-7b9f-4fd1-b407-6d0cb2b946d1"
      unitRef="U_USD">-258999000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_bb012ce1-1c5b-43ee-b1c2-7dc18037b140"
      unitRef="U_USD">-244919000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_bb0a6e14-fcdc-44c0-b909-3e20cd2fa978"
      unitRef="U_USD">-222059000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_b57bb250-c7e3-4d28-a381-947cb29c01f5"
      decimals="0"
      id="F_f52f00a8-f4e7-4eb0-a514-7074b5a2b82f"
      unitRef="U_shares">64505889</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b57bb250-c7e3-4d28-a381-947cb29c01f5"
      decimals="-3"
      id="F_e10deb3e-1877-44ab-b10c-c3f726268f78"
      unitRef="U_USD">645000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b1dc6b9-f15b-42c3-88cc-60968fdcd0ff"
      decimals="-3"
      id="F_6f07c320-ff35-4705-846a-cfab63cc1476"
      unitRef="U_USD">946152000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c05bc945-3f19-4133-993a-f7a7c46cf63f"
      decimals="-3"
      id="F_a68fac39-b781-4a12-8ce1-503ec795cef3"
      unitRef="U_USD">-161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5579d6c9-7175-4d28-8d03-b3467227e674"
      decimals="-3"
      id="F_e71ebc0c-ff1e-42c9-8dd7-51dcf7916bbe"
      unitRef="U_USD">-491912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801"
      decimals="-3"
      id="F_ee84757b-514d-405d-9868-d4eb25997e19"
      unitRef="U_USD">454724000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_d5c7b00e-e5bd-4e20-aeb3-76c46fb6fd84"
      unitRef="U_shares">7820000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="-3"
      id="F_70069f56-433e-4bab-8cdf-436c3e642958"
      unitRef="U_USD">78000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120"
      decimals="-3"
      id="F_06e4a98c-a057-4cc7-98e7-04bff506f325"
      unitRef="U_USD">108060000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_12284021-d8be-4870-807d-2764aae41ce3"
      unitRef="U_USD">108138000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_8b95e3fe-c4e0-494e-a968-0de8a11c34d1"
      unitRef="U_shares">66887</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="-3"
      id="F_41f01bd5-75ef-4394-983a-3e069c8ad121"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120"
      decimals="-3"
      id="F_14bdbf06-0a1e-43ea-b63f-4078fa324d5e"
      unitRef="U_USD">630000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_16340594-3b25-47fb-8128-d572b633a23c"
      unitRef="U_USD">631000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_3e0a092e-6c8a-4d22-85d6-9a926796fd64"
      unitRef="U_shares">10168</rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_7b795b90-5744-4ee8-bb31-93bfaeb5f98f"
      unitRef="U_shares">3420774</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="-3"
      id="F_2e1ef674-24f9-496f-a108-dd7a5d3242ef"
      unitRef="U_USD">34000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120"
      decimals="-3"
      id="F_a983c426-be25-4633-b75c-9a7a69b6a1e7"
      unitRef="U_USD">70690000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_2b821b39-63a8-4665-95da-13e95f386f7d"
      unitRef="U_USD">70724000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_117ed893-fa10-4287-9495-d0b03b5345ce"
      unitRef="U_shares">5101</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <rckt:StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_610152ae-4f4d-45f2-ae4d-7a163788941f"
      unitRef="U_shares">3291922</rckt:StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms>
    <rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="-3"
      id="F_211f2281-03e1-4bbb-904d-09f22cb7edfe"
      unitRef="U_USD">33000</rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms>
    <rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
      contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120"
      decimals="-3"
      id="F_d487e7b4-0297-40a3-b32d-868b6cc38bac"
      unitRef="U_USD">46533000</rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms>
    <rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_42406da9-3417-4ad0-88ff-04c61b765087"
      unitRef="U_USD">46566000</rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_ec293a7f-d32b-4a44-a134-201656a16ec8"
      decimals="0"
      id="F_2c8848c5-5aa1-4023-8401-7fd84a6d746c"
      unitRef="U_shares">2571</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_c72bc269-579c-4d57-ac72-5d5633259ea5"
      decimals="-3"
      id="F_2b04a279-7383-40a8-8101-8014538b0cea"
      unitRef="U_USD">47000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_d4143e41-381d-4dd5-bd0e-844f3df8dcc5"
      unitRef="U_USD">47000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
      contextRef="C_c3286afb-2e4a-4c4c-99a2-97e9d815732a"
      decimals="-3"
      id="F_5d19fee2-fcf3-4587-8623-a363fec2bc82"
      unitRef="U_USD">-196000</rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_0864d817-32cb-49c9-a6eb-f40db56916f9"
      unitRef="U_USD">-196000</rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_da15f6ac-8878-4d40-8036-e1c273a0e120"
      decimals="-3"
      id="F_56813cb2-3903-4bd1-b652-5b71004ff0ac"
      unitRef="U_USD">31009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_6406081b-ad3a-4853-ad7b-c79e405a606e"
      unitRef="U_USD">31009000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_2c3ff4eb-7ecb-4647-a320-5c43c59dd844"
      decimals="-3"
      id="F_cce3f6e5-f880-426e-aa57-df0114e14bbf"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_017a7178-cc3c-40cb-9606-436b42dac906"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_74f8d0f8-a7bf-4f11-928f-7f1a09f755c1"
      decimals="0"
      id="F_5ede8d5a-0715-4620-a2a6-d7c34958b120"
      unitRef="U_shares">79123312</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_74f8d0f8-a7bf-4f11-928f-7f1a09f755c1"
      decimals="-3"
      id="F_b67d8320-a00c-45c3-9511-68a8e4dd67e6"
      unitRef="U_USD">791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2f0b3d23-92ac-4213-bd74-31dcf6bf23dc"
      decimals="-3"
      id="F_97c3b59b-ede7-4723-b437-1a64380b0af7"
      unitRef="U_USD">-47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_df19c97a-a904-4e39-bf6b-380f08b81962"
      decimals="-3"
      id="F_8d21eb6b-3af2-4a71-b038-be1f829dc70b"
      unitRef="U_USD">1203074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_79626284-c57a-465a-9017-f3638fa6a020"
      decimals="-3"
      id="F_9c1a947d-eac5-4fbb-804b-8eb639f269ea"
      unitRef="U_USD">-357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_58974243-708a-4a81-a595-749260b730ad"
      decimals="-3"
      id="F_7cc4c15a-7ab4-4d11-9c8b-672c755c0bad"
      unitRef="U_USD">-713775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_b7de3afc-077b-4813-972c-bad50133f565"
      unitRef="U_USD">489686000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="0"
      id="F_f7acd4d2-ac8b-404f-90c6-f572f703e899"
      unitRef="U_shares">9453418</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="-3"
      id="F_11ed4d26-15ac-457d-bd41-7e36aae88923"
      unitRef="U_USD">95000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_1f4d2e8e-53d3-41ff-a28d-5337f6d0ef20"
      unitRef="U_USD">188790000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_405f634d-f00f-47a7-b76a-7e752f183a91"
      unitRef="U_USD">188885000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="0"
      id="F_0b277c0e-9bdf-4a69-abbf-9c7c2443acde"
      unitRef="U_shares">223145</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="-3"
      id="F_a138133f-fd20-4498-aedd-80383b482761"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_76867a89-e6b3-4ffc-8301-c00a9d31e524"
      unitRef="U_USD">2229000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_07c61760-a56f-4c67-b517-1baff06a8a16"
      unitRef="U_USD">2231000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="0"
      id="F_b2342ab0-27ce-439d-97e5-12a3de586c1a"
      unitRef="U_shares">407999</rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="-3"
      id="F_ef898ab2-c13a-473e-92e2-6ec3c0a59374"
      unitRef="U_USD">4000</rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_51228714-df5f-45d7-bee2-1d3cc9f56197"
      unitRef="U_USD">-4000</rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <rckt:StockIssuedDuringSharesCommonStockWarrantExercised
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="0"
      id="F_74e3fe1a-851b-4489-9d6e-94ed3b143c39"
      unitRef="U_shares">126093</rckt:StockIssuedDuringSharesCommonStockWarrantExercised>
    <rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="-3"
      id="F_44a94317-de54-4fb1-a257-a25368549d38"
      unitRef="U_USD">1000</rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_0934ab05-546a-4427-a4ed-0e2ac0f94170"
      unitRef="U_USD">6000</rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_e2160f12-14a1-422c-9842-7ee3014e90c1"
      unitRef="U_USD">7000</rckt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <rckt:StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="0"
      id="F_aa15753a-87d9-4893-8438-65910cc22a40"
      unitRef="U_shares">948300</rckt:StockIssuedDuringPeriodSharesAtTheMarketOfferingPrograms>
    <rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
      contextRef="C_61ed228c-04b4-492d-9653-316c1c51bb39"
      decimals="-3"
      id="F_8005ae70-0cb4-4339-8ee6-4bb758405abe"
      unitRef="U_USD">10000</rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms>
    <rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_f8da073b-df68-4d04-8aa6-eb7ae303a540"
      unitRef="U_USD">17212000</rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms>
    <rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d4b09172-05f9-427e-be0e-26a42f6fb6bb"
      unitRef="U_USD">17222000</rckt:StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms>
    <rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
      contextRef="C_95348ff1-8262-49b2-97f9-9288584683e3"
      decimals="-3"
      id="F_6f9550c1-62f4-45e9-b37d-26f63f2c7a3c"
      unitRef="U_USD">676000</rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_05651522-ec5d-4378-a2f5-9a00bbc7b885"
      unitRef="U_USD">676000</rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_46f31250-5670-4e2c-961d-6755291c25a1"
      decimals="-3"
      id="F_87e25641-f1ad-4caf-b9c9-be34963f21ce"
      unitRef="U_USD">47000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_05d1d820-c484-4fba-ba2f-5d59c2071449"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_1bc346a4-657b-4220-afae-510ca316b423"
      unitRef="U_USD">56000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5347e5c1-b419-4ff4-ad5e-96291a7f8ac3"
      decimals="-3"
      id="F_c4ddaab3-62bc-41c8-a974-77f4e24334c1"
      unitRef="U_USD">39406000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d61f858b-e56b-4db2-ba5d-de57aa1b19d2"
      unitRef="U_USD">39406000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_053815b6-adc7-4370-b942-f77a4c14f8b7"
      decimals="-3"
      id="F_d4c6021c-6ba4-4328-9662-e48c97f27d58"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_0fbb1786-0137-48b4-aaba-7e1b165521c1"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0ea9594b-03e6-487e-a61a-c1acf9b39205"
      decimals="0"
      id="F_a228f9b3-c09f-4dfd-9294-8264aec6738e"
      unitRef="U_shares">90282267</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0ea9594b-03e6-487e-a61a-c1acf9b39205"
      decimals="-3"
      id="F_810281cb-6b72-45c9-8d3b-65b2bc53dbb5"
      unitRef="U_USD">903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1f827aab-8c58-4267-acb7-76cf53e8db5b"
      decimals="-3"
      id="F_e0ec4bc7-1282-4c14-a77a-27884596d9c5"
      unitRef="U_USD">1450722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c9cbcf73-650e-4bae-b575-14bb681c7fcb"
      decimals="-3"
      id="F_10a229f9-64b0-43ab-b209-45f37453f669"
      unitRef="U_USD">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c3c68b77-90ed-4616-a582-7d53b5f05ebe"
      decimals="-3"
      id="F_796b60da-8cfb-4d18-bf87-01f5c397a76e"
      unitRef="U_USD">-959370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_cddbed12-8009-438e-aeba-caaef0a1e287"
      unitRef="U_USD">492574000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427"
      decimals="0"
      id="F_b4515e27-1256-40cf-9723-3b0e0e88893b"
      unitRef="U_shares">15180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427"
      decimals="-3"
      id="F_7958580e-9337-4a82-9edc-b54ae2dba8b1"
      unitRef="U_USD">152000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2"
      decimals="-3"
      id="F_916d6376-5adc-49e2-ab7e-b5fe06296592"
      unitRef="U_USD">182376000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_f2725c73-d935-4a9f-a324-1eb25bd9efbc"
      unitRef="U_USD">182528000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427"
      decimals="0"
      id="F_7a8ab8a5-e0dc-45be-bf13-315c85882fc5"
      unitRef="U_shares">269080</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427"
      decimals="-3"
      id="F_4c36175a-1820-498f-8ed8-7d80ca8147c5"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2"
      decimals="-3"
      id="F_55279587-bab4-46c8-9765-2f663b8a4925"
      unitRef="U_USD">3208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_3444da97-c2d8-4f81-8312-35b2a0902aac"
      unitRef="U_USD">3211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427"
      decimals="0"
      id="F_81ef9a5c-07b8-4160-a65d-3e734a382bd4"
      unitRef="U_shares">722471</rckt:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="C_74b364e5-c1c4-45b4-9711-2e7d66596427"
      decimals="-3"
      id="F_57338723-659f-4411-a28e-6a4b849a6401"
      unitRef="U_USD">7000</rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2"
      decimals="-3"
      id="F_f5498880-0999-47f5-9f4a-299b6d2ba908"
      unitRef="U_USD">-7000</rckt:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
      contextRef="C_b75d21e1-b615-445e-a851-9927373017c8"
      decimals="-3"
      id="F_88a85eca-e1d2-4d7f-94f1-426612aba76a"
      unitRef="U_USD">-253000</rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_4dd12b83-2240-487c-9766-657bd9a60f48"
      unitRef="U_USD">-253000</rckt:OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_30eee4ca-639d-42b3-9810-aa01632a49b2"
      decimals="-3"
      id="F_cffd1c15-9b4b-429a-8153-dc3573a05de9"
      unitRef="U_USD">43920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_b9d0cc8e-8fc8-4650-88aa-c529cebe51d6"
      unitRef="U_USD">43920000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_2401d799-1468-4c2d-8db7-16420132a1ab"
      decimals="-3"
      id="F_fe0b1f07-bfb0-4301-b5f5-08ce614b5fd1"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_895536d9-de1d-4b1f-8b22-706116e405c1"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4610418f-69ff-4383-8d4b-b7f932f3e7ca"
      decimals="0"
      id="F_9cadd7ce-7f2c-4f7c-add7-294e39a21e95"
      unitRef="U_shares">106453818</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4610418f-69ff-4383-8d4b-b7f932f3e7ca"
      decimals="-3"
      id="F_c18df1ef-12d1-4dfd-97af-6d3641b4a72e"
      unitRef="U_USD">1065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c0a9f08c-83d5-4fde-9bc3-f69654e05e5c"
      decimals="-3"
      id="F_69c05045-91e2-4ca1-aa43-bca593895775"
      unitRef="U_USD">1680219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d6baac6b-72b3-4bad-a3e9-4bd2c34ab5f5"
      decimals="-3"
      id="F_85859f69-1243-4edb-977d-a6d64452720a"
      unitRef="U_USD">66000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f68555a5-2282-4a77-abe9-8ff2dee0202d"
      decimals="-3"
      id="F_a035ce33-fd04-4f1a-9a51-cc7c4629f7d0"
      unitRef="U_USD">-1218116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_fc3e3055-65da-41bf-ab8a-10c8c575fb33"
      unitRef="U_USD">463234000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_0eef2905-01b8-4e8e-a2b3-e813a03d4dae"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_1f0f5b38-ae38-46b6-9eef-d7881e9a499a"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_fc34f49c-f035-4622-b6d1-bab838fb955d"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_b4bc3070-5228-4b08-92fa-f34e980430c3"
      unitRef="U_USD">7221000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_5f842cd0-a08d-47bd-bf85-33084fd5b401"
      unitRef="U_USD">4944000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_b122579e-d872-49ac-8688-506b6ed5756a"
      unitRef="U_USD">3932000</us-gaap:OtherDepreciationAndAmortization>
    <rckt:AdjustmentOfRightOfUseAssets
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_42758cf6-a905-4a1a-9672-9825c7e11c40"
      unitRef="U_USD">2154000</rckt:AdjustmentOfRightOfUseAssets>
    <rckt:AdjustmentOfRightOfUseAssets
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_2444005f-6093-4c22-992f-eeb069dc1675"
      unitRef="U_USD">2154000</rckt:AdjustmentOfRightOfUseAssets>
    <rckt:AdjustmentOfRightOfUseAssets
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_5b7ae06b-7e7c-4636-9dce-a70598c31e6e"
      unitRef="U_USD">2334000</rckt:AdjustmentOfRightOfUseAssets>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_ac5e9a3f-d77d-445e-844e-8423cba642bc"
      unitRef="U_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_bfeddd31-b689-4d90-add7-ea146ec77307"
      unitRef="U_USD">574000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_6210009e-8ae5-409e-b230-673f8c7896d8"
      unitRef="U_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <rckt:PropertyPlantAndEquipmentWriteDown
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7f838ae9-96a0-4de9-b355-5fc649723c54"
      unitRef="U_USD">0</rckt:PropertyPlantAndEquipmentWriteDown>
    <rckt:PropertyPlantAndEquipmentWriteDown
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_55cd6be5-0c81-45ea-8b82-98bb67accd7c"
      unitRef="U_USD">311000</rckt:PropertyPlantAndEquipmentWriteDown>
    <rckt:PropertyPlantAndEquipmentWriteDown
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_0233c7ae-1542-4352-8a0a-d46883ad0ba3"
      unitRef="U_USD">236000</rckt:PropertyPlantAndEquipmentWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e82682e5-b250-46e9-84b4-589f73ae4fc9"
      unitRef="U_USD">43920000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_a85937ed-9035-4fae-8fbc-a081e57dccbb"
      unitRef="U_USD">39406000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_fe5481ed-3c54-479a-be23-9302b8b670a1"
      unitRef="U_USD">31009000</us-gaap:ShareBasedCompensation>
    <rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_fd190fbd-7036-4406-b855-0b3061017a93"
      unitRef="U_USD">8068000</rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments>
    <rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_4335d8b1-efb9-4c04-8d7a-27e8e6a0f0fe"
      unitRef="U_USD">10168000</rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments>
    <rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_739cf89d-7c96-44a4-86b8-b25e02a4caaf"
      unitRef="U_USD">-134000</rckt:AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_82fb787d-1827-4742-8e98-30a4aa8f0434"
      unitRef="U_USD">1876000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_c01acbf4-6c4d-420d-9e4e-08ae29d7c392"
      unitRef="U_USD">-364000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_759d787f-0155-4f19-8c50-7a521d4951f8"
      unitRef="U_USD">661000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_0800ca1b-4a05-44f3-bf5a-7003aa06b384"
      unitRef="U_USD">-2694000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_10dc9bea-8c52-4588-8fd6-86fa4adefc12"
      unitRef="U_USD">3593000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7bb44ce3-4712-48c1-902e-c3f797d85d8a"
      unitRef="U_USD">6067000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_efb3ebb2-74af-4655-9fe9-45dd0e667bd9"
      unitRef="U_USD">10147000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_a0fd32d1-aa35-4756-8f75-a42f2ddcfb9d"
      unitRef="U_USD">9674000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_430a6c17-6091-4e8b-839c-7d67dcb5a7a9"
      unitRef="U_USD">89000</rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet>
    <rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_8aa22c77-80f0-433d-acbe-6cd59609afcb"
      unitRef="U_USD">137000</rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet>
    <rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_2ad5a55c-fb31-4289-ba96-025b93d5f55b"
      unitRef="U_USD">-120000</rckt:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet>
    <rckt:IncreaseDecreaseInFinanceLeaseLiabilities
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_2e48f85f-254c-45fd-88bd-feb6b25b5c17"
      unitRef="U_USD">95000</rckt:IncreaseDecreaseInFinanceLeaseLiabilities>
    <rckt:IncreaseDecreaseInFinanceLeaseLiabilities
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_e09d5dc9-f114-4f77-9b8c-5b2c57785335"
      unitRef="U_USD">139000</rckt:IncreaseDecreaseInFinanceLeaseLiabilities>
    <rckt:IncreaseDecreaseInFinanceLeaseLiabilities
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_4461df21-15b8-44a2-bd8d-68ee677d1e1b"
      unitRef="U_USD">172000</rckt:IncreaseDecreaseInFinanceLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_ae7a0729-9d6b-4cb2-a67e-9ad8e3e5a9b4"
      unitRef="U_USD">-3671000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_8eff91db-5000-4a59-91b9-9a3c46df16db"
      unitRef="U_USD">705000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_c63d5da2-720d-4033-a840-dba7f3393f3d"
      unitRef="U_USD">-57000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_0cdcca1d-405f-49ed-8b56-b13b5ee99403"
      unitRef="U_USD">-209724000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_361f857b-027a-4bed-aef8-37a12a75e6a1"
      unitRef="U_USD">-194916000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_1e51d61c-44b2-4dd4-abbd-aacf5f5d1186"
      unitRef="U_USD">-178142000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_54e1dbec-f61d-4daa-8879-de82843caafe"
      unitRef="U_USD">245886000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_857d82ec-e147-4c09-8477-0a7536e0cf22"
      unitRef="U_USD">390920000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_32b7bd80-abb5-4338-bc56-d8b973a23097"
      unitRef="U_USD">376327000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_ef9a7782-52ff-4737-8c91-6d0b260484c8"
      unitRef="U_USD">383454000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d44e2698-95cb-4a2d-98c9-b06e9c5b5461"
      unitRef="U_USD">309326000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_f26502fb-63ad-4a56-a833-fa12da9a9ad6"
      unitRef="U_USD">272894000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_1663eac9-53e4-42e0-a68b-0fc21b5fb476"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_83b451d1-44a6-4e97-9963-9731b9b0ccb9"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_b6eea194-1171-4880-a57e-f4b2963dc04f"
      unitRef="U_USD">42726000</us-gaap:CashAcquiredFromAcquisition>
    <rckt:PaymentsToAcquireRightOfUseAsset
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e5381ba4-88e3-4b5f-8607-05a99da2e977"
      unitRef="U_USD">0</rckt:PaymentsToAcquireRightOfUseAsset>
    <rckt:PaymentsToAcquireRightOfUseAsset
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_6c0e532e-8a92-4c04-aaf3-71cc2460c4f1"
      unitRef="U_USD">36000</rckt:PaymentsToAcquireRightOfUseAsset>
    <rckt:PaymentsToAcquireRightOfUseAsset
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_c1d6a2d1-2758-49b1-8050-eb22e6cd43f4"
      unitRef="U_USD">261000</rckt:PaymentsToAcquireRightOfUseAsset>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_f4ae7f50-08b3-404d-93b7-66ff4d6bd2ec"
      unitRef="U_USD">5862000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_e3e1ca6d-e9b1-4631-8cb3-69629d9858c1"
      unitRef="U_USD">16436000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_fff3ccae-f98f-4df3-a7f5-cade43912842"
      unitRef="U_USD">8358000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_b3c1e85b-3df4-4c75-8b44-bbb6c5dd49b7"
      unitRef="U_USD">131706000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_e7a81177-c3c8-41ee-b603-0ac806c5ded4"
      unitRef="U_USD">-98066000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_7ae2ac65-cc94-4bcc-b65a-44769ffb78ba"
      unitRef="U_USD">-69326000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8248820b-9b6e-4904-9222-9f0abb8fa0d0"
      decimals="-3"
      id="F_21d6868b-d25c-4364-9ea9-eeec318383fc"
      unitRef="U_USD">182528000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_81130365-ff4b-4a54-b76d-5c0eadb8eb25"
      decimals="-3"
      id="F_e68e43aa-7dea-4385-a657-12176e6a0ac5"
      unitRef="U_USD">188885000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_25bb15f2-0efc-482c-a2c6-da231c955822"
      decimals="-3"
      id="F_efc0e7d9-adf0-4aa9-85e9-444bba68c889"
      unitRef="U_USD">108138000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_8c62eb6b-b857-4807-8ea1-e71167a9a6e4"
      unitRef="U_USD">3211000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_90ecbf95-1480-4cb9-8b14-a8dcb0abebca"
      unitRef="U_USD">2231000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_f739f78d-b4b0-4e68-b66a-ecfe4de2b5e8"
      unitRef="U_USD">631000</us-gaap:ProceedsFromStockOptionsExercised>
    <rckt:PaymentsForRepurchaseTreasuryStock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_b40bab02-0b8d-4e85-a981-702ebb7b674d"
      unitRef="U_USD">0</rckt:PaymentsForRepurchaseTreasuryStock>
    <rckt:PaymentsForRepurchaseTreasuryStock
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_b9b022d2-d523-4817-bd09-96a512a997b2"
      unitRef="U_USD">0</rckt:PaymentsForRepurchaseTreasuryStock>
    <rckt:PaymentsForRepurchaseTreasuryStock
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_1e642702-ac6e-4588-a4bb-96118cd45a43"
      unitRef="U_USD">47000</rckt:PaymentsForRepurchaseTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_6aebad3c-6055-4f90-9289-500fbb30a66f"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_25bf31d4-9937-4af1-a5f9-4de81a1a4328"
      unitRef="U_USD">56000</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_ca82feba-6662-4cb4-8569-fe5dc97e442a"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e289c72e-5a2f-4c23-8a80-507c89a70c8e"
      decimals="-3"
      id="F_28a39841-1ef7-42c7-b31c-7e27465d4077"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-3"
      id="F_3c9b74d5-e36f-429d-a4bd-cb9b6d30da46"
      unitRef="U_USD">17222000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a7d9a7dd-fff1-4380-9e5f-b878d0a03f2b"
      decimals="-3"
      id="F_da80f227-645f-4126-97de-471361705abb"
      unitRef="U_USD">46566000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_ebd21725-55c3-4afc-a0ec-6f4060486a60"
      unitRef="U_USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_b9ea2646-605c-4050-9387-0498eefa0e1b"
      unitRef="U_USD">7000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_2c1bfd75-7a95-4bbf-a146-ea4a0942ae05"
      unitRef="U_USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_25865acf-2a7b-4787-93d9-f25eba6206f0"
      unitRef="U_USD">185739000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_fa794b92-b690-4b30-9a9b-aa331e1b74ae"
      unitRef="U_USD">208401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_64a3df9e-fbce-4773-8157-1e6623be14a5"
      unitRef="U_USD">155288000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_47555fbd-2e57-444d-89b1-aedcbb238bd5"
      unitRef="U_USD">107721000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_13dd2da2-d141-427c-ac4f-a8792c61f7e3"
      unitRef="U_USD">-84581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_20e483a0-8648-42d5-9795-312184c8aaf8"
      unitRef="U_USD">-92180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_6ca62b47-db58-4468-b0c2-ce29d159ec29"
      unitRef="U_USD">57276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_bbd65eeb-3804-4614-9f63-8b1c5c771b9b"
      unitRef="U_USD">141857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5989dbfe-68f5-4cf2-a1c3-bf34d6bb1801"
      decimals="-3"
      id="F_9733d198-441a-4371-bd0b-df6ec50481db"
      unitRef="U_USD">234037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_ec42e24c-8607-4406-b48e-70abc121d781"
      unitRef="U_USD">164997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_546d9a41-41a1-470d-99c5-3cc86791cb3b"
      unitRef="U_USD">57276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_0e15d5b6-7c89-4610-805d-1f49e487df6d"
      unitRef="U_USD">141857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e4ae6074-27f1-4a76-9a59-32af0bcd720b"
      unitRef="U_USD">185000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_b29a5cff-d426-4640-bebc-b8516e07e498"
      unitRef="U_USD">1077000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_f64f9914-feec-4b08-9769-6b862f4e93fa"
      unitRef="U_USD">2095000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_dcb01ab6-0c0a-44ce-97f7-d10ed3882fb8"
      unitRef="U_USD">135000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_e4ecf003-8be1-488b-ab26-8c8a2daab1db"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_b7850730-da5e-4c3a-a496-023139137469"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <rckt:NonCashOperatingLeaseLiability
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_6265c391-c8f6-4324-8b79-a23ebd75b5ce"
      unitRef="U_USD">1134000</rckt:NonCashOperatingLeaseLiability>
    <rckt:NonCashOperatingLeaseLiability
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_8a8477f3-b997-4fc7-b2b4-831c5ebfca78"
      unitRef="U_USD">2929000</rckt:NonCashOperatingLeaseLiability>
    <rckt:NonCashOperatingLeaseLiability
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_75ece17b-63b1-4c41-a550-3b5092e75cac"
      unitRef="U_USD">0</rckt:NonCashOperatingLeaseLiability>
    <rckt:NonCashOperatingLeaseRightOfUseAssets
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_fbd34ddf-043d-4761-b1ee-a17852584e5e"
      unitRef="U_USD">1134000</rckt:NonCashOperatingLeaseRightOfUseAssets>
    <rckt:NonCashOperatingLeaseRightOfUseAssets
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_7374f306-ae56-4955-8ed3-79a635429e56"
      unitRef="U_USD">2958000</rckt:NonCashOperatingLeaseRightOfUseAssets>
    <rckt:NonCashOperatingLeaseRightOfUseAssets
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_5f859d59-6b97-4e69-aaac-03b0cfb584a3"
      unitRef="U_USD">0</rckt:NonCashOperatingLeaseRightOfUseAssets>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_79ac9655-06dc-4d5e-940d-90290600f15e"
      unitRef="U_USD">-253000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_8b424849-9d93-491f-8d4c-e4101335fb66"
      unitRef="U_USD">676000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_2a80af70-0fa8-4f28-9a29-83f21a088dcd"
      unitRef="U_USD">-196000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_0fd76f69-eaa8-427a-9d19-1596bd484e06"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_0fd9b3cd-7c01-422d-b3b7-a1f1f16a93d8"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_89632d08-91ac-46df-a070-adb3636c9148"
      unitRef="U_USD">70724000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7f95108e-80ec-45e9-ae2b-508ecd58d9c1"
      unitRef="U_USD">0</rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset>
    <rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_dd567073-629a-4925-9335-5d7d0bd92a4d"
      unitRef="U_USD">0</rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset>
    <rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_55802080-5aa7-41ec-b41d-09badc325a20"
      unitRef="U_USD">261000</rckt:ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_846fcb70-bf5d-42ed-ba65-b4f31d360cad">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nature of Business and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; clinical stage and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-clinical stage &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; adeno-associated viral (AAV) programs in the U.S., which include programs for:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The DD program is currently in an ongoing Phase 2 trial (RP-A501);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601); and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. The Company utilizes recombinant adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to slow or halt progression of BAG3-DCM.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the Company announced its alignment with the FDA on its pivotal study design for RP-A501 in Danon Disease. Completion of enrollment in this study was announced in September 2024, and dosing and follow-up are ongoing. The Company has received FDA clearance of an investigational new drug (IND) application for RP-A601, and has initiated a Phase 1 study for this program. For the BAG3 program, nonclinical and IND enabling studies are ongoing. Submission of the IND is anticipated in the first half of 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; clinical-stage ex vivo &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lentiviral (LV) programs, which include programs for:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) and granted priority review for RP-L201 for the treatment of severe LAD-I. In June 2024, the Company announced that the FDA had issued a CRL in response to the BLA wherein the FDA requested limited additional CMC information to complete its review. Submission of complete BLA to resolve Complete Response Letter anticipated in 2025. With respect to RP-L201, treatments in the FA Phase 2 studies were completed in 2023 and submission of a BLA on a rolling review basis was initiated in September 2024. In April 2024, the European Medicines Agency (EMA) accepted our Marketing Authorization Applications (MAA) for RP-L102. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. With respect to RP-L301, the Company has reached agreement with the FDA on the study design of the Phase 2 pivotal trial for RP-L301, our ex vivo LV-based program targeting PKD. While the Phase 2 RP-L301 study is ready for patient enrollment, the Company is currently focusing our resources on other programs and have not initiated enrollment in the Phase 2 RP-L301 study.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has global commercialization and development rights to all of these product candidates under royalty-bearing license agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <rckt:NumberOfClinicalStagePrograms
      contextRef="C_479a9661-05cc-4e37-ac7c-06504e617691"
      decimals="INF"
      id="F_c26c7b1e-322a-4ba5-9f7c-5de8e7a430c4"
      unitRef="U_Program">2</rckt:NumberOfClinicalStagePrograms>
    <rckt:NumberOfPreClinicalStagePrograms
      contextRef="C_479a9661-05cc-4e37-ac7c-06504e617691"
      decimals="INF"
      id="F_c7ea95ba-3a5c-4c1e-ad3e-9b4856a241db"
      unitRef="U_Program">1</rckt:NumberOfPreClinicalStagePrograms>
    <rckt:NumberOfClinicalStagePrograms
      contextRef="C_5d1d40da-cfd2-4824-a96b-b4971b74b346"
      decimals="INF"
      id="F_d612c735-bb24-48ca-b897-8414bc665954"
      unitRef="U_Program">3</rckt:NumberOfClinicalStagePrograms>
    <rckt:RisksAndLiquidityTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_61da8605-0af8-417c-9ab0-8ce3641eee70">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risks and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development, technological uncertainty, uncertainty regarding patents and proprietary rights, having no commercial manufacturing experience, marketing or sales capability or experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s product candidates are in the development and clinical stage. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion as of December 31, 2024. As of December 31, 2024, the Company has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;372.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash, cash equivalents, and investments. The Company expects such resources will be sufficient to fund the Company&#x2019;s operating expenses and capital expenditure requirements into the third quarter of 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 28, 2022, the Company entered into a sales agreement (&#x201c;the Sales Agreement&#x201d;) with Cowen  with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million through Cowen as its sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to the Company. The Company may consider reactivating the at-the-market offering program in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Through December 31, 2024, the Company has sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million pursuant to the at-the-market offering program (see Note 8 &#x201c;Stockholders&#x2019; Equity&#x201d;). The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares under the at-the-market offering program for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, less commissions of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 12, 2024, the Company completed the Offering of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and Private Placement of pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant. The gross proceeds from the Offering and Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(see Note 8 &#x201c;Stockholder&#x2019;s Equity&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the longer term, the future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company&#x2019;s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.&lt;/span&gt;&lt;/p&gt;</rckt:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-7"
      id="F_c71f63a3-5da5-4f9c-96b4-349d39029ced"
      unitRef="U_USD">-1220000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-5"
      id="F_846e3175-57dc-438c-b617-82c31f18beb1"
      unitRef="U_USD">372300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a1502da7-9920-4457-8a72-b7448a4ac6aa"
      decimals="INF"
      id="F_08ce0be6-46e2-4535-9102-bc7c448eae47"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <rckt:SaleOfStockAggregateOfferingPrice
      contextRef="C_39d4c570-76ba-4c52-80e3-dde4aa7b4c66"
      decimals="-6"
      id="F_0d1a96fa-2802-436c-9731-834f8a456050"
      unitRef="U_USD">200000000</rckt:SaleOfStockAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c"
      decimals="-5"
      id="F_31de9a02-1197-46a7-861b-7ff5ac44269e"
      unitRef="U_shares">4200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6f626844-ba06-4567-931e-02c5cb0a1650"
      decimals="-5"
      id="F_6a027eb7-0c9a-4187-8bef-09ed4ad9ab0c"
      unitRef="U_USD">63800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e289c72e-5a2f-4c23-8a80-507c89a70c8e"
      decimals="0"
      id="F_9bbcbeaa-de46-4fbe-bcc2-3e980fcde1dc"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_7b1baab8-686f-40b4-85db-ea539a622c11"
      unitRef="U_shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rckt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_b4bf333f-f53e-4d4d-92c4-2c262367ef64"
      unitRef="U_USD">17800000</rckt:GrossProceedsFromIssuanceOfCommonStock>
    <rckt:StockIssuedIssuanceCosts
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_a4b03894-b162-447c-b6f6-0a7b639dfd08"
      unitRef="U_USD">600000</rckt:StockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_f5015ee7-ff9d-463d-8236-8f4579eeebd1"
      unitRef="U_USD">17200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_abe62c65-86b2-4c28-a166-de2d40714fe1"
      decimals="-5"
      id="F_d003e0ae-dfce-42e4-99dc-bde1c3606bd2"
      unitRef="U_shares">15200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_b7504ddd-7215-4a12-a2a7-05b47998068b"
      decimals="2"
      id="F_50397ede-c048-4a15-a79e-c23b78de3567"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.5</us-gaap:SaleOfStockPricePerShare>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_69408d2a-0545-4d3a-a4f7-3c54eb9825f9"
      decimals="-5"
      id="F_0bfabda7-38ad-4a6d-be73-0b5088227bd3"
      unitRef="U_shares">400000</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3abe252d-55ed-4732-a04d-1b253a82ba3b"
      decimals="INF"
      id="F_124ab93a-d303-42a1-bd3d-3a3e8faf1ff3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rckt:GrossProceedsFromSaleOfStock
      contextRef="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8"
      decimals="-5"
      id="F_7c911a5c-4494-4721-8a00-77e744cb787f"
      unitRef="U_USD">194700000</rckt:GrossProceedsFromSaleOfStock>
    <rckt:SharesIssuanceCost
      contextRef="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8"
      decimals="-5"
      id="F_7f37505d-09c3-4260-8702-94b5eeb5d005"
      unitRef="U_USD">12200000</rckt:SharesIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_2bddede3-4d9a-429c-b61d-ec77f97dc9a8"
      decimals="-5"
      id="F_62fdb304-3b5d-4a12-ad0c-11ba3fac072d"
      unitRef="U_USD">182500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ea7350b9-b776-40dd-8afc-7c8ca82d064e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with U.S. GAAP&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. All intercompany accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of R&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;expenses, the valuation of equity transactions, and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company&#x2019;s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#x2019;s operating leases (see Note &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13 &#x201c;Leases&#x201d; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#x2019;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:65.633%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:15.183%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:15.183%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:403.95pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;	&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expense was presented net of reimbursements from CIRM (See Note 16 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CIRM Grant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for additional disclosure).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of credit risk and off-balance sheet risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#x2019;s marketable securities consist of U.S. Treasury Securities, and Corporate Bonds. The Company&#x2019;s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AA-/Aa3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rated, thereby reducing credit risk exposure.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments consist of U.S. Treasury Securities and Corporate Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to ASC 320, Investments&#x2014;Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company&#x2019;s Consolidated Statement of Operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; realized gains or losses on investments for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022. For the years ended December 31, 2024,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2023 and 2022, there were net unrealized loss on investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net unrealized gains on investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and net unrealized loss on investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets consisted of an indefinite lived intangible IPR&amp;amp;D asset and a mice colony model. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&amp;amp;D intangible assets which are determined to have had a decrease&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in their fair value are adjusted downward and an expense is recognized in R&amp;amp;D expenses in the Consolidated Statements of Operations. These IPR&amp;amp;D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&amp;amp;D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. If a triggering event occurs that would indicate a potential impairment, the Company will perform a quantitative analysis to determine whether it is more likely than not that the fair value is below carrying amount. The annual impairment assessment for the IPR&amp;amp;D asset was performed as of December 1. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment of the IPR&amp;amp;D asset was recorded for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded an impairment of the&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; intangible long-lived asset &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;related to the mice colony model of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Business combinations are accounted for under the acquisition method. The total cost of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, asset lives and market multiples, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reporting unit and as such review&#x2019;s goodwill for impairment at the consolidated level. When testing goodwill, the Company has the option to first assess qualitative factors for reporting units that carry goodwill. The qualitative assessment includes assessing the totality of relevant events and circumstances that affect the fair value or carrying value of the reporting unit. These events and circumstances include macroeconomic conditions, industry and competitive environment conditions, overall financial performance, reporting unit specific events and market considerations. The Company also considers recent valuations of the reporting unit, including the magnitude of the difference between the most recent fair value estimate and the carrying value, as well as both positive and adverse events and circumstances, and the extent to which each of the events and circumstances identified may affect the comparison of a reporting unit&#x2019;s fair value with its carrying value. If the qualitative assessment results in a conclusion that it is more likely than not that the fair value of a reporting unit exceeds the carrying value, then no further testing is performed for that reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company performed the qualitative assessment of its goodwill and determined that it is more likely than not that the fair value of a reporting unit exceeds the carrying value of the reporting unit. As a result, the Company has determined there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; goodwill impairment as of and for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful lives of the asset which are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;fifteen years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company capitalizes purchases of laboratory equipment, machinery and equipment, furniture and fixtures and leasehold improvements in relation to the facility at Cranbury, New Jersey, since it has been determined these assets have alternative future uses to the Company. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. Costs incurred in connection with development or purchase of internal use software and cloud computing arrangements, including in-substance software licenses, are capitalized. Amortization is computed on a straight-line basis over the estimated useful life of the asset, which is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Capitalized software is included in property and equipment in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. The Company conducted its impairment analyses of long-lived assets to be held and used in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.  The Company also recorded write downs of property and equipment in each of the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 - Valuations that require inputs that reflect the Company&#x2019;s own assumptions that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company&#x2019;s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity and/or ASC Topic 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company&#x2019;s Consolidated Statements of Operations. Warrants classified as equity instruments are recorded within additional paid-in capital at the time of issuance and not subject to remeasurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D expenses, which include salaries and staff costs, license costs, manufacturing and development costs, clinical trial expenses, depreciation and amortization expenses, regulatory and scientific consulting fees, as well as contract research, and stock-based compensation expense, are accounted for in accordance with ASC Topic 730, Research and Development. Accordingly, R&amp;amp;D costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain foreign currency transactions during the years ended December 31, 2024, 2023 and 2022 were primarily denominated in Euros and British pounds. Gains and losses on foreign currency transactions were not significant for the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records treasury stock at cost.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issues stock-based awards to employees and non-employees, generally in the form of stock options, RSUs, and PSUs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. The cost of stock options and RSUs is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The vesting condition for PSUs is performance based and the cost of a PSU is recognized when it is likely that the performance goal associated with the PSU will be achieved and the award will vest.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as expected volatility and expected term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its Consolidated Statements of Operations in the same manner in which the award recipient&#x2019;s payroll costs and services are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet differences. In accordance with ASC 740, Income Taxes, the Company recorded a full valuation allowance to fully offset the net deferred tax asset because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates net loss per share in accordance with ASC 260, Earnings per Share. Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Warrants that meet the definition of equity classification and that requires the holder to pay little or no consideration to receive shares upon exercise are considered outstanding in the context of basic earnings per share. Diluted net loss attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, outstanding options are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment. The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e4e33013-0944-4e5f-ae6a-24eab71a59cf;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the senior leadership team. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM manages the Company&#x2019;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Included in these expenses are R&amp;amp;D expenses by program.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources and consists of net loss and changes in unrealized gains and losses on investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company&#x2019;s Consolidated Balance Sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company&#x2019;s lease agreements contain renewal options&#x37e;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company&#x2019;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company&#x2019;s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company&#x2019;s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Pronouncements Not Adopted as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-09: Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This update standardized categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update was effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the effect that ASU 2023-09 will have on its financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2024-03: Expense Disaggregation Disclosures. This update requires disaggregated disclosure of income statement expenses. This update is effective for the Company for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the effect that ASU 2024-03 will have on its financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Pronouncements Adopted as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update was effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The adoption of ASU 2023-07 resulted in a new footnote disclosure for Segment Reporting.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_432aaf86-0f7f-45fa-aa99-92a59ecbfff9">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with U.S. GAAP&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. All intercompany accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_517e2007-9033-4c9f-92c6-ba9f5882790e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of R&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;expenses, the valuation of equity transactions, and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_314c077c-c6c5-4a39-8bee-442f501e61cc">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company&#x2019;s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#x2019;s operating leases (see Note &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13 &#x201c;Leases&#x201d; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#x2019;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:65.633%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:15.183%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:15.183%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <rckt:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_5bb08086-29a2-4113-bdf0-70db0eba2eb1">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company&#x2019;s operating leases (see Note &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13 &#x201c;Leases&#x201d; for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company&#x2019;s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:65.633%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:15.183%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:15.183%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</rckt:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_79f46501-a359-4575-814e-2a0a804ec480"
      unitRef="U_USD">163635000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_71d985a2-39ff-4523-a52d-bf994cfba6e8"
      unitRef="U_USD">55904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_516ccdb5-7587-4673-9c6b-45d0f10575e3"
      unitRef="U_USD">1362000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_9507a363-61f3-46d3-bf2b-66b6e46c6786"
      unitRef="U_USD">1372000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_a9c95b8c-94eb-43be-94ee-125f54a6801a"
      unitRef="U_USD">164997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_7a1c657a-a84d-4d94-b96d-5a22ecf2b2ea"
      unitRef="U_USD">57276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <rckt:GovernmentGrantsPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_b3b57f01-f704-4bab-adee-1b8cd62ac141">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expense was presented net of reimbursements from CIRM (See Note 16 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CIRM Grant&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for additional disclosure).&lt;/span&gt;&lt;/p&gt;</rckt:GovernmentGrantsPolicyTextBlock>
    <rckt:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ea593b77-55bd-49e4-9e66-82420bfd0ce0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of credit risk and off-balance sheet risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company&#x2019;s marketable securities consist of U.S. Treasury Securities, and Corporate Bonds. The Company&#x2019;s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;AA-/Aa3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rated, thereby reducing credit risk exposure.&lt;/span&gt;&lt;/p&gt;</rckt:ConcentrationsOfCreditRiskAndOffBalanceSheetRiskPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_2c0b41c5-3729-4c75-80e4-95fb16ba2be2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments consist of U.S. Treasury Securities and Corporate Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to ASC 320, Investments&#x2014;Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company&#x2019;s Consolidated Statement of Operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; realized gains or losses on investments for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022. For the years ended December 31, 2024,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2023 and 2022, there were net unrealized loss on investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net unrealized gains on investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and net unrealized loss on investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_bb44dc7c-8a44-42cf-b483-3bcd0fe566bf"
      unitRef="U_USD">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="INF"
      id="F_f50521ca-7d30-4804-85fb-2d0b15be9917"
      unitRef="U_USD">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="INF"
      id="F_0fedd2d9-5dba-4f8f-8250-46e543dc5ef3"
      unitRef="U_USD">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-5"
      id="F_5aaa599e-0aea-4409-bd12-29ff61e40627"
      unitRef="U_USD">-300000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-5"
      id="F_52425483-8a18-45c8-a2de-69fe67d66403"
      unitRef="U_USD">700000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-5"
      id="F_b03c4dc7-1d20-4e6a-aa33-d60b50b6185b"
      unitRef="U_USD">-200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_c4fc7d47-9874-4af9-b1e5-290cbe58eb19">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets consisted of an indefinite lived intangible IPR&amp;amp;D asset and a mice colony model. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&amp;amp;D intangible assets which are determined to have had a decrease&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in their fair value are adjusted downward and an expense is recognized in R&amp;amp;D expenses in the Consolidated Statements of Operations. These IPR&amp;amp;D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&amp;amp;D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets. If a triggering event occurs that would indicate a potential impairment, the Company will perform a quantitative analysis to determine whether it is more likely than not that the fair value is below carrying amount. The annual impairment assessment for the IPR&amp;amp;D asset was performed as of December 1. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment of the IPR&amp;amp;D asset was recorded for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded an impairment of the&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6aa581d7-59ac-4bd5-8060-d2e9b5d2c3ef;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; intangible long-lived asset &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;related to the mice colony model of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_4cc5a08c-63d7-46f3-a258-faf597ff6e6c"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="INF"
      id="F_4345ba6f-c1e0-41c9-9985-14b27deda8b7"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-5"
      id="F_769e2ecc-97c0-4cd8-a681-61c50b7eb123"
      unitRef="U_USD">600000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e11f1a60-7aff-43f6-b019-179865f62041">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Business combinations are accounted for under the acquisition method. The total cost of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, asset lives and market multiples, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill is tested for impairment annually as of December 31, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reporting unit and as such review&#x2019;s goodwill for impairment at the consolidated level. When testing goodwill, the Company has the option to first assess qualitative factors for reporting units that carry goodwill. The qualitative assessment includes assessing the totality of relevant events and circumstances that affect the fair value or carrying value of the reporting unit. These events and circumstances include macroeconomic conditions, industry and competitive environment conditions, overall financial performance, reporting unit specific events and market considerations. The Company also considers recent valuations of the reporting unit, including the magnitude of the difference between the most recent fair value estimate and the carrying value, as well as both positive and adverse events and circumstances, and the extent to which each of the events and circumstances identified may affect the comparison of a reporting unit&#x2019;s fair value with its carrying value. If the qualitative assessment results in a conclusion that it is more likely than not that the fair value of a reporting unit exceeds the carrying value, then no further testing is performed for that reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company performed the qualitative assessment of its goodwill and determined that it is more likely than not that the fair value of a reporting unit exceeds the carrying value of the reporting unit. As a result, the Company has determined there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; goodwill impairment as of and for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_546a459d-d911-4740-8d24-f8be78c16cd8"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_17db49ed-b127-494b-a0c9-fabf2d9d8763"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e9a6e43e-61f3-4e42-9581-ab023265fd01"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d8dff593-a267-4821-adf4-4066e7424daf"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_bdc135a4-00f3-44c8-8887-89ec09239a9b"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e40884d1-38e3-4fe1-9a51-0525cd63aaf0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful lives of the asset which are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1947ba28-26d0-4b7e-861f-d6a5ae9e4323;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;fifteen years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company capitalizes purchases of laboratory equipment, machinery and equipment, furniture and fixtures and leasehold improvements in relation to the facility at Cranbury, New Jersey, since it has been determined these assets have alternative future uses to the Company. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. Costs incurred in connection with development or purchase of internal use software and cloud computing arrangements, including in-substance software licenses, are capitalized. Amortization is computed on a straight-line basis over the estimated useful life of the asset, which is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Capitalized software is included in property and equipment in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_65579abf-153c-44b1-82d0-fd8168b17b2d"
      id="F_0694d6e1-d557-4d2f-9915-e0723669ef60">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4"
      id="F_c6350954-56e9-42cb-a2bf-0b8deb1cb4b7">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_17873ccb-cba9-4667-8606-db7fc5b10abf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. The Company conducted its impairment analyses of long-lived assets to be held and used in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. ASC 360-10-15 requires the Company to group assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities and evaluate the asset group against the sum of the undiscounted future cash flows. If the undiscounted cash flows do not indicate the carrying amount of the asset is recoverable, an impairment charge is measured as the amount by which the carrying amount of the asset group exceeds its fair value based on discounted cash flow analysis or appraisals.  The Company also recorded write downs of property and equipment in each of the years ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ac6df31e-6a76-4925-9d6d-a1076032d795">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 - Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 - Valuations that require inputs that reflect the Company&#x2019;s own assumptions that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company&#x2019;s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ae6b0738-7067-4637-a87b-b0aaf765095a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity and/or ASC Topic 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company&#x2019;s Consolidated Statements of Operations. Warrants classified as equity instruments are recorded within additional paid-in capital at the time of issuance and not subject to remeasurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_d424b1e1-79a8-4db2-b213-956236221aca">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D expenses, which include salaries and staff costs, license costs, manufacturing and development costs, clinical trial expenses, depreciation and amortization expenses, regulatory and scientific consulting fees, as well as contract research, and stock-based compensation expense, are accounted for in accordance with ASC Topic 730, Research and Development. Accordingly, R&amp;amp;D costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_847080ca-ffb9-41d2-9449-169b446d3bf8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain foreign currency transactions during the years ended December 31, 2024, 2023 and 2022 were primarily denominated in Euros and British pounds. Gains and losses on foreign currency transactions were not significant for the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <rckt:TreasuryStockPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_3e437bb2-8ff2-425c-bdfb-d8a975d890b0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records treasury stock at cost.&lt;/span&gt;&lt;/p&gt;</rckt:TreasuryStockPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_6e163df6-4f41-4b29-92db-8286f408c73d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issues stock-based awards to employees and non-employees, generally in the form of stock options, RSUs, and PSUs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. The cost of stock options and RSUs is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur. The vesting condition for PSUs is performance based and the cost of a PSU is recognized when it is likely that the performance goal associated with the PSU will be achieved and the award will vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as expected volatility and expected term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its Consolidated Statements of Operations in the same manner in which the award recipient&#x2019;s payroll costs and services are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_f6c9a1fe-82c1-4483-8c75-681cd6c967ee">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method. The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. The Company measures deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the Company expects to recover or settle those temporary differences. The Company recognizes the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet differences. In accordance with ASC 740, Income Taxes, the Company recorded a full valuation allowance to fully offset the net deferred tax asset because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_2d289cb8-396e-48e8-a47e-f0832fc22af0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates net loss per share in accordance with ASC 260, Earnings per Share. Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Warrants that meet the definition of equity classification and that requires the holder to pay little or no consideration to receive shares upon exercise are considered outstanding in the context of basic earnings per share. Diluted net loss attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, outstanding options are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_87629888-3be2-480b-a9ed-d339f77a5cef">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment. The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e4e33013-0944-4e5f-ae6a-24eab71a59cf;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the senior leadership team. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM manages the Company&#x2019;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Included in these expenses are R&amp;amp;D expenses by program.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_86d09636-9f2f-4276-9186-0467bcc8836b"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_6e9b8c7e-d69c-4398-8ee2-51b60f066351">The CODM manages the Company&#x2019;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4d4a8f8a-7c30-40c4-bb2e-72ef7810d0ef">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances from non-owner sources and consists of net loss and changes in unrealized gains and losses on investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_c33bf18e-185f-42ff-84c8-007279746032">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company&#x2019;s Consolidated Balance Sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company&#x2019;s lease agreements contain renewal options&#x37e;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company&#x2019;s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company&#x2019;s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company&#x2019;s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_10d736da-8224-4483-a5e5-5f1aeb329898">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Pronouncements Not Adopted as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-09: Income Taxes Topic 740 - Improvements to Income Tax Disclosures. This update standardized categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update was effective for the Company for fiscal periods beginning after December 15, 2024. The Company is evaluating the effect that ASU 2023-09 will have on its financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2024-03: Expense Disaggregation Disclosures. This update requires disaggregated disclosure of income statement expenses. This update is effective for the Company for fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the effect that ASU 2024-03 will have on its financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounting Pronouncements Adopted as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07: Segment Reporting Topic 280 - Improvements to Reportable Segment Disclosures. This update requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. This update was effective for fiscal years beginning after December 15, 2023, and is to be applied retrospectively to all periods presented in the financial statements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The adoption of ASU 2023-07 resulted in a new footnote disclosure for Segment Reporting.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_6fba30f3-71cf-4243-955b-778148ec6be1">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Items measured at fair value on a recurring basis are the Company&#x2019;s investments. The following table sets forth the Company&#x2019;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.87%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements as of December 31, 2024 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;356,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements as of December 31, 2023 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;354,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies its money market mutual funds as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its U.S. Treasury Securities and Corporate Bonds as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of the Company&#x2019;s warrant liability, which is recorded as part of Other Liabilities in the Consolidated Balance Sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company utilizes a Black-Scholes model to value the warrant liability (see Note 10 &#x201c;Warrants&#x201d;) at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in an options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the expected volatility of its common stock based on historical volatility of its common stock, considering the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the valuation date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the warrant liability has been estimated with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.572%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value per warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ee2b0b97-80c1-4b43-8661-4b740b93f460">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Items measured at fair value on a recurring basis are the Company&#x2019;s investments. The following table sets forth the Company&#x2019;s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.87%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.282%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements as of December 31, 2024 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;216,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;356,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements as of December 31, 2023 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;312,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;354,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0037c99e-c1ca-4b23-b24c-81e17fdc512c"
      decimals="-3"
      id="F_155568d5-f023-41d0-8130-0b5a5fde31cd"
      unitRef="U_USD">139948000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20f6fd52-2ba1-4fa6-be1d-d13c170008e6"
      decimals="-3"
      id="F_c45a8dbe-92ad-4885-bdc6-7f04ea187e09"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_614d6896-e6d5-492d-9c77-ffb84b0406db"
      decimals="-3"
      id="F_9b708602-18ed-4112-94c6-1595cbfeb20c"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_56deae45-2475-4724-92a9-1a0f1898168d"
      decimals="-3"
      id="F_be178e25-e741-442d-9597-c960cdca6303"
      unitRef="U_USD">139948000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dc209532-0fd3-44e9-9598-91da8bb7ea6a"
      decimals="-3"
      id="F_9fa98b77-ba3e-4552-80c6-d6a29e434118"
      unitRef="U_USD">7453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8fde949d-0acd-44a3-9e91-5d4c632ff5be"
      decimals="-3"
      id="F_98c2ce38-6a5a-48ae-be75-f096d41925d8"
      unitRef="U_USD">7453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7"
      decimals="-3"
      id="F_f1e66d55-0fea-44c2-97d2-5d36c64f4662"
      unitRef="U_USD">139948000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_78dca576-a930-4462-aa00-b27c81826e49"
      decimals="-3"
      id="F_b46da520-095a-4044-9f80-da21cc7d22be"
      unitRef="U_USD">7453000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e"
      decimals="-3"
      id="F_e1d4fe19-04fc-4a6b-a84d-38e03289df16"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c"
      decimals="-3"
      id="F_7fef7da7-9ef2-4ac6-9ae1-dde45995d275"
      unitRef="U_USD">147401000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_5bed0892-88b1-4193-a2a6-7964d153c972"
      decimals="-3"
      id="F_6dd8f859-2362-438a-9f00-5611c83dcc5c"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_dc209532-0fd3-44e9-9598-91da8bb7ea6a"
      decimals="-3"
      id="F_b5d92689-1cb2-4525-a4d6-2f386b644b16"
      unitRef="U_USD">208701000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_88bd68f9-d4e7-4d24-ad5b-0cfd4a8572fd"
      decimals="-3"
      id="F_0b9e7dfb-245e-4482-b79c-79f3bbcbe340"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8fde949d-0acd-44a3-9e91-5d4c632ff5be"
      decimals="-3"
      id="F_232a7646-abf6-45ca-82fc-b5a8174ef8b5"
      unitRef="U_USD">208701000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7"
      decimals="-3"
      id="F_5d2558ca-824a-4b3a-a20e-275549f77b08"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_78dca576-a930-4462-aa00-b27c81826e49"
      decimals="-3"
      id="F_d0c39a5f-d7a1-4e45-841f-26dfba1c1584"
      unitRef="U_USD">208701000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e"
      decimals="-3"
      id="F_2ae89525-3220-48ad-8acc-d8a2bc71232e"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c"
      decimals="-3"
      id="F_af138a1d-6dd4-4836-890f-3c1ea8d632fc"
      unitRef="U_USD">208701000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7"
      decimals="-3"
      id="F_f26dcb8d-2bd6-487a-a8a2-c5c87e31ee2e"
      unitRef="U_USD">139948000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_78dca576-a930-4462-aa00-b27c81826e49"
      decimals="-3"
      id="F_5bda94bb-2227-473a-b3f7-a65972856b17"
      unitRef="U_USD">216154000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e"
      decimals="-3"
      id="F_a1048046-1b02-4893-b9be-07051c10a201"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c"
      decimals="-3"
      id="F_7842cc84-496a-4502-9c05-604ce9215178"
      unitRef="U_USD">356102000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_1e1369d9-110a-42d0-b7c0-84ac9ece8089"
      decimals="-3"
      id="F_a20af349-e3cf-477c-8b27-a6099698d828"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_ec6889e5-cd60-493d-a8e3-c53b58b5fa3d"
      decimals="-3"
      id="F_fc012807-5227-4227-a896-1326dd464ebd"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_a20e6031-eb30-4c47-8d1b-adc6495a52e1"
      decimals="-3"
      id="F_0a0fbfbc-66b2-4099-ade1-de7a6ecf1e53"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_07c3747f-e2f3-42a9-89ac-9acfd5f74970"
      decimals="-3"
      id="F_0c684803-9fbf-4100-9fac-acd3cb18d9bc"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_d2c1c330-8750-4b70-8dba-88ed15df03d7"
      decimals="-3"
      id="F_5db80b78-44a4-4ee7-937d-e131791f6fb1"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_78dca576-a930-4462-aa00-b27c81826e49"
      decimals="-3"
      id="F_13d914df-426e-4aab-82d1-45bf9ac2ecfb"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_7cc8f8b0-38d5-4bfe-93dd-17002be68d4e"
      decimals="-3"
      id="F_fc45900f-1167-4a46-a4a1-09da43cd27d4"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_8258573d-c82d-41f2-ba1a-9620f4a7976c"
      decimals="-3"
      id="F_213b2921-5880-4dd7-b6eb-0b8a0c9aa902"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e1b43b69-998d-4796-b42a-aea9aafdd667"
      decimals="-3"
      id="F_43dd3c7f-7ad2-4bdf-a4ef-56681a613a84"
      unitRef="U_USD">50737000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7192b875-69fe-4a97-bfab-df69481b623d"
      decimals="-3"
      id="F_cb6cf75e-038a-4ef4-af8d-63b47e1ce34a"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f8197a09-186b-424a-b44f-83d44b69c54d"
      decimals="-3"
      id="F_2f31d11e-a30e-48e6-a5a1-94522ae42906"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e1c16979-17a8-4d46-9822-2b46b4a8cb39"
      decimals="-3"
      id="F_8cd17a7e-5819-44f9-a2b3-38b2ea32fa2e"
      unitRef="U_USD">50737000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_37654162-418a-45b1-acc3-24642763a46c"
      decimals="-3"
      id="F_11479cac-f252-4b31-8e9d-9d9f4d68ccd7"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_bfe02d27-19e3-433a-95db-5d94f0827b20"
      decimals="-3"
      id="F_6d20950f-693a-4876-8323-151cceca22a3"
      unitRef="U_USD">2487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_943dc870-40c2-4855-8570-af751ebf236a"
      decimals="-3"
      id="F_887a721e-99fa-4abc-8f1d-87a07ea90936"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d48d3908-3513-4784-ae1b-75c7c67ca6e0"
      decimals="-3"
      id="F_a0715a01-a92c-4501-b3b9-0ff4610cbcf1"
      unitRef="U_USD">2487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482"
      decimals="-3"
      id="F_212c003f-a9a3-4d86-887f-defb34d75a67"
      unitRef="U_USD">50737000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025"
      decimals="-3"
      id="F_f9d42055-613f-4185-a5af-55add2deaba8"
      unitRef="U_USD">2487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985"
      decimals="-3"
      id="F_803eb681-441c-44ae-a675-b4397d26fdaf"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f"
      decimals="-3"
      id="F_5f32b771-b4c3-4dfa-9a09-125b08e3f63d"
      unitRef="U_USD">53224000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_37654162-418a-45b1-acc3-24642763a46c"
      decimals="-3"
      id="F_f915b451-2cc8-48c9-9602-95f21a36b1a0"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_bfe02d27-19e3-433a-95db-5d94f0827b20"
      decimals="-3"
      id="F_b8c072ba-fe80-49da-b910-6fb7f6a9e0e7"
      unitRef="U_USD">312696000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_943dc870-40c2-4855-8570-af751ebf236a"
      decimals="-3"
      id="F_5e70835d-61e9-470f-b8e9-878dcd057d0d"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d48d3908-3513-4784-ae1b-75c7c67ca6e0"
      decimals="-3"
      id="F_09b6bc1b-b806-44c8-ae52-a23c5457fdd7"
      unitRef="U_USD">312696000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8cfc4f1d-1cde-40f3-8c46-dd26d0bccc8c"
      decimals="-3"
      id="F_f3a718ae-ac10-4265-b91b-b1454c1c36fc"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_a6f9948b-434e-4c07-bdf1-b761c191b422"
      decimals="-3"
      id="F_2a2ed78f-050b-4446-9d4c-42cba76405c4"
      unitRef="U_USD">38895000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3a2dd3b1-3fb8-410c-ab6a-47d3ffbd35f8"
      decimals="-3"
      id="F_71f341fd-a265-403a-a782-68825d0d565b"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_522afc24-fadc-4b87-92bc-1830764fccf5"
      decimals="-3"
      id="F_f7849f05-1ea8-4787-b15d-1ea67d20adc4"
      unitRef="U_USD">38895000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482"
      decimals="-3"
      id="F_9bde57f0-a4af-4e81-873e-4022873d1da3"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025"
      decimals="-3"
      id="F_32ef690e-2da8-4cfb-b1c3-1d8f349bf051"
      unitRef="U_USD">351591000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985"
      decimals="-3"
      id="F_f928e70d-2056-45d9-8e3d-68320ccd2f33"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f"
      decimals="-3"
      id="F_9eb1eecf-4e4a-4964-88b1-8cb6d3b5f1d7"
      unitRef="U_USD">351591000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482"
      decimals="-3"
      id="F_505db33e-5f05-4946-87a6-6311d8372bc6"
      unitRef="U_USD">50737000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025"
      decimals="-3"
      id="F_74b41d2d-5173-4b6f-ace1-90d5be7907bd"
      unitRef="U_USD">354078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985"
      decimals="-3"
      id="F_90abf815-df90-479e-a8c7-2e8732b146a2"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f"
      decimals="-3"
      id="F_28976b5d-d1a3-41ff-89f3-a12488815767"
      unitRef="U_USD">404815000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_92d0c82e-65b5-4c8a-8b1c-a545c812be74"
      decimals="-3"
      id="F_047cd4b7-22d7-41e1-bc17-6671c296c14a"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_6d0adb09-8317-454a-af5e-3df33b3384e2"
      decimals="-3"
      id="F_47948316-9b0a-4c7b-a33d-749840f3b009"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c"
      decimals="-3"
      id="F_850995f0-8fa1-40ef-bde3-96e8541083a9"
      unitRef="U_USD">1876000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_991c71a4-2d8b-4a30-b81d-b081fa3aa360"
      decimals="-3"
      id="F_03cf6f2b-3ca9-427c-974b-f01e466fa688"
      unitRef="U_USD">1876000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_42ab997b-8a8e-49ef-9fed-ef65dbe12482"
      decimals="-3"
      id="F_1f9254f9-ec31-4292-834c-b8d889995550"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_5f9d43f8-45ec-4f28-93a5-f42279655025"
      decimals="-3"
      id="F_3ccb5be9-cd8a-42b2-9824-570f568905db"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_995a47c0-d6eb-4aac-a735-b345f6e0d985"
      decimals="-3"
      id="F_73dbf0bf-d331-4c7e-a144-301693208811"
      unitRef="U_USD">1876000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_3300233d-86ba-4c8f-9f81-9fb876b5012f"
      decimals="-3"
      id="F_829107d2-da70-4506-a405-ee6f861540e1"
      unitRef="U_USD">1876000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_87b3373a-02c3-4c8f-8b4d-ff407424f121">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of the Company&#x2019;s warrant liability, which is recorded as part of Other Liabilities in the Consolidated Balance Sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.439999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_1d96ec30-1174-441b-a600-2e0b2c261eb0"
      decimals="-3"
      id="F_ed4c600f-8f2a-4df4-903e-6546fccc6a47"
      unitRef="U_USD">1512000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="C_8e233e0a-2ea3-41c0-89a4-fc2fd285a9ab"
      decimals="-3"
      id="F_13138c0f-4757-4ae8-8d6b-0640aa85b8bb"
      unitRef="U_USD">-364000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_8eb784c5-3224-4e70-a1fa-a303c08d3c6c"
      decimals="-3"
      id="F_47af7ef5-e0df-424c-acaf-07d84cdc3dcb"
      unitRef="U_USD">1876000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="C_23045695-c17e-4d48-ab1f-bb772f60c66e"
      decimals="-3"
      id="F_4b71596e-00f8-4361-beec-b06b184fa114"
      unitRef="U_USD">1876000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a20e6031-eb30-4c47-8d1b-adc6495a52e1"
      decimals="-3"
      id="F_a5e8c367-fbc2-4d24-8152-eaabb5d4edd7"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e49cd440-b95b-4530-a06c-b253abebbdef">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the warrant liability has been estimated with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.572%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.563%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value per warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_f7122f45-e86b-4832-8a3c-08b89787f233"
      decimals="2"
      id="F_5b29c55a-a984-43d1-aec6-e50da918abae"
      unitRef="U_USD">12.57</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_88e568be-e56e-4e25-9251-014e7a901a92"
      decimals="2"
      id="F_92802939-9270-4965-9bd2-cc9e54c23609"
      unitRef="U_USD">29.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_6949dc0c-ac58-42f1-b238-512744e2f55a"
      decimals="2"
      id="F_cd6ebbed-4f65-48db-bc96-4d222419fc5d"
      unitRef="U_USD">65.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_546e10b4-ff00-4699-b1d3-6c11db3121d3"
      decimals="2"
      id="F_30318837-b4df-44bd-bd32-ebc4bd7738a8"
      unitRef="U_USD">65.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_5de73c69-3b3e-412b-a788-62510c450a86"
      decimals="4"
      id="F_adb910d0-4b00-4523-b1f0-d6e890dbfa61"
      unitRef="U_USD">0.5224</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_9ca4967a-2d36-4cf3-813a-a556cf2894e6"
      decimals="4"
      id="F_da6e7ca3-d261-4865-a622-7abdeed54c63"
      unitRef="U_pure">0.6883</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_5788384e-0e15-4c14-b7f3-ea8098caef5a"
      decimals="4"
      id="F_befb0d17-279f-4c8a-9f51-663ff34b2c0f"
      unitRef="U_USD">0.0424</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_231c38bb-1d40-4602-a048-1a166b10048d"
      decimals="4"
      id="F_d9c9af6c-cee6-40bf-8e6a-48b845b53fa9"
      unitRef="U_pure">0.047</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_3f829c1c-8313-4171-8476-384337e26d5d"
      decimals="0"
      id="F_89e4dd22-d324-459b-9dba-bf3e2f28e03d"
      unitRef="U_USD">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_956a0bae-50e5-4afb-9e3f-ce6ad3fb91df"
      decimals="2"
      id="F_f2c4865c-7419-48de-9aed-7690221c62d7"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef"
      id="F_124e40b1-01ad-4598-af79-5c6fd71fb8a2">P0Y3M21D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_df02e688-dcfc-497e-8173-c2fefd94643a"
      id="F_e87d8582-c398-4c3f-9667-df1edc319ba0">P1Y3M21D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e2ad129c-df49-41f6-ab9a-df2ebcae32ef"
      decimals="2"
      id="F_82622006-8c4f-463a-a843-07fcdf84af9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_df02e688-dcfc-497e-8173-c2fefd94643a"
      decimals="2"
      id="F_a5ae67f3-f76a-42d0-a7c4-27704527e890"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_250be423-6fde-4b43-861f-602a64663a79">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s property and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.113%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.442999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.442999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal use software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization during the years ended December 31, 2024, 2023, and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_731dc541-43f1-4a57-8718-f1fc8dd32ede">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s property and equipment consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.113%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.442999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.442999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Machinery and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal use software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8b46be80-cf70-47f1-91fb-b0731982128f"
      decimals="-3"
      id="F_f5a603b4-d33d-4159-b71e-12f0d1080de9"
      unitRef="U_USD">32205000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a111d06c-dc8e-4e3a-8e0d-78a1e5369023"
      decimals="-3"
      id="F_a0b4af88-16f3-419d-b8a7-1832d016a2cc"
      unitRef="U_USD">29232000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_906a09af-a884-4b84-bbef-d07f25a1fe78"
      decimals="-3"
      id="F_cb4bcf83-1e84-45c2-9993-493d654f53b7"
      unitRef="U_USD">12857000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dab486eb-7044-4902-b0e7-0bf059248bfa"
      decimals="-3"
      id="F_ecf626ea-712f-4866-8156-1a5d8c778c9b"
      unitRef="U_USD">12325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b579542c-2ebf-4d4c-99f6-66f0c8bde726"
      decimals="-3"
      id="F_a0ec35db-93ba-4394-b002-8627e1971468"
      unitRef="U_USD">1015000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3c6df573-5d38-4acd-8c24-1b20574901cf"
      decimals="-3"
      id="F_ea4bf9fb-559f-4a16-b337-43a337f94b28"
      unitRef="U_USD">244000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_600a0f88-6bde-40ff-97bd-99954442846a"
      decimals="-3"
      id="F_b4fa56bc-8649-4cfa-ad73-c8997600b9d1"
      unitRef="U_USD">2777000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f89a9364-484a-44e7-a942-5ef3c5798d0a"
      decimals="-3"
      id="F_a7e66c9e-2ab9-4c52-a73a-a97c80171e97"
      unitRef="U_USD">2777000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_427ef717-f6ba-4ddc-87e2-99ea816b4e39"
      decimals="-3"
      id="F_833e1249-7c77-4b65-a5c2-1b43580e0553"
      unitRef="U_USD">7282000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0cfac2e7-eea8-42c7-88ef-e2f0746599fd"
      decimals="-3"
      id="F_f0402796-a048-4ac8-a771-e1b908395c31"
      unitRef="U_USD">6723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0053a3ab-9acc-483f-9ebb-d8ec869ad7a4"
      decimals="-3"
      id="F_c7bc0f31-016c-4df9-add1-7fa749ab2c91"
      unitRef="U_USD">1903000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c0e3b9f1-cd58-4ddc-8dac-3bce6794b077"
      decimals="-3"
      id="F_514889c8-abbe-4f2f-9a4f-1dbbfefba741"
      unitRef="U_USD">1903000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_27bfbdc9-896c-4826-b6b9-0bc5d751f42a"
      unitRef="U_USD">58039000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_fdd5bc54-63e7-4267-8fa9-4e2766680690"
      unitRef="U_USD">53204000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_94297495-36ff-41b6-abee-a993fe8f99c8"
      unitRef="U_USD">21253000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_3ae0ee3d-2454-4a44-ba89-e9a9638209ba"
      unitRef="U_USD">14032000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_1e177889-e3e9-4919-9988-0da01c2afcf9"
      unitRef="U_USD">36786000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_0766487f-f0a3-4107-abda-ad2512335699"
      unitRef="U_USD">39172000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-5"
      id="F_d774c14a-5ce9-41c4-b18a-e559548b6656"
      unitRef="U_USD">7200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-5"
      id="F_c1c40040-1146-4fcb-941a-7afc19d34558"
      unitRef="U_USD">4900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-5"
      id="F_0c80041a-e4a6-4f9e-82a8-86eaf92b514d"
      unitRef="U_USD">3900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_f2d3a8c5-46d3-420b-818b-f864647566fc">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s intangible assets consisted of an acquired IPR&amp;amp;D asset received in the acquisition of Renovacor. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.872%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying value of Goodwill as of December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4730d440-9a76-44c3-8d0e-759e731ac846">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.872%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_7dc36083-813e-46e4-b396-cc3aeb4379ae"
      unitRef="U_USD">25150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_31a7af20-f3d7-4f45-9a8b-2b0b450986ab"
      unitRef="U_USD">25150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_a05fe374-b919-4494-b825-0152ebdf72b2"
      unitRef="U_USD">25150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_42417453-9797-4a8d-b4a3-ff0e3670b73e"
      unitRef="U_USD">25150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-5"
      id="F_8cb63c48-1276-4729-9f72-e06c4f462e63"
      unitRef="U_USD">39200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-5"
      id="F_e870b8c0-06cd-4c7e-80fe-5efe5cef14b9"
      unitRef="U_USD">39200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-5"
      id="F_27fd6e68-326a-4127-bd8c-ce4b0d34a2f3"
      unitRef="U_USD">39200000</us-gaap:Goodwill>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_8054cee3-c41f-4d2d-ae95-4f76eb3a3b14">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts Payable and Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.872%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million investment payable was related to investment purchases of available-for-sale securities in 2023 that settled in 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_105c032d-199b-4550-8dbb-d0836658ebf6">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.872%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.063%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <rckt:ResearchAndDevelopmentCostsCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_38c754cf-230f-4035-a098-2b72a21bc6a1"
      unitRef="U_USD">16768000</rckt:ResearchAndDevelopmentCostsCurrent>
    <rckt:ResearchAndDevelopmentCostsCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_55e35a16-1c2e-486f-b4ba-65209b53b691"
      unitRef="U_USD">13867000</rckt:ResearchAndDevelopmentCostsCurrent>
    <rckt:InvestmentPayableCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_797aa44f-58fd-459d-9d1c-207149af6012"
      unitRef="U_USD">0</rckt:InvestmentPayableCurrent>
    <rckt:InvestmentPayableCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_091bf55e-f7cc-46e5-b605-b88184b66420"
      unitRef="U_USD">13137000</rckt:InvestmentPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_3e86d53a-b344-4406-875e-70aab6a0badd"
      unitRef="U_USD">11944000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_400b8fe7-d411-461f-903d-0ba73d53aee8"
      unitRef="U_USD">9930000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_46f4c5f0-a04e-4229-a4a7-fda2c3565aae"
      unitRef="U_USD">185000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_82020e1b-a357-40ad-aa58-2e655c90765c"
      unitRef="U_USD">1077000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_b3835782-01fe-4484-a507-ed48bebadc7b"
      unitRef="U_USD">7305000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_8caf370e-25f6-4322-9ea5-92ea59b14e26"
      unitRef="U_USD">6006000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_40949ab4-2439-45bd-b5c3-41eaffa0c58a"
      unitRef="U_USD">1625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_93a3c4a8-c14c-44ea-93b8-6aad310b3596"
      unitRef="U_USD">1772000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_9f65dd54-8b73-4589-b72a-cd4a37be39e1"
      unitRef="U_USD">37827000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_95c376c5-24b8-45ed-97f1-6a720f573dc7"
      unitRef="U_USD">45789000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <rckt:InvestmentPayableCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-5"
      id="F_0f5e61ce-5021-4da8-8340-09d3e02ba2e8"
      unitRef="U_USD">13100000</rckt:InvestmentPayableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_20933eeb-f050-484d-81a5-2448b3a7ab3f">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is currently authorized to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value common stock. All issued shares of common stock are entitled to vote on a 1 share/&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Treasury Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; treasury stock transactions were recorded for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. During the year ended December 31, 2023, the Company recorded sale of treasury stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. During the year ended December 31, 2022, the Company recorded a repurchase of treasury stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for shares withheld to pay the payroll tax liability of the vesting of RSUs. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; treasury stock as of December 31, 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-the-Market Offering Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 28, 2022, the Company entered into a Sales Agreement with Cowen with respect to an at-the-market offering program pursuant to which the Company could offer and sell, from time to time at its sole discretion, shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of its common stock, par value $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;through Cowen as its sales agent. The shares offered and sold under the Sales Agreement were offered and sold pursuant to a shelf registration statement on Form S-3 that expired in September 2024. As a result of the expiration of such registration statement, the at-the-market offering program in not currently available to the Company. The Company may consider reactivating the at-the-market offering program in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Through December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares under the at-the-market offering program for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, less commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company did not sell any shares under the at-the-market offering program during the year ended December 31, 2024. During the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares under the at-the-market offering program for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, less commissions of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Public Offerings and Private Placements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 6, 2022, the Company completed a public offering of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of our common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The gross proceeds from the public offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of offering costs, commissions, legal and other expenses for net proceeds from the offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 15, 2023, the Company completed a public offering of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant. The gross proceeds from the public offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 12, 2024, the Company completed the Offering of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and Private Placement of pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per warrant. The gross proceeds from the Offering and Private Placement were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of offering costs, underwriting discounts and commissions, legal and other expenses for net proceeds from the Offering and Private Placement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="INF"
      id="F_a18ec170-711e-49eb-bca2-c8ea1e7d6c1b"
      unitRef="U_shares">180000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="INF"
      id="F_1a7521f0-a10b-45ba-85b3-0bafe1e8f255"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <rckt:CommonStockVotingRightsNumberOfVotesPerShare
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_218d6fa4-9e1e-4f79-a450-dd8c71b00ba4"
      unitRef="U_Vote">1</rckt:CommonStockVotingRightsNumberOfVotesPerShare>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-6"
      id="F_8fe9654f-0d03-47c5-af43-4b2395420701"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:ProceedsFromSaleOfTreasuryStock
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-4"
      id="F_5bb773ee-0699-4823-84eb-ccf62febacd2"
      unitRef="U_USD">60000.00</us-gaap:ProceedsFromSaleOfTreasuryStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_c72bc269-579c-4d57-ac72-5d5633259ea5"
      decimals="-4"
      id="F_539cfeb4-19ff-4b31-b701-375c2a263ea4"
      unitRef="U_USD">50000.00</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_e0a89db5-ae0b-4a17-b75d-9c2a60a086ec"
      decimals="INF"
      id="F_757a7ae5-e5c5-45ba-b4f5-abb979673460"
      unitRef="U_shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_63ad2220-d8b8-479c-b35d-56ecb8208ca7"
      decimals="INF"
      id="F_a73fa87d-e66d-4cdd-b224-6d08ff38b8ad"
      unitRef="U_shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a1502da7-9920-4457-8a72-b7448a4ac6aa"
      decimals="INF"
      id="F_d1bff23d-72b4-46a0-b540-d1b660fda2d1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <rckt:SaleOfStockAggregateOfferingPrice
      contextRef="C_39d4c570-76ba-4c52-80e3-dde4aa7b4c66"
      decimals="-6"
      id="F_5c67babc-00ca-452d-ae15-13926213e838"
      unitRef="U_USD">200000000</rckt:SaleOfStockAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c"
      decimals="-5"
      id="F_85fa8956-9137-4554-83c8-029fd7894fb8"
      unitRef="U_shares">4200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rckt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c"
      decimals="-5"
      id="F_620d1968-ee20-4fe0-af0b-02bfceb04ae3"
      unitRef="U_USD">65800000</rckt:GrossProceedsFromIssuanceOfCommonStock>
    <rckt:StockIssuedIssuanceCosts
      contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c"
      decimals="-5"
      id="F_871e77ed-f7e5-4f10-9ffe-748338a852fa"
      unitRef="U_USD">2000000</rckt:StockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ad72efaf-99b2-46be-9995-845d7bf8494c"
      decimals="-5"
      id="F_15df0372-6f25-424e-bba4-6bf1d09f2c3c"
      unitRef="U_USD">63800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_1cd8c3bc-0da7-4b07-83d1-7fc14092a5c0"
      unitRef="U_shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rckt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_05f1f3df-e359-46aa-b21d-b67a3500a58f"
      unitRef="U_USD">17800000</rckt:GrossProceedsFromIssuanceOfCommonStock>
    <rckt:StockIssuedIssuanceCosts
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_42602293-8b56-4cd4-9fac-566dd9a39d6e"
      unitRef="U_USD">600000</rckt:StockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9571be56-aa2f-48cf-b127-0409e94057d4"
      decimals="-5"
      id="F_5c3a2972-c4aa-4467-903e-b527018dc41a"
      unitRef="U_USD">17200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897"
      decimals="INF"
      id="F_efdc2032-43a8-4b66-973b-03ed53b3362b"
      unitRef="U_shares">7800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_15399861-ccb4-4e70-8bbd-0ddf51277dc0"
      decimals="2"
      id="F_e6a29afc-f906-4462-a830-15fc194f8798"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.75</us-gaap:SaleOfStockPricePerShare>
    <rckt:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897"
      decimals="-5"
      id="F_092ee70c-bad7-4a58-96d2-835cb6f00fb1"
      unitRef="U_USD">115300000</rckt:GrossProceedsFromIssuanceOfCommonStock>
    <rckt:StockIssuedIssuanceCosts
      contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897"
      decimals="-5"
      id="F_d345396e-c255-46c9-9812-d03583687ba1"
      unitRef="U_USD">7200000</rckt:StockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2323ae46-2e58-4ceb-9952-42b0e8c29897"
      decimals="-5"
      id="F_e521351d-3084-47b2-8c11-7444646af68b"
      unitRef="U_USD">108100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa"
      decimals="INF"
      id="F_171a1372-a285-4051-a9cb-0221b83b99a6"
      unitRef="U_shares">9500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_bf567e9b-5f3d-4efa-a215-8c9b02dd65f3"
      decimals="2"
      id="F_ab898071-0bcc-4a41-a3dd-1959179686ab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16</us-gaap:SharesIssuedPricePerShare>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_2c62f640-e90d-405f-b768-464bdc8fe131"
      decimals="-5"
      id="F_9d97a30a-f49b-464f-a0ee-3e5b6b2fb5c4"
      unitRef="U_shares">3100000</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9b231eaf-1cc1-439b-be3b-21ff07a55616"
      decimals="2"
      id="F_4677ab4a-128f-4702-a24a-567682222ee5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rckt:GrossProceedsFromSaleOfStock
      contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa"
      decimals="-5"
      id="F_47ffa997-f4f4-451c-9884-8d370331d77d"
      unitRef="U_USD">201300000</rckt:GrossProceedsFromSaleOfStock>
    <rckt:SharesIssuanceCost
      contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa"
      decimals="-5"
      id="F_342aaa1f-afb7-4635-a4ad-f09588e75864"
      unitRef="U_USD">12400000</rckt:SharesIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_b01c1bb2-01c7-4065-879b-e53f333e7aaa"
      decimals="-5"
      id="F_52ca63fd-3d54-4b2b-8aa2-0f053f3dafbd"
      unitRef="U_USD">188900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_abe62c65-86b2-4c28-a166-de2d40714fe1"
      decimals="INF"
      id="F_a904c72b-618a-4fcc-ade2-5e8837bc1491"
      unitRef="U_shares">15200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_b7504ddd-7215-4a12-a2a7-05b47998068b"
      decimals="INF"
      id="F_baa55436-7597-451e-8a62-10b5199b5c49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.5</us-gaap:SharesIssuedPricePerShare>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_69408d2a-0545-4d3a-a4f7-3c54eb9825f9"
      decimals="-5"
      id="F_7187ea24-bc44-4db8-88f9-1b92aac51eae"
      unitRef="U_shares">400000</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3abe252d-55ed-4732-a04d-1b253a82ba3b"
      decimals="INF"
      id="F_997a05ec-6aa5-462f-a766-a4fcf163fb62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rckt:GrossProceedsFromSaleOfShares
      contextRef="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e"
      decimals="-5"
      id="F_97998005-9ae6-4012-9577-aaf2039cbfc9"
      unitRef="U_USD">194700000</rckt:GrossProceedsFromSaleOfShares>
    <rckt:SharesIssuanceCost
      contextRef="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e"
      decimals="-5"
      id="F_ce5fa866-24e0-47a0-b60f-aadf2e2adff1"
      unitRef="U_USD">12200000</rckt:SharesIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e0fa3944-9d55-4253-90ff-cbf09e31bc8e"
      decimals="-5"
      id="F_6b005407-fca2-4bb0-b2b6-76b6036537fa"
      unitRef="U_USD">182500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_afa84c9c-a8e6-4ccb-a29a-f937e66e4db3">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Valuation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of the stock options granted to employees, non-employees and directors were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.851%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.049999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.049999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.049999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.81&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.302%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.362%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.302%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,138,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,370,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.76&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;422,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,863,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,767,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;317,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,044,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,255,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,789,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average grant-date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total fair value of options vested during the years ended December 31, 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the RSU activity for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.119999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;992,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,018,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;408,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,490,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;760,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;722,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Common stock issued is net of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares related to taxes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total fair value of RSU&#x2019;s vested during the years ended December 31, 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company began granting PSU awards in 2024. The following table summarizes the PSU activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PSU vesting and expense recognition is based on achievement of specific performance goals within certain time periods. PSU awards that are not achieved within specific time periods are forfeited. No performance goals were probable of achievement and the time periods for 3 performance goals had expired as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recognized by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had an aggregate of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense, which is expected to be recognized over the weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_17fb3ef9-0536-4837-afa3-f5990ac1849f">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of the stock options granted to employees, non-employees and directors were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.851%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.049999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.049999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.049999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.81&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44"
      decimals="4"
      id="F_130128b0-a39e-4d5a-8166-37f3ba820647"
      unitRef="U_pure">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c"
      decimals="4"
      id="F_f0adc538-e1c6-4181-aa21-099c60cd3744"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff"
      decimals="4"
      id="F_d318e65b-be83-492a-96f2-ffe53595396b"
      unitRef="U_pure">0.0219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44"
      id="F_859eb9a5-3529-429b-a209-7946fbd977ee">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c"
      id="F_ec608e8d-f8e6-4aa8-bd3e-7162308a3e13">P5Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff"
      id="F_d02ea096-c5ba-4187-ab32-83eabfe6367b">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44"
      decimals="4"
      id="F_87c8d435-5953-4b86-836c-46867f05f0e2"
      unitRef="U_pure">0.7372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c"
      decimals="4"
      id="F_5888fdec-6c10-4afe-84e0-8bc589d1e57a"
      unitRef="U_pure">0.7332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff"
      decimals="4"
      id="F_d6f5637d-5bb1-440a-ba73-6ece99c0856a"
      unitRef="U_pure">0.6412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5d022c41-2abf-4b66-9515-d9ce9e263b44"
      decimals="4"
      id="F_1f68e134-789f-43a0-87da-eebceeb35263"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d7655a81-c814-49e4-8f59-bed89f97e80c"
      decimals="4"
      id="F_1fc860aa-8518-429f-ac47-433d5f4db9de"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4ec9d6be-c702-40fd-a041-258f0191e5ff"
      decimals="4"
      id="F_52ea96ec-6d00-43a4-b524-76b3f1a8c4e5"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_ab8144ca-12d4-48b2-a36b-ecea9a99ea61"
      decimals="2"
      id="F_d47ae418-83ef-4d94-bc47-58410c19b477"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_d7da2197-3558-4b5e-baa6-7e95259215a5"
      decimals="2"
      id="F_f4988dd9-3fd7-4d71-82dd-85f7378f8b93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_5f849fe8-09d4-4c36-86ef-cef05c3dbc49"
      decimals="2"
      id="F_ba28f151-b9b3-45a7-8b4b-d81ec2ae9a3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_ab8144ca-12d4-48b2-a36b-ecea9a99ea61"
      decimals="2"
      id="F_4f44f034-6ff4-4f68-8a7b-3da2486c44e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.93</rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_d7da2197-3558-4b5e-baa6-7e95259215a5"
      decimals="2"
      id="F_bd563ded-1dec-485f-93ab-85d9b604e1f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.24</rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_5f849fe8-09d4-4c36-86ef-cef05c3dbc49"
      decimals="2"
      id="F_5c7e9a73-9b07-49cf-a0b3-2a0878b691ea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.56</rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_13af6ab7-e5d1-4faf-a7a3-b63c9d3db948">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes stock option activity for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.189%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.302%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.362%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.302%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,138,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,370,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.76&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;422,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,863,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.16&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,602&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,767,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;317,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,044,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.67&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,255,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.82&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,789,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.72&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903"
      decimals="0"
      id="F_4a22a10b-fa50-47b0-a048-60e5e75e4275"
      unitRef="U_shares">13138870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903"
      decimals="2"
      id="F_facf2ce4-f1e9-43a1-a641-9801118d0ecb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2"
      id="F_fdc2b33d-e011-4dab-8e50-8f786213c5da">P5Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_ac1c7f96-189d-43f3-9d50-b40e1fbef903"
      decimals="-3"
      id="F_4f74a1cc-1827-46e2-b322-716e80d0115c"
      unitRef="U_USD">118767000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="0"
      id="F_1e27ea38-ee93-42f4-a661-f50bbf5b008a"
      unitRef="U_shares">2370862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="2"
      id="F_95fb2ff5-8e75-4a84-9462-1250ea133c52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <rckt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      id="F_2e0c1139-2681-4d61-bfa9-775507472dad">P8Y9M3D</rckt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="0"
      id="F_8547e0e1-213a-44fb-bf31-b9c7da09d784"
      unitRef="U_shares">223145</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="2"
      id="F_b8a7c081-8f12-42cb-a351-52a1b8b10d80"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="-3"
      id="F_aa05c240-5e6a-4925-868c-ea253f588a19"
      unitRef="U_USD">2318000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="0"
      id="F_380f0e6b-5421-43b7-8572-696ca2b7e278"
      unitRef="U_shares">422591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="2"
      id="F_bf36c100-c52d-47bb-a7e7-edebb1ace9da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e6d96dee-383b-4648-a425-7febaa2eae01"
      decimals="0"
      id="F_2fda207e-c17c-41d4-88dd-7ea15e3943ba"
      unitRef="U_shares">14863996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e6d96dee-383b-4648-a425-7febaa2eae01"
      decimals="2"
      id="F_7c33bbc7-ec2e-43e1-ac36-5893e6f4dd82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      id="F_2dcffce3-0ec2-4bb0-9202-322a65642de2">P5Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e6d96dee-383b-4648-a425-7febaa2eae01"
      decimals="-3"
      id="F_2a7bf947-de20-471d-bb34-d61681774dc2"
      unitRef="U_USD">250602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="0"
      id="F_fc2a611e-c79c-47a1-ae5e-518c4c4241c9"
      unitRef="U_shares">1767674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="2"
      id="F_f2770d90-58fa-4cea-9ed7-61ebd5b7edb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <rckt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      id="F_9143d83d-f211-4e6e-a3e0-24759653f531">P8Y11M8D</rckt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="0"
      id="F_687bcd0d-e93c-4f4f-b055-b3b60819cb8f"
      unitRef="U_shares">269080</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="2"
      id="F_9f44f4b8-4b29-41fd-8573-8af0fe300035"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="-3"
      id="F_f051c307-6d1b-4de3-bd6d-57f6f71d5d55"
      unitRef="U_USD">3412000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="0"
      id="F_a7d072e2-ddc2-4ca2-b3b3-402d87f3181a"
      unitRef="U_shares">317904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="2"
      id="F_3a375358-8dde-40c5-9434-52285f107c79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="0"
      id="F_5a1bf0b0-6209-427d-b949-8ed37205ff36"
      unitRef="U_shares">16044686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="2"
      id="F_6b1d48e0-af34-46f7-9a1a-054352882208"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      id="F_ea906107-3ba6-4ae3-ae3b-6e8170257efb">P4Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="-3"
      id="F_7edc9f16-0f4c-4cb2-86c2-95c8116f8b35"
      unitRef="U_USD">63295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="0"
      id="F_0086dcf4-0d25-4945-b62e-d7eda47c1d7b"
      unitRef="U_shares">13255024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="2"
      id="F_a3bbc050-ec07-4ee8-a4ce-d17199d6dd70"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      id="F_e2d6f00a-e5e5-48f9-b43a-8a678ebf0060">P3Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="-3"
      id="F_56e484f1-b1e1-4c46-9ea1-885c660676f2"
      unitRef="U_USD">63285000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="0"
      id="F_5d1d70c1-7e0d-4f00-8629-62304d7fa413"
      unitRef="U_shares">2789662</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="2"
      id="F_e50c24be-b94c-42de-bb61-4df12cb071e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      id="F_f11a4094-fd36-4807-92f7-62d3a37c5822">P8Y8M19D</rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="C_191d7b2e-c625-4abf-b2e2-1a3c618d6eca"
      decimals="-3"
      id="F_eaf4a415-ee06-405b-bec0-17641724af44"
      unitRef="U_USD">10000</rckt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="2"
      id="F_e8b1fe30-881a-4084-bbe7-3712036b67de"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="2"
      id="F_283336b8-db48-42ac-8739-8ff72b67ce4f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2"
      decimals="2"
      id="F_8eefdcd2-1bd8-4d3e-8c65-32e78200a9cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="-5"
      id="F_d539977b-4764-4086-b07a-6bbc6c3255de"
      unitRef="U_USD">27700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="-5"
      id="F_bc07b70e-d9ed-4eac-b7b7-862b4d8604b8"
      unitRef="U_USD">26500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2"
      decimals="-5"
      id="F_f2733809-43fd-42dc-9161-2dfa32d74601"
      unitRef="U_USD">34900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_7ca792ba-6c54-4ce6-a63f-fe7bf76617d5">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the RSU activity for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.119999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;992,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,018,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;408,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,490,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;760,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;722,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Common stock issued is net of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares related to taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_d4b68ab5-2b41-4121-b8f8-df6a4d864157"
      decimals="0"
      id="F_006c05b9-251e-41b7-8f5b-14dc51a0d953"
      unitRef="U_shares">992874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_d4b68ab5-2b41-4121-b8f8-df6a4d864157"
      decimals="2"
      id="F_1c7ae17b-8945-413d-9c8e-2fca22ba6153"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="0"
      id="F_8fb5be14-adb7-41c4-abb9-85a9f89649c6"
      unitRef="U_shares">1018322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="2"
      id="F_24bb6f89-1daa-4b0d-875b-265c416f1104"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="0"
      id="F_b7b045bd-0e24-4eb9-a94e-cb86d4a50eda"
      unitRef="U_shares">408119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="2"
      id="F_8906689b-6302-4a9d-a115-a193dd40e522"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="0"
      id="F_6833653b-d32c-4b1f-9de7-63153ec4e7e0"
      unitRef="U_shares">112720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="2"
      id="F_2a0f3654-8438-47c5-a99f-3b1787531d76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561"
      decimals="0"
      id="F_e111cf5f-6ddc-420b-b703-c8ca21082aff"
      unitRef="U_shares">1490357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_366b9a2f-0cfc-46f2-a60e-1ed0eddb0561"
      decimals="2"
      id="F_ad7321c3-5e1a-40e9-b8a0-06139ba5bae9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="0"
      id="F_7e418830-bb72-4e5c-8902-57014af22778"
      unitRef="U_shares">760423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="2"
      id="F_6e802832-9284-4a31-840d-72dab03de861"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="0"
      id="F_eaa84127-03c1-4f92-9208-e55d15a848bb"
      unitRef="U_shares">722471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="2"
      id="F_d8c6f170-889d-4b86-8a85-87f50f029514"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="0"
      id="F_3374e609-dac2-4789-975a-9a4f5e1455bb"
      unitRef="U_shares">114099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="2"
      id="F_7d5874d6-7135-4dd3-84e0-db51d9098e0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ebdeda00-9ced-49ab-96a0-78c4cdd5ca46"
      decimals="0"
      id="F_908951b7-4041-4648-ba96-15e29dd7e79b"
      unitRef="U_shares">1414210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ebdeda00-9ced-49ab-96a0-78c4cdd5ca46"
      decimals="2"
      id="F_0c7e431c-3841-4188-a992-2b8a84a99d14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="0"
      id="F_32f8d582-919b-41f9-8549-3da361832569"
      unitRef="U_shares">120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="-5"
      id="F_be5e9755-65eb-4519-9ea8-efda08aed205"
      unitRef="U_USD">13500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="-5"
      id="F_90846133-095c-4e4c-9580-3c62f6ba1641"
      unitRef="U_USD">6800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_f889aac3-200d-4251-9867-6d16afb64a27"
      decimals="-5"
      id="F_e46a3e2b-aa6d-4aac-b61a-e0e7b049e2a9"
      unitRef="U_USD">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_9971d52c-7ed5-4e3e-9f49-230ef56de406">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company began granting PSU awards in 2024. The following table summarizes the PSU activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ae6b3516-7a34-414f-a317-8b7d0434e4e3"
      decimals="0"
      id="F_a9e22d16-a33b-4f56-b6de-2632d9664790"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_ae6b3516-7a34-414f-a317-8b7d0434e4e3"
      decimals="0"
      id="F_b227dd84-8120-4340-a03b-b540f1253bae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397"
      decimals="0"
      id="F_469839f1-e0ca-44db-b127-08f3ce204e03"
      unitRef="U_shares">156738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397"
      decimals="2"
      id="F_a51fca5e-4f02-4847-8aaf-b64d6e08d6aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397"
      decimals="0"
      id="F_72a52988-9a6e-4599-9e89-fcb115d05f8b"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397"
      decimals="0"
      id="F_59b16d0f-4a16-4c71-b58e-9dcc9f2e0a80"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397"
      decimals="0"
      id="F_dcf89067-ea25-4030-9f04-8aee38ac42ab"
      unitRef="U_shares">87077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_e769f56b-a3fa-4858-826e-d12445d19397"
      decimals="2"
      id="F_0efadcc5-f332-4a03-b1eb-eea186eb657b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_af781e94-ac4a-4e0a-b76d-1f546fae593e"
      decimals="0"
      id="F_203d9a99-6ae8-46e0-9896-e51610e0ae26"
      unitRef="U_shares">69661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_af781e94-ac4a-4e0a-b76d-1f546fae593e"
      decimals="2"
      id="F_76de9950-f7e3-4320-8802-89d8a8945bd9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_c9f8912d-9f62-4893-9fe4-44a124ce5bdf">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recognized by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7196725c-a392-4a09-b1a2-b1a1aec580da"
      decimals="-3"
      id="F_42bfeba7-c2e8-4b1f-8abf-20cf40fab0bd"
      unitRef="U_USD">28054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_501a8552-7901-4cd9-bf47-33b094f5f3d0"
      decimals="-3"
      id="F_a1611338-87a1-46a9-8f6b-28717659f855"
      unitRef="U_USD">29091000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6aa12542-94ac-49db-b8db-7d0fea16b3c2"
      decimals="-3"
      id="F_0b1099cb-f70c-494f-95d0-796b6bb9f573"
      unitRef="U_USD">27620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7e23f455-be7b-426a-9098-daac61a450fb"
      decimals="-3"
      id="F_632666f1-b655-42a3-a63d-87b3e1aaacf9"
      unitRef="U_USD">15866000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0dc3868d-624e-4ce9-8e45-344e9c7b99d4"
      decimals="-3"
      id="F_48af0aaf-9346-4575-bc7a-25aa8226bc98"
      unitRef="U_USD">10315000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f889aac3-200d-4251-9867-6d16afb64a27"
      decimals="-3"
      id="F_7db32b19-fb0b-4582-96a0-36f68ed2d1e3"
      unitRef="U_USD">3389000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e8173570-ac46-40d2-bbd0-da9598d7286b"
      unitRef="U_USD">43920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_ae7496a8-a539-4804-a2cd-052e2a410d34"
      unitRef="U_USD">39406000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_a2f5dba7-6fc2-49c2-96ce-ab8c56c0d089"
      unitRef="U_USD">31009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_76487ade-f415-46ea-acbd-1e37505bdc1e">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a24c8827-54a1-427b-bed0-b964f5520e1c"
      decimals="-3"
      id="F_9774f910-678e-4a32-a2ab-4712849b34d6"
      unitRef="U_USD">18784000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fadd17aa-74ce-41d1-ba1c-01a9d30e8d5b"
      decimals="-3"
      id="F_5f4fbdd1-d426-4197-ba00-f22cea316892"
      unitRef="U_USD">17509000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a3a9b56e-e418-462d-87f6-73709057c6a8"
      decimals="-3"
      id="F_b47b1294-d6d9-4492-ac97-ece022b29d75"
      unitRef="U_USD">12466000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7d36cd7b-896c-4b98-9546-ea32bed606cf"
      decimals="-3"
      id="F_d768a853-652b-4487-9c9f-c13eceb71dbb"
      unitRef="U_USD">25136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_34f5602a-7c3f-4806-8c95-b68c3340e325"
      decimals="-3"
      id="F_8a520e15-2d4f-4648-b7c2-e4c4490673f3"
      unitRef="U_USD">21897000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_08780583-41ea-448f-ad3c-a32d151f99de"
      decimals="-3"
      id="F_e59cddcc-bc30-4458-83c5-7769cedfe4ff"
      unitRef="U_USD">18543000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_b35114dc-4a63-413e-a448-48064335c91b"
      unitRef="U_USD">43920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_20f3706d-19cc-4c26-83d5-be1cf9359127"
      unitRef="U_USD">39406000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_f57405bd-cd2f-4342-9478-ef82602fbc48"
      unitRef="U_USD">31009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_69c35b9b-2ef7-4ee6-b016-6923857d4819"
      decimals="-5"
      id="F_56911c4a-f8bc-4439-a05c-f3df45f983b7"
      unitRef="U_USD">58500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_775eb4a6-0d31-417a-ac1c-4d459d9a1b5c"
      id="F_18ff41eb-329b-4506-bd4f-6b338fe4ee9a">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DerivativesAndFairValueTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_ebf51842-8c4d-4617-964d-0d6ca7ba66b0">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s outstanding warrants at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:21.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:35.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:25.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant/Assumption Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 21, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 21, 2030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;301,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 9, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 9, 2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;617,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 23, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;760,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;September 15, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 12, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,115,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table below is the summary of changes in the Company&#x2019;s warrants to purchase common stock for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:46.939%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:26.919%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.041%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Warrant Shares Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,721,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,715,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,115,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants Issued in Public Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued warrants to a related party during the years ended December 31, 2024 and 2023. For the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company sold pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common shares, respectively at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (see Note 8 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Stockholders Equity&#x201d;). The pre-funded warrants were acquired by funds affiliated with RTW (see Note 17 &#x201c;Related Party Transactions&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assumed Renovacor Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In conjunction with the acquisition of Renovacor, Rocket assumed outstanding public warrants, which were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;converted into warrants with a right to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;760,086&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Rocket common shares at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In conjunction with the acquisition of Renovacor, Rocket assumed outstanding private warrants, which&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were converted into warrants with a right to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;617,050&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Rocket common shares at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determined that the private warrants did not meet all of the criteria for equity classification. Accordingly, the Company classifies these as a derivative liability in other liabilities in the Consolidated Balance Sheets. The Company measures the fair value of these warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company&#x2019;s operating results for the current period. See Note 4 &#x201c;Fair Value of Financial Instruments&#x201d; for discussion of fair value measurement of the warrant liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In conjunction with the acquisition of Renovacor, Rocket assumed pre-funded warrants, which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were converted into warrants with a right to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,093&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Rocket common shares at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. These warrants were exercised in January 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_b91002c8-2688-43a2-96c5-4d64dbd4eaa5">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s outstanding warrants at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:21.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:35.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:25.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant/Assumption Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 21, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 21, 2030&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;301,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 9, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;August 9, 2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 17, 2031&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;617,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;April 23, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;760,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;September 15, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;December 12, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;N/A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,115,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table below is the summary of changes in the Company&#x2019;s warrants to purchase common stock for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:46.939%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:26.919%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.041%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.082%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Warrant Shares Outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,721,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,715,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,115,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54"
      decimals="2"
      id="F_6bcb8018-2ea4-4964-83cd-ed02026e2566"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">57.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54"
      decimals="INF"
      id="F_68b36fa1-af6f-4cb8-91ab-bf4ba0304e19"
      unitRef="U_shares">603386</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_63ca01b0-e7b0-45e5-aa8a-17201501dd48"
      id="F_d7a83c9e-99f6-4683-bd60-3d79c17b0ee6">2020-12-21</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_f6d08fbd-f40a-4a34-b523-c79a3f66ac54"
      id="F_16b1f5c0-53f4-4be5-87b3-e3a3ec9d94d5">2030-12-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_192b6914-1bac-4600-8f9d-77f09fef2c75"
      decimals="2"
      id="F_c5c9e304-a7c5-4685-a81c-bb18ad4c2981"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_192b6914-1bac-4600-8f9d-77f09fef2c75"
      decimals="INF"
      id="F_767f7cfc-2dda-46fc-a89f-939fffa7d257"
      unitRef="U_shares">301291</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_51821ea0-ebf2-416d-b94b-558384084f5c"
      id="F_e5845706-0c1f-457b-a657-4af76a1009b1">2021-08-09</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_192b6914-1bac-4600-8f9d-77f09fef2c75"
      id="F_a9ae022f-ebf0-49d9-bbe1-39b8c82c2072">2031-08-09</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8"
      decimals="2"
      id="F_02e7e77c-ea5f-487d-8b0b-0f22660e660d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8"
      decimals="INF"
      id="F_ad7b34ba-71e1-4d27-a624-4adb87817c22"
      unitRef="U_shares">153155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_6e010d18-1522-44a9-b62f-331c4708e6ee"
      id="F_80cd9325-2e78-4191-b477-02515e910ecc">2021-12-17</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_dcaae088-0d88-42a6-a6bd-a784e556a8a8"
      id="F_c0f8abd7-7d03-46bb-8f97-5468c7abcc71">2031-12-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0"
      decimals="2"
      id="F_04b3caf5-9ff7-44f5-bbbd-f8988410288e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0"
      decimals="INF"
      id="F_fa431f05-b940-4071-84f4-ba84a6893faa"
      unitRef="U_shares">153155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_a0c2517b-dc96-4c54-8ca8-8365a9a71c1e"
      id="F_a09f1133-e096-49ce-8a1b-ae9f770f361d">2021-12-17</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_a4c8d0b1-1a82-42bf-af82-ef7ca785eec0"
      id="F_0c382776-4a59-4dc6-a3db-2b4c8b092031">2031-12-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2b8daae2-1c08-437a-af18-31fd63828d53"
      decimals="2"
      id="F_00744670-8eff-4ab9-a867-04100a5f800a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">65.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_2b8daae2-1c08-437a-af18-31fd63828d53"
      decimals="INF"
      id="F_670f9a5e-f20e-412c-9f91-844791d9e7a3"
      unitRef="U_shares">617050</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_8cae4c49-ba69-493e-87c2-811bf32aab54"
      id="F_edd411ad-c975-4bc9-8c17-9bad4b0a6515">2022-12-01</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_2b8daae2-1c08-437a-af18-31fd63828d53"
      id="F_1552ebe2-7d22-4bef-8b4d-d14fe5eca5f8">2025-04-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2c739877-da67-4ce9-9177-ac7aba511326"
      decimals="2"
      id="F_c44d0866-7b2a-4df6-ae4c-fd68b1584f30"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">65.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_2c739877-da67-4ce9-9177-ac7aba511326"
      decimals="INF"
      id="F_679c07bc-fd19-4f8f-8746-d230a4cab2b7"
      unitRef="U_shares">760086</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_07a7dd6a-45bf-41e3-812c-421cdda9cc6b"
      id="F_3c73b93b-3f81-4338-af96-f106497d0735">2022-12-01</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_2c739877-da67-4ce9-9177-ac7aba511326"
      id="F_59d33346-af47-41a9-a095-667ba4225b2c">2026-12-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0b068067-3bc4-428c-8a9a-66ff44763c0b"
      decimals="2"
      id="F_fbbb0cb8-d460-4d32-92ef-7a893bbb705a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0b068067-3bc4-428c-8a9a-66ff44763c0b"
      decimals="INF"
      id="F_26a391fe-23ab-4c34-ad17-20383d7a5bb3"
      unitRef="U_shares">3126955</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_a62b5264-3059-4dbe-b8df-0bb7b813db23"
      id="F_10507d8e-66ee-4ffa-94da-74e394b6b460">2023-09-15</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ad2fb098-5ecf-47f9-9732-d89dedec0a31"
      decimals="2"
      id="F_df5a2a15-8109-40a8-8b42-1183a56e6461"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_ad2fb098-5ecf-47f9-9732-d89dedec0a31"
      decimals="INF"
      id="F_d692a41c-e52b-489c-bc0e-782074b7aea3"
      unitRef="U_shares">400000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <rckt:ClassOfWarrantOrRightGrantDate
      contextRef="C_84c34b9d-6390-46b6-8bd7-a209b92ac32e"
      id="F_307a2f34-0070-4311-905d-4124ab2dd9e7">2024-12-12</rckt:ClassOfWarrantOrRightGrantDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="INF"
      id="F_76e39a8a-0332-4a75-b3ec-b0014a5e33f5"
      unitRef="U_shares">6115078</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_61647b0b-b5df-4485-8420-e20842c8ff39"
      decimals="0"
      id="F_bae73696-d50c-4f18-ad1b-b4ac344d9f44"
      unitRef="U_shares">2721267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"
      decimals="0"
      id="F_0764471c-f123-4c12-8c09-808d72f16790"
      unitRef="U_shares">3126955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"
      decimals="2"
      id="F_4a2a32da-3e1e-4652-94c6-54171f8daa29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"
      decimals="0"
      id="F_992a4e48-869d-4661-9817-433881d69364"
      unitRef="U_shares">126093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"
      decimals="2"
      id="F_611c8370-0735-4bfb-97c2-5a135226a8bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.06</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"
      decimals="0"
      id="F_f05b47de-22c8-4335-a6a1-29cc1bfdac5a"
      unitRef="U_shares">7051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited
      contextRef="C_f11c9e2b-d66b-476b-b2f3-dce58a96dff5"
      decimals="2"
      id="F_df378ebe-c5eb-4f62-b7f5-d630f3ca0687"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.42</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_55db9cf5-dacb-451e-bc48-da645969b76a"
      decimals="0"
      id="F_5c91baa9-8540-4087-aeaf-2dc78c4622bb"
      unitRef="U_shares">5715078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332"
      decimals="0"
      id="F_03464235-cfc4-4c7b-8f76-2bf3351971ee"
      unitRef="U_shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332"
      decimals="2"
      id="F_dd3f1325-e5f9-4baf-8576-e1a8feb632c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332"
      decimals="0"
      id="F_19304011-8756-49a8-905e-aa97e87dbe63"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332"
      decimals="0"
      id="F_d2a2ac6f-3ee7-4801-b2e9-17b7c9caa4e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332"
      decimals="0"
      id="F_ca05ac39-adba-458f-8c39-d45bce74fcd7"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited
      contextRef="C_41fabef3-0abe-4db6-b3ec-ae0243277332"
      decimals="0"
      id="F_6fec4c5e-b767-46a7-92ed-2d5b34cc557e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a2ac1bfa-acd2-4922-9ccd-25d39d1ed512"
      decimals="0"
      id="F_6fae8166-0488-4bc1-924e-097274306dc5"
      unitRef="U_shares">6115078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_a589b03e-fb9c-4bfa-83f1-f8a8d07ed1fa"
      decimals="0"
      id="F_f893811a-6847-4256-84ca-66b03c7991bb"
      unitRef="U_shares">400000</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_2752ee0c-715c-4d1f-bee7-73f449628989"
      decimals="0"
      id="F_3889022f-64ed-4fcc-89ee-951f8c4a3496"
      unitRef="U_shares">3126955</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_594c6d62-c2cf-41a3-886a-1934d4223d53"
      decimals="2"
      id="F_c2738496-35d3-4892-b384-db9177a913d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2c40b128-241d-4c5e-acaf-fed48f581245"
      decimals="2"
      id="F_21824dad-afc0-441e-b8fb-0283457624e7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_c72cfefa-5df0-4873-ad35-93e437d2fecc"
      decimals="INF"
      id="F_98814ce0-875d-4d42-809b-0e98243c1c2e"
      unitRef="U_shares">760086</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c72cfefa-5df0-4873-ad35-93e437d2fecc"
      decimals="2"
      id="F_bd516057-2876-4ad0-98f5-e64a8c06f6ea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">65.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_e9d92f5a-8151-4cab-ad6d-17971fdc56a0"
      decimals="INF"
      id="F_70beb675-fca2-4cc1-acfc-96ec8670abd8"
      unitRef="U_shares">617050</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e9d92f5a-8151-4cab-ad6d-17971fdc56a0"
      decimals="2"
      id="F_672c08af-627b-4d8c-9640-a8187f17a99b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">65.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_b27c603f-0be6-4a87-b784-35a6acc0b66b"
      decimals="0"
      id="F_c06f5208-2552-414c-ba3e-974e9606cd4d"
      unitRef="U_shares">126093</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_b27c603f-0be6-4a87-b784-35a6acc0b66b"
      decimals="2"
      id="F_da2b0545-7d7a-4733-99e6-fe3b55d4bd91"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_870f9bb6-4763-4fb1-a2fa-ec0aa2cefd9e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,807,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,009,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,148,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023, the Company included the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential shares from the pre-funded warrants acquired by RTW in 2023 in the basic weighted-average common shares outstanding as it only requires the holder to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share upon exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, the Company included the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,126,955&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential shares from the pre-funded warrants acquired by RTW in 2023 and the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; potential shares from the pre-funded warrants acquired by RTW in 2024 in the basic weighted-average common shares outstanding as it only requires the holder to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share upon exercise.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,588,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,588,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,721,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,490,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;992,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,044,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,863,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,138,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total potential shares excluded from diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,116,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,942,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,853,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_2230b44a-64dc-4f31-af45-68cc5efdf5be">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,807,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,009,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,148,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share attributable to common stockholders - basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, &lt;/span&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_f86278e9-85c2-4904-9e65-dc89ba198c2f"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_1a96ceef-c2eb-4127-ba4d-3d23e3f92fa6"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_6693e76f-ab7c-4711-b577-16da81f9a936"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_b22d10a0-acb3-4514-b6ae-70658c8dd40d"
      unitRef="U_shares">94807773</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_de46ca60-1875-47ec-85e8-b70d78fb9d6d"
      unitRef="U_shares">94807773</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_c7947c0e-def2-423d-bb17-61613823b8e8"
      unitRef="U_shares">84009004</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_0397c179-04d5-4e63-bb6c-c13cc45b42f5"
      unitRef="U_shares">84009004</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_657efa99-7f53-4eeb-a2de-13d2f2f0fd8a"
      unitRef="U_shares">68148925</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_9dab512d-b613-49de-b3af-050b15db750e"
      unitRef="U_shares">68148925</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="2"
      id="F_0eea573e-54de-42dd-ad3a-c58a93852cc6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="2"
      id="F_16814a50-9648-4cdd-b19c-4f5861f3a16e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="2"
      id="F_ed758b21-9fb9-4df8-afb4-68193d816d42"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="2"
      id="F_2bc47205-80de-4b16-86e8-2558807c5c60"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="2"
      id="F_df83faa5-df99-490d-98fe-9bdc8807d9c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="2"
      id="F_3cf0904a-f150-48ab-a9b6-f103e47e5e2c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8"
      decimals="INF"
      id="F_68110d64-aa6c-4a14-823e-f9c82de6394e"
      unitRef="U_shares">3126955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8"
      decimals="2"
      id="F_7bb5b11d-0a39-42fc-beae-44d30718ae47"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_eb8a3a7b-414f-4ffc-960f-37e418c1edc8"
      decimals="INF"
      id="F_da976d8f-bb9d-49b6-8df0-a419daadd4ba"
      unitRef="U_shares">3126955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_845cdb5d-eeb4-4f91-b37f-77626c44f34b"
      decimals="INF"
      id="F_41347a42-2759-4f26-a153-397dae1b5738"
      unitRef="U_shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="C_845cdb5d-eeb4-4f91-b37f-77626c44f34b"
      decimals="2"
      id="F_27048268-e719-4726-8a6b-718dd688a07e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</rckt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_e9285cdf-8d75-4e30-90d3-a13bc3a733f5">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,588,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,588,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,721,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,414,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,490,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;992,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Performance stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,044,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,863,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,138,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total potential shares excluded from diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,116,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,942,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,853,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_d8704df7-d6b3-4a8c-a990-d418ea649654"
      unitRef="U_shares">2588123</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_8e795506-6b30-40a6-a70f-a59d237113a6"
      unitRef="U_shares">2588123</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_9435701c-3143-4fc9-b7f0-5f4c9ee09c49"
      unitRef="U_shares">2721267</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_1b20cf0a-1520-43ae-b3ff-43a22fac3d09"
      unitRef="U_shares">1414210</rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares>
    <rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_9f01396f-312b-4a26-a429-9238bb3958ab"
      unitRef="U_shares">1490357</rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares>
    <rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_782251ac-ce4f-459e-b932-fe8a880aac0c"
      unitRef="U_shares">992874</rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares>
    <rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_17680a45-dabc-4742-9679-183718f1c6a0"
      unitRef="U_shares">69661</rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares>
    <rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_a00b67ce-32db-437f-a13c-f59bd998c6d8"
      unitRef="U_shares">0</rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares>
    <rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_bd1fabf5-2493-49d8-9b24-243937515cc1"
      unitRef="U_shares">0</rckt:IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_a352d276-3b11-4ac0-9967-027d7eb56415"
      unitRef="U_shares">16044686</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_95f1dded-b09e-4791-8dc9-d3d7a2df2fcc"
      unitRef="U_shares">14863996</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_b44991b9-888d-4d49-a7a8-c9c76c990c79"
      unitRef="U_shares">13138870</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="0"
      id="F_2e458d8d-d017-45fd-a8d3-8c9d82237044"
      unitRef="U_shares">20116680</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="0"
      id="F_13a4f01b-2d7a-4d5d-a43d-0cbc92cd8798"
      unitRef="U_shares">18942476</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="0"
      id="F_9fd9a3bd-dd21-4761-8c26-db12414d17bb"
      unitRef="U_shares">16853011</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_0668cb6c-7ba9-44b7-999a-6b16fba3ff24">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; provision for federal or state income taxes was recorded during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022, as the Company incurred operating losses and maintains a full valuation allowance against its net deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in state tax apportionment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Return to provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 4, 2023, the Governor of Massachusetts signed into law a bill that included the adoption of a single sales apportionment factor effective on January 1, 2025. As required under ASC 740, the Company has accounted for the deferred tax impacts of this tax law change in the period the tax law was enacted, which has the impact of reducing its state deferred tax assets. The impact of the tax law change is offset by a change in valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intellectual property rights in different jurisdictions are reflected in the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s deferred income tax assets and liabilities after applying the enacted corporate tax rates are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses and credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred income tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company had federal and state net operating loss (&#x201c;NOL&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The state NOL begins to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0a395aa8-c4ae-4063-a1b7-e3d080e5ffcf;"&gt;&lt;span style="-sec-ix-hidden:F_f8ada714-1a3a-4a7f-a2c0-3691e7ff6012;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Additionally, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the federal NOL can be carried forward indefinitely. The Company has federal R&amp;amp;D credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_476f0015-4836-4e88-9984-744d464250a3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As required by ASC 740, Income Taxes, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of NOL carryforwards and capitalized research and development costs. As a result of the fact that the Company has incurred tax losses from inception, management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state net deferred tax assets and, as a result, a full valuation allowance has been established against its net deferred tax assets as of December 31, 2024, 2023 and 2022. The Company has offset certain deferred tax liabilities with deferred tax assets that are expected to generate offsetting deductions within the same period. During the years ended December 31, 2024,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2023 and 2022 the valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Realization of deferred tax assets is dependent upon the generation of future taxable income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under Internal Revenue Code Section 382, if a corporation undergoes an &#x201c;ownership change,&#x201d; the corporation&#x2019;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income may be limited. The Company has completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company became a &#x201c;loss corporation&#x201d; as defined in Section 382. The Company experienced multiple ownership changes occurring in 2005, 2007, 2015, and 2018. The ownership change has and will continue to subject our pre-ownership change net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of our stock at the time of the ownership change multiplied by a specified tax-exempt interest rate. As a result of the merger on January 4, 2018, the Company is limited to an approximate $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million annual limitation on our ability to utilize the NOL&#x2019;s and R&amp;amp;D Credits prior to the ownership change. Due to this limitation, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million pre-merger Federal NOL will expire unutilized as the cumulative limitation amount over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; carryforward period is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Additionally, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of federal R&amp;amp;D credits will expire unutilized. As a result, the Company has reduced its deferred tax assets related to the Federal NOL and federal R&amp;amp;D credits by an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which is offset by the corresponding decrease in the valuation allowance. In conjunction with the acquisition of Renovacor, the Company acquired Renovacor&#x2019;s federal NOL&#x2019;s of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company has completed a study to assess whether an ownership change has occurred as a result of the transaction. The Company experienced ownership changes occurring in 2021 and 2022. As a result of the ownership changes, the Company is limited on our ability to utilize our Renovacor NOL&#x2019;s. As a result of the Company&#x2019;s study, any limitation under IRC Sec. 382 would not result in NOLs expiring unused.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#x2019;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2024 and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2023, the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any uncertain tax positions in its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties are included on the related tax liability line in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2"
      decimals="-3"
      id="F_d151c9be-dabe-4283-b0d0-b39c6c97e225"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fe613fec-8a94-4877-8745-1c95fb74dd4e"
      decimals="-3"
      id="F_82666f1e-3d72-4895-8773-aa7a2e9f4147"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1bae87d0-dd44-44ba-9b20-91cc4df8a8be"
      decimals="-3"
      id="F_b2a371b8-b8e7-4d1d-8128-960153415518"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_4f31d0b2-9168-421f-9d72-9e9a0e804859">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in state tax apportionment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Return to provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_86df5d8d-f1e5-49c2-a9ab-76903b6527cb"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_394d7642-5e38-4273-bdf5-d88d3b654b82"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_7d0a5610-f2db-4b50-bf8f-38ac60255537"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_5c32228e-f364-43ef-9cd4-ac4a196f610b"
      unitRef="U_pure">-0.125</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_6f202b0f-7e34-4cfd-aa98-edbfcdd19caf"
      unitRef="U_pure">-0.173</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_71fff192-d71f-43bb-9334-d61c7db13572"
      unitRef="U_pure">-0.169</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_8e611e06-d86f-4870-b435-f4f84da484fb"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_f89349bc-e79f-432c-bead-ebd58d55d0e4"
      unitRef="U_pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_102ea39e-a29f-4231-b1db-b7553acf9373"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_52060f2e-eff7-4825-aacc-8b5fe142289d"
      unitRef="U_pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_c599d835-2884-4e1d-9fdd-c782e0a968ca"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_f442d8a3-c2d4-452f-8125-15ef13d82b59"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_5da87bbe-d219-440b-88b9-30e0c341df2b"
      unitRef="U_pure">0.015</rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_2af5c56e-3b72-4f07-bd3a-f9bf1fc5c34e"
      unitRef="U_pure">0.02</rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_8cf3b5b2-b415-4b2b-927c-939084023808"
      unitRef="U_pure">-0.027</rckt:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_437e5f45-784b-4e6f-a0a9-d694767e5190"
      unitRef="U_pure">-0.08</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_fc7aad79-34be-4001-b00f-3487b4799b16"
      unitRef="U_pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_83a1d9f2-f3ca-49a1-a2c0-fe0912eaf1c4"
      unitRef="U_pure">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_9e29b193-fe1c-4a29-8b83-17d728b603a2"
      unitRef="U_pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_22211293-c965-4a97-99a6-43c0cc48fd70"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_45974880-b793-4822-8e8f-c5f116af363b"
      unitRef="U_pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="3"
      id="F_841d782a-a34e-4698-9df7-71592a05724c"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="3"
      id="F_a192d399-a3ed-41cb-bca7-1a1328b8f9bf"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="3"
      id="F_ba5776c0-2331-433b-a296-bb2a30116e6a"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="2"
      id="F_ae567a03-ac91-4cd3-b5c7-b9ba52a01427"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="2"
      id="F_b50ad4b1-11cc-4ebc-843d-99bbe6278968"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="2"
      id="F_2ee1f433-624f-412c-94f6-7625dca9049f"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_43ea8552-ba78-445a-9837-145cf4556594">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s deferred income tax assets and liabilities after applying the enacted corporate tax rates are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:59.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred income tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating losses and credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;108,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred income tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_47020e5f-76ee-4942-bf78-cd45ff54e178"
      unitRef="U_USD">21410000</rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_e4553ca3-31f2-4983-bd1c-bc81d7760205"
      unitRef="U_USD">20984000</rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_b0b0d145-acf5-43a4-8b40-62e18e377093"
      unitRef="U_USD">20984000</rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_05ea0911-db48-478e-9352-8452870bbb7e"
      unitRef="U_USD">67591000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_f0faa64f-38bd-46ec-9732-e8b0672043f3"
      unitRef="U_USD">45313000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_94af28b5-0604-40b2-9000-0ad3593cca0b"
      unitRef="U_USD">33718000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_7ac09dbb-7b77-4bee-9531-109071d955f7"
      unitRef="U_USD">14787000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_a197367a-fa87-4aa1-80ea-eb2ab1556e97"
      unitRef="U_USD">17205000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_a6abe1a3-4915-4d15-bffc-6ddcff2ba0f3"
      unitRef="U_USD">19085000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_11b72695-dce1-42eb-b836-798e2a815bd4"
      unitRef="U_USD">29041000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_8ea1729f-b13e-4b71-bdd4-4bbd58cd1253"
      unitRef="U_USD">28499000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_8b1e6f06-3e32-4532-a982-9d24da063673"
      unitRef="U_USD">19781000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <rckt:DeferredTaxAssetsWarrants
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_5154927f-b9f8-4648-81a3-f960d571db3a"
      unitRef="U_USD">8713000</rckt:DeferredTaxAssetsWarrants>
    <rckt:DeferredTaxAssetsWarrants
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_956f85d9-b176-4dee-bdce-05336c43563e"
      unitRef="U_USD">9283000</rckt:DeferredTaxAssetsWarrants>
    <rckt:DeferredTaxAssetsWarrants
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_026d1d06-3654-4b06-ae97-2ed1a4a84732"
      unitRef="U_USD">8390000</rckt:DeferredTaxAssetsWarrants>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_cecf0200-0376-4bf7-93c7-51c67b1725bc"
      unitRef="U_USD">5697000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_da85fd21-ba6e-4576-87bf-121ebf00ef53"
      unitRef="U_USD">5787000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_0fd0275f-3814-4441-b8e0-6622b6294a33"
      unitRef="U_USD">5424000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_3031b860-ab33-4b5a-8a96-1833f67e4132"
      unitRef="U_USD">7829000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_ee969a6d-49cc-4bfa-9fc1-aed3d2357a84"
      unitRef="U_USD">8086000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_d2243b72-142c-4578-a74f-8445579c4b35"
      unitRef="U_USD">6332000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_21fcb97b-3b83-42ca-98e4-a2d843503736"
      unitRef="U_USD">129077000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_cdb375e1-1361-4d71-aa69-a79fad722820"
      unitRef="U_USD">108472000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_d2b3b3d8-09ea-48eb-9676-a6dd56a6dfe7"
      unitRef="U_USD">91263000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_4fa98e66-6564-429e-969e-8ed75f5b0829"
      unitRef="U_USD">1061000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_02ce30c0-df9a-421a-95f4-ba56eb59a36f"
      unitRef="U_USD">1061000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="-3"
      id="F_b97eea29-3e04-4c07-8bf3-ef3466bd468f"
      unitRef="U_USD">1061000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1"
      decimals="-5"
      id="F_8ec042d6-4f0a-4f46-972b-d521b466b15b"
      unitRef="U_USD">303600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_4aa60fef-eb52-492b-9a6b-0ce93d49fb48"
      decimals="-5"
      id="F_5b27e110-9e03-4261-a243-6e08c00b6ac5"
      unitRef="U_USD">78200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1"
      decimals="-5"
      id="F_98e16cf6-c13c-443b-a667-f9daf4aca5da"
      unitRef="U_USD">303600000</us-gaap:OperatingLossCarryforwards>
    <rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1"
      decimals="-5"
      id="F_c38e81f1-9838-40b5-8b8d-d1816eb9a3f8"
      unitRef="U_USD">21400000</rckt:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-5"
      id="F_a55beb85-786d-4bf0-8a18-01b53781e03a"
      unitRef="U_USD">20600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-5"
      id="F_bada1cbe-ff49-4a81-9618-b9a2b1c1b044"
      unitRef="U_USD">17200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-5"
      id="F_509c6230-c386-42f8-8703-fc76b513bbfa"
      unitRef="U_USD">2100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <rckt:AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-5"
      id="F_103545b0-7606-4b1d-9f50-7199415c5edd"
      unitRef="U_USD">1700000</rckt:AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_e74a48a3-05d2-4751-8cd8-1f14b04dcc09"
      decimals="-5"
      id="F_f8399c9a-ea56-4e0e-ac7a-032e017dbba5"
      unitRef="U_USD">91200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_e74a48a3-05d2-4751-8cd8-1f14b04dcc09"
      decimals="-5"
      id="F_acb12e16-ce01-4362-972d-b04b0bb6273b"
      unitRef="U_USD">127100000</us-gaap:OperatingLossCarryforwards>
    <rckt:OperatingLossCarryforwardsCumulativeLimitationPeriod
      contextRef="C_4debd961-aac7-48c4-9e45-f2780c6806f2"
      id="F_3354e879-8a43-4eb3-bbda-8ab4ff0426d2">P20Y</rckt:OperatingLossCarryforwardsCumulativeLimitationPeriod>
    <rckt:DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration
      contextRef="C_417e8c30-0abe-4d04-a2c7-aef8b4c2dbc1"
      decimals="-5"
      id="F_35a775cf-d157-4aaf-8833-928f98875c97"
      unitRef="U_USD">35800000</rckt:DeferredTaxAssetsOperatingLossCarryforwardsCumulativeAmountSubjectToExpiration>
    <rckt:DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration
      contextRef="C_bf12f724-78e9-4689-a9d8-6cfcdb16921d"
      decimals="-5"
      id="F_019201e8-bf12-4b8a-80bf-07d447b41990"
      unitRef="U_USD">4900000</rckt:DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration>
    <rckt:DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration
      contextRef="C_bf12f724-78e9-4689-a9d8-6cfcdb16921d"
      decimals="-5"
      id="F_f9ff68b0-dd8c-4d1b-9118-0949110c8baa"
      unitRef="U_USD">4900000</rckt:DeferredTaxAssetsTaxCreditCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_1a9df4ee-5889-42bf-97e5-3fe2409b390d"
      decimals="-5"
      id="F_bd2132f1-2950-4969-b377-95c3b08b1f30"
      unitRef="U_USD">46400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-6"
      id="F_e8cf2b6b-73f1-4e98-9a32-162a9f42d85d"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-6"
      id="F_4d5006bb-909a-4bc8-92d9-96f4641412cc"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-6"
      id="F_fcf9e0d9-a44e-44f9-ba2b-ffc110eb9aa4"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-6"
      id="F_c495d38e-322c-4226-9a92-4ee1bcf06330"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LessorSalesTypeLeasesTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_fac00edd-f0c0-4e8b-a4f0-e07196f1ea75">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Finance Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a lease for a facility in Cranbury, New Jersey, consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,720&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of space including areas for offices, process development, research and development laboratories and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet dedicated to AAV &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cGMP manufacturing facilities to support the Company&#x2019;s pipeline (such lease, as amended, the &#x201c;NJ Lease Agreement&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The NJ Lease Agreement has a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year term from September 1, 2019, with an option to renew for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; renewal terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated rent payments for the NJ Lease Agreement are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per annum, payable in monthly installments and subject to annual base rent increases of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The total commitment under the lease is estimated to be approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year term of the lease. The Company paid a cash security deposit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to the landlord in connection with the NJ Lease Agreement which has been reflected &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as part of deposits in the Consolidated Balance Sheets as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 7, 2018, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ESB Lease Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In connection with the ESB Lease Agreement, the Company established an irrevocable standby letter of credit &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On March 26, 2021, the Company entered &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;into Amendment No. 1 to the ESB Lease Agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;that extended the term of the lease agreement to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On March 29, 2024, the Company entered into Amendment No. 2 to the ESB Lease Agreement that extended the term of the lease agreement to July 31, 2027.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The letter of credit serves as the Company&#x2019;s security deposit on the lease in which the landlord is the beneficiary and expires &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 30, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a certificate of deposit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million with a bank as collateral for the ESB LeaseAgreement letter of credit which is classified as part of restricted cash in the Consolidated Balance Sheets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 1, 2022, in connection with the acquisition of Renovacor, the Company added &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;operating leases for spaces at facilities in Hopewell, New Jersey and Cambridge, Massachusetts with remaining lease terms of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.25 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years, respectively. As &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of December 31, 2024, lease commencement dates had occurred for all leases and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company recognized total right-of-use assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million with corresponding total lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;at lease commencement dates. The Company intends to sublease the facilities in Hopewell, New Jersey and signed the first agreement to sublease one of these facilities in January 2024. Rental income received under sublease agreements for the facilities in Hopewell, New Jersey totaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rent expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total restricted cash balance for the Company's operating and finance leases as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes lease cost for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years ended December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance lease cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the maturity of the Company&#x2019;s lease liabilities on an undiscounted cash flow basis:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fiscal Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fiscal Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the operating and financing lease liabilities and right-of-use assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.752%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.122999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.122999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating current lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating noncurrent lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance current lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance noncurrent lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.915%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.636%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash flows from finance lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term - finance lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate - finance lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:LessorSalesTypeLeasesTextBlock>
    <rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities
      contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603"
      decimals="INF"
      id="F_c7cd6f49-ef3d-431a-933f-f3ebf1d77849"
      unitRef="U_sqft">103720</rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities>
    <rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities
      contextRef="C_f9abc263-c852-40e4-bb93-fffa5f59bb9a"
      decimals="INF"
      id="F_ea2de813-2eaa-4cad-8477-89d37acee9b4"
      unitRef="U_sqft">50000</rckt:LeaseAreaForInternalProcessDevelopmentAndResearchActivities>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8"
      id="F_9968b89f-48c1-4fa2-aefa-3d3da6c3d9d3">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <rckt:NumberOfOptionsToRenewLeaseAgreement
      contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603"
      decimals="INF"
      id="F_75e7b8d4-1b21-4b25-a5f1-5f39887d73ad"
      unitRef="U_Leaseagreement">2</rckt:NumberOfOptionsToRenewLeaseAgreement>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8"
      id="F_27e92c54-8227-45af-8b2b-76c68d6d326e">P5Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <rckt:FinanceLeasesEstimatedRentPayments
      contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603"
      decimals="-5"
      id="F_1d9f8ad1-5e23-4110-b434-02da9a7fad65"
      unitRef="U_USD">1200000</rckt:FinanceLeasesEstimatedRentPayments>
    <rckt:PercentageOfAnnualIncreaseInBaseRent
      contextRef="C_2f0c010b-87c8-42b0-9da6-1c012fc63603"
      decimals="2"
      id="F_ea714bbf-308a-467b-b2b2-3292f6491d37"
      unitRef="U_pure">0.03</rckt:PercentageOfAnnualIncreaseInBaseRent>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8"
      decimals="-5"
      id="F_beda2212-6286-4566-930b-65628f6dfae4"
      unitRef="U_USD">29300000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8"
      id="F_fcc2ee31-7191-4d5a-9c2e-43ad5fb39b30">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_9cc0dca2-5f03-481d-b71e-be894ad6c9f8"
      decimals="-5"
      id="F_06fb45d0-5e10-4a0b-afb8-d584e97e8a29"
      unitRef="U_USD">300000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_05d3269a-9c6d-44e5-9b7c-99c1bf950fb2"
      id="F_4a63cc39-c47b-4c59-8b00-f9dfb86efce7">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LinesOfCreditCurrent
      contextRef="C_05d3269a-9c6d-44e5-9b7c-99c1bf950fb2"
      decimals="-5"
      id="F_178ba56e-1bfa-4272-b987-ce9fc7befa29"
      unitRef="U_USD">800000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_76dc7d6c-2561-4ef0-81f4-82f6593b6052"
      id="F_20039975-5c75-4a58-a2a0-6bc96dd09d5c">2024-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_842fddb4-2c73-4db6-a334-14dfdfb8754b"
      id="F_f3bc2e57-495b-451d-8524-07b498eb3f62">2027-09-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:CertificatesOfDepositAtCarryingValue
      contextRef="C_71fbe897-d128-4353-aa54-ac82b0209669"
      decimals="-5"
      id="F_147ff651-01ac-4e8d-a0b6-3fe1ae6d8471"
      unitRef="U_USD">800000</us-gaap:CertificatesOfDepositAtCarryingValue>
    <us-gaap:CertificatesOfDepositAtCarryingValue
      contextRef="C_f6f45e22-281d-462c-89e9-34ded8f15e53"
      decimals="-5"
      id="F_8bbd8264-8e16-4e01-847c-83f75aef81cd"
      unitRef="U_USD">800000</us-gaap:CertificatesOfDepositAtCarryingValue>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_2765a887-d17f-45bb-83df-c1b045d9460d"
      id="F_6cc9bf31-3ca9-4869-8ef9-b9ec5e9cc8d2">P10Y3M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_f6793c34-d860-442e-be6e-737f243f3d98"
      id="F_34364d6c-a3bd-4b88-99de-3ba3da3ea782">P1Y3M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f6793c34-d860-442e-be6e-737f243f3d98"
      decimals="-5"
      id="F_4ffcbd43-79cc-4ca9-92ed-0be5afce3158"
      unitRef="U_USD">3800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f6793c34-d860-442e-be6e-737f243f3d98"
      decimals="-5"
      id="F_ae54cdac-9e2e-40fa-8d66-cc0897032590"
      unitRef="U_USD">3600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SubleaseIncome
      contextRef="C_c182ea63-0464-4304-ac90-99a8af5eefc8"
      decimals="-5"
      id="F_f4afdbd1-7998-469f-b97b-94d0d4431dc0"
      unitRef="U_USD">500000</us-gaap:SubleaseIncome>
    <us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-5"
      id="F_cc4b7ebb-cffe-44f1-a81f-35979814c937"
      unitRef="U_USD">1500000</us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment>
    <us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-5"
      id="F_0cd7c6bb-3002-4feb-8d17-d7bd3ef626a0"
      unitRef="U_USD">1400000</us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment>
    <us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-5"
      id="F_6775b515-c106-44ca-ba55-2fabb8877832"
      unitRef="U_USD">900000</us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_c8dbc4c6-e882-4412-ac54-add80894cf82"
      decimals="-5"
      id="F_407486b2-c1fa-45e8-abd7-f3b2b2cffe2f"
      unitRef="U_USD">800000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="C_c12614f0-c656-4035-8e89-9961453df24f"
      decimals="-5"
      id="F_c8004df7-9e42-4c4b-b93c-37c419d550cd"
      unitRef="U_USD">800000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_9925d38f-08c0-48c2-aeb6-fd1977591b08">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes lease cost for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years ended December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance lease cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_6c14a9e8-4412-4977-94ba-9e4f4e5a003d"
      unitRef="U_USD">1247000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d8e711a7-6cac-4f82-b56c-823f0d2c796a"
      unitRef="U_USD">1377000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_d19f195c-c484-491a-a877-d0b83da7d35e"
      unitRef="U_USD">818000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_6ab10d0f-ce37-4071-bacf-fbc9df988969"
      unitRef="U_USD">2154000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_ee0b8e66-4b6b-4a53-8a5d-259129f1ec3c"
      unitRef="U_USD">2154000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_f27b9192-0596-467f-aa95-423f5b650478"
      unitRef="U_USD">2139000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_c9769384-6312-4edf-ad81-1a08f7029703"
      unitRef="U_USD">1886000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_9744bdc8-729b-45d4-b446-e1d065a4cbb0"
      unitRef="U_USD">1875000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_46a52d9d-1d2c-4671-b375-28d6bb6cd1cb"
      unitRef="U_USD">1861000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_a8f3a9f9-e22c-4fea-baba-720cecccbafc"
      unitRef="U_USD">5287000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_6782ce2d-c58e-43ad-b765-261d11c7597f"
      unitRef="U_USD">5406000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_dd3f4a71-1ca9-4352-a1e6-ca1506e13cc6"
      unitRef="U_USD">4818000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_2f9a4a40-ca5d-473e-bde1-8d7653ce9958">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the maturity of the Company&#x2019;s lease liabilities on an undiscounted cash flow basis:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fiscal Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_3669699e-2f9a-4a4a-a0f0-8e5979bc13d8"
      unitRef="U_USD">1001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_60fa7977-95d8-4471-9a19-d4e0fed4d195"
      unitRef="U_USD">1005000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_8d95ef2c-a2ee-43e9-928e-50bad8a183a7"
      unitRef="U_USD">759000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_9f8b1eac-772f-4acc-bad4-0a322d852f67"
      unitRef="U_USD">522000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_27787b45-c3c2-4c82-86e1-0692240a33bc"
      unitRef="U_USD">539000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_16aa04e2-9e3a-41dd-97d2-4559545c4e0f"
      unitRef="U_USD">1881000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_d0230fd4-6476-485e-b7de-259c2c209c04"
      unitRef="U_USD">5707000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_325b4414-6e9e-4653-bfd4-501e02c78a33"
      unitRef="U_USD">1448000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_3f72c4e3-915c-4cf7-99d5-bf2494d37f58"
      unitRef="U_USD">4259000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_8a3c13e5-4e8d-44b6-845c-29d21666c2f5">
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:22.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fiscal Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_76a5a4bd-41a1-4001-ba3d-d3325fc9e1ce"
      unitRef="U_USD">1856000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_fc05b8f5-025e-495a-ad0a-721fffc5e625"
      unitRef="U_USD">1911000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_4f5e2872-38d7-4b15-9535-bcd0f06e3bdb"
      unitRef="U_USD">1969000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_9a5e6cd6-c4c0-4a8b-8689-650c505da05c"
      unitRef="U_USD">2028000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_e98d6a7f-58c4-4093-9f44-712fbc8644d6"
      unitRef="U_USD">2089000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_85b2bb59-fac6-4a28-bca4-953c04a3ce82"
      unitRef="U_USD">38915000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_fdc62a43-0776-477b-82dd-056a0907f0c3"
      unitRef="U_USD">48768000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_7bdc40a0-b88b-43ae-b5de-28c58a88dcda"
      unitRef="U_USD">27529000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_deadf0c3-fd4e-45e5-9a3d-dba6dd2b5db9"
      unitRef="U_USD">21239000</us-gaap:FinanceLeaseLiability>
    <rckt:LeaseBalanceSheetInformationTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_7bd6e2ca-4df5-49e5-b79c-8f6f8e248625">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the operating and financing lease liabilities and right-of-use assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.752%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.122999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.122999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating current lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating noncurrent lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance current lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finance noncurrent lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</rckt:LeaseBalanceSheetInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_b803def2-6ca1-4352-8cb6-6a7dae928ebb"
      unitRef="U_USD">4173000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_8204a373-75bf-418c-9f74-b856e2b9a9eb"
      unitRef="U_USD">3901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_b4954460-8552-4a46-a73e-3d14e848b71c"
      unitRef="U_USD">1001000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_ce214a22-e5d9-44c9-a8f6-88d65c1062e2"
      unitRef="U_USD">925000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_32bb8694-77f1-455c-b1a2-7d939d4585bb"
      unitRef="U_USD">3258000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_ed6d6100-6cef-4bfa-8fd9-60b4da2cd7af"
      unitRef="U_USD">2973000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_fabba31c-9909-4152-8b06-c94166831a01"
      unitRef="U_USD">4259000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_02592ad2-dde8-46dc-ad3e-c7bf17d2b53e"
      unitRef="U_USD">3898000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_50fa84a9-3931-4ce2-b425-882571f78ab7"
      unitRef="U_USD">42363000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_ec12c819-294f-43d7-a745-177aec8eb2fe"
      unitRef="U_USD">44517000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_98ca5d2a-1511-4285-95f1-06a82106a416"
      unitRef="U_USD">1856000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_7e6c525e-8f07-44b9-aa6c-75d9168ece89"
      unitRef="U_USD">1791000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_008a9f32-a6c4-4828-81d7-c36d3432d11b"
      unitRef="U_USD">19383000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_9decadda-f4ff-4a07-a4a1-556dbf4b5287"
      unitRef="U_USD">19353000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="-3"
      id="F_e50913dc-1ee8-4eae-b299-e15fb5ea167d"
      unitRef="U_USD">21239000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="-3"
      id="F_2c50d338-d5f1-490a-b557-f44e8ecf8563"
      unitRef="U_USD">21144000</us-gaap:FinanceLeaseLiability>
    <rckt:LeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_eaf59830-f779-4d1d-9c50-761bea5a97d4">
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.915%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.225%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.636%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash flows from finance lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term - finance lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate - finance lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</rckt:LeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_dba69599-785b-42a5-bcbd-7b5fcbd60e6c"
      unitRef="U_USD">1157000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_f4dd8b7b-789b-4a16-aab1-ed4a46e3e4bb"
      unitRef="U_USD">894000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_23edd121-68d5-45f1-945c-a544a07fbe28"
      unitRef="U_USD">938000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7f039fbd-7020-4460-b97b-9192856d639d"
      unitRef="U_USD">1791000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_d53ef118-bb7d-4462-ba57-217c685c9c9f"
      unitRef="U_USD">1296000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_da0fc314-e69b-4bfb-8b3d-04bd80ff7724"
      unitRef="U_USD">1689000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      id="F_4b21efa4-ba30-4a38-b16d-637fb15a97ac">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      id="F_1914f0be-e1a1-47c0-821e-2fa30bce412a">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      id="F_4bd448d5-6df4-4c9a-a940-ff345413cd93">P4Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      id="F_fccc39ab-bdf5-419b-a4c9-0038ca770035">P19Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      id="F_b73942fb-99f5-4de7-a8aa-310519812489">P20Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      id="F_b4a0c927-56fe-4cfd-8918-6104e04b7337">P21Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="4"
      id="F_815b5301-6f89-4dd6-ac16-444fde6bcb3a"
      unitRef="U_pure">0.0882</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="4"
      id="F_f413963d-2c11-4564-89d9-d170e8a999e1"
      unitRef="U_pure">0.0834</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="4"
      id="F_0a6fabfa-f7c2-4e46-85de-e70d5c23deeb"
      unitRef="U_pure">0.0644</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0a90aae5-1098-4d84-8da8-2fb68133b607"
      decimals="4"
      id="F_bd75fe98-831d-4b39-92ec-27836e05b0fc"
      unitRef="U_pure">0.0896</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4ff6c49f-8407-479c-80d4-c307efd55622"
      decimals="4"
      id="F_fb3f8c4d-13ed-488a-9e6b-0cf581a41e57"
      unitRef="U_pure">0.0896</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0bcf5b2f-1c4b-4bd3-b2a2-88e64b9c6ec1"
      decimals="4"
      id="F_d44feed1-3735-4b65-86c5-5ffc09e177b9"
      unitRef="U_pure">0.0869</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_030c5143-60b9-48ae-a0cd-c1e586d81df7">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to its bylaws and as permitted under Delaware law, the Company has indemnification obligations to directors, officers, employees or agents of the Company or anyone serving in these capacities. The maximum potential amount of future payments the Company could be required to pay is unlimited. The Company has insurance that reduces its monetary exposure and would enable it to recover a portion of any future amounts paid. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Throughout the normal course of business, the Company has agreements with vendors that provide goods and services required by the Company to run its business. In some instances, vendor agreements include language that requires the Company to indemnify the vendor from certain damages caused by the Company&#x2019;s use of the vendor&#x2019;s goods and/or services. The Company has insurance that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rckt:AgreementsRelatedToIntellectualPropertyTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_af94ae88-ae67-4a29-949b-e5cb9f3adef3">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreements Related to Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, directly and through its subsidiary Spacecraft Seven, LLC, has various license and research and collaboration arrangements. The transactions principally resulted in the acquisition of rights to intellectual property which is in the preclinical phase and has not been tested for safety or feasibility. In all cases, the Company did not acquire tangible assets, processes, protocols or operating systems. The Company expenses the acquired intellectual property rights as of the acquisition date on the basis that the cost of intangible assets purchased from others for use in research and development activities, has no alternative future uses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement for PKD with CIEMAT Group&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2016, the Company entered into a license agreement with CIEMAT Group&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, granting Rocket worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human PKLR gene solely within the field of treating PKD. Under the terms of the agreement, the Company is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0f41fdbb-616b-4390-91ca-6c0083fedb69;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, Rocket is obligated to pay CIEMAT Group an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. The Company is responsible for prosecuting and maintaining the licensed patents at its expense, in cooperation with CIEMAT Group. Rocket also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group. For five years following the effective date of the license agreement, the Company has a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group at market value. Rocket is obligated to license (without charge) to CIEMAT Group for non-commercial use any improvements to the licensed intellectual property that it creates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As consideration for the licensed rights, Rocket paid CIEMAT Group an initial upfront license fee of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) which was expensed as R&amp;amp;D costs. The Company is obligated to make aggregate milestone payments of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) to CIEMAT Group upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the PKD license, Rocket is obligated to pay a low to mid-single digit percentage royalty on net sales, subject to specified adjustments, by the Company or its sublicensees or affiliates. In the event that Rocket enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rocket may terminate this agreement at any time by providing CIEMAT Group with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement for FA with CIEMAT Group and FIBHNJS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2016, Rocket entered into a license agreement with CIEMAT Group and FIBHNJS granting it worldwide, exclusive rights to certain patents, know-how, data and other intellectual property relating to LVs containing the FANCA gene solely within the field of human therapeutic uses of VSV-G packaged integration component LVs for FA type-A gene therapy. This license is only sublicensable with the prior consent of CIEMAT Group and FIBHNJS, not to be unreasonably withheld. Under the terms of the agreement, Rocket is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_df646047-6e29-47e2-b2b5-6f058df99877;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, the Company is obligated to pay CIEMAT Group and FIBHNJS an up-front payment, royalty payments based on net sales of products or processes involving any of the licensed intellectual property, regulatory and financing milestone payments, and sublicense revenue payments. The Company is responsible for prosecuting and maintaining the licensed patents at our expense, in cooperation with CIEMAT Group and FIBHNJS. Rocket also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with CIEMAT Group and FIBHNJS. For five years following the effective date of the license agreement, the Company has a right of first refusal to license any improvements to the licensed intellectual property obtained by CIEMAT Group and FIBHNJS at market value. Rocket is obligated to license (without charge) to CIEMAT Group and FIBHNJS for non-commercial use any improvements to the licensed intellectual property that it creates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As consideration for the licensed rights, Rocket paid CIEMAT Group and FIBHNJS an initial upfront license fee of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), which was expensed as R&amp;amp;D costs. The Company is obligated to make aggregate milestone payments of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) to CIEMAT Group and FIBHNJS upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the license, Rocket is obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by Rocket or its sublicensees or affiliates. In the event that the Company enters into a sublicense agreement with a sublicensee, the Company will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rocket may terminate this agreement at any time by providing CIEMAT Group and FIBHNJS with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019; advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement for LAD-I with CIEMAT Group and UCLB&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company entered into a license agreement in November 2017, effective September 2017, with CIEMAT Group and UCLB&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, granting the Company worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human LAD-I gene solely within the field of treating LAD-I. Under the terms of the agreement, Rocket is obligated to use commercially reasonable efforts to (a) develop and obtain regulatory approval for one or more products or processes covered by the licensed intellectual property, introduce such products or processes into the commercial market and then make them reasonably available to the public, (b) develop or commercialize at least one product or process covered by the licensed intellectual property in at least one country for at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_51fd1836-2c76-4d4a-89af-503fa040d252;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; uninterrupted years following regulatory approval, and (c) use the licensed intellectual property in an adequate, ethical and legitimate manner. In exchange for the license, the Company is obligated to pay Licensors an up-front payment, royalty payments in the mid-single digit percentages based on net sales of products or processes involving any of the licensed intellectual property, developmental and regulatory milestone payments, and sublicense revenue payments. Rocket is responsible for prosecuting and maintaining the licensed patents at its expense, in cooperation with Licensors. The Company also has the first responsibility to enforce and defend the licensed patents against infringement and/or challenge, in cooperation with Licensors. For five years following the effective date of the license agreement, Rocket has a right of first refusal to license any improvements to the licensed intellectual property obtained by Licensors at market value. The Company is obligated to license (without charge) to Licensors for non-commercial use any improvements to the licensed intellectual property that it creates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As consideration for the licensed rights, Rocket paid Licensors an initial upfront license fee of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million), which was expensed as R&amp;amp;D costs. The Company is obligated to make aggregate payments of up to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) to Licensors upon the achievement of specified development and regulatory milestones. With respect to any commercialized products covered by the LAD-I license, Rocket is obligated to pay a mid-single digit percentage royalty on net sales, subject to specified adjustments, by the Company or its sublicensees or affiliates. In the event that the Company enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rocket may terminate this agreement at any time by providing the Licensors with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; advance notice. The license is in effect for a duration for each of the countries defined in this agreement for as long as a license right exists that covers the licensed product or process in such country, or until the end of any additional legal protection that should be obtained for the license rights in each country.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement for DD with UCSD&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2017, the Company entered into a License Agreement with The Regents of the UCSD&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, under which UCSD granted us an exclusive, sublicensable, worldwide license to certain intellectual property rights for the treatment of lysosomal storage diseases, including DD. In exchange for the license, the Company became obligated to make an up-front payment, certain clinical and commercial milestone payments, royalty payments (on net sales of products covered by a valid claim within the licensed intellectual property), maintenance fees and sublicense revenue payments. The upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was expensed as research and development costs in 2020. The Company is obligated to make aggregate milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to UCSD upon the achievement of specified development and regulatory milestones for the treatment of DD. A reduced schedule of milestone payments applies to achieving the same milestones for additional indications. With respect to any commercialized products covered by the agreement, the Company is obligated to pay a low single digit percentage royalty on net sales, subject to specified adjustments. If it enters into a sublicense agreement with a sublicensee, it will be obligated to pay a portion of any consideration received from such sublicensees in specified circumstances. The Company is also subject to certain diligence milestones for development of a product using the intellectual property licensed from UCSD under this agreement. The term of the license agreement with UCSD is through the expiration of the licensed patents, some of which are still in the pending application phase.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement for DD with RGNX&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 19, 2018, the Company entered into a license agreement with RGNX, pursuant to which the Company obtained an exclusive license for all U.S. patents and patent applications related to RGNX&#x2019;s NAV AAV-9 vector for the treatment of DD in humans by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;in vivo &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;gene therapy using AAV-9 to deliver any known LAMP2 transgene isoforms and all possible combinations of LAMP2 transgene isoforms, as well as an exclusive option to license&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; all U.S. patents and patent applications for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional NAV AAV vectors in the Field&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the license agreement, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market, promote and sell licensed products incorporating the licensed patents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Unless the license agreement is terminated earlier as provided below, the license from RGNX expires on a country-by-country, licensed product-by-licensed product basis until the later of the expiration date of the last to expire of the last valid claim of the applicable licensed patent or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after the first commercial sale of a licensed product in such country. The license agreement provides that RGNX may terminate the agreement upon a material breach by the Company if the Company does not cure such breach within a specified notice period if the Company commences a challenge against RGNX or certain of its licensors to declare or render invalid or unenforceable the licensed patents or upon the Company&#x2019;s bankruptcy or insolvency. The Company may terminate the agreement in its entirety or terminate one or more of the licensed vectors at any time upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019; notice. The Company&#x2019;s option right expired &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of the license agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In consideration for the rights granted to the Company under the license agreement, the Company made an upfront payment to RGNX of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The license agreement provides for royalties payable to RGNX in the high-single digits to low-teens on net sales levels of licensed products during the royalty term. If successful, the Company will be required to make milestone payments to RGNX of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each licensed product upon the achievement of specified clinical development and regulatory milestones in the U.S. and EU. In addition, the Company shall pay RGNX &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the payment fees received from a priority review voucher issued in connection with or otherwise related to a licensed product. These royalty obligations are subject to specified reductions if additional licenses from third parties are required. The Company must also pay RGNX a portion of all non-royalty sublicense income (if any) received from sublicensees. The Company paid and expensed a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million license fee payment under the RGNX agreement upon the dosing of the first DD patient in 2019 and a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million license fee payment upon initiation of a Phase 2 pivotal trial in 2023. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional milestones achieved or related payments made during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement for BAG3 with Temple University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 1, 2022, the Company acquired Renovacor, including a license agreement for BAG3 with Temple University. The license agreement provides for royalties payable to Temple University in the low-single digits on net sales of licensed products during the royalty term. If successful, the Company will be required to make milestone payments to Temple University of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon achievement of specific clinical development and regulatory milestones.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</rckt:AgreementsRelatedToIntellectualPropertyTextBlock>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_62e99bbf-513f-4f99-b0ea-bcc4f892c8d2"
      decimals="-4"
      id="F_188986a9-4cc8-4bdd-9c03-98c44d17473a"
      unitRef="U_EUR">30000.00</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_62e99bbf-513f-4f99-b0ea-bcc4f892c8d2"
      decimals="-4"
      id="F_de89f22a-1ce0-4f0d-b9bf-3be672c7f4bd"
      unitRef="U_USD">30000.00</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_3ffc89cd-c5e5-47b4-9f7d-0851382b9894"
      decimals="-5"
      id="F_63755f65-40e1-441d-a11a-20fe01112b37"
      unitRef="U_EUR">1400000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_3ffc89cd-c5e5-47b4-9f7d-0851382b9894"
      decimals="-5"
      id="F_200d6794-713f-4f54-86e1-11d6efc964ed"
      unitRef="U_USD">1500000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:AgreementTerminationNoticePeriod
      contextRef="C_392358ca-cf5c-43db-9d21-66153965d64c"
      id="F_d133dfec-81e6-450c-9c50-21040d118d6a">P90D</rckt:AgreementTerminationNoticePeriod>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_f7e81d9b-0896-4ad4-ba24-d00ff70c5380"
      decimals="-5"
      id="F_caac466b-0cdb-494d-8842-4fa25127e414"
      unitRef="U_EUR">100000</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_f7e81d9b-0896-4ad4-ba24-d00ff70c5380"
      decimals="-5"
      id="F_48a79660-7c68-4ac1-92de-827d306d8fdf"
      unitRef="U_USD">100000</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_9db51dfa-02b3-4033-8f63-ae0680935120"
      decimals="-5"
      id="F_2af23534-8b27-456a-845d-87ac2c019614"
      unitRef="U_EUR">5000000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_9db51dfa-02b3-4033-8f63-ae0680935120"
      decimals="-5"
      id="F_6a4f4b3f-525d-4b66-b4c6-b6bf34c4b6fe"
      unitRef="U_USD">5500000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:AgreementTerminationNoticePeriod
      contextRef="C_d25d260a-f7e7-4db6-8072-fa02e589a560"
      id="F_e2fa6dcd-ac41-4841-ac2c-fa7e83d11413">P90D</rckt:AgreementTerminationNoticePeriod>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_f58025d4-77f4-4bb3-a4eb-7fe3d5f5ebf7"
      decimals="-4"
      id="F_ee4c081d-995c-4a6e-beed-b19ad5d86af5"
      unitRef="U_EUR">30000.00</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_f58025d4-77f4-4bb3-a4eb-7fe3d5f5ebf7"
      decimals="-4"
      id="F_bf079268-bc8e-4ef4-ba60-b854c39937a6"
      unitRef="U_USD">40000.00</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_648e9485-2de4-4dbf-b7be-6f5b0c53d513"
      decimals="-5"
      id="F_c7b7e9b1-71b0-42c0-ab17-1aa8331d1f0f"
      unitRef="U_EUR">1400000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_648e9485-2de4-4dbf-b7be-6f5b0c53d513"
      decimals="-5"
      id="F_09d0953f-6d1c-4914-bcdb-85e46bed11ca"
      unitRef="U_USD">1500000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:AgreementTerminationNoticePeriod
      contextRef="C_743963e7-e2f3-4156-9218-0e77929607dc"
      id="F_89b6b2ea-a918-48f1-9249-cfa870ddeb8d">P90D</rckt:AgreementTerminationNoticePeriod>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_3d43c909-ed76-4cd3-8437-c11a815217b6"
      decimals="-4"
      id="F_e06297f5-f341-4904-94c5-7f662179eb8f"
      unitRef="U_USD">50000.00</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_cc91e4ce-92d4-493e-b585-ed3ef5272e3c"
      decimals="-5"
      id="F_1b28ace5-1e06-4ccf-a0d3-9462a7c000c1"
      unitRef="U_USD">1500000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:LicenseAgreementNumberOfPatents
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      decimals="INF"
      id="F_cfa66298-6aca-49b4-9dc9-f3b653ccadf9"
      unitRef="U_Patent">2</rckt:LicenseAgreementNumberOfPatents>
    <rckt:ResearchAgreementInitialTerm
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      id="F_0df930b9-fc40-4f63-9dcb-136deed3612c">P10Y</rckt:ResearchAgreementInitialTerm>
    <rckt:AgreementTerminationNoticePeriod
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      id="F_02e6c1a0-699a-4d17-b92e-d4a581e12d4c">P6M</rckt:AgreementTerminationNoticePeriod>
    <rckt:LicenseAgreementOptionsRightExpiryTerm
      contextRef="C_50276bb0-33c1-4f8f-878e-9cd8590b54aa"
      id="F_d4c6b54f-23b8-4dd4-86cb-4cd66a0f019b">P4Y</rckt:LicenseAgreementOptionsRightExpiryTerm>
    <rckt:ResearchAndDevelopmentCosts
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      decimals="-5"
      id="F_4e48535e-3be5-42bf-9fda-9a8c8032e48c"
      unitRef="U_USD">7000000</rckt:ResearchAndDevelopmentCosts>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_c0959b18-8b8a-48d0-97a6-aefc2f4ade16"
      decimals="-5"
      id="F_1a4635e1-7c87-47c6-9b11-a894f0c26a4a"
      unitRef="U_USD">13000000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:RoyaltiesPayableOnFeesReceived
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      decimals="2"
      id="F_3ce9f0cb-3bc1-4565-98dc-813d71eb2424"
      unitRef="U_pure">0.20</rckt:RoyaltiesPayableOnFeesReceived>
    <rckt:PaymentAndExpensesForLicenseFee
      contextRef="C_308b60bc-adf6-4c0d-98f7-6dd8faf1845b"
      decimals="-5"
      id="F_43cee9b5-7d4a-4566-98e3-c75631ba9e7c"
      unitRef="U_USD">1000000</rckt:PaymentAndExpensesForLicenseFee>
    <rckt:PaymentAndExpensesForLicenseFee
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      decimals="-5"
      id="F_240958aa-4f8a-4a93-a28d-53b9f420c8eb"
      unitRef="U_USD">2000000</rckt:PaymentAndExpensesForLicenseFee>
    <rckt:NumberOfMilestonesAchieved
      contextRef="C_c7874f61-2268-4af4-888a-25b614890494"
      decimals="INF"
      id="F_15dac136-0307-4b8d-b137-da895b72843a"
      unitRef="U_Milestone">0</rckt:NumberOfMilestonesAchieved>
    <rckt:NumberOfMilestonesAchieved
      contextRef="C_fe041e39-6da1-43a6-9419-34b2d437cff8"
      decimals="INF"
      id="F_b8b4e19f-408f-4db9-892b-e041fe7eb066"
      unitRef="U_Milestone">0</rckt:NumberOfMilestonesAchieved>
    <rckt:NumberOfMilestonesAchieved
      contextRef="C_58582e6a-472e-48eb-b983-e4e33afabbd1"
      decimals="INF"
      id="F_382a8fd2-ef96-4dea-b66d-70b2a615fff3"
      unitRef="U_Milestone">0</rckt:NumberOfMilestonesAchieved>
    <rckt:ResearchAndDevelopmentCostsPotentialFutureObligation
      contextRef="C_59178516-f6c7-4b30-a565-d0b9d51d21d3"
      decimals="-4"
      id="F_915139c6-58ce-423d-a088-9100c1f827dd"
      unitRef="U_USD">19250000</rckt:ResearchAndDevelopmentCostsPotentialFutureObligation>
    <rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_3f409fb0-4fb2-4d5d-8aea-7ad86faa9ac2">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CIRM Grants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;LAD-I CIRM Grant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 30, 2019, CIRM awarded the Company up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy, RP-L201. Proceeds from the grant helped fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients enrolled at the U.S. clinical site, University of California, Los Angeles Mattel Children&#x2019;s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edy the Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. As of December 31, 2024, the Company has received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in total RP-L201 grants from CIRM. These were recorded as reductions of R&amp;amp;D expenses. The Company received a final milestone grant of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on January 2, 2024 and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional payments are available under the grant awards program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;DD CIRM Grant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 18, 2024, CIRM awarded the Company up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under a CLIN2 grant award to support the clinical development of its AAV-based gene therapy, RP-A501 for the treatment of DD. Proceeds from the grant would help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients. As of December 31, 2024, the Company has received RP-A501 grants of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from CIRM, which was recorded as a reduction of R&amp;amp;D expenses for the RP-A501 program for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</rckt:CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock>
    <rckt:GrantAwardForClinicalDevelopmentSupport
      contextRef="C_a067d039-439e-4ceb-af2b-1cde0cbe0191"
      decimals="-5"
      id="F_8790e37f-a711-419a-8aed-de5aea36f385"
      unitRef="U_USD">7500000</rckt:GrantAwardForClinicalDevelopmentSupport>
    <rckt:ProceedsFromMilestonePayments
      contextRef="C_6b479ce2-ba9e-4e7a-9b6e-64a21f473b06"
      decimals="-5"
      id="F_1884790a-bd71-47e5-acba-b9a248859e35"
      unitRef="U_USD">5900000</rckt:ProceedsFromMilestonePayments>
    <rckt:ProceedsFromMilestonePayments
      contextRef="C_ad45b344-bcc3-4fab-a36c-d35bf9065472"
      decimals="-4"
      id="F_b83a5076-b55f-4e1b-b5fe-c8098d88c5d4"
      unitRef="U_USD">50000.00</rckt:ProceedsFromMilestonePayments>
    <rckt:AdditionalPaymentsAvailableUnderGrantAwardsProgram
      contextRef="C_6b479ce2-ba9e-4e7a-9b6e-64a21f473b06"
      decimals="INF"
      id="F_2203c09a-2413-4c5c-b82f-51943c52d168"
      unitRef="U_USD">0</rckt:AdditionalPaymentsAvailableUnderGrantAwardsProgram>
    <rckt:GrantAwardForClinicalDevelopmentSupport
      contextRef="C_4e8fe46b-7cf9-4f88-b35f-815f319dccc5"
      decimals="-5"
      id="F_78b23da4-7c36-4358-a697-88e09ed42f22"
      unitRef="U_USD">5800000</rckt:GrantAwardForClinicalDevelopmentSupport>
    <rckt:ProceedsFromMilestonePayments
      contextRef="C_7132f227-a70e-41d6-9438-433555a0c26d"
      decimals="-5"
      id="F_ae069295-f82d-46e2-baf5-27752d872003"
      unitRef="U_USD">2300000</rckt:ProceedsFromMilestonePayments>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_a0c31432-64fa-4592-9de4-9daaf781917d">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;17.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2023, the Company entered into a consulting agreement with the spouse of one of the Company&#x2019;s executive officers for information technology advisory services. The Company incurred expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.002&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.02&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively, relating to services provided under this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 15, 2023, in connection with the Company&#x2019;s public offering, the Company sold approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million pre-funded warrants to purchase shares of the Company&#x2019;s common stock to funds affiliated with RTW, the Company&#x2019;s largest shareholder (see Note 8 &#x201c;Stockholders&#x2019; Equity&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 12, 2024, in connection with the Company&#x2019;s public offering, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million pre-funded warrants to purchase shares of the Company&#x2019;s common stock to funds affiliated with RTW, the Company&#x2019;s largest shareholder (see Note 8 &#x201c;Stockholders&#x2019; Equity&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2025, the Company enter into a consulting agreement &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with one of the Company&#x2019;s board members, effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 3, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for services related to the Company&#x2019;s research and development activities. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As compensation for services rendered, the consultant will receive $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to be paid in equal monthly installments and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of RSU&#x2019;s valued as of the closing price on March 3, 2025 which will cliff vest on December 31, 2025.  The agreement will terminate on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unless terminated earlier by the Company for cause or voluntarily by consultant.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_dafcda54-97f8-4761-aa4c-f2218e1ce458"
      unitRef="U_USD">2000.000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-4"
      id="F_fded40e9-b4bd-4320-aad1-286e8b9c58fd"
      unitRef="U_USD">20000.00</us-gaap:CostsAndExpensesRelatedParty>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_c85f9ea7-c5e2-4223-8d66-d75ebaec1617"
      decimals="-5"
      id="F_1057749c-8917-43a6-a1fe-9959c0e502ce"
      unitRef="U_shares">3100000</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <rckt:NumberOfStockWarrantsIssuedToPurchaseShares
      contextRef="C_1adde562-4738-4477-bfc6-f6adc114c4a6"
      decimals="-5"
      id="F_1255b7d2-7800-42e8-92d5-6fbe33e9b72c"
      unitRef="U_shares">400000</rckt:NumberOfStockWarrantsIssuedToPurchaseShares>
    <rckt:ConsultingAgreementEffectiveDate
      contextRef="C_f241f631-e65d-4cb2-96fd-2e31846e930f"
      id="F_ca96f9bc-a1f2-42a7-bb8d-7b9585a1db66">2025-03-03</rckt:ConsultingAgreementEffectiveDate>
    <rckt:ConsultingFeeMonthlyInstalment
      contextRef="C_f241f631-e65d-4cb2-96fd-2e31846e930f"
      decimals="-3"
      id="F_0e45e994-e31f-4789-9a3d-577143a39c02"
      unitRef="U_USD">125000</rckt:ConsultingFeeMonthlyInstalment>
    <rckt:ConsultingFeeMonthlyInstalment
      contextRef="C_a390a215-8672-44fe-88df-66981bedc86b"
      decimals="-3"
      id="F_21988e6a-ee2e-4cff-b1eb-d98d5b26bd9e"
      unitRef="U_USD">125000</rckt:ConsultingFeeMonthlyInstalment>
    <rckt:ConsultingAgreementTerminationDate
      contextRef="C_069e4998-345d-4f31-93a6-b24211692b71"
      id="F_52d9b42f-a8be-44f5-ac53-3af46adfb745">2025-12-31</rckt:ConsultingAgreementTerminationDate>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_2fd7d3b7-bfb7-41a5-be50-cac49197dc06">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;18.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;401(k) Savings Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has a defined contribution savings plan (the &#x201c;Plan&#x201d;) under Section 401(k) of the Internal Revenue Code of 1986. This Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the Plan may be made at the discretion of the Company&#x2019;s Board of Directors. The Company has elected the safe harbor&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; match of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of employee contributions to the Plan, subject to certain limitations. The Company&#x2019;s matching contribution for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023, and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="2"
      id="F_6dff296d-a569-4725-9d8f-1e41c676bac1"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-5"
      id="F_3d4decc2-8c3a-4229-8ef5-7287b54caf72"
      unitRef="U_USD">1700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-5"
      id="F_867794a6-d6eb-461f-b044-95fc13137c88"
      unitRef="U_USD">900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-5"
      id="F_44d1edc5-5695-4b8a-a412-a5972fdfb633"
      unitRef="U_USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_bfd94744-829e-4cc8-ba6b-fdcedb4e4a06">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;19.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment related to R&amp;amp;D and commercial readiness of its gene therapies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM is its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_451a042b-eab6-4290-938a-8e09ce736c2b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the senior leadership team. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM manages the Company&#x2019;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Included in these expenses are R&amp;amp;D expenses by program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below is a summary of the segment loss, including significant segment expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.851%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.623000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.623000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-commercial general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development incentives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accretion of discount and amortization of premium on investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net Segment loss and Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM uses net loss to evaluate past spending and to guide decisions of future spending. Net loss is used to monitor budget versus actual results. The CODM also uses net loss in analysis of programs and along with the monitoring of budgeted versus actual results in assessing performance of the segment and in establishing manager&#x2019;s compensation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="INF"
      id="F_a9158b7b-34e9-4db2-8436-4ad1d5293f7f"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_b3fc3dd3-7cf5-4c32-be07-c2e8bd6aea0a">The CODM manages the Company&#x2019;s operations on an integrated basis for the purpose of allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and expenses by significant areas to make decisions on a company wide basis.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      id="F_99f9a9e2-470a-49ed-bb41-1e6e506bc8fb">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below is a summary of the segment loss, including significant segment expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:52.851%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.623000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.623000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="8" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-commercial general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;259,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development incentives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accretion of discount and amortization of premium on investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net Segment loss and Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_ae247529-45ad-45dd-b50f-47d6120480e2"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_cb5f16c3-144b-45f8-a5fd-9d91bb7953cd"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_96514368-8b25-4bf4-8ef8-5c1ae43e278d"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_a066d385-78ba-4e1f-8ba4-bddff62ec9ca"
      unitRef="U_USD">171244000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_165c2ddd-295f-42db-9c10-59a7f9c0d8cf"
      unitRef="U_USD">186342000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_a664d614-dfc9-4f65-ab04-bc1130d22285"
      unitRef="U_USD">165570000</us-gaap:ResearchAndDevelopmentExpense>
    <rckt:NonCommercialGeneralAndAdministrativeExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_47e87829-ab21-412d-8235-e2fcdea0c35a"
      unitRef="U_USD">63878000</rckt:NonCommercialGeneralAndAdministrativeExpense>
    <rckt:NonCommercialGeneralAndAdministrativeExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_b8a6bf20-b505-4b61-bfd4-f72ff3e9677b"
      unitRef="U_USD">54805000</rckt:NonCommercialGeneralAndAdministrativeExpense>
    <rckt:NonCommercialGeneralAndAdministrativeExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_0e9ade3c-0270-4877-951b-77090948896d"
      unitRef="U_USD">50211000</rckt:NonCommercialGeneralAndAdministrativeExpense>
    <rckt:CommercialGeneralAndAdministrativeExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7a29ceb0-f60a-47fe-a37b-0aff8f7ed86c"
      unitRef="U_USD">38083000</rckt:CommercialGeneralAndAdministrativeExpense>
    <rckt:CommercialGeneralAndAdministrativeExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_6fd6bc0f-9b6e-4efe-9a13-adf78bf7b865"
      unitRef="U_USD">18512000</rckt:CommercialGeneralAndAdministrativeExpense>
    <rckt:CommercialGeneralAndAdministrativeExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_e4499068-abb5-4696-93c2-de48277960db"
      unitRef="U_USD">8562000</rckt:CommercialGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e6a3568a-cb6e-4fcf-bda8-489eac87fbd5"
      unitRef="U_USD">273205000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_62ce5953-c948-4daf-b2a2-5b35803ff6f4"
      unitRef="U_USD">259659000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_8ce3956c-c6ca-461c-8c3a-028c0aaf932d"
      unitRef="U_USD">224343000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_4e765de2-9b59-4c01-a8f2-c4e808363887"
      unitRef="U_USD">-273205000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_746871bc-f3fd-4962-b979-8d77850d8314"
      unitRef="U_USD">-259659000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_b171a371-9752-43cf-a487-2266db5ad96f"
      unitRef="U_USD">-224343000</us-gaap:OperatingIncomeLoss>
    <rckt:ResearchAndDevelopmentIncentives
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_4321a462-d872-4d5e-93b1-25b86741f91c"
      unitRef="U_USD">0</rckt:ResearchAndDevelopmentIncentives>
    <rckt:ResearchAndDevelopmentIncentives
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_9c5cfd7f-558f-4d30-b043-e2ee745ddb2f"
      unitRef="U_USD">0</rckt:ResearchAndDevelopmentIncentives>
    <rckt:ResearchAndDevelopmentIncentives
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_11f7cc78-14f4-41b1-add6-882e64a99b6a"
      unitRef="U_USD">500000</rckt:ResearchAndDevelopmentIncentives>
    <us-gaap:InterestExpense
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_cefb3ea9-4f66-490b-af62-5aeb4101ce13"
      unitRef="U_USD">1886000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_bdc2f9c8-c593-41fb-9c08-8393f427f564"
      unitRef="U_USD">1875000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_53cbed1b-ace3-40a2-a822-b3ed90f6ff3d"
      unitRef="U_USD">1862000</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_08a96fe1-d710-4c8a-83c1-915b6cdfa709"
      unitRef="U_USD">8267000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_99ea9d04-0cea-4834-b972-ec9eb239144a"
      unitRef="U_USD">5288000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_724d07f8-4b6d-4e0a-9298-1ef3aeb5954b"
      unitRef="U_USD">3889000</us-gaap:InterestAndOtherIncome>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_7246bf03-03fa-460e-b266-91509c085d51"
      unitRef="U_USD">8078000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_cace42a2-8109-424f-905d-cc61d66d082f"
      unitRef="U_USD">10651000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_206ec1f3-a4d1-49f9-b3ff-7118ca81b218"
      unitRef="U_USD">-47000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_5d4ff701-3d41-47cd-8660-59707d56d468"
      decimals="-3"
      id="F_e2a5062e-66b1-45f8-8395-48daeba1e177"
      unitRef="U_USD">-258746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9361b9bf-214e-472d-94a2-17fca7cba2ff"
      decimals="-3"
      id="F_274a76d8-fc8f-462b-85b2-28e1f041f3b4"
      unitRef="U_USD">-245595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8bb47019-2fa3-40cd-a3c6-abc9ad2b49a9"
      decimals="-3"
      id="F_7a821f65-593a-4a27-9d60-06e33827c501"
      unitRef="U_USD">-221863000</us-gaap:NetIncomeLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
